<SEC-DOCUMENT>0001193125-26-151378.txt : 20260410
<SEC-HEADER>0001193125-26-151378.hdr.sgml : 20260410
<ACCEPTANCE-DATETIME>20260410164115
ACCESSION NUMBER:		0001193125-26-151378
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		44
FILED AS OF DATE:		20260410
DATE AS OF CHANGE:		20260410

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Hemab Therapeutics Holdings, Inc.
		CENTRAL INDEX KEY:			0002114044
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				414241952
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-294989
		FILM NUMBER:		26855445

	BUSINESS ADDRESS:	
		STREET 1:		101 MAIN STREET
		STREET 2:		SUITE 1220
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		45 2138 7627

	MAIL ADDRESS:	
		STREET 1:		101 MAIN STREET
		STREET 2:		SUITE 1220
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>d50309ds1.htm
<DESCRIPTION>S-1
<TEXT>
<HTML><HEAD>
<TITLE>S-1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>As filed with the Securities and Exchange Commission on April 10, 2026 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-&#8195;&#8195;&#8195;</FONT> </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:15pt; font-family:ARIAL" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:ARIAL" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">S-1</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>REGISTRATION STATEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><I>UNDER </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><I>THE SECURITIES ACT OF 1933 </I></B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>HEMAB THERAPEUTICS HOLDINGS, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Exact name
of registrant as specified in its charter) </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2836</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">41-4241952</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:ARIAL" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7.5pt; font-family:ARIAL" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:ARIAL" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7.5pt; font-family:ARIAL" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:ARIAL" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7.5pt; font-family:ARIAL" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>101 Main Street, Suite 1220 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Cambridge, MA
02142 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(617) 553-3952 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:ARIAL" ALIGN="center"><B>(Address,
including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices) </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Benny S&oslash;rensen, M.D., Ph.D. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>President
and Chief Executive Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Hemab Therapeutics Holdings, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>101 Main Street, Suite 1220 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Cambridge, MA
02142 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(617) 553-3952 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:ARIAL" ALIGN="center"><B>(Name,
address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Cynthia T. Mazareas, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Scott N. Lunin, Esq.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Wilmer Cutler Pickering
Hale and Dorr LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>60 State Street</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Boston, Massachusetts 02109</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(617) <FONT
STYLE="white-space:nowrap">526-6000</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Benjamin K. Marsh, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Kristopher D. Brown, Esq.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Justin S. Platt,
Esq.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Goodwin Procter LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>The New York
Times Building</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>620 Eighth Avenue</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>New
York, NY 10018</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(212) <FONT STYLE="white-space:nowrap">813-8800</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL"><B>Approximate date of commencement of proposed sale to the public: </B>As soon as practicable after this registration statement is declared effective.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities
Act of 1933, check the following box.&#8194;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">If this Form is filed to register additional
securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;<FONT
STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act,
check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.&#8194;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting
company&#8221; and &#8220;emerging growth company&#8221; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&#8194;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a
further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective
on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#de1a1e">The information in this prospectus is not complete and may be changed. We may not sell
these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities, and we are not soliciting offers to buy these securities in any state or
other jurisdiction where the offer or sale is not permitted. </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT
 COLOR="#de1a1e"><B>SUBJECT TO COMPLETION, DATED APRIL 10, 2026 </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>PRELIMINARY PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center">&#8195;&#8195;&#8195;Shares </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g62g77.jpg" ALT="LOGO" STYLE="width:1.76267in;height:0.348971in;">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center">Common Stock </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This is the initial public offering of shares of common stock of Hemab Therapeutics Holdings, Inc. We are offering&#8195;&#8195;&#8195;&#8195; shares of
our common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to this offering, there has been no public market for our common stock. It is currently estimated that the initial public
offering price per share will be between $&#8195;&#8195;&#8195;&#8195;and $&#8195;&#8195;&#8195;&#8195;. We have applied to list our common stock on the Nasdaq Global Select Market under the symbol &#8220;COAG.&#8221; We believe that upon the
completion of this offering, we will meet the standards for listing on Nasdaq, and the completion of this offering is contingent upon such listing. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; as defined under the U.S. federal securities laws, and, as
such, have elected to comply with certain reduced reporting requirements in this prospectus. See the section titled &#8220;<I>Prospectus Summary&#8212;Implications of Being an Emerging Growth Company and a Smaller Reporting Company</I>.&#8221; </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>See the section titled &#8220;<A HREF="#tx50309_3">Risk Factors</A>&#8221; beginning on page 13 to read about factors that you should consider before
deciding to invest in shares of our common stock. </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Per&nbsp;Share</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Underwriting discounts and commissions(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">See the section titled &#8220;<I>Underwriting</I>&#8221; for additional information regarding compensation payable to the
underwriters. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have granted the underwriters the option to purchase up to an additional&#8195;&#8195;&#8195;&#8195;shares of
common stock from us, at the initial public offering price, less the underwriting discounts and commissions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters expect to deliver the
shares of common stock on or about&#8195;&#8195;&#8195;&#8195; , 2026. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>Joint Book-Running Managers </I></B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" NOWRAP ALIGN="center"><B>Goldman Sachs&nbsp;&amp; Co. LLC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><B>Evercore ISI</B></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>Lead Manager </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Wedbush PacGrow </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">&#8195;&#8195;&#8195;, 2026 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_1">About this Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">i<FONT STYLE="font-size:5pt">&#8201;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_2">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_3">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_4">Cautionary Note Regarding Forward-Looking Statements and Industry Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_6">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_7">Corporate Reorganization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_8">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_9">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_10">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_11">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_12">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_13">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_14">Transactions with Related Persons</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_15">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_16">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_17">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_18">Material U.S. Federal Income Tax Considerations for <FONT STYLE="white-space:nowrap">Non-U.S.
</FONT> Holders of Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_19">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_20">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_21">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_22">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_23">Index to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Neither we nor the underwriters have authorized anyone to provide you any information or make any representations other
than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of,
any other information that others may give you. We and the underwriters are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this
prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have
changed since that date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For investors outside of the United States: we have not, and the underwriters have not, done anything that would permit
this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform
themselves about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">All trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners. Solely for convenience, the
trademarks and trade names in this prospectus may be referred to without the&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>&nbsp;and&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>&nbsp;symbols, but such references
should not be construed as any indicator that their respective owners will not assert their rights thereto. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We previously operated as Hemab ApS, a private limited company organized under the laws of the Kingdom of Denmark. For purposes of this offering, we
formed Hemab Therapeutics Holdings, Inc., a Delaware corporation, which is the registrant whose name appears on the cover of the registration statement of which this prospectus is a part. In March&nbsp;2026, we completed a corporate reorganization
pursuant to which the shareholders of Hemab&nbsp;ApS exchanged their shares in Hemab ApS for the same number, class and series of newly issued shares in the newly incorporated Delaware company, Hemab Therapeutics Holdings, Inc. and, as a result,
Hemab ApS became a wholly owned subsidiary of Hemab Therapeutics Holdings, Inc. Additionally, promptly following the corporate reorganization, Hemab ApS transferred its shares of Hemab Therapeutics Inc., a Delaware corporation and wholly-owned
subsidiary of Hemab ApS, to Hemab Therapeutics Holdings, Inc. in exchange for the issuance of a promissory note and, as a result, Hemab Therapeutics Inc. became a wholly owned subsidiary of Hemab Therapeutics Holdings, Inc. Hemab Therapeutics
Holdings, Inc. had nominal assets and liabilities and did not conduct any operations prior to the corporate reorganization other than its incorporation. We refer to this reorganization transaction throughout this prospectus as the &#8220;corporate
reorganization.&#8221; See the section of the prospectus titled &#8220;<I>Corporate Reorganization</I>&#8221; for further details. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Unless otherwise
indicated or the context otherwise requires, all references in this prospectus to the terms &#8220;Hemab ApS,&#8221; &#8220;Hemab Therapeutics Holdings, Inc.,&#8221; &#8220;the company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221;
refer to (1)&nbsp;Hemab ApS and its wholly owned U.S. subsidiary, Hemab Therapeutics Inc., prior to the completion of our corporate reorganization and (2)&nbsp;Hemab Therapeutics Holdings, Inc. and its
<FONT STYLE="white-space:nowrap">wholly-owned</FONT> subsidiaries, Hemab ApS and Hemab Therapeutics Inc., after the completion of the corporate reorganization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">References in this prospectus to &#8220;ordinary shares&#8221; and &#8220;preference shares&#8221; refer to the historic share capital of Hemab ApS
prior to the completion of the corporate reorganization. All references to &#8220;common stock&#8221; and &#8220;preferred stock&#8221; refer to the capital structure of Hemab Therapeutics Holdings, Inc. following completion of the corporate
reorganization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Unless otherwise indicated, all references to &#8220;$&#8221; or &#8220;dollars&#8221; in this prospectus refer to U.S. dollars.
References to &#8220;DKK&#8221; in this prospectus refer to Danish kroner. The rate of exchange on December 31, 2025, as reported by the U.S. Treasury for the conversion of U.S. dollars to DKK was $1.00 equals DKK 6.3550. Numerical figures presented
in this prospectus have been subject to rounding adjustments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Unless otherwise indicated, the historical financial and operating information
presented in this prospectus as of and for the years ended December&nbsp;31, 2024 and 2025 is that of Hemab ApS. Upon consummation of the corporate reorganization, the historical consolidated financial statements of Hemab ApS became the historical
consolidated financial statements of Hemab Therapeutics Holdings, Inc., the entity whose shares are being sold in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Shares of common
stock of Hemab Therapeutics Holdings, Inc. are being offered by the prospectus included in this registration statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>This summary highlights information contained elsewhere in this prospectus and does not contain all of the information that you should consider in
making your investment decision. Before investing in our common stock, you should carefully read this entire prospectus, including our consolidated financial statements and the related notes thereto and the information set forth in the sections
titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life
and human resilience. Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases.
Coagulation disorders encompass a broad and heterogeneous group of conditions, and many patients experience significant life-long disease burden due to either a lack of available prophylactic therapies or limitations associated with existing
treatment approaches. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our lead asset, sutacimig (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the
prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Our second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the
subcutaneous prophylactic treatment of Von Willebrand Disease. We are also advancing multiple preclinical and discovery-stage assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We estimate
that there are approximately an aggregate of 10,000 patients with Glanzmann thrombasthenia and Factor VII deficiency and an aggregate of 120,000 patients with Von Willebrand Disease in the geographies where we intend to commercialize our assets,
including the United States, the European Union, Japan, the Gulf Cooperation Council countries and other select regions. With greater disease burden awareness, potential regulatory approvals of new prophylactic options and expanding global reach of
these options, we believe the overall number of addressable patients for our clinical-stage assets, and preclinical and discovery stage programs could be greater than we currently estimate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We aim to establish the industry&#8217;s leading coagulation franchise through the execution of our &#8220;Hemab 2x3 by 2030&#8221; strategic roadmap,
which is designed to build a franchise consisting of <B>2</B> commercial medicines, <B>2</B> new late-stage clinical programs, and <B>2</B> new early-stage clinical programs by 2030. We have not yet initiated pivotal trials for any of our product
candidates, and due to the novel and unproven nature of our programs, their current stage of development and the lack of approved prophylactic therapies to inform endpoint selection and trial design, we may not be able to achieve our strategic goals
on the timeline we expect or at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Franchise </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We
are building a franchise designed to address select coagulation disorders where we believe advances in biology, drug modality, and care delivery have the potential to meaningfully improve disease management. We design our assets to address critical
gaps in the treatment of coagulation disorders. Based on our plans to commence a Phase 3 clinical trial of sutacimig in Glanzmann thrombasthenia, report data from our Phase 2 clinical trial of sutacimig in Factor VII deficiency and commence clinical
development of one of our preclinical assets, we anticipate multiple potentially </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
value-driving clinical data events in&nbsp;2026, 2027 and beyond. The following table summarizes our assets and our target indications, as well as the status of development and anticipated
clinical data events. We maintain all global economic development and commercialization rights to the assets in our franchise. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g16g01.jpg" ALT="LOGO" STYLE="width:6.31944in;height:2.60974in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our lead asset, sutacimig, is a bispecific antibody, which we are currently evaluating in a Phase&nbsp;1/2 clinical
trial for the prophylactic treatment of Glanzmann thrombasthenia and in a Phase 2 clinical trial for the prophylactic treatment of Factor VII deficiency. Glanzmann thrombasthenia and Factor VII deficiency are both congenital, severe, chronic
bleeding disorders for which there are no approved subcutaneous prophylactic therapies. Patients with Glanzmann thrombasthenia and Factor&nbsp;VII deficiency suffer from what can be a devastating combination of life-threatening acute hemorrhages and
relentless chronic bleeding that profoundly impact patients&#8217; physical health, mental health, and quality of life. Both disorders also carry additional risks for female patients, including heavy menstrual bleeding and potentially
life-threatening post-partum hemorrhage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In our Phase 1/2 clinical trial of sutacimig in patients with Glanzmann thrombasthenia, we have completed
the Part A (single ascending dose) and Part B (three-month multiple ascending dose) portions of the trial, and the Part C (long-term extension up to 24 months) portion is currently ongoing. The data from Part A of the trial established
proof-of-mechanism. In Part B, the reduction in mean annualized treated bleed rate, or ATBR, for patients treated with sutacimig ranged from 19% to 87%, indicating clinical activity at all regimens tested. Sutacimig also achieved a 100% reduction in
mean high-intensity ATBR during the Part B treatment period. In addition, 92% of patients in Part B who had at least one bleed event during the six week prospective run-in period experienced a reduction in ATBR and over 50% of those patients
experienced a 50% or greater reduction in ATBR. Based on the clinical data observed as of the data cutoff date of October 14, 2025, we expect to commence a Phase&nbsp;3 clinical trial of sutacimig in Glanzmann thrombasthenia in the second half of
2026. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are also conducting a Phase 2 clinical trial that aims to establish proof-of-concept by demonstrating sutacimig&#8217;s ability to
increase Factor VII levels for patients with Factor VII deficiency. We anticipate reporting clinical data from our Phase 2 trial in late 2026 or early 2027. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Beyond these two initial indications, we believe sutacimig&#8217;s mechanism of action has potential applicability across multiple other inherited and
acquired bleeding conditions characterized by platelet dysfunction, and other causes of impaired hemostasis where platelet activation occurs at bleeding </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
sites. We believe this represents a significant opportunity for potential label expansion if sutacimig receives regulatory approval for Glanzmann thrombasthenia or Factor VII deficiency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our second clinical-stage asset, HMB-002, is a monovalent antibody, which we are developing for the subcutaneous prophylactic treatment of Von
Willebrand Disease. HMB-002 is designed to address the underlying biological drivers of Von Willebrand Disease by increasing endogenous levels of von Willebrand factor, or VWF, and Factor VIII, a blood coagulation protein. Von Willebrand Disease is
the most common inherited bleeding disorder and results from a reduced quantity or function of VWF, a plasma protein essential for normal hemostasis. Von Willebrand Disease is characterized by life-threatening hemorrhagic events and chronic
mucocutaneous bleeding episodes that combine to harm patients&#8217; physical health, mental well-being, and quality of life. Despite the availability of approved treatments, many patients continue to experience recurrent bleeding and substantial
treatment burden, as the approved therapies either require frequent intravenous administration or do not address the underlying biology of the disease. Beyond this initial indication, we believe HMB-002&#8217;s intended mechanism of action has
potential applicability across other bleeding conditions associated with low VWF levels. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are currently conducting a Phase 1/2 clinical trial of
HMB-002 for Von Willebrand Disease, which we refer to as Velora Pioneer. Velora Pioneer employs an adaptive dose-escalation design with two parts (Part A and Part B). In Part A, we are evaluating the safety, tolerability, pharmacokinetics, and
pharmacodynamics of single ascending doses of HMB-002. In Part B, participants transition from Part&nbsp;A into multiple-dose cohorts. As of the data cutoff date of September 2, 2025 for Velora Pioneer, we have completed treatment of two cohorts of
patients in Part A at dose levels of 20 mg and 50 mg and are currently evaluating patients in an ongoing 150 mg cohort. In the 20 mg and 50 mg cohorts, VWF and Factor VIII levels increased over 1.5-fold from baseline in a dose-dependent manner. In
addition, in the 20 mg cohort, HMB-002 corrected prolonged activated partial thromboplastin time and improved thrombin generation assays, resulting in enhanced overall coagulation activity for patients. Furthermore, a sustained VWF multimer
distribution was observed, suggesting that HMB-002 did not impact the protein structure of VWF. We expect to report initial data from Part B of Velora Pioneer in late 2026 or early 2027. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to sutacimig and HMB-002, we are advancing multiple preclinical and discovery-stage assets. The first of our preclinical assets is expected
to enter clinical development in the second half of 2026, subject to regulatory submission and clearance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Strategy and Approach </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are guided by our &#8220;All Patients Matter&#8221; philosophy and by the conviction that individuals living with serious bleeding disorders should
not have to live with inadequate treatment options. Our mission is to deliver therapeutics that provide meaningful clinical benefit and enable patients to live full lives that are not defined or limited by their diseases. We aim to establish the
industry&#8217;s leading coagulation franchise through the execution of our &#8220;Hemab 2x3 by 2030&#8221; strategic roadmap, which is designed to build a franchise consisting of <B>2</B> commercial medicines, <B>2</B> new late-stage clinical
programs, and <B>2</B> new early-stage clinical programs by 2030. We have not yet initiated pivotal trials for any of our product candidates, and due to the novel and unproven nature of our programs, their current stage of development and the lack
of approved prophylactic therapies to inform endpoint selection and trial design, we may not be able to achieve our strategic goals on the timeline we expect or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following core pillars underpin our strategy and guide our approach to reimagining the treatment of coagulation disorders. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We deploy a fundamentally patient-centric approach to drug development, beginning with listening, understanding, and
collaboration. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We leverage our deep domain expertise to identify optimal therapeutic targets and match them to the most appropriate
validated drug technology platforms. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We apply a flexible approach to clinical trial design, to maximize development outcomes and efficiency by leveraging our
patient-driven insights. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We are building the foundations of an efficient and scalable commercial franchise. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We bring an exceptional depth of experience across the entire value chain of drug discovery, development and
commercialization. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Team and History </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have assembled a leadership team and board of directors with deep experience in coagulation medicine and building life sciences companies. Members of
our board of directors and leadership and scientific teams have been directly involved in the discovery, development, regulatory approval, or commercialization of an extensive number of drugs approved for hemophilia, Von Willebrand Disease, and
other coagulation disorders, including ADYNOVATE, VONVENDI, QFITLIA, ELOCTATE, ALPROLIX, REFIXIA, NOVOEIGHT, ESPEROCT and ANGIOMAX. This collective expertise positions us to efficiently navigate the scientific, regulatory, and commercial
complexities inherent in developing therapies for coagulation disorders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since inception, we have raised approximately $346.0 million from
investors, including Access Biotechnology, Avoro Capital Advisors, Deep Track Capital, HealthCap, Novo Holdings, RA Capital Management, SMALLCAP World Fund and Sofinnova. Prospective investors should not rely on the investment decisions of our
existing investors, as these investors may have different risk tolerances and in certain cases received their shares in prior private financings at prices lower than the price offered to the public in this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Summary of Risks Associated with Our Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our business
is subject to a number of risks of which you should be aware before making an investment decision. These risks are discussed more fully in the &#8220;Risk Factors&#8221; section of this prospectus. These risks include, but are not limited to, the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We have incurred significant losses since our inception and have no products approved for sale. We expect to incur
significant losses for the foreseeable future and may never achieve or maintain profitability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We have never generated revenue from product sales and may never achieve or maintain profitability. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We are heavily dependent on the success of sutacimig and <FONT STYLE="white-space:nowrap">HMB-002,</FONT> which are our
only clinical-stage product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We will need substantial additional funding. If we are unable to raise capital on acceptable terms when needed, or at all,
we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess
our future viability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We are early in our clinical development efforts. If we are unable to successfully complete clinical development, obtain
marketing approval for, and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We will be required to incur
substantial costs and may experience delays in completing, or ultimately be unable to complete, the development and commercialization of any product candidates. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The outcome of preclinical studies and earlier-stage clinical trials may not be predictive of the success of later-stage
clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Serious adverse events of thrombosis have been identified in the development of sutacimig, and if additional serious
adverse events or unacceptable side effects are identified during the development of our product candidates and any other product candidates we may develop, we may need to abandon or limit our development of those product candidates.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">If we engage in future acquisitions, this may increase our capital requirements, dilute our stockholders, cause us to incur
debt or assume contingent liabilities, and subject us to other risks. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Even if any product candidate receives marketing approval, it may fail to achieve the degree of market acceptance by
physicians, patients, third-party payors and others in the medical community necessary for commercial success. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We face substantial competition, which may result in others discovering, developing or commercializing products before or
more successfully than we do. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We rely, and expect to continue to rely, on third parties to conduct our clinical trials, and those third parties may not
perform satisfactorily, including failing to meet deadlines for the completion of such trials, which may harm our business. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We contract with third parties for the manufacture of our product candidates, plan to contract with third parties for any
other product candidates we may develop for preclinical and clinical testing and expect to continue to do so for commercialization. This reliance on third parties entails risks, including that such third parties may not be able to comply with
applicable regulatory requirements. Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We may enter into collaborations with third parties for the development or commercialization of product candidates. If our
collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates and our business could be adversely affected. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">If we fail to comply with our obligations under our existing license agreements with Novo Nordisk A/S and Genmab A/S, or
under any future intellectual property licenses, or otherwise experience disruptions to our business relationships with our current or any future licensors, we could lose intellectual property rights that are important to our business.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">If we are unable to obtain, maintain, enforce, defend and otherwise protect the intellectual property relating to our
technology and product candidates, and if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize technology and products similar or identical to
ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive,
time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of some or all of our product candidates. As a result, we cannot predict when or if, and in which territories, we will obtain marketing approval to
commercialize a product candidate. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We have identified material weaknesses in our internal control over financial reporting. If we are unable to remedy our
material weaknesses, or if we fail to establish and maintain an effective system of internal control over financial reporting, we may be unable to produce timely and accurate financial statements or prevent fraud, which could adversely impact our
business and our stock price. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">An active trading market for our common stock may not develop. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We were incorporated under the
laws of the State of Delaware on February&nbsp;12, 2026 under the name Hemab Therapeutics Holdings, Inc. We previously operated as Hemab ApS, a private limited company organized under the laws of the Kingdom of Denmark. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In March 2026, we completed a corporate reorganization, pursuant to which the shareholders of Hemab ApS exchanged their shares in Hemab ApS for the same
number, class and series of newly issued shares in Hemab Therapeutics Holdings, Inc. and, as a result, Hemab ApS became a wholly owned subsidiary of Hemab Therapeutics Holdings, Inc. Additionally, promptly following the corporate reorganization,
Hemab ApS transferred its shares of Hemab Therapeutics Inc., a Delaware corporation and wholly-owned subsidiary of Hemab ApS, to Hemab Therapeutics Holdings, Inc. in exchange for the issuance of a promissory note and, as a result, Hemab Therapeutics
Inc. became a wholly owned subsidiary of Hemab Therapeutics Holdings, Inc. Hemab Therapeutics Holdings, Inc. had nominal assets and liabilities and did not conduct any operations prior to the corporate reorganization other than its incorporation.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our principal executive offices are located at 101 Main Street, Suite 1220, Cambridge, MA 02142, and our telephone number is (617) 553-3952. We
also maintain operations in Copenhagen, Denmark. Our website address is www.hemab.com. The information contained on, or that can be accessed through, our website is not incorporated by reference into this prospectus and you should not consider any
such information to be a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Implications
of Being an Emerging Growth Company and a Smaller Reporting Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are an &#8220;emerging growth company&#8221; as defined in the Jumpstart
Our Business Startups Act of 2012, or the JOBS Act. As a result, we are able to take advantage of certain reduced reporting requirements that are otherwise applicable to public companies, including delaying auditor attestation of internal control
over financial reporting, providing only two years of audited financial statements and related management&#8217;s discussion and analysis of financial condition and results of operations and reduced executive compensation disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may remain an emerging growth company until the end of the fiscal year in which the fifth anniversary of this offering occurs. However, if certain
events occur prior to the end of such period, including if we become a &#8220;large accelerated filer&#8221; under rules of the Securities and Exchange Commission, or the SEC, our annual gross revenue exceeds $1.235&nbsp;billion, or we issue more
than $1&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt in any three-year period, we will cease to be an emerging growth company prior to the end of such period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have elected to take advantage of certain of the reduced disclosure obligations in the registration statement of which this prospectus is a part and
may elect to take advantage of other reduced reporting requirements in future filings. In particular, we have provided only two years of audited financial statements and have not included all of the executive compensation-related
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
information that would be required if we were not an emerging growth company. As a result, the information that we provide to our stockholders may be different than what you might receive from
other public reporting companies in which you hold equity interests. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. We
have elected not to &#8220;opt out&#8221; of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we can adopt the new or revised standard at
the time private companies adopt the new or revised standard and may do so until such time that we either (1)&nbsp;irrevocably elect to &#8220;opt out&#8221; of such extended transition period or (2)&nbsp;no longer qualify as an emerging growth
company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are also a &#8220;smaller reporting company&#8221; as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act.
We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies until the fiscal year following the
determination that (1)&nbsp;our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is $250&nbsp;million or more, measured on the last business day of our second fiscal quarter, or (2)&nbsp;our annual revenues are
$100&nbsp;million or more, during the most recently completed fiscal year and our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is $700&nbsp;million or more, measured on the last business day of our second fiscal
quarter. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>THE OFFERING </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Common stock offered by us </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="52%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"><FONT STYLE="font-size:8pt">&nbsp;</FONT>&#8195;&#8195;&#8195;shares. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Option to purchase additional shares of common stock </P></TD>
<TD>We have granted the underwriters an option for a period of 30 days to purchase up to &#8195;&#8195;&#8195; additional shares of our common stock at the initial public offering price, less the underwriting discounts and commissions.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Common stock to be outstanding immediately following this offering </P></TD>
<TD>&#8195;&#8195;&#8195;shares (or &#8195;&#8195;&#8195;shares if the underwriters exercise their option to purchase additional shares of common stock in full). </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Use of proceeds </P></TD>
<TD>We estimate that the net proceeds to us from this offering will be approximately $&#8195;&#8195;&#8195; million (or approximately $&#8195;&#8195;&#8195; million if the underwriters exercise their option to purchase additional shares in full),
based on an assumed initial public offering price of $&#8195;&#8195;&#8195; per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated
offering expenses payable by us. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="52%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We intend to use the net proceeds to us from this offering, together with our existing cash, cash equivalents, and marketable securities, to fund clinical development of sutacimig for the treatment of Glanzmann
thrombasthenia and Factor VII deficiency and <FONT STYLE="white-space:nowrap">HMB-002</FONT> for the treatment of Von Willebrand Disease; additional discovery, preclinical, and clinical activities for current and future programs; and the remainder
for working capital and other general corporate purposes. See &#8220;Use of Proceeds.&#8221; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Risk factors </P></TD>
<TD>You should read the &#8220;Risk Factors&#8221; section of this prospectus for a discussion of factors to consider carefully before deciding to invest in our common stock. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Proposed Nasdaq Global Select Market symbol </P></TD>
<TD>&#8220;COAG&#8221; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The number of shares of our common stock to be outstanding immediately following this offering is based on
1,247,405 shares of our common stock outstanding as of March&nbsp;31, 2026, after giving </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
effect to the automatic conversion of 1,204,405&nbsp;shares of our preferred stock into an aggregate of 1,204,405 shares of common stock upon the completion of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The number of shares of our common stock to be outstanding immediately following this offering excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">198,761 shares of common stock issuable upon exercise of warrants outstanding as of March&nbsp;31, 2026 with a
weighted-average exercise price of $128.42 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#8195;&#8195;&#8195; shares of our common stock that will become available for future issuance under our 2026 Equity
Incentive Plan, or the 2026 Plan, which will become effective immediately prior to the effectiveness of the registration statement of which this prospectus is a part, as well as any automatic increases in the number of shares of common stock
reserved for future issuance under the 2026 Plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#8195;&#8195;&#8195;shares of our common stock that will become available for future issuance under our 2026 Employee
Stock Purchase Plan, or the 2026 ESPP, which will become effective immediately prior to the effectiveness of the registration statement of which this prospectus is a part, as well as any automatic increases in the number of shares of common stock
reserved for future issuance under the 2026 ESPP. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Unless otherwise indicated, all information in this prospectus reflects and
assumes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the consummation of the transactions described under the section titled &#8220;<I>Corporate</I>
<I>Reorganization</I>&#8221;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">no issuance or exercise of outstanding warrants after &#8195;&#8195;&#8195;&#8195;; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">no exercise by the underwriters of their option to purchase additional shares of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the automatic conversion of all outstanding shares of our preferred stock into an aggregate of 1,204,405 shares of our
common stock upon the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a &#8195;&#8195;&#8195;&#8195; <FONT STYLE="white-space:nowrap">-for-&#8195;&#8195;&#8195;&#8195;stock</FONT> split of our
common stock, which will become effective prior to the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the filing and effectiveness of our restated certificate of incorporation and the adoption of our amended and restated
bylaws immediately prior to the completion of this offering. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>SUMMARY CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>The following tables set forth our summary consolidated financial data for the years ended December&nbsp;31, 2024 and 2025. We have derived the summary statement of
operations and comprehensive loss data for the years ended December&nbsp;31, 2024 and 2025 and the balance sheet data from our consolidated financial statements included elsewhere in this prospectus. Our consolidated financial statements have been
prepared in accordance with U.S. generally accepted accounting principles, or GAAP. Our historical results are not necessarily indicative of the results that may be expected for any period in the future. You should read the following summary
financial data together with the &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; section of this prospectus and our consolidated financial statements and the related notes included elsewhere
in this prospectus. The summary consolidated financial data included in this section are not intended to replace the consolidated financial statements and are qualified in their entirety by our consolidated financial statements and the related notes
included elsewhere in this prospectus. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024 </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands, except<BR>share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Statements of Operations and Comprehensive Loss Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating Expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,383</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70,119</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income (expense), net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss before income tax (expense) benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,522</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,140</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Income tax (expense) benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(48,707</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(63,913</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share, basic and diluted(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,132.72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,486.35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average shares outstanding, basic and diluted(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other comprehensive income (loss):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net unrealized (loss) gain on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(50,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(63,373</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net loss per share, basic and diluted(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(51.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma weighted-average shares outstanding, basic and diluted(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,247,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">See Note 2 and Note 14 to our consolidated financial statements included elsewhere in this prospectus for an explanation
of the calculations of our net loss per share, basic and diluted, and the weighted-average number of shares used in the computation of <FONT STYLE="white-space:nowrap">per-share</FONT> amounts. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The unaudited pro forma net loss per share, basic and diluted, for the year ended December&nbsp;31, 2025 has been
prepared to give effect to (1)&nbsp;the corporate reorganization, as if the corporate </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
reorganization had occurred on the first day of the period presented, including the exchange by existing shareholders of their shares in Hemab ApS for the same number, classes and series of newly
issued shares in Hemab Therapeutics Holdings, Inc. and the assumption and conversion of each outstanding warrant to subscribe for the purchase of ordinary shares of Hemab ApS into a warrant to purchase the same number of shares of our common stock,
and (2)&nbsp;the automatic conversion of all outstanding shares of convertible preferred stock into shares of common stock, which conversion will occur upon the completion of this offering, as if such conversion had occurred on the first day of the
period presented. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro</B><br><B>Forma(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma&nbsp;As<BR>Adjusted(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands, except for share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash, cash equivalents and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">185,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">185,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Working capital(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">181,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">181,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Convertible preference shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">360,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">365,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(181,858</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(181,858</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stockholders&#8217; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(176,635</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The pro forma consolidated balance sheet data gives effect to (1)&nbsp;the corporate reorganization, as if the corporate
reorganization had occurred as of December 31, 2025, including the exchange by existing shareholders of their shares in Hemab ApS for the same number, classes and series of newly issued shares in Hemab Therapeutics Holdings, Inc. and the assumption
and conversion of each outstanding warrant to subscribe for the purchase of ordinary shares of Hemab ApS into a warrant to purchase the same number of shares of our common stock, (2)&nbsp;the automatic conversion of all outstanding shares of
convertible preferred stock into shares of common stock, which conversion will occur upon the completion of this offering, and (3)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation, which will occur
immediately prior to the effectiveness of the registration statement of which this prospectus forms a part. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The pro forma as adjusted balance sheet data give effect to (i) the pro forma adjustments set forth in footnote (1) above
and (ii) the issuance and sale of &#8195;&#8195;&#8195;&#8195;shares of our common stock in this offering at an assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share, the midpoint of the price range set forth on the cover
page of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">We define working capital as current assets less current liabilities. See our consolidated financial statements and the
related notes included elsewhere in this prospectus for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The
pro forma as adjusted information discussed above is illustrative only and will change based on the actual initial public offering price and other terms of this offering determined at pricing. Each $1.00 increase (decrease) in the assumed initial
public offering price of $&#8195;&#8195;&#8195; per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) our pro forma as adjusted amount of each of our cash, cash equivalents, and
marketable securities, working capital, total assets and total stockholders&#8217; (deficit) equity by approximately $&#8195;&#8195;&#8195;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus,
remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase (decrease) the number of shares </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
we are offering. A 1.0&nbsp;million share increase (decrease) in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the pro forma
adjusted amount of each of our cash, cash equivalents, and marketable securities, working capital, total assets and total stockholders&#8217; (deficit) equity by approximately $&#8195;&#8195; , assuming the assumed initial public offering price per
share remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below together with
all of the other information contained in this prospectus, including our consolidated financial statements and the related notes appearing at the end of this prospectus, before deciding to invest in our common stock. The risks described below are
not the only risks facing our company. The occurrence of any of the following risks, or of additional risks and uncertainties not presently known to us or that we currently believe to be immaterial, could cause our business, prospects, operating
results and financial condition to suffer materially. In such an event, the trading price of our common stock could decline, and you might lose all or part of your investment.</I> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Financial Position, Need for Additional Capital and Limited Operating History </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are a clinical-stage biopharmaceutical company, have no products approved for sale and have incurred significant losses since our inception. We expect to incur
significant losses for the foreseeable future and may never achieve or maintain profitability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are a clinical-stage biopharmaceutical
company with a limited operating history. Since our inception, we have devoted substantially all of our financial resources and efforts to research and development, including clinical trials and preclinical studies of our product candidates,
sutacimig and <FONT STYLE="white-space:nowrap">HMB-002,</FONT> and have incurred significant operating losses. Our net losses were $48.7&nbsp;million and $63.9&nbsp;million for the years ended December&nbsp;31, 2024 and 2025, respectively. As of
December&nbsp;31, 2025, we had an accumulated deficit of $181.9&nbsp;million. We have no approved products, and we have not generated any revenue from product sales. We have financed our operations primarily through private placements of convertible
preference shares, including our Series C financing, which we completed in October 2025, for aggregate gross proceeds of $156.9&nbsp;million, and issuances of convertible debt. We are still continuing to research and develop our product candidates,
and we have not yet completed the development of any of our product candidates. We expect to continue to incur significant operating expenses and net losses for the foreseeable future. Our operating expenses and net losses may fluctuate
significantly from quarter to quarter and year to year. Accordingly, you should not rely upon the results of any particular quarterly or annual period as indications of future operating performance. Because of the numerous risks and uncertainties
associated with developing pharmaceutical products, we are unable to predict the extent of any future losses or when we will become profitable, if at all. Even if we become profitable, we may not be able to sustain or increase our profitability on a
quarterly or annual basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We anticipate that our expenses will increase substantially, if and as, we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">continue to advance the clinical development of our product candidates, including our ongoing Phase 1/2 clinical trial of
sutacimig in patients with Glanzmann thrombasthenia, our ongoing Phase 2 clinical trial of sutacimig in patients with Factor VII deficiency, and our ongoing Phase 1/2 clinical trial of <FONT STYLE="white-space:nowrap">HMB-002</FONT> in patients with
Von Willebrand Disease, as well as any other product candidates that we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">advance our clinical-stage product candidates into later-stage clinical trials, including our planned Phase 3 clinical
trial of sutacimig in patients with Glanzmann thrombasthenia, which will be required in order to seek marketing approval of our product candidates, and which we expect will be substantially more expensive than our earlier-stage clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">continue to advance our research and preclinical activities and seek to discover and develop additional product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establish and <FONT STYLE="white-space:nowrap">scale-up</FONT> manufacturing processes and capabilities, or arrange for a
third party to do so on our behalf, to support our clinical trials of our product candidates and commercialization of any of our product candidates for which we obtain marketing approval; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">seek regulatory and marketing approvals for any of our product candidates that successfully complete clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">ultimately establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any products for
which we may obtain marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">continue to develop, maintain, expand and protect our intellectual property portfolio (including intellectual property
obtained through license agreements) and provide reimbursement of third-party expenses related to our patent portfolio; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> products, product candidates or technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establish or maintain collaborations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">maintain, expand, enforce, defend and protect our intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">hire additional clinical, medical, regulatory, quality control, manufacturing and other scientific and technical personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">add operational, financial, clinical, quality and management information systems and personnel, including personnel to
support our product development and planned future commercialization efforts of our product candidates and our operations as a public company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">incur additional audit, legal, regulatory, tax and other expenses with being a public company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">make any milestone, royalty, or other payments to Novo Nordisk A/S, or Novo Nordisk, under our license agreement with Novo
Nordisk, or the Novo Nordisk Agreement, and to Genmab A/S, or Genmab, under our license agreement with Genmab, or the Genmab Agreement, and under any additional future collaboration or license agreements that we may enter into.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL">In addition, our expenses will further increase if, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we are required by the U.S. Food and Drug Administration, or the FDA, the European Medicines Agency, or the EMA, or other
regulatory authorities to perform clinical trials or preclinical studies that are in addition to, or different than, those expected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">there are any delays in completing our clinical trials or preclinical studies or the development of any of our product
candidates; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">there are any third-party challenges to our intellectual property or we need to defend against any intellectual
property-related claim. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if we obtain marketing approval for, and are successful in commercializing, one or more of our
product candidates, we expect to incur substantial additional research and development and other expenditures to develop and market additional product candidates and/or to expand the approved indications of any marketed product. We may encounter
unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to
generate revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have never generated revenue from product sales and may never achieve or maintain profitability. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect that it will be several years before we have a product candidate ready for commercialization, if ever. To become and remain profitable, we must
succeed in developing, obtaining the necessary marketing approvals and eventually commercializing, a product or products that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
generate significant revenue. The ability to achieve this success will require us to be effective in a range of challenging activities, including completing preclinical testing and clinical
trials of our product candidates and any other product candidates we may identify and pursue, obtaining marketing approval for these product candidates and manufacturing, marketing and selling any products for which we may obtain marketing approval.
We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. Because of the numerous risks and uncertainties associated with biopharmaceutical product development, we
are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to generate revenue or achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on
a quarterly or annual basis. Our failure to become and remain profitable may have an adverse effect on the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts,
diversify our product candidates, achieve our strategic objectives or even continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if we are able to generate revenue from the sale of any approved products, we may not become profitable and may need to obtain additional funding
to continue operations. Our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain marketing approval, the accepted price for the product, the ability to obtain coverage and reimbursement, and whether
we own the commercial rights for that territory. If the number of our addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect, or the treatment population is narrowed by
competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We will need
substantial additional funding. If we are unable to raise capital on acceptable terms when needed, or at all, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our operations have consumed substantial amounts of cash since inception. Identifying potential product candidates and conducting preclinical testing and
clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approvals and achieve product sales. We expect to devote
substantial financial resources to our ongoing and planned activities, particularly as we commence our planned Phase 3 clinical trial of sutacimig in patients with Glanzmann thrombasthenia and continue our ongoing Phase 1/2 clinical trial of
sutacimig in patients with Glanzmann thrombasthenia, Phase 2 clinical trial of sutacimig in patients with Factor VII deficiency and Phase 1/2 trial of <FONT STYLE="white-space:nowrap">HMB-002</FONT> in patients with Von Willebrand Disease, continue
research and development and initiate additional clinical trials of, and seek marketing approval for, these and other product candidates. We expect our expenses to increase substantially in connection with our ongoing and planned activities,
particularly as we advance our preclinical activities and clinical trials of and potentially seek marketing approval for our product candidates and other product candidates we may identify, and if and as we expand our research and development and <FONT
STYLE="white-space:nowrap">scale-up</FONT> and manufacture our product candidates for our current and future indications. We will be required to incur substantial costs and may experience delays in completing, or ultimately be unable to complete,
the development and commercialization of any product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, if we obtain marketing approval for our product candidates and any
other product candidates we may identify and pursue, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution. Furthermore, upon the completion of this offering, we expect to incur
additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding to support our continuing operations and pursue our growth strategy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Identifying potential product candidates and conducting preclinical testing and clinical trials is a
time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, any product candidates, if approved,
may not achieve commercial success. We will not generate commercial revenues, if any, unless and until we, alone or with partners, can achieve sales of products, which we do not anticipate will occur for many years, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2025, we had cash, cash equivalents and marketable securities of $185.5&nbsp;million. We believe that our existing cash, cash
equivalents and marketable securities, together with the anticipated net proceeds from this offering, will enable us to fund our operating expenses and capital expenditure requirements into &#8195;&#8195;&#8195;&#8195;. However, we have based this
estimate on assumptions that may prove to be wrong, and our operating plan may change as a result of many factors currently unknown to us. As a result, we could deplete our capital resources sooner than we currently expect and could be forced to
seek additional funding sooner than planned. We would be required to obtain substantial additional funding in order to initiate and conduct registrational and other clinical trials for our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We currently do not have a credit facility or any committed sources of capital. If we are unable to raise capital or obtain adequate funds when needed
or on acceptable terms, we may be forced to delay, limit, reduce or terminate our research and development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to
develop and market ourselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL">Our future capital requirements will depend on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the scope, progress, costs and results of our current and future preclinical studies and clinical trials for our product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of clinical trials required for regulatory approval of our current or future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">whether we partner our programs with collaborators for later-stage clinical development or commercialization;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number and development requirements of any other product candidates we may identify and develop; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs, timing and outcome of regulatory review of our product candidates and any other product candidates we may
identify and develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs of obtaining clinical and commercial supplies of our product candidates and any other product candidates we may
identify and develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to successfully commercialize our product candidates and any other product candidates we may identify and
develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the manufacturing, selling and marketing costs associated with our product candidates and any other product candidates we
may identify and develop, including the cost and timing of establishing sales and marketing capabilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the scope, progress, costs and results of any post-marketing studies that could be required by regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the amount and timing of sales and other revenues from our product candidates and any other product candidates we may
identify and develop, including the sales price and the availability of coverage and adequate third-party reimbursement; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the time and cost necessary to respond to technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the extent to which we may acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of
such arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">milestone payments and other collaboration-based payments, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to attract, hire and retain qualified personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate
reimbursement from third-party and government payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the effect of macroeconomic trends including inflation, foreign exchange rate, interest rates and tariffs; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining, enforcing and protecting our
intellectual property and proprietary rights and defending any intellectual property-related claims. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any additional fundraising
efforts may divert our management from their <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to develop and commercialize any product candidates.
Additionally, volatility in the financial markets and general economic conditions may be a significant obstacle to raising the required funds. We cannot be certain that adequate additional financing will be available to us on acceptable terms, or at
all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. If adequate funds are not available to us on a
timely basis or on terms acceptable to us, we may be required to delay, limit, reduce or terminate preclinical studies, clinical trials or other development activities for one or more product candidates or discovery stage programs or delay, limit,
reduce or terminate our establishment of sales and marketing capabilities or other activities that may be necessary to commercialize any product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Raising additional capital may cause dilution to our stockholders, including purchasers of our common stock in this offering, restrict our operations or require
us to relinquish rights to our technologies or product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Until such time, if ever, as we can generate substantial product
revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, royalty financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. We do not have any source of
committed capital or external funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or
other preferences that adversely affect your rights as a stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as
incurring additional debt, selling or licensing our assets, making capital expenditures, declaring dividends or encumbering our assets to secure future indebtedness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we raise additional funds through partnerships, collaborations, strategic alliances or marketing, distribution or licensing arrangements with third
parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when
needed or on terms acceptable to us, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to
develop and market ourselves. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our limited operating history may make it difficult for you to evaluate the success of our business to date and
to assess our future viability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We commenced operations in 2020 and are a clinical-stage biotechnology company. Our operations to date have
been limited to organizing and staffing our company, business planning, raising capital, securing intellectual property rights, <FONT STYLE="white-space:nowrap">in-licensing</FONT> technology, discovering product candidates, undertaking preclinical
studies and conducting clinical trials. While we are in the process of conducting Phase 1/2 and Phase 2 trials, we have not yet initiated or completed a Phase 3 clinical trial of any product candidate. We have not yet demonstrated our ability to
successfully develop any product candidate, obtain marketing approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product
commercialization. Therefore, we cannot be certain that our ongoing preclinical studies and clinical trials will be completed on time or that our planned preclinical studies and clinical trials will begin or be completed on time, if at all. Further,
biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. You should consider our prospects in light of the costs, uncertainties, delays, and difficulties frequently encountered by companies
in clinical development, especially clinical-stage biopharmaceutical companies such as ours. Any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of
successfully developing and commercializing products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, as our business grows, we may encounter unforeseen expenses, difficulties,
restrictions, complications, delays and other known and unknown factors. We will need to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful
in such a transition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect our financial condition and operating results to fluctuate significantly from quarter to quarter and year to year
due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our future ability to use our net operating losses and research and development tax credit carryforwards to offset future taxable income may be subject to certain
limitations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2025, we had $170.9&nbsp;million of net operating losses, or NOLs. Our anticipated activities are also
expected to result in future significant NOLs in Denmark and the United States resulting in additional deferred tax assets. Utilization of most deferred tax assets is dependent on generating sufficient future taxable income in the appropriate
jurisdiction and/or entity. We have recorded a full valuation allowance on our net deferred tax assets as of December&nbsp;31, 2025, based on all available evidence, it is considered more likely than not that all the recorded deferred tax assets
will not be realized in a future period. Additionally, most of our deferred tax assets are determined by reference to applicable corporate income tax rates in Denmark. Accordingly, in the event of a reduction of any such corporate income tax rates,
the carrying value of certain of our deferred tax assets would decrease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, our ability to use our NOLs and other deferred tax assets to
offset future taxable income in Denmark and the United States may be limited if we experience an ownership change. For Danish income tax purposes, an ownership change will generally occur when one, or several shareholders together, at once or
successively, acquire shares representing more than 50% of the share capital or voting power. Although such an ownership change entails no reduction of the amount of NOLs to be carried forward, the utilization is restricted to exclude offsetting
against positive net capital income (e.g. income from interest, dividend and royalty) on NOLs incurred in a previous income year, where the ownership has changed by more than by 50% (under section 12D of the Danish
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Corporate Tax Act). In the United States, in general, under Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, a corporation that
undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period, is subject to limitations on its ability to utilize its <FONT
STYLE="white-space:nowrap">pre-change</FONT> NOLs and research and development tax credit carryforwards to offset future taxable income. We have not conducted a study to assess whether any such ownership changes have occurred. We may have
experienced such ownership changes in the past and may experience such ownership changes in the future as a result of this offering and/or subsequent changes in our stock ownership (which may be outside our control). As a result, if, and to the
extent that, we earn net taxable income, our ability to use our <FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs and research and development tax credit carryforwards to offset such taxable income may be subject to limitations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs, or other unforeseen reasons, our existing NOLs could expire
or otherwise become unavailable to offset future income tax liabilities. Additionally, in the United States, state NOLs generated in one state cannot be used to offset income generated in another state. For these reasons, even if we attain
profitability, we may be unable to use a material portion of our NOLs and other tax attributes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The tax authorities in the jurisdictions in which we operate
may challenge our transfer pricing procedures. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are a multinational business that has operations in Denmark and other tax jurisdictions,
and the tax laws of those jurisdictions generally require that royalty and other payments between affiliated companies in different jurisdictions be the same as those between unrelated companies dealing at arm&#8217;s length, and that such prices
are supported by contemporaneous documentation. While we believe that we operate in compliance with applicable transfer pricing laws and intend to continue to do so, our transfer pricing procedures are not binding on applicable tax authorities. If
tax authorities in any of these jurisdictions were to successfully challenge our transfer prices as not reflecting arm&#8217;s length transactions, they could require us to adjust our transfer prices and thereby reallocate our income or deductions
to reflect these revised transfer prices, which could result in a higher overall tax liability to us and possibly interest and penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, tax authorities in the jurisdictions in which we operate may challenge our treatment of our corporate reorganization. No assets (either
physical or intangible) were transferred from Denmark to the United States pursuant to our corporate reorganization, nor were any existing business functions or units operating from Denmark transferred from Hemab ApS to Hemab Therapeutics Holdings,
Inc. as part of our corporate reorganization to form part of our U.S. operations. Accordingly, we have not treated and do not intend to treat our corporate reorganization as a deemed sale of all or part of our business by Hemab ApS to Hemab
Therapeutics Holdings, Inc. If Danish tax authorities were to disagree with our position and treat our corporate reorganization or any of our activities thereafter as a deemed sale, in whole or in part, of intellectual property rights and/or other
assets owned by Hemab ApS to Hemab Therapeutics Holdings, Inc., we could be subject to a Danish tax, the current rate of which is 22%, on the gain realized calculated as the difference between the fair market value and the tax value of the assets,
at the time of the deemed sale of the assets from Denmark as determined by the Danish tax authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Finally, the nature of our operations can
produce conflicting claims from tax authorities in different countries as to the profits to be taxed in the individual countries. The jurisdictions in which we operate have double tax treaties with other jurisdictions, which provide a framework for
mitigating the impact of double taxation on our revenues and capital gains. However, mechanisms developed to resolve such conflicting claims are largely untested, can be expected to be very lengthy, and do not always contain a mandatory dispute
resolution clause. In recent years, tax authorities around the world have increased their scrutiny of company tax filings and have become more rigid in exercising any discretion they may have. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In general, tax reform efforts, including with respect to transfer pricing, will require us to
continually assess our organizational structure and could lead to an increased risk of international tax disputes, an increase in our effective tax rate and an adverse effect on our financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to the Discovery, Development and Commercialization of Our Product Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are heavily dependent on the success of sutacimig and <FONT STYLE="white-space:nowrap">HMB-002,</FONT> which are our only clinical-stage product candidates.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We currently have no products that are approved for commercial sale and may never be able to develop marketable products. We expect that a
substantial portion of our efforts and expenditures over the next several years will be devoted to sutacimig and <FONT STYLE="white-space:nowrap">HMB-002,</FONT> which are currently our only clinical-stage product candidates. Accordingly, our
business currently depends heavily on the successful development, marketing approval and commercialization of these product candidates. We cannot be certain that sutacimig or <FONT STYLE="white-space:nowrap">HMB-002</FONT> will receive marketing
approval, be approved for the indications that we may seek or be successfully commercialized even if we receive marketing approvals. If we were required to discontinue development of sutacimig or <FONT STYLE="white-space:nowrap">HMB-002,</FONT> or
if any of these product candidates do not receive marketing approvals or fail to achieve significant market acceptance, we would be delayed by many years in our ability to achieve profitability, if ever, and may not be able to generate sufficient
revenue to continue our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we are unable to successfully complete clinical development, obtain marketing approval for, and ultimately commercialize
our product candidates, or experience significant delays in doing so, our business will be materially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To date, we have invested a
majority of our efforts and financial resources in the preclinical and clinical development of our product candidates, including our ongoing Phase 1/2 clinical trial of sutacimig in patients Glanzmann thrombasthenia, Phase 2 clinical trial of
sutacimig in patients with Factor VII deficiency and our ongoing Phase 1/2 clinical trial of <FONT STYLE="white-space:nowrap">HMB-002</FONT> in patients with Von Willebrand Disease. We have not yet initiated a Phase 3 trial of any product candidate.
Our future success is heavily dependent on our ability to successfully develop, obtain marketing approval for and ultimately commercialize our product candidates. We cannot be certain that our product candidates will be successful in clinical trials
or receive marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The success of our product candidates will depend on several factors, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">successfully completing clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">acceptance by the FDA or other regulatory agencies of regulatory filings for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">expanding and maintaining a workforce of experienced scientists and others to continue to develop our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">obtaining and maintaining intellectual property protection and regulatory exclusivity for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">making arrangements with third-party manufacturers for, or establishing, commercial manufacturing capabilities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establishing sales, marketing and distribution capabilities and successfully launching commercial sales, if and when
approved, whether alone or in collaboration with others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">acceptance of the products, if and when approved, by patients, the medical community and third-party payors;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">further chemistry, manufacturing and controls, manufacturing or development and optimization of the formulation and
presentation of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">effectively competing or successfully being administered with other approved therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">obtaining and maintaining coverage, adequate pricing and adequate reimbursement from third-party payors, including
government payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">patients&#8217; willingness to pay out of pocket for our products in the absence of coverage and/or adequate reimbursement
from third-party payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">maintaining, enforcing, defending and protecting our rights in our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">not infringing, misappropriating or otherwise violating others&#8217; intellectual property or proprietary rights; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">maintaining a continued acceptable safety and tolerability profile following receipt of any marketing approvals.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Although we are planning to conduct a multinational, multicenter, Phase 3, single-arm, open-label clinical trial evaluating
sutacimig as a prophylactic therapy in adults with Glanzmann thrombasthenia, the FDA may determine that a randomized controlled clinical trial is necessary to support filing and approval of our Biologics License Application, or BLA. We intend to
schedule a Type D meeting with the FDA in the coming months to obtain the FDA&#8217;s feedback on, and seek alignment regarding, our proposed Phase 3 trial design. A Type D meeting is intended to facilitate focused discussion on a limited number of
specific issues, but there can be no assurance that the FDA will agree with our proposed approach. If the FDA requires us to conduct a randomized controlled Phase 3 clinical trial, we could incur additional costs and delays, to the extent any such
trial is more complex, time-consuming and/or expensive to design, initiate and complete. A randomized trial may require a larger number of patients, longer enrollment and follow-up periods, and additional clinical sites, which could delay the timing
of any regulatory submission and potential approval. In addition, the use of a control arm may introduce ethical, operational and recruitment challenges, particularly if patients or investigators are reluctant to participate in a study where
treatment assignment is randomized. There is also a risk that a randomized trial could fail to meet its primary or secondary endpoints, even if a single-arm study might have demonstrated favorable results, which could materially and adversely affect
our ability to obtain regulatory review and approval and commercialize our product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Many of these factors are beyond our control,
including clinical outcomes, the regulatory review process, potential threats to our intellectual property rights and the manufacturing, marketing and sales efforts of any future collaborators. If we are unable to develop, receive marketing approval
for and successfully commercialize our product candidates, or if we experience delays as a result of any of these factors or otherwise, we may need to spend significant additional time and resources to identify other product candidates, advance them
through preclinical and clinical development, and apply for marketing approvals, which would adversely affect our business, prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We will be required to incur substantial costs and may experience
delays in completing, or ultimately be unable to complete, the development and commercialization of any product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The risk of
failure for our product candidates and any other product candidates we may develop is high. It is impossible to predict when or if our product candidates and any other product candidates we may develop will prove effective or safe in humans or will
receive marketing approval. The time required to obtain approval from the FDA, EMA or other comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of clinical trials and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
depends upon numerous factors, including the substantial discretion of regulatory authorities. Before obtaining marketing approval from regulatory authorities for the sale of any product
candidate, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of such product candidate in humans. We have not yet initiated a pivotal clinical trial for any of our product
candidates. Clinical trials may fail to demonstrate that our current or future product candidates are safe for humans and effective for indicated uses. Even if initial clinical trials in any of our product candidates we may develop are successful,
these product candidates may fail to show the desired safety and efficacy in later stages of clinical development despite having successfully advanced through preclinical studies and initial clinical trials. There is a high failure rate for drugs
proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in later-stage clinical trials even after achieving promising results in earlier-stage clinical trials.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Furthermore, clinical trials for blood disorders present unique challenges: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The small patient populations in the indications we are pursuing, such as Glanzmann thrombasthenia and Factor VII
deficiency (which we estimate to be approximately 10,000 patients in the aggregate in the geographies where we intend to commercialize sutacimig, including the United States, the European Union, Japan, the Gulf Cooperation Council, or GCC, countries
and other select regions), may make it challenging to enroll a sufficient number of patients in our clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The variability in bleeding phenotypes and disease severity in these conditions can make it difficult to demonstrate
statistical significance in clinical endpoints. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The lack of validated biomarkers and endpoints in blood disorders requires us to develop novel endpoints, which may not be
accepted by regulatory authorities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Patients with coagulation disorders may be geographically dispersed, requiring multi-national clinical trials with
associated regulatory complexity. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Recruitment of patients for our clinical trials may be slower than anticipated due to the low prevalence of these
conditions, competition for patients from other clinical trials and the burden of our clinical trials on patients, including due to the duration of our clinical trials, the need for a higher degree of oversight by principal investigators, and the
requirement of patient adherence to strict electronic bleed diary protocol requirements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The potential that rare and severe side effects of our product candidates may be uncovered in the later stages of clinical
development due to accelerated development, which could result in disruptions and delays or a need for increased sample sizes for our clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">As with most procoagulant drugs, our product candidates have the potential for adverse effects, including thrombotic
events, which can occur at any active dose level due to sporadic or patient-specific factors that are hard to identify. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The patient populations in coagulation disorders are not as accustomed to participation in clinical trials, as in other
indications, which may impact the ability to recruit and maintain patients in our clinical trials. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if the clinical trials
are successful, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or guidance or changes in regulatory review for each submitted product application
may cause delays in the approval or rejection of an application. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Before we can commence clinical trials for a product candidate, we must complete extensive preclinical
testing and studies that support investigational new drug applications, or INDs, and other regulatory filings in the United States, marketing applications in the European Union and other applications and filings in other jurisdictions. We cannot be
certain of the timely completion or outcome of preclinical testing and studies and cannot predict if the FDA or other regulatory agencies will accept any proposed clinical programs or if the outcome of any preclinical testing and studies will
ultimately support the further development of any product candidates. As a result, we cannot be sure that we will be able to submit INDs or similar applications for any preclinical programs on the timelines we expect, if at all, and we cannot be
sure that submission of INDs or similar applications will result in the FDA or other regulatory authorities allowing clinical trials to begin. Furthermore, product candidates are subject to continued preclinical safety studies, which may be
conducted concurrently with clinical testing. The outcomes of these safety studies may delay the launch of, or enrollment in, future clinical trials and could impact our ability to continue to conduct our clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Clinical testing is expensive and is difficult to design and implement, can take many years to complete, and is uncertain as to outcome. We cannot
guarantee that any of our clinical trials will be conducted as planned or completed on schedule, or at all. A failure of one or more clinical trials can occur at any stage of testing, which may result from a multitude of factors, including, but not
limited to, flaws in study design, dose selection issues, placebo effects, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product
candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. Furthermore, the failure of any of our product candidates to demonstrate safety and efficacy in
any clinical trial could negatively impact the perception of our other product candidates and/or cause the FDA, EMA or other regulatory authorities to require additional testing before approving any of our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product
candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability
to receive marketing approval or commercialize our product candidates and any other product candidates we may develop, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulators or institutional review boards, or IRBs, or independent ethics committees may not authorize us or our
investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial
protocols with prospective trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulators may decide that longer <FONT STYLE="white-space:nowrap">follow-up</FONT> data are needed before they will
consider our marketing applications, which would delay our ability to obtain marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulators may decide the design of our clinical trials is flawed, for example, if our trial protocol does not evaluate
treatment effects in trial subjects for a sufficient length of time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">clinical trials of our product candidates and any other product candidates we may develop may produce negative or
inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may be unable to establish clinical endpoints that applicable regulatory authorities would consider clinically
meaningful, or, if we seek accelerated approval, biomarker efficacy endpoints that applicable regulatory authorities would consider likely to predict clinical benefit; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">preclinical testing may produce results based on which we may decide, or regulators may require us, to conduct additional
preclinical studies before we proceed with certain clinical trials, limit the scope of our clinical trials, halt ongoing clinical trials or abandon product development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of patients required for clinical trials of our product candidates and any other product candidates we may
develop may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, or participants may drop out of these clinical trials at a higher rate than we anticipate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in
a timely manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may decide, or regulators or IRBs may require us, to suspend or terminate clinical trials of our product candidates and
any other product candidates we may develop for various reasons, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulators may require us to perform additional or unanticipated clinical trials to obtain approval or we may be subject to
additional post-marketing testing requirements to maintain marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulators may revise the requirements for approving our product candidates and any other product candidates we may
develop, or such requirements may not be as we anticipate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the cost of clinical trials of our product candidates and any other product candidates we may develop may be greater than
we anticipate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the supply or quality of our product candidates and any other product candidates we may develop or other materials
necessary to conduct clinical trials of such product candidates may be insufficient or inadequate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our product candidates and any other product candidates we may develop may have undesirable side effects or other
unexpected characteristics, causing us or our investigators, regulators or IRBs or ethics committees to suspend or terminate the trials; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulators may withdraw their approval of a product or impose restrictions on its distribution, such as in the form of a
risk evaluation and mitigation strategy, or REMS. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We could encounter delays if a clinical trial is suspended or terminated by us,
by the IRBs of the institutions in which such trials are conducted or their ethics committees, by the data review committee or data safety monitoring board for such trial or by the FDA, EMA or other foreign regulatory authorities. Such authorities
may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by
the FDA, EMA or other foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, including those relating to the class of products to which our product candidates belong. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we
are unable to successfully complete clinical trials or other testing of our product candidates or any other product candidates we may develop, if the results of these trials or tests are not positive or are only modestly positive, or if there are
safety concerns, we may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">be delayed in obtaining marketing approval for any product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">not obtain marketing approval at all; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">obtain approval for indications or patient populations that are not as broad as intended or desired; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">obtain approval with labeling or a REMS that includes significant use or distribution restrictions or safety warnings;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">be subject to additional post-marketing testing requirements; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">have the product removed from the market after obtaining marketing approval. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our product development costs will also increase if we experience delays in preclinical studies or clinical trials or in obtaining marketing approvals.
We do not know whether any of our preclinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. We may also determine to change the design or protocol of one or more of our
clinical trials, including to add additional patients or arms, which could result in increased costs and expenses and/or delays. Significant preclinical study or clinical trial delays also could shorten any periods during which we may have the
exclusive right to commercialize any product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize any product candidates and may harm our business and results of
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The outcome of preclinical studies and earlier-stage clinical trials may not be predictive of the success of later-stage clinical trials.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The outcome of preclinical testing and earlier-stage clinical trials may not be predictive of the success of later-stage clinical trials.
Our product candidates and any other product candidates we may develop may fail to show the desired safety, potency and purity in clinical development despite positive results in preclinical studies or having successfully advanced through initial
clinical trials. For example, we are currently planning our Phase 3 clinical trial of sutacimig in patients with Glanzmann thrombasthenia, based off the positive results of our Phase 1/2 dose-finding study in patients with Glanzmann thrombasthenia.
However, we cannot provide assurances that the evidence of activity we observed in our Phase 1/2 trial of sutacimig will translate to our planned Phase 3 clinical trial. Additionally, any positive results generated in our ongoing and planned
clinical trials do not ensure that we will achieve similar results in later-stage clinical trials of these product candidates, and we cannot provide assurances that we will be able to seek or obtain marketing approval for any of our product
candidates even if our clinical trials are successful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Many companies in the pharmaceutical and biotechnology industries have suffered significant
setbacks in late-stage clinical trials after achieving promising results in preclinical testing and earlier-stage clinical trials, and we cannot be certain that we will not face similar setbacks. In addition, while the animal models used in
preclinical studies are designed to be representative of disease states in humans, these preclinical models may not be able to accurately predict the way a product candidate will affect patients in clinical trials. Moreover, preclinical and clinical
data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing
approval of their products. Furthermore, the failure of any product candidate to demonstrate safety, potency and purity in any clinical trial could negatively impact the perception of any other product candidates we may developing at the time and/or
cause the FDA or other regulatory authorities to require additional testing before approving any other product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Interim, <FONT
STYLE="white-space:nowrap">top-line</FONT> and preliminary results from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures, which
could result in material changes in the final data. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">From time to time, we may publish or report interim,
<FONT STYLE="white-space:nowrap">top-line</FONT> or preliminary results from our clinical trials. For example, we plan to report data for our Phase 2 clinical trial of sutacimig in Factor VII </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
deficiency in late 2026 or early 2027, and data from our Phase 1/2 clinical trial of <FONT STYLE="white-space:nowrap">HMB-002</FONT> in patients with Von Willebrand Disease in late 2026 or early
2027. Interim results from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary, interim or <FONT
STYLE="white-space:nowrap">top-line</FONT> results also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary or interim data we previously published. As a result,
interim, <FONT STYLE="white-space:nowrap">top-line</FONT> and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could be material and could
significantly harm our reputation and business prospects and may cause the trading price of our common stock to fluctuate significantly. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>As an organization,
we have never conducted pivotal clinical trials, and we may be unable to do so for our product candidates or any other product candidates we may develop. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We will need to successfully complete pivotal clinical trials in order to obtain the approval of the FDA, the EMA, or other regulatory agencies to market
our product candidates or any future product candidate. Carrying out later-stage clinical trials is a complicated process. As an organization, we have not previously conducted any pivotal clinical trials. In order to do so, we will need to
significantly expand our clinical development and regulatory capabilities. In addition, we may be unable to recruit and train qualified personnel. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical
trials in a way that leads to approval of our product candidates or future product candidates. We may require more time and incur greater costs than our competitors and may not succeed in obtaining marketing approvals of product candidates that we
develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Due to the complexity, expense, scale and size of clinical trials, we may have to find one or more collaborators to conduct such a trial,
and there can be no assurance that we would be able to do so. Even if we are able to find a collaborator, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant
licenses on terms that may not be favorable to us. See &#8220;&#8212;Risks Related to Our Dependence on Third Parties&#8212;We may enter into collaborations with third parties for the development or commercialization of product candidates. If our
collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates and our business could be adversely affected.&#8221; Failure to commence or complete, or delays in, our planned clinical trials,
could prevent us from or delay us in commercializing our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we do not achieve our projected development and commercialization goals in
the timeframes we announce and expect, the development and commercialization of our product candidates may be delayed, and our business and results of operations may be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For planning purposes, we sometimes estimate the timing of the accomplishment of various scientific, clinical, regulatory and other product development
objectives. These milestones may include our expectations regarding the commencement or completion of scientific studies and clinical trials, the submission of regulatory filings or commercialization objectives. From time to time, we may publicly
announce the expected timing of some of these milestones, such as the completion of an ongoing clinical trial, the initiation of other clinical programs, receipt of marketing approval or a commercial launch of a product. The achievement of many of
these milestones may be outside of our control. All of these milestones are based on a variety of assumptions which, if not realized as expected, may cause the timing of achievement of the milestones to vary considerably from our estimates,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our available capital resources or capital constraints we experience; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the rate of progress, costs and results of our clinical trials and research and development activities, including the
extent of scheduling conflicts with participating clinicians and collaborators; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to identify and enroll patients who meet clinical trial eligibility criteria; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our receipt of approvals by the FDA, EMA, and other comparable regulatory authorities and the timing thereof;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">other actions, decisions or rules issued by regulators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to access sufficient, reliable and affordable supplies of materials used to manufacture our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the efforts of our collaborators with respect to the commercialization of our product candidates; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the securing of, costs related to, and timing issues associated with, product manufacturing as well as sales and marketing
activities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we fail to achieve announced milestones in the timeframes we expect, the development and commercialization of our
product candidates may be delayed, and our business and results of operations may be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we experience delays or difficulties in the enrollment of
patients in clinical trials, our receipt of necessary marketing approvals could be delayed or prevented. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Identifying and qualifying patients
to participate in clinical trials for our product candidates and any other product candidates we may develop is critical to our success. Successful and timely completion of clinical trials will require that we enroll a sufficient number of patients,
as required by the FDA, EMA or similar regulatory authorities in other jurisdictions, who remain in the trial until its conclusion. Additionally, the prevalence of patients in our target indications is estimated to be low, and we estimate that there
are approximately an aggregate of 10,000 patients with Glanzmann thrombasthenia and Factor VII deficiency and an aggregate of 120,000 patients with Von Willebrand Disease in the geographies where we intend to commercialize, including the United
States, the European Union, Japan, the GCC countries and other select regions. We may not be able to identify, recruit, and enroll a sufficient number of patients to complete our clinical trials of our product candidates because of the perceived
risks and benefits of our product candidates, the availability of competing therapies and clinical trials, the proximity and availability of clinical trial sites for prospective subjects and the subject referral practices of physicians, among other
factors. Patient enrollment is affected by a variety of other factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the prevalence and severity of the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the eligibility and the discontinuation criteria for the trial in question; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the perceived risks and benefits of the product candidate under trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the requirements of the trial protocols; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the availability of existing commercially available treatments for the targeted indications; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ability to recruit clinical trial investigators with the appropriate competencies and experience;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">efforts to facilitate timely enrollment in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the patient referral practices of physicians; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ability to monitor patients adequately during and after treatment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the proximity and availability of clinical trial sites for prospective patients; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the conduct of clinical trials by competitors for product candidates that treat the targeted indications;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ability to identify specific patient populations for biomarker-defined trial cohort(s); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the cost to, or lack of adequate compensation for, prospective patients. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our inability to locate and enroll a sufficient number of patients for our clinical trials would result in significant delays, could require us to
abandon one or more clinical trials altogether and could delay or prevent our receipt of necessary marketing approvals, any of which would have an adverse effect on our business, financial condition, results of operations and prospects. Enrollment
delays in our clinical trials may result in increased development costs for our product candidates and any other product candidates we may develop, which would cause the value of our company to decline and limit our ability to obtain additional
financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if we are able to enroll a sufficient number of patients for our future clinical trials, we may have difficulty maintaining
patients in our clinical trials, including that patients may drop out of our clinical trials. If we have difficulty enrolling or maintaining a sufficient number of patients to conduct our clinical trials, we may need to delay, limit or terminate
clinical trials, any of which would harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Changes in methods of product candidate
manufacturing or formulation may result in additional costs or delay. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As product candidates proceed through preclinical studies to
late-stage clinical trials towards potential approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered over the course of development in an effort to
optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or
other future clinical trials conducted with the materials manufactured using altered processes. Such changes may also require additional testing, FDA notification or FDA approval. This could delay completion of clinical trials, require the conduct
of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commence sales and generate revenue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Serious adverse events of thrombosis have been identified in the development of sutacimig, and if additional serious adverse events or unacceptable side effects
are identified during the development of our product candidates and any other product candidates we may develop, we may need to abandon or limit our development of those product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited duration of exposure,
rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the product candidate. For example, our Phase 1/2 clinical trial of sutacimig for the treatment of Glanzmann
thrombasthenia has included only 34 patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, as we continue to evaluate our product candidates, rare and severe side effects of our
product candidates may be uncovered in the later stages of our current and future clinical development. For example, in our Phase 1/2 clinical trial of sutacimig in Glanzmann thrombasthenia, several patients have experienced events of thrombosis. In
particular, one patient experienced a grade&nbsp;2 proximal deep vein thrombotic event at the highest exposure level (0.9 mg/kg) and one patient at the 0.3 mg/kg dose level (whose dose had been reduced from 0.6 mg/kg) experienced grade 2
subsegmental pulmonary embolism. These events were reported to the FDA on an expedited reporting basis as an event of a type </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
referred to as a Suspected Unexpected Serious Adverse Reaction (SUSAR). While we expect to select a lower dose than 0.6 mg/kg for purposes of our planned Phase 3 clinical trial, thrombotic events
have been reported at the 0.3 mg/kg dose level, and there is no guarantee that thrombotic events or other serious adverse events will not occur even at lower doses. In addition, sutacimig&#8217;s mechanism of action inherently carries the risk of
thrombotic complications if the drug achieves excessive systemic exposure or if patients have concurrent prothrombotic conditions or other risk factors. <FONT STYLE="white-space:nowrap">HMB-002&#8217;s</FONT> intended mechanism of increasing von
Willebrand factor, or VWF, and Factor VIII levels could also increase thrombotic risk, particularly in patients with concurrent conditions that increase VWF levels, such as pregnancy, acute illness, or hormonal contraception use, or result in other
adverse events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Furthermore, many product candidates that initially showed promise in early-stage testing have later been found to cause side
effects that prevented their further development. If our product candidates and any other product candidates we may develop are associated with undesirable side effects in clinical trials or have characteristics that are unexpected in clinical
trials or preclinical testing, we may need to abandon their development or limit development to more narrow uses or subpopulations in which the side effects or other characteristics are less prevalent, less severe or more acceptable from a
risk-benefit perspective. In biopharmaceutical development, many compounds that initially show promise in early-stage or clinical testing are later found to cause side effects that delay or prevent further development of the compound. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, if results of our clinical trials reveal unacceptable side effects, we, the FDA or the IRBs at the institutions in which our studies are
conducted could suspend or terminate our clinical trials, or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates and any other product candidates we may develop for
any or all targeted indications. Furthermore, we expect that our clinical trial protocol for our planned Phase 3 trial may require us to pause or stop enrollment in the trial if one or more thrombotic events occur in order to assess whether it is
safe to proceed with further enrollment and dosing. Any such event could cause significant delays in the execution and completion of the trial, or lead to discontinuation altogether. Treatment-related side effects could also affect patient
recruitment or the ability of enrolled patients to complete any of our clinical trials. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We may need to train medical personnel using our
product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates
could result in harm to patients that are administered our product candidates. Any of these occurrences may adversely affect our business, financial condition and prospects significantly. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If any product candidate receives marketing approval and we, or others, later discover that the drug is less effective than previously believed or causes
undesirable side effects that were not previously identified, our ability to market the drug could be compromised. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We conduct, and intend to
conduct in the future, clinical trials of product candidates in carefully defined subsets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our clinical trials may indicate an apparent positive effect of a
product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. If any product candidate receives marketing approval, and we, or others, later discover that it is less effective
than previously believed, or causes undesirable side effects, a number of potentially significant negative consequences could result, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">withdrawal or limitation by regulatory authorities of approvals of such product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">seizure of the product by regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">recall of the product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restrictions on the marketing of the product or the manufacturing process for any component thereof; </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">requirement by regulatory authorities of additional warnings on the label, such as a &#8220;black box&#8221; warning or
contraindication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">requirement that we implement a REMS or create a medication guide outlining the risks of such side effects for distribution
to patients; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">commitment to expensive post-marketing studies as a prerequisite of approval by regulatory authorities of such product;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the product may become less competitive; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">initiation of regulatory investigations and government enforcement actions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">initiation of legal action against us to hold us liable for harm caused to patients; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">harm to our reputation and resulting harm to physician or patient acceptance of our products. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any of these events could prevent us from achieving or maintaining market acceptance of a particular product candidate, if approved, and could
significantly harm our business, financial condition, and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Some data for our product candidates comes from clinical trials conducted
outside the United States or European Union. The FDA, EMA, or other comparable regulatory authorities, may not accept data from trials conducted in such locations, which could subject us to additional delays and expense. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may conduct one or more of our clinical trials with one or more trial sites that are located outside the United States or European Union. The
acceptance of data from clinical trials conducted outside the United States or another jurisdiction by the FDA may be subject to certain conditions or may not be accepted at all. Similarly, the EMA, and other equivalent foreign regulatory
authorities may not accept data from trials conducted outside their jurisdiction. For example, we are currently conducting our ongoing Phase 2 clinical trial of sutacimig in patients with Factor VII deficiency at sites in the United Kingdom, and our
ongoing Phase 1/2 trial of <FONT STYLE="white-space:nowrap">HMB-002</FONT> in patients with Von Willebrand Disease at sites in United Kingdom, Australia, and the United States. We plan to conduct our Phase 3 clinical trial of sutacimig in patients
with Glanzmann thrombasthenia in the United States, Europe and potentially other jurisdictions. In cases where data from clinical trials outside of the United States are intended to serve as the basis for marketing approval in the United States,
acceptance of these data is subject to conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and be performed by qualified investigators in accordance with ethical principles. The FDA must be able to
validate the data from the trial through an onsite inspection, if necessary. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the
FDA deems clinically meaningful. In addition, while these clinical trials are subject to the applicable local laws, whether the FDA accepts the data will depend on its determination that the trials also complied with all applicable U.S. laws and
regulations. Additionally, recent policy proposals in the United States, if enacted in the future, may make acceptance by the FDA or inclusion in a marketing application of <FONT STYLE="white-space:nowrap">non-U.S.</FONT> data more difficult or
costly. There can be no assurance that the FDA will accept data from trials conducted outside of the United States. If the FDA does not accept the data from any trial that we conduct outside the United States, it would likely result in the need for
additional trials, which would be costly and time-consuming and could delay or permanently halt our development of the applicable product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may not be successful in our efforts to identify or discover additional product candidates and may fail to
capitalize on programs or product candidates that may present a greater commercial opportunity or for which there is a greater likelihood of success. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we do not successfully develop and eventually commercialize products, we will not generate product revenue in future periods, resulting in significant
harm to our financial position and adversely affecting our share price. Research programs to identify new product candidates require substantial technical, financial and human resources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Although our product candidates are currently in clinical development, we may fail to identify other potential product candidates for clinical
development. Our focus on blood coagulation disorders limits our opportunities to a specific therapeutic area. If there are fewer than anticipated viable product targets in this area, or if competitors develop superior products for these
indications, our business may suffer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, because we have limited resources, we may forego or delay pursuit of opportunities with certain
programs or product candidates or for indications that later prove to have greater commercial potential. For example, we currently intend to focus our capital resources primarily on the development of our product candidates. We have prioritized the
development of sutacimig for Glanzmann thrombasthenia and Factor VII deficiency, which are both blood disorders with small patient populations, instead of potentially expanding into larger platelet disorder indications, which may have larger markets
and potentially greater commercial returns. The development of our product candidates may ultimately prove to be unsuccessful or less successful than another potential product candidate in our pipeline that we might have chosen to pursue on a more
aggressive basis with our capital resources. If we do not accurately evaluate the commercial potential for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic collaborations, licensing or
other arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. Alternatively, we may allocate internal resources to a product candidate in a
therapeutic area in which it would have been more advantageous to enter into a partnering arrangement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we engage in future acquisitions, this may increase
our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">From time to time, we evaluate various acquisition opportunities, including licensing or acquiring complementary products, product candidates,
intellectual property rights, technologies or businesses. Any potential acquisition may entail numerous risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">increased operating expenses and cash requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the assumption of additional indebtedness or contingent liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the issuance of our equity securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">assimilation of operations, intellectual property, products and product candidates of an acquired company, including
difficulties associated with integrating new personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the diversion of our management&#8217;s attention from our existing programs and initiatives in pursuing such a strategic
merger or acquisition; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business
relationships; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and
their existing products, product candidates and marketing approvals; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our inability to generate revenue from acquired product candidates or products sufficient to meet our objectives in
undertaking the acquisition or even to offset the associated acquisition and maintenance costs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We do not know if we will be able
to identify acquisitions or strategic relationships we deem suitable, whether we will be able to successfully complete any such transactions on favorable terms, if at all, or whether we will be able to successfully integrate any acquired business,
product or technology into our business or retain any key personnel or suppliers. Our ability to successfully grow through strategic transactions depends upon our ability to identify, negotiate, complete and integrate suitable target businesses,
technologies or products and to obtain any necessary financing. These efforts could be expensive and time-consuming and may disrupt our ongoing business and prevent management from focusing on our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To finance any acquisitions, investments or strategic alliances, we may choose to issue shares of our common stock as consideration, which could dilute
the ownership of our stockholders. If the price of our common stock is low or volatile, we may be unable to consummate any acquisitions, investments or strategic alliances using our common stock as consideration. Additional funds may not be
available on terms that are favorable to us, or at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Even if any product candidate receives marketing approval, it may fail to achieve the degree of
market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If any
product candidate receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. Sales of medical products depend in part on the willingness
of physicians to prescribe the treatment, which is likely to be based on a determination by these physicians that the products are safe, therapeutically effective and cost-effective. In addition, the inclusion or exclusion of products from treatment
guidelines established by various physician groups and the viewpoints of influential physicians can affect the willingness of other physicians to prescribe the treatment. We cannot predict whether physicians, physicians&#8217; organizations,
hospitals, other healthcare providers, government agencies or private insurers will determine that our product is safe, therapeutically effective and cost-effective as compared with competing treatments. Efforts to educate the medical community and
third-party payors on the benefits of our product candidates and any other product candidates we may develop may require significant resources, including management time and financial resources, and may not be successful. If our product candidates
and any other product candidates we may develop do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of our product candidates and any
other product candidates we may develop, if approved for commercial sale, will depend on a number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the efficacy, safety and potential advantages of our product candidates compared to the advantages and relative risks of
alternative treatments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the effectiveness of sales and marketing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the cost of treatment in relation to alternative treatments, including any similar generic or biosimilar treatments;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">whether the product is designated under physician treatment guidelines as a first-, second- or third-line therapy;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">limitations or warnings, including distribution or use restrictions contained in the product&#8217;s approved labeling;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the clinical indications for which the product is approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the convenience and ease of administration compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the willingness of the target patient population to try new therapies and to continue treatment over time and of physicians
to prescribe these therapies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the strength of marketing and distribution support; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing of market introduction of competitive products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the availability of third-party coverage and adequate reimbursement, and patients&#8217; willingness to pay out of pocket
for required <FONT STYLE="white-space:nowrap">co-payments</FONT> or in the absence of third-party coverage or adequate reimbursement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the prevalence and severity of any side effects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any restrictions on the use of our products, if approved, together with other medications; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any failure by one or more of our product candidates that obtains regulatory approval to achieve market acceptance or
commercial success would adversely affect our business prospects. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If the market opportunities for any product candidates we develop are
smaller than we believe they are, our revenue may be adversely affected, and our business may suffer. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We focus our research and product
development on treatments for bleeding disorders. Given the small number of patients who have certain of the diseases that we are targeting, it is critical to our ability to grow and become profitable that we continue to successfully identify
patients with these diseases. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with any product candidates we may develop, are
based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations or market research, and &#8220;360&#8221; natural history studies that we
conducted, and may prove to be incorrect or contain errors. New studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected. The effort to identify patients with diseases
we seek to treat is in early stages, and we cannot accurately predict the number of patients for whom treatment might be possible. Additionally, the potentially addressable patient population for each of our product candidates may be limited or may
not be amenable to treatment with our product candidates, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business. Further, even if we obtain
significant market share for our product candidates, because the potential target populations are very small, we may never achieve profitability despite obtaining such significant market share.&nbsp;Additionally, if the actual market for any product
candidates we may develop is smaller than we estimate, our revenues, if any, may be limited and it may be more difficult for us to achieve or maintain profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even with high penetration rates and premium pricing typical of orphan drugs, the revenue potential for sutacimig for the treatment of Glanzmann
thrombasthenia and Factor VII deficiency may be limited due to the small patient populations. The pricing and reimbursement of any product candidates we may develop, if approved, is uncertain, and it may not be adequate to support commercial
infrastructure. If we are unable to obtain adequate levels of pricing or reimbursement, our ability to successfully market and sell product candidates will be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we are unable to establish sales, marketing and distribution capabilities or enter into sales, marketing and distribution agreements with third parties, we may
not be successful in commercializing any product candidates if and when they are approved. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We do not have a sales or marketing
infrastructure and have no experience in the sale, marketing or distribution of pharmaceutical products. To achieve commercial success for any product for which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
we have obtained marketing approval, we will need to establish a sales, marketing and distribution organization, either ourselves or through collaborations or other arrangements with third
parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the future, we expect to build a sales and marketing infrastructure to market our product candidates and any other product candidates
we may develop in the United States, Europe and potentially other jurisdictions, if and when approved by the respective regulatory authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There
are risks involved with establishing our own sales, marketing and distribution capabilities. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product
candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. These efforts may be costly, and our
investment would be lost if we cannot retain or reposition our sales and marketing personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Factors that may inhibit our efforts to commercialize
our products on our own include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our inability to recruit, train and retain adequate numbers of effective sales, marketing, coverage or reimbursement,
customer service, medical affairs and other support personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the inability of sales personnel to educate adequate numbers of physicians on the benefits of any future products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement and other
acceptance by payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the inability to price our products at a sufficient price point to ensure an adequate and attractive level of
profitability; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restricted or closed distribution channels that make it difficult to distribute our products to segments of the patient
population; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage
relative to companies with more extensive product lines; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we are unable to establish our own sales, marketing and distribution capabilities and we enter into arrangements with third
parties to perform these services, our product revenues and our profitability, if any, are likely to be lower than if we were to market, sell and distribute any products that we develop ourselves. In addition, we may not be successful in entering
into arrangements with third parties to sell, market and distribute any product candidates or may be unable to do so on terms that are acceptable to us. We likely will have little control over such third parties, and any of them may fail to devote
the necessary resources and attention to sell and market our products effectively. If we do not establish sales, marketing and distribution capabilities successfully, either on our own or in collaboration with third parties, we will not be
successful in commercializing any product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We face substantial competition, which may result in others discovering, developing or commercializing
products before or more successfully than we do. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The development and commercialization of new drug products is highly competitive. We face
competition with respect to our product candidates, and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies
and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology companies that currently </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
market and sell products or are pursuing the development of products for the treatment of the same disease indications we are pursuing. Some of these competitive products and therapies are based
on scientific approaches that are the same as or similar to our approach, and others are based on entirely different approaches. Potential competitors also include academic institutions, government agencies and other public and private research
organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. Any product candidates that we successfully develop and commercialize will compete
with existing products and new products that may become available in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There are currently no subcutaneous prophylactic therapies for
Glanzmann thrombasthenia or Factor VII deficiency that are in development or approved. However, companies could develop new therapies or repurpose existing therapies for Glanzmann thrombasthenia or Factor VII deficiency, such as emicizumab
(Hemlibra), which was developed for hemophilia A, but could potentially be studied in other bleeding disorders, potentially including our target indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For Von Willebrand Disease, the competitive landscape includes currently available therapies and products in development. The current standard of care
includes desmopressin and VWF replacement products, including both plasma-derived products <FONT STYLE="white-space:nowrap">(Humate-P,</FONT> Wilate, Alphanate) and recombinant VWF (Vonvendi). These products have established positions in the market
and physician familiarity. In addition, Star Therapeutics Inc. is currently developing <FONT STYLE="white-space:nowrap">VGA-039,</FONT> an investigational monoclonal antibody that inhibits protein S, which is currently in Phase 3 clinical
development for Von Willebrand Disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize
products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other marketing approval for their products more
rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other
third-party payors seeking to encourage the use of generic and/or biosimilar products. If any product candidates achieve marketing approval, we expect that they would be priced at a significant premium over competitive generic or biosimilar
products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial
resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining marketing approvals and marketing approved products than we do. If we successfully obtain approval for any product
candidate, we will face competition based on many different factors, including the safety, tolerability and effectiveness of our products, the ease with which our products can be administered, the timing and scope of regulatory approvals for these
products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, tolerable
or convenient, safer, less expensive or marketed and sold more effectively than any products we may develop. Competing products may render any product candidates we develop obsolete or noncompetitive before we recover the expense of developing and
commercializing our product candidates. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our products we may develop, if approved, could be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Mergers and acquisitions in the pharmaceutical, biopharmaceutical and biotechnology industries may result in even more resources being concentrated
among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring
technologies complementary to, or necessary for, our programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Even if we are able to commercialize any product candidates, the products may become subject
to unfavorable pricing regulations, third-party coverage or reimbursement practices or healthcare reform initiatives, which could harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Current
and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In
many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is
granted. As a result, we might obtain marketing approval for a product in a particular country but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the
revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if any product candidates obtain marketing approval.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our ability to commercialize any product candidates successfully will depend in part on the extent to which coverage and adequate reimbursement for
these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third- party payors, such as private health insurers and
health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and other third-party payors
have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are
challenging the prices charged for medical products. Coverage and reimbursement may not be available for any product that we commercialize and, even if these are available, the level of reimbursement may not be satisfactory. Reimbursement may affect
the demand for, or the price of, any product candidate for which we obtain marketing approval. Obtaining and maintaining adequate reimbursement for our products may be difficult. There can be no assurance that any product candidates, even if they
are approved for sale in the United States, Europe or in other jurisdictions, will be considered medically reasonable and necessary for a specific indication or cost-effective by third-party payors. We may be required to conduct expensive
pharmacoeconomic studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies. If coverage and adequate reimbursement are not available, we may not be able to successfully commercialize any product
candidate for which we obtain marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs,
and coverage may be more limited than the purposes for which the drug is approved by the FDA, European Commission or similar regulatory authorities in other jurisdictions. Moreover, eligibility for coverage and reimbursement does not imply that a
drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our
costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into
existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Further, no uniform policy
for coverage and reimbursement exists in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies, but also have their own methods and processes apart from
Medicare determinations. As a result, obtaining and maintaining coverage and adequate reimbursement is often time-consuming and costly. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and
private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our future growth depends, in part, on our ability to penetrate markets outside the United States and the European Union, where we would be subject to additional
regulatory burdens and other risks and uncertainties that, if they materialize, could harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our future profitability will
depend, in part, on our ability to commercialize our product candidates and any other product candidates we may develop in markets outside of the United States and the European Union. We are not permitted to market or promote any product candidate
before we receive regulatory approval from applicable regulatory authorities in foreign markets, and we may never receive such regulatory approvals for any product candidates. If we commercialize our product candidates and any other product
candidates we may develop in foreign markets, we will be subject to additional risks and uncertainties, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">economic weakness, including inflation, or political instability in particular economies and markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements, many of which
vary between countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">different medical practices and customs in foreign countries affecting acceptance in the marketplace;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">tariffs and trade barriers, as well as other governmental controls and trade restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">other trade protection measures, import or export licensing requirements or other restrictive actions by governments in the
jurisdictions in which we operate or plan to operate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">longer accounts receivable collection times; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">longer lead times for shipping; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">workforce uncertainty in countries where labor unrest is common; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">language barriers for technical training; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reduced protection of intellectual property rights in some foreign countries, and related prevalence of generic
alternatives to therapeutics; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">foreign currency exchange rate fluctuations and currency controls; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">differing foreign reimbursement landscapes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">uncertain and potentially inadequate reimbursement of our products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If risks related to any of these uncertainties materialize, it could have a material adverse effect on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Clinical trial and product liability lawsuits against us could divert our resources, could cause us to incur
substantial liabilities and could limit commercialization of any products that we may develop. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We face an inherent risk of clinical trial
and product liability exposure related to the testing of our product candidates and any other product candidates we may develop in clinical trials, and we will face an even greater risk if we commercially sell any products that we may develop. While
we currently have no products that have been approved for commercial sale, the current and future use of product candidates by us in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These
claims might be made by patients that use the product, healthcare providers, pharmaceutical companies or others selling such products. If we cannot successfully defend ourselves against claims that our product candidates and any other product
candidates or products we may develop caused injuries, we will incur substantial liabilities. Even a successful defense would require significant financial and management resources. Regardless of merit or eventual outcome, liability claims may
result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">decreased demand for our product candidates and any other product candidates or products that we may develop;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">injury to our reputation and significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">significant costs to defend any related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">loss of revenue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reduced resources of our management to pursue our business strategy; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the inability to commercialize any products that we may develop. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Although we currently hold clinical trial liability insurance coverage in amounts we believe to be adequate, the coverage limits may be inadequate to
cover all liabilities we may incur, and we may need to increase our insurance coverage as we expand our clinical trials or if we commence commercialization of any product candidates. Insurance coverage is increasingly expensive. We may not be able
to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. If a successful clinical trial or product liability claim or series of claims is brought against us for uninsured liabilities or in
excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If any product candidate
receives marketing approval, we will be required to report to regulatory authorities if the product causes or contributes to adverse medical events, and any failure to do so would result in sanctions that would materially harm our business.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we are successful in commercializing any product candidate, the FDA and foreign regulatory authorities would require that we report
certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the
nature of the event. We may fail to report adverse events within the prescribed timeframe. If we fail to comply with such reporting obligations, the FDA or a foreign regulatory authority could take action, including criminal prosecution, the
imposition of civil monetary penalties, seizure of our products or delay in approval or clearance of future products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Dependence on Third Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We rely, and expect to continue to rely, on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing
to meet deadlines for the completion of such trials, which may harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We currently rely on third-party clinical research
organizations, or CROs, to conduct our planned and ongoing clinical trials. We do not plan to independently conduct clinical trials of our product candidates. We expect to continue to rely on third parties, such as CROs, clinical data management
organizations, medical institutions and clinical investigators, to conduct our clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These third parties are not our employees, and
except for remedies available to us under our agreements with such third parties, we have limited ability to control the amount or timing of resources that any such third party will devote to our preclinical studies or our clinical trials. The third
parties we rely on for these services may also have relationships with other entities, some of which may be our competitors, for whom they may also be conducting clinical trials or other drug development activities, which could affect their
performance on our behalf. Some of these third parties may terminate their engagements with us at any time. We also have to negotiate budgets and contracts with CROs and clinical trial sites and we may not be able to do so on favorable terms, which
may result in delays to our development timelines and increased costs. If we need to enter into alternative arrangements with, or replace or add any such third parties, it would involve substantial cost and require extensive management time and
focus, or involve a transition period, and may delay our drug development activities, as well as materially impact our ability to meet our desired clinical development timelines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, while our reliance on these third parties for research and development activities will reduce our control over these activities, it will
not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us
to comply with standards, commonly referred to as good clinical practices, or GCPs, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights,
integrity and confidentiality of trial participants are protected. Our failure or the failure of third parties to comply with the applicable protocol, legal and regulatory requirements and scientific standards can result in rejection of our clinical
trial data or other sanctions. Additionally, if we or our third-party contractors fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional
clinical trials before approving our product candidates, which would delay the regulatory approval process. We cannot be certain that, upon inspection, the FDA will determine that any of our clinical trials comply with GCPs. We also are required to
register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal
sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We also rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part
of our distributors could delay clinical development or regulatory approval of our product candidates or commercialization of any resulting products, producing additional losses and depriving us of potential product revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with
regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for any product candidates and will not be able to, or may be delayed in our efforts to, successfully develop and
commercialize any product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Manufacturing biologics is complex, and we may experience manufacturing problems that result in delays in our
development or future commercialization programs. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The manufacturing of biologics is complex and difficult and we, or our CMOs, may
experience production issues or interruptions for sutacimig, <FONT STYLE="white-space:nowrap">HMB-002</FONT> or any other product candidate we may develop, including raw material or starting material variability in terms of quality, cell line
viability, productivity or stability issues, shortages of any kind, shipping, distribution, storage and supply chain failures, growth media contamination, equipment malfunctions, operator errors, facility contamination, labor problems, natural
disasters, disruption in utility services, terrorist activities, or acts of god that are beyond our control or the control of our third party manufacturers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Given the nature of biologics manufacturing, there is a risk of contamination during manufacturing. Any contamination could materially harm our or our
third party manufacturers&#8217; ability to produce sutacimig, <FONT STYLE="white-space:nowrap">HMB-002</FONT> or any other product candidate we may develop on schedule and could harm our results of operations and cause reputational damage. Some of
the raw materials that we require in our manufacturing process are derived from biologic sources. Such raw materials may be difficult to procure and may be subject to contamination or recall. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Problems with the manufacturing process, even minor deviations from the normal process, could result in product defects or manufacturing failures that
result in lot failures, product recalls, product liability claims, insufficient inventory or potentially delay progression of our preclinical or clinical development of sutacimig, <FONT STYLE="white-space:nowrap">HMB-002</FONT> and any other product
candidate we may develop. If we successfully develop sutacimig, <FONT STYLE="white-space:nowrap">HMB-002</FONT> and any other product candidate, we may encounter problems achieving adequate quantities and quality that meet FDA, EMA or other
comparable applicable foreign standards or specifications with consistent and acceptable production yields and costs. The ability to scale our manufacturing through manufacturers of drug substance for our product candidates and for finished drug
product and maintain the manufacturing process at the same levels of quality and efficiency is yet to be tested. If we or our third party manufacturers are unable to scale our manufacturing at the same levels of quality and efficiency, we may not be
able to supply the required number of doses for clinical trials or commercial supply. A material shortage, contamination or manufacturing failure in the manufacture of sutacimig, <FONT STYLE="white-space:nowrap">HMB-002</FONT> and any other product
candidate we may develop or other adverse impact or disruption in the commercial manufacturing or the production of clinical material could materially harm our development timelines and our business, financial condition, results of operations and
prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We contract with third parties for the manufacture of our product candidates, plan to contract with third parties for any other product candidates
we may develop for preclinical and clinical testing and expect to continue to do so for commercialization. This reliance on third parties entails risks, including that such third parties may not be able to comply with applicable regulatory
requirements. Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We do not have any manufacturing facilities. We currently rely on a small number of manufacturers of drug substance for our product candidates and for
finished drug product, and we expect to continue to rely on third parties to manufacture clinical supplies of our product candidates and any other product candidates we may develop and commercial supplies of our products, if and when approved for
marketing by applicable regulatory authorities, as well as for packaging, sterilization, storage, distribution and other production logistics. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Reliance on third-party manufacturers may expose us to different risks than if we were to manufacture product candidates ourselves. If these third
parties do not successfully carry out their contractual duties, meet expected deadlines or manufacture any product candidates in accordance with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
regulatory requirements, if there are disagreements between us and such parties or if such parties are unable to expand capacities to support commercialization of any product candidates for which
we obtain marketing approval, we may not be able to fulfill, or may be delayed in producing sufficient product candidates to meet, our supply requirements. These facilities may also be affected by natural disasters, such as floods or fire, or
geopolitical developments, or such facilities could face manufacturing issues, such as contamination or regulatory concerns following a regulatory inspection of such facility. In such instances, we may need to locate an appropriate replacement
third-party facility and establish a contractual relationship, which may not be readily available or on acceptable terms, which would cause additional delay and increased expense, and may have a material adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Third-party manufacturers may not be able to comply with current good manufacturing practices, or cGMP, regulations or similar regulatory requirements
outside of the United States. Our failure, or the failure of our third- party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays,
suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our product candidates and any other product candidates or products that we may develop may compete with other product candidates and products for
access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We or our third-party manufacturers may also encounter shortages in the raw materials or drug substance necessary to produce our product candidates and
any other product candidates we may develop in the quantities needed for our clinical trials or, if our product candidates and any other product candidates we may develop are approved, in sufficient quantities for commercialization or to meet an
increase in demand, as a result of capacity constraints or delays or disruptions in the market for the raw materials or drug substance, including shortages caused by the purchase of such raw materials or drug substance by our competitors or others.
Even if raw materials or drug substance are available, we may be unable to obtain sufficient quantities at an acceptable cost or quality. The failure of us or our third-party manufacturers to obtain the raw materials or drug substance necessary to
manufacture sufficient quantities of our product candidates and any other product candidates we may develop could delay, prevent or impair our development efforts and may have a material adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not have
long-term supply agreements in place for drug product or drug substance for our product candidates. If any of our future contract manufacturers cannot perform as agreed, or decline to continue to supply us, we may be required to replace such
manufacturers. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates and any other product candidates we may develop, we may incur added costs and delays in identifying and
qualifying any such replacement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our current and anticipated future dependence upon others for the manufacture of our product candidates and any
other product candidates or products we may develop may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may from time to time be dependent on single-source suppliers for some of the components and materials used
in the product candidates we may develop. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may from time to time depend on single-source suppliers for some of the components and
materials used in any product candidate we may develop. We cannot ensure that these suppliers or service providers will remain in business, have sufficient capacity or supply to meet our needs or that they will not be purchased by one of our
competitors or another company that is not interested in continuing to work with us. Our use of single-source suppliers of raw materials, components, key processes and finished goods could expose us to several risks, including disruptions in supply,
price increases or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be unable or unwilling to meet our future demands for our clinical trials or commercial sale.
Establishing additional or replacement suppliers for these components, materials and processes could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in
supply from any single-source supplier or service provider could lead to supply delays or interruptions which would damage our business, financial condition, results of operations and prospects.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we have to switch to a replacement supplier, the manufacture and delivery of any product candidates we may develop could be interrupted for an
extended period, which could adversely affect our business. Establishing additional or replacement suppliers, if required, may not be accomplished quickly. If we are able to find a replacement supplier, the replacement supplier would need to be
qualified and may require additional regulatory authority approval, which could result in further delay. While we seek to maintain adequate inventory of the single source components and materials used in our products, any interruption or delay in
the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand for our investigational medicines. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may enter into collaborations with third parties for the development or commercialization of product candidates. If our collaborations are not successful, we
may not be able to capitalize on the market potential of these product candidates and our business could be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may
utilize collaboration, distribution and other marketing arrangements with third parties to develop our product candidates or any future product candidates of ours or to commercialize any product for which we obtain marketing approval. Our likely
collaborators for any sales, marketing, distribution, development, licensing or broader collaboration arrangements include large and <FONT STYLE="white-space:nowrap">mid-size</FONT> pharmaceutical companies, regional and national pharmaceutical
companies and biotechnology companies. We are not currently party to any such arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We face significant competition in seeking appropriate
collaborators, and a number of more established companies may also be pursuing strategies to license or acquire third-party intellectual property rights that we consider attractive. These established companies may have a competitive advantage over
us due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Whether we reach a
definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s
evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by regulatory authorities, the potential market for the subject product candidate, the costs and complexities of
manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard
to the merits of the challenge, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and
whether such a collaboration could be more attractive than the one with us for our product candidate. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business
combinations among large pharmaceutical and biotechnology companies that have resulted in a reduced number of potential future collaborators. As a result, we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at
all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms or at all, we may have to curtail the
development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our
expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital,
which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to
further develop any product candidates or bring them to market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we are able to enter into collaborations with any third parties in the future,
we will likely have limited control over the amount and timing of resources that any future collaborators of ours dedicate to the development or commercialization of our product candidates and any future product candidates of ours. Our ability to
generate revenues from these arrangements will depend on any future collaborators of ours abilities and efforts to successfully perform the functions assigned to them in these arrangements. We cannot be certain that, following a collaboration,
license or strategic transaction, we will achieve an economic benefit that justifies such transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Collaborations that we enter into may not be
successful, and any success will depend heavily on the efforts and activities of such collaborators. Collaborations pose a number of risks, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators have significant discretion in determining the amount and timing of efforts and resources that they will
apply to these collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may not perform their obligations as expected; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may not pursue development of our product candidates and any future product candidates of ours or may elect
not to continue or renew development programs based on results of clinical trials or other studies, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or
create competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial
or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may not have access to, or may be restricted from disclosing, certain information regarding product candidates being
developed or commercialized under a collaboration and, consequently, may have limited ability to inform our stockholders about the status of such product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with
any product candidates and products if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">product candidates discovered in collaboration with us may be viewed by any future collaborators of ours as competitive
with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of any product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a collaborator may fail to comply with applicable regulatory requirements regarding the development, manufacture,
distribution or marketing of a product candidate or product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a collaborator with marketing and distribution rights to one or more of any product candidates that achieves marketing
approval may not commit sufficient resources to the marketing and distribution of such product or products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">disagreements with collaborators, including disagreements over intellectual property or proprietary rights, contract
interpretation or the preferred course of development, might cause delays or terminations of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates,
or might result in litigation or arbitration, any of which would be time-consuming and expensive; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may not properly obtain, maintain, enforce, defend or protect our intellectual property or proprietary rights
or may use our proprietary information in such a way as to potentially lead to disputes or legal proceedings that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">disputes may arise with respect to the ownership of intellectual property developed pursuant to our collaborations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may infringe, misappropriate or otherwise violate the intellectual property or proprietary rights of third
parties, which may expose us to litigation and potential liability; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may be required to invest resources and attention into collaborations, which could distract from other business
objectives; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborations may be terminated by the collaborator (including for convenience), and, if terminated, we could be required
to raise additional capital to pursue further development or commercialization of the applicable product candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner, or at all. If any
collaborations that we enter into do not result in the successful development and commercialization of products or if one of our future collaborators terminates its agreement with us, we may not receive any future research funding or milestone or
royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of any product candidates could be delayed and we may need additional resources to develop any product candidates. All of
the risks relating to product development, marketing approval and commercialization described in this prospectus also apply to the activities of any future collaborators of ours. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, subject to its contractual obligations to us, if a collaborator of ours is involved in a business combination, the collaborator might
deemphasize or terminate the development or commercialization of any product candidate licensed to it by us. If any future collaborators of ours terminates its agreement with us, we may find it more difficult to attract new collaborators and our
perception in the business and financial communities could be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may be subject to claims that our employees, consultants or independent
contractors have wrongfully used or disclosed confidential information or trade secrets of third parties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We employ individuals who were
previously employed at other biotechnology or biopharmaceutical companies. Although we try to ensure that our employees, consultants and advisors </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
do not use the proprietary information, trade secrets or <FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be subject to claims that we or our employees,
consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third parties. Litigation may be necessary to defend against these claims. There is
no guarantee of success in defending these claims, and even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we fail to comply with
our obligations under our existing license agreements with Novo Nordisk and Genmab, or under any future intellectual property licenses, or otherwise experience disruptions to our business relationships with our current or any future licensors, we
could lose intellectual property rights that are important to our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are party to existing license agreements with each of Novo
Nordisk and Genmab with respect to sutacimig. Termination of either of these agreements or a reduction or elimination of our licensed rights could lead to the loss of our ability to develop and commercialize sutacimig. Under the Novo Nordisk
Agreement, we have been granted an exclusive (even as to Novo Nordisk), worldwide and sublicensable license under specified patent rights, and a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide and sublicensable license under
specified <FONT STYLE="white-space:nowrap">know-how,</FONT> to research, develop, make, have made, use, offer for sale, sell, import, export or otherwise exploit, or transfer possession of or title in, products containing bispecific IgG antibodies
targeting <FONT STYLE="white-space:nowrap">TLT-1</FONT> and Factor VII, including sutacimig, for the treatment of bleeding conditions, including hemophilia. Under the Genmab Agreement, we have been granted an exclusive (even as to Genmab and its
affiliates), worldwide and sublicensable license under platform technology patent rights and <FONT STYLE="white-space:nowrap">know-how</FONT> relating to Genmab&#8217;s proprietary DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>
platform to research, develop, make, have made, use, manufacture, import, export and commercialize products containing bispecific IgG antibodies targeting <FONT STYLE="white-space:nowrap">TLT-1</FONT> and Factor VII, including sutacimig, for the
treatment of bleeding conditions, including hemophilia. For further information regarding our license agreements with Novo Nordisk and Genmab see &#8220;Business&#8212;License Agreements.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may enter into additional license agreements in the future. Our future license agreements may not provide us with exclusive rights to use the
licensed intellectual property and technology or may not provide us with exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our
product candidates and technology in the future. Additionally, future agreements may impose various development, diligence, commercialization and other obligations on us and require us to meet development timelines, or to exercise commercially
reasonable efforts to develop and commercialize licensed products, in order to maintain the licenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our license agreements with Novo Nordisk and
Genmab impose, and we expect that future licenses may impose, specified diligence, milestone payments, royalties and other obligations on us. Furthermore, Novo Nordisk and Genmab each has the right to terminate their respective license agreement if
we materially breach such agreement and fail to cure such breach within a specified period or in the event of insolvency. In spite of our best efforts, our current or any future licensors might conclude that we have materially breached our license
agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize product candidates and technology covered by these license agreements. As a result, we may be required to cease our
development and commercialization of our product candidates and use of our proprietary technologies covered by the patent rights owned by such licensors. If these <FONT STYLE="white-space:nowrap">in-licenses</FONT> are terminated, or if the <FONT
STYLE="white-space:nowrap">in-licensed</FONT> intellectual property fails to provide the intended exclusivity, competitors may have the freedom to seek regulatory approval of, and to market, products identical to ours. This could have a material
adverse effect on our competitive position, business, financial condition, results of operations, and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL">Disputes may arise regarding intellectual property subject to a licensing agreement, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to
the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the sublicensing of patent and other rights under our collaborative development relationships; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the inventorship and ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint
creation or use of intellectual property by our current or future licensors, and us and our partners; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, license agreements are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of
any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the
relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability
to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected technology and product candidates, which could have a material adverse effect on our business,
financial conditions, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we are unable to obtain licenses from third parties on commercially reasonable terms or fail to
comply with our obligations under such agreements, our business could be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We currently have rights to intellectual property, through
licenses from third parties, to identify and develop certain product candidates, and we may enter into additional licenses in the future as we expand our product candidate pipeline. Although we have succeeded in licensing intellectual property from
third-party licensors, including Genmab and Novo Nordisk, in the past, we cannot assure our stockholders that we will be able to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire the rights to any potential product candidates from third
parties on acceptable terms or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, our license agreements may provide that our fields of use exclude particular fields. If we
determine that rights to such fields are necessary to commercialize our product candidates or maintain our competitive advantage, we may need to obtain additional license rights in order to continue developing, manufacturing or marketing our product
candidates. In addition, we may seek to obtain additional licenses from our licensors and, in connection with obtaining such licenses, we may agree to amend our existing licenses in a manner that may be more favorable to the licensors, including by
agreeing to terms that could enable third parties (potentially including our competitors) to receive licenses to a portion of the intellectual property that is subject to our existing licenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Various third parties practice in competitive areas and may have issued patents or patent applications that will issue as patents in the future, which
could impede or preclude our ability to commercialize our product candidates. For any third-party patents that could be relevant to our product candidates, we rely in part on the &#8220;safe harbor&#8221; or research exemption under 35 U.S.C. &#167;
271(e)(1), which exempts activities related to pursuing FDA approval for a drug product from patent infringement. However, while U.S. patent law provides such a &#8220;safe harbor&#8221; to our clinical product candidates under this provision, that
exemption may expire when a BLA is submitted. Given the uncertainty of clinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
trials, we cannot be certain of the timing of their completion and it is possible that we may submit a BLA for one of our future product candidates at a time when one or more relevant third-party
patents is in force. It may therefore be necessary for us to use the patented or proprietary intellectual property of third parties to commercialize our products, in which case we would be required to obtain a license from these third parties. If we
are unable to license such intellectual property, or if we are forced to license such intellectual property on unfavorable terms, our business could be materially harmed. If we are unable to obtain a necessary license, we may be unable to develop or
commercialize the affected product candidates, which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales or an obligation on our part to pay
royalties and/or other forms of compensation. Even if we are able to obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same intellectual property licensed to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, we may collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these
institutions. In certain cases, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in intellectual property resulting from the collaboration. Even if we hold such an option, we may be unable
to negotiate a license from the institution within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our ability to
pursue our program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, the licensing or acquisition of third-party intellectual property rights is a highly competitive area, and a
number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due
to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or
acquire third party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third party intellectual property rights or maintain
the existing intellectual property rights we have, we may have to abandon development of the applicable product candidate, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we are unable to obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we
may be required to expend significant time and resources to redesign our product candidates, or the methods for manufacturing them or to develop or license replacement intellectual property, all of which may not be feasible on a technical or
commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business, financial condition, results of operations, and prospects significantly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, if we fail to comply with our obligations under license agreements, our counterparties may have the right to terminate these agreements,
in which event we might not be able to develop, manufacture or market, or may be forced to cease developing, manufacturing or marketing, any product that is covered by these agreements or may face other penalties under such agreements. Such an
occurrence could materially adversely affect the value of the product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements, or current and future
restrictions on our ability to freely assign or sublicense our rights under such agreements when it is in the interest of our business to do so, may result in our having to negotiate new or reinstated agreements with less favorable terms, cause us
to lose our rights under these agreements, including our rights to important intellectual property or impede, or delay or prohibit the further development or commercialization of one or more potential product candidates that rely on such agreements.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we are unable to obtain, maintain, enforce, defend and otherwise protect the intellectual property relating
to our technology and product candidates, and if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize technology and products similar or
identical to ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our success depends in large part on our ability to obtain and maintain protection of the intellectual property we may own solely and jointly with others
or may license from others, particularly patents with respect to any proprietary technology and product candidates we develop. We seek to protect our proprietary position by filing patent applications in the United States, Europe and other
jurisdictions in which we plan to market any products, if approved, related to our product candidates and any other product candidates we may develop that are important to our business and by <FONT STYLE="white-space:nowrap">in-licensing</FONT>
intellectual property related to our technologies and product candidates. If we, or our licensors, are unable to obtain or maintain patent protection with respect to any proprietary technology or product candidates, our business, financial
condition, results of operations and prospects could be materially harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The patent prosecution process is expensive, time-consuming and complex,
and we may not be able to file, prosecute, maintain, defend or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research
and development output before it is too late to obtain patent protection. Therefore, these <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and applications may not be prepared, filed, prosecuted, maintained, defended and enforced in a
manner consistent with the best interests of our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The patent position of pharmaceutical and biotechnology companies generally is highly
uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. With respect to both owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights, we cannot predict whether the
patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors. Further, we may not be aware of all
third-party intellectual property rights potentially relating to our product candidates and any other product candidates we may develop. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries,
and patent applications are typically not published until 18 months after filing of the priority application, or in some cases not published at all. Therefore, neither we nor our licensors can know with certainty whether either we or our licensors
were the first to make the inventions claimed in the patents and patent applications we own or <FONT STYLE="white-space:nowrap">in-license</FONT> now or in the future, or that either we or our licensors were the first to file for patent protection
of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights are highly uncertain. Moreover, our owned and <FONT
STYLE="white-space:nowrap">in-licensed</FONT> pending and future patent applications may not result in patents being issued that protect our technology and product candidates, in whole or in part, or that effectively prevent others from
commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States, the European Union and other countries may diminish the value of our patents and our ability to
obtain, protect, maintain, defend and enforce our patent rights, narrow the scope of our patent protection and, more generally, could affect the value of, or narrow the scope of, our patent rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of March&nbsp;31, 2026, we own, <FONT STYLE="white-space:nowrap">co-own,</FONT> or hold exclusive license rights to approximately 11 issued patents
and 71 pending patent applications related to our product candidates. In order to continue to pursue protection based on provisional patent applications, we will need to file Patent Cooperation Treaty applications,
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> applications and/or U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications prior to applicable deadlines. Even then, as highlighted above, patents may never issue from our
patent applications, or the scope of any patent may not be sufficient to provide a competitive advantage. With respect to sutacimig, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
our foundational composition of matter patent application was filed in April 2020 (and claims priority to April 2019) with an expected expiration in April 2040, potentially extending to 2045 with
patent term extension. The foundational sutacimig composition of matter patent family is exclusively licensed to us from Novo Nordisk. For <FONT STYLE="white-space:nowrap">HMB-002,</FONT> our initial composition of matter patent application was
filed in February 2023 (and claims priority to February 2022) with an expected expiration in February&nbsp;2043. We solely own the initial HMB-002 composition of matter patent family. A second composition of matter patent application covering
HMB-002 was filed in August&nbsp;2024 (and claims priority to August 2023), with an expected expiration in August 2044. We also solely own the second HMB-002 composition of matter patent family. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, we or our licensors may be subject to a third-party preissuance submission of prior art to the United States Patent and Trademark Office, or
USPTO, or become involved in opposition, derivation, revocation, <FONT STYLE="white-space:nowrap">re-examination,</FONT> inter partes review, post-grant review, interference or other similar proceedings challenging our patent rights or the patent
rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize technology and product candidates that are identical or
similar to ours and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights. If the breadth or strength of protection provided by our patents and
patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted
after issuance, including as a result of challenges brought in patent offices or court proceedings. Even if our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent applications issue as patents, they may not issue in a form that
will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability,
and our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents may be challenged in the courts or patent offices in the United States, the European Union and other jurisdictions. Such challenges may result in loss of exclusivity or
freedom to operate, or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the
duration of the patent protection of our technology and product candidates. Such proceedings also may result in substantial cost and require significant time from our management and employees, even if the eventual outcome is favorable to us. Given
the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Moreover, some of our owned and <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications may in the future be, and certain of our current patent applications are, <FONT STYLE="white-space:nowrap">co-owned</FONT> with third parties. If we are unable to obtain
an exclusive license to any such third-party <FONT STYLE="white-space:nowrap">co-owners&#8217;</FONT> interest in such patents or patent applications, we may need the cooperation of any such <FONT STYLE="white-space:nowrap">co-owners</FONT> of our
patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Furthermore, our competitors may be able to circumvent our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents by
developing similar or alternative technologies or products in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. As a result, our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent portfolio may not provide us with
sufficient rights to exclude others from using or commercializing technology and products similar or identical to any of our technology and product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Patent terms may be inadequate to protect our competitive position on any product candidates for an adequate amount of time. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years
from its earliest U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
patent term of a U.S. patent may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in granting a patent, or may be shortened if a patent
is terminally disclaimed over an earlier-filed patent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Notwithstanding these and other extensions that may be available, the life of a patent, and
the protection it affords, is limited. Even if patents covering any product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of
time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent
portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. Given the expected expiration date of these patents, and the fact that safe harbor protections in many jurisdictions
permit third parties to engage in development, including clinical trials, prior to patent expiry, these patents may not provide us with a meaningful competitive advantage. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we are unable to obtain licenses from third parties on commercially reasonable terms, or fail to comply with our obligations under such agreements, our
business could be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">It may be necessary for us to use the patented or proprietary technology of one or more third parties to develop
or commercialize our current and future product candidates, in which case we would be required to obtain a license from these third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we
are unable to license such technology, or if we are forced to license such technology on unfavorable terms, our business could be materially harmed. If we are unable to obtain a necessary license, or to otherwise acquire the relevant intellectual
property rights, we may be unable to develop or commercialize the affected product candidates, or such development and commercialization may be delayed, which could materially harm our business. In addition, the third parties owning such
intellectual property rights could seek either an injunction prohibiting our sales or an obligation on our part to pay royalties and/or other forms of compensation. Even if we are able to obtain a license, it may be
<FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we are
unable to obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may be required to expend significant time and resources to redesign our technology, product candidates,
or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected
technology and product candidates, which could materially harm our business, financial condition, results of operations and prospects significantly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, if we fail to comply with our obligations under our current and future license agreements, our counterparties may have the right to
terminate these agreements, in which event we might not be able to develop, manufacture or market, or may be forced to cease developing, manufacturing or marketing, any product that is covered by these agreements or may face other penalties under
such agreements. Such an occurrence could materially adversely affect the value of the product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements, or
restrictions on our ability to freely assign or sublicense our rights under such agreements when it is in the interest of our business to do so, may result in our having to negotiate new or reinstated agreements with less favorable terms, cause us
to lose our rights under these agreements, including our rights to important intellectual property or technology or impede, or delay or prohibit the further development or commercialization of one or more product candidates that rely on such
agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may not have the right to control the prosecution, maintenance, enforcement or defense of patents
and patent applications that we license from third parties. In such cases, we would be reliant on the licensor to take any necessary actions. We cannot be certain that such licensor would act with our best interests in mind, or in compliance with
applicable laws and regulations, or that their actions would result in valid and enforceable patents. For example, it is possible that a licensor&#8217;s actions in enforcing and/or defending a patent licensed by use may be less vigorous than had we
conducted them ourselves. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we do not obtain patent term extensions in the United States under the Hatch-Waxman Act and in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> countries under
similar legislation, thereby potentially limiting the term of our marketing exclusivity for any product candidates we may develop, our business may be materially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the United States, the patent term of a patent that covers an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug may be eligible for limited
patent term extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act,
permits a patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent extension cannot extend the remaining term
of a patent beyond a total of 14 years from the date of product approval, and only one patent applicable to an approved drug may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it
may be extended. Similar provisions are available in the European Union and certain other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions to extend the term of a patent that covers an approved drug. While, in the future, if and when
any product candidates receive FDA approval or equivalent approvals in foreign jurisdictions, if available, we expect to apply for patent term extensions on patents covering those product candidates, there is no guarantee that the applicable
authorities will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. We may not be granted patent term extensions either in the United States or in any <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> country because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration
of relevant patents or otherwise failing to satisfy applicable requirements. In addition, to the extent we wish to pursue patent term extension based on a patent that we <FONT STYLE="white-space:nowrap">in-license</FONT> from a third party, we would
need the cooperation of that third party. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request. If we are unable to obtain any
patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products earlier than if such extension was granted as requested by us, and our business, financial condition, results
of operations and prospects could be materially harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">It is possible that we will not obtain patent term extension under the Hatch-Waxman Act for
a U.S. patent covering any of any product candidates that we may identify even where that patent is eligible for patent term extension, or if we obtain such an extension, it may be for a shorter period than we had sought. Further, for our licensed
patents, we may not have the right to control prosecution, including filing with the USPTO a petition for patent term extension under the Hatch-Waxman Act. Thus, if one of our licensed patents is eligible for patent term extension under the
Hatch-Waxman Act, we may not be able to control whether a petition to obtain a patent term extension is filed, or obtained, from the USPTO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Also,
there are detailed rules and requirements regarding the patents that may be submitted to the FDA for listing in the Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. We may be unable to obtain patents covering any
product candidates that contain one or more claims that satisfy the requirements for listing in the Orange Book. Even if we submit a patent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
for listing in the Orange Book, the FDA may decline to list the patent, or a manufacturer of generic drugs may challenge the listing. If a product candidate is approved and a patent covering that
product candidate is not listed in the Orange Book, a manufacturer of generic drugs would not have to provide advance notice to us of any abbreviated new drug application, or ANDA, filed with the FDA to obtain permission to sell a generic version of
such product candidate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing
our ability to protect our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Changes in either the patent laws or interpretation of patent laws in the United States, including
patent reform legislation such as the Leahy-Smith America Invents Act, or the Leahy-Smith Act, could increase the uncertainties and costs surrounding the prosecution of our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent
applications and the maintenance, enforcement or defense of our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> issued patents. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These changes include
provisions that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for competitors to challenge the validity of patents, and enable third-party submission of prior art to the
USPTO during patent prosecution and additional procedures to attack the validity of a patent at USPTO-administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Assuming that other requirements
for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After
March 2013, under the Leahy-Smith Act, the United States transitioned to a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-to-file</FONT></FONT> system in which, assuming that the other statutory requirements for
patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. As such, the Leahy-Smith Act and its
implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial
condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, the patent positions of companies in the development and commercialization of
biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This
combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by Congress, the federal courts, and the USPTO, the laws and regulations governing patents could
change in unpredictable ways that could have a material adverse effect on our patent rights and our ability to protect, defend and enforce our patent rights in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Further, a new court system recently became operational in the European Union. The Unified Patent Court, or UPC, began accepting patent cases on
June&nbsp;1, 2023. The UPC is a common patent court with jurisdiction over patent infringement and revocation proceedings effective for multiple European Union member states. The broad geographic reach of the UPC could enable third parties to seek
revocation of any of our European patents in a single proceeding at the UPC rather than through multiple proceedings in each of the individual European Union member states in which the European patent is validated. Under the UPC, a successful
revocation proceeding for a European Patent under the UPC would result in loss of patent protection in those European Union countries. Accordingly, a single proceeding under the UPC could result in the partial or complete loss of patent protection
in numerous European Union countries. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize our technology and product candidates and, resultantly, on our business, financial
condition, prospects and results of operations. Moreover, the controlling laws and regulations of the UPC will develop over time and we cannot predict what the outcomes of cases tried before the UPC will be. The case law of the UPC may adversely
affect our ability to enforce or defend the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
validity of our European patents. Patent owners have the option to <FONT STYLE="white-space:nowrap">opt-out</FONT> their European Patents from the jurisdiction of the UPC, defaulting to <FONT
STYLE="white-space:nowrap">pre-UPC</FONT> enforcement mechanisms. We have decided to opt out certain European patents and patent applications from the UPC. However, if certain formalities and requirements are not met, our European patents and patent
applications could be subject to the jurisdiction of the UPC. We cannot be certain that our European patents and patent applications will avoid falling under the jurisdiction of the UPC, if we decide to opt out of the UPC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We and our licensors, and any future licensors, may become involved in lawsuits to protect or enforce our patent or other intellectual property rights, which
could be expensive, time-consuming and unsuccessful, and which may result in our patents being found invalid or unenforceable. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Competitors
and other third parties may infringe, misappropriate or otherwise violate our or our current and future licensors&#8217; issued patents or other intellectual property. As a result, we or any current or future licensors may need to file infringement,
misappropriation or other intellectual property related claims, which can be expensive and time- consuming. Any claims we assert against perceived infringers could provoke such parties to assert counterclaims against us alleging that we infringe,
misappropriate or otherwise violate their intellectual property. In addition, in a patent infringement proceeding, such parties could counterclaim that the patents we or our licensors have asserted are invalid or unenforceable. In patent litigation
in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty,
obviousness, or <FONT STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a
misleading statement, during prosecution. Third parties may institute such claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include
<FONT STYLE="white-space:nowrap">re-examination,</FONT> post-grant review, inter partes review, interference proceedings, derivation proceedings, and equivalent proceedings in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions (e.g.,
opposition proceedings). The outcome following legal assertions of invalidity and unenforceability is unpredictable, and the outcome of any intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance,
including the demeanor and credibility of witnesses and the identity of any adverse party. This is especially true in intellectual property cases that may turn on the testimony of experts as to technical facts upon which experts may reasonably
disagree. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">An adverse result in any such proceeding could put one or more of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT>
patents at risk of being invalidated or interpreted narrowly and could put any of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent applications at risk of not yielding an issued patent. A court may also refuse to stop the
third party from using the technology at issue in a proceeding on the grounds that our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents do not cover such technology. Furthermore, because of the substantial amount of discovery
required in connection with intellectual property litigation, there is a risk that some of our confidential information or trade secrets could be compromised by disclosure during this type of litigation. Any of the foregoing could allow such third
parties to develop and commercialize competing technologies and products and have a material adverse impact on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Interference or derivation proceedings provoked by third parties, or brought by us or by our licensors, or declared by the USPTO may be necessary to
determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome in such proceedings could require us to cease using the related technology or to attempt to license rights to it from the prevailing
party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license is offered and our competitors gain access to
the same technology. Our defense of litigation or interference or derivation proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, the uncertainties associated with litigation could have a material adverse effect on our
ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring any product candidates to market.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the
outcome of which would be uncertain and could have a material adverse effect on the success of our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our commercial success depends
upon our ability and the ability of any future collaborators of ours to develop, manufacture, market and sell any product candidates we may develop and use our proprietary technologies without infringing, misappropriating or otherwise violating the
intellectual property and proprietary rights of third parties. There is considerable patent and other intellectual property litigation in the pharmaceutical and biotechnology industries. We may become party to, or threatened with, adversarial
proceedings or litigation regarding intellectual property rights with respect to our technology and product candidates, including interference proceedings, post-grant review, inter partes review, and derivation proceedings before the USPTO and
similar proceedings in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions, such as oppositions before the European Patent Office. Numerous U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> issued patents and pending patent
applications, which are owned by third parties, exist in the fields in which we are pursuing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our technologies or
product candidates that we may identify may be subject to claims of infringement of the patent rights of third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The legal threshold for
initiating litigation or contested proceedings is low, so that even lawsuits or proceedings with a low probability of success might be initiated and require significant resources to defend. Litigation and contested proceedings can also be expensive
and time-consuming, and our adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we can. The risks of being involved in such litigation and proceedings may increase
if and as any product candidates near commercialization and as we gain the greater visibility associated with being a public company. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in
the future, regardless of merit. We may not be aware of all such intellectual property rights potentially relating to our technology and product candidates and their uses, or we may incorrectly conclude that third-party intellectual property is
invalid or that our activities and product candidates do not infringe such intellectual property. Thus, we do not know with certainty that our technology and product candidates, or our development and commercialization thereof, do not and will not
infringe, misappropriate or otherwise violate any third party&#8217;s intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Third parties may assert that we are employing their
proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations or methods, such as methods of manufacture or methods for treatment, related to the discovery, use or
manufacture of the product candidates that we may identify or related to our technologies. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that the
product candidates that we may identify may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Moreover, as noted above, there may be existing patents that we
are not aware of or that we have incorrectly concluded are invalid or not infringed by our activities. If any third-party patents were held by a court of competent jurisdiction to cover, for example, the manufacturing process of the product
candidates that we may identify, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license
under the applicable patents, or until such patents expire. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Parties making claims against us may obtain injunctive or other equitable relief, which could
effectively block our ability to further develop and commercialize the product candidates that we may identify. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of
employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our
infringing products, be forced to indemnify our customers or collaborators or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may choose to take a license or, if we are found to infringe, misappropriate or otherwise violate a third party&#8217;s intellectual property rights,
we could also be required to obtain a license from such third party to continue developing, manufacturing and marketing our technology and product candidates. However, we may not be able to obtain any required license on commercially reasonable
terms or at all. Even if we were able to obtain a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors and other third parties access to the same technologies licensed to us and could require us
to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product. A finding of infringement could prevent us from
commercializing any product candidates or force us to cease some of our business operations, which could materially harm our business. In addition, we may be forced to redesign any product candidates, seek new marketing approvals and indemnify third
parties pursuant to contractual agreements. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on our business, financial condition, results of operations
and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Intellectual property litigation or other legal proceedings relating to intellectual property could cause us to spend substantial resources
and distract our personnel from their normal responsibilities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Litigation or other legal proceedings relating to intellectual property
claims, with or without merit, are unpredictable and generally expensive and time-consuming. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and
could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or
investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for
development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs
of such litigation or proceedings more effectively than we can because of their greater financial resources and may also have an advantage in such proceedings due to their more mature and developed intellectual property portfolios. Uncertainties
resulting from the initiation and continuation of intellectual property litigation or other proceedings could compromise our ability to compete in the marketplace. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by
governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Periodic maintenance, renewal and annuity fees and various other government fees on any issued patent and pending patent application must be paid to the
USPTO and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent agencies in several stages or annually over the lifetime of our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
patent applications. The USPTO and various <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent agencies also require compliance with a number of procedural, documentary and other similar
provisions during the patent application process. With respect to our patents, we rely on an annuity service, outside firms and outside counsel to remind us of the due dates and to make payment after we instruct them to do so. While an inadvertent
lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which <FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment or lapse of the
patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. <FONT STYLE="white-space:nowrap">Non-compliance</FONT> events that could result in abandonment or lapse of a patent or patent
application include failure to respond to official actions within prescribed time limits, <FONT STYLE="white-space:nowrap">non-payment</FONT> of fees and failure to properly legalize and submit formal documents. In such an event, potential
competitors might be able to enter the market with similar or identical products or technology. If we or our current or future licensors fail to maintain the patents and patent applications covering any product candidates, it may have a material
adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may not be able to protect our intellectual property and
proprietary rights throughout the world. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Filing, prosecuting and defending patents on product candidates in all countries throughout the
world would be prohibitively expensive, and the laws of <FONT STYLE="white-space:nowrap">non-U.S.</FONT> countries may not protect our rights to the same extent as the laws of the United States. In addition, the laws of some <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> countries do not protect intellectual property rights to the same extent as federal and state laws in the United States, and even where such protection is nominally available, judicial and governmental
enforcement of such intellectual property rights may be lacking. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using
our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing
products to territories where we have patent protection or licenses but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be
effective or sufficient to prevent them from competing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Many companies have encountered significant problems in protecting and defending
intellectual property rights in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions. The legal systems of certain countries do not favor the enforcement of patents, trade secrets, and other intellectual property rights, particularly those
relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. In addition, certain
jurisdictions do not protect to the same extent or at all inventions that constitute new methods of treatment. Proceedings to enforce our intellectual property and proprietary rights in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions
could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and
could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual
property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. Many countries have compulsory licensing laws under which a patent owner may
be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could
materially diminish the value of such patent. If we or any of our current or future licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patents, trade secrets or other intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> For example, we or our licensors may have inventorship disputes arise from
conflicting obligations of employees, consultants or others who are involved in developing any product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#8217; ownership
of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable
intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to any product candidates. Even if we are successful in defending against such claims, litigation could result in substantial
costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may be subject to claims by third parties asserting that our employees, consultants or contractors have wrongfully used or disclosed confidential information
of third parties, or we have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting we have misappropriated their intellectual property, or claiming ownership of what we regard as our own
intellectual property. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Certain of our employees, consultants and contractors were previously employed at universities or other
pharmaceutical or biotechnology companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and contractors do not use the proprietary information or
<FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any
such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, while it is our policy
to require that our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with
each party who in fact develops intellectual property that we regard as our own. In addition, even when we obtain agreements assigning intellectual property to us, such intellectual property assignment agreements may not be self-executing or may be
breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. Furthermore, individuals executing agreements with us may
have preexisting or competing obligations to a third party, such as an academic institution, and thus an agreement with us may be ineffective in perfecting ownership of inventions developed by that individual. Such claims could have a material
adverse effect on our business, financial conditions, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, we or our licensors may in the future be
subject to claims by former employees, consultants or other third parties asserting an ownership right in our owned or licensed patents or patent applications. An adverse determination in any such claim or proceeding may result in loss of
exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar technology and product candidates. Such
challenges may also result in our inability to develop, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
manufacture or commercialize technology and product candidates infringing third-party patent rights. Any of the foregoing could have a material adverse effect on our business, financial
condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we
may lose valuable intellectual property rights or personnel, which could have a material adverse effect on our competitive business position and prospects. Such intellectual property rights could be awarded to a third party, and we could be required
to obtain a license from such third party to commercialize our technology or products, which license may not be available on commercially reasonable terms, or at all, or such license may be <FONT STYLE="white-space:nowrap">non-exclusive.</FONT> Even
if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and employees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we are unable to protect the confidentiality of our proprietary information, our business and competitive position may be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to seeking patents for any product candidates, we also rely on confidentiality agreements to protect our unpatented <FONT
STYLE="white-space:nowrap">know-how,</FONT> technology and other proprietary information, to maintain our competitive position. We seek to protect our proprietary technology, in part, by entering into
<FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants,
advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants, but we cannot guarantee that we have entered into such agreements with each party that may have or
has had access to our proprietary technology. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information and we may not be able to obtain adequate remedies for such breaches. We may also rely on
trade secrets to maintain our competitive position. Detecting the disclosure or misappropriation of a trade secret and enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming,
and the outcome is unpredictable. In addition, some courts inside and outside of the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a
competitor or other third party, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently
developed by a competitor or other third party, our competitive position may be materially and adversely harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If our trademarks and trade names are not
adequately protected, then we may not be able to build name recognition in our markets of interest. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our future trademark applications in the
United States and in foreign jurisdictions may not be allowed or may subsequently be opposed. Once filed and registered, our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on
other marks. As a means to enforce our trademark rights and prevent infringement, we may be required to file trademark claims against third parties or initiate trademark opposition proceedings. This can be expensive and time-consuming. We may not be
able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours,
thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that
incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our
business </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be
ineffective and could result in substantial costs and diversion of resources. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Intellectual property rights do not necessarily address all potential threats. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may
not adequately protect our business or permit us to maintain our competitive advantage. For example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">others may be able to make product candidates that are similar to ours but that are not covered by the claims of the
patents that we own or license; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we, or our licensors or current or future collaborators, might not have been the first to make the inventions covered by
the issued patent or pending patent applications that we own or license; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we, or our licensors or current or future collaborators, might not have been the first to file patent applications covering
certain of our or their inventions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">others may independently develop similar or alternative technologies or duplicate our technologies without infringing our
owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">others may circumvent our regulatory exclusivities, such as by pursuing approval of a competitive product via the
traditional approval pathway based on their own clinical data, rather than relying on the abbreviated pathway provided for biosimilar or generic applicants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">it is possible that our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> pending patent applications or those
we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> in the future will not lead to issued patents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">issued patents that we hold rights to now or in the future may be held invalid or unenforceable, including as a result of
legal challenges by our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our competitors might conduct research and development activities in countries where we do not have patent rights, or in
countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights which will be
costly and time consuming regardless of outcome; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on
our business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we cannot ensure that any of our patents, or any of our pending patent applications, if issued, or those of our licensors,
will include claims having a scope sufficient to protect any product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we cannot ensure that any patents issued to us or our current or future licensors will provide a basis for an exclusive
market for our commercially viable product candidates or will provide us with any competitive advantages; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we cannot ensure that our commercial activities or product candidates will not infringe upon the patents of others;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we cannot ensure that we will be able to successfully commercialize any product candidates on a substantial scale, if
approved, before the relevant patents that we own or license expire; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may not develop additional proprietary technologies that are patentable; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the patents of others may harm our business; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may choose not to file a patent in order to maintain certain technology as trade secrets or <FONT
STYLE="white-space:nowrap">know-how,</FONT> and a third party may subsequently file a patent application covering such technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Marketing Approval of Our Product Candidates and Other Legal Compliance Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may
prevent us from obtaining approvals for the commercialization of some or all of our product candidates. As a result, we cannot predict when or if, and in which territories, we will obtain marketing approval to commercialize a product candidate.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The research, testing, manufacturing, labeling, approval, selling, marketing, promotion and distribution of products are subject to
extensive regulation by the FDA, EMA and comparable regulatory authorities in other jurisdictions. We are not permitted to market our product candidates in the United States, the European Union or in other jurisdictions until we receive approval of
a BLA from the FDA or marketing approval from the European Union or other applicable regulatory authorities. Our product candidates are in various stages of development and are subject to the risks of failure inherent in development. We have not
submitted an application for or received marketing approval for any of our product candidates in the United States, the European Union or in any other jurisdiction. Additionally, we have no experience as a company in filing and supporting the
applications necessary to gain marketing approvals and expect to rely on third-party CROs to assist us in this process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The process of obtaining
marketing approvals, both in the United States, the European Union and in other jurisdictions, is lengthy, expensive and uncertain. It may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors,
including the type, complexity and novelty of the product candidates involved. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information, including manufacturing information, to
regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety, potency and purity. The FDA or other regulatory authorities may determine that our product candidates are not safe, potent or pure, only
moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us and receive compensation in connection
with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or a comparable foreign regulatory authority may conclude that a financial
relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the clinical trial. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data
generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory
authority, as applicable, and may ultimately lead to the denial of marketing approval of one or more of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Further, under the
Pediatric Research Equity Act of 2003, or PREA, a BLA or supplement thereto must contain data that are adequate to assess the safety, potency and purity of the product for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe, potent or pure, unless
granted a deferral or waiver. A deferral may be granted for several reasons, including a finding that the product or therapeutic candidate is ready for approval for use in adults before pediatric trials are complete or that additional data needs to
be collected before the pediatric trials begin. The applicable legislation in the European Union also requires sponsors to either conduct clinical trials in a pediatric population in accordance with a Pediatric Investigation Plan approved by the
Pediatric Committee of the EMA or to obtain a waiver or deferral from the conduct of these studies by this Pediatric Committee. For any of our product candidates for which we are seeking marketing approval in the United States or the European Union,
we cannot guarantee that we will be able to obtain a waiver or alternatively complete any required studies and other requirements in a timely manner, or at all, which could result in associated reputational harm and subject us to enforcement action.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional
statutes, regulations or guidance or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. For example, in December 2022, with the passage of the Food and Drug Omnibus
Reform Act, or FDORA, Congress required sponsors to develop and submit a diversity action plan, or DAP, for each Phase 3 clinical trial or any other &#8220;pivotal study&#8221; of a new drug product. These plans are meant to encourage the enrollment
of more diverse patient populations in late-stage clinical trials of <FONT STYLE="white-space:nowrap">FDA-regulated</FONT> products. In June 2024, as mandated by FDORA, the FDA issued draft guidance outlining the general requirements for DAPs.
Unlike most guidance documents issued by the FDA, the DAP guidance, when finalized, will have the force of law because FDORA specifically dictates that the form and manner for submission of DAPs are specified in FDA guidance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On January&nbsp;27, 2025, in response to an Executive Order issued by President Trump on January&nbsp;21, 2025, relating to Diversity, Equity and
Inclusion programs, the FDA removed the draft DAP guidance from its website. That action, along with similar actions by the Trump Administration to remove many other healthcare webpages, is currently the subject of ongoing litigation. In late July
2025, pursuant to a court order, the FDA restored the draft DAP guidance to its website with a statement that &#8220;information on this page may be modified and/or removed in the future subject to the terms of the court&#8217;s order and
implemented consistent with applicable law.&#8221; Accordingly, in light of these ongoing actions, there is considerable uncertainty surrounding the draft DAP guidance and how the FDA will consider diversity action plans in connection with its
review of BLAs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Further, in January 2022, the new Clinical Trials Regulation (EU) No 536/2014, or CTR, became effective in the European Union and
replaced the prior Clinical Trials Directive 2001/20/EC. This regulation aims at simplifying and streamlining the authorization, conduct and transparency of clinical trials in the European Union. Under the coordinated procedure for the approval of
clinical trials, the sponsor of a clinical trial to be conducted in more than one European Union member state is only required to submit a single application for approval by each applicable European Union member state. The submission will be made
through the Clinical Trials Information System, a clinical trials portal overseen by the EMA and available to clinical trial sponsors, competent authorities of the European Union member states and the public. While the CTR has been in place for
several years, and applied to all clinical studies in the European Union as of January&nbsp;31, 2025, we will need to carefully navigate our compliance with the CTR to ensure that it does not delay our ability to commence and conduct clinical
studies in the European Union. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, the FDA may determine that we must provide additional evidence and data before approving a BLA for any
of our product candidates. For example, the novel nature of our product candidates may create further challenges in obtaining regulatory approval. That may be because: sutacimig is a bispecific antibody with a novel mechanism targeting Factor VII to
activated platelets via <FONT STYLE="white-space:nowrap">TLT-1,</FONT> which has not been previously exploited therapeutically, and regulatory authorities may have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
limited experience reviewing similar mechanisms and may require additional data to support approval; our product candidates target bleeding disorders where traditional clinical trial designs and
endpoints used in more common bleeding disorders (such as hemophilia A and B) may not be fully applicable or validated; for Glanzmann thrombasthenia and Factor VII deficiency, there are no approved prophylactic therapies, so we cannot rely on
precedent for endpoint selection, trial design, or benefit-risk assessment; and for Von Willebrand Disease, we will need to demonstrate that increasing endogenous VWF and Factor VIII levels translates to clinically meaningful bleeding reduction,
which may require longer-term trials with bleed rate endpoints. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA reviews an application to determine whether there is &#8220;substantial
evidence&#8221; to support a finding of effectiveness for the proposed product for its intended use(s). The FDA has interpreted this evidentiary standard to generally require two adequate and well-controlled clinical trials to establish
effectiveness of a new product. Under certain circumstances, however, the FDA has indicated that a single trial with certain characteristics and additional information may satisfy this standard. The FDA issued draft guidance in September 2023 that
outlines considerations for relying on confirmatory evidence in lieu of a second clinical trial to demonstrate efficacy. The FDA has not yet finalized such guidance but, in February 2026, the Commissioner of the FDA and the Director of the
FDA&#8217;s Center for Biologics Evaluation and Research published an editorial in the New England Journal of Medicine in which they declared that, in most cases, the new default requirement for FDA approval of a new product will be one robust
pivotal clinical trial plus confirmatory evidence, rather than two pivotal clinical trials. In determining whether to rely on one trial, the FDA will focus on the single trial&#8217;s quality, including magnitude of effect, appropriateness of
control arms, endpoint selection, statistical power, blinding, handling of missing data, biological plausibility and alignment with intermediate biomarkers. While the FDA has long had authority to approve new products in this manner and, in recent
years, has exercised that authority with respect to certain types of products, the publication declares that this will be the new official default standard for most new products. This approach will reportedly be implemented as the FDA places a
greater emphasis on collecting robust post-marketing data on all pharmaceutical products. At this point, it is unclear how this new policy will be implemented by the FDA and how, if at all, it will affect our clinical development programs. Moreover,
although we are planning to conduct a multinational, multicenter, Phase 3, single-arm, open-label clinical trial evaluating sutacimig as a prophylactic therapy in adults with Glanzmann thrombasthenia, the FDA may determine that a randomized
controlled clinical trial is necessary to support filing and approval of our BLA. We intend to schedule a Type D meeting with the FDA in the coming months to obtain the FDA&#8217;s feedback on, and seek alignment regarding, our proposed Phase 3
trial design. A Type D meeting is intended to facilitate focused discussion on a limited number of specific issues, but there can be no assurance that the FDA will agree with our proposed approach. Our failure to timely agree with the FDA on the
design of our planned Phase 3 clinical trial may lead to delays in its initiation and completion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Regulatory authorities have substantial
discretion in the approval process and varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be
limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. Regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not
approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials or may approve a product candidate with a label that does not include the labeling claims necessary or
desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We could also be adversely affected by several significant administrative law cases decided by the U.S. Supreme Court in 2024. In <I>Loper Bright
Enterprises v. Raimondo</I>, for example, the court overruled <I>Chevron U.S.A., Inc. v. Natural Resources Defense Council, Inc.</I>, which for 40 years required federal courts to defer to permissible agency interpretations of statutes that are
silent or ambiguous on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
a particular topic. The U.S. Supreme Court stripped federal agencies of this presumptive deference and held that courts must exercise their independent judgment when deciding whether an agency
such as the FDA acted within its statutory authority under the Administrative Procedure Act, or APA. Additionally, in <I>Corner Post, Inc. v. Board of Governors of the Federal Reserve System</I>, the U.S. Supreme Court held that actions to challenge
a federal regulation under the APA can be initiated within six years of the date of injury to the plaintiff, rather than the date the rule is finalized. The decision appears to give prospective plaintiffs a personal statute of limitations to
challenge longstanding agency regulations. Another decision, <I>Securities and Exchange Commission v. Jarkesy</I>, overturned regulatory agencies&#8217; ability to impose civil penalties in administrative proceedings. These decisions could introduce
additional uncertainty into the regulatory process and may result in additional legal challenges to actions taken by federal regulatory agencies, including the FDA and the Center for Medicare&nbsp;&amp; Medicaid Services, or CMS, on which we rely.
In addition to potential changes to regulations as a result of legal challenges, these decisions may result in increased regulatory uncertainty and delays and other impacts, any of which could adversely impact our business and operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Finally, our ability to develop and market new drug products may be impacted if litigation challenging the FDA&#8217;s approval of another
company&#8217;s drug product continues. In April 2023, the U.S. District Court for the Northern District of Texas invalidated the approval by the FDA of mifepristone, a drug product which was originally approved in 2000 and whose distribution is
governed by various measures adopted under a REMS. The Court of Appeals for the Fifth Circuit declined to order the removal of mifepristone from the market but did hold that plaintiffs were likely to prevail in their claim that changes allowing for
expanded access of mifepristone, which the FDA authorized in 2016 and 2021, were arbitrary and capricious. In June 2024, the U.S. Supreme Court reversed that decision after unanimously finding that the plaintiffs did not have standing to bring this
legal action against the FDA. On October&nbsp;11, 2024, the Attorneys General of three states filed an amended complaint in the district court in Texas challenging the FDA&#8217;s actions. On January&nbsp;16, 2025, the district court in Texas agreed
to allow these states to file an amended complaint and continue to pursue this challenge. Thereafter, on September&nbsp;30, 2025, the district court in Texas declined to dismiss the case and, instead, transferred it to the federal district court in
the Eastern District of Missouri. Depending on the outcome of this litigation, our ability to develop new product candidates and to maintain approval of any then-existing drug products could be at risk and could be delayed, undermined or subject to
protracted litigation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Failure to obtain marketing approval in the European Union or other jurisdictions outside the United States would prevent our product
candidates from being marketed in those jurisdictions. Any approval we may be granted for our product candidates in the United States would not ensure approval of our product candidates in the European Union or any other jurisdictions and any of our
product candidates that may be approved for marketing in the European Union or another jurisdiction will be subject to risks associated with operation in such jurisdiction. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We intend to market our current product candidates, if approved, in the European Union and other markets outside of the United States either directly or
through collaborations. In order to market and sell our products in the European Union and other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying
regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The marketing approval process
outside the United States generally includes all of the risks associated with obtaining FDA approval. We may not obtain approvals from the European Union and regulatory authorities outside the United States on a timely basis, if at all. Approval by
the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions
or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
by the FDA. We may file for marketing approvals but not receive necessary approvals to commercialize our product candidates in any market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In many countries outside the United States, a product candidate must also be approved for reimbursement before it can be sold in that country. In some
cases, the price that we intend to charge for our products, if approved, is also subject to approval. Obtaining <FONT STYLE="white-space:nowrap">non-U.S.</FONT> marketing approvals and compliance with <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our product candidates in certain countries. In addition, if we fail to obtain the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> approvals required to market our product candidates outside the United States or if we fail to comply with applicable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory requirements, our target
markets will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business, financial condition, results of operations and prospects may be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, we could face heightened risks with respect to obtaining marketing authorization in the United Kingdom as a result of the withdrawal of
the United Kingdom from the European Union, commonly referred to as Brexit. The United Kingdom is no longer part of the European Single Market and EU Customs Union. As of January&nbsp;1, 2025, the Medicines and Healthcare products Regulatory Agency,
or MHRA, is responsible for approving all medicinal products destined for the U.K. market (i.e., Great Britain and Northern Ireland). On April&nbsp;28, 2025, the U.K. Parliament adopted amendments to improve and strengthen the United Kingdom&#8217;s
clinical trials regulatory regime, which will take effect on April&nbsp;28, 2026. Since the United Kingdom left the European Union prior to the date on which the EU Clinical Trials Regulation (Regulation EU No 536/2014) took effect, the U.K. legal
framework (which was based upon the <FONT STYLE="white-space:nowrap">now-repealed</FONT> EU Clinical Trials Directive (2001/20/EC)) did not benefit from the same revisions as occurred in the European Union. In anticipation of these new requirements,
on October&nbsp;1, 2025, the MHRA updated its guidance for clinical trials to address, among other things, research transparency requirements for clinical trials, the approvals process, the Research Ethics Committee review of clinical trials,
simplified arrangements for consent in clinical trials and pharmacovigilance. We will need to ensure that we comply with the new U.K. regulatory regime for any clinical trials we conduct in the United Kingdom, which could add time and expense to our
conduct of such trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">At the same time, the United Kingdom has introduced a new international recognition procedure, or IRP, which is intended to
facilitate approval of pharmaceutical products in the United Kingdom. The IRP is open to applicants that have already received an authorization for the same product from one of the MHRA&#8217;s specified Reference Regulators, or RRs. The RRs notably
include the EMA and regulators in the European Union/European Economic Area, or EEA, member states for approvals in the European Union centralized procedure and mutual recognition procedure as well as the FDA (for product approvals granted in the
United States). However, the IRP does not guarantee that a marketing authorization will be granted in the United Kingdom for all products with an approval from the EMA, and the MHRA retains the authority to reject applications if the evidence
provided is considered insufficiently robust. Any delay in obtaining, or an inability to obtain, any marketing approvals may force us or any of our future collaborators to restrict or delay efforts to seek regulatory approval in the United Kingdom
for our product candidates, which could significantly and materially harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, the EU pharmaceutical legislation is currently
undergoing a complete review process, in the context of the Pharmaceutical Strategy for Europe initiative, launched by the European Commission in November 2020. The European Commission&#8217;s proposal for revision of several legislative instruments
related to medicinal products, which may reduce the duration of regulatory data protection and exclusivity periods for orphan drugs, and revise the eligibility for expedited pathways in addition to other changes, was published on April&nbsp;26,
2023. On June&nbsp;4, 2025, after almost two years of negotiations among the European Union member states, the Council of the European Union adopted </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
its position on the proposed overhaul of the EU general pharmaceutical legislative framework, which is known as the new Pharma Package. On December&nbsp;11, 2025, the European Parliament and
European Council reached a provisional political agreement on the legislation. The revisions may have a significant impact on the pharmaceutical industry and our business. The new Pharma Package would, among other things, set a baseline period of
eight years of data exclusivity and one year of market exclusivity with possible extensions for new indications up to a maximum of 11 years total. The new framework is expected to be adopted by <FONT STYLE="white-space:nowrap">mid-2026</FONT> and
there will likely be a transition period of 24 months, with the changes taking effect in <FONT STYLE="white-space:nowrap">mid-2028.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We
expect that we will be subject to additional risks in commercializing any of our product candidates that receive marketing approval outside the United States, including tariffs, trade barriers and regulatory requirements; economic weakness,
including inflation or political instability in particular foreign economies and markets; compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; foreign currency fluctuations, which could result in
increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; and workforce uncertainty in countries where labor unrest is more common than in the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Any marketing approval to market our products will be limited by indication. If we fail to comply or are found to be in violation of FDA regulations restricting
the promotion of our products for unapproved uses, we could be subject to criminal penalties, substantial fines or other sanctions and damage awards. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The regulations relating to the promotion of products for unapproved uses are complex and subject to substantial interpretation by the FDA, EMA, MHRA and
other government agencies. In September 2021, the FDA published final regulations which describe the types of evidence that the FDA will consider in determining the intended use of a drug product. Moreover, with the passage of the <FONT
STYLE="white-space:nowrap">Pre-Approval</FONT> Information Exchange Act in December 2022, sponsors of products that have not been approved may proactively communicate to payors certain information about products in development to help expedite
patient access upon product approval. Physicians may nevertheless prescribe our products <FONT STYLE="white-space:nowrap">off-label</FONT> to their patients in a manner that is inconsistent with the approved label. The use of our product candidates
for indications other than those approved by the FDA may not effectively treat such conditions. Any such <FONT STYLE="white-space:nowrap">off-label</FONT> use of our product candidates could harm our reputation in the marketplace among physicians
and patients. There may also be increased risk of injury to patients if physicians attempt to use our product candidates for these uses for which they are not approved, which could lead to product liability suits that might require significant
financial and management resources and that could harm our reputation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In January 2025, the FDA published final guidance outlining its policies
governing the distribution of scientific information to healthcare providers about unapproved uses of approved products. The final guidance calls for such communications to be truthful, <FONT STYLE="white-space:nowrap">non-misleading</FONT> and
scientifically sound and to include all information necessary for healthcare providers to interpret the strengths and weaknesses and validity and utility of the information about the unapproved use of the approved product. Notwithstanding these
programs, the FDA or other government agencies may allege or find that our practices constitute prohibited promotion of our products for unapproved uses. We also cannot be sure that our employees will comply with company policies and applicable
regulations regarding the promotion of products for unapproved uses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, companies may also communicate information that is consistent
with the prescribing information and may proactively speak to payors, formulary committees, and similar entities regarding healthcare economic information data for an unapproved drug or unapproved uses of an approved drug. We may engage in these
discussions and communicate with healthcare providers, payors and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
other constituencies in compliance with all applicable laws, regulatory guidance and industry best practices. We will need to carefully navigate the FDA&#8217;s various regulations, guidance and
policies, along with recently enacted legislation, to ensure compliance with restrictions governing promotion of our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In recent years, a
significant number of pharmaceutical and biotechnology companies have been the target of inquiries and investigations by various federal and state regulatory, investigative, prosecutorial and administrative entities in connection with the promotion
of products for unapproved uses and other sales practices, including the Department of Justice and various U.S. Attorneys&#8217; Offices, the Office of Inspector General of the Department of Health and Human Services, the FDA, the Federal Trade
Commission, or the FTC, and various state Attorneys General offices. These investigations have alleged violations of various federal and state laws and regulations, including claims asserting antitrust violations, violations of the Federal Food,
Drug and Cosmetic Act, or FDCA, the False Claims Act, the Prescription Drug Marketing Act and anti-kickback laws and other alleged violations in connection with the promotion of products for unapproved uses, pricing and Medicare and/or Medicaid
reimbursement. Many of these investigations originate as &#8220;<I>qui tam</I>&#8221; actions under the False Claims Act. Under the False Claims Act, any individual can bring a claim on behalf of the government alleging that a person or entity has
presented a false claim or caused a false claim to be submitted to the government for payment. The person bringing a <I>qui tam </I>suit is entitled to a share of any recovery or settlement. <I>Qui tam </I>suits, also commonly referred to as
&#8220;whistleblower suits,&#8221; are often brought by current or former employees. In a <I>qui tam </I>suit, the government must decide whether to intervene and prosecute the case. If it declines, the individual may pursue the case alone. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For example, in September 2025, President Trump issued a Memorandum&nbsp;directing the U.S. Department of Health and Human Services, or HHS, to
&#8220;ensure transparency and accuracy in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> prescription drug advertising, including by increasing the amount of information regarding any risks
associated with the use of any such prescription drug required to be provided in prescription drug advertisements.&#8221; To that end, the FDA announced that it is initiating a rulemaking process &#8220;to eliminate the &#8216;adequate
provision&#8217; loophole that allows pharmaceutical advertisements to hide safety information by placing it in another format or location.&#8221; In this context, the FDA declared that it will no longer tolerate what it characterized as
&#8220;deceptive practices&#8221; in prescription drug advertising and that the FDA would &#8220;aggressively deploy&#8221; its available enforcement tools, with &#8220;heightened scrutiny&#8221; of fair balance and disclosures in social media
promotions. The FDA also issued a generic &#8220;notice letter&#8221; directing companies to &#8220;remove any noncompliant advertising and bring all promotional communications into compliance.&#8221; The FDA has subsequently increased its
enforcement scrutiny over prescription drug advertising, particularly <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> product promotion and advertising. If the FDA finds any of our promotional
communications or advertising to be violative, we may receive an untitled or warning letter, requests for corrective advertising, or fines, amongst other enforcement tools available to the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If the FDA or any other governmental agency initiates an enforcement action against us or if we are the subject of a <I>qui tam </I>suit and it is
determined that we violated prohibitions relating to the promotion of products for unapproved uses, we could be subject to substantial civil or criminal fines or damage awards and other sanctions such as consent decrees and corporate integrity
agreements pursuant to which our activities would be subject to ongoing scrutiny and monitoring to ensure compliance with applicable laws and regulations. Any such fines, awards or other sanctions would have an adverse effect on our revenue,
business, financial prospects and reputation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Any product for which we obtain marketing approval in the future could be subject to post-marketing
restrictions or withdrawal from the market, and we may be subject to substantial </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>
penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with any such product following approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any product for which we obtain marketing approval, as well as the manufacturing processes, post-approval studies and measures, labeling, advertising and
promotional activities for such product, among other things, will be subject to ongoing requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and
reports, registration and listing requirements, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and
recordkeeping. Manufacturers of approved products and their facilities are subject to continual review and periodic and unannounced inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and standards. Even if
marketing approval of a product is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including the requirement to implement a REMS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a
product. The FDA and other agencies, including the Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are manufactured, marketed and distributed only for the approved
indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding <FONT STYLE="white-space:nowrap">off-label</FONT> use and if we market any product
for an indication that is not approved, we may be subject to warnings or enforcement action for <FONT STYLE="white-space:nowrap">off-label</FONT> marketing. Violation of the FDCA and other statutes, including the False Claims Act, relating to the
promotion and advertising of prescription drugs may lead to investigations or allegations of violations of federal and state healthcare fraud and abuse laws and state consumer protection laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, later discovery of previously unknown adverse events or other problems with any product for which we may obtain marketing approval and its
manufacturers or manufacturing processes or failure to comply with regulatory requirements, may yield various results, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restrictions on such product, manufacturers or manufacturing processes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restrictions on the labeling or marketing of the product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restrictions on product distribution or use; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">requirements to conduct post-marketing studies or clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">warning letters or untitled letters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">withdrawal of the product from the market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">refusal to approve pending applications or supplements to approved applications that we submit; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">recall of the product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restrictions on coverage by third-party payors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">fines, restitution or disgorgement of profits or revenues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">suspension or withdrawal of marketing approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">refusal to permit the import or export of the product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">product seizure; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Similar restrictions apply to the authorization and post-authorization supervision of our products in
the European Union. The holder of a marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. These include: compliance with the European
Union&#8217;s stringent pharmacovigilance or safety reporting rules, which can impose post-authorization studies and additional monitoring obligations; the manufacturing of authorized medicinal products, for which a separate manufacturer&#8217;s
license is mandatory; and the marketing and promotion of authorized drugs, which are strictly regulated in the European Union and are also subject to European Union member state laws. The failure to comply with these and other EU requirements can
also lead to significant penalties and sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Accordingly, assuming we, or any future collaborators of ours, receive marketing approval for one
or more of our product candidates, we, and any future collaborators of ours, and our and their contract manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product
surveillance and quality control. If we, and any future collaborators of ours, are not able to comply with post-approval regulatory requirements, our or any future collaborators of ours ability to market any future products could be limited, which
could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If approved, our product candidates that are licensed and regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory
pathway. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Biologics Price Competition and Innovation Act of 2009, or the BPCIA, was enacted as part of the Patient Protection and
Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Amendment, or ACA, to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway
establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an approved biologic. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the BPCIA, a reference biological product is granted 12 years of data exclusivity from the time of first licensure of the product, and the FDA
will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product. In addition, the licensure of a biosimilar product may
not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity, another company may still develop and receive
licensure of a competing biologic, so long as its BLA does not rely on the reference product, sponsor&#8217;s data or submit the application as a biosimilar application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe that any of the product candidates we develop as a biological product under a BLA should qualify for the
<FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity. However, there is a risk that this exclusivity could be shortened due to U.S. congressional action or otherwise, or that the FDA will not consider our product candidates to be
reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. Further, the FDA may revise the standards governing the approval of biosimilars so as to bring such products to the
market more quickly. For example, in October 2025, the FDA issued draft guidance which proposes to eliminate the need for sponsors of biosimilar products to conduct comparative human clinical efficacy studies in many circumstances, allowing them to
rely instead on analytical testing to assess product differences from a reference product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, the extent to which a biosimilar, once
approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for <FONT STYLE="white-space:nowrap">non-biological</FONT> products will depend on a number of marketplace and
regulatory factors that are still developing. There have been recent government proposals to reduce the <FONT STYLE="white-space:nowrap">12-year</FONT> reference product exclusivity period, but </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
none has been enacted to date. At the same time, since passage of the BPCIA, many states have passed laws or amendments to laws, which address pharmacy practices involving biosimilar products.
The approval of a biosimilar to our product candidates would have a material adverse impact on our business due to increased competition and pricing pressure. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have sought and received Fast Track designation, Breakthrough Therapy designation and ILAP designation in the United Kingdom and may in the future seek
additional designations for our product candidates, including but not limited to Priority Review designation in the United States, and PRIority Medicines, or PRIME, Designation in the European Union, but we might not receive such designations, and
even if we do, such designations may not lead to a faster development or regulatory review or approval process. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have received and may in
the future seek certain designations for one or more of our product candidates that could expedite review and approval by the FDA. A Breakthrough Therapy product is defined as a product that is intended, alone or in combination with one or more
other products, to treat a serious condition, and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment
effects observed early in clinical development. For products that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical
development while minimizing the number of patients placed in ineffective control regimens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA may also designate a product for Fast Track
review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease
or condition. For Fast Track products, sponsors may have greater interactions with the FDA, and the FDA may initiate review of sections of a Fast Track product&#8217;s application before the application is complete. This rolling review may be
available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a Fast Track product may be effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have received Fast Track and Breakthrough Therapy designations for sutacimig for the treatment of Glanzmann thrombasthenia and may seek Fast Track
and Breakthrough Therapy designations for sutacimig in other indications or for other of our product candidates, but such designation may not lead to a faster development or regulatory review and approval process or increase the likelihood that such
product candidate will receive regulatory approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may also seek a Priority Review designation for one or more of our product candidates. If
the FDA determines that a product candidate is intended to treat a serious condition and, if approved, offers a significant improvement in safety or effectiveness, the FDA may designate the product candidate for priority review. Significant
improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to
improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A Priority Review designation means that the goal for the FDA to review an application is six months, rather than the standard review period of ten
months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These designations are within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the
criteria for these designations, the FDA may disagree and instead determine not to make such designation. Further, even if we receive a designation, the receipt of such designation for a product candidate may not result in a faster development or
regulatory review or approval process compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualifies for these
designations, the FDA may later decide that the product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In September 2025, the FDA introduced a framework intended to streamline the approval of new therapies
for ultrarare diseases. The Rare Disease Evidence Principles framework is intended to allow sponsors to rely on a <FONT STYLE="white-space:nowrap">single-arm</FONT> trial in support of approval of biologics that treat rare diseases with very small
patient populations and where the disease is linked to a known genetic defect and characterized by progressive functional deterioration leading to disability or death in a short period of time. The targeted diseases should also lack adequate
alternative therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the European Union, we may seek PRIME designation for our product candidates in the future. PRIME is a voluntary program
aimed at enhancing the EMA&#8217;s role to reinforce scientific and regulatory support in order to optimize development and enable accelerated assessment of new medicines that are of major public health interest with the potential to address unmet
medical needs. The program focuses on medicines that target conditions for which there exists no satisfactory method of treatment in the European Union or, if such a method exists, the medicine offers a major therapeutic advantage over existing
treatments. PRIME is limited to medicines under development and not authorized in the European Union, where the applicant intends to apply for an initial marketing authorization application through the centralized procedure. To be accepted for
PRIME, a product candidate must meet the eligibility criteria in respect of its major public health interest and therapeutic innovation based on information that is capable of substantiating the claims. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The benefits of a PRIME designation include the appointment of a Committee for Medicinal Products for Human Use, or CHMP, rapporteur to provide
continued support and help to build knowledge ahead of a marketing authorization application, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review, meaning reduction in the
review time for an opinion on approvability to be issued earlier in the application process. PRIME enables an applicant to request parallel EMA scientific advice and health technology assessment advice to facilitate timely market access. Even if we
receive PRIME designation for any of our product candidates, the designation may not result in a materially faster development process, review or approval compared to conventional EMA procedures. Further, obtaining PRIME designation does not assure
or increase the likelihood of the European Commission&#8217;s grant of a marketing authorization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the United Kingdom, sutacimig has received
innovative licensing and access pathway, or ILAP. designation from the MHRA for the treatment of Glanzmann thrombasthenia. The ILAP is open to sponsors of potentially transformative medicines or drug-device combination products that address unmet
medical needs. It supports products with evidence of safe use in humans but before confirmatory trials have started. It is designed to reduce the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> timeline for
research and development, regulatory approval and timely adoption of new technologies to benefit patients and the healthcare system in the United Kingdom. To these ends, the ILAP comprises an Innovation Passport designation, a Target Development
profile and a toolkit to support all stages of the design, development and approval process. As with expedited review and approval programs in other jurisdictions, the designation of sutacimig under the ILAP does not guarantee approval of this
candidate product in the United Kingdom by the MHRA. Further, we will need to carefully navigate the requirements of the ILAP to ensure that we benefit from this accelerated pathway to approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have received orphan drug designation for sutacimig for the treatment of Glanzmann thrombasthenia, but we may be unable to maintain this designation or realize
the benefits associated with orphan drug designation, including exclusivity. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We sought and obtained orphan drug designation for sutacimig
from the FDA and the EMA for the treatment of Glanzmann thrombasthenia, however, we may not be able to maintain these designations. We also may seek orphan drug designation for sutacimig in other specific orphan indications, or for <FONT
STYLE="white-space:nowrap">HMB-002</FONT> or any future product candidates, but we may never receive such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
designations.&nbsp;Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition. A similar regulatory scheme governs
orphan designation by the European Commission, following a recommendation from the EMA&#8217;s Committee for Orphan Medicinal Products in the European Union. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Generally, if a product candidate with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has
such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or EMA from approving another marketing authorization application for the same product (or a similar medicinal product in the European Union) for
the same approved use indication for that time period, subject to limited exceptions. The applicable period is seven years in the United States and ten years in the European Union. The exclusivity period in the European Union can be reduced to six
years if a product no longer meets the criteria for orphan drug designation, including if the product is sufficiently profitable so that market exclusivity is no longer justified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In order for the FDA to grant orphan drug exclusivity, the FDA must find that the product is indicated for the treatment of a condition or disease with
a patient population of fewer than 200,000 individuals annually in the United States. The FDA may conclude that the condition or disease for which we seek orphan drug exclusivity does not meet this standard. Even if orphan drug exclusivity is
obtained for a product, that exclusivity may not effectively protect the product from competition because different products can be approved for the same approved use or indication. In addition, even after an orphan drug is approved, the FDA can
subsequently approve the same product for the same condition if the FDA concludes that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusivity
may also be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of the patients with the rare disease or
condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA and Congress may further reevaluate and revise the Orphan Drug Act and its regulations and policies. For example, in September
2021, the Court of Appeals for the 11th Circuit held that, for the purpose of determining the scope of orphan drug exclusivity, the term &#8220;same disease or condition&#8221; means the designated &#8220;rare disease or condition&#8221; and not the
&#8220;indication or use&#8221; for which the product is approved.&nbsp;Subsequently, in another case, a federal district court in Washington, D.C. followed the reasoning of the 11th Circuit decision, and that decision was appealed to the U.S. Court
of Appeals for the D.C. Circuit.&nbsp;On February&nbsp;3, 2026, the Consolidated Appropriations Act of 2026 was enacted into law. It overruled these court decisions and codified the FDA&#8217;s longstanding interpretation of the scope of orphan drug
exclusivity to apply to &#8220;the same drug for the same approved use or indication within such [designated] rare disease or condition.&#8221; This change, which applies retroactively, expressly authorizes the FDA to approve multiple versions of
the same orphan drug for different <FONT STYLE="white-space:nowrap">sub-indications</FONT> and subpopulations, such as adult and pediatric patients or multiple variations of the same disease that are caused by different genetic variants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We do not know if, when, or how the FDA or Congress may change the orphan drug regulations and policies in the future, and it is uncertain how any
changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, obtaining orphan drug designation in the European Union requires demonstrating that there exists no satisfactory method of diagnosis,
prevention or treatment of the condition in question that has been authorized in the European Union or, if such method exists, the medicinal product will be of significant benefit to those affected by that condition. There is no assurance that we
would be able to meet that standard for sutacimig in indications other than Glanzmann thrombasthenia or for any of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
product candidates. Further, orphan drug designation for a product candidate in the European Union cannot be maintained at the time of a marketing authorization application without a showing, to
the satisfaction of the EU regulatory authorities, that the product candidate is of significant benefit to patients over available commercial products for the indication in the European Union and any additional products that are ahead of our product
candidate in clinical development for the indication. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Disruptions at the FDA and other government agencies from funding cuts, personnel losses, regulatory
reform, government shutdowns and other developments could hinder our ability to obtain guidance from the FDA regarding our clinical development programs and develop and secure approval of our product candidates in a timely manner, which would
negatively impact our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA and comparable regulatory agencies in foreign jurisdictions, such as the EMA and CHMP, play a
critical role in the development of our product candidates by providing guidance on our clinical development programs and reviewing and approving our regulatory submissions, including INDs, requests for special designations and marketing
applications. If these oversight and review activities are disrupted or delayed, then correspondingly our ability to develop and secure timely approval of our product candidates could be impacted in a negative manner. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For example, the loss of FDA leadership and personnel could lead to disruptions and delays in FDA guidance, review and potential approval of our product
candidates. In November 2025, a Congressional Continuing Resolution ended the government shutdown, which began on October 1, 2025, providing full-year funding of the FDA for the 2026 federal fiscal year of approximately $7&nbsp;billion with a slight
increase in user fees for drug and device companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">While the FDA&#8217;s review of marketing applications and other activities for new drugs and
biologics is largely funded through the user fee program established under the Prescription Drug User Fee Act, or PDUFA, it remains unclear how the FDA&#8217;s 2025 reduction in force and budget cuts will impact this program and the ability of the
FDA to provide guidance and review our product candidates in a timely manner. For example, while the FDA&#8217;s 2025 reduction in force did not reportedly specifically target FDA reviewers, many operations, administrative and policy staff that help
support such reviews were affected and those losses could lead to delays in PDUFA reviews and related activities. There has been at least one report in which the FDA failed to meet a PDUFA goal date for approval of an NDA or BLA due to heavy
workload and limited resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There is also substantial uncertainty as to how regulatory reform measures being implemented by the Trump
Administration across the government will impact the FDA and other federal agencies with jurisdiction over our activities. For example, since taking office, the President has issued a number of executive orders that could have a significant impact
on the manner in which the FDA conducts its operations and engages in regulatory and oversight activities. These include E.O. 14192, &#8220;Unleashing Prosperity Through Deregulation,&#8221; January&nbsp;31, 2025; E.O. 14212, &#8220;Establishing the
President&#8217;s Make America Healthy Again Commission,&#8221; February&nbsp;13, 2025; and E.O. 14219, &#8220;Ensuring Lawful Governance and Implementing the President&#8217;s &#8216;Department of Government Efficiency&#8221; Deregulatory
Initiative,&#8221; February&nbsp;21, 2025. If these or other orders or executive actions impose constraints on the FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively
impacted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Similarly, actions by the U.S. government have significantly disrupted the operations of U.S. government agencies such as the National
Institutes of Health, National Science Foundation, Centers for Disease Control and Prevention, and the FDA, which have traditionally provided funding for basic research, research and development, and clinical testing. These U.S. government actions
have included, among other things, suspending, terminating and withholding of disbursements of funds </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
owed under ongoing contracts, grants, and other financial assistance agreements; declining to continue multi-year research projects for additional annual budget periods; canceling or delaying
solicitations for new contract, grant and other financial assistance awards; canceling or delaying proposal evaluation processes and issuance of such new awards; substantially reducing federal agency staff responsible for managing contract and
financial assistance programs; eliminating agency information and resources for facilitating research activity; delaying or terminating federal agency procedures for authorizing international transactions; initiating aggressive enforcement actions
that may disrupt the operations of major research universities that are significant contributors to life sciences research in the United States, and threatening access to federal agency contracts and other funding awards based on companies&#8217;
otherwise lawful corporate policies and choice of counsel. These U.S. government actions could, directly or indirectly, significantly disrupt, delay, prevent, or increase the costs of our research and product commercialization programs, including
our ability to develop new product candidates, conduct clinical trials, implement research collaborations with other companies or institutions, and obtain approvals to market and sell new products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and
development activities, is subject to the political process, which is inherently fluid and unpredictable. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and
the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory
submissions and could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For example, the federal government shut down on October&nbsp;1, 2025, and reopened on November&nbsp;13, 2025. At the outset of that shutdown, the FDA
issued a public notice stating that FDA operations would continue to the extent permitted by law, such as activities necessary to address imminent threats to the safety of human life and activities funded by carryover user fee funds. The FDA
declared that, during the shutdown period, it does not have legal authority to accept user fees assessed for fiscal year 2026 until a fiscal year 2026 appropriation or Continuing Resolution for the FDA is enacted. As a result, during the government
shutdown, the FDA did not accept any regulatory submissions for fiscal year 2026 that require a fee payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">At the same time, disruptions at the
FDA and other government agencies may result from public health events similar to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. For example, during the pandemic, a number of companies announced receipt of complete response letters
due to the FDA&#8217;s inability to complete required inspections for their applications. In the event of a similar public health emergency in the future, the FDA may not be able to continue its current pace and review timelines could be extended.
Regulatory authorities outside the United States facing similar circumstances may adopt similar restrictions or other policy measures in response to a similar public health emergency and may also experience delays in their regulatory activities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Accordingly, if any of the foregoing developments and others impact the ability of the FDA to provide us with guidance regarding our clinical
development programs or delay the FDA&#8217;s review and processing of our regulatory submissions, including INDs and BLAs, our business would be negatively impacted. Further, any future government shutdown could impact our ability to access the
public markets and obtain necessary capital in order to properly capitalize and continue our operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Accelerated approval by the FDA, even if granted for any of our current or future product candidates, may not
lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the future, we may seek approval of our product candidates using the FDA&#8217;s accelerated approval pathway. A product candidate may be eligible for
accelerated approval if it treats a serious or life-threatening condition, generally provides a meaningful advantage over available therapies, and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit.
The FDA or other applicable regulatory agency makes the determination regarding whether a surrogate endpoint is reasonably likely to predict long-term clinical benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to seeking such accelerated approval, we will seek feedback from the FDA and otherwise evaluate our ability to seek and receive such accelerated
approval. As a condition of approval, the FDA requires that a sponsor of a product receiving accelerated approval perform an adequate and well-controlled post-marketing confirmatory clinical trial or trials. These confirmatory trials must be
completed with due diligence and we may be required to evaluate different or additional endpoints in these post-marketing confirmatory trials. These confirmatory trials may require enrollment of more patients than we currently anticipate and will
result in additional costs, which may be greater than the estimated costs we currently anticipate. In addition, the FDA currently requires as a condition for accelerated approval preapproval of promotional materials, which could adversely impact the
timing of the commercial launch of the product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There can be no assurance that the FDA will agree with any proposed surrogate endpoints or that we
will decide to pursue or submit an NDA for accelerated approval or any other form of expedited development, review or approval for any of our current or future product candidates. Similarly, there can be no assurance that, after feedback from FDA,
we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval or under
another expedited regulatory designation, there can be no assurance that such submission or application will be accepted or that any expedited review or approval will be granted on a timely basis, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA may withdraw approval of a product candidate approved under the accelerated approval pathway if, for example, the trial required to verify the
predicted clinical benefit of our product candidate fails to verify such benefit or does not demonstrate sufficient clinical benefit to justify the risks associated with the drug. The FDA may also withdraw approval if other evidence demonstrates
that our product candidate is not shown to be safe or effective under the conditions of use, we fail to conduct any required post approval trial of our product candidate with due diligence or we disseminate false or misleading promotional materials
relating to our product candidate. A failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidates, or withdrawal of a product candidate, would result in a longer time period for
commercialization of such product candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Further, there can be no assurance that we will satisfy all FDA requirements, including new provisions, that govern accelerated approval. For example,
with the passage of FDORA in December 2022, Congress modified certain provisions governing accelerated approval of products. Specifically, the legislation authorized the FDA to require a sponsor to have its confirmatory clinical trial underway
before accelerated approval is awarded and to submit progress reports on its post-approval studies to FDA every six months until the study is completed. Moreover, FDORA established expedited procedures authorizing FDA to withdraw an accelerated
approval if certain conditions are met, including where a required confirmatory study fails to verify and describe the predicted clinical benefit or where evidence demonstrates the product is not shown to be safe or effective under the conditions
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
of use. The FDA may also use such procedures to withdraw an accelerated approval if a sponsor fails to conduct any required post-approval study of the product with due diligence, including with
respect to &#8220;conditions specified by the Secretary.&#8221; The new procedures include the provision of due notice and an explanation for a proposed withdrawal, and opportunities for a meeting with the Commissioner of the FDA or the designee of
the Commissioner of the FDA and a written appeal, among other things. We will need to fully comply with these and other requirements in connection with the development and approval of any product candidate that qualifies for accelerated approval.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In March 2023, the FDA issued draft guidance that outlines its views and approach to accelerated approval. The FDA indicated that the accelerated
approval pathway is commonly used for approval of oncology drugs due to the serious and life-threatening nature of cancer. Although <FONT STYLE="white-space:nowrap">single-arm</FONT> trials have been commonly used to support accelerated approval, a
randomized controlled trial is the preferred approach as it provides a more robust efficacy and safety assessment and allows for direct comparisons to an available therapy. To that end, the FDA outlined considerations for designing, conducting, and
analyzing data for trials intended to support accelerated approvals of oncology therapeutics. Subsequently, in December 2024 and January 2025, the FDA issued additional draft guidances relating to accelerated approval. These guidances describe the
FDA&#8217;s views on what it means to conduct a confirmatory trial with due diligence and how the FDA plans to interpret whether such a study needs to be underway at the time of approval. While these guidances are currently only in draft form and
will ultimately not be legally binding even when finalized, sponsors typically observe the FDA&#8217;s guidance closely to ensure that their investigational products qualify for accelerated approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the European Union, a conditional marketing authorization may be granted for certain medicines on less comprehensive clinical data than normally
required, where the benefit of immediate availability of the medicine outweighs the risk inherent in the fact that additional data are still required. A conditional marketing authorization is subject to conditions to be fulfilled for generating
missing data or ensuring increased safety measures. A conditional marketing authorization is valid for one year and has to be renewed annually until fulfillment of all relevant conditions. Once the applicable pending studies are provided, a
conditional marketing authorization can be converted to a standard marketing authorization. However, if the conditions are not fulfilled within the timeframe set by the EMA, the marketing authorization will cease to be renewed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our activities, including our interactions with healthcare providers, third party payors, patients and government officials, are, and will continue to be, subject
to extensive regulation involving healthcare, anti-corruption, data privacy and security and consumer protection laws. Failure to comply with applicable laws could result in substantial penalties, contractual damages, reputational harm, diminished
revenues and curtailment or restructuring of our operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our activities may now or in the future be directly or indirectly subject to
various federal and state laws related to healthcare, anti-corruption, data privacy and security consumer protection. If we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our
potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. These laws include, but are not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">federal false claims, false statements and civil monetary penalties laws prohibiting, among other things, any person from
knowingly presenting, or causing to be presented, a false claim for payment of government funds or knowingly making, or causing to be made, a false statement to get a false claim paid; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the federal anti-kickback law, which prohibits, among other things, persons from offering, soliciting, receiving or
providing any remuneration, directly or indirectly, to induce, either the referral of an individual for, or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as Medicare and
Medicaid; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the federal anti-kickback prohibition known as Eliminating Kickbacks in Recovery Act, enacted in 2018, which prohibits
certain payments related to referrals of patients to certain providers (recovery homes, clinical treatment facilities and laboratories) and applies to services reimbursed by private health plans as well as government healthcare programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the federal law known as Health Insurance Portability and Accountability Act of 1996, or HIPAA, which, in addition to
privacy protections to healthcare providers and other entities, prohibits executing a scheme to defraud any healthcare benefit program (which may include private health plans) or making false statements relating to healthcare matters;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the FDCA, which among other things, strictly regulates drug marketing, prohibits manufacturers from marketing such products
for <FONT STYLE="white-space:nowrap">off-label</FONT> use and regulates the distribution of samples; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or
provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government healthcare programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the <FONT STYLE="white-space:nowrap">so-called</FONT> &#8220;federal sunshine&#8221; law, which requires pharmaceutical and
medical device companies to monitor and report certain financial interactions with teaching hospitals, physicians and certain <FONT STYLE="white-space:nowrap">non-physician</FONT> practitioners to the federal government for <FONT
STYLE="white-space:nowrap">re-disclosure</FONT> to the public; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the privacy, security and breach provisions of HIPAA, which impose obligations on certain &#8220;covered entities&#8221;
(healthcare providers, health plans and healthcare clearinghouses) and certain of their &#8220;business associate&#8221; contractors with respect to safeguarding the privacy, security and transmission of individually identifiable health information;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">federal and state laws and regulations, including state security breach notification laws, state comprehensive privacy
laws, state health information privacy laws, and federal and state consumer protection laws, govern the collection, use, disclosure and protection of health-related and other personal information; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that
potentially harm consumers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the Foreign Corrupt Practices Act, or FCPA, a United States law which regulates certain financial relationships with
foreign government officials (which could include, for example, certain medical professionals); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">state law analogues of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items
or services reimbursed by any third-party payor, including private health plans, state privacy laws, state consumer protection laws, and state laws regulating interactions between pharmaceutical manufacturers and healthcare providers, requiring
disclosure of such financial interactions or mandating adoption of certain compliance standards, many of which differ from each other in significant ways and often are not preempted by federal laws, thus complicating compliance efforts.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Companies that violate these laws can be subject to civil and criminal fines and penalties for each violation, plus up to three
times the remuneration involved, imprisonment, and exclusion from government healthcare programs. Further, lack of knowledge (anti-kickback laws, HIPAA) or lack of intent (false claims laws) may not be valid defenses to violating such laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, the marketing approval and commercialization of any of our product candidates in the European Union and other jurisdictions outside the
United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial
costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting
applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including,
without limitation, civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm,
diminished profits and future earnings and curtailment or restructuring of our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Current and future legislation may increase the difficulty and
cost for us to obtain reimbursement for our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the United States and some foreign jurisdictions, there have been and
continue to be a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval
activities and affect our ability to profitably sell any products for which we obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous
coverage criteria and additional downward pressure on the price that we may receive for any approved products. If reimbursement of our products is unavailable or limited in scope, our business could be materially harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The ACA was enacted in March 2010, and other legislative changes have been proposed and adopted since its enactment. In August 2011, the Budget Control
Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021,
was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went
into effect in April 2013 and will remain in effect through 2031 under the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations
period for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our products or
product candidates for which we may obtain marketing approval or the frequency with which any such product is prescribed or used. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since enactment
of the ACA, there have been and continue to be numerous legal challenges and U.S. congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts and Jobs Act, or the Tax Act, in 2017, Congress repealed
the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. On June&nbsp;17, 2021, the U.S. Supreme Court dismissed a challenge to the ACA
brought by several states without specifically ruling on the constitutionality of the ACA. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the European Union, on December&nbsp;13, 2021, Regulation (EU) 2021/2282 on Health Technology Assessment, or HTA, amending Directive 2011/24/EU, was
adopted. While the Regulation entered into force in January 2022, it only began to apply from January 2025 onwards and has a phased implementation depending on the concerned products. The Regulation intends to boost cooperation among European Union
member states in assessing health technologies, including new medicinal products as well as certain high-risk medical devices, and provide the basis for cooperation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
at the EU level for joint clinical assessments in these areas. It permits European Union member states to use common HTA tools, methodologies, and procedures across the European Union, working
together in four main areas, including joint clinical assessment of the innovative health technologies with the highest potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities,
identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual European Union member states will continue to be responsible for assessing <FONT
STYLE="white-space:nowrap">non-clinical</FONT> (e.g., economic, social, ethical) aspects of health technology and making decisions on pricing and reimbursement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect that these healthcare reforms, as well as other healthcare reform measures that may be adopted in the future, may result in additional
reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product and/or the level of reimbursement physicians
receive for administering any approved product we might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or the frequency with which our products are prescribed or administered. Any reduction in
reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. Accordingly, such reforms, if enacted, could have an adverse effect on anticipated revenue from product candidates that we
may successfully develop and for which we may obtain marketing approval and may affect our overall financial condition and ability to develop or commercialize product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The prices of prescription pharmaceuticals in the United States and foreign jurisdictions are subject to considerable legislative and executive actions and could
impact the prices we obtain for our products, if and when licensed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The prices of prescription pharmaceuticals have also been the subject of
considerable discussion in the United States. There have been U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the
relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For example,
in October 2020, HHS and the FDA published a final rule allowing states and other entities to develop a Section&nbsp;804 Importation Program, or SIP, to import certain prescription drugs from Canada into the United States. That regulation was
challenged in a lawsuit by the Pharmaceutical Research and Manufacturers of America, or PhRMA, but the case was dismissed by a federal district court in February 2023 after the court found that PhRMA did not have standing to sue HHS. Several states
have passed laws allowing for the importation of drugs from Canada. On January&nbsp;5, 2024, the FDA approved Florida&#8217;s plan for Canadian drug importation. That state now has authority to import certain drugs from Canada for a period of two
years once certain conditions are met. Florida will first need to submit a <FONT STYLE="white-space:nowrap">pre-import</FONT> request for each drug selected for importation, which must be approved by the FDA. The state will also need to relabel the
drugs and perform quality testing of the products to meet FDA standards. On May&nbsp;21, 2025, the FDA announced that it would offer individual states the opportunity to submit a draft proposal for <FONT STYLE="white-space:nowrap">pre-review</FONT>
and meet with the FDA to obtain initial feedback from FDA prior to formally submitting their SIP proposals. The intent of these meetings is to assist states in developing their proposals by further clarifying requirements, enhancing the quality of
proposals submitted to the FDA and ultimately shortening the review timeline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In August 2022, the Inflation Reduction Act, or IRA, was signed into
law by President Biden. The legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for
outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
prices that can be negotiated subject to a cap, and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). In addition, the IRA established
inflation rebate programs under Medicare Part B and Part D. These programs require manufacturers to pay rebates to Medicare if they raise their prices for certain Part B and Part D drugs faster than the rate of inflation. On December&nbsp;9, 2024,
with issuance of its 2025 Physician Fee Schedule final regulation, CMS finalized its rules governing the IRA inflation rebate programs. The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to
regulation, for the initial years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Further, the IRA subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing
to comply with the legislation by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. The legislation also requires manufacturers to
pay rebates for drugs in Medicare Part D whose price increases exceed inflation. The law also capped Medicare <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> drug costs at an estimated $4,000 a year in
2024 and at $2,000 a year in 2025 and onwards. In addition, the IRA potentially raises legal risks with respect to individuals participating in a Medicare Part D prescription drug plan who may experience a gap in coverage if they required coverage
above their initial annual coverage limit before they reached the higher threshold, or &#8220;catastrophic period&#8221; of the plan. Individuals requiring services exceeding the initial annual coverage limit and below the catastrophic period, must
pay 100% of the cost of their prescriptions until they reach the catastrophic period. Among other things, the IRA contains many provisions aimed at reducing this financial burden on individuals by reducing the
<FONT STYLE="white-space:nowrap">co-insurance</FONT> and <FONT STYLE="white-space:nowrap">co-payment</FONT> costs, expanding eligibility for lower income subsidy plans, and price caps on annual <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, each of which could have potential pricing and reporting implications. Accordingly, while it is currently unclear how the IRA will be effectuated, we cannot predict with certainty what
impact any federal or state health reforms will have on us, but such changes could impose new or more stringent regulatory requirements on our activities or result in reduced reimbursement for our products, any of which could adversely affect our
business, results of operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Specifically, with respect to price negotiations, Congress authorized Medicare to
negotiate lower prices for certain costly single-source drug products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D. CMS may negotiate prices for ten high-cost drugs paid for by Medicare Part
D starting in 2026, followed by 15 additional Medicare Part D drugs in 2027, 15 additional Medicare Part B or Part D drugs in 2028, and 20 additional Medicare Part B or Part D drugs per year in 2029 and beyond. This provision applies to drug
products that have been approved for at least nine years. Drugs that have been approved for a single rare disease or condition were originally categorically excluded from price negotiation. With the passage of the One Big Beautiful Bill Act, or
OBBBA, on July&nbsp;3, 2025, which was signed into law on July&nbsp;4, 2025, Congress extended this exemption to drugs with multiple orphan drug designations. Nonetheless, since CMS may establish a maximum price for these products in price
negotiations, we would be fully at risk of government action if our products are the subject of Medicare price negotiations. Moreover, given the risk that could be the case, these provisions of the IRA may also further heighten the risk that we
would not be able to achieve the expected return on any of our product candidates, if approved, or the full value of our patents protecting any such approved drug products if prices are set after any such approved products have been on the market
for nine years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The first cycle of negotiations for the Medicare Drug Price Negotiation Program commenced in the summer of 2023 with the negotiated
prices for ten selected drug products becoming effective on January&nbsp;1, 2026. The second cycle of negotiations with participating drug companies occurred during 2025, and the negotiated prices for this second set of 15 drugs will become
effective on January&nbsp;1, 2027. On January&nbsp;27, 2026, CMS published the list of 15 drugs selected for the third cycle of negotiations. These negotiated prices will become effective on January&nbsp;1, 2028. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On June&nbsp;6, 2023, Merck&nbsp;&amp; Co. filed a lawsuit against HHS and CMS asserting that, among
other things, the IRA&#8217;s Drug Price Negotiation Program for Medicare constitutes an uncompensated taking in violation of the Fifth Amendment of the U.S. Constitution. Subsequently, a number of other parties also filed lawsuits in various courts
with similar constitutional claims. HHS has generally won the substantive disputes in these cases or succeeded in getting claims dismissed for lack of standing or on the merits. For example, on May&nbsp;8, 2025, the U.S. Court of Appeals for the
Third Circuit rejected AstraZeneca L.P.&#8217;s challenge to the Medicare price negotiation program, finding that the program did not violate the company&#8217;s due process rights under the U.S. Constitution. Litigation involving these and other
provisions of the IRA will continue with unpredictable and uncertain results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect that litigation involving these and other provisions of the
IRA will continue, with unpredictable and uncertain results. Accordingly, while it is currently unclear how the IRA will be effectuated, we cannot predict with certainty what impact any federal or state health reforms will have on us, but such
changes could impose new or more stringent regulatory requirements on our activities or result in reduced reimbursement for our products, if approved, any of which could adversely affect our business, results of operations and financial condition.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, the Trump Administration has taken a number of actions to reduce the costs of pharmaceutical products. For example, on April&nbsp;15,
2025, President Trump issued an Executive Order which directs HHS to take steps to reduce the prices of pharmaceutical products.&nbsp;Such measures include streamlining the state drug importation program and modifying provisions of the 340B program.
Further, on May&nbsp;12, 2025, President Trump issued an additional Executive Order calling on pharmaceutical manufacturers to voluntarily reduce the prices of medicines in the United States. The Executive Order provides that if such actions do not
lower the costs of pharmaceuticals, the Secretary of HHS would pursue other actions, including proposing a rulemaking that imposes most-favored nation, or MFN, pricing in the United States. Thereafter, on July&nbsp;31, 2025, President Trump issued
letters to 17 pharmaceutical companies reiterating the requirements of the May&nbsp;12, 2025 Executive Order and demanding that such companies extend MFN pricing to Medicaid patients, guarantee MFN pricing for newly-launched drug products, return
increased revenues abroad to American patients and provide for direct purchasing at MFN pricing. Since that time, virtually all of these pharmaceutical companies have entered into agreements with the Trump Administration to provide for lower prices
on certain pharmaceuticals. On February&nbsp;5, 2026, President Trump launched TrumpRx.gov, a website that directs individuals to pharmaceutical manufacturer websites that are offering price discounts based on the administration&#8217;s pricing
agreements with pharmaceutical manufacturers.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On December&nbsp;23, 2025, CMS, through its Center for Medicare and Medicaid Innovation, proposed two
five-year pilot programs to implement a &#8220;reference pricing&#8221; regime for drugs paid for under Medicare for 25% of covered beneficiaries. The programs are referred to as the Global Benchmark for Efficient Drug Pricing Model for Medicare
Part B drugs, referred to as GLOBE, and the Guarding U.S. Medicare Against Rising Drug Costs for Medicare Part D drugs, referred to as GUARD. Under the proposed pilot programs, a manufacturer would owe rebates to Medicare if prices for their drugs
exceeded the prices paid by other economically comparable reference countries, defined in the proposed regulations as Organisation for Economic <FONT STYLE="white-space:nowrap">Co-operation</FONT> and Development countries with a gross domestic
product of $400&nbsp;billion and a per capita gross domestic product that is at least 60% of the U.S. per capita gross domestic product (an initial list of 19 reference countries is included in the proposed rule). The pilot programs are proposed to
go into effect beginning October&nbsp;1, 2026. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">At the state level, individual states are increasingly aggressive in passing legislation and
implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency
measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. This is increasingly true with respect to products </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
approved pursuant to the accelerated approval pathway. States, including through their Medicaid programs and regulatory agencies, as well as other payers are developing strategies and
implementing significant coverage barriers, or refusing to cover these products outright, arguing that accelerated approval products have insufficient or limited evidence despite meeting the FDA&#8217;s standards for accelerated approval. Certain
states are also pursuing cost containment efforts through Prescription Drug Affordability Boards, or PDABs, and similar entities. While many PDABs have been granted authority to promote drug price transparency and reporting, some states have granted
PDABs more expansive authority, including to set Upper Payment Limits, or UPLs, on select, high price drugs. The adoption and implementation of UPLs may put downward pressure on drug prices and impact our company&#8217;s future revenues. In
addition, regional healthcare organizations and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs.
These measures could reduce the ultimate demand for our products, if approved, or put pressure on our product pricing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect that additional
state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product
candidates or additional pricing pressures. This is increasingly true with respect to products approved pursuant to the accelerated approval pathway. State Medicaid programs and other payers are developing strategies and implementing significant
coverage barriers, or refusing to cover these products outright, arguing that accelerated approval drugs have insufficient or limited evidence despite meeting the FDA&#8217;s standards for accelerated approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product
candidates, if approved. In markets outside of the United States and the European Union, reimbursement and healthcare payment systems vary significantly by country and many countries have instituted price ceilings on specific products and therapies.
In many countries, including those of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control and access. In these countries, pricing negotiations with governmental authorities can take considerable time
after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we or any future collaborators of ours may be required to conduct a clinical trial that compares the cost-effectiveness of our
product to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount or if pricing is set at unsatisfactory levels, our business could be materially harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are subject to stringent privacy laws, information security laws, regulations, policies and contractual obligations related to data privacy and security, and a
failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are subject to data privacy and protection laws and regulations that apply to the collection, transmission, storage, use, disclosure and other
processing of sensitive, confidential and personally identifying information, which among other things, impose certain requirements relating to the privacy, security and transmission of such information, including comprehensive regulatory systems in
the United States, European Union and United Kingdom. The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection
issues with the potential to affect our business. Failure to comply with any of these laws and regulations could result in enforcement action against us, including fines, imprisonment of company officials and public censure, claims for damages by
affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There are numerous U.S. federal and state laws and regulations related to the privacy and security of
personal information. At the federal level, regulations promulgated pursuant to HIPAA establish privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and
require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information.
Determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation. These obligations may be applicable to
some or all of our business activities now or in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we are unable to properly protect the privacy and security of protected health
information, we could be found to have breached our contracts. Further, if we fail to comply with applicable privacy laws, including applicable HIPAA privacy and security standards, we could face civil and criminal penalties. HHS enforcement
activity under HIPAA can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources. In addition, state attorneys general are authorized to bring civil actions seeking
either injunctions or damages in response to violations that threaten the privacy or security of the personal information of state residents, including pursuant to the state privacy laws discussed below. We cannot be sure how these regulations will
be interpreted, enforced or applied to our operations. In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at the federal and state
level may be costly and require ongoing modifications to our policies, procedures and systems. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We make public statements about our use, collection,
disclosure and other processing of personal information through our privacy policies and information provided on our website. Although we endeavor to comply with our public statements and documentation, we may at times fail to do so or be alleged to
have failed to do so. The publication of our privacy policies and other statements that provide promises and assurances about data privacy and security can subject us to potential government or legal action if they are found to be deceptive, unfair
or misrepresentative of our actual practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to potential enforcement by HHS, we are also potentially subject to privacy enforcement
from the FTC. The FTC has been particularly focused on the unpermitted processing of health and genetic data through its recent enforcement actions and is expanding the types of privacy violations that it interprets to be &#8220;unfair&#8221; under
Section&nbsp;5 of the Federal Trade Commission Act of 1914, as well as the types of activities it views to trigger the Health Breach Notification Rule (which the FTC also has the authority to enforce). We will need to account for the FTC&#8217;s
evolving rules and guidance for proper privacy and data security practices in order to mitigate our risk for a potential enforcement action, which may be costly. If we are subject to a potential FTC enforcement action, we may be subject to a
settlement order that requires us to adhere to very specific privacy and security practices (depending on the nature of the alleged violations). If we violate any consent order that we reach with the FTC, we may be subject to additional fines and
compliance requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There are also increased restrictions at the federal level relating to transferring sensitive data outside of the United
States to certain foreign countries. For example, the Department of Justice&#8217;s January&nbsp;8, 2025, rule on &#8220;Preventing Access to U.S. Sensitive Personal Data and Government-Related Data by Countries of Concern or Covered Persons,&#8221;
prohibits data brokerage transactions involving certain sensitive personal data categories, including health data, genetic data, and biospecimens, to countries of concern, including China. The regulations also restrict certain investment agreements,
employment agreements and vendor agreements involving such data and countries of concern, absent specified cybersecurity controls. Actual or alleged violations of these regulations may be punishable by
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
criminal and/or civil sanctions and may result in exclusion from participation in federal and state programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Numerous states have also created comprehensive privacy laws which govern the processing of personal information. For example, the California Consumer
Privacy Act, or the CCPA, took effect on January&nbsp;1, 2020 and imposed many requirements on businesses that process the personal information of California residents. Many of the CCPA&#8217;s requirements are similar to those found in the EU
General Data Protection Regulation, or the EU GDPR, which is further described below, including requiring businesses to provide notice to data subjects regarding the information collected about them and how such information is used and shared, and
providing data subjects the right to request access to such personal information and, in certain cases, request the erasure of such personal information. The CCPA also affords California residents the right to opt out of &#8220;sales&#8221; of their
personal information. The CCPA contains significant penalties for companies that violate its requirements. The California Privacy Rights Act, or the CPRA, went into effect on January&nbsp;1, 2023 and significantly expanded the CCPA to incorporate
additional EU GDPR-like provisions including requiring that the use, retention and sharing of personal information of California residents be reasonably necessary and proportionate to the purposes of collection or processing, granting additional
protections for sensitive personal information, and requiring greater disclosures related to notice to residents regarding retention of information. The CPRA also created an enforcement agency&#8212;the California Privacy Protection Agency&#8212;the
sole responsibility of which is to enforce the CPRA and other California privacy laws, which will further increase compliance risk. The provisions in the CPRA may apply to some of our business activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to California, a number of other states have passed similarly comprehensive privacy laws. Like the CCPA, these laws create obligations
related to the processing of personal information, as well as special obligations for the processing of &#8220;sensitive&#8221; data (which includes health data in some cases). Some of the provisions of these laws may apply to our business
activities. There are also states that are specifically regulating specific categories of personal information, such as health information that may affect our business. For example, the State of Washington recently passed a health privacy law that
will regulate the collection and sharing of health information, and the law also has a private right of action, which further increases the relevant compliance risk. Additionally, a small number of states, such as Illinois and Texas, have enacted
laws that specifically target the collection and use of biometric information. These laws may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and
distribution of our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, laws in all 50 states require businesses to provide notice to customers whose personal information has
been disclosed as a result of a data breach. These laws are not consistent, and compliance in the event of a widespread data breach is difficult and may be costly. Moreover, states have been frequently amending existing laws, requiring attention to
changing regulatory requirements. We also may be contractually required to notify affected individuals or other counterparties of a cybersecurity incident, data breach, or other compromise. Although we may have contractual protections with our
vendors, any actual or perceived security breach, incident, or compromise could harm our reputation and brand, expose us to potential liability or require us to expend significant resources on data security and in responding to any such actual or
perceived cybersecurity incident, data breach, or other compromise. Any contractual protections we may have from our vendors may not be sufficient to adequately protect us from any such liabilities and losses, and we may be unable to enforce any
such contractual protections. In addition to government regulation, privacy advocates and industry groups have and may in the future propose self-regulatory standards from time to time. These and other industry standards may legally or contractually
apply to us, or we may elect to comply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Plaintiffs&#8217; lawyers are also increasingly using privacy-related statutes at both the state and
federal level to bring lawsuits against companies for their data-related practices. In particular, there have been </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
a significant number of cases filed against companies for their use of pixels and other web trackers. These cases often allege violations of the California Invasion of Privacy Act and other state
laws regulating wiretapping, as well as the federal Video Privacy Protection Act. The rise in these types of lawsuits creates potential risk for our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Similar to the laws in the United States, there are significant and evolving privacy and data security laws that apply in Europe and other countries.
The collection, use, disclosure, transfer or other processing of personal data, including personal health data, regarding individuals who are located in the EEA and the United Kingdom and the processing of personal data that takes place in the EEA
and the United Kingdom, is regulated by the EU GDPR with respect to the EEA, and the U.K. General Data Protection Regulation, or U.K. GDPR, with respect to the United Kingdom, and collectively with the EU GDPR referred to as the &#8220;GDPR&#8221;
in this report unless specified otherwise. The GDPR applies to all organizations processing or holding personal data of EEA and/or U.K. data subjects (regardless of the organization&#8217;s location) as well as to organizations outside these
jurisdictions that offer goods or services in the EEA and United Kingdom, or that monitor the behavior of EEA and/or U.K. data subjects. The GDPR imposes extensive obligations on companies that process personal data, including requirements relating
to lawful bases for processing, transparency, consent where required, security safeguards, data processing agreements, data subject rights, breach notification, record-keeping, data protection impact assessments and, in some cases, appointment of a
data protection officer. It also restricts transfers of personal data outside the EEA and United Kingdom (including to the United States). Breaches can result in significant penalties (up to
<FONT STYLE="font-family:Times New Roman">&#128;</FONT>20&nbsp;million / &pound;17.5&nbsp;million or 4% of global annual turnover, whichever is higher), and data subjects have rights to lodge complaints and seek compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The GDPR imposes strict rules on the transfer of personal data out of the EEA/United Kingdom to countries not regarded by the European Commission and
the U.K. government as providing adequate protection, or third countries, including the United States. These transfers are prohibited unless an appropriate safeguard specified by data protection laws is implemented, such as the Standard Contractual
Clauses, or SCCs, approved by the European Commission, or a derogation applies. Transfers made pursuant to the SCCs need to be assessed on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis to ensure
the law in the recipient country provides &#8220;essentially equivalent&#8221; protections to safeguard the transferred data. If the standard is not met, businesses will be required to adopt supplementary measures. Further, the European Union and
United States have adopted its adequacy decision for the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Data Privacy Framework, or the Framework, which entered into force on July&nbsp;11, 2023. This Framework provides that the protection of
personal data transferred between the European Union and the United States is comparable to that offered in the European Union. This provides a further avenue to ensuring transfers to the United States are carried out in line with the GDPR. The
United Kingdom is not subject to the European Commission&#8217;s SCCs but the U.K. Information Commissioner&#8217;s Office has published the United Kingdom&#8217;s own transfer mechanisms for personal data originating from the United Kingdom (the
International Data Transfer Agreement and International Data Transfer Addendum, or, each, an IDTA), which have been in force since March&nbsp;21, 2022. The IDTA requires the same
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> risk assessment of the transfer. In addition, there has been an extension to the Framework to cover U.K. transfers to the United States. The Framework could
be challenged like its predecessor frameworks. The international transfer obligations under the EEA and U.K. data protection regimes will require significant effort and cost, and may result in us needing to make strategic considerations around where
EEA/U.K. personal data is located and which service providers we can utilize for the processing of EEA/U.K. personal data, particularly as the enforcement around GDPR international transfer compliance obligations is currently unclear. The above
transfer requirements and other future developments regarding the flow of data across borders could increase the cost and complexity of delivering our services in some markets and may lead to governmental enforcement actions, litigation, fines, and
penalties or adverse publicity, which could adversely affect our business and financial position. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Although the United Kingdom is regarded as a third country under the EU GDPR, the European Commission
has now issued a decision recognizing the United Kingdom as providing adequate protection under the EU GDPR and, therefore, transfers of personal data originating in the European Union to the United Kingdom remain unrestricted. In December 2025, the
European Commission adopted a decision to extend the validity of the U.K. adequacy decision for six years until December 2031, determining that the United Kingdom continues to offer a level of data protection that is &#8220;essentially
equivalent&#8221; to the EU standards. This follows the United Kingdom&#8217;s adoption of the Data (Use and Access) Act 2025 on June&nbsp;19, 2025. Like the EU GDPR, the U.K. GDPR restricts personal data transfers outside the United Kingdom to
countries not regarded by the United Kingdom as providing adequate protection. The U.K. government has confirmed that personal data transfers from the United Kingdom to the EEA remain free flowing. The respective provisions and enforcement of the EU
GDPR and U.K. GDPR may further diverge in the future and create additional regulatory challenges and uncertainties. This lack of clarity on future U.K. laws and regulations and their interaction with EU laws and regulations could add legal risk,
complexity and cost to our handling of personal data and our privacy and data security compliance programs and could require us to implement different compliance measures for the United Kingdom and the EEA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Beyond GDPR, there are privacy and data security laws in a growing number of countries around the world. While many loosely follow GDPR as a model,
other laws contain different or conflicting provisions. These laws will impact our ability to conduct our business activities, including both our clinical trials and the sale and distribution of commercial products, if approved, through increased
compliance costs, costs associated with contracting and potential enforcement actions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">While we continue to address the implications of the recent
changes to data privacy regulations, data privacy remains an evolving landscape at both the domestic and international level, with new regulations coming into effect and continued legal challenges, and our efforts to comply with such evolving data
protection laws, rules and regulations may be unsuccessful. These laws are not consistent, and compliance in the event of a widespread data breach is costly and time-consuming. It is possible that these laws may be interpreted and applied in a
manner that is inconsistent with our practices, which could adversely affect our business. We must devote significant resources to understanding and complying with this changing landscape. Failure by us or our third-party vendors to comply with
federal, state and international laws regarding privacy and security of personal information could expose us to the risk of enforcement actions taken by data protection authorities and can carry with it the potential for significant fines and
penalties under such laws if we are found to be <FONT STYLE="white-space:nowrap">non-compliant.</FONT> Even if we are not determined to have violated these laws, rules or regulations, government investigations into these issues typically require the
expenditure of significant resources and generate negative publicity, which could harm our business, financial condition, results of operations or prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Laws and regulations governing international operations may preclude us from developing, manufacturing and selling certain products outside of the United States
and require us to develop and implement costly compliance programs. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have operations in Denmark and are required to dedicate additional
resources to comply with U.S. laws regarding international operations and the laws and regulations in Denmark and any additional jurisdiction in which we operate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FCPA prohibits any U.S. individual or business from paying, offering or authorizing payment or offering of anything of value, directly or
indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates
companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
maintain books and records that accurately and fairly reflect all transactions of the company, including international subsidiaries and to devise and maintain an adequate system of internal
accounting controls for international operations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption
is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry because in many countries, hospitals are operated by the government and doctors and other hospital employees are considered foreign
officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. </P>
<P STYLE="margin-top:11pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States or the sharing with certain <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. Further, the provision of benefits or advantages to physicians
to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the European Union. The provision of benefits or advantages to physicians is also governed by the national
anti-bribery laws of European Union member states, such as the U.K. Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment. Payments made to physicians in certain European Union member states must be publicly
disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual
European Union member states. These requirements are provided in the national laws, industry codes or professional codes of conduct applicable in the European Union member states. Failure to comply with these requirements could result in
reputational risk, public reprimands, administrative penalties, fines or imprisonment. </P> <P STYLE="margin-top:11pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we expand our international presence beyond Denmark, it
will require us to dedicate additional resources to comply with these laws and these laws may preclude us from developing, manufacturing or selling certain products and product candidates outside of the United States, which could limit our growth
potential and increase our development costs. The creation, implementation and maintenance of international business practices compliance programs may be necessary and costly, and such programs are difficult to enforce, particularly where reliance
on third parties is required. The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar
issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions. </P> <P STYLE="margin-top:11pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We and our third-party contract manufacturers
must comply with environmental, health and safety laws and regulations, and failure to comply with these laws and regulations could expose us to significant costs or liabilities. </I></B></P>
<P STYLE="margin-top:11pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We and our third-party manufacturers are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory
procedures and the use, generation, manufacture, distribution, storage, handling, treatment, remediation and disposal of hazardous materials and wastes. Hazardous chemicals, including flammable and biological materials, are involved in certain
aspects of our business, and we cannot eliminate the risk of injury or contamination from the use, generation, manufacture, distribution, storage, handling, treatment or disposal of hazardous materials and wastes. In the event of contamination or
injury, or failure to comply with environmental, health and safety laws and regulations, we could be held liable for any resulting damages and any such liability could exceed our assets and resources. We could also incur significant costs associated
with civil or criminal fines and penalties for failure to comply with such laws and regulations. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting
from the use of hazardous materials, this insurance may not provide adequate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of
biological, hazardous or radioactive materials. </P> <P STYLE="margin-top:11pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Environmental, health and safety laws and regulations are becoming increasingly more stringent. We
may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to
comply with these laws and regulations also may result in substantial fines, penalties or other sanctions or business disruption, any of which could have a material adverse effect on our business, financial condition, results of operations, and
prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Further, with respect to the operations of our third-party contract manufacturers, it is possible that if they fail to operate in
compliance with applicable environmental, health and safety laws and regulations or properly dispose of wastes associated with our products, we could be held liable for any resulting damages, suffer reputational harm or experience a disruption in
the manufacture and supply of our product candidates or products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our employees, consultants and business partners may engage in misconduct or other improper
activities, including noncompliance with regulatory standards and requirements and insider trading. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are exposed to the risk of fraud or
other misconduct by our employees, consultants and business partners. Misconduct by these parties could include intentional failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with manufacturing standards
we have established, to comply with federal and state healthcare fraud and abuse laws and regulations, to comply with state and federal securities laws, to report financial information or data accurately or to disclose unauthorized activities to us.
In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may
restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the
course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and serious harm to our reputation. We are also exposed to risks in connection with any insider trading violations by
employees or others affiliated with us. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or
in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other
misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of
civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and
future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Changes in and uncertainty surrounding U.S. and international trade policies, particularly with respect to China, may adversely impact our business and operating
results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the spring of 2025, the U.S. government initiated a series of tariff-related actions against U.S. trading partners. On
April&nbsp;2, 2025, an Executive Order announced a &#8220;baseline&#8221; reciprocal tariff of 10% on all U.S. trading partners effective April 5, 2025, and higher individualized reciprocal tariffs on 57&nbsp;countries (with certain product
exemptions for pharmaceutical-related products, among others). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Previously, the U.S. government had imposed a 25% tariff on Canada and Mexico for goods not covered by the United States-Mexico-Canada Agreement, and tariffs due to drug trafficking equaling 20%
on imports from China. In response, several countries threatened retaliatory measures, including Canada and China, which then imposed retaliatory tariffs. Prior to when the country-specific reciprocal tariffs were scheduled to take effect, the U.S.
delayed the effective date of such tariffs for all countries except China to August&nbsp;1, 2025. Later, the United States and China reached a framework agreement that ultimately resulted in the suspension of the higher reciprocal tariffs on China
until November&nbsp;10, 2025. Shortly before that expiration date, the United States and China reached a one-year agreement with an expiration of November&nbsp;10, 2026, that includes the continued suspension of the heightened reciprocal tariffs on
China and delayed enforcement of new U.S. export rules targeting affiliates of blacklisted firms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since the April 2025 reciprocal tariffs
announcement, the European Union, Japan, South Korea, Switzerland and the United Kingdom, among others, have reached deals with the United States that include reduced tariff rates to varying levels and other measures. On July&nbsp;31, 2025, the
Trump Administration issued an Executive Order detailing new reciprocal tariff rates for individual countries that took effect on August&nbsp;7, 2025. The deals with the European Union, Japan, South Korea, Switzerland (and Liechtenstein), the United
Kingdom and others cap pharmaceutical tariffs at 15%. In addition, an agreement with Malaysia provides a zero percent tariff exemption for pharmaceutical products that are not patented in the United States and are used in pharmaceutical applications
and an agreement with Switzerland and Lichenstein caps tariffs on pharmaceuticals imported from those two countries at 15%. Finally, an agreement with Taiwan concluded on January 15, 2026 eliminates tariffs on generic pharmaceuticals and their
active ingredients imported from Taiwan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The reciprocal tariffs and the fentanyl tariffs were imposed pursuant to the International Emergency
Economic Powers Act, or the IEEPA. These tariffs were found to be unconstitutional by multiple federal courts in the spring and summer of 2025. On February&nbsp;20, 2026, the U.S. Supreme Court held that the IEEPA does not authorize the U.S.
President to impose tariffs, invalidating both the reciprocal tariffs and the drug trafficking tariffs. Shortly thereafter, President Trump issued a new Executive Order revoking the IEEPA tariffs and Customs and Border Protection ceased collecting
the tariffs on February&nbsp;24, 2026. At the same time, however, the Trump Administration imposed a new 10% global tariff under Section 122 of the Trade Act of 1974, effective February&nbsp;24, 2026. Pursuant to the statute, absent an extension by
Congress, these tariffs will expire in 150 days on July&nbsp;24, 2026. For those countries that have concluded trade deals with the United States, the tariff rates agreed to, including with regard to pharmaceuticals and pharmaceutical ingredients,
have now reverted to 10% until July&nbsp;24, 2026. Like the IEEPA tariffs, pharmaceuticals and pharmaceutical ingredients are exempt from the Section 122 tariffs along with a list of other products. The Trump Administration has announced that it
also plans to initiate new investigations on &#8220;most major trading partners&#8221; under Section&nbsp;301 of the same act, which will likely lead to additional tariffs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Neither the U.S. Supreme Court&#8217;s decision nor the Executive Order revoking the IEEPA tariffs addressed refunds, leaving the issue to renewed
proceedings before the U.S. Court of International Trade, where importers may need to pursue administrative remedies and/or litigation amid continued uncertainty. Sustained uncertainty about, or the further escalation of, trade and political
tensions between the United States and China could result in a disadvantageous research and manufacturing environment in China, particularly for U.S.-based companies, including retaliatory restrictions that hinder or potentially inhibit our ability
to rely on CMOs and other service providers that operate in China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Separately, in April 2025, the Department of Commerce announced an investigation
under Section&nbsp;232 of the Trade Expansion Act of 1962 into imports of pharmaceuticals and pharmaceutical ingredients, including finished products, medical countermeasures, critical inputs such as active
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
pharmaceutical ingredients, and key starting materials, and derivative products of those items. On September&nbsp;25, 2025, via a post on Truth Social, President Trump announced that, beginning
October&nbsp;1, 2025, all branded or patented drugs imported in the United States would face a 100% tariff. At the same time, President Trump indicated that these tariffs could be avoided by building pharmaceutical manufacturing facilities in the
United States. Thereafter, President Trump delayed the October&nbsp;1, 2025 effective date of the tariffs on branded or patented pharmaceutical products announcing that the Trump Administration had now &#8220;begun preparing&#8221; tariffs on
manufacturers that do not build in the United States or enter into a most-favored-nation drug pricing agreement with the Trump Administration. A host of other U.S. tariff actions remain possible, including additional 25% tariffs on products from
countries that do certain business with Iran or Cuba. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As a result of changes in tariffs that have been announced and/or implemented, and the
underlying uncertainty currently surrounding international trade, we could experience a negative impact to our costs of materials and production processes, and supply chain disruptions and delays as a result of any new tariff policies or trade
restrictions. If we are unable to obtain necessary raw materials or product components in sufficient quantity and in a timely manner due to disruptions in the global supply chain caused by macroeconomic events and conditions, the development,
testing and clinical trials of our product candidates may be delayed or infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business. We cannot yet
predict the effect of the recently imposed U.S. tariffs on imports, or the extent to which other countries will impose quotas, duties, tariffs, taxes or other similar restrictions upon imports or exports in the future, nor can we predict future
trade policy or the terms of any renegotiated trade agreements and their impact on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Further, some of our manufacturers and suppliers
are located in China. Trade tensions and conflicts between the United States and China have been escalated in recent years and, as such, we are exposed to the possibility of product supply disruption and increased costs and expenses in the event of
changes to the laws, rules, regulations and policies of the governments of the United States or China, or due to geopolitical unrest and unstable economic conditions. Certain Chinese biotechnology companies may become subject to trade restrictions,
sanctions, other regulatory requirements or proposed legislation by the U.S. government, which could restrict or even prohibit our ability to work with such entities, thereby potentially disrupting their supply of material to us. For example, in
February 2024, U.S. lawmakers called for investigations into and the imposition of possible economic sanctions against Chinese biotechnology companies WuXi AppTec and WuXi Biologics, or collectively WuXi, over alleged ties to the Chinese military.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Subsequently, in December 2025, as part of the Fiscal Year 2026 National Defense Authorization Act, President Trump signed into law the BIOSECURE
Act. Under the BIOSECURE Act, U.S. government agencies cannot (1)&nbsp;buy or obtain biotechnology equipment or services provided by biotechnology companies of concern, or BCCs, (2)&nbsp;enter into, extend, or renew a contract with any entity using
biotechnology equipment or services provided by a BCC to perform a government contract, or (3)&nbsp;expend, loan or grant funds for biotechnology equipment or services provided by a BCC, whether directly or through a loan or grant recipient. The
BIOSECURE Act does not name specific companies as BCCs but treats any company on the Department of Defense 1260H list of &#8220;Chinese military companies&#8221; as a BCC. On December&nbsp;18, 2025, the Chairs of multiple Senate and House
committees, including the House Select Committee on China, sent a letter to the Department of Defense recommending that WuXi be added to the 1260H list, which would make it a BCC. The 1260H list was updated by the Department of Defense in January
2024 and January 2025. On February&nbsp;13, 2026, the Department published an updated list, which included WuXi, but then abruptly withdrew the list. The implications of this action remain unclear. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Employee Matters and Managing Growth </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are highly dependent on the research and development, clinical, regulatory, and business development expertise of Benny S&oslash;rensen, M.D., Ph.D.,
our president and chief executive officer, as well as the other principal members of our management, scientific and clinical teams. Although we have entered into employment agreements with our executive officers, each of them may terminate their
employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. This lack of insurance means that we may not have adequate compensation for the loss of the services of these
individuals. Recruiting and retaining qualified scientific, clinical, manufacturing, accounting, legal and sales and marketing personnel will also be critical to our success. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and
commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited
number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain marketing approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to
hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical
personnel from universities and research institutions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, we rely on consultants and advisors, including scientific and clinical
advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other
entities that may limit their availability to us. Our success as a public company also depends on implementing and maintaining internal controls and the accuracy and timeliness of our financial reporting. If we are unable to continue to attract and
retain high quality personnel, our ability to pursue our growth strategy will be limited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We expect to expand our development and regulatory capabilities and
potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development,
clinical, regulatory affairs, manufacturing and quality control and, if any product candidate receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our
managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company
with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management
and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Future acquisitions or strategic alliances could disrupt our business and harm our financial condition and
results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may acquire additional businesses, technologies or assets, form strategic alliances or create joint ventures with
third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, those markets or technologies may not achieve the outcomes that we expect. Acquiring new product
candidates is inherently risky, and there can be no assurance that any acquired product candidates would prove to be successful. In addition, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully
integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new products or product candidates resulting from a strategic alliance or acquisition that may
delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure our stockholders that, following any such acquisition, we will achieve the expected synergies to justify the transaction. The risks we face in
connection with acquisitions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">diversion of management time and focus from operating our business to addressing acquisition integration challenges;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">coordination of research and development efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">retention of key employees from the acquired company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in relationships with collaborators as a result of product acquisitions or strategic positioning resulting from the
acquisition; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">cultural challenges associated with integrating employees from the acquired company into our organization;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the need to implement or improve controls, procedures and policies at a business that prior to the acquisition may have
lacked sufficiently effective controls, procedures and policies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">liability for activities of the acquired company before the acquisition, including intellectual property infringement
claims, violation of laws, commercial disputes, tax liabilities and other known liabilities unanticipated write-offs or charges; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">litigation or other claims in connection with the acquired company, including claims from terminated employees, customers,
former stockholders or other third parties. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The internal information technology systems, or those of any future collaborators of ours,
vendors or other contractors or consultants, on which we depend have in the past and may in the future fail or suffer cybersecurity incidents, data breaches, loss of data and other disruptions, which could result in a material disruption of our
product development programs, compromise sensitive information related to our business or prevent us from accessing critical information, trigger contractual and legal obligations, potentially exposing us to liability, reputational harm or otherwise
adversely affect our business and financial results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are dependent upon information technology systems, infrastructure and data to
operate our business. In the ordinary course of business, we collect, store and transmit confidential information, including but not limited to intellectual property, proprietary business information and personal information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Despite the implementation of security measures, our internal information technology systems and those of any collaborators, vendors, contractors or
consultants are vulnerable to breakdowns, damage or interruption from computer viruses, computer hackers, malicious code, ransomware, malware, malicious conduct or error by employees or other users, theft or misuse, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">denial-of-service</FONT></FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
attacks, sophisticated nation-state and nation-state-supported actors, unauthorized access, natural disasters, terrorism, wars or other armed conflict, telecommunication and electrical failures
or other compromise. There could also be an increase in cybersecurity attacks generally as a result of ongoing military conflicts and the resulting sanctions imposed by the United States and European governments, together with any additional future
sanctions or other actions by them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Cyberattacks are increasing in their frequency, sophistication and intensity, and have become increasingly
difficult to detect. Cyberattacks could include the deployment of harmful malware, ransomware, business email compromises, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks, unauthorized access
to or deletion of files, social engineering (including phishing attacks) and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. Cyberattacks also could include phishing attempts or <FONT
STYLE="white-space:nowrap">e-mail</FONT> fraud to cause payments or information to be transmitted to an unintended recipient. These attacks and activity are also being facilitated or enhanced by evolving technologies, including artificial
intelligence. We may not be able to anticipate all types of security threats, and we may not be able to implement preventive measures effective against all such security threats. The techniques used by cyber criminals change frequently, may not be
recognized until launched, and can originate from a wide variety of sources, including outside groups such as external service providers, organized crime affiliates, terrorist organizations or hostile foreign governments or agencies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Like other companies in our industry, we, and our third-party vendors, have experienced threats and cybersecurity incidents relating to our information
systems and infrastructure. We cannot guarantee that the measures we have taken to date, and actions we may take in the future, will be sufficient to prevent any future system failures, cyberattacks, accidents or cybersecurity incidents or data
breaches with respect to our information technology systems, or the information technology systems of our vendors, collaborators or other contractors or consultants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To the extent we or our vendors, collaborators or other contractors or consultants experience a material system failure, accident, cyberattack or
security breach, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary or confidential information or other disruptions. For example, the
loss of clinical trial data from our ongoing or planned clinical trials could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. If we do not allocate and effectively manage the
resources necessary to build and sustain the proper technology and cybersecurity infrastructure, we could suffer significant business disruption (and may suffer such disruption notwithstanding the building and sustaining of such infrastructure),
including transaction errors, supply chain or manufacturing interruptions, processing inefficiencies, data loss or the loss of or damage to intellectual property or other proprietary information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To the extent that any disruption, cybersecurity incident or data breach were to result in a loss of, or damage to, our or our vendors&#8217;,
collaborators&#8217; or other contractors&#8217; or consultants&#8217; data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, including litigation exposure, penalties and fines, we
could become the subject of regulatory action or investigation, our competitive position and reputation could be harmed and the further development and commercialization of our product candidates could be delayed. As a result of such an event, we
may also be in breach of our contractual obligations. Due to applicable laws, rules, regulations and standards or contractual obligations, we may be held responsible for any system failure or security incident attributed to our third-party vendors
as they relate to the information we share with them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Furthermore, any such event that leads to unauthorized access, use, or disclosure of personal
information, including personal information regarding our customers or employees, could harm our reputation, compel us to comply with federal and/or state breach notification laws and foreign law </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could
result in significant legal and financial exposure and reputational damage. Any of the above could have a material adverse effect on our business, financial condition, results of operations or prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The financial exposure from the events referenced above could either not be insured against or not be fully covered through any insurance that we
maintain and could have a material adverse effect on our business, financial condition, results of operations or prospects. In addition, we cannot be sure that our existing insurance coverage will continue to be available on acceptable terms or that
our insurers will not deny coverage as to any future claim. There can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or would otherwise protect us from liabilities or damages as a result of the
events referenced above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>While we do not currently use artificial intelligence, or AI, in a manner that is central to our operations, we may decide to do so,
which may cause us to expend material resources in the future. Our current use of AI is limited, but we are still exposed to the inherent risks of the use of AI. The risks and challenges associated with the use of AI, whether in the more limited
manner that we currently do so or the manner that we may do so in the future, include security and other risks to our confidential information, proprietary information and personal information, any of which may result in reputational harm and
liability, &#8220;hallucinations&#8221; or other errors, and biases, among other potential adverse effects to our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may use and
integrate AI into our business processes both in our own development and implementation of AI and through the adoption of commercially available tools. The rapid evolution of AI will require the application of significant resources to design,
develop, test and maintain such systems to help ensure that AI is implemented in accordance with applicable law and regulation and in a socially responsible manner and to minimize any real or perceived unintended harmful impact. Engaging appropriate
resources (including computing power) to properly develop such technologies may require substantial expense and it may require substantial time to develop a properly functioning AI system, including because expertise in the use of AI for drug
discovery or other life sciences applications is rare, and we may be unable to successfully integrate AI tools into our business or to do so efficiently. We may also need to license data from third-party sources or develop data internally, each of
which may take substantial time and require substantial expense. If we enable or offer solutions that draw controversy due to perceived or actual negative societal impact, we may experience brand or reputational harm, competitive harm or legal
liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Whether with our current, limited use of AI or a future, more fundamental use of AI, we are exposed to the risk related to the use and
integration of AI. Use of this technology could pose cybersecurity, data privacy, IT, intellectual property, regulatory, legal, operational, competitive, reputational and other risks and challenges that could affect our business. Specifically, risks
related to accuracy, bias, AI hallucinations, discrimination, harmful content, misinformation, fraud, scams, targeted attacks (including model poisoning or data poisoning), surveillance, data leakage, inequality, environmental harms, and other harms
may flow from our development, use, or deployment of AI technologies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">No assurance can be provided that the use of AI will enhance our business or
assist our business in becoming more efficient or profitable. The use of AI can give rise to intellectual property risks, including compromises to our proprietary intellectual property and risks of infringement or misappropriation of third party
intellectual property, each of which may result in time-consuming and costly litigation and could require us to purchase a costly license or cease use of any material created using AI (and any intellectual property derived from such material). In
addition, there is currently significant uncertainty around the extent to which we would be able to claim ownership in, or otherwise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
protect using intellectual property or similar proprietary rights, any inventions or other materials, which we develop through the use of AI. As a result, we could have no remedy if third parties
reused those same materials, or similar materials also generated by AI. In addition, the use of AI by any of our personnel or our third-party providers could include the input of proprietary or confidential information (including material <FONT
STYLE="white-space:nowrap">non-public</FONT> information) into any AI systems, resulting in such proprietary or confidential information becoming part of a dataset that is accessible by other third-party AI users. Not all providers of AI tools may
offer an option to <FONT STYLE="white-space:nowrap">opt-out</FONT> of usage of such inputs or prompts to further train the tools, and, even where we do <FONT STYLE="white-space:nowrap">opt-out,</FONT> we cannot guarantee that the <FONT
STYLE="white-space:nowrap">opt-out</FONT> will be fully effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">AI is generally highly reliant on the collection and analysis of large amounts
of data. The data we may use to train AI models may be inaccurate, such as if we do not generate the data in an accurate manner, we license third-party data that is inaccurate, or we use a third-party AI system trained on data that is inaccurate. As
a result of this potential inaccuracy, we may have analyses, recommendations or other outputs that are deficient, inaccurate, incomplete, overbroad, or biased, which may in turn adversely affect our business, financial condition and results of
operations. Another data-related risk of the use of AI, even if the underlying data is accurate, is that AI may be subject to data herding and interconnectedness (i.e., multiple market participants utilizing the same data to generate the same or
similar results), and if those results are important to our business, that may adversely impact our financial or operational condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, we may see increasing government and supranational regulation and ethical concerns related to AI use which may also significantly increase
the burden and cost of research, development and compliance in this area. For example, the European Union began implementing the Artificial Intelligence Act, or the AI Act, on August&nbsp;1, 2024, with a significant part of the law scheduled to come
into effect in August 2026. As currently enacted, the AI Act, which may be amended as part of the EU&#8217;s Digital Omnibus, imposes significant obligations on providers and deployers of high-risk artificial intelligence systems, and encourages
providers and deployers of artificial intelligence systems to account for EU ethical principles in their development and use of these systems. The scope of requirements depends on judicial interpretations and forthcoming legislative amendments, and <FONT
STYLE="white-space:nowrap">non-compliance</FONT> can lead to significant fines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the United States, the AI regulatory environment is complex and
uncertain. Over the past year, states have advanced, and in some cases passed, dozens of laws focusing on AI governance and regulation, including on deployment of AI in healthcare settings. At the federal level, the Trump Administration has endorsed
a federal moratorium on the enforcement of state AI laws, including through a December&nbsp;11, 2025, Executive Order on &#8220;Ensuring a National Policy Framework for Artificial Intelligence.&#8221; So far, these efforts have not been successful
at curtailing state action on AI regulation, contributing to a complicated legislative patchwork, which may be litigated in state and federal courts. If we develop or use AI systems that are governed by the these laws or regulations, we will need to
meet higher standards of data quality, transparency, and human oversight, and we would need to adhere to specific and potentially burdensome and costly ethical, accountability, and administrative requirements. Because of the interest in AI by many
governmental authorities, there may be additional laws or regulations that limit our ability to use AI or apply novel liability frameworks to the use of AI, and these risks may cause adverse effects to our business, operations or financial
condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may collaborate with third parties, or source work from vendors, that use AI, with or without our knowledge that those third parties
or vendors are using AI. As a result, we may face the risks associated with the use of AI without knowingly using AI. Bad actors around the world also use increasingly sophisticated methods, including the use of AI, to engage in illegal activities
involving the theft and misuse of personal information, confidential information and intellectual property. In addition, the use of generative AI models in our internal or third-party systems may create new attack surfaces
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
or methods for adversaries, which could impact us and our vendors. Any of these effects could damage our reputation, result in the loss of valuable property and information, cause us to breach
applicable laws and regulations, and adversely impact our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may be exposed to significant foreign exchange risk. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our consolidated financial statements are presented in U.S. dollars. We have operations in Denmark, and we incur portions of our expenses, and may in the
future derive revenues, in a variety of currencies. As a result, we are exposed to foreign currency exchange risk as our results of operations and cash flows are subject to fluctuations in foreign currency exchange rates. Fluctuations in currency
exchange rates have had, and will continue to have, an impact on our results as expressed in U.S. dollars. We currently do not engage in hedging transactions to protect against uncertainty in future exchange rates between particular foreign
currencies and the U.S. dollar. We cannot predict the impact of foreign currency fluctuations, and foreign currency fluctuations in the future may adversely affect our financial condition, results of operations and cash flows. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to this Offering, Ownership of Our Common Stock and Operating as a Public Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>An active trading market for our common stock may not develop. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to this offering, there has not been a public market for our common stock. The initial public offering price for our common stock will be
determined through negotiations with the underwriters. Although we have applied to list our common stock on the Nasdaq Global Select Market, an active trading market for our shares may never develop or be sustained following this offering. If an
active market for our common stock does not develop, it may be difficult for you to sell shares you purchase in this offering without depressing the market price for the shares or at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may not be able to satisfy listing requirements of Nasdaq or obtain or maintain a listing of our common stock on Nasdaq. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If our common stock is listed on Nasdaq, we must meet certain financial and liquidity criteria to maintain such listing. If we violate Nasdaq&#8217;s
listing requirements, our common stock may be delisted. If we fail to meet any of Nasdaq&#8217;s listing standards, our common stock may be delisted. In addition, our board of directors may determine that the cost of maintaining our listing on a
national securities exchange outweighs the benefits of such listing. A delisting of our common stock from Nasdaq may materially impair our stockholders&#8217; ability to buy and sell our common stock and could have an adverse effect on the market
price of, and the efficiency of the trading market for, our common stock. The delisting of our common stock could significantly impair our ability to raise capital and the value of your investment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If you purchase shares of common stock in this offering, you will suffer immediate dilution of your investment. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The initial public offering price of our common stock will be substantially higher than the pro forma as adjusted net tangible book value per share of
our common stock after this offering. Therefore, if you purchase shares of our common stock in this offering, you will pay a price per share that substantially exceeds our pro forma as adjusted net tangible book value per share as
of&#8195;&#8195;&#8195;&#8195;&#8195;. Based on an assumed initial public offering price of $&#8195;&#8195;&#8195; per share, the midpoint of the price range set forth on the cover page of this prospectus, you will experience immediate dilution of
$&#8195;&#8195;&#8195; per share. To the extent outstanding warrants are exercised, you will incur further dilution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The price of our common stock may be volatile and fluctuate substantially, which could result in substantial
losses for purchasers of our common stock in this offering. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our stock price is likely to be volatile. The stock market in general and the
market for smaller biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your common
stock at or above the initial public offering price. The market price for our common stock may be influenced by many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">results of or developments in preclinical studies and clinical trials of our product candidates and any other product
candidates we may develop or those of our competitors or potential collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the results of our preclinical studies and clinical trials of our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our success in commercializing any product candidates, if and when approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">developments with respect to competitive products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulatory or legal developments in the United States and other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">announcements by us or our competitors of significant acquisitions, <FONT STYLE="white-space:nowrap">in-licensing</FONT>
arrangements, strategic partnerships, joint ventures or collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">developments or disputes concerning patent applications, issued patents or other intellectual property or proprietary
rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the level of expenses related to our development efforts with respect to our product candidates and any future product
candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the results of our efforts to discover, develop, acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> products,
product candidates, technologies or data referencing rights, and the costs of commercializing any products we are able to successfully develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities
analysts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">announcements or expectations of additional financing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">variations in our financial results or the financial results of companies that are perceived to be similar to us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">sales of common stock by us, our executive officers, directors or principal stockholders, or others; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">market conditions in the pharmaceutical and biotechnology sectors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">general economic, industry and market conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the other factors described in this &#8220;Risk Factors&#8221; section. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class-action litigation has often been
instituted against that company. Any lawsuit to which we are a party, with or without merit, may result in an unfavorable judgment. We also may decide to settle lawsuits on unfavorable terms. Any such negative outcome could result in payments of
substantial damages or fines, damage to our reputation or adverse changes to our offerings or business practices. Such litigation may also cause us to incur other substantial costs to defend such claims and divert management&#8217;s attention and
resources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>After this offering, our executive officers, directors and principal stockholders, if they choose to act
together, will continue to have the ability to control all matters submitted to stockholders for approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon the completion of this
offering, our executive officers and directors and our stockholders who owned more than 5% of our outstanding common stock before this offering will, in the aggregate, beneficially own shares representing approximately&#8195;% of our capital stock.
As a result, if these stockholders were to choose to act together, they would be able to control all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act
together, would control the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This
concentration of ownership control may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delay, defer or prevent a change in control; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">entrench our management and board of directors; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delay or prevent a merger, consolidation, takeover or other business combination involving us that other stockholders may
desire. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Participation in this offering by our existing stockholders and their affiliated entities may reduce the public float for our
common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To the extent certain of our existing stockholders and their affiliated entities participate in this offering, such purchases
would reduce <FONT STYLE="white-space:nowrap">the&nbsp;non-affiliate&nbsp;public</FONT> float of our shares, meaning the number of shares of our common stock that are not held by officers, directors and principal stockholders. A reduction in the
public float could reduce the number of shares that are available to be traded at any given time, thereby adversely impacting the liquidity of our common stock and depressing the price at which you may be able to sell shares of common stock
purchased in this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have broad discretion in the use of the net proceeds from this offering and may not use them effectively. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that do not
improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could cause the price of our common stock to decline and delay the
development of our product candidates and any other product candidates we may develop. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of
gain. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any,
to finance the growth and development of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. There is no guarantee that our common stock will appreciate or even
maintain the price at which our stockholders purchase it. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>A significant portion of our total outstanding shares are eligible to be sold into the market in
the near future, which could cause the market price of our common stock to drop significantly, even if our business is doing well. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Sales of
a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
reduce the market price of our common stock. After this offering, we will have &#8195;&#8195;&#8195;&#8195;shares of common stock outstanding based on the number of shares outstanding as of
&#8195;&#8195;&#8195;&#8195;, &#8195;&#8195;&#8195;&#8195;. This includes the shares that we are selling in this offering, which may be resold in the public market immediately without restriction, unless purchased by our affiliates. The remaining
shares are currently restricted as a result of securities laws or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements but will become eligible to be sold at various times after the offering as described in the section of this prospectus
titled &#8220;Shares Eligible for Future Sale.&#8221; The representatives of the underwriters may release some or all of the shares of common stock subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements at any time and without notice,
which would allow for earlier sales of shares in the public market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, certain of our executive officers, directors and stockholders
affiliated with our directors may enter into Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plans providing for sales of shares of our common stock from time to time. Under a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan, a broker
executes trades pursuant to parameters established by the executive officer, director or affiliated stockholder when entering into the plan, without further direction from the executive officer, director or affiliated stockholder. A Rule <FONT
STYLE="white-space:nowrap">10b5-1</FONT> plan may be amended or terminated in some circumstances. Our executive officers, directors and stockholders affiliated with our directors also may buy or sell shares outside of a Rule <FONT
STYLE="white-space:nowrap">10b5-1</FONT> plan when they are not in possession of material, nonpublic information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, beginning 180 days
after the completion of this offering, holders of an aggregate of &#8195;&#8195;&#8195;&#8195;shares of our common stock will have rights, subject to specified conditions, to require us to file registration statements covering their shares or to
include their shares in registration statements that we may file for ourselves or other stockholders. We also intend to register all shares of common stock that we may issue under our equity compensation plans. Once we register these shares, they
can be freely sold in the public market upon issuance, subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described in the &#8220;Underwriting&#8221; section of this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to emerging
growth companies and smaller reporting companies may make our common stock less attractive to investors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are an &#8220;emerging growth
company,&#8221; or EGC, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We may remain an EGC until the end of the fiscal year in which the fifth anniversary of this offering occurs, although if the market value of our
common stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700.0&nbsp;million as of any June&nbsp;30 before that time or if we have annual gross revenues of $1.235&nbsp;billion or more in any fiscal year, we would
cease to be an EGC as of December&nbsp;31 of the applicable year. We also would cease to be an EGC if we issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt over a three-year period. For so long as we
remain an EGC, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not EGCs. These exemptions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">being permitted to provide only two years of audited financial statements in this prospectus, in addition to any required
unaudited interim financial statements, with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">not being required to comply with the auditor attestation requirements in the assessment of our internal control over
financial reporting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reduced disclosure obligations regarding executive compensation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval
of any golden parachute payments not previously approved. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have taken advantage of reduced reporting obligations in this prospectus. In particular, in this
prospectus, we have provided only two years of audited financial statements and have not included all of the executive compensation-related information that would be required if we were not an EGC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock
less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition,
the JOBS Act permits an EGC to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected not to
opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt
the new or revised standard and will do so until such time that we either (1)&nbsp;irrevocably elect to &#8220;opt out&#8221; of such extended transition period or (2)&nbsp;no longer qualify as an EGC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are also a &#8220;smaller reporting company&#8221; as defined in the Securities Exchange Act of 1934, or the Exchange Act. We may continue to be a
smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for
so long as our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0&nbsp;million during
the most recently completed fiscal year and our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million measured on the last business day of our second fiscal quarter. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance
initiatives and corporate governance practices. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As a public company, and particularly after we are no longer an EGC or smaller reporting
company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing
requirements of the Nasdaq Global Select Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and
corporate governance practices. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted additional rules and regulations in these areas, such as mandatory &#8220;say on pay&#8221; voting
requirements that will apply to us when we cease to be an emerging growth company. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new
regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. Our management and other personnel will need to devote a substantial
amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs, particularly as we hire additional financial and accounting employees to meet public company internal
control and financial reporting requirements, and will make some activities more time-consuming and costly compared to when we were a private company. For example, we expect that these rules and regulations may make it more difficult and more
expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified members of our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are evaluating these rules and regulations and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs.
These rules and regulations are often subject </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and
governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act, or Section&nbsp;404, in our second annual report due to be filed with the SEC after becoming a
public company, we will be required to furnish a report by our management on our internal control over financial reporting. However, while we remain an EGC, we will not be required to include an attestation report on internal control over financial
reporting issued by our independent registered public accounting firm. To achieve compliance with Section&nbsp;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting,
which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, including through hiring additional financial and accounting personnel, potentially engage outside consultants and adopt a detailed work
plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous
reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting
is effective as required by Section&nbsp;404. If we are unable to conclude that our internal control over financial reporting is effective, it could result in an adverse reaction in the financial markets due to a loss of confidence in the
reliability of our financial statements. Moreover, any material weakness or other deficiencies in our internal control over financial reporting may impede our ability to file timely and accurate reports with the SEC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have identified material weaknesses in our internal control over financial reporting. If we are unable to remedy our material weaknesses, or if we fail to
establish and maintain an effective system of internal control over financial reporting, we may be unable to produce timely and accurate financial statements or prevent fraud, which could adversely impact our business and our stock price.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to this offering, we were a private company and have limited accounting and financial reporting personnel and other resources with
which to address our internal controls and related procedures. In connection with the audit of our consolidated financial statements for the years ended December&nbsp;31, 2024 and 2025, we identified material weaknesses in our internal control over
financial reporting. As defined in the standards of the Public Company Accounting Oversight Board (United States), a material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there
is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The material weaknesses were (1)&nbsp;controls around the financial statement close process were not designed or operating effectively, including as a
result of an inappropriate segregation of conflicting duties and insufficient evidence of performance and review of controls, and (2)&nbsp;information system controls around user access, segregation of conflicting duties and change management were
not designed or operating effectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To remediate these material weaknesses, we have made and plan to continue to make improvements to the design
and operating effectiveness of our internal controls over financial reporting, including the monitoring, oversight and evaluation of our internal controls. We also plan to allocate more internal resources to our internal controls, including by
hiring additional staff, and intend to engage external advisors to provide training and to reassess and redesign processes and develop new controls as appropriate, including information technology controls covering access and change management as
well as cyber risks, and assisting with the evaluation and documentation of the risk assessment, design and operating effectiveness of our internal controls over financial reporting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We cannot assure you that the measures we have taken to date, and actions we plan to take in the
future, will be sufficient to remediate the control deficiencies that led to the material weaknesses in our internal control over financial reporting or that they will prevent or avoid potential future material weaknesses. In addition, neither our
management nor an independent registered public accounting firm has performed an evaluation of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act because no such evaluation has been required.
Had we or our independent registered public accounting firm performed an evaluation of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act, additional material weaknesses may have been
identified. If we are unable to successfully remediate our existing or any future material weaknesses in our internal control over financial reporting, or identify any additional material weaknesses in the future, or otherwise fail to maintain an
effective system of internal controls, the accuracy and timing of our financial reporting may be adversely affected, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to
applicable stock exchange listing requirements, investors may lose confidence in our financial reporting, and the market price of our common stock may decline as a result. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon completion of this offering, we will become subject to certain reporting requirements of the Exchange Act. Our disclosure controls and procedures
are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized and reported within the time periods
specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the
objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented
by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error
or fraud may occur and not be detected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which
may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current directors and members of management. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Provisions in our certificate of incorporation and our bylaws that will become effective upon the completion of this offering may discourage, delay or
prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that
investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team,
these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establish a classified board of directors such that only one of three classes of directors is elected each year;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">allow the authorized number of our directors to be changed only by resolution of our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">limit the manner in which stockholders can remove directors from our board of directors; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and
nominations to our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our
stockholders by written consent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">limit who may call stockholder meetings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a
&#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to
amend or repeal specified provisions of our certificate of incorporation or bylaws that will become effective upon the completion of this offering. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law, or the
DGCL, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding
voting stock, unless the merger or combination is approved in a prescribed manner. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our certificate of incorporation designates the Court of Chancery of the
State of Delaware and the federal district courts of the United States of America as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217;
ability to obtain a favorable judicial forum for disputes with us or our directors, officers and employees. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our certificate of incorporation
that will become effective upon the completion of this offering provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the State of
Delaware does not have jurisdiction, the federal district court for the District of Delaware) will be the sole and exclusive forum for any action asserting an internal corporate claim as defined in Section&nbsp;115 of the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These choice of forum provisions will not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore,
Section&nbsp;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to
litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our certificate of incorporation provides that, unless we consent in writing to the selection of an
alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any claims arising under the Securities Act. While the Delaware
courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to
vigorously assert the validity and enforceability of the exclusive forum provisions of our certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no
assurance that the provisions will be enforced by a court in those other jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These exclusive forum provisions may limit the ability of
our stockholders to bring a claim in a judicial forum that such stockholders find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees. If a
court were to find either exclusive forum provision contained in our certificate of incorporation to be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving such action in other jurisdictions, all of which could materially adversely
affect our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If securities analysts do not publish or cease publishing research or reports or publish
misleading, inaccurate or unfavorable research about our business or if they publish negative evaluations of our stock, the price and trading volume of our stock could decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The trading market for our common stock will rely, in part, on the research and reports that industry or financial analysts publish about us or our
business. We do not currently have, and may never obtain, research coverage by industry or financial analysts. If no, or few, analysts commence coverage of us, the trading price of our stock would likely decrease. Even if we do obtain analyst
coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock or publish inaccurate or unfavorable research about our business, or provides more favorable relative recommendations about our competitors, the
price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price and trading volume to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>General Risk Factors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Unfavorable global economic conditions could
adversely affect our business, financial condition, stock price, and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The global credit and financial markets have in
recent years experienced volatility and disruptions (including as a result of actual or perceived changes in interest rates, inflation and macroeconomic uncertainties), which has included severely diminished liquidity and credit availability,
declines in consumer confidence, declines in economic growth, high inflation, uncertainty about economic stability, global supply chain disruptions, and increases in unemployment rates. The financial markets and the global economy may also be
adversely affected by the current or anticipated impact of military conflict, terrorism, or other geopolitical events. Sanctions imposed by the United States and other countries in response to such conflicts may also continue to adversely impact the
financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. There can be no assurance that further deterioration in credit and financial markets and
confidence in economic conditions will not occur. A severe or prolonged economic downturn could result in a variety of risks to our business, including a decrease in the demand for our product candidates and in our ability to raise additional
capital when needed on acceptable terms, if at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Furthermore, any disruptions to our supply chain as a result of unfavorable global economic
conditions, including due to geopolitical conflicts or public health crises, could negatively impact the timely execution of our ongoing and future clinical trials. In addition, current inflationary trends in the global economy may impact salaries
and wages, costs of goods and transportation expenses, among other things, and recent and potential future disruptions in access to bank deposits or lending commitments due to bank failures may create market and economic instability. We cannot
anticipate all of the ways in which the foregoing, and the current economic climate and financial market conditions generally, could adversely impact our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Changes in tax laws or in their interpretation could adversely affect our business and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Income, sales, use or other tax laws, statutes, rules or regulations could be enacted or amended at any time, which could affect our business or
financial condition, including causing potentially adverse </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
impacts to our effective tax rate, tax liabilities and cash tax obligations. For example, the IRA was signed into law in August 2022, and the OBBBA was signed into law in July 2025. The IRA
introduced new tax provisions, including a one percent excise tax imposed on certain stock repurchases by publicly traded companies. The one percent excise tax generally applies to any acquisition of stock by the publicly traded company (or certain
of its affiliates) from a stockholder of the company in exchange for money or other property (other than stock of the company itself), subject to a de minimis exception. Thus, the excise tax could apply to certain transactions that are not
traditional stock repurchases. The OBBBA contains numerous tax provisions that we are currently in the process of evaluating, and which may significantly affect our business or financial condition. The recent changes under the OBBBA include tax rate
extensions and changes to the business interest deduction limitation, the expensing of domestic research and development expenditures (in contrast to the continued capitalization and amortization of foreign research and development expenditures),
the bonus depreciation deduction rules and the international tax framework. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Regulatory guidance under the IRA, the OBBBA and additional legislation
is and continues to be forthcoming, and such guidance could ultimately increase or lessen the impact of these laws on our business and financial condition. Congress may enact additional legislation, some of which could have an impact on our company.
In addition, it is uncertain if and to what extent various states will conform to such legislation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may become involved in litigation that could divert
management&#8217;s attention and harm our business, and insurance coverage may not be sufficient to cover all costs and damages. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">From time
to time, we may be subject to litigation claims through the ordinary course of our business operations regarding, but not limited to, securities litigation, employment matters, security of patient and employee personal data, contractual relations
with collaborators and licensors and intellectual property rights. In the past, securities class action litigation has often followed certain significant business transactions, such as the sale of a company or announcement of any other strategic
transaction, the announcement of negative events, such as negative results from clinical trials, or periods of volatility in the market price of a company&#8217;s securities. These events may also result in or be concurrent with investigations by
the SEC. We may be exposed to such litigation or investigation even if no wrongdoing occurred. Litigation and investigations are usually expensive and divert management&#8217;s attention and resources, which could adversely affect our business and
cash resources and our ability to consummate a potential strategic transaction or the ultimate value our stockholders receive in any such transaction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our
insurance policies are expensive and only protect us from some business risks, which will leave us exposed to significant uninsured liabilities. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">While we maintain commercial insurance at a level we believe is appropriate against certain risks commonly insured in the industry in which we operate,
there is no guarantee that our insurer will cover costs or that we will be able to obtain the desired level of coverage on acceptable terms in the future. Some of the policies we currently maintain include property, general liability, crime
insurance, workers&#8217; compensation, and directors&#8217; and officers&#8217;, employment practices and fiduciary liability insurance, clinical trial insurance, transportation insurance and umbrella insurance. We do not know, however, if we will
be able to maintain insurance with adequate levels of coverage. Changes in the market conditions and our business operations may necessitate the addition of new insurance policies or change of our existing insurance policies. Any significant
uninsured liability may require us to pay substantial amounts, which would adversely affect our financial position and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We
also expect that operating as a U.S. public company will make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified people
to serve on our board of directors, on our board committees or as executive officers. We do not know, however, if we will be able to maintain existing insurance with adequate levels of coverage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any significant uninsured liability may require us to pay substantial amounts, which would negatively affect our business, financial condition and
results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our operations are vulnerable to interruption by disasters, terrorist activity, pandemics and other events beyond our control, which
could harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our main facilities are located in Cambridge, Massachusetts and Copenhagen, Denmark. We have not undertaken a
systematic analysis of the potential consequences to our business and financial results from a major flood, power loss, terrorist activity, pandemics or other regional or global disasters and generally do not have a recovery plan for such events. In
addition, we do not carry sufficient insurance to compensate us for actual losses from interruption of our business that may occur, and any losses or damages incurred by us could harm our business. The occurrence of any of these business disruptions
could seriously harm our operations and financial condition and increase our costs and expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_4"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This prospectus contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of
historical fact, contained in this prospectus, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management, are forward-looking statements.
The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221;
&#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of these words or other similar expressions are intended
to identify forward-looking statements, although not all forward-looking statements contain these identifying words. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The forward-looking statements
in this prospectus include, among other things, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the initiation, timing, progress and results of our research and development programs and preclinical studies and clinical
trials, including the timing of our planned Phase 3 clinical trial of sutacimig in patients with Glanzmann thrombasthenia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our estimates regarding expenses, future revenue, capital requirements, need for additional financing and the period over
which we believe that the net proceeds from this offering, together with our existing cash, cash equivalents, and marketable securities, will be sufficient to fund our operating expenses and capital expenditure requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing of and our ability to complete clinical development of, submit applications for and obtain and maintain
regulatory approvals for our current and future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the potential advantages of our current and future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our plans to develop and, if approved, subsequently commercialize any product candidates we may develop;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the rate and degree of market acceptance and clinical utility of our products, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our estimates regarding the addressable patient population and potential market opportunity for our current and future
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our commercialization, marketing and manufacturing capabilities and strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our expectations regarding our ability to obtain and maintain intellectual property protection and to remain in compliance
with our existing license agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to identify additional products, product candidates or technologies with significant commercial potential that
are consistent with our commercial objectives; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to attract and retain key scientific and management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our expectations regarding milestone and/or royalty payments under any of our current or future license agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the impact of government laws and regulations, including any new regulatory requirements in the countries in which we
operate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our competitive position and expectations regarding developments and projections relating to our competitors and any
competing therapies that are or become available; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">developments relating to our competitors and our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our reliance on and the performance of third parties that conduct clinical trials of our product candidates and manufacture
our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to identify, establish and maintain collaborations or obtain additional funding; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">general economic, industry and market conditions, including rising interest rates, inflation and tariffs;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our expectations regarding the time during which we will be an emerging growth company under the JOBS Act or a smaller
reporting company; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our anticipated use of our existing cash, cash equivalents, and marketable securities and the proceeds from this offering.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should
not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements we make. We have included important factors in the
cautionary statements included in this prospectus, particularly in the &#8220;<I>Risk Factors</I>&#8221; section, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Moreover,
we operate in a competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements
contained in this prospectus. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures, or investments we may make or enter into. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">You should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the registration statement of which
this prospectus is a part completely and with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements contained in this prospectus are made as of the date of this prospectus,
and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements
are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete. Our statements should not be read to
indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We estimate that the net proceeds from our issuance and sale of&#8195;&#8195;&#8195;&#8195;shares of our common stock in this offering will be
approximately $&#8195;&#8195;&#8195;&#8195;million, or approximately $&#8195;&#8195;&#8195;&#8195;million if the underwriters exercise in full their option to purchase additional shares of our common stock, assuming an initial public offering price
of $&#8195;&#8195;&#8195;&#8195;per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Each $1.00 increase (decrease) in the assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share, the midpoint of the price range
set forth on the cover page of this prospectus, would increase (decrease) the net proceeds to us from this offering by approximately $&#8195;&#8195;&#8195;&#8195;million, assuming the number of shares offered by us, as set forth on the cover page of
this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, a 1.0&nbsp;million share increase (decrease) in the number of shares offered by us, as
set forth on the cover page of this prospectus, would increase (decrease) the net proceeds to us from this offering by approximately $&#8195;&#8195;&#8195;&#8195;million, assuming that the assumed initial public offering price per share remains the
same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We do not expect that a change in the initial price to the public or the number of shares by these amounts would have a
material effect on uses of the proceeds from this offering, although a decrease in the initial offering price without a corresponding increase in the number of shares offered may accelerate the time at which we will need to seek additional capital.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2025, we had cash, cash equivalents, and marketable securities of $185.5&nbsp;million. We currently expect to use the net
proceeds from this offering, together with our cash, cash equivalents, and marketable securities, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approximately $&#8195;&#8195;&#8195;&#8195;million to fund clinical development of sutacimig for the treatment of Glanzmann
thrombasthenia and Factor VII deficiency; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approximately $&#8195;&#8195;&#8195;&#8195;million to fund clinical development of
<FONT STYLE="white-space:nowrap">HMB-002</FONT> for the treatment of Von Willebrand Disease; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approximately $&#8195;&#8195;&#8195;&#8195;million for additional discovery, preclinical, and clinical activities for
current and future programs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the remainder for working capital and other general corporate purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our expected use of net proceeds from this offering and our existing cash, cash equivalents, and marketable securities represents our intentions based
upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve. The amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the
scope, progress, costs and results of our research and development efforts, as well as any collaborations that we may enter into with third parties, and any unforeseen cash needs. We believe opportunities may exist from time to time to expand our
current business through acquisitions of complementary companies, products or technologies. While we have no current agreements, commitments or understandings for any specific acquisitions at this time, we may also use a portion of the net proceeds
for these purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect that the net proceeds from this offering, together with our existing cash, cash equivalents, and marketable
securities, will be sufficient to enable us to&#8195;&#8195;&#8195;&#8195; . The expected net proceeds from this offering will not be sufficient for us to fund any of our product candidates through regulatory approval, and we will need to raise
substantial additional capital to complete the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
development and commercialization of our product candidates. The specific allocation of the net proceeds from this offering and our existing cash, cash equivalents, and marketable securities to
any product candidate will depend on, among other things, the results of our research and development efforts, the timing and success of our preclinical studies and clinical trials and the timing and outcome of regulatory submissions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on our current plans, we believe that the anticipated net proceeds from this offering, together with our cash, cash equivalents, and marketable
securities, will be sufficient to enable us to fund our operating expenses and capital expenditure requirements into&#8195;&#8195;&#8195;&#8195;. We have based our estimates as to how long we expect we will be able to fund our operations on
assumptions that may prove to be wrong. We could use our available capital resources sooner than we currently expect, in which case we would be required to obtain additional financing, which may not be available to us on acceptable terms, or at all.
Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We will have broad discretion over how to use the net proceeds to us from this offering. Pending our use of the net proceeds from this offering, we
intend to invest the net proceeds in a variety of capital preservation investments, including short-term, investment-grade, interest-bearing instruments and U.S. government securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_6"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to fund
the development and expansion of our business, and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination to declare and pay dividends will be made at the discretion of our board of directors and will
depend on then-existing conditions, including our results of operations, financial condition, contractual restrictions, capital requirements, business prospects, and other factors our board of directors may deem relevant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, our ability to pay cash dividends on our capital stock in the future may be limited by the terms of any future debt or preferred securities
we issue or any credit facilities we enter into. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_7"></A>CORPORATE REORGANIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We previously operated as Hemab ApS, a private limited company organized under the laws of the Kingdom of Denmark. For purposes of this offering, we
formed Hemab Therapeutics Holdings, Inc., a Delaware corporation, which is the registrant whose name appears on the cover of the registration statement of which this prospectus is a part. In March 2026, we completed a corporate reorganization
pursuant to which the shareholders of Hemab ApS exchanged their shares in Hemab ApS for the same number, class and series of newly issued shares in the newly incorporated Delaware company, Hemab Therapeutics Holdings, Inc. and, as a result, Hemab
ApS became a wholly owned subsidiary of Hemab Therapeutics Holdings, Inc. Additionally, promptly following the corporate reorganization, Hemab ApS transferred its shares of Hemab Therapeutics Inc., a Delaware corporation and wholly-owned subsidiary
of Hemab ApS, to Hemab Therapeutics Holdings, Inc. in exchange for the issuance of a promissory note and, as a result, Hemab Therapeutics Inc. became a wholly owned subsidiary of Hemab Therapeutics Holdings, Inc. Hemab Therapeutics Holdings, Inc.
had nominal assets and liabilities and did not conduct any operations prior to the corporate reorganization other than its incorporation. Upon completion of the corporate reorganization, the historical consolidated financial statements of Hemab ApS
became the historical consolidated financial statements of Hemab Therapeutics Holdings, Inc. Investors in this offering will only acquire, and this prospectus only describes the offering of, shares of the common stock of Hemab Therapeutics Holdings,
Inc. We refer to this reorganization transaction throughout this prospectus as the &#8220;corporate reorganization.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We, Hemab ApS, and the
holders of all of the issued and outstanding shares of Hemab ApS entered into a share contribution and exchange agreement, pursuant to which the corporation reorganization was effected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Exchange of Hemab ApS Ordinary Shares for Hemab Therapeutics Holdings, Inc. Common Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to the corporate reorganization, the share capital of Hemab ApS was divided into ordinary shares, Seed Preference Shares, Series A Preference
Shares, Series B Preference Shares and Series C Preference Shares. In connection with the corporation reorganization, the shareholders of Hemab ApS exchanged each of these classes of shares of Hemab ApS for the same number, class and series of
common stock and preferred stock of Hemab Therapeutics Holdings, Inc. on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis. The newly issued shares of Hemab Therapeutics Holdings, Inc. have
substantially identical rights to the exchanged shares of Hemab ApS. As a result of the exchange, Hemab Therapeutics Holdings, Inc. became the sole shareholder of Hemab ApS, and the prior shareholders of Hemab ApS solely hold shares of Hemab
Therapeutics Holdings, Inc. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Assumption and Conversion of Hemab ApS Warrants for Hemab Therapeutics Holdings, Inc. Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with the corporate reorganization, each outstanding warrant to subscribe for the purchase of ordinary shares of Hemab ApS was assumed by
Hemab Therapeutics Holdings, Inc. and converted into a warrant to purchase the same number of shares of common stock of Hemab Therapeutics Holdings, Inc. Each new warrant otherwise has and is subject to the same terms and conditions as were in
effect immediately prior to the assumption and conversion, except that any warrant exercise price that had been denominated in DKK prior to the corporate reorganization was converted into an exercise price in U.S. dollars at the exchange rate as in
effect at the close of business on the business day prior to the corporate reorganization. No warrants of Hemab ApS are outstanding following the assumption and conversion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_8"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth our cash, cash equivalents, and marketable securities and our capitalization as of December&nbsp;31, 2025: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on a pro forma basis to give effect to (1)&nbsp;the corporate reorganization, (2)&nbsp;the automatic conversion of all
outstanding shares of our preferred stock into an aggregate of&#8195;&#8195;&#8195;&#8195; shares of our common stock, which conversion will occur upon the completion of this offering, and (3)&nbsp;the filing and effectiveness of our restated
certificate of incorporation immediately prior to the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on a pro forma as adjusted basis to give further effect to our issuance and sale of&#8195;&#8195;&#8195;&#8195;shares of
our common stock in this offering at an assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share, the midpoint of the estimated offering price range set forth on the cover page of this prospectus, after deducting estimated
underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The pro forma as adjusted information below
is illustrative only and our capitalization following the completion of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. You should read the information in this
table together with our consolidated financial statements and the related notes appearing elsewhere in this prospectus and the &#8220;<I>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</I>&#8221; section
of this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro</B><br><B>Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>As&nbsp;Adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="10" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash, cash equivalents, and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">185,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">185,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Preference Shares:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Convertible Seed Preference Shares, DKK 1 par value: 23,343 shares authorized, issued and outstanding,
actual; no shares authorized, issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Convertible Series A Preference Shares, DKK 1 par value; 225,866 shares authorized, issued and outstanding,
actual; no shares authorized, issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Convertible Series B Preference Shares, DKK 1 par value; 442,205 shares authorized, issued and outstanding,
actual; no shares authorized, issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Convertible Series C Preference Shares, DKK 1 par value; 512,991 shares authorized, issued and outstanding,
actual; no shares authorized, issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Shareholder&#8217;s (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Ordinary shares, DKK 1 par value; 43,000 shares authorized, issued and outstanding, actual; no shares
authorized, issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro</B><br><B>Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>As&nbsp;Adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="10" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock, $0.0001 par value; no shares authorized, issued and outstanding, actual; 1,446,166&nbsp;shares
authorized, 1,247,405&nbsp;shares issued and outstanding, pro forma; &#8195;&#8195;&#8195;&#8195;shares authorized, &#8195;&#8195;&#8195;&#8195;shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Preferred stock, $0.0001 par value; no shares authorized, issued and outstanding, actual;
&#8195;&#8195;&#8195;&#8195;shares authorized, no shares issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">365,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(181,858</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(181,858</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stockholders&#8217; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(176,635</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">183,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">183,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The pro forma as adjusted information in the table above is illustrative only, and our capitalization following the
completion of this offering will change based on the actual initial public offering price and other terms of this offering determined at pricing. Each $1.00 increase (decrease) in the assumed initial public offering price of
$&#8195;&#8195;&#8195;&#8195;per share, the midpoint of the estimated offering price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash, cash equivalents, and marketable
securities, total stockholders&#8217; equity, and total capitalization by approximately $&#8195;&#8195;&#8195;&#8195;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and
after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase (decrease) the number of shares we are offering. A 1.0&nbsp;million share increase (decrease) in the number of
shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash, cash equivalents, and marketable securities, total stockholders&#8217; equity, and total
capitalization by $&#8195;&#8195;&#8195;&#8195;million, assuming the assumed initial public offering price per share remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by
us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The table above does not include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">94,837 shares of common stock issuable upon exercise of warrants outstanding as of December&nbsp;31, 2025 with a
weighted-average exercise price of $124.60 per share, after giving effect to the corporate reorganization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#8195;&#8195;&#8195;shares of our common stock that will become available for future issuance under our 2026 Plan which
will become effective immediately prior to the effectiveness of the registration statement of which this prospectus is a part, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2026
Plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#8195;&#8195;&#8195;shares of our common stock that will become available for future issuance under our 2026 ESPP, which
will become effective immediately prior to the effectiveness of the registration statement of which this prospectus is a part, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2026
ESPP. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_9"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between the
initial public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock immediately after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The historical net tangible book value (deficit) of Hemab ApS as of December 31, 2025 was $(176.6)&nbsp;million, or $(4,107.79) per ordinary share.
Historical net tangible book value (deficit) is the amount of total tangible assets less total liabilities and the carrying value of convertible preference shares, which is not included within stockholders&#8217; (deficit) equity. Historical net
tangible book value (deficit) per share represents historical net tangible book value (deficit) divided by the 43,000 ordinary shares outstanding as of December 31, 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our pro forma net tangible book value (deficit) as of December 31, 2025 was $183.5&nbsp;million, or $147.13&nbsp;per share of our common stock. Pro
forma net tangible book value represents the amount of our total tangible assets less our total liabilities, after giving effect to (1)&nbsp;the corporate reorganization, (2)&nbsp;the automatic conversion of all outstanding shares of our preferred
stock into an aggregate of 1,204,405 shares of our common stock, which conversion will occur upon the completion of this offering, and (3)&nbsp;the filing and effectiveness of our restated certificate of incorporation immediately prior to the
completion of this offering. Pro forma net tangible book value (deficit) per share represents pro forma net tangible book value (deficit) divided by the total number of shares of common stock outstanding as of December 31, 2025, after giving effect
to the pro forma adjustments described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">After giving further effect to our issuance and sale of&#8195;&#8195;&#8195;&#8195;shares of our
common stock in this offering at an assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts
and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of&#8195;&#8195;&#8195;&#8195;,&#8195;&#8195;&#8195;&#8195;would have been $&#8195;&#8195;&#8195;&#8195;million, or
$&#8195;&#8195;&#8195;&#8195;per share. This represents an immediate increase in pro forma as adjusted net tangible book value per share of $&#8195;&#8195;&#8195;&#8195;to existing stockholders and an immediate dilution of
$&#8195;&#8195;&#8195;&#8195;in pro forma as adjusted net tangible book value per share to new investors purchasing shares of common stock in this offering. Dilution per share to new investors is determined by subtracting pro forma as adjusted net
tangible book value per share after this offering from the assumed initial public offering price per share paid by new investors. The following table illustrates this dilution on a per share basis: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Historical net tangible book value (deficit) per share as of December 31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,107.79</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Increase per share attributable to the pro forma adjustments described above</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,254.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net tangible book value per share as of &#8195;,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Increase in pro forma as adjusted net tangible book value per share attributable to new investors purchasing
shares of common stock in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma as adjusted net tangible book value per share immediately after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dilution per share to new investors purchasing shares of common stock in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The dilution information discussed above is illustrative only and will change based on the actual
initial public offering price and other terms of this offering determined at pricing. Each $1.00 increase (decrease) in the assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share, the midpoint of the price range set forth on
the cover page of this prospectus, would increase (decrease) our pro forma as adjusted net tangible book value per share after this offering by $&#8195;&#8195;&#8195;&#8195;, dilution per share to new investors purchasing shares of common stock in
this offering by $&#8195;&#8195;&#8195;&#8195;, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated
offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may also increase or decrease the number of shares we are offering. A 1.0&nbsp;million share increase in the
number of shares offered by us, as set forth on the cover page of this prospectus, would increase our pro forma as adjusted net tangible book value per share after this offering by $&#8195;&#8195;&#8195;&#8195;and decrease the dilution per share to
new investors purchasing shares of common stock in this offering by $&#8195;&#8195;&#8195;&#8195;, assuming the assumed initial public offering price per share remains the same, and after deducting estimated underwriting discounts and commissions
and estimated offering expenses payable by us. A 1.0&nbsp;million share decrease in the number of shares offered by us, as set forth on the cover page of this prospectus, would decrease our pro forma as adjusted net tangible book value per share
after this offering by $&#8195;&#8195;&#8195;&#8195;and increase the dilution per share to new investors purchasing shares of common stock in this offering by $&#8195;&#8195;&#8195;&#8195;, assuming the assumed initial public offering price per
share remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If the
underwriters exercise in full their option to purchase additional shares of our common stock, our pro forma as adjusted net tangible book value per share after this offering would be $&#8195;&#8195;&#8195;&#8195;, representing an immediate increase
in pro forma as adjusted net tangible book value per share of $&#8195;&#8195;&#8195;&#8195;to existing stockholders and immediate dilution in pro forma as adjusted net tangible book value per share of $&#8195;&#8195;&#8195;&#8195;to new investors
purchasing shares of common stock in this offering, assuming an initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated
underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table summarizes, as of December 31, 2025 on
the pro forma as adjusted basis described above, the total number of shares of common stock purchased from us on an as converted to common stock basis, the total consideration paid or to be paid and the weighted average price per share paid or to be
paid by existing stockholders and by new investors in this offering at the assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share, the midpoint of the estimated offering price range set forth on the cover page of this
prospectus, before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. As the table shows, new investors purchasing shares of common stock in this offering will pay an average price per share
substantially higher than our existing stockholders paid. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Price</B><br><B>Per</B><br><B>Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Investors purchasing shares of common stock in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The table above assumes no exercise of the underwriters&#8217; option to purchase additional shares in this offering. If
the underwriters exercise in full their option to purchase additional shares of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
common stock, the number of shares of our common stock held by existing stockholders would be reduced to&#8195;&#8195;&#8195;&#8195; % of the total number of shares of our common stock
outstanding after this offering, and the number of shares of common stock held by new investors purchasing shares of common stock in this offering would be increased to&#8195;&#8195;&#8195;&#8195;% of the total number of shares of our common stock
outstanding after this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The tables and discussion above are based on the number of shares outstanding as of December&nbsp;31, 2025, and
exclude: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">94,837 shares of common stock issuable upon exercise of warrants outstanding as of December&nbsp;31, 2025 with a
weighted-average exercise price of $124.60 per share, after giving effect to the corporate reorganization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#8195;&#8195;&#8195;shares of our common stock that will become available for future issuance under our 2026 Plan which
will become effective immediately prior to the effectiveness of the registration statement of which this prospectus is a part, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2026
Plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#8195;&#8195;&#8195;shares of our common stock that will become available for future issuance under our 2026 ESPP, which
will become effective immediately prior to the effectiveness of the registration statement of which this prospectus is a part, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2026
ESPP. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To the extent that outstanding stock options are exercised, new stock options are issued, or we issue additional shares of
common stock in the future, there will be further dilution to our stockholders, including investors purchasing shares of common stock in this offering. In addition, we may choose to raise additional capital because of market conditions or strategic
considerations, even if we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in
further dilution to our stockholders, including investors purchasing shares of common stock in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_10"></A>MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>You should
read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated financial statements and related notes and other financial information included elsewhere in this prospectus. This
discussion and analysis and other parts of this prospectus contain forward-looking statements based upon our current plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, strategies,
objectives, expectations, intentions and beliefs. Our actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under
&#8220;Risk Factors&#8221; and elsewhere in this prospectus. You should carefully read the &#8220;Risk Factors&#8221; section of this prospectus to gain an understanding of the important factors that could cause actual results to differ materially
from our forward-looking statements. Please also see &#8220;Cautionary Note Regarding Forward-Looking Statements and Industry Data.&#8221; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human
resilience. Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases, including
Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease and other conditions of abnormal bleeding, all of which can cause significant life-long burden to patients. We are building a comprehensive franchise of investigational
therapeutics spanning from Phase 2 clinical development through discovery research. Our assets address critical gaps in the treatment of coagulation disorders, with multiple value-driving clinical data events anticipated in 2026, 2027 and beyond.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our lead asset, sutacimig <FONT STYLE="white-space:nowrap">(HMB-001),</FONT> is a bispecific antibody currently in Phase 1/2 clinical development
for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Our second clinical-stage asset, <FONT STYLE="white-space:nowrap">HMB-002,</FONT> is a monovalent
antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. We are also advancing multiple preclinical and discovery-stage assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since our inception in 2020, we have devoted substantially all of our resources to drug discovery, the development of our lead product candidates,
sutacimig and <FONT STYLE="white-space:nowrap">HMB-002,</FONT> along with several preclinical programs focusing on coagulation disorders. In addition to our research and development efforts, our operations to date have been limited to organizing and
staffing our company, business planning, raising capital, securing intellectual property rights, <FONT STYLE="white-space:nowrap">in-licensing</FONT> technology, discovering product candidates, undertaking preclinical studies, conducting clinical
trials and providing general and administrative support for these operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have no approved products, and we have not generated any revenue
from product sales. We have financed our operations primarily through private placements of convertible preference shares and issuance of convertible debt. Since our inception through December&nbsp;31, 2025, we have received aggregate gross proceeds
of approximately $346.0&nbsp;million from such transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have incurred significant operating losses since inception. Our net losses were
$48.7&nbsp;million and $63.9&nbsp;million for the years ended December&nbsp;31, 2024 and 2025, respectively. As of December&nbsp;31, 2025, we had an accumulated deficit of $181.9&nbsp;million. We expect to continue to incur significant operating
expenses and net losses for the foreseeable future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We anticipate that our expenses will increase substantially if and as we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">continue to advance the clinical development of our product candidates, including our ongoing Phase 1/2 clinical trial of
sutacimig in patients with Glanzmann thrombasthenia, our ongoing Phase 2 clinical trial of sutacimig in patients with Factor VII deficiency, and our ongoing Phase 1/2 clinical trial of <FONT STYLE="white-space:nowrap">HMB-002</FONT> in patients with
Von Willebrand Disease, as well as any other product candidates that we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">advance our clinical-stage product candidates into later-stage clinical trials, including our planned Phase 3 clinical
trial of sutacimig in patients with Glanzmann thrombasthenia, which will be required in order to seek marketing approval of our product candidates, and which we expect will be substantially more expensive than our earlier-stage clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">continue to advance our research and preclinical activities and seek to discover and develop additional product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establish and <FONT STYLE="white-space:nowrap">scale-up</FONT> manufacturing processes and capabilities, or arrange for a
third party to do so on our behalf, to support our clinical trials of our product candidates and commercialization of any of our product candidates for which we obtain marketing approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">seek regulatory and marketing approvals for any of our product candidates that successfully complete clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">ultimately establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any products for
which we may obtain marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">continue to develop, maintain, expand and protect our intellectual property portfolio (including intellectual property
obtained through license agreements) and provide reimbursement of third-party expenses related to our patent portfolio; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> products, product candidates or technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establish or maintain collaborations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">maintain, expand, enforce, defend and protect our intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">hire additional clinical, medical, regulatory, quality control, manufacturing and other scientific and technical personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">add operational, financial, clinical, quality and management information systems and personnel, including personnel to
support our product development and planned future commercialization efforts of our product candidates and our operations as a public company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">incur additional audit, legal, regulatory, tax and other expenses with being a public company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">make any milestone, royalty, or other payments to Novo Nordisk A/S, or Novo Nordisk, under our license agreement with Novo
Nordisk, or the Novo Nordisk Agreement, and to Genmab A/S, or Genmab, under our license agreement with Genmab, or the Genmab Agreement, and under any additional future collaboration or license agreements that we may enter into.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, our expenses will further increase if, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we are required by the U.S. Food and Drug Administration, the European Medicines Agency, or other regulatory authorities to
perform clinical trials or preclinical studies that are in addition to, or different than, those expected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">there are any delays in completing our clinical trials or preclinical studies or the development of any of our product
candidates; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">there are any third-party challenges to our intellectual property or we need to defend against any intellectual
property-related claim. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We will not generate revenue from product sales unless and until we successfully complete the clinical
development or future clinical development of, and obtain regulatory approval for, one or more of our current or future product candidates, which may not occur for several years, if at all. In addition, if we obtain marketing approval for our
product candidates and any other product candidates we may identify and pursue, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our net losses may fluctuate significantly from period to period, depending on the timing of our current and potential future clinical trials and
expenditures related to our research and developmental activities. Furthermore, upon the closing of this offering, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial
additional funding to support our continuing operations and pursue our growth strategy. Until such a time when we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of equity
offerings, debt financings, royalty financings, collaborations, strategic alliances, and marketing, distribution or licensing arrangements. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed,
on favorable terms, or at all. Our failure to raise capital or enter into such agreements or arrangements as, and when needed, could have a material adverse effect on our business, results of operations and financial condition, including potentially
requiring us to delay, limit, reduce or eliminate product development or future commercialization efforts, or grant rights to develop and market current or future development product candidates that we would otherwise prefer to develop and market
ourselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As there are numerous risks and uncertainties associated with product development, we are unable to accurately predict the timing or
amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a
continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of
December&nbsp;31, 2025, we had cash, cash equivalents and marketable securities of $185.5&nbsp;million. We believe that our existing cash, cash equivalents and marketable securities, together with the anticipated net proceeds from this offering,
will enable us to fund our operating expenses and capital expenditure requirements into &#8195;&#8195;&#8195;&#8195;. For more information, see the section titled &#8220;<I>Liquidity and Capital Resources</I>&#8221; below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Corporate Reorganization </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On March&nbsp;30, 2026, we
completed a corporate reorganization pursuant to which the shareholders of Hemab ApS exchanged their shares in Hemab ApS for the same number, class and series of newly issued shares, on a one to one basis, in the newly incorporated Delaware company,
Hemab Therapeutics Holdings, Inc. and, as a result, Hemab ApS became a wholly owned subsidiary of Hemab Therapeutics Holdings, Inc. The newly issued shares of Hemab Therapeutics Holdings, Inc. have substantially identical rights to the exchanged
shares of Hemab ApS. As a result of the exchange, Hemab Therapeutics Holdings, Inc. became the sole shareholder of Hemab ApS, and the prior shareholders of Hemab ApS solely hold shares of Hemab Therapeutics Holdings, Inc. Hemab Therapeutics
Holdings, Inc. had nominal assets and liabilities and did not conduct any operations prior to the corporate reorganization other than its incorporation. Upon completion of the corporate reorganization, the historical consolidated financial
statements of Hemab ApS became the historical consolidated financial statements of Hemab Therapeutics Holdings, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with the
corporate reorganization, each outstanding warrant to subscribe for the purchase of ordinary shares of Hemab ApS was assumed by Hemab Therapeutics Holdings, Inc. and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
converted into a warrant to purchase the same number of shares of common stock of Hemab Therapeutics Holdings, Inc. Each new warrant otherwise has and is subject to the same terms and conditions
as were in effect immediately prior to the assumption and conversion, except that any warrant exercise price that had been denominated in DKK prior to the corporate reorganization was converted into an exercise price in U.S. dollars at the exchange
rate as in effect at the close of business on the business day prior to the corporate reorganization. No warrants of Hemab ApS are outstanding following the assumption and conversion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, promptly following the corporate reorganization, on April&nbsp;1, 2026, Hemab ApS transferred its shares of Hemab Therapeutics Inc., a
Delaware corporation and wholly-owned subsidiary of Hemab ApS, to Hemab Therapeutics Holdings, Inc. in exchange for the issuance of a promissory note and, as a result, Hemab Therapeutics Inc. became a wholly owned subsidiary of Hemab Therapeutics
Holdings, Inc. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Components of Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Revenue
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have not generated any revenues from the sale of products to date and do not expect to generate any revenue from the sale of products
until we successfully complete development and obtain regulatory approval for one or more of our product candidates, which may not occur for several years, if at all. If our development efforts for our product candidates are successful and result in
regulatory approval or we successfully enter into collaboration or license agreements with third parties, we may generate revenues in the future from product sales, or payments from such collaboration or license agreements, or a combination thereof.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Operating Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our operating expenses
consist of research and development expenses and general and administrative expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Research and development expenses consist primarily of external and internal costs incurred for our research and development activities, including our
product candidate discovery and development efforts. These expenses include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">external costs, including expenses incurred under arrangements with third-parties, such as contract manufacturing
organizations, or CMOs, contract research organizations, or CROs, providers of sponsored research, consultants and our scientific advisors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">laboratory and vendor costs related to the execution of preclinical studies and planned and ongoing clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">costs related to compliance with regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">direct costs of conducting internal research and development for our internal preclinical programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">acquisition of intellectual property and related future payments should certain development and regulatory milestones be
achieved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">personnel-related costs, including salaries, bonuses, benefits and equity-based compensation for employees engaged in
research and development functions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">expenses incurred for the procurement of materials, laboratory supplies and
<FONT STYLE="white-space:nowrap">non-capital</FONT> equipment used in the research and development process; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">depreciation, amortization and other direct and allocated expenses, including rent, insurance, maintenance of facilities
and other operating costs, incurred as a result of our research and development activities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expense research and development
costs as incurred. <FONT STYLE="white-space:nowrap">Non-refundable</FONT> advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid
amounts are expensed as the related goods are delivered or the services are performed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We record accruals for estimated ongoing research costs and
receive updated estimates of costs and amounts owed on a monthly basis from our third-party service providers. When evaluating the adequacy of the prepaid expenses and accrued liabilities, we analyze progress of the studies, including the phase or
completion of events, invoices received and contracted cost estimates from its third-party service providers. Estimates are made in determining the balances at the end of any reporting period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A significant portion of our research and development costs have been, and will continue to be, external costs. External costs, which are specific to a
product candidate, are tracked on a product <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">candidate-by-product</FONT></FONT> candidate basis upon our designation of a preclinical asset as a product candidate. Because we can use
certain resources across several product candidates, personnel-related expenses and indirect or shared operating costs incurred for our research and development activities are not recorded or allocated on a product <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">candidate-by-product</FONT></FONT> candidate basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have historically met the requirements to receive a tax credit in
Denmark of up to 5.5&nbsp;million Danish Kroner, or DKK, per year for losses resulting from research and development costs of up to DKK 25&nbsp;million per year. The tax credit is presented as a reduction to research and development expense in the
consolidated statements of operations and comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We anticipate that our research and development expenses will increase substantially
for the foreseeable future in connection with our ongoing clinical trials and our planned clinical development activities. However, we cannot reasonably estimate the costs or timing of the efforts that will be necessary to complete the development
of any of our product candidates due to the numerous risks and uncertainties associated with their development, including the uncertainty of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the scope, progress, costs and results of our current and future preclinical studies and clinical trials for our product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of clinical trials required for regulatory approval of our current or future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">whether we partner our programs with collaborators for later-stage clinical development or commercialization;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number and development requirements of any other product candidates we may identify and develop; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs, timing and outcome of regulatory review of our product candidates and any other product candidates we may
identify and develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs of obtaining clinical and commercial supplies of our product candidates and any other product candidates we may
identify and develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to successfully commercialize our product candidates and any other product candidates we may identify and
develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the time and cost necessary to respond to technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the extent to which we may acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and
technologies; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of
such arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">milestone payments and other collaboration-based payments, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to attract, hire and retain qualified personnel; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the effect of macroeconomic trends including inflation, foreign exchange rate, interest rates and tariffs.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any changes in the outcome of any of these variables with respect to the development of our programs and product candidates or
any future programs and product candidates that we may develop could result in a significant change in the costs and timing associated with the development of that program or product candidate. We may never succeed in achieving regulatory approval
for any of our product candidates or any future product candidates that we may identify and develop. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">General and administrative expenses consist primarily of personnel-related costs, including salaries, bonuses, benefits and equity-based compensation
expenses for employees in executive, accounting and finance, business development, human resources, legal and other administrative functions. Other significant general and administrative expenses include facility related costs including
depreciation, legal fees relating to corporate and intellectual property matters and other corporate matters, professional fees for accounting, audit and tax services, consulting fees and insurance costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We anticipate that our general and administrative expenses will increase as we increase our headcount to support our research and development activities
and the potential commercialization of our product candidates, if approved. Additionally, these increases will likely include increased costs related to the hiring of additional personnel, among other expenses. We also expect to incur increased
expenses associated with being a public company, including increased costs of accounting, audit, legal, regulatory and <FONT STYLE="white-space:nowrap">tax-related</FONT> services associated with maintaining compliance with Nasdaq listing
requirements and the requirements of the Securities and Exchange Commission, or the SEC, director and officer insurance costs, and investor and public relations costs. We also expect to incur additional intellectual property-related expenses as we
file patent applications to protect innovations arising from our research and development activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Other Income (Expense), Net </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Other income (expense), net primarily consists of interest income generated from interest on cash, cash equivalents and marketable securities, realized
and unrealized gains and losses on foreign currency transactions and interest expense associated with our finance lease for certain laboratory equipment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Income
Taxes </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are subject to taxation in the United States and Denmark. As of December&nbsp;31, 2025, we had $170.9&nbsp;million of net operating
loss carryforwards that can be carried forward indefinitely according to Danish Tax Authority regulations. These loss carryforwards are available to reduce future taxable income, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying
amounts of existing assets and liabilities and their respective tax bases, and operating losses and tax credit carry forwards. Deferred tax assets and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
liabilities are measured using enacted statutory tax rates expected to apply to taxable income in the jurisdictions and years in which those temporary differences are expected to be recovered or
settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on the level of historical operating results and projections for the taxable income for the future, we have determined that it is more likely than
not that our net deferred tax assets will not be realized. Accordingly, we have recorded a full valuation allowance to reduce our net deferred tax assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We recognize tax benefits from uncertain tax positions only if, based on the technical merits of the position, it is more likely than not that the tax
positions will be sustained on examination by the tax authority. The tax benefits recognized in the financial statements from such positions are measured based on the largest amount that is more than 50% likely to be realized upon ultimate
settlement. We recognize interest and penalties related to unrecognized tax benefits within the provision for taxes in our statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We operate in Denmark and may be subject to audits from various tax authorities. Management&#8217;s judgment is required in determining our provision
for income taxes, our deferred tax assets and liabilities, liabilities for uncertain tax positions, and any valuation allowance recorded against our net deferred tax assets. We plan to monitor the extent to which our deferred tax assets may be
realized and adjust the valuation allowance accordingly. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Comparison of the Years Ended December&nbsp;31, 2024 and 2025 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table summarizes our results of operations for the years presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2024&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2025&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,383</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70,119</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,736</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income (expense), net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,766</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss before income tax (expense) benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,522</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,140</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,618</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Income tax (expense) benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(48,707</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(63,913</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,206</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table summarizes our research and development expenses for the years presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2024&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">External research and development costs by product candidate:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">sutacimig</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">HMB-002</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,699</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other research and development costs:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Personnel-related (excluding equity-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Equity-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Discovery and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Total research and development expenses were $41.4&nbsp;million for the year ended December&nbsp;31, 2024, compared to
$59.6&nbsp;million for the year ended December&nbsp;31, 2025. The $18.2&nbsp;million increase in research and development expenses for the year ended December&nbsp;31, 2025 was primarily due to an increase of $9.4&nbsp;million in spending on the
clinical development of sutacimig and an increase of $6.4&nbsp;million in personnel-related costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">External research and development expenses
related to sutacimig for the years ended December&nbsp;31, 2024 and 2025 were $12.7&nbsp;million and $22.1&nbsp;million, respectively. The increase of $9.4&nbsp;million for the year ended December&nbsp;31, 2025 was primarily driven by continued
clinical development of sutacimig, including increased <FONT STYLE="white-space:nowrap">scale-up</FONT> activities and Good Manufacturing Practices batch production to support our planned Phase 3 clinical trial as well as increased CRO costs from
our ongoing Phase 1/2 clinical trials of sutacimig. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">External research and development expenses related to
<FONT STYLE="white-space:nowrap">HMB-002</FONT> for the years ended December&nbsp;31, 2024 and 2025 were $15.3&nbsp;million and $12.6&nbsp;million, respectively. The decrease of $2.7&nbsp;million for the year ended December&nbsp;31, 2025 was
primarily driven by Chemistry, Manufacturing, and Controls, or CMC, costs and preclinical toxicology studies and costs related to submission of an investigational new drug application in 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Other external research and development expenses increased by $3.2&nbsp;million for the year ended December&nbsp;31, 2025 compared to the year ended
December&nbsp;31, 2024, primarily driven by the initiation of preclinical toxicology studies and CMC activities to support investigational new drug enabling studies for a product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Personnel-related expenses and equity-based compensation increased by $6.4&nbsp;million and $0.3&nbsp;million in the year ended December&nbsp;31, 2025,
respectively, compared to the year ended December&nbsp;31, 2024, primarily driven by an increase in average headcount across clinical development, CMC, and clinical operations related to the pursuit of identifying and developing product candidates.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Discovery and other costs increased by $1.6&nbsp;million for the year ended December&nbsp;31, 2025 compared to the year ended December&nbsp;31,
2024, primarily driven by an increase in discovery activities and consultancy expense related to clinical operations, clinical research, and regulatory research. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table summarizes our general and administrative expenses for the years presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2024&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Personnel-related (excluding equity-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Equity-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(190</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Professional services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total general and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Total general and administrative expenses were $9.0&nbsp;million for the year ended December&nbsp;31, 2024, compared to
$10.5&nbsp;million for the year ended December&nbsp;31, 2025. The $1.5&nbsp;million increase was primarily due to an increase in personnel-related costs of $0.6&nbsp;million driven by an increase in average headcount as well as an increase in
professional service fees of $0.7&nbsp;million. These costs were partially offset by a $0.2&nbsp;million decrease in equity-based compensation expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Other
Income (Expense), Net </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Other income (expense), net for the years ended December&nbsp;31, 2024 and 2025 were net income of $1.9&nbsp;million and
$6.0&nbsp;million, respectively. The $4.1&nbsp;million increase was primarily related to foreign currency gains recognized due to favorable movements between the currencies which we regularly transact in, including DKK, Euros, British Pounds and our
functional currency, the U.S.&nbsp;dollar. This was offset by a decrease in interest income of $1.8&nbsp;million due to a decrease in our cash, cash equivalents and marketable securities throughout the year prior to the closing of our Series C
financing in October 2025. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Sources of Liquidity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since our inception, we have
incurred significant operating losses. To date, we have financed our operations primarily through private placements of convertible preference shares and issuance of convertible debt. Through December&nbsp;31, 2025, we have received aggregate gross
proceeds of approximately $346.0&nbsp;million from such transactions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table provides information regarding our cash flows for the years presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(45,592</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(61,475</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,883</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(81,482</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(143,385</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash (used in) provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Effect of&nbsp;foreign exchange&nbsp;rate changes on cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Operating Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our cash flows from operating activities are significantly influenced by our use of cash for operating expenses and working capital requirements to
support our business. We have historically experienced negative cash flows from operating activities as we invested in the research and development of our product candidates and programs, including preclinical studies, clinical trials, manufacturing
and manufacturing process development. The cash used in operating activities resulted primarily from our net losses adjusted for <FONT STYLE="white-space:nowrap">non-cash</FONT> charges, which are generally due to equity-based compensation,
depreciation and amortization and <FONT STYLE="white-space:nowrap">non-cash</FONT> lease expense, <FONT STYLE="white-space:nowrap">non-cash</FONT> interest income, as well as changes in components of operating assets and liabilities, which are
generally due to increased expenses and timing of vendor payments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the year ended December&nbsp;31, 2024, net cash used in operating
activities was $45.6&nbsp;million, due to a net loss of $48.7&nbsp;million, which was partially offset by changes in operating assets and liabilities that provided $1.4&nbsp;million in cash and net <FONT STYLE="white-space:nowrap">non-cash</FONT>
expenses of $1.7&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the year ended December&nbsp;31, 2025, net cash used in operating activities was $61.5&nbsp;million, due to a
net loss of&#8201; $63.9&nbsp;million, which was partially offset by changes in operating assets and liabilities that provided $1.3&nbsp;million in cash and net <FONT STYLE="white-space:nowrap">non-cash</FONT> expenses of $1.1&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Investing Activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the year ended December&nbsp;31,
2024, net cash provided by investing activities was $61.9&nbsp;million, which primarily consisted of maturities of marketable securities, which were partially offset by purchases of marketable securities and property and equipment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the year ended December&nbsp;31, 2025, net cash used in investing activities was $81.5&nbsp;million, which primarily consisted of purchases of
marketable securities, which were partially offset by maturities of marketable securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Financing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the year ended December&nbsp;31, 2024, net cash used in financing activities was $0.1&nbsp;million, related to principal payments on finance lease
obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the year ended December&nbsp;31, 2025, net cash provided by financing activities of $156.3&nbsp;million, which primarily
related to proceeds received from the issuance of Series C preference shares of Hemab ApS, net of issuance costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Funding Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect our expenses to increase substantially in connection with our ongoing and planned activities, particularly as we commence our planned Phase 3
clinical trial of sutacimig in patients with Glanzmann thrombasthenia and continue our ongoing Phase 1/2 clinical trial of sutacimig in patients with Glanzmann thrombasthenia, Phase 2 clinical trial of sutacimig in patients with Factor VII
deficiency and Phase 1/2 trial of <FONT STYLE="white-space:nowrap">HMB-002</FONT> in patients with Von Willebrand Disease, continue research and development and initiate additional clinical trials of, and seek marketing approval for, these and other
product candidates. In addition, if we obtain marketing approval for our product candidates and any other product candidates we may identify and pursue, we expect to incur significant commercialization expenses related to product manufacturing,
sales, marketing and distribution. Furthermore, upon the closing of this offering, we expect to incur additional costs associated with operating as a public company. As a result, we expect to continue to incur significant operating expenses and net
losses for the foreseeable future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2025, we had total cash, cash equivalents and marketable securities of
$185.5&nbsp;million. We believe that our existing cash, cash equivalents and marketable securities, together with the anticipated net proceeds from this offering, will enable us to fund our operating expenses and capital expenditure requirements
into&#8195;&#8195;&#8195;&#8195;. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Because of the numerous risks and uncertainties associated with product development, and because the extent to which we may enter into collaborations
with third-parties for the development of our product candidates is unknown, we may incorrectly estimate the timing and amounts of increased capital outlays and operating expenses associated with completing the research and development of our
product candidates. Our funding requirements and timing and amount of our operating expenditures will depend on many factors. We anticipate that our expenses will increase substantially if and as we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">continue to advance the clinical development of our product candidates, including our ongoing Phase 1/2 clinical trial of
sutacimig in patients with Glanzmann thrombasthenia, our ongoing Phase 2 clinical trial of sutacimig in patients with Factor VII deficiency, and our ongoing Phase 1/2 clinical trial of <FONT STYLE="white-space:nowrap">HMB-002</FONT> in patients with
Von Willebrand Disease, as well as any other product candidates that we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">advance our clinical-stage product candidates into later-stage clinical trials, including our planned Phase 3 clinical
trial of sutacimig in patients with Glanzmann thrombasthenia, which will be required in order to seek marketing approval of our product candidates, and which we expect will be substantially more expensive than our earlier-stage clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">continue to advance our research and preclinical activities and seek to discover and develop additional product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establish and <FONT STYLE="white-space:nowrap">scale-up</FONT> manufacturing processes and capabilities, or arrange for a
third party to do so on our behalf, to support our clinical trials of our product candidates and commercialization of any of our product candidates for which we obtain marketing approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">seek regulatory and marketing approvals for any of our product candidates that successfully complete clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">ultimately establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any products for
which we may obtain marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">continue to develop, maintain, expand and protect our intellectual property portfolio (including intellectual property
obtained through license agreements) and provide reimbursement of third-party expenses related to our patent portfolio; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> products, product candidates or technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establish or maintain collaborations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">maintain, expand, enforce, defend and protect our intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">hire additional clinical, medical, regulatory, quality control, manufacturing and other scientific and technical personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">add operational, financial, clinical, quality and management information systems and personnel, including personnel to
support our product development and planned future commercialization efforts of our product candidates and our operations as a public company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">incur additional audit, legal, regulatory, tax and other expenses with being a public company; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">make any milestone, royalty, or other payments under the Novo Nordisk Agreement, under the Genmab Agreement, and under any
additional future collaboration or license agreements that we may enter into. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, our expenses will further increase if,
among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we are required by the U.S. Food and Drug Administration, the European Medicines Agency, or other regulatory authorities to
perform clinical trials or preclinical studies that are in addition to, or different than, those expected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">there are any delays in completing our clinical trials or preclinical studies or the development of any of our product
candidates; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">there are any third-party challenges to our intellectual property or we need to defend against any intellectual
property-related claim. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Identifying potential product candidates and conducting preclinical studies and clinical trials is a time
consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may
not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if ever. Accordingly, we will need to obtain substantial additional funds to
achieve our business objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our expectation with respect to our ability to fund current planned operations is based on estimates that are
subject to risks and uncertainties. Our operating plan may change as a result of many factors currently unknown to management and there can be no assurance that the current operating plan will be achieved in the time frame anticipated by us, and we
may need to seek additional funds sooner than planned. If we are unable to raise this capital when needed, we may be forced to delay, limit, reduce or eliminate one or more of our research and development programs or other operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Adequate additional funds may not be available to us on acceptable terms, or at all. We do not have any source of committed capital or external funds.
To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect
your rights as stockholder. Additional debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring debt, selling or
licensing our assets, making capital expenditures or declaring dividends or encumbering our assets to secure future indebtedness. If we raise additional funds through equity offerings, debt financings, royalty financings, collaborations, strategic
alliances and marketing, distribution or licensing arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or development product candidates or grant licenses on terms that may not be
favorable to us. If we are unable to raise additional funds when needed or on terms acceptable to us, we may be required to delay, limit, reduce or terminate our product development programs or future commercialization efforts or grant rights to
develop and market product candidates that we would otherwise prefer to develop and market ourselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For additional information on risks
associated with our substantial capital requirements, please see &#8220;<I>Risk Factors &#8212; We will need substantial additional funding. If we are unable to raise capital on acceptable terms when needed, or at all, we could be forced to delay,
reduce or eliminate our product development programs or commercialization efforts</I>.&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Contractual Obligations and Commitments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Purchase and Other Obligations </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We enter into contracts in the
normal course of business with CROs, CMOs and other third-parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts typically do not contain minimum purchase commitments and are cancellable by
us upon written notice. Payments due upon cancellation generally consist of payments for services provided or expenses incurred up to the date of cancellation, including <FONT STYLE="white-space:nowrap">non-cancelable</FONT> obligations of our
service providers and, in some cases, wind-down costs. For further information regarding certain of our license agreements and amounts that could become payable in the future under those agreements, please see Note 8 in our consolidated financial
statements appearing elsewhere in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>License Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Below is a summary of the key terms for certain of our license agreements. For a more detailed description of these agreements, see the section titled
&#8220;<I>Business&#8212;License Agreements.</I>&#8221; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>License Agreement with Novo Nordisk </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In November 2019, we entered into a license agreement with Novo Nordisk A/S, or Novo Nordisk, pursuant to which Novo Nordisk granted us an exclusive
(even as to Novo Nordisk), worldwide and sublicensable license under specified patent rights, and a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide and sublicensable license under specified
<FONT STYLE="white-space:nowrap">know-how,</FONT> to research, develop, make, have made, use, offer for sale, sell, import, export or otherwise exploit, or transfer possession of or title in, products, or Novo Licensed Products, containing
bispecific IgG antibodies targeting <FONT STYLE="white-space:nowrap">TLT-1</FONT> and Factor VII, including sutacimig, for the treatment of bleeding conditions, including hemophilia. We refer to this agreement as the Novo Nordisk Agreement. Under
the terms of the Novo Nordisk Agreement, we have agreed to use commercially reasonable efforts to develop and commercialize a Novo Licensed Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are obligated to pay to Novo Nordisk a <FONT STYLE="white-space:nowrap">one-time</FONT> DKK 40&nbsp;million milestone payment upon achievement by a
Novo Licensed Product of a specified regulatory milestone event, and we are also obligated to pay Novo Nordisk tiered royalties, in the low single-digit percentages, on aggregate annual net sales of all Novo Licensed Products, on a Novo Licensed <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Novo</FONT></FONT> Licensed Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, until the later of the
expiration of the last valid claim in the licensed patents under the Novo Nordisk Agreement covering such Novo Licensed Product in such country and ten years following the first commercial sale of such Novo Licensed Product in such country. We
currently expect that all of the licensed patents under the Novo Nordisk Agreement will expire by 2040, potentially extending to 2045 with patent term extension. To date, we have not made any payments to Novo Nordisk under the Novo Nordisk
Agreement. Under the Novo Nordisk Agreement, we initially granted to Novo Nordisk a right of first negotiation, following a specified clinical event and during a specified period of time, to obtain a license back from us to exploit Novo Licensed
Products if we determined to engage with a third party with respect to a license of any Novo Licensed Products. However, Novo Nordisk&#8217;s right of first negotiation under the Novo Nordisk Agreement has expired. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Novo Nordisk Agreement will continue in force until it is terminated. On expiration of each royalty term, our license becomes royalty-free,
perpetual, and irrevocable with respect to the applicable Novo Licensed Product in the applicable country. Either party may terminate the Novo Nordisk Agreement for the other party&#8217;s uncured material breach or insolvency. We may terminate the
Novo Nordisk Agreement for any reason upon 90 days&#8217; written notice to Novo Nordisk. In the event that Novo Nordisk regains control of the exclusive right to exploit the Novo Licensed Product, the Novo Nordisk Agreement will automatically
terminate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>License Agreement with Genmab </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In April 2020, we entered into a license agreement with Genmab A/S, or Genmab, pursuant to which Genmab granted us an exclusive (even as to Genmab and
its affiliates), worldwide and sublicensable license under platform technology patent rights and <FONT STYLE="white-space:nowrap">know-how</FONT> relating to Genmab&#8217;s proprietary
DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> platform to research, develop, make, have made, use, manufacture, import, export and commercialize products comprising bispecific IgG antibodies targeting <FONT
STYLE="white-space:nowrap">TLT-1</FONT> and Factor&nbsp;VII, or <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products, including sutacimig, for the treatment of bleeding conditions, including hemophilia. Under the terms of the
Genmab Agreement, we have agreed to use commercially reasonable efforts to develop, manufacture, obtain regulatory approval for and commercialize <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products worldwide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the Genmab Agreement, we are obligated to pay Genmab a percentage of all net profit (i.e., revenue and other proceeds less specified direct costs
we incur to conduct research, development, manufacture and commercialization of <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products) we or our affiliates receive with respect to any
<FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products, including (1)&nbsp;net profit from commercial sales of <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products and any revenue from third parties, other
than Novo Nordisk, in respect of a sublicense or assignment with respect to <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products, including assignment fees, sublicensing fees, upfront and milestone fees, royalties and other
consideration, whether in kind or cash, and (2)&nbsp;the net profit allocated to <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products that we or our affiliates receive if we undergo a change of control (other than an
acquisition by Novo Nordisk). The percentage of net profit we owe with respect to each TLT-1/Factor VII Antibody Product is in the low teens from the effective date of the Genmab Agreement until the first commercial sale of such <FONT
STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Product. From and after the first commercial sale of a TLT-1/Factor&nbsp;VII Antibody Product, the percentage of net profit we owe with respect to such TLT-1/Factor VII Antibody Product is
in the high single digits in all territories in which we commercialize such TLT-1/Factor&nbsp;VII Antibody Product and in the mid-teens in all territories in which a third party, other than Novo Nordisk, commercializes such TLT-1/Factor VII Antibody
Product. We are obligated to pay such percentage of net profit on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-TLT-1/Factor</FONT></FONT></FONT> VII Antibody Product basis until the later of the expiration of the last-to-expire of the platform technology
patent rights licensed under the Genmab Agreement covering such <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Product in such country and twelve years following the first commercial sale of such
<FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Product in such country, which we refer to as the net profit share term. Following the expiration of the last-to-expire of the platform technology patent rights licensed under the
Genmab Agreement covering a given <FONT STYLE="white-space:nowrap">TLT-1/Factor&nbsp;VII</FONT> Antibody Product in a given country, the percentage of net profit that we are obligated to pay with respect to sales of such TLT-1/Factor VII Antibody
Product in such country will be reduced by a specified percentage for the remainder of the net profit share term for such TLT-1/Factor VII Antibody Product in such country. We currently expect that all of the platform technology patent rights
licensed under the Genmab Agreement will expire by 2032, though this date may be extended if, for example, Genmab files additional patents covering its platform technology. To date, we have not made any payments to Genmab under the Genmab Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the event we seek to sell, license or otherwise dispose of our rights to TLT-1/Factor VII Antibody Products, including through a change of
control to any third party other than Novo Nordisk, we are obligated to provide Genmab the right to participate in any bidding process as a <I>bona fide</I> potential acquirer of such rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Unless earlier terminated, the Genmab Agreement will expire, on a TLT-1/Factor VII Antibody Product-by-TLT-1/Factor VII Antibody Product and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, upon the expiration of the last net profit share term for such TLT-1/Factor VII Antibody Product in such country. On expiration of each net profit
share term, our license becomes perpetual, fully <FONT STYLE="white-space:nowrap">paid-up</FONT> and <FONT STYLE="white-space:nowrap">non-exclusive</FONT> with respect to the applicable TLT-1/Factor VII Antibody Product in the applicable country.
Either party may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
terminate the Genmab Agreement for the other party&#8217;s uncured material breach or insolvency or in certain events of force majeure. Genmab may terminate the Genmab Agreement if we or our
affiliates or sublicensees challenge any of the platform technology patent rights licensed under the Genmab Agreement. We may terminate the Genmab Agreement for any reason upon 120 days written notice to Genmab. If Novo Nordisk obtains from us the
exclusive right to exploit TLT-1/Factor VII Antibody Products, including upon termination of the Novo Nordisk Agreement, then the Genmab Agreement will terminate in all territories in which Novo Nordisk obtains such exclusive rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Internal Control Over Financial Reporting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Internal control
over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP. As defined in the standards of the Public Company
Accounting Oversight Board (United States), a material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual
or interim financial statements will not be prevented or detected on a timely basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with the audit of our consolidated financial
statements for the years ended December&nbsp;31, 2024 and 2025, we identified material weaknesses in our internal control over financial reporting. The material weaknesses were (1)&nbsp;controls around the financial statement close process were not
designed or operating effectively, including as a result of an inappropriate segregation of conflicting duties and insufficient evidence of performance and review of controls, and (2)&nbsp;information system controls around user access, segregation
of conflicting duties and change management were not designed or operating effectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To remediate these material weaknesses, we have made and
plan to continue to make improvements to the design and operating effectiveness of our internal controls over financial reporting, including the monitoring, oversight and evaluation of our internal controls. We also plan to allocate more internal
resources to our internal controls, including by hiring additional staff, and intend to engage external advisors to provide training and to reassess and redesign processes and develop new controls as appropriate, including information technology
controls covering access and change management as well as cyber risks, and assisting with the evaluation and documentation of the risk assessment, design and operating effectiveness of our internal controls over financial reporting. See the section
titled &#8220;<I>Risk</I> <I>Factors</I>&#8212;<I>We have identified material weaknesses in our internal control over</I> <I>financial reporting. If we are unable to remedy our material weaknesses, or if we fail to establish and maintain an
effective system of internal control over financial reporting, we may be unable to produce timely and accurate financial statements or prevent fraud, which could adversely impact our business and our stock price.&#8221; </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Critical Accounting Estimates </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our management&#8217;s
discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The
preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, costs and expenses and the disclosure of contingent assets and liabilities at the date of
the consolidated financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances,
the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">While our significant accounting policies are described in more detail in Note 2 to our consolidated
financial statements included elsewhere in this prospectus, we believe the following accounting policies used in the preparation of our consolidated financial statements are the most critical for fully understanding and evaluating our financial
condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Research and Development Expenses and Related Accruals and Prepaid Expenses&#8195; </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Research and development costs are expensed as incurred and include internal and external costs incurred in the development of the Company&#8217;s
product candidates. These costs primarily consist of personnel costs, including equity-based compensation, expenses incurred under agreements with third-party laboratories, CROs, CMOs and other vendors, facility-related costs, supplies, and
consulting costs. Research and development costs that are paid in advance of performance (if any) are capitalized as a prepaid expense and amortized over the service period as the services are provided. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued and prepaid expenses as of each
balance sheet date. We make estimates of these based on facts and circumstances known to us at that time. This process involves recording accruals and prepaids for estimated ongoing research costs and receiving updated estimates of costs and amounts
owed on a monthly basis from our third-party service providers. When evaluating the adequacy of the accrued liabilities and prepaid expenses, we analyze progress of the studies, including the phase or completion of events, invoices received and
contracted cost estimates from its third-party service providers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Although we do not expect our estimates to be materially different from amounts
incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting accrued amounts that are overstated or understated in any particular period. To
date, there have been no material differences between our estimates of such expenses and the amounts incurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Equity-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have issued and continue to issue equity-based awards to our employees, managers, executives, and
<FONT STYLE="white-space:nowrap">non-employees</FONT> in the form of warrants. We account for equity-based compensation awards in accordance with the Financial Accounting Standards Board ASC Topic 718, <I>Compensation&#8212;Stock Compensation</I>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We measure equity-based awards based on the fair value on the date of the grant using the Black-Scholes option-pricing model, or the Black-Scholes
OPM, and recognize compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. For equity-based awards with service-based vesting conditions, we recognize compensation
expense using the straight-line method. For equity-based awards with performance-based vesting conditions, we recognize compensation expense using the accelerated attribution method over the requisite service period, commencing when achievement of
the performance condition becomes probable. Forfeitures are recorded as they occur. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Determination of the Fair Value of Equity-Based Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The fair value of each warrant grant is estimated on the date of grant using the Black-Scholes OPM , which requires inputs based on the fair value of the
ordinary shares of Hemab ApS and certain subjective assumptions, including (i) the expected share price volatility, (ii)&nbsp;the expected term of the award, (iii)&nbsp;the risk-free interest rate, and (iv)&nbsp;expected dividends. Due to the lack
of a public market for the ordinary shares of Hemab ApS to date and lack of company-specific historical and implied volatility </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
data, we have based our computation of expected volatility on the historical volatility of a representative group of publicly traded peer companies. We estimate the expected term of our warrants
granted to employees and directors using the simplified method for awards that qualify as &#8220;plain-vanilla&#8221; warrants, whereby the expected term equals the midpoint between the vesting date and the end of the contractual term of the
warrant. We utilize this method as we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. For awards with service-based and performance-based conditions, the expected term is
determined based on the expected period to vest and the contractual term. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield
is assumed to be zero as we have never paid dividends and have no current plans to pay any dividends on the ordinary shares of Hemab ApS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of
December&nbsp;31, 2025, there was approximately $3.1&nbsp;million of unrecognized compensation expense related to unvested warrants which were subject to service-based vesting or performance-based vesting awards for which the performance condition
had been achieved and have a remaining service condition. That cost is expected to be recognized over a weighted-average period of 2.1 years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Determination of
the Fair Value of Ordinary Shares </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As there has been no public market for the ordinary shares of Hemab ApS to date, the estimated fair value of
the ordinary shares of Hemab ApS has been determined by the board of directors of Hemab ApS, or the Board, with input from management, considering our most recently available third-party valuations of ordinary shares, as well as additional factors
which may have changed since the date of the most recent valuation through the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Significant changes to the key assumptions underlying
the factors used could result in different fair values of ordinary shares at each valuation date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In accordance with the guidance outlined in the
American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide, <I>Valuation of Privately-Held-Company Equity Securities</I> <I>Issued as Compensation</I>, a third-party valuation firm prepared valuations of ordinary shares
of Hemab ApS, using the option-pricing method, or OPM, which used a market approach to estimate its enterprise value. The OPM treats ordinary shares and preference shares as call options on the total equity value of a company, with exercise prices
based on the value thresholds at which the allocation among the various holders of a company&#8217;s securities changes. Under this method, the ordinary shares have value only if the funds available for distribution to stockholders exceed the value
of the preference share liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. A&nbsp;discount for lack of marketability of the ordinary shares is then applied to arrive at an indication of value for the
ordinary shares. These third-party valuations were performed at various dates, which resulted in valuation of the ordinary shares of Hemab ApS of $153.28 per share as of December&nbsp;31, 2023, $168.72 per share as of December&nbsp;31, 2024, and
$131.98 as of October&nbsp;23, 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to considering the results of these third-party valuations, the Board, with input from management,
considered various objective and subjective factors to determine the fair value of the ordinary shares of Hemab ApS as of each grant date, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our operating results and financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the progress of our research and development efforts, including the status of our programs, and the preclinical studies,
clinical trials, and manufacturing process development for our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the lack of an active public market for the ordinary shares or preference shares of Hemab ApS as a private company;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the price at which Hemab ApS sold preference shares, and the rights, preferences and privileges of such preference shares
relative to its ordinary shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our stage of development and business strategy and the material risks related to our business and industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the achievement of enterprise milestones, including entering into strategic alliance and license agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the valuation of publicly traded companies in the life sciences and biotechnology sectors, as well as recently completed
mergers and acquisitions of peer companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any external market conditions affecting the biotechnology industry, and trends within the biotechnology industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the likelihood of achieving a liquidity event, such as an IPO, or a sale of our company, given prevailing market
conditions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the analysis of IPOs and the market performance of similar companies in the biotechnology industry. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There are significant judgments and estimates inherent in these valuations. These judgments and estimates include assumptions regarding our future
operating performance and the stage of development of our product candidates. If our Board had made different assumptions, our equity-based compensation expense and net loss could have been significantly different. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Once a public trading market for our common stock has been established in connection with the consummation of this offering, our board of directors, or
a committee thereof, will not have to estimate the fair value of our common stock in connection with our accounting for granted warrants and other awards, as the fair value of our common stock will be determined based on the quoted market price of
our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Emerging Growth Company and Smaller Reporting Company Status </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act, or the JOBS Act. As a result, we are able to take
advantage of certain reduced reporting requirements that are otherwise applicable to public companies, including delaying auditor attestation of internal control over financial reporting, providing only two years of audited financial statements and
related management&#8217;s discussion and analysis of financial condition and results of operations and reduced executive compensation disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may remain an emerging growth company until the end of the fiscal year in which the fifth anniversary of this offering occurs. However, if certain
events occurs prior to the end of such period, including if we become a &#8220;large accelerated filer&#8221; under SEC rules, our annual gross revenue exceeds $1.235&nbsp;billion, or we issue more than $1.0&nbsp;billion of <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debt in any three-year period, we will cease to be an emerging growth company prior to the end of such period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have elected to take advantage of certain of the reduced disclosure obligations in the registration statement of which this prospectus is a part and
may elect to take advantage of other reduced reporting requirements in future filings. In particular, we have provided only two years of audited financial statements and have not included all of the executive compensation related information that
would be required if we were not an emerging growth company. As a result, the information that we provide to our stockholders may be different than what you might receive from other public reporting companies in which you hold equity interests. In
addition, the JOBS Act provides that an &#8220;emerging growth company&#8221; can take advantage of an extended transition period for complying with new or revised accounting standards. We have elected not to &#8220;opt out&#8221; of such extended
transition </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we can adopt the new or revised standard at the time private
companies adopt the new or revised standard and may do so until such time that we either (1)&nbsp;irrevocably elect to &#8220;opt out&#8221; of such extended transition period or (2)&nbsp;no longer qualify as an emerging growth company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are also a &#8220;smaller reporting company&#8221; as defined in the Securities Exchange Act of 1934. We may continue to be a smaller reporting
company even after we are no longer an &#8220;emerging growth company&#8221;. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so
long as our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the
most recently completed fiscal year and our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million measured on the last business day of our second fiscal quarter. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Recently Issued Accounting Pronouncements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A description of
recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to our consolidated financial statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the periods presented, we did not have, nor do we currently have, any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements as
defined under SEC rules and regulations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Quantitative and Qualitative Disclosures About Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are a smaller reporting company as defined by Item 10 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> and are not required to provide the
information otherwise required under this item. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_11"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are a clinical-stage biotechnology company
developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for
the millions of patients worldwide suffering from serious bleeding and thrombotic diseases, including Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease and other conditions of abnormal bleeding, all of which can cause
significant life-long burden to patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are executing on an ambitious strategic roadmap, which we call &#8220;Hemab 2x3 by 2030,&#8221; to
establish our company as the leading franchise in blood coagulation disorders. This strategy targets six&nbsp;major milestones by 2030: <B>2</B> commercial medicines, <B>2</B> new late-stage clinical programs, and <B>2</B> new early-stage clinical
programs (2+2+2 = 6 major milestones). We believe that executing this strategy has the potential to enable us to treat the millions of people living with neglected blood coagulation conditions worldwide. We have not yet initiated pivotal trials for
any of our product candidates, and due to the novel and unproven nature of our programs, their current stage of development and the lack of approved prophylactic therapies to inform endpoint selection and trial design, we may not be able to achieve
our strategic goals on the timeline we expect or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our lead asset, sutacimig <FONT STYLE="white-space:nowrap">(HMB-001),</FONT> is a
bispecific antibody, which we are currently evaluating in a Phase 1/2 clinical trial for the prophylactic treatment of Glanzmann thrombasthenia and in a Phase&nbsp;2 clinical trial for the prophylactic treatment of Factor VII deficiency. In our
ongoing Phase 1/2 clinical trial in Glanzmann thrombasthenia, 34 patients were treated with sutacimig and amongst 31&nbsp;efficacy evaluable patients, we observed a significant reduction in annualized treated bleed rate, or ATBR, and we expect to
commence a Phase 3 clinical trial of sutacimig in Glanzmann thrombasthenia in the second half of 2026. In addition, we are conducting a Phase 2 clinical trial of sutacimig in Factor VII deficiency and expect to report clinical data in late 2026 or
early 2027. Our second clinical-stage asset, <FONT STYLE="white-space:nowrap">HMB-002,</FONT> is a monovalent antibody, which we are developing for the subcutaneous prophylactic treatment of Von Willebrand Disease. In Part A of our ongoing Phase 1/2
clinical trial of <FONT STYLE="white-space:nowrap">HMB-002,</FONT> patients with Von Willebrand Disease treated with <FONT STYLE="white-space:nowrap">HMB-002</FONT> demonstrated an over <FONT STYLE="white-space:nowrap">1.5-fold</FONT> increase in
von Willebrand factor and Factor VIII, with correction of coagulation parameters such as activated partial thromboplastin time, or aPTT, and thrombin generation, and we expect to report data from our ongoing Phase 1/2 clinical trial in late 2026 or
early 2027. We are also advancing multiple preclinical and discovery-stage assets, the first of which is expected to enter the clinic in the second half of 2026, subject to regulatory submission and clearance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>Our Franchise </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are building a franchise designed to
address select coagulation disorders where we believe advances in biology, drug modality, and care delivery have the potential to meaningfully improve disease management. We design our assets to address critical gaps in the treatment of coagulation
disorders. Based on our plans to commence a Phase 3 clinical trial of sutacimig in Glanzmann thrombasthenia, report data from our Phase 2 clinical trial of sutacimig in Factor VII deficiency and commence clinical development of one of our
preclinical assets, we anticipate multiple potentially value-driving clinical data events in 2026, 2027 and beyond. The following table summarizes our assets and our target indications, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
as well as the status of development and anticipated clinical data events. We maintain all global economic development and commercialization rights to the assets in our franchise. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g16g01.jpg" ALT="LOGO" STYLE="width:6.31944in;height:2.60974in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I>Sutacimig for the Prophylactic Treatment of Glanzmann Thrombasthenia, Factor VII Deficiency and Other Platelet
Disorders</I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are developing sutacimig as a subcutaneous prophylactic treatment for patients with Glanzmann thrombasthenia and Factor
VII deficiency, which are both congenital, severe, chronic bleeding disorders with no approved prophylactic therapies. Glanzmann thrombasthenia is characterized by deficient or dysfunctional glycoprotein IIb/IIIa expression on platelets, which
impairs platelet-fibrinogen binding and platelet aggregation during primary hemostasis. Patients with Glanzmann thrombasthenia suffer from what can be a devastating combination of life-threatening acute hemorrhages and relentless chronic bleeding
that profoundly impact patients&#8217; physical health, mental health, and quality of life. Factor VII deficiency is characterized by reduced levels of Factor VII, a naturally circulating blood coagulation protein. Patients with clinically severe
Factor VII deficiency suffer from recurrent, unpredictable, life-threatening or potentially disabling bleeding at critical sites, such as in the central nervous system, gastrointestinal tract and intra-articular locations, as well as recurrent
mucocutaneous bleeds of the nose and gums. Both Glanzmann thrombasthenia and Factor VII deficiency also carry additional risks for female patients, including heavy menstrual bleeding and potentially life-threatening post-partum hemorrhage. We
estimate there are approximately 10,000 patients in the aggregate with Glanzmann thrombasthenia and Factor VII deficiency in the geographies where we intend to commercialize sutacimig, including the United States, the European Union, Japan, the Gulf
Cooperation Council, or GCC, countries and other select regions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Sutacimig is a bispecific antibody engineered with high-affinity binding sites for
both endogenous Factor VII and TREML1, or <FONT STYLE="white-space:nowrap">TLT-1,</FONT> a receptor that is exclusively expressed on the surface of activated platelets. When Factor&nbsp;VII is converted to activated Factor VII, or Factor VIIa, it
plays a critical role in initiating the coagulation cascade and generating thrombin, a key enzyme in blood coagulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are currently evaluating
sutacimig in two clinical trials, a Phase 1/2 clinical trial in Glanzmann thrombasthenia and a Phase 2 clinical trial in Factor VII deficiency. In our Phase 1/2 clinical trial of sutacimig in patients with Glanzmann thrombasthenia, we have completed
the Part A (single ascending dose) and Part B (three-month multiple ascending dose) portions of the trial, and the Part C (long-term extension up to 24 months) portion is currently ongoing. The data from Part A of the trial established <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-mechanism</FONT></FONT> for sutacimig in Glanzmann thrombasthenia by demonstrating an impact on pharmacodynamic markers, and in addition was generally well tolerated and
demonstrated predictable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
dose-dependent pharmacokinetics, all of which supported advancement to Part B of the trial. In Part B, we evaluated several, multi-dose regimens and sutacimig was generally well tolerated. In
addition, mean ATBR reduction for patients treated with sutacimig in Part B of the trial ranged from 19% to 87%, indicating clinical activity at all regimens tested. Sutacimig also achieved a 100% reduction in mean high-intensity ATBR during the
Part B treatment period. In addition, 92% of patients in Part B who had at least one bleed event during the six-week prospective <FONT STYLE="white-space:nowrap">run-in</FONT> period experienced a reduction in ATBR and over 50% of those patients
experienced a 50% or greater reduction in ATBR. Overall, we believe the Part A and Part B data support sutacimig&#8217;s potential to deliver meaningful prophylactic ATBR reduction with a convenient low dose administered weekly. We expect to
commence a Phase 3 clinical trial of sutacimig in Glanzmann thrombasthenia in the second half of 2026. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our ongoing Phase 2 clinical trial of
sutacimig in patients with Factor VII deficiency follows a dose-escalation design. In the trial, we are evaluating multiple dose levels, progressing from initial lower doses through higher dose cohorts and utilizing interim analyses to assess safety
and pharmacodynamics. Our goal is to establish <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> by demonstrating sutacimig&#8217;s ability to increase Factor VII levels for patients with Factor VII
deficiency. We anticipate reporting clinical data from our Phase 2 trial in late 2026 or early 2027. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Beyond these two initial indications, we
believe sutacimig&#8217;s mechanism of action has potential applicability across multiple other inherited and acquired bleeding conditions characterized by platelet dysfunction, and other causes of impaired hemostasis where platelet activation
occurs at bleeding sites. We believe this represents a significant opportunity for potential label expansion if sutacimig receives regulatory approval for Glanzmann thrombasthenia or Factor VII deficiency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Sutacimig has received Fast Track designation from the U.S. Food and Drug Administration, or the FDA, for Glanzmann thrombasthenia, Breakthrough Therapy
designation from the FDA for Glanzmann thrombasthenia, orphan drug designation from the FDA and European Medicines Agency, or EMA, for Glanzmann thrombasthenia, and innovative licensing and access pathway, or ILAP, designation from the U.K.
Medicines and Healthcare products Regulatory Agency, or MHRA, for Glanzmann thrombasthenia. However, the receipt of such designations for sutacimig may not result in a faster development or regulatory review or approval process compared to product
candidates considered for approval under conventional regulatory procedures and does not assure ultimate approval by the applicable regulatory authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I><FONT STYLE="white-space:nowrap">HMB-002</FONT> for the Prophylactic Treatment of Von Willebrand Disease</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are developing <FONT STYLE="white-space:nowrap">HMB-002</FONT> as a novel subcutaneous prophylactic treatment for Von Willebrand Disease. HMB-002 is
designed to address the underlying biological drivers of Von Willebrand Disease by increasing endogenous levels of von Willebrand factor, or VWF, and Factor VIII, a blood coagulation protein. Von Willebrand Disease is the most common inherited
bleeding disorder and results from a reduced quantity or function of VWF, a plasma protein essential for normal hemostasis through its dual role in platelet adhesion and as a carrier protein protecting coagulation Factor VIII from premature
degradation and clearance. Beyond its role in hemostasis, VWF plays an essential role in maintaining normal vascular structure, and reduced VWF levels have been associated with an increased risk of angiodysplasia &#8212; a potential contributing
factor to bleeding in patients with Von Willebrand Disease. Von Willebrand Disease is characterized by life-threatening hemorrhagic events and chronic mucocutaneous bleeding episodes that combine to harm patients&#8217; physical health, mental
well-being, and quality of life. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Moderate-to-severe</FONT></FONT> levels of Von Willebrand Disease are estimated to affect approximately 1 in 10,000 to 1 in 5,000 individuals
globally. In the United States, there are approximately 140,000 patients who have been diagnosed with Von Willebrand Disease across all severity levels, of whom more than an estimated 50,000 require treatment for bleeding events. The treatment
landscape in Von Willebrand Disease is more established than for Glanzmann thrombasthenia and Factor VII deficiency, with approved therapies available for the management of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
acute bleeding episodes. However, despite the availability of approved treatments, many patients continue to experience recurrent bleeding and substantial treatment burden, as the approved
therapies either require frequent intravenous administration or do not address the underlying biology of the disease. Beyond this initial indication, we believe <FONT STYLE="white-space:nowrap">HMB-002&#8217;s</FONT> intended mechanism of action
&#8211; stabilizing and extending the half-life of endogenous VWF and Factor VIII &#8211; has potential applicability across other bleeding conditions associated with low VWF levels. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">HMB-002</FONT> is a monovalent antibody that selectively binds the <FONT STYLE="white-space:nowrap">C-terminal</FONT>
cystine knot, or CK, domain of the coagulation protein VWF with high affinity and is designed to target the CK domain. VWF is a large multimeric glycoprotein that serves two essential functions in hemostasis: mediating platelet adhesion to damaged
vessel walls and serving as the carrier protein for Factor VIII, protecting it from premature degradation and clearance. The CK domain plays a critical regulatory role in VWF clearance from circulation. By selectively binding to the inactive CK
domain, <FONT STYLE="white-space:nowrap">HMB-002</FONT> is designed to stabilize VWF structure, endow it with an extended half-life and thereby reduce its clearance rate and increase circulating levels of VWF. Because VWF functions as the carrier
molecule for Factor VIII, increases in VWF levels lead to corresponding increases in Factor VIII levels, as Factor VIII bound to VWF is protected from degradation. This dual effect on both VWF and Factor VIII levels is particularly important because
Von Willebrand Disease is fundamentally characterized by low levels of VWF, which in turn directly limits platelet adhesion and results in low levels of Factor VIII due to accelerated Factor VIII degradation in the absence of adequate VWF. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are currently conducting a Phase 1/2 clinical trial of <FONT STYLE="white-space:nowrap">HMB-002</FONT> for the subcutaneous prophylactic treatment of
Von Willebrand Disease, which we refer to as Velora Pioneer. Velora Pioneer employs an adaptive dose-escalation design with two parts (Part A and Part B). Part A of Velora Pioneer explores sequential dose escalation across multiple cohorts,
evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of <FONT STYLE="white-space:nowrap">HMB-002,</FONT> and Part B of Velora Pioneer explores several multi-dose cohorts. In addition, we are conducting a
prospective natural history study, which we refer to as Velora Discover, running in parallel with Velora Pioneer and enrolling Von Willebrand Disease patients to establish baseline disease characteristics, bleeding patterns, and quality of life
measures. As of the data cutoff date of September&nbsp;2, 2025, for Velora Pioneer, we have completed treatment of two cohorts of patients in Part A at dose levels of 20 mg and 50 mg and are currently evaluating patients in an ongoing 150 mg cohort.
In the 20 mg and 50 mg cohorts, VWF and Factor VIII levels increased over <FONT STYLE="white-space:nowrap">1.5-fold</FONT> from baseline in a dose-dependent manner. In addition, in the 20 mg cohort, <FONT STYLE="white-space:nowrap">HMB-002</FONT>
corrected prolonged aPTT and improved thrombin generation assays, resulting in enhanced overall coagulation activity for patients. Furthermore, a sustained VWF multimer distribution, a measure of protein integrity structure, was observed, suggesting
that <FONT STYLE="white-space:nowrap">HMB-002</FONT> did not impact the protein structure of VWF. We expect to report initial data from Part B of Velora Pioneer in late 2026 or early 2027. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I>Preclinical and Discovery Stage Assets for Additional Coagulation Disorders</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to sutacimig and <FONT STYLE="white-space:nowrap">HMB-002,</FONT> we are advancing multiple preclinical and discovery-stage assets. The first
of our preclinical assets is expected to enter clinical development in the second half of 2026, subject to regulatory submission and clearance. We plan to report initial clinical data for this asset in mid-2027. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>Our Strategy and Approach </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are guided by our &#8220;All
Patients Matter&#8221; philosophy and by the conviction that individuals living with serious bleeding disorders should not have to live with inadequate treatment options. Our mission is to deliver therapeutics that provide meaningful clinical
benefit and enable patients to live full lives that are not defined or limited by their diseases. We aim to establish the industry&#8217;s leading coagulation franchise through the execution of our &#8220;Hemab 2x3 by 2030&#8221; strategic roadmap,
which is designed to build a franchise consisting of <B>2</B> commercial medicines, <B>2</B> new late-stage clinical programs, and <B>2</B> new </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
early-stage clinical programs by 2030. We have not yet initiated pivotal trials for any of our product candidates, and due to the novel and unproven nature of our programs, their current stage of
development and the lack of approved prophylactic therapies to inform endpoint selection and trial design, we may not be able to achieve our strategic goals on the timeline we expect or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following core pillars underpin our strategy and guide our approach to reimagining the treatment of coagulation disorders. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>We deploy a fundamentally patient-centric approach to drug development, beginning with listening, understanding, and
collaboration. </B>We conduct comprehensive natural history studies, which we refer to as our &#8220;360&#8221; natural history studies. These studies capture detailed insights into patients&#8217; lived experiences, including bleed rates, treatment
patterns, and the impact of bleeding disorders on social life, economic status, psychological wellbeing, and work or education. We engage patients through advisory boards and collaborate extensively with patient advocacy organizations and expert
physicians and nurses. These &#8220;360&#8221; insights inform every aspect of our development strategy, from target selection to clinical trial design and commercial positioning. We believe our comprehensive approach demonstrates authentic
patient-centricity that differentiates us and builds trust and credibility across the bleeding disorder community, benefiting our entire franchise. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>We leverage our deep domain expertise to identify optimal therapeutic targets and match them to the most appropriate
validated drug technology platforms. </B>Our deep understanding of the underlying biology of blood coagulation enables us to match ideal pharmacological targets with the best suited technologies to deliver prophylactic therapies for our target
indications. We are modality agnostic, adopting multiple validated technologies, including bispecific antibodies, monovalent antibodies, peptides and oligonucleotides, when designing our product candidates and programs. We focus on building
proprietary product candidates that are optimally designed for the therapeutic target and patient experience rather than being constrained by a single platform. We believe that this approach of utilizing validated modalities and applying them to
therapeutic targets with the highest scientific rationale maximizes our probability of success. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>We apply a flexible approach to clinical trial design, to maximize development outcomes and efficiency by leveraging our
patient-driven insights.</B> Our approach to clinical trial design is grounded in identifying the most efficient path to establishing meaningful clinical data. Where appropriate, and subject to the underlying disease biology and current treatment
paradigm, we conduct <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> studies directly in patient populations rather than exclusively in healthy volunteers. This provides more relevant safety data, early
pharmacodynamic assessment and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-mechanism,</FONT></FONT> accelerated timelines, and improved capital efficiency through informed decision-making on dose selection and program
advancement. In addition, we leverage the insights generated by our &#8220;360&#8221; natural history studies and our extensive engagement with physicians and patient advocacy communities to inform endpoint selection, support regulatory interactions
and facilitate trial enrollment. For example, we have leveraged these insights to design a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#8220;fit-for-indication&#8221;</FONT></FONT> electronic bleed diary that patients in our
clinical trials utilize to record bleeding events and help ensure precision in our clinical data generation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>We are building the foundations of an efficient and scalable commercial franchise.</B> We maintain all global economic
development and commercialization rights to the assets in our franchise, and our ongoing engagement with bleeding-disorder communities provides insights into patient-care patterns and the organization of treatment networks globally. Across our
indications, patients are predominantly treated within a concentrated network of specialized centers, including federally funded Hemophilia Treatment Centers and comprehensive bleeding disorder centers in the United States. The concentration of care
within these sites allows for </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
operational efficiencies in patient identification, engagement, and education, and may reduce the incremental commercial infrastructure required as potential future product candidates advance
through development and, if approved, commercialization. This structure is expected to support a commercial model that we believe can be scaled efficiently as we aim to expand our franchise. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>We bring an exceptional depth of experience across the entire value chain of drug discovery, development and
commercialization.</B> Members of our leadership and scientific teams have been directly involved in the discovery, development, regulatory approval, or commercialization of an extensive number of drugs approved for hemophilia, Von Willebrand
Disease, and other coagulation disorders. This collective expertise positions us to efficiently navigate the scientific, regulatory, and commercial complexities inherent in developing therapies for coagulation disorders. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>Our Team and History </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have assembled a leadership team
with deep experience in coagulation medicine, drug discovery and development, regulatory affairs, launching specialty pharmaceuticals and building life sciences companies. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Benny Sorensen, M.D., Ph.D., our Chief Executive Officer, has more than 25 years of leadership and clinical experience in
coagulation medicine. He previously held positions at Codiak Biosciences, Inc., Alnylam Pharmaceuticals, Inc., or Alnylam, and Baxter Healthcare Corporation, where he advanced the development of ADYNOVATE, VONVENDI, QFITLIA and other hematology
drugs. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Catherine Madigan, M.D., our Chief Medical Officer, has more than 15 years of hematology experience, most recently at
Syndax Pharmaceuticals, Inc., where she led regulatory approval efforts for REVUFORJ and NIKTIMVO. She previously held positions at Alnylam and Biogen Inc.&#8217;s Rare Disease Innovation Unit, advancing treatments including ELOCTATE, ALPROLIX and
QFITLIA. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Erik Bjornson, our Vice President of Regulatory Affairs, has more than 30 years of pharmaceutical industry experience
focused on rare bleeding disorders. Most recently at Galderma S.A., he has advanced multiple treatments including ADVATE, ADYNOVATE, VONVENDI, RIXUBIS and CEPROTIN. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Ananthram Murthy, Ph.D., our Chief Operating Officer, has more than 25 years of healthcare leadership experience, most
recently as General Manager of Europe, Middle East and Africa for argenx SE, where he led the international commercial launch of VYVGART. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Henrik Ostergaard, Ph.D., MSc, our Scientific Vice President, has 18 years of experience in early-stage drug discovery and
development, most recently as Scientific Director at Novo Nordisk A/S. He has led several drug development projects within the hemophilia space, including REFIXIA, NOVOEIGHT and ESPEROCT. Mr.&nbsp;Ostergaard is also a
<FONT STYLE="white-space:nowrap">co-inventor</FONT> of sutacimig. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our leadership team is supported by our board of directors,
which is chaired by John M. Maraganore, Ph.D., founding Chief Executive Officer of Alnylam, who pioneered RNA interference therapeutics. Akshay Vaishnaw, M.D., Ph.D., also serves on our board of directors and is President of Research and Development
at Scholar Rock Holding Corporation and a Venture Partner at Atlas Ventures. He was previously Chief Innovation Officer and President of Alnylam. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since inception, we have raised approximately $346.0&nbsp;million from investors, including Access Biotechnology, Avoro Capital Advisors, Deep Track
Capital, HealthCap, Novo Holdings, RA Capital Management, SMALLCAP World Fund and Sofinnova. Prospective investors should not rely on the investment decisions of our existing investors, as these investors may have different risk tolerances and in
certain cases received their shares in private financings at prices lower than the price offered to the public in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>Our Programs, Disease Background and Market Opportunity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Coagulation disorders encompass a broad and heterogeneous group of conditions affecting millions of people worldwide. While these conditions differ
substantially in prevalence, many patients continue to experience significant disease burden and limitations associated with existing treatment approaches. Our franchise is designed to address select bleeding and thrombotic disorders where we
believe advances in biology, drug modality, and care delivery have the potential to meaningfully improve disease management. Our lead clinical-stage assets, sutacimig and <FONT STYLE="white-space:nowrap">HMB-002,</FONT> are subcutaneous prophylactic
therapeutics that we believe have the potential to significantly improve the lives of patients. Sutacimig is currently in clinical development for Glanzmann thrombasthenia and Factor VII deficiency, and
<FONT STYLE="white-space:nowrap">HMB-002</FONT> is currently in clinical development for Von Willebrand Disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on patient registries,
published prevalence estimates, and our market insights we estimate that there are approximately an aggregate of 10,000 patients with Glanzmann thrombasthenia and Factor VII deficiency and an aggregate of 120,000 patients with Von Willebrand Disease
in the geographies where we intend to commercialize, including the United States, the European Union, Japan, the GCC countries and other select regions. However, the emergence of prophylactic options in other diseases has changed the treatment
paradigm for patients with blood coagulation disorders such as hemophilia. With greater disease burden awareness, potential regulatory approvals of new prophylactic options and expanding global reach of these options, we believe the overall number
of addressable patients for our clinical-stage assets, and preclinical and discovery stage programs could be greater than we currently estimate. We also believe that there are a number of other coagulation disorders with prevalence rates that range
from 5,000 patients to tens of millions of patients that are in need of new treatment options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Sutacimig &#8211; Bispecific Antibody for the Prophylactic
Treatment of Glanzmann Thrombasthenia and Factor VII Deficiency </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I>Overview of Glanzmann Thrombasthenia</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Glanzmann thrombasthenia is a congenital severe, lifelong bleeding disorder with no approved prophylactic therapies. Most patients are diagnosed before
the age of two, and the disease is characterized by a devastating combination of life-threatening acute hemorrhages and chronic bleeding that profoundly impacts patients&#8217; physical health, mental health, and quality of life. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The clinical severity of Glanzmann thrombasthenia is significant, with over 75% of patients experiencing at least one major, potentially
life-threatening bleeding episode requiring blood component transfusions during their lifetime. The frequency of bleeding is similarly alarming. In our Glanzmann thrombasthenia &#8220;360&#8221; natural history study of 117 Glanzmann thrombasthenia
patients and caregivers across 20 countries, patients reported an average of three bleeding events per week, with 88% experiencing at least one bleeding event within the preceding seven days and 65% requiring a bleed-related hospital visit in the
prior six months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Glanzmann thrombasthenia&#8217;s bleeding manifestations create particularly challenging circumstances for patients. The two most
common bleeding sites are the nose and mouth, highly visible facial locations that can create social stigma and psychological distress. Bleeding into joints, muscles and the central nervous system can also cause serious complications. For women with
Glanzmann thrombasthenia, the burden is especially severe: heavy menstrual bleeding is extremely common and more than 50% of childbirths of patients with Glanzmann thrombasthenia are complicated by potentially life-threatening postpartum hemorrhage.
As a result, women with Glanzmann thrombasthenia may be counseled to avoid pregnancy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to the impact of bleeding manifestation, Glanzmann thrombasthenia frequently leads to
chronic iron deficiency anemia, which triggers a cascade of systemic effects including debilitating fatigue, cognitive impairment, compromised cardiovascular health, adverse obstetric outcomes, and further deterioration in quality of life. These
adverse impacts can compound the direct effects of the bleeding disorder itself. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The psychosocial impact of Glanzmann thrombasthenia can also be
challenging for patients. Patients can face unpredictable, potentially severe bleeding episodes&#8212;often in visible or stigmatized locations&#8212;that fundamentally restrict their ability to live normal lives. For example, approximately 30% of
Glanzmann thrombasthenia patients meet the criteria for symptomatic depression, nearly five times the rate in the general population. Based on our &#8220;360&#8221; natural history studies, over 85% of patients reported that Glanzmann thrombasthenia
has negatively affected their mood and caused emotional problems or social isolation. The practical and economic consequences for patients are similarly stark based on data collected from our &#8220;360&#8221; natural history studies: over 80% have
missed work or school, over 50% face limitations in attending social events, and over 50% experience restrictions in travel. Glanzmann thrombasthenia is not merely a bleeding disorder, it is a disease that pervades most aspects of patients&#8217;
lives. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I>Overview of Factor VII Deficiency</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Factor VII deficiency<B> </B>is a congenital severe bleeding disorder characterized by reduced levels of a blood coagulation protein called Factor VII.
There are no subcutaneous prophylactic treatment options for Factor VII deficiency, and while the clinical manifestations of bleeding in the disorder are highly variable, they are potentially devastating. Patients with clinically severe Factor VII
deficiency are usually diagnosed before two years of age and suffer from recurrent unpredictable life-threatening or potentially disabling severe bleeding at critical sites, including central nervous system, gastrointestinal tract, and
intra-articular locations, as well as recurrent mucocutaneous bleeds of the nose and gums with additional risks for female patients, consisting of heavy menstrual bleeding and potentially life-threatening post-partum hemorrhage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Unlike patients with hemophilia, who mainly experience bleeding events when their factor levels are under 1%, patients with Factor VII deficiency are 10
times more likely to have bleeding when factor levels are under 26% than those with levels above this threshold. Patients live with the risk of recurrent bleeding that ranges from mucocutaneous bleeding to life-threatening and potentially disabling
events. Further, the mucocutaneous bleeds of the nose and gums are from highly visible sites, creating potential social stigma and psychological distress. As with Glanzmann thrombasthenia, recurrent, suboptimally treated bleeding events contribute
to chronic iron deficiency anemia, which similarly can trigger a cascade of systemic health consequences. Despite this high-risk profile, there are no subcutaneous prophylactic treatment options available to patients. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I>Market Opportunity in Glanzmann Thrombasthenia and Factor VII Deficiency</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Glanzmann thrombasthenia demonstrates substantial geographic variation in prevalence. Based on the available scientific literature, we estimate the
prevalence of Glanzmann thrombasthenia ranges from approximately 1 in 100,000 individuals in high-prevalence regions, such as the GCC countries, to a range of approximately 1 in 250,000 to 1 in 500,000 in the United States, Europe, and Japan. In the
United States, we estimate the prevalence of Glanzmann thrombasthenia at between 1 in 350,000 and 1 in 600,000, with approximately 500 to 1,000 patients in the United States. For Factor VII Deficiency, we estimate that prevalence of moderate and
severe forms of Factor VII deficiency are approximately 1 in 500,000 globally. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We estimate there are approximately 10,000 patients in the aggregate
with Glanzmann thrombasthenia and Factor VII deficiency in the geographies where we intend to commercialize </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
sutacimig, including the United States, the European Union, Japan, the GCC countries and other select regions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on our &#8220;360&#8221; natural history studies of 117 patients and caregivers with Glanzmann thrombasthenia and 100 patients and caregivers with
Factor VII deficiency, and market insights, we believe patients most likely to benefit from prophylactic therapy include those with a history of recurrent bleeding episodes that require medical intervention or that impact quality of life, a history
of major bleeding events or severe mucocutaneous bleeding, chronic iron deficiency anemia, or the inability to manage bleeding adequately with available <FONT STYLE="white-space:nowrap">on-demand</FONT> treatments. While the data from our
&#8220;360&#8221; natural history study suggests there are already a significant number of Glanzmann thrombasthenia and Factor VII deficiency patients who would benefit from a prophylactic blood coagulation treatment to prevent severe bleeding
events, we believe the total number of Glanzmann thrombasthenia patients who would seek treatment may be greater than we currently estimate. This is based on the experience in other blood coagulation disorders, such as hemophilia, where the number
of patients seeking treatment increased as convenient and effective treatment options became available and more widely adopted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I>Current Treatment
Landscape and Limitations in Glanzmann Thrombasthenia and Factor VII Deficiency</I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There are no subcutaneous prophylactic medicines
approved to treat Glanzmann&#8217;s thrombasthenia or Factor VII deficiency. Patients with these disorders mainly receive reactive treatment in response to bleeding events without the ability to prevent them. This results in significant negative
impact to physical health, mental health, and quality of life, along with marked healthcare system utilization. As a result, some patients with severe disease attempt <FONT STYLE="white-space:nowrap">off-label</FONT> prophylactic regimens using
recombinant Factor VIIa, typically administered intravenously several times per week. This approach requires frequent venous access, is associated with substantial treatment burden, has uncertain effectiveness in preventing bleeding over time, and
has not been validated in rigorous clinical trials. In addition, the cost of such regimens can be significant. Consequently, many patients continue to rely on reactive management strategies rather than preventive treatment approaches. In addition,
we are not aware of any other companies with active clinical development programs specifically targeting Glanzmann thrombasthenia or Factor VII deficiency as primary indications. Current treatment options for patients with Glanzmann thrombasthenia
and Factor VII deficiency, and their limitations, are summarized below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Platelet Transfusions (primarily for Glanzmann
thrombasthenia).</B>&nbsp;Platelet transfusions may temporarily provide functional platelets capable of supporting clot formation. However, repeated exposure to allogeneic platelets carries significant risks including alloimmunization, with many
patients developing antibodies against platelet antigens (particularly human leukocyte antigen antibodies or anti-integrin IIb&szlig;3 antibodies in Glanzmann thrombasthenia), leading to platelet refractoriness and reduced effectiveness of
subsequent transfusions. Additional limitations include the need for hospital-based intravenous administration, the potential for transfusion reactions, and residual risk of infectious disease transmission despite modern screening practices. With
recurrent transfusion, 30% to 40% of patients become refractory and experience no benefit from platelet transfusion over time. Physicians often prioritize use of antifibrinolytics, which is less effective than platelet transfusion, to increase the
chance that platelet transfusion will be effective if the patient has a future major life-threatening bleeding event. The lack of preventive options leaves patients to cope with less effective treatments, which may prolong bleeding events and result
in more significant medical consequences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Recombinant Factor</B><B></B><B>&nbsp;VIIa.</B> Recombinant Factor&nbsp;VIIa, or rFVIIa,&nbsp;is
administered intravenously, often every two to three hours, until bleeding is controlled.&nbsp;While&nbsp;rFVIIa&nbsp;can be effective in certain settings,&nbsp;including as a&nbsp;bypassing agent for patients with Glanzmann thrombasthenia who have
developed platelet antibodies&nbsp;and as replacement therapy for patients with Factor VII deficiency,&nbsp;its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
short circulating half-life of&nbsp;approximately two&nbsp;to three hours necessitates frequent repeat dosing.&nbsp;This often requires repeated venous access, which can be burdensome for
patients and caregivers.&nbsp;Clinical response may be variable, particularly in Glanzmann thrombasthenia, where effectiveness can depend on residual platelet function and the use of supraphysiologic levels of Factor&nbsp;VIIa&nbsp;is associated
with a potential risk of thrombotic&nbsp;complications.&nbsp;In addition, the cost of treatment is substantial, with management of a single bleeding event potentially requiring significant healthcare resources.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Bone Marrow Transplantation.</B> Allogeneic hematopoietic stem cell transplantation, or HSCT, has been employed in rare cases of Glanzmann
thrombasthenia, primarily for patients with severe, refractory bleeding or who have developed antibodies against platelet antigens rendering standard of care treatments ineffective. While HSCT can theoretically cure Glanzmann thrombasthenia by
replacing defective platelet-producing cells, the procedure carries substantial risks including transplant-related mortality of 10% to 20%, graft-versus-host disease, opportunistic infections, organ toxicity from conditioning regimens, and graft
failure. Given that Glanzmann thrombasthenia is not inherently fatal when managed with appropriate hemostatic support, the risk-benefit calculus of HSCT remains unfavorable for most patients. Transplantation is therefore reserved only for the most
severe cases where quality of life is profoundly compromised despite maximal medical intervention, alloimmunization precludes effective treatment, or life-threatening bleeding events occur with unacceptable frequency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Antifibrinolytic Therapy.</B> Antifibrinolytic agents, such as tranexamic acid, are commonly used as adjunctive therapy, particularly for mucosal
bleeding, including heavy menstrual bleeding. While these agents can help reduce bleeding in certain settings, they have limited efficacy and are contraindicated in the urological/upper urinary tract bleeding. Antifibrinlytic therapy may also cause
neurological side effects, particular when taking high doses of tranexamic acid intravenously. In addition, patients may experience gastrointestinal intolerability and the risk of plasminogen deficiency symptoms with long-term use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Other treatment modalities</B> for Glanzmann thrombasthenia and Factor VII deficiency include blood component transfusion resulting from blood loss
and intravenous iron supplementation to help stabilize clots and reduce bleeding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Solution - Sutacimig</B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Sutacimig is a bispecific antibody engineered with high-affinity binding sites for both endogenous Factor VII and
<FONT STYLE="white-space:nowrap">TLT-1,</FONT> a receptor that is exclusively expressed on the surface of activated and adhered platelets at sites of vascular injury. Factor VII is a naturally circulating coagulation protein that, when converted to
Factor VIIa, plays a critical role in initiating the coagulation cascade and generating thrombin, a key enzyme in blood coagulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As described
above, high-dose rFVIIa has been administered intravenously for decades to manage acute bleeding events in patients with Glanzmann thrombasthenia and Factor VII deficiency, establishing a well-validated clinical mechanism for hemostatic control.
This extensive real-world experience across thousands of patients has demonstrated that pharmacologic augmentation of thrombin generation through exogenous Factor VIIa administration effectively controls acute bleeds in these bleeding disorders,
providing strong clinical precedent for Factor VIIa-based therapeutic interventions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Sutacimig captures Factor VII from circulation with high
affinity, effectively carrying it through the bloodstream, and then targets it specifically to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">TLT-1-expressing</FONT></FONT> activated platelets that have adhered to sites of vessel
lesions. By concentrating Factor VII/VIIa precisely where hemostasis is needed, sutacimig enhances local thrombin generation at bleeding sites to promote clot formation to stop bleeding events. This targeted approach represents a fundamentally
different strategy from traditional Factor VIIa replacement therapy, which distributes Factor VIIa systemically rather than directing it to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
specific sites of need. The image below depicts sutacimig&#8217;s mechanism of action. As illustrated, following subcutaneous administration, one arm of sutacimig captures endogenous Factor VII
and carries it through the blood stream. Once vessel damage occurs, platelets adhere to the vessel lesion site and become activated and begin to express <FONT STYLE="white-space:nowrap">TLT-1</FONT> on the surface. At this stage, sutacimig targets
Factor VII to the surface of activated platelets via binding to <FONT STYLE="white-space:nowrap">TLT-1.</FONT> Then, Factor VIIa on the surface of an activated platelet activates coagulation Factor X and converts prothrombin to thrombin, leading to
the formation of a hemostatic plug that stops bleeding. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Mechanism of Action of Sutacimig </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g16g02.jpg" ALT="LOGO" STYLE="width:6.30555in;height:3.2815in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are initially developing sutacimig as a prophylactic treatment for patients with Glanzmann thrombasthenia and
Factor VII deficiency. Beyond these two initial indications, we believe sutacimig&#8217;s mechanism of action&#8212;redirecting endogenous Factor VII coagulation to sites of platelet activation marked by <FONT STYLE="white-space:nowrap">TLT-1</FONT>
expression&#8212;has potential applicability across multiple other inherited and acquired bleeding conditions characterized by platelet dysfunction, and other causes of impaired hemostasis where platelet activation occurs at bleeding sites. We
believe this represents a significant opportunity for potential label expansion if sutacimig receives regulatory approval for Glanzmann thrombasthenia or Factor VII deficiency. If approved, sutacimig could represent an important prophylactic option
for patients with significant coagulation disorders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Clinical Development of Sutacimig </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are currently evaluating sutacimig in two clinical trials, a Phase 1/2 clinical trial in Glanzmann thrombasthenia and a Phase 2 clinical trial in
Factor VII deficiency. We are conducting our Phase 1/2 clinical trial at trial sites in Belgium, France, Italy, The Netherlands, the United Kingdom and the United States and our Phase 2 clinical trial at trial sites in the United Kingdom. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In our Phase 1/2 clinical trial of sutacimig in patients with Glanzmann thrombasthenia, we have completed the Part A (single ascending dose) and Part B
(three-month multiple ascending dose) portions of the trial, and the Part C (long-term extension up to 24 months) portion is currently ongoing. We have dosed a total of 36 patients with Glanzmann thrombasthenia in the trial, including a total of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
seven patients in Part A and a total of 34 patients in Part B, five of whom participated in both Part A and Part B. In our Phase 2 clinical trial of sutacimig in patients with Factor VII
deficiency, which we initiated in October 2025, we are evaluating the pharmacokinetics, pharmacodynamics, and preliminary safety and tolerability of single ascending doses of sutacimig in patients with Factor VII deficiency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I>Phase 1/2 Clinical Trial of Sutacimig for Glanzmann Thrombasthenia</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Trial Design and Demographics. </B>In Part A, we evaluated the safety and tolerability, pharmacokinetics, and pharmacodynamics of sutacimig in
patients with Glanzmann thrombasthenia across three single ascending dose cohorts, with doses of 0.2 mg/kg, 0.5 mg/kg, and 1.25 mg/kg, which were then followed by 56 days of observation. In Part A, we enrolled seven patients with Glanzmann
thrombasthenia, who ranged from age 27 to 49 years, with a mean age of 38.9 years. The cohort was comprised of six female participants and one male participant, six of whom were Asian and one of whom was White. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In Part B, we evaluated the pharmacokinetic and pharmacodynamic profile and the safety and tolerability profile of sutacimig and explored clinical
efficacy over three months at multiple dose levels, with the last visit of the last patient in Part B occurring in July 2025. In Part C, we are evaluating the long-term safety and tolerability profile of sutacimig and the persistence of clinical
activity following up to 24 months of dosing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In Part B, before receiving the first dose of sutacimig, all patients completed a minimum <FONT
STYLE="white-space:nowrap">six-week</FONT> prospective <FONT STYLE="white-space:nowrap">run-in</FONT> period. During the three-month treatment period, patients received doses of sutacimig according to one of four regimens: 0.3 mg/kg, 0.6 mg/kg, or
0.9 mg/kg every two weeks, or 0.3 mg/kg weekly. Throughout the <FONT STYLE="white-space:nowrap">run-in</FONT> and treatment periods, patients recorded bleeding events and treatments in an electronic diary, and patients were examined at the trial
site and contacted by investigators regularly between visits to monitor for adverse events and ensure adherence to strict electronic diary data entry protocol requirements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Part B and Part C &#8211; Trial Design </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g84u21.jpg" ALT="LOGO" STYLE="width:5.43in;height:2.52512in;">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In Part B, we enrolled 34 patients with Glanzmann thrombasthenia, who ranged from age 18 to 66 years,
with a median age of 40.5 years. The cohort had 16 female participants and 18 male participants. Additional demographic information and baseline characteristics are included in the image below. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Part B &#8211; Demographics and Baseline Characteristics </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g05a01.jpg" ALT="LOGO" STYLE="width:4.55333in;height:2.25in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Sutacimig Phase 1/2 Clinical Efficacy Data.</B>&nbsp;In our Phase 1/2 clinical trial in patients with Glanzmann
thrombasthenia, sutacimig demonstrated clinical activity at all evaluated dose levels. Of the 34 patients participating in the trial, 31 patients met the protocol criteria to be analyzed for clinical activity. Three participants were excluded either
due to a technical malfunction with the patient&#8217;s electronic bleed diary (one patient) or due to failure to participate in the trial for at least the protocol specified <FONT STYLE="white-space:nowrap">six-week</FONT> minimum <FONT
STYLE="white-space:nowrap">run-in</FONT> period (two patients). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We present data below for both Part B and for the combined Part B and Part C
treatment period, which reflect continuous treatment through both Parts B and C as of October&nbsp;14, 2025, the data cutoff date. In Part B, 34 patients were treated with sutacimig and had a median exposure of 3.3 months (with a range of 1.9 to 3.5
months), while in the combined Part B and Part C portions, 34 patients were treated with sutacimig and had a median exposure of 6.9 months (with a range of 1.9 to 15.9 months). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">ATBR was selected as the clinical efficacy endpoint for the Phase 1/2 clinical trial, analogous to the annualized bleeding rate used for regulatory
approval in other bleeding disorders, such as hemophilia, and includes only bleeding events that required treatment with a prescribed medication consisting of antifibrinolytics, rFVIIa, platelet transfusion, or medical procedures. The statistical
methodology used to generate and compare mean ATBR for the <FONT STYLE="white-space:nowrap">run-in</FONT> period and treatment period was negative binomial regression with general estimating equation. This is a methodology commonly found in labels
for approved drugs in bleeding disorders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Individual patient-level data was also analyzed to determine the proportion of patients experiencing ATBR
reduction, among patients with treated bleeding events in the <FONT STYLE="white-space:nowrap">run-in</FONT> period (N=24). This was performed to understand the generalizability of the mean ATBR reduction results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Key Clinical Efficacy Data Findings.</B> In our Phase 1/2 clinical trial of sutacimig for Glanzmann thrombasthenia, mean ATBR reduction&nbsp;ranged
from 19% to 87% across regimens in the treatment period, indicating clinical activity at all tested doses, with a mean 47% reduction when patients treated at all doses were combined. In three out of four tested regimens and the <FONT
STYLE="white-space:nowrap">all-regimen</FONT> analysis, the 95% </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
confidence intervals around the mean ATBR excluded zero, suggesting a consistent reduction in ATBR as compared to the run-in period. Clinical activity was also consistent across bleed location
and causality, whether spontaneous or traumatic. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Confidence intervals are constructed to convey the precision of an estimated effect. If a 95%
confidence interval excludes zero, that suggests it is unlikely that there is no treatment effect. In this instance, the fact that the 95% confidence interval excludes zero suggests that it is unlikely that the mean ATBR during the treatment period
was not lower than the mean ATBR during the run-in period. However, our Phase 1/2 clinical trial was not designed or powered to detect statistically significant differences, and statistical hypothesis testing was not prespecified. As a result, the
ATBR reductions and related analyses are exploratory in nature and should not be considered statistically significant, and any observed trends relating to clinical responses or activity may not be reproduced in subsequent or pivotal clinical trials.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on the clinical efficacy data accrued as of the data cutoff date, we believe the 0.3 mg/kg weekly dose cohort established that a low dose
weekly dosing regimen has the potential to deliver optimal exposure for prophylaxis. As depicted in the image below, the weekly 0.3 mg/kg dose achieved an 87% mean ATBR reduction (95% CI: <FONT STYLE="white-space:nowrap">80-92%)</FONT> in the
treatment period, consistent with attainment of sustained exposure throughout the dosing interval, avoiding high peaks and low troughs in drug exposure seen in the every-other-week regimens. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Part B &#8211; Mean ATBR Reduction </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g06a01.jpg" ALT="LOGO" STYLE="width:5.07333in;height:3.11in;">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, as depicted in the table below, the clinical activity observed in Part B of the trial
persisted with extended treatment, with a mean ATBR reduction of 47% (95% CI: <FONT STYLE="white-space:nowrap">75-90%).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Part B and Part B
and C Combined &#8211; Mean ATBR Reduction </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g06a02.jpg" ALT="LOGO" STYLE="width:5.56in;height:1.49in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A particularly notable finding was the impact that sutacimig had on limiting the types of severe bleeding events that
required high-intensity interventions with rFVIIa infusion, platelet transfusion, or medical procedures, which reflects sutacimig&#8217;s potential to meaningfully impact the most severe bleeds experienced by Glanzmann thrombasthenia patients.
Fourteen patients (41%) required this treatment in the 12 months prior to receiving sutacimig. However, there was a 100% reduction in mean high-intensity ATBR during the treatment period, and a 62.4% reduction in mean high-intensity ATBR was
maintained through the combined treatment and extension period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Part B and Part B and C Combined &#8211; Mean High Intensity ATBR Reduction
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g07a01.jpg" ALT="LOGO" STYLE="width:5.56in;height:1.38667in;">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe these substantial rates of reduction in medically significant, potentially life-threatening bleeding events
during active treatment demonstrate sutacimig&#8217;s potential to prevent even the most severe manifestations of Glanzmann thrombasthenia. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The patient-level ATBR reductions observed in the Phase 1/2 clinical trial further support the
clinical findings described above. As depicted in the image below, nearly 92% of patients who had at least one bleed event during the <FONT STYLE="white-space:nowrap">run-in</FONT> period experienced an ATBR reduction, and over 50% of these<B>
</B>patients&nbsp;experienced a 50% or higher ATBR reduction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Part B &#8211; Patient-Level ATBR Reduction </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g36y62.jpg" ALT="LOGO" STYLE="width:5.56in;height:2.44371in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Overall, we believe this data demonstrates sutacimig&#8217;s potential to deliver meaningful prophylactic ATBR
reduction with convenient weekly subcutaneous dosing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Part A Pharmacokinetics and Pharmacodynamics</B>. In Part A of the trial, we observed
dose-dependent plasma exposure to sutacimig across all dose levels evaluated, as depicted in the image on the left below. In addition, as depicted in the image on the right below, we observed dose-dependent increases in Factor VIIa accumulation,
with peak levels occurring three to seven days following dosing and higher doses achieving a longer duration of Factor VIIa elevation. Sutacimig also remained quantifiable through approximately day 42 in most participants, and in certain
patients&#8217; plasma for the entire 56 day observation period. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Part A &#8211; Pharmacokinetics and Pharmacodynamics </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g19r25.jpg" ALT="LOGO" STYLE="width:6.30556in;height:2.05664in;">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The data from Part A of the trial established <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-mechanism</FONT></FONT> for sutacimig in Glanzmann thrombasthenia by demonstrating an impact on pharmacodynamic. In addition, in Part A, sutacimig was generally well tolerated and demonstrated predictable
dose-dependent pharmacokinetics, all of which supported advancement to Part B of the trial. <B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Part A Safety and Tolerability Profile</B>.
In Part A, no patients experienced dose-limiting toxicities. One serious adverse event of moderate iron deficiency anemia occurred, which was deemed unrelated to study drug and subsequently resolved. In addition, there were no adverse events of
disseminated intravascular coagulation. We did detect anti-drug antibodies, or ADAs, which is an identified potential risk for sutacimig as a protein therapeutic, in four patients and two of these patients entered Part B with a positive ADA titer.
However, there was no measurable impact on pharmacokinetics and pharmacodynamics, and no safety events related to immunogenicity were observed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Part B Pharmacokinetics and Pharmacodynamics</B>. In Part B of the trial, we observed dose proportional exposure, pharmacodynamic activity, and
higher peak elevation in Factor VIIa in the 0.9&nbsp;mg/kg dose cohort. The weekly dosing regimen of 0.3 mg/kg notably provided consistent exposure and Factor VIIa activity, while avoiding the high peaks and lower troughs seen in the dose levels
administered every two weeks. The image below depicts the mean sutacimig plasma concentration levels observed on the left, the total Factor VIIa levels observed in the middle and the change in Factor VIIa levels compared to baseline on the right
over 84 days across the four dose levels evaluated. The 0.9 mg/kg regimen administered every two weeks demonstrated higher peak Factor VIIa levels compared to other regimens, while the 0.3 mg/kg weekly regimen provided consistent exposure with
minimal peak-trough fluctuation. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Part B &#8211; Pharmacokinetics and Pharmacodynamics </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g64w16.jpg" ALT="LOGO" STYLE="width:6.31in;height:2.2061in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Part B and Part C Safety and Tolerability. </B>As of the data cutoff date, 34 patients had completed Part B of the
trial and 27 of those patients continued long-term dosing in Part C of the trial. Safety data is presented for all patients who received at least one dose of sutacimig and includes patients treated in Part B and Part C of the trial. In Part B and
Part C of the trial, sutacimig was generally well tolerated. Of the 34 patients evaluated, 32 (94.1%) experienced at least one treatment-emergent adverse event, or TEAE, the majority of which were mild to moderate in severity. The image below
summarizes the TEAEs reported in Part B and Part C of the trial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Summary of Part B and Part C Treatment-Emergent Adverse Events </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g77z52.jpg" ALT="LOGO" STYLE="width:4.58667in;height:3.09667in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The most frequently reported TEAEs have been either nonspecific symptoms, low-grade laboratory abnormalities related
to the coagulation system, or complications of the underlying disease, including headache and fibrin <FONT STYLE="white-space:nowrap">D-dimer</FONT> increases (each 23.5%), nasopharyngitis (20.6%), and back pain (17.6%). The image below summarizes
the TEAEs reported in Part B and Part C of the trial that occurred in three or more participants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Treatment-Emergent Adverse Events Occurring in Three or More Participants </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g89f01.jpg" ALT="LOGO" STYLE="width:5.24in;height:5.53333in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As with most approved procoagulant drugs, sutacimig carries an inherent risk of thromboembolic events. As a result,
such events were monitored as adverse events of special interest, or AESI, in the trial. As of the data cutoff date, three participants had experienced thromboembolic events deemed related to sutacimig: one proximal deep vein thrombosis, or DVT, of
the lower extremity, one isolated distal DVT, and one subsegmental pulmonary embolism, or SSPE. All three events were Grade 2 in severity, and the proximal DVT and SSPE were reported to the FDA on an expedited basis as Suspected Unexpected Serious
Adverse Reactions (SUSARs). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As depicted in the image below, analysis of these AESI revealed an association with high dose levels of sutacimig, the
presence of multiple concurrent venous thromboembolism risk factors (such as smoking, obesity, hypertension, hospitalization for acute illness, or gastrointestinal bleeding and administration of concurrent hemostatic agents), or both. We believe the
proximal DVT event is the one with the highest potential medical significance due to higher risk of embolism. This is reflected in treatment guidelines that recommend a full course of anticoagulation for a proximal DVT, but offer the option to
monitor patients with isolated distal or SSPE without anticoagulation. The proximal DVT event occurred in a patient with multiple DVT risk factors who was dosed at the highest dose level of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
0.9&nbsp;mg/kg, which achieved mean peak levels notably higher than the other regimens evaluated. The other two AESI were thrombotic events that occurred in patients at lower dose levels with
multiple (more than two) venous thromboembolism risk factors. Notably, the other 31 patients in the trial in whom no treatment-related AESIs occurred, had no more than two identified concurrent venous thromboembolism risk factors. This pattern
suggests a potential relationship to elevated drug exposure with potential contribution from other venous thromboembolism risk factors. We believe this is one key principle to leverage in our planned Phase 3 clinical trial design and dose
optimization, along with the finding that high exposures appear unnecessary for clinical efficacy, and weekly regimens have yielded sustained exposures. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Part B and Part C&#8212;Adverse Events of Special Interest </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g89f02.jpg" ALT="LOGO" STYLE="width:5.41667in;height:1.56667in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There were no instances of other protocol-defined <FONT STYLE="white-space:nowrap">non-bleeding</FONT> AESI, such as
cerebrovascular accident, acute cardiac events, peripheral arterial embolism or disseminated intravascular coagulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Among the five patients
experiencing six serious adverse events during treatment, two events (33.3%) were deemed treatment-related &#8211; the DVT and the subsegmental pulmonary embolism described above. The remaining four serious adverse events were judged unrelated to
study drug (one each of intra-abdominal hemorrhage, gastrointestinal bleeding, epistaxis, and invasive ductal carcinoma). In addition, treatment discontinuation due to adverse events occurred in four participants (11.8%), including two cases of DVT,
one case of pulmonary embolism, and one case of invasive ductal breast carcinoma. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In Part B and Part C of the trial, ADAs were detected in a total
of six patients, two of whom had been positive for ADAs at their last Part A assessment. In three of these six patients, the ADAs were resolved or resolving at the last assessment prior to the data cutoff date. Notably, although the assessment of
ADA impact on ATBR was inconclusive given the variability of ATBR at baseline and the small sample size, these ADAs did not appear to cause Factor VII levels to drop below the lower limit of normal in patients, and there were no adverse events
associated with immunogenicity reported in association with these ADA events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe the data observed as of the data cutoff date supports
continued clinical development of sutacimig with appropriate dose selection and patient monitoring protocols. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I>Phase 3 Development Plans for Glanzmann
Thrombasthenia</I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are planning to conduct a multinational, multicenter, Phase 3, <FONT STYLE="white-space:nowrap">single-arm,</FONT>
open-label clinical trial evaluating sutacimig as a prophylactic therapy in adults with Glanzmann thrombasthenia. However, the FDA may require a randomized controlled clinical trial to support filing and approval of our Biologics License
Application, or BLA. We intend to schedule a Type D meeting with the FDA in the coming months to obtain the FDA&#8217;s feedback on, and seek alignment regarding, whether a single-arm trial will be sufficient to support filing and approval or,
alternatively, whether the FDA may determine that a randomized controlled clinical trial is necessary to support filing and approval of our BLA. We anticipate initiating enrollment in the clinical trial in the second half of 2026 and, subject to
discussions with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
regulators, we intend for the data generated by this trial to form the basis of our regulatory submissions for marketing approval of sutacimig as the first prophylactic treatment for Glanzmann
thrombasthenia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I>Preclinical Study of Sutacimig for Factor VII Deficiency</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We evaluated sutacimig for Factor VII deficiency in a cynomolgus monkey model of Factor VII deficiency created through siRNA-mediated reduction of Factor
VII. In the study, sutacimig demonstrated the ability to restore deficient coagulation Factor VII levels. The study employed a siRNA to reduce endogenous Factor VII to approximately 10% of normal levels, mimicking severe Factor VII deficiency.
Following subcutaneous administration of sutacimig at 5.0 mg/kg, the bispecific antibody accumulated and elevated both Factor VII and Factor VIIa levels, with treated animals achieving accumulation levels approaching those observed in normal
animals. We believe this preclinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data supports sutacimig&#8217;s mechanism of accumulating residual Factor VII and Factor VIIa at sites of vascular
injury and the potential to restore hemostatic function even for patients with severe Factor VII deficiency. The image below depicts the study design and results. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Sutacimig Demonstrated Restoration of Factor VII Levels in <FONT STYLE="white-space:nowrap">Non-Human</FONT> Primates </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g89f03.jpg" ALT="LOGO" STYLE="width:6.30694in;height:2.14672in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I>Ongoing Phase 2 Clinical Trial of Sutacimig for Severe Factor VII Deficiency</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Building on the mechanistic rationale observed in our preclinical study of sutacimig in the cynomolgus monkey model, we initiated a Phase 2 single
ascending dose clinical trial in patients with severe Factor VII deficiency, which includes those patients with 10% or less of normal Factor VII levels. The ongoing clinical trial follows a dose-escalation design, evaluating multiple dose levels,
and progressing from initial lower doses through higher dose cohorts with planned interim analyses to assess safety and pharmacodynamics. This trial aims to establish
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> by demonstrating sutacimig&#8217;s ability to increase Factor VII&nbsp;levels in patients with Factor VII deficiency. The image below depicts the
clinical trial design of our ongoing Phase 2 clinical trial. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g89f04.jpg" ALT="LOGO" STYLE="width:3.19306in;height:1.81239in;">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If successful, we expect this trial would support advancement to a Phase 3 clinical trial, potentially
expanding sutacimig&#8217;s utility beyond Glanzmann thrombasthenia to address additional bleeding disorders characterized by factor deficiencies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I>Regulatory Status and Designations for Sutacimig</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Sutacimig has received multiple regulatory designations, including Fast Track, Breakthrough Therapy, orphan drug and ILAP: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>FDA Fast Track Designation in Glanzmann Thrombasthenia:</B>&nbsp;Potentially facilitates development and expedites
review, providing more frequent FDA interactions and eligibility for priority review if criteria are met at the time of BLA submission. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Breakthrough Therapy Designation in Glanzmann Thromathenia:</B> FDA designation provides that the FDA may take certain
actions, including holding meetings with the sponsor throughout the development process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a
cross-disciplinary project lead for the review team; and taking other steps to design the clinical trials in an efficient manner. Breakthrough designation may be rescinded if a product candidate no longer meets the qualifying criteria.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Orphan Drug Designations in Glanzmann Thrombasthenia:</B>&nbsp;FDA designation provides the potential for seven years of
market exclusivity upon approval, user fee exemption, and tax credits. The European Commission orphan medicinal product designation provides the potential for ten years of market exclusivity in the European Union, protocol assistance eligibility,
and reduced regulatory fees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>UK MHRA ILAP Designation in Glanzmann Thrombasthenia:</B>&nbsp;Provides the potential for enhanced regulatory support
through the Innovation Passport and Target Development Profile and coordinated engagement with the National Institute for Health and Care Excellence and the Scottish Medicines Consortium to support timely patient access following marketing
authorization in the United Kingdom. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These designations may provide sutacimig with the opportunity for expedited regulatory
pathways, extended market exclusivity, reduced fees, and enhanced regulatory support throughout development and commercialization. However, the receipt of such designations for sutacimig may not result in a faster development or regulatory review or
approval process compared to product candidates considered for approval under conventional regulatory procedures and does not assure ultimate approval by the applicable regulatory authority. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">HMB-002</FONT> &#8211; Monovalent Antibody for the Subcutaneous Prophylactic Treatment of Von Willebrand Disease </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Overview of Von Willebrand Disease </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Von Willebrand
Disease is the most common inherited bleeding disorder. It is characterized by both life-threatening hemorrhagic events and relentless mucocutaneous bleeding episodes that combine to inflict significant harm to physical health, mental well-being,
and quality of life. The age of diagnosis varies considerably. Patients with early severe bleeding manifestations are diagnosed shortly after birth, while patients with more variable bleeds may be diagnosed later in life. First described by Erik von
Willebrand in 1926, Von Willebrand Disease results from reduced quantity or function of VWF, a plasma protein essential for normal hemostasis through its dual role in platelet adhesion and as a carrier protein protecting coagulation Factor VIII from
degradation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The clinical severity of Von Willebrand Disease varies by subtype but is substantial across the
disease spectrum. Von Willebrand Disease is classified into three main types: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Type 1</B> &#8211; 70% to 80% of cases, characterized by partial quantitative VWF deficiency </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Type 2</B> &#8211; 20% of cases, with qualitative functional defects </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Type 3</B> &#8211; Less than 1% of cases, representing near-complete absence of functional VWF </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Patients with Von Willebrand Disease can experience potentially life-threatening bleeding events regardless of subtype. While Type 3 patients face the
most severe hemorrhagic complications, even patients with Type 1 disease, which has traditionally been considered &#8220;mild&#8221;, experience a serious clinical burden, with up to 15% reporting gastrointestinal bleeding events and approximately
20% experiencing joint bleeding events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Findings from our &#8220;360&#8221; natural history study in Von Willebrand Disease of 611 patients and
caregivers highlight the substantial burden across all disease subtypes. For example, patients across subtypes experienced frequent weekly bleeding events as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Type 1</B> &#8211; 1.2 bleeds per week </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Type 2</B> &#8211; 1.4 bleeds per week </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Type 3</B> &#8211; 1.9 bleeds per week </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">More than half of participants required hospital admission for bleeding management within the prior year, demonstrating both the severity of bleeding
episodes and the failure of existing treatments to prevent clinically significant hemorrhage necessitating acute medical intervention. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The most
common bleeding manifestations of Von Willebrand Disease are mucocutaneous events that can cause both physical and psychosocial harm in men and women. Women face a particularly severe burden, with 94% having experienced heavy menstrual bleeding in
our &#8220;360&#8221; natural history study, which can profoundly impact quality of life, reproductive choices, and iron status. Across both genders, over 60% of patients report cutaneous and oral cavity bleeding and over 50% experienced nose
bleeds, which are highly visible and socially disruptive. Patients also suffered gastrointestinal hemorrhage, hemarthrosis, and other critical bleeding events. This relentless frequency can create a constant burden pervading every aspect of
patients&#8217; lives. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I>Market Opportunity in Von Willebrand Disease</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Moderate-to-severe</FONT></FONT> Von Willebrand Disease is estimated to affect
approximately 1 in 5,000 to 1 in 10,000 individuals globally. In the United States, based on published prevalence estimates and our market insights, we estimate there are approximately 140,000 patients with Von Willebrand Disease across all severity
levels and types. Of these patients, between 40,000 and 50,000 patients have sought medical treatment for bleeding events based on healthcare claims analysis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the geographies where we intend to commercialize HMB-002, including the United States, the European Union, Japan, the GCC countries and other select
regions, we estimate the diagnosed Von Willebrand Disease population includes approximately 120,000 symptomatic patients who have sought medical care across all disease types, which likely represents only a portion of the overall patient population
in these markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Epidemiological data indicate that approximately 35% to 40% of patients with Von Willebrand Disease have concomitant anemia or
iron deficiency, objective markers of ongoing bleeding that can adversely affect health and quality of life. This subset of patients represents those most likely to benefit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
from a prophylactic therapy that increases VWF and Factor VIII levels to reduce bleeding frequency. Notably, the joint evidence-based clinical practice guidelines published in 2021 by the
American Society of Hematology, the International Society on Thrombosis and Haemostasis, the National Hemophilia Foundation and the World Federation of Hemophilia conditionally recommended long-term prophylaxis treatment for Von Willebrand Disease
patients with a history of severe and frequent bleeds. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I>Current Treatment Landscape and Limitations in Von Willebrand Disease</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The treatment landscape in Von Willebrand Disease is more established than in Glanzmann Thrombasthenia or Factor VII deficiency, with therapies available
for management of acute bleeding episodes. Despite existing treatments, many patients continue to experience recurrent bleeding and substantial treatment burden, particularly in the context of therapies that require frequent intravenous
administration or do not address the underlying biology of the disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Current management of Von Willebrand Disease focuses primarily on acute bleeding event
management rather than prevention. Patients are typically managed using a combination of the following pharmacologic and replacement therapies depending on disease type, severity, and bleeding risk. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Desmopressin.</B>&nbsp;Desmopressin, or DDAVP, is a synthetic vasopressin analog that stimulates release of VWF stored in endothelial cells and is
administered intranasally or intravenously. DDAVP is effective in patients with Type 1 and Type 2 Von Willebrand Disease. However, its use is limited by tachyphylaxis, resulting in diminished response with repeated dosing, and it is ineffective in
patients with Type 3 disease. As a result, DDAVP is generally used in anticipation of bleeding risk, such as prior to procedures, rather than as a continuous preventive therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Antifibrinolytic Therapy. </B>Antifibrinolytic agents, such as tranexamic acid, are commonly used as adjunctive therapy, particularly for mucosal
bleeding, including heavy menstrual bleeding. While these agents can help reduce bleeding in certain settings, they do not address the underlying deficiency of VWF and are generally insufficient for controlling more severe bleeding or bleeding at <FONT
STYLE="white-space:nowrap">non-mucosal</FONT> sites. Treatment often requires multiple daily doses during bleeding episodes, which can affect adherence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>VWF Intravenous Replacement Products.</B>&nbsp;Plasma-derived and recombinant VWF replacement products are approved for the treatment and prevention
of bleeding in Von Willebrand Disease. These therapies are administered intravenously and have relatively short circulating half-lives, typically requiring repeated infusions. For patients receiving prophylaxis, this often involves intravenous
administration two to three times per week, which can impose a significant burden related to venous access, time commitment, and interference with daily activities. In some patients, particularly children or those with difficult venous access,
long-term intravenous therapy may require central venous catheters. As a result, adherence to prophylactic regimens can be challenging for many patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Blood Component Transfusions.</B>&nbsp;Patients with severe bleeding episodes may require a transfusion of red blood cells to manage anemia resulting
from blood loss and, in some cases, fresh frozen plasma to provide coagulation factors. While these interventions can be necessary to stabilize patients during acute events, they address the consequences of bleeding rather than preventing future
episodes and usually require hospital-based care.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Intravenous Iron Supplementation.</B>&nbsp;Chronic blood loss&nbsp;frequently&nbsp;leads to
iron deficiency,&nbsp;necessitating&nbsp;repeated intravenous iron supplementation. This treatment addresses a downstream consequence of ongoing bleeding but does not reduce bleeding frequency or underlying disease activity.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Pipeline Competition. </B>We are aware of other therapies in clinical development for the
prophylactic treatment of Von Willebrand Disease that focus on other mechanisms of action, such as monoclonal antibody inhibition of the natural anticoagulation called protein S, aiming to act as a bypassing agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our <FONT STYLE="white-space:nowrap">Solution&#8212;HMB-002</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are developing <FONT STYLE="white-space:nowrap">HMB-002</FONT> as a subcutaneous prophylactic treatment for Von Willebrand Disease. <FONT
STYLE="white-space:nowrap">HMB-002,</FONT> a monovalent antibody, is designed to address the underlying biological drivers of Von Willebrand Disease by increasing endogenous levels of VWF and Factor VIII. Rather than bypassing the deficiency or
providing exogenous replacement protein, <FONT STYLE="white-space:nowrap">HMB-002</FONT> aims to stabilize patients&#8217; own VWF, extend its circulating half-life, and thereby increase VWF and Factor VIII levels over time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We believe this approach offers several potential advantages: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Restoration of Hemostasis by Directly Addressing the Root Cause:</B> By increasing endogenous VWF and Factor VIII
levels, <FONT STYLE="white-space:nowrap">HMB-002</FONT> is designed to support restoration of hemostasis rather than creating an artificial rebalancing of the coagulation system. We believe this approach has the potential to carry lower thrombotic
risk than rebalancing agents that promote hemostasis by inhibiting natural anticoagulants. Preclinical studies in animal models of Von Willebrand Disease have demonstrated that an approximately <FONT STYLE="white-space:nowrap">1.5-fold</FONT>
increases in VWF and Factor VIII levels can meaningfully improve coagulation parameters and reduce bleeding. In addition, clinical observations in patients with Von Willebrand Disease demonstrate that even modest increases in VWF and Factor VIII
levels can meaningfully reduce bleeding symptoms. In our Phase 1 clinical study, <FONT STYLE="white-space:nowrap">HMB-002</FONT> achieved greater than <FONT STYLE="white-space:nowrap">1.5-fold</FONT> increases in both VWF and Factor VIII levels,
along with correction of laboratory coagulation measures, such as aPTT and thrombin generation, supporting continued clinical evaluation of this approach. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Convenient Subcutaneous Administration:</B> We are developing <FONT STYLE="white-space:nowrap">HMB-002</FONT> to be
administered subcutaneously, with potential dosing intervals ranging from weekly to monthly, reflecting both the extended half-life of VWF achieved through stabilization and the inherent pharmacokinetic properties of an antibody therapeutic. We
believe that this dosing profile could reduce the treatment burden associated with frequent intravenous infusions required for current prophylactic options. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Applicability Across Von Willebrand Disease Types:</B> Because <FONT STYLE="white-space:nowrap">HMB-002</FONT> acts by
reducing clearance of endogenous VWF, we believe it may potentially be applicable across multiple Von Willebrand Disease subtypes, including Type 1, Type 2, and potentially Type 3 disease in patients receiving baseline VWF replacement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Potential for Transformative Impact:</B> In other inherited bleeding disorders, such as hemophilia A, the introduction
of subcutaneously administered prophylactic therapies has been associated with reduced treatment burden and improved disease management. We are developing <FONT STYLE="white-space:nowrap">HMB-002</FONT> with the goal of enabling a similar shift
toward preventive care in Von Willebrand Disease by facilitating more consistent bleeding control while minimizing disruption to daily life. If our ongoing and future clinical trials are successful, we believe
<FONT STYLE="white-space:nowrap">HMB-002</FONT> could represent an important subcutaneous prophylactic treatment option for patients with Von Willebrand Disease who require ongoing bleeding prevention. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">HMB-002</FONT> is a monovalent antibody that selectively binds the CK domain of the coagulation protein VWF with high
affinity, specifically targeting this domain in its inactive conformation. VWF is a large multimeric glycoprotein that serves two essential functions in hemostasis: mediating platelet </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
adhesion to damaged vessel walls and serving as the carrier protein for Factor VIII, protecting it from premature degradation and clearance. By selectively binding to the inactive CK domain, <FONT
STYLE="white-space:nowrap">HMB-002</FONT> stabilizes VWF structure and endows it with an extended half-life, thereby reducing its clearance rate. As a result, circulating levels of VWF increase. Because VWF functions as the carrier molecule for
Factor VIII, increases in VWF levels lead to corresponding increases in Factor VIII levels, as Factor VIII bound to VWF is protected from degradation. This dual effect on both VWF and Factor VIII levels is particularly important because Von
Willebrand Disease is fundamentally characterized by low levels of VWF, which in turn directly limits platelet adhesion and results in low levels of Factor VIII due to accelerated Factor VIII degradation in the absence of adequate VWF. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As described above, DDAVP has been used for over 50 years as the standard of care to manage acute bleeding episodes and provide short-term hemostatic
prophylaxis in patients with Type 1 and Type 2 Von Willebrand Disease. DDAVP functions by stimulating the release of endogenous VWF stored in endothelial cells, resulting in greater than <FONT STYLE="white-space:nowrap">1.5-fold</FONT> increases in
both VWF and Factor VIII levels that persist for approximately four to six hours. The decades-long clinical experience with DDAVP demonstrates that acute elevation of VWF levels provides effective hemostatic control in Von Willebrand Disease
patients and serves as important clinical validation for the therapeutic mechanism of <FONT STYLE="white-space:nowrap">HMB-002.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The image
below depicts <FONT STYLE="white-space:nowrap">HMB-002&#8217;s</FONT> intended mechanism of action. As illustrated, following subcutaneous administration, <FONT STYLE="white-space:nowrap">HMB-002</FONT> binds to circulating VWF, preventing clearance
via neonatal Fc receptor-mediated rescue from vascular endothelium, leading to increased circulating VWF available for platelet adhesion and Factor VIII carrier function at sites of vascular injury. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Mechanism of Action of <FONT STYLE="white-space:nowrap">HMB-002</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g89f05.jpg" ALT="LOGO" STYLE="width:5.55694in;height:3.0378in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are initially developing <FONT STYLE="white-space:nowrap">HMB-002</FONT> as a subcutaneous prophylactic treatment
for patients with Von Willebrand Disease. Beyond this initial indication, we believe <FONT STYLE="white-space:nowrap">HMB-002&#8217;s</FONT> intended mechanism of action &#8211; stabilizing and extending the half-life of endogenous VWF and Factor
VIII &#8211; has potential applicability across other bleeding conditions associated with low VWF levels. We believe this represents a significant opportunity for potential label expansion if <FONT STYLE="white-space:nowrap">HMB-002</FONT> receives
regulatory approval for Von Willebrand Disease. If approved, <FONT STYLE="white-space:nowrap">HMB-002</FONT> could represent an important subcutaneous prophylactic option for patients with significant coagulation disorders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Clinical Development of <FONT STYLE="white-space:nowrap">HMB-002</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are currently conducting a Phase 1/2 clinical trial of <FONT STYLE="white-space:nowrap">HMB-002</FONT> for Von Willebrand Disease, which we refer to
as Velora Pioneer. This trial is supported by a prospective identification and <FONT STYLE="white-space:nowrap">run-in</FONT> natural history study, which we refer to as Velora Discover, that has enrolled more than 80 patients as of March 31, 2026
and is generating prospectively collected data on bleeding and treatment patterns based on an electronic bleed diary. We are conducting our Phase 1/2 clinical trial at trial sites in Australia, the United Kingdom and the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I>Phase 1/2 Clinical Trial of <FONT STYLE="white-space:nowrap">HMB-002</FONT> for Von Willebrand Disease</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Study Design and Enrolled Patient Demographics</B>. Velora Pioneer employs an adaptive dose-escalation design with two parts (Part A and Part B). The
adaptive design allows real-time dose optimization based on emerging safety and efficacy data. Velora Discover is a prospective natural history study running in parallel with Velora Pioneer and enrolling Von Willebrand Disease patients to establish
baseline disease characteristics, bleeding patterns, and quality of life measures. The purpose of Velora Discover is to provide contemporary control data and contextualize treatment effects observed in the interventional components of the trial, and
the majority of patients are expected to complete Velora Discover before progressing to Part A of Velora Pioneer. In Part A of Velora Pioneer, we are evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending
doses of <FONT STYLE="white-space:nowrap">HMB-002.</FONT> In Part B, participants transition from Part A into multiple-dose cohorts, with the first cohort in Part B (Cohort B1) receiving repeated dosing based on Part A data, with potential expansion
for additional efficacy and safety assessment, and the second cohort in Part B (Cohort B2) receive a higher dose than the first Part B cohort with its own expansion cohort to further characterize the therapeutic profile. In each case, the doses
administered in Part B will be informed by the safety data from Part A. The image below depicts the design of our Phase 1/2 clinical trial of <FONT STYLE="white-space:nowrap">HMB-002</FONT> for Von Willebrand Disease. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Phase 1/2 Clinical Trial of <FONT STYLE="white-space:nowrap">HMB-002</FONT> &#8211; Trial Design </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g89f06.jpg" ALT="LOGO" STYLE="width:6.30694in;height:3.59921in;">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of the data cutoff date of September 2, 2025, we have completed dosing of a total of six patients
in the 20 mg (Cohort A1) and 50 mg (Cohort A2) dose levels in Part A of the trial and are currently enrolling patients into a 150 mg dose cohort (Cohort A3). Demographic information and baseline characteristics of the patients from the first two
dose cohorts of Part A of the trial are included in the image below. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Phase 1/2 Clinical Trial of
<FONT STYLE="white-space:nowrap">HMB-002&#8211;</FONT> Demographics and Baseline Characteristics </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g16k00.jpg" ALT="LOGO" STYLE="width:4.51389in;height:2.31082in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Initial Safety and Tolerability Data:</B>&nbsp;As of the data cutoff date,
<FONT STYLE="white-space:nowrap">HMB-002</FONT> was generally well tolerated. None of the patients in the 20 mg cohort reported adverse events and only two Grade 1 adverse events that were deemed unrelated to treatment were reported in the 50 mg
cohort. In addition, no safety signals of concern have been observed, including no thrombotic events, thrombocytopenia, <FONT STYLE="white-space:nowrap">D-dimer</FONT> elevations, injection site reactions, or hypersensitivity reactions.
Additionally, interim immunogenicity assessments showed no ADA formation at any timepoint evaluated, and inflammatory markers (C3a and cytokines) remained unchanged, indicating no complement activation or inflammatory response to the drug at the
dose levels evaluated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Pharmacokinetic Data</B>. Initial data from the first two cohorts in the Phase 1/2 clinical trial suggest dose dependent
plasma exposure of <FONT STYLE="white-space:nowrap">HMB-002</FONT> after subcutaneous administration, as depicted in the image below. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Cohorts A1
and A2 &#8211; Pharmacokinetics </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g16k02.jpg" ALT="LOGO" STYLE="width:2.99999in;height:2.4627in;">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Pharmacodynamic Data.</B>&nbsp;In the first two cohorts from Part A of the trial, following
administration with <FONT STYLE="white-space:nowrap">HMB-002,</FONT> we observed dose-dependent accumulation of plasma VWF antigen, as depicted in the image on the left below, VWF activity, as depicted in the image in the middle below, and Factor
VIII coagulant activity, as depicted in the image on the right below. Notably, VWF and Factor VIII&nbsp;levels increased over <FONT STYLE="white-space:nowrap">1.5-fold</FONT> from baseline in a dose-dependent manner, with sustained increases for at
least eight to ten days, commensurate with the pharmacokinetic data described above. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Cohorts A1 and A2 &#8211; Pharmacodynamics </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g89f07.jpg" ALT="LOGO" STYLE="width:6.31944in;height:1.86999in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Data from Cohort A1 demonstrated that <FONT STYLE="white-space:nowrap">HMB-002</FONT> corrected aPTT and improved
thrombin generation assays, resulting in enhanced overall coagulation activity. Furthermore, a sustained VWF multimer distribution was observed, suggesting that <FONT STYLE="white-space:nowrap">HMB-002</FONT> did not impact the protein structure of
VWF. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Cohorts A1 and A2 &#8211; Coagulation Parameters and Multimer Distribution </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g89f08.jpg" ALT="LOGO" STYLE="width:6.30694in;height:2.3225in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Status and Next Steps </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We anticipate reporting initial data from Part B of the trial in late 2026 or early 2027. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Preclinical and Discovery Stage Assets for Additional Coagulation Disorders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to sutacimig and <FONT STYLE="white-space:nowrap">HMB-002,</FONT> we are advancing multiple preclinical and discovery-stage assets. The first
of our preclinical assets, which is expected to enter clinical development in the second half of 2026, subject to regulatory submission and clearance. We plan to report initial clinical data for this asset in mid-2027. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We strive to protect and enhance the proprietary technology, inventions and improvements that are commercially important to the development of our
business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. We also rely on trademarks, copyrights and trade secrets relating to our proprietary technology platforms and <FONT
STYLE="white-space:nowrap">on&nbsp;know-how,&nbsp;continuing</FONT> technological innovation <FONT STYLE="white-space:nowrap">and&nbsp;in-licensing&nbsp;opportunities</FONT> to develop, strengthen and maintain our proprietary and intellectual
property position. We additionally may rely on regulatory and other protections afforded through data exclusivity, market exclusivity and patent term extensions, where available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our commercial success may depend in part on our ability to: obtain, maintain, enforce and protect our intellectual property and other proprietary
rights for commercially important technology, inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> related to our business; defend and enforce any patents we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> in the future;
prevent others from infringing any patents we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> in the future; preserve the confidentiality of our trade secrets; and operate without infringing the valid enforceable patents and
proprietary rights of third parties. Our ability to limit third parties from making, using, selling, offering to sell or importing our products may depend on the extent to which we have rights under valid and enforceable licenses, patents or trade
secrets that cover these activities. In some cases, enforcement of these rights may depend on third party licensors. With respect to both licensed and company-owned intellectual property, we cannot be sure that patents will be granted with respect
to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents that may be granted to us in the future will be commercially useful in
protecting our commercial products and methods of manufacturing the same. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Sutacimig </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our intellectual property portfolio for sutacimig includes a foundational composition of matter patent application filed in April 2020 (and claims
priority to April 2019) covering the bispecific antibody composition, with an expected expiration in April 2040, excluding any potential available patent term extensions or similar regulatory extensions. The foundational sutacimig composition of
matter patent application family is exclusively licensed to us from Novo Nordisk, as described under the section entitled &#8220;&#8212;License Agreements&#8221; below. This application family has granted patents in the United States, Bahrain,
Russia, China, Malaysia, South Africa, Saudi&nbsp;Arabia, South Korea, and Japan; and also has currently pending applications in the United States, Europe, Australia, Brazil, Israel, India, Kuwait, Mexico, Peru, Qatar, Thailand, United Arab
Emirates, Canada, Chile, Algeria, Egypt, Morocco, Oman, Russia and Japan. We filed an additional patent application in February 2025 (which claims priority to February 2024) covering dosing regimens for sutacimig, with an expected expiration in
February 2045, excluding any potential available patent term extensions or similar regulatory extensions, and national phase entry due in August 2026. We solely own the dosing application. We are actively pursuing additional patent filings covering
formulation improvements, biomarkers for patient selection, manufacturing processes, and routes of administration to further strengthen and extend our intellectual property protection for sutacimig. These additional filings are designed to create
multiple layers of patent protection extending the commercial exclusivity period beyond the expiration of our composition of matter patents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT
STYLE="white-space:nowrap">HMB-002</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our patent portfolio for <FONT STYLE="white-space:nowrap">HMB-002</FONT> includes multiple patent
families providing layered protection. Our initial composition of matter patent application for the <FONT STYLE="white-space:nowrap">VWF-targeting</FONT> antibody was filed in February 2023 (and claims priority to February 2022) with an expected
expiration in February 2043, excluding any potential available patent term extensions or similar regulatory extensions. This application family </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
is currently pending in the United States, Europe, Saudi Arabia, Brazil, Japan, South Korea, Russia, Canada, Australia, China, India, and Hong Kong. We solely own the initial HMB-002 composition
of matter patent family. We filed a subsequent composition of matter patent application in August 2024 (which claims priority to August 2023) with an expected expiration in August 2044, excluding any potential available patent term extensions or
similar regulatory extensions. The second HMB-002 composition of matter patent family is currently pending in the United States, Europe, United Arab Emirates, Argentina, Bahrain, Brazil, Canada, Chile, China, Colombia, Algeria, Egypt, Indonesia,
Israel, India, Japan, Korea, Kuwait, Morocco, Malaysia, Oman, Peru, Philippines, Qatar, Russia, Saudi Arabia, Thailand, Taiwan, Vietnam, and South Africa. We solely own the second HMB-002 composition of matter patent family. We filed an additional
patent application covering combination therapy of <FONT STYLE="white-space:nowrap">HMB-002</FONT> with VWF replacement products and dosing regimens in February 2026 (which claims priority to February&nbsp;2025), with expected expiration in
February&nbsp;2046, excluding any potential available patent term extensions or similar regulatory extensions. We solely own the HMB-002 combination therapy and dosing regimens patent family. This application is not yet published. Similar to
sutacimig, we are pursuing additional patent filings covering formulation, biomarkers, manufacturing processes, and routes of administration to maximize the duration of intellectual property protection for
<FONT STYLE="white-space:nowrap">HMB-002.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>License Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are a party to license agreements under which we license patents, patent applications, and other intellectual property from third parties. The
licensed intellectual property covers, in part, our lead product candidate, sutacimig. These licenses impose various diligence and financial payment obligations on us. We consider the following license agreements to be material to our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>License Agreement with Novo Nordisk </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In November 2019, we
entered into a license agreement with Novo Nordisk A/S, or Novo Nordisk, pursuant to which Novo Nordisk granted us an exclusive (even as to Novo Nordisk), worldwide and sublicensable license under specified patent rights, and a <FONT
STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide and sublicensable license under specified <FONT STYLE="white-space:nowrap">know-how,</FONT> to research, develop, make, have made, use, offer for sale, sell, import, export or otherwise
exploit, or transfer possession of or title in, products, or Novo Licensed Products, containing bispecific IgG antibodies targeting <FONT STYLE="white-space:nowrap">TLT-1</FONT> and Factor VII, including sutacimig, for the treatment of bleeding
conditions, including hemophilia. We refer to this agreement as the Novo Nordisk Agreement. Under the terms of the Novo Nordisk Agreement, we have agreed to use commercially reasonable efforts to develop and commercialize a Novo Licensed Product.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are obligated to pay to Novo Nordisk a <FONT STYLE="white-space:nowrap">one-time</FONT> DKK 40&nbsp;million milestone payment upon achievement
by a Novo Licensed Product of a specified regulatory milestone event, and we are also obligated to pay Novo Nordisk tiered royalties, in the low single-digit percentages, on aggregate annual net sales of all Novo Licensed Products, on a Novo
Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Novo</FONT></FONT> Licensed Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, until the later
of the expiration of the last valid claim in the licensed patents under the Novo Nordisk Agreement covering such Novo Licensed Product in such country and ten years following the first commercial sale of such Novo Licensed Product in such country.
We currently expect that all of the licensed patents under the Novo Nordisk Agreement will expire by 2040, potentially extending to 2045 with patent term extension. To date, we have not made any payments to Novo Nordisk under the Novo Nordisk
Agreement. Under the Novo Nordisk Agreement, we initially granted to Novo Nordisk a right of first negotiation, following a specified clinical event and during a specified period of time, to obtain a license back from us to exploit Novo Licensed
Products if we determined to engage with a third party with respect to a license of any Novo Licensed Products. However, Novo Nordisk&#8217;s right of first negotiation under the Novo Nordisk Agreement has expired. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Novo Nordisk Agreement will continue in force until it is terminated. On expiration of each royalty term, our license becomes royalty-free,
perpetual, and irrevocable with respect to the applicable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Novo Licensed Product in the applicable country. Either party may terminate the Novo Nordisk Agreement for the other party&#8217;s uncured material breach or insolvency. We may terminate the Novo
Nordisk Agreement for any reason upon 90 days&#8217; written notice to Novo Nordisk. In the event that Novo Nordisk regains control of the exclusive right to exploit the Novo Licensed Product, the Novo Nordisk Agreement will automatically terminate.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>License Agreement with Genmab </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In April 2020, we entered
into a license agreement with Genmab A/S, or Genmab, pursuant to which Genmab granted us an exclusive (even as to Genmab and its affiliates), worldwide and sublicensable license under platform technology patent rights and <FONT
STYLE="white-space:nowrap">know-how</FONT> relating to Genmab&#8217;s proprietary DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> platform to research, develop, make, have made, use, manufacture, import, export and commercialize
products comprising bispecific IgG antibodies targeting <FONT STYLE="white-space:nowrap">TLT-1</FONT> and Factor&nbsp;VII, or <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products, including sutacimig, for the treatment of
bleeding conditions, including hemophilia. We refer to this agreement as the Genmab Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the terms of the Genmab Agreement, we have
agreed to use commercially reasonable efforts to develop, manufacture, obtain regulatory approval for and commercialize TLT-1/Factor VII Antibody Products worldwide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the Genmab Agreement, we are obligated to pay Genmab a percentage of all net profit (i.e., revenue and other proceeds less specified direct costs
we incur to conduct research, development, manufacture and commercialization of <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products) we or our affiliates receive with respect to any
<FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products, including (1)&nbsp;net profit from commercial sales of <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products and any revenue from third parties, other
than Novo Nordisk, in respect of a sublicense or assignment with respect to <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products, including assignment fees, sublicensing fees, upfront and milestone fees, royalties and other
consideration, whether in kind or cash, and (2)&nbsp;the net profit allocated to <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products that we or our affiliates receive if we undergo a change of control (other than an
acquisition by Novo Nordisk). The percentage of net profit we owe with respect to each TLT-1/Factor VII Antibody Product is in the low teens from the effective date of the Genmab Agreement until the first commercial sale of such TLT-1/Factor VII
Antibody Product. From and after the first commercial sale of a <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Product, the percentage of net profit we owe with respect to such <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT>
VII Antibody Product is in the high single digits in all territories in which we commercialize such TLT-1/Factor VII Antibody Product and in the mid-teens in all territories in which a third party, other than Novo Nordisk, commercializes such
TLT-1/Factor VII Antibody Product. We are obligated to pay such percentage of net profit on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT>
VII Antibody <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-TLT-1/Factor</FONT></FONT></FONT> VII Antibody Product basis until the later of the expiration of the last-to-expire of the
platform technology patent rights licensed under the Genmab Agreement covering such <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Product in such country and twelve years following the first commercial sale of such <FONT
STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Product in such country, which we refer to as the net profit share term. Following the expiration of the last-to-expire of the platform technology patent rights licensed under the Genmab
Agreement covering a given TLT-1/Factor VII Antibody Product in a given country, the percentage of net profit that we are obligated to pay with respect to sales of such TLT-1/Factor VII Antibody Product in such country will be reduced by a specified
percentage for the remainder of the net profit share term for such TLT-1/Factor VII Antibody Product in such country. We currently expect that all of the platform technology patent rights licensed under the Genmab Agreement will expire by 2032,
though this date may be extended if, for example, Genmab files additional patents covering its platform technology. To date, we have not made any payments to Genmab under the Genmab Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the event we seek to sell, license or otherwise dispose of our rights to TLT-1/Factor VII Antibody Products, including through a change of control to
any third party other than Novo Nordisk, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
we are obligated to provide Genmab the right to participate in any bidding process as a <I>bona fide</I> potential acquirer of such rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Unless earlier terminated, the Genmab Agreement will expire, on a TLT-1/Factor VII Antibody Product-by-TLT-1/Factor VII Antibody Product and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, upon the expiration of the last net profit share term for such TLT-1/Factor VII Antibody Product in such country. On expiration of each net profit
share term, our license becomes perpetual, fully <FONT STYLE="white-space:nowrap">paid-up</FONT> and <FONT STYLE="white-space:nowrap">non-exclusive</FONT> with respect to the applicable TLT-1/Factor VII Antibody Product in the applicable country.
Either party may terminate the Genmab Agreement for the other party&#8217;s uncured material breach or insolvency or in certain events of force majeure. Genmab may terminate the Genmab Agreement if we or our affiliates or sublicensees challenge any
of the platform technology patent rights licensed under the Genmab Agreement. We may terminate the Genmab Agreement for any reason upon 120 days written notice to Genmab. If Novo Nordisk obtains from us the exclusive right to exploit TLT-1/Factor
VII Antibody Products, including upon termination of the Novo Nordisk Agreement, then the Genmab Agreement will terminate in all territories in which Novo Nordisk obtains such exclusive rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>Manufacturing and Supply Chain </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have leveraged multiple
third-party manufacturers to support the manufacturing of our assets for clinical trials and, if we receive regulatory approval, we intend to rely on third parties for commercial manufacture. We do not own or operate, and currently have no plans to
establish, any manufacturing facilities. We expect this strategy will enable us to maintain a more efficient infrastructure, outsourcing instead of building manufacturing and supply chain capabilities, while simultaneously enabling us to focus our
expertise on the clinical development of our assets. We expect to enter into commercial supply agreements with such manufacturers prior to any potential approval of our assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The biotechnology and pharmaceutical industries
are characterized by rapidly advancing innovative technologies under intense competition with an emphasis on proprietary products or product candidates. While we believe we have competitive advantages, we face substantial competition from many
different sources, including from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. Any product candidates that we successfully develop and commercialize will compete with existing products and
new products that may become available in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We face potential competition from many different sources, including larger and better-funded
pharmaceutical and biotechnology companies. Moreover, we may also compete with academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative
arrangements for research, development, manufacturing and commercialization. Many of our potential competitors, either alone or through strategic partnerships, have significantly greater access to financial, technical, manufacturing, marketing,
sales and supply resources. These entities may also compete with us in hiring and retaining scientific and management personnel, establishing clinical trial sites, enrolling patients in clinical trials and pursuing strategic collaborations. As a
result, our competitors may discover, develop or commercialize products before or more successfully than we do. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There are currently no
subcutaneous, prophylactic therapies for Glanzmann thrombasthenia or Factor VII deficiency that are in development or approved. Patients with these disorders mainly receive reactive treatment in response to bleeding events without the ability to
prevent them. However, companies could develop new therapies or repurpose existing therapies for Glanzmann thrombasthenia or Factor VII deficiency, such as emicizumab (Hemlibra), which was developed for
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
hemophilia A, but could potentially be studied in other bleeding disorders, potentially including our target indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For Von Willebrand Disease, the competitive landscape includes currently available therapies and products in development. The current standard of care
includes DDAVP and VWF replacement products, including both plasma-derived products <FONT STYLE="white-space:nowrap">(Humate-P,</FONT> Wilate, Alphanate) and recombinant Won Willebrand Factor (Vonvendi). These products have established positions in
the market and physician familiarity. In addition, Star Therapeutics Inc. is currently developing <FONT STYLE="white-space:nowrap">VGA-039,</FONT> an investigational monoclonal antibody that inhibits protein S, which is currently in Phase 3 clinical
development for Von Willebrand Disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we obtain marketing approval for any of our product candidates, there will be several factors that will
be important to the commercial success of such products. These factors include efficacy, safety, tolerability, convenience, price and the availability of reimbursement. Inability to be competitive in any of these categories could potentially reduce
the commercial opportunity of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>Sales and Marketing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In light of our stage of development, we have not yet established a commercial organization or distribution capabilities. We maintain all global economic
development and commercialization rights to the assets in our franchise. If our product candidates receive marketing approval, we may choose to commercialize them with our own sales force and will also consider commercial partnerships to maximize
the worldwide opportunity for and value of our product candidates and programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, particularly with respect to sutacimig for the
treatment of Glanzmann thrombasthenia and Factor VII deficiency, if approved, we intend to build a focused, commercial organization targeting the specialized bleeding disorders care network. In the United States, approximately 140 federally-funded
Hemophilia Treatment Centers and comprehensive bleeding disorder centers manage many patients with inherited bleeding disorders across our target indications. We expect that this concentrated care model will enable us to efficiently commercialize
sutacimig with relatively small field teams. In addition to the United States, we intend to commercialize our product candidates in the European Union, Japan, the GCC countries and other select regions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>Government Regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Government authorities in the United
States, at the federal, state and local level, and in other countries and jurisdictions, such as the European Union, or EU, extensively regulate, among other things, the research, development, testing, manufacture, pricing, quality control,
approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, sales, reimbursement, post-approval monitoring and reporting, and import and export of pharmaceutical products. The processes for obtaining
marketing approvals in the United States and in foreign countries and jurisdictions, along with compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial
resources. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Approval and Regulation of Biologics in the United States </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the United States, our product candidates are regulated and licensed as biological products, or biologics, under the Public Health Service Act, or the
PHSA, and the Food, Drug, and Cosmetic Act, or FDCA, and applicable implementing regulations and guidance. A company, institution, or organization which takes responsibility for the initiation and management of a clinical development program for
investigational products, and for their regulatory approval, is typically referred to as a sponsor. The failure of a sponsor to comply with the applicable regulatory requirements at any time during the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
product development process, including nonclinical testing, clinical testing, the approval process or post-approval process, may result in delays to the conduct of a study, regulatory review and
approval and/or administrative or judicial sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A sponsor seeking approval to market and distribute a new biologic product in the United
States generally must satisfactorily complete each of the following steps before the product candidate will be approved by the FDA: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">preclinical testing including laboratory tests, animal studies and formulation studies, which must be performed in
accordance with the FDA&#8217;s good laboratory practice, or GLP, regulations and standards; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">completion of the manufacture, under current good manufacturing practices, or cGMP, conditions, of the drug substance and
product that the sponsor intends to use in human clinical trials along with required analytical and stability testing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">design of a clinical protocol and submission to the FDA of an investigational new drug application, or IND, for human
clinical testing, which must become effective before human clinical trials may begin; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approval by an independent institutional review board, or IRB, representing each clinical site before each clinical trial
may be initiated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">performance of adequate and well-controlled human clinical trials to establish the safety, potency and purity of the
product candidate for each proposed indication, in accordance with good clinical practices, or GCP; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">preparation and submission to the FDA of a biologic license application, or BLA, for a biologic product, which includes not
only the results of the clinical trials, but also, detailed information on the chemistry, manufacture controls, or CMC, for the product candidate and proposed labeling for one or more proposed indication(s); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">review of the product candidate by an FDA advisory committee, where appropriate or if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities, including those of third parties,
at which the product candidate or components thereof are manufactured to assess compliance with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality and
purity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">satisfactory completion of any FDA audits of the clinical trial sites to assure compliance with GCP and the integrity of
clinical data in support of the BLA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">payment of user fees pursuant to the Prescription Drug User Fee Act, or PDUFA, and securing FDA approval of the BLA to
allow marketing of the new product; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and
Mitigation Strategies, or REMS, and the potential requirement to conduct any post-approval studies or other post-marketing commitments required by the FDA. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Preclinical Studies </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Before a sponsor begins testing a
product candidate with potential therapeutic value in humans, the product candidate enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as other studies to
evaluate, among other things, the toxicity of the product candidate. These studies are generally referred to as <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies. The conduct of the preclinical tests and formulation of the compounds for
testing must comply with federal regulations and requirements, including GLP regulations and standards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">With passage of the FDA&#8217;s Modernization Act 2.0 in December 2022, Congress eliminated provisions
in both the FDCA and the PHSA that required animal testing in support of a BLA. While animal testing may still be conducted, the FDA was authorized to rely on alternative <FONT STYLE="white-space:nowrap">non-clinical</FONT> tests, including
cell-based assays, microphysiological systems, or bioprinted or computer models. The results of the preclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND. Some long-term
preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, and long-term toxicity studies, may continue after the IND is submitted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>The IND and IRB Processes </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">An IND is an exemption from the
FDCA that allows an unapproved product candidate to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA authorization to administer such investigational product to humans. An IND must be secured prior
to interstate shipment and administration of any product candidate that is not the subject of an approved BLA. In support of a request for an IND, sponsors must submit a protocol for each clinical trial and any subsequent protocol amendments must
also be submitted to the FDA as part of the IND. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials or studies and
places the trial on a clinical hold. The FDA may also place a hold or partial hold on a clinical trial based on chemistry, manufacturing, and controls issues involving the investigational product. In either case, the IND sponsor and the FDA must
resolve any outstanding concerns before the clinical trial may proceed. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Following commencement of a clinical trial under an IND, the FDA may also place a clinical hold or partial clinical hold on that trial. A clinical hold
is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example,
a partial clinical hold might state that a specific protocol or part of a protocol may not proceed, while other parts of a protocol or other protocols may do so. No more than 30 days after the imposition of a clinical hold or partial clinical hold,
the FDA will provide the sponsor a written explanation of the basis for the hold. Following the issuance of a clinical hold or partial clinical hold, a clinical investigation may only resume once the FDA has notified the sponsor that the
investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed or recommence. Occasionally,
clinical holds are imposed due to manufacturing issues that may present safety issues for the clinical study subjects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">An IRB representing each
institution participating in the clinical trial must also review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB,
which must operate in compliance with Health and Human Services, or HHS, and FDA regulations, must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects before the study can
commence at the institution and must monitor the trial until it is completed. An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in
accordance with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data monitoring
committee, or DMC. This group provides an independent recommendation as to whether or not a trial may move forward at designated checkpoints based on review of available data from the study, to which only the DMC has access. Suspension or
termination </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
of development during any phase of a clinical trial can occur if the DMC recommends stopping a trial due to safety, potency, purity or other issues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Expanded Access to an Investigational Product </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Expanded access, sometimes called &#8220;compassionate use,&#8221; is the use of investigational products outside of clinical trials to treat patients
with serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options. The rules and regulations related to expanded access are intended to improve access to investigational
products for patients who may benefit from investigational therapies. FDA regulations allow access to investigational products under an IND by the company or the treating physician for treatment purposes on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis for: individual patients (single-patient IND applications for treatment in emergency settings and <FONT STYLE="white-space:nowrap">non-emergency</FONT> settings); <FONT
STYLE="white-space:nowrap">intermediate-size</FONT> patient populations; and larger populations for use of the investigational product under a treatment protocol or treatment IND application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">When considering an IND application for expanded access to an investigational product with the purpose of treating a patient or a group of patients, the
sponsor and treating physicians or investigators will determine suitability when all of the following criteria apply: patient(s) have a serious or immediately life-threatening disease or condition, and there is no comparable or satisfactory
alternative therapy to diagnose, monitor, or treat the disease or condition; the potential patient benefit justifies the potential risks of the treatment and the potential risks are not unreasonable in the context or condition to be treated; and the
expanded use of the investigational product for the requested treatment will not interfere with initiation, conduct, or completion of clinical investigations that could support marketing approval of the product or otherwise compromise the potential
development of the product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There is no obligation for a sponsor to make its investigational products available for expanded access. However, if a
sponsor has a policy regarding how it responds to expanded access requests, it must make that policy publicly available. Specifically, sponsors are required to make such policies publicly available upon the earlier of initiation of a Phase 2 or
Phase 3 clinical trial, or 15 days after the investigational product receives designation as a breakthrough therapy, fast track product, or regenerative medicine advanced therapy. In October 2025, the FDA issued final guidance further clarifying the
statutory and regulatory requirements governing expanded access. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to and separate from expanded access, the Right to Try Act, which was
enacted in 2018, provides a federal framework for certain patients to access certain investigational new products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances,
eligible patients can seek treatment without enrolling in clinical trials and without needing FDA permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its investigational products available to
eligible patients under the Right to Try Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Human Clinical Trials in Support of a BLA </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Clinical trials involve the administration of the investigational product candidate to human subjects under the supervision of a qualified investigator
in accordance with GCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before they participate in any clinical trial. Clinical trials are conducted under written
clinical trial protocols detailing, among other things, the objectives of the trial, inclusion and exclusion criteria, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. Each protocol, and any subsequent
material amendment to the protocol, must be submitted to the FDA as part of the IND, and progress reports detailing the status of the clinical trials must be submitted to the FDA annually. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Human clinical trials are typically conducted in three sequential phases, but the phases may overlap
or be combined. Additional studies may also be required after approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Phase 1 clinical trials are initially conducted in a limited population,
which may be healthy volunteers or patients with the target disease, to test the product candidate for safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion and pharmacodynamics. During Phase 1 clinical
trials, information about the product candidate&#8217;s pharmacokinetics and pharmacological effects may be obtained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Phase 2 clinical trials are
generally conducted in a patient population to identify possible adverse effects and safety risks, evaluate the efficacy of the product candidate for specific targeted indications and determine dose tolerance and optimal dosage. Multiple Phase 2
clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more costly Phase 3 clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Phase 3
clinical trials proceed if the prior clinical trials demonstrate that the product candidate is potentially effective and has an acceptable safety profile. Phase 3 clinical trials are undertaken in the proposed patient population to provide evidence
of clinical safety, potency and purity. A well-controlled, statistically robust Phase 3 clinical trial is designed to deliver the data that regulatory authorities will use to decide whether or not to approve the product candidate, and, if approved,
how to appropriately label a new biologic product. Such Phase 3 clinical trials are referred to as &#8220;pivotal&#8221; trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A clinical trial
may combine the elements of more than one phase. The FDA has often required more than one Phase 3 trial to support marketing approval of a product candidate. A company&#8217;s designation of a clinical trial as being of a particular phase is not
necessarily indicative that the study will be sufficient to satisfy the FDA requirements of that phase because this determination cannot be made until the protocol and data have been submitted to and reviewed by the FDA. Moreover, as noted above, a
pivotal trial is a clinical trial that is believed to satisfy FDA requirements for the evaluation of a product candidate&#8217;s safety, potency and purity such that it can be used, alone or with other pivotal or
<FONT STYLE="white-space:nowrap">non-pivotal</FONT> trials, to support regulatory approval. Generally, pivotal trials are Phase 3 trials, but they may be Phase 2 trials if the design provides a well-controlled and reliable assessment of clinical
benefit, particularly in an area of unmet medical need or rare patient population. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In some cases, the FDA may approve a BLA for a product candidate
but require the sponsor to conduct additional clinical trials to further assess the product candidate&#8217;s safety, potency and purity after approval. Such post-approval trials, typically referred to as post-marketing studies or clinical trials,
may be conducted after initial marketing approval. These trials are used to either gain additional experience from the treatment of a larger number of patients in the intended treatment group or to evaluate a specific outcome of interest (safety or
efficacy). In certain instances, the FDA may mandate the performance of post-marketing studies or clinical trials, such as to verify clinical benefit in the case of products approved under accelerated approval regulations. Failure to exhibit due
diligence with regard to conducting mandatory post-marketing studies or clinical trials could result in withdrawal of FDA approval for products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Sponsors of clinical trials are required to register and disclose certain clinical trial information on a public registry (clinicaltrials.gov)
maintained by the U.S. National Institutes of Health. In particular, information related to the product candidate, patient population, phase of investigation, study sites and investigators and other aspects of the clinical trial is made public as
part of the registration of the clinical trial. The failure of a sponsor to submit clinical trial information to clinicaltrials.gov is a prohibited act under the FDCA, with violations subject to potential civil monetary penalties of up to $10,000
for each day the violation continues. Violations may also result in injunctions and/or criminal prosecution or disqualification from federal grants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Clinical Studies Outside of the United States </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">When a foreign clinical study is conducted under an IND, all IND requirements must be met unless waived. When a foreign clinical study is not conducted
under an IND, the sponsor must ensure that the study complies with certain regulatory requirements of the FDA in order to use the study as support for a BLA. Specifically, the studies must be conducted in accordance with GCPs, including undergoing
review and receiving approval by an independent ethics committee and seeking and receiving informed consent from subjects. GCP requirements encompass both ethical and data integrity standards for clinical studies. The FDA&#8217;s regulations are
intended to help ensure the protection of human subjects enrolled in <FONT STYLE="white-space:nowrap">non-IND</FONT> foreign clinical studies, as well as the quality and integrity of the resulting data. They further help ensure that <FONT
STYLE="white-space:nowrap">non-IND</FONT> foreign studies are conducted in a manner comparable to that required for IND studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The acceptance by
the FDA of study data from clinical trials conducted outside the United States in support of United States approval may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to
serve as the sole basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i)&nbsp;the data are applicable to the U.S. population and U.S. medical practice;
(ii)&nbsp;the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii)&nbsp;the data may be considered valid without the need for an <FONT STYLE="white-space:nowrap">on-site</FONT>
inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection or other appropriate means. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, even where the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for
an application for marketing approval unless the study is well-designed and well-conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary. Many foreign
regulatory authorities have similar approval requirements. In addition, such foreign trials are subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Interactions with the FDA During the Clinical Development Program </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Following the clearance of an IND and the commencement of clinical trials, a sponsor is given the opportunity to meet with the FDA at certain points in
the clinical development program. There are five types of meetings that occur between sponsors and the FDA. Type A meetings are those that are necessary for an otherwise stalled product development program to proceed or to address an important
safety issue. Type B meetings include <FONT STYLE="white-space:nowrap">pre-IND</FONT> and <FONT STYLE="white-space:nowrap">pre-BLA</FONT> meetings as well as end of phase meetings, such as end of Phase 2, or EOP2, meetings. A Type C meeting is any
meeting other than a Type A or Type B meeting regarding the development and review of a product candidate. A Type D meeting is focused on a narrow set of issues and should not require input from more than three disciplines or divisions. Finally,
INTERACT meetings are intended for novel products and development programs that present unique challenges early in the development of an investigational product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">At the conclusion of these meetings, the FDA will typically provide its responses to questions posed by the sponsor regarding the clinical development
program. The FDA will not indicate whether a BLA will be approved, but it will provide guidance to the sponsor on various questions, including whether an application should be submitted in the first place on the basis of the studies and data
proposed by the sponsor. The FDA may also generally express support for the sponsor&#8217;s approach in the clinical development program but indicate that questions concerning whether the data support approval will be subject to review by the FDA
following its acceptance for filing of the BLA. The FDA has indicated that its responses, as conveyed in meeting minutes and advice letters, only constitute mere recommendations and/or advice made to a sponsor and, as such, sponsors are not bound by
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
such recommendations and/or advice. Nonetheless, from a practical perspective, a sponsor&#8217;s failure to follow the FDA&#8217;s recommendations for design of a clinical program may put the
program at significant risk of failure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Manufacturing Requirements </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Concurrently with clinical trials, sponsors usually complete additional animal safety studies, develop additional information about the chemistry and
physical characteristics of the product candidate and finalize a process for manufacturing commercial quantities of the product candidate in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing
quality batches of the product candidate and, among other criteria, the sponsor must develop methods for testing the identity, strength, quality, and purity of the finished product. Additionally, appropriate packaging must be selected and tested,
and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Specifically, the FDA&#8217;s regulations require that pharmaceutical products be manufactured in specific approved facilities and in accordance with
cGMPs. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and product containers and closures, production and process controls, packaging and labeling controls,
holding and distribution, laboratory controls, records and reports and returned or salvaged products. Manufacturers and other entities involved in the manufacture and distribution of approved pharmaceuticals are required to register their
establishments with the FDA and some state agencies and are subject to periodic unannounced inspections by the FDA for compliance with cGMPs and other requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The PREVENT Pandemics Act, which was enacted in December 2022, clarifies that foreign manufacturing establishments are subject to registration and
listing requirements even if a biologic undergoes further manufacture, preparation, propagation, compounding, or processing at a separate establishment outside of the United States prior to being imported or offered for import into the United
States. Inspections must follow a &#8220;risk-based schedule&#8221; that may result in certain establishments being inspected more frequently. Manufacturers may also have to provide, on request, electronic or physical records regarding their
establishments. Delaying, denying, limiting, or refusing inspection by the FDA may lead to a product being deemed to be adulterated. Changes to the manufacturing process, specifications or container closure system for an approved product are
strictly regulated and often require prior FDA approval before being implemented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Pediatric Studies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the Pediatric Research Equity Act of 2003, or PREA, a BLA or supplement thereto must contain data that are adequate to assess the safety, potency
and purity of the product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective, unless granted a deferral or
waiver. The sponsor must submit an initial pediatric study plan within 60 days of an EOP2 meeting or as may be agreed between the sponsor and the FDA. Sponsors must also submit pediatric study plans prior to the assessment data. Those plans must
contain an outline of the proposed pediatric study or studies the sponsor plans to conduct, including study objectives and design, any deferral or waiver requests, and other information required by regulation. The sponsor, the FDA, and the
FDA&#8217;s internal review committee must then review the information submitted, consult with each other, and agree upon a final plan. The FDA or the sponsor may request an amendment to the plan at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA may, on its own initiative or at the request of the sponsor, grant deferrals for submission of some or all pediatric data until after approval
of the product for use in adults, or full or partial waivers </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
from the pediatric data requirements. A deferral may be granted for several reasons, including a finding that the product or therapeutic candidate is ready for approval for use in adults before
pediatric trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric trials begin. A waiver may be granted when the disease or condition does not occur in pediatrics. Unless otherwise required by
regulation, the pediatric data requirements generally do not apply to products with orphan designation, although FDA has taken steps to limit what it considers abuse of this statutory exemption in the PREA by announcing that it does not intend to
grant any additional orphan drug designations for rare pediatric subpopulations of what is otherwise a common disease. The FDA maintains a list of diseases that are exempt from PREA requirements due to low prevalence of disease in the pediatric
population. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Expedited Review Programs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA is
authorized to expedite the review of applications in several ways. None of these expedited programs, however, changes the standards for approval but each may help expedite the development or approval process governing product candidates. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><U>Fast Track Designation</U>. Product candidates are eligible for Fast Track designation if they are intended to treat a
serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being
studied. In addition to other benefits, such as the ability to have greater interactions with the FDA, this designation enables a company to petition the FDA to initiate review of sections of a BLA before the application is complete, a process known
as rolling review. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><U>Breakthrough therapy designation</U>. To qualify for the breakthrough therapy program, a product candidate must be
intended to treat a serious or life-threatening disease or condition, and preliminary clinical evidence must indicate that such product candidate may demonstrate substantial improvement on one or more clinically significant endpoints over existing
therapies. The FDA will seek to ensure the sponsor of a breakthrough therapy product candidate receives intensive guidance on an efficient development program, involvement of senior managers and experienced staff on a proactive, collaborative and
cross-disciplinary review and rolling review. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><U>Priority review</U>. A product candidate is eligible for priority review if it treats a serious condition and, if
approved, it would be a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention compared to marketed products. Significant improvement may be illustrated by evidence of increased effectiveness in the
treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new
subpopulation. The FDA aims to complete its review of priority review applications within six months as opposed to ten months for standard review. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><U>Regenerative Medicine Advanced Therapy designation</U>. With the passage of the 21st Century Cures Act in December 2016,
Congress authorized the FDA to accelerate review and approval of product candidates designated as regenerative advanced therapies. A product candidate is eligible for this designation if it is a regenerative medicine therapy that is intended to
treat, modify, reverse or cure a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product candidate has the potential to address unmet medical needs for such disease or condition. The benefits of
a regenerative advanced therapy designation include early interactions with the FDA to expedite development and review, benefits available to breakthrough therapies, potential eligibility for priority review and accelerated approval based on
surrogate or intermediate endpoints. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><U>Commissioner&#8217;s National Priority Voucher Program</U>. On June&nbsp;17, 2025, the FDA announced the creation of the
&#8220;Commissioner&#8217;s National Priority Voucher, or CNPV, Program. Vouchers issued under this program can be redeemed by sponsors to shorten the review time of a BLA from approximately ten to twelve months to one to two months. The CNPV
Program convenes experts from the FDA&#8217;s offices for a team-based review rather than using the standard review system. Clinical data will be reviewed by a multidisciplinary team of physicians and scientists who will <FONT
STYLE="white-space:nowrap">pre-review</FONT> the submitted information and convene for a <FONT STYLE="white-space:nowrap">one-day</FONT> meeting. Vouchers under the CNPV Program will be given to companies aligned with U.S. national priorities.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><U>Rare Disease Evidence Principles</U>. In September 2025, the FDA introduced a framework intended to streamline the
approval of new therapies for ultrarare diseases. The Rare Disease Evidence Principles framework is intended to allow sponsors to rely on a <FONT STYLE="white-space:nowrap">single-arm</FONT> trial in support of approval of biologics that treat rare
diseases with very small patient populations and where the disease is linked to a known genetic defect and characterized by progressive functional deterioration leading to disability or death in a short period of time. The targeted diseases should
also lack adequate alternative therapies. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Accelerated Approval </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to programs that allow for expedited review of BLAs, the FDA is authorized to approve new products through an accelerated approval pathway.
Under this pathway, a product candidate may be approved on the basis of adequate and well controlled clinical trials establishing that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict a clinical
benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity and prevalence of the condition and the availability or lack
of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a biologic product candidate receiving accelerated approval perform adequate and well controlled post-marketing studies or clinical trials. In addition, the
FDA currently requires as a condition for accelerated approval <FONT STYLE="white-space:nowrap">pre-approval</FONT> of all promotional materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In 2022, Congress directed the FDA to require a sponsor to have its confirmatory clinical trial underway before accelerated approval is awarded and to
submit progress reports on its post-approval studies to the FDA every six months until the trial is completed. Moreover, the FDA was authorized to withdraw an accelerated approval if certain conditions are met, including where a required
confirmatory study fails to verify and describe the predicted clinical benefit or where evidence demonstrates the product candidate is not shown to be safe or effective under the conditions of use. The FDA may also use such procedures to withdraw an
accelerated approval if a sponsor fails to conduct any required post-approval study of the product with due diligence, including with respect to &#8220;conditions specified by the Secretary.&#8221; The procedures include the provision of due notice,
an explanation for a proposed withdrawal, opportunities to meet with the FDA Commissioner or the FDA Commissioner&#8217;s designee and a written appeal, among other things. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Submission of a BLA to the FDA </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA&#8217;s approval is
required before any new biologic product can be marketed in the United States. Assuming successful completion of all required preclinical and human testing in accordance with all applicable regulatory requirements, detailed product information is
submitted to the FDA in the form of a BLA. Under the Prescription Drug User Fee Act, or PDUFA, each BLA must be accompanied by a significant user fee, unless an exception or waiver applies, such as the first application filed by a small business or
BLAs for product candidates designated as orphan drugs for indications that are rare diseases or conditions. For federal fiscal year 2026, the application user fee is $4,682,003 for an application requiring clinical data, and the sponsor of a
licensed BLA is subject to an annual program fee, which for fiscal year 2026 is $442,213. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA conducts a preliminary review of all applications within 60 days of receipt and must inform
the sponsor during that period whether an application is sufficiently complete to permit substantive review. The FDA&#8217;s regulations state that an application &#8220;shall not be considered as filed until all pertinent information and data have
been received&#8221; by the FDA. In the event the FDA determines that an application does not satisfy this standard, it will issue a Refuse to File, or RTF, determination to the sponsor. In this event, the BLA must be resubmitted. In October 2025,
the FDA issued internal guidance clarifying that &#8220;materially incomplete or inadequately organized&#8221; applications that would not permit timely, efficient and complete review will be the subject of an RTF. The internal guidance also
provides that the FDA will issue an RTF for an application that relies on a single, adequate and well-controlled investigation to support approval if prior communications with the FDA determined the need for more than one clinical trial and any
justification for a single investigation is inadequate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If the BLA submission is accepted for filing, the FDA&#8217;s goal is to review the BLA,
within ten months for a standard review, or, if the BLA relates to an unmet medical need in the treatment of a serious or life-threatening condition, perform a priority review, within six months. The review process may be extended by the FDA for
three additional months to consider new information or after a clarification provided by the sponsor to address an outstanding deficiency identified by the FDA following the original submission. Despite these review goals, it is not uncommon for FDA
review of an application to extend beyond the PDUFA target action date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA seeks to meet these timelines for review of a BLA but its ability
to do so may be affected by a variety of factors, including government budget and funding levels, the ability to hire and retain key personnel and statutory, regulatory and policy changes. Average review times at the FDA have fluctuated in recent
years as a result. For example, the U.S. government has shut down several times during the past decade and certain regulatory agencies, including the FDA, have had to furlough critical employees and stop critical activities, including the review of
BLAs, when funding from PDUFA fee payments was exhausted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA may refer applications for novel biological products or biological products that
present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the BLA should be approved and under what conditions.
The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the biological product approval process, the FDA also will determine whether a REMS is necessary to
assure the safe use of the biological product. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS, and the FDA will not approve the BLA without a REMS, if required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, the FDA will review a sponsor&#8217;s financial relationship with the principal investigators who conducted the clinical trials in support of
the BLA. Depending on the level of compensation and any other financial interest a principal investigator may have in a sponsor, the sponsor may be required to report these relationships to the FDA. The FDA will then evaluate that financial
relationship and determine whether it creates a conflict of interest or otherwise affects the interpretation of the clinical trial, or the integrity of the data generated at the principal investigator&#8217;s clinical trial site. If so, the FDA may
exclude data from the clinical trial site in connection with its determination of the approvability of the application for the investigational product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with its review of a BLA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product
candidate unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, the FDA will
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
typically inspect one or more clinical trial sites to assure that the clinical trials were conducted in compliance with IND requirements and GCP requirements. With passage of FDORA, Congress
expressly permitted inspection by the FDA of facilities involved in the preparation, conduct, or analysis of clinical and <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies submitted to the FDA as well as other persons holding clinical
trial records or involved in the clinical trial process. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>The FDA&#8217;s Decision on a BLA </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA reviews a BLA to determine, among other things, whether the product is safe, pure, and potent. To reach this determination, the FDA must
determine that the investigational product is effective and that its expected benefits outweigh its potential risks to patients. This &#8220;benefit-risk&#8221; assessment is informed by the extensive body of evidence about the product
candidate&#8217;s safety, purity and potency in the BLA. This assessment is also informed by other factors, including the severity of the underlying condition and how well patients&#8217; medical needs are addressed by currently available therapies,
uncertainty about how the premarket clinical trial evidence will extrapolate to real-world use of the product candidate in the post-market setting, and whether risk management tools are necessary to manage specific risks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In February 2026, the Commissioner of the FDA and the Director of Center for Biologics Evaluation and Research published an editorial in the New England
Journal of Medicine in which they declared that, in most cases, the new default requirement for FDA approval of a new product will be one adequate and well-controlled pivotal clinical trial plus confirmatory evidence, rather than two pivotal
clinical trials. In determining whether to rely on one trial, the FDA will focus on the single trial&#8217;s quality, including magnitude of effect, appropriateness of control arms, endpoint selection, statistical power, blinding, handling of
missing data, biological plausibility and alignment with intermediate biomarkers. The FDA has long had authority to approve new products on the basis of one trial plus confirmatory evidence and, in recent years, the FDA has exercised that authority
with respect to certain types of products. The FDA now takes the position that this will be the new official default standard for most new products. At this point, it is unclear how this new policy will be implemented by the FDA and how, if at all,
it will affect our clinical development programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">After evaluating the BLA and all related information, including the advisory committee
recommendations, if any, and inspection reports of manufacturing facilities and clinical trial sites, the FDA will issue either a Complete Response Letter, or CRL, or an approval letter. A CRL indicates that the review cycle of the application is
complete, and the application will not be approved in its present form. A CRL generally outlines the deficiencies in the BLA submission and may require substantial additional testing or information in order for the FDA to reconsider the application.
If a CRL is issued, the sponsor will have one year to respond to the deficiencies identified by the FDA, at which time the FDA can deem the application withdrawn or, in its discretion, grant the sponsor an additional
<FONT STYLE="white-space:nowrap">six-month</FONT> extension to respond. While CRLs were previously treated by the FDA as confidential and were only disclosed in action packages for approved products, the FDA announced in September 2025 that it will
now release CRLs promptly after they are issued to sponsors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">An approval letter, on the other hand, authorizes commercial marketing of the product
with specific prescribing information for specific indications. That is, the approval will be limited to the conditions of use (e.g., patient population, indication) described in the <FONT STYLE="white-space:nowrap">FDA-approved</FONT> labeling.
Further, depending on the specific risk(s) to be addressed, the FDA may require that contraindications, warnings or precautions be included in the product labeling, require that post-approval trials, including post-marketing studies or clinical
trials, be conducted to further assess a product&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization or impose other conditions, including distribution and use restrictions or other
risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies, clinical trials, or surveillance programs. After approval, some types of
changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Post-Approval Requirements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Biologic products manufactured or
distributed pursuant to regulatory approvals are subject to pervasive and continuing regulation by the regulatory authorities, including, among other things, requirements relating to formal commitments for post approval clinical trials and studies,
manufacturing, recordkeeping, periodic reporting, product sampling and distribution, marketing, labeling, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as
adding new indications or other labeling claims, are subject to prior FDA review and approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Manufacturers are subject to periodic unannounced
inspections by regulatory authorities and country or state agencies for compliance with cGMP and other requirements. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA
approval. The FDA&#8217;s regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon a company and any third-party manufacturers that it may decide to use. Accordingly,
manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Further, although physicians may prescribe legally available products for unapproved uses or patient populations, which are commonly referred to as <FONT
STYLE="white-space:nowrap">&#8220;off-label</FONT> uses,&#8221; manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of
<FONT STYLE="white-space:nowrap">off-label</FONT> uses, and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant liability. In September 2021, the FDA published
final regulations which describe the types of evidence that the FDA will consider in determining the intended use of a biologic. If a company is found to have promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses, it may become subject to
administrative and judicial enforcement by the FDA, the Department of Justice, or the Office of the Inspector General of the HHS, as well as state authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">It may be permissible under very specific and narrow conditions for a manufacturer to engage in nonpromotional,
<FONT STYLE="white-space:nowrap">non-misleading</FONT> communication regarding <FONT STYLE="white-space:nowrap">off-label</FONT> information, such as distributing scientific or medical journal information. Moreover, with passage of the <FONT
STYLE="white-space:nowrap">Pre-Approval</FONT> Information Exchange Act in December 2022, sponsors of product candidates that have not been approved may proactively communicate to payors certain information about product candidates in development to
help expedite patient access upon approval. Previously, such communications were permitted under FDA guidance, but this legislation explicitly provides protection to sponsors who convey certain information about product candidates in development to
payors, including unapproved uses of approved products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, in January 2025, the FDA published final guidance outlining its policies
governing the distribution of scientific information to healthcare providers about unapproved uses of approved products. The final guidance calls for such communications to be truthful, <FONT STYLE="white-space:nowrap">non-misleading</FONT> and
scientifically sound and to include all information necessary for healthcare providers to interpret the strengths and weaknesses and validity and utility of the information about the unapproved use of the approved product. If a company engages in
such communications consistent with the guidance&#8217;s recommendations, the FDA indicated that it will not treat such communications as evidence of unlawful promotion of a new intended use for the approved product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Further, the distribution of prescription pharmaceutical products is subject to a variety of federal
and state laws. The Prescription Drug Marketing Act, or PDMA, was the first federal law to set minimum standards for the registration and regulation of distributors by the states and to regulate the distribution of samples. Both the PDMA and state
laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. In November 2013, the federal Drug Supply Chain Security Act became effective in the United States,
mandating an industry-wide, electronic, interoperable system to trace prescription products through the pharmaceutical distribution supply chain with a <FONT STYLE="white-space:nowrap">ten-year</FONT> <FONT STYLE="white-space:nowrap">phase-in</FONT>
process. Manufacturers were required by November 2023 to have such systems and processes in place. So as not to disrupt supply chains, the FDA granted certain exemptions from enhanced distribution security requirements for eligible trading partners
for particular periods of time. The exemptions for manufacturers have expired, and entities that are unable to meet the enhanced drug distribution security requirements must now request a waiver, exception, or exemption from the FDA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Reference Product Exclusivity </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">When a biological product is
licensed for marketing by the FDA with approval of a BLA, the product may be entitled to certain types of market and data exclusivity barring the FDA from approving competing products for certain periods of time. In March 2010, the Biologics Price
Competition and Innovation Act of 2009, or the BPCIA, was enacted into law. The BPCIA amended the PHSA to create an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an
<FONT STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product. To date, the FDA has approved both biosimilar products and interchangeable biosimilar products. In December 2022, Congress clarified through FDORA that the FDA may
approve multiple first interchangeable biosimilar biological products so long as the products are all approved on the first day on which such a product is approved as interchangeable with the reference product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the BPCIA, the approval of a BLA for a biosimilar product may not be made effective until twelve years after the date of first licensure of the
reference product, which under the statute excludes the date of licensure of supplements and certain other applications. Additionally, an application for a biosimilar or interchangeable biosimilar product cannot be submitted for review until four
years after the date on which the reference product was first licensed under the PHSA. Even if a product is considered to be a reference product eligible for exclusivity, however, another company could market a competing version of that product if
the FDA approves a full BLA for such product containing the sponsor&#8217;s own preclinical data and data from adequate and well controlled clinical trials to demonstrate the safety, purity, and potency of their product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The BPCIA also includes provisions to protect reference products that have patent protection. The biosimilar product sponsor and reference product
sponsor may exchange certain patent and product information for the purpose of determining whether there should be a legal patent challenge. Based on the outcome of negotiations surrounding the exchanged information, the reference product sponsor
may bring a patent infringement suit and injunction proceedings against the biosimilar product sponsor. The biosimilar applicant may also be able to bring an action for declaratory judgment concerning the patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA maintains a publicly-available online database of licensed biological products, which is commonly referred to as the &#8220;Purple Book.&#8221;
The Purple Book lists product names, dates of licensure, and applicable periods of exclusivity. Further, the reference product sponsor must provide patent information and patent expiry dates to FDA following the exchange of patent information
between biosimilar and reference product sponsors. This information is then published in the Purple Book. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Orphan Drug Designation and Exclusivity </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A biologic product may qualify for orphan drug designation under the Orphan Drug Act, if it is intended to treat a rare disease or condition, which is
generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United&nbsp;States and for which there is no reasonable expectation that the cost of developing and making a
biological product available in the United States for this type of disease or condition will be recovered from sales of the product as stipulated in the Orphan Drug Act. Orphan drug designation must be requested before submitting a BLA. After the
FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation entitles a party to financial incentives such as opportunities for grant funding
towards clinical study costs, tax advantages and <FONT STYLE="white-space:nowrap">user-fee</FONT> waivers. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If a product that has orphan drug designation receives the first FDA approval for the disease or condition for which it has such designation, the
product is entitled to orphan product exclusivity. That exclusivity bars the FDA from approving any other applications to market the same product for the same indication for seven years, except in limited circumstances, such as not being able to
supply the product for patients or showing clinical superiority to the product with orphan exclusivity. Competitors, however, may receive approval of a different therapy for the indication for which the orphan product has exclusivity or obtain
approval for the same product but for a different indication for which the orphan product has exclusivity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA and Congress may further
reevaluate and revise the Orphan Drug Act and its regulations and policies. For example, in September 2021, the Court of Appeals for the 11th Circuit held that, for the purpose of determining the scope of orphan drug exclusivity, the term
&#8220;same disease or condition&#8221; means the designated &#8220;rare disease or condition&#8221; and not the &#8220;indication or use&#8221; for which the product is approved. Subsequently, in another case, a federal district court in
Washington, D.C. followed the reasoning of the 11th Circuit decision and that decision was appealed to the U.S. Court of Appeals for the D.C. Circuit. On February&nbsp;3, 2026, the Consolidated Appropriations Act of 2026 was enacted into law. It
overruled these court decisions and codified the FDA&#8217;s longstanding interpretation of the scope of orphan drug exclusivity to apply to &#8220;the same drug for the same approved use or indication within such [designated] rare disease or
condition.&#8221; This change, which applies retroactively, expressly authorizes the FDA to approve multiple versions of the same orphan drug for different <FONT STYLE="white-space:nowrap">sub-indications</FONT> and subpopulations, such as adult and
pediatric patients or multiple variations of the same disease that are caused by different genetic variants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Pediatric Exclusivity </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pediatric exclusivity is a type of <FONT STYLE="white-space:nowrap">non-patent</FONT> marketing exclusivity in the United States and, if granted,
provides for the attachment of an additional six months of exclusivity. For biologic products, the <FONT STYLE="white-space:nowrap">six-month</FONT> period may be attached to any existing regulatory exclusivities but not to any patent terms. The
conditions for pediatric exclusivity include the FDA determining that information relating to the use of a new product in the pediatric population may produce health benefits in that population, the FDA making a written request for pediatric
clinical trials, and the sponsor agreeing to perform, and report on, the requested clinical trials within the statutory time period. This <FONT STYLE="white-space:nowrap">six-month</FONT> exclusivity may be granted if a sponsor submits pediatric
data that fairly responds to a written request from the FDA for such data within statutory time limits. The data does not need to show the product to be effective in the pediatric population studied, rather if the clinical trial is deemed to fairly
respond to the FDA&#8217;s request, the additional protection is granted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Patent Term Restoration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Depending upon the timing, duration and specifics of FDA approval of the use of our product candidates, some of our U.S. patents may be eligible for
limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as
compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The
patent term restoration period is generally <FONT STYLE="white-space:nowrap">one-half</FONT> the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date and approval of a BLA, less any
time the sponsor failed to act with due diligence. Only one patent applicable to an approved biological product is eligible for extension, and the application for the extension must be submitted prior to the expiration of the patent. The U.S. Patent
and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for one of our owned or licensed patents, depending on
the expected length of the applicable clinical trials and other factors involved in the filing of the relevant BLA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Healthcare Reform </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. There have been a number of federal and state proposals during the
last few years regarding the pricing of biologic products, limiting coverage and reimbursement for medical products and other changes to the healthcare system in the United States. In March 2010, the U.S. Congress enacted the Affordable Care Act, or
ACA, which, among other things, changed the coverage and payment for pharmaceutical products under government healthcare programs. The ACA was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending,
enhance remedies against fraud and abuse, add transparency requirements for the healthcare and health insurance industries, impose taxes and fees on the health industry and impose additional health policy reforms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The American Taxpayer Relief Act of 2012, which was enacted in January 2013, among other things, further reduced Medicare payments to several providers,
including hospitals, imaging centers, and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in
Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. Under
current legislation, the actual reductions in Medicare payments may vary up to 4%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since enactment of the ACA, there have been, and continue to be,
numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with the enactment of the Tax Cuts and Jobs Act of 2017, which was signed by President Trump on December&nbsp;22, 2017, Congress repealed
the &#8220;individual mandate.&#8221; The repeal of this provision, which required most Americans to carry a minimal level of health insurance, became effective in 2019. Further, on June&nbsp;17, 2021, the U.S. Supreme Court dismissed a challenge to
the ACA after finding that the plaintiffs did not have standing to challenge the constitutionality of the ACA. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Pharmaceutical Price Reform </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The prices of prescription
pharmaceuticals have also been the subject of considerable discussion in the United States. There have been U.S. congressional inquiries, as well as proposed and enacted </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and
reduce the costs of pharmaceuticals under Medicare and Medicaid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For example, on August&nbsp;16, 2022, the Inflation Reduction Act, or IRA, was
signed into law. The legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B providing the option of paying a monthly premium for outpatient
prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare, with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare
Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (first due in 2025). The IRA permits the Secretary of the HHS to implement many of
these provisions through guidance, as opposed to regulation, for the initial years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Specifically, with respect to price negotiations, Congress
authorized Medicare to negotiate lower prices for certain single-source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D. The Center for Medicare&nbsp;&amp; Medicaid
Services, or CMS, was directed to negotiate prices for ten high-cost drugs paid for by Medicare Part D, beginning in 2026, followed by 15 Part D drugs in 2027, 15 Part B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and beyond. This
provision applies to drug products that have been approved for at least 9 years and biologics that have been licensed for 13 years. Drugs and biologics that have been approved for a single rare disease or condition were originally categorically
excluded from price negotiation but, with passage of the One Big Beautiful Bill Act in July 2025, Congress extended this exemption to drugs and biologics with multiple orphan drug designations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The IRA subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a
price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. In addition, the IRA established inflation rebate programs under Medicare Part B and Part D.
These programs require manufacturers to pay rebates to Medicare if they raise their prices for certain Part B and Part D drugs faster than the rate of inflation. The legislation also requires manufacturers to pay rebates for drugs in Medicare Part D
whose price increases exceed inflation. The new law also caps Medicare <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> drug costs at an estimated $2,000 a year beginning in 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The first cycle of negotiations for the Medicare Drug Price Negotiation Program commenced in the summer of 2023 with the negotiated prices for ten
selected drug products becoming effective on January&nbsp;1, 2026. The second cycle of negotiations with participating drug companies occurred during 2025, and the negotiated prices for this second set of 15 drugs will become effective on
January&nbsp;1, 2027. On January&nbsp;27, 2026, CMS published the list of 15 drugs selected for the third cycle of negotiations, and the negotiated prices will become effective on January&nbsp;1, 2028. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On June&nbsp;6, 2023, Merck&nbsp;&amp; Co. filed a lawsuit against HHS and CMS asserting that, among other things, the IRA&#8217;s Drug Price
Negotiation Program for Medicare constitutes an uncompensated taking in violation of the Fifth Amendment of the U.S. Constitution. Subsequently, a number of other parties also filed lawsuits in various courts with similar constitutional claims. HHS
has generally won the substantive disputes in these cases or succeeded in getting claims dismissed for lack of standing or on the merits. Litigation involving these and other provisions of the IRA will likely continue with unpredictable and
uncertain results. Since adoption of the IRA, the Trump Administration has taken a number of actions to reduce the costs of pharmaceutical products. For example, on April&nbsp;15, 2025, President Trump issued an Executive Order which directs HHS to
take steps to reduce the prices of pharmaceutical products. Further, on May&nbsp;12, 2025, President Trump issued an additional Executive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Order calling on pharmaceutical manufacturers to voluntarily reduce the prices of medicines in the United States. The Executive Order provides that if such actions do not lower the costs of
pharmaceuticals, the Secretary of HHS would pursue other actions, including proposing a rulemaking that imposes most-favored nation, or MFN, pricing in the United States. Thereafter, on July&nbsp;31, 2025, the President issued letters to 17
pharmaceutical companies reiterating the requirements of the May&nbsp;12, 2025 Executive Order and demanding that such companies extend MFN pricing to Medicaid patients. Virtually all of these pharmaceutical companies have entered into agreements
with the Trump Administration to provide for lower prices on certain pharmaceuticals. On February&nbsp;5, 2026, President Trump launched TrumpRx.gov, a website that directs individuals to pharmaceutical manufacturer websites that are offering
pricing discounts based on the Trump Administration&#8217;s pricing agreements with pharmaceutical manufacturers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On December&nbsp;23, 2025, CMS,
through its Center for Medicare and Medicaid Innovation, proposed two five-year pilot programs to implement a &#8220;reference pricing&#8221; regime for drugs paid for under Medicare for 25% of covered beneficiaries. The programs are referred to as
the Global Benchmark for Efficient Drug Pricing Model for Medicare Part B drugs, referred to as GLOBE, and the Guarding U.S. Medicare Against Rising Drug Costs for Medicare Part D drugs, referred to as GUARD. Under the proposed pilot programs, a
manufacturer would owe rebates to Medicare if prices for their drugs exceeded the prices paid by other economically comparable reference countries, defined in the proposed regulations as Organisation for Economic
<FONT STYLE="white-space:nowrap">Co-operation</FONT> and Development countries with a gross domestic product of $400&nbsp;billion and a per capita gross domestic product that is at least 60% of the U.S. per capita gross domestic product (an initial
list of 19 reference countries is included in the proposed rule). The pilot programs are proposed to go into effect beginning October&nbsp;1, 2026. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical
and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures. In some cases, these regulations are designed to
encourage importation from other countries and bulk purchasing, which may be increasingly true with respect to products approved pursuant to the accelerated approval pathway. State Medicaid programs and other payers are developing strategies and
implementing significant coverage barriers, or refusing to cover these products outright, arguing that accelerated approval drugs have insufficient or limited evidence despite meeting the FDA&#8217;s standards for accelerated approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Federal and State Data Privacy Laws </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There are multiple
privacy and data security laws that may impact our business activities in the United States and in other countries where we operate, conduct clinical trials or may do business in the future. These laws are evolving and may increase both our
obligations and our regulatory risks in the future. In the health care industry generally, under the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, the HHS has issued regulations to protect the privacy and security of
protected health information used or disclosed by covered entities including certain healthcare providers, health plans and healthcare clearinghouses. HIPAA also regulates standardization of data content, codes and formats used in healthcare
transactions and standardization of identifiers for health plans and providers. HIPAA also imposes certain obligations on the business associates of covered entities that obtain protected health information in providing services to or on behalf of
covered entities. HIPAA may apply to us in certain circumstances and may also apply to our business partners in ways that may impact our relationships with them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Clinical trials are regulated by the Common Rule, which also includes specific privacy-related provisions. In addition to federal privacy regulations,
there are a number of state laws governing the confidentiality and security of health information that may be applicable to our business. In addition to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
possible federal civil and criminal penalties for HIPAA violations, state attorneys general are authorized to file civil actions for damages or injunctions in federal courts to enforce HIPAA and
seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, state attorneys general (along with private plaintiffs) have brought civil actions seeking injunctions and damages resulting from alleged violations of
HIPAA&#8217;s privacy and security rules. State attorneys general also have authority to enforce state privacy and security laws. New laws and regulations governing privacy and security may be adopted in the future as well. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">At the state level, California has enacted legislation that has been dubbed the first &#8220;GDPR-like&#8221; law in the United States, referring to the
EU&#8217;s General Data Protection Regulation, which is described in more detail below. Known as the California Consumer Privacy Act, or CCPA, it creates new individual privacy rights for consumers (as that word is broadly defined in the law) and
places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA went into effect on January&nbsp;1, 2020 and requires covered companies to provide new disclosures to California consumers,
provides such consumers new ways to <FONT STYLE="white-space:nowrap">opt-out</FONT> of certain sales of personal information, and allows for a new cause of action for data breaches. In November 2020, California voters passed a ballot initiative for
the California Privacy Rights Act, or the CPRA, which went into effect on January&nbsp;1, 2023, and significantly expanded the CCPA to incorporate additional GDPR-like provisions, including requiring that the use, retention, and sharing of personal
information of California residents be reasonably necessary and proportionate to the purposes of collection or processing, granting additional protections for sensitive personal information, and requiring greater disclosures related to notice to
residents regarding retention of information. The CPRA also created a new enforcement agency &#8211; the California Privacy Protection Agency &#8211; whose sole responsibility is to enforce the CPRA, which will further increase compliance risk. The
provisions in the CPRA may apply to some of our business activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to California, at least eighteen other states have passed
comprehensive privacy laws similar to the CCPA and CPRA. These laws are either in effect or will go into effect sometime before the end of 2026. Like the CCPA and CPRA, these laws create obligations related to the processing of personal information,
as well as special obligations for the processing of &#8220;sensitive&#8221; data, which includes health data in some cases. Some of the provisions of these laws may apply to our business activities. There are also states that are strongly
considering additional laws that will go into effect that could go into effect in 2026 and beyond. Other states will be considering similar laws in the future, and Congress has also been debating passing a federal privacy law. There are also states
that are specifically regulating health information that may affect our business. For example, the State of Washington passed the My Health My Data Act in 2023 which specifically regulated health information that is not otherwise regulated by the
HIPAA rules, and the law also has a private right of action, which further increases the relevant compliance risk. Connecticut and Nevada have also passed similar laws regulating consumer health data, and more states are considering such
legislation. These laws may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Plaintiffs&#8217; lawyers are also increasingly using privacy-related statutes at both the state and federal level to bring lawsuits against companies
for their data-related practices. In particular, there have been a significant number of cases filed against companies for their use of pixels and other web trackers. These cases often allege violations of the California Invasion of Privacy Act and
other state laws regulating wiretapping, as well as the federal Video Privacy Protection Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Approval and Regulation of Biologics in the European Union
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To market any product outside of the United States, a sponsor must also comply with numerous regulatory requirements of other countries and
jurisdictions regarding quality, safety and efficacy and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products. Whether or not it obtains FDA approval for a product, a sponsor will need
to obtain the necessary approvals by the comparable regulatory authorities of foreign countries or economic areas, such as the <FONT STYLE="white-space:nowrap">27-member</FONT> EU, before it can commence clinical trials or marketing of the product
in those countries or jurisdictions. This process in the EU generally follows the same lines as in the United States and requires the satisfactory completion of preclinical studies and adequate and well-controlled clinical trials to establish the
safety and efficacy of the product for each proposed indication. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Preclinical Studies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Before a product enters clinical testing in the EU, the sponsor must conduct preclinical studies to demonstrate the safety of the investigational product
for such clinical testing. These studies must be conducted in compliance with the principles of GLP, as set forth in EU Directive 2004/10/EC. In particular, preclinical studies, both <I>in vitro</I> and <I>in vivo</I>, must be planned, performed,
monitored, recorded, reported and archived in accordance with GLP principles, which reflect the requirements of the Organization for Economic <FONT STYLE="white-space:nowrap">Co-operation</FONT> and Development. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Human Clinical Trials in Support of a Marketing Authorization </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Clinical trials in the EU are governed by the Clinical Trials Regulation (EU) No 536/2014, or CTR, which replaced the prior Clinical Trials Directive
2001/20/EC, or CTD. The CTR is designed to simplify and streamline the authorization, conduct and transparency of clinical trials in the EU. Under the new coordinated procedure for the approval of clinical trials, the sponsor of a clinical trial to
be conducted in more than one Member State of the EU submits a single application for approval. The submission is made through the Clinical Trials Information System, the new clinical trials portal overseen by the EMA and available to clinical trial
sponsors, competent authorities of the EU Member States and the public. All clinical trials in the EU are now subject to the CTR following completion of the transition from the Clinical Trials Directive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The CTR streamlines the process and includes a single set of documents to be prepared and submitted for the application, simplified reporting procedures
for clinical trial sponsors, and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part I is assessed by the competent authorities of all EU Member States in which an application for
authorization of a clinical trial has been submitted, and Part II is assessed separately by each Member State concerned. Strict deadlines have been established for the assessment of clinical trial applications under the CTR. The role of the relevant
ethics committees in the assessment procedure is governed by the national law of the relevant EU Member State. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As in the United States, sponsors
conducting certain clinical studies in the EU must submit clinical and make public trial information through the Clinical Trials Information System (CTIS) which has replaced Edura CT under the CTR. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Pediatric Studies </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to obtaining a marketing
authorization in the EU, sponsors must demonstrate compliance with all measures included in an <FONT STYLE="white-space:nowrap">EMA-approved</FONT> Pediatric Investigation Plan, or PIP, covering all subsets of the pediatric population, unless the
EMA has granted a product-specific waiver, a class waiver, or a deferral for one or more of the measures included in the PIP. This requirement also applies when a sponsor wants to add a new indication, pharmaceutical form or route of administration
for a medicine that is already authorized. The Pediatric Committee of the EMA, or PDCO, may grant deferrals for some products, allowing a company to delay development of the medicine for children until there is enough information to demonstrate its
effectiveness and safety in adults. The PDCO may also grant waivers </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
when the development of a medicine for children is not needed or is not appropriate, such as for diseases that only affect the elderly population. Before a Marketing Authorization Application, or
MAA, can be filed, or an existing marketing authorization can be amended, the EMA determines whether a sponsor has complied with the agreed studies and measures listed in each relevant PIP. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>PRIME Designation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In March 2016, the EMA launched an
initiative to facilitate development of product candidates in indications, which are often rare, for which few or no therapies currently exist. The PRIority MEdicines, or PRIME, scheme is intended to encourage drug development in areas of unmet
medical need, and it provides for the accelerated regulatory review of product candidates that represent substantial innovation. Products from small- and <FONT STYLE="white-space:nowrap">medium-sized</FONT> enterprises, or SMEs, may qualify for
earlier entry into the PRIME scheme than larger companies. Many benefits accrue to sponsors of product candidates with PRIME designation, including early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs
and other development program elements, and accelerated MAA assessment once an application has been submitted. Importantly, a dedicated EMA contact and rapporteur from the CHMP, or Committee for Advanced Therapies, or CAT, are appointed early in
PRIME scheme facilitating increased understanding of the product candidate at the EMA committee level. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Marketing Authorization </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To obtain a marketing authorization, or MA, for a product under the EU regulatory system, a sponsor must submit an MAA either under a centralized
procedure administered by the EMA or one of the procedures administered by competent authorities in EU Member States, including the decentralized procedure, national procedure, or mutual recognition procedure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The centralized procedure provides for the grant of an MA by the European Commission, or EC, that is valid for all EU Member States. Pursuant to
Regulation (EC) No.&nbsp;726/2004, the centralized procedure is compulsory for certain types of product candidates, including those produced by certain biotechnological processes, designated as orphan drugs, that are advanced therapies, and that
have a new active substance indicated for the treatment of certain diseases, including cancer. However, the centralized procedure may be optional for product candidates with a new active substance indicated for the treatment of other diseases and
product candidates that are highly innovative or for which a centralized process is in the interest of patients. Sponsors must demonstrate the quality, safety, and efficacy of their product candidates to the EMA, which provides an opinion regarding
the MAA. The EC then decides whether to grant or refuse marketing authorization in light of the opinion delivered by the EMA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The CHMP was
established at the EMA and plays a vital role in the authorization of products in the EU. The CHMP provides scientific advice to sponsors investigating and developing new products, prepares scientific guidelines and regulatory guidance to help
sponsors prepare MAAs, and cooperates with international partners on the harmonization of regulatory requirements. With respect to MAAs filed under the centralized procedure, the CHMP is responsible for conducting an initial assessment of a product
candidate and the data supporting the MAA. The maximum timeframe for the evaluation of an MAA is 210 days, excluding interruptions when additional information or written or oral explanation is to be provided by the sponsor in response to questions
from the CHMP. Accelerated assessment with a time limit of 150 days may be granted by the CHMP in exceptional cases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On the basis of its review,
the CHMP provides a scientific opinion on whether or not an MA should be granted for a product candidate. Within 15 calendar days of receipt of a final opinion from the CHMP, the EC must prepare a draft decision concerning an MAA. This draft
decision must take the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
CHMP opinion and any relevant provisions of EU law into account. Before arriving at a final decision, the EC must consult the Standing Committee on Medicinal Products for Human Use. This
committee is composed of representatives of the EU Member States and is chaired by a <FONT STYLE="white-space:nowrap">non-voting</FONT> EC representative. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The decentralized marketing authorization procedure requires a separate application to, and leads to separate approval by, the competent authorities of
each EU Member State in which the product candidate is applying to be marketed. This application is substantially the same as an MAA submitted to the EMA in the centralized procedure. The reference Member State, or RMS, prepares a draft assessment
and drafts of the related materials within 120 days after receipt of a valid application. The resulting assessment report is submitted to the concerned EU Member States which, within 90 days of receipt, must decide whether to approve the assessment
report and related materials. If the relevant EU Member State cannot approve the RMS&#8217;s assessment report and related materials due to concerns relating to a potential serious risk to public health, disputed elements may be referred to the CMDh
and, if unresolved, to the CHMP for arbitration, following which the European Commission adopts a binding decision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The mutual recognition
procedure similarly is based on the acceptance by the competent authorities of the EU Member States of the MA of a product by the competent authorities of other EU Member States. The holder of a national MA may submit an application to the competent
authority of an EU Member State requesting that this authority recognize the MA delivered by the competent authority of another EU Member State. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Periods of Authorization and Renewals </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">An MA
is initially valid for five years and may be renewed after five years following a <FONT STYLE="white-space:nowrap">re-evaluation</FONT> of the risk-benefit balance by the EMA or by the competent authority of the EU Member State. In connection with
seeking a renewal, the MA holder must provide the EMA or the competent authority of the EU Member State with a consolidated version of the file in respect of quality, safety and efficacy or the medicine, including all variations introduced since the
MAwas granted, at least six months before the MA ceases to be valid. The EC or the competent authority of the EU Member State may decide, on justified grounds relating to pharmacovigilance, to proceed with an additional five-year period of MA. Once
definitively renewed, the MA shall be valid for an unlimited period. If a renewed MA is not followed by the actual placing of the medicine on the EU market (in the case of the centralized procedure) or on the market of the authorizing EU Member
State within three years after renewal, and is no longer actually present on the applicable market for three consecutive years, the MA ceases to be valid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Marketing Authorization Under Exceptional Circumstances </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The EC may grant a &#8220;marketing authorization under exceptional circumstances&#8221; under Article 14(8) of Regulation (EC) No 726/2004. This
authorization is intended for products for which the sponsor can demonstrate that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use, because: the indications for which the product in question is
intended are encountered so rarely that the sponsor cannot reasonably be expected to provide comprehensive evidence; given the present state of scientific knowledge, comprehensive information cannot be provided; or it would be contrary to generally
accepted principles of medical ethics to collect such information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A marketing authorization under exceptional circumstances may be granted subject
to certain specific obligations, which may include the following: the sponsor must complete an identified program of studies within a time period specified by the competent authority, the results of which form the basis of a reassessment of the
benefit-risk profile; the medicine in question may be supplied by medical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
prescription only and may in certain cases be administered only under strict medical supervision, possibly in a hospital and in the case of a radiopharmaceutical, by an authorized person; and the
package leaflet and any medical information must draw the attention of the medical practitioner to the fact that the particulars available concerning the product in question are as yet inadequate in certain specified respects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A marketing authorization under exceptional circumstances is subject to an annual process to review and reassess the risk-benefit balance. Continuation
of the authorization is linked to the annual reassessment and a negative assessment could potentially result in the marketing authorization being suspended or revoked. The renewal of a marketing authorization under exceptional circumstances,
however, follows the same rules as a standard MA. Thus, it is granted for an initial five year period, after which the authorization will become valid indefinitely, unless the EMA decides that safety grounds merit one additional five-year renewal.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Conditional Marketing Authorization </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The EC may also grant a &#8220;conditional marketing authorization&#8221; to a product prior to obtaining the comprehensive clinical data required for
an application for a full MA under Article <FONT STYLE="white-space:nowrap">14-a</FONT> of Regulation (EC) No 726/2004. A conditional marketing authorization may be granted for product candidate (including product candidates designated as orphan
drugs) if: (i)&nbsp;the risk-benefit balance of the product candidate is positive, (ii)&nbsp;it is likely that the sponsor will be in a position to provide the required comprehensive clinical trial data, (iii)&nbsp;the product candidate fulfills an
unmet medical need and (iv)&nbsp;the benefit to public health of the immediate availability on the market of the product candidate outweighs the risk inherent in the fact that additional data are still required. A conditional marketing authorization
may contain specific obligations to be fulfilled by the holder, including obligations with respect to the completion of ongoing or new studies and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are
valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional or modified conditions and/or specific obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Post-Approval Regulatory Requirements </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Following the issuance of an MA for a medicine, the sponsor of the MA is required to comply with a range of requirements applicable to the
manufacturing, marketing, promotion and sale of products. These requirements include compliance with the EU&#8217;s stringent pharmacovigilance or safety reporting rules, which may include post-authorization studies and additional monitoring
obligations. Further, the manufacturing of authorized products, for which a separate manufacturer&#8217;s license is mandatory, must also be conducted in strict compliance with the applicable EU laws, regulations and guidance, including Directive
2001/83/EC, Directive 2003/94/EC, Regulation (EC) No 726/2004 and the EC Guidelines for Good Manufacturing Practice. These requirements include compliance with EU Good Manufacturing Practice (GMP) standards when manufacturing products and active
pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the EU with the intention to import the active pharmaceutical ingredients into the EU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">At the same time, the marketing and promotion of authorized drugs, including industry-sponsored continuing medical education and advertising directed
toward the prescribers of drugs and/or the general public, are strictly regulated in the EU under Directive 2001/83/EC, as amended, and are also subject to EU Member State laws.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Direct-to-consumer</FONT></FONT> advertising of prescription medicines is prohibited across the EU. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Regulatory Exclusivity </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">New products approved on the basis of a complete data package currently qualify for eight years of data exclusivity and an additional two years of
market exclusivity. Data exclusivity prevents sponsors that seek MA of generic products from referencing the innovator&#8217;s data in support of an abbreviated application. During the additional <FONT STYLE="white-space:nowrap">two-year</FONT>
period of market exclusivity, a generic MAA can be submitted and the innovator&#8217;s data may be referenced in that application, but no generic product can be placed on the EU market until the expiration of the market exclusivity. The overall <FONT
STYLE="white-space:nowrap">ten-year</FONT> period may be extended to a maximum of 11 years if, during the first eight years of those ten years, the MA holder for the innovative product obtains an authorization for one or more new therapeutic
indications which are determined to bring a significant clinical benefit in comparison with existing therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In November 2020, the EC launched a
review of the EU&#8217;s pharmaceutical legislation, including its provisions governing regulatory exclusivity. The EC&#8217;s proposal for revision of several legislative measures was published in April 2023 and includes, among other things,
provisions that would potentially reduce the duration of regulatory exclusivity protection. On December&nbsp;11, 2025, the European Parliament and Council reached a provisional political agreement&nbsp;on the legislation, which is expected to be
adopted by <FONT STYLE="white-space:nowrap">mid-2026.</FONT> Key changes include updating regulatory exclusivity to a new system with eight years of data exclusivity and a reduced market exclusivity period to one year, which can be extended if
specific conditions are fulfilled up to a maximum of 11 years. This measure, and others, are expected to be adopted by <FONT STYLE="white-space:nowrap">mid-2026</FONT> and, following a transition period of 24 months, will likely take effect in <FONT
STYLE="white-space:nowrap">mid-2028.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Orphan Drug Designation and Exclusivity </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As in the United States, a product candidate can be designated as an orphan medicinal product by the EC if its sponsor can establish that the product
candidate is intended for the diagnosis, prevention or treatment of (1)&nbsp;a life-threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the EU when the application is made, or (2)&nbsp;a
life-threatening, seriously debilitating or serious and chronic condition in the EU that without incentives is unlikely to generate sufficient return from marketing in the EU to justify the necessary investment. For either of these categories, the
sponsor must demonstrate that there is no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, the drug will be of significant benefit to those affected
by the condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If a product candidate is designated as an orphan medicinal product, the product will be eligible for a range of benefits during
the development and regulatory review process, including scientific assistance for study protocols, authorization through the centralized marketing authorization procedure, which is mandatory for orphan medicinal products and results in a single
marketing authorization covering all EU Member States and a reduction or elimination of registration and MA fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Further, if and when the product
is authorized for marketing, the orphan medicinal product will be entitled to ten years of market exclusivity in all EU Member States. However, MA may be granted to a similar product with the same orphan indication during the <FONT
STYLE="white-space:nowrap">10-year</FONT> period with the consent of the MA holder of the original orphan drug or if the manufacturer of the original orphan drug is unable to supply sufficient quantities. MA may also be granted to a similar product
with the same orphan indication if the product is safer, more effective or otherwise clinically superior to the original orphan drug. The period of market exclusivity may, in addition, be reduced to six years if it can be demonstrated on the basis
of available evidence that the original orphan drug is sufficiently profitable not to justify maintenance of market exclusivity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Pediatric Exclusivity </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If a sponsor obtains a MA in all EU Member States, or a MA granted in the centralized procedure by the EC, and the study results for the pediatric
population are included in the application, even when negative, the product is eligible for an additional <FONT STYLE="white-space:nowrap">six-month</FONT> period of qualifying patent protection through extension of the term of the SPC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Patent Term Extensions </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The EU provides for
patent term extension through SPCs. The rules and requirements for obtaining a SPC are set out in Regulation (EC) 469/2009 and are similar to those in the United States. An SPC may extend the term of a patent for up to five years after its
originally scheduled expiration date and can provide up to a maximum of fifteen years of marketing exclusivity for a drug. Although SPCs are available throughout the EU, sponsors must apply on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Pricing Decisions </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a
reimbursement price has been agreed. Other countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies or
<FONT STYLE="white-space:nowrap">so-called</FONT> health technology assessments, in order to obtain reimbursement or pricing approval. For example, EU Member States have the option to restrict the range of products for which their national health
insurance systems provide reimbursement and to control the prices of products for human use. EU Member States may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the
company placing the product on the market. Other EU Member States allow companies to fix their own prices for products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Recently, many countries in the EU have increased the amount of discounts required on pharmaceuticals, and these efforts could continue as countries
attempt to manage health care expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the EU. The downward pressure on health care costs in general, particularly prescription products, has become
intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement
has been obtained. Reference pricing used by various EU Member States, and parallel trade, i.e., arbitrage between <FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced EU Member States, can further reduce prices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>General Data Protection Regulation </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There
are significant privacy and data security laws that apply in Europe and other countries. The collection, use, disclosure, transfer, or other processing of personal data, including personal health data, regarding individuals who are located in the
European Economic Area, or EEA, and the processing of personal data that takes place in the EEA, is subject to the EU&#8217;s General Data Protection Regulation, or GDPR, which became effective in 2018. The GDPR is wide-ranging in scope, imposes
numerous requirements on companies that process personal data, and imposes heightened requirements on companies that process health and other sensitive data. These requirements include, in many situations, that a company obtain consent from an
individual before processing their sensitive personal data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Examples of obligations imposed by the GDPR on companies processing personal data
within its scope include providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, appointing a data protection
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
officer, providing notifications of data breaches, and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to
countries outside the EEA, including the U.S., and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to the greater of
<FONT STYLE="font-family:Times New Roman">&#128;</FONT>20&nbsp;million or 4% of annual global revenues. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek
judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR is a rigorous and time-intensive process that may increase the cost of doing business or require companies to change their
business practices to ensure full compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Following the July 2020 Court of Justice of the EU judgement invalidating the <FONT
STYLE="white-space:nowrap">so-called</FONT> <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Privacy Shield, the EC adopted an adequacy decision for the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Data Privacy Framework in July 2023. This
adequacy decision permits U.S. companies who self-certify under the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Data Privacy Framework to rely on it as a valid data transfer mechanism for data transfers from the EU to the United States. However,
some privacy advocacy groups have already suggested that they will be challenging the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Data Privacy Framework, and there is currently one pending litigation against the
<FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Data Privacy Framework before the Court of Justice of the EU (CJEU), <FONT STYLE="white-space:nowrap">C-703/25</FONT> P &#8211; <I>Latombe v Commission</I>. If these challenges are successful, they may
not only impact the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Data Privacy Framework, but also further limit the viability of the <FONT STYLE="white-space:nowrap">so-called</FONT> standard contractual clauses and other data transfer
mechanisms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Approval and Regulation of Biologics in the United Kingdom </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of January&nbsp;1, 2025, the Medicines and Healthcare Products Regulatory Agency, or the MHRA, is responsible for approving all products destined for
the United Kingdom market (Great Britain and Northern Ireland). The MHRA relies on the Human Medicines Regulations 2012 (SI 2012/1916) (as amended), or the HMR, as the basis for regulating products. The HMR has incorporated into domestic law the
body of EU law instruments governing products that existed prior to the United Kingdom&#8217;s withdrawal from the EU. On April&nbsp;28, 2025, the U.K. Parliament adopted amendments to improve and strengthen the clinical trials regulatory regime in
the United Kingdom. These revisions will take effect on April&nbsp;28, 2026, and were needed to replace the prior requirements in the United Kingdom that were based on the repealed CTD, which has been replaced by the CTR, while the United Kingdom
has established its own standalone clinical trials regime. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, as of January&nbsp;1, 2024, an international recognition procedure, or IRP,
applies in the United Kingdom and is designed to facilitate approval of pharmaceutical products in the United Kingdom. The IRP is open to sponsors that have previously received an authorization for the same product from one of the MHRA&#8217;s
specified Reference Regulators, or RRs. The RRs include the EMA and regulators in the EEA member states, for approvals in the EU centralized procedure and mutual recognition procedure, and the FDA for approvals granted in the United States. The RR
assessment must have undergone a full and standalone review. RR assessments based on reliance or recognition cannot be used to support an IRP application. A CHMP positive opinion is an RR authorization for the purposes of IRP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Following the withdrawal of the United Kingdom from the EU, the U.K. Data Protection Act applies to the processing of personal data that takes place in
the United Kingdom and includes parallel obligations to those set forth by GDPR. The United Kingdom government has determined that it considers all EU Member States and EEA member states to be adequate for the purposes of data protection, ensuring
that data flows from the United Kingdom to the EU/EEA remain unaffected. Further, the EC decided in June 2021 that the level of data protection in the United Kingdom is &#8220;essentially adequate&#8221; for purposes of data transfer from the EU to
the United Kingdom. On December&nbsp;19, 2025, the EC renewed this decision until December&nbsp;27, 2031. The United Kingdom and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the U.S. have also agreed to a U.S.- United Kingdom &#8220;Data Bridge,&#8221; which functions similarly to the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Data Privacy Framework and provides
an additional legal mechanism for companies to transfer personal data from the United Kingdom to the United States.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the United Kingdom, following Brexit, the MHRA has established and administers the Innovation Licensing and Access Pathway, or ILAP, to accelerate
the development and approval of new pharmaceutical products. The ILAP is open to sponsors of potentially transformative medicines or drug-device combination products that address unmet medical needs. It supports products with evidence of safe use in
humans but before confirmatory trials have started. It is designed to reduce the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> timeline for research and development, regulatory approval and timely
adoption of new technologies to benefit patients and the healthcare system in the United Kingdom. To these ends, the ILAP comprises an Innovation Passport designation, a Target Development profile and a toolkit to support all stages of the design,
development and approval process. In 2025, the MHRA relaunched the ILAP with updated eligibility criteria, simplified application steps, and an increased focus on advanced therapy medicinal products, rare diseases and high unmet medical needs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>Employees and Human Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of March&nbsp;31,
2026, we had 72 full-time employees, of which 33 employees are based in the United States and 34 employees are based in Denmark. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our
relationship with our employees to be good. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining,
incentivizing and integrating our existing and new employees, advisors and consultants. Our compensation program is designed to retain, motivate and, as needed, attract highly qualified employees. Accordingly, we use a mix of competitive base
salary, cash-based annual incentive compensation, equity awards and other employee benefits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>Facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our principal facilities consist of office space. We occupy approximately 6,200 square feet of office space in Copenhagen, Denmark under a lease that
currently expires in January 2029. We also occupy 4,274 square feet of office space in Cambridge, Massachusetts under a lease that currently expires in October 2026. We believe our facilities are adequate and suitable for our current needs and that
should it be needed, suitable additional or alternative space will be available to accommodate our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>Legal Proceedings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently subject to any
material legal proceedings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_12"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Executive Officers and Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets
forth the name, age as of March&nbsp;31, 2026 and position of each of our executive officers and directors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="44%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Position</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><I>Executive Officers</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Benny S&oslash;rensen, M.D., Ph.D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">52</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer, Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Mads Behrndt, M.Sc</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">43</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer and General Manager</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Catherine Madigan, M.D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">54</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Medical Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Ananthram Murthy, Ph.D., M.Sc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">48</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Operating Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">John Maraganore, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">63</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chair of the Board of Directors</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Linda Bain</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">55</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Laura Tadvalkar, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">38</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Akshay Vaishnaw, M.D., Ph.D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">63</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Member of the Audit Committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Member of the Compensation Committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Member of the Nominating and Corporate Governance Committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Executive Officers </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Benny S&oslash;rensen, M.D.,
Ph.D.</I></B> has served as our president and chief executive officer since July 2021 and as a member of our board of directors since November 2021. Prior to that, Dr.&nbsp;S&oslash;rensen served as Senior Vice President, Strategic Projects at
Codiak Biosciences, Inc., or Codiak, a biopharmaceutical company, from October 2016 to July 2021. Previously, Dr.&nbsp;S&oslash;rensen served as Senior Director of Clinical Research at Alnylam Pharmaceuticals, Inc., or Alnylam, a biopharmaceutical
company, from October 2013 to October 2016. From May 2012 to October 2013, Dr.&nbsp;S&oslash;rensen served as a Global Medical Director at Baxter Healthcare Corporation, or Baxter, a medical equipment manufacturing company. Prior to Baxter,
Dr.&nbsp;S&oslash;rensen was the Director of the Haemostasias Research Unit and Honorary Lecturer at Guy&#8217;s and St. Thomas&#8217; Hospital and King&#8217;s College London School of Medicine. Dr.&nbsp;S&oslash;rensen previously served on the
Scientific Advisory Board of Codiak from July 2021 to March 2023. He also served as an Associate Professor of Thrombosis and Haemostasis at Aarhus University, Denmark from 2007 until 2016. Dr.&nbsp;S&oslash;rensen holds an M.D. and Ph.D. from Aarhus
University. We believe that Dr.&nbsp;S&oslash;rensen is qualified to serve on our board of directors based on his extensive knowledge of our company and the biopharmaceutical industry, his experience in hematological research and his current role as
our president and chief executive officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Mads Behrndt-Eriksen, M.Sc. </I></B>has served as our chief financial officer and general manager
since September 2021. Prior to that, Mr.&nbsp;Behrndt served in roles of increasing responsibility, including as a Partner, in PricewaterhouseCoopers&#8217; Corporate Finance practice from 2007 to September 2021. Mr.&nbsp;Behrndt holds an M.Sc. in
Finance&nbsp;&amp; Strategic and a B.Sc. in Economics and Business Administration Management from the Copenhagen Business School. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Catherine
Madigan, M.D. </I></B>has served as our chief medical officer since January 2025. Prior to that, Dr.&nbsp;Madigan served as Chief Medical Officer at Syndax Pharmaceuticals, Inc., a biopharmaceutical company, from March 2022 to December 2024.
Previously, Dr.&nbsp;Madigan served as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Vice President, Head of Clinical Development at Syros Pharmaceuticals, Inc., a biopharmaceutical company, from June 2019 to February 2022. Prior to that, she served as Senior Medical Director,
Clinical Research at Alnylam from March 2018 to June 2019 and as Medical Director from June 2016 to March 2018. Dr. Madigan also was a Medical Director in the Rare Disease Innovation Unit of Biogen Inc., a biotechnology company, from February 2016
to May 2016 and served as Associate Medical Director from January 2014 to January 2016. Dr.&nbsp;Madigan previously held various academic positions of increasing responsibility at the University of California San Diego/Rady Children&#8217;s Hospital
San Diego. Dr.&nbsp;Madigan holds an M.D. from the Keck School of Medicine of the University of Southern California and a B.A. in Asian Studies from Dartmouth College. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Ananthram Murthy, Ph.D., M.Sc.</I></B> has served as our chief operating officer since September&nbsp;2025. Prior to that, Dr.&nbsp;Murthy served
as General Manager of Europe, the Middle East and Africa at argenx SE, a biotechnology company, from December 2020 to April 2025. From February 2017 to December 2020, Dr.&nbsp;Murthy served as Vice President, General Manager, Midsize EU Markets
&amp; Canada, and Vice President, Market Access, Pricing &amp; Policy at Alnylam. From December 2012 to February 2017, Dr.&nbsp;Murthy served as Head of Pricing &amp; Market Access at ARIAD Pharmaceuticals, Inc., a pharmaceutical company, which was
acquired by Takeda Pharmaceutical Company Limited in February 2017. He also served in roles of increasing responsibility, including as Executive Director, Global Pricing &amp; Market Access, at Celgene Corporation, or Celgene, a biopharmaceutical
company, which was acquired by Bristol-Myers Squibb Company in November 2019, from October 2008 to December 2012. Prior to Celgene, Dr.&nbsp;Murthy was a Reimbursement Manager at Medtronic plc, a medical device company, from June 2005 to October
2008. Earlier in his career, Dr.&nbsp;Murthy served as a health economics and policy consultant at several private, public and non-profit organizations and held roles at Johnson &amp; Johnson and Ernst &amp; Young. From February 2001 to August 2002,
Dr. Murthy also served as a Legislative Advisor at the U.S. Congress. Dr.&nbsp;Murthy holds a Ph.D. in Health Systems from the Johns Hopkins Bloomberg School of Public Health, an M.Sc. in International Health Policy from the London School of
Economics and a B.A. in Health and Society and Political Science from the University of Rochester. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Directors </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>John Maraganore, Ph.D.</I></B> has served as chair of our board of directors since January 2022. Dr.&nbsp;Maraganore has
served as the <FONT STYLE="white-space:nowrap">co-chief</FONT> executive officer at Corsera Health, Inc., a privately-held clinical-stage cardiovascular company, since September 2025. He has also served as a Senior Advisor at Jefferies Financial
Services, an investment banking and capital markets firm, since November 2024, a Venture Advisor at Atlas Venture, an early-stage venture capital firm, since January 2022, a Senior Advisor at Blackstone Life Sciences, a private equity investment
strategy firm, since January 2022, an Executive Partner at RTW Investments, LP, a life sciences investment and innovation firm, since January 2022, a principal and Chief Executive Officer of JMM Innovations, LLC, a biotechnology strategic advisory
practice, since January 2022, and a Venture Partner at ARCH Venture Partners, an early stage venture capital firm, since October 2021. Previously, Dr.&nbsp;Maraganore served as the founding Chief Executive Officer and a member of the board of
directors of Alnylam from December&nbsp;2002 to December 2021, and as President of Alnylam from December 2002 to December&nbsp;2007. Dr.&nbsp;Maraganore has been a member of the boards of directors of Rapport Therapeutics, Inc. since March 2024,
Takeda Pharmaceutical Company Limited since June 2022, Kymera Therapeutics, Inc. since February 2022 and Beam Therapeutics Inc. since November 2021, which are all biopharmaceutical companies. He also previously served on the boards of directors of
ProKidney Corp. from August 2022 to May 2024 and Agios Pharmaceuticals, Inc. from June 2010 to May 2023. Dr.&nbsp;Maraganore holds an M.S. and a Ph.D. in Biochemistry and Molecular Biology and a B.A. in Biological Sciences from the University of
Chicago. We believe that Dr.&nbsp;Maraganore is qualified to serve on our board of directors based on his scientific background, his experience in the venture capital industry, and his leadership and management experience in building
biopharmaceutical companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Linda Bain</I></B> has served as a member of our board of directors since January 2022. Since
April&nbsp;2025, Ms.&nbsp;Bain has served as a Venture Partner at Atlas Venture. Prior to that, Ms.&nbsp;Bain was the Chief Operating Officer and Chief Financial Officer of Mariana Oncology, Inc., a radiopharmaceutical company and a Novartis company
as of May 2024, from May 2023 to April 2025. Ms.&nbsp;Bain also served as the Chief Financial Officer of Codiak from December 2015 to April 2023, and the Chief Financial Officer and Treasurer of Avalanche Biotechnologies, Inc., a clinical stage gene
therapy company, from April 2014 to November 2015. Previously, Ms.&nbsp;Bain served at bluebird bio, Inc., a gene therapy biotechnology company, as Vice President of Finance and Business Operations from October 2011 to March 2014 and as the
Principal Accounting Officer from June 2013 to March 2014. Ms.&nbsp;Bain previously held senior roles at Genzyme Corporation, a biotechnology company, including Vice President of Finance, Global Manufacturing and Operations, and Vice President of
Finance, Genzyme Genetics, and earlier in her career at Fidelity Investments, AstraZeneca plc, and Deloitte&nbsp;&amp; Touche LLP. Ms.&nbsp;Bain has served as a member of the boards of directors of Arvinas, Inc. since June 2020 and Autolus since
June 2018. She also previously served on the board of directors of VBI Vaccines, Inc. from July 2021 to September 2022. Ms.&nbsp;Bain holds a B.S. degree in Accounting and Business Administration and an Honors Degree in Accounting and Business
Administration from the University of the Free State in South Africa. She is a certified public accountant. We believe that Ms.&nbsp;Bain is qualified to serve on our board of directors based on her extensive experience in the biopharmaceutical
industry and her background in accounting and finance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Laura Tadvalkar, Ph.D.</I></B> has served as a member of our board of directors since
July 2021. Dr.&nbsp;Tadvalkar is currently a Managing Director on the Venture Team at RA Capital Management, a venture capital firm, where she has served in roles of increasing responsibility since April 2020. Prior to that, Dr.&nbsp;Tadvalkar
served at MP Healthcare Venture Management, Inc., the strategic venture capital fund for Mitsubishi Tanabe Pharma Corporation, a pharmaceutical company, from March 2017 through April 2020. Previously, Dr.&nbsp;Tadvalkar was a consultant at Clarion
Healthcare, a life sciences consultancy company, from September 2014 to March 2017. Dr.&nbsp;Tadvalkar previously served on the board of directors of Cidara Therapeutics, Inc. from April 2024 to January 2025. Dr.&nbsp;Tadvalkar holds a Ph.D. in
Chemical Biology from Harvard University and a B.S. in Chemistry from Yale University. We believe that Dr.&nbsp;Tadvalkar is qualified to serve on our board of directors based on her extensive experience in the life sciences and venture capital
industries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Akshay Vaishnaw, M.D., Ph.D.</I></B> has served as a member of our board of directors since January&nbsp;2024. Dr.&nbsp;Vaishnaw
has served as President of Research&nbsp;&amp; Development at Scholar Rock Holding Corporation, or Scholar Rock, a global biopharmaceutical company, since April 2025, and as a member of the board of directors of Scholar Rock since May 2019. He also
has been a Venture Partner at Atlas Venture since August 2024. Previously, at Alnylam, Dr.&nbsp;Vaishnaw served as Chief Innovation Officer and Member of the Scientific Advisory Board from October 2023 to December 2024, as President from January
2022 to September 2023 and as President of Research&nbsp;&amp; Development from March 2018 to January 2022. Prior to that, Dr.&nbsp;Vaishnaw served in various other roles of increasing responsibility at Alnylam from January 2006 to February 2018. He
previously served on the board of directors of Editas Medicine, Inc. from 2016 to July 2024. Dr.&nbsp;Vaishnaw holds an MBBCh from Cardiff University School of Medicine (formerly, the University of Wales College of Medicine, U.K.), and a Ph.D. in
Molecular Immunology from the University of London, U.K. He is a Fellow of the Royal College of Physicians, U.K. We believe that Dr.&nbsp;Vaishnaw is qualified to serve on our board of directors based on his scientific background and his experience
in the life sciences and venture capital industries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Composition and Election of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Composition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Effective upon the completion of this
offering, our board of directors will be authorized to have&#8195;&#8195;&#8195;&#8195;members and will consist of&#8195;&#8195;&#8195;&#8195;members. Our directors hold office until their successors have been elected and qualified or until the
earlier of their death, resignation or removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our restated certificate of incorporation and amended and restated bylaws that will become
effective upon the completion of this offering provide that the authorized number of directors may be changed only by resolution of our board of directors. Our restated certificate of incorporation and amended and restated bylaws will also provide
that any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In accordance with the terms of our restated certificate of incorporation and amended and restated bylaws that will become effective upon the completion
of this offering, our board of directors will be divided into three classes, class I, class II and class III, with members of each class serving staggered three-year terms. As a result, only one class of directors will be elected at each annual
meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Upon the completion of this offering, the members of the classes will be divided as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the class I directors will be&#8195;&#8195;&#8195;&#8195;and&#8195;&#8195;&#8195;&#8195;, and their term will expire at the
annual meeting of stockholders to be held in&#8195;&#8195;&#8195;&#8195;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the class II directors will be&#8195;&#8195;&#8195;&#8195;and&#8195;&#8195;&#8195;&#8195;, and their term will expire at
the annual meeting of stockholders to be held in&#8195;&#8195;&#8195;&#8195;; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the class III directors will be&#8195;&#8195;&#8195;&#8195; ,&#8195;&#8195;&#8195;&#8195; and&#8195;&#8195;&#8195;&#8195; ,
and their term will expire at the annual meeting of stockholders to be held in&#8195;&#8195;&#8195;&#8195;. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon the expiration
of the term of a class of directors, directors in that class will be eligible to be elected for a new three-year term at the annual meeting of stockholders in the year in which their term expires. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The classification of our board of directors may have the effect of delaying or preventing changes in our control or management. See the section titled,
&#8220;<I>Description of Capital Stock&#8212;Delaware Anti-Takeover Law and Certain Charter and Bylaw Provisions</I>&#8221;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Director Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have applied to list our common stock on the Nasdaq Global Select Market. Nasdaq rules require a majority of a listed company&#8217;s board of
directors to be comprised of independent directors within one year of listing. In addition, Nasdaq rules require that, subject to specified exceptions, each member of a listed company&#8217;s audit, compensation and nominating and corporate
governance committees be independent. Audit committee members must also satisfy the independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act and compensation committee members must also satisfy the
independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10C-1</FONT> under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under applicable Nasdaq rules, a
director will only qualify as an &#8220;independent director&#8221; if, in the opinion of the listed company&#8217;s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in
carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10A-3,</FONT> a member of an audit committee of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee, accept, directly or indirectly, any consulting,
advisory, or other compensatory fee from the listed company or any of its subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries. In order to be considered independent for purposes of Rule <FONT
STYLE="white-space:nowrap">10C-1,</FONT> the board must consider, for each member of a compensation committee of a listed company, all factors specifically relevant to determining whether a director has a relationship to such company which is
material to that director&#8217;s ability to be independent from management in connection with the duties of a compensation committee member, including, but not limited to: (1)&nbsp;the source of compensation of the director, including any
consulting, advisory or other compensatory fee paid by such company to the director; and (2)&nbsp;whether the director is affiliated with the company or any of its subsidiaries or affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In&#8195;&#8195;&#8195;&#8195;, our board of directors undertook a review of the composition of our board of directors and its committees and the
independence of each director. Based upon information requested from and provided by each director concerning his or her background, employment, and affiliations, including family relationships, our board of directors has determined that each of our
directors, with the exception of Dr.&nbsp;S&oslash;rensen, is an &#8220;independent director&#8221; as defined under applicable Nasdaq rules, including, in the case of all the members of our audit committee, the independence criteria set forth in
Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act, and in the case of all the members of our compensation committee, the independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10C-1</FONT> under the Exchange
Act. In making such determination, our board of directors considered the relationships that each such <FONT STYLE="white-space:nowrap">non-employee</FONT> director has with our company and all other facts and circumstances that our board of
directors deemed relevant in determining his or her independence, including the beneficial ownership of our capital stock by each <FONT STYLE="white-space:nowrap">non-employee</FONT> director. Dr.&nbsp;S&oslash;rensen is not an independent director
under these rules because he is our president and chief executive officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There are no family relationships among any of our directors or
executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Bankruptcies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Ms.&nbsp;Bain
previously served as Chief Financial Officer of Codiak from December 2015 to April 2023. In March 2023, Codiak filed a voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board leadership structure </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of directors is
currently chaired by John Maraganore, who has authority, among other things, to call and preside over meetings of the board of directors, to set meeting agendas and to determine materials to be distributed to the board of directors. Accordingly, the
chair has substantial ability to shape the work of the board of directors. We believe that separation of the positions of chair and chief executive officer reinforces the independence of the board of directors in its oversight of our business and
affairs. In addition, we have a separate chair for each committee of our board of directors. The chair of each committee is expected to report annually to our board of directors on the activities of their committee in fulfilling their
responsibilities as detailed in their respective charters or specify any shortcomings should that be the case. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Role of the Board of Directors in Risk Oversight
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">One of the key functions of our board of directors is informed oversight of our risk management process. Our board of directors does not have a
standing risk management committee but rather administers this oversight function directly through the board of directors as a whole, as well as through various standing committees of our board of directors that address risks inherent in their
respective </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
areas of oversight. In particular, our board of directors is responsible for monitoring and assessing strategic risk exposure and our audit committee has the responsibility to consider and
discuss our major financial risk exposures and the steps our management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. The audit
committee also monitors compliance with legal and regulatory requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Committees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance committee, each of which
will operate under a charter to be adopted by our board of directors and which, together with the composition of each committee, will become effective upon the effectiveness of the registration statement of which this prospectus forms a part. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Audit Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The members of our audit committee
are&#8195;&#8195;&#8195;&#8195;,&#8195;&#8195;&#8195;&#8195;and&#8195;&#8195;&#8195;&#8195;.&#8195;&#8195;&#8195;&#8195;is the chair of the audit committee. Effective upon the effectiveness of the registration statement of which this prospectus
forms a part, our audit committee&#8217;s responsibilities will include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">appointing, evaluating, and when necessary, terminating and setting the compensation of, and overseeing the independence of
our registered public accounting firm; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">overseeing the work of our independent registered public accounting firm, including through the receipt and consideration
of reports from that firm; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly
financial statements and related disclosures; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">coordinating our board of director&#8217;s oversight of our internal control over financial reporting, disclosure controls
and procedures and code of business conduct and ethics; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">overseeing our risk assessment and risk management policies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establishing procedures for the receipt, retention and treatment of accounting related complaints and concerns;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">meeting independently with our internal auditing staff, if any, our independent registered public accounting firm and
management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and approving or ratifying any related person transactions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">preparing the audit committee report required by SEC rules. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">All audit and <FONT STYLE="white-space:nowrap">non-audit</FONT> services, other than <I>de minimis</I> <FONT STYLE="white-space:nowrap">non-audit</FONT>
services, to be provided to us by our independent registered public accounting firm must be approved in advance by our audit committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board
of directors has determined that&#8195;&#8195;&#8195;&#8195;is an &#8220;audit committee financial expert&#8221; as defined in applicable SEC rules and that each of the members of our audit committee possesses the financial sophistication required
for audit committee members under Nasdaq rules. We believe that the composition of our audit committee will meet the requirements for independence under current Nasdaq and SEC rules and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our audit committee will operate under a written charter, which will be effective upon the completion of this offering, that satisfies the applicable
Nasdaq Listing Rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The members of our compensation committee
are&#8195;&#8195;&#8195;&#8195;,&#8195;&#8195;&#8195;&#8195;and&#8195;&#8195;&#8195;&#8195;.&#8195;&#8195;&#8195;&#8195; is the chair of the compensation committee. Effective upon the effectiveness of the registration statement of which this
prospectus forms a part, our compensation committee&#8217;s responsibilities will include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and approving, or making recommendations to our board of directors with respect to, the compensation of our chief
executive officer and our other executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">overseeing an evaluation of our senior executives; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">overseeing and administering our cash and equity incentive plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and making recommendations to our board of directors with respect to director compensation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and discussing annually with management our &#8220;Compensation Discussion and Analysis&#8221; disclosure if and
to the extent then required by SEC rules; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">preparing the compensation committee report if and to the extent then required by SEC rules; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">retaining or obtaining the advice of compensation consultants, legal counsel or other advisors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approving or recommending for approval by our board of directors, the implementation or revision of any compensation
recovery or &#8220;clawback&#8221; policies and overseeing the administration of such policies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe that the composition
of our compensation committee will meet the requirements for independence under current Nasdaq and SEC rules and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our compensation
committee will operate under a written charter, which will be effective upon the completion of this offering, that satisfies the applicable Nasdaq Listing Rules. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Nominating and Corporate Governance Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The
members of our nominating and corporate governance committee are&#8195;&#8195;&#8195;&#8195; ,&#8195;&#8195;&#8195;&#8195;and&#8195;&#8195;&#8195;&#8195;.&#8195;&#8195;&#8195;&#8195;is the chair of the nominating and corporate governance committee.
Effective upon the effectiveness of the registration statement of which this prospectus forms a part, our nominating and corporate governance committee&#8217;s responsibilities will include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">identifying individuals and recommending to our board of directors the nominees for election as directors and to each of
our board&#8217;s committees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and making recommendations to our board with respect to our board leadership structure; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and making recommendations to our board with respect to management succession planning; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">developing and recommending to our board of directors corporate governance principles; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">overseeing a periodic evaluation of our board of directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe that the composition of our nominating and corporate governance committee will meet the requirements for independence under current Nasdaq
and SEC rules and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our nominating and corporate governance committee will operate under a written charter, which will be effective upon
the completion of this offering, that satisfies the applicable Nasdaq Listing Rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">None of our executive officers serves, or in the past year has served, as a member of the board of directors or compensation committee, or other
committee serving an equivalent function, of any other entity that has one or more of its executive officers serving as a member of our board of directors or our compensation committee. None of the members of our compensation committee is, or has
ever been, an officer or employee of our company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Code of Ethics and Code of Conduct </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We intend to adopt, upon the effectiveness of the registration statement of which this prospectus is a part, a written code of business conduct and
ethics that applies to our directors, officers, and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. We intend to post a current
copy of the code on our website, www.hemab.com. In addition, we intend to post on our website all disclosures that are required by law or Nasdaq listing standards concerning any amendments to, or waivers from, any provision of the code. Our website
is not incorporated by reference into this prospectus, and you should not consider any information contained in or accessible from our website to be a part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_13"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following discussion relates to the compensation of Benny S&oslash;rensen, our president and chief executive officer, Mads Behrndt, our chief
financial officer and general manager, and Catherine Madigan, our chief medical officer. Dr.&nbsp;S&oslash;rensen, Mr.&nbsp;Behrndt, and Dr.&nbsp;Madigan are collectively referred to in this prospectus as our named executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In preparing to become a public company, we have begun a thorough review of all elements of our executive compensation program, including the function
and design of our equity incentive programs. We have begun, and expect to continue in the coming months, to evaluate the need for revisions to our executive compensation program to ensure that our program is competitive with the companies with which
we compete for executive talent and is appropriate for a public company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth information regarding compensation awarded to, earned by or paid to each of our named executive officers for the year
ended December&nbsp;31, 2025. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive Plan<BR>Compensation<BR>($)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Benny S&oslash;rensen (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">561,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">238,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,501</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">819,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Mads Behrndt (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">493,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,112</TD>
<TD NOWRAP VALIGN="bottom">(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">689,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><I>Chief Financial Officer and General Manager</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Catherine Madigan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">457,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,267,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,241</TD>
<TD NOWRAP VALIGN="bottom">(7)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,907,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><I>Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The amount reported in the &#8220;Option Awards&#8221; column reflects the aggregate grant date fair value of warrants
granted during 2025 and computed in accordance with the provisions of Financial Accounting Standards Board Accounting Standards Codification Topic 718. See Note 2 to our financial statements appearing elsewhere in this prospectus regarding
assumptions underlying the valuation of equity awards. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The amounts reported in the <FONT STYLE="white-space:nowrap">&#8220;Non-Equity</FONT> Incentive Plan Compensation&#8221;
column represent performance-based cash bonuses earned by our named executive officers in the year ended December&nbsp;31, 2025, which amounts were paid in February 2026. See &#8220;&#8212;<I>Narrative Disclosure to Summary Compensation
Table&#8212;Annual Bonus</I>&#8221; below for a general description of the criteria that our board of directors used to determine the performance-based cash bonuses. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Dr.&nbsp;S&oslash;rensen also serves as a member of our board of directors but does not receive any additional
compensation for service as a director. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">All other compensation for 2025 to Dr.&nbsp;S&oslash;rensen reflects: (1)&nbsp;matching contributions of $18,535 made by
us under our 401(k) plan and (2)&nbsp;premiums of $966 paid by us during 2025 with respect to life insurance policies. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">For Mr.&nbsp;Behrndt, amounts reported in the Salary, <FONT STYLE="white-space:nowrap">Non-Equity</FONT> Incentive Plan
Compensation, and All Other Compensation columns were paid in Danish kroner and converted to U.S. dollars using a U.S. dollar/Danish kroner exchange rate of 0.1573 (rounded to 0.16) as of December&nbsp;31, 2025. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">All other compensation for 2025 to Mr.&nbsp;Behrndt reflects a contribution to our Pension Plan (as defined below) for
Mr.&nbsp;Behrndt. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">All other compensation for 2025 to Dr.&nbsp;Madigan reflects: (1)&nbsp;matching contributions of $12,312 made by us under
our 401(k) plan and (2)&nbsp;premiums of $929 paid by us during 2025 with respect to life insurance policies. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Narrative Disclosure to Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Base Salary.</I> In 2025, we paid Dr.&nbsp;S&oslash;rensen an annualized base salary of $561,269, Mr.&nbsp;Behrndt an annualized base salary of DKK
3,083,535, and Dr.&nbsp;Madigan an annualized base salary of $457,019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We use base salaries to recognize the experience, skills, knowledge, and
responsibilities required of all our employees, including our named executive officers. None of our named executive officers is currently party to an employment agreement or other agreement or arrangement that provides for automatic or scheduled
increases in base salary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Annual Bonus.</I> Our board of directors may, in its discretion, award annual cash bonuses to our named executive
officers from time to time based on the executive&#8217;s achievement of milestones for the applicable year. Our existing employment arrangements with our named executive officers provide that they will be eligible for annual cash bonuses up to a
specified percentage of their salary (50% for Dr.&nbsp;S&oslash;rensen, 40% for Mr.&nbsp;Behrndt, and 40% for Dr. Madigan), subject to approval by our board of directors. Annual cash bonuses, which are calculated as a percentage of base salary, are
designed to motivate our employees to achieve annual goals based on our strategic, financial and operating performance objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">With respect to
2025, our board of directors awarded performance-based cash bonuses of $238,900, DKK 1,085,400 and $170,300 to Dr.&nbsp;S&oslash;rensen, Mr.&nbsp;Behrndt and Dr.&nbsp;Madigan, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Equity Incentives.</I> To further align the interests of our executive officers with the interests of our stockholders and to further focus our
executive officers on our long-term performance, we have historically granted equity compensation in the form of warrants. Warrants operate in a manner similar to options in that the recipient is allowed to exercise the warrant and receive shares
upon exercise, with the exercise price determined by the board of directors in connection with each issuance of warrants at the time of grant. Please see the &#8220;<I>Outstanding Equity Awards at December</I><I></I><I>&nbsp;31, 2025</I>&#8221;
table for further information regarding the outstanding warrants held by our named executive officers as of December&nbsp;31, 2025. In connection with the corporate reorganization, each outstanding warrant to subscribe for the purchase of ordinary
shares of Hemab ApS was assumed by us and converted into a warrant to purchase the same number of shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>All Other
Compensation. </I>We provide an employer-matching contribution on the behalf of our U.S.-based employees under our 401(k) plan of up to 3.5% of their respective eligible compensation as well as payment of insurance premiums on our employees&#8217;
behalf. We also provide a pension plan, or the Pension Plan, to all of our employees in Denmark. Contributions to the Pension Plan for each Denmark-based employee are calculated as a percentage of base salary and paid to an external pension fund.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Outstanding Equity Awards at December&nbsp;31, 2025 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth information regarding all outstanding warrants to subscribe for ordinary shares of Hemab ApS held by each of our named
executive officers as of December&nbsp;31, 2025. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Option Awards</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Number of
securities<BR>underlying<BR>unexercised&nbsp;options&nbsp;(#)<BR>exercisable <BR></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Number
of<BR>securities<BR>underlying<BR>unexercised&nbsp;options&nbsp;(#)</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>unexercisable <BR></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Option<BR>exercise<BR>price <BR>($) <BR></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Option<BR>expiration<BR>date <BR></B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Benny S&oslash;rensen, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,492</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138.64(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/01/2031</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,451</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49.22(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">03/20/2032</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,676</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,762(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155.50</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">08/23/2033</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Mads Behrndt, M.Sc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,317</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49.22(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">03/20/2032</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,204</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,911(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155.50</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">08/28/2033</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Catherine Madigan, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,511(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168.72</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/10/2035</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Of the shares underlying the warrant, 25% vested on March&nbsp;1, 2024, and the remaining shares vest in 36 equal monthly
installments thereafter, subject to the officer&#8217;s continued service through each vesting date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Of the shares underlying the warrant, 25% vested on January&nbsp;1, 2026, and the remaining shares vest in 36 equal
monthly installments thereafter, subject to the officer&#8217;s continued service through each vesting date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Converted from Danish kroner to U.S. dollars using a U.S. dollar/Danish kroner exchange rate of 0.1573 (rounded to 0.16)
as of December&nbsp;31, 2025. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employment Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to the completion of this offering, we expect to enter into written employment agreements with each of our executive officers. These agreements are
expected to set forth the terms of the executive officer&#8217;s compensation, including base salary, annual discretionary bonus eligibility and severance benefits, among other matters. Our named executive officers are eligible to participate in
company-sponsored benefit programs that are generally available to all of our similarly-situated employees. Under these agreements, each named executive officer is also eligible to receive equity awards at such times and on such terms and conditions
as the board of directors may determine. Furthermore, each of our named executive officers has entered into a standard confidential information and inventions assignment agreement with us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Equity Compensation Plans and Other Benefit Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In
connection with this offering, our board of directors expects to adopt, and our current stockholders expect to approve, the 2026 Plan and the 2026 ESPP. Prior to this offering, we granted equity compensation in the form of warrants. Following this
offering, we expect to grant awards to eligible participants from time to time only under the 2026 Plan. In this section, we describe the 2026 Plan and the 2026 ESPP. These summaries of the equity incentive plans are qualified in their entirety by
reference to the actual text of the of plans, which are filed as exhibits to the registration statement of which this prospectus is a part. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>2026 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect our board of directors to adopt and that our stockholders will approve the 2026 Plan, to become effective immediately prior to the
effectiveness of the registration statement of which this prospectus forms a part. The 2026 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock
units and other stock-based awards. Upon effectiveness of the 2026 Plan, the number of shares of our common stock that will be reserved for issuance under the 2026 Plan will be the sum of (1)&#8195;&#8195;&#8195;&#8195;; (2)&nbsp;the number of
shares of our common stock subject to warrants that are outstanding as of immediately prior to the effectiveness of the registration statement for the offering and which warrants expire, terminate or are otherwise cancelled without the issuance of
shares of common stock (subject to any limitations under the U.S. Internal Revenue Code of 1986, as amended, or the Code); plus (3)&nbsp;an annual increase, to be added on the first day of each fiscal year, beginning with the fiscal year ending
December&nbsp;31, 2027 and continuing until, and including, the fiscal year ending December&nbsp;31, 2036, equal to the lowest of (i)&nbsp;5% of the sum of (I)&nbsp;the number of shares of our common stock outstanding on such date and (II)&nbsp;the
number of shares of our common stock subject to <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants or other investment warrants issued by us (without giving effect to any restrictions or limitations on conversion) as of such date, and
(ii)&nbsp;an amount determined by our board of directors. A maximum of&#8195;&#8195;&#8195;&#8195; shares of common stock may be issued pursuant to incentive stock options granted under the 2026 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our employees, officers, directors, consultants and advisors are eligible to receive awards under the 2026 Plan; however, incentive stock options may
only be granted to our employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the terms of the 2026 Plan, our board of directors (or a committee delegated by our board of
directors) will administer the 2026 Plan and, subject to any limitations set forth in the 2026 Plan, will select the recipients of awards and determine: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of shares of our common stock covered by options and the dates upon which the options become exercisable;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the type of options to be granted; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the exercise price of options, which price must be at least equal to the fair market value of our common stock on the date
of grant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the duration of options, which may not be in excess of ten years; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the methods of payment of the exercise price of options; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of shares of our common stock subject to and the terms and conditions of any stock appreciation rights, awards
of restricted stock, restricted stock units or other stock-based awards, including conditions for repurchase, measurement price, issue price and repurchase price, if any (though the measurement price of stock appreciation rights must be at least
equal to the fair market value of our common stock on the date of grant and the duration of such awards may not be in excess of ten years) and any performance conditions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If our board of directors delegates authority to one or more delegated persons to grant awards under the 2026 Plan, the delegated person will have the
power to make awards to all of our employees, except officers and executive officers (as such terms are defined in the 2026 Plan). Our board of directors will fix (i)&nbsp;the maximum number of shares that may be issued (which number shall include,
for the avoidance of doubt, the maximum number of shares issuable upon exercise or settlement of awards), (ii) the time period during which such awards, and during which the shares issuable upon exercise thereof, may be issued, and (iii)&nbsp;the
minimum consideration (if any) for which such awards may be issued, and the minimum consideration for the shares issuable upon exercise thereof; provided, however that no delegated person may be authorized to grant awards to itself. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The 2026 Plan contains limits on the compensation that may be paid to our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors. The maximum aggregate amount of cash and value (calculated based on grant date fair value for financial reporting purposes) of awards granted under the plan in any calendar year to any
individual <FONT STYLE="white-space:nowrap">non-employee</FONT> director in his or her capacity as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director may not exceed $750,000, or in the case of a new director during his or her first year
of service, $1,000,000; provided, however, that fees paid by us on behalf of any <FONT STYLE="white-space:nowrap">non-employee</FONT> director in connection with regulatory compliance, any amounts paid or awards made pursuant to a bona fide
consulting agreement for services other than as a director, any amounts paid to a <FONT STYLE="white-space:nowrap">non-employee</FONT> director as reimbursement of an expense and any financial statement expense associated with the modification of an
outstanding award (whether or not granted under the 2026 Plan) shall not count against the foregoing limit. Our board of directors may make additional exceptions to this limit for individual <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors in extraordinary circumstances, as the board of directors may determine in its discretion, provided that the <FONT STYLE="white-space:nowrap">non-employee</FONT> director receiving such additional compensation may not participate in the
decision to award such compensation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Effect of certain changes in capitalization </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares, <FONT
STYLE="white-space:nowrap">spin-off</FONT> or other similar change in capitalization or event, or any dividend or distribution to holders of our common stock other than an ordinary cash dividend, we are required by the 2026 Plan to make equitable
adjustments (or make substitute awards, if applicable), in the manner determined by our board of directors, to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number and class of shares available under the 2026 Plan, and the number and class of shares available for issuance
under the 2026 Plan that may be issued as incentive stock options under the Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the share counting rules of the 2026 Plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number, class, exercise, measurement or purchase price and any other per share related provisions of shares subject to
each outstanding award; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any performance goals applicable to an award. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Effect of certain corporate transactions </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon the occurrence
of a merger or other reorganization event (as defined in the 2026 Plan), our board of directors may, on such terms as our board of directors determines (except to the extent specifically provided otherwise in an applicable award agreement or other
agreement between the participant and us), take any one or more of the following actions pursuant to the 2026 Plan as to all or any (or any portion of) outstanding awards, other than awards of restricted stock: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that outstanding awards will be assumed, or substantially equivalent awards will be substituted, by the acquiring
or succeeding corporation (or an affiliate thereof); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">upon written notice to a participant, provide that all of the participant&#8217;s unvested awards will be forfeited
immediately prior to the consummation of such reorganization event and/or vested but unexercised awards will terminate immediately prior to the consummation of such transaction unless exercised, to the extent exercisable, by the participant within a
specified period following the date of such notice; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that outstanding awards will become exercisable, realizable or deliverable, or restrictions applicable to an award
will lapse, in whole or in part, prior to or upon the reorganization event; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">make or provide for a payment in such form (which may include, without limitation, cash, cash equivalents and/or securities
of the acquiring or succeeding corporation (or an affiliate thereof)) to participants with respect to an award held by a participant equal to (1)&nbsp;the number of shares of our common stock subject to the vested portion of the award (after giving
effect to any acceleration of vesting that occurs upon or immediately prior to such reorganization event) multiplied by (2)&nbsp;the excess, if any, of (i)&nbsp;the amount of cash and/or value, as determined by our board of directors in its
discretion, of any <FONT STYLE="white-space:nowrap">non-cash</FONT> consideration per share of common stock to be received by holders of common stock as a result of the reorganization event (referred to as the acquisition price) over (ii)&nbsp;the
exercise, measurement or purchase price of such award and any applicable tax withholdings, in exchange for the termination of such award, <I>provided</I> that any escrow, holdback, earn out or similar provisions in the definitive agreement governing
the reorganization event may, as determined by our board of directors, apply to such payment to the same extent and in the same manner as such provisions apply to holders of our common stock, and <I>provided further</I> that if the acquisition price
does not exceed the exercise price of such award, then the award shall be cancelled without any payment of consideration therefor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that, in connection with our liquidation or dissolution, awards shall convert into the right to receive liquidation
proceeds (if applicable, net of the exercise, measurement or purchase price thereof and any applicable tax withholdings); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any combination of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In taking any of the foregoing actions, our board of directors is not obligated by the 2026 Plan to treat all awards, all awards held by a participant,
or all awards of the same type, identically. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the case of certain restricted stock units, no assumption or substitution is permitted, and the
restricted stock units will instead be settled in accordance with the terms of the applicable restricted stock unit agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of
directors may impose a limitation on the ability of participants holding options and/or stock appreciation rights to exercise their awards for the minimum number of days prior to the closing of the reorganization event as is reasonably necessary to
facilitate the orderly closing of the reorganization event. We shall provide reasonable notice to participants of any such limitation on exercise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon the occurrence of a reorganization event other than our liquidation or dissolution, our repurchase and other rights with respect to each
outstanding award of restricted stock will continue for the benefit of the acquiring or succeeding company (or any affiliate thereof) and will, unless our board of directors determines otherwise, apply to the cash, securities, or other property
which our common stock is converted into or exchanged for pursuant to the reorganization event in the same manner and to the same extent as they applied to the common stock subject to the restricted stock award; provided, however, that our board of
directors may provide for the termination or deemed satisfaction of such repurchase or other rights under the restricted stock award agreement or in any other agreement between a participant and us, either initially or by amendment, or to provide
for forfeiture of such restricted stock if issued at no cost. Upon the occurrence of a reorganization event involving our liquidation or dissolution, except to the extent specifically provided to the contrary in the restricted stock award agreement
or any other agreement between the participant and us, all restrictions and conditions on each outstanding restricted stock award will automatically be deemed terminated or satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of directors may, at any time, provide that any award under the 2026 Plan will become immediately exercisable in whole or in part, free of
some or all restrictions or conditions, or otherwise realizable in whole or in part, as the case may be. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Except with respect to certain actions requiring stockholder approval under the Code, or Nasdaq Stock
Market rules, our board of directors may amend, modify or terminate any outstanding award under the 2026 Plan, including but not limited to, substituting for the award another award of the same or a different type, changing the date of exercise or
realization, and converting an incentive stock option to a nonstatutory stock option, subject to certain participant consent requirements. In addition, our board of directors may, without the approval of our stockholders: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">amend any outstanding stock option or stock appreciation right granted under the 2026 Plan to provide an exercise or
measurement price per share that is lower than the then-current exercise or measurement price per share of such outstanding award; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">cancel any outstanding stock option or stock appreciation right (whether or not granted under the 2026 Plan) and grant a
new award under the 2026 Plan in substitution for the cancelled award covering the same or a different number of shares of our common stock and having an exercise or measurement price per share lower than the then-current exercise or measurement
price per share of the cancelled award; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">cancel in exchange for a cash payment any outstanding option or stock appreciation right with an exercise or measurement
price per share above the then-current fair market value of our common stock (valued in the manner determined by (or in the manner approved by) our board of directors); or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">take any other action that constitutes a &#8220;repricing&#8221; within the meaning of Nasdaq Stock Market rules or rules
of any other exchange or marketplace on which our common stock is listed or traded. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">No award may be granted under the 2026 Plan
on or after the date that is ten years from the effectiveness of the 2026 Plan. Our board of directors may amend, suspend or terminate the 2026 Plan at any time, except that stockholder approval may be required to comply with applicable law or stock
market requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>2026 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect our board of directors to adopt and that our stockholders will approve the 2026 ESPP, to become effective immediately prior to the
effectiveness of the registration statement of which this prospectus forms a part. The 2026 ESPP will be administered by our board of directors or by a committee appointed by our board of directors. The 2026 ESPP initially provides participating
employees with the opportunity to purchase up to an aggregate of&#8195;&#8195;&#8195;&#8195;shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The number of shares of our
common stock reserved for issuance under the 2026 ESPP will automatically increase on the first day of each fiscal year, commencing on January&nbsp;1, 2027 and continuing for each fiscal year until, and including the fiscal year commencing on,
January&nbsp;1, 2036, in an amount equal to the least of (i)&#8195;&#8195;&#8195;&#8195;shares of our common stock, (ii)&nbsp;1% of the sum of (I)&nbsp;the number of shares of our common stock outstanding on such date and (II)&nbsp;the number of
shares of our common stock subject to <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants or other investment warrants issued by us as of such date, and (iii)&nbsp;an amount determined by our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the terms of the 2026 ESPP, our board of directors (or a committee delegated by our board of directors) will administer the 2026 ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">All of our employees and employees of any designated subsidiary, as defined in the 2026 ESPP, are eligible to participate in the 2026 ESPP, provided
that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">such person is customarily employed by us or a designated subsidiary for more than 20 hours a week and for more than five
months in a calendar year; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">such person has been employed by us or by a designated subsidiary for at least three months prior to the first day of the
applicable plan period (as defined in the 2026 ESPP); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">such person was our employee or an employee of a designated subsidiary on the first day of the applicable plan period under
the 2026 ESPP. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We retain the discretion to determine which eligible employees may participate in an offering under applicable
regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect to make one or more offerings to our eligible employees to purchase stock under the 2026 ESPP beginning at such time and on
such dates as our board of directors may determine, or on the first business day thereafter. Each offering will consist of a <FONT STYLE="white-space:nowrap">six-month</FONT> plan period during which payroll deductions will be made and held for the
purchase of our common stock at the end of the plan period. Our board of directors or a committee designated by our board of directors may, at its discretion, choose a different period of not more than
<FONT STYLE="white-space:nowrap">twenty-seven</FONT> months for offerings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On each offering commencement date, each participant will be granted an
option to purchase, on the last business day of the plan period, up to a number of shares of our common stock determined by multiplying $2,083 by the number of full months in the plan period and dividing that product by the closing price of our
common stock on the first day of the plan period. No employee may be granted an option under the 2026 ESPP that permits the employee&#8217;s rights to purchase shares under the 2026 ESPP and any other employee stock purchase plan of ours or of any
of our subsidiaries to accrue at a rate that exceeds $25,000 of the fair market value of our common stock (determined as of the first day of each plan period) for each calendar year in which the option is outstanding. In addition, no employee may
purchase shares of our common stock under the 2026 ESPP that would result in the employee owning 5% or more of the total combined voting power or value of our stock or the stock of any of our subsidiaries. Our board of directors may, in its
discretion, set a fixed maximum number of shares of our common stock that each eligible employee may purchase per plan period which number may not be greater than the number of shares of our common stock determined by applying the formulas and
limitations set forth in the 2026 ESPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On the commencement date of each plan period, each eligible employee may authorize up to a maximum of 15%
of his or her compensation to be deducted by us during the plan period. Each employee who continues to be a participant in the 2026 ESPP on the last business day of the plan period will be deemed to have exercised an option to purchase from us the
number of whole shares of our common stock that his or her accumulated payroll deductions on such date will pay for, not in excess of the maximum numbers set forth above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the terms of the 2026 ESPP, the purchase price will be determined by our board of directors for each plan period, including whether such option
price shall be determined based on the lesser of the closing price of our common stock on (i)&nbsp;the first business day of the plan period or (ii)&nbsp;the exercise date, or shall be based solely on the closing price of the common stock on the
exercise date; provided, however, that such option price will be at least 85% of the applicable closing price of our common stock. If our board of directors does not make a determination of the purchase price, the purchase price will be 85% of the
lesser of the closing price of our common stock on (i)&nbsp;the first business day of the plan period or (ii)&nbsp;the last day of the plan period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">An employee may at any time prior to the close of business on the fifteenth business day prior to the end of the plan period (or such other number of
days as is determined by us), and for any reason, permanently withdraw from participating in the offering and permanently withdraw the balance accumulated in the employee&#8217;s account. If an employee elects to discontinue his or her payroll
deductions during a plan period but does not elect to withdraw his or her funds, funds previously deducted will be applied to the purchase of common stock at the end of the plan period. If a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
participating employee&#8217;s employment ends before the last business day of a plan period, no additional payroll deductions will be taken and the balance in the employee&#8217;s account will
be paid to the employee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We will be required to make equitable adjustments to the extent determined by our board of directors to the number and
class of securities available under the 2026 ESPP, the share limitations under the 2026 ESPP, and the purchase price for a plan period under the 2026 ESPP to reflect stock splits, reverse stock splits, stock dividends, recapitalizations,
combinations of shares, reclassifications of shares, spin-offs and other similar changes in capitalization or events or any dividends or distributions to holders of our common stock other than ordinary cash dividends. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with a merger or other reorganization event, as defined in the 2026 ESPP, our board of directors or a committee of our board of directors
may take any one or more of the following actions as to outstanding options to purchase shares of our common stock under the 2026 ESPP on such terms as our board of directors or committee thereof determines: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that options will be assumed, or substantially equivalent options will be substituted, by the acquiring or
succeeding corporation (or an affiliate thereof); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">upon written notice to employees, provide that all outstanding options will be terminated immediately prior to the
consummation of such reorganization event and that all such outstanding options will become exercisable to the extent of accumulated payroll deductions as of a date specified by board of directors in such notice, which date will not be less than ten
days preceding the effective date of the reorganization event; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">upon written notice to employees, provide that all outstanding options will be cancelled as of a date prior to the
effective date of the reorganization event and that all accumulated payroll deductions will be returned to participating employees on such date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">in the event of a reorganization event under the terms of which holders of our common stock will receive upon consummation
thereof a cash payment for each share surrendered in the reorganization event, change the last day of the plan period to be the date of the consummation of the reorganization event and make or provide for a cash payment to each employee equal to
(1)&nbsp;the cash payment for each share surrendered in the reorganization event times the number of shares of our common stock that the employee&#8217;s accumulated payroll deductions as of immediately prior to the reorganization event could
purchase at the applicable purchase price, where the cash payment for each share surrendered in the reorganization event is treated as the fair market value of our common stock on the last day of the applicable plan period for purposes of
determining the purchase price and where the number of shares that could be purchased is subject to the applicable limitations under the 2026 ESPP minus (2)&nbsp;the result of multiplying such number of shares by the purchase price;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that, in connection with our liquidation or dissolution, options will convert into the right to receive liquidation
proceeds (net of the purchase price thereof); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any combination of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of directors may at any time, and from time to time, amend or suspend the 2026 ESPP or any portion of the 2026 ESPP. We will obtain
stockholder approval for any amendment if such approval is required by Section&nbsp;423 of the Code. Further, our board of directors may not make any amendment that would cause the 2026 ESPP to fail to comply with Section&nbsp;423 of the Code. The
2026 ESPP may be terminated at any time by our board of directors. Upon termination, we will refund all amounts in the accounts of participating employees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Pension Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We provide the Pension Plan to all of our employees in Denmark. Contributions for each employee are calculated as a percentage of base salary and paid to
an external pension fund. For 2025 and 2026, the base salary contribution percentage was 3.5%. All contributions to the Pension Plan begin at the time of employment and cease upon termination of employment, with contributions distributed by the
pension fund to the participant at retirement. In addition to the Pension Plan, we also maintain a 401(k) Plan for our employees in the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>401(k)
Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We maintain the Hemab Therapeutics Inc. 401(k) Plan, a defined contribution employee retirement plan for our eligible employees in the
United States. Our 401(k) plan is intended to qualify as a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> plan under Section&nbsp;401(a) of the Code so that contributions to our 401(k) plan, and income earned on such contributions, are not
taxable to participants until withdrawn or distributed from the plan. Our 401(k) plan provides that each participant may contribute up to 100% of his or her eligible compensation, subject to annual statutory limits under the Code. Eligible employees
may make both <FONT STYLE="white-space:nowrap">pre-tax</FONT> and Roth elective deferral contributions to the plan, as well as <FONT STYLE="white-space:nowrap">catch-up</FONT> contributions for participants who are at least 50 years old, in each
case, subject to applicable statutory limits under the Code. We may make discretionary employer matching contributions under the plan, determined annually at our discretion. In addition, the Code imposes a limit on the amount of compensation that
may be taken into account for plan purposes, including employer contributions. Each employee is always fully vested in his or her own contributions. Employer matching contributions vest based on years of service, with participants becoming fully
vested after completing two years of service with us. Participants direct the investment of their accounts among investment options offered under the plan. The plan is intended to comply with Section&nbsp;404(c) of ERISA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Health and Welfare Benefits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">All of our full-time employees,
including our named executive officers, are eligible to participate in our health and welfare plans, including medical and dental benefits, short-term and long-term disability insurance, and life insurance. We believe these benefits are necessary
and appropriate to provide a competitive compensation package to our named executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Dodd-Frank Compensation Recovery Policy or &#8220;Clawback&#8221;
Policy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with this offering, we intend to adopt a compensation recovery policy in accordance with Nasdaq Listing Rule 5608, which
implements Rule <FONT STYLE="white-space:nowrap">10D-1</FONT> under the Exchange Act. The policy will provide that, in the event that we are required to prepare an accounting restatement due to our material noncompliance with any financial reporting
requirement under U.S. federal securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a
material misstatement if the error were corrected in the current period or left uncorrected in the current period, we will attempt to recover, reasonably promptly from each covered executive, any erroneously awarded incentive-based compensation
received by our covered executives during the recovery period under the policy. The policy will be administered by our compensation committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For
purposes of this policy, covered executives means any person who served as an executive officer (as defined in Rule <FONT STYLE="white-space:nowrap">16a-1(f)</FONT> under the Exchange Act) at any time during the performance period for the applicable
incentive-based compensation. Incentive-based compensation means any compensation that is granted, earned or vested based wholly or in part upon the attainment of (1)&nbsp;measures that are determined and presented in accordance with the accounting
principles used in preparing our financial statements, and any measures that are derived wholly or in part from such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
measures, (2)&nbsp;stock price and (3)&nbsp;total shareholder return. Erroneously awarded incentive-based compensation means the amount of incentive-based compensation that was received that
exceeds the amount of incentive-based compensation that otherwise would have been received had it been determined based on the restated amounts, computed without regard to any taxes paid by the covered executives (or by us on their behalf). If the
incentive-based compensation is based on our stock price or total shareholder return and the amount of the erroneously awarded incentive-based compensation is not subject to recalculation directly from the information in an accounting restatement,
the amount to be recovered shall be based on a reasonable estimate by the compensation committee of the effect of the accounting restatement on the stock price or total shareholder return upon which the incentive-based compensation was received. The
policy will not apply to incentive-based compensation received prior to our adoption of the policy or to incentive-based compensation that was received by a covered executive before beginning service as an executive officer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Limitation of Liability and Indemnification </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our restated
certificate of incorporation, which will become effective immediately prior to the completion of this offering, limits the personal liability of directors and officers for breach of fiduciary duty to the maximum extent permitted by the Delaware
General Corporation Law, or the DGCL, and provides that no director or officer will have personal liability to us or to our stockholders for monetary damages for a breach of their fiduciary duty of care as a director or officer. However, these
provisions do not eliminate or limit the liability of any of our directors or officers: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">for any breach of the director&#8217;s or officers&#8217; duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">for voting for or assenting to unlawful payments of dividends, stock repurchases or other distributions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">for our officers, any derivative action by or in the right of the corporation; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">for any transaction from which the director or officer derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any amendment to or repeal of these provisions will not eliminate or reduce the effect of these provisions in respect of any act, omission, or claim
that occurred or arose prior to such amendment or repeal. If the DGCL is amended to provide for further limitations on the personal liability of directors or officers of corporations, then the personal liability of our directors and officers will be
further limited to the greatest extent permitted by the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, our restated certificate of incorporation, which will become effective
immediately prior to the completion of this offering, provides that we must indemnify our directors and officers and we must advance expenses, including attorneys&#8217; fees, to our directors and officers in connection with legal proceedings,
subject to very limited exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We maintain a general liability insurance policy that covers specified liabilities of our directors and
officers arising out of claims based on acts or omissions in their capacities as directors or officers. In addition, we intend to enter into indemnification agreements with all of our executive officers and directors prior to the completion of this
offering. These indemnification agreements may require us, among other things, to indemnify each such executive officer or director for some expenses, including attorneys&#8217; fees, judgments, fines, and settlement amounts incurred by him or her
in any action or proceeding arising out of his or her service as one of our executive officers or directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Some of our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors may, through their relationships with their employers, be insured or indemnified against specified liabilities incurred in their capacities as members of our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Insofar as indemnification for liabilities arising under the Securities Act, may be permitted to
directors, executive officers, or persons controlling us, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> Sales Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our directors and executive officers may adopt written plans, known as Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plans, in which they will
contract with a broker to buy or sell shares of our common stock on a periodic basis. Under a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan, a broker executes trades pursuant to parameters established by the director or officer when
entering into the plan, without further direction from the director or officer. It also is possible that the director or officer could amend or terminate the plan when not in possession of material, nonpublic information. In addition, our directors
and executive officers may buy or sell additional shares outside of a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan when they are not in possession of material, nonpublic information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Director Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The table below shows all compensation
to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors during the year ended December&nbsp;31, 2025. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned&nbsp;or</B><br><B>Paid&nbsp;in&nbsp;Cash&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option&nbsp;Awards</B><br><B>($)(1)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">John Maraganore, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Joseph Anderson, Ph.D.(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Linda Bain</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dan Becker, M.D., Ph.D.(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Uya Chuluunbaatar, Ph.D.(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Laura Tadvalkar, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Akshay Vaishnaw, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">(7)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">J&oslash;rgen S&oslash;berg Petersen, M.D., Ph.D., D.M.Sc., M.B.A(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">M&aring;rten Steen, M.D., Ph.D.(8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The amount reported in the &#8220;Option Awards&#8221; column reflects the aggregate grant date fair value of warrants
granted during 2025 and computed in accordance with the provisions of Financial Accounting Standards Board Accounting Standards Codification Topic 718. See Note 2 to our financial statements appearing elsewhere in this prospectus regarding
assumptions underlying the valuation of equity awards. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">As of December&nbsp;31, 2025, the aggregate number of ordinary shares subject to outstanding warrants for each <FONT
STYLE="white-space:nowrap">non-employee</FONT> director was as follows: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="18%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate&nbsp;Number&nbsp;of<BR>Ordinary Shares<BR>Underlying<BR>Outstanding<BR>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">John Maraganore, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Joseph Anderson, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Linda Bain</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dan Becker, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Uya Chuluunbaatar, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Laura Tadvalkar, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Akshay Vaishnaw, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">J&oslash;rgen S&oslash;berg Petersen, M.D., Ph.D., D.M.Sc., M.B.A</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">M&aring;rten Steen, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">214 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The amounts reported in the &#8220;All Other Compensation&#8221; column represent reimbursements we paid related to
travel expenses. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Reflects fees paid to Dr.&nbsp;Maraganore as the chair of our board of directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Each of Dr. Anderson, Dr. Becker, Dr. Chuluunbaatar and Dr. Petersen resigned from our board of directors in April 2026.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Reflects fees paid to Ms.&nbsp;Bain as a member of our board of directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Reflects fees paid to Dr.&nbsp;Vaishnaw as a member of our board of directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Dr.&nbsp;Steen no longer serves on our board of directors as of November 2025. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to this offering, we paid cash fees and granted warrants to subscribe for ordinary shares to certain of our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors for their service on our board of directors. We have reimbursed our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, on an as requested basis, for reasonable travel and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with attending board of director and committee meetings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Dr.&nbsp;S&oslash;rensen, one of our directors who also serves as our president and chief executive officer, does not receive any additional
compensation for his service as a director. Dr.&nbsp;S&oslash;rensen is one of our named executive officers and, accordingly, the compensation that we pay to Dr.&nbsp;S&oslash;rensen is discussed above under &#8220;&#8212;<I>Summary Compensation
Table</I>&#8221; and &#8220;&#8212;<I>Narrative Disclosure to Summary Compensation Table</I>.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In&#8195;&#8195;&#8195;&#8195;, 2026, our
board of directors approved a director compensation program that will become effective on the effective date of the registration statement of which this prospectus is a part. Under this director compensation program, we will pay our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors a cash retainer for service on the board of directors and for service on each committee on which the director is a member. The chair of the board of directors and of each committee will
receive higher retainers for such service. These fees are payable in arrears in four equal quarterly installments on the last day of each quarter, provided that (i) the amount of such payment will be prorated for any portion of such quarter (based
on the number of days served in the applicable quarter) that the director is not serving on our board of directors, on such committee or in such position, and (ii)&nbsp;no retainer under the program will be payable in respect of any period prior to
the completion of this offering and the first payment under the program will be prorated. The cash retainers paid to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for service on the board of directors and for service on each
committee of the board of directors on which the director is a member are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Member<BR>Annual<BR>Fee</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Chair</B><br><B>Incremental</B><br><B>Annual Fee</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Board of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Audit Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Compensation Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Nominating and Corporate Governance Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We also will continue to reimburse our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for reasonable
travel and other expenses incurred in connection with attending meetings of our board of directors and any committee of our board of directors on which he or she serves. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, under our director compensation program to be effective on the effective date of the registration statement of which this prospectus is a
part, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director will receive, upon his or her initial election or appointment to our board of directors, an option to purchase&#8195;&#8195;&#8195;&#8195;shares of our common stock under the
2026 Plan. Each of these options will vest as to&#8195;% of the shares of our common stock underlying such option at the end of each successive&#8195;&#8195;&#8195;&#8195;period following the grant date until
the&#8195;&#8195;&#8195;&#8195;anniversary of the grant date, subject to the <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#8217;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">215 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
continued service as a director through the applicable vesting date. Further, on the date of the first board meeting held after each annual meeting of stockholders commencing with
our&#8195;&#8195;&#8195;&#8195; annual meeting of stockholders, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director will receive an option to purchase&#8195;&#8195;&#8195;&#8195;shares of our common stock under the 2026 Plan;<B>
</B>provided, however, that for a <FONT STYLE="white-space:nowrap">non-employee</FONT> director who was initially elected to our board of directors within the 12 months preceding the annual meeting of stockholders, the number of shares subject to
such option shall be prorated based on the number of days served by such director during the preceding year. The foregoing share numbers for initial and annual option grants to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors are
subject to adjustment in the event of stock splits, reverse stock splits and other events. Each of these options will vest on the one-year anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of
stockholders following the date of grant of the award). All options issued to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors under our director compensation program will be issued at exercise prices equal to the fair market value
of our common stock on the date of grant, will vest based on continued service, and will become exercisable in full upon specified change in control events. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">216 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_14"></A>TRANSACTIONS WITH RELATED PERSONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since January&nbsp;1, 2023, we have engaged in the following transactions in which the amounts involved exceeded $120,000 and any of our directors,
executive officers or holders of more than 5% of our voting securities, or any member of the immediate family of, or person sharing the household with, the foregoing persons, had or will have a direct or indirect material interest. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Agreements and Transactions with Stockholders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Series B Preference
Shares Financing </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In February 2023, we issued and sold an aggregate of 442,205 shares of our Series B Preference Shares at a purchase price
of $305.85 per share for aggregate gross proceeds of $135,248,399.25. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth the aggregate number of shares of our Series B
Preference Shares that were issued to our directors, executive officers and holders of more than 5% of our voting securities and their affiliates in the transaction and the aggregate amount of consideration for such shares: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Purchaser (1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of&nbsp;Series&nbsp;B<BR>Preference&nbsp;Shares<BR>Purchased&nbsp;for&nbsp;Cash&nbsp;(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total Cash<BR>Purchase&nbsp;Price&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">AI <FONT STYLE="white-space:nowrap">DEN-MAB</FONT> LLC (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,999,944.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with Deep Track Capital, LP (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,999,837.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Novo Holdings A/S (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,999,707.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with RA Capital Management, L.P. (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,499,948.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Avoro Ventures Fund L.P. (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,999,718.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">HealthCap VIII, L.P. (7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,499,747.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">John Maraganore (8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">249,879.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">See &#8220;<I>Principal Stockholders</I>&#8221; for additional information about shares held by these entities.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">AI <FONT STYLE="white-space:nowrap">DEN-MAB</FONT> LLC is a holder of five percent or more of our capital stock. Dan
Becker, M.D., Ph.D., who was a member of our board of directors until his resignation in April 2026, is the managing director of Access Biotechnology, the biopharmaceutical investing arm of Access Industries Management, LLC, which controls Access
Industries Holdings LLC, which directly controls all of the outstanding voting interest in AI <FONT STYLE="white-space:nowrap">DEN-MAB</FONT> LLC. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Entities affiliated with Deep Track Capital, LP are holders of five percent or more of our capital stock.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Novo Holdings A/S, or Novo Holdings, is a holder of five percent or more of our capital stock. J&oslash;rgen
S&oslash;berg Petersen, who was a member of our board of directors until his resignation in April 2026, is employed as a senior partner at Novo Holdings. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Entities affiliated with RA Capital Management, L.P. are holders of five percent or more of our capital stock. Laura
Tadvalkar, Ph.D., a member of our board of directors, is a managing director at RA Capital Healthcare Fund, L.P. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Entities affiliated with Avoro Ventures are holders of five percent or more of our capital stock. Uya Chuluunbaatar,
Ph.D., who was a member of our board of directors until her resignation in April 2026, is a partner at Avoro Ventures. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">HealthCap VIII, L.P., or HealthCap, is a holder of five percent or more of our capital stock. Novo Holdings is also an
investor in HealthCap. M&aring;rten Steen, M.D., who was a member of our board of directors until his resignation in November 2025, is a managing partner of HealthCap. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">John Maraganore is the chair of our board of directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Series C Preference Shares Financing </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In October 2025,
we issued and sold an aggregate of 512,991 shares of our Series C Preference Shares at a purchase price of $305.85 per share for aggregate gross proceeds of $156,898,297.35. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">217 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth the aggregate number of shares of our Series C Preference Shares that
were issued to our directors, executive officers and holders of more than 5% of our voting securities and their affiliates in the transaction and the aggregate amount of consideration for such shares: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Purchaser (1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of&nbsp;Series&nbsp;C<BR>Preference Shares</B><br><B>Purchased&nbsp;for&nbsp;Cash&nbsp;(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total Cash</B><br><B>Purchase&nbsp;Price&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Sofinnova Crossover II SLP (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,999,991.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">SMALLCAP World Fund, Inc. (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,999,908.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with RA Capital Management, L.P. (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,499,902.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">AI <FONT STYLE="white-space:nowrap">DEN-MAB</FONT> LLC (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,499,819.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with Avoro Ventures (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,999,848.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with Deep Track Capital, LP (7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,499,830.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Novo Holdings A/S (8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,999,765.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">John Maraganore (9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">249,879.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">See &#8220;<I>Principal Stockholders</I>&#8221; for additional information about shares held by these entities and
person. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Sofinnova Crossover II SLP, or Sofinnova, is a holder of 5% or more of our capital stock. Joseph Anderson, who was a
member of our board of directors until his resignation in April 2026, is a member of the investment committee of Sofinnova. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">SMALLCAP World Fund, Inc. is a holder of 5% or more of our capital stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Entities affiliated with RA Capital Management, L.P. are holders of five percent or more of our capital stock. Laura
Tadvalkar, Ph.D., a member of our board of directors, is a managing director at RA Capital Healthcare Fund, L.P. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">AI <FONT STYLE="white-space:nowrap">DEN-MAB</FONT> LLC is a holder of five percent or more of our capital stock. Dan
Becker, M.D., Ph.D., who was a member of our board of directors until his resignation in April 2026, and is the managing director of Access Biotechnology, the biopharmaceutical investing arm of Access Industries Management, LLC, which controls
Access Industries Holdings LLC, which directly controls all of the outstanding voting interest in AI <FONT STYLE="white-space:nowrap">DEN-MAB</FONT> LLC. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Entities affiliated with Avoro Ventures are holders of five percent or more of our capital stock. Uya Chuluunbaatar,
Ph.D., who was a member of our board of directors until her resignation in April 2026, is a partner at Avoro Ventures. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Entities affiliated with Deep Track Capital, LP are holders of five percent or more of our capital stock.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Novo Holdings is a holder of five percent or more of our capital stock. J&oslash;rgen S&oslash;berg Petersen, who was a
member of our board of directors until his resignation in April 2026, is employed as a senior partner at Novo Holdings. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">John Maraganore is the chair of our board of directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Corporate Reorganization </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On March&nbsp;30, 2026, we
effected the corporate reorganization. Pursuant to the corporate reorganization, the shareholders of Hemab ApS, including our 5% stockholders, our executive officers, and certain of our directors, contributed and exchanged all of their securities of
Hemab ApS for securities of Hemab Therapeutics Holdings, Inc. See &#8220;<I>Corporate Reorganization</I>&#8221; for additional details. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Management Rights
Letters </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with the issuance and sale of our preference shares of Hemab ApS, Hemab ApS entered into management rights letters
with certain holders of more than 5% of our capital stock and entities with which certain of our directors or officers are affiliated, pursuant to which these entities are entitled to certain management rights, including, among other things, the
right to consult with and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">218 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
advise our management on significant business issues, review operating plans, examine our books and records and inspect our facilities. On March&nbsp;30, 2026, in connection with the corporation
reorganization, Hemab ApS assigned the management rights letters to us. These management rights letters will terminate upon completion of this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Transactions with Novo Holdings and Affiliated Entities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>License
Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Novo Holdings is wholly owned by the Novo Nordisk Foundation and serves as the holding company for the Novo group of companies,
including Novo Nordisk A/S, or Novo Nordisk. In November 2019, we entered into a license agreement with Novo Nordisk, pursuant to which Novo Nordisk granted us an exclusive (even to Novo Nordisk) worldwide and sublicensable license under specified
patent rights, and a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide and sublicensable license under specified <FONT STYLE="white-space:nowrap">know-how,</FONT> to research, develop, make, have made, use, offer for sale, sell,
import, export or otherwise exploit, or transfer possession of or title in, products containing bispecific IgG antibodies targeting <FONT STYLE="white-space:nowrap">TLT-1</FONT> and Factor VII, including sutacimig, for the treatment of bleeding
conditions, including hemophilia. For additional information about our license agreement with Novo Nordisk, see &#8220;<I>Business &#8211; License Agreements &#8211; License Agreement with Novo Nordisk.&#8221;</I> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Preference Shares Financing </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to Novo Holdings
purchasing shares of our Series B Preference Shares and Series&nbsp;C Preference Shares, Novo Holdings is also an investor in HealthCap. HealthCap purchased shares of our Series B Preference Shares in our Series B Preference Shares financing in
February 2023. For more information, see &#8220;<I> &#8211; Series B Preference Shares Financing</I>&#8221; and <I>&#8211; Series C Preference Shares Financing</I>&#8221; above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Agreements with Catalent </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In December 2024, Novo Holdings
completed its acquisition of Catalent, Inc., including its subsidiary, Catalent Pharma Solutions GmbH, or Catalent. In December 2023, we entered into an agreement with Catalent related to the development and manufacturing of sutacimig for
approximately <FONT STYLE="font-family:Times New Roman">&#128;</FONT>1.27&nbsp;million. Additionally, in April 2025, we entered into an agreement with Catalent to perform an analytical study related to sutacimig for approximately <FONT
STYLE="font-family:Times New Roman">&#128;</FONT>1.18&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Registration Rights and Agreements with Stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are a party to an investors&#8217; rights agreement with the holders of our convertible preferred stock, including our 5% stockholders and their
affiliates and entities affiliated with some of our directors. This investors&#8217; rights agreement provides these holders the right, subject to certain conditions, beginning 180 days following the completion of this offering, to demand that we
file a registration statement or to request that their shares be covered by a registration statement that we are&nbsp;otherwise filing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In
addition, we are also a party to voting and right of first refusal and co-sale agreements containing information rights, voting rights and rights of first refusal, among other things, with holders of&nbsp;our convertible preferred stock and certain
holders of our common stock. Our voting agreement provides for drag-along rights in respect of certain transactions approved by the requisite holders of our capital stock. The voting agreement also contains provisions with respect to the composition
of our board of directors and the right of certain of our stockholders to designate directors. These agreements will terminate upon the closing of this offering, except for the registration rights granted under our investors&#8217; rights agreement,
as more fully described in &#8220;<I>Description of Capital Stock &#8211; Registration Rights</I>.&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">219 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to the corporate reorganization, we were party to a shareholders agreement, or the Shareholders
Agreement, with our shareholders, including our 5% shareholders and their affiliates and entities affiliated with some of our directors, that provided for substantially the same rights as those described above, which terminated in connection with
our corporate reorganization. Laura Tadvalkar, a member of our board of directors, is affiliated with entities affiliated with RA Capital Management, L.P., which beneficially owns 5% or more of our voting securities. Dr. Tadvalkar was elected to our
board of directors pursuant to the board composition provisions of the Shareholders Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our restated certificate of incorporation, which will become effective immediately prior to the completion of this offering, provides that we will
indemnify our directors and officers to the fullest extent permitted by Delaware law. In addition, we intend to enter into indemnification agreements with all of our directors and executive officers prior to the completion of this offering. These
indemnification agreements may require us, among other things, to indemnify each such director or executive officer for some expenses, including attorneys&#8217; fees, judgments, fines, and settlement amounts incurred by him or her in any action or
proceeding arising out of his or her service as one of our directors or executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Warrant Grants to Directors and Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have granted warrants to subscribe for ordinary shares to our directors and executive officers as more fully described in the section titled
&#8220;<I>Executive Compensation</I>.&#8221; In connection with the corporate reorganization, each outstanding warrant to subscribe for the purchase of ordinary shares of Hemab ApS was assumed by us and converted into a warrant to purchase the same
number of shares of our common stock, provided that any warrant exercise price that had been denominated in DKK prior to the corporate reorganization was converted into an exercise price in U.S. dollars at the exchange rate as in effect at the close
of business on the business day prior to the corporate reorganization. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employment Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to the completion of this offering, we expect to enter into written employment agreements with each of our executive officers other than Dr.
Murthy. In July 2025, we entered into the Murthy Service Agreement with Ancora Global Advisory AG of which Dr. Murthy is a director, pursuant to which Dr. Murthy provides us with services as our chief operating officer. For more information
regarding these agreements, see the section titled &#8220;<I>Executive Compensation &#8211; Employment Agreements</I>.&#8221; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Policies and Procedures for
Related Person Transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of directors intends to adopt written policies and procedures for the review of any transaction,
arrangement or relationship in which our company is a participant, the amount involved exceeds $120,000 and one of our executive officers, directors, director nominees, or 5% stockholders, or their immediate family members, each of whom we refer to
as a &#8220;related person,&#8221; has a direct or indirect material interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If a related person proposes to enter into such a transaction,
arrangement, or relationship, which we refer to as a &#8220;related person transaction,&#8221; the related person must report the proposed related person transaction to our chief executive officer or chief financial officer. The policy calls for the
proposed related person transaction to be reviewed and, if deemed appropriate, approved by our audit committee. Whenever practicable, the reporting, review and approval will occur prior to entry into the transaction. If advance review and approval
is not practicable, the audit committee will review, and, in its discretion, may ratify the related person transaction. The policy also permits the chair of the audit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">220 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
committee to review and, if deemed appropriate, approve proposed related person transactions that arise between committee meetings, subject to ratification by the committee at its next meeting.
Any related person transactions that are ongoing in nature will be reviewed annually. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A related person transaction reviewed under the policy will
be considered approved or ratified if it is authorized by the audit committee after full disclosure of the related person&#8217;s interest in the transaction. As appropriate for the circumstances, the audit committee will review and consider: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the related person&#8217;s interest in the related person transaction; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the approximate dollar value of the amount involved in the related person transaction; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the approximate dollar value of the amount of the related person&#8217;s interest in the transaction without regard to the
amount of any profit or loss; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">whether the transaction was undertaken in the ordinary course of our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">whether the terms of the transaction are no less favorable to us than terms that could have been reached with an unrelated
third party; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the purpose, and the potential benefits to us, of the transaction; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any other information regarding the related person transaction or the related person in the context of the proposed
transaction that would be material to investors in light of the circumstances of the particular transaction. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our audit committee
may approve or ratify the transaction only if it determines that, under all of the circumstances, the transaction is in, or is not inconsistent with, our best interests. Our audit committee may impose any conditions on the related person transaction
that it deems appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to the transactions that are excluded by the instructions to the SEC&#8217;s related person transaction
disclosure rule, our board of directors has determined that the following transactions, among others, do not create a material direct or indirect interest on behalf of related persons and, therefore, are not related person transactions for purposes
of this policy: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">interests arising solely from the related person&#8217;s position as an executive officer of another entity, whether or not
the person is also a director of the entity, that is a participant in the transaction where the related person and all other related persons own in the aggregate less than a 10% equity interest in such entity, the related person and his or her
immediate family members are not involved in the negotiation of the terms of the transaction and do not receive any special benefits as a result of the transaction and the amount involved in the transaction is less than the greater of $200,000 or 5%
of the annual gross revenues of the company receiving payment under the transaction; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a transaction that is specifically contemplated by provisions of our restated certificate of incorporation or amended and
restated bylaws. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The policy provides that transactions involving compensation of executive officers shall be reviewed and
approved by our compensation committee in the manner specified in the compensation committee&#8217;s charter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We did not have a written policy
regarding the review and approval of related person transactions prior to this offering. Nevertheless, with respect to such transactions, it has been the practice of our board of directors to consider the nature of and business reasons for such
transactions, how the terms of such transactions compared to those which might be obtained from unaffiliated third parties and whether such transactions were otherwise fair to and in the best interests of, or not contrary to, our best interests.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">221 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_15"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth information with respect to the beneficial ownership of our capital stock as of March&nbsp;31, 2026 by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each of our directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each of our named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">all of our directors and executive officers as a group; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our capital stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The column entitled &#8220;Percentage of Shares Beneficially Owned&#8212;Before Offering&#8221; is based on a total of
1,247,405&nbsp;shares of our common stock outstanding as of March&nbsp;31, 2026, after giving effect to the automatic conversion of 1,204,405&nbsp;shares of our preferred stock into an aggregate of 1,204,405&nbsp;shares of our common stock upon the
completion of this offering. The column entitled &#8220;Percentage of Shares Beneficially Owned&#8212;After Offering&#8221; are based on shares of our common stock to be outstanding after this offering, including the shares of our common stock that
we are selling in this offering, but not including any additional shares issuable pursuant to the underwriters&#8217; option to purchase additional shares in this offering or any additional shares issuable upon exercise of outstanding warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Beneficial ownership is determined in accordance with the rules and regulations of the Securities and Exchange Commission and includes voting or
investment power with respect to our securities. Shares of our common stock subject to warrants that are currently exercisable or exercisable within 60&nbsp;days after March&nbsp;31, 2026 are considered outstanding and beneficially owned by the
person holding the warrants for the purpose of calculating the percentage ownership of that person but not for the purpose of calculating the percentage ownership of any other person. Except as otherwise noted, the persons and entities in this table
have sole voting and investment power with respect to all of the shares of our common stock beneficially owned by them, subject to community property laws, where applicable. Except as otherwise set forth below, the address of each beneficial owner
is c/o Hemab Therapeutics Holdings, Inc., 101 Main Street, Suite 1220, Cambridge, Massachusetts 02142. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">222 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage of Shares<BR>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before&nbsp;Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>5% Stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with RA Capital Management, L.P. (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">219,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.63</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Novo Holdings A/S (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">AI DEN-MAB LLC (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Sofinnova Crossover II SLP (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with Deep Track Capital, LP (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">SMALLCAP World Fund, Inc. (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Healthcap VIII, L.P. (7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with Avoro Ventures (8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Directors and Named Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Benny S&oslash;rensen (9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.31</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Mads Behrndt (10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Catherine Madigan (11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">John Maraganore (12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Linda Bain (13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Laura Tadvalkar (14)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">219,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Akshay Vaishnaw (15)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>All executive officers and directors as a group (8 persons) (16)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>276,856<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>22.1<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>%<B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Less than one percent </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of (a) 163,993 shares of common stock held by RA Capital Healthcare Fund, L.P., or RACHF, (b) 45,866 shares of
common stock held by RA Capital Nexus Fund II, L.P., or RACNFII, and (c) 10,054 shares of common stock held by RA Capital Nexus Fund IV, L.P., or RACNFIV. We refer to RACHF, RACNFII, and RACNFIV, collectively as the RA Capital Funds. RA Capital
Healthcare Fund GP, LLC is the general partner of RACHF, RA Capital Nexus Fund II GP, LLC is the general partner of RACNFII and RA Capital Nexus Fund IV GP, LLC is the general partner of RACNFIV. RA Capital Management, L.P., or RACM, is the
investment manager for RACHF, RACNFII and RACNFIV. The general partner of RACM is <I>RA Capital</I> Management GP, LLC, or RACM GP, of which Peter Kolchinsky, Ph.D. and Rajeev Shah are the managing members. Each of RACM, RACM GP, Dr. Kolchinsky and
Mr. Shah may be deemed to have voting and investment power over the shares held of record by RACHF, RACNFII and RACNFIV. RACM, RACM GP, Dr. Kolchinsky and Mr. Shah expressly disclaim beneficial ownership of all shares held by RACHF, RACNFII and
RACNFIV except to the extent of any pecuniary interest therein. The principal business address for each of RACHF, RACNFII, RACNFIV and RACM is 200 Berkeley Street, 18th Floor, Boston, MA 02116. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of 190,025 shares of common stock held by Novo Holdings A/S, or Novo Holdings. Novo Holdings is an investment
firm focused on life sciences and finance that is wholly owned by Novo Nordisk Foundation, or Novo Foundation, a Danish commercial foundation. Novo Holdings is the holding company in the group of Novo companies, currently comprised of Novo Nordisk
A/S and Novozymes A/S (also known as Novonesis A/S), and is responsible for managing Novo Foundation&#8217;s assets, including its financial assets. Based on the governance structure of Novo Holdings and Novo Foundation, Novo Foundation is not
deemed to have any beneficial ownership of the securities of the Company held by Novo Holdings. Novo Holdings has the sole power to vote and dispose of the shares held by Novo Holdings, and no individual or other entity
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">223 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
is deemed to hold any beneficial ownership in such shares. The business address of Novo Holdings is Tuborg Havnevej 19, 2900 Hellerup, Denmark. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of 171,652 shares of common stock held directly by AI DEN-MAB LLC, or AI DMAB. The shares held by AI DMAB may be
deemed to be beneficially owned by AI Biotechnology LLC, or AIB, Access Industries Management, LLC, or AIM, Access Industries Holdings LLC, or AIH and Len Blavatnik, because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH and AIB
(iii)&nbsp;AIH owns all of the voting units of AIB, and (iv) AIB owns all of the voting units of AI DMAB. Each of AIH, AIB, AIM and Mr. Blavatnik, and each of their affiliated entities and the officers, partners, members and managers thereof,
disclaims beneficial ownership of the common stock held by AI DEN-MAB LLC. The address of AI DEN-MAB LLC is c/o AIM, 40 West 57th Street, 28th Floor, New York, NY 10019. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of 107,896 shares of common stock held by Sofinnova Crossover II SLP, or Sofinnova. Sofinnova Partners SAS is
the management company of Sofinnova and has voting and investment control over the securities. The address of Sofinnova Crossover is 7-11, boulevard Haussmann 75009 Paris, France. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of (a) 82,556 shares of common stock held by Deep Track Biotechnology Master Fund, LTD, or Deep Track Master
Fund, and (b) 17,165 shares of common stock held by Deep Track Special Opportunities Fund, LP, or Deep Track Opportunities Fund. We refer to Deep Track Master Fund and Deep Track Opportunities Fund, together as the Deep Track Funds. Deep Track
Capital, LP, or Deep Track Capital, is the investment manager of the Deep Track Funds, and Deep Track Capital GP, LLC, or Deep Track GP, is the general partner of Deep Track Capital. Each of Deep Track Capital and Deep Track GP have shared voting
and dispositive power with respect to the securities held by the Deep Track Funds. The address for each of Deep Track Capital, Deep Track GP and the Deep Track Funds is 200 Greenwich Avenue, 3rd Floor Greenwich, CT 06830. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of 98,087 shares of common stock held by SMALLCAP World Fund, Inc, or SCWF. Capital Research and Management
Company, or CRMC, is the investment adviser of SCWF. For purposes of the reporting requirements of the Exchange Act, CRMC, Capital World Investors, or CWI, and Capital International Investors, or CII may be deemed to be the beneficial owner of the
shares of common stock held by SCWF; however, each of CRMC, CWI, and CII expressly disclaims that it is, in fact, the beneficial owner of such securities. Julian N. Abdey, Peter Eliot, Brady L. Enright, Brittain Ezzes, Bradford F. Freer, Peter
Gusev, Leo Hee, M. Taylor Hinshaw, Roz Hongsaranagon, Shlok Melwani, Dimitrije Mitrinovic, Aidan O&#8217;Connell, Samir Parekh, Piyada Phanaphat, Andraz Razen, Arun Swaminathan, Thatcher Thompson, as portfolio managers, have voting and investment
powers over the shares held by SCWF. The portfolio managers named above expressly disclaim beneficial ownership of the shares of common stock owned by SCWF. The address for SCWF is c/o Capital Research and Management Company, 333 S. Hope St., 55th
Floor, Los Angeles, California 90071. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of 86,121 shares of common stock held by HealthCap VIII, L.P., or HealthCap Fund. HealthCap VIII GP LLC, or
HealthCap GP, is the general partner of HealthCap Fund. HealthCap GP has delegated voting and dispositive power over the shares held by HealthCap Fund to HealthCap Investments S.A., a Swiss registered company, or HealthCap Investments, and disclaims
beneficial ownership over the shares held by the HealthCap Fund, except to the extent of its pecuniary interest therein. Vanessa Malier and Thomas Ramdahl are each directors of HealthCap GP. Fabrice Bernhard is the General Manager of HealthCap
Investments, and Oern&nbsp;Stuge, Francois Kaiser and Daniel Schafer are each Directors of HealthCap Investments, who we refer to collectively as the HealthCap Managers. Each of the HealthCap Managers may
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">224 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
be deemed to share voting and investment power with respect to the shares held by HealthCap Fund and disclaim beneficial ownership of all shares held by HealthCap Fund, except to the extent of
their pecuniary interest therein. The business address of HealthCap Fund is c/o HealthCap Investments S.A., 23 Avenue Villamont, Lausanne, CH 1005, Switzerland. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of (a) 29,426 shares of common stock held by Avoro Life Science Fund LLC, or Avoro Life Science Fund, and (b)
52,312 shares of common stock held by Avoro Ventures Fund L.P., or Avoro Ventures Fund. We refer to Avoro Life Science Fund and Avoro Ventures Fund together as the Avoro Funds. Avoro Capital Advisors LLC, or Avoro Capital, is the investment advisor
for Avoro Life Sciences Fund and Avoro Ventures LLC, or Avoro Ventures, is the investment manager for Avoro Ventures Fund. Avoro Capital has sole voting power and sole dispositive power with regard to the securities held by Avoro Life Science Fund
and Avoro Ventures has sole dispositive power with regard to securities held by Avoro Ventures Fund. Behzad Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital and Avoro Ventures and may be deemed to have investment
discretion and voting power over the shares held by Avoro Capital. Mr.&nbsp;Aghazadeh disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. The address of each of the Avoro Funds,
Avoro Capital, Avoro Ventures and Mr.&nbsp;Aghazadeh is 110 Greene Street, Suite 800, New York, NY 10012. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of 29,540 shares of common stock issuable upon exercise of warrants held by Dr.&nbsp;S&oslash;rensen exercisable
within 60 days of March 31, 2026. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of (a) 2,300 shares of common stock held by Mabe Invest ApS, (b) 1,660 shares of common stock held by Ebumab
Holdings ApS and (c) 9,158 shares of common stock issuable upon exercise of warrants held by Mr. Behrndt exercisable within 60 days of March 31, 2026. Mabe Invest ApS is a shareholder of Ebumab Holding ApS. Mr.&nbsp;Behrndt, our chief financial
officer and general manager, is the sole shareholder of Mabe Invest ApS and may be deemed to have shared voting and investment power over the shares of common stock held by Mabe Invest ApS. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of 2,503 shares of common stock issuable upon exercise of warrants held by Dr.&nbsp;Madigan exercisable within
60 days of March 31, 2026. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of (a) 1,634 shares of common stock held directly by Dr. Maraganore and (b)&nbsp;6,801shares of common stock
issuable upon exercise of warrants held by Dr. Maraganore exercisable within 60 days of March 31, 2026. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of 2,184 shares of common stock issuable upon exercise of warrants held by Ms.&nbsp;Bain exercisable within 60
days of March 31, 2026. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of the shares of common stock held by the RA Capital Funds described in note (1)&nbsp;above.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of 1,163 shares of common stock issuable upon exercise of warrants held by Dr.&nbsp;Vaishnaw exercisable within
60 days of March 31, 2026. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of (a) 276,856 shares of common stock held directly or indirectly by all current executive officers and
directors as a group and (b) 51,349 shares of common stock issuable upon exercise of warrants held by all current executive officers and directors as a group within 60 days of March&nbsp;31, 2026. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">225 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_16"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Following the completion of this offering, our authorized capital stock will consist of&#8195;&#8195;&#8195;&#8195; shares of common stock, par value
$0.0001 per share, and&#8195;&#8195;&#8195;&#8195;shares of preferred stock, par value $0.0001 per share, all of which preferred stock will be undesignated. The following description of our capital stock and provisions of our restated certificate of
incorporation and amended and restated bylaws are summaries only and are qualified by reference to the restated certificate of incorporation and the amended and restated bylaws that will be in effect immediately prior to the completion of this
offering. We will file copies of these documents with the SEC as exhibits to our registration statement of which this prospectus is a part. The description of the capital stock reflects changes to our capital structure that will be in effect
immediately prior to the completion of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of March&nbsp;31, 2026, we had issued and outstanding: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">43,000 shares of our common stock held by six stockholders of record; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">23,343 shares of our Series Seed Preferred Stock held by one stockholder of record, convertible into 23,343 shares of our
common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">225,866 shares of our Series A Preferred Stock held by four stockholders of record, convertible into 225,866 shares of our
common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">442,205 shares of our Series B Preferred Stock held by twelve stockholders of record, convertible into 442,205 shares of
our common stock; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">512,991 shares of our Series C Preferred Stock held by seventeen stockholders of record, convertible into 512,991 shares of
our common stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of March&nbsp;31, 2026, after giving effect to the automatic conversion of 1,204,405&nbsp;shares of our
preferred stock into an aggregate of 1,204,405&nbsp;shares of our common stock upon the completion of this offering, there would have been 1,247,405 shares of our common stock issued and outstanding held by 25&nbsp;stockholders of record and no
shares of preferred stock outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Voting Rights. </I>Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders, except
on matters relating solely to terms of preferred stock, and do not have cumulative voting rights. Each election of directors by our stockholders will be determined by a plurality of the votes cast by the stockholders entitled to vote on the
election. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Dividends</I>. Dividends may be declared and paid on our common stock from funds lawfully available therefor if, as and when
determined by our board of directors, subject to any preferential dividend or other rights or preferences of any then outstanding shares of preferred stock that we may designate and issue in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Liquidation, Dissolution and Winding Up</I>. Upon our dissolution, liquidation or winding up, whether voluntary or involuntary, the holders of our
common stock, as such, will be entitled to receive all of our assets available for distribution to our stockholders subject to any preferential liquidation or other rights or preferences of any then outstanding shares of preferred stock that we
designate and issue in the future. Holders of our common stock have no preemptive, subscription, redemption or conversion </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">226 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
rights. The rights, preferences and privileges of holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred
stock that we may designate and issue in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Other Rights. </I>Holders of the common stock have no right to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">convert the stock into any other security; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">have the stock redeemed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">purchase additional stock; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">maintain their proportionate ownership interest. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Holders of shares of the common stock are not required to make additional capital contributions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the terms of our restated certificate
of incorporation that will become effective immediately prior to the completion of this offering, our board of directors is authorized to issue shares of preferred stock in one or more series without stockholder approval. Our board of directors has
the discretion to determine the rights, preferences, privileges, and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges, and liquidation preferences, of each series of preferred stock. The ability of our
board of directors, without action by the stockholders, to issue shares of preferred stock with voting or other rights or preferences as designated by our board of directors could impede the success of any attempt to change control of us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The purpose of authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated
with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings, and other corporate purposes, could have the effect of making it more difficult
for a third party to acquire, or could discourage a third party from seeking to acquire, a majority of our outstanding voting stock. These provisions may also have the effect of deferring hostile takeovers or delaying changes in control or
management of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to
holders of shares of common stock. Upon the completion of this offering, there will be no shares of preferred stock outstanding, and we have no present plans to issue any shares of preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Equity Grants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of March 31, 2026, warrants for the
subscription for an aggregate of 198,761 shares of our common stock at a weighted average exercise price of $128.42, were outstanding. See &#8220;<I>Executive Compensation &#8211;Equity Compensation Plans and Other Benefit Plans</I>&#8221; for
additional information regarding the terms of the outstanding warrants. In connection with the corporate reorganization, each outstanding warrant to subscribe for the purchase of ordinary shares of Hemab ApS was assumed by us and converted into a
warrant to purchase the same number of shares of our common stock. Any warrant exercise price that had been denominated in DKK prior to the corporate reorganization was converted into an exercise price in U.S. dollars at the exchange rate as in
effect at the close of business on the business day prior to the corporate reorganization. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">227 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Delaware Anti-Takeover Law and Certain Charter and Bylaw Provisions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Delaware Law </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon completion of this offering, we will
be subject to Section&nbsp;203 of the DGCL. Subject to certain exceptions, Section&nbsp;203 prevents a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with any &#8220;interested stockholder&#8221; for three
years following the date that the person became an interested stockholder, unless either the interested stockholder attained such status with the approval of our board of directors, the business combination is approved by our board of directors and
stockholders in a prescribed manner or the interested stockholder acquired at least 85% of our outstanding voting stock in the transaction in which it became an interested stockholder. A &#8220;business combination&#8221; includes, among other
things, a merger or consolidation involving us and the &#8220;interested stockholder&#8221; and the sale of more than 10% of our assets. In general, an &#8220;interested stockholder&#8221; is any entity or person beneficially owning 15% or more of
our outstanding voting stock and any entity or person affiliated with or controlling or controlled by such entity or person. The restrictions contained in Section 203 are not applicable to any of our existing stockholders that will own 15% or more
of our outstanding voting stock upon the completion of this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Staggered Board; Removal of Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our restated certificate of incorporation and our amended and restated bylaws to be effective immediately prior to the completion of this offering divide
our board of directors into three classes with staggered three-year terms. In addition, our restated certificate of incorporation and our amended and restated bylaws to be effective immediately prior to the completion of this offering provide that,
subject to the rights of holders of any series of preferred stock, our directors may be removed only for cause and only by the affirmative vote of the holders of at least&#8195;&#8195;&#8195;&#8195;% of the voting power of the outstanding shares of
our capital stock entitled to vote in the election of directors. Under our restated certificate of incorporation and our amended and restated bylaws to be effective immediately prior to the completion of this offering, subject to the rights of any
holders of any series of preferred stock, any vacancies or newly-creased directorships on our board of directors, however occurring, shall be filled only by vote of a majority of our directors then in office, although less than a quorum, or by a
sole remaining director and shall not be filled by the stockholders. Furthermore, our restated certificate of incorporation to be effective immediately prior to the completion of this offering provides that subject to the rights of any holders of
any series of preferred stock, the number of directors shall be established from time to time by our board of directors. The classification of our board of directors and the limitations on the ability of our stockholders to remove directors, change
the authorized number of directors and fill vacancies could make it more difficult for a third party to acquire, or discourage a third party from seeking to acquire, control of our company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Super-Majority Voting </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The DGCL provides generally
that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&#8217;s certificate of incorporation or bylaws, unless a corporation&#8217;s certificate of incorporation or bylaws, as the case
may be, requires a greater percentage. Our amended and restated bylaws to be effective immediately prior to the completion of this offering may be amended or repealed by a majority vote of our board of directors or the affirmative vote of the
holders of at least&#8195;&#8195;&#8195;&#8195;% of the votes that all our stockholders would be entitled to cast in any annual election of directors. In addition, the affirmative vote of the holders of at least&#8195;&#8195;&#8195;&#8195;% of the
votes that all our stockholders would be entitled to cast in any election of directors is required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of our restated certificate of incorporation described above.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">228 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Undesignated Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The ability of our board of directors, without action by the stockholders, to issue up to&#8195;&#8195;&#8195;&nbsp;shares of undesignated preferred
stock with voting or other rights or preferences as designated by our board of directors could impede the success of any attempt to change control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying
changes in control or management of our company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>No Written Consent of Stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our restated certificate of incorporation will provide that all stockholder actions are required to be taken by a vote of the stockholders at an annual
or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of our amended and restated
bylaws or removal of directors by our stockholders without holding a meeting of stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Stockholder Action; Special Meeting of Stockholders; Advance
Notice Requirements for Stockholder Proposals and Director Nominations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our restated certificate of incorporation and our amended and
restated bylaws to be effective immediately prior to the completion of this offering provide that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any action required or permitted to be taken by our stockholders at an annual meeting or special meeting of stockholders
may only be taken if it is properly brought before such meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">stockholders may not take action by written consent in lieu of a meeting; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">except as otherwise required by law, special meetings of the stockholders can only be called by our board of directors.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our amended and restated bylaws to be effective immediately prior to the completion of this offering establish an advance notice
procedure for stockholder proposals to be brought before an annual or special meeting of stockholders, including proposed nominations of candidates for election to our board of directors. Stockholders at an annual or special meeting may only
consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors, or by a stockholder of record on the record date for the meeting who is entitled to vote at the
meeting and who has delivered timely written notice in proper form to our secretary of the stockholder&#8217;s intention to bring such business before the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The advance notice provisions in our amended and restated bylaws could have the effect of delaying stockholder actions that are favored by the holders
of a majority of our outstanding voting securities. Moreover, the prohibition on stockholder action by written consent except as noted above could discourage a third party from making a tender offer for our common stock because even if the third
party acquired a majority of our outstanding voting stock, it would be able to take action as a stockholder, such as electing new directors or approving a merger, only at a duly called stockholders meeting and not by written consent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Indemnification Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our restated certificate
of incorporation, which will become effective immediately prior to the completion of this offering, provides that we will indemnify our directors and officers to the fullest extent permitted by Delaware law. In addition, we intend to enter into
indemnification agreements with all of our directors and executive officers prior to the completion of this offering. These indemnification agreements may require us, among other things, to indemnify each such director or executive officer
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">229 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
for some expenses, including attorneys&#8217; fees, judgments, fines, and settlement amounts incurred by him or her in any action or proceeding arising out of his or her service as one of our
directors or executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Exclusive Forum Selection </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our restated certificate of incorporation to be effective immediately prior to the completion of this offering provides that, unless we consent in
writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware does not have jurisdiction, the federal district court for the District of Delaware) shall, to
the fullest extent permitted by law, be the sole and exclusive forum for any action asserting an internal corporate claim as defined in Section&nbsp;115 of the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This choice of forum provision does not apply to claims arising under the Securities Act, the Exchange Act or any other claim for which the federal
courts have exclusive jurisdiction. Furthermore, Section&nbsp;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to
entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our restated certificate of incorporation that will become
effective immediately prior to the completion of this offering provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted
by law, be the sole and exclusive forum for the resolution of any claims that are brought by stockholders, when acting in their capacity as stockholders or in our right, and that relate to our business, the conduct of its affairs, or our rights or
powers or pir stockholders, directors or officers, including without limitation claims arising under the Securities Act, the Exchange Act and other applicable claims for which the federal courts have exclusive jurisdiction. While the Delaware courts
have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously
assert the validity and enforceability of the exclusive forum provisions of our restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no
assurance that the provisions will be enforced by a court in those other jurisdictions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with the corporate reorganization, we entered into an investors&#8217; rights agreement dated as of March&nbsp;30, 2026, or the
Investors&#8217; Rights Agreement, with holders of our convertible preferred stock. Beginning 180&nbsp;days after this offering, holders of a total of&#8195;&#8195;&#8195;&#8195; shares of our common&nbsp;stock, including those issued upon the
conversion of our convertible preferred stock upon the closing of this offering, will have the right to require us to register these shares under the Securities&nbsp;Act upon demand and in connection with any registration statement that we plan to
file, as described below under &#8220;&#8212;<I>Demand Registration Rights</I>&#8221; and &#8220;&#8212;<I>Incidental Registration Rights</I>.&#8221; We refer to the shares with these registration rights as registrable securities. After registration
pursuant to these rights, the registrable securities will become freely tradable without restriction under the Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I>Demand Registration
Rights</I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Beginning 180&nbsp;days after the effective date of the registration statement of which this prospectus is a part, subject to
specified limitations set forth in the Investors&#8217; Rights Agreement, at any time, the holders of at least 30% of the then outstanding registrable securities may demand that we register at least 25% of the registrable securities then outstanding
on a Registration Statement on Form&nbsp;S-1 under the Securities Act for purposes of a public offering. We are not obligated to file a registration&nbsp;statement pursuant to this provision on more than two occasions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">230 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, subject to specified limitations set forth in the Investors&#8217; Rights Agreement, at
any time after we become eligible to file a registration statement on Form S-3, the holders of at least 20% of the then outstanding registrable securities may request that we register their registrable securities on Form&nbsp;S-3 for purposes of a
public offering for which the reasonably anticipated aggregate offering price to the public of at least $5&nbsp;million, net of selling expenses. We are not obligated to file a registration statement pursuant to this provision on more than two
occasions in any 12-month&nbsp;period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I>Incidental Registration Rights</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If, at any time after the closing of this offering, we propose to register for our own account any of our securities under the Securities Act, the
holders of registrable securities will be entitled to notice of the registration and, subject to specified exceptions, have the right to require us to register all or a portion of the registrable securities then held by them in that registration. We
have the right to terminate or withdraw any registration initiated by us before the effective date of such registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the event that any
registration in which the holders of registrable securities participate pursuant to our Investors&#8217; Rights Agreement is an underwritten public offering, we have agreed to enter into an underwriting agreement in usual and customary form. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I>Expiration of Registration Rights</I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The
demand registration rights and incidental registration rights granted under the Investors&#8217; Rights Agreement will terminate on the earliest to occur of (i) the closing of certain liquidation events, (ii)&nbsp;the third anniversary of the
completion of this offering or (iii) at such time after this offering when the holder&#8217;s shares may be sold without limitation pursuant to Rule 144 or another similar exemption under&nbsp;the Securities Act during a three- month period without
registration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I>Expenses</I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to
the Investors&#8217; Rights Agreement, we are required to pay all registration expenses, including all registration, filing and qualification fees, printing and accounting expenses, and reasonable fees and disbursements, not to exceed $50,000, of
one counsel selected by the selling stockholders to represent the selling stockholders, but excluding estimated underwriting discounts, selling commissions, stock transfer taxes applicable to the sale of any registrable securities and the fees and
disbursements of the selling stockholders&#8217; own counsel (other than the counsel selected to represent all selling stockholders). If a registration is withdrawn at the request of the stockholders initiating the registration, then the
stockholders will bear the expenses of the registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Investors&#8217; Rights Agreement contains customary cross-indemnification provisions,
pursuant to which we are obligated to indemnify the selling stockholders in the event of material misstatements or omissions in the registration statement attributable to us or any violation or alleged violation whether by action or inaction by us
under the Securities Act, the Exchange Act, any state securities or Blue&nbsp;Sky&nbsp;law or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities or Blue Sky law in connection with such registration
statement or the qualification or compliance of the offering, and they are obligated to indemnify us for material misstatements or omissions in the registration statement attributable to them. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Transfer Agent and Registrar</B><I> </I><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The transfer
agent and registrar for our common stock will be Computershare Trust Company, N.A. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">231 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Nasdaq Global Select Market </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have applied to have our common stock listed on the Nasdaq Global Select Market under the symbol &#8220;COAG&#8221;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">232 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_17"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to this offering, there has been no public market for our common stock, and a liquid trading market for our common stock may not develop or be
sustained after this offering. As described below, only a limited number of shares will be available for sale shortly after this offering due to contractual and legal restrictions on resale. Future sales of substantial amounts of our common stock in
the public market, including shares issued upon exercise of outstanding warrants, or the anticipation of these sales, could adversely affect market prices prevailing from time to time and could impair our ability to raise capital through sales of
equity securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon the completion of this offering, we will have outstanding&#8195;&#8195;&#8195;&#8195; shares of our common stock, based on
the 43,000&nbsp;shares of our common stock that were outstanding on March&nbsp;31, 2026, and after giving effect to (i)&nbsp;the issuance of&#8195;&#8195;&#8195;&#8195;shares of our common stock in this offering, assuming no exercise by the
underwriters of their option to purchase additional shares of our common stock and (ii)&nbsp;the automatic conversion of all outstanding shares of our preferred stock into an aggregate of 1,204,405 shares of our common stock upon the completion of
this offering. Of these shares, all shares sold in this offering will be freely tradable without restriction or further registration under the Securities Act, unless purchased by our &#8220;affiliates,&#8221; as that term is defined in Rule 144
under the Securities Act, or Rule 144. The remaining&#8195;&#8195;&#8195;&#8195; shares of our common stock will be &#8220;restricted securities&#8221; under Rule 144, and we expect that substantially all of these restricted securities will be
subject to the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period under the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements as described below. These restricted securities may be sold in
the public market only upon release or waiver of any applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, which release or waiver may be effected with the consent of Goldman Sachs&nbsp;&amp; Co. LLC, Jefferies LLC, and Evercore
Group L.L.C. in their sole discretion at any time, and only if registered under the Securities Act or pursuant to an exemption from registration under the Securities Act, such as the exemptions provided by Rule 144 or Rule 701 under the Securities
Act, or Rule 701. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule 144 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In general, under Rule 144,
beginning 90 days after the date of this prospectus, any person who is not our affiliate and has held their shares for at least six months, including the holding period of any prior owner other than one of our affiliates, may sell those shares
without restriction, subject to the availability of current public information about us. In addition, under Rule 144, any person who is not our affiliate and has not been our affiliate at any time during the preceding three months and has held their
shares for at least one year, including the holding period of any prior owner other than one of our affiliates, would be entitled to sell an unlimited number of shares immediately upon the completion of this offering without regard to whether
current public information about us is available, subject to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Beginning 90 days after the date of this prospectus, a person who is our affiliate or who was our affiliate at any time during the preceding three
months and who has beneficially owned restricted securities for at least six months, including the holding period of any prior owner other than one of our affiliates, is entitled to sell a number of shares within any three-month period that does not
exceed the greater of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">1% of the number of shares of our common stock then outstanding, which will equal
approximately&#8195;&#8195;&#8195;&#8195;shares immediately after this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the average weekly trading volume in our common stock on the Nasdaq Global Select Market during the four calendar weeks
preceding the date of filing of a Notice of Proposed Sale of Securities Pursuant to Rule 144 with respect to the sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Sales
under Rule 144 by our affiliates are also subject to manner of sale provisions and notice requirements and to the availability of current public information about us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">233 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon waiver or expiration of the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT
STYLE="white-space:nowrap">lock-up</FONT> period described below, approximately &#8195;&#8195;&#8195;&#8195;shares of our common stock will be eligible for sale under Rule 144. We cannot estimate the number of shares of our common stock that our
existing stockholders will elect to sell under Rule 144. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule 701 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In general, under Rule 701, any of our employees, consultants, or advisors, other than our affiliates, who purchased shares from us in connection with a
qualified compensatory stock plan or other written agreement is eligible to resell these shares 90 days after the date of this prospectus in reliance on Rule 144, but without compliance with the various restrictions, including the availability of
public information about us and holding period and volume limitations, contained in Rule 144. Substantially all Rule 701 shares are subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below and will become eligible for
sale upon the expiration of the restrictions set forth in those agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We, each of our executive officers and directors and the holders of substantially all of our outstanding equity securities and securities convertible
into or exchangeable for our common stock have agreed that, without the prior written consent of Goldman Sachs&nbsp;&amp; Co. LLC, Jefferies LLC, and Evercore Group L.L.C., we and they will not, subject to limited exceptions, during the period
ending 180 days after the date of this prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">offer, sell, contract to sell, pledge, grant any option, right or warrant to purchase, purchase any option or contract to
sell, lend or otherwise transfer or dispose of any ordinary shares or preference shares of Hemab ApS, any shares of our common stock, or any options or warrants to purchase any shares of our common stock, or any securities convertible into,
exchangeable for or that represent the right to receive shares of our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">enter into any hedging, swap or other arrangement that transfers to another, in whole or in part, any of the economic
consequences of ownership of our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">make any demand for or exercise any right with respect to the registration of any such equity securities; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">make any public announcement of an intention to do any of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These agreements are subject to certain exceptions, as described in the section of this prospectus titled &#8220;<I>Underwriting</I>.&#8221; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Beginning 180 days after the completion
of this offering, the holders of an aggregate of&#8195;&#8195;&#8195;&#8195;shares of our common stock will have rights, subject to certain conditions, to require us to file registration statements covering their shares or to include their shares in
registration statements that we may file for ourselves or other stockholders. After registration pursuant to these rights, these shares will become freely tradable without restriction under the Securities Act. See &#8220;<I>Description of Capital
Stock&#8212;Registration Rights</I>&#8221; for additional information regarding these registration rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Form <FONT STYLE="white-space:nowrap">S-8</FONT>
Registration Statement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Following this offering, we intend to file one or more registration statements on Form
<FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act to register all of the shares of our common stock subject to outstanding warrants and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">234 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
reserved for future options and other awards under the 2026 Plan and the 2026 ESPP. See &#8220;<I>Executive Compensation&#8212;Equity Compensation Plans and Other Benefit Plans</I>&#8221; for
additional information regarding these plans. The registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> we intend to file will become effective immediately upon filing. Shares covered by these registration statements will then
be eligible for sale in the public markets, subject to vesting restrictions, any applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above, and Rule 144 limitations applicable to affiliates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">235 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_18"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>HOLDERS OF COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following is a discussion of material U.S. federal income tax considerations relating to ownership and disposition of shares of our common stock
acquired pursuant to this offering by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder. For purposes of this discussion, the term <FONT STYLE="white-space:nowrap">&#8220;non-U.S.</FONT> holder&#8221; means a beneficial owner (other than a
partnership or other entity or arrangement treated as a pass-through entity) of our common stock that is not, for U.S. federal income tax purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a corporation, or other entity treated as a corporation for U.S. federal income tax purposes, created or organized in or
under the laws of the United States, any state thereof, or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a trust, if (i)&nbsp;a U.S. court is able to exercise primary supervision over the administration of the trust and one or
more U.S. persons has authority to control all substantial decisions of the trust, or (ii)&nbsp;the trust has a valid election in effect to be treated as a U.S. person under applicable U.S. Treasury Regulations. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This discussion is based on current provisions of the Code, existing and proposed U.S. Treasury Regulations promulgated thereunder, current
administrative rulings, and judicial decisions, as in effect as of the date of this prospectus and all of which are subject to change or to differing interpretation, possibly with retroactive effect. Any change or differing interpretation could
alter the tax consequences to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders described in this prospectus. We have not requested a ruling from the Internal Revenue Service, or the IRS, with respect to statements made and the conclusions
reached in the following summary, and there can be no assurance that the IRS will not challenge one or more of the tax consequences described in this prospectus or that any such challenge would not be sustained by a court. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This discussion addresses only <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders that hold shares of our common stock as a capital asset within
the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This discussion does not address all aspects of U.S. federal income taxation that may be relevant to a particular
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in light of that <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s individual circumstances nor does it address the alternative minimum tax, the special tax accounting rules under
Section&nbsp;451(b) of the Code, the Medicare tax on net investment income, or any aspects of U.S. state, local, or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> taxes. This discussion also does not consider any specific facts or circumstances
that may apply to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and does not address the special tax rules applicable to particular <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders, such as: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations or governmental organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">financial institutions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">brokers or dealers in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">pension plans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">controlled foreign corporations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">passive foreign investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">corporations that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">236 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#8220;qualified foreign pension funds&#8221; as defined in Section&nbsp;897(1)(2) of the Code and entities all of the
interests of which are held by qualified foreign pension funds; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons that own, or are deemed to own, more than 5% of our capital stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">owners that hold our common stock as part of a straddle, hedge, conversion transaction, synthetic security, or other
integrated investment; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">certain U.S. expatriates and former citizens or long-term residents of the United States. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, this discussion does not address the tax treatment of partnerships or persons who hold their common stock through partnerships or other
entities or arrangements that are treated as pass-through entities for U.S. federal income tax purposes. A partner in a partnership or other pass-through entity that will hold our common stock should consult his, her, or its own tax advisor
regarding the tax consequences of the purchase, ownership, and disposition of our common stock through a partnership or other pass-through entity, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Prospective investors should consult their own tax advisors regarding the U.S. federal, state, local, and
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> income and other tax considerations of acquiring, holding, and disposing of our common stock in light of their particular situations as well as any consequences of any U.S. federal <FONT
STYLE="white-space:nowrap">non-income</FONT> tax laws. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Distributions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we pay distributions on our common stock, those distributions generally will constitute dividends for U.S. federal income tax purposes to the extent
paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings and profits, the excess will be treated as a <FONT
STYLE="white-space:nowrap">tax-free</FONT> return of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s investment, up to such holder&#8217;s tax basis in the common stock. Any remaining excess will be treated as capital gain,
subject to the tax treatment described below under the heading &#8220;&#8212;Gain on Disposition of Common Stock.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Dividends paid to a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be subject to withholding of U.S. federal income tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the United States and such
holder&#8217;s country of residence. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder who claims the benefit of an applicable income tax treaty between the United States and such holder&#8217;s country of residence generally will be
required to provide a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or successor form) and satisfy applicable certification and
other requirements. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is eligible for a reduced rate of U.S. withholding tax under an income tax treaty may obtain a refund or credit of any excess amounts withheld by timely filing an
appropriate claim with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders are urged to consult their own tax advisors regarding their entitlement to benefits under a relevant income tax treaty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Dividends that are treated as effectively connected with a trade or business conducted by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder
within the United States and, if an applicable income tax treaty so provides, that are attributable to a permanent establishment or a fixed base maintained by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder within the United States, are
generally exempt from the 30% withholding tax if the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder delivers a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> stating that the dividends are so connected and
satisfies applicable certification and disclosure requirements. However, such U.S. effectively connected income is taxed on a net income basis at the same U.S. federal income tax rates applicable to United States persons (as defined in the Code).
Any U.S. effectively connected income received by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a corporation may also, under certain circumstances, be subject to an additional &#8220;branch profits tax&#8221; at a 30% rate or
such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#8217;s country of residence. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">237 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Gain on Disposition of Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Subject to the discussions below under the sections entitled &#8220; - <I>Information Reporting and Backup Withholding</I>&#8221; and &#8220; -
<I>FATCA</I>,&#8221; a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will not be subject to U.S. federal income tax on gain realized on a disposition of our common stock unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s conduct of a
trade or business in the United States and, if an applicable income tax treaty so provides, the gain is attributable to a permanent establishment or fixed base maintained by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United
States; in these cases, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be taxed on a net income basis at the same U.S. federal income tax rates applicable to United States persons (as defined in the Code), and if the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder is a foreign corporation, an additional branch profits tax at a 30% rate, or such lower rate as may be specified by an applicable income tax treaty, may also apply; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a nonresident alien present in the United States for 183
days or more in the taxable year of the disposition and certain other conditions are met, in which case the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be subject to a 30% tax (or such lower rate as may be specified by an applicable
income tax treaty) on the net gain derived from the disposition, which may be offset by U.S.-source capital losses of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder provided the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder
has timely filed U.S. federal income tax returns with respect to such losses, if any; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we are, or have been at any time during the five-year period preceding such disposition (or the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s holding period, if shorter), a &#8220;U.S. real property holding corporation,&#8221; unless our common stock is regularly traded on an established securities market and the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder held no more than 5% of our outstanding common stock, directly or indirectly, during the shorter of the five-year period ending on the date of the disposition or the period that the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder held our common stock. If we are determined to be a U.S. real property holding corporation and the foregoing exception does not apply, then the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder
generally will be taxed on its net gain derived from the disposition at the U.S. federal income tax rates applicable to United States persons (as defined in the Code). Generally, a corporation is a &#8220;U.S. real property holding
corporation&#8221; if the fair market value of its &#8220;U.S. real property interests&#8221; equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade or
business. Although there can be no assurance, we believe that we are not currently, and we do not anticipate becoming, a &#8220;U.S. real property holding corporation&#8221; for U.S. federal income tax purposes. No assurance can be provided that our
common stock will be regularly traded on an established securities market for purposes of the rule described above. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Information Reporting and
Backup Withholding </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We must report annually to the IRS and to each <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder the gross amount of
the distributions on our common stock paid to such holder and the tax withheld, if any, with respect to such distributions. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders may have to comply with specific certification procedures to
establish that the holder is not a United States person (as defined in the Code) in order to avoid backup withholding at the applicable rate with respect to dividends on our common stock. Generally, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder will comply with such procedures if it provides a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> or <FONT
STYLE="white-space:nowrap">W-8ECI</FONT> (or other applicable Form <FONT STYLE="white-space:nowrap">W-8)</FONT> or otherwise meets documentary evidence requirements for establishing that it is a <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder, or otherwise establishes an exemption. Dividends paid to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders subject to withholding of U.S. federal income tax, as described above under the heading &#8220;&#8212;Distributions,&#8221;
will generally be exempt from U.S. backup withholding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Information reporting and backup withholding generally will apply to the proceeds of a
disposition of our common stock by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder effected by or through the U.S. office of any broker, U.S. or foreign, unless the holder certifies its status as a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and satisfies certain other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">238 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
requirements, or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment of disposition proceeds to a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder where the transaction is effected outside the United States through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker. However, for information reporting purposes, dispositions
effected through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their own tax advisors regarding the application of the information reporting and backup withholding rules to them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Copies of information returns may be made available to the tax authorities of the country in which the <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder resides or is incorporated under the provisions of a specific treaty or agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Backup withholding is not an additional tax. Rather, any
amounts withheld under the backup withholding rules from a payment to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder may be refunded or credited against the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s U.S. federal
income tax liability, if any, provided that an appropriate claim is timely filed with the IRS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>FATCA </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Sections 1471 to 1474 of the Code, commonly referred to as the Foreign Account Tax Compliance Act, or FATCA, generally impose a 30% U.S. federal
withholding tax on dividends on, and gross proceeds from the sale or other disposition of, our common stock if paid to a foreign entity unless (i)&nbsp;if the foreign entity is a &#8220;foreign financial institution,&#8221; the foreign entity
undertakes certain due diligence, reporting, withholding, and certification obligations, (ii)&nbsp;if the foreign entity is not a &#8220;foreign financial institution,&#8221; the foreign entity identifies certain of its U.S. investors, or
(iii)&nbsp;the foreign entity is otherwise excepted under FATCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Withholding under FATCA generally will apply to payments of dividends on our
common stock. While withholding under FATCA may also apply to payments of gross proceeds from a sale or other disposition of our common stock, under proposed U.S. Treasury Regulations, withholding on payments of gross proceeds is not required.
Although such regulations are not final, applicable withholding agents are permitted to rely on such proposed regulations until final regulations are issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If withholding under FATCA is required on any payment related to our common stock, investors not otherwise subject to withholding (or that otherwise
would be entitled to a reduced rate of withholding) on such payment may be required to seek a refund or credit from the IRS. An intergovernmental agreement between the United States and an applicable foreign country may modify the requirements
described in this section. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their own tax advisors regarding the possible implications of FATCA on their investment in our common stock and the entities through which they hold
our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>The preceding discussion of material U.S. federal income tax considerations is for prospective investors&#8217; information
only. It is not tax advice. Prospective investors should consult their own tax advisors regarding the particular U.S. federal, state, local, and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of purchasing, holding, and disposing
of our common stock, including the consequences of any proposed changes in applicable laws. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">239 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_19"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The company and the underwriters named below have entered into an underwriting agreement with respect to the shares being offered. Subject to certain
conditions, each underwriter has severally agreed to purchase the number of shares indicated in the following table. Goldman Sachs&nbsp;&amp; Co. LLC, Jefferies LLC and Evercore Group L.L.C. are the representatives of the underwriters. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Underwriters</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Evercore Group L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Wedbush Securities Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters are committed to take and pay for all of the shares being offered, if any are taken, other than the
shares covered by the option described below unless and until this option is exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters have an option to buy up to an additional
&#8195;&#8195;&#8195;&#8195; shares from the company to cover sales by the underwriters of a greater number of shares than the total number set forth in the table above. The underwriters may exercise that option for 30 days from the date of this
prospectus. If any shares are purchased pursuant to this option, the underwriters will severally purchase shares in approximately the same proportion as set forth in the table above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters by the company. Such amounts are
shown assuming both no exercise and full exercise of the underwriters&#8217; option to purchase&#8195;&#8195;&#8195;&#8195;additional shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><U>Paid by the Company </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No<BR>Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full<BR>Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Shares sold by the underwriters to the public will initially be offered at the initial public offering price set forth
on the cover of this prospectus. Any shares sold by the underwriters to securities dealers may be sold at a discount of up to $&#8195;&#8195;per share from the initial public offering price. After the initial offering of the shares, the
representatives may change the offering price and the other selling terms. The offering of the shares by the underwriters is subject to receipt and acceptance and subject to the underwriters&#8217; right to reject any order in whole or in part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The company and its officers, directors and holders of substantially all of the company&#8217;s equity securities have agreed with the underwriters,
subject to certain exceptions, not to dispose of or hedge any of their ordinary shares or preference shares of Hemab ApS, any shares of common stock, or any options or warrant to purchase any share of common stock, or any securities convertible
into, exchangeable for or that represent the right to receive shares of common stock (the <FONT STYLE="white-space:nowrap">&#8220;Lock-Up</FONT> Securities&#8221;) during the period from the date of such
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement continuing through the date 180&nbsp;days after the date of this prospectus, except with the prior written consent of Goldman Sachs&nbsp;&amp; Co. LLC, Jefferies LLC and Evercore Group L.L.C.
See the section titled &#8220;<I>Shares Eligible for Future Sale</I>&#8221; for a discussion of certain transfer restrictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">240 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The restrictions described in the immediately preceding paragraph do not apply to our officers,
directors and holders of substantially all of our capital stock and securities convertible into or exchangeable for our common stock with respect to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Transfers of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities (i)&nbsp;as one or more bona fide gifts or charitable contributions, or for bona
fide estate planning purposes, (ii)&nbsp;upon death by will, testamentary document or intestate succession, (iii)&nbsp;if the <FONT STYLE="white-space:nowrap">lock-up</FONT> party is a natural person, to any member of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> party&#8217;s immediate family or to any trust for the direct or indirect benefit of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or the immediate family of the
<FONT STYLE="white-space:nowrap">lock-up</FONT> party or, if the <FONT STYLE="white-space:nowrap">lock-up</FONT> party is a trust, to a trustor, trustee (or <FONT STYLE="white-space:nowrap">co-trustee)</FONT> or beneficiary of the trust or the
estate of a beneficiary of such trust, (iv)&nbsp;to a corporation, partnership, limited liability company or other entity of which the <FONT STYLE="white-space:nowrap">lock-up</FONT> party and the immediate family of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> party are the legal and beneficial owner of all of the outstanding equity securities or similar interests, (v)&nbsp;to a nominee or custodian of a person or entity to whom a disposition or transfer would be
permissible under clauses (a)(i) through (iv)&nbsp;above, (vi) if the undersigned is a corporation, partnership, limited liability company, trust or other business entity, (A)&nbsp;to another corporation, partnership, limited liability company,
trust or other business entity that is a subsidiary or an affiliate (as defined in Rule 405 promulgated under the Securities Act) of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or immediate family of the
<FONT STYLE="white-space:nowrap">lock-up</FONT> party, or to any investment fund or other entity which fund or entity is directly or indirectly controlled or managed by or under common control or common investment management with the <FONT
STYLE="white-space:nowrap">lock-up</FONT> party or affiliates of the undersigned, or (B)&nbsp;as part of a disposition, transfer or distribution by the <FONT STYLE="white-space:nowrap">lock-up</FONT> party to its stockholders, partners, members or
other equityholders or to the estate of any such stockholders, partners, members or other equityholders of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party, (vii)&nbsp;by operation of law, such as pursuant to a merger, acquisition,
reorganization, qualified domestic order, divorce settlement, divorce decree or separation agreement, (viii)&nbsp;to the company from an employee of the company upon death, disability or termination of employment, in each case, of such employee,
(ix)&nbsp;if the <FONT STYLE="white-space:nowrap">lock-up</FONT> party is not an officer or director of the company, in connection with a sale of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party&#8217;s shares of common stock acquired
(A)&nbsp;from the underwriters in the Public Offering or (B)&nbsp;in open market transactions after the closing date of this offering, (x)&nbsp;to the company in connection with the vesting, settlement or exercise of restricted stock units, options,
warrants or other rights to purchase shares of common stock or other <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities (including, in each case, by way of &#8220;net&#8221; or &#8220;cashless&#8221; exercise) that are scheduled to expire or
automatically vest during the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, including any transfer to the company for the payment of tax withholdings or remittance payments due as a result of the vesting, settlement or exercise of such
restricted stock units, options, warrants or other rights, or in connection with the conversion of convertible securities, in all cases pursuant to equity awards granted under a stock incentive plan, other equity award plan or otherwise, or pursuant
to the terms of convertible securities, each as described in the prospectus, provided that any securities received upon such vesting, settlement, exercise or conversion shall be subject to the terms of the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, or (xi)&nbsp;with the prior written consent of Goldman Sachs&nbsp;&amp; Co. LLC, Jefferies LLC and Evercore Group L.L.C. on behalf of the underwriters; provided that (A)&nbsp;in the case of
clauses (a)(i), (ii), (iii), (iv), (v) and (vi)&nbsp;above, such transfer or distribution shall not involve a disposition for value, (B)&nbsp;in the case of clauses (a)(i), (ii), (iii), (iv), (v), (vi) and (vii)&nbsp;above, it shall be a condition
to the transfer or distribution that the donee, devisee, transferee or distributee, as the case may be, shall sign and deliver a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement in the form of the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, (C)&nbsp;in the case of clauses (a)(ii), (iii), (iv), (v) and (vi)&nbsp;above, no filing by any party (including, without limitation, any donor, donee, devisee, transferor, transferee,
distributor or distributee) under the Exchange Act, or other public filing, report or announcement reporting a reduction in beneficial ownership of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities shall be required or shall be voluntarily
made in connection with such transfer or distribution, and (D)&nbsp;in the case of clauses (a)(i), (vii), (viii), (ix) and (x)&nbsp;above, no filing under the Exchange Act or other public filing, report or announcement shall be voluntarily made, and
if any such filing, report or announcement shall be legally required during the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, such filing, report or announcement shall clearly indicate in the footnotes thereto (A)&nbsp;the circumstances of
such transfer or distribution and (B)&nbsp;in the case of a transfer or distribution pursuant to clauses (a)(i) or (vii)&nbsp;above, that the donee, devisee, transferee or distributee has agreed to be bound by a
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement containing the same restrictions set forth above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">241 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, the <FONT STYLE="white-space:nowrap">lock-up</FONT> party may (a)&nbsp;enter into a
written plan meeting the requirements of Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act relating to the transfer, sale or other disposition of the undersigned&#8217;s <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Securities, if then permitted by the company, provided that none of the securities subject to such plan may be transferred, sold or otherwise disposed of until after the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period and no
public announcement, report or filing under the Exchange Act, or any other public filing, report or announcement, shall be voluntarily made regarding the establishment of such plan during the <FONT STYLE="white-space:nowrap">lock-up</FONT> period,
and if any such filing, report or announcement shall be legally required during the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, such filing, report or announcement shall clearly indicate that none of the securities subject to such plan
may be transferred, sold or otherwise disposed of pursuant to such plan until after the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period; (b)&nbsp;(i) transfer the <FONT STYLE="white-space:nowrap">lock-up</FONT> party&#8217;s
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction that is approved by the board of directors of the company and made to all holders of the
company&#8217;s capital stock involving a change of control of the company, in one transaction or a series of related transactions, to a person or group of affiliated persons, of shares of capital stock if, after such transfer, such person or group
of affiliated persons would hold at least a majority of the outstanding voting securities of the company (or the surviving entity) and (ii)&nbsp;enter into any <FONT STYLE="white-space:nowrap">lock-up,</FONT> voting or similar agreement pursuant to
which the <FONT STYLE="white-space:nowrap">lock-up</FONT> party may agree to transfer, sell, tender or otherwise dispose of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities in connection with a transaction described in clause (b)(i) above;
provided that in the event that such tender offer, merger, consolidation or other similar transaction is not completed, the <FONT STYLE="white-space:nowrap">lock-up</FONT> party&#8217;s <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities
shall remain subject to the provisions of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement; (c)&nbsp;convert or exchange outstanding preferred stock or preference shares of the company into ordinary shares or shares of common stock,
provided that any such shares received upon such conversion shall remain subject to the provisions of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement; and (d)&nbsp;transfer the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities
or take any other action in connection with the corporate reorganization; provided that any securities converted, transferred pursuant to or otherwise affected by the corporate reorganization shall remain subject to the terms of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to the offering, there has been no public market for the shares. The initial public
offering price has been negotiated among the company and the representatives. Among the factors to be considered in determining the initial public offering price of the shares, in addition to prevailing market conditions, will be the company&#8217;s
historical performance, estimates of the business potential and earnings prospects of the company, an assessment of the company&#8217;s management and the consideration of the above factors in relation to market valuation of companies in related
businesses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have applied to list the common stock on The Nasdaq Global Select Market under the symbol &#8220;COAG.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with the offering, the underwriters may purchase and sell shares of common stock in the open market. These transactions may include short
sales, stabilizing transactions and purchases to cover positions created by short sales. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in the offering, and a short position
represents the amount of such sales that have not been covered by subsequent purchases. A &#8220;covered short position&#8221; is a short position that is not greater than the amount of additional shares for which the underwriters&#8217; option
described above may be exercised. The underwriters may cover any covered short position by either exercising their option to purchase additional shares or purchasing shares in the open market. In determining the source of shares to cover the covered
short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase additional shares pursuant to the option described above.
&#8220;Naked&#8221; short sales are any short sales that create a short position greater than the amount of additional shares for which the option described above may be exercised. The underwriters must cover any such naked short position by
purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">242 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
pressure on the price of the common stock in the open market after pricing that could adversely affect investors who purchase in the offering. Stabilizing transactions consist of various bids for
or purchases of common stock made by the underwriters in the open market prior to the completion of the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters may also impose
a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in
stabilizing or short covering transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Purchases to cover a short position and stabilizing transactions, as well as other purchases by the
underwriters for their own accounts, may have the effect of preventing or retarding a decline in the market price of the company&#8217;s stock, and together with the imposition of the penalty bid, may stabilize, maintain or otherwise affect the
market price of the common stock. As a result, the price of the common stock may be higher than the price that otherwise might exist in the open market. The underwriters are not required to engage in these activities and may end any of these
activities at any time. These transactions may be effected on Nasdaq, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The company estimates that their share of the total expenses of the offering, including registration, filing and listing fees, printing fees and legal
and accounting expenses, but excluding underwriting discounts and commissions, will be approximately $&#8195;&#8195;. The company has agreed to reimburse the underwriters for certain of their expenses in an amount up to $&#8195;&#8195;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The company has agreed to indemnify the several underwriters against certain liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include sales and
trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other financial and <FONT STYLE="white-space:nowrap">non-financial</FONT> activities and
services. Certain of the underwriters and their respective affiliates have provided, and may in the future provide, a variety of these services to the issuer and to persons and entities with relationships with the issuer, for which they received or
will receive customary fees and expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the ordinary course of their various business activities, the underwriters and their respective
affiliates, officers, directors and employees may purchase, sell or hold a broad array of investments and actively trade securities, derivatives, loans, commodities, currencies, credit default swaps and other financial instruments for their own
account and for the accounts of their customers, and such investment and trading activities may involve or relate to assets, securities and/or instruments of the issuer (directly, as collateral securing other obligations or otherwise) and/or persons
and entities with relationships with the issuer. The underwriters and their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in
respect of such assets, securities or instruments and may at any time hold, or recommend to clients that they should acquire, long and/or short positions in such assets, securities and instruments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Selling Restrictions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>European Economic Area </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In relation to each Member State of the European Economic Area (each, a &#8220;Relevant Member&#8221;), no shares have been offered or will be offered
pursuant to the offering to the public in that Relevant Member prior to the publication of a prospectus in relation to the shares which has been approved by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">243 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the competent authority in that Relevant Member or, where appropriate, approved in another Relevant Member and notified to the competent authority in that Relevant Member, all in accordance with
the Prospectus Regulation, except that the shares may be offered to the public in that Relevant Member at any time: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to any legal entity which is a qualified investor as defined under Article 2 of the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the Prospectus
Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">provided that no such offer of the shares shall require us or any of the representatives to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or
supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For the purposes of this provision, the expression an &#8220;offer to
the public&#8221; in relation to the shares in any Relevant Member means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to
purchase or subscribe for any shares, and the expression &#8220;Prospectus Regulation&#8221; means Regulation (EU) 2017/1129. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the case of any
shares being offered to a financial intermediary as that term is used in Article 5 of the Prospectus Regulation, such financial intermediary will also be deemed to have represented, acknowledged and agreed that the shares acquired by it in the
offering have not been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any
shares to the public other than their offer or resale in a Relevant Member to qualified investors as so defined or in circumstances in which the prior consent of the underwriters has been obtained to each such proposed offer or resale. The company
and the underwriters and their affiliates, and others will rely upon the truth and accuracy of the foregoing representation, acknowledgement and agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>United Kingdom </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">No shares have been offered or will be
offered pursuant to the offering to the public in the United Kingdom prior to the publication of a prospectus in relation to the shares which has been approved by the Financial Conduct Authority, except that the shares may be offered to the public
in the United Kingdom at any time: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK
Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">in any other circumstances falling within Section&nbsp;86 of the FSMA, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">provided that no such offer of the shares shall require the Issuer or Manager to publish a prospectus pursuant to Section&nbsp;85 of the FSMA or supplement a prospectus
pursuant to Article 23 of the UK Prospectus Regulation. For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to the shares in the United Kingdom means the communication in any form and by any means of
sufficient information on the terms of the offer and any shares to be offered so as to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">244 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
enable an investor to decide to purchase or subscribe for any shares and the expression. &#8220;UK Prospectus Regulation&#8221; means Regulation (EU) 2017/1129 as it forms part of domestic law by
virtue of the European Union (Withdrawal) Act 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Canada </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in
National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions, and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with an exemption form, or in a transaction not subject to, the
prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Securities legislation in certain provinces or territories of Canada may provide a purchaser
with remedies for rescission or damages if this offering memorandum (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed
by the securities legislation of the purchaser&#8217;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory of these rights or consult with a
legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT
STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this
offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Hong Kong </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The shares may not be
offered or sold in Hong Kong by means of any document other than (i)&nbsp;in circumstances which do not constitute an offer to the public within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32 of the Laws of
Hong Kong) (&#8220;Companies (Winding Up and Miscellaneous Provisions) Ordinance&#8221;) or which do not constitute an invitation to the public within the meaning of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong)
(&#8220;Securities and Futures Ordinance&#8221;), or (ii)&nbsp;to &#8220;professional investors&#8221; as defined in the Securities and Futures Ordinance and any rules made thereunder, or (iii)&nbsp;in other circumstances which do not result in the
document being a &#8220;prospectus&#8221; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance, and no advertisement, invitation or document relating to the shares may be issued or may be in the possession of any person
for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the securities laws of Hong
Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#8220;professional investors&#8221; in Hong Kong as defined in the Securities and Futures Ordinance and any rules made
thereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Singapore </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This prospectus has not
been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares may not be
circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor (as
defined under Section&nbsp;4A of the Securities and Futures Act, Chapter 289 of Singapore (the &#8220;SFA&#8221;)) under Section&nbsp;274 of the SFA, (ii)&nbsp;to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to
Section&nbsp;275(1) of the SFA, or any person pursuant to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">245 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any
other applicable provision of the SFA, in each case subject to conditions set forth in the SFA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Where the shares are subscribed or purchased under
Section&nbsp;275 of the SFA by a relevant person which is a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned
by one or more individuals, each of whom is an accredited investor, the securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation shall not be transferable for 6 months after that corporation has acquired the shares under
Section&nbsp;275 of the SFA except: (1)&nbsp;to an institutional investor under Section&nbsp;274 of the SFA or to a relevant person (as defined in Section&nbsp;275(2) of the SFA), (2) where such transfer arises from an offer in that
corporation&#8217;s securities pursuant to Section&nbsp;275(1A) of the SFA, (3)&nbsp;where no consideration is or will be given for the transfer, (4)&nbsp;where the transfer is by operation of law, (5)&nbsp;as specified in Section&nbsp;276(7) of the
SFA or (6)&nbsp;as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore (&#8220;Regulation 32&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is a trust (where the trustee is not an
accredited investor (as defined in Section&nbsp;4A of the SFA)) whose sole purpose is to hold investments and each beneficiary of the trust is an accredited investor, the beneficiaries&#8217; rights and interest (howsoever described) in that trust
shall not be transferable for 6 months after that trust has acquired the shares under Section&nbsp;275 of the SFA except: (1)&nbsp;to an institutional investor under Section&nbsp;274 of the SFA or to a relevant person (as defined in
Section&nbsp;275(2) of the SFA), (2) where such transfer arises from an offer that is made on terms that such rights or interest are acquired at a consideration of not less than S$200,000 (or its equivalent in a foreign currency) for each
transaction (whether such amount is to be paid for in cash or by exchange of securities or other assets), (3) where no consideration is or will be given for the transfer, (4)&nbsp;where the transfer is by operation of law, (5)&nbsp;as specified in
Section&nbsp;276(7) of the SFA or (6)&nbsp;as specified in Regulation 32. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Solely for the purposes of its obligations pursuant to Section&nbsp;309B
of the SFA, the company has determined, and hereby notify all relevant persons (as defined in the CMP Regulations 2018), that the shares are &#8220;prescribed capital markets products&#8221; (as defined in the CMP Regulations 2018) and Excluded
Investment Products (as defined in MAS Notice SFA <FONT STYLE="white-space:nowrap">04-N12:</FONT> Notice on the Sale of Investment Products and MAS Notice <FONT STYLE="white-space:nowrap">FAA-N16:</FONT> Notice on Recommendations on Investment
Products). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Japan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The securities have not been
and will not be registered under the Financial Instruments and Exchange Act of Japan (Act No.&nbsp;25 of 1948, as amended) (&#8220;the FIEA&#8221;). The securities may not be offered or sold, directly or indirectly, in Japan or to or for the benefit
of any resident of Japan (including any person resident in Japan or any corporation or other entity organized under the laws of Japan) or to others for reoffering or resale, directly or indirectly, in Japan or to or for the benefit of any resident
of Japan, except pursuant to an exemption from the registration requirements of the FIEA and otherwise in compliance with any relevant laws and regulations of Japan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Australia </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">No placement document, prospectus, product
disclosure statement or other disclosure document has been lodged with the Australian Securities and Investments Commission, in relation to the offering. This offering document does not constitute a prospectus, product disclosure statement or other
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">246 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
disclosure document under the Corporations Act 2001 (the &#8220;Corporations Act&#8221;), and does not purport to include the information required for a prospectus, product disclosure statement
or other disclosure document under the Corporations Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any offer in Australia of the shares may only be made to persons (&#8220;Exempt
Investors&#8221;) who are &#8220;sophisticated investors&#8221; (within the meaning of Section&nbsp;708(8) of the Corporations Act), &#8220;professional investors&#8221; (within the meaning of Section&nbsp;708(11) of the Corporations Act) or
otherwise pursuant to one or more exemptions contained in Section&nbsp;708 of the Corporations Act so that it is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The shares applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date of allotment
under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under Section&nbsp;708 of the Corporations Act or otherwise or where the offer is
pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring shares must observe such Australian <FONT STYLE="white-space:nowrap">on-sale</FONT> restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This offering document contains general information only and does not take account of the investment objectives, financial situation or particular needs
of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this offering document is appropriate to their
needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Dubai International Financial Centre </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This offering document relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority
(&#8220;DFSA&#8221;). This offering document is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility
for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth in this prospectus and has no responsibility for the offering document. The
securities to which this offering document relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not understand
the contents of this offering document you should consult an authorized financial advisor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Switzerland </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This offering document is not intended to constitute an offer or solicitation to purchase or invest in the shares of our common stock. The shares of
common stock may not be publicly offered, directly or indirectly, in Switzerland within the meaning of the Swiss Financial Services Act (&#8220;FinSA&#8221;), and no application has or will be made to admit the shares of common stock to trading on
any trading venue (exchange or multilateral trading facility) in Switzerland. Neither this offering document nor any other offering or marketing material relating to the shares of common stock constitutes a prospectus pursuant to the FinSA, and
neither this offering document nor any other offering or marketing material relating to the shares of common stock may be publicly distributed or otherwise made publicly available in Switzerland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Neither this offering document nor any other offering or marketing material relating to the offering, us or the securities have been or will be filed
with or approved by any Swiss regulatory authority. In particular, this offering document will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority, and the offer of securities
has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (&#8220;CISA&#8221;). The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">247 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Brazil </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The offer and sale of the securities have not
been and will not be registered with the Brazilian Securities Commission (Comiss&atilde;o de Valores Mobili&aacute;rios, or &#8220;CVM&#8221;) and, therefore, will not be carried out by any means that would constitute a public offering in Brazil
under CVM Resolution No 160, dated 13&nbsp;July 2022, as amended (&#8220;CVM Resolution 160&#8221;) or unauthorized distribution under Brazilian laws and regulations. The securities may only be offered to Brazilian professional investors (as defined
by applicable CVM regulation), who may only acquire the securities through a <FONT STYLE="white-space:nowrap">non-Brazilian</FONT> account, with settlement outside Brazil in <FONT STYLE="white-space:nowrap">non-Brazilian</FONT> currency. the trading
of these securities on regulated securities markets in Brazil is prohibited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">248 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_20"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The validity of the shares of common stock offered hereby is being passed upon for us by Wilmer Cutler Pickering Hale and Dorr LLP, Boston,
Massachusetts. Goodwin Procter LLP, New York, New York, is acting as counsel for the underwriters in connection with this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">249 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_21"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The consolidated financial statements of Hemab ApS at December&nbsp;31, 2024 and 2025, and for each of the two years in the period ended
December&nbsp;31, 2025, appearing in this prospectus and registration statement, have been audited by EY Godkendt Revisionspartnerselskab, independent registered public accounting firm, as set forth in their report thereon appearing elsewhere
herein, and are included in reliance upon such report given the authority of such firm as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">250 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_22"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act with respect to the
shares of common stock we are offering to sell. This prospectus, which constitutes part of the registration statement, does not include all of the information contained in the registration statement or the exhibits, schedules and amendments to the
registration statement. For further information with respect to us and our common stock, we refer you to the registration statement and to the exhibits and schedules to the registration statement. Statements contained in this prospectus about the
contents of any contract, agreement or other document are not necessarily complete, and in each instance, we refer you to the copy of the contract, agreement or other document filed as an exhibit to the registration statement. Each of these
statements is qualified in all respects by this reference to such contract, agreement or document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The SEC maintains a website, which is located at
www.sec.gov, that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. You may access the registration statement of which this prospectus is a part at the SEC&#8217;s
website at www.sec.gov. Upon completion of this offering, we will be subject to the informational requirements of the Exchange Act and will file annual, quarterly and current reports, proxy statements and other information with the SEC. We also
maintain a website at www.hemab.com and upon completion of this offering, you may access, free of charge, our annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on Form
<FONT STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and any amendments to those reports, as soon as reasonably practicable after such material is electronically filed with, or furnished
to, the SEC. The information contained on, or that can be accessed through, our website is not a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">251 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_23"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin50309_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Consolidated Financial Statements as of and for the Years Ended December&nbsp;31, 2024 and 2025:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin50309_2">Consolidated Balance Sheets </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin50309_3">Consolidated Statements of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin50309_4">Consolidated Statements of Changes in Convertible Preference Shares and Stockholders&#8217;
 Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin50309_5">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin50309_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin50309_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>To the Shareholders and the Board of Directors of Hemab ApS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Opinion on
the Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We have audited the accompanying consolidated balance sheets of Hemab ApS (the Company) as of December 31, 2024 and 2025, the related
consolidated statements of operations and comprehensive loss<B>,</B>&nbsp;convertible preference shares and stockholders&#8217; deficit and cash flows for each of the two years in the period ended December 31, 2025, and the related
notes<B>&nbsp;</B>(collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December
31, 2024 and 2025, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Basis for Opinion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">These financial statements are the responsibility of the
Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States)
(PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about
whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express
no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud,
and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">/s/ EY Godkendt Revisionspartnerselskab </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We have served as the Company&#8217;s
auditor since 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Copenhagen, Denmark </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">February 27, 2026, except for Note 16,
as to which the date is April&nbsp;10, 2026. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin50309_2"></A>HEMAB APS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Consolidated Balance Sheets </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">(in thousands,
except share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">74,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">87,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Operating <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">96,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">194,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><B>Liabilities, convertible preference shares and stockholders&#8217; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Operating lease liabilities, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Commitments and contingencies (Note 8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Convertible preference shares:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Series Seed convertible preference shares, DKK 1 par value; 23,343 shares authorized, issued, and outstanding
as of December&nbsp;31, 2024 and December&nbsp;31, 2025; liquidation preference of $2,611 and $2,939 as of December&nbsp;31, 2024 and December&nbsp;31, 2025, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Series A convertible preference shares, DKK 1 par value; 225,866 shares authorized, issued, and outstanding
as of December&nbsp;31, 2024 and December&nbsp;31, 2025; liquidation preference of $48,496 and $54,528 as of December&nbsp;31, 2024 and December&nbsp;31, 2025, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Series B convertible preference shares, DKK 1 par value; 442,205 shares authorized, issued, and outstanding
as of December&nbsp;31, 2024 and December&nbsp;31, 2025; liquidation preference of $135,248 as of December&nbsp;31, 2024 and December&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Series C convertible preference shares, DKK 1 par value; no shares authorized, issued, and outstanding as of
December&nbsp;31, 2024 and 512,991 shares authorized, issued, and outstanding as of December&nbsp;31, 2025; liquidation preference of $0 and $156,898 as of December&nbsp;31, 2024 and December&nbsp;31, 2025, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Stockholders&#8217; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Ordinary shares, DKK 1 par value; 43,000 shares authorized, issued, and outstanding as of December&nbsp;31,
2024 and December&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Accumulated other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(365</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(117,945</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(181,858</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Total stockholders&#8217; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(115,273</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(176,635</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Total liabilities, convertible preference shares and stockholders&#8217; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">96,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">194,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>See accompanying notes to the financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin50309_3"></A>HEMAB APS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Consolidated Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">(in thousands, except share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,383</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70,119</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income (expense), net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss before income tax (expense) benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,522</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,140</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Income tax (expense) benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(48,707</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(63,913</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,132.72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,486.35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted average ordinary shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other comprehensive income (loss):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net unrealized gain (loss) on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(50,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(63,373</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>See accompanying notes to the financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin50309_4"></A>HEMAB APS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Consolidated Statements of Changes in Convertible Preference Shares and Stockholders&#8217; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">(in thousands, except share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series Seed<BR>Convertible<BR>Preference<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A<BR>Convertible<BR>Preference Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B</B><br><B>Convertible<BR>Preference Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series C</B><br><B>Convertible</B><br><B>Preference Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-In</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Other<BR>Comprehensive<BR>Income (Loss)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#8217;<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL"><B>Balance at December&nbsp;31, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">63,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">442,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">134,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(69,238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(67,139</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Equity-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,707</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,707</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL"><B>Balance at December&nbsp;31, 2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">63,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">442,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">134,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(365</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(117,945</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(115,273</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Issuance of Series C convertible preference shares, net of issuance costs of $477</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">512,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Equity-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63,913</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63,913</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL"><B>Balance at December&nbsp;31, 2025</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">63,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">442,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">134,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">512,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">156,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(181,858</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(176,635</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>See accompanying notes to the financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin50309_5"></A>HEMAB APS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Consolidated Statements of Cash Flows </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">(in
thousands) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;&#8195;2024&#8195;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;&#8195;2025&#8195;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(48,707</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(63,913</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Equity-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-cash</FONT> lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accretion of discount on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,280</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(768</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other <FONT STYLE="white-space:nowrap">non-cash</FONT> items</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,042</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(344</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,156</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(470</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(505</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,592</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61,475</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Purchases of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53,289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(252,497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Maturities of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(282</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(81,482</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds from issuance of Series C convertible preference shares, net of issuance costs of $477</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Principal payments on finance lease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash provided by (used in) financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Effect of&nbsp;foreign exchange&nbsp;rate changes on cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">74,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">87,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Supplemental disclosure of cash flow activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash paid for interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash paid for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Supplemental disclosure of <FONT STYLE="white-space:nowrap">non-cash</FONT> investing and financing
activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> assets obtained
in exchange for operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>See accompanying notes to the financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin50309_6"></A>HEMAB APS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>1. Description
of Business and Liquidity </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Nature of Business </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Hemab ApS (the &#8220;Company&#8221;) is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation
disorders to sustain life and human resilience. Based in Denmark and the United States, the Company&#8217;s mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of
patients worldwide suffering from serious bleeding and thrombotic diseases, including Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease and other conditions of abnormal bleeding, all of which can cause significant life-long
burden to patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company&#8217;s lead asset, sutacimig <FONT STYLE="white-space:nowrap">(HMB-001),</FONT> is a bispecific antibody currently
in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. The Company&#8217;s second clinical-stage asset, <FONT
STYLE="white-space:nowrap">HMB-002,</FONT> is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. The Company is also advancing multiple preclinical and discovery-stage
assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Risks and Uncertainties </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company is
subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need
to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to
commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company&#8217;s product candidates and programs are in preclinical and clinical development. There can be no assurance that
the Company&#8217;s research and development efforts will be successfully completed, that adequate protection for its intellectual property will be obtained, that any product candidates developed will obtain necessary government regulatory approval
or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates
in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees and consultants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Liquidity and Managements Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Since inception, the
Company has devoted substantially all its efforts to business planning, conducting research and development, recruiting management and technical staff, and raising capital. The Company has financed its operations primarily through private placements
of convertible preference shares and issuance of convertible debt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company&#8217;s continued discovery and development of product candidates
will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate
personnel, infrastructure, and compliance-reporting capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company has incurred losses since inception and had an accumulated deficit of $181.9&nbsp;million
as of December&nbsp;31, 2025. The Company expects that its operating losses and negative cash flows will continue for the foreseeable future as it continues development of its product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2025, the Company had cash and cash equivalents, and marketable securities of $185.5&nbsp;million. The Company believes that its
existing cash, cash equivalents, and marketable securities will enable it to fund its operating expenses and capital expenditure requirements for at least one year from the date of the issuance of these consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Until such a time when the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operations through a
combination of equity offerings, debt financings, collaborations, strategic alliances, and marketing, distribution or licensing arrangements. The company may be unable to raise additional funds or enter into such other agreements or arrangements
when needed, on favorable terms, or at all. The Company&#8217;s failure to raise capital or enter into such agreements or arrangements as, and when needed, could have a material adverse effect on its business, results of operations and financial
condition, including potentially requiring it to delay, limit, reduce or eliminate product development or future commercialization efforts, or grant rights to develop and market current or future development product candidates that the Company would
otherwise prefer to develop and market itself. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Principles of Consolidation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The consolidated financial
statements comprise the Company and its wholly-owned subsidiary, Hemab Therapeutics, Inc. All intercompany amounts have been eliminated in consolidation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Basis of Presentation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The accompanying consolidated
financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative
U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Foreign Currency </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The financial statements are
presented in U.S. dollars, the Company&#8217;s reporting currency. The functional currency of Hemab ApS and Hemab Therapeutics, Inc. is the U.S. dollar. Transaction gains and losses resulting from exchange rate changes on transactions denominated in
currencies other than the U.S. dollar are recognized in other (expense) income, net in the consolidated statements of operations and comprehensive loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Use
of Estimates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that
affect the amounts reported in the consolidated financial statements and in these accompanying notes. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors and assumptions that it
believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, which include, but are not limited to, accrued research and development expenses, the fair value of the ordinary shares for equity-based
compensation expense, and the valuation of the Company&#8217;s deferred tax assets. Changes in estimates are recorded in the period in which they become known. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Cash and Cash Equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company&#8217;s cash as of December&nbsp;31, 2024 and 2025 was held in standard checking accounts maintained by major financial institutions. Cash
equivalents are highly liquid investments that are readily convertible into cash with original maturities of three months or less when purchased. As of December&nbsp;31, 2024, the Company had no cash equivalents. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Marketable Securities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company classifies its
investments in debt instruments as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale.</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Available-for-sale</FONT></FONT> debt securities
are carried at fair value with the unrealized gains and losses included in other comprehensive income (loss) as a component of stockholders&#8217; deficit until realized. Any premium or discount arising at purchase is amortized and/or accreted to
interest income and/or expense over the life of the instrument. Realized gains and losses are recognized in the income statement, using the specific identification method and are included in other income (expense), net. The Company also reviews its
portfolio <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">of&nbsp;available-for-sale&nbsp;debt</FONT></FONT> securities, using both quantitative and qualitative factors, to determine if declines in fair value below cost have
resulted from a credit-related loss. If the decline in fair value is due to credit-related factors, a loss is recognized in other income (expense), net. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Concentrations of Credit Risk </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Financial instruments
that potentially expose the Company to concentrations of credit risk primarily consist of cash, cash equivalents, and marketable securities. The Company&#8217;s investment portfolio is primarily comprised of short term debt securities issued by the
U.S., Danish, and German governments. The Company places its cash in financial institutions that management believes to be of high credit quality and, consequently, the Company does not believe it is subject to unusual credit risk beyond the normal
credit risk associated with commercial banking relationships. Bank accounts in the United States are insured by the Federal Deposit Insurance Corporation up to $250,000. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Fair Value Measurements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company follows ASC 820,
<I>Fair Value Measurement</I> (&#8220;ASC 820&#8221;), which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair
value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Accordingly, fair
value is a market-based measurement determined based on assumptions that market participants would use in pricing an asset or liability. The fair value hierarchy requires an entity to maximize the use of observable inputs and minimize the use of
unobservable inputs when measuring fair value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">ASC 820 establishes a fair value hierarchy based on three levels of inputs, of which the first two
are considered observable and the last unobservable, that may be used to measure fair value, which are as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL"><B>Level&nbsp;1</B>: Quoted
prices in active markets for identical assets and liabilities; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL"><B>Level&nbsp;2</B>: Inputs other than Level&nbsp;1 that are observable, either
directly or indirectly, such as quoted market prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full
term of the assets or liabilities; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL"><B>Level&nbsp;3</B>: Unobservable inputs that are supported by little or no market activity and that are
significant to determining the fair value of the assets, including pricing models, discounted cash flow methodologies and similar techniques. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The carrying values of the Company&#8217;s prepaid expenses, accounts payable, and certain accruals
approximate their fair value due to their short-term nature. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Property and Equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Property and equipment is recorded at cost, less accumulated depreciation. Depreciation is recorded using the straight-line method over the following
estimated useful lives of the assets: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Asset</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Estimated Useful Life</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Three years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Three years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Five years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Shorter&nbsp;period&nbsp;of&nbsp;useful&nbsp;life&nbsp;or&nbsp;remaining&nbsp;lease&nbsp;term</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Major replacements and improvements are capitalized, while general repairs and maintenance are expensed as incurred.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain
or loss is included in the consolidated statements of operations and comprehensive loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to ASC Topic 842, <I>Leases</I>, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based
on the unique facts and circumstances present. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. At the lease commencement date, when
control of the underlying asset is transferred from the lessor to the Company, the Company classifies a lease as either an operating or finance lease. The Company has elected not to recognize leases with an original term of one year or less on the
balance sheet. Options to renew a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will renew. Leases with a term greater than one year are recognized on the balance sheet as <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets, lease liabilities and, if applicable, <FONT STYLE="white-space:nowrap">non-current</FONT> operating lease liabilities. Lease liabilities and their
corresponding <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets are recorded based on the present value of lease payments over the expected remaining lease term. However, certain adjustments to the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset may be required for items such as incentives received. The Company has elected as an accounting policy to combine lease and
<FONT STYLE="white-space:nowrap">non-lease</FONT> components, such as common area maintenance, for all classes of underlying assets. The interest rate implicit in lease contracts has not historically been readily determinable. As a result, the
Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Impairment of Long-lived Assets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Long-lived assets
consist of property and equipment and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets. The Company continually evaluates whether events or circumstances have occurred that indicate that the
estimated remaining useful life of its long-lived assets may warrant revision or that the carrying value of these assets may be impaired. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from
the use or disposition of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. No
impairment losses were recorded during the years ended December&nbsp;31, 2024 and 2025. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Research and Development Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Research and development costs are expensed as incurred and include internal and external costs incurred in the development of the Company&#8217;s
product candidates and programs. These costs primarily consist of personnel costs, including equity-based compensation, expenses incurred under agreements with third-party laboratories, contract research organizations (&#8220;CROs&#8221;), contract
manufacturing organizations (&#8220;CMOs&#8221;) and other vendors, facility-related costs, supplies, and consulting costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company has
historically met the requirements to receive a tax credit in Denmark for losses resulting from research and development costs. The tax credit is reported as a reduction to research and development expense in the consolidated statements of operations
and comprehensive loss. For each of the years ended December&nbsp;31, 2024 and 2025, research and development expenses include refundable tax credits of $0.8&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Accrued Research and Development Costs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Substantial
portions of the Company&#8217;s preclinical studies and clinical trials are performed by CROs, CMOs and other vendors. These vendors generally bill monthly or quarterly for services performed. For studies and trials, the Company accrues expenses
based upon estimated percentage of work completed by each vendor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company&#8217;s estimates depend on the timeliness and accuracy of the data
provided by the CROs regarding the status of each program and total program spending. The Company evaluates the estimates to determine if adjustments are necessary or appropriate based on information received. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">CROs invoice the Company upon the occurrence of predetermined contractual or activity-based milestones; however, the timing of these invoices and the
Company&#8217;s related payments often do not correspond directly to the level of performance of contracted activities. To the extent payments are made by the Company in advance of the related activities performed by the vendors, they are recorded
as prepaid expenses and are recognized as expense when the activities are performed by the vendors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Patent Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Costs to secure, defend and maintain patents are expensed as incurred, and are classified as general and administrative expenses due to the uncertainty
of future benefits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Convertible Preference Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company records all convertible preference shares at their respective fair values on the dates of issuance, net of tranche assets and liabilities and
associated issuance costs, if applicable. The Company has classified its convertible preference shares as temporary equity in the consolidated balance sheets due to terms that allow for redemption of the shares upon certain events that are outside
of the Company&#8217;s control. The carrying value of the convertible preference shares is not adjusted to the redemption value until the contingent redemption events are considered probable of occurring. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Equity-Based Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company issues
equity-based awards to employees, managers, executives, and <FONT STYLE="white-space:nowrap">non-employees</FONT> in the form of warrants. The Company accounts for equity-based compensation awards in accordance with ASC 718,
<I>Compensation&#8212;Stock Compensation</I>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The fair value of the Company&#8217;s ordinary shares issued was determined by management, considering
third-party valuations and an assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company estimates the fair value of its warrants using the Black-Scholes option pricing model, which uses as inputs certain management estimates,
including the fair value of the Company&#8217;s ordinary shares, the expected stock price volatility, the expected term of the award, the risk-free rate, and expected dividends. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The fair value of the Company&#8217;s ordinary shares issued was determined by management, considering third-party
valuations and an assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. The independent third-party valuations
were prepared in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#8217; Technical Practice Aid, <I>Valuation of Privately-Held Company Equity Securities Issued as Compensation</I>.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Expected volatility is calculated based on reported volatility data for a representative group of publicly traded companies
for which historical information is available. The Company selects companies with comparable characteristics with historical share price information that approximates the expected term of the equity-based awards. The Company computes the historical
volatility data using the daily closing prices for the selected companies&#8217; shares during the equivalent period that approximates the calculated expected term of the warrants. The Company will continue to apply this method until a sufficient
amount of historical information regarding the volatility of its stock price becomes available. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The risk-free interest rate is based on the U.S. Treasury, or applicable government issues denominated in the currency of
the applicable underlying share, yield curve in effect at the time of grant commensurate with the expected term assumption. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The expected term is determined by the simplified method for service-based awards, under which the expected term is
presumed to be the midpoint between the vesting date and the end of the contractual term. For awards with service-based and performance-based conditions, the expected term is determined based on the expected period to vest and the contractual term.
The Company utilizes these methods due to a lack of historical exercise data. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The expected dividend yield is assumed to be zero as the Company has no current plans to pay any dividends on ordinary
shares. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company generally issues equity awards that are subject to service-based vesting conditions and in limited instances,
service-based and performance-based vesting conditions. Compensation expense for awards issued to grantees with service-based vesting conditions are recognized on a straight-line basis based on the grant date fair value over the associated requisite
service period of the award, which is generally the vesting term. Compensation expense for awards to grantees with service-based and performance-based vesting conditions are recognized based on the grant-date fair value over the requisite service
period using the accelerated attribution method to the extent achievement of the performance condition is probable. As of each reporting date, the Company estimates the probability that specified performance criteria will be met and does not
recognize compensation expense until it is probable that the performance-based vesting condition will be achieved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company evaluates whether an
equity award should be classified and accounted for as a liability award or equity award for all equity-based compensation awards granted. As of December&nbsp;31, 2024 and 2025, all of the Company&#8217;s equity-based awards were equity classified.
Forfeitures are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
recognized as they occur. The Company classifies equity-based compensation expense in the consolidated statements of operations and comprehensive loss in the same manner in which the award
recipient&#8217;s salary and related costs are classified or in which the award recipient&#8217;s service payments are classified, as applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Income
Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Deferred income tax assets and liabilities arise from temporary differences between the financial statements and tax basis of assets
and liabilities, as measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current or <FONT STYLE="white-space:nowrap">non-current,</FONT> depending
upon the classification of the asset or liabilities to which they relate. Deferred tax assets and liabilities not related to an asset or liability are classified as current or <FONT STYLE="white-space:nowrap">non-current</FONT> depending on the
periods in which the temporary differences are expected to reverse. Valuation allowances are established when necessary, to reduce deferred tax assets to the amount expected to be realized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company has generated net losses since inception and accordingly has not recorded a provision for income taxes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company follows the provisions of ASC <FONT STYLE="white-space:nowrap">740-10,</FONT> <I>Uncertainty in Income Taxes</I> (&#8220;ASC <FONT
STYLE="white-space:nowrap">740-10&#8221;).</FONT> The Company has not recognized a liability related to ASC <FONT STYLE="white-space:nowrap">740-10.</FONT> A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been
provided since there is no unrecognized benefit since the date of adoption. The Company has not recognized interest expense or penalties related to ASC <FONT STYLE="white-space:nowrap">740-10.</FONT> If there were an unrecognized tax benefit, the
Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company
has identified Denmark as its major tax jurisdiction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Net Loss Per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Basic net loss per share is calculated by dividing basic net loss by the weighted average number of ordinary shares outstanding for the period. Diluted
net loss per share is calculated by dividing diluted net loss by the weighted average number of ordinary shares outstanding for the period, including potentially dilutive ordinary shares. For purpose of this calculation, outstanding warrants to
purchase ordinary shares and convertible preference shares are considered potentially dilutive ordinary shares. The Company has generated a net loss in all periods presented, and therefore basic and diluted net loss per share is the same, as the
inclusion of the potentially dilutive securities would be anti-dilutive. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Segments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company has one operating segment and one reporting unit. The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) is a committee that
includes its Chief Executive Officer and Chief Financial Officer. The CODM manages the Company&#8217;s operations on a consolidated basis for the purposes of assessing performance and allocating resources. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Comprehensive Loss </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Comprehensive loss includes net
loss as well as other changes in stockholders&#8217; deficit that result from transactions and events other than those with stockholders. The Company&#8217;s unrealized gains and losses on <FONT STYLE="white-space:nowrap">available-for</FONT>
sale-debt securities represent the only component of other comprehensive income (loss). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Emerging Growth Company Status </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act (&#8220;JOBS Act&#8221;). The JOBS Act provides that an
&#8220;emerging growth company&#8221; can take advantage of an extended transition period for complying with new or revised accounting standards. The Company has elected not to &#8220;opt out&#8221; of such extended transition period, which means
that when a standard is issued or revised and it has different application dates for public or private companies, the Company can adopt the new or revised standard at the time private companies adopt the new or revised standard and may do so until
such time that the Company either (1)&nbsp;irrevocably elect to &#8220;opt out&#8221; of such extended transition period or (2)&nbsp;no longer qualify as an emerging growth company. As a result, these consolidated financial statements may not be
comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Recently Adopted Accounting
Standards </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In November 2023, the FASB issued ASU <FONT STYLE="white-space:nowrap">2023-07,</FONT> <I>Segment Reporting (Topic 280):
Improvements to Reportable Segment Disclosures</I> (&#8220;ASU <FONT STYLE="white-space:nowrap">2023-07&#8221;).</FONT> ASU <FONT STYLE="white-space:nowrap">2023-07</FONT> improved reportable segment disclosure requirements, primarily through
enhanced disclosures about significant segment expenses. ASU <FONT STYLE="white-space:nowrap">2023-07</FONT> also enhanced interim disclosure requirements, clarifies circumstances in which an entity can disclose multiple segment measures of profit
or loss, provided new segment disclosure requirements for entities with a single reportable segment and contained other disclosure requirements. The enhanced segment disclosure requirements apply retrospectively to all prior periods presented in the
financial statements. The guidance is effective in the annual periods beginning after December&nbsp;15, 2023, and interim periods in fiscal years beginning after December&nbsp;15, 2024, with early adoption permitted. The Company adopted ASU <FONT
STYLE="white-space:nowrap">2023-07</FONT> effective December&nbsp;31, 2024. For additional information, refer to Note 15. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Recently Issued Accounting
Standards </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In December 2023, the FASB issued ASU <FONT STYLE="white-space:nowrap">2023-09,</FONT> <I>Income Taxes (Topic 740): Improvements
to Income Tax Disclosures</I> (&#8220;ASU <FONT STYLE="white-space:nowrap">2023-09&#8221;).</FONT> ASU <FONT STYLE="white-space:nowrap">2023-09</FONT> will require disclosure of additional information in specified categories with respect to the
reconciliation of the effective tax rate to the statutory rate (the rate reconciliation) for federal, state and foreign income taxes. ASU <FONT STYLE="white-space:nowrap">2023-09</FONT> will also require information pertaining to taxes paid (net of
refunds received) to be disaggregated for federal, state and foreign taxes and further disaggregated for specific jurisdictions to the extent the related amounts exceed a quantitative threshold. ASU <FONT STYLE="white-space:nowrap">2023-09</FONT>
will be effective for the Company in the annual periods beginning after December&nbsp;15, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently
assessing the impact adoption of ASU <FONT STYLE="white-space:nowrap">2023-09</FONT> will have on its consolidated financial statements and related disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In November 2024, the FASB issued ASU <FONT STYLE="white-space:nowrap">2024-03,</FONT> <I>Income Statement&#8212;Reporting Comprehensive
Income&#8212;Expense Disaggregation Disclosures (Subtopic <FONT STYLE="white-space:nowrap">220-40):</FONT> Disaggregation of Income Statement Expenses</I> (&#8220;ASU <FONT STYLE="white-space:nowrap">2024-03&#8221;).</FONT> ASU <FONT
STYLE="white-space:nowrap">2024-03</FONT> will require disclosure of disaggregated information about certain income statement expense line items on an annual and interim basis, including purchases of inventory, employee compensation, depreciation,
intangible asset amortization and depletion for each income statement line item that contains those expenses. ASU <FONT STYLE="white-space:nowrap">2024-03</FONT> also will require certain amounts already disclosed under existing U.S. GAAP to also be
disclosed as a separate category in disaggregated expense table(s), if those amounts are recognized in the relevant expense line item. The amendments in ASU <FONT STYLE="white-space:nowrap">2024-03</FONT> will be effective for the Company in annual
reporting periods beginning after December&nbsp;15, 2026, and interim reporting periods within annual reporting periods beginning after December&nbsp;15, 2027. The Company is currently assessing the impact adoption of ASU <FONT
STYLE="white-space:nowrap">2024-03</FONT> will have on its consolidated financial statements and related disclosures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In September 2025, the FASB issued ASU <FONT STYLE="white-space:nowrap">2025-06,</FONT>
<I>Intangibles&#8212;Goodwill and <FONT STYLE="white-space:nowrap">Other&#8212;Internal-Use</FONT> Software (Subtopic <FONT STYLE="white-space:nowrap">350-40):</FONT> Targeted Improvements to the Accounting for
<FONT STYLE="white-space:nowrap">Internal-Use</FONT> Software</I> (&#8220;ASU <FONT STYLE="white-space:nowrap">2025-06&#8221;).</FONT> ASU <FONT STYLE="white-space:nowrap">2025-06</FONT> eliminates accounting considerations of software project
development stages and clarifies the threshold applied to begin capitalizing costs. ASU <FONT STYLE="white-space:nowrap">2025-06</FONT> will now require entities to capitalize costs associated with
<FONT STYLE="white-space:nowrap">internal-use</FONT> software only when management has authorized and committed funding, and it is probable that the project will be completed and the software will be used to perform its intended function. The
guidance is effective for fiscal years beginning after December&nbsp;15, 2027 and interim periods within those fiscal years. Early adoption is permitted, and entities may apply the standard prospectively or retrospectively. The Company is currently
assessing the impact adoption of ASU <FONT STYLE="white-space:nowrap">2025-06</FONT> will have on its consolidated financial statements and related disclosures. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>3. Fair Value Measurements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following tables present
information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values as of December&nbsp;31, 2024 and 2025 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Marketable securities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">U.S. treasury securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total assets measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash equivalents:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Certificates of deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Marketable securities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">U.S. treasury securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">97,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">97,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total assets measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">166,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">166,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company&#8217;s cash equivalents and marketable securities were valued based on Level&nbsp;2 inputs and in
determining the fair value the Company relied on quoted prices for similar securities in active markets or other inputs that are observable or can be corroborated by observable market data. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>4. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Available-For-Sale</FONT></FONT> Debt Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Available-for-sale&nbsp;debt</FONT></FONT> securities consisted of the following as of
December&nbsp;31, 2024 and 2025 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized</B><br><B>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B><br><B>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B><br><B>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Marketable securities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">U.S. treasury securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(369</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(369</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized</B><br><B>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B><br><B>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B><br><B>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash equivalents:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Marketable securities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">U.S. treasury securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">114,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">115,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">All of the Company&#8217;s
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities as of December&nbsp;31, 2024 and 2025 had a contractual maturity of less than 12 months. The Company did not realize any gains or
losses recognized on the sale of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities during the years ended December&nbsp;31, 2024 and 2025, and, as a result, the Company did not
reclassify any amounts out of accumulated comprehensive loss. All of the Company&#8217;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities as of December&nbsp;31, 2024 and 2025 are
classified as current as they mature within one year from the balance sheet date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2024, the Company held two securities in
an unrealized loss position with an aggregate fair value of $9.9&nbsp;million. As of December&nbsp;31, 2025, the Company held three securities in an unrealized loss position with an aggregate fair value of $97.5&nbsp;million. None of the securities
were in an unrealized loss position for greater than 12 months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company has the intent and ability to hold its debt securities until recovery
of their amortized cost bases, which may be maturity. As a result, the Company did not recognize any differences between the fair value and amortized cost basis as a loss in its consolidated statements of operations and comprehensive loss for the
years ended December&nbsp;31, 2024 and 2025. The Company did not record any credit-related impairments for its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities for the years ended
December&nbsp;31, 2024 and 2025. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>5. Prepaid Expenses and Other Current Assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prepaid expenses and other current assets consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>6. Property and Equipment, net </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Property and equipment, net, consisted of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total property and equipment, at cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Less: accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(723</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2024 and 2025, property and equipment, net included finance leased assets of
approximately $0.5&nbsp;million, with accumulated depreciation of approximately $0.2&nbsp;million and $0.3&nbsp;million, respectively. Depreciation expense for each of the years ended December&nbsp;31, 2024 and 2025 was approximately
$0.2&nbsp;million and $0.3&nbsp;million, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>7. Accrued Expenses and Other Current Liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Accrued expenses and other current liabilities consist of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued employee compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued contract research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>8. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>License and Collaboration Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company is
party to certain agreements that may require future payments upon the achievement of specified development, regulatory, and commercial milestones, as well as royalty payments. These potential obligations are not recorded as liabilities until the
underlying milestone event is deemed probable of occurrence and the related amount is reasonably estimable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Agreement with Novo Nordisk
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In November 2019, the Company entered into a license agreement with Novo Nordisk A/S (&#8220;Novo Nordisk&#8221;), pursuant to which Novo
Nordisk granted the Company an exclusive (even as to Novo Nordisk), worldwide and sublicensable license under specified patent rights, and a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide and sublicensable license under specified
know-how, to research, develop, make, have made, use, offer for sale, sell, import, export or otherwise exploit, or transfer possession of or title in, products (&#8220;Novo Licensed Products&#8221;), containing bispecific IgG antibodies targeting <FONT
STYLE="white-space:nowrap">TLT-1</FONT> and Factor VII, including sutacimig, for the treatment of bleeding conditions, including hemophilia (the &#8220;Novo Nordisk Agreement&#8221;). Under the terms of the Novo Nordisk Agreement, the Company has
agreed to use commercially reasonable efforts to develop and commercialize a Novo Licensed Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company is obligated to pay to Novo Nordisk
a <FONT STYLE="white-space:nowrap">one-time</FONT> DKK 40&nbsp;million milestone payment upon achievement by a Novo Licensed Product of a specified regulatory milestone event, and the Company is also obligated to pay Novo Nordisk tiered royalties,
in the low single-digit percentages, on aggregate annual net sales of all Novo Licensed Products, on a Novo Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Novo</FONT></FONT> Licensed Product and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, until the later of the expiration of the last valid claim in the licensed patents under the Novo Nordisk Agreement covering such Novo Licensed
Product in such country and ten years following the first commercial sale of such Novo Licensed Product in such country. The Company currently expects that all of the licensed patents under the Novo Nordisk Agreement will expire by 2040, potentially
extending to 2045 with patent term extension. To date, the Company has not made any payments to Novo Nordisk under the Novo Nordisk Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The
Novo Nordisk Agreement will continue in force until it is terminated. On expiration of each royalty term, the Company&#8217;s license becomes royalty-free, perpetual, and irrevocable with respect to the applicable Novo Licensed Product in the
applicable country. Either party may terminate the Novo Nordisk Agreement for the other party&#8217;s uncured material breach or insolvency. The Company may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
terminate the Novo Nordisk Agreement for any reason upon 90 days&#8217; written notice to Novo Nordisk. In the event that Novo Nordisk regains control of the exclusive right to exploit the Novo
Licensed Product, the Novo Nordisk Agreement will automatically terminate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Agreement with Genmab </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In April 2020, the Company entered into a license agreement with Genmab A/S (&#8220;Genmab&#8221;), pursuant to which Genmab granted the Company an
exclusive (even as to Genmab and its affiliates), worldwide and sublicensable license under platform technology patent rights and <FONT STYLE="white-space:nowrap">know-how</FONT> relating to Genmab&#8217;s proprietary DuoBody<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> platform to research, develop, make, have made, use, manufacture, import, export and commercialize products comprising bispecific IgG antibodies targeting
<FONT STYLE="white-space:nowrap">TLT-1</FONT> and Factor VII (the &#8220;TLT-1/Factor VII Antibody Products&#8221;), including sutacimig, for the treatment of bleeding conditions, including hemophilia (the &#8220;Genmab Agreement&#8221;). Under the
terms of the Genmab Agreement, the Company has agreed to use commercially reasonable efforts to develop, manufacture, obtain regulatory approval for and commercialize TLT-1/Factor VII Antibody Products worldwide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the Genmab Agreement, the Company is obligated to pay Genmab a percentage of all net profit (i.e., revenue and other proceeds less specified
direct costs the Company incurs to conduct research, development, manufacture and commercialization of <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products) the Company or its affiliates receive with respect to any <FONT
STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products, including (1)&nbsp;net profit from commercial sales of <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products and any revenue from third parties, other than
Novo Nordisk, in respect of a sublicense or assignment with respect to <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products, including assignment fees, sublicensing fees, upfront and milestone fees, royalties and other
consideration, whether in kind or cash, and (2)&nbsp;the net profit allocated to <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products that the Company or its affiliates receive if the Company undergoes a change of control
(other than an acquisition by Novo Nordisk). The percentage of net profit the Company owes with respect to each TLT-1/Factor VII Antibody Product is in the low teens from the effective date of the Genmab Agreement until the first commercial sale of
such TLT-1/Factor VII Antibody Product. From and after the first commercial sale of a TLT-1/Factor VII Antibody Product, the percentage of net profit the Company owes with respect to such TLT-1/Factor VII Antibody Product is in the high single
digits in all territories in which the Company commercializes such TLT-1/Factor VII Antibody Product and in the mid-teens in all territories in which a third party, other than Novo Nordisk, commercializes such
<FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Product. The Company is obligated to pay such percentage of net profit on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT
STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-TLT-1/Factor</FONT></FONT></FONT> VII Antibody Product basis until the later of
the expiration of the last-to-expire of the platform technology patent rights licensed under the Genmab Agreement covering such <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Product in such country and twelve years following the
first commercial sale of such <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Product in such country, which the Company refers to as the net profit share term. Following the expiration of the last-to-expire of the platform
technology patent rights licensed under the Genmab Agreement covering a given TLT-1/Factor VII Antibody Product in a given country, the percentage of net profit that the Company is obligated to pay with respect to sales of such TLT-1/Factor VII
Antibody Product in such country will be reduced by a specified percentage for the remainder of the net profit share term for such TLT-1/Factor VII Antibody Product in such country. The Company currently expects that all of the platform technology
patent rights licensed under the Genmab Agreement will expire by 2032, though this date may be extended if, for example, Genmab files additional patents covering its platform technology. To date, the Company has not made any payments to Genmab under
the Genmab Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the event the Company seeks to sell, license or otherwise dispose of its rights to TLT-1/Factor VII Antibody Products,
including through a change of control to any third party other than Novo Nordisk, the Company is obligated to provide Genmab the right to participate in any bidding process as a <I>bona fide</I> potential acquirer of such rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Unless earlier terminated, the Genmab Agreement will expire, on a TLT-1/Factor VII Antibody
Product-by-TLT-1/Factor VII Antibody Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, upon the expiration of the last net profit share term for such TLT-1/Factor VII Antibody
Product in such country. On expiration of each net profit share term, the Company&#8217;s license becomes perpetual, fully <FONT STYLE="white-space:nowrap">paid-up</FONT> and <FONT STYLE="white-space:nowrap">non-exclusive</FONT> with respect to the
applicable TLT-1/Factor VII Antibody Product in the applicable country. Either party may terminate the Genmab Agreement for the other party&#8217;s uncured material breach or insolvency or in certain events of force majeure. Genmab may terminate the
Genmab Agreement if the Company or its affiliates or sublicensees challenge any of the platform technology patent rights licensed under the Genmab Agreement. The Company may terminate the Genmab Agreement for any reason upon 120 days written notice
to Genmab. If Novo Nordisk obtains from us the exclusive right to exploit <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products, including upon termination of the Novo Nordisk Agreement, then the Genmab Agreement will terminate
in all territories in which Novo Nordisk obtains such exclusive rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Indemnification Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other
parties with respect to certain matters arising out of the relationship between such parties and the Company. In addition, the Company has entered into indemnification agreements with members of its board of directors that will require the Company,
among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors. The maximum potential amount of future payments the Company could be required to make under these indemnification
agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any claims under indemnification arrangements, and it has not accrued any liabilities
related to such obligations as of December&nbsp;31, 2024 and 2025. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Legal Proceedings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company, from time to time, may be party to litigation arising in the ordinary course of business. The Company was not subject to any material legal
proceedings during the years ended December&nbsp;31, 2024 and 2025 and, to the best of its knowledge, no material legal proceedings are currently pending or threatened. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>9. Leases </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Finance Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In January 2023, the Company entered into a finance lease for certain laboratory equipment in Copenhagen, Denmark. The laboratory equipment was
classified as a finance lease due to the existence of a bargain purchase option in the lease agreement. In connection with this lease, the Company recorded a finance lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and finance lease liability of approximately $0.5&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Operating Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In September 2023, the Company
entered into a <FONT STYLE="white-space:nowrap">non-cancelable</FONT> operating lease for office space in Cambridge, Massachusetts. The lease requires the Company to pay annual base rent of approximately $0.4&nbsp;million, which is subject to a 2%
annual increase over the term of the lease. The lease expires in October 2026 and contains a <FONT STYLE="white-space:nowrap">two-year</FONT> renewal option exercisable by the Company. The renewal option is not reasonably certain to be exercised by
the Company and as such, the additional term is not included in the measurement of the lease. In connection with the signing of the lease, the Company is required to maintain a cash deposit of $0.2&nbsp;million which is classified in other <FONT
STYLE="white-space:nowrap">non-current</FONT> assets as of December&nbsp;31, 2024 and 2025. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In March 2024, the Company entered into a <FONT STYLE="white-space:nowrap">non-cancelable</FONT>
operating sublease for office and laboratory space in Copenhagen, Denmark. The lease requires the Company to pay annual base rent of approximately $0.3&nbsp;million, which is subject to a 3% annual increase over the term of the lease. The lease
expires in February 2029 and contains a <FONT STYLE="white-space:nowrap">one-year</FONT> renewal option exercisable by the Company. The renewal option is not reasonably certain to be exercised by the Company and as such, the additional term is not
included in the measurement of the lease. In connection with the signing of the lease, the Company is required to maintain a cash deposit of $0.2&nbsp;million which is classified in other <FONT STYLE="white-space:nowrap">non-current</FONT> assets as
of December&nbsp;31, 2024 and 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and
lease liabilities are recorded within the consolidated balance sheets as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Consolidated Balance Sheet<BR>Classifications</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> assets,
operating</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> assets,
finance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Current:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Lease liabilities, operating</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Lease liabilities, finance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-current:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Lease liabilities, operating</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating lease liabilities, net of current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Lease liabilities, finance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The components of lease costs for the years ended December&nbsp;31, 2024 and 2025 were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2024&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2025&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating lease costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Finance lease costs:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Amortization of finance lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest expense on finance lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Variable lease costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Short-term lease costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Variable lease costs include payments for the Company&#8217;s proportionate share of facilities operating expenses under
its operating leases. Such amounts are not included in the measurement of lease liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Supplemental disclosure of cash flow information
related to the leases was as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash paid for amounts included in the measurement of lease liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating cash flows used in operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating cash flows used in finance leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Financing cash flows used in finance leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The weighted-average remaining lease terms and discount rates were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average remaining lease term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Finance leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average remaining lease term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Because the interest rate implicit in the lease was not readily determinable, the Company&#8217;s estimated incremental
borrowing rate was used to calculate the present value of the lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2025, the future minimum lease payments due under the <FONT
STYLE="white-space:nowrap">non-cancelable</FONT> leases was as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Operating&nbsp;Leases</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Finance&nbsp;Leases</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2029</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2030</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total future minimum lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;1,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Less: amounts representing interest or imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(130</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>10. Convertible Preference Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Series Seed Convertible Preference Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In November
2020, the Company executed an investment agreement under which it issued and sold 23,343 shares of Series Seed convertible preference shares (&#8220;Series Seed Convertible Preference Shares&#8221;) for gross cash proceeds of <FONT
STYLE="font-family:Times New Roman">&#128;</FONT>2.5&nbsp;million ($3.0 million). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Series A Convertible Preference Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In July 2021, the Company executed an investment agreement (&#8220;Series A Investment Agreement&#8221;) to issue and sell up to 225,866 shares of Series
A convertible preference shares (&#8220;Series A Convertible Preference Shares&#8221;) for gross proceeds of up to DKK 346.4&nbsp;million ($50.9 million). In the initial closing in July 2021, the Company issued 61,600 shares of Series A Convertible
Preference Shares. This included DKK 57.2&nbsp;million ($9.0&nbsp;million) in gross cash proceeds (37,297 shares) and DKK 37.3&nbsp;million ($5.9&nbsp;million) from the conversion of the principal and interest balance of debt (24,303 shares).
Pursuant to the Series A Investment Agreement, the Company was obligated to issue and the investors were obligated to purchase an additional 164,266 shares of Series A Convertible Preference Shares for total cash proceeds of DKK 251.9&nbsp;million
($36.0&nbsp;million) in three separate closings upon the satisfaction of certain conditions related to clinical development. All of the conditions were achieved prior to February 2023. The Company incurred DKK 1.8&nbsp;million ($0.3&nbsp;million) of
issuance costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Series B Convertible Preference Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In February 2023, the Company executed an investment agreement under which it issued and sold 442,205 shares of Series B convertible preference shares
(&#8220;Series B Convertible Preference Shares&#8221;) for gross cash proceeds of $135.2&nbsp;million. The Company incurred $0.3&nbsp;million of issuance costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Series C Convertible Preference Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In October
2025, the Company executed an investment agreement under which it issued and sold 512,991 shares of Series C convertible preference shares (&#8220;Series C Convertible Preference Shares&#8221;) for gross cash proceeds of $156.9&nbsp;million. The
Company incurred $0.5&nbsp;million of issuance costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2024 and 2025, the convertible preference shares consisted of the
following (in thousands, except share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preference<BR>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preference<BR>Shares<BR>Issued and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary<BR>Shares<BR>Issuable<BR>Upon<BR>Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series Seed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">442,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">442,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">442,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">691,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">691,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">203,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">186,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">691,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preference<BR>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preference<BR>Shares<BR>Issued and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary<BR>Shares<BR>Issuable<BR>Upon<BR>Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series Seed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">442,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">442,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">442,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">512,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">512,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">512,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,204,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,204,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">360,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">349,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,204,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The rights, preferences, and privileges of the convertible preference shares were as follows as of December&nbsp;31,
2025: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Liquidity Preference </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company liquidity
events (&#8220;Liquidity Events&#8221;) under its articles of association include: (i)&nbsp;the sale, or other transfer of shares, involving all or part of the shares in which shares from more than one share class are transferred, and which
represents more than 20% of the share capital, or by payment for an option to subsequently purchase shares from the shareholders as a whole, (ii)&nbsp;listing of the Company&#8217;s shares on an alternative or regulated market, (iii)&nbsp;payment of
dividends, (iv)&nbsp;reduction of the share capital for distribution to shareholders, (v)&nbsp;liquidation or other dissolution of the Company, (vi)&nbsp;a merger whereby the Company is dissolved, (vii)&nbsp;a demerger of the Company, or
(viii)&nbsp;a combination of Liquidity Events as well as any other situations leading to allocation of proceeds and/or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
any other consideration among the shareholders. In the case of a Liquidity Event, the proceeds, if any, shall be distributed to the shareholders in accordance with the following priority: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">First, the holders of Series C Convertible Preference Shares shall, for every Series C Convertible Preference Share of
DKK 1, receive in advance the part of the proceeds or other consideration equal to the subscription price paid for the Series C Convertible Preference Share (as adjusted for any stock splits, combinations, and, to the extent relevant, capital
reductions or capital increases or any other similar actions); if the available proceeds are insufficient to make payment in full on the Series C Convertible Preference Shares, then the available proceeds shall be allocated pro rata amongst the
holders in proportion to their holdings of Series C Convertible Preference Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Second, the holders of Series A and/or Series B Convertible Preference Shares shall, for every Series A and/or Series B
Convertible Preference Share of DKK 1, receive in advance the part of the proceeds or other consideration equal to the applicable subscription price paid for the Series A and/or Series B Convertible Preference Shares (as adjusted for any stock
splits, combinations, and, to the extent relevant, capital reductions or capital increases or any other similar actions); if the available proceeds are insufficient to make payment in full on the Series A and/or Series B Convertible Preference
Shares, then the available proceeds shall be allocated pro rata amongst the holders in proportion to their holdings of Series A and/or Series B Convertible Preference Shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Third, the holders of Series Seed Convertible Preference Shares shall, for every Series Seed Convertible Preference Share
of DKK 1, receive in advance the part of the proceeds or other consideration equal to the subscription price paid for the Series Seed Convertible Preference Share (as adjusted for any stock splits, combinations, and, to the extent relevant, capital
reductions or capital increases or any other similar actions); if the available proceeds are insufficient to make payment in full on the Series Seed Convertible Preference Shares, then the available proceeds shall be allocated pro rata amongst the
holders in proportion to their holdings of Series Seed Convertible Preference Shares (together with clauses (i)&nbsp;and (ii) above, the &#8220;Liquidity Preference&#8221;). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The remaining proceeds, if any, following distribution of the Liquidity Preference shall be distributed to the ordinary shares on a pro rata basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If a Liquidity Event will result in all holders of convertible preference shares receiving a higher amount of proceeds by allocating such proceeds pro
rata to all shares in the Company compared to applying the Liquidity Preference, the Liquidity Preference shall not apply, and the convertible preference shares shall automatically convert into ordinary shares on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis (adjusted for any stock splits, combinations, and to the extent relevant, capital reductions or capital increases or any other similar actions), following which the total proceeds shall be
allocated pro rata to all shares in the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Conversion </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The convertible preference shares are convertible at the option of the holder at any time on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis (adjusted for any stock splits, combinations, and to the extent relevant, capital reductions or capital increases or any other similar actions). In addition, the convertible preference
shares will be automatically converted into ordinary shares on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis (adjusted for any stock splits, combinations, and to the extent relevant, capital
reductions or capital increases or any other similar actions)&nbsp;(i) in the event that 50% of all Preference Shares voting as one share class, including 60% of the Series C Convertible Preference Shares (the &#8220;Investor Majority&#8221;),
consents to such conversion, or (ii)&nbsp;in the event of a public offering which generates gross proceeds of not less than $100&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Voting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The holders of convertible preference shares are entitled to one vote per share on all matters to be voted upon at all general meetings and written
actions in lieu of meetings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Redemption </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The
convertible preference shares are not subject to mandatory redemption. Upon certain events that are outside of the Company&#8217;s control, the convertible preference shares are contingently redeemable at a price equal to the greater of the
Liquidity Preference or the amount that would be received on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>11. Ordinary Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2024 and 2025, the Company had 43,000 ordinary shares authorized, issued and outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The holders of ordinary shares are entitled to an allocation and distribution of proceeds in a Liquidity Event subject to the Liquidity Preference. When
the Liquidity Preference has been paid in full, any remaining proceeds shall be distributed to the ordinary shares on a pro rata basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The holders
of ordinary shares are entitled to one vote per share on all matters to be voted upon at all general meetings and written actions in lieu of meetings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>12.
Equity-Based Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of
December&nbsp;31, 2025, the Company is authorized to award up to 237,601 warrants. Each vested warrant will entitle the warrant holder the right to subscribe for one ordinary share. Holders of stock warrants are entitled to exercise the vested
portion of the warrant. The service-based warrant grants generally vest over a four-year service period, with the first 25% vesting on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the vesting start date and the remaining
vesting in equal monthly installments over the following 36 months. The service-based and performance-based warrant grants vest in the same manner as the service-based only awards to the extent the performance condition is met. The Company&#8217;s
warrants expire ten years after the initial grant date if they remain unexercised. Upon the exercise date, the Company issues new ordinary shares to the participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2025, the Company had 142,085 warrants available for future grant. No warrants were exercised during the years ended
December&nbsp;31, 2024 or 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following assumptions were used in determining the fair value of warrants granted during the periods: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>&#8195;&#8195;2024&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>&#8195;&#8195;2025&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">89.2%&nbsp;-&nbsp;90.2%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">89.5%&nbsp;-&nbsp;89.7%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.9% - 4.5%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.2% - 4.4%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.7 - 6.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Fair value per ordinary share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">153.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">168.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table summarizes the Company&#8217;s warrants for the years ended December&nbsp;31, 2024
and 2025: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>&#8195;Warrants&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-average</FONT><BR>exercise price<BR>per&nbsp;share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-average</FONT><BR>remaining<BR>contractual term</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>intrinsic value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Outstanding, December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">114.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">153.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(626</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">155.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Outstanding, December&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">117.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">168.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,042</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">160.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Outstanding, December&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">124.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Exercisable at December&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">108.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Vested and expected to vest, December&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">124.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The weighted-average grant date fair value of the warrants granted during the years ended December&nbsp;31, 2024 and
2025 was $117.06 and $129.76, respectively. The total fair value of the warrants that vested during the years ended December&nbsp;31, 2024 and 2025 was $2.4&nbsp;million and $1.8&nbsp;million, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Performance-Based Warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During 2022, the Company
issued warrants to certain employees that included two components: (i)&nbsp;a performance condition that is achieved upon the separate closings of the Series A Convertible Preferred Shares, and (ii)&nbsp;a service condition where the employee
provides service over a four-year period. Upon the final closing of the Series A Convertible Preferred Shares in January 2023, all performance conditions had been satisfied and the warrants were subject to ongoing service conditions. Equity-based
compensation expense is recognized using an accelerated attribution method over the remaining requisite service period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Equity-Based Compensation
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Equity-based compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2024&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2025&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2025, the total unrecognized compensation expense related to the Company&#8217;s warrants was
$3.1&nbsp;million, which the Company expects to recognize over a weighted-average period of approximately 2.1 years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>13. Income Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company is subject to taxation in the United States and Denmark. The Company had income tax expense of $0.2&nbsp;million and income tax benefit of
$0.2&nbsp;million for the years ended December&nbsp;31, 2024 and 2025, respectively. The Company&#8217;s effective tax rate differs from the statutory rate each year mainly due to a valuation allowance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company&#8217;s loss before income tax expense for income taxes for the years ended December&nbsp;31, 2024 and 2025 consisted of the following (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2024&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2025&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Domestic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(49,165</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(65,274</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(48,522</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(64,140</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Reconciliation of Effective Tax Rate </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company&#8217;s effective tax rate for the years ended December&nbsp;31, 2024 and 2025 is different from the statutory rate in Denmark primarily due
to the valuation allowance against deferred tax assets as a result of insufficient sources of income. The reconciliation of the statutory income tax rate to the Company&#8217;s effective income tax rate is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2024&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2025&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Income tax benefit at the statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21.5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23.3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Permanent adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Federal research and development tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.4</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Deferred Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Deferred tax assets and liabilities represent future tax consequences of temporary differences between the financial statement carrying amounts and the
tax basis of assets and liabilities and for loss carryforwards using enacted tax rates expected to be in effect in the years in which the differences reverse. A valuation allowance is recorded when it is more likely than not that some or all of the
deferred tax assets will not be realized. The principal components of the Company&#8217;s deferred tax assets consisted of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2024&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2025&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Deferred tax assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development tax credits&#8212;Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development tax credits&#8212;State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Less: valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,282</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,270</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2024&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2025&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Deferred tax liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Depreciation/fixed assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net deferred tax assets (liabilities)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it
is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more likely than not recognition threshold is
calculated as the largest amount that is more than 50%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">When realization of a deferred tax asset is more likely than not to occur, the benefit
related to the deductible temporary differences attributable to operations is recognized as a reduction of income tax expense. Valuation allowances are provided against deferred tax assets when, based on all available evidence, it is considered more
likely than not that some portion or all of the recorded deferred tax assets will not be realized in future periods. The Company cannot be certain that future income in Denmark will be sufficient to realize the Company&#8217;s deferred tax assets.
Accordingly, a full valuation allowance has been provided only against the net deferred tax assets of Hemab ApS. The valuation allowance increased by $15.0&nbsp;million in 2025. The increase in 2025 is primarily the result of an increase in net
operating loss carryforwards (&#8220;NOLs&#8221;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Available Carryforward Tax Losses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">At December&nbsp;31, 2025, the Company had NOL carryforwards of approximately $170.9&nbsp;million that can be carried forward indefinitely according to
Danish Tax Authority regulations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Uncertain Tax Positions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company determines its uncertain tax positions based on whether and how much of a tax benefit taken by the Company in its tax filings is more likely
than not to be sustained upon examination by the relevant income tax authorities. The Company has reviewed the tax positions taken, or to be taken, in its tax returns for all tax years currently open to examination by the Danish Tax Authority. As of
December&nbsp;31, 2024 and 2025, the Company has not recorded an uncertain tax position liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Tax filings in Denmark remain subject to
examination by the Danish Tax Authority. As of December&nbsp;31, 2025, tax years 2022 and forward were generally open to examination by the Danish Tax Authority. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Other Tax Matters </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company recognizes accrued
interest related to unrecognized tax benefits and penalties as income tax expense. The Company does not have any material unrecognized tax benefits which would affect the effective tax rate if recognized. The Company does not have any unrecognized
tax benefits which would reverse within the next twelve months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company is eligible for the Danish enhanced research and development tax
allowance, providing for an increase in the deductible value of the amount of certain R&amp;D expenditures. The deduction for R&amp;D expenditures is set at 108% for 2023 through 2025, 114% for 2026, 116% for 2027 and 120% for 2028 and onwards. A
combined cap applies to the enhanced deduction at the consolidated group level; expenditures exceeding the cap may be deducted at 110%. For 2026, the cap amounts to DKK&nbsp;1,088.8 million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, in 2012 the Folketinget, or Danish Parliament, introduced a tax credit policy that allows
companies with losses resulting from research and development costs to receive payment of the tax base of losses of up to DKK 25&nbsp;million. The Company has historically met the requirements to receive payment. The tax credit is reported as a
reduction to research and development expense in the consolidated statements of operations and comprehensive loss. For the years ended December&nbsp;31, 2024 and 2025, the Company applied for refundable tax credit of DKK 25&nbsp;million for each
year and a receivable was recorded for $0.8&nbsp;million. Starting in 2027, the limit will increase to DKK 35&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>14. Net Loss Per Share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth the outstanding ordinary share equivalents, presented based on amounts outstanding at each period end, that were excluded
from the calculation of diluted net loss per share for the periods indicated because including them would have been anti-dilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2024&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2025&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Convertible preference shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">691,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,204,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Warrants to purchase ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>15. Segment Reporting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The
Company has one operating segment. The Company&#8217;s operating segment is engaged in the research and development of prophylactic therapeutics for bleeding disorders. The Company&#8217;s Chief Executive Officer and Chief Financial Officer/General
Manager are together considered the Company&#8217;s CODM and together manage the Company&#8217;s operations on a consolidated basis for the purposes of assessing performance and allocating resources based on net loss that also is reported on the
consolidated statement of operations as consolidated net loss. This financial metric is used by the CODM to make key operating decisions such as the allocation of capital between program expenses, early-stage discovery expenses, and general and
administrative expense, including headcount and facilities decisions. The measure of segment assets is reported on the balance sheet as total consolidated assets. The following table presents long-lived assets by geographic location as of
December&nbsp;31, 2024 and 2025 (amounts in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2024&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2025&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">United States of America</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">873</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Denmark</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table presents selected financial information about the Company&#8217;s single operating segment for the
years ended December&nbsp;31, 2024 and 2025 (amounts in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2024&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2025&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating Expenses<SUP STYLE="font-size:75%; vertical-align:top">(a)</SUP>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development personnel-related (excluding equity-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">External research and development costs&#8212;sutacimig</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">External research and development <FONT STYLE="white-space:nowrap">costs&#8212;HMB-002</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">External&#8212;discovery related costs and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Personnel-related (excluding equity-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2024&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2025&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">External&#8212;general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Equity-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Depreciation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other segment (income) expenses<SUP STYLE="font-size:75%; vertical-align:top">(b)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,005</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,740</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,974</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Income tax expense (benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(227</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Consolidated net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">63,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The significant expense categories and amounts align with the segment-level information that is regularly provided to the
CODM. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Other segment expenses include foreign currency exchange loss and other income/expense. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>16. Subsequent Events </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company has evaluated subsequent
events through February 27, 2026, the original date the financial statements were issued, except for the corporate reorganization as described below, for which the date is April 10, 2026. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Corporate Reorganization </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On March 30, 2026, the
Company completed a corporate reorganization pursuant to which the shareholders of Hemab ApS exchanged their shares in Hemab ApS for the same number, class and series of newly issued shares, on a one to one basis, in the newly incorporated Delaware
company, Hemab Therapeutics Holdings, Inc. and, as a result, Hemab ApS became a wholly owned subsidiary of Hemab Therapeutics Holdings, Inc. The newly issued shares of Hemab Therapeutics Holdings, Inc. have substantially identical rights to the
exchanged shares of Hemab ApS. As a result of the exchange, Hemab Therapeutics Holdings, Inc. became the sole shareholder of Hemab ApS, and the prior shareholders of Hemab ApS solely hold shares of Hemab Therapeutics Holdings, Inc.&nbsp;Hemab
Therapeutics Holdings, Inc. had nominal assets and liabilities and did not conduct any operations prior to the corporate reorganization other than its incorporation. Upon completion of the corporate reorganization, the historical consolidated
financial statements of Hemab ApS became the historical consolidated financial statements of Hemab Therapeutics Holdings, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with
the corporate reorganization, each outstanding warrant to subscribe for the purchase of ordinary shares of Hemab ApS was assumed by Hemab Therapeutics Holdings, Inc. and converted into a warrant to purchase the same number of shares of common stock
of Hemab Therapeutics Holdings, Inc. Each new warrant otherwise has and is subject to the same terms and conditions as were in effect immediately prior to the assumption and conversion, except that any warrant exercise price that had been
denominated in DKK prior to the corporate reorganization was converted into an exercise price in U.S. dollars at the exchange rate as in effect at the close of business on the business day prior to the corporate reorganization. No warrants of Hemab
ApS are outstanding following the assumption and conversion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, promptly following the corporate reorganization, on April 1, 2026, Hemab
ApS transferred its shares of Hemab Therapeutics Inc., a Delaware corporation and wholly-owned subsidiary of Hemab ApS, to Hemab Therapeutics Holdings, Inc. in exchange for the issuance of a promissory note and, as a result, Hemab Therapeutics Inc.
became a wholly owned subsidiary of Hemab Therapeutics Holdings, Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<DIV STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center">&#8195;&#8195;&#8195;&#8195;Shares </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g62g77.jpg" ALT="LOGO" STYLE="width:1.76267in;height:0.348971in;">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="font-size:96pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Preliminary Prospectus </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:140pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I></I></B><I></I><B><I>J</I></B><I></I><B><I>oint Book-Running Managers</I></B><I></I><B><I> </I></B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" NOWRAP ALIGN="center"><B>Goldman Sachs&nbsp;&amp; Co. LLC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><B>Evercore ISI</B></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>Lead Manager </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-size:10pt"><B>Wedbush PacGrow</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Until&#8195;&#8195;&#8195;&#8195;, 2026 (25 days after the date of this prospectus), all dealers that effect
transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the dealers&#8217; obligation to deliver a prospectus when acting as underwriters
and with respect to their unsold allotments or subscriptions. </I></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">&#8195;&#8195;&#8195;, 2026 </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&#8201;13.
Other Expenses of Issuance and Distribution. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth the expenses to be incurred in connection with the offering
described in this registration statement, other than underwriting discounts and commissions, all of which will be paid by the registrant. All amounts are estimates except the SEC registration fee, the Financial Industry Regulatory Authority, Inc.
filing fee and the Nasdaq Global Select Market initial listing fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Amount</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Securities and Exchange Commission registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$13,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Financial Industry Regulatory Authority, Inc. filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Nasdaq Global Select Market initial listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Transfer agent and registrar&#8217;s fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Printing and mailing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">* To be filed by amendment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&#8201;14.
Indemnification of Directors and Officers. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Section&nbsp;102(b)(7) of the DGCL provides, generally, that a corporation may include in its
certificate of incorporation a provision eliminating or limiting the personal liability of a director or officer to the corporation or its shareholders for monetary damages for breach of fiduciary duty as a director or officer, provided that such
provision may not eliminate or limit the liability of (i)&nbsp;a director or officer for any breach of the director&#8217;s or officer&#8217;s duty of loyalty to the corporation or its shareholders, (ii)&nbsp;a director or officer for acts or
omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&nbsp;a director under section 174 of the DGCL, (iv)&nbsp;a director or officer for any transaction from which the director or officer derived an
improper personal benefit or (v)&nbsp;an officer in any action by or in the right of the corporation. No such provision may eliminate or limit the liability of a director or officer for any act or omission occurring prior to the date when such
provision became effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Section&nbsp;145 of the DGCL provides, generally, that a corporation shall have the power to indemnify any person who
was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (except actions by or in the right of the corporation) by reason of the fact that such person is or was a director, officer,
employee or agent of the corporation against all expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a
manner such person reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. A corporation may
similarly indemnify such person for expenses actually and reasonably incurred by such person in connection with the defense or settlement of any action or suit by or in the right of the corporation, provided that such person acted in good faith and
in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in the case of claims, issues and matters as to which such person shall have been adjudged liable to the corporation, provided that a
court shall have determined, upon application, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which such court
shall deem proper. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our restated certificate of incorporation that will be effective immediately prior to the completion of this offering provides
that we will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the
right of us), by reason of the fact that he or she is or was, or has agreed to become, our director or officer or, while our director or officer, is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or
trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (including any employment benefit plan) (all such persons being referred to as an &#8220;Indemnitee&#8221;), or by reason of any
action alleged to have been taken or omitted by an Indemnitee in such capacity, against all expenses (including attorneys&#8217; fees), liabilities, losses judgments, fines (including excise taxes and penalties arising under the Employee Retirement
Income Security Act of 1974), and amounts paid in settlement actually and reasonably incurred on or on behalf of the Indemnitee in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and
in a manner he or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our restated certificate of incorporation that will be effective immediately prior to the completion of this offering also provides that we will
indemnify any Indemnitee who was or is a party to or threatened to be made a party to any threatened, pending or completed action or suit by or in the right of us to procure a judgment in our favor by reason of the fact that the Indemnitee is or
was, or has agreed to become, our director or officer or, while our director or officer, is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee, or trustee of, or in a similar capacity with, another
corporation, partnership, joint venture, trust, or other enterprise (including any employee benefit plan), or by reason of any action alleged to have been taken or omitted by he or she in such capacity, against all expenses (including
attorneys&#8217; fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred by or on behalf of the Indemnitee in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee
acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged
to be liable to us, unless, and only to the extent, that the Court of Chancery of Delaware or the court in which such action or suit was brought shall determine upon applications that, despite the adjudication of such liability but in view of all
the circumstances of the case, he or she is fairly and reasonably entitled to indemnify for expenses (including attorney&#8217;s fees) which the Court of Chancery of Delaware or such other court shall deem proper. Notwithstanding the foregoing, to
the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us against all expenses (including attorneys&#8217; fees) actually and reasonably incurred by him or her or on his or her behalf in
connection therewith. If we do not assume the defense, expenses must be advanced to an Indemnitee under certain circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, we
intend to enter into indemnification agreements with all of our executive officers and directors prior to the completion of this offering. In general, these agreements provide that we will indemnify the executive officer or director to the fullest
extent permitted by law for claims arising in his or her capacity as an executive officer or director of our company or in connection with his or her service at our request for another corporation or entity. The indemnification agreements also
provide for procedures that will apply in the event that an executive officer or director makes a claim for indemnification and establish certain presumptions that are favorable to the executive officer or director. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We maintain a general liability insurance policy that covers certain liabilities of our directors and
officers arising out of claims based on acts or omissions in their capacities as directors or officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriting agreement filed as Exhibit
1.1 to this registration statement provides for indemnification of us and our directors and officers by the underwriters against certain liabilities under the Securities Act and the Exchange Act in connection with such offering. Insofar as the
foregoing provisions permit indemnification of directors, executive officers or persons controlling us for liability arising under the Securities Act we have been informed that, in the opinion of the SEC, such indemnification is against public
policy as expressed in the Securities Act and is therefore unenforceable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&#8201;15. Recent Sales of Unregistered Securities. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Set forth below is information regarding securities issued by us within the past three years that were not registered under the Securities Act. Also
included is the consideration, if any, received by us for such securities and information relating to the section of the Securities Act, or rule of the SEC, under which exemption from registration was claimed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>(a) Issuances of Share Capital </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On February&nbsp;15,
2023, Hemab ApS issued and sold 442,205 shares of its Series B Preference Shares to twelve investors at a price per share of $305.85 in cash, for an aggregate purchase price of $135,248,399.25. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On October&nbsp;23, 2025, Hemab ApS issued and sold 512,991 shares of its Series C Preference Shares to seventeen investors at a price per share of
$305.85 in cash, for an aggregate purchase price of $156,898,297.35. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On March 30, 2026, in connection with the corporate reorganization, we issued
23,343 shares of Series Seed Preferred Stock, 225,866 shares of Series A Preferred Stock, 442,205 shares of Series&nbsp;B Preferred Stock, 512,991 shares of Series C Preferred Stock and 43,000 shares of common stock, to the then-existing
shareholders of Hemab ApS in exchange for the same number and class of shares of Hemab ApS. No cash consideration was paid in connection with the corporate reorganization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">No underwriters were involved in the foregoing issuances of securities. The securities described in this section (a)&nbsp;of Item 15 were issued to
investors in reliance upon the exemption from the registration requirements of the Securities Act, as set forth in Section&nbsp;4(a)(2) under the Securities Act and, in certain cases, Regulation D thereunder relative to transactions by an issuer not
involving any public offering, or pursuant to Regulation S thereunder in that offers, sales and issuances were not made to persons in the United States and no directed selling efforts were made in the United States, to the extent an exemption from
such registration was required. All purchasers received written disclosures that the securities had not been registered under the Securities Act and that any resale must be made pursuant to a registration statement or an available exemption from
such registration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>(b) Equity Grants and Exercises </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">From March&nbsp;28, 2023 to December&nbsp;14, 2023, Hemab ApS granted to certain of its employees, directors, advisors and consultants warrants to
subscribe for an aggregate of 44,056 ordinary shares at an exercise price of $155.50. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">From May&nbsp;13, 2024 to October&nbsp;21, 2024, Hemab ApS
granted to certain of its employees, directors, advisors and consultants warrants to subscribe for an aggregate of 7,968 ordinary shares at an exercise price of $153.28. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">From February&nbsp;11, 2025 to June&nbsp;19, 2025, Hemab ApS granted to certain of its employees,
directors, advisors and consultants warrants to subscribe for an aggregate of 13,781 ordinary shares at an exercise price of $168.72. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">From
January&nbsp;4, 2026 to February&nbsp;16, 2026, Hemab ApS granted to certain of its employees, directors, advisors and consultants warrants to subscribe for an aggregate of 104,309 ordinary shares at an exercise price of $131.98. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On March&nbsp;30, 2026, in connection with the corporate reorganization, each outstanding warrant to subscribe for the purchase of ordinary shares of
Hemab ApS was assumed by Hemab Therapeutics Holdings, Inc. and converted into a warrant to purchase the same number of shares of common stock of Hemab Therapeutics Holdings, Inc. Any warrant exercise price that had been denominated in DKK prior to
the corporate reorganization was converted into an exercise price in U.S. dollars at the exchange rate as in effect at the close of business on the business day prior to the corporate reorganization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The securities described in this section (b)&nbsp;of Item 15 were issued pursuant to written compensatory plans or arrangements with our employees,
directors, advisors, and consultants, in reliance on the exemption provided by Rule 701 promulgated under the Securities Act, or pursuant to Section&nbsp;4(a)(2) under the Securities Act, relative to transactions by an issuer not involving any
public offering, or pursuant to Regulation S thereunder in that offers, sales and issuances were not made to persons in the United States and no directed selling efforts were made in the United States, relative to transactions by an issuer not
involving any public offering, to the extent an exemption from such registration was required. All recipients either received adequate information about our company or had access, through employment or other relationships, to such information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&#8201;16. Exhibits and Financial Statement Schedules. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">(a)
<B><I>Exhibits</I></B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B><br><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;1.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d50309dex21.htm">Share Contribution and Exchange Agreement, dated March 30, 2026, by and between the Registrant and the parties thereto </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d50309dex31.htm">Certificate of Incorporation of the Registrant, as currently in effect </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d50309dex32.htm">Bylaws of the Registrant, as currently in effect </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Restated Certificate of Incorporation of the Registrant (to be effective immediately prior to the completion of this offering)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Bylaws of the Registrant (to be effective immediately prior to the completion of this offering)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Specimen Stock Certificate evidencing the shares of common stock</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d50309dex42.htm">Form of Warrant Agreement </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d50309dex43.htm">Investors&#8217; Rights Agreement, dated March 30, 2026, by and between the Registrant and the parties thereto </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;5.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Wilmer Cutler Pickering Hale and Dorr LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2026 Equity Incentive Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Agreements under 2026 Equity Incentive Plan</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B><br><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2026 Employee Stock Purchase Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d50309dex104.htm">License Agreement, dated November 22, 2019, by and between Novo Nordisk A/S and the Registrant (formerly, Ebumab Hemophilia ApS), as amended by Amendment Agreement to License Agreement, dated March&nbsp;
26, 2020, by and between Novo Nordisk A/S and the Registrant </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d50309dex105.htm">DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> License Agreement, dated April&nbsp;1, 2020, by and between Genmab A/S and the Registrant (formerly, Ebumab Hemophilia ApS) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Executive Employment Agreement by and between Hemab Therapeutics Inc. and Benny&nbsp;S&oslash;rensen, as amended</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Service Agreement by and between Hemab ApS and Mads Behrndt, as amended</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Offer Letter by and between Hemab Therapeutics Inc. and Catherine Madigan, as amended</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement between the Registrant and each of its Executive Officers and Directors</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Non-Employee Director Compensation Policy</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d50309dex211.htm">Subsidiaries of the Registrant </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d50309dex231.htm">Consent of EY Godkendt Revisionspartnerselskab, independent registered public accounting firm </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Wilmer Cutler Pickering Hale and Door (included in Exhibit 5.1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#sig">Power of Attorney (included on signature page)</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">107</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="d50309dexfilingfees.htm">Filing Fee Table </A></P></TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">To be filed by amendment. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation
<FONT STYLE="white-space:nowrap">S-K.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B>(b) </B><B><I>Financial Statement Schedules</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">No financial statement schedules are provided because the information called for is not required or is shown either in the financial statements or the
related notes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B>(c) </B><B><I>Filing Fee Table</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The information required to be furnished by paragraph (c)&nbsp;of this Item is incorporated herein by reference to Exhibit 107. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&#8201;17. Undertakings. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">(a) Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC
such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the
registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the
Securities Act and will be governed by the final adjudication of such issue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">(b) The undersigned registrant hereby undertakes that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:ARIAL">(1) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this
registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of
the time it was declared effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:ARIAL">(2) For the purpose of determining any liability under the Securities Act, each post-effective amendment that
contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <I>bona fide</I> offering thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its
behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 10th day of April, 2026. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>Hemab Therapeutics Holdings, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">By: /s/ Benny S&oslash;rensen, M.D., Ph.D. </P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Benny S&oslash;rensen, M.D., Ph.D.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL"><I>President and Chief
Executive Officer</I></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>SIGNATURES AND POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We, the undersigned officers and directors of Hemab Therapeutics Holdings, Inc., hereby severally constitute and appoint Benny S&oslash;rensen and Mads
Behrndt, and each of them singly (with full power to each of them to act alone), our true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, with full power of substitution and
resubstitution in each of them for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and any other registration
statement for the same offering pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting
unto said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in
and about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and
agents or any of them, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the
requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Benny S&oslash;rensen, M.D., Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Benny S&oslash;rensen, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">President and Chief Executive Officer, Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">(<I>Principal Executive Officer</I>)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">April 10, 2026</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Mads Behrndt, M.Sc.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Mads
Behrndt, M.Sc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">(<I>Principal Financial and Accounting Officer</I>)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">April 10, 2026</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ John Maraganore, Ph.D.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">John
Maraganore, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Chair of the Board </TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">April 10, 2026</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Linda Bain</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Linda Bain</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">April 10, 2026</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Laura Tadvalkar, Ph.D.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Laura
Tadvalkar, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">April 10, 2026</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Akshay Vaishnaw, M.D., Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Akshay Vaishnaw, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">April 10, 2026</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-7 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>d50309dex21.htm
<DESCRIPTION>EX-2.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-2.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 2.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHARE CONTRIBUTION AND EXCHANGE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Share Contribution and Exchange Agreement (this &#8220;<B>Agreement</B>&#8221;) is made as of March&nbsp;30, 2026 by and among Hemab ApS,
company registration no. 40 83 75 90 (the &#8220;<B>Company</B>&#8221;), Hemab Therapeutics Holdings, Inc., a Delaware corporation (&#8220;<B>Parent</B>&#8221;) and each of the holders of Company Shares (as defined below) listed on
<U>Schedule</U><U></U><U>&nbsp;I</U> attached hereto (each a &#8220;<B>Holder</B>&#8221;) (each of the Company, Parent and each Holder herein collectively referred to as the &#8220;<B>Parties</B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,
</B>the Holders collectively own all of the issued and outstanding (i)&nbsp;ordinary shares of the Company, nominally DKK 43,000 (the &#8220;<B>Company Ordinary Shares</B>&#8221;) and (ii)&nbsp;Preferred Seed Shares of the Company, nominally DKK
23,343 (the &#8220;<B>Company Preferred Seed Shares</B>&#8221;), Series A Preference Shares of the Company, nominally DKK 225,866 (the &#8220;<B>Company Preferred A Shares</B>&#8221;), Series B Preference Shares of the Company, nominally DKK 442,205
(the &#8220;<B>Company Preferred B Shares</B>&#8221;) and Series C Preference Shares of the Company, nominally DKK 512,991 (the &#8220;<B>Company Preferred C Shares</B>&#8221;, and each of the Company Preferred Seed Shares, the Company Preferred A
Shares, the Company Preferred B Shares and the Company Preferred C Shares, collectively, the &#8220;<B>Company Preference Shares</B>&#8221;, and together with the Company Ordinary Shares, the &#8220;<B>Company Shares</B>&#8221;), in each case,
having the benefits and privileges set forth in the articles of association of the Company (the &#8220;<B>Articles</B>&#8221;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company has issued certain warrants to subscribe for new Company Ordinary Shares as set forth on <U>Schedule II</U> (the
&#8220;<B>Company Warrants</B>&#8221;) on the terms and conditions set forth in the Articles and in Appendices 3.8, 3.14 and 3.15 to the Articles; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS, </B>each of the Holders desires to contribute to Parent, and Parent desires to accept from each such Holder, the number and class
of Company Shares owned by such Holder, as set forth on <U>Schedule</U><U></U><U>&nbsp;I</U> attached hereto, in exchange for an issuance by Parent to such Holder of (i)&nbsp;in respect of the Company Ordinary Shares, such number of shares of common
stock, par value $0.0001 per share, of Parent (the &#8220;<B>Parent Common Stock</B>&#8221;) as is set forth on Schedule I and (ii)&nbsp;in respect of the Company Preference Shares, such number of shares of the applicable series of preferred stock
of Parent (the &#8220;<B>Parent Preferred Stock</B>,&#8221; and together with the Parent Common Stock, the &#8220;<B>Parent Stock</B>&#8221;) as set forth on <U>Schedule I</U> attached hereto; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, in connection with such exchange of Company Shares for Parent Stock, the outstanding Company Warrants, as set forth on
Schedule II attached hereto, shall be assumed by Parent in their entirety and converted into warrants with a right to purchase Parent Common Stock, as further described in <U>Section</U><U></U><U>&nbsp;3.1(a)</U> herein; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS, </B>as a condition to and in connection with the exchange of Company Shares for Parent Stock and the assumption of the Company
Warrants by Parent contemplated by this Agreement, Parent and the Holders desire to (i)&nbsp;enter into the Transaction Agreements (as defined below) in respect of the shares of Parent Common Stock and Parent Preferred Stock, (ii)&nbsp;terminate the
Shareholders Agreement, dated October&nbsp;23, 2025, by and among the Company and the Holders and all schedules and appendices thereto (the &#8220;<B>Company Shareholders&#8217; Agreement</B>&#8221;), and (iii)&nbsp;terminate the Investment
Agreement, dated October&nbsp;23, 2025, by and among the Company and certain of the Holders (the &#8220;<B>Company Investment Agreement</B>&#8221;); and </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS, </B>the Parties desire for U.S. federal income tax purposes that this Agreement
constitutes a &#8220;plan of reorganization&#8221; for purposes of Sections 368, 354 and 361 of the United States Internal Revenue Code of 1986, as amended (the &#8220;<B>Code</B>&#8221;) and that the Company and Parent be a &#8220;party to the
reorganization&#8221; within the meaning of Section&nbsp;368(b) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE, </B>for and in consideration of the
promises and of the mutual agreements, representations, warranties, provisions and covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as
follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE CONTRIBUTION AND EXCHANGE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.1</B> <B>Contribution and Exchange of Company Shares</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Contribution</U>. Contemporaneously with the execution and delivery of this Agreement (the &#8220;<B>Effective Date</B>&#8221;), each
Holder of Company Shares shall contribute, transfer, grant, assign and deliver to Parent all of its right, title and interest in and to all Company Shares owned by such Holder (the &#8220;<B>Contribution</B>&#8221;), as set forth on
<U>Schedule</U><U></U><U>&nbsp;I</U> attached hereto (the &#8220;<B>Contributed Shares</B>&#8221;), free and clear of all liens, charges, claims, encumbrances or other restrictions of any kind (&#8220;<B>Liens</B>&#8221;), other than restrictions
under applicable securities laws and restrictions set forth in the Articles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Exchange</U>. In exchange for (i)&nbsp;each Company
Ordinary Share contributed by a Holder, on the Effective Date, the Parent shall issue to such Holder one share of Parent Common Stock, (ii)&nbsp;each Company Preferred Seed Share contributed by a Holder, Parent shall issue to such Holder one share
of Series Seed preferred stock, par value $0.0001 per share, of Parent (the &#8220;<B>Parent Series Seed Stock</B>&#8221;), (iii) each Company Preferred A Share contributed by a Holder, Parent shall issue to such Holder one share of Series A
preferred stock, par value $0.0001 per share, of Parent (the &#8220;<B>Parent Series A Stock</B>&#8221;), (iv) each Company Preferred B Share contributed by a Holder, Parent shall issue to such Holder one share of Series B preferred stock, par value
$0.0001 per share, of Parent (the &#8220;<B>Parent Series B Stock</B>&#8221;) and (v)&nbsp;each Company Preferred C Share contributed by a Holder, Parent shall issue to such Holder one share of Series C preferred stock, par value $0.0001 per share,
of Parent (the &#8220;<B>Parent Series C Stock</B>&#8221;), in each case, having the rights, preferences and privileges set forth in Parent&#8217;s Amended and Restated Certificate of Incorporation to be filed on or before the Effective Date (the
&#8220;<B>Restated Certificate</B>&#8221;), substantially in the form set forth in <U>Exhibit</U><U></U><U>&nbsp;A</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.2</B>
<B>Closing Deliverables</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Deliverables by the Holders</U>. In order to effectuate the contributions and exchanges described in
<U>Section</U><U></U><U>&nbsp;1.1</U> of this Agreement, contemporaneously with the execution and delivery of this Agreement, each Holder shall execute, deliver and enter into (i)&nbsp;an Investors&#8217; Rights Agreement with respect to the Parent
Stock held thereby after giving effect to this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement, in substantially the form attached hereto as <U>Exhibit</U><U></U><U>&nbsp;B</U><B> </B>(the &#8220;<B>Investors&#8217; Rights Agreement</B>&#8221;), (ii) a Voting Agreement in
substantially the form attached hereto as <U>Exhibit</U><U></U><U>&nbsp;C</U><B> </B>(the &#8220;<B>Voting Agreement</B>&#8221;), and (iii)&nbsp;a Right of First Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement in substantially
the form attached hereto as <U>Exhibit D</U> (the &#8220;<B>ROFR and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement</B>&#8221;, and together with the Investors&#8217; Rights Agreement and the Voting Agreement, &#8220;<B>Transaction
Agreements</B>&#8221;), in each case to be effective as of the Effective Date. By entering into this Agreement, and provided that it has not been terminated in accordance with <U>Section</U><U></U><U>&nbsp;4.3</U> hereof, the Holders consent to, and
direct, the board of directors of the Company to update the Company&#8217;s share register with the Parent as holder of all the Company&#8217;s shares as of the Effective Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Deliverables by Parent</U>. In order to effectuate the contributions and exchanges described in <U>Section</U><U></U><U>&nbsp;1.1</U>
of this Agreement, Parent shall deliver or cause to be delivered (x)&nbsp;on the Effective Date, (i)&nbsp;the Investors&#8217; Rights Agreement executed by Parent, (ii)&nbsp;the Voting Agreement executed by Parent, and (iii)&nbsp;the ROFR and <FONT
STYLE="white-space:nowrap">Co-Sale</FONT> Agreement executed by Parent, and (y)&nbsp;as soon as practicable following the Effective Date, to each Holder, a physical or electronic stock certificate in the name of such Holder for the number of fully
paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Parent Common Stock, Parent Series Seed Stock, Parent Series A Stock, Parent Series B Stock or Parent Series C Stock, as applicable, to be issued to such Holder in accordance
with the terms and conditions set forth in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Further Action</U>. Each Holder, from time to time as and when
requested by Parent or the Company, but in each case subject to the other provisions of this Agreement shall execute and deliver, or shall cause to be executed and delivered, such documents and other papers and shall take, or shall cause to be
taken, such further actions, after the date hereof, as may be reasonably required to carry out the provisions of this Agreement and give effect to the Contribution and the other transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.3</B> <B>Miscellaneous</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>No Further Ownership Rights in Company Shares</U>. All shares of Parent Stock issued pursuant to this Agreement will be deemed to have
been issued in full satisfaction of all rights pertaining to Company Shares exchanged therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Limitation of Liability</U>. The
Company and each Holder agree that the aggregate liability of each Holder and its respective officers, directors, affiliates, employees and agents, for any and all claims, losses, costs or damages, including attorneys&#8217; and accountants&#8217;
fees and expenses and costs of any nature whatsoever or claims or expenses resulting from or in any way related to such Holder&#8217;s breach of this Agreement or the Transaction Agreements shall be several and not joint and shall not exceed the
total pro rata invested amount actually paid to the Company by such Holder for any shares of capital stock of the Company, except in case of willful misconduct or fraud by such Holder, in which case the liability shall not be limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Right to Conduct Activities</U>. Each of Parent and the Company hereby agrees and acknowledges that each Holder of Company Preference
Shares other than Wandall Holding ApS (each such Holder together with its affiliates, a &#8220;<B>Professional Investment Organization</B>&#8221;) is a professional investment organization, and as such reviews the business plans and related
proprietary information of many enterprises, some of which may compete directly or indirectly </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with the Company&#8217;s or Parent&#8217;s business (as currently conducted or as currently proposed to be conducted). Nothing in this Agreement shall preclude or in any way restrict any
Professional Investment Organization from evaluating or purchasing securities, including publicly traded securities, of a particular enterprise, or investing or participating in any particular enterprise whether or not such enterprise has products
or services that compete with those of the Company or Parent (as currently conducted or as currently proposed to be conducted); and the Company and Parent hereby agree that, to the extent permitted under applicable law, no Professional Investment
Organization shall be liable to the Company or to Parent for any claim arising out of, or based upon, (i)&nbsp;the investment by such Professional Investment Organization in any entity competitive with the Company or Parent, or (ii)&nbsp;actions
taken by any partner, officer, employee or other representative of such Professional Investment Organization to assist any such competitive company, whether or not such action was taken as a member of the board of directors of such competitive
company or otherwise, and whether or not such action has a detrimental effect on the Company or Parent; provided, however, that the foregoing shall not contravene the confidentiality obligations in Section&nbsp;3.5 or otherwise in the
Investors&#8217; Rights Agreement or relieve any director or officer of the Company or of Parent from any liability associated with such person&#8217;s fiduciary duties to the Company or to Parent. This Section&nbsp;1.3(c) may not be amended or
waived in a manner adverse to each Professional Investment Organization without such Professional Investment Organization&#8217;s written consent. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1</B> <B>Representations and Warranties of the Company</B>. The Company represents and warrants, to the extent legally permissible, to
Parent and to each of the Holders as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Due Organization</U>. The Company (i)&nbsp;is duly organized and validly existing
under Danish law, (ii)&nbsp;is duly authorized to conduct its business and is in good standing under Danish law, and (iii)&nbsp;has the requisite power and authority necessary to own or lease its properties and to carry on its businesses as
currently conducted. There is no pending or, to the Company&#8217;s knowledge, threatened action or other proceeding for its dissolution, liquidation, insolvency or restructuring. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Authorization; Enforceability</U>. The Company has the power and authority to execute and deliver this Agreement and to perform its
obligations hereunder. The execution, delivery and performance by the Company of this Agreement has been duly authorized by all necessary action on the part of the Company. This Agreement has been duly executed and delivered by the Company and is,
to the extent legally permissible, the legal, valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, receivership,
conservatorship, reorganization, liquidation, moratorium, or similar events affecting the Company or its assets, or by general principles of equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>No Violation; Breach etc.</U> The execution and delivery by the Company of this Agreement and the fulfillment by the Company of the
terms hereof will not conflict with, violate or result in a breach of any judgment decree or order of any court or governmental body, or, subject to <U>Section</U><U></U><U>&nbsp;2.1(b</U>), applicable law or the Articles or any other material
agreement to which Company or any of its subsidiaries is a party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>No consent</U>. No consent, approval, order or authorization of, or registration,
qualification, designation, declaration or filing with, or notice to, any governmental authority on the part of the Company is required in connection with the execution and delivery of this Agreement and the consummation of the transactions
contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>CFIUS</U>. The Company does not engage in (a)&nbsp;the design, fabrication, development, testing, production
or manufacture of one (1)&nbsp;or more &#8220;critical technologies&#8221; within the meaning of the Defense Production Act of 1950, as amended, including all implementing regulations thereof (the &#8220;<B>DPA</B>&#8221;); (b) the ownership,
operation, maintenance, supply, manufacture, or servicing of &#8220;covered investment critical infrastructure&#8221; within the meaning of the DPA (where such activities are covered by column 2 of Appendix A to 31 C.F.R. Part 800); or (c)&nbsp;the
maintenance or collection, directly or indirectly, of &#8220;sensitive personal data&#8221; of U.S. citizens within the meaning of the DPA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2</B> <B>Representations and Warranties of Parent</B>. Parent represents and warrants to the Company and to each of the Holders as
follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Due Organization</U>. Parent (i)&nbsp;is duly organized, validly existing and in good standing under the laws of the
jurisdiction of its incorporation, (ii)&nbsp;is duly authorized to conduct its business and is in good standing under the laws of each jurisdiction where such qualification is required, and (iii)&nbsp;has the requisite corporate power and authority
necessary to carry on its businesses as currently conducted. There is no pending or, to Parent&#8217;s knowledge, threatened action or other proceeding for its dissolution, liquidation, insolvency or restructuring. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Authorization; Enforceability.</U> Parent has the power and authority to execute and deliver this Agreement and to perform its
obligations hereunder. The execution, delivery and performance by Parent of this Agreement and each of the other Transaction Agreements has been duly authorized by all necessary action on the part of Parent. This Agreement has been duly executed and
delivered by Parent and is the legal, valid and binding obligation of Parent enforceable against Parent in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, receivership, conservatorship,
reorganization, liquidation, moratorium, or similar events affecting Parent or its assets, or by general principles of equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>No
Violation; Breach etc.</U> The execution and delivery by Parent of this Agreement and the other Transaction Agreements and the fulfillment by Parent of the terms hereof and thereof will not conflict with, violate or result in a breach of any
judgment decree or order of any court or governmental body, or applicable law or the organizational documents of Parent or any other material agreement to which Parent is a party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>No consent</U>. No consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing
with, or notice to, any governmental authority on the part of Parent is required in connection with the execution and delivery of this Agreement or the Transaction Agreements and the consummation of the transactions contemplated hereby, except for
the filing of the Restated Certificate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Issuance of Shares of Parent Stock</U>. Upon issuance, all of the shares of Parent
Stock to be issued pursuant to this Agreement, will have been duly authorized and validly issued, and shall be fully paid and nonassessable and free and clear of all Liens, other than restrictions under applicable securities laws and set forth in
the Restated Certificate, the Parent&#8217;s Bylaws or the Transaction Agreements. As of the Effective Date, the shares of Parent Stock issued pursuant to this Agreement will constitute all of the issued and outstanding shares of capital stock of
the Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>No options, warrants etc.</U> Except for any Company Warrants assumed in accordance with
<U>Section</U><U></U><U>&nbsp;3.1</U> of this Agreement, there are, and will as of the Effective Date be, no outstanding options, warrants, equity securities, calls, rights, convertible securities, commitments or agreements of any character by which
the Parent is bound obligating the Parent to issue, exchange, transfer, deliver or sell, or cause to be issued, exchanged, transferred, delivered or sold, additional shares of capital stock or other equity interests to any person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3</B> <B>Representations and Warranties of the Holders</B>. Each Holder represents and warrants to the Company, Parent and each of the
other Holders as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Authority</U>. Such Holder has the power and authority to execute and deliver this Agreement and to
perform its obligations hereunder. The execution, delivery, and performance by such Holder of this Agreement has been duly authorized by all necessary action on the part of such Holder. This Agreement has been duly executed and delivered by such
Holder and is the legal, valid and binding obligation of Holder enforceable against Holder in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, receivership, conservatorship, reorganization,
liquidation, moratorium, or similar events affecting such Holder or its assets, or by general principles of equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Ownership of
Company Shares</U>. Such Holder is the record and beneficial owner of Company Shares set forth opposite such Holder&#8217;s name on <U>Schedule</U><U></U><U>&nbsp;I</U> attached hereto, in each case free and clear of all Liens, other than
restrictions under applicable securities laws and restrictions set forth in the Articles or in the Company Shareholders&#8217; Agreement. Except for the Company Shares set forth opposite such Holder&#8217;s name on
<U>Schedule</U><U></U><U>&nbsp;I</U> attached hereto, such Holder is not the record or beneficial owner of any shares of capital stock of the Company. Upon the contribution by such Holder of Company Shares set forth opposite such Holder&#8217;s name
on <U>Schedule</U><U></U><U>&nbsp;I</U> attached hereto, Parent will acquire good, marketable and unencumbered title thereto, free and clear of all Liens, other than restrictions under applicable securities laws and restrictions set forth in the
Articles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>No Violation; Breach etc.</U> The execution and delivery by such Holder of this Agreement and the other Transaction
Agreements and the fulfillment by the Holder of the terms hereof and thereof will not conflict with, violate or result in a breach of any judgment decree or order of any court or governmental body, or applicable law or the organizational documents
of such Holder (as applicable) or any other material agreement to which such Holder is a party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>No consent</U>. No consent,
approval, order or authorization of, or registration, qualification, designation, declaration or filing with, or notice to, any governmental authority on the part of such Holder is required in connection with the execution and delivery of this
Agreement or the Transaction Agreements and the consummation of the transactions contemplated hereby and thereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>No options, warrants etc.</U> Except as set forth in this Agreement and the Company
Shareholders&#8217; Agreement, there are no other options, warrants, equity securities, calls, rights, commitments or agreements of any character to which such Holder is a party or by which the Company is bound obligating the Company to issue,
exchange, transfer, deliver or sell, or cause to be issued, exchanged, transferred, delivered or sold, additional shares of capital stock or other equity interests to such Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Investment Representations</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Such Holder is acquiring Parent Stock for its own account with the intention of holding such securities for investment
purposes, and such Holder has no intention of selling such securities in a public distribution in violation of federal securities laws or any applicable state securities laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) Such Holder is able to bear the economic risk and lack of liquidity of an investment in Parent Stock for an indefinite
period of time. Such Holder is aware that transfers of Parent Stock may not be possible because (i)&nbsp;such transfer is subject to contractual restrictions on transfer as set forth in the Transaction Agreements, and (ii)&nbsp;the shares of Parent
Stock have not been registered under the securities laws of any jurisdiction and, therefore, cannot be sold unless subsequently registered under such applicable securities laws or an exemption from such registration is available. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) Such Holder has obtained, to the extent such Holder deems it necessary, such Holder&#8217;s own personal professional
advice with respect to the tax consequences of receiving, and the risks inherent in an investment in, Parent Stock, and the suitability of an investment in Parent Stock in light of such Holder&#8217;s financial condition and investment needs. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) Such Holder has had an opportunity to ask questions and receive answers from Company and Parent concerning their business,
management, financial affairs and the terms and conditions of the contribution and exchange of the Contributed Shares and has had full access to such other information concerning Company and Parent as it has requested for purposes of making its
investment decision. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) Such Holder is an accredited investor as defined in Rule 501(a) of Regulation D promulgated under
the Securities Act of 1933, as amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) Such Holder understands that the shares of Parent Stock and any securities
issued in respect of or in exchange for the shares of Parent Stock, may be notated with the following legend, any legend set forth in, or required by, the other Transaction Agreements and any legend required by the securities laws of any state or
jurisdiction to the extent such laws are applicable to such shares of Parent Stock: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#8220;THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A
FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.&#8221; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADDITIONAL AGREEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1</B> <B>Agreements with Respect to Company Warrants</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Assumption of Company Warrants</U>. At and as of the Effective Date, each Company Warrant that remains outstanding immediately prior to
the Effective Date (as set out in <U>Schedule</U><U></U><U>&nbsp;II</U>) shall be assumed by the Parent (each such warrant as assumed by the Parent, a &#8220;<B>Parent Warrant</B>&#8221;) and shall be converted into a warrant to purchase Parent
Common Stock, on the same terms and conditions, and representing the same value, as were applicable to such Company Warrant, including that the Parent Warrant shall be with respect to the same number of shares, and at the exercise price per share,
as were applicable to the Company Warrant, as further set forth on <U>Schedule II</U>. The assumption of the Company Warrants by Parent shall and is intended to comply with Sections 409A and 424 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Reservation of Shares</U>. Following the Effective Date, Parent shall take all corporate actions necessary to reserve for issuance a
sufficient number of shares of Parent Common Stock for delivery upon exercise of the Parent Warrants as are then subject to the Parent Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2</B> <B>Agreements with respect to Company Shareholders&#8217; Agreement</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Consent to Transfer; Waiver of Provisions</U>. To the extent that the contribution of the Contributed Shares would be deemed to be
restricted by, or require as a condition precedent to such contribution, any consent or additional documentation, pursuant to the Articles or the Company Shareholders&#8217; Agreement, by the Company, its board of directors or the shareholders of
the Company, each Holder who is a shareholder of the Company and party to the Company Shareholders&#8217; Agreement shall be deemed to have given such consent and agreed to the waiver of any other conditions precedent to the transfer of the
Contributed Shares to Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Termination</U>. The Parties acknowledge and agree that the Company Shareholders&#8217; Agreement is
hereby terminated upon the execution of this Agreement for all purposes, and the Company Shareholders&#8217; Agreement shall have no further force or effect and none of the parties thereto shall have any rights, obligations or liabilities thereunder
or with respect thereto, notwithstanding anything in the Company Shareholders&#8217; Agreement to the contrary; provided that, for the avoidance of doubt, such termination shall be expressly conditioned upon the contributions and exchanges set forth
in <U>Section</U><U></U><U>&nbsp;1.1</U> taking effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.3</B> <B>Agreements with respect to Taxation Matters</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Parties agree to treat the transactions set forth in this Agreement (the &#8220;<B>Transactions</B>&#8221;) as a reorganization within
the meaning of Section&nbsp;368(a)(1)(B) of the Code and/or as an exchange described in Section&nbsp;351(a) of the Code, and treat this Agreement as a &#8220;plan or reorganization&#8221; under Sections 368, 354 and 361 of the Code, and no Party
shall make any representation to any tax authority or take any position on its federal, state local and foreign tax returns that is inconsistent with such treatment unless otherwise required by a final determination (as defined in Section&nbsp;1313
of the Code). The Parent shall file the applicable statements that are required under Treasury Regulations <FONT STYLE="white-space:nowrap">1.368-3</FONT> and, upon request, (i)&nbsp;each Holder shall reasonably cooperate and provide the Parent with
the information necessary for such filing, and (ii)&nbsp;the Parent shall reasonably cooperate and provide the Holders with any information necessary for the filing of the statements required under Treasury Regulations 1.3683(b) and <FONT
STYLE="white-space:nowrap">1.1291-6(g).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Upon the execution of this Agreement, each Holder shall provide the Parent with the
applicable Internal Revenue Service Forms <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> <FONT STYLE="white-space:nowrap">W-8ECI</FONT> (or any other
applicable form <FONT STYLE="white-space:nowrap">W-8)</FONT> or <FONT STYLE="white-space:nowrap">W-9,</FONT> duly filled out and executed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Parties mutually acknowledge that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) No consideration other than Parent Stock will be paid in connection with the Transactions to the Holders in exchange for
their Company Shares (or otherwise used to acquire any Company Shares), and no cash or other assets of the Company or the Parent will be used to pay any dissenting Holder (if any) in connection with the Contribution; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) Each party to this Agreement will pay its respective expenses, if any, incurred in connection with the Transactions,
provided that it is expected that certain expenses incurred by Parent in connection with the Transactions will be funded with distributions from the Company following the Effective Date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) Following the Transactions, Parent will own stock possessing at least 80% of the combined voting power of all classes of
Company stock entitled to vote and at least 80% of the total number of shares of all other classes of Company stock. The Company has no plan or intention to issue additional shares of its stock before the Transaction; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) The Parent and Company will not take (or permit to be taken on their behalf) any action that is intended to cause the
Transactions to fail to qualify as a reorganization within the meaning of Section&nbsp;368(a)(1)(B) of the Code and there is no plan or intention by the Company or the Parent to liquidate or distribute substantially all of the assets of the Company
to Parent (or otherwise elect to be treated as a disregarded entity) following, or in connection with, the Contribution; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) Neither the Parent nor the Company is (A)&nbsp;acquiring any indebtedness or any liability of any person in connection with
the Transactions or (B)&nbsp;issuing any indebtedness or transferring any liability to any person in connection with the Transactions. No liabilities of any Holder are being extinguished or forgiven in connection with the Transactions; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) The Parent Stock to be issued pursuant to the Transaction confers upon
its holders the right to significant participation in the management and affairs of the Parent, including the ability to vote on the election of directors; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii) None of the Parent Stock that will be received by any stockholder-employee or stockholder-independent contractor of the
Company pursuant to the Transaction represents separately <FONT STYLE="white-space:nowrap">bargained-for</FONT> consideration which is allocable to any employment agreement or arrangement, it being understood that it is expected that Parent Stock
will be exchanged for Company Shares issued upon exercise of outstanding Company Warrants; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(viii) Parent has been formed
as a Delaware corporation for purposes of the Transaction, having, as of the time of the Transaction, no material assets and no liabilities, except for liabilities incurred prior to the Effective Date in connection with the Transactions; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ix) The fair market value of Parent&#8217;s assets will exceed the amount of its liabilities immediately after the
Transactions; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x) With respect to each Holder, as of the Effective Date, such Holder has no current plan or intention,
contractual obligation, legally binding commitment, or similar obligation to transfer any Parent Stock received in the Contribution. It being understood that nothing in this representation shall prevent any Holder from selling any Parent Stock
following the Effective Date or changing its plans or intentions following the Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.4</B> <B>Agreements with respect to
Company Investment Agreement</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Immediately upon the Effective Date, each Holder who is a party to the Company Investment Agreement
hereby (i)&nbsp;waives any rights such Holder may have pursuant to the Company Investment Agreement, other than rights pursuant to Clause 7 thereof and (ii)&nbsp;approves the termination of the Company Investment Agreement, other than with respect
to Clause 7 thereof, which shall survive the termination of the Investment Agreement; provided, however, that for the avoidance of doubt, the representations and warranties referred to in Clause 7.1 of the Company Investment Agreement shall continue
to be made as of the date referenced therein, and not as of the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.5</B> <B>Agreements with respect to Company
Articles of Association</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Consent to Transfer; Waiver of Provisions</U>. To the extent that the contribution of the Contributed
Shares would be deemed to be restricted by or require as a condition precedent any consent or additional documentation by virtue of the provisions of the Articles, each Holder and the board of directors of the Company shall be deemed to have given
such consent and agreed to the waiver of any other conditions precedent to the transfer of the Contributed Shares to Parent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1</B>
<B>Entire Agreement</B>. This Agreement, together with the Exhibits and Schedules hereto, constitutes the entire agreement and understanding of the Parties in respect of its subject matter and supersedes all prior understandings, agreements or
representations by or among the Parties, written or oral, to the extent they relate in any way to the subject matter hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2</B>
<B>Assignment</B>. This Agreement shall be binding upon, and inure to the benefit of, the Parties and their respective successors and permitted assigns. No Party may assign any of its rights or obligations hereunder without the prior written consent
of the other Parties, which consent shall not be unreasonably withheld or delayed; provided, that the Parent or Company may assign their respective rights and obligations hereunder with the consent of each other and the holders of a majority of the
Contributed Shares, or Parent Stock for which such shares are exchanged pursuant hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3</B> <B>Amendment</B>. This Agreement may
not be amended, modified or supplemented without the written consent of each of (i)&nbsp;the Company, (ii)&nbsp;Parent and (iii)&nbsp;the Requisite Investor Majority; provided, however, that no such amendment or waiver which disproportionately and
materially adversely affects any one Party relative to the other Parties, shall be effective against such adversely affected Party without its consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.4</B> <B>Governing Law</B>. This Agreement will be governed by and construed in accordance with the laws of the State of Delaware,
without regard to conflicts of laws principles, provided that mandatory Danish rules shall apply to the transfer of Company Shares and the assumption of Company Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.5</B> <B>Headings</B>. Headings are for reference only and shall not in any manner affect the meaning or interpretation of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.6</B> <B>Effectiveness; Counterparts</B>. This Agreement shall be effective as to the Company, Parent and each Holder as
of the date first written above. This Agreement may be executed in two or more counterparts, each of which will be deemed to be an original and all of which together will constitute one and the same instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>signature page follows</I>] </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Share Contribution and Exchange Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COMPANY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Hemab ApS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Benny S&oslash;rensen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Benny S&oslash;rensen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">John Maraganore</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chair of Board of Directors</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Share Contribution and Exchange Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COMPANY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Hemab ApS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Benny S&oslash;rensen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Maraganore</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">John Maraganore</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chair of Board of Directors</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Share Contribution and Exchange Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PARENT:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Hemab Therapeutics Holdings, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Benny S&oslash;rensen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Benny S&oslash;rensen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Share Contribution and Exchange Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>NOVO HOLDINGS A/S</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ J&oslash;rgen S&oslash;berg Petersen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">J&oslash;rgen S&oslash;berg Petersen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Senior Partner</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Share Contribution and Exchange Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HEALTHCAP VIII L.P.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">through its investment manager HealthCap Investments S.A.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Oern Stuge</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Oern Stuge</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Senior Advisor</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Fabrice Bernhard</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Fabrice Bernhard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General manager</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Share Contribution and Exchange Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-size:11pt"><B>HOLDERS:</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>RA CAPITAL HEALTHCARE FUND, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">By: RA Capital Healthcare Fund GP, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rajeev Shah</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rajeev Shah</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manager</P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Share Contribution and Exchange Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-size:11pt"><B>HOLDERS:</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>RA CAPITAL NEXUS FUND II, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">By: RA Capital Nexus Fund II GP, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rajeev Shah</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rajeev Shah</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manager</P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Share Contribution and Exchange Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-size:11pt"><B>HOLDERS:</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>RA CAPITAL NEXUS FUND IV, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">By: RA Capital Nexus Fund IV GP, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rajeev Shah</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rajeev Shah</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manager</P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Share Contribution and Exchange Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-size:11pt"><B>HOLDERS:</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>AI <FONT STYLE="white-space:nowrap">DEN-MAB</FONT> LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">By ACCESS INDUSTRIES MANAGEMENT, LLC,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">its manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John McDonough</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John McDonough</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter L. Thor&eacute;n</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter L. Thor&eacute;n</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President</P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Share Contribution and Exchange Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AVORO VENTURES FUND L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Avoro Ventures LLC,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">its Investment Manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Scott Epstein</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Scott Epstein</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Partner, Chief Operating Officer&nbsp;&amp; Chief Compliance Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Share Contribution and Exchange Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>DEEP TRACK BIOTECHNOLOGY MASTER FUND, LTD.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Nir Messafi</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Nir Messafi</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Person</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Share Contribution and Exchange Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVUS PUBLIC EQUITIES, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Raymond Debbane</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Raymond Debbane</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President of its General Partner</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Share Contribution and Exchange Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ROCK SPRINGS CAPITAL MASTER FUND LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Rock Springs General Partner LLC,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">its general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kris Jenner</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Kris Jenner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Member</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Share Contribution and Exchange Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>FOUR PINES MASTER FUND LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Four Pines General Partner LLC,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">its general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kris Jenner</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Kris Jenner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Member</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Share Contribution and Exchange Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MAJ INVEST MINORITIES I K/S</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jannick Dam Mortensen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jannick Dam Mortensen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Eva Buciek Foss</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Eva Buciek Foss</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Share Contribution and Exchange Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>John Maraganore</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Maraganore</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">John Maraganore</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Share Contribution and Exchange Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SOFINNOVA CROSSOVER II SLP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Joseph Anderson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Joseph Anderson</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Signatory</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Share Contribution and Exchange Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SMALLCAP WORLD FUND, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Capital Research and Management Company,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">as investment adviser for and on behalf of SMALLCAP World Fund, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jae W. Chung</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jae W. Chung</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Signatory</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Share Contribution and Exchange Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><FONT STYLE="white-space:nowrap">AL-RAYYAN</FONT> HOLDING LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ahmad Mohammed <FONT STYLE="white-space:nowrap">Al-Khanji</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ahmad Mohammed <FONT STYLE="white-space:nowrap">Al-Khanji</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> S<SMALL>HARE</SMALL>
C<SMALL>ONTRIBUTION</SMALL> <SMALL>AND</SMALL> E<SMALL>XCHANGE</SMALL> A<SMALL>GREEMENT</SMALL>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Share Contribution and Exchange Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AVORO LIFE SCIENCE FUND LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Avoro Capital Advisors LLC,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">its Investment Manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Scott Epstein</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Scott Epstein</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Partner, Chief Operating Officer&nbsp;&amp; Chief Compliance Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Share Contribution and Exchange Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>DEEP TRACK SPECIAL OPPORTUNITIES FUND, LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Nir Messafi</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Nir Messafi</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Person</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Share Contribution and Exchange Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MAJ INVEST MINORITIES II K/S</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jannick Dam Mortensen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jannick Dam Mortensen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Eva Buciek Foss</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Eva Buciek Foss</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Share Contribution and Exchange Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>EBUMAB HOLDING APS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Johan Faber</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Johan Faber</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director &#8211; Founder</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hans Wandall</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Share Contribution and Exchange Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EBUMAB HOLDING APS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Johan Faber</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Hans Wandall</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Hans Wandall</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chairman</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Share Contribution and Exchange Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>GV1 HOLDING APS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ S&oslash;ren Bj&oslash;rn</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">S&oslash;ren Bj&oslash;rn</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Member</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Share Contribution and Exchange Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>WANDALL HOLDING APS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Hans Wandall</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Hans Wandall</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chairman</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Share Contribution and Exchange Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>JOHAN H. FABER APS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Johan Faber</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Johan Faber</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director &#8211; Founder</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Share Contribution and Exchange Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BATCHELOR HOLDING APS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Thomas Dal Stenfeldt Batchelor</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Thomas Dal Stenfeldt Batchelor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">SVP, Novonesis</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Share Contribution and Exchange Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MABE INVEST APS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mads Nikolaj Behrndt-Eriksen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mads Nikolaj Behrndt-Eriksen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule I </U></B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule II </U></B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Amended and Restated Certificate of Incorporation </U></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Investors&#8217; Rights Agreement </U></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Voting Agreement </U></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit D </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Right of First Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement </U></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>3
<FILENAME>d50309dex31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HEMAB THERAPEUTICS
HOLDINGS, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Pursuant to Sections 241 and 245 of the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">General Corporation Law of the State of Delaware) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Hemab Therapeutics Holdings, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law
of the State of Delaware (the &#8220;<B>General Corporation Law</B>&#8221;), </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>DOES HEREBY CERTIFY: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.</B> That the name of this corporation is Hemab Therapeutics Holdings, Inc., and that this corporation was originally incorporated
pursuant to the General Corporation Law on February&nbsp;12, 2026. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.</B> That the Board of Directors of this corporation (the
&#8220;<B>Board of Directors</B>&#8221;) duly adopted resolutions proposing to amend and restate the Certificate of Incorporation of this corporation and declaring said amendment and restatement to be advisable and in the best interests of this
corporation, which resolution setting forth the proposed amendment and restatement is as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED</B>, that the Certificate
of Incorporation of this corporation be amended and restated in its entirety to read as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>FIRST</B>:&nbsp;The name of this
corporation is Hemab Therapeutics Holdings, Inc. (the &#8220;<B>Corporation</B>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>SECOND</B>:&nbsp;The address of the
registered office of the Corporation in the State of Delaware is 850 New Burton Road, Suite 201, in the City of Dover, County of Kent, Delaware 19904. The name of its registered agent at that address is Cogency Global Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>THIRD</B>:&nbsp;The nature of the business or purposes to be conducted or promoted is to engage in any lawful act or activity for which
corporations may be organized under the General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>FOURTH</B>:&nbsp;The total number of shares of all classes of stock
which the Corporation shall have the authority to issue is 2,650,571. The Corporation has two classes of stock, referred to as Common Stock and Preferred Stock. There are 1,446,166 shares of authorized Common Stock, $0.0001 par value per share
(&#8220;<B>Common Stock</B>&#8221;), and 1,204,405 shares of authorized Preferred Stock, $0.0001 par value per share (&#8220;<B>Preferred Stock</B>&#8221;), of which 23,343 shares are hereby designated as &#8220;<B>Series Seed Preferred
Stock</B>,&#8221; 225,866 shares are hereby designated as &#8220;<B>Series A Preferred Stock</B>,&#8221; 442,205 shares are hereby designated as &#8220;<B>Series B Preferred Stock</B>&#8221; and 512,991 shares are hereby designated as
&#8220;<B>Series C Preferred Stock</B>&#8221;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a statement of the designations and the powers, preferences and special
rights, and the qualifications, limitations or restrictions thereof in respect of each class of capital stock of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A.
COMMON STOCK </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. <U>General</U>. The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and
qualified by the powers, preferences and special rights of the holders of the Preferred Stock set forth herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.&#8195;<U>Voting</U>. Except as otherwise provided herein or by applicable law, the
holders of the Common Stock shall be entitled to one vote for each share of Common Stock held as of the applicable record date for each meeting of stockholders (and written actions in lieu of meetings); <U>provided</U>, <U>however</U>, that, except
as otherwise required by law, holders of Common Stock, as such, shall not be entitled to vote on any amendment to this Amended and Restated Certificate of Incorporation (this &#8220;<B>Certificate of Incorporation</B>&#8221;) that relates solely to
the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to this Certificate of
Incorporation or pursuant to the General Corporation Law. There shall be no cumulative voting. The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by (in
addition to any vote of the holders of one or more series of Preferred Stock that may be required by the terms of this Certificate of Incorporation) the affirmative vote of the holders of shares of capital stock of the Corporation representing a
majority of the votes represented by all outstanding shares of capital stock of the Corporation entitled to vote, irrespective of the provisions of Section&nbsp;242(b)(2) of the General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. PREFERRED STOCK </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares
of the Preferred Stock shall have the powers, preferences and special rights set forth in this Part B of this <U>Article Fourth</U>. Unless otherwise indicated, references to &#8220;sections&#8221; or &#8220;Sections&#8221; in this Part B of this
<U>Article Fourth</U> refer to sections of Part B of this <U>Article Fourth</U>. References to &#8220;<B>Preferred Stock</B>&#8221; mean the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred
Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. <U>Dividends</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Corporation
(other than dividends on shares of Common Stock payable in shares of Common Stock) unless (in addition to the obtaining of any consents required elsewhere in this Certificate of Incorporation): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the holders of the Series C Preferred Stock then outstanding shall first receive, or simultaneously receive, a dividend on each
outstanding share of Series C Preferred Stock in an amount at least equal to (i)&nbsp;in the case of a dividend on Common Stock, the product of (A)&nbsp;the dividend declared, paid or set aside on such Common Stock and (B)&nbsp;the number of shares
of Common Stock issuable upon conversion of a share of such Series C Preferred Stock; (ii)&nbsp;in the case of a dividend on a class or series of capital stock that is convertible into Common Stock, the product of (A)&nbsp;the dividend declared,
paid or set aside per share of such class or series of capital stock and (B)&nbsp;the number of shares of Common Stock issuable upon conversion of a share of such Series C Preferred Stock, <U>divided</U> by the number of shares of Common Stock
issuable upon conversion of a share of such class or series of capital stock; or (iii)&nbsp;in the case of a dividend on any class or series that is not convertible into Common Stock, the product of (A)&nbsp;the amount of the dividend payable on
each share of such class or series of capital stock <U>divided</U> by the original issuance price of such class or series of capital stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other
similar recapitalization with respect to such class or series) and (B)&nbsp;the applicable Original Issue Price (as defined below); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
after payment of the Series C Preferred Stock dividend, as provided in the foregoing clause (a), the holders of the Series B Preferred Stock and Series A Preferred Stock then outstanding shall next receive a dividend on each outstanding share of
Series B Preferred Stock and Series A Preferred Stock, respectively, in an amount at least equal to (i)&nbsp;in the case of a dividend on Common Stock, the product of (A)&nbsp;the dividend declared, paid or set aside on such Common Stock and
(B)&nbsp;the number of shares of Common Stock issuable upon conversion of a share of such Series B Preferred Stock or Series A Preferred Stock, respectively; (ii) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in the case of a dividend on a class or series of capital stock that is convertible into Common Stock, the product of (A)&nbsp;the dividend declared, paid or set aside per share of such class or
series of capital stock and (B)&nbsp;the number of shares of Common Stock issuable upon conversion of a share of such Series B Preferred Stock or Series A Preferred Stock, respectively, <U>divided</U> by the number of shares of Common Stock issuable
upon conversion of a share of such class or series of capital stock; or (iii)&nbsp;in the case of a dividend on any class or series that is not convertible into Common Stock, the product of (A)&nbsp;the amount of the dividend payable on each share
of such class or series of capital stock <U>divided</U> by the original issuance price of such class or series of capital stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar
recapitalization with respect to such class or series) and (B)&nbsp;the applicable Original Issue Price (as defined below); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) after
payment of the Series B Preferred Stock and Series A Preferred Stock dividend, as provided in the foregoing clause (b), the holders of the Series Seed Preferred Stock then outstanding shall next receive a dividend on each outstanding share of Series
Seed Preferred Stock in an amount at least equal to (i)&nbsp;in the case of a dividend on Common Stock, the product of (A)&nbsp;the dividend declared, paid or set aside on such Common Stock and (B)&nbsp;the number of shares of Common Stock issuable
upon conversion of a share of such Series Seed Preferred Stock; (ii)&nbsp;in the case of a dividend on a class or series of capital stock that is convertible into Common Stock, the product of (A)&nbsp;the dividend declared, paid or set aside per
share of such class or series of capital stock and (B)&nbsp;the number of shares of Common Stock issuable upon conversion of a share of such Series Seed Preferred Stock, <U>divided</U> by the number of shares of Common Stock issuable upon conversion
of a share of such class or series of capital stock; or (iii)&nbsp;in the case of a dividend on any class or series that is not convertible into Common Stock, the product of (A)&nbsp;the amount of the dividend payable on each share of such class or
series of capital stock <U>divided</U> by the original issuance price of such class or series of capital stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with
respect to such class or series) and (B)&nbsp;the applicable Original Issue Price (as defined below); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>provided</U> in the case of each
of <U>subsections (a)</U>&nbsp;through <U>(c)</U> that, if the Corporation declares, pays or sets aside, on the same date, a dividend on shares of more than one class or series of capital stock of the Corporation, the dividend payable to the holders
of Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;1</U> shall be calculated based upon the dividend on the class or series of capital stock that would result in the highest Preferred Stock dividend for the applicable series of
Preferred Stock. The &#8220;<B>Original Issue Price</B>&#8221; shall mean, (i)&nbsp;with respect to the Series Seed Preferred Stock, $133.92 per share, (ii)&nbsp;with respect to the Series A Preferred Stock, $236.39 per share, (iii)&nbsp;with
respect to the Series B Preferred Stock, $305.85 per share and (iv)&nbsp;with respect to the Series C Preferred Stock, $305.85 per share, in each case subject to appropriate adjustment in the event of any stock dividend, stock split, combination or
other similar recapitalization with respect to the applicable Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. <U>Liquidation, Dissolution or Winding Up; Certain
Mergers, Consolidations and Asset Sales.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.1 <U>Preferential Payments to Holders of Preferred Stock</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.1.1 In the event of (a)&nbsp;any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of shares
of Series C Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Corporation available for distribution to its stockholders, and (b)&nbsp;a Deemed Liquidation Event (as defined below), the holders of shares of
Series C Preferred Stock then outstanding shall be entitled to be paid out of the consideration payable to stockholders in such Deemed Liquidation Event or out of the Available Proceeds (as defined below), as applicable, based on the Series C
Liquidation Amount (as defined below) and before any payment shall be made to the holders of the other series of Preferred Stock or of Common Stock by reason of their ownership thereof, an amount </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
per share of Series C Preferred Stock equal to the greater of (i)&nbsp;one times (1x) the applicable Original Issue Price, plus any dividends declared but unpaid thereon, or (ii)&nbsp;such amount
per share as would have been payable had all shares of Series C Preferred Stock been converted into Common Stock pursuant to <U>Section</U><U></U><U>&nbsp;4</U> immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation
Event (the amount payable pursuant to this sentence is hereinafter referred to as the &#8220;<B>Series C Liquidation Amount</B>&#8221;).<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>If upon any such liquidation, dissolution or winding up of
the Corporation or Deemed Liquidation Event, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the holders of shares of Series C Preferred Stock the full amount to which they shall be entitled
under this <U>Section</U><U></U><U>&nbsp;2.1.1</U>, the holders of shares of Series C Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be
payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.1.2 In the event of (a)&nbsp;any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of shares
of Series B Preferred Stock and Series A Preferred Stock then outstanding shall be entitled, on a <I>pari passu</I> basis, to be paid out of the assets of the Corporation available for distribution to its stockholders, and (b)&nbsp;a Deemed
Liquidation Event, the holders of shares of Series B Preferred Stock and Series A Preferred Stock then outstanding shall be entitled, on a <I>pari passu</I> basis, to be paid out of the consideration payable to stockholders in such Deemed
Liquidation Event or out of the Available Proceeds (as defined below), as applicable, after payment in full of the Series C Liquidation Amount pursuant to <U>Subsection 2.1.1</U>, based on the Series A/B Liquidation Amount (as defined below) and
before any payment shall be made to the holders of Series Seed Preferred Stock or of Common Stock by reason of their ownership thereof, an amount per share of Series B Preferred Stock and Series A Preferred Stock, respectively, equal to the greater
of (i)&nbsp;one times (1x) the applicable Original Issue Price, plus any dividends declared but unpaid thereon, or (ii)&nbsp;such amount per share as would have been payable had all shares of Series B Preferred Stock and Series A Preferred Stock
been converted into Common Stock pursuant to <U>Section</U><U></U><U>&nbsp;4</U> immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event (the amount payable pursuant to this sentence is hereinafter referred to as
the &#8220;<B>Series A/B Liquidation Amount</B>&#8221;).<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>If upon any such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the assets of the Corporation
available for distribution to its stockholders shall be insufficient to pay the holders of shares of Series B Preferred Stock and Series A Preferred Stock the full amount to which they shall be entitled under this
<U>Section</U><U></U><U>&nbsp;2.1.2</U>, the holders of shares of Series B Preferred Stock and Series A Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which
would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.1.3 In the event of (a)&nbsp;any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of shares
of Series Seed Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Corporation available for distribution to its stockholders, and (b)&nbsp;a Deemed Liquidation Event, the holders of shares of Series Seed Preferred
Stock then outstanding shall be entitled to be paid out of the consideration payable to stockholders in such Deemed Liquidation Event or out of the Available Proceeds (as defined below), as applicable, after payment in full of the Series A/B
Liquidation Amount pursuant to <U>Subsection 2.1.2</U>, based on the Series Seed Liquidation Amount (as defined below) and before any payment shall be made to the holders of Common Stock by reason of their ownership thereof, an amount per share of
Series Seed Preferred Stock equal to the greater of (i)&nbsp;one times (1x) the applicable Original Issue Price, plus any dividends declared but unpaid thereon, or (ii)&nbsp;such amount per share as would have been payable had all shares of Series
Seed Preferred Stock been converted into Common Stock pursuant to <U>Section</U><U></U><U>&nbsp;4</U> immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event (the amount payable pursuant to this sentence is
hereinafter referred to as the &#8220;<B>Series Seed Liquidation Amount,</B>&#8221; and collectively with the Series C Liquidation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Amount and the Series A/B Liquidation Amount, or each individually as the context may dictate, the &#8220;<B>Liquidation Amount</B>&#8221;).<SUP STYLE="font-size:75%; vertical-align:top">
</SUP>If upon any such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the holders of shares of Series
Seed Preferred Stock the full amount to which they shall be entitled under this <U>Section</U><U></U><U>&nbsp;2.1.3</U>, the holders of shares of Series Seed Preferred Stock shall share ratably in any distribution of the assets available for
distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.2 <U>Payments to Holders of Common Stock</U>. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the
Corporation, after the payment in full of all Liquidation Amounts required to be paid to the holders of shares of Preferred Stock, the remaining assets of the Corporation available for distribution to its stockholders or, in the case of a Deemed
Liquidation Event, the consideration not payable to the holders of shares of Preferred Stock pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U> or the remaining Available Proceeds, as the case may be, shall be distributed among the holders of shares
of Common Stock, pro rata based on the number of shares of Common Stock held by each such holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.3 <U>Deemed Liquidation Events</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.3.1 <U>Definition</U>. Each of the following events shall be considered a &#8220;<B>Deemed Liquidation Event</B>&#8221;: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) a merger, consolidation, statutory conversion, transfer of the Corporation, domestication, or continuance in which </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Corporation is a constituent party or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a subsidiary of the Corporation is a constituent party and the Corporation issues shares of its capital stock
pursuant to such merger, consolidation, statutory conversion, transfer of the Corporation, domestication, or continuance, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">except any
such merger, consolidation, statutory conversion, transfer of the Corporation, domestication, or continuance involving the Corporation or a subsidiary in which the shares of capital stock of the Corporation outstanding immediately prior to such
merger, consolidation, statutory conversion, transfer of the Corporation, domestication, or continuance continue to represent, or are converted into or exchanged for shares of capital stock or other equity interests that represent, immediately
following such merger, consolidation, statutory conversion, transfer of the Corporation, domestication, or continuance, a majority of the capital stock or other equity interests of (1)&nbsp;the surviving or resulting corporation or entity; or
(2)&nbsp;if the surviving or resulting corporation or entity is a wholly owned subsidiary of another corporation or entity immediately following such merger, consolidation, statutory conversion, transfer of the Corporation, domestication, or
continuance, the parent corporation or entity of such surviving or resulting corporation or entity; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) (i) the sale, lease,
transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the Corporation or any subsidiary of the Corporation of all or substantially all the assets of the Corporation and its subsidiaries taken
as a whole, or (ii)&nbsp;the sale, lease, transfer, exclusive license or other disposition (whether by merger, consolidation, statutory conversion, transfer of the Corporation, domestication, continuance or otherwise, and whether in a single
transaction or a series of related transactions) of one or more subsidiaries of the Corporation if substantially all of the assets of the Corporation and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where
such sale, lease, transfer, exclusive license or other disposition is to a wholly owned subsidiary of the Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding anything in Section&nbsp;2.3.1 to the contrary, in no event shall the sale and issuance by
the Corporation of Preferred Stock in a bona fide equity financing of the Corporation, in and of itself, be a Deemed Liquidation Event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.3.2 <U>Effecting a Deemed Liquidation Event</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) The Corporation shall not have the power to effect a Deemed Liquidation Event referred to in
<U>Section</U><U></U><U>&nbsp;2.3.1(a)(</U><U>i</U><U>)</U> unless the agreement or plan with respect to such transaction, or terms of such transaction (any such agreement, plan or terms, the &#8220;<B>Transaction Document</B>&#8221;), provide that
the consideration payable to the stockholders of the Corporation in such Deemed Liquidation Event shall be allocated to the holders of capital stock of the Corporation in accordance with <U>Sections 2.1</U> and <U>2.2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) In the event of a Deemed Liquidation Event referred to in <U>Section</U><U></U><U>&nbsp;2.3.1(a)(ii)</U> or <U>2.3.1(b)</U>, if the
Corporation does not effect a dissolution of the Corporation under the General Corporation Law within 90 days after such Deemed Liquidation Event, then (i)&nbsp;the Corporation shall send a written notice to each holder of Preferred Stock no later
than the 90th day after the Deemed Liquidation Event advising such holders of their right (and the requirements to be met to secure such right) pursuant to the terms of the following clause (ii)&nbsp;to require the redemption of such shares of
Preferred Stock, and (ii)&nbsp;if the Investor Majority (as defined below) so requests in a written instrument delivered to the Corporation not later than 120 days after such Deemed Liquidation Event, the Corporation shall use the consideration
received by the Corporation for such Deemed Liquidation Event (net of any retained liabilities associated with the assets sold or technology licensed, any other expenses reasonably related to such Deemed Liquidation Event or any other expenses
incident to the dissolution of the Corporation as provided herein, in each case as determined in good faith by the Board of Directors), together with any other assets of the Corporation available for distribution to its stockholders, all to the
extent permitted by Delaware law governing distributions to stockholders (the &#8220;<B>Available Proceeds</B>&#8221;) on the 150th day after such Deemed Liquidation Event (the &#8220;<B>DLE Redemption Date</B>&#8221;), to redeem all outstanding
shares of Preferred Stock at a price per share equal to the applicable Liquidation Amount; <U>provided</U>, that if the definitive agreements governing such Deemed Liquidation Event contain contingent indemnification obligations on the part of the
Corporation and prohibit the Corporation from distributing all or a portion of the Available Proceeds while such indemnification obligations remain outstanding, then the DLE Redemption Date shall automatically be extended to the date that is ten
business days following the date on which such prohibition expires. Notwithstanding the foregoing, in the event of a redemption pursuant to the preceding sentence, if the Available Proceeds are not sufficient to redeem all outstanding shares of
Preferred Stock, the Corporation shall redeem a pro rata portion of each holder&#8217;s shares of Preferred Stock to the fullest extent of such Available Proceeds, based on the respective amounts which would otherwise be payable in respect of the
shares to be redeemed if the Available Proceeds were sufficient to redeem all such shares, and shall redeem the remaining shares as soon as it may lawfully do so under Delaware law governing distributions to stockholders. Prior to the distribution
or redemption provided for in this <U>Section</U><U></U><U>&nbsp;2.3.2(b)</U>, the Corporation shall not expend or dissipate the Available Proceeds for any purpose, except to discharge expenses incurred in connection with such Deemed Liquidation
Event. In connection with a distribution or redemption provided for in <U>Section</U><U></U><U>&nbsp;2.3.2</U>, the Corporation shall send written notice of the redemption (the &#8220;<B>Redemption Notice</B>&#8221;) to each holder of record of
Preferred Stock. Each Redemption Notice shall state: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="25%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the number of shares of Preferred Stock held by the holder that the Corporation shall redeem on the date
specified in the Redemption Notice; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="25%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the redemption date and the price per share at which the shares of Preferred Stock are being redeemed;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="25%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for holders of shares in certificated form, that the holder is to surrender to the Corporation, in the manner
and at the place designated, his, her or its certificate or certificates representing the shares of Preferred Stock to be redeemed. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
the Redemption Notice shall have been duly given, and if payment is tendered or deposited with an independent payment agent so as to be available therefor in a timely manner, then notwithstanding that any certificates evidencing any of the shares of
Preferred Stock so called for redemption shall not have been surrendered, all rights with respect to such shares shall forthwith after the date terminate, except only the right of the holders to receive the payment without interest upon surrender of
any such certificate or certificates therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.3.3 <U>Amount Deemed Paid or Distributed</U>. The amount deemed paid or distributed to
the holders of capital stock of the Corporation upon any such merger, consolidation, sale, transfer, exclusive license, other disposition or redemption shall be the cash or the value of the property, rights or securities to be paid or distributed to
such holders pursuant to such Deemed Liquidation Event. The value of such property, rights or securities shall be determined in good faith by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.3.4 <U>Allocation of Escrow and Contingent Consideration</U>. In the event of a Deemed Liquidation Event pursuant to
<U>Section</U><U></U><U>&nbsp;2.3.1(a)(</U><U>i</U><U>)</U>, if any portion of the consideration payable to the stockholders of the Corporation is payable only upon satisfaction of contingencies (the &#8220;<B>Additional Consideration</B>&#8221;),
then: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) If the holders of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred unanimously determine, the
Transaction Document shall provide that (a)&nbsp;the portion of such consideration that is not Additional Consideration (such portion, the &#8220;<B>Initial Consideration</B>&#8221;) shall be allocated among the holders of capital stock of the
Corporation in accordance with <U>Sections 2.1</U> and <U>2.2</U> as if the Initial Consideration were the only consideration payable in connection with such Deemed Liquidation Event; and (b)&nbsp;any Additional Consideration which becomes payable
to the stockholders of the Corporation upon satisfaction of such contingencies shall be allocated among the holders of capital stock of the Corporation in accordance with <U>Sections 2.1</U> and <U>2.2</U> after taking into account the previous
payment of the Initial Consideration as part of the same transaction. For the purposes of this <U>Section</U><U></U><U>&nbsp;2.3.4(a)</U>, consideration placed into escrow or retained as a holdback to be available for satisfaction of indemnification
or similar obligations in connection with such Deemed Liquidation Event shall be deemed to be Additional Consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) If the
holders of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock do not determine that the Additional Consideration shall be treated as set forth in subsection (a), the Transaction Document shall provide that the Initial
Consideration and any Additional Consideration shall be allocated among the holders of capital stock of the Corporation in accordance with <U>Sections 2.1</U> and <U>2.2</U> as if payable upon the initial consummation of such Deemed Liquidation
Event. For the purposes of this <U>Section</U><U></U><U>&nbsp;2.3.4(a)</U>, consideration placed into escrow or retained as a holdback to be available for satisfaction of indemnification or similar obligations in connection with such Deemed
Liquidation Event shall be deemed to be Initial Consideration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3. <U>Voting</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.1 <U>General</U>. On any matter presented to the stockholders of the Corporation for their action or consideration at any meeting of
stockholders of the Corporation (or by written consent of stockholders in lieu of a meeting), each holder of outstanding shares of Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into
which the shares of Preferred Stock held by such holder are convertible (as provided in <U>Section</U><U></U><U>&nbsp;4</U> below) as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by
the other provisions of this Certificate of Incorporation, holders of Preferred Stock shall vote together with the holders of Common Stock as a single class and on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.2 <U>Election of Directors</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) (i) At all times when any shares of Preferred Stock remain outstanding (subject to appropriate adjustment in the event of any stock
dividend, stock split, combination, or other similar recapitalization with respect to the Preferred Stock), the holders of record of the shares of Preferred Stock, exclusively and voting together as a separate class on an <FONT
STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis, shall be entitled to elect four directors of the Corporation (the &#8220;<B>Preferred </B><B>Directors</B>&#8221;); and (ii)&nbsp;the holders of record of the shares of Common
Stock and of any other class or series of voting stock (including the Preferred Stock), exclusively and voting together as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis, shall be entitled to elect
the balance of the total number of directors of the Corporation (the &#8220;<B><FONT STYLE="white-space:nowrap">At-Large</FONT> Directors</B>&#8221;).<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>Notwithstanding the foregoing, for
administrative convenience, the initial Preferred Directors and <FONT STYLE="white-space:nowrap">At-Large</FONT> Directors may also be appointed by the Board of Directors in connection with the approval of this Amended and Restated Certificate of
Incorporation without a separate action by the holders of Preferred Stock or Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) Any director elected as provided in
<U>Section</U><U></U><U>&nbsp;3.2(a)(i)</U> or <U>Section</U><U></U><U>&nbsp;3.2(a)(ii)</U> or appointed by the last sentence of <U>Section</U><U></U><U>&nbsp;3.2(a)</U> may be removed without cause by, and only by, the affirmative vote of the
holders of a majority of the shares of the class or series of capital stock entitled to elect such director or directors, given either at a special meeting of such stockholders duly called for that purpose or pursuant to a written consent of
stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="25%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the holders of shares of Preferred Stock or Common Stock, as the case may be, fail to elect a sufficient
number of directors to fill all directorships for which they are entitled to elect directors pursuant to <U>Section</U><U></U><U>&nbsp;3.2(a)</U> (and to the extent any of such directorships is not otherwise filled by a director appointed in
accordance with the last sentence of <U>Section</U><U></U><U>&nbsp;3.2(a)</U>), then any directorship not so filled shall remain vacant until such time as the holders of the Preferred Stock or Common Stock, as the case may be, fill such directorship
in accordance with <U>Section</U><U></U><U>&nbsp;3.2(a)</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="25%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A vacancy in any <FONT STYLE="white-space:nowrap">At-Large</FONT> Director seat can be filled by either
(A)&nbsp;the vote or written consent in lieu of a meeting of the stockholders entitled to elect the <FONT STYLE="white-space:nowrap">At-Large</FONT> Directors, or (B)&nbsp;the vote or written consent in lieu of a meeting of a majority of the
remaining director(s). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) At any meeting held for the purpose of electing a director, the presence in person or
by proxy of the holders of a majority of the outstanding shares of the class or series of capital stock entitled to elect such director shall constitute a quorum for the purpose of electing such director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(e) For purposes of this Certificate of Incorporation, &#8220;<B>Requisite Directors</B>&#8221; means the Board of Directors including a
majority of the Preferred Directors then seated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.3 <U>Preferred Stock Protective Provisions</U>. At any time when shares of Preferred
Stock are outstanding, the Corporation shall not, either directly or indirectly by amendment, merger, consolidation, domestication, transfer of the Corporation, continuance, reorganization, recapitalization, reclassification, waiver, statutory
conversion, or otherwise, effect any of the following acts or transactions without (in addition to any other vote required by law or this Certificate of Incorporation) the written consent or affirmative vote of the holders of at least 50% of the
outstanding shares of Preferred Stock, including the holders of at least 60% of the outstanding shares of Series C Preferred Stock (the &#8220;<B>Investor Majority</B>&#8221;), and any such&nbsp;act or transaction that has not been approved by such
consent or vote prior to such act or transaction being effected shall be null and void <I>ab initio</I>, and of no force or effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.1 liquidate, dissolve or <FONT STYLE="white-space:nowrap">wind-up</FONT> the business and affairs of the Corporation or effect any Deemed
Liquidation Event; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.2 exclude or limit <FONT STYLE="white-space:nowrap">pre-emption</FONT> rights in the case of issuance of shares
or a grant of rights to subscribe for shares or other securities; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.3 amend, alter or repeal any provision of this Certificate of
Incorporation or Bylaws of the Corporation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.4 effect any merger, consolidation, reorganization, statutory conversion, transfer of
the Corporation, domestication, or continuance (other than a Deemed Liquidation Event), or consummate an initial sale of shares to the public in an offering pursuant to an effective registration statement under the Securities Act of 1933, as
amended; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.5 create, or authorize the creation of, or issue or obligate itself to issue shares of, any additional class or series of
capital stock; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.6 increase or decrease the authorized number of shares of Common Stock, Preferred Stock, or any series thereof; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.7 purchase or redeem (or permit any subsidiary to purchase or redeem) or pay or declare any dividend or make any distribution on, any
shares of capital stock of the Corporation other than (i)&nbsp;redemptions of or dividends or distributions on the Preferred Stock as expressly authorized herein, (ii)&nbsp;dividends or other distributions payable on the Common Stock solely in the
form of additional shares of Common Stock and (iii)&nbsp;repurchases of stock from former employees, officers, directors, consultants or other persons who performed services for the Corporation or any subsidiary in connection with the cessation of
such employment or service at no greater than the original purchase price thereof; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.8 create, relocate or dissolve any subsidiary, except for the establishment, relocating
or dissolution of subsidiaries for the sole purpose of engaging new employees in other jurisdictions; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.9 increase or decrease the
authorized number of directors constituting the Board of Directors, change the number of votes entitled to be cast by any director or directors on any matter or change the compensation of the directors; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.10 (i) create or adopt any equity (or equity-linked) compensation plan; or (ii)&nbsp;amend any such plan to increase or decrease the
number of shares authorized for issuance thereunder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.11 license or transfer any of the Corporation&#8217;s (or its
subsidiaries&#8217;) material technology or intellectual property or royalties related thereto or assets to a third party, other than in the ordinary course of business; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.12 appoint or dismiss the Corporation&#8217;s independent auditors; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.13 change the principal business of the Corporation, enter new lines of business, or exit the current line of business; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.14 grant to any person the right to receive any bonus, share of the proceeds or other payments upon a Deemed Liquidation Event; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.15 unless otherwise approved by the Requisite Directors: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) other than equipment leases, bank lines of credit or trade payables incurred in the ordinary course of business, create, or issue, any
debt security, create any lien or security interest (except for purchase money liens or statutory liens of landlords, mechanics, materialmen, workmen, warehousemen and other similar persons arising or incurred in the ordinary course of business), or
incur other indebtedness for borrowed money, including but not limited to obligations and contingent obligations under guarantees, or permit any subsidiary to take any such action with respect to any debt security lien, security interest or other
indebtedness for borrowed money; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) make, or permit any subsidiary to make, any loan, granting of any debt, or advance to any entity or
individual, including, without limitation, any employee, director or holder of shares of Common Stock of the Corporation or any subsidiary; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) hire, terminate, or change the compensation of, approve or amend any stock or option awards to, or enter into any <FONT
STYLE="white-space:nowrap">non-employment</FONT> related transaction with, the Chief Executive Officer, any individual reporting directly to the Board of Directors, or executive-level individual reporting directly to the Chief Executive Officer, or
any immediate family member of any such individual; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) enter into or be a party to or modify any transaction with any director,
officer, or employee of the Corporation or any &#8220;associate&#8221; (as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> promulgated under the Exchange Act) of any such Person; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(e) approve or modify the annual budget or change the Corporation&#8217;s approved business
plan or strategy; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(f) issue any shares of Common Stock or Preferred Stock, including securities convertible into such shares, approve
any equity grant to any employee or change the vesting of any outstanding equity grant, including acceleration of vesting in connection with a Deemed Liquidation Event or other such transaction; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(g) dispose in a single disposal or series of related disposals of any material assets of the Corporation with a value that, in the
aggregate, is greater than $500,000, other than disposals in the ordinary course of business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(h) sell, assign, license, pledge,
granting of royalty rights or otherwise encumber technology or intellectual property, or otherwise enter into transactions relating to intellectual property rights owned or controlled by the Corporation or a third party, other than transactions in
the ordinary course of business and the conclusion or termination or any patent, license, <FONT STYLE="white-space:nowrap">know-how</FONT> or cooperation agreement in relation to intellectual property, provided that such disposal, conclusion or
termination falls outside the Corporation&#8217;s ordinary course of business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(i) effect any acquisition, investment, expenditure, sale
or lease of assets, or enter into any licensing or distribution agreement, if such transaction (i)&nbsp;has a value exceeding $500,000 in the aggregate over a <FONT STYLE="white-space:nowrap">12-month</FONT> period or which extends for a period of
more than two years, and (ii)&nbsp;was not already included in the Corporation&#8217;s approved budget. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(j) enter into any corporate
strategic relationship outside the ordinary course of business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(k) make any investment, including entering into investment contracts or
commitments, irrespective of size, inconsistent with any investment policy approved by the Board of Directors, including the direct or indirect participation in capital increases in other companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(l) initiate, conduct or settle any litigation, other than legal actions requiring immediate action or the purpose of which is solely to
reserve rights (provided that the Board of Directors is promptly informed thereof), or actions taken to collect claims on behalf of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(m) grant a power of attorney or appoint a proxy-holder on behalf of the Corporation; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(n) enter into any agreement relating to the purchase or sale of real property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4. <U>Optional Conversion</U>. The holders of the Preferred Stock shall have conversion rights as follows (the &#8220;<B>Conversion
Rights</B>&#8221;): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.1 <U>Right to Convert</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.1.1 <U>Conversion Ratio</U>. Each share of Preferred Stock shall be convertible, at the option of the holder thereof, at any time, and
without the payment of additional consideration by the holder thereof, into such whole number of fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock (calculated as provided in
<U>Section</U><U></U><U>&nbsp;4.2</U> below), as is determined by dividing the applicable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Original Issue Price by the applicable Conversion Price (as defined below) in effect at the time of conversion. The &#8220;<B>Conversion Price</B>&#8221; applicable to each series of the
Preferred Stock as of the Original Issue Date shall be equal to $133.92 per share of Series Seed Preferred Stock, $236.39 per share of Series A Preferred Stock, $305.85 per share of Series B Preferred Stock and $305.85 per share of Series C
Preferred Stock, respectively. Such initial Conversion Price for a series of Preferred Stock, and the rate at which shares of Preferred Stock may be converted into shares of Common Stock, shall be subject to adjustment as provided in this
<U>Section</U><U></U><U>&nbsp;4</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.1.2 <U>Termination of Conversion Rights</U>. In the event of a notice of redemption of any shares
of Preferred Stock pursuant to <U>Section</U><U></U><U>&nbsp;2.3.2(b)</U>, the Conversion Rights of the shares designated for redemption shall terminate at 5:00 p.m. Eastern time (the &#8220;<B>close of business</B>&#8221; for purposes hereof) on
the last full day preceding the date fixed for redemption, unless the redemption price is not fully paid on such redemption date, in which case the Conversion Rights for such shares shall continue until such price is paid in full. In the event of a
liquidation, dissolution or winding up of the Corporation or a Deemed Liquidation Event, the Conversion Rights shall terminate at the close of business on the last full day preceding the date fixed for the payment of any such amounts distributable
on such event to the holders of Preferred Stock; provided that the foregoing termination of Conversion Rights shall not affect the amount(s) otherwise paid or payable in accordance with <U>Section</U><U></U><U>&nbsp;2.1</U> to the holders of
Preferred Stock pursuant to such liquidation, dissolution or winding up of the Corporation or a Deemed Liquidation Event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.2 <U>Number
of Shares Issuable Upon Conversion</U>. The number of shares of Common Stock issuable to a holder of Preferred Stock upon conversion of such Preferred Stock shall be the nearest whole share, after aggregating all fractional interests in shares of
Common Stock that would otherwise be issuable upon conversion of all shares of that same series of Preferred Stock being converted by such holder (with any fractional interests after such aggregation representing 0.5 or greater of a whole share
being entitled to a whole share). For the avoidance of doubt, no fractional interests in shares of Common Stock shall be created or issuable as a result of the conversion of the Preferred Stock pursuant to <U>Section</U><U></U><U>&nbsp;4.1.1</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.3 <U>Mechanics of Conversion</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.1 <U>Notice of Conversion</U>. In order for a holder of Preferred Stock to voluntarily convert shares of Preferred Stock into shares of
Common Stock, such holder shall (a)&nbsp;provide written notice to the Corporation at the principal office of the Corporation that such holder elects to convert all or any number of such holder&#8217;s shares of Preferred Stock and, if applicable,
any event on which such conversion is contingent and (b)&nbsp;if such holder&#8217;s shares are certificated, tender to the Corporation at its principal office (1)&nbsp;the certificate or certificates for such shares of Preferred Stock or (2)&nbsp;a
stock assignment separate from certificate if such certificate or certificates are electronic (or, if such registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably
acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate). If required by the Corporation, any certificates
surrendered for conversion shall be endorsed or accompanied by a written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or his, her or its attorney duly authorized in writing.
The close of business on the date of receipt by the transfer agent (or by the Corporation if the Corporation serves as its own transfer agent) of such notice and, if applicable, certificates (or lost certificate affidavit and agreement) shall be the
time of conversion (the &#8220;<B>Conversion Time</B>&#8221;), and the shares of Common Stock issuable upon conversion of the specified shares shall be deemed to be outstanding of record as of such date. The Corporation shall, as soon as practicable
after the Conversion Time (i)&nbsp;issue and deliver to such holder of Preferred Stock, or to his, her or its nominees, a certificate or certificates (whether electronic or physical) for the number of full shares of Common Stock issuable upon such
conversion in accordance with the provisions hereof and a certificate for the number (if any) of the shares of Preferred Stock represented by the surrendered certificate that were not converted into Common Stock, and (ii)&nbsp;pay all declared but
unpaid dividends on the shares of Preferred Stock converted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.2 <U>Reservation of Shares</U>. The Corporation shall at all times when the Preferred
Stock shall be outstanding, reserve and keep available out of its authorized but unissued capital stock, for the purpose of effecting the conversion of the Preferred Stock, such number of its duly authorized shares of Common Stock as shall from time
to time be sufficient to effect the conversion of all outstanding Preferred Stock; and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all then outstanding shares of the
Preferred Stock, the Corporation shall take such corporate action as may be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes, including, without limitation,
engaging in best efforts to obtain the requisite stockholder approval of any necessary amendment to this Certificate of Incorporation. Before taking any action that would cause an adjustment reducing the Conversion Price for any series of Preferred
Stock below the then par value of the shares of Common Stock issuable upon conversion of such series of Preferred Stock, the Corporation will take any corporate action which may, in the opinion of its counsel, be necessary in order that the
Corporation may validly and legally issue fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock at such adjusted Conversion Price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.3 <U>Effect of Conversion</U>. All shares of Preferred Stock which shall have been surrendered for conversion as herein provided shall no
longer be deemed to be outstanding and all rights with respect to such shares shall immediately cease and terminate at the Conversion Time, except only the right of the holders thereof to receive shares of Common Stock in exchange therefor and to
receive payment of any dividends declared but unpaid thereon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.4 <U>No Further Adjustment</U>. Upon any such conversion, no
adjustment to the Conversion Price <U>shall</U> be made for any declared but unpaid dividends on the Preferred Stock surrendered for conversion or on the Common Stock delivered upon conversion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.5 <U>Taxes</U>. The Corporation shall pay any and all issue and other similar taxes that may be payable in respect of any issuance or
delivery of shares of Common Stock upon conversion of shares of Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;4</U>. The Corporation shall not, however, be required to pay any tax which may be payable in respect of any transfer
involved in the issuance and delivery of shares of Common Stock in a name other than that in which the shares of Preferred Stock so converted were registered, and no such issuance or delivery shall be made unless and until the person or entity
requesting such issuance has paid to the Corporation the amount of any such tax or has established, to the satisfaction of the Corporation, that such tax has been paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.4 <U>Adjustments to </U><U>Preferred Stock Conversion</U><U> Price for Diluting Issues</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.1 <U>Special Definitions</U>. For purposes of this <U>Article Fourth</U>, the following definitions shall apply: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) &#8220;<B>Additional Shares of Common Stock</B>&#8221; means all shares of Common Stock issued (or, pursuant to
<U>Section</U><U></U><U>&nbsp;4.4.3</U> below, deemed to be issued) by the Corporation after the Original Issue Date (as defined below), other than (1)&nbsp;the following shares of Common Stock and (2)&nbsp;shares of Common Stock deemed issued
pursuant to the following Options and Convertible Securities (clauses (1)&nbsp;and (2), collectively, &#8220;<B>Exempted Securities</B>&#8221;): </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="25%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as to any series of Preferred Stock, shares of Common Stock, Options or Convertible Securities issued as a
dividend or distribution on such series of Preferred Stock (including dividends payable in connection with dividends on other classes or series of stock); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="25%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued by reason of a dividend, stock split, <FONT
STYLE="white-space:nowrap">split-up</FONT> or other distribution on shares of Common Stock that is covered by <U>Section</U><U></U><U>&nbsp;4.5</U>, <U>4.6</U>, <U>4.7</U> or <U>4.8</U>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="25%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued to banks, equipment lessors or other financial
institutions, or to real property lessors, pursuant to a debt financing, equipment leasing or real property leasing transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="25%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock or Options issued to employees or directors of, or consultants or advisors to, the
Corporation or any of its subsidiaries pursuant to a plan, agreement or arrangement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="25%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock or Convertible Securities actually issued upon the exercise of Options or shares of
Common Stock actually issued upon the conversion or exchange of Convertible Securities, in each case provided such issuance is pursuant to the terms of such Option or Convertible Security; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="25%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued as acquisition consideration pursuant to the
acquisition of another corporation by the Corporation by merger, purchase of substantially all of the assets or other reorganization or to a joint venture agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="25%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock issued in connection with a firm underwritten public offering of the Corporation&#8217;s
Common Stock pursuant to an effective registration statement; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="25%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Preferred Stock or Options issued pursuant to the Share Contribution and Exchange
Agreement, dated on or about the date hereof, by and among the Corporation and the other parties named therein. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) &#8220;<B>Convertible Securities</B>&#8221; means any evidences of indebtedness, shares
or other securities directly or indirectly convertible into or exchangeable for Common Stock, but excluding Options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c)
&#8220;<B>Option</B>&#8221; means any rights, options or warrants to subscribe for, purchase or otherwise acquire Common Stock or Convertible Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) &#8220;<B>Original Issue Date</B>&#8221; means the date on which the first share of Series A Preferred Stock is issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.2 <U>No Adjustment of </U><U>Preferred Stock</U><B> </B><U>Conversion Price</U>. No adjustment in the Conversion Price of any series of
Preferred Stock shall be made as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the Investor Majority, agreeing that no such adjustment shall be made as the result
of the issuance or deemed issuance of such Additional Shares of Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.3 <U>Deemed Issue of Additional Shares of Common
Stock</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) If the Corporation at any time or from time to time after the Original Issue Date shall issue any Options or Convertible
Securities (excluding Options or Convertible Securities which are themselves Exempted Securities) or shall fix a record date for the determination of holders of any class of securities entitled to receive any such Options or Convertible Securities,
then the maximum number of shares of Common Stock (as set forth in the instrument relating thereto, assuming the satisfaction of any conditions to exercisability, convertibility or exchangeability but without regard to any provision contained
therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or, in the case of Convertible Securities and Options therefor, the conversion or exchange of such Convertible Securities, shall be deemed to be
Additional Shares of Common Stock issued as of the time of such issue or, in case such a record date shall have been fixed, as of the close of business on such record date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) If the terms of any Option or Convertible Security, the issuance of which resulted in an adjustment to the Conversion Price of any series
of Preferred Stock pursuant to the terms of <U>Section</U><U></U><U>&nbsp;4.4.4</U>, are revised as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible Security (but excluding
automatic adjustments to such terms pursuant to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (1)&nbsp;any increase or decrease in the number of shares of Common Stock issuable upon the exercise,
conversion and/or exchange of any such Option or Convertible Security or (2)&nbsp;any increase or decrease in the consideration payable to the Corporation upon such exercise, conversion and/or exchange, then, effective upon such increase or decrease
becoming effective, the Conversion Price of such series of Preferred Stock computed upon the original issue of such Option or Convertible Security (or upon the occurrence of a record date with respect thereto) shall be readjusted to such Conversion
Price for such series of Preferred Stock as would have obtained had such revised terms been in effect upon the original date of issuance of such Option or Convertible Security. Notwithstanding the foregoing, no readjustment pursuant to this
<U>Section</U><U></U><U>&nbsp;4.4.3(b)</U> shall have the effect of increasing the Conversion Price applicable to a series of Preferred Stock to an amount which exceeds the lower of (i)&nbsp;the Conversion Price for such series of Preferred Stock in
effect immediately prior to the original adjustment made as a result of the issuance of such Option or Convertible Security, or (ii)&nbsp;the Conversion Price for such series of Preferred Stock that would have resulted from any issuances of
Additional Shares of Common Stock (other than deemed issuances of Additional Shares of Common Stock as a result of the issuance of such Option or Convertible Security) between the original adjustment date and such readjustment date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) If the terms of any Option or Convertible Security (excluding Options or Convertible
Securities which are themselves Exempted Securities), the issuance of which did not result in an adjustment to the Conversion Price of a series of Preferred Stock pursuant to the terms of <U>Section</U><U></U><U>&nbsp;4.4.4</U> (either because the
consideration per share (determined pursuant to <U>Section</U><U></U><U>&nbsp;4.4.5</U>) of the Additional Shares of Common Stock subject thereto was equal to or greater than the applicable Conversion Price then in effect, or because such Option or
Convertible Security was issued before the Original Issue Date), are revised after the Original Issue Date as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible Security (but
excluding automatic adjustments to such terms pursuant to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (1)&nbsp;any increase in the number of shares of Common Stock issuable upon the exercise,
conversion or exchange of any such Option or Convertible Security or (2)&nbsp;any decrease in the consideration payable to the Corporation upon such exercise, conversion or exchange, then such Option or Convertible Security, as so amended or
adjusted, and the Additional Shares of Common Stock subject thereto determined in the manner provided in <U>Section</U><U></U><U>&nbsp;4.4.3(a)</U> shall be deemed to have been issued effective upon such increase or decrease becoming effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) Upon the expiration or termination of any unexercised Option or unconverted or unexchanged Convertible Security (or portion thereof)
which resulted (either upon its original issuance or upon a revision of its terms) in an adjustment to the Conversion Price of any series of Preferred Stock pursuant to the terms of <U>Section</U><U></U><U>&nbsp;4.4.4</U>, the Conversion Price of
such series of Preferred Stock shall be readjusted to such Conversion Price for such series of Preferred Stock as would have obtained had such Option or Convertible Security (or portion thereof) never been issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(e) If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security, or
the consideration payable to the Corporation upon such exercise, conversion and/or exchange, is calculable at the time such Option or Convertible Security is issued or amended but is potentially subject to adjustment based upon subsequent events,
any adjustment to the Conversion Price of a series of Preferred Stock provided for in this <U>Section</U><U></U><U>&nbsp;4.4.3</U> shall be effected at the time of such issuance or amendment based on such number of shares or amount of consideration
without regard to any provisions for subsequent adjustments (and any subsequent adjustments shall be treated as provided in <U>clauses (b)</U>&nbsp;and <U>(c)</U> of this <U>Section</U><U></U><U>&nbsp;4.4.3</U>). If the number of shares of Common
Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security, or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, cannot be calculated at all at the time such Option
or Convertible Security is issued or amended, any adjustment to the Conversion Price of a series of Preferred Stock that would result under the terms of this <U>Section</U><U></U><U>&nbsp;4.4.3</U> at the time of such issuance or amendment shall
instead be effected at the time such number of shares and/or amount of consideration is first calculable (even if subject to subsequent adjustments), assuming for purposes of calculating such adjustment to the Conversion Price for such series of
Preferred Stock that such issuance or amendment took place at the time such calculation can first be made. In the event an Option or Convertible Security contains alternative conversion terms, such as a cap on the valuation of the Corporation at
which such conversion will be effected, or circumstances where the Option or Convertible Security may be repaid in lieu of conversion, then the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of such Option or
Convertible Security shall be deemed not calculable until such time as the applicable conversion terms are determined. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.4
<U>Adjustment of Conversion Price Upon Issuance of Additional Shares of Common Stock</U>. In the event the Corporation shall at any time after the Original Issue Date issue Additional Shares of Common Stock (including Additional Shares of Common
Stock deemed to be issued pursuant to <U>Section</U><U></U><U>&nbsp;4.4.3</U>), without consideration or for a consideration per share less than the Conversion Price of a series of Preferred Stock in effect immediately prior to such issuance or
deemed issuance, then the Conversion Price for such series of Preferred Stock shall be reduced, concurrently with such issue, to a price (calculated to the nearest <FONT STYLE="white-space:nowrap">one-hundredth</FONT> of a cent) determined in
accordance with the following formula: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CP<SUB STYLE="font-size:75%; vertical-align:bottom">2</SUB> = CP<SUB
STYLE="font-size:75%; vertical-align:bottom">1</SUB>* (A + B) / (A + C). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of the foregoing formula, the following definitions shall apply:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) &#8220;CP<SUB STYLE="font-size:75%; vertical-align:bottom">2</SUB>&#8221; shall mean the Conversion Price of such series of
Preferred Stock in effect immediately after such issuance or deemed issuance of Additional Shares of Common Stock; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) &#8220;CP<SUB
STYLE="font-size:75%; vertical-align:bottom">1</SUB>&#8221; shall mean the Conversion Price of such series of Preferred Stock in effect immediately prior to such issuance or deemed issuance of Additional Shares of Common Stock; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) &#8220;A&#8221; shall mean the number of shares of Common Stock outstanding immediately prior to such issuance or deemed issuance of
Additional Shares of Common Stock (treating for this purpose as outstanding all shares of Common Stock issuable upon exercise of Options outstanding immediately prior to such issuance or deemed issuance or upon conversion or exchange of Convertible
Securities (including the Preferred Stock) outstanding (assuming exercise of any outstanding Options therefor) immediately prior to such issue); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) &#8220;B&#8221; shall mean the number of shares of Common Stock that would have been issued if such Additional Shares of Common Stock had
been issued or deemed issued at a price per share equal to CP<SUB STYLE="font-size:75%; vertical-align:bottom">1</SUB> (determined by dividing the aggregate consideration received by the Corporation in respect of such issue by CP<SUB
STYLE="font-size:75%; vertical-align:bottom">1</SUB>); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(e) &#8220;C&#8221; shall mean the number of such Additional Shares of Common
Stock issued in such transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.5 <U>Determination of Consideration</U>. For purposes of this
<U>Section</U><U></U><U>&nbsp;4.4</U>, the consideration received by the Corporation for the issuance or deemed issuance of any Additional Shares of Common Stock shall be computed as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) <U>Cash and Property</U>. Such consideration shall: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">insofar as it consists of cash, be computed at the aggregate amount of cash received by the Corporation,
excluding amounts paid or payable for accrued interest; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">insofar as it consists of property other than cash, be computed at the fair market value thereof at the time of
such issue, as determined in good faith by the Board of Directors; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the event Additional Shares of Common Stock are issued together with other shares or securities or other
assets of the Corporation for consideration which covers both, be the proportion of such consideration so received, computed as provided in <U>clauses (i)</U>&nbsp;and <U>(ii)</U> above, as determined in good faith by the Board of Directors.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) <U>Options and Convertible Securities</U>. The consideration per share received by the
Corporation for Additional Shares of Common Stock deemed to have been issued pursuant to <U>Section</U><U></U><U>&nbsp;4.4.3</U>, relating to Options and Convertible Securities, shall be determined by dividing: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The total amount, if any, received or receivable by the Corporation as consideration for the issue of such
Options or Convertible Securities, plus the minimum aggregate amount of additional consideration (as set forth in the instruments relating thereto, without regard to any provision contained therein for a subsequent adjustment of such consideration)
payable to the Corporation upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such Options for Convertible Securities and the
conversion or exchange of such Convertible Securities, by </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the maximum number of shares of Common Stock (as set forth in the instruments relating thereto, without regard
to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the
exercise of such Options for Convertible Securities and the conversion or exchange of such Convertible Securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.6 <U>Multiple Closing Dates</U>. In the event the Corporation shall issue on more than one date Additional Shares of Common Stock that
are a part of one transaction or a series of related transactions and that would result in an adjustment to the Conversion Price of a series of Preferred Stock pursuant to the terms of <U>Section</U><U></U><U>&nbsp;4.4.4</U> then, upon the final
such issuance, the Conversion Price for such series of Preferred Stock shall be readjusted to give effect to all such issuances as if they occurred on the date of the first such issuance (and without giving effect to any additional adjustments as a
result of any such subsequent issuances within such period). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.5 <U>Adjustment for Stock Splits and Combinations</U><SUP
STYLE="font-size:75%; vertical-align:top">.</SUP> If at any time or from time to time after the Original Issue Date the Corporation shall effect a subdivision of the outstanding Common Stock, the Conversion Price of each series of Preferred Stock in
effect immediately before that subdivision shall be proportionately decreased so that the number of shares of Common Stock issuable on conversion of each share of such series shall be increased in proportion to such increase in the aggregate number
of shares of Common Stock outstanding. If the Corporation shall at any time or from time to time after the Original Issue Date combine the outstanding shares of Common Stock, the Conversion Price of each series
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of Preferred Stock in effect immediately before the combination shall be proportionately increased so that the number of shares of Common Stock issuable on conversion of each share of such series
shall be decreased in proportion to such decrease in the aggregate number of shares of Common Stock outstanding. Any adjustment under this <U>Section</U><U></U><U>&nbsp;4.5</U> shall become effective at the close of business on the date the
subdivision or combination becomes effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.6 <U>Adjustment for Certain Dividends and Distributions</U>. If at any time or from time
to time after the Original Issue Date the Corporation shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable on the Common Stock in additional shares
of Common Stock, then and in each such event the Conversion Price of each series of Preferred Stock in effect immediately before such event shall be decreased as of the time of such issuance or, if such a record date shall have been fixed, as of the
close of business on such record date, by multiplying the Conversion Price of each such series of Preferred Stock then in effect by a fraction: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(1) the numerator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such
issuance or the close of business on such record date, and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(2) the denominator of which shall be the total number of shares of Common
Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date plus the number of shares of Common Stock issuable in payment of such dividend or distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, (a)&nbsp;if such record date shall have been fixed and such dividend is not fully paid or if such distribution is not fully
made on the date fixed therefor, the Conversion Price of each series of Preferred Stock shall be recomputed accordingly as of the close of business on such record date and thereafter the Conversion Price of each series of Preferred Stock shall be
adjusted pursuant to this <U>Section</U><U></U><U>&nbsp;4.6</U> as of the time of actual payment of such dividends or distributions; and (b)&nbsp;no such adjustment shall be made if the holders of such series of Preferred Stock simultaneously
receive a dividend or other distribution of shares of Common Stock in a number equal to the number of shares of Common Stock as they would have received if all outstanding shares of such series of Preferred Stock had been converted into Common Stock
on the date of such event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.7 <U>Adjustments for Other Dividends and Distributions</U>. If at any time or from time to time after the
Original Issue Date the Corporation shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable in securities of the Corporation (other than a distribution
of shares of Common Stock in respect of outstanding shares of Common Stock) or in other property and the provisions of <U>Section</U><U></U><U>&nbsp;1</U> do not apply to such dividend or distribution, then and in each such event the holders of
Preferred Stock shall receive, simultaneously with the distribution to the holders of Common Stock, a dividend or other distribution of such securities or other property in an amount equal to the amount of such securities or other property as they
would have received if all outstanding shares of Preferred Stock had been converted into Common Stock on the date of such event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.8
<U>Adjustment for Merger or Reorganization, etc</U>. Subject to the provisions of <U>Section</U><U></U><U>&nbsp;2.3</U>, if there shall occur any reorganization, recapitalization, reclassification, consolidation or merger involving the Corporation
in which the Common Stock (but not the Preferred Stock) is converted into or exchanged for securities, cash or other property (other than a transaction covered by <U>Sections 4.4</U>, <U>4.6</U> or <U>4.7</U>), then, following any such
reorganization, recapitalization, reclassification, consolidation or merger, each share of Preferred Stock shall thereafter be convertible in lieu of the Common Stock into </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which it was convertible prior to such event into the kind and amount of securities, cash or other property which a holder of the number of shares of Common Stock of the Corporation issuable upon
conversion of one share of such Preferred Stock immediately prior to such reorganization, recapitalization, reclassification, consolidation or merger would have been entitled to receive pursuant to such transaction; and, in such case, appropriate
adjustment (as determined in good faith by the Board of Directors) shall be made in the application of the provisions in this <U>Section</U><U></U><U>&nbsp;4</U> with respect to the rights and interests thereafter of the holders of the Preferred
Stock, to the end that the provisions set forth in this <U>Section</U><U></U><U>&nbsp;4.8</U> (including provisions with respect to changes in and other adjustments of the Conversion Price of each series of Preferred Stock) shall thereafter be
applicable, as nearly as reasonably may be, in relation to any securities or other property thereafter deliverable upon the conversion of the Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.9 <U>Certificate as to Adjustments</U>. Upon the occurrence of each adjustment or readjustment of the Conversion Price of a series of
Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;4</U>, the Corporation at its expense shall, as promptly as reasonably practicable but in any event not later than ten days thereafter, compute such adjustment or readjustment in
accordance with the terms hereof and furnish to each holder of such series of Preferred Stock a certificate setting forth such adjustment or readjustment (including the kind and amount of securities, cash or other property into which such series of
Preferred Stock is convertible) and showing in detail the facts upon which such adjustment or readjustment is based. The Corporation shall, as promptly as reasonably practicable after the written request at any time of any holder of Preferred Stock
(but in any event not later than 10 days thereafter), furnish or cause to be furnished to such holder a certificate setting forth (i)&nbsp;the Conversion Price then in effect for each series of Preferred Stock held by such holder, and (ii)&nbsp;the
number of shares of Common Stock and the amount, if any, of other securities, cash or property which then would be received upon the conversion of each such series of Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.10 <U>Notice of Record Date</U>. In the event: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) the Corporation shall take a record of the holders of its Common Stock (or other capital stock or securities at the time issuable upon
conversion of the Preferred Stock) for the purpose of entitling or enabling them to receive any dividend or other distribution, or to receive any right to subscribe for or purchase any shares of capital stock of any class or series or any other
securities, or to receive any other security; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) of any capital reorganization of the Corporation, any reclassification of the
Common Stock of the Corporation, or any Deemed Liquidation Event; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) of the voluntary or involuntary dissolution, liquidation or <FONT
STYLE="white-space:nowrap">winding-up</FONT> of the Corporation, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">then, and in each such case, the Corporation will send or cause to be sent to the
holders of the Preferred Stock a notice specifying, as the case may be, (i)&nbsp;the record date for such dividend, distribution or right, and the amount and character of such dividend, distribution or right, or (ii)&nbsp;the effective date on which
such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or <FONT STYLE="white-space:nowrap">winding-up</FONT> is proposed to take place, and the time, if any is to be fixed, as of which the holders of record
of Common Stock (or such other capital stock or securities at the time issuable upon the conversion of the Preferred Stock) shall be entitled to exchange their shares of Common Stock (or such other capital stock or securities) for securities or
other property deliverable upon such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or <FONT STYLE="white-space:nowrap">winding-up,</FONT> and the amount per share and character of such exchange
applicable to the Preferred Stock and the Common Stock. Such notice shall be sent at least 10 days prior to the record date or effective date for the event specified in such notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5. <U>Mandatory Conversion</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.1 <U>Trigger Events</U>. All outstanding shares of Preferred Stock shall automatically be converted into shares of Common Stock, at the
then effective conversion rate as calculated pursuant to <U>Sections</U><U></U><U>&nbsp;4.1.1</U> and <U>4.2</U>, upon the earliest to occur of (the time of such conversion is referred to herein as the &#8220;<B>Mandatory Conversion
Time</B>&#8221;): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) (i) immediately prior to the closing of the sale of shares of Common Stock to the public in a firm-commitment
underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $100,000,000 of gross proceeds to the Corporation and in connection with such offering the shares of
Common Stock are listed for trading on the Nasdaq Stock Market, the New York Stock Exchange or another exchange or marketplace approved by the Board of Directors (a &#8220;<B>Qualified IPO</B>&#8221;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) the date and time, or upon the occurrence of an event, specified by vote or written consent of the Investor Majority.<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.2 <U>Procedural Requirements</U>. All holders of record of shares of Preferred Stock
(or the applicable series thereof) shall be sent written notice of the Mandatory Conversion Time and the place designated for mandatory conversion of all such shares of Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;5</U>. Such
notice need not be sent in advance of the occurrence of the Mandatory Conversion Time. Upon receipt of such notice, each holder of shares of Preferred Stock being converted that holds such shares of Preferred Stock in certificated form shall
surrender his, her or its certificate or certificates for all such shares (or, if such holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to
indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to the Corporation at the place designated in such notice. If so required by the
Corporation, any certificates surrendered for conversion shall be endorsed or accompanied by written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or by his, her or its
attorney duly authorized in writing. All rights with respect to the Preferred Stock converted pursuant to <U>Section</U><U></U><U>&nbsp;5.1</U>, including the rights, if any, to receive notices and vote (other than as a holder of Common Stock), will
terminate at the Mandatory Conversion Time (notwithstanding the failure of the holder or holders thereof to surrender any certificates at or prior to such time), except only the rights of the holders thereof, upon surrender of any certificate or
certificates of such holders (or lost certificate affidavit and agreement) therefor, to receive the items provided for in the next sentence of this <U>Section</U><U></U><U>&nbsp;5.2</U>. As soon as practicable after the Mandatory Conversion Time
and, if applicable, the surrender of any certificate or certificates (or lost certificate affidavit and agreement) for Preferred Stock, the Corporation shall (a)&nbsp;issue and deliver to such holder, or to his, her or its nominees, a certificate or
certificates for the number of full shares of Common Stock issuable on such conversion in accordance with the provisions hereof or issue and deliver to such holder, or to his, her or its nominees, a notice of issuance of uncertificated shares and
may, upon written request, issue and deliver a certificate for the number of full shares of Common Stock issuable upon such conversion in accordance with the provisions hereof; and (b)&nbsp;pay any declared but unpaid dividends on the shares of
Preferred Stock converted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6. <U>Redemption</U>. Other than as set forth in <U>Section</U><U></U><U>&nbsp;2.3.2(b)</U>, the Preferred
Stock is not redeemable at the option of the holder or the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7. <U>Redeemed or Otherwise Acquired Shares</U>. Unless approved
by the Board of Directors and the Investor Majority, any shares of Preferred Stock that are redeemed, converted or otherwise acquired by the Corporation or any of its subsidiaries shall be automatically and immediately cancelled and retired and
shall not be reissued, sold or transferred. Neither the Corporation nor any of its subsidiaries may exercise any voting or other rights granted to the holders of Preferred Stock following redemption, conversion or acquisition. The Corporation may
thereafter take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of Preferred Stock accordingly. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8. <U>Waiver</U>. Except as otherwise set forth herein, at any time more than one series of
Preferred Stock is issued and outstanding, any of the rights, powers, preferences and other terms of any series of Preferred Stock set forth herein may be waived on behalf of all holders of such series of Preferred Stock by the affirmative written
consent or vote of the holders of such series that would otherwise be required to amend such right, power, preference, or other term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.
<U>Notices</U>. Any notice required or permitted by the provisions of this <U>Article Fourth</U> to be given to a holder of shares of Preferred Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the
Corporation, or given by electronic transmission in compliance with the provisions of the General Corporation Law, and shall be deemed sent upon such mailing or electronic transmission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>FIFTH</B>:&nbsp;Subject to any additional vote required by this Certificate of Incorporation or the Bylaws of the Corporation, in
furtherance and not in limitation of the powers conferred by statute, the Board of Directors is expressly authorized to make, repeal, alter, amend and rescind any or all of the Bylaws of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>SIXTH</B>:&nbsp;Subject to any additional vote required by this Certificate of Incorporation, the number of directors of the Corporation
shall be determined in the manner set forth in the Bylaws of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>SEVENTH</B>:&nbsp;Elections of directors need not be by
written ballot unless the Bylaws of the Corporation shall so provide. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>EIGHTH</B>:&nbsp;Meetings of stockholders may be held within or
outside of the State of Delaware, as the Bylaws of the Corporation may provide. The books of the Corporation may be kept (subject to any provision of applicable law) outside of the State of Delaware at such place or places or in such manner or
manners as may be designated from time to time by the Board of Directors or in the Bylaws of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>NINTH</B>:&nbsp;To the
fullest extent permitted by law, a director or officer of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer. If the General Corporation
Law or any other law of the State of Delaware is amended after approval by the stockholders of this <U>Article Ninth</U> to authorize corporate action further eliminating or limiting the personal liability of directors or officers, then the
liability of a director or officer of the Corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law as so amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any amendment, repeal or elimination of the foregoing provisions of this <U>Article Ninth</U> by the stockholders of the Corporation shall not
adversely affect any right or protection of a director or officer of the Corporation existing at the time of, or increase the liability of any director or officer of the Corporation with respect to any acts or omissions of such director or officer
occurring prior to, such amendment, repeal or elimination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>TENTH</B>:<B></B>&nbsp;To the fullest extent permitted by applicable law, the Corporation
is authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of the Corporation (and any other persons to which the General Corporation Law permits the Corporation to provide indemnification) through
Bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted by Section&nbsp;145 of the General Corporation Law.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any amendment, repeal, modification or elimination of the foregoing provisions of this <U>Article Tenth</U> shall not (a)&nbsp;adversely
affect any right or protection of any director, officer or other agent of the Corporation existing at the time of such amendment, repeal, modification or elimination; or (b)&nbsp;increase the liability of any director, officer or agent of the
Corporation with respect to any acts or omissions of such director, officer or agent occurring prior to such amendment, repeal, modification or elimination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>ELEVENTH</B>:&nbsp;The Corporation renounces, to the fullest extent permitted by law, any interest or expectancy of the Corporation in, or
in being offered an opportunity to participate in, any Excluded Opportunity. An &#8220;<B>Excluded Opportunity</B>&#8221; is any matter, transaction or interest that is presented to, or acquired, created or developed by, or which otherwise comes
into the possession of (i)&nbsp;any director of the Corporation who is not an employee of the Corporation or any of its subsidiaries, or (ii)&nbsp;any holder of Preferred Stock or any partner, member, director, stockholder, employee, affiliate or
agent of any such holder, other than someone who is an officer or employee of the Corporation or any of its subsidiaries (collectively, the persons referred to in <U>clauses (</U><U>i</U><U>)</U>&nbsp;and <U>(ii)</U> are &#8220;<B>Covered
Persons</B>&#8221;), unless such matter, transaction or interest is presented to, or acquired, created or developed by, or otherwise comes into the possession of, a Covered Person expressly and solely in such Covered Person&#8217;s capacity as a
director of the Corporation while such Covered Person is performing services in such capacity. Any repeal or modification of this <U>Article Eleventh</U> will only be prospective and will not affect the rights under this <U>Article Eleventh</U> in
effect at the time of the occurrence of any actions or omissions to act giving rise to liability. Notwithstanding anything to the contrary contained elsewhere in this Certificate of Incorporation, in addition to any other vote required by law or
this Certificate of Incorporation, the affirmative vote of the Investor Majority will be required to amend or repeal, or to adopt any provisions inconsistent with this <U>Article Eleventh</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>TWELFTH</B>:&nbsp;Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery in the State
of Delaware shall be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (i)&nbsp;any derivative action or proceeding brought on behalf of the Corporation, (ii)&nbsp;any action asserting a claim of breach of
fiduciary duty owed by any director, officer or other employee of the Corporation to the Corporation or the Corporation&#8217;s stockholders, (iii)&nbsp;any action asserting a claim against the Corporation, its directors, officers or employees
arising pursuant to any provision of the General Corporation Law or the Corporation&#8217;s certificate of incorporation or bylaws or (iv)&nbsp;any action asserting a claim against the Corporation, its directors, officers or employees governed by
the internal affairs doctrine or that otherwise relates to the internal affairs of the Corporation, except for, as to each of (i)&nbsp;through (iv) above, any claim as to which the Court of Chancery determines that there is an indispensable party
not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within 10 days following such determination), which is vested in the exclusive jurisdiction
of a court or forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>THIRTEENTH</B>:&nbsp;If any provision or provisions of this Certificate of Incorporation shall be held to be invalid, illegal or
unenforceable as applied to any person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability of such provisions in any other circumstance and of the remaining
provisions of this Certificate of Incorporation (including, without limitation, each portion of any sentence of this Certificate of Incorporation containing any such provision held to be invalid, illegal or unenforceable that is not itself held to
be invalid, illegal or unenforceable) and the application of such provision to other persons or entities and circumstances shall not in any way be affected or impaired thereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.</B> The corporation has not received payment for any of its stock as of the date of this Certificate of Incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.</B> That this Certificate of Incorporation, which restates and integrates and further amends the provisions of the Corporation&#8217;s
Certificate of Incorporation, has been duly adopted in accordance with Sections 241 and 245 of the General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature
Page Follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, this Amended and Restated Certificate of Incorporation has been
executed by a duly authorized officer of this corporation on March&nbsp;30, 2026. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Benny S&oslash;rensen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Benny S&oslash;rensen, President</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>4
<FILENAME>d50309dex32.htm
<DESCRIPTION>EX-3.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> B<SMALL>YLAWS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><SMALL>OF</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>H<SMALL>EMAB</SMALL> T<SMALL>HERAPEUTICS</SMALL> H<SMALL>OLDINGS</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(a Delaware corporation) </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>ABLE</SMALL> <SMALL>OF</SMALL> C<SMALL>ONTENTS</SMALL> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE I STOCKHOLDERS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Place of Meetings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Annual Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Special Meetings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notice of Meetings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Voting List</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Quorum</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Adjournments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Voting and Proxies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Action at Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conduct of Meetings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Action without Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE II DIRECTORS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>General Powers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Number, Election and Qualification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chairman of the Board; Vice Chairman of the Board</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tenure</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Quorum</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Action at Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Removal</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Vacancies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Resignation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Regular Meetings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Special Meetings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notice of Special Meetings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.13</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Meetings by Conference Communications Equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.14</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Action by Consent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.15</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Committees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.16</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compensation of Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE III OFFICERS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>7</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Titles</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Election</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Qualification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tenure</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Resignation and Removal</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Vacancies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>President; Chief Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Vice Presidents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Secretary and Assistant Secretaries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Treasurer and Assistant Treasurers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Salaries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Delegation of Authority</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE IV CAPITAL STOCK</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>10</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Issuance of Stock</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Stock Certificates; Uncertificated Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Transfers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Lost, Stolen or Destroyed Certificates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Record Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Regulations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Restrictions on Transfer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE V GENERAL PROVISIONS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>13</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Fiscal Year</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Corporate Seal</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Waiver of Notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Voting of Securities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Evidence of Authority</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certificate of Incorporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Severability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Pronouns</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE VI AMENDMENTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>14</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>By the Board of Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>By the Stockholders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>STOCKHOLDERS </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1
<U>Place of Meetings</U>. All meetings of stockholders shall be held at such place, if any, as may be designated from time to time by the Board of Directors, the Chairman of the Board, the Chief Executive Officer or the President or, if not so
designated, at the principal executive office of the corporation. The Board of Directors may, in its sole discretion, determine that a meeting shall not be held at any place, but shall instead be held solely by means of remote communication in a
manner consistent with the General Corporation Law of the State of Delaware. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2 <U>Annual Meeting</U>. The annual meeting of stockholders
for the election of directors and for the transaction of such other business as may properly be brought before the meeting shall be held on a date and at a time designated by the Board of Directors, the Chairman of the Board, the Chief Executive
Officer or the President. The Board of Directors may postpone, reschedule or cancel any previously scheduled annual meeting of stockholders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3 <U>Special Meetings</U>. Special meetings of stockholders for any purpose or purposes may be called at any time only by the Board of
Directors, the Chairman of the Board, the Chief Executive Officer or the President, and may not be called by any other person or persons. Business transacted at any special meeting of stockholders shall be limited to matters relating to the purpose
or purposes stated in the notice of meeting. The Board of Directors may postpone, reschedule or cancel any previously scheduled special meeting of stockholders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.4 <U>Notice of Meetings</U>. Except as otherwise provided by law, the Certificate of Incorporation or these Bylaws, notice of each meeting of
stockholders, whether annual or special, shall be given not less than 10 nor more than 60 days before the date of the meeting to each stockholder entitled to vote at such meeting. Without limiting the manner by which notice otherwise may be given to
stockholders, any notice shall be effective if given by a form of electronic transmission consented to (in a manner consistent with the General Corporation Law of the State of Delaware) by the stockholder to whom the notice is given. The notices of
all meetings shall state the place, if any, date and time of the meeting and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting. The notice of a special
meeting shall state, in addition, the purpose or purposes for which the meeting is called. If notice is given by mail, such notice shall be deemed given when deposited in the United States mail, postage prepaid, directed to the stockholder at such
stockholder&#8217;s address as it appears on the records of the corporation. If notice is given by electronic transmission, such notice shall be deemed given at the time specified in Section&nbsp;232 of the General Corporation Law of the State of
Delaware. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.5 <U>Voting List</U>. The corporation shall prepare, at least 10 days before every meeting of stockholders, a complete list of
the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any
stockholder, for any purpose germane to the meeting, for a period of at least 10 days prior to the meeting: (a)&nbsp;on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with
the notice of the meeting, or (b)&nbsp;during ordinary business </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
hours, at the principal place of business of the corporation. If the meeting is to be held at a physical location (and not solely by means of remote communication), then the list shall be
produced and kept at the time and place of the meeting during the whole time thereof, and may be examined by any stockholder who is present. If the meeting is to be held solely by means of remote communication, then the list shall also be open to
the examination of any stockholder during the whole time of the meeting on a reasonably accessible electronic network, and the information required to access such list shall be provided with the notice of the meeting. Except as otherwise provided by
law, such list shall be the only evidence as to who are the stockholders entitled to examine the list of stockholders required by this Section&nbsp;1.5 or to vote in person or by proxy at any meeting of stockholders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.6 <U>Quorum</U>. Except as otherwise provided by law, the Certificate of Incorporation or these Bylaws, the holders of a majority in voting
power of the shares of the capital stock of the corporation issued and outstanding and entitled to vote at the meeting, present in person, present by means of remote communication in a manner, if any, authorized by the Board of Directors in its sole
discretion, or represented by proxy, shall constitute a quorum for the transaction of business; provided, however, that where a separate vote by a class or classes or series of capital stock is required by law or the Certificate of Incorporation,
the holders of a majority in voting power of the shares of such class or classes or series of the capital stock of the corporation issued and outstanding and entitled to vote on such matter, present in person, present by means of remote
communication in a manner, if any, authorized by the Board of Directors in its sole discretion, or represented by proxy, shall constitute a quorum entitled to take action with respect to the vote on such matter. A quorum, once established at a
meeting, shall not be broken by the withdrawal of enough votes to leave less than a quorum. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.7 <U>Adjournments</U>. Any meeting of
stockholders may be adjourned from time to time to reconvene at any other time and to any other place at which a meeting of stockholders may be held under these Bylaws by the chairman of the meeting or by the stockholders present or represented at
the meeting and entitled to vote, although less than a quorum. It shall not be necessary to notify any stockholder of any adjournment of less than 30 days if the time and place, if any, of the adjourned meeting, and the means of remote
communication, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such adjourned meeting, are announced at the meeting at which adjournment is taken, unless after the adjournment a new record date is
fixed for the adjourned meeting. At the adjourned meeting, the corporation may transact any business that might have been transacted at the original meeting. If the adjournment is for more than 30 days, a notice of the adjourned meeting shall be
given to each stockholder of record entitled to vote at the meeting. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.8 <U>Voting and Proxies</U>. Each stockholder shall have one vote
upon the matter in question for each share of stock entitled to vote held of record by such stockholder and a proportionate vote for each fractional share so held, unless otherwise provided by law or the Certificate of Incorporation. Each
stockholder of record entitled to vote at a meeting of stockholders, or to express consent or dissent to corporate action without a meeting, may vote or express such consent or dissent in person (including by means of remote communications, if any,
by which stockholders may be deemed to be present in person and vote at such meeting) or may authorize another person or persons to vote or act for such stockholder by a proxy executed or transmitted in a manner permitted by the General Corporation
Law of the State of Delaware by the stockholder or such stockholder&#8217;s authorized agent and delivered (including by electronic transmission) to the Secretary of the corporation. No such proxy shall be voted or acted upon after three years from
the date of its execution, unless the proxy expressly provides for a longer period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.9 <U>Action at Meeting</U>. When a quorum is present at any meeting, any matter other than
the election of directors to be voted upon by the stockholders at such meeting shall be decided by the vote of the holders of shares of stock having a majority in voting power of the votes cast by the holders of all of the shares of stock present or
represented at the meeting and voting affirmatively or negatively on such matter (or if there are two or more classes or series of stock entitled to vote as separate classes, then in the case of each such class or series, the holders of a majority
in voting power of the shares of stock of that class or series present or represented at the meeting and voting affirmatively or negatively on such matter), except when a different vote is required by law, the Certificate of Incorporation or these
Bylaws. When a quorum is present at any meeting, any election by stockholders of directors shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.10 <U>Conduct of Meetings</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Chairman of Meeting</U>. Unless otherwise provided by the Board of Directors, meetings of stockholders shall be presided over by the
Chairman of the Board, if any, or in the Chairman&#8217;s absence by the Vice Chairman of the Board, if any, or in the Vice Chairman&#8217;s absence by the Chief Executive Officer, or in the Chief Executive Officer&#8217;s absence, by the President,
or in the President&#8217;s absence by a Vice President, or in the absence of all of the foregoing persons by a chairman designated by the Board of Directors, or in the absence of such designation by a chairman chosen by vote of the stockholders at
the meeting. The Secretary shall act as secretary of the meeting, but in the Secretary&#8217;s absence the chairman of the meeting may appoint any person to act as secretary of the meeting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Rules, Regulations and Procedures</U>. The Board of Directors may adopt by resolution such rules, regulations and procedures for the
conduct of any meeting of stockholders of the corporation as it shall deem appropriate including, without limitation, such guidelines and procedures as it may deem appropriate regarding the participation by means of remote communication of
stockholders and proxyholders not physically present at a meeting. Except to the extent inconsistent with such rules, regulations and procedures as adopted by the Board of Directors, the chairman of any meeting of stockholders shall have the right
and authority to convene and (for any or no reason) to recess and/or adjourn the meeting and prescribe such rules, regulations and procedures and to do all such acts as, in the judgment of such chairman, are appropriate for the proper conduct of the
meeting. Such rules, regulations or procedures, whether adopted by the Board of Directors or prescribed by the chairman of the meeting, may include, without limitation, the following: (i)&nbsp;the establishment of an agenda or order of business for
the meeting; (ii)&nbsp;rules and procedures for maintaining order at the meeting and the safety of those present; (iii)&nbsp;limitations on attendance at or participation in the meeting to stockholders entitled to vote at the meeting, their duly
authorized and constituted proxies or such other persons as shall be determined; (iv)&nbsp;restrictions on entry to the meeting after the time fixed for the commencement thereof; and (v)&nbsp;limitations on the time allotted to questions or comments
by participants. Unless and to the extent determined by the Board of Directors or the chairman of the meeting, meetings of stockholders shall not be required to be held in accordance with the rules of parliamentary procedure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.11 <U>Action without Meeting</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Taking of Action by Consent</U>. Any action required or permitted to be taken at any annual or special meeting of stockholders of the
corporation may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock having not less than the minimum number
of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote on such action were present and voted. Except as otherwise provided by the Certificate of Incorporation, stockholders may act by
written consent to elect directors; provided, however, that, if such consent is less than unanimous, such action by written consent may be in lieu of holding an annual meeting only if all of the directorships to which directors could be elected at
an annual meeting held at the effective time of such action are vacant and are filled by such action. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Electronic Transmission of
Consents</U>. A telegram, cablegram or other electronic transmission consenting to an action to be taken and transmitted by a stockholder or proxyholder, or by a person or persons authorized to act for a stockholder or proxyholder, shall be deemed
to be written, signed and dated for the purposes of this section, provided that any such telegram, cablegram or other electronic transmission sets forth or is delivered with information from which the corporation can determine (i)&nbsp;that the
telegram, cablegram or other electronic transmission was transmitted by the stockholder or proxyholder or by a person or persons authorized to act for the stockholder or proxyholder and (ii)&nbsp;the date on which such stockholder or proxyholder or
authorized person or persons transmitted such telegram, cablegram or electronic transmission. The date on which such telegram, cablegram or electronic transmission is transmitted shall be deemed to be the date on which such consent was signed. No
consent given by telegram, cablegram or other electronic transmission shall be deemed to have been delivered until such consent is reproduced in paper form and until such paper form shall be delivered to the corporation by delivery to its registered
office in the State of Delaware, its principal place of business or an officer or agent of the corporation having custody of the book in which proceedings of meetings of stockholders are recorded. Delivery made to a corporation&#8217;s registered
office shall be made by hand or by certified or registered mail, return receipt requested. Notwithstanding the foregoing limitations on delivery, consents given by telegram, cablegram or other electronic transmission may be otherwise delivered to
the principal place of business of the corporation or to an officer or agent of the corporation having custody of the book in which proceedings of meetings of stockholders are recorded if, to the extent and in the manner provided by resolution of
the Board of Directors. Any copy, facsimile or other reliable reproduction of a consent in writing may be substituted or used in lieu of the original writing for any and all purposes for which the original writing could be used, provided that such
copy, facsimile or other reproduction shall be a complete reproduction of the entire original writing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Notice of Taking of
Corporate Action</U>. Prompt notice of the taking of corporate action without a meeting by less than unanimous written consent shall be given to those stockholders who have not consented in writing and who, if the action had been taken at a meeting,
would have been entitled to notice of the meeting if the record date for such meeting had been the date that written consents signed by a sufficient number of holders to take the action were delivered to the corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>DIRECTORS </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1
<U>General Powers</U>. The business and affairs of the corporation shall be managed by or under the direction of a Board of Directors, who may exercise all of the powers of the corporation except as otherwise provided by law or the Certificate of
Incorporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>Number, Election and Qualification</U>. Subject to the rights of holders of any series of Preferred Stock to elect
directors, the number of directors of the corporation shall be established from time to time by the stockholders or the Board of Directors. The directors shall be elected at the annual meeting of stockholders by such stockholders as have the right
to vote on such election. Election of directors need not be by written ballot. Directors need not be stockholders of the corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3
<U>Chairman of the Board; Vice Chairman of the Board</U>. The Board of Directors may appoint from its members a Chairman of the Board and a Vice Chairman of the Board, neither of whom need be an employee or officer of the corporation. If the Board
of Directors appoints a Chairman of the Board, such Chairman shall perform such duties and possess such powers as are assigned by the Board of Directors and, if the Chairman of the Board is also designated as the corporation&#8217;s Chief Executive
Officer, shall have the powers and duties of the Chief Executive Officer prescribed in Section&nbsp;3.7 of these Bylaws. If the Board of Directors appoints a Vice Chairman of the Board, such Vice Chairman shall perform such duties and possess such
powers as are assigned by the Board of Directors or the Chairman of the Board. Unless otherwise provided by the Board of Directors, the Chairman of the Board or, in the Chairman&#8217;s absence, the Vice Chairman of the Board, if any, shall preside
at all meetings of the Board of Directors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4 <U>Tenure</U>. Each director shall hold office until the next annual meeting of
stockholders and until a successor is elected and qualified, or until such director&#8217;s earlier death, resignation or removal. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5
<U>Quorum</U>. A majority of the directors at any time in office, including a majority of the directors who are elected by the holders of any Preferred Stock if any are then seated, shall constitute a quorum of the Board of Directors. If at any
meeting of the Board of Directors there shall be less than such a quorum, a majority of the directors present may adjourn the meeting from time to time without further notice other than announcement at the meeting, until a quorum shall be present.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.6 <U>Action at Meeting</U>. Every act or decision done or made by a majority of the directors present at a meeting duly held at which a
quorum is present shall be regarded as the act of the Board of Directors, unless a greater number is required by law or by the Certificate of Incorporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.7 <U>Removal</U>. Except as otherwise provided by the General Corporation Law of the State
of Delaware, any one or more or all of the directors of the corporation may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors, except that the directors elected by the
holders of a particular class or series of stock may be removed without cause only by vote of the holders of a majority of the outstanding shares of such class or series. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.8 <U>Vacancies</U>. Subject to the rights of holders of any series of Preferred Stock to elect directors, unless and until filled by the
stockholders, any vacancy or newly-created directorship on the Board of Directors, however occurring, may be filled by vote of a majority of the directors then in office, although less than a quorum, or by a sole remaining director. A director
elected to fill a vacancy shall be elected for the unexpired term of such director&#8217;s predecessor in office, and a director chosen to fill a position resulting from a newly-created directorship shall hold office until the next annual meeting of
stockholders and until a successor is elected and qualified, or until such director&#8217;s earlier death, resignation or removal. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.9
<U>Resignation</U>. Any director may resign by delivering a resignation in writing or by electronic transmission to the corporation at its principal executive office or to the Chairman of the Board, the Chief Executive Officer, the President or the
Secretary. Such resignation shall be effective upon receipt unless it is specified to be effective at some later time or upon the happening of some later event. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.10 <U>Regular Meetings</U>. Regular meetings of the Board of Directors may be held without notice at such time and place as shall be
determined from time to time by the Board of Directors; provided that any director who is absent when such a determination is made shall be given notice of the determination. A regular meeting of the Board of Directors may be held without notice
immediately after and at the same place as the annual meeting of stockholders. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.11 <U>Special Meetings</U>. Special meetings of the Board
of Directors may be held at any time and place designated in a call by the Chairman of the Board, the Chief Executive Officer, the President, two or more directors, or by one director in the event that there is only a single director in office. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.12 <U>Notice of Special Meetings</U>. Notice of the date, place and time of any special meeting of directors shall be given to each director
by the Secretary or by the officer or one of the directors calling the meeting. Notice shall be duly given to each director (a)&nbsp;in person or by telephone at least 24 hours in advance of the meeting, (b)&nbsp;by sending an electronic
transmission, or delivering written notice by hand or reputable overnight delivery service, to such director&#8217;s last known business, home or electronic transmission address at least 48 hours in advance of the meeting, or (c)&nbsp;by sending
written notice by first-class mail to such director&#8217;s last known business or home address at least 72 hours in advance of the meeting. A notice or waiver of notice of a meeting of the Board of Directors shall specify the purposes and agenda of
the meeting. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.13 <U>Meetings by Conference Communications Equipment</U>. Directors may participate in meetings of the Board of Directors
or any committee thereof by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and participation by such means shall constitute presence in person at such
meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.14 <U>Action by Consent</U>. Any action required or permitted to be taken at any meeting
of the Board of Directors or of any committee thereof may be taken without a meeting, if all members of the Board of Directors or committee, as the case may be, consent to the action in writing or by electronic transmission, and the written consents
or electronic transmissions are filed with the minutes of proceedings of the Board of Directors or committee. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are
maintained in electronic form. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.15 <U>Committees</U>. The Board of Directors may designate one or more committees, each committee to
consist of one or more of the directors of the corporation with such lawfully delegable powers and duties as the Board of Directors thereby confers, to serve at the pleasure of the Board of Directors. The Board of Directors may designate one or more
directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member of a committee, the member or members of the committee present at any
meeting and not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified member. Any
such committee, to the extent provided in the resolution of the Board of Directors and subject to the provisions of law, shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs
of the corporation and may authorize the seal of the corporation to be affixed to all papers that may require it. Each such committee shall keep minutes and make such reports as the Board of Directors may from time to time request. Except as the
Board of Directors may otherwise determine, any committee may make rules for the conduct of its business, but unless otherwise provided by the directors or in such rules, its business shall be conducted as nearly as possible in the same manner as is
provided in these Bylaws for the Board of Directors. Except as otherwise provided in the Certificate of Incorporation, these Bylaws, or the resolution of the Board of Directors designating the committee, a committee may create one or more
subcommittees, each subcommittee to consist of one or more members of the committee, and delegate to a subcommittee any or all of the powers and authority of the committee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.16 <U>Compensation of Directors</U>. Directors may be paid such compensation for their services and such reimbursement for expenses of
attendance at meetings as the Board of Directors may from time to time determine. No such payment shall preclude any director from serving the corporation or any of its parent or subsidiary entities in any other capacity and receiving compensation
for such service. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>OFFICERS </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1
<U>Titles</U>. The officers of the corporation shall consist of a Chief Executive Officer, a President, a Secretary, a Treasurer and such other officers with such other titles as the Board of Directors shall determine, including one or more Vice
Presidents, Assistant Treasurers and Assistant Secretaries. The Board of Directors may appoint such other officers as it may deem appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 <U>Election</U>. The Chief Executive Officer, President, Treasurer and Secretary shall
be elected annually by the Board of Directors at its first meeting following the annual meeting of stockholders. Other officers may be appointed by the Board of Directors at such meeting or at any other meeting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3 <U>Qualification</U>. No officer need be a stockholder. Any two or more offices may be held by the same person. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.4 <U>Tenure</U>. Except as otherwise provided by law, by the Certificate of Incorporation or by these Bylaws, each officer shall hold office
until such officer&#8217;s successor is elected and qualified, unless a different term is specified in the resolution electing or appointing such officer, or until such officer&#8217;s earlier death, resignation or removal. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.5 <U>Resignation and Removal</U>. Any officer may resign by delivering a resignation in writing or by electronic transmission to the
corporation at its principal executive office or to the Chief Executive Officer, the President or the Secretary. Such resignation shall be effective upon receipt unless it is specified to be effective at some later time or upon the happening of some
later event. Any officer may be removed at any time, with or without cause, by vote of a majority of the directors then in office. Except as the Board of Directors may otherwise determine, no officer who resigns or is removed shall have any right to
any compensation as an officer for any period following such officer&#8217;s resignation or removal, or any right to damages on account of such removal, whether such officer&#8217;s compensation be by the month or by the year or otherwise, unless
such compensation is expressly provided for in a duly authorized written agreement with the corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.6 <U>Vacancies</U>. The Board
of Directors may fill any vacancy occurring in any office for any reason and may, in its discretion, leave unfilled for such period as it may determine any offices. Each such successor shall hold office for the unexpired term of such officer&#8217;s
predecessor and until a successor is elected and qualified, or until such officer&#8217;s earlier death, resignation or removal. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.7
<U>President; Chief Executive Officer</U>. Unless the Board of Directors has designated another person as the corporation&#8217;s Chief Executive Officer, the President shall be the Chief Executive Officer of the corporation. The Chief Executive
Officer shall have general charge and supervision of the business of the corporation subject to the direction of the Board of Directors, and shall perform all duties and have all powers that are commonly incident to the office of the chief executive
or that are delegated to such officer by the Board of Directors. The President shall perform such other duties and shall have such other powers as the Board of Directors or the Chief Executive Officer (if the President is not the Chief Executive
Officer) may from time to time prescribe. In the event of the absence, inability or refusal to act of the Chief Executive Officer or the President (if the President is not the Chief Executive Officer), the Vice President (or if there shall be more
than one, the Vice Presidents in the order determined by the Board of Directors) shall perform the duties of the Chief Executive Officer and when so performing such duties shall have all the powers of and be subject to all the restrictions upon the
Chief Executive Officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.8 <U>Vice Presidents</U>. Each Vice President shall perform such duties and possess such
powers as the Board of Directors or the Chief Executive Officer may from time to time prescribe. The Board of Directors may assign to any Vice President the title of Executive Vice President, Senior Vice President or any other title selected by the
Board of Directors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.9 <U>Secretary and Assistant Secretaries</U>. The Secretary shall perform such duties and shall have such powers as
the Board of Directors or the Chief Executive Officer may from time to time prescribe. In addition, the Secretary shall perform such duties and have such powers as are incident to the office of the secretary, including without limitation the duty
and power to give notices of all meetings of stockholders and special meetings of the Board of Directors, to attend all meetings of stockholders and the Board of Directors and keep a record of the proceedings, to maintain a stock ledger and prepare
lists of stockholders and their addresses as required, to be custodian of corporate records and the corporate seal and to affix and attest to the same on documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any Assistant Secretary shall perform such duties and possess such powers as the Board of Directors, the Chief Executive Officer or the
Secretary may from time to time prescribe. In the event of the absence, inability or refusal to act of the Secretary, the Assistant Secretary (or if there shall be more than one, the Assistant Secretaries in the order determined by the Board of
Directors) shall perform the duties and exercise the powers of the Secretary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the absence of the Secretary or any Assistant Secretary
at any meeting of stockholders or directors, the chairman of the meeting shall designate a temporary secretary to keep a record of the meeting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.10 <U>Treasurer and Assistant Treasurers</U>. The Treasurer shall perform such duties and shall have such powers as may from time to time be
assigned by the Board of Directors or the Chief Executive Officer. In addition, the Treasurer shall perform such duties and have such powers as are incident to the office of treasurer, including without limitation the duty and power to keep and be
responsible for all funds and securities of the corporation, to deposit funds of the corporation in depositories selected in accordance with these Bylaws, to disburse such funds as ordered by the Board of Directors, to make proper accounts of such
funds, and to render as required by the Board of Directors statements of all such transactions and of the financial condition of the corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Assistant Treasurers shall perform such duties and possess such powers as the Board of Directors, the Chief Executive Officer or the
Treasurer may from time to time prescribe. In the event of the absence, inability or refusal to act of the Treasurer, the Assistant Treasurer (or if there shall be more than one, the Assistant Treasurers in the order determined by the Board of
Directors) shall perform the duties and exercise the powers of the Treasurer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.11 <U>Salaries</U>. Officers of the corporation shall be
entitled to such salaries, compensation or reimbursement as shall be fixed or allowed from time to time by the Board of Directors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.12
<U>Delegation of Authority</U>. The Board of Directors may from time to time delegate the powers or duties of any officer to any other officer or agent, notwithstanding any provision hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CAPITAL STOCK </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1
<U>Issuance of Stock</U>. Subject to the provisions of the Certificate of Incorporation, the whole or any part of any unissued balance of the authorized capital stock of the corporation or the whole or any part of any shares of the authorized
capital stock of the corporation held in the corporation&#8217;s treasury may be issued, sold, transferred or otherwise disposed of by vote of the Board of Directors in such manner, for such lawful consideration and on such terms as the Board of
Directors may determine. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 <U>Stock Certificates; Uncertificated Shares</U>. The shares of the corporation shall be represented by
certificates, provided that the Board of Directors may provide by resolution or resolutions that some or all of any or all classes or series of the corporation&#8217;s stock shall be uncertificated shares. Any such resolution shall not apply to
shares represented by a certificate until such certificate is surrendered to the corporation. Every holder of stock of the corporation represented by certificates shall be entitled to have a certificate, in such form as may be prescribed by law and
by the Board of Directors, representing the number of shares held by such holder registered in certificate form. Each such certificate shall be signed in a manner that complies with Section&nbsp;158 of the General Corporation Law of the State of
Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each certificate for shares of stock that are subject to any restriction on transfer pursuant to the Certificate of
Incorporation, these Bylaws, applicable securities laws or any agreement among any number of stockholders or among such holders and the corporation shall have conspicuously noted on the face or back of the certificate either the full text of the
restriction or a statement of the existence of such restriction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the corporation shall be authorized to issue more than one class of
stock or more than one series of any class, the powers, designations, preferences and relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such
preferences and/or rights shall be set forth in full or summarized on the face or back of each certificate representing shares of such class or series of stock, provided that in lieu of the foregoing requirements there may be set forth on the face
or back of each certificate representing shares of such class or series of stock a statement that the corporation will furnish without charge to each stockholder who so requests a copy of the full text of the powers, designations, preferences and
relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within a reasonable time after the issuance or transfer of uncertificated shares, the registered owner thereof shall be given a notice, in
writing or by electronic transmission, containing the information required to be set forth or stated on certificates pursuant to Sections 151, 156, 202(a) or 218(a) of the General Corporation Law of the State of Delaware or, with respect to
Section&nbsp;151 of the General Corporation Law of the State of Delaware, a statement that the corporation will furnish without charge to each stockholder who so requests the powers, designations, preferences and relative participating, optional or
other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3 <U>Transfers</U>. Shares of stock of the corporation shall be transferable in the manner
prescribed by law and in these Bylaws. Transfers of shares of stock of the corporation shall be made only on the books of the corporation or by transfer agents designated to transfer shares of stock of the corporation. Subject to applicable law,
shares of stock represented by certificates shall be transferred only on the books of the corporation by the surrender to the corporation or its transfer agent of the certificate representing such shares properly endorsed or accompanied by a written
assignment or power of attorney properly executed, and with such proof of authority or the authenticity of signature as the corporation or its transfer agent may reasonably require. Uncertificated shares may be transferred by delivery of a written
assignment or power of attorney properly executed, and with such proof of authority or the authenticity of signature as the corporation or its transfer agent may reasonably require. Except as may be otherwise required by law, by the Certificate of
Incorporation or by these Bylaws, the corporation shall be entitled to treat the record holder of stock as shown on its books as the owner of such stock for all purposes, including the payment of dividends and the right to vote with respect to such
stock, regardless of any transfer, pledge or other disposition of such stock until the shares have been transferred on the books of the corporation in accordance with the requirements of these Bylaws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4 <U>Lost, Stolen or Destroyed Certificates</U>. The corporation may issue a new certificate of stock in place of any previously issued
certificate alleged to have been lost, stolen or destroyed, upon such terms and conditions as the corporation may prescribe, including the presentation of reasonable evidence of such loss, theft or destruction and the giving of such indemnity and
posting of such bond as the corporation may require for the protection of the corporation or any transfer agent or registrar. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.5
<U>Record Date</U>. The Board of Directors may fix in advance a date as a record date for the determination of the stockholders entitled to notice of or to vote at any meeting of stockholders or to express consent (or dissent) to corporate action
without a meeting, or entitled to receive payment of any dividend or other distribution or allotment of any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action. Such record date shall not
precede the date on which the resolution fixing the record date is adopted, and such record date shall not be more than 60 nor less than 10 days before the date of such meeting, nor more than 10 days after the date of adoption of a record date for a
consent without a meeting, nor more than 60 days prior to any other action to which such record date relates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If no record date is fixed,
the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day before the day on which notice is given, or, if notice is waived, at the close of business on the
day before the day on which the meeting is held. If no record date is fixed, the record date for determining stockholders entitled to express consent to corporate action without a meeting, when no prior action by the Board of Directors is necessary,
shall be the day on which the first consent is properly delivered to the corporation. If no record date is fixed, the record date for determining stockholders for any other purpose shall be at the close of business on the day on which the Board of
Directors adopts the resolution relating to such purpose. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A determination of stockholders of record entitled to notice of or to vote at a meeting of
stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for the adjourned meeting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.6 <U>Regulations</U>. The issue, transfer, conversion and registration of shares of stock of the corporation shall be governed by such other
regulations as the Board of Directors may establish </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.7 <U>Restrictions on Transfer</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) No holder of any of the shares of capital stock of the corporation (the &#8220;Shares&#8221;) may sell, transfer, assign, pledge, or
otherwise dispose of or encumber any of the Shares or any right or interest therein, whether voluntarily or by operation of law, or by gift or otherwise (each, a &#8220;Transfer&#8221;) without the prior written consent of the corporation, upon duly
authorized action of its Board of Directors. The corporation may withhold consent for any legitimate corporate purpose, as determined by the Board of Directors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If a stockholder desires to Transfer any Shares, then the stockholder will first give written notice to the corporation (the
&#8220;Transfer Notice&#8221;). The Transfer Notice must name the proposed transferee and state the number of Shares to be transferred, the proposed consideration, and all other terms and conditions of the proposed Transfer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) At the option of the corporation, the stockholder will be obligated to pay to the corporation a reasonable transfer fee related to the
costs and time of the corporation and its legal and other advisors related to any proposed Transfer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Any Transfer, or purported
Transfer, of Shares not made in strict compliance with this Section will be null and void, will not be recorded on the books of the corporation and will not be recognized by the corporation. Transfers of record of Shares of stock of the corporation
will be made only upon its books by the holders thereof, in person or by attorney duly authorized, and, in the case of stock represented by certificate, upon the surrender of a properly endorsed certificate or certificates for a like number of
shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The restriction on Transfer set forth in Section&nbsp;4.7(a) will terminate upon the date securities of the corporation are
first offered to the public pursuant to a registration statement filed with, and declared effective by, the SEC under the Securities Act of 1933, as amended (the &#8220;1933 Act&#8221;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) The certificates representing Shares of the corporation will bear on their face the following legend so long as the foregoing Transfer
restrictions are in effect: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#8220;THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A TRANSFER RESTRICTION, AS PROVIDED IN THE
BYLAWS OF THE CORPORATION.&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Anything to the contrary contained herein notwithstanding, the following transactions
are exempt from the Transfer restrictions contained in Section&nbsp;4.7(a): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">i. A stockholder&#8217;s Transfer of any or all Shares held
either during such stockholder&#8217;s lifetime or on death by will or intestacy to such stockholder&#8217;s immediate family or to any custodian or trustee for the account of such stockholder or such stockholder&#8217;s immediate family or to any
limited partnership or limited liability company of which the stockholder, members of such stockholder&#8217;s immediate family or any trust for the account of such stockholder or such stockholder&#8217;s immediate family will be the general or
limited partner(s) of such partnership or the controlling member(s) of such limited liability company. &#8220;Immediate family&#8221; as used herein means spouse, lineal descendant, father, mother, brother, or sister of the stockholder making such
Transfer; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">ii. A stockholder&#8217;s Transfer of any or all of such stockholder&#8217;s Shares to the corporation; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">iii. A corporate stockholder&#8217;s Transfer of any or all of its Shares pursuant to and in accordance with the terms of any merger,
consolidation, reclassification of shares or capital reorganization of the corporate stockholder, or pursuant to a sale of all or substantially all of the stock or assets of a corporate stockholder; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">iv. A corporate stockholder&#8217;s Transfer of any or all of its Shares to any or all of its stockholders; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">v. A Transfer by a stockholder that is a limited or general partnership to any or all of its partners or former partners in accordance with
partnership interests. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) In any such case, the transferee, assignee, or other recipient will receive and hold such stock subject to the
provisions of this Section and any other restrictions set forth in these Bylaws, and there will be no further Transfer of such stock except in accordance with this Section and the other provisions of these Bylaws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) To the extent this Section conflicts with any written agreements between the corporation and the stockholder attempting to Transfer Shares,
such agreement will control. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>GENERAL PROVISIONS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1 <U>Fiscal Year</U>. Except as from time to time otherwise designated by the Board of Directors, the fiscal year of the corporation shall
begin on the first day of January of each year and end on the last day of December in each year. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 <U>Corporate Seal</U>. The corporate
seal shall be in such form as shall be approved by the Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3 <U>Waiver of Notice</U>. Whenever notice is required to be given by law, by the
Certificate of Incorporation or by these Bylaws, a written waiver, signed by the person entitled to notice, or a waiver by electronic transmission by the person entitled to notice, whether provided before, at or after the time of the event for which
notice is to be given, shall be deemed equivalent to notice required to be given to such person. Neither the business nor the purpose of any meeting need be specified in any such waiver. Attendance of a person at a meeting shall constitute a waiver
of notice of such meeting, except when the person attends a meeting for the express purpose of objecting at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4 <U>Voting of Securities</U>. Except as the Board of Directors may otherwise designate, the Chief Executive Officer, the President or the
Treasurer may waive notice of, vote, or appoint any person or persons to vote, on behalf of the corporation at, and act as, or appoint any person or persons to act as, proxy or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> for this corporation (with or without power of substitution) at, any meeting of stockholders or securityholders of any other entity, the securities of
which may be held by this corporation, or with respect to the execution of any written or electronic consent in the name of the corporation as a holder of such securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5 <U>Evidence of Authority</U>. A certificate by the Secretary, or an Assistant Secretary, or a temporary Secretary, as to any action taken
by the stockholders, directors, a committee or any officer or representative of the corporation shall as to all persons who rely on the certificate in good faith be conclusive evidence of such action. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.6 <U>Certificate of Incorporation</U>. All references in these Bylaws to the Certificate of Incorporation shall be deemed to refer to the
Certificate of Incorporation of the corporation, as amended and in effect from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.7 <U>Severability</U>. Any determination
that any provision of these Bylaws is for any reason inapplicable, illegal or ineffective shall not affect or invalidate any other provision of these Bylaws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.8 <U>Pronouns</U>. All pronouns used in these Bylaws shall be deemed to refer to the masculine, feminine or neuter, singular or plural, as
the identity of the person or persons may require. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>AMENDMENTS </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1
<U>By the Board of Directors</U>. These Bylaws may be altered, amended or repealed, in whole or in part, or new bylaws may be adopted by the Board of Directors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2 <U>By the Stockholders</U>. These Bylaws may be altered, amended or repealed, in whole or in part, or new bylaws may be adopted by the
affirmative vote of the holders of a majority of the shares of the capital stock of the corporation issued and outstanding and entitled to vote at any annual meeting of stockholders, or at any special meeting of stockholders, provided notice of such
alteration, amendment, repeal or adoption of new bylaws shall have been stated in the notice of such special meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>5
<FILENAME>d50309dex42.htm
<DESCRIPTION>EX-4.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g50309dsp3a.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">WARRANTAFTALE </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">WARRANT AGREEMENT
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dato/Date: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g50309dsp3.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The English part of this document is an unofficial translation of the Danish text. In the event of
disputes or misunderstandings arising from the translation, the Danish text shall prevail. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="51%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:Times New Roman">WARRANTAFTALE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">WARRANT AGREEMENT</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:Times New Roman">INDG&Aring;ET MELLEM</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BETWEEN</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:Times New Roman">Hemab ApS</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">(CVR-nr.</FONT> 40837590)</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; font-size:10pt; font-family:Times New Roman">(&#8220;<B>Selskabet</B>&#8221;)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hemab ApS</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">(CBR-no.</FONT> 40837590)</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(the
&#8220;<B>Company</B>&#8221;)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:Times New Roman">OG</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AND</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:Times New Roman">[&#9679;]</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; font-size:10pt; font-family:Times New Roman">(&#8220;<B>Warrantindehaveren</B>&#8221;)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#9679;]</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(the &#8220;<B>Warrantholder</B>&#8221;)</P></TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="52%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>INTRODUKTION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>INTRODUCTION</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrantindehaveren er ansat i Selskabet og modtager warrants i sin egenskab heraf. Lov nr. 309 af 5. maj 2004 om brug af k&oslash;beret eller tegningsret til aktier mv. i ans&aelig;ttelsesforhold som &aelig;ndret ved lov nr. 1524 af
18. december 2018 finder anvendelse.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Warrantholder is employed by the Company and receives his/her warrants in such capacity. The Danish Act no. 309 of 5&nbsp;May 2004 on the application of warrants, share subscription obligation rights etc. in employment
relationships as amended by the Danish Act no. 1524 of 18&nbsp;December 2018 shall apply.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.2.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Vilk&aring;rene for de tildelte warrants fremg&aring;r af denne aftale (&#8220;<B>Warrantaftalen</B>&#8221;), punkt 3.22 i Selskabets vedt&aelig;gter og de til Warrantaftalen vedlagte generelle vilk&aring;r for warrants
(&#8220;<B>Vilk&aring;r for Warrants</B>&#8221;), der er identisk med bilag 3.14 til Selskabets vedt&aelig;gter.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The terms and conditions applicable to the granted warrants are set out on this agreement (the &#8220;<B>Warrant Agreement</B>&#8221;), article 3.22 of the Company&#8217;s articles of association and the general warrant terms (the
&#8220;<B>Warrant Terms</B>&#8221;) enclosed to the Warrant Agreement, which are identical to appendix 3.14 to the Company&#8217;s articles of association.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g50309dsp3.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="52%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>TILDELING AF WARRANTS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>GRANT OF WARRANTS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Selskabet har den ____ / ____ ________ tildelt [&#149;] warrants til Warrantindehaveren. Tildelingen af warrants sker ved underskrivelse af Warrantaftalen.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">On ____ / ____ ________ the Company has granted [&#149;] warrants to the Warrantholder. The allocation of warrants takes place by conclusion of the Warrant Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.2.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hver warrant giver ret til tegning af &eacute;n ordin&aelig;r anpart af nominelt DKK 1 i Selskabet mod kontant betaling af USD [&#149;] pr. ordin&aelig;r anpart af nominelt DKK 1, dog s&aring;ledes at reguleringsmekanismerne i punkt
5 i Vilk&aring;r for Warrants kan resultere i et andet antal anparter og/eller en anden tegningskurs.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Each warrant confers the right to subscribe for one ordinary share of nominally DKK 1 in the Company against cash payment of USD [&#149;] per ordinary share of nominally DKK 1, provided, however, that the adjustment mechanisms in
clause 5 of the Warrant Terms may result in a different number of shares and/or a different subscription price.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>OPTJENING AF WARRANTS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>VESTING OF WARRANTS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrantindehaveren optjener ret til sine warrants, og warrants bortfalder, som beskrevet i Vilk&aring;r for Warrants, idet de tildelte warrants i forhold til optjening skal anses for tildelt den [&#149;]. For s&aring; vidt
ang&aring;r accelereret optjening af warrants i forbindelse med exit, likvidation, fusion, spaltning eller salg af Selskabet m.v. henvises dog til punkt 3.4 og <FONT STYLE="white-space:nowrap">5.10-5.12</FONT> i Vilk&aring;r for Warrants.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The warrants issued shall vest and terminate as described in the Warrant Terms, given that the warrants issued for the purpose of vesting shall be deemed to have been issued on [&#149;]. As regards accelerated vesting of warrants in
connection with exit, a liquidation, merger, demerger or sale of the company etc., reference is, however made to clauses 3.4 and <FONT STYLE="white-space:nowrap">5.10-5.12</FONT> of the Warrant Terms.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>UDNYTTELSE AF WARRANTS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>EXERCISE OF WARRANTS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Optjente warrants kan med de modifikationer, som f&oslash;lger af punkt <FONT STYLE="white-space:nowrap">4.2-4.6</FONT> i Vilk&aring;r for Warrants, udnyttes i en periode p&aring; 10 &aring;r fra tildelingstidspunktet, dvs. til og
med ____ / ____ ________.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Vested warrants may, subject to the modifications set out in clauses <FONT STYLE="white-space:nowrap">4.2-4.6</FONT> of the Warrant Terms, be exercised during a period of 10 years from the time of grant, i.e. until and including
____ / ____ ________.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g50309dsp3.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="52%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>&Oslash;VRIGE FORHOLD</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>MISCELLANEOUS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tildeling af warrants har ingen umiddelbare &oslash;konomiske konsekvenser for Warrantindehaveren. Det pr&aelig;ciseres, at v&aelig;rdien af de tildelte warrants er afh&aelig;ngig af kursudviklingen p&aring; Selskabets anparter, og
at der ikke er nogen sikkerhed for at Warrantindehaveren vil opn&aring; en gevinst p&aring; sine warrants og/eller de anparter, som Warrantindehaveren m&aring;tte tegne i Selskabet.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Grant of warrants has no immediate economic consequences for the Warrantholder. It is specifically noted that the value of the granted warrants is depending on fluctuations in the value of the Company&#8217;s shares and that there
is no certainty that the Warrantholder will receive a gain on his/her warrants and/or the shares that the Warrantholder may subscribe for in the Company.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.2.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Selskabet og Warrantindehaveren aftaler hermed, at tildelingen af warrants i videst muligt omfang er omfattet af Ligningsloven &#167; 7P, og parterne er s&aring;ledes forpligtede til at overholde vilk&aring;rene i Ligningslovens
&#167; 7P, stk. 2, nr. <FONT STYLE="white-space:nowrap">2-7.</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Company and the Warrantholder agree on their mutual intention to make the warrant subject to the special tax scheme Section&nbsp;7P of the Danish Tax Assessment Act, to the extent possible, and each party must perform their
obligations for the warrants to qualify for Section&nbsp;7P of the Danish Tax Assessment Act.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Til brug for vurdering af 50% gr&aelig;nsen i <FONT STYLE="white-space:nowrap">lig-ningslovens</FONT> &#167; 7P, stk. 2 nr. 2) er <FONT STYLE="white-space:nowrap">warrant-v&aelig;rdien</FONT> opgjort af DCF Group efter Black Scholes
v&aelig;rdians&aelig;ttelsesmodellen. Den beregnede warrantv&aelig;rdi er opgjort af DCF Group til DKK 1.022,10 pr. warrant.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">For purpose of the qualifications in Section&nbsp;7P (2)(no 2) and the 50% limitation, the Company informs that Black Scholes valuation model has been applied by DCF Group for valuation of the warrants. The valuation of the warrants
has been assessed by DCF Group to the value DKK [&#149;] per warrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Den samlede opgjorte v&aelig;rdi af de tildelte warrants udg&oslash;r [&#149;]* DKK [&#149;] = DKK [&#149;]. Warrantindehaverens &aring;rsl&oslash;n som medarbejder i Selskabet er p&aring; aftaletidspunktet opgjort som 12*
m&aring;nedsl&oslash;n DKK [&#149;] <FONT STYLE="white-space:nowrap">(afrun-det)</FONT> + estimeret bonus p&aring; [&#149;], i alt DKK [&#149;]. S&aring;ledes udg&oslash;r 50% af &aring;rsl&oslash;nnen DKK [&#149;].</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Based on the value assessment, the total value of the warrants granted is [&#149;]* DKK [&#149;]= DKK [&#149;]. When entering into this Warrant Agreement, the Warrantholder holds for her engagement in the Company, an annual salary
of 12* monthly salary DKK [&#149;] (rounded) + bonus as estimated [&#149;], in total DKK [&#149;]. Accordingly, 50% of the annual salary amounts to DKK [&#149;].</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Den samlede tildeling af [&#149;]warrants omfattes s&aring;ledes af Ligningsloven &#167; 7P.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The total grant of [&#9679;]warrants will qualify for taxation under Section&nbsp;7P of the Danish Tax Assessment Act.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g50309dsp3.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="52%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8195;&#8199;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">De skattem&aelig;ssige konsekvenser for Warrantindehaveren som f&oslash;lge af tildelingen af warrants er Selskabet uvedkommende. Warrantaftalen udg&oslash;r ikke en garanti eller indest&aring;else for, at modtageren af warrants kan
blive beskattet i henhold til Ligningslo-vens &#167; 7P eller andre favorable skatteregler og Warrantindehaveren b&aelig;rer selv risikoen herfor.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Company takes no responsibility for the tax implications to the Warrantholder as a result of the grant of warrants. The Warrant Agreement does not provide any warranty for taxation under special tax schemes such as
Section&nbsp;7P of the Danish Tax Assessment Act or other taxation favorable to the Warrantholder. The Warrantholder assumes all risk in respect of taxation.</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">For Selskabet/the Company:</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dato/Date:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#8195;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benny S&oslash;rensen</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mads Behrndt</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="padding-bottom:12pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">For Warrantindehaveren/the Warrantholder:</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dato/Date:</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#9679;]</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Articles of Association </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vedt&aelig;gter</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hemab ApS</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">CVR-nr.</FONT> 40 83 75 90</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Articles of Association</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hemab ApS</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CVR no. 40 83 75 90</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The English part of this document is an unofficial translation of the Danish text. In the event of
disputes or misunderstandings arising from the translation, the Danish text shall prevail. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BILAG 3.8 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TIL VEDT&AElig;GTERNE </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HEMAB APS</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">(CVR-NR.</FONT> 40837590)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(&#8220;<B>Selskabet</B>&#8221;)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">APPENDIX 3.8 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TO THE ARTICLES OF ASSOCIATION
</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HEMAB APS</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(COMPANY REG. NO. (CBR) 40837590)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(the &#8220;<B>Company</B>&#8221;)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>INTRODUKTION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>INTRODUCTION</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">I henhold til bemyndigelse i vedt&aelig;gternes punkt 3.8 og punkt 3.10 har bestyrelsen bestemt, at nedenst&aring;ende vilk&aring;r og betingelser skal v&aelig;re g&aelig;ldende for warrants, der udstedes til bestyrelsesmedlemmer,
direkt&oslash;rer, &oslash;vrige medarbejdere og konsulenter i Selskabet og Selskabets eventuelle datterselskaber m.v. (hver en &#8221;<B>Warrantindehaver</B>&#8221;) i henhold til bemyndigelserne.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Pursuant to the authorisation set out in article 3.8 and article 3.10 of the articles of association, the board of directors has resolved that the below terms and conditions shall apply to warrants, which are granted to directors,
managers, other employees and consultants of the Company and its subsidiaries, if any, etc. (each a &#8220;<B>Warrantholder</B>&#8221;), according to the authorisations.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.2.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrants tildeles efter bestyrelsens sk&oslash;n. Antallet af warrants, der tilbydes en Warrantindehaver, er baseret p&aring; en individuel vurdering af dennes jobfunktion eller anden relation til Selskabet og/eller Selskabets
eventuelle datterselskaber.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrants are offered at the discretion of the board of directors. The number of warrants offered to a Warrantholder shall be based on an individual evaluation of the Warrantholder&#8217;s employment or other association with the
Company and/or its subsidiaries, if any.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.3.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">En warrant er en ret, men ikke en pligt, til i en eller flere n&aelig;rmere fastlagte perioder (udnyttelsesperioden) at tegne nye anparter i Selskabet til en kurs, der er fastsat p&aring; forh&aring;nd (udnyttelsesprisen).
Udnyttelsesprisen og udnyttelsesperioden fasts&aelig;ttes af bestyrelsen i forbindelse med hver udstedelse/tildeling af warrants. &Eacute;n warrant giver ret til at tegne &eacute;n ordin&aelig;r anpart af nominelt DKK 1 i Selskabet til den af
bestyrelsen ved udstedelsen fastsatte kurs.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">A warrant is a right, but not an obligation, during one or more fixed periods (the exercise period) to subscribe for new shares in the Company at a price fixed in advance (the exercise price). The exercise price and the exercise
period shall be determined by the board of directors in connection with each issuance of warrants. Each warrant carries the right to subscribe for one ordinary share of nominally DKK 1 in the Company at the subscription price determined by the board
of directors at the issuance.</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.4.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tildeling af warrants har ingen umiddelbare &oslash;konomiske konsekvenser for Warrantindehaveren. V&aelig;rdien af warrants indg&aring;r ikke i beregningen af eventuelle feriepenge, pensionsbidrag eller &oslash;vrige
vederlagsafh&aelig;ngige ydelser fra Selskabet eller dets eventuelle datterselskaber.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Grant of warrants has no immediate economic consequences for the Warrantholder. The value of warrants will not form part of the calculation of holiday allowances, pension contributions or other contributions or payments, which are
based on the Warrantholder&#8217;s remuneration from the Company or its subsidiaries, if any.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>TILDELING AF WARRANTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>GRANT OF WARRANTS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrantindehavere, der &oslash;nsker at tegne warrants, skal underskrive en warrantaftale (&#8221;<B>Warrantaftalen</B>&#8221;), som henviser til dette bilag, samt, s&aring;fremt dette kr&aelig;ves af bestyrelsen, en
ejeraftale.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrantholders who wish to subscribe for warrants shall sign a warrant agreement (the &#8220;<B>Warrant Agreement</B>&#8221;), which refers to this appendix, and, to the extent required by the board of directors, a
shareholders&#8217; agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.2.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Det skal fremg&aring; af Warrantaftalen, hvor mange warrants Warrantindehaveren f&aring;r tildelt, samt til hvilken kurs warrants kan udnyttes.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">It must appear from the Warrant agreement, how many warrants that are granted to the Warrantholder and at which price the warrants can be exercised.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.3.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">En Warrantindehaver skal ikke betale noget vederlag for tildelingen af warrants.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">A Warrantholder shall not pay any consideration for the grant of warrants.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.4.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Selskabet f&oslash;rer en fortegnelse over tildelte warrants, der ajourf&oslash;res l&oslash;bende.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Company shall keep records of granted warrants and update the records on an ongoing basis.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>OPTJENING AF WARRANTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>VESTING OF WARRANTS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">En Warrantindehaver optjener &#8211; med de modifikationer, som f&oslash;lger af punkt 3.2 nedenfor &#8211; som udgangspunkt ret til at udnytte warrants med 1/36 pr. m&aring;ned regnet fra tildelingstidspunktet. Bestyrelsen skal dog
v&aelig;re berettiget til at fravige n&aelig;vnte udgangspunkt og bestemme, at tildelte warrants anses for optjent pr. tildelingstidspunktet, eller at der skal g&aelig;lde andre regler for optjeningen. S&aring;danne eventuelle fravigelser skal
specificeres i Warrantaftalen og vedt&aelig;gterne i forbindelse med udstedelsen. For s&aring; vidt ang&aring;r accelereret optjening af warrants i forbindelse med exit, likvidation, fusion, spaltning og salg af Selskabet m.v. henvises til punkt
3.4, 5.10, 5.11 og 5.12 nedenfor.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrants issued to a Warrantholder shall &#8211; subject to such modifications as set out in clause 3.2 below &#8211; as a general rule vest with 1/36 per month from the date of grant. The board of directors shall, however, be
entitled to deviate from the general rule and determine that warrants shall be deemed to vest as of the date of issuance or that special rules shall apply in relation to vesting. Such deviations, if any, shall be specified in the Warrant Agreement
and the articles of association in connection with the issuance. As regards accelerated vesting of warrants in connection with an exit liquidation, merger, demerger or sale of the Company etc., reference is made to clauses 3.4,5.10, 5.11 and 5.12
below.</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.2.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrantindehaveren optjener kun ret til sine warrants, s&aring; l&aelig;nge denne er ansat, konsulent eller bestyrelsesmedlem i Selskabet eller dets eventuelle datterselskaber (i dette punkt 3 og punkt 4.6 nedenfor samlet
ben&aelig;vnt &#8221;<B>Selskabet</B>&#8221;), medmindre:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrants shall only vest while the Warrantholder remains an employee, consultant or board member, as applicable, of the Company or its subsidiaries, if any (in this clause 3 and clause 4.6 below collectively, the
&#8221;<B>Company</B>&#8221;), unless:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(a)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>For warrants tildelt direkt&oslash;rer, &oslash;vrige medarbejdere og konsulenter:</U></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Warrantindehaveren bringer ans&aelig;ttelses- eller konsulentforholdet til oph&oslash;r
gennem opsigelse, og opsigelsen er begrundet i Selskabets v&aelig;sentlige misligholdelse af sine forpligtelser over for Warrantindehaveren.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>For warrants issued to managers, other employees and consultants:</U></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Warrantholder terminates the employment or consultancy contract and the termination
is caused by a material breach by the Company of its obligations towards the Warrantholder.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>For warrants tildelt bestyrelsesmedlemmer:</U></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Warrantindehaveren v&aelig;lger at udtr&aelig;de af Selskabets bestyrelse eller undlader at stille sig til r&aring;dighed for genvalg til Selskabets bestyrelse
og beslutningen om at udtr&aelig;de eller ikke at stille sig til r&aring;dighed for genvalg er begrundet i Selskabets v&aelig;sentlige misligholdelse af sine forpligtelser over for Warrantindehaveren.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>For warrants issued to directors</U>:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Warrantholder decides to leave the board of directors of the Company or not make himself/herself available for
<FONT STYLE="white-space:nowrap">re-election</FONT> to the board of directors of the Company and the decision to leave or not make himself/herself available for <FONT STYLE="white-space:nowrap">re-election</FONT> is caused by a material breach by
the Company of its obligations towards the Warrantholder</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Eller</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Or</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>For warrants tildelt direkt&oslash;rer,
&oslash;vrige medarbejdere og konsulenter:</U></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Selskabet bringer ans&aelig;ttelses-
eller konsulentforholdet til oph&oslash;r, og dette ikke er begrundet i Warrantindehaverens v&aelig;sentlige misligholdelse af sine forpligtelser over for Selskabet, samt i tilf&aelig;lde af Warrantindehaverens d&oslash;d.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>For warrants tildelt bestyrelsesmedlemmer:</U></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><U></U>Warrantindehaveren udtr&aelig;der af Selskabets bestyrelse eller ikke
genv&aelig;lges til bestyrelsen, og dette ikke skyldes Warrantindehaverens beslutning om at forlade Selskabets bestyrelse eller ikke stille sig til r&aring;dighed for genvalg til bestyrelsen, og dette desuden ikke er begrundet i Warrantindehaverens
v&aelig;sentlige misligholdelse af sine forpligtelser over for Selskabet.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>For warrants issued to managers, other
employees and consultants:</U></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company terminates the employment or consultancy
contract and the this is not a result of a material breach by the Warrantholder of its obligations towards the Company, and in case of the Warrantholder&#8217;s death</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>For warrants issued to directors:</U></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Warrantholder leaves the board of directors of the Company or is not <FONT STYLE="white-space:nowrap">re-elected</FONT> to the board of directors, and this
is not caused by the fact that the Warrantholder decides to leave the board of directors of the Company or not make himself/herself available for <FONT STYLE="white-space:nowrap">re-election</FONT> to the board of directors, and provided further
that this is not a result of a material breach by the Warrantholder of its obligations towards the Company.</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.3.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Alle Warrantindehaverens warrants bortfalder uden yderligere varsel og uden kompensation eller vederlag af nogen art til Warrantindehaveren p&aring; det tidspunkt, hvor ans&aelig;ttelses- eller konsulentforholdet henholdsvis
medlemskabet af bestyrelsen oph&oslash;rer, <U>s&aring;fremt</U>:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">All warrants of the Warrantholder shall without further notice and without compensation or payment of any kind to the Warrantholder automatically become null and void at the time where the employment or consultancy contract or
membership of the board of directors, as applicable, is terminated, <U>in the event that:</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>For warrants tildelt direkt&oslash;rer, &oslash;vrige medarbejdere og konsulenter:</U></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Selskabet bringer ans&aelig;ttelses- eller konsulentforholdet til oph&oslash;r, og dette er begrundet i Warrantindehaverens v&aelig;sentlige misligholdelse af
sine forpligtelser over for Selskabet.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>For warrants issued to managers, other employees and consultants:</U> The Company terminates the employment or consultancy contract, as applicable, and this is caused by the Warrantholder&#8217;s material breach of his/her
obligations towards the Company.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>For warrants tildelt bestyrelsesmedlemmer:</U></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Warrantindehaveren udtr&aelig;der af Selskabets bestyrelse eller ikke genv&aelig;lges til bestyrelsen, og dette er begrundet i Warrantindehaverens
v&aelig;sentlige misligholdelse af sine forpligtelser over for Selskabet.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><U>For warrants issued to directors:</U> The Warrantholder leaves the board of directors of the Company or is not <FONT
STYLE="white-space:nowrap">re-elected</FONT> to the board of directors and this is caused by the Warrantholder&#8217;s material breach of his/her obligations towards the Company.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.4.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">I tilf&aelig;lde af en Exit, fremrykkes optjeningen af warrants, s&aring;ledes at Warrantindehaverens eventuelt ikke-optjente warrants (som er under optjening) optjenes p&aring; et tidspunkt forud for den p&aring;g&aelig;ldende
exit, som fasts&aelig;ttes af Selskabet og meddeles Warrantindehaveren. Ved en &#8220;<B>Exit</B>&#8221; forst&aring;s en begivenhed, hvorved hele eller n&aelig;ste hele Selskabets v&aelig;rdi realiseres mod betaling i kontanter eller likvide
v&aelig;rdipapirer, uanset om en s&aring;dan begivenhed besluttes af bestyrelsen og/eller kapitalejerne. En exit kan</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">In case of an Exit, the vesting of warrants shall be accelerated to the effect that the Warrantholder&#8217;s unvested warrants (that are undergoing vesting), if any, shall vest at a time prior to the exit, which shall be determined
by the Company and notified to the Warrantholder. An &#8220;<B>Exit</B>&#8221; shall mean an event whereby all or materially all of the value of the Company is realized in consideration for cash or liquid securities irrespective of whether such
event is decided (a)&nbsp;by the required majority of board members and/or shareholders. An exit may be carried out in a variety of ways</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">gennemf&oslash;res p&aring; forskellige m&aring;neder, herunder ved (i)&nbsp;en b&oslash;rsnotering af Selskabets kapitalandele, (ii)&nbsp;et salg (trade sale) af Selskabets anparter, (iii)&nbsp;indg&aring;else af en partnerskabs-
eller jointventureaftale, der fasts&aelig;tter partnerens fremtidige erhvervelse af Selskabets v&aelig;rdi, (iv)&nbsp;en fusion med Selskabet som den oph&oslash;rende enhed, (v)&nbsp;et salg af Selskabets aktiviteter, herunder et salg af alle eller
en v&aelig;sentlig andel af Selskabets aktiver eller alle eller en v&aelig;sentlig andel af Selskabets immaterielle rettigheder, (vi)&nbsp;udlicensiering af alle eller en v&aelig;sentlig andel af Selskabets immaterielle rettigheder p&aring; en
m&aring;de, som kan sidestilles med en exit eller (vii)&nbsp;en kombination af ovenst&aring;ende.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">including, but not limited to (i)&nbsp;an initial public offering (IPO) of the Company&#8217;s shares; (ii)&nbsp;a trade sale of the Company&#8217;s shares; (iii)&nbsp;the entering into of a partnership or joint venture agreement
stipulating a future acquisition of the value of the Company by the partner; (iv)&nbsp;a merger whereby the Company is the discontinuing entity, (v)&nbsp;a sale of the Company&#8217;s activities, including a sale of all or a material part of the
Company&#8217;s assets or all or a material part of the Company&#8217;s intellectual property rights; (vi)&nbsp;licensing of all or a material part of the intellectual property rights of the Company in a way, which can be considered equal to an
exit; or (vii)&nbsp;a combination of the above,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>UDNYTTELSE AF WARRANTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>EXERCISE OF WARRANTS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Kun optjente warrants kan udnyttes. Optjente warrants kan med de modifikationer, som f&oslash;lger af punkt <FONT STYLE="white-space:nowrap">4.2-4.6</FONT> nedenfor, udnyttes i den eller de perioder, der fremg&aring;r af
Warrantaftalen.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Only vested warrants can be exercised. Vested warrants may, subject to the modifications set out in clauses <FONT STYLE="white-space:nowrap">4.2-4.6</FONT> below, be exercised during such period or periods as agreed in the Warrant
agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.2.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hvis den sidste dag i en udnyttelsesperiode er en l&oslash;rdag, s&oslash;ndag eller helligdag, omfatter udnyttelsesperioden ogs&aring; den herefter f&oslash;rstkommende hverdag.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If the last day of an exercise period is a Saturday, Sunday or bank holiday, the exercise period shall also include the first business day immediately following the stipulated period.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.3.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrantindehaveren kan &#8211; i det omfang andet ikke fremg&aring;r af punkt 4.6 nedenfor &#8211; frit v&aelig;lge i hvilke udnyttelsesperioder (hvis der er aftalt flere udnyttelsesperioder) og hvorn&aring;r i en udnyttelsesperiode
optjente warrants skal udnyttes. Det er dog en betingelse for hver udnyttelse, at Warrantindehaveren udnytter det mindste af (a)&nbsp;alle sine optjente warrants og (b)&nbsp;optjente warrants, der giver ret til tegning af minimum nominelt DKK 2.000
anparter i Selskabet.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Warrantholder shall &#8211; to the extent not otherwise set forth in clause 4.6 below &#8211; be entitled to choose in which exercise periods (if more exercise periods have been agreed) and when during an exercise period vested
warrants shall be exercised. It is, however, a precondition each exercise that the Warrantholder exercises the lower of (a)&nbsp;all of his/her vested warrants and (b)&nbsp;vested warrants, which provides for subscription of minimum nominally DKK
2,000 shares in the Company.</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.4.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">De warrants, som Warrantindehaveren ikke udnytter i udnyttelsesperioden (eller den sidste udnyttelsesperiode, hvis der er aftalt flere udnyttelsesperioder), bortfalder uden yderligere varsel og uden kompensation eller vederlag af
nogen art til Warrantindehaveren.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrants that are not exercised by the Warrantholder during the exercise period (or last exercise period, if more exercise periods have been agreed) shall become null and void without further notice and without compensation or
payment of any kind to the Warrantholder.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.5.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Selskabet er berettiget til ensidigt at forl&aelig;nge udnyttelsesperioden (eller udnyttelsesperioderne, hvis der er flere). Selskabet er endvidere i tilf&aelig;lde af, at Selskabet b&oslash;rsnoteres, berettiget til ensidigt at
&aelig;ndre udnyttelsesperioden (eller udnyttelsesperioderne, hvis der er flere), s&aring;ledes at udnyttelsesperioden (eller udnyttelsesperioderne, hvis der er flere) tilpasses de til enhver tid g&aelig;ldende regler for insiderhandel.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Company may at its discretion extend the exercise period (or exercise periods, if more exercise periods have been agreed). In addition, the Company is, in the event of a listing of the Company on a stock exchange, entitled at
its discretion to change the exercise period (or exercise periods, if more exercise periods have been agreed) in order to adapt the exercise period (or exercise periods, if more exercise periods have been agreed) to applicable rules on insider
trading.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.6.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">S&aring;fremt Warrantindehaverens tilknytning til Selskabet oph&oslash;rer af &aring;rsager omfattet af punkt 3.2(b), eller fordi Warrantindehaveren bringer ans&aelig;ttelses- eller konsulentforholdet til oph&oslash;r gennem
opsigelse henholdsvis v&aelig;lger at udtr&aelig;de af Selskabets bestyrelse eller ikke at stille sig til r&aring;dighed for genvalg til Selskabets bestyrelse, og dette ikke er begrundet i Selskabets v&aelig;sentlige misligholdelse af sine
forpligtelser over for Warrantindehaveren, kan Warrantindehaveren (eller dennes bo/arvinger), medmindre Selskabet beslutter andet, alene udnytte optjente warrants i perioden fra tilknytningens oph&oslash;r til seks m&aring;neder efter tilknytningens
oph&oslash;r, dog altid indtil tre m&aring;neder efter at alle warrants, som m&aring;tte forts&aelig;tte optjening, er optjente, hvorefter alle ikke-udnyttede warrants bortfalder uden yderligere varsel og uden kompensation eller vederlag af nogen
art.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">In the event of termination of the Warrantholder&#8217;s association with the Company for reasons comprised by clause 3.2(b) or because the Warrantholder terminates the employment or consultancy contract or decides to leave the
board of directors of the Company or not make himself/herself available for <FONT STYLE="white-space:nowrap">re-election</FONT> to the board of directors, as applicable, and this is not a result of a material breach by the Company of its obligations
towards the Warrantholder, the Warrantholder (or his/her estate/heirs) shall, unless otherwise decided by the Company, only be entitled to exercise vested warrants during the period from termination of the association until six months after
termination of the association, however always until three months after all warrants that continue to vest, if any, have vested, after which all unexercised warrants shall become null and void without further notice and without compensation or
payment of any kind.</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">5.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>JUSTERING AF WARRANTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>ADJUSTMENT OF WARRANTS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hvis der sker &aelig;ndringer i Selskabets kapitalforhold, der medf&oslash;rer en &aelig;ndring af den potentielle gevinstmulighed, der er knyttet til warrants, skal s&aring;danne warrants justeres i henhold til dette punkt 5.
Justeringer skal, medmindre Selskabet tr&aelig;ffer anden beslutning med forn&oslash;den tilslutning fra dets kapitalejere, dog alene ske i det omfang, justeringerne kan foretages indenfor rammerne af den i vedt&aelig;gternes punkt 3.8 henholdsvis
punkt 3.10 givne bemyndigelse til bestyrelsen.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If changes are made to the Company&#8217;s capital structure, which cause a change of the possibility of a gain attached to warrants, such warrants shall be adjusted in accordance with this clause 5. Adjustments shall, however,
unless otherwise decided by the Company with the necessary support from its shareholders, only take place to the extent that the adjustments can be made within the scope of the authorization to the board of directors set out in article 3.8 and
article 3.10 of the articles of association, respectively.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.2.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">En justering skal ske, s&aring;ledes at den potentielle gevinstmulighed, der er knyttet til en warrant, s&aring; vidt muligt er den samme som f&oslash;r og efter indtr&aelig;den af den h&aelig;ndelse, der begrunder justeringen.
Justeringen gennemf&oslash;res af Selskabet. Justeringen kan ske enten ved en for&oslash;gelse eller en formindskelse af det antal anparter, der kan udstedes i henhold til en warrant, og/eller en for&oslash;gelse eller formindskelse af
udnyttelseskursen.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">An adjustment shall be made to the effect that the possibility of a gain attached to a warrant, in so far as possible, shall remain the same before and after the occurrence of the incident causing the adjustment. The adjustment
shall be carried out by the Company. The adjustment may be effected either by an increase or decrease of the number of shares that can be issued following an exercise of the warrant and/or an increase or decrease of the exercise price.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.3.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Selskabets udstedelse af medarbejderanparter, anpartsoptioner og/eller warrants som led i medarbejderincitamentsordninger (herunder til bestyrelsesmedlemmer, r&aring;dgivere og konsulenter) s&aring;vel som senere udnyttelse af
s&aring;danne optioner og/eller warrants, medf&oslash;rer ikke krav p&aring; justering af warrants. En kapitalforh&oslash;jelse, der finder sted som f&oslash;lge af warrantindehaveres udnyttelse af warrants i Selskabet, medf&oslash;rer heller ikke
justering af warrants. Herudover skal en Warrantindehaver, uanset punkt 5.6, ikke v&aelig;re berettiget til justering, s&aring;fremt der sker anpartsudstedelser til under markedskurs, som f&oslash;lge af eksempelvis anti-udvandingsbestemmelserne i
vedt&aelig;gternes bilag 3.2(b), som beskytter mod udvanding af Selskabets pr&aelig;ferenceanparter.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrants shall not be adjusted as a result of the Company&#8217;s issue of employee shares, share options and/or warrants as part of employee incentive schemes (including to directors, advisors and consultants) as well as future
exercise of such options and/or warrants. Warrants shall, furthermore, not be adjusted as a result of a capital increase following warrantholders&#8217; exercise of warrants in the Company. In addition, a Warrantholder shall, irrespective of clause
5.6, not be entitled to any adjustment in the event of capital increases below market price pursuant to, for example, the anti-dilution provisions in appendix 3.2(b) of the articles of association of the Company that protect against dilution of the
preference shares of the Company.</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.4.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Enhver regulering af udnyttelseskursen og/eller det antal anparter, som kan tegnes ved udnyttelse af warrants i henhold til dette punkt 5, skal alene g&aelig;lde for warrants, som endnu ikke er udnyttet p&aring; tidspunktet for den
begivenhed, der medf&oslash;rer en regulering. Allerede udnyttede warrants p&aring;virkes s&aring;ledes ikke af reguleringer.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Any adjustments of the exercise price and/or and/or the number of shares that may be subscribed for by exercise of warrants pursuant to this clause 5, shall only apply to warrants not exercised by the Warrantholder at the time of
the event triggering the adjustment. Accordingly, no adjustment shall affect already exercised warrants.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.5.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Fondsanparter</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Bonus Shares</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hvis det besluttes at udstede fondsanparter i Selskabet, skal warrants justeres som f&oslash;lger:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If it is decided to issue bonus shares in the Company, warrants shall be adjusted as follows:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Udnyttelsesprisen p&aring; enhver endnu ikke udnyttet warrant ganges med faktoren:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The exercise price for each warrant not yet exercised shall be multiplied by the factor:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#945; = &#8195;<U>&#8194;&#8195;A&#8195;&#8195;</U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.60em; font-size:10pt; font-family:Times New Roman">(A+B)</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">og antallet af endnu ikke udnyttede warrants ganges med</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">faktoren:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>1</U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#945;</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">hvor:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A = den nominelle anpartskapital f&oslash;r udstedelsen af fondsanparter, og</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">B = den samlede nominelle v&aelig;rdi p&aring; fondsanparterne.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#945; = <U>&#8195;&#8195;A&#8195;&#8195;</U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">(A+B)</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and the number of warrants not yet exercised shall be multiplied by the factor:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>1</U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#945;</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">where:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A = the nominal share capital before the issue of bonus shares, and</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">B = the total nominal value of the bonus shares.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hvis det justerede antal anparter ikke er et helt tal, skal der afrundes nedad til det n&aelig;rmeste hele tal.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If the adjusted number of shares does not amount to a whole number, the number shall be rounded down to the nearest whole number.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.6.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Kapital&aelig;ndringer til en anden kurs end markedskursen</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Changes of capital at a price different from the market price</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hvis det besluttes at forh&oslash;je eller neds&aelig;tte anpartskapitalen i Selskabet til en kurs under markedskursen (vedr&oslash;rende kapitalneds&aelig;ttelser ogs&aring; til over markedskursen), skal warrants justeres som
f&oslash;lger:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If it is decided to increase or decrease the share capital in the Company at a price below the market price (in relation to capital decreases also above the market price), warrants shall be adjusted as
follows:</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Udnyttelsesprisen p&aring; enhver endnu ikke udnyttet warrant ganges med faktoren:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The exercise price for each <FONT STYLE="white-space:nowrap">non-exercised</FONT> warrant shall be multiplied by the factor:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#945; =&#8195;<U>(A x K) + (B x T)</U>&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">(A+B) x K</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#945; = &#8194;<U>(A_x K) + (B x T)</U></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">(A+B) x K</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">og antallet af endnu ikke udnyttede warrants ganges med faktoren</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">and the number of <FONT STYLE="white-space:nowrap">non-exercised</FONT> warrants shall be multiplied by the factor:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>1</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&#945;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>1</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&#945;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">hvor:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">where:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">A = den nominelle anpartskapital f&oslash;r &aelig;ndringen i kapitalen</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">A = nominal share capital before the change in capital</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">B = den nominelle &aelig;ndring i anpartskapitalen</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">B = nominal change in the share capital</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">K = anpartens markedskurs / lukkekurs dagen forinden annoncering af &aelig;ndringen i anpartskapitalen, og</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">K = market price / closing price of the share on the day prior to the announcement of the change in the share capital, and</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">T = tegningskurs/neds&aelig;ttelseskurs ved &aelig;ndringen i anpartskapitalen</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">T = subscription price/reduction price in relation to the change in the share capital</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hvis det det justerede antal anparter ikke er et helt tal, skal der afrundes nedad til det n&aelig;rmeste hele tal.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If the adjusted number of shares does not amount to whole numbers, each number shall be rounded down to the nearest whole number.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.7.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&AElig;ndringer i den enkelte anparts p&aring;lydende v&aelig;rdi</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Changes in the nominal value of each individual share</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hvis det besluttes at &aelig;ndre anparternes p&aring;lydende v&aelig;rdi, skal warrants justeres som f&oslash;lger:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If it is decided to change the nominal value of the shares, warrants shall be adjusted as follows:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Udnyttelsesprisen p&aring; enhver endnu ikke udnyttet warrant ganges med faktoren:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The exercise price for each <FONT STYLE="white-space:nowrap">non-exercised</FONT> warrant shall be multiplied by the factor:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#945; =&#8195;<U>&#8195;&#8194;A&#8195;&#8195;</U></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:3.00em; font-size:10pt; font-family:Times New Roman">B</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#945; = &#8195;<U>&#8195;A&#8195;&#8195;</U></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:3.00em; font-size:10pt; font-family:Times New Roman">B</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">og antallet af endnu ikke udnyttede warrants ganges med faktoren:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">and the number of <FONT STYLE="white-space:nowrap">non-exercised</FONT> warrants shall be multiplied by the factor:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>1</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&#945;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>1</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&#945;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">hvor:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">where:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">A = den enkelte anparts nominelle v&aelig;rdi efter &aelig;ndringen, og</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">A = nominal value of each share after the change, and</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">B = den enkelte anparts nominelle v&aelig;rdi f&oslash;r &aelig;ndringen.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Hvis det justerede antal anparter ikke er et helt tal, skal der afrundes nedad til det
n&aelig;rmeste hele tal.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">B = nominal value of each share before the change.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">the adjusted number of shares does not amount to a whole number, the number shall be rounded down to the nearest whole number.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.8.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Udbetaling af udbytte</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Payment of dividend</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hvis det besluttes at udbetale udbytte, skal udbyttet, medf&oslash;re en justering af udnyttelsesprisen efter f&oslash;lgende formel:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If it is decided to pay dividends, the dividends shall lead to adjustment of the exercise price according to the following formula:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E2 = E1 - <U>U</U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:3.00em; font-size:10pt; font-family:Times New Roman">A</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">hvor:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E2 = den justerede udnyttelsespris</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E1 = den oprindelige udnyttelsespris</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U = det udbetalte udbytte og</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">A = det samlede antal anparter i Selskabet.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E2 = E1 - <U>U</U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:3.00em; font-size:10pt; font-family:Times New Roman">A</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">where:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E2 = the adjusted exercise price</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E1 = the original exercise price</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U = dividends paid out and</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">A = total number of shares in the Company.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.9.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Andre &aelig;ndringer i Selskabets kapitalforhold</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Other changes to the Company&#8217;s capital structure</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hvis der sker andre &aelig;ndringer i Selskabets kapitalforhold, der medf&oslash;rer en &aelig;ndring i warrants &oslash;konomiske v&aelig;rdi, skal warrant (medmindre andet er angivet ovenfor) justeres, s&aring;ledes at
&aelig;ndringen ikke p&aring;virker warrants &oslash;konomiske v&aelig;rdi.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">In the event of other changes in the Company&#8217;s capital structure causing changes to the financial value of warrants, warrants shall (unless otherwise indicated above) be adjusted to the effect that the changes do not influence
the financial value of the warrants.</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Den beregningsmetode, der skal anvendes ved justeringen, fasts&aelig;ttes af Selskabet.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The calculation method to be applied to the adjustment shall be decided by the Company.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Det pr&aelig;ciseres, at forh&oslash;jelse eller neds&aelig;ttelse af Selskabets anpartskapital til markedskurs ikke medf&oslash;rer, at der skal finde regulering sted af tegningskursen eller antallet af anparter, der kan
tegnes.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">It is emphasized that increase or decrease of the Company&#8217;s share capital at market price does not lead to an adjustment of the subscription price or the number of shares to be subscribed.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.10.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Likvidation</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Liquidation</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hvis Selskabet bliver likvideret, fremskyndes et evt. optjeningstidspunkt for alle ikke-optjente warrants, s&aring;ledes at Warrantindehaveren kan udnytte warrants i en ekstraordin&aelig;r udnyttelsesperiode umiddelbart f&oslash;r
likvidationens afslutning.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Should the Company be liquidated, the vesting time, if any, for all unvested warrants shall be changed so that the Warrantholder may exercise his/her warrants in an extraordinary exercise period immediately preceding completion of
the liquidation.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.11.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Fusion og spaltning</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Merger and split</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hvis Selskabet indg&aring;r i en fusion som det forts&aelig;ttende selskab, bliver warrants ikke p&aring;virket, medmindre der i forbindelse med fusionen sker en kapitalforh&oslash;jelse til en anden kurs end markedskursen, idet
warrants i s&aring; fald justeres i henhold til punkt 5.6.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If the Company merges as the continuing company, warrants shall remain unaffected unless, in connection with the merger, the capital is increased at a price other than the market price and in that case warrants shall be adjusted in
accordance with clause 5.6.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hvis Selskabet fusionerer som det oph&oslash;rende selskab eller bliver spaltet, kan de(t) forts&aelig;ttende selskab(er) v&aelig;lge &eacute;n af f&oslash;lgende muligheder:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If the Company merges as the terminating company or is split, the continuing company(ies) may choose one of the following options:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrantindehaveren kan umiddelbart inden fusionen/spaltningen udnytte alle ikke udnyttede warrants, der ikke er bortfaldet (inklusive warrants der endnu ikke er optjent), eller warrants bliver erstattet af nye
aktie/anpartsinstrumenter i de(t) forts&aelig;ttende selskab(er) af tilsvarende &oslash;konomisk v&aelig;rdi f&oslash;r skat. Ved spaltning kan de forts&aelig;ttende selskaber selv bestemme, i hvilke(t) selskab(er) Warrantindehaveren skal modtage de
nye aktie/anpartsinstrumenter.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Warrantholder may exercise all <FONT STYLE="white-space:nowrap">non-exercised</FONT> warrants that are not declared null and void (inclusive of warrants not yet vested) immediately before the merger/split, or new share
instruments in the continuing company(ies) of a corresponding financial <FONT STYLE="white-space:nowrap">pre-tax</FONT> value shall replace the warrants. In case of a demerger, the continuing company(ies) may decide in which company(ies) the
Warrantholder shall receive the new share instruments.</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="45%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.12.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Salg og anpartsombytning</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Sale and exchange of shares</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hvis mere end 50% af anpartskapitalen i Selskabet bliver solgt (ikke tegnet eller udstedt) eller indg&aring;r i en anpartsombytning, kan Selskabet v&aelig;lge &eacute;n af f&oslash;lgende muligheder, idet Selskabet dog i
tilf&aelig;lde af et salg, som udg&oslash;r en Exit, skal v&aelig;lge den under a) beskrevne mulighed:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If more than 50&nbsp;per cent of the share capital of the Company is sold (not subscribed for or issued) or is part of a share swap, the Company may choose one of the following options, provided however that in case of a sale
constituting an Exit, the Company must chose the option described under a):</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">a)&#8195;&#8201;Warrantindehaveren kan umiddelbart inden salget/anpartsombytningen udnytte alle
ikke-udnyttede warrants, der ikke er bortfaldet (inklusive warrants der endnu ikke er optjent). Herudover indtr&aelig;der der en pligt, hvorefter Warrantindehaveren skal s&aelig;lge de tegnede anparter p&aring; samme vilk&aring;r som de
&oslash;vrige anpartshavere (ved salg).</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">b)&#8195;&#8202;Tildelte warrants erstattes af anpartsinstrumenter i det erhvervende selskab af tilsvarende
&oslash;konomisk v&aelig;rdi f&oslash;r skat.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">c)&#8195;&#8201;Tildelte warrants forts&aelig;tter u&aelig;ndret.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">a)&#8195;&#8201;The Warrantholder may exercise all
<FONT STYLE="white-space:nowrap">non-exercised</FONT> warrants that are not declared null and void (inclusive of warrants not yet vested) immediately before the sale/swap of shares. Furthermore, the Warrantholder shall undertake an obligation to
sell the subscribed shares on the same conditions as the other shareholders (when selling)</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">b)&#8195;&#8202;Share instruments in the acquiring company of a corresponding
<FONT STYLE="white-space:nowrap">pre-tax</FONT> value shall replace the issued warrants.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">c)&#8195;&#8201;Issued warrants continue unchanged.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.13.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>F&aelig;lles bestemmelser for punkt <FONT STYLE="white-space:nowrap">5.10-5.12</FONT></U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>General provisions for clauses <FONT STYLE="white-space:nowrap">5.10-5.12</FONT></U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Selskabet er forpligtet til at give Warrantindehaveren skriftlig meddelelse, hvis en af de ovenfor n&aelig;vnte transaktioner finder sted. N&aring;r Warrantindehaveren har modtaget den skriftlige meddelelse, har Warrantindehaveren
&#8211; i de tilf&aelig;lde, hvor Warrantindehaveren ekstraordin&aelig;rt kan udnytte warrants, jf. punkt <FONT STYLE="white-space:nowrap">5.10-5.12</FONT> &#8211; 2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If one of the transactions mentioned above is made, the Company shall inform the Warrantholder hereof by written notice. Upon receipt of the written notice, the Warrantholder shall &#8211; in cases where the Warrantholder may
extraordinarily exercise warrants, see clauses <FONT STYLE="white-space:nowrap">5.10-5.12</FONT> &#8211; inform the Company in writing whether he/she will make use of the offer. If the</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="45%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">uger til skriftligt at informere Selskabet om, hvorvidt han/hun vil g&oslash;re brug af tilbuddet. Hvis Warrantindehaveren ikke har givet Selskabet skriftligt svar inden <FONT STYLE="white-space:nowrap">2-uger</FONT> eller undlader
at betale inden for den betalingsfrist, der er fastsat, bortfalder warrants uden yderligere varsel og uden kompensation. Udnyttelseskursen kan ikke komme under anparternes nominelle v&aelig;rdi.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrantholder has not answered the Company in writing within 2 weeks or fails to pay within the fixed time, warrants shall become null and void without further notice or compensation. The exercise price cannot go below the nominal
value of the shares.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrantindehaverens rettigheder i anledning af en beslutning truffet af et kompetent organ i Selskabet, jf. punkt <FONT STYLE="white-space:nowrap">5.10-5.12,</FONT> er betinget af, at den relevante beslutning efterf&oslash;lgende
registreres i Erhvervsstyrelsen, hvis registrering er en gyldighedsbetingelse.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Warrantholder&#8217;s rights in connection with decisions made by any competent company body, see clauses <FONT STYLE="white-space:nowrap">5.10-5.12,</FONT> shall be contingent on subsequent registration of the relevant decision
with the Danish Business Authority if registration is a condition of its validity.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">6.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>OVERGANG AF WARRANTS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>ASSIGNMENT OF WARRANTS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">6.1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tildelte warrants kan ikke g&oslash;res til genstand for udl&aelig;g, overdrages eller p&aring; anden m&aring;de overf&oslash;res, ej heller i forbindelse med bodeling, og hverken til eje eller til sikkerhed, uden bestyrelsens
samtykke. Warrantindehaverens warrants kan dog overg&aring; til Warrantindehaverens &aelig;gtef&aelig;lle/samlever og/eller livsarvinger i tilf&aelig;lde af Warrantindehaverens d&oslash;d. Det er en betingelse herfor, at modtageren underskriver den
g&aelig;ldende Warrantaftale samt, s&aring;fremt dette kr&aelig;ves af bestyrelsen, en ejeraftale.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrants shall not be subject to charging orders, transfer of any kind, including in connection with division of property on divorce or legal separation, for ownership or as security without the consent of the board of directors.
The Warrantholder&#8217;s warrants may, however, be transferred to the Warrantholder&#8217;s spouse/cohabitant and/or heirs of the body in the event of the Warrantholder&#8217;s death. It is a condition precedent that the recipient signs the
applicable Warrant Agreement and, to the extent required by the board of directors a shareholders&#8217; agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">7.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>TEGNING AF ANPARTER VED UDNYTTELSE AF WARRANTS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>SUBSCRIPTION FOR SHARES BY EXERCISE OF WARRANTS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">7.1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tegning af anparter ved udnyttelse af warrants finder sted ved, at Warrantindehaveren afleverer en af Selskabet udarbejdet udnyttelsesmeddelelse til Selskabet senest kl. 16:00 CET den sidste dag i den relevante udnyttelsesperiode.
Udnyttelsesmeddelelsen skal v&aelig;re</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Subscription for shares by exercise of warrants must be made through submission by the Warrantholder no later than the last day of the relevant exercise period at 16:00 CET to the Company of an exercise notice prepared by the
Company. The exercise notice shall be completed with all required information. The Company</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="45%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">udfyldt med alle p&aring;kr&aelig;vede informationer. Udnyttelsesprisen for de nye anparter, der skal betales ved et kontant indskud, skal v&aelig;re modtaget af Selskabet senest tre dage efter, at Selskabet har modtaget
udnyttelsesmeddelelse fra Warrantindehaveren.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">must have received the exercise price payable for the new shares in cash no later than three days after the Company has received exercise notice from the Warrantholder.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">7.2.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hvis den i punkt. 7.1 angivne frist overskrides, enten s&aring;ledes at udnyttelsesmeddelelsen i udfyldt stand eller betalingen ikke er Selskabet i h&aelig;nde inden kl. 16:00 CET p&aring; den sidste dag i udnyttelsesperioden, anses
tegningen for ugyldig, og Warrantindehaveren kan i denne situation ikke anses for herved at have udnyttet sine warrants for en eventuel efterf&oslash;lgende udnyttelsesperiode.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If the limitation period set forth in clause 7.1 expires as a result of the Company not having received the duly completed exercise notice or the payment by 16:00 CET of the last day of the exercise period, the subscription shall be
deemed invalid, and in this event the Warrantholder shall not be considered as having exercised his/her warrants for a possible subsequent exercise period.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">7.3.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">De warrants, som Warrantindehaveren ikke har udnyttet i den sidste udnyttelsesperiode, bortfalder uden yderligere varsel og uden kompensation.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrants not exercised by the Warrantholder during the last exercise period shall become null and void without further notice and without compensation.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">7.4.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">N&aring;r den kapitalforh&oslash;jelse, som udnyttelsen af warrants har medf&oslash;rt, er registreret i Erhvervsstyrelsen, modtager Warrantindehaveren dokumentation for sit ejerskab til anparter i Selskabet.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">When the capital increase caused by exercise of warrants has been registered with the Danish Business Authority, the Warrantholder shall receive proof of his shareholding in the Company.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">7.5.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Forud for udnyttelse skal Warrantindehaveren, s&aring;fremt dette kr&aelig;ves af bestyrelsen, tiltr&aelig;de Selskabets til enhver tid g&aelig;ldende ejeraftale eller en s&aelig;rskilt ejeraftale omfattende de af Selskabets
anpartshavere, som har tegnet anparter ved udnyttelse af warrants. Det samme g&aelig;lder Warrantindehaverens arvinger /d&oslash;dsbo.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Prior to exercise of warrants, the Warrantholder shall adhere to the Company&#8217;s shareholders&#8217; agreement or a separate shareholders&#8217; agreement comprising those shareholders of the Company that have subscribed for
shares by exercise of warrants. The same applies to the heirs/estate of the Warrantholder.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">7.6.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrantindehaveren er bekendt med og accepterer, at de i punkt 7.5 n&aelig;vnte ejeraftaler kan indeholde (i)&nbsp;forpligtelser til at s&aelig;lge anparterne ved Warrantindehaverens fratr&aelig;den, uanset &aring;rsag, til en pris
der kan afvige fra markedsv&aelig;rdien, (ii)&nbsp;konkurrence- og kundeklausuler, (iii)&nbsp;salgsbegr&aelig;nsninger og (iv)&nbsp;andre restriktioner p&aring; Warrantindehaveren, som kan v&aelig;re byrdefulde.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Warrantholder accepts and acknowledges that the shareholders&#8217; agreements referred to in clause 7.5 may contain (i)&nbsp;obligations to sell shares upon termination of the Warrantholder&#8217;s employment or other
association with the Company, irrespective of the cause, at a price which may deviate from the market value; <FONT STYLE="white-space:nowrap">(ii)&nbsp;non-competition</FONT> and <FONT STYLE="white-space:nowrap">non-solicitation</FONT> clauses;
(iii)&nbsp;sales restrictions and (iv)&nbsp;other restrictions on the Warrantholder that may be burdensome.</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="45%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">8.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>VILK&Aring;R FOR NYE ANPARTER</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>TERMS APPLICABLE TO NEW SHARES</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">8.1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Udover de ovenfor anf&oslash;rte vilk&aring;r g&aelig;lder f&oslash;lgende vilk&aring;r for de til de udstedte warrants h&oslash;rende kapitalforh&oslash;jelser:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">In addition to the terms and conditions set forth above, the following terms and conditions shall apply to the increases of the share capital, which are associated with the warrants:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">De nye anparter udstedes i anparter &agrave; DKK 1,</P></DIV></DIV>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">De nye anparter skal give ret til udbytte i Selskabet for det l&oslash;bende regnskabs&aring;r, hvori anparterne tegnes, p&aring; lige fod med de
eksisterende ordin&aelig;re anparter og andre rettigheder i selskabet fra og med datoen for tegningen af anparterne,</P></DIV></DIV>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">De nye anparter skal tilh&oslash;re samme anpartsklasse, som de eksisterende ordin&aelig;re anparter i Selskabet,</P></DIV></DIV>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">Kapitalforh&oslash;jelsen sker uden fortegningsret for de hidtidige anpartshavere, idet tegningen sker p&aring; baggrund af warrants udstedt til
Warrantindehavere,</P></DIV></DIV> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">Der skal ikke g&aelig;lde indskr&aelig;nkninger i den til de nye anparter knyttede fortegningsret ved fremtidige kapitalforh&oslash;jelser udover det
i vedt&aelig;gternes punkt 3.6 anf&oslash;rte,</P></DIV></DIV></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">The new shares will be divided into shares of nominally DKK 1 each;</P></DIV></DIV>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">The new shares will carry dividend rights for the financial year in which subscription takes place on equal terms with the existing ordinary shares
as well as other rights in the Company as from the day of subscription of the shares;</P></DIV></DIV>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">The new shares shall belong to the same share class as the existing ordinary shares in the Company;</P></DIV></DIV>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">The capital increase shall be made without any <FONT STYLE="white-space:nowrap">pre-emption</FONT> rights for the existing shareholders, given that
the subscription is based on warrants issued to the Warrantholders;</P></DIV></DIV>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">pre-emption</FONT> rights attached to the new shares shall not be subject to any restrictions in the event of
future capital increases besides what is stated in article 3.6 of the articles of association;</P></DIV></DIV></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="45%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">Fristen for tegning af de nye anparter beregnes p&aring; baggrund af bestemmelserne ovenfor,</P></DIV></DIV>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">Det fulde bel&oslash;b til tegning af det antal anparter, som de omfattede Warrantindehavere &oslash;nsker at tegne, skal indbetales kontant som
beskrevet ovenfor og senest samtidig med tegningen af de p&aring;g&aelig;ldende anparter,</P></DIV></DIV>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">Der skal g&aelig;lde indskr&aelig;nkninger i de nye anparters oms&aelig;ttelighed, idet enhver overgang af anparter i henhold til vedt&aelig;gternes
punkt 3.5 kr&aelig;ver bestyrelsens godkendelse, og</P></DIV></DIV> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">De nye anparter skal lyde p&aring; navn, noteres i Selskabets ejerbog og v&aelig;re
<FONT STYLE="white-space:nowrap">ikke-oms&aelig;tningspapirer.</FONT></P></DIV></DIV></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">The deadline for subscription of the new shares shall be calculated pursuant to the provisions set forth above;</P></DIV></DIV>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">The full subscription amount for the number of shares which the Warrantholders wish to subscribe for, shall be paid in cash as described above and no
later than on the day of subscription of the shares in question;</P></DIV></DIV> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">The new shares will be subject to restrictions on transferability as any share transfer requires approval from the board of directors pursuant to
article 3.5 of the articles of association; and</P></DIV></DIV> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">The new shares shall be made out in the name of the holder, be recorded in the Company&#8217;s register of shareholders and be <FONT
STYLE="white-space:nowrap">non-negotiable</FONT> instruments.</P></DIV></DIV></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">9.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>LOVVALG OG V&AElig;RNETING</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>LAW AND VENUE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">9.1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tegningen af warrants, vilk&aring;rene herfor og udnyttelsen, samt vilk&aring;rene for senere tegning af anparter i Selskabet skal reguleres af dansk ret.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The grant of warrants, the associated terms and conditions and the exercise, as well as the terms and conditions for future subscription of shares in the Company shall be governed by Danish law.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">9.2.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hvis der m&aring;tte opst&aring; en tvist mellem Warrantindehaveren og Selskabet i relation til forst&aring;elsen eller gennemf&oslash;relsen af warrantprogrammet, skal denne s&oslash;ges bilagt i mindelighed ved forhandling mellem
parterne.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Any disagreement between the Warrantholder and the Company in relation to the understanding or implementation of the warrant scheme shall be settled amicably by negotiation between the
parties.</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="45%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">9.3.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hvis parterne ikke kan opn&aring; enighed, skal eventuelle tvister afg&oslash;res ved de almindelige danske domstole.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If the parties fail to reach consensus, any disputes shall be settled by the ordinary Danish courts.</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The English part of this document is an unofficial translation of the Danish text. In the event of
disputes or misunderstandings arising from the translation, the Danish text shall prevail. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BILAG 3.14 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TIL VEDT&AElig;GTERNE </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HEMAB APS</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">(CVR-NR.</FONT> 40837590)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(&#8220;<B>Selskabet</B>&#8221;)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">APPENDIX 3.14 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TO THE ARTICLES OF ASSOCIATION
</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HEMAB APS</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(COMPANY REG. NO. (CBR) 40837590)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(the &#8220;<B>Company</B>&#8221;)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>INTRODUKTION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>INTRODUCTION</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">I henhold til bemyndigelse i vedt&aelig;gternes punkt 3.13 har bestyrelsen bestemt, at nedenst&aring;ende vilk&aring;r og betingelser skal v&aelig;re g&aelig;ldende for warrants, der udstedes til bestyrelsesmedlemmer,
direkt&oslash;rer, &oslash;vrige medarbejdere og konsulenter i Selskabet og Selskabets eventuelle datterselskaber (hver en &#8221;<B>Warrantindehaver</B>&#8221;) i henhold til bemyndigelserne.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Pursuant to the authorisation set out in article 3.13 of the articles of association, the board of directors has resolved that the below terms and conditions shall apply to warrants, which are granted to directors, managers, other
employees and consultants of the Company and its subsidiaries, if any (each a &#8220;<B>Warrantholder</B>&#8221;), according to the authorisations.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.2.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrants tildeles efter bestyrelsens sk&oslash;n. Antallet af warrants, der tilbydes en Warrantindehaver, er baseret p&aring; en individuel vurdering af dennes jobfunktion eller anden relation til Selskabet og/eller Selskabets
eventuelle datterselskaber.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrants are offered at the discretion of the board of directors. The number of warrants offered to a Warrantholder shall be based on an individual evaluation of the Warrantholder&#8217;s employment or other association with the
Company and/or its subsidiaries, if any.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.3.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">En warrant er en ret, men ikke en pligt, til i en eller flere n&aelig;rmere fastlagte perioder (udnyttelsesperioden) at tegne nye anparter i Selskabet til en kurs, der er fastsat p&aring; forh&aring;nd (udnyttelsesprisen).
Udnyttelsesprisen og udnyttelsesperioden fasts&aelig;ttes af bestyrelsen i forbindelse med hver udstedelse/tildeling af warrants. &Eacute;n warrant giver ret til at tegne &eacute;n ordin&aelig;r anpart af nominelt DKK 1 i Selskabet til den af
bestyrelsen ved udstedelsen fastsatte kurs.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">A warrant is a right, but not an obligation, during one or more fixed periods (the exercise period) to subscribe for new shares in the Company at a price fixed in advance (the exercise price). The exercise price and the exercise
period shall be determined by the board of directors in connection with each issuance of warrants. Each warrant carries the right to subscribe for one ordinary share of nominally DKK 1 in the Company at the subscription price determined by the board
of directors at the issuance.</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="45%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.4.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tildeling af warrants har ingen umiddelbare &oslash;konomiske konsekvenser for Warrantindehaveren. V&aelig;rdien af warrants indg&aring;r ikke i beregningen af eventuelle feriepenge, pensionsbidrag eller &oslash;vrige
vederlagsafh&aelig;ngige ydelser fra Selskabet eller dets eventuelle datterselskaber.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Grant of warrants has no immediate economic consequences for the Warrantholder. The value of warrants will not form part of the calculation of holiday allowances, pension contributions or other contributions or payments, which are
based on the Warrantholder&#8217;s remuneration from the Company or its subsidiaries, if any.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>TILDELING AF WARRANTS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>GRANT OF WARRANTS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrantindehavere, der &oslash;nsker at tegne warrants, skal underskrive en warrantaftale (&#8221;<B>Warrantaftalen</B>&#8221;), som henviser til dette bilag, samt, s&aring;fremt dette kr&aelig;ves af bestyrelsen, en
ejeraftale.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrantholders who wish to subscribe for warrants shall sign a warrant agreement (the &#8220;<B>Warrant Agreement</B>&#8221;), which refers to this appendix, and, to the extent required by the board of directors, a
shareholders&#8217; agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.2.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Det skal fremg&aring; af Warrantaftalen, hvor mange warrants Warrantindehaveren f&aring;r tildelt, samt til hvilken kurs warrants kan udnyttes.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">It must appear from the Warrant agreement, how many warrants that are granted to the Warrantholder and at which price the warrants can be exercised.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.3.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">En Warrantindehaver skal ikke betale noget vederlag for tildelingen af warrants.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">A Warrantholder shall not pay any consideration for the grant of warrants.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.4.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Selskabet f&oslash;rer en fortegnelse over tildelte warrants, der ajourf&oslash;res l&oslash;bende.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Company shall keep records of granted warrants and update the records on an ongoing basis.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>OPTJENING AF WARRANTS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>VESTING OF WARRANTS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">En Warrantindehaver optjener &#8211; med de modifikationer, som f&oslash;lger af punkt 3.2 nedenfor &#8211; som udgangspunkt ret til at udnytte 25% af de tildelte warrants et &aring;r efter tildelingen og de resterende 75% af de
tildelte warrants med 1/36 pr. m&aring;ned regnet fra et &aring;r efter tildelingstidspunktet. Bestyrelsen skal dog v&aelig;re berettiget til at fravige n&aelig;vnte udgangspunkt og bestemme, at tildelte warrants anses for optjent pr.
tildelingstidspunktet, eller at der skal g&aelig;lde andre regler for optjeningen. S&aring;danne eventuelle fravigelser skal specificeres i Warrantaftalen og vedt&aelig;gterne i forbindelse med udstedelsen. For s&aring; vidt ang&aring;r accelereret
optjening af warrants i forbindelse med exit, likvidation, fusion, spaltning og salg af Selskabet m.v. henvises til punkt 3.4, 5.10, 5.11 og 5.12 nedenfor.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrants issued to a Warrantholder shall &#8211; subject to such modifications as set out in clause 3.2 below &#8211; as a general rule vest with 25% one year after the time of issue, and the remaining 75% of the warrants issued
shall vest with 1/36 per month from one year after the time of issue. The board of directors shall, however, be entitled to deviate from the general rule and determine that warrants shall be deemed to vest as of the date of issuance or that special
rules shall apply in relation to vesting. Such deviations, if any, shall be specified in the Warrant Agreement and the articles of association in connection with the issuance. As regards accelerated vesting of warrants in connection with an exit
liquidation, merger, demerger or sale of the Company etc., reference is made to clauses 3.4,5.10, 5.11 and 5.12 below.</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="45%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.2.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Warrantindehaveren optjener kun ret til sine warrants, s&aring; l&aelig;nge denne er ansat, konsulent eller bestyrelsesmedlem i Selskabet
eller dets eventuelle datterselskaber (i dette punkt 3 og punkt 4.6 nedenfor samlet ben&aelig;vnt &#8221;<B>Selskabet</B>&#8221;), <U>medmindre</U>:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>For warrants tildelt direkt&oslash;rer, &oslash;vrige medarbejdere og konsulenter</U>:</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Warrantindehaveren bringer ans&aelig;ttelses- eller konsulentforholdet til oph&oslash;r
gennem opsigelse, og opsigelsen er begrundet i Selskabets v&aelig;sentlige misligholdelse af sine forpligtelser over for Warrantindehaveren.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>For warrants tildelt bestyrelsesmedlemmer</U>:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Warrantindehaveren v&aelig;lger at udtr&aelig;de af Selskabets bestyrelse eller undlader at stille sig til r&aring;dighed for genvalg til Selskabets bestyrelse
og beslutningen om at udtr&aelig;de eller ikke at stille sig til r&aring;dighed for genvalg er begrundet i Selskabets v&aelig;sentlige misligholdelse af sine forpligtelser over for Warrantindehaveren.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Warrants shall only vest while the Warrantholder remains an employee, consultant or board member, as applicable, of the Company or its
subsidiaries, if any (in this clause 3 and clause 4.6 below collectively, the &#8221;<B>Company</B>&#8221;), <U>unless</U>:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>For warrants issued to managers, other employees and consultants</U>:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Warrantholder terminates the employment or consultancy contract, and the termination is caused by a material breach by the Company of its obligations
towards the Warrantholder.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>For warrants issued to directors</U>:</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Warrantholder decides to resign from the board of directors of the Company or not
make himself/herself available for <FONT STYLE="white-space:nowrap">re-election</FONT> to the board of directors of the Company and the decision to leave or not make himself/herself available for <FONT STYLE="white-space:nowrap">re-election</FONT>
is caused by a material breach by the Company of its obligations towards the Warrantholder.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.3.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alle Warrantindehaverens warrants bortfalder uden yderligere varsel og uden kompensation eller vederlag af nogen art til Warrantindehaveren
p&aring; det tidspunkt, hvor ans&aelig;ttelses- eller konsulentforholdet henholdsvis medlemskabet af bestyrelsen oph&oslash;rer, <U>s&aring;fremt</U>:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>For warrants tildelt direkt&oslash;rer, &oslash;vrige medarbejdere og konsulenter:</U></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Selskabet bringer ans&aelig;ttelses- eller konsulentforholdet til oph&oslash;r, og dette
er begrundet i Warrantindehaverens v&aelig;sentlige misligholdelse af sine forpligtelser over for Selskabet.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All warrants of the Warrantholder shall without further notice and without compensation or payment of any kind to the Warrantholder
automatically become null and void at the time where the employment or consultancy contract or membership of the board of directors, as applicable, is terminated, <U>in the event that</U>:</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><U>For warrants issued to managers, other employees and consultants:</U> The Company
terminates the employment or consultancy contract, as applicable, and this is caused by the Warrantholder&#8217;s material breach of his/her obligations towards the Company.</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="45%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>For warrants tildelt bestyrelsesmedlemmer:</U></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Warrantindehaveren udtr&aelig;der af Selskabets bestyrelse eller ikke genv&aelig;lges til bestyrelsen, og dette er begrundet i Warrantindehaverens
v&aelig;sentlige misligholdelse af sine forpligtelser over for Selskabet.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>For warrants issued to directors:</U> The Warrantholder leaves the board of directors of the Company or is not <FONT STYLE="white-space:nowrap">re-elected</FONT> to the board of directors and this is caused by the
Warrantholder&#8217;s material breach of his/her obligations towards the Company.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.4.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">I tilf&aelig;lde af en Exit, hvis Warrantindehaveren oplever en Kvalificeret Oph&oslash;rsbegivenhed indenfor tolv (12)&nbsp;m&aring;neder efter gennemf&oslash;relsen af en s&aring;dan Exit, fremrykkes optjeningen af warrants,
s&aring;ledes at Warrantindehaverens eventuelt ikke-optjente warrants (som er under optjening) optjenes p&aring; det tidspunkt, hvor Warrantindehaveren henholdsvis Selskabet, giver meddelelse om oph&oslash;r af Warrantindehaverens
ans&aelig;ttelsesforhold eller andet tilknytningsforhold med Selskabet, der udg&oslash;r en Kvalificeret Oph&oslash;rsbegivenhed. Ved en &#8220;<B>Exit</B>&#8221; forst&aring;s en begivenhed, hvorved hele eller n&aelig;sten hele Selskabets
v&aelig;rdi realiseres mod betaling i kontanter eller likvide v&aelig;rdipapirer, uanset om en s&aring;dan begivenhed besluttes af bestyrelsen og/eller kapitalejerne. En exit kan gennemf&oslash;res p&aring; forskellige m&aring;neder, herunder ved ,
(i) et salg (trade sale) af Selskabets anparter, (ii)&nbsp;indg&aring;else af en partnerskabs- eller jointventureaftale, der fasts&aelig;tter partnerens fremtidige erhvervelse af Selskabets v&aelig;rdi, (iii)&nbsp;en fusion med Selskabet som den
oph&oslash;rende enhed, (iv)&nbsp;et salg af Selskabets aktiviteter, herunder et salg af alle eller en v&aelig;sentlig andel af Selskabets aktiver eller alle eller en v&aelig;sentlig andel af Selskabets immaterielle rettigheder,
(v)&nbsp;udlicensiering af alle eller en v&aelig;sentlig andel af Selskabets immaterielle rettigheder p&aring; en m&aring;de, som kan sidestilles med en exit eller (vi)&nbsp;en kombination af ovenst&aring;ende. En b&oslash;rsnotering af Selskabets
kapitalandele skal, medmindre Selskabet beslutter andet, ikke anses for en Exit.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">In case of an Exit, if the Warrantholder experiences a Qualified Termination Event within the twelve (12)&nbsp;month period following the closing of such Exit, then the vesting of warrants shall be accelerated to the effect that all
of the Warrantholder&#8217;s unvested warrants (that are undergoing vesting), if any, shall vest from the time where the Warrantholder or the Company, as applicable, gives notice of the termination of the Warrantholder&#8217;s employment or other
service relationship with the Company constituting a Qualified Termination Event. An &#8220;<B>Exit</B>&#8221; shall mean an event whereby all or materially all of the value of the Company is realized in consideration for cash or liquid securities
irrespective of whether such event is decided by the required majority of board members and/or shareholders. An exit may be carried out in a variety of ways including, but not limited to (i)&nbsp;a trade sale of the Company&#8217;s shares;
(ii)&nbsp;the entering into of a partnership or joint venture agreement stipulating a future acquisition of the value of the Company by the partner; (iii)&nbsp;a merger whereby the Company is the discontinuing entity, (iv)&nbsp;a sale of the
Company&#8217;s activities, including a sale of all or a material part of the Company&#8217;s assets or all or a material part of the Company&#8217;s intellectual property rights; (v)&nbsp;licensing of all or a material part of the intellectual
property rights of the Company in a way, which can be considered equal to an exit; or (vi)&nbsp;a combination of the above. An initial public offering (IPO) of the Company&#8217;s shares shall, unless otherwise decided by the Company, not be
considered an Exit. &#8220;<B>Qualified Termination Event</B>&#8221; means</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="45%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#8195;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#8220;<B>Kvalificeret Oph&oslash;rsbegivenhed</B>&#8221; betyder oph&oslash;r af Warrantindehaverens ans&aelig;ttelse eller andet tilknytningsforhold (herunder, uden begr&aelig;nsning, tilknytning som konsulent eller r&aring;dgiver
eller som bestyrelsesmedlem) hos Selskabet enten (i)&nbsp;foranlediget af Selskabet uden &Aring;rsag, eller (ii)&nbsp;foranlediget af Warrantindehaveren af God Grund. &#8220;<B>&Aring;rsag</B>&#8221; betyder (i)&nbsp;Warrantindehaverens uredelige
udtalelser eller handlinger overfor Selskabet eller Selskabets koncernselskaber, eller overfor nuv&aelig;rende eller potentielle kunder, leverand&oslash;rer, forhandlere eller andre, med hvem der er forretningsm&aelig;ssig samhandel,
(ii)&nbsp;Warrantindehaverens kriminelle handlinger i form af vold, umoralsk adf&aelig;rd, bedrageri, u&aelig;rlighed eller svig, (iii)&nbsp;Warrantindehaverens manglende opfyldelse af sine tildelte pligter og ansvar p&aring; en for Selskabet
rimelig tilfredsstillende m&aring;de, der forts&aelig;tter, efter Warrantindehaveren har modtaget skriftlig meddelelse herom fra Selskabet, (iv)&nbsp;Warrantindehaverens grove uagtsomhed, fors&aelig;tlige misligholdelse eller uredelige adf&aelig;rd
over for Selskabet eller Selskabets koncernselskaber, eller (v)&nbsp;Warrantindehaverens v&aelig;sentlige overtr&aelig;delse af vilk&aring;r i enhver aftale mellem Warrantindehaveren og Selskabet. &#8220;<B>God Grund</B>&#8221; betyder (i)&nbsp;en
v&aelig;sentlig reduktion i Warrantindehaverens grundl&oslash;n, der ikke sker som led i en generel l&oslash;nnedgang hos alle eller substantielt alle ligestillede medarbejdere i Selskabet (i det omfang det er relevant), (ii) en reduktion i
Warrantindehaverens pligter, ansvar og autoritet, der afspejler en v&aelig;sentlig degradering hos Selskabet, (iii)&nbsp;hvis Warrantindehaveren er forpligtet til at stille sin arbejdskraft til r&aring;dighed p&aring; Selskabets adresse, en
&aelig;ndring p&aring; mere end 80 kilometer i Selskabets geografiske placering, hvor Warrantindehaveren s&aring;ledes er forpligtet til at stille sin</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the termination or cessation of the Warrantholder&#8217;s employment or other service relationship (including, without limitation, service as a consultant or advisor or as a member of the board of directors) with the Company either
(i)&nbsp;by the Company without Cause, or (ii)&nbsp;by the Warrantholder for Good Reason. &#8220;<B>Cause</B>&#8221; shall mean (i)&nbsp;the Warrantholder&#8217;s dishonest statements or acts with respect to the Company or any affiliate of the
Company, or any current or prospective customers, suppliers vendors or other third parties with which such entity does business; (ii)&nbsp;the Warrantholder&#8217;s commission of a criminal act involving violence, moral turpitude, deceit, dishonesty
or fraud; (iii)&nbsp;the Warrantholder&#8217;s failure to perform his or her assigned duties and responsibilities to the reasonable satisfaction of the Company, which failure continues, in the reasonable judgment of the Company, after written notice
given to the Warrantholder by the Company; (iv)&nbsp;the Warrantholder&#8217;s gross negligence, willful misconduct or insubordination with respect to the Company or any affiliate of the Company; or (v)&nbsp;the Warrantholder&#8217;s material
violation of any provision of any agreement(s) between the Warrantholder and the Company. &#8220;<B>Good Reason</B>&#8221; shall mean (i)&nbsp;a material diminution in the Warrantholder&#8217;s base compensation, except for <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">across-the-board</FONT></FONT> salary reductions similarly affecting all or substantially all similarly situated employees of the Company (to the extent applicable), (ii) a diminution in
the Warrantholder&#8217;s, duties, responsibilities, and authority which reflects a material demotion within the Company, (iii)&nbsp;if the Warrantholder is required to provide <FONT STYLE="white-space:nowrap">on-site</FONT> services to the Company,
a change of more than 80 kilometer in the geographic location at which the Warrantholder is so required to provide services to the Company, (iv)&nbsp;a material breach by the Company of its obligations towards the Warrantholder, or (v)&nbsp;the
Warrantholder&#8217;s</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="45%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">arbejdskraft til r&aring;dighed, (iv)&nbsp;Selskabets v&aelig;sentlige misligholdelse af sine forpligtelser overfor Warrantindehaveren, eller (v)&nbsp;Warrantindehaverens tilknytning som bestyrelsesmedlem eller nogen komit&eacute;
heraf ufrivilligt oph&oslash;rer (og uden &Aring;rsag), eller Warrantindehaveren undlader at stille sig til r&aring;dighed for genvalg til Selskabets bestyrelse og beslutningen om at udtr&aelig;de eller ikke at stille sig til r&aring;dighed for
genvalg er begrundet i Selskabets v&aelig;sentlige misligholdelse af sine forpligtelser over for Warrantindehaveren, forudsat, at Warrantindehaveren i alle tilf&aelig;lde mindst giver Selskabet besked indenfor 90 dage efter den f&oslash;rste af
begivenhederne beskrevet i punkterne (i), (ii), (iii) og/eller (iv)&nbsp;ovenfor indtr&aelig;der, og Selskabet undlader at afhj&aelig;lpe en s&aring;dan begivenhed inden for 30 dage derefter. Det pr&aelig;ciseres, at en beslutning fra et
bestyrelsesmedlem i Selskabet om at udtr&aelig;de eller ikke at stille sig til r&aring;dighed for genvalg som bestyrelsesmedlem i Selskabet af God Grund, skal anses for at udg&oslash;re en Kvalificeret Oph&oslash;rsgrund, medmindre han/hun fortsat
har et andet tilknytningsforhold til Selskabet.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">service, if any, on the board of directors of the Company or any committee thereof is involuntarily terminated (other than for Cause) or the Warranholder does not make himself/herself available for
<FONT STYLE="white-space:nowrap">re-election</FONT> to the board of directors of the Company and the decision not to make himself/herself available for <FONT STYLE="white-space:nowrap">re-election</FONT> is caused by a material breach by the Company
of its obligations towards the Warranholder, so long as, in any case, the Warrantholder provides at least 90 days&#8217; notice to the Company following the initial occurrence of the event(s) described in items (i), (ii), (iii) and/or (iv)&nbsp;of
the foregoing and the Company fails to cure such event within 30 days thereafter. For the avoidance of doubt, and without limiting the foregoing, the decision by a member of the board of directors of the Company to resign from the board of directors
of the Company or to not make himself/herself available for <FONT STYLE="white-space:nowrap">re-election</FONT> to the board of directors of the Company for Good Reason shall be deemed to constitute a Qualified Termination Event, unless he/she
otherwise has an ongoing service relationship with the Company.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>UDNYTTELSE AF WARRANTS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>EXERCISE OF WARRANTS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Kun optjente warrants kan udnyttes. Optjente warrants kan med de modifikationer, som f&oslash;lger af punkt <FONT STYLE="white-space:nowrap">4.2-4.6</FONT> nedenfor, udnyttes i den eller de perioder, der fremg&aring;r af
Warrantaftalen.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Only vested warrants can be exercised. Vested warrants may, subject to the modifications set out in clauses <FONT STYLE="white-space:nowrap">4.2-4.6</FONT> below, be exercised during such period or periods as agreed in the Warrant
agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.2.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hvis den sidste dag i en udnyttelsesperiode er en l&oslash;rdag, s&oslash;ndag eller helligdag, omfatter udnyttelsesperioden ogs&aring; den herefter f&oslash;rstkommende hverdag.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If the last day of an exercise period is a Saturday, Sunday or bank holiday, the exercise period shall also include the first business day immediately following the stipulated
period.</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="45%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.3.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrantindehaveren kan &#8211; i det omfang andet ikke fremg&aring;r af punkt 4.6 nedenfor &#8211; frit v&aelig;lge i hvilke udnyttelsesperioder (hvis der er aftalt flere udnyttelsesperioder) og hvorn&aring;r i en udnyttelsesperiode
optjente warrants skal udnyttes. Det er dog en betingelse for hver udnyttelse, at Warrantindehaveren udnytter det mindste af (a)&nbsp;alle sine optjente warrants og (b)&nbsp;optjente warrants, der giver ret til tegning af minimum nominelt DKK 2.000
anparter i Selskabet.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Warrantholder shall &#8211; to the extent not otherwise set forth in clause 4.6 below &#8211; be entitled to choose in which exercise periods (if more exercise periods have been agreed) and when during an exercise period vested
warrants shall be exercised. It is, however, a precondition each exercise that the Warrantholder exercises the lower of (a)&nbsp;all of his/her vested warrants and (b)&nbsp;vested warrants, which provides for subscription of minimum nominally DKK
2,000 shares in the Company.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.4.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">De warrants, som Warrantindehaveren ikke udnytter i udnyttelsesperioden (eller den sidste udnyttelsesperiode, hvis der er aftalt flere udnyttelsesperioder), bortfalder uden yderligere varsel og uden kompensation eller vederlag af
nogen art til Warrantindehaveren.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrants that are not exercised by the Warrantholder during the exercise period (or last exercise period, if more exercise periods have been agreed) shall become null and void without further notice and without compensation or
payment of any kind to the Warrantholder.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.5.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Selskabet er berettiget til ensidigt at forl&aelig;nge udnyttelsesperioden (eller udnyttelsesperioderne, hvis der er flere). Selskabet er endvidere i tilf&aelig;lde af, at Selskabet b&oslash;rsnoteres, berettiget til ensidigt at
&aelig;ndre udnyttelsesperioden (eller udnyttelsesperioderne, hvis der er flere), s&aring;ledes at udnyttelsesperioden (eller udnyttelsesperioderne, hvis der er flere) tilpasses de til enhver tid g&aelig;ldende regler for insiderhandel.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Company may at its discretion extend the exercise period (or exercise periods, if more exercise periods have been agreed). In addition, the Company is, in the event of a listing of the Company on a stock exchange, entitled at
its discretion to change the exercise period (or exercise periods, if more exercise periods have been agreed) in order to adapt the exercise period (or exercise periods, if more exercise periods have been agreed) to applicable rules on insider
trading.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.6.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">S&aring;fremt Warrantindehaverens tilknytning til Selskabet som ansat, konsulent eller bestyrelsesmedlem oph&oslash;rer af andre &aring;rsager end Selskabets v&aelig;sentlige misligholdelse af sine forpligtelser over for
Warrantindehaveren, kan Warrantindehaveren (eller dennes bo/arvinger), medmindre Selskabet beslutter andet, alene udnytte optjente warrants i perioden fra tilknytningens oph&oslash;r til 90 dage efter tilknytningens oph&oslash;r, hvorefter alle
ikke-udnyttede warrants bortfalder uden yderligere varsel og uden kompensation eller vederlag af nogen art.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">In the event of termination of the Warrantholder&#8217;s association with the Company as an employee, consultant or a board member for other reasons than a material breach by the Company of its obligations towards the Warrantholder,
the Warrantholder (or his/her estate/heirs) shall, unless otherwise decided by the Company, only be entitled to exercise vested warrants during the period from termination of the association until 90 days after termination of the association, after
which all unexercised warrants shall become null and void without further notice and without compensation or payment of any kind.</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="45%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>JUSTERING AF WARRANTS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>ADJUSTMENT OF WARRANTS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hvis der sker &aelig;ndringer i Selskabets kapitalforhold, der medf&oslash;rer en &aelig;ndring af den potentielle gevinstmulighed, der er knyttet til warrants, skal s&aring;danne warrants justeres i henhold til dette punkt 5.
Justeringer skal, medmindre Selskabet tr&aelig;ffer anden beslutning med forn&oslash;den tilslutning fra dets kapitalejere, dog alene ske i det omfang, justeringerne kan foretages indenfor rammerne af den i vedt&aelig;gternes punkt 3.8 henholdsvis
punkt 3.10 givne bemyndigelse til bestyrelsen.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If changes are made to the Company&#8217;s capital structure, which cause a change of the possibility of a gain attached to warrants, such warrants shall be adjusted in accordance with this clause 5. Adjustments shall, however,
unless otherwise decided by the Company with the necessary support from its shareholders, only take place to the extent that the adjustments can be made within the scope of the authorization to the board of directors set out in article 3.8 and
article 3.10 of the articles of association, respectively.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.2.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">En justering skal ske, s&aring;ledes at den potentielle gevinstmulighed, der er knyttet til en warrant, s&aring; vidt muligt er den samme som f&oslash;r og efter indtr&aelig;den af den h&aelig;ndelse, der begrunder justeringen.
Justeringen gennemf&oslash;res af Selskabet. Justeringen kan ske enten ved en for&oslash;gelse eller en formindskelse af det antal anparter, der kan udstedes i henhold til en warrant, og/eller en for&oslash;gelse eller formindskelse af
udnyttelseskursen.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">An adjustment shall be made to the effect that the possibility of a gain attached to a warrant, in so far as possible, shall remain the same before and after the occurrence of the incident causing the adjustment. The adjustment
shall be carried out by the Company. The adjustment may be effected either by an increase or decrease of the number of shares that can be issued following an exercise of the warrant and/or an increase or decrease of the exercise price.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.3.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Selskabets udstedelse af medarbejderanparter, anpartsoptioner og/eller warrants som led i medarbejderincitamentsordninger (herunder til bestyrelsesmedlemmer, r&aring;dgivere og konsulenter) s&aring;vel som senere udnyttelse af
s&aring;danne optioner og/eller warrants, medf&oslash;rer ikke krav p&aring; justering af warrants. En kapitalforh&oslash;jelse, der finder sted som f&oslash;lge af Warrantindehaveres udnyttelse af warrants i Selskabet, medf&oslash;rer heller ikke
justering af warrants. Herudover skal en Warrantindehaver, uanset punkt 5.6, ikke v&aelig;re berettiget til justering, s&aring;fremt der sker anpartsudstedelser til under markedskurs, som f&oslash;lge af eksempelvis anti-udvandingsbestemmelserne i
vedt&aelig;gternes bilag 3.2(b), som beskytter mod udvanding af Selskabets pr&aelig;ferenceanparter.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrants shall not be adjusted as a result of the Company&#8217;s issue of employee shares, share options and/or warrants as part of employee incentive schemes (including to directors, advisors and consultants) as well as future
exercise of such options and/or warrants. Warrants shall, furthermore, not be adjusted as a result of a capital increase following warrantholders&#8217; exercise of warrants in the Company. In addition, a Warrantholder shall, irrespective of clause
5.6, not be entitled to any adjustment in the event of capital increases below market price pursuant to, for example, the anti-dilution provisions in appendix 3.2(b) of the articles of association of the Company that protect against dilution of the
preference shares of the Company.</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.4.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Enhver regulering af udnyttelseskursen og/eller det antal anparter, som kan tegnes ved udnyttelse af warrants i henhold til dette punkt 5, skal tilpasses det forhold, at forskellige anpartsklasser i Selskabet kan have forskellig
v&aelig;rdi og skal alene g&aelig;lde for warrants, som endnu ikke er udnyttet p&aring; tidspunktet for den begivenhed, der medf&oslash;rer en regulering. Allerede udnyttede warrants p&aring;virkes s&aring;ledes ikke af reguleringer.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Any adjustments of the exercise price and/or and/or the number of shares that may be subscribed for by exercise of warrants pursuant to this clause 5, must be adapted to the fact that different share classes in the Company may have
different values and shall only apply to warrants not exercised by the Warrantholder at the time of the event triggering the adjustment. Accordingly, no adjustment shall affect already exercised warrants.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.5.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Fondsanparter</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Bonus Shares</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hvis det besluttes at udstede fondsanparter i Selskabet, skal warrants justeres som f&oslash;lger:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If it is decided to issue bonus shares in the Company, warrants shall be adjusted as follows:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Udnyttelsesprisen p&aring; enhver endnu ikke udnyttet warrant ganges med faktoren:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The exercise price for each warrant not yet exercised shall be multiplied by the factor:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>= &#8194;<U>&#8195;A&#8195;</U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8195;&#8194;&#8194;(A+B)</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">og antallet af endnu ikke udnyttede warrants ganges med faktoren:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>1</U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">hvor:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A = den nominelle anpartskapital f&oslash;r udstedelsen af fondsanparter, og</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">B = den samlede nominelle v&aelig;rdi p&aring; fondsanparterne.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>= &#8194;<U>&#8195;A&#8195;</U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8195;&#8194;&#8194;(A+B)</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and the number of warrants not yet exercised shall be multiplied by the factor:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>1</U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">where:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A = the nominal share capital before the issue of bonus shares, and</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">B = the total nominal value of the bonus shares.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hvis det justerede antal anparter ikke er et helt tal, skal der afrundes nedad til det n&aelig;rmeste hele tal.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If the adjusted number of shares does not amount to a whole number, the number shall be rounded down to the nearest whole number.</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.6.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Kapital&aelig;ndringer til en anden kurs end markedskursen</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Changes of capital at a price different from the market price</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hvis det besluttes at forh&oslash;je eller neds&aelig;tte anpartskapitalen i Selskabet til en kurs under markedskursen (vedr&oslash;rende kapitalneds&aelig;ttelser ogs&aring; til over markedskursen), skal warrants justeres som
f&oslash;lger:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If it is decided to increase or decrease the share capital in the Company at a price below the market price (in relation to capital decreases also above the market price), warrants shall be adjusted as follows:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Udnyttelsesprisen p&aring; enhver endnu ikke udnyttet warrant ganges med faktoren:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The exercise price for each <FONT STYLE="white-space:nowrap">non-exercised</FONT> warrant shall be multiplied by the factor:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> = &#8195;<U>(A x K) + (B x T)</U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8195;&#8194;&#8195;&#8195;(A+B) x K</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">og antallet af endnu ikke udnyttede warrants ganges med faktoren</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>1</U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">hvor:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A = den nominelle anpartskapital f&oslash;r &aelig;ndringen i kapitalen</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">B = den nominelle &aelig;ndring i anpartskapitalen</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">K = anpartens markedskurs / lukkekurs dagen forinden annoncering af &aelig;ndringen i anpartskapitalen, og</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">T = tegningskurs/neds&aelig;ttelseskurs ved &aelig;ndringen i anpartskapitalen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> = &#8195;<U>(A x K) + (B x T)</U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;&#8194;&#8195;(A+B) x K</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and the number of <FONT STYLE="white-space:nowrap">non-exercised</FONT> warrants shall be multiplied by the factor:</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>1</U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">where:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A = nominal share capital before the change in capital</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">B = nominal change in the share capital</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">K = market price / closing price of the share on the day prior to the announcement of the change in the share capital, and</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">T = subscription price/reduction price in relation to the change in the share
capital</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hvis det det justerede antal anparter ikke er et helt tal, skal der afrundes nedad til det n&aelig;rmeste hele tal.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If the adjusted number of shares does not amount to whole numbers, each number shall be rounded down to the nearest whole number.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.7.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&AElig;ndringer i den enkelte anparts p&aring;lydende v&aelig;rdi</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Changes in the nominal value of each individual share</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hvis det besluttes at &aelig;ndre anparternes p&aring;lydende v&aelig;rdi, skal warrants justeres som f&oslash;lger:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If it is decided to change the nominal value of the shares, warrants shall be adjusted as follows:</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Udnyttelsesprisen p&aring; enhver endnu ikke udnyttet warrant ganges med faktoren:</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> = &#8195;<U>&#8195;A&#8195;</U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8194;&#8201;B</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">og antallet af endnu ikke udnyttede warrants ganges med faktoren:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>1</U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">hvor:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A = den enkelte anparts nominelle v&aelig;rdi efter &aelig;ndringen, og</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">B = den enkelte anparts nominelle v&aelig;rdi f&oslash;r &aelig;ndringen.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Hvis det justerede antal anparter ikke er et helt tal, skal der afrundes nedad til det n&aelig;rmeste hele tal.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exercise price for each <FONT STYLE="white-space:nowrap">non-exercised</FONT> warrant shall be multiplied by the factor:</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> = &#8195;<U>&#8195;A&#8195;</U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8194;&#8201;B</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and the number of <FONT STYLE="white-space:nowrap">non-exercised</FONT> warrants shall be multiplied by the factor:</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>1</U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">where:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A = nominal value of each share after the change, and</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">B = nominal value of each share before the change.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">the adjusted number of shares does not amount to a whole number, the number shall be rounded down to the nearest whole number.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.8.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Udbetaling af udbytte</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Payment of dividend</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hvis det besluttes at udbetale udbytte, skal udbyttet, medf&oslash;re en justering af udnyttelsesprisen efter f&oslash;lgende formel:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If it is decided to pay dividends, the dividends shall lead to adjustment of the exercise price according to the following formula:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E2 = E1 - <U>U</U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195;&#8201;A</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">hvor:</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E2 = den justerede udnyttelsespris</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E1 = den oprindelige udnyttelsespris</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U = det udbetalte udbytte og</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">A = det samlede antal anparter i Selskabet.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E2 = E1 - <U>U</U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195;&#8201;A</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">where:</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E2 = the adjusted exercise price</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E1 = the original exercise price</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U = dividends paid out and</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">A = total number of shares in the
Company.</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.9.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Andre &aelig;ndringer i Selskabets kapitalforhold</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Other changes to the Company&#8217;s capital structure</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hvis der sker andre &aelig;ndringer i Selskabets kapitalforhold, der medf&oslash;rer en &aelig;ndring i warrants &oslash;konomiske v&aelig;rdi, skal warrant (medmindre andet er angivet ovenfor) justeres, s&aring;ledes at
&aelig;ndringen ikke p&aring;virker warrants &oslash;konomiske v&aelig;rdi.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">In the event of other changes in the Company&#8217;s capital structure causing changes to the financial value of warrants, warrants shall (unless otherwise indicated above) be adjusted to the effect that the changes do not influence
the financial value of the warrants.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Den beregningsmetode, der skal anvendes ved justeringen, fasts&aelig;ttes af Selskabet.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The calculation method to be applied to the adjustment shall be decided by the Company.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Det pr&aelig;ciseres, at forh&oslash;jelse eller neds&aelig;ttelse af Selskabets anpartskapital til markedskurs ikke medf&oslash;rer, at der skal finde regulering sted af tegningskursen eller antallet af anparter, der kan
tegnes.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">It is emphasized that increase or decrease of the Company&#8217;s share capital at market price does not lead to an adjustment of the subscription price or the number of shares to be subscribed.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.10.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Likvidation</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Liquidation</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hvis Selskabet bliver likvideret, fremskyndes et evt. optjeningstidspunkt for alle ikke-optjente warrants, s&aring;ledes at Warrantindehaveren kan udnytte warrants i en ekstraordin&aelig;r udnyttelsesperiode umiddelbart f&oslash;r
likvidationens afslutning.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Should the Company be liquidated, the vesting time, if any, for all unvested warrants shall be changed so that the Warrantholder may exercise his/her warrants in an extraordinary exercise period immediately preceding completion of
the liquidation.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.11.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Fusion og spaltning</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Merger and split</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hvis Selskabet indg&aring;r i en fusion som det forts&aelig;ttende selskab, bliver warrants ikke p&aring;virket, medmindre der i forbindelse med fusionen sker en kapitalforh&oslash;jelse til en anden kurs end markedskursen, idet
warrants i s&aring; fald justeres i henhold til punkt 5.6.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If the Company merges as the continuing company, warrants shall remain unaffected unless, in connection with the merger, the capital is increased at a price other than the market price and in that case warrants shall be adjusted in
accordance with clause 5.6.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hvis Selskabet fusionerer som det oph&oslash;rende selskab eller bliver spaltet, kan de(t) forts&aelig;ttende selskab(er) v&aelig;lge &eacute;n af f&oslash;lgende muligheder:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If the Company merges as the terminating company or is split, the continuing company(ies) may choose one of the following options:</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrantindehaveren kan umiddelbart inden fusionen/spaltningen udnytte alle ikke udnyttede warrants, der ikke er bortfaldet (inklusive warrants der endnu ikke er optjent), eller warrants bliver erstattet af nye
anpart/anpartsinstrumenter i de(t) forts&aelig;ttende selskab(er) af tilsvarende &oslash;konomisk v&aelig;rdi f&oslash;r skat. Ved spaltning kan de forts&aelig;ttende selskaber selv bestemme, i hvilke(t) selskab(er) Warrantindehaveren skal modtage
de nye anpart/anpartsinstrumenter.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Warrantholder may exercise all <FONT STYLE="white-space:nowrap">non-exercised</FONT> warrants that are not declared null and void (inclusive of warrants not yet vested) immediately before the merger/split, or new share
instruments in the continuing company(ies) of a corresponding financial <FONT STYLE="white-space:nowrap">pre-tax</FONT> value shall replace the warrants. In case of a demerger, the continuing company(ies) may decide in which company(ies) the
Warrantholder shall receive the new share instruments.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.12.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Salg og anpartsombytning</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Sale and exchange of shares</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hvis mere end 50% af anpartskapitalen i Selskabet bliver solgt (ikke tegnet eller udstedt) eller indg&aring;r i en anpartsombytning, kan Selskabet v&aelig;lge &eacute;n af f&oslash;lgende muligheder:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If more than 50&nbsp;per cent of the share capital of the Company is sold (not subscribed for or issued) or is part of a share swap, the Company may choose one of the following options:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">d)&#8195;&#8202;Warrantindehaveren kan umiddelbart inden salget/anpartsombytningen udnytte alle
ikke-udnyttede warrants, der ikke er bortfaldet (inklusive warrants der endnu ikke er optjent). Herudover indtr&aelig;der der en pligt, hvorefter Warrantindehaveren skal s&aelig;lge de tegnede anparter p&aring; samme vilk&aring;r som de
&oslash;vrige anpartshavere (ved salg).</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">e)&#8195;&#8201;Tildelte warrants erstattes af anpartsinstrumenter i det erhvervende selskab af tilsvarende
&oslash;konomisk v&aelig;rdi f&oslash;r skat.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">f)&#8195;&#8201;&#8202;Tildelte warrants forts&aelig;tter u&aelig;ndret.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">d)&#8195;&#8202;The Warrantholder may exercise all
<FONT STYLE="white-space:nowrap">non-exercised</FONT> warrants that are not declared null and void (inclusive of warrants not yet vested) immediately before the sale/swap of shares. Furthermore, the Warrantholder shall undertake an obligation to
sell the subscribed shares on the same conditions as the other shareholders (when selling)</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">e)&#8195;&#8201;Share instruments in the acquiring company of a corresponding
<FONT STYLE="white-space:nowrap">pre-tax</FONT> value shall replace the issued warrants.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">f)&#8195;&#8201;&#8202;Issued warrants continue unchanged.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.13.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>F&aelig;lles bestemmelser for punkt <FONT STYLE="white-space:nowrap">5.10-5.12</FONT></U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>General provisions for clauses <FONT STYLE="white-space:nowrap">5.10-5.12</FONT></U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Selskabet er forpligtet til at give Warrantindehaveren skriftlig meddelelse, hvis en af de ovenfor n&aelig;vnte transaktioner finder sted. N&aring;r Warrantindehaveren har modtaget den skriftlige meddelelse, har Warrantindehaveren
&#8211; i de tilf&aelig;lde, hvor</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If one of the transactions mentioned above is made, the Company shall inform the Warrantholder hereof by written notice. Upon receipt of the written notice, the Warrantholder shall &#8211; in cases where the Warrantholder may
extraordinarily exercise warrants, see clauses <FONT STYLE="white-space:nowrap">5.10-5.12</FONT> &#8211;</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrantindehaveren ekstraordin&aelig;rt kan udnytte warrants, jf. punkt <FONT STYLE="white-space:nowrap">5.10-5.12</FONT> &#8211; 2 uger til skriftligt at informere Selskabet om, hvorvidt han/hun vil g&oslash;re brug af tilbuddet.
Hvis Warrantindehaveren ikke har givet Selskabet skriftligt svar inden <FONT STYLE="white-space:nowrap">2-uger</FONT> eller undlader at betale inden for den betalingsfrist, der er fastsat, bortfalder warrants uden yderligere varsel og uden
kompensation. Udnyttelseskursen kan ikke komme under anparternes nominelle v&aelig;rdi.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">inform the Company in writing whether he/she will make use of the offer. If the Warrantholder has not answered the Company in writing within 2 weeks or fails to pay within the fixed time, warrants shall become null and void without
further notice or compensation. The exercise price cannot go below the nominal value of the shares.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrantindehaverens rettigheder i anledning af en beslutning truffet af et kompetent organ i Selskabet, jf. punkt <FONT STYLE="white-space:nowrap">5.10-5.12,</FONT> er betinget af, at den relevante beslutning efterf&oslash;lgende
registreres i Erhvervsstyrelsen, hvis registrering er en gyldighedsbetingelse.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Warrantholder&#8217;s rights in connection with decisions made by any competent company body, see clauses <FONT STYLE="white-space:nowrap">5.10-5.12,</FONT> shall be contingent on subsequent registration of the relevant decision
with the Danish Business Authority if registration is a condition of its validity.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">6.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>OVERGANG AF WARRANTS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>ASSIGNMENT OF WARRANTS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">6.1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tildelte warrants kan ikke g&oslash;res til genstand for udl&aelig;g, overdrages eller p&aring; anden m&aring;de overf&oslash;res, ej heller i forbindelse med bodeling, og hverken til eje eller til sikkerhed, uden bestyrelsens
samtykke. Warrantindehaverens warrants kan dog overg&aring; til Warrantindehaverens &aelig;gtef&aelig;lle/samlever og/eller livsarvinger i tilf&aelig;lde af Warrantindehaverens d&oslash;d. Det er en betingelse herfor, at modtageren underskriver den
g&aelig;ldende Warrantaftale samt, s&aring;fremt dette kr&aelig;ves af bestyrelsen, en ejeraftale.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrants shall not be subject to charging orders, transfer of any kind, including in connection with division of property on divorce or legal separation, for ownership or as security without the consent of the board of directors.
The Warrantholder&#8217;s warrants may, however, be transferred to the Warrantholder&#8217;s spouse/cohabitant and/or heirs of the body in the event of the Warrantholder&#8217;s death. It is a condition precedent that the recipient signs the
applicable Warrant Agreement and, to the extent required by the board of directors a shareholders&#8217; agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">7.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>TEGNING AF ANPARTER VED UDNYTTELSE AF WARRANTS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>SUBSCRIPTION FOR SHARES BY EXERCISE OF WARRANTS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">7.1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tegning af anparter ved udnyttelse af warrants finder sted ved, at Warrantindehaveren afleverer en af Selskabet udarbejdet udnyttelsesmeddelelse til Selskabet senest kl. 16:00 CET den sidste dag i den</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Subscription for shares by exercise of warrants must be made through submission by the Warrantholder no later than the last day of the relevant exercise period at 16:00 CET to the Company of an exercise notice prepared by the
Company.</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">relevante udnyttelsesperiode. Udnyttelsesmeddelelsen skal v&aelig;re udfyldt med alle p&aring;kr&aelig;vede informationer. Udnyttelsesprisen for de nye anparter, der skal betales ved et kontant indskud, skal v&aelig;re modtaget af
Selskabet senest tre dage efter, at Selskabet har modtaget udnyttelsesmeddelelse fra Warrantindehaveren.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The exercise notice shall be completed with all required information. The Company must have received the exercise price payable for the new shares in cash no later than three days after the Company has received exercise notice from
the Warrantholder.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">7.2.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hvis den i punkt. 7.1 angivne frist overskrides, enten s&aring;ledes at udnyttelsesmeddelelsen i udfyldt stand eller betalingen ikke er Selskabet i h&aelig;nde inden kl. 16:00 CET p&aring; den sidste dag i udnyttelsesperioden, anses
tegningen for ugyldig, og Warrantindehaveren kan i denne situation ikke anses for herved at have udnyttet sine warrants for en eventuel efterf&oslash;lgende udnyttelsesperiode.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If the limitation period set forth in clause 7.1 expires as a result of the Company not having received the duly completed exercise notice or the payment by 16:00 CET of the last day of the exercise period, the subscription shall be
deemed invalid, and in this event the Warrantholder shall not be considered as having exercised his/her warrants for a possible subsequent exercise period.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">7.3.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">De warrants, som Warrantindehaveren ikke har udnyttet i den sidste udnyttelsesperiode, bortfalder uden yderligere varsel og uden kompensation.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrants not exercised by the Warrantholder during the last exercise period shall become null and void without further notice and without compensation.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">7.4.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">N&aring;r den kapitalforh&oslash;jelse, som udnyttelsen af warrants har medf&oslash;rt, er registreret i Erhvervsstyrelsen, modtager Warrantindehaveren dokumentation for sit ejerskab til anparter i Selskabet.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">When the capital increase caused by exercise of warrants has been registered with the Danish Business Authority, the Warrantholder shall receive proof of his shareholding in the Company.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">7.5.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Forud for udnyttelse skal Warrantindehaveren, s&aring;fremt dette kr&aelig;ves af bestyrelsen, tiltr&aelig;de Selskabets til enhver tid g&aelig;ldende ejeraftale eller en s&aelig;rskilt ejeraftale omfattende de af Selskabets
anpartshavere, som har tegnet anparter ved udnyttelse af warrants. Det samme g&aelig;lder Warrantindehaverens arvinger /d&oslash;dsbo.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Prior to exercise of warrants, the Warrantholder shall adhere to the Company&#8217;s shareholders&#8217; agreement or a separate shareholders&#8217; agreement comprising those shareholders of the Company that have subscribed for
shares by exercise of warrants. The same applies to the heirs/estate of the Warrantholder.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">7.6.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrantindehaveren er bekendt med og accepterer, at de i punkt 7.5 n&aelig;vnte ejeraftaler kan indeholde (i)&nbsp;forpligtelser til at s&aelig;lge anparterne ved Warrantindehaverens fratr&aelig;den, uanset</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Warrantholder accepts and acknowledges that the shareholders&#8217; agreements referred to in clause 7.5 may contain (i)&nbsp;obligations to sell shares upon termination of the
Warrantholder&#8217;s</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&aring;rsag, til en pris der kan afvige fra markedsv&aelig;rdien, (ii)&nbsp;konkurrence- og kundeklausuler, (iii)&nbsp;bestemmelser om bortfald af fortegningsret og bestemmelser indeholdende salgsbegr&aelig;nsninger og
(iv)&nbsp;andre restriktioner p&aring; Warrantindehaveren, som kan v&aelig;re byrdefulde.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">employment or other association with the Company, irrespective of the cause, at a price which may deviate from the market value; <FONT STYLE="white-space:nowrap">(ii)&nbsp;non-competition</FONT> and
<FONT STYLE="white-space:nowrap">non-solicitation</FONT> clauses; (iii)&nbsp;provisions on the abandonment of participation rights and provisions containing sales restrictions and (iv)&nbsp;other restrictions on the Warrantholder that may be
burdensome.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">8.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>VILK&Aring;R FOR NYE ANPARTER</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>TERMS APPLICABLE TO NEW SHARES</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">8.1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Udover de ovenfor anf&oslash;rte vilk&aring;r g&aelig;lder f&oslash;lgende vilk&aring;r for de til de udstedte warrants h&oslash;rende kapitalforh&oslash;jelser:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">In addition to the terms and conditions set forth above, the following terms and conditions shall apply to the increases of the share capital, which are associated with the warrants:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">De nye anparter udstedes i anparter &agrave; DKK 1,</P></DIV></DIV>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">De nye anparter skal give ret til udbytte i Selskabet for det l&oslash;bende regnskabs&aring;r, hvori anparterne tegnes, p&aring; lige fod med de
eksisterende ordin&aelig;re anparter og andre rettigheder i selskabet fra og med datoen for tegningen af anparterne,</P></DIV></DIV>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">De nye anparter skal tilh&oslash;re samme anpartsklasse, som de eksisterende ordin&aelig;re anparter i Selskabet,</P></DIV></DIV>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">Kapitalforh&oslash;jelsen sker uden fortegningsret for de hidtidige anpartshavere, idet tegningen sker p&aring; baggrund af warrants udstedt til
Warrantindehavere,</P></DIV></DIV> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">Der skal ikke g&aelig;lde indskr&aelig;nkninger i den til de nye anparter knyttede fortegningsret ved fremtidige kapitalforh&oslash;jelser udover det
i vedt&aelig;gternes punkt 3.6 anf&oslash;rte,</P></DIV></DIV></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">The new shares will be divided into shares of nominally DKK 1 each;</P></DIV></DIV>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">The new shares will carry dividend rights for the financial year in which subscription takes place on equal terms with the existing ordinary shares
as well as other rights in the Company as from the day of subscription of the shares;</P></DIV></DIV>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">The new shares shall belong to the same share class as the existing ordinary shares in the Company;</P></DIV></DIV>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">The capital increase shall be made without any <FONT STYLE="white-space:nowrap">pre-emption</FONT> rights for the existing shareholders, given that
the subscription is based on warrants issued to the Warrantholders;</P></DIV></DIV>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">pre-emption</FONT> rights attached to the new shares shall not be subject to any restrictions in the event of
future capital increases besides what is stated in article 3.6 of the articles of association;</P></DIV></DIV></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">Fristen for tegning af de nye anparter beregnes p&aring; baggrund af bestemmelserne ovenfor,</P></DIV></DIV>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">Det fulde bel&oslash;b til tegning af det antal anparter, som de omfattede Warrantindehavere &oslash;nsker at tegne, skal indbetales kontant som
beskrevet ovenfor og senest samtidig med tegningen af de p&aring;g&aelig;ldende anparter,</P></DIV></DIV>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">Der skal g&aelig;lde indskr&aelig;nkninger i de nye anparters oms&aelig;ttelighed, idet enhver overgang af anparter i henhold til vedt&aelig;gternes
punkt 3.5 kr&aelig;ver bestyrelsens godkendelse, og</P></DIV></DIV> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">De nye anparter skal lyde p&aring; navn, noteres i Selskabets ejerbog og v&aelig;re
<FONT STYLE="white-space:nowrap">ikke-oms&aelig;tningspapirer.</FONT></P></DIV></DIV></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">The deadline for subscription of the new shares shall be calculated pursuant to the provisions set forth above;</P></DIV></DIV>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">The full subscription amount for the number of shares which the Warrantholders wish to subscribe for, shall be paid in cash as described above and no
later than on the day of subscription of the shares in question;</P></DIV></DIV> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">The new shares will be subject to restrictions on transferability as any share transfer requires approval from the board of directors pursuant to
article 3.5 of the articles of association; and</P></DIV></DIV> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="margin-top:0pt;margin-bottom:0pt; display: table-row;"><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.500000em; font-family:Times New Roman">&#149;</P></DIV><DIV STYLE="display: table-cell">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.150000em; font-family:Times New Roman">The new shares shall be made out in the name of the holder, be recorded in the Company&#8217;s register of shareholders and be <FONT
STYLE="white-space:nowrap">non-negotiable</FONT> instruments.</P></DIV></DIV></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">9.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>LOVVALG OG V&AElig;RNETING</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>LAW AND VENUE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">9.1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tegningen af warrants, vilk&aring;rene herfor og udnyttelsen, samt vilk&aring;rene for senere tegning af anparter i Selskabet skal reguleres af dansk ret.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The grant of warrants, the associated terms and conditions and the exercise, as well as the terms and conditions for future subscription of shares in the Company shall be governed by Danish law.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">9.2.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hvis der m&aring;tte opst&aring; en tvist mellem Warrantindehaveren og Selskabet i relation til forst&aring;elsen eller gennemf&oslash;relsen af warrantprogrammet, skal denne s&oslash;ges bilagt i mindelighed ved forhandling mellem
parterne.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Any disagreement between the Warrantholder and the Company in relation to the understanding or implementation of the warrant scheme shall be settled amicably by negotiation between the
parties.</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">9.3.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hvis parterne ikke kan opn&aring; enighed, skal eventuelle tvister afg&oslash;res ved de almindelige danske domstole.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If the parties fail to reach consensus, any disputes shall be settled by the ordinary Danish courts.</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Appendix 3.15 to the articles of association </I></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Hemab ApS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Company Reg.
Number 40837590 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ole Maaloes Vej 3 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2200 Copenhagen </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Denmark
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(the &#8220;Company&#8221;) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>A<SMALL>DDENDUM</SMALL> <SMALL>TO</SMALL> A<SMALL>PPENDIX</SMALL> 3.14 <SMALL>OF</SMALL> <SMALL>THE</SMALL> A<SMALL>RTICLES</SMALL>
<SMALL>OF</SMALL> A<SMALL>SSOCIATION</SMALL> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERMS AND CONDITIONS APPLICABLE TO WARRANTS ISSUED BY THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPANY TO FRENCH PARTICIPANTS UNDER THE FRENCH BSPCE REGIME </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Article 163 bis G of the French tax code) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
document (the &#8220;<B>Terms and Conditions</B>&#8221;) must be read and applied in conjunction with the provisions of the Articles of Association of the Company (the &#8220;<B>Articles of Association</B>&#8221;), including the Warrants terms
provided for by Appendix 3.14 pertaining to the issuance of warrants by the Company (&#8220;<B>Warrant Terms</B>&#8221;), and any subsequent legal document as it aims at ensuring the qualification of warrants issued by the Company to French
participants to the <FONT STYLE="white-space:nowrap">so-called</FONT> French BSPCE regime provided for by Article 163 bis G of the French tax code and Article L. <FONT STYLE="white-space:nowrap">228-92</FONT> of the French commercial code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company hereby states that it is registered in France with the French register of companies under registration number (SIREN) 923973358. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any deviation provided for by those Terms and Conditions must be construed as supplementing, and superseding in case of variation or addition, to the
provisions of the Articles of Association, including the Warrant Terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RECITALS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the authorisation set out in article 3.13 of the Articles of Association, the board of directors of the Company has resolved that
the below terms and conditions shall apply to warrants, which are granted to French tax resident employees and/or corporate officers who are subject to the French Employee Tax Regime provided for by Article 163 bis G of the French Tax Code in order
to ensure compliance and application of the French legal and tax regime relating to <I>bons de souscription de part de cr&eacute;ateur d&#8217;entreprise</I> (hereinafter the &#8220;<B>BSPCE</B>&#8221;) to awards of warrants granted by the Company
to any French participant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Warrants Terms shall, subject to the modifications, variation and addition set out in these Terms and
Conditions, remain the applicable rules for the grant of warrants by the Company to French tax resident employees and/or corporate officers who are subject to the French Employee Tax Regime (&#8220;<B>French Participants</B>&#8221;). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Definitions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Terms defined by the Warrant Terms are applicable to the Terms and Conditions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the sake of clarity, as used herein, the following definitions shall apply: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="78%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#8221;Board&#8221;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Board of Directors of the Company as defined in the Articles of Association.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#8221;Beneficiary&#8221; or &#8220;French Participant&#8221;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">French tax resident employees and/or corporate officers of the Company (or any subsidiary) who are subject to the French Employee Tax Regime. The term &#8220;Beneficiary&#8221; also refers to their heirs or legatees in case of a
Beneficiary passes away.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#8221;BSPCE&#8221; or &#8220;warrants&#8221;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Bons de souscription de parts de cr&eacute;ateur d&#8217;entreprise</I> under French legislation which are meant to be viewed as the French equivalent of warrants issued by the Company under Danish legislation, for the purpose of
ensuring the application of the French legal and tax regime to the French participants.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#8221;BSPCE Agreement&#8221;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Agreement between the Company and a Beneficiary providing for the allotment of warrants under the French BSPCE regime to such Employee, entered into by the Company and the Employee in accordance with the procedure described in
Section&nbsp;2.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#8220;Executive Functions&#8221;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Functions exercised as a corporate officer subject to the French Employee Tax Regime, if applicable.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#8221;Exercise Notice&#8221;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Such notice as shall be filled in and signed by the Beneficiary and delivered to the Company upon exercise of warrants/BSPCEs according to the Warrant Terms and these Terms and Conditions.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#8221;Exercise Period&#8221;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The period when warrants/BSPCEs become exercisable according to the Warrant Terms, the BSPCE Agreement and these Terms and Conditions.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#8221;Exercise Price&#8221;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The price determined by the Board of Directors at the issuance of the warrants/BSPCEs to be paid per Share upon exercise of a warrant/BSPCE according to the BSPCE Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#8220;Grant&#8221;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Decision of the Board of Directors to allot warrants/BSPCEs to the Beneficiary.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#8221;Group&#8221;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Company and its Subsidiaries from time to time.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#8221;Share&#8221;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">One ordinary share of nominal value of DKK 1 in the Company.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#8221;Subsidiary&#8221;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Company&#8217;s subsidiaries held at more than 75% (75% of the voting rights or 75% of the share capital) and employing a Beneficiary, if any.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#8221;Terms and Conditions&#8221;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">These terms and conditions to be read and applied in conjunction with the Warrant Terms and the Articles of Association.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#8220;Vesting Schedule&#8221;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Means, in relation to any Beneficiary, the Vesting Date(s) specified in the Warrant Terms, as reiterated herein, and the BSPCE Agreement entered into with a Beneficiary.</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Offer and Grant of warrants of the Company under the French BSPCE regime </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company acknowledges that it complies with the provisions of Article 163 bis G of the French tax code to issue warrants to French
participants under the French BSPCE regime. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Board will decide to allot from <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">time-to-time</FONT></FONT> warrants of the Company to Beneficiaries under the French BSPCE regime by sending an electronically signed copy of the BSPCE Agreement, these Terms and Conditions and the Warrant Terms to the
Beneficiaries by <FONT STYLE="white-space:nowrap">e-mail.</FONT> The offer will include information about the number of warrants/BSPCEs offered to issuance. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Grant of warrants/BSPCEs has no immediate economic consequences for the Beneficiary. The value of the warrants/BSPCEs &#8211; if
any&#8212;will not form part of the calculation of holiday allowances, pension contributions or other contributions or payments, which are based on the Beneficiary&#8217;s remuneration from the Company or its subsidiaries, if any. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">By signing the BSPCE Agreement electronically, and sending it to the Company, the Beneficiary accepts the offer in the BSPCE Agreement. The
acceptance must be received by the Company on the date set out in the BSPCE Agreement at the latest. If the Company receives the acceptance by the deadline set out in the BSPCE Agreement, the Board will allot the offered number of warrants/BSPCEs to
the Beneficiary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The BSPCE Agreement and these Terms and Conditions supplementing the Warrant Terms specify the terms and conditions
attached to the warrants granted to a Beneficiary under the French BSPCE regime. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If the Company receives the acceptance after the deadline
set out in the BSPCE Agreement, the Beneficiary is not entitled to be allotted any warrant/BSPCE. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The offer, acceptance and grant
procedure above may be changed from time to time by the Company for any reason. The Beneficiary will be notified of such changes. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Specific features of the warrants issued under the French BSPCE regime </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Each BSPCE confers a right, but not an obligation, on the Beneficiary to acquire one new Share of the Company by making a cash payment of the
Exercise Price during the Exercise Period. This right is however subject to the terms and conditions of the Warrant Terms, BSPCE Agreement and these Terms and Conditions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Exercise Price and the number of Shares that each BSPCE confers a right to acquire shall be proportionately adjusted where required
according to the Clause 5. of the Warrant Terms. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Article 163 <I>bis</I> G of the French Tax Code, the warrants/BSPCEs are not
transferable, they may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by the laws of descent or inheritance. The Beneficiary undertakes to ensure that his/her warrants/BSPCEs shall constitute
private property within any existing or future marriages. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The warrants/BSPCEs may, during the lifetime of the Beneficiary, be exercised by
the Beneficiary only. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Vesting </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The provisions of Warrant Terms relating to vesting fully applies to warrants/BSPCEs granted to a Beneficiary. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In accordance with the Warrant Terms, granted warrants/BSPCEs will vest over a four-year period, in accordance with the following schedule:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">25% of the granted warrants/BSPCEs vests on the 1<SUP STYLE="font-size:75%; vertical-align:top">st</SUP>
anniversary of the grant date; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The remaining 75% of the granted BSPCEs vests with 1/36 per month from one year after the grant date.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The granted warrants/BSPCEs will fully vest on the 4<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> anniversary
of the grant date subject to the Beneficiary still being an employee or a corporate officer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Board shall, however, be entitled to
deviate from the Vesting Schedule set out above and determine that warrants/BSPCEs shall be deemed to vest as of the date of issuance or that special rules shall apply in relation to vesting. Such deviations, if any, shall be specified in the BSPCE
Agreement as amended, in connection with the grant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As regards accelerated Vesting of warrants/BSPCEs in connection with an exit,
liquidation, merger, demerger or sale of the Company, reference is made to Clauses 3.4, 5.10, 5.11 and 5.12 of the Warrant Terms. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Vesting
requires that the Beneficiary be still employed by the Group as of the day when the relevant Vesting occurs, unless the Beneficiary terminates his/her employment contract or his/her Executive Functions, and the termination is caused by a material
breach by the Company or its Subsidiaries of their obligations towards the Beneficiary. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Leaver provisions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The provisions of the Warrant Terms fully apply to warrants issued under these Terms and Conditions subject to the following precisions in
order to comply with the prohibition of financial sanctions provided under Article L. <FONT STYLE="white-space:nowrap">1331-2</FONT> of the French labour code. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Good Leaver </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If the Beneficiary&#8217;s employment or Executive Functions in the Group cease by any reason other than those set out in Section&nbsp;5.2, he
or she is entitled to keep the warrants/BSPCEs granted to him/her that have vested as per the last employment or executive functions. The Beneficiary shall be entitled to exercise vested warrants/BSPCEs during the period
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
from termination of the employment or Executive Functions until 90 days after termination of such employment or Executive Functions, after which all unexercised warrants/BSPCEs shall become null
and void without further notice and without compensation or payment of any kind. Any <FONT STYLE="white-space:nowrap">non-vested</FONT> warrants/BSPCEs shall lapse automatically and not be capable of exercise or further vesting. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Bad Leaver </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If the Beneficiary&#8217;s employment or Executive Functions in the Group ceases as a result of termination of the employment or Executive
Functions by the employer due to a material breach by the Beneficiary of his/her obligations towards the Company whether or not qualified as a <I>faute lourde</I> under the meaning set forth by the French <I>Cour de cassation</I>, <FONT
STYLE="white-space:nowrap">non-vested</FONT> warrants/BSPCEs allotted to him/her shall immediately lapse upon termination and not be capable of exercise. At the discretion of the Board, exercise of vested warrants/BSPCEs may be authorized during the
leave period notified by the Company. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Death </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">To comply with French mandatory provisions relating to the BSPCE regime, the beneficiary&#8217;s death triggers the accelerated vesting of the
warrants/BSPCEs which become immediately exercisable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Based on article 163 bis G of the French Tax Code, his or her heirs or legatees
shall have a period of six month from the date of death to notify the Company of their decision to exercise the Beneficiary&#8217;s warrants/BSPCEs. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The BSPCE that are not exercised by the heirs or legatees at the expiry date of this <FONT STYLE="white-space:nowrap">six-month</FONT> period
will become null and void. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exercise of BSPCE </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The provisions of the Warrant Terms fully apply to warrants issued under those Terms and Conditions subject to the following precisions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Beneficiary may only exercise vested warrants/BSPCEs at any time during the Exercise Period, as agreed in the Warrants Terms and BSPCE
Agreement, subject to the Leaver Provisions set out in Sections 5.1. and 5.2. of these Terms and Conditions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Beneficiary may exercise
part or all the vested BSPCEs, in one or several time during the Exercise Period. However, it is a precondition that upon each exercise the Beneficiary exercises the lower of (a)&nbsp;all of his/her vested BSPCEs and (b)&nbsp;vested BSPCEs, which
provides for subscription of minimum nominally DKK 2,000 Shares in the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company may at its discretion extend the exercise
period. In addition, the Company is, in the event of a listing of the Company on a stock exchange, entitled at its discretion to change the exercise period in order to adapt the exercise period to applicable rules on insider trading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The subscription of Shares by exercise of warrants/BSPCEs is carried out in accordance with the procedure described in Clause 7 of the Warrant
Terms. Upon termination of the Beneficiary&#8217;s employment or Executive Functions with the Company, whether for material breach or not and irrespective of the French labour law grounds on which any redundancy procedure is initiated, the sales
price of the Participant&#8217;s Shares cannot be lower than the fair market value at the termination date. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The warrants/BSPCEs that are not exercised by the Beneficiary at the expiry of the Exercise
Period shall become null and void (i.e. no longer exercisable) without further notice and without compensation or payment of any kind to the Beneficiary. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Taxes and other fees </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Beneficiary shall be responsible for the payment of all taxes and/or fees which may be payable in respect of the holding or exercise of
BSPCEs, as a consequence of French or foreign legislation or decisions of French or foreign governmental authorities. If required, the Company and its Subsidiaries shall also have the right to withhold taxes and/or fees related to the BSPCEs from
any other cash payments made to the Beneficiary such as salary payments, bonus payments, pension payments etc, if required under French legislation or if the Beneficiary is no longer a French tax resident at the time of exercise of the
warrants/BSPCEs or sale of the Participant&#8217;s Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company and its Subsidiaries shall be responsible for payment of the social
security contributions payable by the Company and its Subsidiaries by law in the respective jurisdiction in respect of the Beneficiary&#8217;s holding or exercise of BSPCEs, as a consequence of French or foreign legislation or decisions of French or
foreign governmental authorities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company will send to the Beneficiary, upon request, any certificate acknowledging the duration of
the presence in the Company upon the date of exercise of the BSPCE, in order to benefit, where applicable, from the favourable tax treatment thereof provided under Article 163 bis G of the French tax code. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Employment Right </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Grant and allotment of warrants/BSPCEs in accordance with the BSPCE Agreement and the Terms and Conditions is made at the sole discretion
of the Board. Nothing in the BSPCE Agreement or the Terms and Conditions, or any warrants/BSPCEs offered or allotted hereunder shall confer upon the Beneficiary, any right with respect to continuation of employment with the Company or a Subsidiary,
nor shall it interfere in any way with the Beneficiary&#8217;s or the Company&#8217;s or a Subsidiary&#8217;s right to terminate or alter the terms and conditions of the employment relationship at any time. The offer and allotment of warrants/BSPCEs
in accordance with the BSPCE Agreement and the Terms and Conditions does not confer any right for the Beneficiary to be selected to be offered any warrant/BSPCE in any future equity incentive programs (if any). Neither the warrants/BSPCEs nor any
benefits arising under the BSPCE Agreement and these Terms and Conditions shall constitute part of the Beneficiary&#8217;s employment agreement with the Company or any Subsidiary and, accordingly, the BSPCE Agreement and the Terms and Conditions and
the benefits hereunder may be terminated at any time in the sole discretion of the Company. Hence, the warrants/BSPCEs shall not give rise to liability and not be included in the basis for pension rights, severance payments, damages or other benefit
or compensation from the Company or any Subsidiary. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Data Protection </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company and its Subsidiaries may collect and process personal data relating to the Beneficiary for the purpose of fulfilling their
obligations notably towards the French tax and social security authorities and exercise their rights under the BSPCE Agreement and the Terms and Conditions, issue certificates (if any), statements and communications relating to the BSPCE Agreement
and the Terms and Conditions, and generally administer and manage the warrants/BSPCEs, including keeping records of participation levels from time to time. Any such processing shall be in accordance with the purpose and provision of this data
protection provision. References in this provision to the Company and its Subsidiaries include the Beneficiary&#8217;s employer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Personal
data about the Beneficiary may be transferred not only within the country in which the Beneficiary is resident or based from time to time or within the EU or the EEA, but also worldwide, to other employees and officers of the Company and its
Subsidiaries and to third parties for the purpose described above. If personal data is exported outside the EU or the EEA, the Company and its Subsidiaries will implement appropriate safeguards by the use of standard data protection clauses, binding
corporate rules or other available solutions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">All national and international transfer of personal data is only done in order to fulfil the
obligations and rights of the Company and/or its Subsidiaries under the BSPCE Agreement and those Terms and Conditions or if the transfer is otherwise necessary to comply with a legal obligation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Personal data may be stored by the Company and its Subsidiaries until their rights and obligations under the BSPCE Agreement and the Terms and
Conditions have been exhausted. The Beneficiary may contact the Company for any matter relating to the processing of its personal data (such as for example access to or correction of it). The Beneficiary may also exercise any additional rights
he/she may have according to applicable law including to lodge complaint with the supervisory authority. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Amendments </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company may without consent from the Beneficiary amend the BSPCE Agreement and these Terms and Conditions to the extent legislation, court
practice or authority regulations so require or if it is appropriate or necessary for practical or economic reasons. The Company may also make other adjustments to the BSPCE Agreement and the Terms and Conditions if significant changes in the
Company or its Subsidiaries or circumstances would result in a situation where the Terms and Conditions become inappropriate to use, including limiting the economic outcome of the Beneficiary&#8217;s participation in the BSPCE Program or terminate
the BSPCE Program, fully or partly. If any provision in the BSPCE Agreement or in the Terms and Conditions, or part thereof, is held to be invalid or is adjusted by court of law or an arbitral tribunal, the remainder of the provision and all other
provisions of the BSPCE Agreement and the Terms and Conditions shall remain valid to the fullest extent permitted by applicable law, and the Company and the Beneficiary shall negotiate loyally with each other with the aim to, if possible, agree on
necessary changes of the BSPCE Agreement and the Terms and Conditions to maintain the structure, purpose and general spirit of the BSPCE Agreement and the Terms and Conditions. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Acknowledgement </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">By entering into the BSPCE Agreement with the Company in accordance with the procedure described in Section&nbsp;2, the Beneficiary
acknowledges receipt of a copy of these Terms and Conditions. The Beneficiary understands and agrees that the granted warrants/BSPCEs are subject to all the terms, conditions, and restrictions stated in the BSPCE Agreement, the Articles of
Association and the Warrant Terms subject to deviation and addition provided for by those Terms and Conditions. The Beneficiary also confirms that he/she has not relied on any tax advice from the Company related to the warrants/BSPCEs. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>6
<FILENAME>d50309dex43.htm
<DESCRIPTION>EX-4.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.3 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INVESTORS&#8217; RIGHTS AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
INVESTORS&#8217; RIGHTS AGREEMENT (this &#8220;<B>Agreement</B>&#8221;) is made as of March&nbsp;30, 2026, by and among Hemab Therapeutics Holdings, Inc., a Delaware corporation (the &#8220;<B>Company</B>&#8221;), the Investors (as defined below)
and the Key Holders (as defined below). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company, the Investors and the Key Holders are parties to that certain Share Contribution and Exchange Agreement of even
date herewith by and among the Company, Hemab ApS, the Investors and the Key Holders (the &#8220;<B>Exchange Agreement</B>&#8221;), under which certain of the Company&#8217;s, such Investors&#8217; and such Key Holders&#8217; obligations are
conditioned upon the execution and delivery of this Agreement by the undersigned parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, the parties agree as
follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Definitions</U>. For purposes of this Agreement: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1 &#8220;<B>Affiliate</B>&#8221; means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is
controlled by, or is under common control with such Person, including, without limitation, any general partner, managing member, officer, director or trustee of such Person, or any venture capital fund or other investment fund now or hereafter
existing that is controlled by one or more general partners, managing members or investment advisers of, or shares the same management company or investment adviser with, such Person. With respect to <FONT STYLE="white-space:nowrap">Al-Rayyan</FONT>
Holding LLC (&#8220;<B>QIA</B>&#8221;), (a) Qatar Investment Authority and any individual, corporation, partnership, firm, joint venture, investment fund, association, trust, unincorporated association or organization, governmental body or other
entity, which controls, is controlled by or is under common control with, QIA, and (b)&nbsp;government entities or instrumentalities of, or entities that are wholly-owned or controlled by, the State of Qatar, the Amiri Diwan of the State of Qatar or
any entities that are wholly-owned or controlled by any one or more of the foregoing under (a)&nbsp;and (b). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2 &#8220;<B>Board of
Directors</B>&#8221; means the board of directors of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3 &#8220;<B>Certificate of Incorporation</B>&#8221; means the
Company&#8217;s Amended and Restated Certificate of Incorporation, as amended and/or restated from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.4 &#8220;<B>Common
Stock</B>&#8221; means shares of the Company&#8217;s common stock, par value $0.0001 per share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.5 &#8220;<B>Damages</B>&#8221; means any
loss, damage, claim or liability (joint or several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect
thereof) arises out of or is based upon: (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein
or any amendments or supplements thereto; (ii)&nbsp;an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii)&nbsp;any violation or alleged
violation by the indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities
law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.6 &#8220;<B>Deemed Liquidation Event</B>&#8221; shall have the meaning ascribed to it in
the Company&#8217;s Amended and Restated Certificate of Incorporation, as in effect on the date of this Agreement and regardless of the date on which such event occurs. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.7 &#8220;<B>Derivative Securities</B>&#8221; means any securities or rights convertible into, or exercisable or exchangeable for (in each
case, directly or indirectly), Common Stock, including options and warrants. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.8 &#8220;<B>DPA</B>&#8221; means Section&nbsp;721 of the
Defense Production Act, as amended, including all implementing regulations thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.9 &#8220;<B>DPA Triggering Rights</B>&#8221; means
(i) &#8220;control&#8221; (as defined in the DPA); (ii) access to any &#8220;material <FONT STYLE="white-space:nowrap">non-public</FONT> technical information&#8221; (as defined in the DPA) in the possession of the Company; (iii)&nbsp;membership or
observer rights on the Board of Directors or equivalent governing body of the Company or the right to nominate an individual to a position on the Board of Directors or equivalent governing body of the Company; or (iv)&nbsp;any
&#8220;involvement,&#8221; other than through the voting of shares, in &#8220;substantive decisionmaking&#8221; of the Company (as defined in the DPA) regarding (x)&nbsp;the use, development, acquisition or release of any Company &#8220;critical
technology&#8221; (as defined in the DPA), (y) the use, development, acquisition, safekeeping, or release of &#8220;sensitive personal data&#8221; (as defined in the DPA) of U.S. citizens maintained or collected by the Company, or (z)&nbsp;the
management, operation, manufacture, or supply of &#8220;covered investment critical infrastructure&#8221; (as defined in the DPA). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.10
&#8220;<B>Ebumab Holding</B>&#8221; means Ebumab Holding ApS, owned by GV1 Holding ApS, Johan H. Faber ApS, Mabe Invest ApS, Wandall Holding ApS (&#8220;<B>Wandall</B>&#8221;) and Batchelor Holding ApS. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.11 &#8220;<B>Exchange Act</B>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated
thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.12 &#8220;<B>Excluded Registration</B>&#8221; means (i)&nbsp;a registration relating to the sale or grant of securities to
employees of the Company or a subsidiary pursuant to a stock option, stock purchase, equity incentive or similar plan (including but not limited to a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-8);</FONT> (ii) a registration
relating to an SEC Rule 145 transaction; or (iii)&nbsp;a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable
Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.13 &#8220;<B>Form <FONT STYLE="white-space:nowrap">S-1</FONT></B>&#8221; means such form under the Securities Act as in
effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.14 &#8220;<B>Form
<FONT STYLE="white-space:nowrap">S-3</FONT></B>&#8221; means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits forward incorporation of
substantial information by reference to other documents filed by the Company with the SEC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.15 &#8220;<B>GAAP</B>&#8221; means generally
accepted accounting principles in the United States as in effect from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.16 &#8220;<B>Holder</B>&#8221; means any holder of
Registrable Securities who is a party to this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.17 &#8220;<B>Immediate Family Member</B>&#8221; means a child, stepchild,
grandchild, parent, stepparent, grandparent, spouse, life partner or similar statutorily recognized domestic partner, sibling, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mother-in-law,</FONT></FONT> <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">father-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">son-in-law,</FONT></FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">daughter-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">brother-in-law,</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">sister-in-law,</FONT></FONT> including adoptive relationships of a natural person referred to herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.18 &#8220;<B>Initiating Holders</B>&#8221; means, collectively, Holders who properly
initiate a registration request under this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.19 &#8220;<B>Investor Majority</B>&#8221; means (a)&nbsp;prior to the IPO, the
holders of at least 50% of the outstanding shares of Preferred Stock, including the holders of at least 60% of the outstanding shares of Series C Preferred Stock and (b)&nbsp;following the IPO, the Investors holding a majority of the then
outstanding shares of Registrable Securities; provided that any shares of Preferred Stock and/or Registrable Securities held by a Sanctioned Party shall be disregarded for the purpose of calculating the percentages set forth in this definition. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.20 &#8220;<B>Investors</B>&#8221; means the persons named on <U>Schedule</U><U></U><U>&nbsp;A</U> hereto, each person to whom the rights of
an Investor are assigned pursuant to <U>Section</U><U></U><U>&nbsp;6.1</U>, and each person who hereafter becomes a party to this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;6.9</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.21 &#8220;<B>IPO</B>&#8221; means the Company&#8217;s first underwritten public offering of its Common Stock under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.22 &#8220;<B>Key Holders</B>&#8221; means the persons named on <U>Schedule</U><U></U><U>&nbsp;B</U> hereto and each person to whom the rights
of a Key Holder are assigned pursuant to <U>Section</U><U></U><U>&nbsp;6.1</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.23 &#8220;<B>Key Person</B>&#8221; means Benny
S&oslash;rensen and Mads Behrndt. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.24 &#8220;<B>New Securities</B>&#8221; means, collectively, equity securities of the Company, whether
or not currently authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.25 &#8220;<B>Person</B>&#8221; means any individual, corporation, partnership, trust, limited liability company, association, or other
entity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.26 &#8220;<B>Preferred Director</B>&#8221; means a member of the Board of Directors elected by the holders of Preferred Stock.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.27 &#8220;<B>Preferred Stock</B>&#8221; means, collectively, shares of the Company&#8217;s Series Seed Preferred Stock, Series A
Preferred Stock, Series B Preferred Stock and Series C Preferred Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.28 &#8220;<B>Qualified Key Holder</B>&#8221; means a Key Holder
and (i)&nbsp;if an individual, is providing services to the Company or its subsidiaries as a full-time employee and (ii)&nbsp;if an entity, is owned or controlled by an individual providing services to the Company or its subsidiaries as a full-time
employee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.29 &#8220;<B>Registrable Securities</B>&#8221; means (i)&nbsp;the shares of Common Stock issuable or issued upon conversion of
the Series A Preferred Stock; (ii)&nbsp;the shares of Common Stock issuable or issued upon conversion of the Series B Preferred Stock; (iii)&nbsp;the shares of Common Stock issuable or issued upon conversion of the Series C Preferred Stock;
(iv)&nbsp;any shares of Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company held by the Investors; and (v)&nbsp;any shares of Common Stock issued as (or issuable upon the
conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses (i)&nbsp;through (iv) above; but excluding
in all cases, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to this Agreement, and excluding for purposes of <U>Section</U><U></U><U>&nbsp;2</U> any shares
for which registration rights have terminated pursuant to <U>Section</U><U></U><U>&nbsp;2.12</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.30 &#8220;<B>Registrable Securities then outstanding</B>&#8221; means the number of shares
determined by adding the number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are
Registrable Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.31 &#8220;<B>Restricted Securities</B>&#8221; means the securities of the Company required to be notated with
the legend set forth in <U>Section</U><U></U><U>&nbsp;2.11(b)</U> hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.32 &#8220;<B>Sanctioned Party</B>&#8221; means any Person:
(i)&nbsp;organized under the laws of, ordinarily resident in, or located in a country or territory that is the subject of comprehensive Sanctions (&#8220;<B>Restricted Countries</B>&#8221;); (ii) 50% or more owned or controlled by the government of
a Restricted Country; or (iii)&nbsp;(A) designated on a sanctioned parties list administered by the United States, European Union, or United Kingdom, including, without limitation, the U.S. Department of the Treasury&#8217;s Office of Foreign Assets
Control&#8217;s Specially Designated Nationals and Blocked Persons List, Foreign Sanctions Evaders List, and Sectoral Sanctions Identification List, the Consolidated List of Persons, Groups, and Entities Subject to EU Financial Sanctions, and the
UK&#8217;s Consolidated Sanctions List (collectively, &#8220;<B>Designated Parties</B>&#8221;); or (B) 50% or more owned or, where relevant under applicable Sanctions, controlled, individually or in the aggregate, by one or more Designated Party, in
each case only to the extent that dealings with such Person is are prohibited pursuant to applicable Sanctions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.33
&#8220;<B>Sanctions</B>&#8221; means applicable laws and regulations pertaining to trade and economic sanctions administered by the United States, European Union, or United Kingdom. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.34 &#8220;<B>SEC</B>&#8221; means the Securities and Exchange Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.35 &#8220;<B>SEC Rule 144</B>&#8221; means Rule 144 promulgated by the SEC under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.36 &#8220;<B>SEC Rule 145</B>&#8221; means Rule 145 promulgated by the SEC under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.37 &#8220;<B>Securities Act</B>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.38 &#8220;<B>Selling Expenses</B>&#8221; means all underwriting discounts, selling commissions, and stock transfer taxes applicable to
the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in <U>Section</U><U></U><U>&nbsp;2.6</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.39 &#8220;<B>Series A Preferred Stock</B>&#8221; means shares of the Company&#8217;s Series A Preferred Stock, par value $0.0001 per share.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.40 &#8220;<B>Series B Preferred Stock</B>&#8221; means shares of the Company&#8217;s Series B Preferred Stock, par value $0.0001 per
share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.41 &#8220;<B>Series C Preferred Stock</B>&#8221; means shares of the Company&#8217;s Series C Preferred Stock, par value $0.0001
per share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.42 &#8220;<B>Series Seed Preferred Stock</B>&#8221; means shares of the Company&#8217;s Series Seed Preferred Stock, par
value $0.0001 per share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.43 &#8220;<B>Side Letters</B>&#8221; has the meaning ascribed to it in the Exchange Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Registration Rights</U>. The Company covenants and agrees as follows: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 <U>Demand Registration</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <B>Form <FONT STYLE="white-space:nowrap">S-1</FONT> Demand</B>. If at any time after 180 days after the effective date of the registration
statement for the IPO, the Company receives a request from Holders of at least 30% of the Registrable Securities then outstanding that the Company file a Form <FONT STYLE="white-space:nowrap">S-1</FONT> registration statement with respect to at
least 25% of the Registrable Securities then outstanding (or a lesser percent if the anticipated aggregate offering price, net of Selling Expenses, would exceed $10 million), then the Company shall: (x)&nbsp;within ten days after the date such
request is given, give notice thereof (which notice shall not convey material <FONT STYLE="white-space:nowrap">non-public</FONT> information, within the meaning of the Exchange Act (except as may relate to the fact that the Company has received such
request for registration), unless a Holder subsequently agrees in writing to accept such information after being advised of a potential transaction that relates to such Holder&#8217;s rights under this Agreement) (the &#8220;<B>Demand
Notice</B>&#8221;) to all Holders other than the Initiating Holders; and (y)&nbsp;as soon as practicable, and in any event within 60 days after the date such request is given by the Initiating Holders, file a Form
<FONT STYLE="white-space:nowrap">S-1</FONT> registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included
in such registration by any other Holders, as specified by notice given by each such Holder to the Company within 20 days of the date the Demand Notice is given, and in each case, subject to the limitations of <U>Sections 2.1(c)</U> and <U>2.3</U>.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <B>Form <FONT STYLE="white-space:nowrap">S-3</FONT> Demand</B>. If at any time when it is eligible to use a Form <FONT
STYLE="white-space:nowrap">S-3</FONT> registration statement, the Company receives a request from Holders of at least 20% of the Registrable Securities then outstanding that the Company file a Form <FONT STYLE="white-space:nowrap">S-3</FONT>
registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $5,000,000, then the Company shall (i)&nbsp;within ten days after the date
such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii)&nbsp;as soon as practicable, and in any event within 45 days after the date such request is given by the Initiating Holders, file a Form <FONT
STYLE="white-space:nowrap">S-3</FONT> registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the
Company within 20 days of the date the Demand Notice is given, and in each case, subject to the limitations of <U>Sections 2.1(c)</U> and <U>2.3</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this
<U>Section</U><U></U><U>&nbsp;2.1(c)</U> a certificate signed by the Company&#8217;s chief executive officer stating that in the good faith judgment of the Board of Directors it would be materially detrimental to the Company and its stockholders to
timely file such registration statement, because such action would (i)&nbsp;materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii)&nbsp;require premature disclosure of
material information that the Company has a bona fide business purpose for preserving as confidential; or (iii)&nbsp;render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the
right to defer taking action with respect to such filing for a period of not more than 45 days after the request of the Initiating Holders is given; <U>provided</U>,<U> however</U>, that the Company may not invoke this right more than once in any <FONT
STYLE="white-space:nowrap">12-month</FONT> period ; and <U>provided further</U> that the Company shall not register any securities for its own account or that of any other stockholder during such 45 day period other than an Excluded Registration.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to
<U>Section</U><U></U><U>&nbsp;2.1(a)</U>, (i) during the period that is 30 days before the Company&#8217;s good faith estimate of the date of filing of, and ending on a date that is 90 days (or 180 days, solely in the case of an IPO) after the
effective date of, a Company-initiated registration, <U>provided</U> that the Company is actively </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii)&nbsp;after the Company has effected two registrations pursuant to
<U>Section</U><U></U><U>&nbsp;2.1(a)</U>; or (iii)&nbsp;if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form <FONT STYLE="white-space:nowrap">S-3</FONT> pursuant to a request
made pursuant to <U>Section</U><U></U><U>&nbsp;2.1(b)</U>. The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to <U>Section</U><U></U><U>&nbsp;2.1(b)</U>, (i) during the period that is 30 days
before the Company&#8217;s good faith estimate of the date of filing of, and ending on a date that is 90 days after the effective date of, a Company-initiated registration, <U>provided</U> that the Company is actively employing in good faith
commercially reasonable efforts to cause such registration statement to become effective; or (ii)&nbsp;if the Company has effected two registrations pursuant to <U>Section</U><U></U><U>&nbsp;2.1(b)</U> within the
<FONT STYLE="white-space:nowrap">12-month</FONT> period immediately preceding the date of such request. A registration shall not be counted as &#8220;effected&#8221; for purposes of this <U>Section</U><U></U><U>&nbsp;2.1(d)</U> until such time as
the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand
registration statement pursuant to <U>Section</U><U></U><U>&nbsp;2.6</U>, in which case such withdrawn registration statement shall be counted as &#8220;effected&#8221; for purposes of this <U>Section</U><U></U><U>&nbsp;2.1(d)</U>; <U>provided</U>,
that if such withdrawal is during a period the Company has deferred taking action pursuant to <U>Section</U><U></U><U>&nbsp;2.1(c)</U>, then the Initiating Holders may withdraw their request for registration and such registration will not be counted
as &#8220;effected&#8221; for purposes of this <U>Section</U><U></U><U>&nbsp;2.1(d)</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>Company Registration</U>. If the Company
proposes to register (including for this purpose a registration effected by the Company for stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the public offering of such securities solely for
cash (other than in an Excluded Registration or a registration pursuant to Section&nbsp;2.1), the Company shall, at such time, promptly give each Holder notice of such registration (which notice shall not convey material <FONT
STYLE="white-space:nowrap">non-public</FONT> information, within the meaning of the Exchange Act (except as may relate to the fact that the Company proposes to register shares of its Common Stock), unless a Holder subsequently agrees in writing to
accept such information after being advised of a potential transaction that relates to such Holder&#8217;s rights under this Agreement). Upon the request of each Holder given within 20 days after such notice is given by the Company, the Company
shall, subject to the provisions of Section&nbsp;2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any
registration initiated by it under this Section&nbsp;2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such
withdrawn registration shall be borne by the Company in accordance with <U>Section</U><U></U><U>&nbsp;2.5</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 <U>Underwriting
Requirements</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If, pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U>, the Initiating Holders intend to distribute the Registrable
Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U>, and the Company shall include such information in the Demand Notice.
The underwriter(s) will be selected by the Board of Directors and such selection, as well as the underwriters&#8217; discount, shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder
to include such Holder&#8217;s Registrable Securities in such registration shall be conditioned upon such Holder&#8217;s participation in such underwriting and the inclusion of such Holder&#8217;s Registrable Securities in the underwriting to the
extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company as provided in <U>Section</U><U></U><U>&nbsp;2.4(e)</U>) enter into an underwriting agreement in customary form
with the underwriter(s) selected for such underwriting; <U>provided</U>, <U>however</U>, that no Holder (or any of their assignees) shall be required to make any representations, warranties or indemnities except as they relate to such Holder&#8217;s
ownership of shares and authority to enter into the underwriting agreement and to such Holder&#8217;s intended method of distribution, and the liability of such Holder shall be several and not joint, and limited
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to an amount equal to the net proceeds from the offering received by such Holder. Notwithstanding any other provision of this <U>Section</U><U></U><U>&nbsp;2.3</U>, if the underwriter(s)
advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would be
underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as
practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; <U>provided</U>,<U> however</U>, that the number of Registrable Securities held by the
Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company or the
underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In connection with any offering
involving an underwriting of shares of the Company&#8217;s capital stock pursuant to <U>Section</U><U></U><U>&nbsp;2.2</U>, the Company shall not be required to include any of the Holders&#8217; Registrable Securities in such underwriting unless the
Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the
Company. If the total number of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable
discretion determine is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their
sole discretion determine will not jeopardize the success of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities
that are included in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to
by all such selling Holders. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. Notwithstanding the
foregoing, in no event shall (i)&nbsp;the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or
(ii)&nbsp;the number of Registrable Securities included in the offering be reduced below 30% of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if
the underwriters make the determination described above and no other stockholder&#8217;s securities are included in such offering. For purposes of the provision in this <U>Section</U><U></U><U>&nbsp;2.3(b)</U> concerning apportionment, for any
selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners,
retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single &#8220;selling Holder,&#8221; and any pro rata reduction with respect to such &#8220;selling Holder&#8221;
shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such &#8220;selling Holder,&#8221; as defined in this sentence. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) For purposes of <U>Section</U><U></U><U>&nbsp;2.1</U>, a registration shall not be counted as &#8220;effected&#8221; if, as a result of an
exercise of the underwriter&#8217;s cutback provisions in <U>Section</U><U></U><U>&nbsp;2.3(a)</U>, fewer than 50% of the total number of Registrable Securities that Holders have requested to be included in such registration statement are actually
included. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4 <U>Obligations of the Company</U>. Whenever required under this
<U>Section</U><U></U><U>&nbsp;2.4</U> to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable
efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to 120 days or, if
earlier, until the distribution contemplated in the registration statement has been completed; <U>provided</U>,<U> however</U>, that (i)&nbsp;such <FONT STYLE="white-space:nowrap">120-day</FONT> period shall be extended for a period of time equal to
the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii)&nbsp;in the case of any registration of Registrable Securities
on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such <FONT STYLE="white-space:nowrap">120-day</FONT> period shall be extended as
necessary to keep the registration statement effective until all such Registrable Securities are sold; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) prepare and file with the SEC
such amendments and supplements to such registration statement, and the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities
covered by such registration statement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary
prospectus, as required by the Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or <FONT STYLE="white-space:nowrap">blue-sky</FONT> laws of such jurisdictions as shall be reasonably requested by the selling Holders; <U>provided</U> that the Company shall not be required to qualify to do business or to file a general
consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter(s) of such offering; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) use its commercially reasonable efforts to cause all such Registrable
Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for
all such Registrable Securities, in each case not later than the effective date of such registration; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) promptly make available for
inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling
Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company&#8217;s officers, directors, employees, and independent accountants to supply all information reasonably requested by any
such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) notify each selling Holder, promptly after the Company receives notice thereof, of the
time when such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or
supplement such registration statement or prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Company shall ensure that, at all times after any registration
statement covering a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company&#8217;s directors may implement a trading program under Rule <FONT
STYLE="white-space:nowrap">10b5-1</FONT> of the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5 <U>Furnish Information</U>. It shall be a condition precedent to the
obligations of the Company to take any action pursuant to this <U>Section</U><U></U><U>&nbsp;2</U> with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the
Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder&#8217;s Registrable Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.6 <U>Expenses of Registration</U>. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or
qualifications pursuant to <U>Section</U><U></U><U>&nbsp;2</U>, including all registration, filing, and qualification fees; printers&#8217; and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and
disbursements, not to exceed $50,000, of one counsel for the selling Holders selected by Holders of a majority of the Registrable Securities to be registered (&#8220;<B>Selling Holder Counsel</B>&#8221;), shall be borne and paid by the Company;
<U>provided</U>, <U>however</U>, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to <U>Section</U><U></U>&nbsp;2.1 if the registration request is subsequently withdrawn at the request of
the Holders of a majority of the Registrable Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration),
unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one registration pursuant to <U>Sections </U>2.1(a) or 2.1(b), as the case may be; <U>provided</U> <U>further</U> that if, at the time of such withdrawal,
the Holders shall have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning
of such information then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to <U>Sections </U>2.1(a) or 2.1(b). All Selling Expenses relating to Registrable Securities
registered pursuant to this <U>Section</U><U></U><U>&nbsp;2.6</U> shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.7 <U>Indemnification</U>. If any Registrable Securities are included in a registration statement under this
<U>Section</U><U></U><U>&nbsp;2</U>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder,
and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who controls
such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other expenses
reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; <U>provided</U>,<U> however</U>, that the indemnity agreement contained in this
<U>Section</U><U></U><U>&nbsp;2.7(a)</U> shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the
Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling
Person, or other aforementioned Person expressly for use in connection with such registration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) To the extent permitted by law, each selling Holder, severally and not jointly, will
indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and
accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each
case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such
registration and that has not been corrected in a subsequent writing at least one business day prior to the sale of Registrable Securities to the Person asserting the claim; and each such selling Holder will pay to the Company and each other
aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; <U>provided</U>,<U> however</U>, that
the indemnity agreement contained in this <U>Section</U><U></U><U>&nbsp;2.7(b)</U> shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall
not be unreasonably withheld; and <U>provided further</U> that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under <U>Sections 2.6(b)</U> and <U>2.6(d</U>) exceed the proceeds from the offering
received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Promptly after receipt by an indemnified party under this <U>Section</U><U></U><U>&nbsp;2.7</U> of notice of the commencement of any action
(including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this
<U>Section</U><U></U><U>&nbsp;2.7</U>, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate
jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; <U>provided</U>,<U> however</U>, that an indemnified party (together with all other
indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the
counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the
indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this <U>Section</U><U></U><U>&nbsp;2.7</U>, only to the extent that such failure
materially prejudices the indemnifying party&#8217;s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this
<U>Section</U><U></U><U>&nbsp;2.7</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) To provide for just and equitable contribution to joint liability under the Securities Act in
any case in which either: (i)&nbsp;any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this <U>Section</U><U></U><U>&nbsp;2.7</U> but it is judicially determined (by the entry of a final judgment
or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this
<U>Section</U><U></U><U>&nbsp;2.7</U> provides for indemnification in such case, or (ii)&nbsp;contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this
<U>Section</U><U></U><U>&nbsp;2.7</U>, then, and in each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss,
claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the
untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties&#8217; relative intent, knowledge,
access to information, and opportunity to correct or prevent such statement or omission; <U>provided</U>, <U>however</U>, that, in any such case (x)&nbsp;no Holder will be required to contribute any amount in excess of the public offering price of
all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y)&nbsp;no Person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) will be entitled
to contribution from any Person who was not guilty of such fraudulent misrepresentation; and <U>provided</U> <U>further</U> that in no event shall a Holder&#8217;s liability pursuant to this <U>Section</U><U></U><U>&nbsp;2.7(d)</U>, when combined
with the amounts paid or payable by such Holder pursuant to <U>Section</U><U></U><U>&nbsp;2.7(b)</U>, exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful
misconduct or fraud by such Holder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and
contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control; <U>provided</U>,<U>
however</U>, that any matter expressly provided for or addressed by the provisions of this <U>Section</U><U></U><U>&nbsp;2.7</U> that is not expressly provided for or addressed by the underwriting agreement shall be controlled by the foregoing
provisions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering,
the obligations of the Company and Holders under this <U>Section</U><U></U><U>&nbsp;2.7</U> shall survive the completion of any offering of Registrable Securities in a registration under this <U>Section</U><U></U><U>&nbsp;2</U>, and otherwise shall
survive the termination of this Agreement or any provision(s) of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.8 <U>Reports Under Exchange Act</U>. With a view to
making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form <FONT
STYLE="white-space:nowrap">S-3,</FONT> the Company shall: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) make and keep available adequate current public information, as those terms
are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under
the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) furnish
to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i)&nbsp;to the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after
90 days after the effective date of the registration statement filed by the Company for the IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a
registrant whose securities may be resold pursuant to Form <FONT STYLE="white-space:nowrap">S-3</FONT> (at any time after the Company so qualifies); and (ii)&nbsp;such other information as may be reasonably requested in availing any Holder of any
rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form <FONT
STYLE="white-space:nowrap">S-3</FONT> (at any time after the Company so qualifies to use such form). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.9 <U>Limitations on Subsequent Registration Rights</U>. From and after the date of this
Agreement, the Company shall not, without the prior written consent of the Investor Majority, enter into any agreement with any holder or prospective holder of any securities of the Company that would (i)&nbsp;provide to such holder the right to
include securities in any registration on other than a subordinate basis after all Holders have had the opportunity to include in the registration and offering all shares of Registrable Securities that they wish to so include or (ii)&nbsp;allow such
holder or prospective holder to initiate a demand for registration of any securities held by such holder or prospective holder; <U>provided</U> that this limitation shall not apply to Registrable Securities acquired by any additional Investor that
becomes a party to this Agreement in accordance with <U>Section</U><U></U><U>&nbsp;6.9</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.10 <U>&#8220;</U><U>Market <FONT
STYLE="white-space:nowrap">Stand-off</FONT></U><U>&#8221;</U><U> Agreement</U>. Each Investor hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final
prospectus relating to the registration by the Company for its own behalf of shares of its Common Stock or any other equity securities under the Securities Act on a registration statement (other than an Excluded Registration) on Form <FONT
STYLE="white-space:nowrap">S-1,</FONT> and ending on the date specified by the Company and the managing underwriter (such period not to exceed 180 days in the case of the IPO or, if the Company is not then an emerging growth company as defined in
the applicable SEC regulations, such other period as may be requested by the Company or an underwriter to accommodate regulatory restrictions on (1)&nbsp;the publication or other distribution of research reports and (2)&nbsp;analyst recommendations
and opinions, including, but not limited to, the restrictions contained in applicable FINRA rules, or any successor provisions or amendments thereto), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase
any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or
indirectly) for Common Stock held immediately before the effective date of the registration statement for such offering or (ii)&nbsp;enter into any swap, hedging, or other transaction or arrangement that transfers, or is designed to transfer, to
another, in whole or in part, any of the economic consequences of ownership, directly or indirectly, of such securities, whether or not any such transaction or arrangement described in <U>clauses</U> <U>(i</U>)&nbsp;or (<U>ii</U>) above is to be
settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this <U>Section</U><U></U><U>&nbsp;2.10</U> shall apply only to the IPO, shall only apply to shares held by the Investor immediately prior to
the IPO, shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement or to the establishment of a trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1,</FONT> <U>provided</U>, that such plan
does not permit transfers during the restricted period, or the transfer of any shares to any trust for the direct or indirect benefit of the Investor or one or more of the Investor&#8217;s Immediate Family Members, <U>provided</U> that the trustee
of the trust agrees to be bound in writing by the restrictions set forth herein, and <U>provided further</U> that any such transfer shall not involve a disposition for value, and shall be applicable to the Investors only if all officers and
directors of the Company are subject to the same restrictions and the Company obtains a similar agreement from all stockholders individually owning more than 1% of the Company&#8217;s outstanding Common Stock (after giving effect to the conversion
into Common Stock of all outstanding Preferred Stock). The underwriters in connection with such registration are intended third-party beneficiaries of this <U>Section</U><U></U><U>&nbsp;2.10</U> and shall have the right, power and authority to
enforce the provisions hereof as though they were a party hereto. Each Investor further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this
<U>Section</U><U></U><U>&nbsp;2.10</U>. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Company stockholders that are subject to such
agreements, based on the number of shares subject to such agreements. Such agreement shall further provide that if and when a Stockholder becomes liable to payment of Danish taxes in the form of &#8220;<I>lagerbeskatning</I>&#8221; related to the
shares covered by such agreement, such stockholder may freely divest shares to the extent necessary to cover the payment of such taxes with the sales proceeds. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.11 <U>Restrictions on Transfer</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Registrable Securities and Preferred Stock shall not be sold, pledged, or otherwise transferred, and the Company shall not recognize
and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the provisions of
the Securities Act and all other applicable U.S. laws and regulations. A transferring Investor will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Investor to agree to take and
hold such securities subject to the provisions and upon the conditions specified in this Agreement. Notwithstanding the foregoing, the Company shall not require any transferee of shares pursuant to an effective registration statement or, following
the IPO, SEC Rule 144, in each case, to be bound by the terms of this <U>Section</U><U></U><U>&nbsp;2.11</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each certificate,
instrument, or book entry representing (i)&nbsp;the Preferred Stock, (ii)&nbsp;the Registrable Securities, and (iii)&nbsp;any other securities issued in respect of the securities referenced in <U>clauses</U> <U>(i)</U>&nbsp;and <U>(ii)</U>, upon any
stock split, stock dividend, recapitalization, merger, consolidation, or similar event, shall (unless otherwise permitted by the provisions of <U>Section</U><U></U><U>&nbsp;2.11(c)</U>) be notated with a legend substantially in the following form:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES MAY NOT BE
SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF
WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Investors consent to the Company making a notation in its records and giving
instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this <U>Section</U><U></U><U>&nbsp;2.11</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions of this
<U>Section</U><U></U><U>&nbsp;2</U>. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction or following the IPO, the
transfer is made pursuant to SEC Rule 144, the holder thereof shall give notice to the Company of such holder&#8217;s intention to effect such sale, pledge, or transfer, <U>provided</U> that no such notice shall be required in connection if the
intended sale, pledge or transfer complies with SEC Rule 144. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be
accompanied at such holders&#8217;s expense by either (i)&nbsp;a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed
transaction may be effected without registration under the Securities Act; (ii)&nbsp;a &#8220;no action&#8221; letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without registration will not
result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii)&nbsp;any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the
Restricted Securities may be effected without registration under the Securities Act, whereupon the holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the
notice given by the holder to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company. The Company will not require such a notice, legal opinion or &#8220;no action&#8221; letter (x)&nbsp;in any transaction in compliance with SEC Rule 144; or (y)&nbsp;in any transaction in
which such holder distributes Restricted Securities to an Affiliate of such holder for no consideration; <U>provided</U> that with respect to transfers under the foregoing clause (y), each transferee agrees in writing to be subject to the terms of
this <U>Section</U><U></U><U>&nbsp;2.11</U>. Each certificate, instrument, or book entry representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144, the
appropriate restrictive legend set forth in <U>Section</U><U></U><U>&nbsp;2.11(b)</U>, except that such certificate, instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such holder and the
Company, such legend is not required in order to establish compliance with any provisions of the Securities Act and the Company will use commercially reasonable efforts to cause any such legend to be removed. Notwithstanding anything to the contrary
in this agreement, the Company may in its sole discretion waive compliance with this <U>Subsection 2.11(c)</U> and the Company&#8217;s failure to object within five (5)&nbsp;Business Days in writing after notification of a proposed assignment
allegedly in violation of <U>Subsection 2.11(c)</U> shall be deemed to be such a waiver. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Subject to compliance with the Exchange Act,
Securities Act and other applicable securities laws and regulations and any contractual restrictions entered into by a holder of Restricted Securities (such as a <FONT STYLE="white-space:nowrap">lock-up</FONT> or market standoff agreement), at such
holder&#8217;s request and at the Company&#8217;s expense, the Company will use commercially reasonable efforts to promptly remove all transfer restrictions (and any legends relating thereto) that are no longer required to restrict transfers of the
Registrable Securities of the Company (or its successor) held by such holder; provided, however, that such holder may be required to produce customary seller representation letters and, as applicable, broker representation letters as required
pursuant to SEC Rule 144, as well as (except if a transfer is made pursuant to SEC Rule 144) an opinion of its counsel at the holder&#8217;s expense in connection with any such removal of transfer restrictions (and any legends relating thereto).
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.12 <U>Termination and Suspension of Registration Rights</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to
<U>Section</U><U></U><U>&nbsp;2.1</U> or <U>2.2</U> shall terminate, as to such Holder, upon the earliest to occur of: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) the closing of
a Deemed Liquidation Event; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) such time after consummation of an IPO when a Holder may sell all of the Holder&#8217;s Registrable
Securities under SEC Rule 144 without limitation (including without observance of the manner of sale, volume limitation and notice provisions of SEC Rule 144), or another similar exemption under the Securities Act is available for the sale of all of
such Holder&#8217;s shares without limitation, during a three-month period without registration; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) the third anniversary of the
IPO. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to
<U>Section</U><U></U><U>&nbsp;2.1</U> or <U>2.2</U> shall be suspended during any time as such Holder is a Sanctioned Party. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Information and Observer Rights</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 <U>Delivery of Financial Statements</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company shall deliver to each Investor (in each case, as relevant, on a consolidated group basis): </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) as soon as practicable, but in any event within 180 days after the end of each fiscal
year of the Company (A)&nbsp;a balance sheet as of the end of such year, (B)&nbsp;statements of income and of cash flows for such year and (C)&nbsp;a statement of stockholders&#8217; equity as of the end of such year, all such financial statements
prepared in accordance with GAAP and audited and certified by independent public accountants of nationally recognized standing selected by the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) as soon as practicable, but in any event within 45 days after the end of each quarter of each fiscal year of the Company,
(i)&nbsp;unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet and a statement of stockholders&#8217; equity as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such
financial statements may (A)&nbsp;be subject to normal <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments; and (B)&nbsp;not contain all notes thereto that may be required in accordance with GAAP) and (ii)&nbsp;an update on
scientific, clinical and development activities of the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) upon request of an Investor, a statement showing the number of
shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock outstanding as of such request, the Common Stock issuable upon conversion or exercise of any outstanding securities
convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock options not yet issued but reserved for issuance, if any, all in sufficient detail as
to permit the Investor to calculate its respective percentage equity ownership in the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) as soon as practicable, the Approved
Annual Budget (as defined below); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) such other information relating to the financial condition, business, prospects, or corporate
affairs of the Company as any Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this <U>Subsection 3.1(a)(v)</U> to provide information (i)&nbsp;that the Company reasonably determines
in good faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in a form acceptable to the Company) or (ii)&nbsp;the disclosure of which could reasonably be expected to adversely affect
the attorney-client privilege between the Company and its counsel. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company shall, prior to the last meeting of the Board of
Directors in a fiscal year, prepare an annual budget and operating plan for the next fiscal year, prepared on a monthly basis, including balance sheets, income statements, and statements of cash flow for such months (the
&#8220;<B>Budget</B>&#8221;). The Company shall submit the Budget to the Board of Directors for approval and the Budget, as may be revised by the Board of Directors, shall be approved by the Board of Directors (&#8220;<B>Approved</B> <B>Annual
Budget</B>&#8221;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Company shall, to the extent permitted under applicable law and unless such disclosure could reasonably be
expected to adversely affect the attorney-client privilege between the Company and its Counsel, give notice to the Investors of any material adverse change, involvement in illegal activities or the commencement or threat of commencement of any
material litigation or dispute (including bankruptcy and insolvency proceedings and formal investigation by any regulatory or administrative body), immediately upon the Company becoming aware of such change, involvement, commencement or threat and
will keep the Investors informed on a regular basis of any development in relation thereto and of the steps and actions that are being taken by and/or against the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) If, for any period, the Company has any subsidiary whose accounts are consolidated with
those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Any other information reasonably requested by an Investor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Notwithstanding anything else in this <U>Section</U><U></U><U>&nbsp;3.1</U> to the contrary, the Company may cease providing the
information set forth in this <U>Section</U><U></U><U>&nbsp;3.1</U> during the period starting with the date 60 days before the Company&#8217;s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must
do so to comply with the SEC rules applicable to such registration statement and related offering; <U>provided</U> that the Company&#8217;s covenants under this <U>Section</U><U></U><U>&nbsp;3.1</U> shall be reinstated at such time as the Company is
no longer actively employing its commercially reasonable efforts to cause such registration statement to become effective. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2
<U>Inspection</U>. The Company shall permit each Investor, at such Investor&#8217;s expense, to visit and inspect the Company&#8217;s properties; examine its books of account and records; and discuss the Company&#8217;s affairs, finances, and
accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Investor in connection with monitoring or making decisions with respect to its investment in the Company; <U>provided</U>, <U>however</U>,
that the Company shall not be obligated pursuant to this <U>Section</U><U></U>&nbsp;3.2 to (a)&nbsp;create any new information or materials or (b)&nbsp;provide access to any information that it reasonably and in good faith considers to be a trade
secret or confidential information or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3 <U>Observer Rights</U>. As long as Avoro Ventures Fund L.P., together with its Affiliates (&#8220;<B>Avoro Ventures</B>&#8221;) continues
to own shares of Preferred Stock, and at such time as Uya Chuluunbaatar is no longer serving on the Board of Directors in accordance with <U>Section</U><U></U><U>&nbsp;1.2(f)</U> of the Voting Agreement, the Company shall invite a representative of
Avoro Ventures to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to the Board of
Directors at the same time as they are provided to the directors; <U>provided</U>, <U>however</U>, that such representative shall agree to hold in confidence all information so provided; and <U>provided</U> <U>further</U>, that the Company reserves
the right to withhold any information and to exclude such representative from any meeting or portion thereof if (x)&nbsp;access to such information or attendance at such meeting would be reasonably likely to adversely affect the attorney-client
privilege between the Company and its counsel, result in disclosure of trade secrets or highly confidential information, or create a competitive harm or competitive disadvantage, or (y)&nbsp;the portion as to which such representative is excluded
relates solely to subject matter in which the Investor or such representative may have a conflict of interest. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.4 <U>Termination of
Information and Observer Rights</U>. The covenants set forth in <U>Sections 3.1, 3.2 and 3.3</U> shall terminate and be of no further force or effect (i)&nbsp;immediately before the consummation of the IPO; (ii)&nbsp;with respect to any Investor
that is or becomes a Sanctioned Party, for so long as such Investor is a Sanctioned Party; (iii)&nbsp;when the Company first becomes subject to the periodic reporting requirements of Section&nbsp;12(g) or 15(d) of the Exchange Act, or (iv)&nbsp;upon
the closing of a Deemed Liquidation Event, whichever event occurs first; provided, that, with respect to clause (iv), the covenants set forth in Section&nbsp;3.1 shall only terminate if the consideration received by the Investors in such Deemed
Liquidation Event is in the form of cash and/or publicly traded securities or if the Investors receive financial information from the acquiring company or other successor to the Company comparable to those set forth in Section&nbsp;3.1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.5 <U>Confidentiality</U>. Each Investor agrees that such Investor will keep confidential
and will not disclose, divulge, or use for any purpose (other than to monitor or make decisions with respect to its investment in the Company) any confidential information obtained from the Company (including notice of the Company&#8217;s intention
to file a registration statement), unless such confidential information (a)&nbsp;is known or becomes known to the public in general (other than as a result of a breach of this <U>Section</U><U></U><U>&nbsp;3.5</U> by such Investor), (b) is or has
been independently developed or conceived by such Investor without use of the Company&#8217;s confidential information, or (c)&nbsp;is or has been made known or disclosed to such Investor by a third party without a breach of any obligation of
confidentiality such third party may have to the Company; <U>provided</U>,<U> however</U>, that an Investor may disclose confidential information (i)&nbsp;to its attorneys, accountants, consultants, and other professionals to the extent reasonably
necessary to obtain their services in connection with monitoring its investment in the Company; (ii)&nbsp;to any prospective transferee of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the
provisions of this <U>Section</U><U></U><U>&nbsp;3.5</U>; (iii) to any existing or prospective Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, or to any existing or prospective
provider of debt or equity financing, <U>provided</U> that such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information; or (iv)&nbsp;as may otherwise be required
by law, regulation, rule, court order or subpoena, <U>provided</U> that such Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.6 <U>Waiver of Statutory Information Rights</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.7 Each Investor hereby acknowledges and agrees that until the consummation of the IPO, such Investor shall hereby be deemed to have
unconditionally and irrevocably, to the fullest extent permitted by law, on behalf of such Investor and all beneficial owners of the shares of Common Stock or Preferred Stock owned by such Investor (a &#8220;<B>Beneficial Owner</B>&#8221;), waived,
and does hereby so waive, any rights such Investor or a Beneficial Owner might otherwise have had under Section&nbsp;220 of the Delaware General Corporation Law (or under similar rights under other applicable law) to inspect for any proper purpose
and to make copies and extracts from the Company&#8217;s stock ledger, a list of its stockholders and its other books and records or the books and records of any subsidiary. This waiver applies only in such Investor&#8217;s capacity as a stockholder
and does not affect any other information and inspection rights such Investor may expressly have pursuant to <U>Sections 3.1</U> or <U>3.2</U> of this Agreement. Each Investor hereby further warrants and represents that such Investor has reviewed
this waiver with its legal counsel, and that such Investor knowingly and voluntarily waives its rights as a stockholder otherwise provided by Section&nbsp;220 of the Delaware General Corporation Law (or under similar rights under other applicable
law). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Rights to Future Stock Issuances</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1 <U>Right of First Offer</U>. Subject to the terms and conditions of this <U>Section</U><U></U><U>&nbsp;4.1</U> and applicable securities
laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Investor and Key Holder. An Investor or Key Holder shall be entitled to apportion the right of first offer hereby granted to
it in such proportions as it deems appropriate, among (i)&nbsp;itself, (ii) its Affiliates and (iii)&nbsp;its beneficial interest holders, such as limited partners, members or any other Person having &#8220;beneficial ownership,&#8221; as such term
is defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> promulgated under the Exchange Act, of such Investor or Key Holder (&#8220;<B>Stockholder Beneficial Owners</B>&#8221;); <U>provided</U> that each such Affiliate or Stockholder
Beneficial Owner enters into this Agreement and the Voting Agreement of even date herewith among the Company, the Investors and the other parties named therein, as amended and/or restated from time to time (the &#8220;<B>Voting
Agreement</B>&#8221;), as an &#8220;Investor&#8221; or &#8220;Key Holder,&#8221; as applicable, under each such agreement and <U>provided </U>that the Company shall not be obligated to offer or sell any New Securities to any person or entity that is
a Sanctioned Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company shall give notice (the &#8220;<B>Offer Notice</B>&#8221;) to each Investor
and Key Holder, stating (i)&nbsp;its bona fide intention to offer such New Securities, (ii)&nbsp;the number of such New Securities to be offered, and (iii)&nbsp;the price and terms, if any, upon which it proposes to offer such New Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) By notification to the Company within 20 days after the Offer Notice is given, each Investor and Key Holder may elect to purchase or
otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that (x)&nbsp;the Common Stock then held by such Investor or Key Holder (including all shares of
Common Stock then issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Investor or Key Holder) bears to (y)&nbsp;the total Common Stock of the
Company then outstanding (assuming full conversion and/or exercise, as applicable, of all Preferred Stock and any other Derivative Securities then outstanding). At the expiration of such <FONT STYLE="white-space:nowrap">20-day</FONT> period, the
Company shall promptly notify each Investor that elects to purchase or acquire all the shares available to it (each, a &#8220;<B>Fully Exercising Investor</B>&#8221;) of any other Investor&#8217;s or Key Holder&#8217;s failure to do likewise. During
the <FONT STYLE="white-space:nowrap">10-day</FONT> period commencing after the Company has given such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares
specified above, up to that portion of the New Securities for which Investors and Key Holders were entitled to subscribe but that were not subscribed for by the Investors and Key Holders which is equal to the proportion that the Common Stock issued
and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of Preferred Stock and any other Derivative Securities then held, by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable
(directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares (the &#8220;<B>Secondary
Participation Right</B>&#8221;). For the avoidance of doubt, the Key Holders shall not be entitled to participate in the Secondary Participation Right. The closing of any sale pursuant to this <U>Section</U><U></U><U>&nbsp;4.1(b)</U> shall occur
within the later of 120 days of the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to <U>Section</U><U></U><U>&nbsp;4.1(c)</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in
<U>Section</U><U></U><U>&nbsp;4.1(b)</U>, the Company may, during the 120 day period following the expiration of the periods provided in <U>Section</U><U></U><U>&nbsp;4.1(b)</U>, offer and sell the remaining unsubscribed portion of such New
Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such
period, or if such agreement is not consummated within 30 days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Investors and Key Holders
in accordance with this <U>Section</U><U></U><U>&nbsp;4.1</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The right of first offer in this <U>Section</U><U></U><U>&nbsp;4.1</U>
shall not be applicable to (i)&nbsp;Exempted Securities (as defined in the Certificate of Incorporation); (ii) shares of Common Stock issued in the IPO; and (iii)&nbsp;the issuance of shares of Common Stock, Preferred Stock, warrants or other
securities convertible into shares of Common Stock or Preferred Stock pursuant to the Exchange Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 <U>Termination</U>. The
covenants set forth in <U>Section</U><U></U><U>&nbsp;4.1</U> shall terminate and be of no further force or effect (i)&nbsp;immediately before the consummation of the IPO, or (ii)&nbsp;upon the closing of a Deemed Liquidation Event, whichever event
occurs first. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Additional Covenants</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1 <U>Insurance</U>. The Company shall maintain, from financially sound and reputable insurers, Directors and Officers liability insurance in
an amount and on terms and conditions approved by the Board of Directors and will use commercially reasonable efforts to cause such insurance policies to be maintained until such time as the Board of Directors determines that such insurance should
be discontinued. No such policy shall be cancelable by the Company without prior approval by the Board of Directors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 <U>Board
</U><U>Matters</U>. Unless otherwise determined by the vote of a majority of the directors then in office, the Board of Directors shall meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse the directors for
all reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> travel expenses incurred (consistent with the Company&#8217;s travel policy) in connection with attending meetings of the Board of
Directors. Each Preferred Director then serving on the Board of Directors shall be entitled to serve as a member of any committee or subcommittee of the Board of Directors, which service on any such committee or subcommittee may be waived or
deferred only at the discretion of any such Preferred Director with respect to itself. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3 <U>Successor Indemnification</U>. If the
Company or any of its successors or assignees consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be
made so that the successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are
contained in the Company&#8217;s Bylaws, the Certificate of Incorporation, or elsewhere, as the case may be. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4 <U>Indemnification
Matters</U>. The Company hereby acknowledges that one or more of the directors affiliated with one or more Investors (&#8220;<B>Investor Directors</B>&#8221;) may have certain rights to indemnification, advancement of expenses and/or insurance
provided by one or more of the Investors and certain of their Affiliates (collectively, the &#8220;Investor Indemnitors&#8221;). The Company hereby agrees (a)&nbsp;that it is the indemnitor of first resort (i.e., its obligations to any such Investor
Director are primary and any obligation of the Investor Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by such Investor Director are secondary), (b) that it shall be required to advance
the full amount of expenses incurred by such Investor Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf of any such Investor Director to the extent legally
permitted and as required by the Certificate of Incorporation or Bylaws of the Company (or any agreement between the Company and such Investor Director), without regard to any rights such Investor Director may have against the Investor Indemnitors,
and, (c)&nbsp;that it irrevocably waives, relinquishes and releases the Investor Indemnitors from any and all claims against the Investor Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company
further agrees that no advancement or payment by the Investor Indemnitors on behalf of any such Investor Director with respect to any claim for which such Investor Director has sought indemnification from the Company shall affect the foregoing and
the Investor Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Investor Director against the Company. The Investor Directors and the Investor
Indemnitors are intended third-party beneficiaries of this Section&nbsp;5.4 and shall have the right, power and authority to enforce the provisions of this Section&nbsp;5.4 as though they were a party to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5 <U>Right to Conduct Activities</U>. The Company hereby agrees and acknowledges that each Investor other than Wandall (together with its
Affiliates) (each, a &#8220;<B>Professional Investment Organization</B>&#8221;) is a professional investment organization, and as such reviews the business plans and related proprietary information of many enterprises, some of which may compete
directly or indirectly with the Company&#8217;s business (as currently conducted or as currently propose to be conducted). Nothing in this Agreement shall preclude or in any way restrict the Professional Investment Organization from evaluating or
purchasing securities, including publicly traded securities, of a particular enterprise, or investing or participating in any particular enterprise whether or not such enterprise has products or services that
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
compete with those of the Company (as currently conducted or as currently propose to be conducted); and the Company hereby agrees that, to the extent permitted under applicable law, no
Professional Investment Organization shall be liable to the Company for any claim arising out of, or based upon, (i)&nbsp;the investment by such Professional Investment Organization in any entity competitive with the Company, or (ii)&nbsp;actions
taken by any partner, officer, employee or other representative of such Professional Investment Organization to assist any such competitive company, whether or not such action was taken as a member of the board of directors of such competitive
company or otherwise, and whether or not such action has a detrimental effect on the Company; <U>provided</U>,<U> however</U>, that the foregoing shall not contravene the confidentiality obligations in <U>Section</U><U></U><U>&nbsp;3.5</U> or
otherwise in this Agreement or relieve any director or officer of the Company from any liability associated with such person&#8217;s fiduciary duties to the Company. Further, this clause 5.5 may not be amended or waived in a manner adverse to each
Professional Investment Organization without such Professional Investment Organization&#8217;s written consent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.6 <U>Passive Foreign
Investment Company</U>. No later than the later of (i) 60 days following the end of each Company or Hemab ApS taxable year, as applicable, or (ii) 30 days following the request of an Investor, the Company shall provide the following information to
each Investor upon such investor&#8217;s reasonable request: (i)&nbsp;Hemab ApS&#8217;s capitalization table as of the end of the last day of such taxable year and (ii)&nbsp;all information that would reasonably permit the Investor to determine
whether Hemab ApS was a &#8220;passive foreign investment company&#8221; (&#8220;<B>PFIC</B>&#8221;) as such term is defined in Section&nbsp;1297 of the United States Internal Revenue Code of 1986, as amended (the &#8220;<B>Code</B>&#8221;) or a
&#8220;Controlled Foreign Corporation&#8221; (&#8220;<B>CFC</B>&#8221;) as defined in the Code for any prior taxable year and to determine whether such Investor or any of such Investor&#8217;s Partners is required to report its pro rata portion of
Hemab ApS&#8217;s Subpart F Income on its United States federal income tax return, or to allow such Investor or such Investor&#8217;s Partners to otherwise comply with applicable United States federal income tax laws. If an Investor reasonably
believes, upon advice of its tax advisors, that there is a reasonable likelihood that Hemab ApS was a PFIC or CFC for any prior taxable year, the Company will, with such advice as may be reasonably requested from such Investor, prepare the
information required to comply with applicable PFIC and / or CFC reporting requirements. For purposes of the foregoing, (i)&nbsp;the term &#8220;Investor&#8217;s Partners&#8221; shall mean each of the Investor&#8217;s partners and any direct or
indirect equity owners of such partners and (ii) &#8220;Hemab ApS&#8221; shall mean Hemab ApS and any of its subsidiaries. In connection with a &#8220;Qualified Electing Fund&#8221; election made by the Investor or any of the Investor&#8217;s
Partners pursuant to Section&nbsp;1295 of the Code or a &#8220;Protective Statement&#8221; filed by the Investor or any of Investor&#8217;s Partners pursuant to Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.1295-3,</FONT> as
amended (or any successor thereto), the Company shall provide annual financial information to the relevant Investor(s) in the form provided in the attached Schedule C&#8212;PFIC Annual Information Statement (or in such other form as may reasonably
be required to reflect changes in applicable law) as soon as reasonably practicable following the end of each taxable year of the Company or of Hemab ApS (but in no event later than 60 days following the end of each such taxable year), and shall
provide such Investor(s) with access to such other Hemab ApS information as may reasonably be required for purposes of filing U.S. federal income tax returns of the Investor and such Investor&#8217;s Partners in connection with any such Qualified
Electing Fund election or Protective Statement. At the reasonable request of such Investor, the Company will obtain advice of professionals experienced in matters relating to the relevant aspects of the Code of its choice, to the extent necessary to
make the determination and to provide the information described above. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.7 <U>FCPA</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company covenants that it shall not (and shall not permit any of its subsidiaries or any of its or their respective directors,
officers, managers, employees, independent contractors, representatives or agents to) promise, authorize or make any payment to, or otherwise contribute any item of value to, directly or indirectly, to any third party, including any
&#8220;Government Official&#8221; (as defined in the Purchase Agreement), in each case, in violation of the U.S. Foreign Corrupt Practices Act (the &#8220;<B>FCPA</B>&#8221;) or any other applicable anti-bribery or anti-corruption law (collectively,
&#8220;<B>Anti-</B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<B>Corruption Laws</B>&#8221;). The Company further covenants that it shall (and shall cause each of its subsidiaries to) cease all of its or their respective known activities, as well as
remediate any known actions taken by the Company or its subsidiaries, or any of their respective directors, officers, managers, employees, independent contractors, representatives or agents, in violation of applicable Anti-Corruption Laws. The
Company further covenants that it shall (and shall cause each of its subsidiaries to) maintain commercially reasonable systems of internal controls (including, but not limited to, accounting systems, purchasing systems and billing systems) to
provide reasonable assurances regarding compliance with applicable Anti-Corruption Laws. Neither the Company or, to the knowledge of the Company, any representative of the Company, acting in such capacity, has or shall unlawfully establish or
maintain any unrecorded pool of the Company funds or assets or make any false, incomplete or misleading entries on any books or records of the Company for any purpose in any case which could reasonably result in a violation by or liability of the
Company pursuant to any applicable Anti-Corruption Laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.8 <U>CFIUS</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If and only if (i)&nbsp;the Committee on Foreign Investment in the United States, or any member agency thereof acting in such capacity
(&#8220;<B>CFIUS</B>&#8221;) requests or requires that the Company or an Investor file a notice or declaration with CFIUS pursuant to the U.S Defense Production Act of 1950 (&#8220;DPA&#8221;) with respect to an Investor&#8217;s investment in the
Company (the &#8220;<B>Covered Transaction</B>&#8221;), or (ii)&nbsp;the Company and an Investor mutually determine in good faith that a filing with CFIUS with respect to the Covered Transaction is advisable or required by applicable law, then in
either case (i)&nbsp;or (ii) (a &#8220;<B>CFIUS Filing Requirement</B>&#8221;), then (x)&nbsp;the Company and such Investor shall, and shall cause any affiliates to, cooperate and promptly make a CFIUS filing in the requested, required or advisable
form in accordance with the DPA; and (y)&nbsp;the Company and the Investor shall, and shall cause any Affiliates to, use commercially reasonable efforts to obtain, as applicable, the CFIUS Satisfied Condition. The &#8220;<B>CFIUS Satisfied
Condition</B>&#8221; shall be achieved when (i)&nbsp;the Company and the Investor shall have received written notice from CFIUS stating that: (A)&nbsp;CFIUS has concluded that the Covered Transactions do not constitute a &#8220;covered
transaction&#8221; subject to review under the DPA; or (B)&nbsp;the assessment, review or investigation of the Covered Transactions under the DPA has concluded that there are no unresolved national security concerns with respect to the Covered
Transaction; (ii)&nbsp;CFIUS has sent a report to the President of the United States requesting the President&#8217;s decision with respect to the Covered Transactions and either (A)&nbsp;the fifteen (15)&nbsp;day period under the DPA subsequent to
the President&#8217;s receipt of the CFIUS report during which the President may announce his decision to take action to suspend, prohibit or place any limitations on the Covered Transaction has expired without any such action being taken or
(B)&nbsp;the President of the United States has announced a decision not to take any action to suspend, prohibit or place any limitations on the Covered Transactions; or (iii)&nbsp;CFIUS has provided written notice that it is not able to complete
action under the DPA with respect to the Covered Transaction on the basis of a CFIUS declaration, but CFIUS has not requested that the Company and the Investor submit a CFIUS notice and has not initiated a unilateral CFIUS review, and the Company
and the Investor reasonably decide that the notice from CFIUS that it is not able to complete action is sufficient to constitute the CFIUS Satisfied Condition.. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company and any Investor subject to a CFIUS Filing Requirement shall cooperate with CFIUS and the other parties hereto in the event of
a CFIUS Filing Requirement. For the avoidance of doubt, neither the Company nor any Investor shall have an obligation to accept or take any action, condition or restriction with respect to the Covered Transactions in order to achieve the CFIUS
Satisfied Condition.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.9 <U>Sanctions</U>. The Company covenants that it shall not
engage in any unlawful dealings or transactions with or for the benefit of any Sanctioned Party, and that it shall comply in all material respects with all applicable Sanctions and other export control laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.10 <U>Anti-Money Laundering</U>. The Company covenants that it will not employ any
practice, procedure or policy in the conduct of its business that would constitute violation of any anti-money laundering laws or regulations applicable to the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.11 <U>ESG Matters</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The
Investors believe that companies proactively managing the environmental, social and governance (ESG) impacts of their business activities are better positioned for long-term success. As engaged owners, the Investors promote and support companies in
improving their ESG integration efforts. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company and the Investors recognize the importance of ESG and the Investors and the Key
Holders shall instruct the Board of Directors to work with the Company&#8217;s management team to agree on a plan aiming to define and strengthen the Company&#8217;s ESG efforts. The Board of Directors shall include ESG on the agenda of its meetings
at least annually and shall be responsible for monitoring progress made. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Company shall provide the Investors, if requested, with
reasonable assistance, including providing additional documents, reports and information, such as ESG KPIs, on a regular basis or on request and respond diligently to requests for information on ESG matters received from the Investors. In case any
breach of ESG laws and regulations has occurred, the Company shall proactively inform the Investors as soon as possible and the Company shall keep the Investors promptly informed of any material developments in ESG issues. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company recognizes the importance of effectively managing the climate impact of its business activities from a long-term risk and value
creation perspective. The Company commits to use reasonable efforts to evaluate and implement measures improve the Company&#8217;s CO2 footprint. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.12 <U>Limitation of Liability</U>. The aggregate liability of each Investor and its respective officers, directors, Affiliates, employees and
agents, for any and all claims, losses, costs or damages, including attorneys&#8217; and accountants&#8217; fees and expenses and costs of any nature whatsoever or claims or expenses resulting from or in any way related to such Investor&#8217;s
breach of the Transaction Agreements shall be several and not joint and shall not exceed the total pro rata invested amount actually paid to the Company or to Hemab ApS by such Investor for any shares of capital stock of the Company or Hemab ApS,
except in case of willful misconduct or fraud by such Investor, in which case the liability shall not be limited. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.13 <U>Termination of
Covenants</U>. The covenants set forth in this <U>Section</U><U></U><U>&nbsp;5</U>, except for <U>Section</U><U></U><U>&nbsp;5.4</U>, <U>Section</U><U></U><U>&nbsp;5.5</U> and <U>Section</U><U></U><U>&nbsp;5.11</U>, shall terminate and be of no
further force or effect (i)&nbsp;immediately before the consummation of the IPO; (ii)&nbsp;upon a Deemed Liquidation Event, whichever event occurs first; or (iii)&nbsp;with respect to any obligation to an Investor that is or becomes a Sanctioned
Party, for so long as such Investor is a Sanctioned Party. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Miscellaneous</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1 <U>Successors and Assigns</U>. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a
transferee of Registrable Securities in a transfer that complies with the provisions of the Right of First Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement, dated as of the date hereof, by and among the Company and the other
parties named therein; <U>provided</U>,<U> however</U>, that (x)&nbsp;the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect
to which such rights are being transferred; (y)&nbsp;such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of
<U>Section</U><U></U><U>&nbsp;2.11</U>; and (z)&nbsp;such assignee is not a Sanctioned Party. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties.
Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this
Agreement, except as expressly provided herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2 <U>Governing Law</U>. This Agreement shall be governed by the internal law of the
State of Delaware, without regard to conflict of law principles that would result in the application of any law other than the law of the State of Delaware. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3 <U>Counterparts</U>. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. Counterparts may be delivered via electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, <I>e.g.</I>, www.docusign.com) or other
transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.4 <U>Titles and Subtitles</U>. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in
construing or interpreting this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.5 <U>Notices</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. All notices and other communications given or made pursuant to this Agreement shall be in writing (including electronic
mail as permitted in this Agreement) and shall be deemed effectively given upon the earlier of actual receipt or (i)&nbsp;personal delivery to the party to be notified; (ii)&nbsp;when sent, if sent by electronic mail during the recipient&#8217;s
normal business hours, and if not sent during normal business hours, then on the recipient&#8217;s next business day; (iii)&nbsp;five days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or
(iv)&nbsp;one business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying <FONT STYLE="white-space:nowrap">next-day</FONT> delivery, with written verification of receipt. All
communications shall be sent to the respective parties at their addresses as set forth on <U>Schedule A</U> or <U>Schedule B</U> (as applicable) hereto, or (as to the Company) to the address set forth on the signature page hereto, or in any case to
such email address or address as subsequently modified by written notice given in accordance with this <U>Section</U><U></U><U>&nbsp;6.5</U>. If notice is given to the Company, a copy (which copy shall not constitute notice) shall also be sent to
Wilmer Cutler Pickering Hale and Dorr LLP, 60 State Street, Boston, MA 02109, Attn: Cynthia T. Mazareas, and if notice is given to any Investor, a copy (which copy shall not constitute notice) shall also be given to any &#8220;cc&#8221; address
noted on <U>Schedule A</U> for such Investor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Consent to Electronic Notice</U>. Each party to this Agreement consents to the
delivery of any stockholder notice pursuant to the Delaware General Corporation Law (the &#8220;<B>DGCL</B>&#8221;), as amended or superseded from time to time, by electronic mail pursuant to Section&nbsp;232 of the DGCL (or any successor thereto)
at the electronic mail address set forth below such party&#8217;s name on the Schedules hereto, as updated from time to time by notice to the Company, or as on the books of the Company. To the extent that any notice given by means of electronic mail
is returned or undeliverable for any reason, the foregoing consent shall be deemed to have been revoked until a new or corrected electronic mail address has been provided, and such attempted electronic notice shall be ineffective and deemed to not
have been given. Each party to this Agreement agrees to promptly notify the Company of any change in such stockholder&#8217;s electronic mail address, and that failure to do so shall not affect the foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.6 <U>Amendments and Waivers</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Any term of this Agreement may be amended, modified or terminated and the observance of any term of this Agreement may be waived (either
generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the Investor Majority; provided that the Company may in its sole discretion waive compliance with Section&nbsp;2.11(c)
(and the Company&#8217;s failure to object promptly in writing after notification of a proposed assignment allegedly in violation of Section&nbsp;2.11(c) shall be deemed to be a waiver); and <U>provided further</U> that any provision hereof may be
waived by any waiving party on such party&#8217;s own behalf, without the consent of any other party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding anything in this
Agreement to the contrary, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) this Agreement may not be amended, modified or terminated and the observance of any term hereof may not be
waived with respect to any Investor without the written consent of such Investor, unless such amendment, modification, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of
<U>Section</U><U></U><U>&nbsp;4</U> with respect to a particular transaction shall be deemed to apply to all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by
agreement with the Company, purchase securities in such transaction), provided further that the Company may in its sole discretion waive compliance with any provision of this Agreement if observance of the terms would cause the Company or any
Investor to be in violation of applicable Sanctions, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) no provision that names a specific Investor by name (nor this
<U>Section</U><U></U><U>&nbsp;6.6(b)(ii)</U> with respect to such Investor) may be amended or waived with respect to, or terminated pursuant to this <U>Section</U><U></U><U>&nbsp;6.6</U> relative to, such Investor without such Investor&#8217;s
written consent, and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) this Agreement may not be amended, modified or terminated, and no provision hereof may be waived, in each
case, in any way which would adversely affect the rights of the Key Holders hereunder in a manner disproportionate to any adverse effect such amendment, modification, termination or waiver would have on the rights of the Investors hereunder, without
also the written consent of the Qualified Key Holders holding a majority of the shares of Common Stock then held by the Qualified Key Holders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Further notwithstanding anything in this Agreement to the contrary, <U>Schedule A</U> hereto may be amended by the Company from time to
time to add transferees of any Registrable Securities in compliance with the terms of this Agreement without the consent of the other parties; and Schedule A hereto may also be amended by the Company after the date of this Agreement without the
consent of the other parties to add information regarding any additional Investor who becomes a party to this Agreement in accordance with <U>Section</U><U></U><U>&nbsp;6.9</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company shall give prompt written notice of any amendment, modification or termination hereof or waiver hereunder to any party hereto
whose rights and/or obligations were affected by such amendment, modification, termination, or waiver and that did not consent in writing to such amendment, modification, termination, or waiver; provided that the failure to provide such notice shall
not invalidate any amendment, modification, termination or waiver in accordance with this <U>Section</U><U></U><U>&nbsp;6.6</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Any
amendment, modification, termination, or waiver effected in accordance with this <U>Section</U><U></U><U>&nbsp;6.6</U> shall be binding on all parties hereto, regardless of whether any such party has consented thereto or received notice thereof.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) No waivers of or exceptions to any term, condition, or provision of this Agreement, in
any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.7 <U>Severability</U>. In case any provision contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in
any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid, legal, and
enforceable to the maximum extent permitted by law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.8 <U>Aggregation of Stock; Apportionment</U>. All shares of Registrable Securities
held or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliates may apportion such rights as among themselves in any manner they deem appropriate.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.9 <U>Additional Investors</U>. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of
Preferred Stock after the date hereof, any purchaser of such shares of Preferred Stock may become a party to this Agreement by executing and delivering a counterpart signature page to this Agreement, and thereafter shall be deemed an
&#8220;Investor&#8221; for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional Investor, so long as such additional Investor has agreed in writing to be bound by all
of the obligations as an &#8220;Investor&#8221; hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.10 <U>Entire Agreement</U>. This Agreement (including the Exhibits and
Schedules hereto) together with the other Transaction Agreements (as defined in the Exchange Agreement) and any Side Letters constitute the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and
any other written or oral agreement relating to the subject matter hereof existing between or among any of the parties are expressly canceled. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.11 <U>Dispute Resolution</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except as (i)&nbsp;otherwise provided in this Agreement, or (ii)&nbsp;any disputes, controversies, or claims arising out of either
party&#8217;s intellectual property rights for which a provisional remedy or equitable relief is sought, any unresolved dispute, controversy, or claim arising out of or relating to this Agreement or the breach, termination, enforcement,
interpretation, or validity thereof, including the determination of the scope or applicability of this agreement to arbitrate, shall be resolved by arbitration before a single arbitrator. Such arbitrator shall be mutually agreed upon by the parties,
and if no agreement can be reached within 30 days after names of potential arbitrators have been proposed by Judicial Arbitration and Mediation Services, Inc. (&#8220;<B>JAMS</B>&#8221;), then JAMS shall choose one arbitrator having reasonable
experience in corporate finance transactions of the type provided for in this Agreement. The arbitration shall take place in Delaware, pursuant to the JAMS Comprehensive Arbitration Rules and Procedures and in accordance with the Expedited
Procedures in those rules; provided, however, that there shall be limited discovery prior to the arbitration hearing as follows: (x)&nbsp;exchange of witness lists and copies of documentary evidence and documents relating to the issues to be
arbitrated, (y)&nbsp;depositions of all party witnesses, and (z)&nbsp;such other depositions as may be allowed by the arbitrators upon a showing of good cause. Depositions shall be conducted in accordance with the Delaware Code of Civil Procedure,
the arbitrator shall be required to provide in writing to the parties the basis for the award or order of such arbitrator, and a court reporter shall record all hearings, with such record constituting the official transcript of such proceedings.
Judgment on the award may be entered in any court having jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each of the parties to this Agreement consents to personal jurisdiction for any
equitable action sought in the U.S. District Court for the District of Delaware or any state court of Delaware having subject matter jurisdiction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) WAIVER OF JURY TRIAL:<B> </B>EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT
OF THIS AGREEMENT, THE OTHER TRANSACTION AGREEMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE <FONT STYLE="white-space:nowrap">ALL-ENCOMPASSING</FONT> OF ANY AND ALL DISPUTES THAT MAY BE
FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS
BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH
PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.12 <U>Costs of Enforcement</U>.
Each party will bear its own costs in respect of any disputes arising under this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.13 <U>Use of Name</U>. The Company, the
Investors and the Key Holders agree that without the prior written consent of the concerned party, which consent shall not be unreasonably withheld or delayed, none of the other parties hereto shall use, publish, reproduce, or refer to such other
party&#8217;s or its Affiliates&#8217; names, trademarks or logos, or any similar names, trademarks or logos in any public disclosures, including for marketing, advertising or publicity purposes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.14 <U>Delays or Omissions</U>. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon
any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or <FONT STYLE="white-space:nowrap">non-defaulting</FONT> party, nor shall it be construed to be a waiver of or
acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All
remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page Follows</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Investors&#8217; Rights Agreement as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COMPANY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Hemab Therapeutics Holdings, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Benny S&oslash;rensen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Benny S&oslash;rensen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Investors&#8217; Rights Agreement as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>NOVO HOLDINGS A/S</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ J&oslash;rgen S&oslash;berg Petersen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">J&oslash;rgen S&oslash;berg Petersen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Senior Partner</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Investors&#8217; Rights Agreement as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HEALTHCAP VIII L.P.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">through its investment manager HealthCap Investments S.A.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Oern Stuge</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Oern Stuge</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Senior Advisor</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Fabrice Bernhard</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Fabrice Bernhard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General manager</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Investors&#8217; Rights Agreement as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>RA CAPITAL HEALTHCARE FUND, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: RA Capital Healthcare Fund GP, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rajeev Shah</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Rajeev Shah</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Manager</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Investors&#8217; Rights Agreement as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>RA CAPITAL NEXUS FUND II, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: RA Capital Nexus Fund II GP, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rajeev Shah</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Rajeev Shah</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Manager</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Investors&#8217; Rights Agreement as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>RA CAPITAL NEXUS FUND IV, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: RA Capital Nexus Fund IV GP, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rajeev Shah</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Rajeev Shah</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Manager</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Investors&#8217; Rights Agreement as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AI <FONT STYLE="white-space:nowrap">DEN-MAB</FONT> LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: ACCESS INDUSTRIES MANAGEMENT, LLC,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Its Manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John McDonough</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">John McDonough</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Executive Vice President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Peter L. Thor&eacute;n</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter L. Thor&eacute;n</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President</P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Investors&#8217; Rights Agreement as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AVORO VENTURES FUND L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Avoro Ventures LLC,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">its Investment Manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Scott Epstein</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Scott Epstein</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Partner, Chief Operating Officer&nbsp;&amp; Chief Compliance Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Investors&#8217; Rights Agreement as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>DEEP TRACK BIOTECHNOLOGY MASTER FUND, LTD.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Nir Messafi</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Nir Messafi</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Person</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Investors&#8217; Rights Agreement as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVUS PUBLIC EQUITIES, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Raymond Debbane</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Raymond Debbane</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President of its General Partner</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Investors&#8217; Rights Agreement as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ROCK SPRINGS CAPITAL MASTER FUND LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Rock Springs General Partner LLC,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">its general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kris Jenner</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Kris Jenner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Member</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Investors&#8217; Rights Agreement as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>FOUR PINES MASTER FUND LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Four Pines General Partner LLC,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">its general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kris Jenner</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Kris Jenner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Member</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Investors&#8217; Rights Agreement as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MAJ INVEST MINORITIES I K/S</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jannick Dam Mortensen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jannick Dam Mortensen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Eva Buciek Foss</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Eva Buciek Foss</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Investors&#8217; Rights Agreement as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>John Maraganore</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Maraganore</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">John Maraganore</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Investors&#8217; Rights Agreement as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SOFINNOVA CROSSOVER II SLP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Joseph Anderson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Joseph Anderson</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Signatory</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Investors&#8217; Rights Agreement as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SMALLCAP WORLD FUND, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Capital Research and Management Company,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">as investment adviser for and on behalf of SMALLCAP World Fund, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jae W. Chung</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jae W. Chung</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Signatory</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Investors&#8217; Rights Agreement as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><FONT STYLE="white-space:nowrap">AL-RAYYAN</FONT> HOLDING LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ahmad Mohammed <FONT STYLE="white-space:nowrap">Al-Khanji</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ahmad Mohammed <FONT STYLE="white-space:nowrap">Al-Khanji</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> I<SMALL>NVESTORS</SMALL>&#8217;
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Investors&#8217; Rights Agreement as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AVORO LIFE SCIENCE FUND LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Avoro Capital Advisors LLC,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">its Investment Manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Scott Epstein</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Scott Epstein</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Partner, Chief Operating Officer&nbsp;&amp; Chief Compliance Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Investors&#8217; Rights Agreement as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>DEEP TRACK SPECIAL OPPORTUNITIES FUND, LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Nir Messafi</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Nir Messafi</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Person</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Investors&#8217; Rights Agreement as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MAJ INVEST MINORITIES II K/S</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jannick Dam Mortensen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jannick Dam Mortensen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Eva Buciek Foss</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Eva Buciek Foss</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Investors&#8217; Rights Agreement as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>KEY PERSONS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Benny S&oslash;rensen</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Benny S&oslash;rensen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Benny S&oslash;rensen</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Investors&#8217; Rights Agreement as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>KEY PERSONS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Mads Nikolaj Behrndt-Eriksen</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mads Nikolaj Behrndt-Eriksen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mads Nikolaj Behrndt-Eriksen</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Investors&#8217; Rights Agreement as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>KEY HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EBUMAB HOLDING APS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Johan Faber</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Johan Faber</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director &#8211; Founder</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#8195;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hans Wandall</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Investors&#8217; Rights Agreement as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>KEY HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EBUMAB HOLDING APS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#8195;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Johan Faber</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Hans Wandall</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Hans Wandall</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chairman</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Investors&#8217; Rights Agreement as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>KEY HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>GV1 HOLDING APS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ S&oslash;ren Bj&oslash;rn</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">S&oslash;ren Bj&oslash;rn</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Member</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Investors&#8217; Rights Agreement as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>KEY HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>WANDALL HOLDING APS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Hans Wandall</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Hans Wandall</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chairman</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Investors&#8217; Rights Agreement as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>KEY HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>JOHAN H. FABER APS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Johan Faber</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Johan Faber</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director &#8211; Founder</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Investors&#8217; Rights Agreement as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>KEY HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BATCHELOR HOLDING APS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Thomas Dal Stenfeldt Batchelor</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Thomas Dal Stenfeldt Batchelor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">SVP, Novonesis</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Investors&#8217; Rights Agreement as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>KEY HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MABE INVEST APS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mads Nikolaj Behrndt-Eriksen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mads Nikolaj Behrndt-Eriksen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INVESTORS </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE B </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KEY HOLDERS </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>7
<FILENAME>d50309dex104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain portions of this exhibit have been omitted because they are not material and is the type of information that the registrant treats as
private or confidential. Double asterisks denote omissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">for BiAb <FONT STYLE="white-space:nowrap">FVII/TLT-1</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">by and between </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Novo Nordisk
A/S </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ebumab
Hemophilia ApS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Effective Date </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>22 November 2019 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This LICENSE AGREEMENT (this &#8220;<B>Agreement</B>&#8221;)<B> </B>is entered into as of 22&nbsp;November 2019 (the &#8220;Effective Date&#8221;) by and
between Novo Nordisk A/S, a Danish corporation, CVR No.&nbsp;24256790, with address at Novo All&eacute;, <FONT STYLE="white-space:nowrap">DK-2880</FONT> Bagsv&aelig;rd, Denmark (&#8220;<B>Novo Nordisk</B>&#8221;),<B> </B>and Ebumab Hemophilia ApS, a
Danish corporation, CVR No.40837590, with address at Ole Maal&oslash;es Vej 3, <FONT STYLE="white-space:nowrap">DK-2200</FONT> Copenhagen N, Denmark (&#8220;<B>Licensee</B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novo Nordisk and Licensee are sometimes referred to herein individually as a &#8220;<B>Party</B>&#8221;<B> </B>and collectively as the
&#8220;<B>Parties</B>&#8221;. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,<B> </B>in 2017, Novo Nordisk and Genmab A/S have entered into a License and Option Agreement (the
&#8220;<B>LOA</B>&#8221;),<B> </B>granting Novo Nordisk a license under Genmab&#8217;s proprietary technology relating to bispecific antibodies for targeting proteins involved in various diseases (the &#8220;<B>DuoBody</B><B><SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP></B><B> Platform Technology</B>&#8221;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,<B> </B>with use of the
DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Platform Technology, Novo Nordisk has conducted a research project (&#8220;<B>Project</B>&#8221;),<B> </B>resulting in certain patents,
<FONT STYLE="white-space:nowrap">know-how</FONT> and materials (&#8220;<B>Novo Technology</B>&#8221;)<B> </B>with regard to the therapeutic approach and the concept of a bispecific human IgGl antibody targeting
<FONT STYLE="white-space:nowrap">TLT-1</FONT> and FVII for the treatment of haemophilia A; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,<B> </B>Novo Nordisk
discontinued the Project in June 2018 due to strategical changes of resource prioritisation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,<B> </B>Johan Faber was
employed as a research scientist and department manager at Novo Nordisk and was involved in the Project; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,<B> </B>upon
termination of his employment at Novo Nordisk, Johan Faber incorporated Ebumab Hemophilia ApS (Licensee); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,<B> </B>Licensee
desires to obtain from Novo Nordisk a commercial license under the Novo Technology for the further validation and engineering of, and to make, use, distribute and sell a bispecific antibody drug targeting
<FONT STYLE="white-space:nowrap">TLT-1</FONT> and FVII for the treatment of bleeding conditions, including haemophilia (&#8220;<B>Products</B>&#8221;). To be able to share the Novo Technology with EH, or with any other Third Party, Novo Nordisk
requires the express written authorization from Genmab. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,<B> </B>Genmab has granted Licensee a preliminary license under
the DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Platform Technology to allow for further research of the Novo Technology (the &#8220;<B>Research Evaluation Agreement</B>&#8220;<B> </B>and Genmab has, in a side letter to the
LOA, authorized Novo Nordisk the right to, simultaneously and under certain restrictions, grant Licensee a commercial license under the Novo Technology; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,<B> </B>Novo Nordisk now wishes to grant Licensee such commercial license in accordance with the terms and conditions of this
agreement (this &#8220;<B>Agreement</B>&#8221;); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOW THEREFORE</B>,<B> </B>in consideration of the premises and the mutual promises and covenants
contained in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 1. DEFINITIONS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All references to particular
Exhibits, Articles and Sections shall mean the Exhibits to and Articles and Sections of this Agreement, unless otherwise specified. For the purposes of this Agreement and the Exhibits hereto, the following words and phrases shall have the following
meanings: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Affiliate</B>&#8221;<B> </B>means, with respect to any Person, any other Person which controls, is controlled by or is under common
control with such Person, for as long as such control exists. For purposes of this Section, &#8220;control&#8221; shall mean the direct or indirect ownership of more than fifty percent (50%) of the voting or economic interest of a Person, or the
power, whether pursuant to contract, ownership of securities or otherwise, to direct the management and policies of a Person. For clarity, once a Person ceases to be an Affiliate of a Party, then, without any further action, such Person shall cease
to have any rights, including license and sublicense rights, under this Agreement by reason of being an Affiliate of such Party. For purposes of this definition Novo A/S and the Novo Foundation and their affiliates (other than Novo Nordisk and its
subsidiaries) are not considered Affiliates of Novo Nordisk. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Audited Party</B>&#8221;<B> </B>shall have the meaning set forth in
Section&nbsp;3.7 (Records and Audits). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Auditor</B>&#8221;<B> </B>shall have the meaning set forth in Section&nbsp;3.7 (Records and Audits).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>BiAb <FONT STYLE="white-space:nowrap">FVII/TLT-1</FONT></B>&#8221;<B> </B>shall mean an IgG antibody with two (2)&nbsp;different binding arms,
targeting <FONT STYLE="white-space:nowrap">TLT-1</FONT> and FVII. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Confidential Information</B>&#8221;<B> </B>shall have the meaning set forth
in Section&nbsp;8.1.1 (Confidential Information). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Control</B>&#8221;<B> </B>or &#8220;<B>Controlled</B>&#8221;<B> </B>means, with respect to
any <FONT STYLE="white-space:nowrap">Know-How,</FONT> Materials, Patent Right, or other intellectual property right, the possession (whether by ownership or license) by a Party or its Affiliate of the ability to grant to the other Party a license or
access as provided herein to such <FONT STYLE="white-space:nowrap">Know-How,</FONT> Materials, Patent Right, or other intellectual property right, without violating the terms of any agreement or other arrangement with any Third Party in existence as
of the time such Party or its Affiliates would first be required hereunder to grant the other Party such license or access. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Cover</B>&#8221;<B>
</B>means a Valid Claim of a Patent Right that would (absent a license thereunder or ownership thereof) be Infringed by the Exploitation of the Product; provided, however, that in determining whether a Valid Claim that is a claim of a pending
application would be Infringed, such claim shall be treated as if issued as then currently being prosecuted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Disclosing Party</B>&#8221;<B>
</B>shall have the meaning set forth in Section&nbsp;8.1.1 (Confidential Information). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>EMA</B>&#8221;<B> </B>means the European Medicines
Agency or any successor entity thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Exploit</B>&#8221;<B> </B>means to research, develop, make, have made, use, offer for sale, sell,
import, export or otherwise exploit, or transfer possession of or title in, a Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>FDA</B>&#8221;<B> </B>means the United States Food and
Drug Administration or any successor entity thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>First Commercial Sale</B>&#8221;<B> </B>means, with respect to any Product in any country,
the first sale for end use or consumption of such Product in such country after Marketing Approval has been granted in such country. Sales for clinical studies, compassionate use, named patient programs, sales under the treatment IND, any <FONT
STYLE="white-space:nowrap">non-registrational</FONT> studies, or any similar instance where the Product is sold at cost or supplied without charge such as clinical supplies, free samples (promotional or otherwise) or as donations (for example to <FONT
STYLE="white-space:nowrap">non-profit</FONT> institutions or government agencies for a <FONT STYLE="white-space:nowrap">non-commercial</FONT> purpose) shall not constitute a First Commercial Sale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>FVII</B>&#8221;<B> </B>means the coagulation factor VII protein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>GAAP</B>&#8221;<B> </B>means the enacted Generally Accepted Accounting Principles, consistently applied. Unless otherwise defined or stated herein,
financial terms shall be calculated under GAAP, or under IFRS if in the EU. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Genmab</B>&#8221;<B> </B>means Genmab A/S, a Danish company, with
principal offices located at Kalvebod Brygge 43, <FONT STYLE="white-space:nowrap">DK-1560</FONT> Copenhagen V, Denmark, CVR no. 2102 3884. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Gcnmab-Licensee CLA</B>&#8221;<B> </B>means the license agreement for commercial use by Licensee of the DuoBody<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Platform Technology for the development and commercialization of bispecific antibody drug directed at <FONT STYLE="white-space:nowrap">TLT-l/FVII.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Governmental Authority</B>&#8221;<B> </B>means any court, agency, department, authority or other instrumentality of any national, state, county,
city or other political subdivision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>IFRS</B>&#8221;<B> </B>means the enacted International Financial Reporting Standards, consistently
applied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Infringe</B>&#8221;<B> </B>or &#8220;<B>Infringement</B>&#8221;<B> </B>means any infringement as determined by Law, including, without
limitation, direct infringement, contributory infringement or any inducement to infringe. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Initiation</B>&#8221;<B> </B>means, with respect to a
clinical trial, the first dosing in the first human subject in such clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B><FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#8221;<B> </B>means techniques, technology, inventions (whether patentable or not), methods, <FONT
STYLE="white-space:nowrap">know-how,</FONT> data and results (including pharmacological, toxicological and clinical data and results), analytical and quality control data and results, and other similar information, in any tangible or intangible form
whatsoever, that is not in the public domain or otherwise publicly known. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Law</B>&#8221;<B> </B>means, individually and collectively, any and
all laws, ordinances, rules, directives, administrative circulars and regulations of any kind whatsoever of any Governmental Authority within the applicable jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>License</B>&#8221;<B> </B>means the license granted by Novo Nordisk to Licensee as defined in Section&nbsp;2.1.1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Licensed Field</B>&#8221;<B> </B>means the treatment of bleeding conditions, including
haemophilia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Licensee Indemnified Parties</B>&#8221;<B> </B>shall have the meaning set forth in Section&nbsp;7.1.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Licensee Patents</B>&#8221;<B> </B>means any Patent Right that (a)&nbsp;is Controlled by Licensee during the Term of this Agreement and
(b)&nbsp;claims an invention that is developed by Licensee, its Affiliates or Sublicensees during the Exploitation of the Product(s) and incorporates, is derived from, or relied on, the Novo Technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>LOA</B>&#8221;<B> </B>means the License and Option Agreement, with effective date 22&nbsp;December 2017, between Novo Nordisk and Genmab A/S for the
use by Novo Nordisk of Genmab&#8217;s proprietary DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Platform Technology; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Losses</B>&#8221;<B> </B>shall have the meaning set forth in Section&nbsp;7.1.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Marketing Approval</B>&#8221;<B> </B>means all approvals, licenses, registrations or authorizations of the Regulatory Authority in a country,
necessary for the manufacture, use, storage, import, marketing and sale of a Product in such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Materials</B>&#8221;<B> </B>means those
samples and/or materials that are part of the Novo <FONT STYLE="white-space:nowrap">Know-How</FONT> and listed in Exhibit B. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Milestone
Event</B>&#8221;<B> </B>shall have the meaning set forth in Section&nbsp;3.1.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Milestone Payment</B>&#8221;<B> </B>shall have the meaning set
forth in Section&nbsp;3.1.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Net Sales</B>&#8221;<B> </B>means, [**]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Novo Indemnified Parties</B>&#8221;<B> </B>shall have the meaning set forth in Section&nbsp;7.1.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Novo <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#8221;<B> </B>means the materials and <FONT STYLE="white-space:nowrap">Know-How</FONT>
relating to the therapeutic approach and the format of Bi Ab <FONT STYLE="white-space:nowrap">FVII/TLT-1,</FONT> as existing on the Effective Date, Controlled by Novo Nordisk and either generated as a result of, or applied in, the Project, as listed
in <U>Exhibit B</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Novo Patents</B>&#8221;<B> </B>means the Patent Rights listed in <U>Exhibit A</U>, and any additions, divisions,
continuations, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> substitutions, and reissues claiming priority thereto, as well as any <FONT STYLE="white-space:nowrap">re-examinations,</FONT>
extensions, registrations, patent term extensions, supplemental protection certificates, renewals and the like with respect to any of the foregoing and all foreign counterparts thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Novo Technology</B>&#8221;<B> </B>means the Novo Patents and Novo <FONT STYLE="white-space:nowrap">Know-How,</FONT> Controlled by Novo Nordisk at
the Effective Date of the Agreement. For clarity, Novo Technology does not include the DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Platform Technology as licensed by Novo Nordisk from Genmab and used by Novo during the Project.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Patent Rights</B>&#8221;<B> </B>means any provisional and <FONT STYLE="white-space:nowrap">non-provisional</FONT> patents and patent
applications, together with all additions, divisions, continuations, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> substitutions, and reissues claiming priority thereto, as well as any <FONT
STYLE="white-space:nowrap">re-examinations,</FONT> extensions, registrations, patent term extensions, supplemental protection certificates, renewals and the like with respect to any of the foregoing and all foreign counterparts thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Person</B>&#8221;<B> </B>means any corporation, limited or general partnership, limited liability
company, joint venture, trust, unincorporated association, governmental body, authority, bureau or agency, any other entity or body, or an individual. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Phase 2 Clinical Trial</B>&#8221;<B> </B>means any human clinical trial of a Product that would satisfy the requirements of 21 CFR &#167; 312.21(b)
(as amended or any replacement thereof), or its <FONT STYLE="white-space:nowrap">non-United</FONT> States equivalents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Product</B>&#8221;<B>
</B>means any product, containing BiAb <FONT STYLE="white-space:nowrap">FVII/TLT-1,</FONT> which (i)&nbsp;is Covered by a Valid Claim of the Novo Patents, or (ii)&nbsp;incorporates, is derived from, or is developed using, or relied on, the Novo <FONT
STYLE="white-space:nowrap">Know-How</FONT> or (iii)&nbsp;is made by a process Covered by any Valid Claim of the Novo Patents and/or that utilizes the Novo <FONT STYLE="white-space:nowrap">Know-How.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Project</B>&#8221;<B> </B>means the BiAb <FONT STYLE="white-space:nowrap">FVII/TLT-1</FONT> research project conducted by Novo Nordisk, with
internal reference code [**], which was discontinued in [**]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Receiving Party</B>&#8221;<B> </B>shall have the meaning set forth in
Section&nbsp;8.1.1 (Confidential Information). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Regulatory Authority</B>&#8221;<B> </B>means any Governmental Authority or other authority
responsible for granting Marketing Approvals for Products, including without limitation, the FDA, EMA and any corresponding national or regional regulatory authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Research Evaluation Agreement</B>&#8221;<B> </B>means the preliminary license agreement entered into between Genmab and Licensee, which allows for
Licensee&#8217;s research of the Novo Technology using the DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Platform Technology, with effective date [**]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Royalty Term</B>&#8221;<B> </B>shall have the meaning set forth in Section&nbsp;3.2.3 (Royalty Term). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Selling Party</B>&#8221;<B> </B>shall have the meaning set forth in the definition of Net Sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Sublicensee</B>(<B>s</B>)&#8221;<B> </B>shall mean any Third Party to which Licensee has granted a sublicense under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Term</B>&#8221;<B> </B>shall have the meaning set forth in Section&nbsp;9.1 (Term). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Territory</B>&#8221;<B> </B>means the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Third Party</B>&#8221;<B> </B>means a Person other than (a)&nbsp;Novo Nordisk or any of its Affiliates and (b)&nbsp;Licensee or any of its
Affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B><FONT STYLE="white-space:nowrap">TLT-1</FONT></B>&#8221;<B> </B>means the TREM-like transcript 1 protein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Valid Claim</B>&#8221;<B> </B>means, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis,
an issued and unexpired claim within the Novo Patents or a pending claim in a patent application within the Novo Patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Work
Plan</B>&#8221;<B> </B>means the research work plan as set out in <U>Exhibit C</U> of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 2. INTELLECTUAL PROPERTY AND LICENSE GRANT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section<U></U>&nbsp;2.1 <U>License Grant</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.1.1</B> <B><U>License. </U></B>Subject to the terms and conditions of this Agreement, Novo Nordisk hereby grants to Licensee: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an exclusive (even with respect to Novo Nordisk), worldwide, royalty-bearing license, including the right to
sublicense, to the Novo Patents; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide, royalty-bearing license, including the
right to sublicense, to the Novo <FONT STYLE="white-space:nowrap">Know-How;</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in each case, to Exploit Product(s) in the Licensed
Field in the Territory (the &#8220;<B>License</B>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.1.2</B> <B><U>Temporary Limited License</U></B>. The Parties have agreed that, during the
first [**] of the Term, Licensee shall strictly limit its activities under the License to the <FONT STYLE="white-space:nowrap">non-</FONT> clinical activities as specified in the Work Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;2.2</B> <B><U>Ownership of IP</U></B>. As between the Parties and subject to the License grant, Novo Nordisk will
continue to own the rights in the Novo Technology. For clarity, Licensee will own all data, <FONT STYLE="white-space:nowrap">Know-How,</FONT> and inventions (including Patent Rights claiming such inventions) generated by or on behalf of Licensee,
its Affiliates and Sublicensees during the Exploitation of the Product(s) in the Licensed Field in the Territory after the Effective Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;2.3</B> <B><U>Sublicenses</U></B>. As of [**], and on the condition that the Genmab- Licensee CLA is effective, Licensee
shall be entitled, subject to Section&nbsp;2.6 (Right of First Negotiation) and the payments as set forth in Article 3, to grant sublicenses by a written agreement to its Affiliates or to Third Parties (with the right to sublicense through multiple
tiers) without the prior written consent of Novo Nordisk, provided, however, that as a condition precedent to and requirement of any such sublicense: (a)&nbsp;any such permitted sublicense shall be consistent with and subject to the terms and
conditions of this Agreement; and (b)&nbsp;Licensee will continue to be responsible for full performance of its obligations under this Agreement and will be responsible for all actions of the Sublicensee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section<U></U>&nbsp;2.4 <U>Transfer of Novo <FONT STYLE="white-space:nowrap">Know-How</FONT></U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.4.1</B> Upon the Effective Date, Novo Nordisk shall transfer to Licensee the Novo <FONT STYLE="white-space:nowrap">Know-How</FONT> listed in Exhibit B.
The Parties will agree on a transfer plan to initiate the transfer to Licensee. On Novo Nordisk&#8217;s side, all communications regarding the transfer plan shall go through [**] (employee initials as known to the Parties). Licensee shall not
contact or communicate with any other Novo Nordisk <FONT STYLE="white-space:nowrap">co-worker</FONT> for this purpose, unless instructed otherwise in writing. Novo Nordisk shall compile and provide Licensee with access to the Novo <FONT
STYLE="white-space:nowrap">Know-How</FONT> in accordance with the transfer plan, including in the format specified therein. During the transfer of Novo <FONT STYLE="white-space:nowrap">Know-How,</FONT> Novo Nordisk shall reasonably assist Licensee
with advice and support free of charge. The work includes preparation of data in interpreted format as necessary to complete the transfer. The Parties estimate that the transfer of Novo <FONT STYLE="white-space:nowrap">Know-How</FONT> will have been
completed within [**]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.4.2</B> Licensee acknowledges that, except as expressly set forth in Section&nbsp;6.2 (Additional Novo
Nordisk Representations and Warranties), the Novo <FONT STYLE="white-space:nowrap">Know-How</FONT> is provided &#8220;as is&#8221; and without any representation or warranty, express or implied, as to its accuracy or completeness, including, without
limitation, any implied warranty of merchantability or fitness for a particular purpose, or any warranty that use of the Novo <FONT STYLE="white-space:nowrap">Know-How</FONT> will not infringe or violate any patent or other proprietary rights of any
third party. Acceptance of the Novo <FONT STYLE="white-space:nowrap">Know-How</FONT> will constitute acceptance by Licensee of liability for any damages or injuries resulting from its possession or use of the Novo
<FONT STYLE="white-space:nowrap">Know-How.</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.4.3</B> Licensee hereby agrees to use the Materials in compliance with any and all applicable laws
and regulations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.4.4</B> Licensee acknowledges that the Materials transferred by Novo Nordisk to Licensee under this Agreement are experimental in
nature and may have unknown characteristics and therefore agrees to use prudence and reasonable care in the use, handling, storage, transportation and disposition and containment of any such Materials. Accordingly, no Materials shall be used in any
human application, including any clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;2.5</B> <B><U>No Other Rights</U></B>. Licensee acknowledges that
the rights and licenses granted under this Article 2 (Intellectual Property and License Grant) and elsewhere in this Agreement are limited to the scope expressly granted. Accordingly, except for the rights expressly granted under this Agreement, no
right, title, or interest of any nature whatsoever is granted whether by implication, estoppel, reliance, or otherwise, by Novo Nordisk to Licensee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;2.6</B> <B><U>Right of First Negotiation</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.6.1</B> Licensee hereby grants to Novo Nordisk a right of first negotiation (&#8220;<B>ROFN</B>&#8221;)<B> </B>to obtain a license back from Licensee to
Exploit the Product in the Licensed Field in the Territory. Novo Nordisk&#8217;s ROFN shall expire [**] after Licensee [**] (the &#8220;<B>ROFN Expiration Date</B>&#8221;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.6.2</B> If, before the ROFN Expiration Date, Licensee decides to discuss with a Third Party the terms under which such Third Party, either alone or
together with Licensee or Licensee&#8217;s Affiliate(s), shall Exploit the Product in the Licensed Field, Licensee shall notify Novo Nordisk in writing, and provide to Novo Nordisk all information in Licensee&#8217; Control as reasonably necessary
or useful for Novo Nordisk to evaluate its interest, and Novo Nordisk shall have [**] to exercise its ROFN by providing Licensee with a written notice to confirm its interest in obtaining an exclusive license from Licensee to Exploit the Product in
the Licensed Field. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.6.3</B> If Novo Nordisk exercises its ROFN within such [**], Novo Nordisk shall have the exclusive right, during the next [**],
which period may be extended by mutual written agreement of the Parties, to negotiate with Licensee in good faith regarding the terms and conditions of a license agreement under which Licensee would grant such an exclusive license to Novo Nordisk.
During this exclusive negotiation period, Licensee shall neither license or otherwise grant to any Third Party, nor engage in any negotiations or other discussions with any Third Party regarding any agreement to license or otherwise grant to any
Third Party, any rights to Exploit the Product in the Licensed Field in the Territory. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.6.4</B> If Novo Nordisk does not exercise its ROFN within such [**], or if Novo Nordisk exercises its
ROFN within such [**] but the negotiation has not resulted in a binding written agreement by the end of such [**], then Licensee shall be free to negotiate with any Third Party with respect to such a license and to grant such a license to any Third
Party, without any further obligations to Novo Nordisk. For clarity, Licensee shall have no obligation to share with or offer to Novo Nordisk the terms negotiated by Licensee with such Third Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.6.5</B> In all instances Licensee shall provide Novo Nordisk and the Third Party or Third Parties with information that is substantially the same. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 3. FEES, ROYALTIES&nbsp;&amp; PAYMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section<U></U>&nbsp;3.1 <U>Milestone Payment and Milestone Event</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.1.1 Licensee shall pay to Novo Nordisk the following <FONT STYLE="white-space:nowrap">one-time</FONT> milestone payment (&#8220;Milestone Payment&#8221;)
following the first occurrence of the milestone event set forth below with respect to a Product (the &#8220;Milestone Event&#8221;): </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Milestone Event</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Figures in Danish kroner (DKK)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[**]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">40,000,000</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.1.2</B> Licensee shall pay to Novo Nordisk the applicable Milestone Payment within [**] after the first achievement by
Licensee, its Affiliates or its Sublicensees of an applicable Milestone Event. The Milestone Payment shall be <FONT STYLE="white-space:nowrap">non-refundable</FONT> and <FONT STYLE="white-space:nowrap">non-creditable.</FONT> For clarity, the
Milestone Payment is a <FONT STYLE="white-space:nowrap">one-time</FONT> payment only, regardless of the number of times the Milestone Event is achieved or the number of Products that achieve the Milestone Event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section<U></U>&nbsp;3.2 <U>Royalties and Other Payments</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.2.1</B> <B><U>Royalty Rate</U></B>. Licensee shall pay to Novo Nordisk the tiered royalties set forth in the following table on annual worldwide Net Sales
of the Product(s) sold by a Selling Party calculated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> during the applicable Royalty Term for each country, and then aggregated to determine the
following tiers of annual worldwide Net Sales: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Annual Net Sales in DKK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Royalty Rate</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#8804; [**]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[**]%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">between [**] and <BR>&#8804; [**]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[**]%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&gt; [**]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[**]%</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Example: if the aggregate annual Net Sales of the Product(s) is DKK [**], the amount of the royalties
payable for that period (without considering any applicable royalty reductions) is calculated as follows: [**]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.2.2</B> <B><U>Royalty Term</U></B>.
Any such royalty payments shall be made within [**] of the end of each calendar quarter. Licensee&#8217; obligation to pay royalties with respect to a Product in a particular country of sale shall commence upon the First Commercial Sale of such
Product in such country and shall expire on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT>
basis on the later of (a)&nbsp;the expiration of the last to expire Valid Claim within any Novo Patent that Covers such Product in such country, or (b)&nbsp;the tenth (10th) anniversary of the First Commercial Sale of such Product in such country
(the &#8220;<B>Royalty Term</B>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;3.3</B> <B><U>Method of Payment</U></B>. Unless otherwise agreed by the
Parties, all payments due from Licensee to Novo Nordisk under this Agreement shall be paid Danish kroner by wire transfer or electronic funds transfer of immediately available funds to the following account: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficiary Name: [**] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficiary Account #: [to be specified
at the time] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bank Name: [to be specified at the time] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BIC
Code: [to be specified at the time] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;3.4</B> <B><U>Royalty Reports</U></B>. After the First Commercial Sale of the
first Product and until expiration of the last Royalty Term, Licensee shall prepare and deliver to Novo Nordisk royalty reports of the sale of Products by the Selling Parties for each calendar quarter within [**] of the end of each such calendar
quarter specifying in the aggregate and on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> basis: (a)&nbsp;total gross amounts for Products sold or otherwise disposed of by a Selling Party;
(b)&nbsp;amounts deducted by category, in accordance with the definition of Net Sales in Article 1, from gross amounts to calculate Net Sales; (c)&nbsp;Net Sales; and (d)&nbsp;royalties payable. To the extent Licensee generates for its own purposes
such information on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, then it shall provide such information on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;3.5</B>
<B><U>Currency Conversion</U></B>. In the case of sales outside Denmark, payments received by Licensee will be expressed in the DKK equivalent calculated on a quarterly basis in the currency of the country of sale and converted to their DKK
equivalent using the average rate of exchange over the applicable calendar quarter to which the sales relate, in accordance with the rates of exchange used by Licensee in producing its quarterly and annual reports to its shareholders, as confirmed
by Licensee&#8217;s independent public accountants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;3.6</B> <B><U>Late Payments</U></B>. In the event that any
undisputed payment due hereunder is not made when due, Novo Nordisk is entitled to charge interest on such late payment beginning on the day following the due date thereof, calculated annually at the sum of (a) [**] percent ([**]%) plus (b)&nbsp;the
LIBOR interest rate on the date said payment is due, the interest being compounded on the last day of each calendar quarter; provided, however, that in no event shall said annual interest rate exceed the maximum rate permitted by Law. If requested
by Novo Nordisk each such undisputed late payment when made shall be accompanied by all interest so accrued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;3.7</B> <B><U>Records and Audits</U></B>. Licensee will keep complete
and accurate records relating to the calculations of Net Sales generated in the then current calendar year and payments required under this Agreement, and during the preceding [**]. Novo Nordisk will have the right during the Term and for a period
of [**] thereafter, [**] at its own expense, to have an internationally recognized, independent, certified public accounting firm, currently one of the following: [**] (the &#8220;<B>Auditor</B>&#8221;),<B> </B>selected by it, review any such
records of Licensee and its Affiliates and Sublicensees (the &#8220;<B>Audited Party</B>&#8221;)<B> </B>in the location(s) where such records are maintained by the Audited Party subject to the following terms: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Novo Nordisk shall give Licensee at least [**] prior written notice of when its Auditor shall visit the Audited
Party; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at least [**] prior to inspecting any records, the Auditor must enter into a confidentiality agreement with the
Audited Party that is reasonably satisfactory to the Audited Party; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Licensee shall make their books and records available for review by the Auditor solely to verify the accuracy
of its Net Sales report and payments under this Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Licensee shall give access to the Auditor during regular business hours at the place or places where the books
and records are usually kept. While inspecting such accounts and records, the Auditor must abide by all of Licensee&#8217; standard rules and regulations and the Auditor will not be entitled to take copies of any such accounts and records;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Auditor shall prepare and deliver to each Party a report setting out its findings no later than [**] after
the audit has been completed. The Auditor shall share its findings with Licensee prior to delivering the report in order for the parties to in good faith discuss any discrepancies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any report by the Auditor under this Section&nbsp;3.7 shall be deemed Confidential Information of Licensee and
Novo Nordisk shall keep such report and any other information received or learnt in connection with the audit confidential; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">no [**] will be subject to audit under this Section&nbsp;3.7 more than [**]; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">should such inspection lead to the discovery of a discrepancy to Novo Nordisk&#8217;s detriment, Licensee will,
within [**] after receipt of such report from the accounting firm, pay any undisputed amount of the discrepancy together with interest at the rate set forth in Section&nbsp;3.6 (Late Payments). Novo Nordisk will pay the full cost of the review
unless the underpayment of amounts due to Novo Nordisk is greater than [**] percent ([**]%) of the amount due for the entire period being examined, in which case Licensee will pay the cost charged by such accounting firm for such review. Should the
audit lead to the discovery of a discrepancy to Licensee&#8217; detriment, Licensee may deduct the amount of the discrepancy, without interest, against future payments payable to Novo Nordisk under this Agreement, and if there are no such payments
payable, then Novo Nordisk shall pay to Licensee the amount of the discrepancy, without interest, within [**] of Novo Nordisk&#8217;s receipt of the report. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;3.8</B> <B><U>Taxes</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.8.1</B> <B><U>Sales Tax</U></B>. Licensee is responsible for the payment of any state or local, sales or use, or similar fees or taxes arising as a result
of the transfer of Materials by Novo Nordisk to Licensee pursuant to Section&nbsp;2.4.1 (but excluding any income taxes), and Licensee will remit such fees or taxes to Novo Nordisk, as the collection agent, upon invoice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.8.2</B> <B><U>Withholding</U></B>. If the applicable Law requires that taxes be withheld with respect to any payments by Licensee to Novo Nordisk under
this Agreement, Licensee may: (a)&nbsp;deduct those taxes from the remittable payment, (b)&nbsp;pay the taxes to the proper taxing authority, and (c)&nbsp;send evidence of the obligation together with proof of tax payment to Novo Nordisk on a timely
basis following that tax payment. Each Party agrees to reasonably cooperate with the other Party in claiming refunds or exemptions from such deductions or withholdings under any relevant agreement or treaty which is then in effect (e.g., Licensee
shall not withhold withholding tax without first confirming with Novo Nordisk that Novo Nordisk is not able to provide the documentation of its taxable status and Licensee shall delay making any payment to the extent requested by Novo Nordisk for
the purpose of Novo Nordisk receiving and/or providing such documentation). Upon written request by Novo Nordisk, Licensee shall provide Novo Nordisk with official receipts issued by the appropriate governmental agency documenting the amount of any
withholding tax or any other information as is reasonably requested by Novo Nordisk. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.8.3</B> <B><U>VAT</U></B><B>. </B>All payments shall be based on
invoices and applied value added tax according to local regulation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 4. PATENT PROSECUTION, MAINTENANCE, &amp; INFRINGEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section<U></U>&nbsp;4.1 <U>Prosecution, Maintenance and Enforcement</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.1.1</B> Until [**] after the Effective Date, Novo Nordisk shall be responsible, at its own risk and cost, for the prosecution, maintenance and enforcement
of the Novo Patents, including the defense and settlement of claims from Third Parties regarding the Novo Patents; provided that Novo Nordisk may not discontinue its prosecution, maintenance or enforcement of the Novo Patents without
Licensee&#8217;s prior written approval. Licensee shall reasonably cooperate with and assist Novo Nordisk in the prosecution, maintenance and enforcement of the Novo Patents and Novo Nordisk shall reimburse Licensee for its reasonable expenses
incurred in connection herewith. Upon expiry of [**] from the Effective Date, the costs of the prosecution, maintenance and enforcement of the Novo Patents will be borne by Licensee, and, at Licensee&#8217;s option, and if so notified by Licensee in
writing, Novo Nordisk shall transfer to Licensee, and Licensee will take over, the prosecution and maintenance of the Novo Patents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.1.2</B> Each
Party shall keep the other Party reasonably informed of its prosecution of the Novo Patents and shall promptly provide the other Party with all material correspondence received from any patent authority in connection therewith. In addition, each
Party shall promptly provide the other Party with drafts of all proposed material filings and correspondence to any patent authority with respect to the Novo Patents for review and comment prior to the submission of such proposed filings and
correspondences and shall consider and implement in good faith any reasonable comment received from the other Party (including request to expand the scope of the claims) that are supported by the disclosure in the Novo
<FONT STYLE="white-space:nowrap">Know-How.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.1.3</B> As the exclusive licensee, Licensee shall the first right, but not the obligation, to enforce
the Novo Patents against any infringement in the Licensed Field in the Territory, at its own expense and as it reasonably determines appropriate. Novo Nordisk shall have the right to be represented by counsel of its choice at its own expense. If
Licensee decides not to enforce the Novo Patents against any particular infringement, Licensee shall promptly notify Novo Nordisk, in which case, Novo Nordisk shall have the right to enforce the Novo Patent against such infringement at its own
expense. At the request and expense of the enforcing Party, the other Party shall provide reasonable assistance in connection therewith, including by executing reasonably appropriate documents, cooperating in discovery and joining as a party to the
action if required. Any recoveries resulting from the enforcement of the Novo Patents shall be first applied against payment of each Party&#8217;s costs and expenses in connection therewith. Any such recoveries in excess of such costs and expenses
shall be retained by the enforcing Party; provided however that if the enforcing Party is Licensee, then such excess recovery shall be deemed Net Sales and subject to royalty payment under Section&nbsp;3.2. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 5. OBLIGATIONS OF THE PARTIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;5.1</B> <B><U>Responsibility</U></B>. Following the Effective Date and at all times during the Term, Licensee shall be
responsible for, and shall bear and be responsible for any costs, expenses and payments associated with, any further research, development and/or commercialization of the Product(s), including regulatory, manufacturing, distribution, marketing and
sales activities, such as, but not limited to, any payments to Genmab in connection with the DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> License. Subject only to the express written terms of this Agreement, all decisions
concerning the research, development, marketing and sales of Product(s), including the clinical and regulatory strategy, design, sale, price and promotion of Product(s) covered under this Agreement, shall be within the sole discretion of Licensee.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;5.2</B> <B><U>Diligence</U></B>. Licensee shall (directly and/or through one or more Affiliates and/or Sublicensees)
use commercially reasonable efforts to develop and commercialize a Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;5.3</B> <B><U>Reports</U></B>. Within
[**] of each calendar year, Licensee shall submit to Novo Nordisk a report summarizing the status of Licensee&#8217;s and its Affiliates&#8217; and Sublicensees&#8217; activities related to the Exploitation of Products during the preceding
calendar-year period in relation to the development plan including any updates to the clinical plans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 6. REPRESENTATIONS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;6.1</B> <B><U>Mutual Warranties</U></B>. Each of Novo Nordisk and Licensee represent and warrant that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it is duly organized and validly existing under the Law of the jurisdiction of its incorporation, and has full
corporate power and authority to enter into this Agreement and to carry out the provisions hereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the
individual executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate action; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">this Agreement is legally binding upon it and enforceable in accordance with its terms; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the execution, delivery and performance of this Agreement by it does not conflict with any agreement,
instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material applicable Law; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as of the Effective Date, there is no announced investigation, suit, action or proceeding pending or, to such
Party&#8217;s knowledge, threatened, against such Party before or by any court, arbitrator, or Governmental Authority that, individually or in the aggregate, is reasonably expected to (i)&nbsp;materially impair the ability of such Party to perform
its obligations under this Agreement, or (ii)&nbsp;prevent or materially delay or alter the consummation of any or all of the transactions contemplated hereby. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;6.2</B> <B><U>Additional Novo Nordisk Representations and Warranties</U></B><B>. </B>Novo Nordisk represents and warrants
to Licensee that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Novo Nordisk is the sole and exclusive owner of the Novo Technology, free and clear of all liens, has the right
to grant to Licensee the rights and licenses as purposed to be granted hereunder, and has not granted (and will not grant during the Term) any rights in Novo Technology that are inconsistent with the rights granted to Licensee hereunder. The Novo
Technology is not subject to any pending reexamination, opposition, interference or litigation proceedings. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to Novo Nordisk&#8217;s knowledge, there have been no inventorship or ownership challenges with respect to the
Novo Patents. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to Novo Nordisk&#8217;s knowledge, and without any obligation on Novo Nordisk to conduct an enquiry into
potential infringement of Third Party-rights and without Novo Nordisk having done an FOO analysis, Novo Nordisk&#8217;s performance of the Project did not infringe or misappropriate any intellectual property rights of a Third Party.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to Novo Nordisk&#8217;s knowledge, Novo Nordisk has complied with all applicable laws and regulations in its
performance of the Project. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;6.3</B> <B><U>Additional Licensee Representation</U></B>. Licensee
represents and warrants to Novo Nordisk that, on the Effective Date, Johan H. Faber is 100% shareholder of Licensee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;6.4</B> <B><U>Disclaimer</U></B>. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS ARTICLE 6 (REPRESENTATIONS), NEITHER
PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, QUALITY, FITNESS FOR A PARTICULAR PURPOSE, <FONT STYLE="white-space:nowrap">NON-INFRINGEMENT,</FONT> OR
VALIDITY OF PATENT CLAIMS. NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION MADE OR WARRANTY GIVEN BY EITHER PARTY THAT EITHER PARTY WILL BE SUCCESSFUL IN OBTAINING ANY PATENT RIGHTS. WITHOUT LIMITING THE RESPECTIVE RIGHTS AND
OBLIGATIONS OF THE PARTIES EXPRESSLY SET FORTH HEREIN, EACH PARTY SPECIFICALLY DISCLAIMS ANY GUARANTEE THAT THE PRODUCTS WILL BE SUCCESSFUL, IN WHOLE OR IN PART. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 7. INDEMNIFICATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section<U></U>&nbsp;7.1 <U>Indemnity</U>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.1.1</B>
<B>By Novo Nordisk</B>. Novo Nordisk agrees to defend Licensee and its (and its Affiliates&#8217;) directors, officers, employees and agents (the &#8220;<B>Licensee Indemnified Parties</B>&#8221;)<B> </B>at Novo Nordisk&#8217;s cost and expense, and
will indemnify and hold Licensee and the other Licensee Indemnified Parties harmless from and against any claims, losses, costs, damages, fees or expenses (including legal fees and expenses) (collectively, &#8220;<B>Losses</B>&#8221;) resulting from
any Third Party claim (including product liability claims) arising out of or otherwise relating to (a)&nbsp;the material breach of this Agreement or the representations and warranties made hereunder by Novo Nordisk or (b)&nbsp;the negligence or
wilful misconduct of Novo Nordisk or its Affiliates in connection with its activities under this Agreement; except, in each case, to the extent such Losses result from clause (a), (b), (c) or (d)&nbsp;of Section&nbsp;7.1.2 (&#8216;By
Licensee&#8217;). In the event of any such claim against the Licensee Indemnified Parties by a Third Party, Licensee shall promptly notify Novo Nordisk in writing of the claim (provided, however, that any failure or delay to notify shall not excuse
any obligations of Novo Nordisk except to the extent Novo Nordisk is actually prejudiced thereby) and Novo Nordisk shall solely manage and control, at its sole expense, the defense of the claim and its settlement; provided, however, that Novo
Nordisk shall not settle any such claim without the prior written consent of Licensee if such settlement does not include a complete release from liability or if such settlement would involve undertaking an obligation (including the payment of money
by a Licensee Indemnified Party), would bind or impair a Licensee Indemnified Party, or includes any admission of wrongdoing or that any intellectual property or proprietary right of Licensee or this Agreement is invalid, narrowed in scope or
unenforceable. The Licensee Indemnified Parties shall cooperate with Novo Nordisk and may, at their option and expense, be represented in any such action or proceeding by counsel of their own choosing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.1.2</B> <B>By Licensee</B>. Licensee agrees to defend Novo Nordisk and its (and its Affiliates&#8217;) directors, officers, employees and agents (the
&#8220;<B>Novo Indemnified Parties</B>&#8221;)<B> </B>at Licensee&#8217; cost and expense, and will indemnify and hold Novo Nordisk and the other Novo Indemnified Parties harmless from and against any Losses resulting from any Third Party claim
(including product liability claims) arising out of or otherwise relating to (a)&nbsp;the negligence or wilful misconduct of Licensee, its Affiliates, or their respective Sublicensees in connection with its activities under this Agreement,
(b)&nbsp;the material breach of this Agreement or the representations, warranties and covenants made hereunder by Licensee, (c)&nbsp;the Exploitation of any Product by or on behalf of Licensee, its Affiliates, or their respective Sublicensees
(including from product liability and intellectual property infringement claims), or (d)&nbsp;the use of any Materials by or on behalf of Licensee, its Affiliates, or their respective Sublicensees; except, in each case, to the extent such Losses
result from clause (a)&nbsp;or (b) of Section&nbsp;7.1.1 (By Novo Nordisk). In the event of any such claim against the Novo Indemnified Parties by a Third Party, Novo Nordisk shall promptly notify Licensee in writing of the claim (provided, however,
that any failure or delay to notify shall not excuse any obligation of Licensee except to the extent Licensee is actually prejudiced thereby) and Licensee shall solely manage and control, at its sole expense, the defense of the claim and its
settlement; provided, however, that Licensee shall not settle any such claim without the prior written consent of Novo Nordisk if such settlement does not include a complete release from liability or if such settlement would involve undertaking an
obligation (including the payment of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
money by a Novo Indemnified Party), would bind or impair an Novo Indemnified Party, or includes any admission of wrongdoing or that any intellectual property or proprietary right of Novo Nordisk
or this Agreement is invalid, narrowed in scope or unenforceable. The Novo Indemnified Parties shall cooperate with Licensee and may, at their option and expense, be represented in any such action or proceeding by counsel of their own choosing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.2</B> <B>LIMITATION OF DAMAGES</B>. IN NO EVENT SHALL EITHER PARTY BE LIABLE HEREUNDER TO THE OTHER PARTY FOR ANY PUNITIVE,
INDIRECT, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES (INCLUDING LOST REVENUE, LOST PROFITS, OR LOST SAVINGS) HOWEVER CAUSED AND UNDER ANY THEORY, EVEN IF IT HAS NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. THE LIMITATIONS SET FORTH IN THIS SECTION
7.2 (LIMITATION OF DAMAGES) SHALL NOT APPLY WITH RESPECT TO (A)&nbsp;ANY BREACH OF ARTICLE 8 (CONFIDENTIALITY) OR (B)&nbsp;THE INTENTIONAL MISCONDUCT OR GROSS NEGLIGENCE OF A PARTY. NOTHING IN THIS SECTION 7.2 (LIMITATION OF DAMAGES) IS INTENDED TO
LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF A PARTY UNDER THIS ARTICLE 7 (INDEMNIFICATION) WITH RESPECT TO ANY DAMAGES PAID BY THE OTHER PARTY TO A THIRD PARTY IN CONNECTION WITH A THIRD-PARTY CLAIM. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 8. CONFIDENTIALITY </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.1
Confidential Information. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.1.1</B> <B><U>Confidential Information</U></B>. Each Party (&#8220;<B>Disclosing Party</B>&#8221;)<B> </B>may disclose
to the other Party (&#8220;<B>Receiving Party</B>&#8221;),<B> </B>and Receiving Party may acquire during the course and conduct of activities under this Agreement, certain proprietary or confidential information of Disclosing Party in connection
with this Agreement. The term &#8220;<B>Confidential Information</B>&#8221;<B> </B>means all information of any kind, whether in written, oral, graphical, machine-readable or other form, whether or not marked as confidential or proprietary, which
are transferred, disclosed or made available by Disclosing Party to Receiving Party under this Agreement. Without limiting the foregoing, all Novo <FONT STYLE="white-space:nowrap">Know-How</FONT> will be considered Confidential Information of Novo
Nordisk, and all financial and business disclosures from Licensee to Novo Nordisk will be considered Confidential Information of Licensee. In addition to its confidentiality obligations with respect to Licensee&#8217;s Confidential Information,
Licensee agrees to keep the Novo <FONT STYLE="white-space:nowrap">Know-How</FONT> in confidence in accordance with the terms of <FONT STYLE="white-space:nowrap">non-disclosure</FONT> set forth in Section&nbsp;8.1.2 (Restrictions) as if the Novo <FONT
STYLE="white-space:nowrap">Know-How</FONT> were Confidential Information of Licensee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.1.2</B> <B><U>Restrictions</U></B>. During the Term and for
[**] thereafter, Receiving Party will keep all Disclosing Party&#8217;s Confidential Information in confidence with a high degree of care. Receiving Party will not use Disclosing Party&#8217;s Confidential Information except in connection with the
performance of its obligations and exercise of its rights under this Agreement. Receiving Party has the right to disclose Disclosing Party&#8217;s Confidential Information without Disclosing Party&#8217;s prior written consent, to the extent
reasonably necessary, to Receiving Party&#8217;s Affiliates and their employees, directors, subcontractors, consultants or agents who have a need to know such Confidential Information in order to perform the relevant Party&#8217;s obligations and
exercise its rights under this Agreement and who are required to comply with the restrictions on use and disclosure in this Section&nbsp;8.1.2. Receiving Party will ensure that those entities and persons comply with the restrictions on use and
disclosure in this Section&nbsp;8.1.2. Receiving Party assumes responsibility for those entities and persons maintaining Disclosing Party&#8217;s Confidential Information in confidence and using same only for the purposes described herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.1.3</B> <B><U>Exceptions</U></B>. Receiving Party&#8217;s obligation of nondisclosure and the
limitations upon the right to use Disclosing Party&#8217;s Confidential Information will not apply to the extent that Receiving Party can demonstrate that Disclosing Party&#8217;s Confidential Information: (a)&nbsp;was known to Receiving Party or
any of its Affiliates prior to the time of disclosure; (b)&nbsp;is or becomes public knowledge through no fault or omission of Receiving Party or any of its Affiliates in breach of the confidentiality obligations set forth herein; (c)&nbsp;is
obtained by Receiving Party or any of its Affiliates from a Third Party under no obligation of confidentiality to Disclosing Party; or (d)&nbsp;has been independently developed by employees, subcontractors, consultants or agents of Receiving Party
or any of its Affiliates without the use of Disclosing Party&#8217;s Confidential Information, as evidenced by contemporaneous written records. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.2</B> <B>Publication</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.2.1</B> <B><U>Special Limitations</U></B>. Licensee is not at any time during the Term or thereafter entitled to make any publications or other disclosure
to a Third Party with regard to the Novo Technology until the effective date of the Gcnmab-Licensee CLA. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.2.2</B> <B><U>General Principles</U></B>.
After the effective date of the Genmab-Licensee CLA, Licensee shall have the right to publish information arising from the development of the Product. However, up to and until the start of a [**], Licensee shall provide Novo Nordisk with the
opportunity to review the draft prior to such publication. If Licensee&#8217;s publication contains Confidential Information of Novo Nordisk, then Licensee shall provide Novo Nordisk with the proposed publication at least [**] prior to the intended
date of submission or disclosure. If Novo Nordisk reasonably determines that the publication would entail disclosure of its Confidential Information, Novo Nordisk shall have the right to reasonably require modifications of the proposed publication.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 9. TERM&nbsp;&amp; TERMINATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;9</B>.<B>1 </B><B><U>Term</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.1.1</B> <B><U>Term of this Agreement</U></B>. The term of this Agreement (the &#8220;<B>Term</B>&#8221;)<B> </B>shall commence on the Effective Date and
shall continue to be effective until it: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">automatically terminates as provided for in Section&nbsp;9.2, or; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is terminated by a Party as provided for in Sections 9.3, 9.4 or 9.5; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">whichever date of (i)&nbsp;or (ii) comes first. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.1.2</B>
<B><U>Expiry of Royalty Term</U></B>. Effective upon the expiration of the Royalty Term for a Product in a country, this Agreement shall continue in force but the License shall, on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, become royalty-free, perpetual and
irrevocable with respect to such Product in such country. For clarity, if this Agreement terminates as set out in Section&nbsp;9.1.1, the License shall terminate with this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;9.2</B> <B><U>Automatic Termination</U></B>. This Agreement will
automatically terminate: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">upon expiry or termination, on or before 1&nbsp;April 2020, of the LOA, unless upon such expiry or termination
the amendment agreement as referred to under Section&nbsp;9.2 (b) has been entered into, or; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on <B>1</B><B></B><B>&nbsp;April 2020</B>,<B> </B>if, on this date, Genmab and Novo Nordisk have not entered
into an amendment agreement to the LOA which amendment authorizes Novo Nordisk (i)&nbsp;to publish its NN Patents in November 2020, and, (ii)&nbsp;to share, or continue to share, the Novo Technology with Licensee without Novo Nordisk first having to
enter into a commercial license agreement with Genmab, or; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on <B>15</B><B></B><B>&nbsp;September 2020</B>,<B> </B>if, on this date, (i)&nbsp;the Genmab-Licensee CLA is
not in effect, or (ii)&nbsp;Genmab has not agreed to Novo Nordisk&#8217;s cancelation of the <FONT STYLE="white-space:nowrap">TLT-1/FVI1</FONT> Target Binding Pair under the LOA or to publication of the NN Patents, or; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">upon expiry or termination, for any reason whatsoever, of the Research Evaluation Agreement, unless it is
replaced by the Genmab-Licensee CLA. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">whichever date under Section&nbsp;9.2 under (a), (b), (c) or (d)&nbsp;comes first. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;9.3</B> <B><U>Termination for Convenience</U></B>. Licensee shall have the right to terminate this Agreement without
cause upon ninety (90)&nbsp;days&#8217; prior written notice to Novo Nordisk. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;9.4</B> <B><U>Termination upon
Breach</U></B>. Either Party may terminate this Agreement upon delivery of written notice to the other Party in the event of a material breach by the other Party of any terms and conditions of this Agreement, which notice shall include details
specifying the description of such breach; provided, however, that such termination will not be effective if such breach has been cured within [**] after such written notice has been given; provided further, however, that to the extent such material
breach involves the failure to make a payment when due, such breach must be cured within [**] after written notice thereof is given by Novo Nordisk to Licensee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;9.5</B> <B><U>Termination upon Bankruptcy</U></B>. Either Party may terminate this Agreement with immediate effect if, at
any time, the other Party files in any court or agency pursuant to any statute or regulation of any state, country or jurisdiction, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a
receiver or trustee of that Party or of its assets, or if the other Party proposes a written agreement of composition or extension of its debts, or if the other Party is served with an involuntary petition against it, filed in any insolvency
proceeding, and such petition is not dismissed within [**] after the filing thereof, or if the other Party proposes, or becomes a Party to, any dissolution or liquidation, or if the other Party makes an assignment for the benefit of its creditors.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section<U></U> 9.6 <U>Effects of Termination</U>. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Novo Nordisk terminates this Agreement, and Licensee has entered into a sublicense under this Agreement,
Novo Nordisk agrees that, provided that the sublicense agreement is consistent with the terms of this Agreement, upon the Sublicensee&#8217;s written notice to Novo Nordisk, within [**] from Novo Nordisk providing notice of termination of this
Agreement, and provided the Sublicensee is not (a)&nbsp;in breach of its Sublicense or (b)&nbsp;an Affiliate of Licensee, Novo Nordisk shall allow such Sublicensee to step into this Agreement and assume all of Licensee&#8217;s obligations under this
Agreement and become a direct licensee of Novo Nordisk. For such direct license to become effective, the Sublicensee shall provide to Novo Nordisk written notice wherein the Sublicensee: (a)&nbsp;agrees to abide by all of the terms and conditions of
this Agreement and fulfil any obligations formerly applicable to Licensee; (b)&nbsp;acknowledges that Novo Nordisk shall have no duties, obligations or liabilities to the Sublicensee other than or in addition to its obligations set forth in this
Agreement with regard to Novo Nordisk; and (c)&nbsp;confirms it will make any payments earned and due after such termination directly to Novo Nordisk in accordance with this Agreement. The failure of Sublicensee to comply with the provisions of this
Section&nbsp;9.6(a) shall result in the termination of the sublicense contemporaneously with the termination of the License hereunder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In case of termination of the License, for any reason whatsoever: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all rights and licenses granted by Novo Nordisk to Licensee in Article 2 (Intellectual Property and License
Grant) will terminate, and Licensee and its Affiliates, and Sublicensees (except to the extent set forth in Section&nbsp;9.6(a)) will cease all use of the Novo Technology and shall not use or exploit the Novo Technology or use a Product that relies
on, or has been developed through use of, the Novo Technology, and; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Novo Nordisk is automatically granted a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide, fully
paid, royalty-free, transferable license, including the right to sublicense, under the Licensee Patents to Exploit the Product in the Licensed Field in the Territory. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the avoidance of doubt, this Section&nbsp;9.6 does not apply to continuation of the License upon expiry of
the Royalty Term as per Section&nbsp;9.1.2. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;9.7</B> <B><U>Survival</U></B>. Those provisions that,
by their nature, are intended to survive termination of this Agreement, irrespective the cause, shall remain in effect after termination, including Article 1 (Definitions), Section&nbsp;2.2 (Ownership of IP), Section&nbsp;3.7 (Records and Audits),
Article 7 (Indemnity), Article 8 (Confidentiality), Section&nbsp;9.6 (Effects of Termination), Section&nbsp;9.7 (Survival), Section&nbsp;10.4 (Dispute Resolution; Jurisdiction), Section&nbsp;10.5 (Governing Law), Section&nbsp;10.6 (Notice), and
Section&nbsp;10.8 <FONT STYLE="white-space:nowrap">(Non-Use</FONT> of Names. Termination or expiration of this Agreement will not relieve the Parties of any liability or obligation which accrued hereunder prior to the effective date of such
termination or expiration nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement nor prejudice either Party&#8217;s right to obtain performance of any
obligation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 10. MISCELLANEOUS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;10.1</B> <B><U>Entire Agreement</U></B><U>;</U><B><U> Amendment</U></B>. This Agreement and all Exhibits to this Agreement
constitute the entire agreement between the Parties as to the subject matter hereof. All prior and contemporaneous negotiations, representations, warranties, agreements, statements, promises and understandings with respect to the subject matter of
this Agreement are hereby superseded and merged into, extinguished by and completely expressed by this Agreement. None of the Parties shall be bound by or charged with any written or oral agreements, representations, warranties, statements, promises
or understandings not specifically set forth in this Agreement. No amendment, supplement or other modification to any provision of this Agreement shall be binding unless in writing and signed by all Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;10.2</B> <B><U>Independent Contractors</U></B>. The relationship between Licensee and Novo Nordisk created by this
Agreement is solely that of independent contractors. This Agreement does not create any agency, distributorship, employee-employer, partnership, joint venture or similar business relationship between the Parties. Neither Party is a legal
representative of the other Party, and neither Party can assume or create any obligation, representation, warranty or guarantee, express or implied, on behalf of the other Party for any purpose whatsoever. Each Party shall use its own discretion and
shall have complete and authoritative control over its employees and the details of performing its obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;10.3</B> <B><U>Force Majeure</U></B>. Except for the obligation to make payment when due, each Party shall be excused
from liability for the failure or delay in performance of any obligation under this Agreement by reason of any event beyond such Party&#8217;s reasonable control including but not limited to Acts of God, fire, flood, explosion, earthquake, or other
natural forces, epidemic, quarantine, terrorism, war, acts of war, embargo, civil unrest, accident, destruction or other casualty, any lack or failure of transportation facilities, any lack or failure of supply of raw materials, any strike or labour
disturbance, or any other event similar to those enumerated above. Such excuse from liability shall be effective only to the extent and duration of the event(s) causing the failure or delay in performance and provided that the Party has not caused
such event(s) to occur. Notice of a Party&#8217;s failure or delay in performance due to force majeure must be given to the other Party within [**] after its occurrence. All delivery dates under this Agreement that have been affected by force
majeure shall be tolled for the duration of such force majeure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;10.4</B> <B><U>Dispute
Resolution</U></B><U>;</U><B><U> Jurisdiction</U></B>. The Parties will use commercially reasonable efforts to settle all matters in dispute amicably. Any dispute or claim arising out of or in connection with this Agreement, or the breach,
termination or invalidity thereof, shall be settled by arbitration in accordance with the Rules of Procedure of the Danish Institute of Arbitration (the &#8220;Institute&#8221;) in force when such proceedings are commenced. The arbitration tribunal
shall be composed of a sole arbitrator appointed by the Institute. The place of arbitration shall be Copenhagen, Denmark. The language of the arbitral proceedings shall be English. The award of the arbitrator shall be final and binding on both
Parties. Notwithstanding, without resorting to prior arbitration and in addition to any other remedies provided by law, either Party shall be entitled to seek temporary and permanent injunctive relief against any threatened or actual breach of this
Agreement or the continuation of any such breach in any court of competent jurisdiction. Any award of the arbitrator and the fact that arbitration proceedings are pending or have been instigated shall be regarded Confidential Information of both
Parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;10.5</B> <B><U>Governing Law</U></B>. The validity, construction and
performance of this Agreement will be governed by and construed in accordance with the laws of Denmark excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the
substantive law of another jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;10.6</B> <B><U>Notice</U></B>. All notices or communication required or
permitted to be given by either Party hereunder shall be deemed sufficiently given if mailed by registered mail or certified mail, return receipt requested, or sent by courier to the other Party at its respective address set forth below or to such
other address as one Party shall give notice of to the other from time to time hereunder. Mailed notices shall be deemed to be received on the third (3rd) business day following the date of mailing. Notices sent by courier shall be deemed received
the following business day. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="77%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to Novo Nordisk:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novo Nordisk A/S</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novo All&eacute;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2880 Bagsv&aelig;rd</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Denmark</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attn: Head of Business Development</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">With a copy to:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">General Counsel, Legal Department</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to Licensee:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ebumab Hemophilia ApS</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ole Maal&oslash;es Vej
3</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2200 K&oslash;benhavn N</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Denmark</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attn: Johan Faber, CEO</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;10.7</B> <B><U>Compliance with Law</U></B><U>;</U><B><U> Severability</U></B>. Nothing in
this Agreement shall be construed to require the commission of any act contrary to Law. If any one or more provisions of this Agreement is held to be invalid, illegal or unenforceable, the affected provisions of this Agreement shall be curtailed and
limited only to the extent necessary to bring it within the applicable legal requirements and the validity, legality and enforceability of the remaining provisions of this Agreement shall not in any way be affected or impaired thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;10.8</B> <B><U><FONT STYLE="white-space:nowrap">Non-Use</FONT> of Names</U></B>. Neither Party nor its Affiliates and
Sublicensees shall use the name, trademark, logo, physical likeness or name of the other Party or any of its Affiliates, its and its Affiliates&#8217; officers, directors or employees, in any advertising, promotional or sales literature, without the
other Party&#8217;s prior written consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><U></U><B>&nbsp;10.9</B> <B><U>Successors and Assigns</U></B>. Neither this Agreement nor any of
the rights or obligations created herein may be assigned by either Party, in whole or in part, without the prior written consent of the other Party, not to be unreasonably withheld or delayed; provided however that Licensee may, upon payment to Novo
Nordisk of any amounts due as per Article 3 (Fees, Royalties&nbsp;&amp; Payments) at the time of assignment, assign this Agreement, without Novo Nordisk&#8217;s consent, to its Affiliate and its successor to all or substantially all of its business
to which this Agreement relates, whether in a merger, acquisition, sale of asset or similar transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;10.10</B> <B><U>Waivers</U></B>. A Party&#8217;s consent to or waiver,
express or implied, of any other Party&#8217;s breach of its obligations hereunder shall not be deemed to be or construed as a consent to or waiver of any other breach of the same or any other obligations of such breaching Party. A Party&#8217;s
failure to complain of any act, or failure to act, by the other Party, to declare the other Party in default, to insist upon the strict performance of any obligation or condition of this Agreement or to exercise any right or remedy consequent upon a
breach thereof, no matter how long such failure continues, shall not constitute a waiver by such Party of its rights hereunder, of any such breach, or of any other obligation or condition. A Party&#8217;s consent in any one instance shall not limit
or waive the necessity to obtain such Party&#8217;s consent in any future instance and in any event no consent or waiver shall be effective for any purpose hereunder unless such consent or waiver is in writing and signed by the Party granting such
consent or waiver. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;10.11</B> <B><U>No Third Party Beneficiaries</U></B>. Nothing in this Agreement shall be
construed as giving any Person, other than the Parties hereto and their successors and permitted assigns, any right, remedy or claim under or in respect of this Agreement or any provision hereof, except for the provisions of Article 7 (Indemnity)
(with respect to which the persons to which Article 7 (Indemnity) applies shall be Third Party beneficiaries in accordance with Article 7 (Indemnity)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;10.12</B> <B><U>Headings</U></B><U>;</U><B><U> Exhibits</U></B>. Article and Section headings used herein are for
convenient reference only and are not a part of this Agreement. All Exhibits are incorporated herein by this reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;10.13</B> <B><U>Interpretation</U></B>. Except where the context otherwise requires, wherever used, the singular shall
include the plural, the plural the singular, the use of any gender shall be applicable to all genders and the word &#8220;or&#8221; is used in the inclusive sense (and/or). The term &#8220;including&#8221; as used herein shall mean including,
without limiting the generality of any description preceding such term. All references to a &#8220;business day&#8221; or &#8220;business days&#8221; in this Agreement means any day other than a day which is a Saturday, a Sunday or any day banks are
authorized or required to be closed in Denmark. The language in all parts of this Agreement shall be deemed to be the language mutually chosen by the Parties. The Parties and their counsel have cooperated in the drafting and preparation of this
Agreement, and this Agreement therefore shall not be construed against any Party by virtue of its role as the drafter thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;10.14</B> <B><U>Counterparts</U></B>. This Agreement may be executed in counterparts by a single Party, each of which
when taken together shall constitute one and the same agreement and may be executed through the use of facsimiles or .pdf documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>signature page follows</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, and intending to be legally bound hereby, the Parties have caused this
Agreement to be executed by their respective duly authorized representatives: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Lars Fogh Iversen</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Johan H. Faber</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Novo Nordisk A/S</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: Lars Fogh Iversen</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title: Senior Vice President</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Date: 19&nbsp;November 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ebumab Hemophilia ApS</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: Johan H. Faber</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title: CEO</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Date: ___ November 2019</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Exhibit A: </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Novo Patents </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Exhibit B: </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Description of Novo <FONT STYLE="white-space:nowrap">Know-How</FONT> including the Materials
</P></TD></TR></TABLE> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">to the </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>License Agreement for
BiAb <FONT STYLE="white-space:nowrap">FVII/TLT-1</FONT> of 22&nbsp;November 2019 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">by and between </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Novo Nordisk A/S </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ebumab Hemophilia ApS </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This AMENDMENT AGREEMENT (this &#8220;<B>Amendment</B>&#8221;) is entered into as of March&nbsp;26, 2020 (the &#8220;<B>Amendment Effective Date</B>&#8221;)
by and between Novo Nordisk A/S, a Danish corporation, CVR No.&nbsp;24256790, with address at Novo All&eacute;, <FONT STYLE="white-space:nowrap">DK-2880</FONT> Bagsv&aelig;rd, Denmark (&#8220;<B>Novo Nordisk</B>&#8221;), and <U>Ebumab Hemophilia
ApS</U>, a Danish corporation, CVR No.&nbsp;40837590, with address at Ole Maal&oslash;es Vej 3, <FONT STYLE="white-space:nowrap">DK-2200</FONT> Copenhagen N, Denmark (&#8220;<B>Licensee</B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novo Nordisk and Licensee are sometimes referred to herein individually as a &#8220;<B>Party</B>&#8221;<B> </B>and collectively as the
&#8220;<B>Parties</B>&#8221;. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS, </B>by License Agreement, effective 22&nbsp;November 2019, (the &#8220;<B>LA</B>&#8221;)<B> </B>Novo Nordisk has granted EH an
exclusive license to the Novo Patents and a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to the Novo <FONT STYLE="white-space:nowrap">Know-How,</FONT> in each case relating to the <FONT STYLE="white-space:nowrap">TLT-1/FVII</FONT>
Target Binding Pair, to Exploit Product(s) in the Licensed Field in the Territory; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS, </B>under Section&nbsp;2.6 of the LA, Novo
Nordisk has a Right of First Negotiation (&#8220;<B>ROFN</B>&#8221;) to obtain, under certain conditions, a license back from Licensee to Exploit the Product in the Licensed Field in the Territory (&#8220;<B>Grant-Back License</B>&#8221;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS, </B>the Parties now wish to amend the LA to reflect certain financial consequences of such Grant-Back License; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE, </B>in consideration of the foregoing and the mutual covenants contained in this Amendment Agreement, Novo Nordisk and
Licensee, intending to be legally bound, hereby agree as follows, effective upon the Amendment Effective Date: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In the event that, by any means whatsoever, including but not limited to a Grant-Back License, Novo
Nordisk regains control of the exclusive rights to Exploit the Product (&#8220;<B>Regained Licensed Product Event</B>&#8221;),<B> </B>the LA shall automatically terminate. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Promptly upon such Regained Licensed Product Event, Novo Nordisk will notify Genmab and Novo Nordisk
will pay Genmab: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(i) the [**] fee in accordance with and as set forth in the LOA in the amount of US$[**]; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(ii) any and all payments that would have been due and payable by Novo Nordisk to Genmab under the LOA prior to the Regained Licensed Product
Event, if such corresponding milestone events have occurred. For clarity, the payments up to and including a [**] as agreed in the LOA (in addition to the [**] fee mentioned under (i)) are the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">US$[**] upon [**]; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">US$[**] upon [**]; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2/3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">US$[**] upon [**]. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Parties hereby agree that any monies payable by Novo Nordisk to Genmab under (i)&nbsp;and (ii) above will be credited against any monies
paid by Novo Nordisk to EH in connection with the Regained Licensed Product Event. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For clarification, any and all payments by Novo Nordisk
to Genmab that become due under the LOA for milestone events that occur after the Regained Licensed Product Event will not be credited against any monies paid by Novo Nordisk to EH. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Except as expressly modified by this Amendment Agreement, all definitions, terms and provisions of the
LA shall remain in full force and effect. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF, </B>and intending to be legally bound hereby, the Parties have caused
this Agreement to be executed by their respective duly authorized representatives: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Lars Fogh Iversen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Johan H. Faber</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novo Nordisk A/S</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:Lars Fogh Iversen</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title:Senior Vice President</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Date: 26/3 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ebumab Hemophilia ApS</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Johan H. Faber</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title: CEO</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Date: 25/3 2020</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3/3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>8
<FILENAME>d50309dex105.htm
<DESCRIPTION>EX-10.5
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain
identified information has been excluded from the exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> License Agreement </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">by and between </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Genmab A/S</B>, CVR no. 2102 3884,
Kalvebod Brygge 43, <FONT STYLE="white-space:nowrap">DK-1560</FONT> Copenhagen V, Denmark </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(&#8220;<U>Genmab</U>&#8221;) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">And </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ebumab Hemophilia ApS</B>, CVR no. 4083 7590, Ole
Maal&oslash;es Vej 3, <FONT STYLE="white-space:nowrap">DK-2200</FONT> Copenhagen N, Denmark </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(&#8220;<U>Ebumab</U>&#8221;) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Genmab and Ebumab individually referred to as &#8220;<U>Party</U>&#8221; or together as &#8220;<U>Parties</U>&#8221;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 1 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exhibits</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit 1.37</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Licensed Target Binding Pair</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit 1.46</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Platform Technology Patent Rights</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit 4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Examples of Profit-Share Calculation</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 2 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preamble </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%" VALIGN="top" ALIGN="left">WHEREAS</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Genmab has developed a novel approach for the generation of bispecific antibodies to target antigens using its
proprietary DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Platform; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%" VALIGN="top" ALIGN="left">WHEREAS</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Genmab and Novo Nordisk A/S (&#8220;<U>Novo</U>&#8221;) in 2017 entered into the Genmab-Novo Agreement,
granting Novo certain licenses under the DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Platform. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%" VALIGN="top" ALIGN="left">WHEREAS</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Novo conducted a research project (&#8220;<U>Project</U>&#8221;) with the use of the DuoBody<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Platform, resulting in certain patents, <FONT STYLE="white-space:nowrap">know-how</FONT> and materials with regard to the therapeutic approach and the concept of a bispecific human IgG4 antibody
targeting <FONT STYLE="white-space:nowrap">TLT-1</FONT> and FVII for the treatment of hemophilia A, but later discontinued the Project; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%" VALIGN="top" ALIGN="left">WHEREAS</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Johan Faber, previously employed as a research scientist in Novo and involved with the Project, incorporated
Ebumab upon termination of his employment with Novo. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%" VALIGN="top" ALIGN="left">WHEREAS</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ebumab has <FONT STYLE="white-space:nowrap">in-licensed</FONT> that certain Novo Technology pursuant to that
certain License Agreement dated November&nbsp;22, 2019 between Novo and Ebumab (&#8220;<U>Ebumab-Novo Agreement</U>&#8221;) and desires to obtain a license from Genmab to develop and commercialize bispecific antibodies targeting <FONT
STYLE="white-space:nowrap">TLT-1</FONT> and FVII for the treatment of hemophilia using the DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Platform; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%" VALIGN="top" ALIGN="left">WHEREAS</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ebumab and Genmab entered into a Research Evaluation Agreement dated 22&nbsp;November 2019
(&#8220;<U>REA</U>&#8221;) granting a research license to conduct specific research and preclinical development activities while the Parties continued the negotiation of a commercial license agreement for the research, development, manufacture and
commercialization of a bispecific antibody product targeting <FONT STYLE="white-space:nowrap">TLT-1</FONT> and FVII; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%" VALIGN="top" ALIGN="left">WHEREAS</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Genmab is willing to grant Ebumab such commercial license, on the terms and conditions set forth in this
Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOW THEREFORE</B> in consideration of the foregoing and the mutual covenants contained in this Agreement, Genmab and
Ebumab, intending to be legally bound, hereby agree as follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 1 DEFINITIONS </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Affiliate</B>&#8221; of an entity means any person or entity which, directly or indirectly,
controls, is controlled by, or is under common control with, such entity. For the purposes of this definition, &#8220;control&#8221; refers to any of the following: (i)&nbsp;direct or indirect ownership of fifty percent (50%) or more of the voting
securities entitled to vote for the election of directors or management, as applicable, in the case of a corporation, or of fifty percent (50%) or more of the equity interest with the power to direct management in the case of any other type of legal
entity; or (ii)&nbsp;any other arrangement where a person or entity possesses, directly or indirectly, the power to direct the management or policies of an entity, whether through ownership of voting securities, by contract or otherwise.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 3 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#8220;Agreement&#8221; </B>means this DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>
License Agreement, including any and all Exhibits to it and as it may be amended from time to time in accordance with the provisions of this document. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Alliance Manager</B>&#8221; has the meaning as set forth in Section&nbsp;3.1.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Audited Party</B>&#8221; has the meaning as set forth in Section&nbsp;4.9.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>BLA</B>&#8221; means a Biologics License Application or equivalent submission filed with the
FDA in connection with seeking Marketing Approval of a Licensed Product, or an equivalent application filed with any equivalent Regulatory Authority in any jurisdiction other than the United States. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Calendar Quarter</B>&#8221; shall mean the respective periods of three (3)&nbsp;consecutive
calendar months ending on March&nbsp;31, June&nbsp;30, September&nbsp;30 and December 31. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Calendar Year</B>&#8221; shall mean the period of twelve (12)&nbsp;consecutive calendar months
ending on 31 December. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;<B>Change of Control</B>&#8221; shall mean, with respect to a Party (i)&nbsp;the sale to a Third Party
of all or substantially all of such Party&#8217;s business or assets to which this Agreement relates; (ii)&nbsp;any merger, consolidation or acquisition of such Party with, by or into a Third Party that result in the voting securities of such Party
outstanding immediately prior thereto cease to represent at least fifty percent (50%) of the combined voting power of the resulting or surviving entity immediately after such merger, reorganization or consolidation; or (iii)&nbsp;any Third Party
acquiring the ownership of more than fifty percent (50%) of the voting capital stock of such Party in one or more related transactions; provided however that, notwithstanding the foregoing, Change of Control shall not include any transaction (or
series of transactions) for bona fide financing purposes (including public offering) or tax purposes (including the change of place of incorporation or domicile) . </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.9</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Combination Product</B>&#8221; means a Licensed Product sold in combination with one or more
other pharmaceutical products, in any dosage form and/or <FONT STYLE="white-space:nowrap">co-formulation</FONT> and/or <FONT STYLE="white-space:nowrap">co-packaging</FONT> based on combination of Licensed Product and any other pharmaceutical product
in any device. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.10</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Commercially Reasonable Efforts</B>&#8221; means the [**]. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.11</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Confidential Information</B>&#8221; means any <FONT STYLE="white-space:nowrap">Know-how</FONT>
and all ideas and information of any kind, whether in written, oral, graphical, machine-readable or other form, whether or not marked as confidential or proprietary, provided by or on behalf of a Party or any of its Affiliates to the other Party or
any of its Affiliates in connection with this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 4 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.12</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Control</B>&#8221; or &#8220;<B>Controlled</B>&#8221; means, with respect to any <FONT
STYLE="white-space:nowrap">Know-How,</FONT> Patent Rights or other intellectual property rights or information, the possession (whether by ownership or license) by a Party or its Affiliate of the right to grant licenses or sublicenses to the other
Party under such <FONT STYLE="white-space:nowrap">Know-How,</FONT> Patent Rights or other intellectual property rights or information without violating the terms of any agreement or other arrangement with a Third Party and without misappropriating
or infringing the proprietary or trade secret information of a Third Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.13</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Cover</B>&#8221;, &#8220;<B>Covering</B>&#8221; or &#8220;<B>Covered</B>&#8221; means, with
respect to a Patent Right and an invention (e.g. the Licensed Product or part thereof), that, in the absence of ownership of, or a license under, such Patent Right, the practice of such invention (for example the manufacture, use, import or export,
sale, distribution, marketing or commercialization of such invention, e.g. the Licensed Product) would infringe a claim of such Patent Right (including in the case of a Patent Right that is a patent application, a claim of such patent application as
if such patent application were an issued patent). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.14</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Direct Cost</B>&#8221; means, with respect to the Licensed Product, the actual direct costs
incurred by Ebumab from the Effective Date to conduct research, development, manufacture and commercialization of the Licensed Product. Direct Costs will include [**]. Direct costs include [**], except such [**]. For the avoidance of doubt, Direct
Costs shall only include costs that (i)&nbsp;are directly attributable or reasonably allocable to Licensed Product; (ii)&nbsp;would be deemed reasonable in the normal course of business given the stage of development or commercialization; and
(iii)&nbsp;represent fair market value. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.15</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>DuoBody</B><B><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP></B><B>
Platform</B>&#8221; means proprietary technology Controlled by Genmab that is generally applicable to the discovery, modification, optimization, generation and manufacturing of IgG Bispecific Antibodies, including, but not limited to, software,
nucleic acids, vectors, cell lines, libraries, screening systems, reagents, methods, databases and instrumentation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.16</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Ebumab Background Intellectual Property</B>&#8221; means any and all intellectual property
rights, including <FONT STYLE="white-space:nowrap">Know-How</FONT> and Patent Rights, Controlled by Ebumab or any of its Affiliates (i)&nbsp;as of the Effective Date, or (ii)&nbsp;thereafter during the Term which are either conceived by Ebumab
outside of this Agreement or the REA, or are licensed or acquired by Ebumab from a Third Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.17</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Ebumab-Novo Agreement</B>&#8221; has the meaning set forth in the preamble to this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.18</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Ebumab Platform Improvement</B>&#8221; has the meaning set forth in Section&nbsp;5.1(b).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.19</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Ebumab Technology</B>&#8221; means all proprietary information and <FONT
STYLE="white-space:nowrap">Know-How</FONT> and other intellectual property generated by or on behalf of Ebumab in the performance of activities under this Agreement or the REA relating to or Covering the research, development, manufacture, use,
import or export, sale, distribution, marketing or commercialization of Licensed Products, excluding, however, any Ebumab Platform Improvement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 5 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.20</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Ebumab Technology Patent Right</B>&#8221; means any and all Patent Rights related to Ebumab
Technology. For the avoidance of doubt, the Ebumab Technology Patent Rights shall not include any of the Ebumab Background Intellectual Property. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.21</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Effective Date</B>&#8221; means the last date on which this Agreement has been duly signed by
the Parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.22</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>EMA</B>&#8221; means the European Medicines Agency or any successor agency thereto.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.23</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>EU</B>&#8221; means the countries of the European Union, as it is constituted as of the
Effective Date and as it may be changed from time to time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.24</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Exhibit</B>&#8221; means an exhibit attached to this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.25</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>FDA</B>&#8221; means the United States Food and Drug Administration or any successor agency
thereto. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.26</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Field</B>&#8221; means the treatment of bleeding conditions, including hemophilia.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.27</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Financial Report</B>&#8221; has the meaning as set forth in Section&nbsp;4.5.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.28</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>First Commercial Sale</B>&#8221; as to a particular country, means the first commercial sale
of a Licensed Product by Ebumab or any of its Affiliates or Sublicensees to a Third Party for end use in such country after approval of the BLA, or if approval of a BLA is not required in such country, then following receipt of such Marketing
Approval as is required to sell such Licensed Product in such country, provided, that &#8220;First Commercial Sale&#8221; shall not include (i)&nbsp;any sale by Ebumab to an Affiliate or Sublicensee, or (ii)&nbsp;sale, disposal or use of a Licensed
Product for marketing, regulatory, development or charitable purposes, such as clinical trials, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> trials, compassionate use, named patient use, or indigent patient programs, without consideration.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.29</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Genmab-Novo Agreement</B>&#8221; has the meaning set forth in the preamble to this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.30</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>IFRS</B>&#8221; means, with respect to Ebumab and Genmab, the then-current IFRS (International
Financial Reporting Standards), in each case, as generally and consistently applied throughout the Party&#8217;s organization. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.31</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>IgG Antibody</B>&#8221; means an immunoglobulin G molecule whether in monospecific,
bispecific, or any other form, that contains at least an Fc region and one (1)&nbsp;or more binding arms. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.32</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>IgG Bispecific Antibody</B>&#8221; means an IgG Antibody with two (2)&nbsp;different binding
arms targeting a Target Binding Pair. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.33</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>IND</B>&#8221; means an Investigational New Drug Application filed with an applicable
Regulatory Authority such as a clinical trial application (CTA) or a clinical trial exemption (CTX). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 6 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.34</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Institute</B>&#8221; has the meaning set forth in Section&nbsp;10.2 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.35</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B><FONT STYLE="white-space:nowrap">Know-how</FONT></B>&#8221; means biological materials and
other tangible materials, information embodied in such biological materials and other tangible materials, inventions, practices, methods, protocols, formulas, knowledge, <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets, processes,
procedures, specifications, assays, skills, experience, techniques, data and results of experimentation and testing, including but not limited to pharmacological, toxicological, safety, stability and
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical test data and analytical and quality control data, patentable or otherwise. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.36</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Licensed Product</B>&#8221; means any product comprising an IgG Bispecific Antibody targeting
the Licensed Target Binding Pair, so that one binding arm targets the first antigen of the Licensed Target Binding Pair, and the second binding arm targets the second antigen of the Licensed Target Binding Pair, which IgG Bispecific Antibody has
been generated by the use of, or incorporating Platform Technology, and which IgG Bispecific Antibody shall be identified by [**]. One Licensed Product will be considered different from another Licensed Product if they do not have identical such
portions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.37</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Licensed Target Binding Pair</B>&#8221; means the Target Binding Pair targeting <FONT
STYLE="white-space:nowrap">TLT-1</FONT> and FVII as further specified in <B><U>Exhibit 1.37</U></B> to this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.38</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Marketing Approval</B>&#8221; means any approval, including a registration, license or
authorization, from any Regulatory Authority required to market and sell a Licensed Product in a jurisdiction and shall include an approval, registration, license or authorization granted in connection with a BLA. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.39</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Genmab-Novo Agreement</B>&#8221; means the DuoBody<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> License and Option Agreement dated 22&nbsp;December 2017 between Novo and Genmab, as amended by Side Letter dated 22&nbsp;November 2019. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.40</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;<B>Net Sales</B>&#8221; means the [**]. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.41</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Novo</B>&#8221; has the meaning set forth in the preamble to this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.42</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Novo Technology</B>&#8221; means the Patent Right and
<FONT STYLE="white-space:nowrap">Know-how</FONT> licensed by Novo to Ebumab under the Ebumab-Novo Agreement. For clarity, Novo Technology does not include the Platform Technology as licensed by Novo and used by Novo under the Genmab-Novo Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.43</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Patent Challenge</B>&#8221; has the meaning set forth in Section&nbsp;9.5.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.44</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Patent Right</B>&#8221; means patents and patent applications and all substitutions,
divisions, continuations, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> reissues, reexaminations, supplementary protection certificates and extensions and the like thereof, and all
counterparts thereof in any country. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 7 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.45</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;<B>Platform Technology</B>&#8221; means any and all proprietary information, <FONT
STYLE="white-space:nowrap">Know-how</FONT> and other intellectual property rights, including the Platform Technology Patent Rights, Controlled by Genmab as of the Effective Date or generated thereafter by or on behalf of either Party during the Term
relating to the DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Platform, including Ebumab Platform Improvement . </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.46</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Platform Technology Patent Rights</B>&#8221; means any and all Patent Rights Controlled by
Genmab and its Affiliates as of the Effective Date or at any time during the Term which claim or Cover the DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Platform. Platform Technology Patent Rights existing as of the Effective
Date are listed in <B><U>Exhibit 1.46</U></B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.47</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Profit</B>&#8221; means any proceeds with respect to Licensed Product received by Ebumab or
its Affiliates from Third Parties, such as, but not limited to, sales of Licensed Product, receipt of revenues in respect of a sublicense to any Third Party for rights to the Licensed Product, the grant of a
<FONT STYLE="white-space:nowrap">sub-sublicense</FONT> by any such Third Party to any other party, or any other revenue stream such as assignment fees or upfront licensing fees, royalties, milestone payments, advanced royalties, other running
royalties, sublicensing fees, equity and options to equity or any other similar proceeds received whether in kind or cash, (market value of such equity, option to equity or other similar proceeds shall be determined by an internationally recognized,
independent, certified public accounting firm, selected by Ebumab and reasonably acceptable to Genmab) deriving from the Licensed Product; less any and all Direct Costs. Proceeds received in transaction that involve both the Licensed Product and
other products of Ebumab shall be equitably allocated all such products and only those allocated to the Licensed Product shall be included in the calculation of Profit under this Agreement. For clarification and notwithstanding the foregoing, Profit
shall exclude (a)&nbsp;proceeds received from its investors or creditors in bona fide equity or debt financing transactions, and (b)&nbsp;grants received from Third Parties which do not claim ownership of or rights to any intellectual property
rights to the Licensed Product, shall not be consider Profit. For further clarification, any Direct Costs deducted from such proceeds shall only be deducted one time from the first applicable profit calculation. Finally, Profit shall be determined
prior to application of any income or other direct taxes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.48</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Profit-Share</B>&#8221; has the meaning set forth in Section&nbsp;4.1. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.49</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Profit-Share Term</B>&#8221; has the meaning set forth in Section&nbsp;4.2.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.50</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>REA</B>&#8221; has the meaning set forth in the preamble to this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.51</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Regulatory Authority</B>&#8221; means any federal, national, multinational, state, county,
city, provincial, or local regulatory agency, department, bureau or other governmental entity with authority over the marketing, commercialization, manufacture or sale of a pharmaceutical product in the Territory, including the FDA in the United
States and the EMA in the EU. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.52</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>The Research Committee</B>&#8221; has the meaning set forth in Section&nbsp;3.2.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 8 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.53</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Sublicensee</B>&#8221; means a Third Party to whom Ebumab or any of its Affiliates grants an
express or implied sublicense under all or part of the Platform Technology to develop, manufacture, commercialize or use Licensed Product. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.54</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Target Binding Pair</B>&#8221; means a combination of two (2)&nbsp;different antigens or two
(2)&nbsp;different epitopes on a single antigen as defined by their unique UniProt/Swiss-Prot numbers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.55</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Term</B>&#8221; means the term of this Agreement determined in accordance with
Section&nbsp;9.1. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.56</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Territory</B>&#8221; means worldwide. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.57</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Third Party</B>&#8221; means any individual, company, partnership or other legal entity of any
kind other than a Party or any of its Affiliates or their respective employees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.58</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>United States</B>&#8221; or &#8220;<B>U.S.</B>&#8221; means the United States of America and
its territories and possessions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.59</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Valid Claim</B>&#8221; means a claim of an issued and unexpired patent within the Platform
Technology Patent Rights that has not been revoked or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction from which no appeal can be taken or with respect to which an appeal is not taken
within the time allowed for appeal, and that has not been disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise or been dedicated to the public. A claim which at the time of the First Commercial Sale is part
of a pending patent application within the Platform Technology Patent Rights that has not been issued (i) [**] after the earliest filing date from which such claim takes priority, or (ii)&nbsp;by the [**] anniversary of the First Commercial Sale,
whichever earlier, shall not constitute a Valid Claim under this Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 2 LICENSE </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>License Grant</B>. Subject to the terms and conditions of this Agreement, Genmab hereby grants to Ebumab an
exclusive (even with respect to Genmab and its Affiliates) license under the Platform Technology to research, develop, make, have made, use, manufacture, import, export, offer for sale, sell, and otherwise commercialize Licensed Product in the
Territory within the Field. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Sublicensing</B>. Subject to Sections 2.3 and 2.4, the rights granted to Ebumab under
Section&nbsp;2.1 may be extended or sublicensed (with the right to sublicense through multiple tiers) to an Affiliate or sublicensed, in whole or in part, to a Third Party (such Third Party, a &#8220;<U>Sublicensee</U>&#8221;). Ebumab will, within
[**] after execution of any such sublicense agreement by Ebumab or any of its Affiliates provide Genmab with a true, complete and unredacted, with respect to sections relevant for assessment of any and all revenues payable to Ebumab, copy of such
sublicense agreement. In addition, Ebumab will provide name and address of the Sublicensee and a description of the rights granted, and the territory covered by the sublicense. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 9 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.3</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Genmab Right to Participate in any Disposal of Rights to Licensed Product</B>. In the event that
Ebumab contemplates the disposal of rights to the Licensed Product to achieve one of the outcomes listed in the examples provided in Exhibit 4.1, Sections (b)&nbsp;to (e) (inclusive), as permitted under this Agreement, by virtue of sale, license, or
otherwise, to a Third Party other than Novo, Genmab shall have the right to participate in any bidding process as a bona fide potential acquirer of such rights. For purposes of clarity, this right of Genmab shall be subject to any rights of first
negotiation to Licensed Product or similar right granted to Novo by Ebumab under the Ebumab-Novo Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.4</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Performance by Sublicensees</B>. Ebumab will be fully responsible for performance by each Sublicensee
of its obligations under this Agreement. Each sublicense granted by Ebumab pursuant to Section&nbsp;2.2 will contain terms and conditions consistent with this Agreement. Without limiting the foregoing, each sublicense agreement will contain
following provisions: (i)&nbsp;a requirement that any Sublicensee selling Licensed Products submit applicable sales or other reports to Ebumab to the extent necessary or relevant to the reports required to be made or records required to be
maintained under this Agreement; (ii)&nbsp;an audit requirement as to those Sublicensees selling Licensed Products consistent with that set forth in Section&nbsp;4.10 (Records and Audit under Financial Provisions); and (iii)&nbsp;a requirement that
such Sublicensee comply with the confidentiality provisions and restrictions on use with respect to Confidential Information of Genmab consistent with ARTICLE 6 (Confidentiality). If Ebumab becomes aware of a material breach by a Sublicensee of the
rights granted to Ebumab, or the obligations of Ebumab or a Sublicensee under this Agreement, Ebumab will promptly notify Genmab in writing of the particulars of the same and will use its Commercially Reasonable Efforts to have the Sublicensee cure
such material breach or to enforce the terms of such sublicense or to terminate such sublicense (which depending on the circumstances may be deemed a cure of the breach of such Sublicensee). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Responsibility</B>. Ebumab will, including through its Affiliates and Sublicensees, have sole responsibility
for research, development, manufacture, marketing, sale and use of the Licensed Products, and will be responsible for all of its costs and expenses associated with such activities. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Diligence </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>General Commitment</B>. Ebumab will use Commercially Reasonable Efforts during the Term to develop,
manufacture and obtain Marketing Approval for, and commercialize Licensed Products in all countries of the Territory. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Status report</B>. Ebumab will provide to Genmab a written report, on a [**] basis during the Term
describing progress on milestones and activities undertaken by Ebumab, its Affiliates and Sublicensees, the progress made on the Licensed Products and status on the use of the Platform Technology since the last report and activities planned for the
subsequent [**] period. Such reports shall include high-level information relating to the progress on <FONT STYLE="white-space:nowrap">pre-clinical,</FONT> clinical and regulatory activities as well as any commercialization plans. Ebumab will send
the written status reports to the Alliance Manager appointed by Genmab. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 10 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 3 GOVERNANCE </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Alliance Managers</B>. No later than [**] after the Effective Date, each Party shall nominate one
(1)&nbsp;individual to act as a central contact for that Party (&#8220;<U>Alliance Manager</U>&#8221;), to whom any relevant queries and comments relating to the research, development, manufacturing and/or commercialization of the Licensed Products,
or other questions arising in respect of the Agreement, and reports and plans related hereto can be addressed by the other Party throughout the Term and who will ensure that such queries and comments are further directed within his/her organization
appropriately and promptly to ensure efficient communication and cooperation between the Parties. Either Party may replace its Alliance Manager at any time upon written notice to the other Party. Alliance Managers would be expected to attend all
meetings of the Research Committee, unless otherwise agreed by the Parties. Each Party shall pay for its own Alliance Manager&#8217;s time and activities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Governance and Communication Management</B>. Promptly after the Effective Date, the Parties shall
form a steering committee consisting of [**] representatives from each Party (the &#8220;<U>Research Committee</U>&#8221;). The function of the Research Committee shall be to exchange information on progress made by Ebumab in respect of the Licensed
Product until Ebumab has filed an IND for such Licensed Product. The Research Committee shall have no authority to amend, modify or supplement the Agreement but it may propose modifications for consideration by the Parties. Any such modification to
the Agreement shall become effective only upon mutual written agreement of the Parties. The Research Committee shall meet from time to time upon the written request by either Party, but not less frequently than [**]. Further, a Party shall promptly
inform the other Party if any major improvements to the DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Platform are developed, and the Parties shall then set up a meeting. Meetings may be conducted by telephone conference or video
conference or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">face-to-face</FONT></FONT> as agreed between the Parties. Prior to a meeting, the Parties&#8217; Alliance Managers shall agree on an agenda specifying the topics to be
discussed at the meeting. Further, the Parties shall decide on which Party&#8217;s Alliance Manager shall record the minutes of the meeting in writing. Such minutes shall be approved subsequently by both Parties. Either Party may change its Research
Committee representatives upon written notice to the other Party. Each Party shall pay for its own time and participation on the Research Committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 4 FINANCIAL PROVISIONS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Profit-Share</B>. Subject to the terms and conditions of this Agreement (including Section&nbsp;4.4
below), in consideration for the licenses granted to Ebumab hereunder: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>With respect to each Licensed Product, for the period commencing upon the Effective Date and ending upon
First Commercial Sale</B> of such Licensed Product, Ebumab shall pay to Genmab [**] Percent ([**]%) of all and any Profit. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 11 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>With respect to each Licensed Product, from First Commercial Sale</B> of such Licensed Product, and lasting
for the remainder of the Term of this Agreement, Ebumab will pay to Genmab [**] Percentage ([**] %) of all and any Profit in territories where Ebumab commercializes Licensed Product itself, and [**] Percent ([**]%) of all and any Profit in
territories where a Third Party, other than Novo, commercializes Licensed Product. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">Examples</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">of Profit-Share calculations are included in <U>Exhibit 4.1</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Profit-Share Term</B>. The Profit-Share shall apply on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis until the later of (i)&nbsp;twelve (12) years from the date of the First
Commercial Sale of the Licensed Product in such country, or (ii)&nbsp;the date of expiration of the last to expire Platform Technology Patent Right Covering the Licensed Product in said country (the &#8220;<U>Profit-Share Term</U>&#8221;). In the
event that during the Profit-Share Term, such Licensed Product in a country is not Covered by a Valid Claim of a Platform Technology Patent Right, and solely with respect to Profit-Share relating to sales of Licensed Product under
Section&nbsp;4.14.1(b) and not other revenue streams relating to Licensed Product, the Profit-Share rate applicable to sales of Licensed Product shall be reduced by [**] percent ([**]%) on a Licensed
<FONT STYLE="white-space:nowrap">Product-by</FONT> Licensed Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis in such country for the remainder of the Profit-Share Term.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.3</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Novo reacquires rights to Licensed Product by direct or indirect means</B>. If Novo requires rights to
Licensed Product, Ebumab shall not be involved in any ongoing agreement between Genmab and Novo with respect to such Licensed Product in such territory for which the rights are granted. [**]. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Sale of </B><B>Ebumab</B><B>&#8217;</B><B>s</B><B> Business or Assets</B>. In the event of a Change of
Control for a lump sum, i.e. no payments of milestones or royalties received after such sale (except in the case of earn-outs or contingent value rights), Genmab is to receive a [**] percent ([**]%) Profit-Share with respect to such lump sum and of
such earn-outs or contingent value rights. For clarity, this Section&nbsp;4.4 shall not apply in case of a sale to Novo. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.5</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Payments; Reports</B>. For the Term of this Agreement, Ebumab shall furnish to Genmab written reports
(hereinafter the &#8220;<U>Financial Report</U>&#8221;), within [**] following the end of each Calendar Quarter, for which Profit-Share are due, showing: (i)&nbsp;the calculation of aggregated Profit of Licensed Products generated during the
relevant Calendar Quarter segmented on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, in United States Dollars (USD) translated from local currency; and (ii)&nbsp;the calculation of the
Profit-Share which have accrued hereunder in respect to Profit in determining the amount due. Furthermore, as soon as reasonably practicable, but in any event no later than [**] after each Calendar Quarter, Ebumab shall provide Genmab with a
&#8220;flash sales report&#8221; in order to give Genmab an indication of the magnitude of the Profit-Share that are likely to be due to it pursuant to the applicable Financial Report. Such &#8220;flash sales report&#8221; shall be provided as a
courtesy estimate only and shall not be considered binding in any way.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 12 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Ebumab will pay Genmab the Profit-Share received in a Calendar Quarter within [**] of the end
of such Calendar Quarter in USD to: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>CASH &#8212; WIRE TRANSFER </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[**] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IBAN: [**] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SWIFT: [**] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For credit to: <B>&#8195;</B>Account Name:<B>
[**]</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">or to such other account as to which Genmab provides written notice to Ebumab in accordance with Section&nbsp;11.3. Genmab shall
invoice Ebumab for the Profit-Share accordingly. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.6</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Taxes</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ebumab shall make all payments to Genmab under this Agreement without deduction or withholding for taxes except
to the extent that any such deduction or withholding is required by law in effect at the time of payment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any tax required to be withheld on amounts payable under this Agreement will promptly be paid by Ebumab on
behalf of Genmab to the appropriate governmental authority, and Ebumab will furnish Genmab with proof and explanation of payment of such tax within [**] from the payment of such tax to the appropriate governmental authority. Any such tax required to
be withheld will be an expense of and borne by Genmab. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ebumab and Genmab will cooperate with respect to all documentation required by any taxing authority or
reasonably requested by Ebumab to secure a reduction in the rate of applicable withholding taxes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Ebumab had a duty to withhold taxes in connection with any payment it made to Genmab under this Agreement
but Ebumab failed to withhold, and such taxes were assessed against and paid by Ebumab, then Genmab will indemnify and hold harmless Ebumab from and against such taxes (including interest but excluding penalties), but only to the extent covered by
the payment received from Ebumab. If Ebumab makes a claim under this Section&nbsp;4.6 (d), it will comply with the obligations imposed by Section&nbsp;4.6 (a) as if Ebumab had originally withheld taxes from a payment to Genmab.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 13 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All payments due to the terms of this Agreement are expressed to be exclusive of value added tax (VAT) or
similar indirect taxes. VAT/indirect taxes shall be added to the payments due to the terms if legally applicable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>United States Dollars</B>. All dollar ($) amounts specified in this Agreement are United States dollar
amounts. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Currency Exchange</B>. All payment to be made hereunder by one Party to the other Party shall be computed
and paid in U.S. dollars. With respect to sales of a Licensed Product invoiced in a currency other than U.S. dollars such amounts and amounts payable will be expressed in such currency and converted to U.S. dollars using the exchange rate mechanism
generally applied by such Party, provided that such mechanism is in compliance with IFRS. Ebumab will disclose sales in its original reporting currency and the U.S. dollar exchange rate used for the Financial Report. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.9</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Late Payments</B>. Any undisputed payments or portions thereof due hereunder which are not paid on
the date such payments are due under this Agreement will bear interest at a rate equal to [**] percent points above the then-applicable base lending rate of the European Central Bank, calculated on the number of days such payment is delinquent,
compounded on the last day of each Calendar Quarter using a three hundred sixty-five (365)&nbsp;day year. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.10</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Records and Audits</B>. Ebumab will keep complete and accurate records relating to the calculations
of Profit (including the allocation of any proceeds received in a transaction that involves both the Licensed Product and other products of Ebumab) generated in the then current Calendar Year, and during the preceding [**]. Genmab will have the
right, [**] at its own expense, to have an internationally recognized, independent, certified public accounting firm, selected by it and reasonably acceptable to Ebumab, review any such records of Ebumab and its Affiliates, including sales reports
and any other reports and records received by Ebumab or its Affiliates from Sublicensees in accordance with Section&nbsp;2.4 (the &#8220;<U>Audited Party</U>&#8221;) in the location(s) where such records are maintained by the Audited Party upon
reasonable written notice (which shall be no less than [**] prior written notice) and during regular business hours and under obligations of strict confidence secured through a confidentiality agreement between the auditor an the Audited Party, for
the sole purpose of verifying the basis and accuracy of payments made and deductions taken under this ARTICLE 4 within the [**] period preceding the date of the request for review. At least [**] prior to inspecting any records, the auditor must
enter into a confidentiality agreement with the Audited Party that is reasonably satisfactory to the Audited Party. While inspecting such accounts and records, the auditor must abide by all of Ebumab&#8217;s standard rules and regulations and the
auditor will not be entitled to take copies of any such accounts and records. The auditor shall prepare and deliver to each Party at the same time a report setting </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 14 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
out its findings no later than [**] after the audit has been completed. Before delivering the report to each Party, the auditor shall if necessary share its findings with Ebumab in order for any
uncertainties or discrepancies to be clarified. Any report by the auditor under this Section&nbsp;4.10 shall be deemed Confidential Information of Ebumab and Genmab shall keep such report and any other information received or learnt in connection
with the audit confidential. For clarification, no Calendar Year will be subject to audit under this Section&nbsp;4.10 more than [**]. In the event such inspection leads to the discovery of a discrepancy to Genmab&#8217;s detriment, Ebumab will,
within [**] after receipt of such report from the accounting firm, pay any undisputed amount of the discrepancy. Genmab will pay the full cost of the review unless the underpayment of amounts due to Genmab is greater than [**] percent ([**]%) of the
amount due for the entire period being examined, in which case Ebumab will pay the reasonable cost charged by such accounting firm for such review. Any undisputed overpayment of Profit-Share by Ebumab revealed by an examination will be paid by
Genmab back to Ebumab or it&#8217;s Affiliate, as applicable, at Ebumab&#8217;s discretion either as a (i)&nbsp;credit against future Profit-Share owed to Genmab or (ii)&nbsp;within [**] of Genmab&#8217;s receipt of notice from Ebumab pursuant to
the applicable report. Any disagreement regarding the results of any audit conducted under this Section&nbsp;4.10 will be subject to the dispute resolution provisions set forth in ARTICLE 10. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 5 INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION AND RELATED MATTERS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ownership</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ebumab Ownership</B>. Ebumab Technology and Ebumab Technology Patent Rights shall be solely Controlled by
Ebumab. As between the Parties, Ebumab shall remain the sole owner of the Ebumab Background Intellectual Property and Novo Technology and nothing in this Agreement shall constitute a transfer of ownership or grant of a license to Genmab of such
Ebumab Background Intellectual Property or Novo Technology. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Genmab Ownership</B>. Platform Technology and Platform Technology Patent Rights shall be solely Controlled
by Genmab and Ebumab shall, notwithstanding anything to the contrary in ARTICLE 3, promptly notify Genmab of any invention, discovery or other intellectual property specifically related to the Platform Technology generated by Ebumab, or its
Affiliates or Sublicensees in performance of activities under this Agreement and the REA (&#8220;Ebumab Platform Improvement&#8221;), and assign or arrange for the assignment of such Ebumab Platform Improvement and all and any rights therein to
Genmab, at Genmab&#8217;s sole expense and such rights shall be considered Platform Technology. For clarity and notwithstanding anything to the contrary herein, Ebumab Platform Improvement shall not include any invention, discovery and intellectual
property that are inseparable from and specifically related to the Licensed Product. For the avoidance of doubt, Ebumab shall have no obligation to assign, license or grant any rights under any of the Ebumab Technology, Ebumab Technology Patent
Rights, Ebumab Background Intellectual Property or Novo Technology to Genmab. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 15 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Prosecution and Maintenance of Patent Rights</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Platform Technology</B>. Genmab shall have the sole right, at its own discretion and expense, to file,
conduct prosecution and maintain (including the defense of any interference or opposition proceedings) all Platform Technology Patent Rights, in Genmab&#8217;s name. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ebumab</B><B> Technology</B>. Ebumab shall have the sole right, at its discretion and expense, to file,
conduct prosecution, and maintain (including the defense of any interference or opposition proceedings) all Ebumab Technology Patent Rights, in Ebumab&#8217;s name. However, Ebumab is only entitled to publish Patent Rights in respect of Ebumab
Technology in relation to the Licensed Target Binding Pair under the Platform Technology. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Patent Term Extension</B>. The Parties shall cooperate with each other in good faith in gaining patent term
extension (including those extensions available under U.S. Drug Price Competition and Patent Term Restoration Act of 1984, the Supplementary Certificate of Protection of Member States of the EU and other similar measures in any other country)
wherever applicable to Patent Rights that Cover the Licensed Product in the Territory. Ebumab shall have the authority to decide on which Ebumab Technology Patent Right to seek patent term extension, <I>provided</I>, however, that Ebumab shall not
have the right to seek any such patent term extension of any Platform Technology Patent Right without Genmab&#8217;s prior written consent, which Genmab may withhold in its sole discretion. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Third Party Infringements</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Notices</B>. Each Party will promptly report in writing to the other Party any (i)&nbsp;known or suspected
infringement of any Ebumab Technology Patent Rights or Platform Technology Patent Rights or (ii)&nbsp;unauthorized use or misappropriation of any <FONT STYLE="white-space:nowrap">Know-How</FONT> comprised by Ebumab Technology or <FONT
STYLE="white-space:nowrap">Know-How</FONT> comprised by Platform Technology by a Third Party, of which such Party becomes aware, in each case only to the extent relevant to the development, manufacture, commercialization or use of the Licensed
Product in the Territory, and will provide the other Party with all available information evidencing such infringement, or unauthorized use or misappropriation. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Genmab First Right to Enforce Certain Patent Rights</B>. Genmab or its designated Affiliate will have the
first right, but not the obligation, to initiate a lawsuit or take other appropriate action that it believes is reasonably required to prevent or abate actual or threatened infringement, or otherwise protect or enforce, Platform Technology Patent
Rights against a Third Party who is researching, making, using, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 16 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
selling, importing or in any other way exploiting a bispecific product in a country within the Territory that is targeting the Licensed Target Binding Pair, provided that Genmab shall not
initiate any lawsuit or take any enforcement action under this Section&nbsp;5.45.4(b) without first consulting Ebumab and giving good faith consideration to any Ebumab recommendation(s), and provided that for any Platform Technology Patent Right
Covering the Licensed Product, Ebumab shall have the right, at its own expense, to join such action as a party by representation in any such action by counsel of its own choice, and to the extent legally permittable, Ebumab will be allowed to make
separate claims towards such Third Party. Further, Ebumab and its Affiliates and Sublicensees will join such suit if the relevant court would lack jurisdiction if Ebumab or such Affiliate or Sublicensee were absent from such suit, and Ebumab or such
Affiliate or Sublicensee will execute such legal papers and cooperate in the prosecution of such suit as may be reasonably requested by Genmab; provided, that Genmab will promptly reimburse all <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses (including reasonable attorneys&#8217; fees and expenses) incurred by Ebumab and such Affiliates or Sublicensees in connection with joining such suit and providing such other requested
cooperation. Genmab and its Affiliates shall not be allowed to enter into any settlement that has a material adverse impact on the rights granted to Ebumab under this Agreement or result in a payment or other liability by Ebumab to a Third Party
without the prior written consent of Ebumab which shall not be unreasonably withheld. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ebumab</B><B>&#8217;</B><B>s</B><B> Rights if Genmab Elects Not to Proceed</B>. If Genmab does not initiate
a lawsuit or take other appropriate action pursuant to Section&nbsp;5.4(b) with respect to a bispecific product which targets the Licensed Target Binding Pair within [**] after knowledge of such infringement or misappropriation or, to the extent
possible, within [**] before any statutory or regulatory deadline for filing such suit (or as soon as practically possible if shorter statutory or regulatory deadlines are applicable), then Ebumab will have the immediate right to initiate a lawsuit
or take other appropriate action that it believes is reasonably required to prevent or abate actual or threatened infringement, or otherwise to protect or enforce the relevant Platform Technology Patent Rights. Genmab and its Affiliates will join
such suit if the relevant court would lack jurisdiction if Genmab or such Affiliates were absent from such suit, and Genmab and such Affiliates will execute such legal papers and cooperate in the prosecution of such suit as may be reasonably
requested by Ebumab provided, that Ebumab will promptly reimburse all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses (including reasonable attorneys&#8217; fees and expenses) incurred by Genmab
and such Affiliates in connection with joining such suit and providing such requested cooperation. Ebumab and its Affiliates and Sublicensees shall not be allowed to enter into any settlement to the detriment of Genmab without the prior written
consent of Genmab which shall not be unreasonably withheld. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 17 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ebumab</B><B>&#8217;</B><B>s</B><B> Right to Enforce Certain Patent Rights</B>. Ebumab or its designated
Affiliate or Sublicensee will have the sole right, but not the obligation, to initiate a lawsuit or take other appropriate action that it believes is reasonably required to prevent or abate actual or threatened infringement, or otherwise protect or
enforce, Ebumab Technology Patent Rights against a Third Party. Genmab and its Affiliates will join such suit if the relevant court would lack jurisdiction if Genmab or such Affiliate were absent from such suit, and Genmab and such Affiliates will
execute such legal papers and cooperate in the prosecution of such suit as may be reasonably requested by Ebumab; provided, that Ebumab will promptly reimburse all
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses (including reasonable attorneys&#8217; fees and expenses) incurred by Genmab and such Affiliates in connection with joining such suit and
providing such other requested cooperation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Enforcement Against Other Infringement of Genmab Patent Rights</B>. Except as provided in Sections 5.4(b)
and (c), Genmab will have the sole right, but not the obligation, to initiate a lawsuit or take other appropriate action that it believes is reasonably required to prevent or abate actual or threatened infringement, or otherwise to protect or
enforce, Platform Technology Patent Rights during the Term. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Right to Enforce <FONT STYLE="white-space:nowrap">Know-How</FONT></B>. Responsibility for preventing or
abating actual or threatened misappropriation of, or otherwise protecting <FONT STYLE="white-space:nowrap">Know-How</FONT> comprised by Platform Technology or <FONT STYLE="white-space:nowrap">Know-How</FONT> comprised by Ebumab Technology will be
determined in the same manner as the right to enforce certain Patent Rights under paragraphs (b), (c), (d) and (e)&nbsp;of this Section&nbsp;5.4. The protecting Party shall keep the other Party informed of the status of all such protecting
activities, and shall consider in good faith all comments of the other Party regarding any aspect of such protecting activities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Conduct of Certain Actions; Costs</B>. The Party initiating litigation for Third Party Infringements under
this Section&nbsp;5.4 will have the sole and exclusive right to select counsel for any litigation initiated by it pursuant to these Sections. The initiating Party will assume and pay all of its own <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs incurred in connection with any litigation or proceedings initiated by it pursuant to this Section, including the fees and expenses of the legal counsel selected by it.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Recoveries</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Ebumab initiates litigation with respect to Platform Technology Patent Rights as permitted in accordance
with Sections 5.4(b) or (c)&nbsp;or, with respect to <FONT STYLE="white-space:nowrap">Know-How</FONT> comprised by Platform Technology under Section&nbsp;5.4(f), if Ebumab initiates proceedings claiming misappropriation of such <FONT
STYLE="white-space:nowrap">Know-How</FONT> (to be conducted in the same manner as if they were Patent Rights under this Section&nbsp;5.4), any damages, settlements, accounts of profits, or other financial compensation actually paid to Ebumab by a
Third Party based upon such litigation, after deducting Ebumab&#8217;s actual out of pocket expenses (including attorneys&#8217; fees and expenses) incurred in pursuing such litigation (such net amount, the &#8220;<U>Recovery</U>&#8221;), will be
treated as [**]. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 18 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Genmab initiates litigation pursuant to Section&nbsp;5.4(b) and (e)&nbsp;or with respect to <FONT
STYLE="white-space:nowrap">Know-how</FONT> comprised by Platform Technology under Section&nbsp;5.4 (f), Genmab [**]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Patent Invalidity Claims</B>. Each of the Parties will promptly notify the other Party in the event of any
legal or administrative action by any Third Party against an Ebumab Technology Patent Right or Platform Technology Patent Right Covering Licensed Product, of which it becomes aware, including any nullity, revocation, reexamination or compulsory
license proceeding. Responsibility for defending against any such action shall be determined in the same manner as enforcement of the relevant Patent Rights pursuant to Section&nbsp;5.4. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Third Party Infringement Claims</B>. If a Party becomes aware of any claim that the development, manufacture
or commercialization of Licensed Product infringes the Patent Rights of any Third Party in the Territory, such Party shall promptly notify the other Party. Ebumab shall have the first right to control the defense against such claims of infringement
at its sole cost, unless the infringement relates to the Platform Technology, in which case Genmab shall have the first right to control the defense at its sole cost, provided that Ebumab shall be entitled to participate in such defense. If Genmab
chooses not to defend against such claims of infringement related to the Platform Techn&#8195;&#8195;&#8195;&#8195;ology, Ebumab shall have the right to control such defense on its own and at its sole costs, provided that Genmab shall be entitled to
participate in such defense. With respect to any claims of infringement related to Platform Technology Patent Rights, no statements regarding the validity of these Patent Rights shall be made by Ebumab without Genmab&#8217;s prior written consent
which shall not be unreasonably withheld. Furthermore, Ebumab shall not admit any infringement of Third Party Patent Rights with respect to any aspects specifically related to the use of Platform Technology without Genmab&#8217;s prior written
consent which shall not be unreasonably withheld. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 6 CONFIDENTIALITY </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Confidential Information</B>. During the Term and for a period of [**] after any termination or
expiration of this Agreement, each Party (the &#8220;<U>Receiving Party</U>&#8221;) agrees to keep Confidential Information in confidence with the same degree of care with which Receiving Party holds its own confidential information and not to
disclose to any Third Party, or use for any purpose, except, in each case, pursuant to, and in order to carry out, the terms and objectives of this Agreement (which, in the case of Ebumab and its Affiliates and Sublicensees, include activities
contemplated by the licenses granted pursuant to Article 2) or as otherwise specifically permitted under this Agreement, any Confidential Information of the other Party (the &#8220;<U>Disclosing Party</U>&#8221;). The terms of this Agreement will be
considered Confidential Information of both Parties, subject to permitted disclosures as set forth in this </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 19 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Article 6. The restrictions on the disclosure and use by the Receiving Party of Confidential Information of the Disclosing Party set forth in the first sentence of this Section&nbsp;6.1 will not
apply to any Confidential Information of the Disclosing Party that the Receiving Party can demonstrate: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">was known by the Receiving Party or any of its Affiliates prior to disclosure by the Disclosing Party under
this Agreement (as evidenced by the receiving Party&#8217;s written records or other competent evidence); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is or becomes part of the public domain through no fault or omission of the Receiving Party or any of its
Affiliates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is disclosed to the Receiving Party or any of its Affiliates by a Third Party, to the best of Receiving
Party&#8217;s knowledge, having a legal right to make such disclosure without violating any confidentiality or <FONT STYLE="white-space:nowrap">non-use</FONT> obligation that such Third Party has to the Disclosing Party and provided such Third Party
is not disclosing such information on behalf of the Disclosing Party; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is independently developed by personnel of the Receiving Party or any of its Affiliates without the use of the
Confidential Information (as evidenced by the Receiving Party&#8217;s written records or other competent evidence) and other than in connection with activities under this Agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">In addition, if either Party is required to disclose Confidential Information of the other Party by regulation, law or legal process, or of any
stock exchange, such Party shall wherever possible provide at least [**] Days prior written notice, along with a copy of such intended disclosure, to such other Party, will consider in good faith the other Party&#8217;s comments, will disclose only
such Confidential Information of such other Party as is required to be disclosed and will cooperate in the Disclosing Party&#8217;s efforts to obtain a protective order or to limit the scope of the required disclosures. Notwithstanding anything in
this Agreement to the contrary, either Party may disclose to bona fide potential or existing investors or lenders, potential acquirors/acquirees, and, in the case of Ebumab, to potential and existing Sublicensees, and, as to either Party, to such
Party&#8217;s consultants and advisors, the existence and terms of this Agreement to the extent necessary in connection with a proposed equity or debt financing of such Party, or a proposed acquisition or business combination or for purposes related
to this Agreement, so long as such recipients are bound in writing to maintain the confidentiality of such information by terms there are not less strict than the terms set forth herein. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Permitted Disclosures</B>. Each Party agrees that it and its Affiliates will provide or permit access to
Confidential Information received from the other Party and such Party&#8217;s Affiliates and representatives only to the Receiving Party&#8217;s employees, consultants, advisors and bona fide potential acquirers and potential investors, and, in the
case of Ebumab as the Receiving </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 20 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Party, to service providers, investigators, Third Party contractors, potential and existing Sublicensees and distributors, in each case who are subject to obligations of confidentiality and <FONT
STYLE="white-space:nowrap">non-use</FONT> that would apply to such Confidential Information and are at least as stringent as the obligations applicable to the receiving Party under this Agreement. Genmab and Ebumab shall each remain responsible for
any failure by its Affiliates, and its and its Affiliates&#8217; respective employees, consultants, advisors and permitted contractors, licensors, Sublicensees and distributors, to treat such Confidential Information as required under
Section&nbsp;6.1 (as if such Affiliates, employees, consultants, advisors, contractors, licensors, Sublicensees and distributors were Parties directly bound to the requirements of Section&nbsp;6.1). Ebumab may also disclose Confidential Information
of Genmab to Regulatory Authorities and other governmental authorities, but solely in connection with the activities contemplated by this Agreement. Furthermore, each Party may disclose Confidential Information to the extent necessary in connection
with patent filings. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Publicity Related to the Agreement</B>. Except as otherwise expressly permitted in this Agreement, neither
Party will issue a press release, statement or public announcement relating to the existence or terms of this Agreement without the prior written approval of the other Party, which approval shall not be unreasonably withheld or delayed, except that
(i)&nbsp;a Party may issue such press release or public announcement if the contents of such press release or public announcement are consistent with a previously approved press release or have otherwise previously been made public other than
through a breach of this Agreement; (ii)&nbsp;either Party may disclose that they have entered into an agreement with the other Party with respect to the Platform Technology without disclosing the therapeutic area or any other information with
respect to the Licensed Product, and; (iii)&nbsp;a Party may issue such a press release or public announcement if required by applicable law or of any stock exchange; provided that to the extent possible, the issuing Party will provide the other
Party with a copy of any such proposed press release, statement or public announcement and give the receiving Party a reasonable period of time within which the receiving Party may provide any comments (but no less than [**]). If the receiving Party
provides any comments, the Parties will consult and work in good faith to prepare a mutually acceptable press release, statement or public announcement, subject to the understanding that the issuing Party shall have the final say in case the Parties
cannot agree. During the Term and except as otherwise provided for in this Agreement, Genmab will not make any public disclosure related to Ebumab&#8217;s or any of its Affiliates&#8217; or Sublicensees&#8217; activities under this Agreement or
related to the results generated by Ebumab or any of its Affiliates or Sublicensees with respect to Licensed Product without the prior written consent of Ebumab (not to be unreasonably withheld or delayed) except to the extent required by applicable
law, rule or regulation (including the disclosure requirements of the United States Securities and Exchange Commission or the securities exchange or other stock market on which such Party&#8217;s securities are traded). During the Term, in the event
Genmab is required by applicable law to publicly disclose any information provided by Ebumab related to Licensed Product or either Party is required by applicable law to disclose the terms of this Agreement, such Party will wherever possible give
the other Party at least [**] prior written notice, will provide to such </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 21 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
other Party a copy of the required disclosure, will, if requested by such other Party, to the extent permitted by applicable law, request confidential treatment of any financial and other
material terms of this Agreement not previously disclosed under this Section&nbsp;6.3, and will consider in good faith any other comments of such other Party on such public disclosure. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Return of Confidential Information</B>. Upon termination of this Agreement, the Receiving Party shall, at
the request of, and as directed by, the Disclosing Party, return or destroy Confidential Information of the Disclosing Party in the Receiving Party&#8217;s possession, and shall destroy any reports or notes in Receiving Party&#8217;s possession to
the extent containing the Disclosing Party&#8217;s Confidential Information, and any electronic copies of any of the foregoing, provided that (i)&nbsp;the Receiving Party may retain one (1)&nbsp;copy of Confidential Information of the Disclosing
Party for archival purposes, and (ii)&nbsp;neither Party shall be required to return or destroy copies of the other Party&#8217;s Confidential Information stored on automatically created system <FONT STYLE="white-space:nowrap">back-up</FONT> media.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.5</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Publication</B>. Subject to this Section&nbsp;6.5, Ebumab may on its own account freely make
publications related to a Licensed Product. However, to the extent such publication partly contains information on the Platform Technology, beyond the mere mentioning of Ebumab&#8217;s use of the
DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Platform to generate bispecific antibodies, Genmab shall have [**] from receipt of a proposed publication to provide comments and/or proposed changes to Ebumab. To the extent such
comments and/or proposed changes pertain to the Platform Technology, Ebumab shall take into account the comments and/or proposed changes made by Genmab on any publication. If Genmab reasonably determines that the publication would entail the public
disclosure of Genmab&#8217;s Confidential Information and/or of a patentable invention upon which a patent application should be filed prior to any such disclosure, submission of the concerned publication to Third Parties shall be delayed for such
period as may be reasonably necessary for deleting any such Confidential Information of Genmab (if Genmab has requested deletion thereof from the proposed publication), and/or the drafting and filing of a patent application covering such invention,
provided such additional period shall not exceed [**] from the date Ebumab first provided the proposed publication to Genmab. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 7 REPRESENTATIONS AND WARRANTIES; CERTAIN COVENANTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Mutual Representations</B>. Each Party hereby represents and warrants to the other Party, as of the
Effective Date, as follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">It is duly organized and validly existing under the laws of its jurisdiction of incorporation and has the
corporate power and authority to execute and deliver this Agreement and to perform its obligations hereunder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The execution, delivery and performance of this Agreement by such Party has been duly and validly authorized
and approved by proper corporate action on the part of such Party. Such Party has taken all other action required by applicable law, its </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 22 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws</FONT> or any agreement to which it is a party or by which it or its assets are bound, to authorize such execution,
delivery and performance. Assuming due authorization, execution and delivery on the part of the other Party, this Agreement constitutes a legal, valid and binding obligation of such Party. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The execution and delivery of this Agreement, and the performance as contemplated hereunder, by such Party will
not violate any applicable law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Neither the execution and delivery of this Agreement nor the performance hereof by such Party requires such
Party to obtain any permit, authorization or consent from any governmental authority (except for any approval by Regulatory Authority, pricing or reimbursement approvals, manufacturing-related approvals or similar approvals necessary for
development, manufacture or commercialization of Licensed Products), or from any other person, and such execution, delivery and performance by such Party, including the granting of the licenses granted under this Agreement, will not result in the
breach of, or give rise to any conflict, termination of, rescission, renegotiation or acceleration under any agreement or contract to which such Party may be a party existing as of the Effective Date. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Genmab&#8217;s Representations and Warranties</B>. Genmab hereby makes the following representations and
warranties to Ebumab as of the Effective Date: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Genmab has the right to grant to Ebumab the licenses described in ARTICLE 2 of this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Genmab has full legal or beneficial title and ownership to the Platform Technology Patent Rights and, to
Genmab&#8217;s knowledge, Exhibit A contains a complete and correct list of all Platform Technology Patent Rights existing as of the Effective Date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Platform Technology Patent Rights are not subject to any restrictions, liens or encumbrances that would
limit the rights to be granted to Ebumab under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To Genmab&#8217;s knowledge, no Third Party is infringing any of the Platform Technology Patent Rights
identified on Exhibit A. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To Genmab&#8217;s knowledge, there are no administrative proceedings or litigation seeking to invalidate or
otherwise challenge the Platform Technology Patent Rights or threat of such proceedings or litigation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">None of the Platform Technology Patent Rights is the subject of any pending
<FONT STYLE="white-space:nowrap">re-examination,</FONT> opposition, interference or litigation proceedings. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 23 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To Genmab&#8217;s knowledge, there have been no inventorship or ownership challenges with respect to any of the
Platform Technology Patent Rights. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Compliance with Law</B>. Each Party shall comply with all applicable laws in its performance of activities
contemplated under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Disclaimer</B>. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY HERETO MAKES ANY
REPRESENTATIONS AND NEITHER PARTY EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT (INCLUDING ANY LICENSED PRODUCT), INCLUDING ANY WARRANTY OF MERCHANTABILITY,
NONINFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS, OR FITNESS FOR A PARTICULAR PURPOSE. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 8 INDEMNIFICATION </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Indemnification by </B><B>Ebumab</B>. Ebumab will indemnify, hold harmless, and defend Genmab, its
Affiliates, and their respective directors, officers, employees and agents (the &#8220;<U>Genmab Indemnitees</U>&#8221;) from and against any and all damages, liabilities, costs, expenses and amounts paid in settlement (collectively,
&#8220;<U>Losses</U>&#8221;) incurred in connection with any Third Party claim arising out of or resulting from, directly or indirectly; (i)&nbsp;any material breach of, or inaccuracy in, any representation or warranty made by Ebumab in this
Agreement, or any material breach or violation of any term of this Agreement by Ebumab; (ii)&nbsp;the negligence or wilful misconduct of Ebumab, its Affiliates and their respective Sublicensees, and their respective directors, officers, employees,
consultants, agents and contractors; and (iii)&nbsp;the research, development, manufacture, commercialization, or use of Licensed Product by Ebumab and its Affiliates and Sublicensees in the Territory under this Agreement. Notwithstanding the
foregoing or anything in this Agreement to the contrary, Ebumab will have no obligation to indemnify the Genmab Indemnitees for any Losses as to which Genmab is obligated to indemnify Ebumab Indemnitees under Section&nbsp;8.2. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnification by Genmab</B>. Genmab will indemnify, hold harmless, and defend Ebumab, its Affiliates and
their respective directors, officers, employees and agents (the &#8220;<U>Ebumab Indemnitees</U>&#8221;) from and against any and all Losses incurred in connection with any Third Party claim arising out of or resulting from, directly or indirectly,
(i)&nbsp;any material breach of, or inaccuracy in, any representation or warranty made by Genmab in this Agreement, or any material breach or violation of any term of this Agreement by Genmab; or (ii)&nbsp;the negligence or wilful misconduct of any
Genmab Indemnitee. Notwithstanding the foregoing, or anything in this Agreement to the contrary, Genmab will have no obligation to indemnify the Ebumab Indemnitees for any Losses as to which Ebumab is obligated to indemnify Genmab Indemnitees under
Section&nbsp;8.8.1. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 24 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnification Procedure</B>. In the event of any such claim against any Ebumab Indemnitee or Genmab
Indemnitee (individually, an &#8220;<U>Indemnitee</U>&#8221; or &#8220;<U>indemnified Party</U>&#8221;), the indemnified Party shall promptly notify the other Party (the &#8220;<U>indemnifying Party</U>&#8221;) in writing of the claim and the
indemnifying Party shall manage and control, at its sole expense, the defense of the claim and its settlement. The indemnified Party will, cooperate with the indemnifying Party and may, at the indemnified Party&#8217;s own cost, be represented in
any such action or proceeding by the indemnified Party&#8217;s own counsel. The indemnifying Party will not be liable for any settlements entered into by any Indemnitee without the indemnifying Party&#8217;s prior written authorization.
Notwithstanding the foregoing, if the indemnifying Party believes that any of the exceptions to its obligation of indemnification of the Indemnitees set forth in this ARTICLE 8&nbsp;may apply, the indemnifying Party will promptly notify the
Indemnitees, who shall then have the right to be represented in any such action or proceeding by separate counsel at their expense; provided that the indemnifying Party will be responsible for payment of such expenses if the Indemnitees are
ultimately determined to be entitled to indemnification from the indemnifying Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.4</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Limitation of Liability</B>. WITH THE EXCEPTION OF DAMAGES ARISING OUT OF ANY BREACH OF ARTICLE 6
(CONFIDENTIALITY) OR OUT OF THE GROSS NEGLIGENCE OR WILFUL MISCONDUCT OF THE LIABLE PARTY, NEITHER PARTY HERETO WILL BE LIABLE TO THE OTHER PARTY FOR SPECIAL, INCIDENTAL, CONSEQUENTIAL, INDIRECT OR PUNITIVE DAMAGES ARISING OUT OF THIS AGREEMENT OR
THE EXERCISE OF ITS RIGHTS HEREUNDER, INCLUDING LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES. FOR AVOIDANCE OF DOUBT, NOTHING IN THIS SECTION 8.4 IS INTENDED TO LIMIT OR RESTRICT THE
INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 9 TERM AND TERMINATION </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Term</B>. This Agreement will become effective as of the Effective Date, and will continue in full
force and effect, on a Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis
until expiration of the last to expire Profit-Share Term for such Licensed Product in such country, unless earlier terminated in accordance with this ARTICLE 9 (&#8220;<U>Term</U>&#8221;). Upon expiration of the Term under the preceding sentence
(but not earlier termination of this Agreement) for a Licensed Product in a country, the licenses granted to Ebumab under ARTICLE 2 with respect to such Licensed Product in such country will continue and will convert to perpetual, fully <FONT
STYLE="white-space:nowrap">paid-up,</FONT> <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination for Convenience by Ebumab</B>. Ebumab will have the right to terminate this Agreement in its
entirety basis at any time and for any reason upon at least <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-hundred-and-twenty</FONT></FONT></FONT> (120)&nbsp;days&#8217; prior written notice to
Genmab. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.3</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Termination for Cause</B>. This Agreement may be terminated at any time during the Term upon written
notice by either Party if the other Party is in material breach of its obligations hereunder and has not cured such material breach within [**] after written notice describing the nature of such material breach is provided to the breaching Party. To
the extent such material breach involves the failure to make payment when due, such breach must be cured within [**] after written notice hereof is given by Genmab to Ebumab. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 25 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination Upon Insolvency or Bankruptcy</B>. Subject to any mandatory provisions of applicable law, either
Party may terminate this Agreement if, at any time, the other Party files in any court or agency, pursuant to any applicable law or regulation, a petition in bankruptcy or insolvency or dissolution or liquidation or for reorganization or for an
arrangement or for the appointment of a receiver or trustee of all or substantially all of its assets, or if the other Party proposes a written agreement of composition or extension of its debts, or if the other Party is served with an involuntary
petition against it, filed in any insolvency, dissolution or liquidation proceeding, and any petition or filing is not be dismissed within [**] after the filing thereof. With respect to any bankruptcy proceeding under U.S. bankruptcy laws, or
applicable foreign equivalent laws, all license rights granted by Genmab to Ebumab under this Agreement are and shall otherwise be deemed licenses of rights to &#8220;intellectual property&#8221; as defined in Section&nbsp;101(35A) of Title 11 of
the United State Code, as amended (such Title 11, the <U>&#8220;Bankruptcy Code&#8221;</U>). In the event of its bankruptcy, Genmab agree not to interfere with Ebumab&#8217;s exercise of rights and licenses to intellectual property licensed
hereunder and embodiments thereof in accordance with this Agreement and agree to use reasonable efforts to assist Ebumab to obtain such intellectual property and embodiments thereof in the possession or control of Third Parties as reasonably
necessary for Ebumab to exercise such rights and licenses in accordance with this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.5</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Termination for Challenge of Platform Technology Patent Rights</B>. Genmab may terminate this
Agreement in its entirety upon [**] written notice if Ebumab or any of its Affiliates or Sublicensees (directly or indirectly, individually or in association with any other person or entity)&nbsp;(a) initiate or request an interference or opposition
proceeding with respect to any Platform Technology Patent Right, (b)&nbsp;make, file or maintain any claim, demand, lawsuit or cause of action to challenge the validity or enforceability of any Platform Technology Patent Right ((a) and
(b)&nbsp;jointly referred to as a &#8220;<U>Patent Challenge</U>&#8221;), then Genmab may terminate this Agreement upon [**] prior written notice to Ebumab. Any such termination shall not become effective if Ebumab has withdrawn such Patent
Challenge before the end of such notice period. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.6</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination if Novo Regains Control of Rights to Licensed Product</B>. In the event that, by any means
whatsoever, Novo regains control from Ebumab of the exclusive rights with respect to a territory to develop, make, have made, use, manufacture, register, import, export, distribute, market, offer for sale, sell, have sold and/or otherwise
commercialize the Licensed Product, this Agreement shall terminate with respect to such territory for which the exclusive rights to Novo are granted and shall otherwise survive. Where such exclusive right to Licensed Product is granted worldwide to
Novo, this Agreement shall terminate in its entirety. For clarity, where the rights regained by Novo with respect to a territory are not exclusive, but <FONT STYLE="white-space:nowrap">co-exclusive</FONT> or
<FONT STYLE="white-space:nowrap">non-exclusive,</FONT> this Agreement shall remain in effect with respect to such territory. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 26 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Effect of Termination</B>. Upon the termination of this Agreement in its entirety, nothing herein shall be
construed to release either Party from any obligation that has accrued prior to the effective date of such termination, and Ebumab shall remain obligated to provide an accounting for and to share Profit earned prior to the date of termination. In
the event of any termination of this Agreement, (i)&nbsp;the licenses granted to Ebumab under ARTICLE 2 shall terminate; and (ii)&nbsp;all rights granted hereunder by Genmab shall revert to Genmab for the benefit of Genmab (iii)&nbsp;all materials,
information and data generated under the license incorporating Platform Technology shall be destroyed by Ebumab immediately and certified in writing to Genmab. With respect to the Licensed Product, Ebumab shall wind-down any clinical trials and
destroy any Licensed Products, in accordance with applicable laws and in a manner designed to preserve the health and welfare of any clinical trial subjects. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Survival</B>. Any expiration or termination of this Agreement will be without prejudice to the rights of
either Party against the other accrued or accruing under this Agreement prior to expiration or termination, including payment obligations arising prior to such expiration or termination. The provisions of ARTICLES 1, 6, 8, 9, 10, 11 and Sections
4.5, 4.6, 4.7, 4.8, 4.9, 4.10, 5.1 and 5.2 will survive any expiration or termination of this Agreement and all other provisions contained in this Agreement that by their explicit terms survive expiration or termination of this Agreement, will
survive. Except as set forth in this ARTICLE 9, upon termination or expiration of this Agreement all other rights and obligations of the Parties under this Agreement terminate. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 10 DISPUTE RESOLUTION AND GOVERNING LAW </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Continuance of Rights and Obligations During Pendency of Dispute Resolution</B>. If there are any disputes
in connection with this Agreement, all rights and obligations of the Parties shall continue until such time as any dispute has been resolved in accordance with the provisions of this ARTICLE 10. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Governing Law and Jurisdiction</B>. The validity, construction and performance of this Agreement will
be governed by and construed in accordance with the laws of the Kingdom of Denmark excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of
another jurisdiction. Any dispute or claim arising out of or in connection with this Agreement, or the breach, termination or invalidity thereof, shall be settled by arbitration in accordance with the Rules of Procedure of the Danish Institute of
Arbitration (the &#8220;<U>Institute</U>&#8221;) in force when such proceedings are commenced. The arbitration tribunal shall be composed of a sole arbitrator appointed by the Institute. The place of arbitration shall be Copenhagen, Denmark. The
language of the arbitral proceedings shall be English. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 11 MISCELLANEOUS </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Force Majeure</B>. Neither Party will be held liable or responsible to the other Party nor be deemed to have
defaulted under or breached this Agreement for failure or delay in fulfilling or performing any term, other than an obligation to make payments hereunder, when such failure or delay is caused by or results from fire, floods, embargoes, government
regulations, prohibitions or interventions, war, acts of war (whether war be declared or not), </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 27 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
insurrections, riots, civil commotions, terrorism, acts of God or any other cause beyond the reasonable control of the affected Party to anticipate, prevent, avoid or mitigate (a &#8220;<U>Force
Majeure Event</U>&#8221;); provided that (i)&nbsp;the affected Party provides prompt written notice to the other Party of such failure or delay, (ii)&nbsp;the affected Party uses Commercially Reasonable Efforts to mitigate the effects of the Force
Majeure Event, and (iii)&nbsp;the affected Party immediately resumes performance upon cessation of the Force Majeure Event. Notwithstanding the foregoing, to the extent that a Force Majeure Event continues for a period in excess of [**], the
affected Party shall promptly notify in writing the other Party of such continued Force Majeure Event and within [**] of the other Party&#8217;s receipt of such notice, the Parties shall negotiate in good faith either (a)&nbsp;a resolution of the
Force Majeure Event, if possible, (b)&nbsp;an extension by mutual agreement of the time period to resolve, eliminate, cure or overcome such Force Majeure Event, (c)&nbsp;an amendment of this Agreement to the extent reasonably possible, or
(d)&nbsp;an early termination of this Agreement. If a solution under subsection (a) - (d) has not been reached after [**] of the other Party&#8217;s receipt of such notice, then the Party not affected shall be entitled to give notice to the affected
Party to terminate this Agreement in relevant part, specifying the date (which shall not be less than [**] after the date on which the notice of termination is given) on which termination will take effect. Such a termination notice shall be
irrevocable, except with the consent of both Parties, and upon termination the effects of termination set forth in Section&nbsp;9.3 shall apply. Notwithstanding the foregoing, any failure or delay in fulfilling a term shall not be considered a
result of a Force Majeure Event if it arises from a failure of Ebumab or Genmab to comply with applicable laws. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Further Assurances</B>. Each Party hereto agrees to perform such acts, execute such further instruments,
documents or certificates, and provide such cooperation in proceedings and actions as may be reasonably requested by the other Party in order to carry out the intent and purpose of this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.3</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Notices</B>. Any notice required or permitted to be given under this Agreement will be in writing and
will be deemed to have been properly given if delivered, in person or by an internationally recognized overnight courier, to the addresses given below or such other addresses as may be designated in writing by the Parties from time to time during
the Term or on the date sent by <FONT STYLE="white-space:nowrap">e-mail</FONT> of a PDF document if sent during normal business hours of the recipient, and on the next Business Day if sent after normal business hours of the recipient; provided
however, such notice shall also be delivered via hand, overnight courier, or certified or registered mail. Delivery made pursuant to this Section&nbsp;11.3 shall be deemed received on the day following the date of the notice. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 28 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="4"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:Times New Roman">In the case of Genmab:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Head of Legal</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> [**]</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">with a copy
to:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">[**]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the address of Genmab as registered in the Danish Central Business
Register (or any successors hereof)</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the address of Genmab as registered at the GENMAB&#8217;s official homepage (currently www.genmab.com)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:Times New Roman">In the case of Ebumab:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> [**]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the address of Ebumab Hemophilia ApS as registered in the Danish Central Business Register (or any successors hereof)</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Assignment</B>. This Agreement may not be assigned or otherwise transferred by either Party, without the
written consent of the other Party such consent not to be unreasonably withheld, conditioned or delayed; provided, however, that either Party may, without such consent, assign this Agreement, in whole or in part, (i)&nbsp;to any of its Affiliates,
and (ii)&nbsp;to a Third Party successor or purchaser of all or substantially all of its business or assets to which this Agreement relates, whether in a merger, sale of stock, sale of assets or other similar transaction, provided that, the Third
Party successor or purchaser provides written notice to the other Party that such Third Party agrees to be bound by the terms of this Agreement. In case of an assignment to an Affiliate of a Party, such Party shall continue to be responsible for the
satisfaction, meeting and fulfilling of any obligation, in whole or in part, under this Agreement after the assignment. Any purported assignment in violation of this Section&nbsp;11.14 will be void. Any permitted assignee shall assume all
obligations of its assignor under this Agreement. Notwithstanding the above, Ebumab shall not have the right to assign this Agreement, in whole or in part, to Novo or any of Novo&#8217;s Affiliates. For clarity, should Novo regain control by any
means whatsoever of rights relating to the Licensed Product, then Novo&#8217;s license to Platform Technology shall be governed by separate agreements already in place between Novo and Genmab. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Affiliate Performance</B>. Any obligation of Genmab or Ebumab under or pursuant to this Agreement may be
satisfied, met or fulfilled, in whole or in part, at such Party&#8217;s sole and exclusive option, either by such Party directly or by any Affiliate or Sublicensee (only in the case of Ebumab and subject to Section&nbsp;2.2 of such Party that such
Party causes to satisfy, meet or fulfill such obligation, in whole or in part. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Amendment</B>. The Parties hereto may amend, modify or alter any of the provisions of this Agreement, but
only by a written instrument duly executed by both Parties hereto. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 29 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Entire Agreement</B>. This Agreement, along with all Exhibits attached hereto, contains the entire
understanding of the Parties with respect to the subject matter hereof and supersedes all prior agreements, whether written or oral, including the REA. Each Party confirms that it is not relying on any representations, warranties or covenants of the
other Party except as specifically set out in this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Benefit to Third Parties</B>. The provisions of this Agreement are for the sole benefit of the Parties
and their successors and permitted assigns, and they shall not be construed as conferring any rights in any other Persons. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.9</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Waiver</B>. The failure of a Party to enforce at any time for any period any of the provisions of this
Agreement will not be construed as a waiver of such provisions or of the rights of such Party thereafter to enforce each such provision. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.10</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Implied Licenses</B>. Except as expressly and specifically provided under this Agreement, the Parties
agree that neither Party is granted any implied rights to or under any of the other Party&#8217;s current or future patents, trade secrets, copyrights, moral rights, trade or service marks, trade dress, or any other intellectual property rights.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.11</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Relationship of the Parties</B>. The Parties agree that their relationship established by this Agreement is
that of independent contractors. Furthermore, the Parties agree that this Agreement does not, is not intended to, and shall not be construed to, establish a partnership or joint venture, and nor shall this Agreement create or establish an
employment, agency or any other relationship. Except as may be specifically provided in this Agreement, neither Party shall have any right, power or authority, nor shall they represent themselves as having any authority to assume, create or incur
any expense, liability or obligation, express or implied, on behalf of the other Party, or otherwise act as an agent for the other Party for any purpose. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.12</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Severability</B>. If any provision of this Agreement is held unenforceable by a court or tribunal of
competent jurisdiction in a final unappealable order because it is invalid or conflicts with any law of any relevant jurisdiction, then such provision will be inoperative in such jurisdiction and the remainder of this Agreement shall remain binding
upon the Parties hereto. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.13</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Interpretation</B>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>11.13.1 General</B>. Unless the context of this Agreement otherwise requires, (i)&nbsp;words of one gender include the other gender; and
(ii)&nbsp;words using the singular or plural number also include the plural or singular number, respectively. Whenever this Agreement refers to a number of days, unless otherwise specified, such number shall refer to calendar days. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>11.13.2 Other Definitional and Agreement References</B>. References to any agreement, contract, statute, act, or regulation are to that
agreement, contract, statute, act, or regulation as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 30 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>11.13.3 Capitalization</B>. Any capitalized terms used in any Exhibit but not otherwise
defined therein, shall have the meaning as defined in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>11.13.4 Date References</B>. References from or through any date
mean, unless otherwise specified, from and including or through and including, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>11.13.5 Exhibits</B>. All Exhibits
annexed hereto or referred to herein are hereby incorporated in and made a part of this Agreement as if set forth in full herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>11.13.6 Person References</B>. References to any Person include the successors and permitted assigns of that Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>11.13.7 References to Parts of this Agreement</B>. References to Articles, Sections and Exhibits are to Articles, Sections and Exhibits of
this Agreement unless otherwise specified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>11.13.8 Other Definitional and Interpretative Provisions</B>. The words
&#8220;hereof&#8221;, &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. Whenever the words
&#8220;include&#8221;, &#8220;includes&#8221; or &#8220;including&#8221; are used in this Agreement, they shall be deemed to be followed by the words &#8220;without limitation&#8221;, whether or not they are in fact followed by those words or words
of like import. The word &#8220;or&#8221; is used in the inclusive sense (and/or). &#8220;Writing&#8221;, &#8220;written&#8221; and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a
visible form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>11.13.9 Headings</B>. The Article and Section headings contained in this Agreement are for reference purposes only and
shall not affect in any way the meaning or interpretation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>11.13.10 Expenses</B>. Except as otherwise expressly
provided in this Agreement, each Party shall pay the fees and expenses of its respective lawyers and other experts and all other expenses and costs incurred by such Party incidental to the negotiation, preparation, execution and delivery of this
Agreement. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.14</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Counterparts</B>. This Agreement may be executed in any number of counterparts (including a portable
document format (&#8220;PDF&#8221;) version), each of which shall be deemed an original, but all of which together shall constitute one and the same document. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The remainder of this page is intentionally left blank; Signature page follows. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 31 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF, </B>Genmab and Ebumab have executed this Agreement as of the Effective Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For and on behalf of </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Genmab A/S </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1 April 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000;"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">/s/ Birgitte Stephensen</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Print Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Birgitte Stephensen</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Position:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Senior&nbsp;Vice&nbsp;President,&nbsp;IPR&nbsp;&amp; Legal</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For and on behalf of </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ebumab
Hemophilia ApS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2020-03-31</FONT></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000;">/s/ Johan Faber</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">Johan H. Faber</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Position:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;"><FONT STYLE="white-space:nowrap">Co-Founder&nbsp;&amp;</FONT> CEO</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ebumab ApS</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ole Maal&oslash;esvej 3</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">[**]</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 32 of 32 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>9
<FILENAME>d50309dex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-21.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 21.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Subsidiaries of the Registrant </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Entity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Jurisdiction of Incorporation</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Hemab ApS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Denmark</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Hemab Therapeutics Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>10
<FILENAME>d50309dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#8220;Experts&#8221; and to the use of our report dated February&nbsp;27, 2026 (except for
Note&nbsp;16, as to which the date is April&nbsp;10, 2026), with respect to the consolidated financial statements of Hemab ApS included in the Registration Statement (Form <FONT STYLE="white-space:nowrap">S-1)</FONT> and related Prospectus of Hemab
Therapeutics Holdings, Inc. for the registration of its common stock. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ EY Godkendt Revisionspartnerselskab</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Copenhagen, Denmark</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">April&nbsp;10, 2026</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>11
<FILENAME>d50309dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:ffd="http://xbrl.sec.gov/ffd/2026">
<head>
<title>EX-FILING FEES</title>
</head>
  <body>
  <div style="display: none"> <ix:header> <ix:hidden> <ix:nonNumeric name="ffd:FormTp" contextRef="rc" id="ixv-330">S-1</ix:nonNumeric> <ix:nonNumeric name="ffd:SubmissnTp" contextRef="rc" id="ixv-331">S-1</ix:nonNumeric> <ix:nonNumeric name="ffd:FeeExhibitTp" contextRef="rc" id="ixv-332">EX-FILING FEES</ix:nonNumeric> <ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="rc" id="ixv-333">0002114044</ix:nonNumeric> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="rc" id="ixv-334">Hemab Therapeutics Holdings, Inc.</ix:nonNumeric> <ix:nonNumeric name="ffd:OfferingTableNa" contextRef="rc" id="hiddenrcOfferingTableNa" xsi:nil="true"></ix:nonNumeric> <ix:nonNumeric name="ffd:OffsetTableNa" contextRef="rc" id="hiddenrcOffsetTableNa">N/A</ix:nonNumeric> <ix:nonNumeric name="ffd:CombinedProspectusTableNa" contextRef="rc" id="hiddenrcCombinedProspectusTableNa">N/A</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:href="https://xbrl.sec.gov/ffd/2026/ffd-2026.xsd" xlink:type="simple"/> </ix:references> <ix:resources> <xbrli:context id="rc"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0002114044</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-04-08</xbrli:startDate> <xbrli:endDate>2026-04-08</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="offrl_1"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0002114044</xbrli:identifier> <xbrli:segment> <xbrldi:typedMember dimension="ffd:OfferingAxis"> <dei:lineNo>1</dei:lineNo> </xbrldi:typedMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-04-08</xbrli:startDate> <xbrli:endDate>2026-04-08</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:unit id="USD"> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit> <xbrli:unit id="pure"> <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit> <xbrli:unit id="Shares"> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit> </ix:resources> </ix:header> </div> <div>
<table style="width: 99%; font-family: Arial, Helvetica, sans-serif; font-size: 20pt; text-align: center;">
<tr>
<td colspan="4" style="padding-bottom: .5em"> <p> <b>Calculation of Filing Fee Tables</b> </p> </td> </tr>
<tr>
<td style="padding-bottom: .25em"> <p> <b> <ix:nonNumeric name="ffd:FormTp" contextRef="rc" id="ixv-362">S-1</ix:nonNumeric> </b> </p> </td> </tr>
<tr>
<td style="padding-bottom: .25em"> <p> <b> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="rc" id="ixv-363">Hemab Therapeutics Holdings, Inc.</ix:nonNumeric> </b> </p> </td> </tr> </table> </div> <div style="padding-bottom: 20px;">
<table style="float: center; width: 100%; text-align: left; ">
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
<th style="vertical-align: bottom; text-align: left; word-wrap: break-word"> <b>Table 1: Newly Registered and Carry Forward Securities</b> </th>
<th style="vertical-align: bottom; word-wrap: break-word; text-align: right;"> <span style="-sec-ix-hidden: hiddenrcOfferingTableNa">&#9744;Not Applicable</span> </th> </tr> </table>
<table style="font-family: Arial, Helvetica, sans-serif; float: center; width: 100%; text-align: center; border: 1px solid black; font-size: 16px;">
<tr style="background-color:#9ADAF6">
<th style="width: 12%;">
 </th>
<th style="width: 2%;">
 </th>
<th style="width: 12%;"> <p style="margin: 0pt; text-align: center;"> <b>Security Type</b> </p> </th>
<th style="width: 14%;"> <p style="margin: 0pt; text-align: center;"> <b>Security Class Title </b> </p> </th>
<th style="width: 2%;"> <p style="margin: 0pt; text-align: center;"> <b>Fee Calculation or Carry Forward Rule</b> </p> </th>
<th style="width: 5%;"> <p style="margin: 0pt; text-align: center;"> <b>Amount Registered</b> </p> </th>
<th style="width: 15%;"> <p style="margin: 0pt; text-align: center;"> <b>Proposed Maximum Offering Price Per Unit</b> </p> </th>
<th style="width: 10%;"> <p style="margin: 0pt; text-align: center;"> <b>Maximum Aggregate Offering Price</b> </p> </th>
<th style="width: 5%;"> <p style="margin: 0pt; text-align: center;"> <b>Fee Rate</b> </p> </th>
<th style="width: 6%;"> <p style="margin: 0pt; text-align: center;"> <b>Amount of Registration Fee</b> </p> </th>
<th style="width: 1%;"> <p style="margin: 0pt; text-align: center;"> <b>Carry Forward Form Type</b> </p> </th>
<th style="width: 7%;"> <p style="margin: 0pt; text-align: center;"> <b>Carry Forward File Number</b> </p> </th>
<th style="width: 6%;"> <p style="margin: 0pt; text-align: center;"> <b>Carry Forward Initial Effective Date</b> </p> </th>
<th style="width: 7%;"> <p style="margin: 0pt; text-align: center;"> <b>Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward</b> </p> </th> </tr>
<tr>
<td colspan="14" style="text-align: center"> <b>Newly Registered Securities</b> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> <ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="offrl_1" format="ixt:booleanfalse" id="ixv-364">Fees to be Paid</ix:nonNumeric> </td>
<td style="text-align: center;"> 1 </td>
<td style="text-align: left;"> <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_1" id="ixv-365">Equity</ix:nonNumeric> </td>
<td style="text-align: left;"> <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_1" id="ixv-366">Common Stock, par value $0.0001 per share</ix:nonNumeric> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:Rule457oFlg" contextRef="offrl_1" format="ixt:booleantrue" id="ixv-367">457(o)</ix:nonNumeric> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> <span>$</span> <ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="2" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-368">100,000,000.00</ix:nonFraction> </td>
<td style="text-align: right;"> <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="7" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-369">0.0001381</ix:nonFraction> </td>
<td style="text-align: right;"> <span>$</span> <ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="2" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-370">13,810.00</ix:nonFraction> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Fees Previously Paid </td>
<td style="text-align: center;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr>
<td colspan="14" style="text-align: center"> <b>Carry Forward Securities</b> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Carry Forward Securities </td>
<td style="text-align: center;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td colspan="3" style="vertical-align: top"> <p style="margin: 0pt; text-align: right">Total Offering Amounts:</p> </td>
<td>
 </td>
<td style="vertical-align: top; width: 16%;"> <p id="MaxAggtOfferingPrice" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:TtlOfferingAmt" contextRef="rc" decimals="2" format="ixt:numdotdecimal" unitRef="USD" id="ixv-371">100,000,000.00</ix:nonFraction> </p> </td>
<td>
 </td>
<td style="vertical-align: top; border-bottom: 1px black; width: 16%;"> <p id="TotalFeeAmt" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:TtlFeeAmt" contextRef="rc" decimals="2" format="ixt:numdotdecimal" unitRef="USD" id="ixv-372">13,810.00</ix:nonFraction> </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td>
 </td> </tr>
<tr>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td colspan="3" style="vertical-align: top"> <p style="margin: 0pt; text-align: right"> Total Fees Previously Paid: </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td style="vertical-align: top"> <p id="TotalPreviouslyPaidAmt" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:TtlPrevslyPdAmt" contextRef="rc" decimals="2" format="ixt:numdotdecimal" unitRef="USD" id="ixv-373">0.00</ix:nonFraction> </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td>
 </td> </tr>
<tr>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td colspan="3" style="vertical-align: top"> <p style="margin: 0pt; text-align: right"> Total Fee Offsets: </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td style="vertical-align: top"> <p id="TotalOffsetAmt" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:TtlOffsetAmt" contextRef="rc" decimals="2" format="ixt:numdotdecimal" unitRef="USD" id="ixv-374">0.00</ix:nonFraction> </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td>
 </td> </tr>
<tr>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td colspan="3" style="vertical-align: top"> <p style="margin: 0pt; text-align: right"> Net Fee Due: </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td style="vertical-align: top"> <p id="NetFeeAmt" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:NetFeeAmt" contextRef="rc" decimals="2" format="ixt:numdotdecimal" unitRef="USD" id="ixv-375">13,810.00</ix:nonFraction> </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td>
 </td> </tr> </table> </div> <div>
<table style="width: 100%; text-indent: 0px;"> <tbody>
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; vertical-align: top;">
<td> <p style="margin:0pt;text-align:left; margin-bottom: 5px;"> <b>Offering Note</b> </p> </td>
<td/> </tr> </tbody> </table> </div> <div style="padding-bottom: 20px;">
<table style="width: 100%; text-indent: 0px;">
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; vertical-align: top;">
<td style="width:10pt;"> <p style="margin:0pt;text-align:left;"> <sup style="vertical-align:top;line-height:120%;font-size:10px">1</sup> </p> </td>
<td colspan="7" style="white-space: pre-line;"> <ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="offrl_1" id="ixv-376">Maximum Aggregate Offering Price estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended. Includes the aggregate offering price of additional shares that the underwriters have the option to purchase from the registrant, if any. Amount of Registration Fee is calculated pursuant to Rule 457(o) under the Securities Act of 1933, as amended, based on an estimate of the proposed Maximum Aggregate Offering Price.</ix:nonNumeric> </td> </tr>
<tr>
<td colspan="7"> <hr style="width:100%;text-align:left;margin-left:0"/> </td> </tr> </table> </div> <div style="padding-bottom: 20px;">
<table style="float: center; width: 100%; text-align: left; ">
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
<th style="vertical-align: bottom; text-align: left; word-wrap: break-word"> <b>Table 2: Fee Offset Claims and Sources</b> </th>
<th style="vertical-align: bottom; word-wrap: break-word; text-align: right;"> <span style="-sec-ix-hidden: hiddenrcOffsetTableNa">&#9745;Not Applicable</span> </th> </tr> </table>
<table style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; float: center; width: 100%; text-align: center; border: 1px solid black;">
<tr style="background-color:#9ADAF6">
<th style="width: 10%; text-align: left;">
 </th>
<th style="width: 8%; text-align: left;">
 </th>
<th style="width: 16%;"> Registrant or Filer Name </th>
<th style="width: 6%;"> Form or Filing Type </th>
<th style="width: 7%;"> File Number </th>
<th style="width: 6%;"> Initial Filing Date </th>
<th style="width: 6%;"> Filing Date </th>
<th style="width: 6%;"> Fee Offset Claimed </th>
<th style="width: 6%;"> Security Type Associated with Fee Offset Claimed </th>
<th style="width: 8%;"> Security Title Associated with Fee Offset Claimed </th>
<th style="width: 6%;"> Unsold Securities Associated with Fee Offset Claimed </th>
<th style="width: 9%;"> Unsold Aggregate Offering Amount Associated with Fee Offset Claimed </th>
<th style="width: 6%;"> Fee Paid with Fee Offset Source </th> </tr>
<tr>
<td colspan="14" style="text-align: center"> <b>Rules 457(b) and 0-11(a)(2)</b> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Fee Offset Claims </td>
<td> </td>
<td style="text-align: left;"> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td style="text-align: right;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Fee Offset Sources </td>
<td> </td>
<td style="text-align: left;"> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td style="text-align: right;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr>
<td colspan="14" style="text-align: center"> <b>Rule 457(p)</b> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Fee Offset Claims </td>
<td> </td>
<td style="text-align: left;"> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td style="text-align: right;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Fee Offset Sources </td>
<td> </td>
<td style="text-align: left;"> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td style="text-align: right;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td> </tr> </table> </div> <div style="padding-bottom: 20px;">
<table style="float: center; width: 100%; text-align: left; ">
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
<th style="vertical-align: bottom; text-align: left; word-wrap: break-word"> <b>Table 3: Combined Prospectuses</b> </th>
<th style="vertical-align: bottom; word-wrap: break-word; text-align: right;"> <span style="-sec-ix-hidden: hiddenrcCombinedProspectusTableNa">&#9745;Not Applicable</span> </th> </tr> </table>
<table style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; float: center; width: 100%; border: 1px solid black;">
<tr style="background-color:#9ADAF6">
<th style="width: 4%">
 </th>
<th style="width: 14%"> <p style="margin: 0pt; text-align: center;"> <b>Security Type</b> </p> </th>
<th style="width: 25%"> <p style="margin: 0pt; text-align: center;"> <b>Security Class Title</b> </p> </th>
<th style="width: 14%"> <p style="margin: 0pt; text-align: center;"> <b>Amount of Securities Previously Registered</b> </p> </th>
<th style="width: 18%"> <p style="margin: 0pt; text-align: center;"> <b>Maximum Aggregate Offering Price of Securities Previously Registered</b> </p> </th>
<th style="width: 6%"> <p style="margin: 0pt; text-align: center;"> <b>Form Type</b> </p> </th>
<th style="width: 10%"> <p style="margin: 0pt; text-align: center;"> <b>File Number</b> </p> </th>
<th style="width: 8%"> <p style="margin: 0pt; text-align: center;"> <b>Initial Effective Date</b> </p> </th> </tr>
<tr style="background-color:#E7E7E2;">
<td style="text-align: center;"> </td>
<td> </td>
<td> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td> </tr> </table> </div> </body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g50309dsp3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309dsp3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  W *,# 1$  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^JS_@JG^V
M?\3OV+/AC\,?&/POL/#^H:GXP\>7OAK4H_$-H]W;QV-OX?O-41[=$92LQN+=
M%+$XV$CO0!]&?L)_M/Q?M>?LU>!?C+/9V>E>([\ZIH'C71K&7S;;2_%?AZ^E
ML=02$,3)';:C;"RUNRBEQ)%9:I;HV2NX@'PC^UY_P5!UOX4?MG?!;]ECX06O
MAO78M3\:> /#?Q?UJ_7[<=.N_'GBK1--BT#26A<QPZCI.A7CWU_*Q)CNM3MK
M5U66SG4 '[74 ?SU?M&_\%AO$'PC_;G_ .%1Z#_PC5_^SQX(\:^#O!/Q/\2#
M3'O=3M;R:1(_'T]EJ"'"S>'99+^UCMD/[ZX\/WPCWJ7( /Z#K6YM[VVM[RTF
MCN+6[@BN;:XA=9(I[>>-989HG4E7CEC=71U)5E8$$@T ?AK\4_VB_P#@KUHW
MQ/\ B/H_P[_9FT?6_A_I7CSQ?IO@76I-*M9)-7\'6/B'4;7PSJDDC7Z,[ZAH
ML5C=NY12S3%BJDX !\9?%_\ X*K_ /!2+X#^*M!\#?%/X0^!O"WC#Q-;PW6B
M>')])2[U>^AN;L6-HR65C=7$RM>79\BTCD59+EP?)5P,T ?T^>#[K7+[PEX7
MOO$UHMAXDO/#NB77B&Q0!4LM<N-,MIM6M$4$@+;7[W$*@$@!  3UH _#GXW_
M /!6#Q7\)O\ @H7:? 9;#0KK]GK1/&W@WX;^./$;Z>_VZP\0^(='LO[=N4UK
M_4QCPMJ^L0O?698.8-%OXRH#$T ?O0"",@Y!Y!'0CUH _ 34_P#@KWK7PK_;
M^^(?P!^-=MX=T?X#>&O&7B'P7#XKLK"<ZSH4\-K!+H6K:I)&Q,]C]M'V+4BJ
M'R+>\-YM;[+M(!^S7QY^(&H?#CX"?&'XH^&?L=YJG@?X3^._'6@FX GT^ZOO
M#OA/4]=TPS!#B:TGGM(=^UL20L=IY!H _,?X<_MD_MA?&K_@GMX7_:'^#OPW
MT7QW\=]:^)NJ^'+CPII&FK)IH\+:3K>M:;=ZA':3W$($EO'9V'F2&7.^8D*<
M\ 'Q5XZ_X**_\%7/AIXD^'GA#QU^SKH'AOQ)\5];G\-_#S2-0T"%;KQ5K=M)
MIT4^G::([^1&GCDU;3E82O$N;N+#')P ?H%^Q=\=O^"COQ#^,P\/?M1_ *#X
M;_"__A$]=OO^$CCTFWLF_P"$BMI=.72+#SHKZX;%U'+>L4\O#>3RPQR /_X)
MU?MP_%7]JWXP?M5> _B#IWARRTCX*Z_INF>%Y-$LWMKFX@N_%'CC1I#J#LS"
M9Q;>'+)E(QB1YC_%0!^M- !0 4 % '\_?_!P8H;X&?L_*P!5OC)J"L#T(/@_
M4@0?8CB@#PSXU>-?BA_P2+^-WQ>^&_P.\'WNM?!3]J7PN=8^!6D>;-=Q^!OC
M#<0:?X=N38.0[3R:7=SRRQZ)AIM1L9_"R,S)93.0#Y_\3_L,^(_V6(/V%_B/
M\8;F;4_V@_C)^VI\/K[QI<3ZE)J;Z'H46MZ%>Z?H,]VS.MWJT]]+<ZKKEYO<
MM<36UD"/L+%P#^I/]H/XU>&?V=?@Q\0_C3XO$DNA^ /#MSK,ME"Z1W.JWQ>.
MSTC1K1I"$%WJ^K7-EIT!;Y4DN1(_R(Q !_+?\)/A[^R;XZ_X)]?')?B9\:OA
M+IW[57QW\57WQDT@:WXEABU?PYK?AR\U&[\&>&[R=T86%SKD>J>+$U4N^(U\
M9A+P&33D* '[B?\ !)/X^WGQ[_8K^'D^OZK#JGC+X8SZA\*?$\@=3=;/"KQC
MPI<7:;FD:6X\%W?A\2W;C%[>07DP)<2A0#W_ /;/_:P\)_L=?!+5_BMXBLGU
M[5I;ZS\.>"?"5M*([SQ1XMU5)VT_3U()ECLX8K:YO=1N8XW:*TMG2,&>6!6
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M2/BMJO\ 9EVFD:?K7B6SDO+VSO\ 6#$(%3P%X*GU>ZEB8_O]2U01>6UU:PH
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MC_;NB?\ 09TK_P &-I_\>H M0ZA87$4LUO?6<\, )GEAN898H0%+DRR([)&
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MG2M5\??#7P+XUU/3+?6;)H--U#Q5X7TO7;RP@:;6%F:&SN;^2WC,JK(4C4R
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MW44>A:=_:=S/807&EQ0VMLVI7Q# 'T?\"/\ @DYH/P6\<^$_B;^SA^V+\4-
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M@G'X9A\236\-G/JRVFNZ;)]JGM(+N^BMI6\[#0K=S[0 =YS0!\#? ;]DZ_\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g50309dsp3a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309dsp3a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !K *,# 1$  A$! Q$!_\0
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M\/Z=HGB1]6EU37_&^H:;\2]6GTZR,UJVB75U;V]E:Q.( #^A#]G'XIV7QN^
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M,'Q$1H(/]I<ZT1I8_P!._<4 >=+^U_\ LENP5?VHOV=69B JK\;/AHS,3T
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MH?XJ?LF?\%(/VKOVA/ FE:OKG@SPE^U'\7_#WQAT2Q?R].USP1XM^,/BZ/\
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M^MZIX9N+F",8L18O%KO@Z*WCEO+:9?!W]H6U[)'>_9[4 ^,?^"=7A#PQX_\
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MBRUG^+]OJ$/C+X6BQL$\(7TM_;Z9(;U[A9C>2W]MKFG-KEK=2Q-+;S:CJ=G
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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40 4 % !0 4 % !0 4 % !0!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g50309g05a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g05a01.jpg
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M*"@H*"@H*"@H*"@H*/_  !$( J,%5@,!(@ "$0$#$0'_Q  <  $  @,! 0$
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M+$%E%6W&FZEB;C3=2Q!915MQINI8FXTW4L0645;<:;J6)N--U+$%AS6O:6O
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MC?H@^HB(*E9Z0?10*>L](/HH$'*;YRK5XU3<K)I+2M5?9+:=FKE9-S8:[H(
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M1'&UX#1G'%Q<3[<KN7(5-)4<D^G7S/<]XA>S+CDX;(YH'\@ /Y(J[<M9B'E
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MB"'FY>O_ .(3FY>O_P"(4R((>;EZ_P#XA.;EZ_\ XA3(@AYN7K_^(3FY>O\
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MDGVC/M16L\E'*(RKJ[+IUVGC:;=5TCGVF05 DYV.(N!V@ ,'S''/CE>M'?\
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MB#ZB(@J5GI!]% IZST@^B@0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M[SF9V7'YD+.W2TT-T92LN%,R9M-.RIA#LC8D9^5PQ[%)SU1\*>\"<]4?"GO
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M^C'U4S/R-^B#ZB(@J5GI!]% IZST@^B@0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0%-#4PPM+99&M=G."H5<H_1'ZH/&_4W7,3?J;KF*RB"MOU-U
MS$WZFZYBLH@K;]3=<Q-^INN8K*(*V_4W7,3?J;KF*RB"MOU-US$WZFZYBLH@
MK;]3=<Q-^INN8K*(*V_4W7,3?J;KF*RB"MOU-US$WZFZYBLH@K;]3=<Q-^IN
MN8K*(*V_4W7,3?J;KF*RB"MOU-US$WZFZYBLH@K;]3=<Q-^INN8K*(*V_4W7
M,3?J;KF*RB"MOU-US$WZFZYBLH@K;]3=<Q-^INN8K*(*V_4W7,3?J;KF*RB"
MMOU-US$WZFZYBLH@K;]3=<Q-^INN8K*(*V_4W7,3?J;KF*RB"MOU-US$WZFZ
MYBLH@K;]3=<Q-^INN8K*(*V_4W7,3?J;KF*RB"MOU-US$WZFZYBLH@K;]3=<
MQ-^INN8K*(*V_4W7,3?J;KF*RB"MOU-US$WZFZYBLH@K;]3=<Q-^INN8K*(*
MV_4W7,3?J;KF*RB"MOU-US$WZFZYBLH@K;]3=<Q-^INN8K*(*V_4W7,3?J;K
MF*RB"MOU-US$WZFZYBLH@K;]3=<Q-^INN8K*(*V_4W7,3?J;KF*RB"MOU-US
M$WZFZYBLH@K;]3=<Q-^INN8K*(*V_4W7,3?J;KF*RB"MOU-US$WZFZYBLH@K
M;]3=<Q-^INN8K*(*V_4W7,3?J;KF*RB"MOU-US$WZFZYBLH@K;]3=<Q-^INN
M8K*(*V_4W7,3?J;KF*RB"MOU-US$WZFZYBLH@K;]3=<Q-^INN8K*(*V_4W7,
M3?J;KF*RB"MOU-US$WZFZYBLH@K;]3=<Q-^INN8K*(*V_4W7,4D-3#,[9BD:
MYV,X"E1 1$01U'H7+F]B_>BY_P 4_P#N*Z14>A<N;V+]Z+G_ !3_ .XH0Z5%
MZ,(D7HPB"*K]&/JIF?D;]%#5^C'U4S/R-^B#ZB(@J5GI!]% IZST@^B@0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%<H_1'ZJFKE'Z(_5!,N82<H
M5=;N5BOL=UAA;I[G(*2&K:TAT-1)$'M:\YZ'>< <=("Z>N7T]BH]2ZOY3[1<
MF%U-4[@TD?F8[=\M<WV$'!'T0;/<+[5P<H]GL<8BW*JH*BIDRWSMMCF!N#GH
M\XKQ<N4;2EMN4U#67B)D\+^;F+8Y'QQ.]CY&M+&GY$A<[T?=;E4\JUHLU^S^
MWK-;:REGE(\VH;M1&*<?^IO3\P5E.3&YV.W<C\U+?JBEAFI14QW:&=[0_G=M
M^V'@\279X>W(0;CRA:VH='6*&X3XF=/+'' QN2'ASV@NRT'@&N)^?0.E9NQ7
MFAOM *RUS.FIBXLVG1NC.1T\' '_ *+CMQBJZ/\ PY:<_:@?')!)022&3@8X
M]X86[7LPW97;J>>&ICYRGECE9T;3'!P^X0<YBNFL;WJ_5%#9+I::*DM,\4,;
M*FA=*Y^W$U_%PD&.)/J65T9K45VF+I<-3&DMTUHK)J&ND8\\QMQD N:3QP<C
M /'/!:7#INY7W67*4ZS:AN=HK&3PMA;3/:V-[S3-V2_+2>GAP(6&NTU--R3Z
M<-MC;:66^_0MO;9V&?=IVN<)'S G+QSA8XY/$$(KL6G-96'4=5+36BO$M3&P
M2.ADBDA?L=&T&O:"6_,9"J73E#TM;)ZB&LNK1/3RNAEBCADE?&YH!.TUC20!
MM#SNCYK!6ZR5%=K6P7BXZTM=QGHF3\Q3TM&R%T[)&8<,B5Q+1@.Z#T*IR:7.
MTT>K^46*JJ:6GKOVL9'F5[6%T0C;@Y/2 =KZ9^:(WUVI+,W3W[==<J46?8YS
M>]L<WLYQT^W/#'3GATJGIW6VGM15CZ2TW$2U;6<YS,D4D+RWW@U[07#YC(7&
M:/F6:4MES>W9TH-:R5;21B)M*7N$;R/5'SG'V<5ONNJRDN.O= PVB>&HND5;
M).]T#P\QTO-.$A<1T-=EH&>DH-CJM?:9IJ\44MU8:PU+J3F8XI'O$C2&D$-:
M2!D@;1X?-8U_*998M;UNGIY'L--'&.>$,CMJ9SW-,> TX  ;YV<<3[%3Y'Z2
M!ERU]5MB:*F34=3$^3'G%K6L+1GV N=]TME3!2<M^HV54T<+IK32.B$C@W;
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M(.SCV\4'2$6EZWU3=+1J/3EFL=OIJRIO+:D-=/(6-B,;6.#G$ ^;ASB1C)P
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M\!Y8JR@@\V@OU :_FQT-JHG!CW >K:8YI/M+5T! 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!$ZI@:XM=/$'#I!>!A>FS1.C+VR,+!T
MN#A@?S6CZWTOHFWVV[ZCONG[;.Z*-U1/(^$%\KO9GVDX'U*U"32-59?\/ERH
M*:W2.N=SQ5U%)21$EKI9&;3&L'NLPW ]U!V:.HAD=LQS1N=[&N!*D) !)( '
M22N7Z-ET+1:HI:>ATQ+I^]RL?NIK+<:9TPQYP8[H)QTC.5O6JK5;+O99X+[
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MDKHX:2H$I_,9-MK"[/M(<5F:?D-L\-+64'[:OAL\Y<]MO%1B)CR,!Y 'G%O
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MQMOCIB1"22 'G/3PS@9X*OR]0B]<F,U[M]XJ6V^*!D\<$!#8ZG;>P-<XXR0
M3YOM(/J6F:<IXA_A3NSA&W,CI'N..EPF: ?K@#[+J7)W::&^<CU@MUUIVU-%
M/0Q"2)Q(#L8(Z./2 @W:A_\ DH/_ +;?^RG7EC0QC6M&&M& /DO2((B("(B
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MLKJTGI,\M/(]P/TR&_\ M16[V^\U]'RD5^G[G/S])64HN%M>6-:8PTADL)(
MVL$M<">.'')*S.FM0T6HJ>LFMPG#*6JDHY.>B,9VV8S@'I''I6K:B.\<M&CX
MH.,E);ZZHGQZHW\VQN?_ '!;=8+Y;[_235-JG,\$4[Z=S]AS1ML.' 9 R ?6
M."(QFI-;6;3MRCM]QDG-=+!S\-/! Z5\PVMG98UHRYV?5[ 3T!?*[65)1T%O
MJ'VR]R2UK'/CI8K?(^9H;C.VT##.D=)'2L%6Q1R<O=L>]C7.CT_,YA(_*>?:
M,C^1(_FJNKM45$>OGV*KU'!I>UPT+*IM2]D7.5;BX@M:^4%@#0!PP3Q0;&S7
M]@=I:HU ^IEBM]-.*6IYV)S)()2]K-E[#Q:07-S\CE0V_E#LU9=J.@,5SI37
M.+*.HJZ*2&&I.,X8]PXD@9&<97'WN95\F/*"345%;#-J*F(GJ8PQ\[#)38>6
MAK1YPP>@9!"ZGRM@;&C> X:DH<?+BY!F=0:QMUFND=L,%?7W)T6\&EH*9T[V
M1YQMNQP SP&3Q52U\HEAN&GZZ^;=72VNC.S)/54SXP79+2UH(RYVT,8'') 6
MDZ_O8TGRL1UE+=;=;'W&U!M1)=(GO@?S<A# S8((?Q=D$XQCUK%7VWT?X6T%
M58+\+K#37^.ZW2OH6->6ESW.D>(O. V2YKMD@\&Y**ZGI_6ULO-T%M$-PH*]
MT9FB@N%(^G=-&.ES-H><!D9]8]BV=<IL$%EO&L+#7?B&Z_U]%STM)2M-/G#X
MRU^1&P$#'M]8"ZLB"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B#
M4^4#4%5:Z2"VV,-DU!<=IE*TC(A:!E\[Q[K!Q^9('K6N0ZRNM/R+66];;*J_
MW&.GIX7RM :Z>5X8'$-P,#).![%%-9==46HM0WF*#3=6ZLVHH9:BHF:^&E;G
M8C: S ];CQXN/R"U:TP7N7D'L%;54M-)!:9J*XTS*1SWR2012 O+P0/.#<G
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MQSG'_5!<CM]%$]KXZ.G8]IR'-B:"/^BEJ8(JFGE@J&-DAE86/8X9#FD8(/\
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MKM]):K?!0VZ".GI(&!D448PUK1Z@J=MT[:;9;JN@M]%%3TE6^26>-F0'N?\
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M5];9WW2F,1IA3"1T1C<]C?/!(.UYSN@^Q:\WE/U91Z;GU;>;-1T^GY*5HH8
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M3)MPRQM +ATGB ?ET'A[='U#K#6^LN334%XDMMKCTO+F+FVN<)V-#QYX.<.
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M>[(\UNV>.RW@,+?4!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M.<CCP72$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MCV'+3(6-RX @'&0,A>*G65XN%ZN=#I#3\5SAMDN[U554UHIF&8 %T;/-<7$
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M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$$=1Z%RYO8OWHN?\4_\
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MXDY!X9/1]5>L=RENM6Z9I+*>&%K)(\?^<>+A_P"T8'\R@S:(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MSHN;!:_+7 C'U=E3NME"ZE;3.HZ<T[3M-C,8V0?;CVJVB"&&DIX"##!%&0"
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MNQ,\<W$/:\\/^G2M;Y/J(M;M$>Q8*LK*C5-Y;*6EM+&[9B8?4,\2?F5TO3M
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D$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g50309g06a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g06a01.jpg
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M @,1$@0A,1-!804B4:$&%#)Q@<'1\"-"D;'_V@ , P$  A$#$0 _ /U2
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MGI[CPZ&5O#?W 347(("3/9QWF:&J8_=G?V*!)!\145-Q]        541%5>
M'E[T8W+B,B/J'97<T)FHEW[FH2VHC4PFY /,<;8T^2F_M/0
M
M
M
M                                             !XDC:]/E)O[2!54
MJIO1<+YG(60<B.145,HH%12UJLDYF?<]/O+6-Z/;E%*FZ4:O9\A<2-WL=_L1
M[-<><;L2;GIN5%7@H&P ^,=M)D^@   (]4_"(Q.*\2014_K*K?P0#/"S88B>
M?SGL
M
M
M
M        /$S-N-4\_F-.O.U07..=BJD<^YV_@Y/XH;H:SK.GV[34.;THE25O
MLX_=D"WMM3SL2+DGFH:7K%>QJ*N3;F+E /H  ^.Z*D:DWR/4DNZ*D>CZ3P)(
M
M
M
M
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M(CW)_>7&]3(8O4
M
M            !15MSJ(=:6FV,5O@M3154\B*F_:C?"C<+W2. O0
M       0[Q<Z2SVRHN%QF2&E@;MO>O[$[57@B'YXU7RSWVX5,C+$K+;1(N&+
ML(^5R=JJN43N1/:II3':_ACES5Q?Q/TF#\J6KE8U=05#9'W)*N/.^*HC:YKO
M:B(J>Q3OG)SKJBUI;GOB9X/7P8Y^F5<[.>#FKYVK_P"_7;X;4C<N<74TR3J/
M+;P 9/0         H]%7.HN]A2KK%:LWA55%\E,)LQU$D;?_ +6H7@
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MUKD9-&CVYVZ??A?/O4#:_*6S?.=%]>S^(\I;-\YT7U[/XE;Y,6'YDM?V2/\
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MB& )GA+.QWN'A+.QWN(8 F>$L['>X>$L['>XA@"Q8Y'-14X*?3Q!U+>X]@
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MY$)=9U:=Y$      !,H^J7O(9,H^J7O S     !7R]8_O4L"OEZQ_>H'D
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M>0R91]4O>!F     "OEZQ_>I8%?+UC^]0/(       +"'JF=QZ/,/5,[CT
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M>IY/4G6.[U/(     !ZBZQO>A8%?%UC>]"P      ,-7U7M(9,J^J]I#
M  !+H^@[O(A+H^@[O S@    ! GZY_>3R!/US^\#P       "?!U+>X]GB#J
M6]Q[              !77O\ $Y_T3OV*6)77O\3G_1._8H',='=-IUBBZDY/
MH[IM.L474@9P !\?T%(U'TGDE_04C4?2>!*
M                 '&^7/\ *!R5?K=?WX3LAQOES_*!R5?K=?WX3L@
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MX     0)^N?WD\@3]<_O \        GP=2WN/9X@ZEO<>P
M5U[_ !.?]$[]BEB5U[_$Y_T3OV*!S'1W3:=8HNI.3Z.Z;3K%%U(&<  ?']!2
M-1])Y)?T%(U'TG@2@                                         !Q
MOES_ "@<E7ZW7]^$[(<;Y<_R@<E7ZW7]^$[(      8*SJT[R(2ZSJT[R(
M    "91]4O>0R91]4O>!F     "OEZQ_>I8%?+UC^]0/(       +"'JF=QZ
M/,/5,[CT    ^/Z#NX^GQ_0=W 5P       ,U)UOL)A#I.M]A,      /C^@
M[N*XL7]!W<5P      ,M)UWL,1EI.N]@$T     (U9Q:22-6<6@1@
M2J+@_P!A((]%P?["0      :['SGE%<-JXQS1[+=FE3&U#N3>OGW_P"Y8%5#
MS/E1<MBW2PR[+=JJ=G9EW)N3S?\ Z%J      "R3@5I9)P      /$_4N[B
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M.[CZ?']!W<!7        S4G6^PF$.DZWV$P      ^/Z#NXKBQ?T'=Q7
M   RTG7>PQ&6DZ[V 30     C5G%I)(U9Q:!&       !*HN#_82"/1<'^PD
M      &N1\]Y1U^W<8IH=ENS2M5-J+<F]?/_ /J6)50\QY57)([?+%-L-VZI
M<[,NY-R>;_\ 0M0      62<"M+).      !XGZEW<0"?/U+NX@       D4
M72=W$<D472=W 2@     AU?6^PF$.KZWV 80       3*3JO:9C#2=5[3,
M    5\G6.[U/)ZDZQW>IY      /476-[T+ KXNL;WH6      !AJ^J]I#)E
M7U7M(8      )='T'=Y$)='T'=X&<     ($_7/[R>0)^N?W@>        3X
M.I;W'L\0=2WN/8              *Z]_B<_Z)W[%+$KKW^)S_HG?L4#F.CNF
MTZQ1=2<GT=TVG6*+J0,X  ^/Z"D:CZ3R2_H*1J/I/ E
M                         #C?+G^4#DJ_6Z_OPG9#C?+G^4#DJ_6Z_OPG
M9      #!6=6G>1"76=6G>1       3*/JE[R&3*/JE[P,P     5\O6/[U+
M KY>L?WJ!Y       !80]4SN/1YAZIG<>@   'Q_0=W'T^/Z#NX"N
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M^@[O(A+H^@[O S@    ! GZY_>3R!/US^\#P       "?!U+>X]GB#J6]Q[
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MES_*!R5?K=?WX3LAQOES_*!R5?K=?WX3L@     !@K.K3O(A+K.K3O(@
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M[3,8:3JO:9@     "ODZQW>IY/4G6.[U/(     !ZBZQO>A8%?%UC>]"P
M   ,%6J<WC._/ B%#<_RFV_]3U'_ #X"^    0*F\6VEEYNIN%)%)Z+YFM7W
M*IS?E,UA4>&RVBURNBBB^3/*Q<.<[SM1?,B><YJ;5Q;C<OSO6_7ZX,DX\5>6
MO,OT[!-%41I)!(R6->#F.1R+[4)]'T'=Y^9K!?*ZQUC9Z"9S4S\N-5^0].Q4
M/T3I2Z0WFS0UU/N9*F]J\6N3<J>Q3F^.:O;]-^JTZ[==:M'LMU5$QE<9!JNO
M.NTQ^N8?W)#:C-]4   @3]<_O)Y GZY_>!X       !/@ZEO<>SQ!U+>X]@
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M/Z#NX^GQ_0=W 5P       ,U)UOL)A#I.M]A,      /C^@[N*XL7]!W<5P
M     ,M)UWL,1EI.N]@$T     (U9Q:22-6<6@1@       2J+@_V$@CT7!_
ML)      !KR>%>4E;SE=#)2[#=BF;C;C7";UW9[?>3RHC6E\KKBD=%-'5<VW
M;J'*NQ(F&[D\W9[BW      !9)P*TLDX      'B?J7=Q )\_4N[B
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M3K%%U)R?1W3:=8HNI S@ #X_H*1J/I/)+^@I&H^D\"4
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M.N]AB,M)UWL F@    !&K.+221JSBT",       "51<'^PD$>BX/]A(
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MDI, #H   @3]<_O)Y GZY_>!X       !/@ZEO<>SQ!U+>X]@
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ML?WJ6!7R]8_O4#R       "PAZIG<>CS#U3.X]    /C^@[N/I\?T'=P%<
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M'=ZGD]2=8[O4\@     'J+K&]Z%@5\76-[T+       PU?5>TADRKZKVD,
M    $NCZ#N\B$NCZ#N\#.     $"?KG]Y/($_7/[P/        )\'4M[CV>(
M.I;W'L              %=>_Q.?]$[]BEB5U[_$Y_P!$[]B@<QT=TVG6*+J3
MD^CNFTZQ1=2!G  'Q_04C4?2>27]!2-1])X$H
M                   <;Y<_R@<E7ZW7]^$[(<;Y<_R@<E7ZW7]^$[(
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MH^@[O S@    ! GZY_>3R!/US^\#P       "?!U+>X]GB#J6]Q[
M      !77O\ $Y_T3OV*6)77O\3G_1._8H',='=-IUBBZDY/H[IM.L474@9P
M !\?T%(U'TGDE_04C4?2>!*
M     '&^7/\ *!R5?K=?WX3LAQOES_*!R5?K=?WX3L@     !@K.K3O(A+K.
MK3O(@      )E'U2]Y#)E'U2]X&8     *^7K']ZE@5\O6/[U \@       L
M(>J9W'H\P]4SN/0   #X_H.[CZ?']!W<!7        S4G6^PF$.DZWV$P
M   ^/Z#NXKBQ?T'=Q7       RTG7>PQ&6DZ[V 30     C5G%I)(U9Q:!&
M      !*HN#_ &$@CT7!_L)      !0.\.\HZKG*F!U!S:<W"G6-=A-Z[N''
MS^<FE,U:'RTKTC@J&U_,MYR5>K<W#=R;^/#S=I<@      LDX%:62<
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M7\PWG)%ZM6X;N3?QX%P      "R3@5I9)P      /$_4N[B 3Y^I=W$
M  $BBZ3NXCDBBZ3NX"4     $.KZWV$PAU?6^P#"       "92=5[3,8:3JO
M:9@     "ODZQW>IY/4G6.[U/(     !ZBZQO>A8%?%UC>]"P      ,-7U7
MM(9,J^J]I#      !+H^@[O(A+H^@[O S@    ! GZY_>3R!/US^\#P
M  "?!U+>X]GB#J6]Q[              !77O\3G_ $3OV*6)77O\3G_1._8H
M',='=-IUBBZDY/H[IM.L474@9P !\?T%(U'TGDE_04C4?2>!*
M        &*JJ8*2G?/531P0,3+I)'(UK4]:KN0R1O;)&U\;FO8Y$5KFKE%1?
M.@'T                    !QOES_*!R5?K=?WX3LAQOES_ "@<E7ZW7]^$
M[(      8*SJT[R(2ZSJT[R(      "91]4O>0R91]4O>!F     "OEZQ_>I
M8%?+UC^]0/(       +"'JF=QZ/,/5,[CT    ^/Z#NX^GQ_0=W 5P
M ,U)UOL)A#I.M]A,      /C^@[N*XL7]!W<5P      ,M)UWL,1EI.N]@$T
M     (U9Q:22-6<6@1@       2J+@_V$@CT7!_L)      !0/\ #_**IYR:
M!;?S:<W&G6([";UW<.)-*9%H/+6N2..=+CS#><>O5JW#>&_CP^\N0      6
M2<"M+).      !XGZEW<0"?/U+NX@       D472=W$<D472=W 2@     AU
M?6^PF$.KZWV 80       3*3JO:9C#2=5[3,      5\G6.[U/)ZDZQW>IY
M     /476-[T+ KXNL;WH6      !AJ^J]I#)E7U7M(8      )='T'=Y$)=
M'T'=X&<     ($_7/[R>0)^N?W@>        3X.I;W'L\0=2WN/8
M      *Z]_B<_P"B=^Q2Q*Z]_B<_Z)W[% YCH[IM.L474G)]'=-IUBBZD#.
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M7O(9,H^J7O S     !7R]8_O4L"OEZQ_>H'D       %A#U3.X]'F'JF=QZ
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M9Q7.-I=^[N/G*9R:4NN;O8*Z>K\&\6R[4K.;V_"(MIKEC5<ICH\=_'@=
M 1KE#45%!/#152T=2]JI'4)&CUC7MV5W+W*:IY-ZM_SY/_I5/_ W0 :7Y-ZM
M_P ^3_Z53_P'DWJW_/D_^E4_\#= !^?^4^V7BW\H7)BMYO\ )=T?=DYM'4D<
M'-X?%GH)OSNX]A^@#C?+G^4#DJ_6Z_OPG9      #!6=6G>1"76=6G>1
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M]5[2&3*OJO:0P      2Z/H.[R(2Z/H.[P,X     0)^N?WD\@3]<_O \
M     GP=2WN/9X@ZEO<>P              5U[_$Y_T3OV*6)77O\3G_ $3O
MV*!S'1W3:=8HNI.3Z.Z;3K%%U(&<  ?']!2-1])Y)?T%(U'TG@2@
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M6G4$X :!R0:BN%SH+M9=02\]?;#5+1U,N,<^S?S<N/I(B^[/G-_.4Z8_L_\
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MOL)A#J^M]@&$       $RDZKVF8PTG5>TS      %?)UCN]3R>I.L=WJ>0
M   #U%UC>]"P*^+K&]Z%@      8:OJO:0R95]5[2&      "71]!W>1"71]
M!W>!G     "!/US^\GD"?KG]X'@       $^#J6]Q[/$'4M[CV
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M?Y0.2K];K^_"=D.-\N?Y0.2K];K^_"=D      ,%9U:=Y$)=9U:=Y$
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MCNFTZQ1=2<GT=TVG6*+J0,X  ^/Z"D:CZ3R2_H*1J/I/ E
M                            #C?+G^4#DJ_6Z_OPG9#C?+G^4#DJ_6Z_
MOPG9      #!6=6G>1"76=6G>1       3*/JE[R&3*/JE[P,P     5\O6/
M[U+ KY>L?WJ!Y       !80]4SN/1YAZIG<>@   'Q_0=W'T^/Z#NX"N
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M?Y0.2K];K^_"=D.-\N?Y0.2K];K^_"=D      ,%9U:=Y$)=9U:=Y$
M!,H^J7O(9,H^J7O S     !7R]8_O4L"OEZQ_>H'D       %A#U3.X]'F'J
MF=QZ    ?']!W<?3X_H.[@*X       &:DZWV$PATG6^PF      'Q_0=W%<
M6+^@[N*X      &6DZ[V&(RTG7>P":     $:LXM))&K.+0(P       )5%P
M?["01Z+@_P!A(      *&;QAY12[44'B[FTV7IT]O=NX\.),*:5M!Y;3JV6?
MQCX.F6+U>QNW\./ N0      62<"M+).      !XGZEW<0"?/U+NX@
M D472=W$<D472=W 2@     AU?6^PF$.KZWV 80       3*3JO:9C#2=5[3
M,      5\G6.[U/)ZDZQW>IY      /476-[T+ KXNL;WH6      !AJ^J]I
M#)E7U7M(8      )='T'=Y$)='T'=X&<     ($_7/[R>0)^N?W@>
M 3X.I;W'L\0=2WN/8              *Z]_B<_Z)W[%+$KKW^)S_ *)W[% Y
MCH[IM.L474G)]'=-IUBBZD#.  /C^@I&H^D\DOZ"D:CZ3P)0
M                              XWRY_E Y*OUNO[\)V0XWRY_E Y*OUN
MO[\)V0      P5G5IWD0EUG5IWD0      $RCZI>\ADRCZI>\#,     %?+U
MC^]2P*^7K']Z@>0       6$/5,[CT>8>J9W'H   !\?T'=Q]/C^@[N K@
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MG     "!/US^\GD"?KG]X'@       $^#J6]Q[/$'4M[CV
M"NO?XG/^B=^Q2Q*Z]_B<_P"B=^Q0.8Z.Z;3K%%U)R?1W3:=8HNI S@ #X_H*
M1J/I/)+^@I&H^D\"4                                          .
M-\N?Y0.2K];K^_"=D.-\N?Y0.2K];K^_"=D      ,%9U:=Y$)=9U:=Y$
M   !,H^J7O(9,H^J7O S     !7R]8_O4L"OEZQ_>H'D       %A#U3.X]'
MF'JF=QZ    ?']!W<?3X_H.[@*X       &:DZWV$PATG6^PF      'Q_0=
MW%<6+^@[N*X      &6DZ[V&(RTG7>P":     $:LXM))&K.+0(P       )
M5%P?["01Z+@_V$@      H)_#O**3-/3^ <TF)O_ )FUNW<>'L)I43I0^6DJ
MI43^'^#IF'_Y>SNW\./M+<      %DG K2R3@      >)^I=W$ GS]2[N(
M     )%%TG=Q')%%TG=P$H     (=7UOL)A#J^M]@&$       $RDZKVF8PT
MG5>TS      %?)UCN]3R>I.L=WJ>0     #U%UC>]"P*^+K&]Z%@      8:
MOJO:0R95]5[2&      "71]!W>1"71]!W>!G     "!/US^\GD"?KG]X'@
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M)=9U:=Y$      !,H^J7O(9,H^J7O S     !7R]8_O4L"OEZQ_>H'D
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M6L)H(JJ-JU<"XJ:=\+OQ:-.B]$7^ZOLPOG0W4#U%UC>]"P*^+K&]Z%@
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MU-RM<BJB*J9:Y?-YD-] %1H^S,T]I:TVB-6JE%31PJYO!SD:FT[VKE?:6X
M    !QOES_*!R5?K=?WX3LAQOES_ "@<E7ZW7]^$[(      8*SJT[R(2ZSJ
MT[R(      "91]4O>0R91]4O>!F     "OEZQ_>I8%?+UC^]0/(       +"
M'JF=QZ/,/5,[CT    ^/Z#NX^GQ_0=W 5P       ,U)UOL)A#I.M]A,
M  /C^@[N*XL7]!W<5P      ,M)UWL,1EI.N]@$T     (U9Q:22-6<6@1@
M      2J+@_V$@CT7!_L)      !K]1X9Y2O_LE/X%S2?VC=SFUV<>'L)Q4U
M/@GEF[^US^&^#I_9]^QL^EPXEL    U?5O\ Q!H[]9R?^DJ#:"DOULGKKKIZ
MH@V.;H:QT\NTN%V5@ECW=JY>W[P+LLDX%:62<      #Q/U+NX@$^?J7=Q
M     !(HND[N(Y(HND[N E     !#J^M]A,(=7UOL PG =>V*6RWZHRQ?!9W
MK)"_&Y45<JWO3A[COQ%N-OI;E2NIJ^!D\+N+7I]Z=B^M#NE^,OF_4_I\==BX
M[U:/#\SDZRVRIO%QAHJ-BNDD7>N-S4\[E]2'79.3.Q/FVVNK&-]!LJ8^],_>
M;)9+';K)"L=MIFQ;72=Q<[O5=YM.:-=GY_I_V=S3?_FF(K\)=!2LHJ&GI8NK
MAC;&WN1,$@ \S]C$16-0F4G5>TS&&DZKVF8*     *^3K'=ZGD]2=8[O4\@
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MDJ_6Z_OPG9      #!6=6G>1"76=6G>1       3*/JE[R&3*/JE[P,P
M 5\O6/[U+ KY>L?WJ!Y       !80]4SN/1YAZIG<>@   'Q_0=W'T^/Z#NX
M"N       !FI.M]A,(=)UOL)@     !\?T'=Q7%B_H.[BN      !EI.N]AB
M,M)UWL F@    !&K.+221JSBT",       "51<'^PD$>BX/]A(      -?JO
M#/*1?['!X%S2?VG=SFUZ/'./83BHJDI/+-5\,F\,YA/[-OV-GTNS);@
M LDX%:62<      #Q/U+NX@$^?J7=Q       !(HND[N(Y(HND[N E     !
M#J^M]A,(=7UOL P@       F4G5>TS&&DZKVF8      KY.L=WJ>3U)UCN]3
MR      >HNL;WH6!7Q=8WO0L      ##5]5[2&3*OJO:0P      2Z/H.[R(
M2Z/H.[P,X     0)^N?WD\@3]<_O \        GP=2WN/9X@ZEO<>P
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M$GFRB,[]E<_^%3JY4:=TY;-/,K$M<"QOK)W5-1(][I'RR.XN<YRJJ_[%N
M   <;Y<_R@<E7ZW7]^$[(<;Y<_R@<E7ZW7]^$[(      8*SJT[R(2ZSJT[R
M(      "91]4O>0R91]4O>!F     "OEZQ_>I8%?+UC^]0/(       +"'JF
M=QZ/,/5,[CT    ^/Z#NX^GQ_0=W 5P       ,U)UOL)A#I.M]A,      /
MC^@[N*XL7]!W<5P      ,M)UWL,1EI.N]@$T     (U9Q:22-6<6@1@
M   2J+@_V$@CT7!_L)      !KU5X5Y3+_8H?!.:3^U;MO:]'CG!/*FK\%\L
MM];,E7X/NI<+L*WTN&,EL      "R3@5I9)P      /$_4N[B 3Y^I=W$
M    $BBZ3NXCDBBZ3NX"4     $.KZWV$PAU?6^P#"       "92=5[3,8:3
MJO:9@     "ODZQW>IY/4G6.[U/(     !ZBZQO>A8%?%UC>]"P      ,-7
MU7M(9,J^J]I#      !+H^@[O(A+H^@[O S@    ! GZY_>3R!/US^\#P
M    "?!U+>X]GB#J6]Q[              !77O\ $Y_T3OV*6)77O\3G_1._
M8H',='=-IUBBZDY/H[IM.L474@9P !\?T%(U'TGDE_04C4?2>!*
M                                 '&^7/\ *!R5?K=?WX3LAQOES_*!
MR5?K=?WX3L@     !@K.K3O(A+K.K3O(@      )E'U2]Y#)E'U2]X&8
M *^7K']ZE@5\O6/[U \@       L(>J9W'H\P]4SN/0   #X_H.[CZ?']!W<
M!7        S4G6^PF$.DZWV$P      ^/Z#NXKBQ?T'=Q7       RTG7>PQ
M&6DZ[V 30     C5G%I)(U9Q:!&       !*HN#_ &$@CT7!_L)      !KM
M6E3Y3Y2@@6EYK?5[MM'>CQS@L"IK/!O+%,UTR5/,;J7?L*F_Y79DM@
M62<"M+).      !XGZEW<0"?/U+NX@       D472=W$<D472=W 2@     A
MU?6^PF$.KZWV 80       3*3JO:9C#2=5[3,      5\G6.[U/)ZDZQW>IY
M      /476-[T+ KXNL;WH6      !AJ^J]I#)E7U7M(8      )='T'=Y$)
M='T'=X&<     ($_7/[R>0)^N?W@>        3X.I;W'L\0=2WN/8
M       *Z]_B<_Z)W[%+$KKW^)S_ *)W[% YCH[IM.L474G)]'=-IUBBZD#.
M  /C^@I&H^D\DOZ"D:CZ3P)0
M      XWRY_E Y*OUNO[\)V0XWRY_E Y*OUNO[\)V0      P5G5IWD0EUG5
MIWD0      $RCZI>\ADRCZI>\#,     %?+UC^]2P*^7K']Z@>0       6$
M/5,[CT>8>J9W'H   !\?T'=Q]/C^@[N K@       9J3K?83"'2=;["8
M  ?']!W<5Q8OZ#NXK@      9:3KO88C+2==[ )H     1JSBTDD:LXM C
M      E47!_L)!'HN#_82      #7JOPCRF3%!"M-S6^KW;:+Z/;@GE56\QY
M8-S<)4J.8W4F_85-_P KLR6H      +).!6EDG       \3]2[N(!/GZEW<0
M       2*+I.[B.2*+I.[@)0     0ZOK?83"'5];[ ,(       )E)U7M,Q
MAI.J]IF      *^3K'=ZGD]2=8[O4\@     'J+K&]Z%@5\76-[T+
MPU?5>TADRKZKVD,      $NCZ#N\B$NCZ#N\#.     $"?KG]Y/($_7/[P/
M       )\'4M[CV>(.I;W'L              %=>_P 3G_1._8I8E=>_Q.?]
M$[]B@<QT=TVG6*+J3D^CNFTZQ1=2!G  'Q_04C4?2>27]!2-1])X$H
M                                    <;Y<_P H')5^MU_?A.R'&^7/
M\H')5^MU_?A.R      &"LZM.\B$NLZM.\B       F4?5+WD,F4?5+W@9@
M    KY>L?WJ6!7R]8_O4#R       "PAZIG<>CS#U3.X]    /C^@[N/I\?T
M'=P%<       #-2=;["80Z3K?83      #X_H.[BN+%_0=W%<      #+2==
M[#$9:3KO8!-     "-6<6DDC5G%H$8       $JBX/\ 82"/1<'^PD
M&NUG/^5#<6^)8.9WUF$VT7?\GMQ_$L"JK4@\L&9N$J3\QNH]^RY-_P KLS_
MM0      62<"M+).      !XGZEW<0"?/U+NX@       D472=W$<D472=W
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MUG5IWD0      $RCZI>\ADRCZI>\#,     %?+UC^]2P*^7K']Z@>0
M 6$/5,[CT>8>J9W'H   !\?T'=Q]/C^@[N K@       9J3K?83"'2=;["8
M     ?']!W<5Q8OZ#NXK@ (WAM/XQ\!YU/"^:Y_F\+G8SLY]Y)    9:3KO8
M8C+2==[ )H     1JSBTDD:LXM C        E47!_L)!'HN#_82      #7:
MU)?*EBI;H70\SOK,)MM7?\G/''\2P*NNYKROCS<9&S<QNH]^RY-_RNS/\"T
M     !9)P*TLDX     -5O6OK!:9W035:S3-7#F0-V]E?6O#[RQ$SX99<^/#
M'+):(CY;//U+NX@%3:-;6.]JL%)5[%0[HQ3-5CG=V=R]R*6PF)CRN+-CS5Y8
M[1,?  "-   "11=)W<1R11=)W<!*     "'5];["80ZOK?8!A       !,I.
MJ]IF,-)U7M/-!6T]PIUGHY4EB21\2N1%3Y3'*QR;^QS53V 2     %?)UCN]
M3R>I.L=WJ>0     #U%UC>]"P*^+K&]Z%@      8:OJO:0R95]5[2&
M "71]!W>1"71]!W>!G     "!/US^\GD"?KG]X'@       $^#J6]Q[/$'4M
M[CV              "NO?XG/^B=^Q2Q*Z]_B<_Z)W[% YCH[IM.L474G)]'=
M-IUBBZD#.  /C^@I&H^D\DOZ"D:CZ3P)0  %%KG3L.J])72R5#^;;60JQK\9
MV'HN6NQZG(BEZ ./,O'*3%II-.)I%'7AL'@B79*V/P?&-GGL<<XWXXY\WF-@
MAM%WY/N22"W:1HXKM>*&)J-CD1=F5[GYD=C**O2<J)E%X'00!15-TNU)I&&X
MNLSZN[I!$^6W02M:NVNSMM:Y=WR<KWX- U!%K'E(IVV2IL+],Z>E>U:ZHJ:A
MDD\S$7/-QM;T<JB;U_\ PO7 !BI*>*DI8:>G8D<$+$C8Q.#6HF$3W&@^(+G^
M'A;_ ."N\4>(O!/"-IN.=YW:V<9SPWYQ@Z& .?Z\L-RN7*+H&Y4-*LM%;9JE
MU5*CFIS2.8U&[E7*Y5%X9/7+/8KE?]/6JGL]*M3-#=::H>U'-;LQM5VT[>J<
M,F_ #C'+#45E]UI8K+IVWMO]3:G.K;A:9L-IG-<W$;I7N5$VDWJC=_'/?ZH=
M97?1$M&S47)[1:?LU;4LIUJK;4Q.;&]W!7,8G#U_MX&Q7[1-ZAUI5ZHT;>::
MAKJZ%D-;35M.LL,VPB(UV45%:J(B)N(TVA-1:EN-OFUW?J2HMU#.VI9;;=2K
M%')(WHJ][E5RHG8%2]/V&Y5?*S?]2WJE6"EIZ>.W6I'.:[:CZ4DF$5<9=PSA
M<*I\Y7M/7#4$ND$M]'X7%1WN"IJD56HC86YVG*CEWIOX)DZ$ CF6L-,W:R:V
MI=8Z*I%JIZA6T]WMS7M8E5%YI$VE1-MO?V>O.G7N>Z:JY2KE=M.Z9I=7VBB@
M2WK'<ECCAIIT7,B1[:X<O#*HGMQC/?CE]!H;56E:VY)HF^VUMJKJE]7X'<J5
MS^8>[I;+V.153<FY>SVJ5]T=K6OH]34&D]2Z1CTY-5Q/DH?!9V2P2;"9<W#$
MPU<(O_M4.EU4$55334]0Q)(96+&]B\'-5,*B^Q31-.:&N7E9#J?6%Z9=;K31
M.AI(8(.9@I4=N<K4RJN54RF5[>[&_A''-/T6M>3%DUGMMD\J-,MD<^B?#4MB
MJ*9KE5=AR.Z29SP[57SX2HIZ^Z<M&H%M%SI8;'8;)5-DK[=)-MU51(W@UR83
M#./_ .5QCO1J]QT/:JO6-)J>)U51WB!O-NEI9$8D[/1D3"HY,;O=V)@-8Y;F
MZQKJ&CM.DK7/4V^ISXPEIZB.&7FT5/ZIKG+\G:3.5PO[<P+%?]8V&TTULM/)
M.^FHJ=NQ'&R[P[O6N[>J\55=ZJ=> &H<IU@FU9R;W>V-@_MM13<Y%$KDW3-P
M]K<\.DB)DK^1'3EQT]HZ1VH(UCO=QJYJVL17(Y4>YV$WHJIT6HO'SF_@#BDO
M)U=5Y>679M/_ /"ZS>-'/VVX2JYO8QLYSG:1'9Q[3M8  $:Y)6+03I;'4[:W
M97F5J&JZ-'>;:1JHJIW*:IS7*)_B])?9:G^8!N@-+YKE$_Q>DOLM3_,'-<HG
M^+TE]EJ?Y@&G\N?Y0.2K];K^_"=D/S_RGMU(WE"Y,?*6:T2-\;)S/B^*1BHN
MW%G:VW+GS8QZS]       &"LZM.\B$NLZM.\B       F4?5+WD,F4?5+W@9
M@     KY>L?WJ6!7R]8_O4#R       "PAZIG<>CS#U3.X]    /C^@[N/I\
M?T'=P%<       #-2=;["80Z3K?83      #X_H.[BN+%_0=W%<!JZ_E-;^I
MU_YR&T&FW1*U>4!Z6M],RL\3_(=4M<Z-/Z],Y1JHO#/G)7-ZT_Q>G?LTW\P#
M: :OS>M/\7IW[--_,'-ZT_Q>G?LTW\P#:#+2==[#4N;UI_B]._9IOYAEIHM:
M\[\FKTYG'GI9_P"8!NH-5YK6_P#B]-_99_Y@YK6_^+TW]EG_ )@&U U7FM;_
M .+TW]EG_F#FM;_XO3?V6?\ F ;41JSBTU[FM;_XO3?V6?\ F$>JBUKENU5Z
M<]E+/_, V &K\WK3_%Z=^S3?S!S>M/\ %Z=^S3?S -H!J_-ZT_Q>G?LTW\P<
MWK3_ !>G?LTW\P#: :OS>M/\7IW[--_,'-ZT_P 7IW[--_, W*BX/]A(--I(
MM:X=LU>G/;2S_P PD<UK?_%Z;^RS_P P#:@:KS6M_P#%Z;^RS_S!S6M_\7IO
M[+/_ # -J!JO-:W_ ,7IO[+/_,'-:W_Q>F_LL_\ , SUW.>5,>+;&Z+F=];N
MVFKO^3V__J6)I-8S5/E&QLEXLS:[FODTK8YTB<W?\I6;>]>._/F)W-ZT_P 7
MIW[--_, V@&K\WK3_%Z=^S3?S!S>M/\ %Z=^S3?S -H!J_-ZT_Q>G?LTW\P<
MWK3_ !>G?LTW\P#:"R3@:+S>M/\ %Z=^S3?S"P2+6^/QO3?V6?\ F ;4#5>:
MUO\ XO3?V6?^8.:UO_B]-_99_P"8!3\L.HYK3:H;?12+'45FUMO:N]L:<<=^
M<>Q3AIO7*S!>67:BEOLE%(]\"MC=1QO8S".5514<Y5S\KM[#13UXHU5^!^M9
M;Y.KM%O$=H?6JK516JJ*F]%3S'=.36_27NQ*VJ=MU=*Y(WN7BY,?)<OKXI[#
MA1O_ "6P7Q67&6QRV^-BJQLBUD3WHJ_*QL[+DX9WY[4)EC[7?T'+>G5Q2OBV
M]_\ FW8P:OS>M/\ %Z=^S3?S!S>M/\7IW[--_,/*_=MH!J_-ZT_Q>G?LTW\P
M<WK3_%Z=^S3?S -H)%%TG=QI_-ZT_P 7IW[--_,,])%K7:=LU>G.'GI9_P"8
M!N8-5YK6_P#B]-_99_Y@YK6_^+TW]EG_ )@&U U7FM;_ .+TW]EG_F#FM;_X
MO3?V6?\ F ;40ZOK?84/-:W_ ,7IO[+/_,(E3%K7G/E5>G,X\U+/_, V,&K\
MWK3_ !>G?LTW\P<WK3_%Z=^S3?S -H!J_-ZT_P 7IW[--_,'-ZT_Q>G?LTW\
MP#: :OS>M/\ %Z=^S3?S!S>M/\7IW[--_, W2DZKVFO<G'_#DWZRN'_K)B/2
MQ:VYKY-7IO&?/2S_ ,P]\ER3)I/%4L;JCP^NYQ8T5&J[PN7.$7*XSV@;8
M  KY.L=WJ>3U)UCN]3R      >HNL;WH6!7Q=8WO0L      ##5]5[2&3*OJ
MO:0P      2Z/H.[R(2Z/H.[P,X     0)^N?WD\@3]<_O \        GP=2
MWN/9X@ZEO<>P              5U[_$Y_P!$[]BEB5U[_$Y_T3OV*!S'1W3:
M=8HNI.3Z.Z;3K%%U(&<  ?']!2-1])Y)?T%(U'TG@2@
M      #4-3:NEH=86/3-HI8ZNY5^9YU>Y4;34S<[4BXXJJIA$\ZH;><HY.?^
ME.63E$NLR[3J1:>W0?18C55R)WJU% S:KY5V:9Y3Z/3=RHF-M4T<:R5^VO\
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MOES_ "@<E7ZW7]^$[(<;Y<_R@<E7ZW7]^$[(      8*SJT[R(2ZSJT[R(
M    "91]4O>0R91]4O>!F     "OEZQ_>I8%?+UC^]0/(       +"'JF=QZ
M/,/5,[CT    ^/Z#NX^GQ_0=W 5P       ,U)UOL)A#I.M]A,      /C^@
M[N*XL7]!W<5P&KK^4UOZG7_G(;08^9BY_G^;9SVSL<YLIM;.<XSQQGS&0
M!EI.N]AB,M)UWL F@    !&K.+221JSBT",       "51<'^PD$>BX/]A(
M    -<KMORICQ;6/9S.^MPFTQ=_R?_?:6)5W!&>5T*K<GL?S&ZBWX>GROE<<
M?_H6@      +).!6EDG    -:U]IAFIK,L#'-960KMP/=PSYVKZE_@?GV[6J
MMM-4ZGN--)!*B\'IN7UHO!4]:'ZG/,D;)6[,K&O;V.3*&E,DU[/C_4?H^/K;
M>I$\;?\ U^7[)9+A>JE(;=3/E7/RGX^0SUN7@AWC2ECBT_9HJ*)4>_IRR8Z;
MUXK_ +>PV61C8Z=S6-1K43<B)A"$+Y)MV=?3OI./H9F^^5I]P &;ZP  !(HN
MD[N(Y(HND[N E     !#J^M]A,(=7UOL P@       F4G5>TU[DX_P"')OUE
M</\ UDQL-)U7M/<$,4#%9!&R)BN5VRQJ-3*JJJN[SJJJJ^M0/8    "ODZQW
M>IY/4G6.[U/(     !ZBZQO>A8%?%UC>]"P      ,-7U7M(9,J^J]I#
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M.K3O(@      )E'U2]Y#)E'U2]X&8     *^7K']ZE@5\O6/[U \@
ML(>J9W'H\P]4SN/0   #X_H.[CZ?']!W<!7        S4G6^PF$.DZWV$P
M    ^/Z#NXKBQ?T'=Q7       RTG7>PQ&6DZ[V 30     C5G%I)(U9Q:!&
M       !*HN#_82"/1<'^PD      &MW#:\JX<6QKV\S^.^=G2^3P_\ >2R*
MRX;/E9#FYN8[F=U%OP_C\KC_ .\%F      "R3@5I9)P      /$_4N[B 3Y
M^I=W$       $BBZ3NXCDBBZ3NX"4     $.KZWV$PAU?6^P#"       "92
M=5[3,8:3JO:9@     "ODZQW>IY/4G6.[U/(     !ZBZQO>A8%?%UC>]"P
M     ,-7U7M(9,J^J]I#      !+H^@[O(A+H^@[O S@    ! GZY_>3R!/U
MS^\#P       "?!U+>X]GB#J6]Q[              !77O\ $Y_T3OV*6)77
MO\3G_1._8H',='=-IUBBZDY/H[IM.L474@9P !\?T%(U'TGDE_04C4?2>!*
M                                         '&^7/\ *!R5?K=?WX3L
MAQOES_*!R5?K=?WX3L@     !@K.K3O(A+K.K3O(@      )E'U2]Y#)E'U2
M]X&8     *^7K']ZE@5\O6/[U \@       L(>J9W'H\P]4SN/0   #X_H.[
MCZ?']!W<!7        S4G6^PF$.DZWV$P      ^/Z#NXKBQ?T'=Q7
M RTG7>PQ&6DZ[V 30     C5G%I)(U9Q:!&       !*HN#_ &$@CT7!_L)
M     !KEPSY4P_\ 1J/3F?QWSQ\?D\/]_.6)67%$\K*=?&BQKS/XC^<W.^5Q
M_P!O,68      +).!6EDG       \3]2[N(!/GZEW<0       2*+I.[B.2*
M+I.[@)0     0ZOK?83"'5];[ ,(       )E)U7M,QAI.J]IF      *^3K
M'=ZGD]2=8[O4\@     'J+K&]Z%@5\76-[T+       PU?5>TADRKZKVD,
M    $NCZ#N\B$NCZ#N\#.     $"?KG]Y/($_7/[P/        )\'4M[CV>(
M.I;W'L              %=>_Q.?]$[]BEB5U[_$Y_P!$[]B@<QT=TVG6*+J3
MD^CNFTZQ1=2!G  'Q_04C4?2>27]!2-1])X$H
M                   <;Y<_R@<E7ZW7]^$[(<;Y<_R@<E7ZW7]^$[(
M 8*SJT[R(2ZSJT[R(      "91]4O>0R91]4O>!F     "OEZQ_>I8%?+UC^
M]0/(       +"'JF=QZ/,/5,[CT    ^/Z#NX^GQ_0=W 5P       ,U)UOL
M)A#I.M]A,      /C^@[N*XL7]!W<5P      ,M)UWL,1EI.N]@$T     (U
M9Q:22-6<6@1@       2J+@_V$@CT7!_L)      !K5Q7_XK@3Q9SG]5^._F
M]SOD\/\ ?SEF5MQ3_P"*X%\9\VG-?B7YS<ORN/\ MYBR      !9)P*TLDX
M     'B?J7=Q )\_4N[B       "11=)W<1R11=)W<!*     "'5];["80ZO
MK?8!A       !,I.J]IF,-)U7M,P     !7R=8[O4\GJ3K'=ZGD      ]1=
M8WO0L"OBZQO>A8      &&KZKVD,F5?5>TA@      ET?0=WD0ET?0=W@9P
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MX.I;W'L@6:ZVZZ12K:JZFK60/YJ1T$B/1KL(N%5//A47VD\
M %=>_P 3G_1._8I8E=>_Q.?]$[]B@<QT=TVG6*+J3D^CNFTZQ1=2!G  'Q_0
M4C4?2>27]!2-1])X$H
M<0_I$VZFNVK.36W5\?.TE5<GPS,VE;M,<Z%%3*;TW+YC8?P$<GOS$_[;/\94
M\N?Y0.2K];K^_"=D YC^ CD]^8G_ &V?XQ^ CD]^8G_;9_C.G #F/X".3WYB
M?]MG^,?@(Y/?F)_VV?XSIP XIKSD8T+:M$W^X4%F?'5TM!//"_PN9VR]L;E1
M<*_"[T3B6=IY#M 5%KHYI;(]TDD+'N7PR=,JK45?[YN/*C^375?ZKJ?^4XN;
M#_U';O\ NT?[J <__ 1R>_,3_ML_QC\!')[\Q/\ ML_QG3@!S'\!')[\Q/\
MML_QC\!')[\Q/^VS_&=. '&M8<BNA+=I*]UM'97QU--0SS1/\+F79>V-RHN%
M?A=Z)Q,^G.1'059I^UU5197OGGI8I)'>&3IESF(JKA']IO\ R@_\!:E_5E3_
M ,IQ)TA_PG9/^XP?\M -'_ 1R>_,3_ML_P 8_ 1R>_,3_ML_QG3@!S'\!')[
M\Q/^VS_&/P$<GOS$_P"VS_&=. ',?P$<GOS$_P"VS_&:QH7D>T3='ZC2NM#Y
M$H[Q/20_VJ9NS&U&*C=SM_%=Z[SNII7)CUFL/_J"I_=C IOP$<GOS$_[;/\
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MYB?]MG^,Z< .&U?(YHB/E$MMK99WI0S6RHJ'Q^%S;Y&20M:N=K/![MWK-D_
M1R>_,3_ML_QE[7_E=LWZFJ_^=3FX@<Q_ 1R>_,3_ +;/\8_ 1R>_,3_ML_QG
M3@!S'\!')[\Q/^VS_&/P$<GOS$_[;/\ &=. '"N43D=T19[!!4VZT/BF=7T<
M"N\*F=\B2H8QR85WG:Y4-G_ 1R>_,3_ML_QEURN?\*TWZUM__JHS= .8_@(Y
M/?F)_P!MG^,?@(Y/?F)_VV?XSIP YC^ CD]^8G_;9_C'X".3WYB?]MG^,Z<
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M'-$630-^N5ML[XJVEI'RQ2+5S.V7(FY<*Y47VFR1\A/)ZK&JMC?E43_][/\
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M:=8HNI.3Z.Z;3K%%U(&<  ?']!2-1])Y)?T%(U'TG@2@
M                         !QOES_*!R5?K=?WX3LAJ6M-$P:HONF;G-62
M4[['5>%,8QB.25<L7"KYNA]YMH     !K'*C^375?ZKJ?^4XN;#_ -1V[_NT
M?[J$NHABJ()(:B-DL,C58^-[4<US5W*BHO%#TQK6,:UC4:UJ81$3"(@'T
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M&M/"ZI;4+#&M0UJL;*K4VD:JHJHB\<*J)N]2&0      TOE<_P"%:;]:V_\
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M4R*CG4ZR[^Q[W/3[G(;X8Z>"*FIXH*>-L<,348QC4PC6HF$1/5@R
M "NO?XG/^B=^Q2Q*Z]_B<_Z)W[% YCH[IM.L474G)]'=-IUBBZD#.  /C^@I
M&H^D\DOZ"D:CZ3P)0
M
M
M
M                      5U[_$Y_P!$[]BEB5U[_$Y_T3OV*!S'1W3:=8HN
MI.3Z.Z;3K%%U(&<  ?']!2-1])Y)?T%(U'TG@2@
M
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MX  H
M                  !77O\ $Y_T3OV*6)77O\3G_1._8H',='=-IUBBZDY/
MH[IM.L474@9P !\?T%(U'TGDE_04C4?2>!*
M
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M7)J<W/'(W&TY/[R>I>/O3S%X <3WEK$:C0 "*
M                                                    5U[_ !.?
M]$[]BEB5U[_$Y_T3OV*!S'1W3:=8HNI.3Z.Z;3K%%U(&<  ?']!2-1])Y)?T
M%(U'TG@2@
M
M
M
M              KKW^)S_HG?L4L2NO?XG/\ HG?L4#F.CNFTZQ1=2<GT=TVG
M6*+J0,X  ^/Z"D:CZ3R2_H*1J/I/ E
M!\:YKL[+D7"X7"\%[ /H/FTW;5NTFTB9QG?@^@
M                   ?'*C6JYRHB(F55?,?45%1%145%X*@
M     'QSFM5$<Y$55PF5XJ?0    ^.<C6JYRHC4WJJ^8^HJ*F4WH
M                                             .5&M57*B(F]57S
M $5%1%145%X*@          ^/<UC5<]R-:G%57"'T
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MF;HV]QIT=IK6:&N-#X+L5+Y9%9"Q<IA9,ICU8-Q:G]6B>? %#9+]4W2FBK?
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M[CS?::H9<K=<Z2!U1X+SC)(6*B.<QZ)O;G=E%1-WG,=#'4W#4+;E-2RTE-!
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MH$C1R\VLJ.QG/'9W9(]<MR;J+3[+EX+(U9I'-DIVN;A>;=E%157WY VX
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MCIV+!(Z6*9K\2,<Y55<+CUKN,UNL\-'+-.Z6>IJ96HQTT[]IVRG]U-R(B=R
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MZHG!/,B(G8@%@"+:Z)MNHF4S)IIFLS\N9^TY<JJ[U]I*
M %;?%1M%4*O!(7+]RED:[K6J2FL5PD5?_DK&G>[=_N!H6CNL:=8HNJ.6:.C7
M::O_ +\YU2DZL#,  /B\%(+U5DRKY\Y0GD.M8J)M-XM EM5'-14X*?2)13(K
M43/R5WH2P
M
M
M
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M%])?]D+G2UHW,54\R$?3UBWL5S>PZ':J%L$;=WF"IE%"D3$1"2$3" (
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MG.3+3;+1IY&856FVP6^./@U/<3&1-:FY B'0T+(6HB)O0G-3"'T
M      83L  83L&$[  &$[!A.P !A.P83L  83L&$[  &$[!A.P !A.P83L
M 83L&$[  &$[!A.P !A.P83L  83L&$[  &$[!A.P !A.P83L  83L&$[  &
M$[!A.P !A.P83L  83L&$[  &$[!A.P !A.P83L  83L&$[  &$[!A.P !A.
MP83L  83L&$[  &$[!A.P !A.P83L  83L&$[  &$[!A.P !A.P83L  83L&
M$[  &$[!A.P !A.P83L  83L&$[  &$[!A.P !A.P83L  83L&$[  &$[!A.
MP !A.P83L  83L&$[  &$[!A.P !A.P83L  83L&$[  &$[!A.P !A.P83L
M 83L&$[  &$[!A.P !A.P83L  83L&$[  &$[!A.P !A.P83L  83L&$[  &
M$[!A.P !A.P83L  83L&$[  &$[!A.P !A.P83L  83L&$[  &$[!A.P !A.
MP83L  83L&$[  &$[!A.P !A.P83L  83L&$[  &$[!A.P !A.P83L  83L&
M$[  &$[!A.P !A.P83L  83L&$[  &$[!A.P !A.P83L  83L&$[  &$[!A.
MP !A.P83L  83L&$[  &$[!A.P !A.P83L  83L&$[  &$[!A.P !A.P83L
M 83L&$[  &$[!A.P !A.P83L  83L&$[  &$[!A.P !A.P83L  83L&$[  &
;$[!A.P !A.P83L  83L             ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g50309g06a02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g06a02.jpg
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MP3=U@K,ETO!#1%:#HN$X8[3"\1@F=H23_\0 &@$!  ,! 0$
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M@$W4?JV> 08NNP>F$Z[!Z867=1^K9X!-U'ZMG@$&+KL'IA.NP>F%EW4?JV>
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M@$W4?JV> 08NNP>F$Z[!Z867=1^K9X!-U'ZMG@$&+KL'IA.NP>F%EW4?JV>
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M?Y;?^L+\XKIP>#QGYC_Y%/\ U^\B(BV>=$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1!];S"^+ZWF%\1(B(B!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MZ8IF_*;VTX?QJU"#HUU'+42Q&GA8(\?I'R@-=D9X=ZUJ]6FLLM>^CN,)BG:
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M>+^ ?@O%;^RR?!>Z;]GB_@'X(,B(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M"^U]AKG5=MF$<KFECLM!#@>\%9Z#4]TM]WJ+C0SMIZBH.U*UC!L/[>+>7_\
M-4B):%Z<?%HB(IJF+:QZ2VB_:ZO=[M[Z*MFB%,_&VR.(#:P<CCSYA>XM?ZBB
MM8H&5WZ,-V!(6#>!O=M?]^?O6J(HV8Z-/UN8VIJVYO.G'DN[IJBZW.XTE=4U
M.*NE $4C&AI&#G[U;5/2/J2=D336,9NW!Q,<0!>0<\?=[EIR)LQT13G,>F9F
M*YUXZ\5K-J"XR7YUY%08[@7!V\C '$#'+ER')6]UZ0+]=+;+0U,\.YE;LR;$
M0!<.[/Y+4T39A%.:QJ8JBFN?BXZ\6UVK7]_MEMCHJ:IC,,;=F,R1ASF#L /Y
MJLMNHKA;K-66NED8VDJ\[UI8"3D8.#V< J=$V8)S>/-KUSI%HUY-CT]K2]6&
MF--0U+339R(I6!X:?=VA0[MJ.YW:Y0UU?4F6>$@QC #68.> '!5"*=F+W1.9
MQIHC#FN=F.5UM?-05][N45?<)&/J(FM8TM8&C )(X?$E-17^OU#5QU-S>Q\L
M;-VTM8&\,D]GQ*J42T(JQ\2J^U5.O'U6FG;[7:?K7U5L>QDSXS$2Y@<-DD'M
M]X"STNI[G2VVX4,,D8IZYSGS@L!)+A@X/8J1$M!3CXM$1335,1%_?C_*XM6H
MKA:[776^CD8VFK&ELP<P$D%NR<'LX%544CHI62,^TQP</B%X1+*3B5U1$3/#
MAZ+^JU;=JJ_TUYEF9U^G;L,>U@ QQX8_]17F355TDU$R]OF8;@P8:[8&R!LE
MO+ER)5$B;,-)S.-/]T\;\>?7YK0WZXB^/N\=08J][]LR1@#C\.6/<KVMZ1]1
M5=%)325$+62-+'N;"T.(/ K3D4;,3R31F\>B)BFN8OQU;%IS65XT_2OIK?.S
MJ[CM;N1@<&GO'<O%SU=>;I;IZ*OJM_!-*)7;31D$8P!W#AR5 BG9B]S]5C;&
M[VYV>E]%Q==17"Z6RBH*R1CJ:C:&Q , ( &.)[>"7+4=QN-FH[752,=1TF-T
MT, (P"!Q[>!5.OK>?W%+0K./BS>]4ZZ3\ES8M2W*QTE73VZ2.-E2,2.+ 7'@
M1P/9S*JZ2HDI*J&H@=LS0O$C'=Q!R%A1+0K.+7,1$SI'#T6U_O\ 77VNBK+B
MZ-T\;0P.8P-X DC./B5]U'J&X:AJ(IKG(Q[XF[#2U@;PSGL50B6A:K'Q*MK:
MJGXN/K\VQZ?UG>+!0FDMLT3("\R$.C#CD@#F?@%\ONL[Y>Z8TU?6DTYXF.-@
M8'?''$_>M=11LQ>]E_U>/L;O;G9Z7T7%XU'<;O;Z*BK9&.@I&AL0:P @  <3
MV\ O=7J>Y5EAAM%5)'+1PXW>TP%S<<L.Y\N'P5(BFT*3F,69F9JG6+3ZP*99
MZ^6UW2EKH.,E/() ._!Y??R45K'.^RUSO@,KUN9/5O\ ])4LZ9JIF*J>,-OU
MA>J$ZKIK_IZH:Z60-E?&^,@Q2@8XY&#V<CSRHE[UW?KQ2OIJFK$=.\8>R%@9
MM#N)YX]V5JZ*L4PZ:\[C535-,[,5:S$:0V;3^M[U8:$4=#-%U8$N:R2(.P3S
MX\U U#J*YZ@F9)=*DRAGV& !K6_ #\54(IV8O=2K-8U5&ZFN=GI?19VF^5MI
MIJV"A>R,5;-W*_9!=L\> /9S[%DTYJ*XZ>J));9,&;UNS(QS0YK@.6054(EH
M4IQ\2B:9IJF+</187R[UM[KW5ERFWL[@&YP &@<@ .07RRW>NLM8*JV5#H)L
M8)&"'#N(/ A0$2T6LC>U[>\O.UUYMNNG2%?[E02T<\\+89F%DFQ$ 7-/,9_)
M55;J.XUMBIK//(PT-.X.C:& $$ @<?O*ID413$<FM>;Q\2\UUS-XMQY-UU/>
MZ"+2%KT]9I^L,9^FJI@TM#G\3@9 )XD^ 6E(BF(LKCX]6/5M5<HB(](@1$4L
M!$1 1$0$1$!$1!?:$_WQLW_-,_%?I9?FG0G^^-F_YIGXK]++FQN+V7Y;_P!F
MOY_81$6+T;2^DW^[(_\ ,9^)6?17[(S^$+!TF_W9'_F,_$K/HK]D9_"$&VHB
M(,%;^RR?!>Z;]GB_@'X+Q6_LLGP7NF_9XOX!^"#(B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MW,!K,\\<3D\,K%?;%'0T%+<;?6MKK;4.,;9=V8W,>.;7-).#]_%;1IVIGJ-
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MA;+LC) +>1^*B:HAMAY2O$IBJFVO"+ZS9IJ*114=572[JBIIJB7&=B%A><?
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MFP: J*JIZ0Q-7N>:J3?F7:X':W;L@CW=R\]%V[\JW.>9\@DI[=-)$Y@VGL/
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MRYGF@<\8]_-*IM*,K@4XF'57,7F)B.,1QOU^32O(%>V^LM%1&VFKGN# V9V
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M5#:6ONM9%;X:EW*#;)VI/N:''/9S5!HJ@Z,O+E*VS5E'7W^)VVRJEJ'OGF>
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M9^D676KN58VOO5TJ#/55+6[(/$D- /9DD_?[EO* B(@(B("(B B(@(B("(B
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M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@-YA62K6\PK) 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 7F;]4_X+TO
M,WZI_P $%>B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MCD :"0"6[?+.3C'$$<<@K:ND:\ZIDZ;Z33NG;W/0QUU*R/!)='%D.+I SEM
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M5'3%P8US\DO<>36M&2X^X!0]%:MM^KJ">HH&5$$U-*8*JDJH]W-3R#FU[?\
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MU#7"CAG?NXW&-[]IV,XPT$\@H6E>D'3.JKA)0V"YBKJHXS,YFYD9A@(!.7-
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M+M#@1%&02?< MDZ-=3VVFH['8J2U7"CM]5$_R;6U(9LUQ9ESWD!Q<USN+_.
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M[R>.2TGACX+H2(A^<^E#HGU%<^D"MFT[3CR+>#$^LD$K&B)VT-LEI()XC;X
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MW(QD'L*AZ?LU#I^STULM4(AI*=NRQN<D]I)/:2223[T%BB(@-YA62K6\PK)
M1$0$1$!$1 1$0:WJO5$VGJBF'T?O-SIIFDNFML&_,3@>3F YX]XRM1I6W/6_
M2/I^]FQW"SV:PLJ'-DN,6YFJ996;&RV/F&@<<GFNI(@T3I4MU9<)]&&AI9J@
M4VH:6HFW;2[=QM#\O=W 9'%;VB(-!M-EFO.N:^[5U$^BMMJ:^AM4+H]C:>\?
MIJD#W\&-/: 3VK3M-6V[S4>A]*SV2XTTVGKCUFLK982VF,<0D#3')R>7[;>
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M.M_0SI"_<_1[_(C_ .16&O.D:;0FE[;8F-MWTNF@:PQT^S'34F>&WQP .X'
M[3PYA6]%EZU'9>EFYZ)O%YEOE'%$7BHE)<YA#6N!R22/M;)!)XJ%T_\ 2-<X
MJN6SZ2JIZ=EM+7W&LIWEI:]W!L0</O)'?_"5*T72V[2^EKO4V"_6S4/2)<XG
M']#5LFD<\G):P9R['%Q/:6]P7-=2P:CL?1G/:KOI2>C94UK:FJNL\NT^:7)P
M"/O[^\]I0=WU.R\7'H3HKA:[I6TUXI[=#7":*4ATI;&'/#O2R,\^W"V3HPU-
M]+M$6R[O#142L+)VMY"1IV7? $C/P(5'T:W.MK>B9DM]MIM\=-1;F,.=M;Z!
ML+<2^X$9X>Y4G]EEDC>C24R9V77"4Q_P[+!^(*(=@1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$&2G_7-^*G*#3_ *YOQ4Y 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%YE_5/^!7
MI>9?U3_@4%>B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@-YA62K
M6\PK) 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 7F;]4_X+TO,WZI_P $%>B(@(B("(B B(@(B("(B B(@(B("(B B(@(
MB("(B B(@(B("(B B(@]P_K6_%3U A_6M^*GH"(B#2^DW^[(_P#,9^)6?17[
M(S^$+!TF_P!V1_YC/Q*SZ*_9&?PA!MJ(B#!6_LLGP7NF_9XOX!^"\5O[+)\%
M[IOV>+^ ?@@R(B(,-7^J^]:K)I"QR:KCU*^@!O<;=AM3O7\!LEOV<[/(D<EM
M57^J^]0T$*\VJAO5MGM]UIHZJCG&S)%(,@]OW'/'(Y+3J/H@T-24U5!'88G,
MJ0&R&2:1[L @@-<79;Q Y$9[5OR(-9ET+IR6X6BN?;0:JT11PT3]])^A8SBT
M8VL''ORI%ZTC8[W>;?=KI0B>X6]P=32[U[=V0[:' $ \>/$%7R("H;?I&QV_
M4M9J"CH1'=ZMI9/4;UYVP2"1LD[(^RWD.Q7R(*&U:1L=IO\ 7WNWT(ANE=D5
M$^\>[>9<''@20.('(!+?I"QV_4M7?Z.@$=WJVELU1O7G;!P3YI.R/LCD.Q7R
M(.4_VEZ>:JZ-'1TT,DTG7(CLQM+CCSNP+UHOHLTC66+3UWN%BB=<C0T[Y=MS
MPUTF[;DNCSLDYYY''M75$04VI]+V75%"VCOUOAK(&'+ [(+#WM<,$?<53Z4Z
M-=*:5N/7[):A!6!I:)G322%H/ @;3B MQ1!0VO2-CM>H:Z^4%"(KK6@BHGWK
MSMY()\TG X@<@E3I&QU.J:?4<]"'7FG;L1U.]>-D8(QLYV>3CV=JOD0:YJ[1
M&GM7-B&H+9'5/B&(Y-IS'M'=M-(./=R6326CK#I*GDBT_;HJ02XWCP7/>_'+
M+G$DCW9PK]$&EUG1=HZLOQO-18X'UQ?O7';>&.?G.T6 [).?=Q[5<Z9TM9M,
M,JVV&A;1MJI-[,UKW.#G=_G$X^ P%=H@T#IET74:PTY!Y*>V.\V^<5-&]QV0
M3VMSV9X'XM"MZW3-'JZR6H:SM;'UM.!*Z)LS@V.;&'$%A&1W96T(@@7VST%^
MM51;;O3-J:*< 21.)&<'(XCB.('$*%I32EETG234NGJ(4<$TF\>T2/?EV ,Y
M<2>0"O$0%J&I.C;2>I;H^Y7NT-JJU[6M=(9Y69 &!P:X!;>B#3+!T8:/T_=J
M>YVBS-IJZ#:,<HJ)7;.6EIX.<1R)[%>ZFT[:]3VPV^^THJJ,O$F[+W,\X<CE
MI![5;(@TGI%LUUEZ/I=/Z.I8Q)-$VB;O)MEL,&,'B>)\T;/?QRKC0NG(=)Z4
MMUEIW!XI8\/?C&V\G+G?>XE7R("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@R4_ZYOQ4Y0:?]<WXJ<@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("\R_JG_ KTO,OZI_P*"O1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0&\PK)5K>85D@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@+S-^J?\%Z7
MF;]4_P"""O1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M;*BHV7J5VGJ.X[IF\GDB869.!M2!I_%*>X5U755[&0T[*2DE=$]SG':?AH/
M#ESYH+Q%KE+<ZAMNL$5!3Q!U;#P$CW%L8# [GQ)6)M^KC='6M[*.&K87%TSR
M[=N:&M<,#(.3M\L\,'F@VA%6:<KI[A:F554(FN>YV!%G9P"1GCSSC.>XA4U)
MJO?RTT@=1F"HF$386R$S-!. XCEW$CL!YH-L1:]?;Z^V32ELUO<R+9)@,AWS
M@<9]P/<I-+75U=5S&DCIF44$Y@<9"XO?LG#B,<!QR!\$%QSY(M1IJVX4-)>J
MJGAIG4U/5SO>V1QVW@')QC@.'?E7=\N,E!;XZB"-K@][6N>\'9B:?\;L<<#_
M +H+-%K=QK[CY/H)::HH7NFJXX]Y"26.:3P_[YXJSBK9A=X:&9L>TZE,SG,S
M]H.#<#/9Q06* YY+6Z6]UUPN=70T,-,U],]^\DE+B-D.+6C [3@_!8-,U\T!
MAAJ(FLCJJJJ!(.=B42..SGM!&UX(-K10+-7/N%-+4%C6PF5[82/\3&G&T?B0
M?NPJI]ZN/4ZZN934QI:.65CV%SMN1K'$$CL' <O<@V1%J]RU-NJNKCII*)@I
MFM);42%KIB6[6&XY<".)SQ*E6R[UETKIFTL,+*2(Q.=)(3M.:^-K\ #M&T>/
MP07R+6Z"Z2"SVF.AIXQ45A<V-KWN+&!NT7$GB3P'+WH;W7"YBT;BG\I$APDR
M[=;O!.UCGGAC'S0;)E%0:=,YO%\ZVV-LPEB#MV26G]&,$9]R]Z@N\EM<\Q3V
M]NQ%O-U,\B1^,\ !RY<^*"\1:_%=;A75%2RWP4S60QQR!TY=YVVS:V<#\?DO
MM/>JJXFBCMT,+))J454CIR2& G :,<SG/@@O^?)%1Z0=(ZBK3,T,D-;/M-!R
M =KC@KY3W6LEJ*][HH(Z&AE>R1Y)+WAK<^:.0^]!>IE:C#JX-$,U2ZC?#*QS
M]U3R%TD.&EPVNP\!CLP5[JY[C/46&6MBIF12U37M$3B7,)C?AISSX'F,<D&U
MHJ(WJ4:<EN6Z9O&2.8&9..$I9^'%9175]7<*J*WQTS8*601/?,79>[ )  Y8
M!'$]J"X1:C7UU<(M0.J13S4E.\-$>7-.-AI !!]_'[U/ENM?(*^>A@IW4M&]
MS'-D<0^4M&78QP'<,Y^Y!?HJ(76LK*\4]LCI]V:6.J$LQ/)Y=@8'P'S5A9*U
MUPML53)&(Y';37M!R YKBTX/=D()J+5Z.Z5.]IZ2WTT#75$M42Z1[B&[$N,]
MYSGE[^Y7%EK9JR*I;5,C9/3SN@?NR2UQ !!&>/(A!8(M=K+O<&NNSJ6"E,-N
M.7;QSLR#8#R!CD>)X_!>V7BK@FI7W"&!M+4Q/E;NB2Z/9;M8=G@>'=VH+]%J
MUMU.:BIHA(^B='5D@1PR$R0G9+AM]AY8/+!4BW7R2:[04<DU!4"9KR#2O+MV
M6X.#GF/?PY(-A1:R;W<>H3W#J]**2"=\;F;3MM[6R%I<.P?!6>I+AY-LU1.U
M[62D".,N. 'N. 3[AG/P""S1:OIUM)<**JM4M5UUE'*"R5DYR]CAEI+FG/#+
MA]R]Z4M\#*.2J&],[9IXPYTSW>:)'- P3CD @V5%SVUO:RUV::)EPIZE[X=Y
M5RR/W+@2-K/G$':Y#AS(Y+[++"X7)L3ZX7A]=+'2N8Z0-VMH[(S]C'/(/8@Z
M"B^,SL-V\;6...]?4!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!I?2;_ '9'
M_F,_$K/HK]D9_"%@Z3?[LC_S&?B5GT5^R,_A"#;41$&"M_99/@O=-^SQ?P#\
M%XK?V63X+W3?L\7\ _!!D1$0$15-!=Y*ZID;3T;C31RNA=*96@M+2026\\9'
MQ]R"1#;8VW"KJYB)I)]EK0YH\QK1P:/O)/WK[;*!M :IL3\Q33&9K,8W9/,#
MW9R?O4!^H6M<Z44LAH&S;AU3MM^UM;.=GGL[7#*QC49ZM)5^3Y^HQ2NBEFVF
M^;AQ:7!O,C_Z[$$@6FJIJB=]KKQ3PS/,CH9(=XT./,MX@C//'%8:>P24D5*Z
MBK3'50,?&9'Q!S9&N=M$%N1V\L%2;O=9;:R29U$^2DB;MOE$C1P[<-SDX^Y*
M>[/J;E/2TU'(]M/(&2S%P#6@M#@1VGGR09*6W2LN$=94U.^F; Z$XCV <N#L
MXSPY849UBP-N"J=%4MJI*F.78!#2_.6D=HP?<LK+K*VX04U51/@;4.<R)YD:
M[) )P0#PR >]0:;4$[8Z^6LHW"*&H,$>P]I<YV6AK,=Y)Y\D$]EMJ)*FCJ*V
ML;-+32/>-B+8!#F%N,9/?E8JJS325U9/3UNY96,:R9NZ#G8 QYKL\.![05BJ
MKM)+076"2%])6PTCIF@2!V6D.PYKAV@A?:"^1MLM1/4M>)**-N\:XY<_+ 6D
M?Q9\4'J>P-EI*6#K#@(*.2C!V>8>UK=KGV;/)>JJSU$E31305K6"DBV&,?#M
MC:Q@O^T...'NX]ZPZIJJN.VTC:>*5CZB>*-^Q(&.:"X9:'=A/+(6?KSZ1T%!
M2TD]35"'>O8^?.[:3CSGN/$YR!\$'QMJK()YI:.XMB=4$.F#J?::7@ %S1M#
M9R .'%9:NV3NKVUM%5B"H,0ADVHMMKV@D@XR,$$GQ6!^H8]Q2.AI9Y)JB5\
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M./N]RR5-[<R2K--0S5%/2'9FE:YHP0,D-!XNP"@EV:W^3::6(SNG=)*^9SW
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MU%6ZME#XRYK80 !P#1EW#EEV>"G(B B(@(B("(B B(@(B("(B B(@(B("(B
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M\0BMKA4-Q'-("70#8 V&-Q@ $<"".?(JYMU#5T5TJGC</I*DM>X[1#V.# W
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JY8W1_N^2L[=I)C' EH70-VWN7T- 05UMMD=*P;+1D*R P,!$0$1$'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g50309g07a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g07a01.jpg
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M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" &@!H0# 2(
M A$! Q$!_\0 '  !  (# 0$!              ,%! 8' @$(_\0 51   0,#
M  8$"@@#!08#!P0# 0 " P0%$082$Q0A,15!49$'(E)35&%QDZ'1%S(S-%6!
ME-)"<[(C-G)TL18D8I+!P@@ELS4W0V-U@N$X@_#Q)D1D_\0 &@$!  ,! 0$
M              $" P0%!O_$ #H1 0 ! P($ P8% P0" @,    ! @,1(3$$
M$A.105%A%18B4G&!!3*AL<$4--$&0N'P(_$D8C.2LO_:  P# 0 "$0,1 #\
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M$Q!UKGS3W6?3UX_%KA^I?\TZ>O'XM</U+_FJQ$Q!UKGS3W6?3UX_%KA^I?\
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M(,>X?=7J6#[&/_"%%</NKU+!]C'_ (0@]HB("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@TGPQ?W(J/YL?]2X"N_>&+^Y%1_-C_ *EP%=5G
M\KXC_4/]U'TC]Y$1%J\$1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MC]V#W-KJ&?8"4'#@ 7 <>WQ6*KTTGWC1+1)SY=I,8IR\EV79+V\3ZU8Z4?\
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M?#;]W2O!7<!:] JRK><,9<VM>3U-=L6D]Q*QK9H\RA\*ERJ)VZM#0M?<,D<
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M3/-K&<_[?%/X):>>KT-TAIZ.415,KBR.0N+=5Q9P.1Q"RM(#/HYX.:JW:27
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MJTSK=(*2&C,$%'01'6;! , GJS\EJZ*,1,Y;47[E%$VZ9Q$[B(BEB(B("(B
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MBEF(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MWQO/^:?_ *K/\)!)N-JR>5LI\?\ *5JCWN>\N>XN<3DDG)*^R2/D(,CW/(&
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MP^ZO4L'V,?\ A"BN'W5ZE@^QC_PA![1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MJI:F5M/ T.D=D@;7.!ZN)434O;X6B(IS.LQ5.,::<WKZ-+AAEGD#((WR//\
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MAFO#K!P;G/+&%JE531SU-0^T05CZ%CF@&5NLYN> #BT8R3G"OJK_ -V%%_\
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MMKW3@QF2F@@''Q&X >3UC'5UKW9+DR[U&E&D;Y8;?411PQ4\KVF04[7'5R
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M_CG*@TAT:N%CJ',J:>9T+6L)G$3@S+F@ZN>7 G'Y+%AL=VF,HAME:\Q'$FK
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M2UJS5@M]WHJPM+Q3S,E+1UZK@<?!(C.ZM5ZBW-,6\8YISMMG1<:<W!M5?;A
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MB#9/!Y1Q5FEE$*D!T$&M4/!ZPQI</B K302HJ+MI/>IW:TE554-2[ YESAP
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MVSP%_P!W:_\ S?\ V-4?T86/SU?[QO[5MVAVC])H]03T]"Z9T<DFT.U<"<X
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M0>)_L7^Q8"SY_L7^Q8" B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M7"JV;3$"/%P7:VM]4NZN91,/UKX0;S?;):(*C1FR&\U;YQ&^ .+=5FJXEW>
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M@J))-!S7W:L=M*VX37B$23O_ .7Q6CD&C@ K;PJ2S7BCT5T==#LKA=ZZ"6>
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M^'>CXK7 Y:3DDG!X@9PNL(@T:A\'T5+X4*W3,7%[I*F+9&EV0 ;XC6YUL_\
M#V=:AI/!Q';?"/-I99KG)1"J&*NA$(='-GZQSD8R<.Y'CQZ\+?T0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$02TOVP6:L*E^V"S4!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1!XG^Q?[%@+/F^R?[%@("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B#ZSZP]JL57,^L/:K% 1$0$1$!$1 1$0$1$!$1
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M**X?=7J6#[&/_"$'M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M1RSO:87ZDCMC)J,/87:NJ.?:JZH;5P:0VAUTF@J0YTD<(@C,98XL.7$$NR,
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M?51T-%/53ZVRA87NU1DX ZE,QP>QKAR(R%H]?#ONBMYN-355 J@Z=FKMG!K
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MNJ83F<L>]K,ZK"_G_P!3A6<3ZBV6NM%Q;4""25L=-&R<OE&O@:H?D'ZW(D\
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MR6^BHA/*R%LQ>^74;@EPP>!.?%[.["@CO[YX:$4U)FKJGR,V4DFJUAC)#\N
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M5TEJ)&OI:ECVQ1CFS: ;0_F6@KW:+U/<*ZL@U(XXW-<^B?@G7:UQ8XGCQ\8
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M5RUUBHZFI<'32,UG$#&3E!9(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M;5R79!X8Y#K*S:@W..UVJ"KGGIYY*\0E[7@O=$=?&2.!.,?F,J[ELEODIJ>
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MGM671L?<:]M)-45$-/3T4+V,AE,9>YV<N)'$XU0,<E:5-BMU3/++-3!SI?M
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M5M;N=IGK9HG#8PF5T>1G@,D9Y+7H['5Q6>GH):"@J]F'ZLIE,1C<7N(+<-)
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M:;761R2ND;/,</:'')!&H=;&3@Y[.2LY:2OI+O55=!'3SQU;6![99"PL<T$
M\ <C&.'J0>-&:QSM&(ZN4R2$"5YUSXQ >[AQ]7!0MTDD,-%,;74""MPV!P>T
MESR,@$9X X/'U++M-NGI='30SOC=4:LH+F_5)<YQ'^JC;:IQ;[!!F/7H9(W2
M\3@AL;FG'#CQ(0!?VQ0UF^4LL-33/8PPAP>7E_U-4\CD]RR;?<W5%9)255,Z
MFJF1B4-UP\.83C(([#S"KKM89:^:Y/S#B8P/B$@UFET><AX[#G"]T=KE;3UK
M8;=06N>2!T4<U,[6=K$<_JC !P4$_3,L55'#6T$E/M6O=$=HUV2T:Q!QR.!Z
MU'2Z0/F90SR6^:*CK'-9'*Y[20YPX9;SP>U5U-H_5"HH9=SH*4T[)&2.C>7O
ME+HRW6+BT'F1P.>?J5GT5/T-9Z7,>UI'P.D.3@AF,XX(+:KJ(Z2EFJ)CJQ1,
M+W'U 96OV&>NJ6U5%<YY(ZF6-M5$]F YC'\VCA_"1C\PK.^T,ERI8J5I:*=\
MK349."8P<EH]I 'L)6*;#%27&BK+5%'"^-Q9,"X^/$X<1U\00TA!B6^FJG72
MYQONM>YE&^/4:7,\8%@<0[Q>T^I5%NN[W4%MDI[S//<YG1A]-(&ECLD:P^J,
M8&>.>I;91T,L-PNT[RW4JG,+,'CPC#3G\PJ6.T7::PT]GJ(J**%C6,?.V9SW
M8:0<M;JCCP[4&/4W!P=>9'WR2FJJ>H>RGIPYA#@&@M&H1DY)(X+;J)\LE' ^
MH9J3.C:Y[?)<1Q'>J4V RT]T;(8V5$]4:BGF;Q=&<-U3WMY*[HS.:6(U;6-J
M-4;0,.6ZW7CU()41$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1!SSPE_>Z/^8?Z0MAT4^[-]BU[PE_>Z/^8?Z0MAT4^[-]B#8D1$
M&/</NKU+!]C'_A"CK6ZU,\>I>J1VO31D>2 @E1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 7F6-DT3XY6-?&\%KFN&00>HA>D0    !@
M#@ B(@(B("(B B(@(B("^. <TM< 01@@]:^H@Q:6VT-)(9*6CIH9#S='$UI/
MY@+*1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%X=%&Z9LKHVF5H+6O
M(X@'F ?R"]H@(B("(B B(@(B("(B L2HME#4S":IHJ:64?QR1-<>\A9:(
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M!ZD$+JE]\T@DJ@#L@=2//DCY\3^:ZG88#%3-&.I:CHG8]F YS1S[%T"",1L
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/!!24S(&8:%D(B B(@__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g50309g16g01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g16g01.jpg
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M*"@H*"@H*"@H*"@H*"@H*"@H*/_  !$( P\': ,!(@ "$0$#$0'_Q  <  $
M @,! 0$              0($!08#!PC_Q !9$  ! P, ! <*"@@% P,# 0D
M 0(#! 41!A(A,1,505%QD>$'%!87(C)35&&Q-5)C@9*3E*+1TB,S-#96<J&S
M0E5SLL$D8O E0X(W=/$()G7BPD1%1H3#_\0 &P$! 0$! 0$! 0
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MU1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8
MTG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4
MW8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@
M3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM
M4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I
M1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z
M!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&
MU1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8
MTG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4
MW8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@
M3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM
M4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I
M1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z
M!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&
MU1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8
MTG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4
MW8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@
M3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM
M4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I
M1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z
M!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&
MU1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8
MTG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4
MW8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@
M3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM
M4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I
M1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z
M!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&
MU1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8 TG&U1Z!.I1QM4>@3J4W8
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M]/*5'J "*
M
M
M                                                 ,@ ,C( #(R
M R,@ ,C( #(R  R,@ ,C( #(R  R,@ ,C( #(R  R,@ ,C( #(R  R
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MQ*O.78^,G2?UZ/ZAGX#QDZ3^O1_4,_ XX#)3L>L.*^)5YR['QDZ3^O1_4,_
M>,G2?UZ/ZAGX'' 9*=CUAQ7Q*O.78^,G2?UZ/ZAGX!.Z3I/E/^NC^H9^!QP;
MO0F6G9JCC^*FJ/\ Y*O.7Z5T&N-3==%J&MKGI)42H_7<C4;G#W(FQ/8B&]R<
MMW,?W&M?1)_<<=0>1^C&2,@ ,D9! #*C64@ -91K*0 &NHUU(( MKJ-=2@ M
MPCO8.$=["@ MPKO8.%=["A %^%=[!PKO8>8 OPSO8.&=[#S(4#TX=_L'#O\
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MQ^X=RZ8O[C2T_NAY./\ \KB?[9_I+\]@ ]C\W
M                                         $W+T )N7H
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M'Q:IO,R  J
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M[C2T_NAY./\ \KB?[9_I+\]@ ]C\W
M                                 $W+T )N7H
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MPH<CW6/W#N73%_<:=<<CW6/W#N73%_<:6G]T/)Q_^5Q/]L_TE^>P >Q^;@
M
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M)Z1$QYV[Q$N% !M\\
M               !=_S +O\ F                          -WH W>A&L
M/]T/T3W,?W&M?1)_<<=0<OW,?W&M?1)_<<=0>)^HH  $$$D 0  (  $$$D 0
M  (  $$$D 0  ((4DA0("@*!!!)  J6*E0Y"">0@"% 4 0020!!5_F*6*O\
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MB?[9_I+\]@ ]C\W
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M6'7U];A-C=N,;/-]IH@6*8ASQ.,QL2)IJG2=.D1WOV^8 #3S
M                                               +O^8!=_S
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M>P >Q^;@
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M7?RJ;23332*1&(^ZSJC&JQ$V;45,+G9MZ5$T2N%Z5PZ9S57O^F_36T6F^O\
M+7:.?O!:_P#[J+_>A](J[=<9>[,M3203I"R6-TDR-5&(S@VZV5W;4RA\JIYI
M*>>.:%RMEC<CVN3D5%RBF\K=,=(*V!T-1=:A8W)AR-5&93FV(AJJF9G1XN$X
MG"PL/+B7TJBJ+?*[MGR4]11=T:6EU'1*]FJY-RKEV53Y\F?::Q]ZT=AMMBGX
MMKJ>CQ+15%(BLF3")KHY4RF<YSGEVH?)Z.Z5E'15=)33NCIZI$29B(F'HF[W
MFS=IC?UMR4/&<R4R,X/51&HNKC&,XSN]IF:)>K#])X<:U1,:3$V^=4SI-XF.
MO_3LG5E;HYH-H_-HY3L62LUG5,J0I(KG<C5V=*?,5ME566G0.>[VNG8MYJ+@
MYE4_@4<Z-,KLQC8F<;/^XXFSZ4WJSTSJ>W7"6&!55=3".1%]F47'S%+5I)=[
M5-/+05\L3YW:TFYR/=SJBY3/M+DEF/2&'$Q-YC]-NWZ9M$7IU[_QU?3ZF>EM
MVFUF6JIXH5O-"D5="C<(CW;EQR+K;#6UEM@T<LMLT?JE;PETN?\ U#N7@&R(
MW?R91&K\ZGS>NN-975RUE94R352JB\(Y=J8W8YB]XN]?>*ED]SJ7U$S&ZC7.
MPF$SG&SI$425^DJ)BNU.M]/I-KW^MOO+[#I!<+925UQM5QEE?0K3ZD=!';O)
MB\G*/:]-J\J^SYC027F6P=SK1RKH:>F=62<+$V:5FLK&ZRJN.G"=1QS],M('
MV]U$^Z3NIW,U%14155N,8UL9_J:VHNE;4VZFH)YW/I*956*-43#<[_;RDBC=
MO&]*TU3551>)F)B-.EYB=YZ6TZ?*'U+1ZCATLMVC5SFU.$M4KHJQ5Y6L;K-5
M>IOTE/FFE%SXXO\ 75R;&2R+J)S,38U.I$.DI+W:K#H=6T=IJZBIN5SC8V?6
M8K&0;/*1,[UVJF4]G,<.6B-9EPX[B(JPZ*(MFZU6UUM:/MU^<@ .CY9_A7I
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M5ASV_B-9Z:1_0 !MX
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M)*FOG75=WS^\VC[G0KI]I+3=^P0OKZ)D-/4J]-1'\&B8UO\ S<2*IM=WKX+
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M39,1OUM;//MY4SE,FJ:IF;/)Q/"T86!3B4WO/6_]HMT^=VJ !M\\
M  !-R] ";EZ  .XLVC=FAT2AOM^DN$D<\JQM91M;^C1%5,N5>C^J'#GTSN=0
MW:DHZ:HI+M;'6J=RK54E3*F8TUE1=BIL543._;LR8KFT/?Z.HIKQ9BJF^GUM
M\[7B[2V;0SP@ENT]EEE6W4R*E,^9&HZ9^$5&KM3'3T&KHM$KO67"LHX8(^&I
M%1)]:9B(S.[;G;\QV]D=:JB\Z:V^T5%-##6P(REUG(UCG:JH["\VL[DY#!T6
ML%!#:KLV9MLK;W3SHQL=14XA1F&KK;%3.]W5UYS3%WL\#A5Y+1[UYB=-)G2-
M)_CY>;D:C1>\07J*TR43^_I4UF,145')MVHN<8V+M,FY:&WBWV^2MJ8H.]8U
MPY[*ACMN<83"[5]A])?6-GTZT66VS4TK$HW1S+ BO8UN%SC&U$SN5?9DU6DM
M)46RPPQT-N@2RTM<VKJ',JTG>JYQC<F$Z_>(KEJKT;@TTUU1,S:]O*)V^<WG
M3HXV30B_QV]:QU J,1G"JS7;PB-Y]3.?Z&HL=*RNO5!23*Y(YZB.)RMWHCG(
MBXZS[)<KB[C62]V:.PSP/A3_ *N:I5KT;J[6N;GV;L'R+1=[6:3VF21S6,2L
MB<JJN$1-="TU3,3=Y^+X3!P,6BFB9F)GOWC37I'7\EW%9H38*BLNMLM57<&7
M2@B654G1JQN3"+C*(G.G7RG)V[0V^7&GIZBDHM>GG8Z1DBO:C=5JX7*YV="G
M3Z>Z:UD-VNUNM;:**GDPQ]3 S,DK5:F<NSA=ZH8>DEPU>YQHU34U4B+F198V
M2;=BKC61.DE,U6=^(P^$JKKM'[(GII?]41$:W[=VEL^AM\N]"E70T6M3KE&.
M>]K-?'Q<KM,6W:-W6X5E5304JMEI?U_"N2-(OYE7")N.^CA9I%:=$I[;<J2F
M;:VM;51RS:CHU;JY<B>W57KZ38V^II[_ '_3%L#636J>*)BN5RQI(]J(W*2;
MDY=^_9[1GDI]&X-66(F=?G&OZ9G332TZ3U\WSVHT)OD%524TE-%PU4JI"UL[
M%U\(KL[]V$7:>%3HE>:9:%M11K')6O6.!CGM1SE3V*NSYSZ&YM92Z;:+RUU/
M34=IIXGT],]M0DC<)&[SG[-NXY>V=XWGNEU3+[5*^C6IFU%=*J-<J.7436SL
M3FQ[!%4L8O X-,Y8O>:LL7FW:)OT^<VT:6]Z)7BS4:5==3-2GUM19(Y&O1J\
MRX789=-H#I%4-1T5 FJZ-LC7+*Q$<B[L;=_L.POSJ>DT"OU"K;52S\-&]M-1
MRZZZNNW"NRNUVQ=W(@N=QA73+0M65<? Q4S-=4D358JHJ+G;LV8&>72?1_#T
MU_JF;?I[QWF8GMVM?HXBJT*OU+:Y*^HH',@B36>BO;KM;SJW.<$V[0J^W"@C
MK*:C;P,J:T>O*QBO3G1%7)U]OKXG7?N@K)51JV6"5L:ND3#\(Y$1.?89>C<3
M+AH[14^E'%4UKBI]:"L94HR:GV;&JF_*;OFVY&>4H]'\/75$1?I/>.L3;6;:
M1/T_E\B5,*J<P+2HQ)7I&Y7,1RZJKL54Y"IU?#/\*]('^%>D =9W+*>&JTTH
MXJF&.:)6R99(U'-7R%Y%-YIS17)ZTE+7VNT4-)-6M9'-1L1)%WHF<+NPN>E$
M.7T#O%-8M)J:OK4D6"-KT5(TR[:U439E.<S+M5:,LK:>MM#[HZI[[;-*E0UF
MKJ955QC;G.#G,3F?6P,3#C@YHF8O>;ZVTT^6OG#>>+RW+=ZFSLOJK=6L66.+
M@%U=7&4UESOZ#FM&++;KBV?C&KK8I6/1B14U(Z953XRJF[H-]3Z86V/NE5%^
M<VH[RDCU$3437SJ(W=GG3G(L>E=K@T56VU$URHIXZATZOHL-=.BJJZJNSLWH
MGS(3]5G6:>#JKO3:(B:M]8BUN_?5M="K [1SNFOH'3).SO1TC)-75RU<;TY%
MV*<U<]$Z%-&ZFZV:Z]_=YR)'4L6)68551,MSO3:GS=!NDTZMOAVR]K%4I3I1
M< K-5%=K[\;]WM-;7Z06*BT3KK7H_'6K+<)&OE6H1/T2(J+JIC?NQ\ZB,UV\
M2>$G"JHB8M$UVUF^MK6WUCNZNXPS3:?Z+,I9FP2K;45)%C1Z)Y+^13D;?HK3
MW*EO5SN%S[UBHJMS)7<#K:R9VJB(N]578AL7::6Q=+['<]6I[VHJ/O>5-1-;
M6U7)L3.[RD-0W2.B31;2*WZLW#U]6D\2ZJ:J-UT7:N=BX0D1,+C8O#8E4S5,
M3K5-KS[L6^[(KM!XUN5BCM5Q2>CNR*L<LD>JK$:F5RG+LZ.8O7:(V>*RW>OI
MKG62<72+3R-=3HFM)G"8\KS<JGM,_1^NAO\ 4Z'6VA21)[8KY*A7KJ(J)A?)
M5,JNXVFDZ1:2V.\2TURN<45'K5*PU%*V*)ZIG9E&HJKLPF55=PO-[2M/#</7
MAU5T4Q-^FO\ ^8F;:]I^NSDNY;%;9M(GLNC:=[UA=WLVH_5NERF,_-G_ /.#
M:WBDJKAI-:+7I):Z*U(^;52>C@V5"*J(C45%Y]GLSM0Y'1M;)PT[-($K$B<U
M.#DIL:S'9Y47DP=/>=,+>U-'Z6V-K*FFM=0V=9JI4X23"YU4]F/^.8U,3?1Y
MN&Q,..&RXDQ%IO\ 76-)CK_,2O>M%[-4Z=16BV5DD3II7-EB2%<089K)A57R
MLX-1:]%8ZV725BU3V<4,D<U49GA-57)MV[/--I<=)+%#II1Z06SOZ61TJR5,
M<K6M1J*W5\GV[UVJ92Z3:,T3-(>+FW%\UVADUGR-;JL>[.&HF<XRY<K[$WDO
M59UG#X6NNJJJ:8_5/29Z6TM_/7_ABV312@HZ6R7"[7;O6KK9624T'!*YJHCD
M5-9>3.4V\F3?UD$\W=!TM[UJ&P*V@R[,2/UDX-FS;NZ301Z26&NLEE;>8J[O
M^THC8V0:NK,B8PBJNY/)3/SGJFF5M\*](;EJU/>]?1\!$FHFLCM5J;4SL38I
M+3+KAXG#8=---,Q$7B>LW_;-[[:[,"Q:&05-CIKG=:RH@CJY%9"RGIUE7"+C
M6=C<FPR:#N>.=>;Q1UM8](K<QLF8(M>29'(JIJMSS)[=NPO8=+Z/P9I;57UE
MTMTM(Y>#J*%?UC555PY,^W^AB4-ZM?'];6S7>_0N34;35.6OD<U$\I)$Y4SC
M"=9?U:N--/!9</2)Z7UMVF]]=^G3:[G-(*.BHK@L-MJY:F%&HJNEA6)S'<K5
M1>8UITW=!OU+I#>V55#$]D;(6Q*^1J(Z545?*5$Z<?,<R=*>FKY7$Q13BU1A
MS>+Z6_)  5Q      [+1*P6:KT8N5WO<E:V.DE:S%,K<JBX3<J<Z\YQI]$T)
MN\5I[G]]E5M)/.E0Q64]2B.1_FIYN=N-_P QBJ]M'M]'TT58L\SI$3.ORAZ4
MVA=K9I3H^V.66KL]TBDE:V7R'IABNPJICG0T.D&A=WM[*VN2A5ENCD=J^6BN
M:S67554SG=@VVBFD]5>NZ#:JJ[30Q10MD8QK<,CC3@W;$S_RID6.NC6/N@\-
M5,_31R*S6>GEKF3&.?DW&;U0^AR^%QZ/TQ:\U6[=*8GYZ7Z1?NYBT:&WJ[4#
M*RBIHWPR9X/,S&J_"X7"*N>0\;1HM=[K-514E(J+2NU)ED<C$8[F557?L/HF
MCM%9[?2Z.UU$EJ=&J-=55=54+PL<BX\EC<[%SE-WXGC;:BKDTBTD92):JZUU
M%6J3TM3.C5>GQVKNQU[AGG5(]&X,11FF;SUM-^U[].E_JX%NBMX=>WVEE&KJ
MYC==S&O:J-;SJ[.$3:G6>-]T?N5C=%QC3ZC)4S'(UR/:[&_"IL/I5GFL%KTH
MT@MMOGI>"JZ5K(N&E58M=$=F/7SNVIR\Z'.:>U%7!8:&VSTMII8&3+)'%1SK
M(YNQ<Y3*X1=8L53,N6-P.#AX-5=]8F>DWB+3:TZ=X[Z?1J=!]'*>^UF:^OBI
M:5DC(U:CDX61SEPUK4_Y-;I3;XK5I#7T-.Y[H8)58U7KE53VGKH6]D6EEH?(
MYK&-J8U5SEPB)GE4]=/)&2Z87:2)[7L=.JHYJY1?G-:YGEF,.>$BJ(_5FM??
M1H0 :>(             #N;1H_H^S0ZEO5]FN#.&J%I_^F5JHB[<+A4YFJ<,
M?2[7I VR]S&@D@CH:JJ2M<G U#4?J)Y:ZVKG*+L3;[3%=^SW^CZ<.:JYQ;6B
MF9UU[QV7MV@M!3Z8U=LJM>MI>\%JH,JK79UD1,XY=YQUZT2O-FH65EPI.#IW
M*C5<CVNU57D7"[#K.Y]I#/<M+KE<;O51MF=0O:USE1C4PYN&M-?:*J-W<LOD
M$]0WA75D;D8YWE*FM'E43>O*9B:HG5[,3"X7&PKT1;]\QT[6F(G^VNC5T^@]
M^J;>RL@HVOC?&DK6MF8KW,WY1N<F/8]$[Q>J5U304R+ UVIKR2-8BNYDRNT^
MK6:ELUEOM#);^*8[<^#595OJ5=/(]478F5PB?-@T&A?#5-!-1US+36V*2J>Y
M[)IT9+!Y6UR>SE3WH,\NGJS!BJFF;ZWO:;]+6F]NFNTN&H-%KO77"KHZ>ES-
M2+B=5>U&QK[79QR&)>[/762K2FN4"PR*W6;M14<G.BIL4^E:/3VAM+I+9+=)
M1U"OJN$IV5DJHR=GD[-;.W"HN/F]IR_=&JZJ1;725<5NA[VB<C(Z.99-1JJB
M(UR\GF[$]I8JF9L\N/P6#A\/S(F\^<=;6Z;:]==F-HU1Z+S4D''%5<75T\O!
M)!3,1$C3.$557.=_)U&!IE96Z/Z0U5NCF6:./5<UR[\*F41?;M.O[GECIJ>V
M<=K4VZ2YKGO2"IG1C(E1537?RYV91/\ Q./TMI:RFO4JW*LIZRJF3A7RP2:[
M5SG9G"<V[H+$_J9Q\')PE-55$1,VUC;YZ]9Z_)I@ ;?,     !=_S +O^8
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M-V%  0
M            !#_-/,]'^:>980                          %H]ZERD>
M]2Y%@                          %'[RI9^\J6$
M        !Z,\TDAGFDD4                          'B_P Y2I9_G*5*
M@                        8MU^"ZS_1?_ +5,HQ;K\%UG^B__ &J!J.YC
M^XUKZ)/[CCJ#E^YC^XUKZ)/[CCJ"*@  0020!@.MS5<J\*_:N2.+6^FD,\&L
MTL9*=FOXM;Z5XXM;Z5YG@9Y,E+7\7-]*\<7-]*\SR!GDY=.S XO;Z5XXO;Z5
MYG 9Y.73LP.+V^E>.+V^E>9P&>3)2P>\&^E>.\&^E>9I SR<NG9A=X)Z5Y'>
M*>E<9H&>3ET[,+O%/2.([Q3TCC-(49Y,E+#[R3TCB.\D](XS HSR<NEA]Y)Z
M1Q'>:>D<9A SR9*6)WFGI'#O-/CN,LJ7-)DI8O>B?'<.]$^.XRN0@9I,E+RB
MBX)%3*KGG/0*#/5J(M"""2 (*O\ ,4L5?YB@6B,V'<841FP[@/=-P0)N"""'
MC5TZ5"-17N;CF,;BUOII#8*1R%BJ89FF)ZM>EN;Z5Y'%S?2O,]-P+FE,E+ X
MN;Z5Y'%[?2O,\JHS29*6#W@WTKR.\6^D>9R[BI<TIDAA=XM](\CO)/2/,T@9
MI,D,/O)/2/([S3TCC,Y"I<TIEAB+2)Z1Q'>B>D<92D#-)EAB=ZI\=P[V3X[C
M)Y%(4N:4RPQ>]T^.I' )\93)7E/-1$RF6'CP*?&4JL7_ '*>ZE5+$RF6'CP:
M<ZD*SVGJI5=Y;EH>>K[2B[#V/)W*6)9LKDHI9"J@44HI=2BFH9(OUT?\R>\[
M8XF+]='_ #)[SMCEB]G; [AB7;X.FZ$]Z&68EV^#INA/>AQAW<9#\+NZ$]P$
M/PN[H3W J.CO7[=!T)[S=FDO7[=!T)[S=A0 $ .5&M57*B(FU57D!@7^CDN-
MDKZ.%Z1RSP/C:Y=R*J*@9JF8IF8B\M.[3W1IM2L"W6+71<:R,<K<_P V,?.=
M,QS7L:]BHYKDRBIN5#XSHW66VP1ML6F5@CB?KJJ5;XD=K97>J[\)SHJG6W^]
MUU/W1K%;J6J5MOJ(4<^-J(J/VOVYQGD0Z31KH^3PWI&JJC/C6O>(M$3$Q,[W
MEW1Y]\0I4)3\+'PZMU^#UDUM7GQOP<5=;U<(>ZE:[7%4N;030:[X=5,.7$FW
M.,\B=1RR4E[K.ZC<:>&\-@KHX=E0V%%1(\-5&(U>E.HD4;NN+Z1BB;443,YL
MO;:^[[$#C--:FII(J")=**>T^1B=71HZ25=GE-3?OR:CN?:55D]VNU!7W!MR
MI:6%U1%5(S55S6JF=GS\O,3)-KNE7I"BC&C!JBTS]-K]+W^SZ4::XZ1T-OOM
M#::A)N^JQ,QJUF6IM5-J_,IPM@J-+=,8:JYT5XCMU.R58X8$C14RB(N%7'M3
M:N>4V>D%TN-#IWHU;TJM:.6-J3_HV_I'95%7=LSCDP7)K9RGTAGPXQ**9B)F
M+3,1K>;;OH /F55=-(KCI]=;%:[DVF@:U'H]\:.6)J-;G5V;U5R;S"T?KM+K
MO<;E86W>*)]$]VO5NB17+A=5&ILW*NW._P!PR?,GTI3FRQ15.LQVUF/Y?5:R
MH924D]3-G@X6.D=A,KA$RNSYC!T<O=+I!;&UU DJ0JY68D;JJBH<9H1I'=*[
M1W2*.XSI)66YC]2;53/FNQR87"M-9!I9=J3N7MN+)4?6R5:TZ2K&W]&W:N<(
MF.3&[E+D[)ZSH_3B:Y9IF;6UTFV_YN^L@^25E9?:6_V6W4^E,E4VXM:Y[XXF
M.6//*B<W+\RGUM$PB(JY7G,S39ZN%XJ.(FJ(IF,N]O[3( #+U@
M                                A_FGF>C_ #3S+"
M             M'O4N4CWJ7(L                           H_>5+/WE
M2P@                          /1GFDD,\TDB@
M       \7^<I4L_SE*E0                        ,6Z_!=9_HO\ ]JF4
M8MU^"ZS_ $7_ .U0-1W,?W&M?1)_<<=0<OW,?W&M?1)_<<=014  """2 (
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MK1]^3J]&KT80ZL53$NGH_A\3AXJIJ_;VC33?I$  ,/H@
M                          A_FGF>C_-/,L(
M     "T>]2Y2/>I<BP                          "C]Y4L_>5+"
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MS=FDO7[=!T)[S=A0 $
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M_HO_ -JF48MU^"ZS_1?_ +5 U'<Q_<:U]$G]QQU!R_<Q_<:U]$G]QQU!%0
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MT)[T.,.[C(?A=W0GN A^%W=">X%1T=Z_;H.A/>;LTEZ_;H.A/>;L*  @
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MBF\/E/<EF>V^54*9U'TZN5/:CDQ[U/JQSKIRU6>GT=Q%7$</%=77H  P]P
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MO0XP[N,A^%W=">X"'X7=T)[@5'1WK]N@Z$]YNS27K]N@Z$]YNPH "
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MR+                           */WE2S]Y4L(
M      #T9YI)#/-)(H                          /%_G*5+/\Y2I4
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MZ_;H.A/>;L*  @
M                    "'^:>9Z/\T\RP@
M+1[U+E(]ZER+                           */WE2S]Y4L(
M                #T9YI)#/-)(H                          /%_G*5
M+/\ .4J5                         Q;K\%UG^B__ &J91BW7X+K/]%_^
MU0-1W,?W&M?1)_<<=0<OW,?W&M?1)_<<=014  """2 (  $  """2 (  $
M"""2 (  $$*20H$!0% @@D@ 5+%2H<A!/(0!"@* (()( @J_S%+%7^8H%HC-
MAW&%$9L.X#W3<$";@@@A*D<A*D<@%4W )N 1!52Q51 A=Q4LNXJ400205$<A
M4MR%0BJD$J0!7D4A2>12%-(JO*>:GHO*>:B$0I52RE5+"2JI5=Y92J[RH@\G
M<IZGD[E+#*B%5+(54L(HI12ZE%-0R1?KH_YD]YVQQ,7ZZ/\ F3WG;'+%[.V!
MW#$NWP=-T)[T,LQ+M\'3=">]#C#NXR'X7=T)[@(?A=W0GN!4='>OVZ#H3WF[
M-)>OVZ#H3WF["@ (
M                       A_FGF>C_-/,L(
M  "T>]2Y2/>I<BP                          "C]Y4L_>5+"
M                   ]&>:20SS22*                          #Q?Y
MRE2S_.4J5                         Q;K\%UG^B__:IE&+=?@NL_T7_[
M5 U'<Q_<:U]$G]QQU!R_<Q_<:U]$G]QQU!%0  (()( @  0  (()( @  0
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MTEZ_;H.A/>;L*  @
M                      "'^:>9Z/\ -/,L(
M   "T>]2Y2/>I<BP                          "C]Y4L_>5+"
M                    ]&>:20SS22*                          #Q?
MYRE2S_.4J5                         Q;K\%UG^B_P#VJ91BW7X+K/\
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M=8 .3\,*G^&+[]G[1X85/\,7W[/VG6 #D_#"I_AB^_9^T>&%3_#%]^S]IU@
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M4='>OVZ#H3WF[-)>OVZ#H3WF["@ (
M                                    A_FGF>C_ #3S+"
M                 M'O4N4CWJ7(L                           H_>5
M+/WE2P@                          /1GFDD,\TDB@
M           \7^<I4L_SE*E0                        ,6Z_!=9_HO\
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M">X%1T=Z_;H.A/>;LTEZ_;H.A/>;L*  @
M                                       "'^:>9Z/\T\RP@
M                   +1[U+E(]ZER+                           */
MWE2S]Y4L(                          #T9YI)#/-)(H
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M1T=Z_;H.A/>;LTEZ_;H.A/>;L*  @
M                                   "'^:>9Z/\T\RP@
M               +1[U+E(]ZER+                           */WE2S
M]Y4L(                          #T9YI)#/-)(H
M         /%_G*5+/\Y2I4                        #%NOP76?Z+_P#:
MIE&+=?@NL_T7_P"U0-1W,?W&M?1)_<<=0<OW,?W&M?1)_<<=014  """2 (
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M;LTEZ_;H.A/>;L*  @
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M!=R!'\/<UVZFK&B].7=I)G-1>68PJ>"](QA8/[:HZ;=?^'TH '!]P
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M,L(                          "T>]2Y2/>I<BP
M        "C]Y4L_>5+"                           ]&>:20SS22*
M                       #Q?YRE2S_ #E*E0
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M$NWP=-T)[T.,.[C(?A=W0GN A^%W=">X%1T=Z_;H.A/>;LTEZ_;H.A/>;L*
M @
M        "'^:>9Z/\T\RP@                          +1[U+E(]ZER+
M                           */WE2S]Y4L(
M    #T9YI)#/-)(H                          /%_G*5+/\ .4J5
M                     Q;K\%UG^B__ &J91BW7X+K/]%_^U0-1W,?W&M?1
M)_<<=0<OW,?W&M?1)_<<=014  """2 (  $  """2 /&LD?%2SR1,621C'.:
MQJ95RHBX1#YO46N]VO1JUTC'7*LC? ^2:&F1L;V2ZF6L5S<.U5>YRJJJJ^2B
M<NWZ:#=->5RQ,*,3N^8S6ZZ26FZT];#=YZ^*B2.C<V5Z1*W@FHJKAR:SU<KU
M5'978@2BO%).]+?3W5O>FLZ!'2N6+O9(%U8T17+K/=(O+M3'(B(?30;YL[.7
MA8W<1=K17T.A-$RA;45UTIIJ>I5)I%>Y\B.;K;578F_H0UBZ-U<5PAIN!EEB
M1U)%-/J[)5X5T\SU7F5R-3YT0^DD$C%F&JN&IF;N!O\ 2UU===(J2*VU$KJZ
M"&C@G>Q$AC8B*KGJY5Y%>NQ,KEJ&HGLMZN"W.*X/N3UFF;3<$B/;%P2S-\K6
MUL*B1M7<U/.7.3ZH!&+,=(2KAHJF9F?S\E\VMU+=*=\25]/>)*9L<L]-%'+(
MNK+PKU:V1=;65$8D:(BY1<KO,)E!I'#)F62YZ]+0HL#8D<K97K"NLCG:V,K(
MY=[578F%1#ZJ0I>=.R>%C35\W2W7:BE=3S+>*BU=\1MFX*9[II,0956KG61K
MI%PN%3S39:+1U4^DERQ52RVF@F<V!>&<])'O:S+555VHS"ITNYT.U/*""*GB
M2*GB9%$W<QC4:B?,A)Q+PU3P\4S$Q/YM]'H020<GH"I8J5#D()Y" (4!0!!!
M) $%7^8I8J_S% M$9L.XPHC-AW >Z;@@3<$$$)4CD)4CD JFX!-P"(*J6*J(
M$+N*EEW%2B""2"HCD*EN0J$54@E2 *\BD*3R*0II%5Y3S4]%Y3S40B%*J64J
MI8255*KO+*57>5$'D[E/4\G<I8940JI9"JEA%%**74HIJ&2+]='_ #)[SMCB
M8OUT?\R>\[8Y8O9VP.X8EV^#INA/>AEF)=O@Z;H3WH<8=W&0_"[NA/<!#\+N
MZ$]P*CH[U^W0=">\W9I+U^W0=">\W84 !
M                                        $/\ -/,]'^:>980
M                     %H]ZERD>]2Y%@
M%'[RI9^\J6$                          !Z,\TDAGFDD4
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MNZ$]P*CH[U^W0=">\W9I+U^W0=">\W84 !
M                                         $/\T\ST?YIYEA
M                     6CWJ7*1[U+D6
M4?O*EG[RI80                          'HSS22&>:210
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MP^TN.N '(^+^S^EN'VEP\7]G]+</M+CK@!R/B_L_I;A]I</%_9_2W#[2XZX
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MIV9BW7X+K/\ 1?\ [5 U'<Q_<:U]$G]QQU!R_<Q_<:U]$G]QQU!%0  (()(
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MPT,TQM.E])+-:))-:%426&5NJ]F=V4RJ87"[451DJMFMH1B4S5EOJZ( &6P
M                                           !#_-/,]'^:>980
M                       %H]ZERD>]2Y%@
M  %'[RI9^\J6$                          !Z,\TDAGFDD4
M                 'B_SE*EG^<I4J                        !BW7X+
MK/\ 1?\ [5,HQ;K\%UG^B_\ VJ!J.YC^XUKZ)/[CCJ#E^YC^XUKZ)/[CCJ"*
M@  0020!   @  0020!   @  0020!   @A22% @* H$$$D "I8J5#D()Y"
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MYIYGH_S3S+"                           M'O4N4CWJ7(L
M                 H_>5+/WE2P@                          /1GFDD
M,\TDB@                          \7^<I4L_SE*E0
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MA/<"HZ.]?MT'0GO-V:2]?MT'0GO-V%  0
M                                       !#_-/,]'^:>980
M                   %H]ZERD>]2Y%@                          %'
M[RI9^\J6$                          !Z,\TDAGFDD4
M             'B_SE*EG^<I4J                        !BW7X+K/\
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MP[:M\+Z,FGB(XF*KT]8WU>@4!3Q/NH()( %2Q4J'(03R$ 0H"@"""2 (*O\
M,4L5?YB@6B,V'<841FP[@/=-P0)N"""$J1R$J1R 53< FX!$%5+%5$"%W%2R
M[BI1!!)!41R%2W(5"*J02I %>12%)Y%(4TBJ\IYJ>B\IYJ(1"E5+*54L)*JE
M5WEE*KO*B#R=RGJ>3N4L,J(54LA52PBBE%+J44U#)%^NC_F3WG;'$Q?KH_YD
M]YVQRQ>SM@=PQ+M\'3=">]#+,2[?!TW0GO0XP[N,A^%W=">X"'X7=T)[@5'1
MWK]N@Z$]YNS27K]N@Z$]YNPH "
M             \._*;A)X^^8=>!NM*W73,:8SER<B8YSSXSH.!AF[^I>!F=J
M1/X5NJ]=V&KG:O0+)>&6 >-15TU,^)M340PNE=JQI(]&J]>9,[U"O8
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M]"@_//CHTD]6M?U+_P Y7QTZ2>K6KZE_YQX>L\7AOT0#\[+W:])?5;5]2_\
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MY3U/)W*9AI1"JED*J6$44HI=2BFH9(OUT?\ ,GO.V.)B_71_S)[SMCEB]G;
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M17^\4M744U.^!T4,*L:B*BHFKS[7*JJN"WHB]OFF7$F8S?+_ +?0  >=[
M  !#_-/,]'^:>980  &/72K#3/<WSMR'.KMSDW]T8KZ-V/\ "J*:!3MA]'GQ
M>JBE5+*54VXJ*54LI52BBE%+J44"BE5+*54(HI52RE5***44NI10*J44NI12
MHJO*44NO*44"JE%+J44(JI12ZE% JI12ZE%*BBE5+*54"B\I5>4LO*57E$(H
MI52RE5***54LI50BBE%+J44"JE5Y2RE5Y2HHO*54LO*54"BE%+J44(JI7D+*
M5Y"BBE5+*54(HO*57E++RE5Y0**54LI52BBE5+*54(HI52RE5 HO*54LO*54
MHJI12ZE%"**57E+*57E"*J44NI10*J44NI12HJO*44NO*44(JO*54LO*54HH
MO*57E++RE5Y0BBE5+*54"B\IYR+AIZ+RGG+YI4?2.XGH)3:4UM37W9JOMM&Y
M&\$BXX61=N%7F1-J]*'Z"=HQ8G4?>JV:W=[XQP?>[,>X^3?_ *;;[3,IKC8Y
M7M94NE[YB15QPB:J-<B>U-5%^?V'W \&/55GF'U>%HIY<3#\O]V?0>#1*ZT]
M1:T<EMK=;48JYX)Z;VYYMJ*GS\Q]+[F5XDO6B%)-4.5]1"JP2.7>Y6[E7VX5
M#F__ -2-\IIYK;9H'MDGIW.GGPN=3*8:U?;C*XZ.<V?<7HY*70ICY$5.^9WS
M-1>;8W_^4[Q,SAQ-3S6BG&F*>CN@ <W4
M #*M\JQU+4SY+O)4Q3VHV*^IC1/C(I)Z-4]6^ !YWK#%NOP76?Z+_P#:IE&+
M=?@NL_T7_P"U0-1W,?W&M?1)_<<=0<OW,?W&M?1)_<<=014  """2 (  $$+
ML1>4D 8-MN4%Q;(M.KOT;M5R.3"H0MSITNB4":ZU"MUEPFQ$QG:II:=4M6E=
M1&Y=6GJF*]%Y$7?_ ,.ZR=$V.JZRONDJ;97ZC,\B;_P3YCQ8>/75:B?W7F)_
MC\ARBN9F([MQ-<J>*Y14,FND\J:S=FQ=_+\Q%1=*:GN,-%(YR3RIEJ(FSEW]
M1I],$[VJ;;<$_P#9E1KE]F<_\+UFCO3Y)[I6W.%<LHIHV-YMBX]Z?U-UX]5,
MS'S^SEB8TT7C\L[.KN=/2UU/22ZZS3KY"-3/+C:7N=?#;J5:BIUN#143R4RN
MTY^C>VYZ:/G9Y45-"FJO2G_\2F7IS\ /_P!1OO.L5S,3*SBU9*ZX[=$P:66J
M61&+*^//*]BHAO&N:]J.8J.:J9147**AJZJAIJRQ(RI8S"0(J/5-K5U=Z*8&
MA-3*[1UZN17<"]S6(O*B(BXZU-Q,])*,2NFN**];Q=T>4SCE/*KG92TLL\N>
M#C:KW83*X0X?OA[KE2QNADGDK&,5]2U[D=Y6WR,+A$:OLY%.NLD[ZFUPR3.U
MW^4U7_'PY4UOGQGYS4)A<1S9FF-):GPSM7//]7VG00R-F@CE9G5>U')GF5#B
M=(W5<5ZCK+G0NDMD#\1M8Y-5?^Y>GF7',=DVH9)0I4P[6.CX1N>5,90Z54Q$
M19RX7'KKKKIQ)Z?*T_7Z-7=])K=;)EAF>^29/.9$W*MZ>0V-NK(KA1QU5/K<
M%(F6ZR87?@^?:.\:MAJ[E14=/4.5ZJ^27:Y>54:F?:=MHY<XKK:V5$4:1*BJ
MQ\:;FN3F]_SG7%PHHIT<N"XRO'K_ %Z7B\1;^_?YO"]Z2V^SS)#4OD?-C*LC
M;E43V[D,RTW.ENM+P]%)KLSA45,*U>94.8T9C94Z8WV:H8CY(WJQNLF<)K*G
MN1!H>U*;2J^TL"8IT=K(U-S5UMV/G7J.M7#T11,1^Z(B?-SPN-QJL6FJJV2J
M9B([Q:^O\V=H5+%3Q/KG(03R$ 0H"@"""2 (*O\ ,4L5?YB@6B,V'<841FP[
M@/=-P0)N"""$J1R$J1R 53<:._V1UUN=DJFSI&ENJ5J%:K<Z_DJW'LWFYG>Z
M*GDD8S7<UJN1F4365$W97<8UNK'5-OIIZJ)*6:6-'NA=(CE8N,JF4V+CG0L7
MC6&9B)TE6^42W*RU]"UZ1K54\D*/5,ZNLU4SCYS17#19]5HU8[4E4UKK=+32
M+)J91_!8RF,[,X.B=5,=1RSTJLJ-1JJU&/3#E1-V=R&N6_4]/36IUS3O.IN"
MHQD"O1^J]6JY45R;,)A=N[=SEIF8Z,U13/5HI]%+FR[7N6W7.F@H[NJ+4*^G
M5\\?DZJHQVLB8QNRBX,B"R7FVV"UVVU5MO<VEIT@F;5TSGLEPB(BIAR*G+LV
M[S?)6RNNS:5M,KJ9U/PW?22-QK:V-35W[MN=Q[-J(73+$V:-94WL1R:R?,:S
M2D44]G&0:"+3Z.TM'!<$BN-+6+7PU#(42..157+4CSYF%QC)T%DAO3))7WNK
MH9D5$2-E) Z-$YU57.55Z"EKO:UVDE[M:P(Q+=P.)-;/"<(Q7;L;,8-K/-%
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M;4?1/OP'/G8\+&[\_KHQ>O\ +:GZ)5=&+U_EM3]$_00'/G8\+&[\]KHO>_\
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M[-)>OVZ#H3WF["@ (
M                        A_FGF>C_ #3S+"
M     M'O4N4CWJ7(L                           H_>5+/WE2P@
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MTEZ_;H.A/>;L*  @
M                      "'^:>9Z/\ -/,L(
M   "T>]2Y2/>I<BP                          "C]Y4L_>5+"
M                    ]&>:20SS22*                          #Q?
MYRE2S_.4J5                         Q;K\%UG^B_P#VJ91BW7X+K/\
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MM,VL5[N":FOP+&QI\RRN5?FP=50:(6BA6V+! [-O?))#K.SY4GG*O.O-S%/
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M>;L*  @
M             "'^:>9Z/\T\RP@                          +1[U+E(
M]ZER+                           */WE2S]Y4L(
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M^W0=">\W9I+U^W0=">\W84 !
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M[U^W0=">\W9I+U^W0=">\W84 !
M
M
M
M     #!&"0!&!@D 1@8) $8&"0!&!@D 1@8) $8&"0!&!@D 1@8) $8&"0!&
M!@D 1@8) $8&"0!&!@D 1@8) $8)P
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M\MTLE'73Q)"^HCX341<HB+N_I@\[7=5K;G=8%8QD%',R!DFMM>Y6HYR?-E$
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M,61$:]6IK(FY%Y0+
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M<J*F,*J\B)G">U3=@
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M16FHV9N#JA7R52_K)&,C7715YERB8W)N.^
M
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M9.%BAGJ7OC8]-RHU5Y.3)[Z-VM]MIIW53VR5U5,Z>H>W.KK*NQ$SR(F$0VP
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ML:CL9V<^Q"+/;8+30MI*19%B:YSLR/5SE5555VKTF:
M
M                      &)=O@Z;H3WH99@WI^K;WIRN5$_KD0./A^%W=">
MX%:9VO=Y,;DV?=!4=A>8>%I55/.9Y2"R5*2TO!JOEQ[/FY#/>W6:J'/3LDH*
MOA8MC<_-T =$#'HJR*J9EBX<F]J[T,@B@
M
M
M
M
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0Q,(@N613Q)&Q$1 >H(K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g50309g16g02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g16g02.jpg
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MRE$)QIRN5X0/XFA>X4)$1$$=<O2KJ%G=QD_@I%1U?_:=#[RI% 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$R$!%QQ#Q
M3B'B@Y1<<0\4XAXH.47'$/%.(>*#E%QQ#Q3B'B@Y1<<0\4XAXH.47'$/%.(>
M*#E%QQ#Q3B'B@Y1<<0\4XAXH.47'$/%.(>*#E%QQ#Q3B'B@Y1<<0\4XAXH.4
M7'$/%.(>*#E%QQ#Q3B'B@Y1<<0\4XAXH.47'$/%.(>*#E%QQ#Q3B'B@Y1<<0
M\4XAXH.47'$/%.(>*#E%QQ#Q3B'B@Y1<<0\4XAXH.47'$/%.(>*#E%QQ#Q3B
M'B@Y1<<0\4XAXH.47'$/%.(>*#E%QQ#Q3B'B@Y1,A$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!7M2MQ/&[Q;^:P*27!^2D=3^M
M'_#^:AJ=V"%*%EHI,@?!23#D*#H'GA'P4S"?1"A+T1$01U?_ &G0^\J14=7_
M -IT/O*D4!$1 1$0%UE>(HGR.SPL:7''DNRX<6AI+\<.-\\L(-<6RYZHU,^I
MJ+95T]+!$[ C('P'(D_%6RBN%1;+&RHU1/%%-QEKG,;D<]O5SOME5B]:5J[*
MZ>ZZ;K70L8TR/ASC#1N<'DX>16/?;S)?.CSM,[ V9E2V)_#R) SD? A2A?Y;
MG1Q6P7!\P%&6A_68/(\CC&>]4_I"O!DL-OK+162LBEF($D3G,X@ 1Y'F%[79
M[6]%D>2-Z6%H]^6JL7K_ *.K#_MI/^)Z0+[2:IL[3!22W"/M/"UKLY(XL=[L
M8S\5+W"OI;=3F>MG9#$-N)QYGP'BJ!K*T6VET90U%+!#',.KX9&@!S\MWR>_
MQ4=>Y'U]5I*FKW.[/)3P\>3SXG8)^0":&P;7J6TW2I%/0U@DF()#"QS2<>\+
M)H[Q05E=/1TU0)*F#/6,X2.'!P=R,<TI+/;J.H;/245/!,&\ =&P-./A[E2]
M%D?Y?WX9W/6_^8%"5R-[MPN,M"ZJ8VJB:7/801P@#)).,<M^:KU%KNADNU;#
M52Q0T4>T,H:XF3QY*+HVQU'2I7,>ULD;F.8YI&01U8!!'S7CH6WT=3J6]Q5-
M)3S11N=P,DC#@WTR-@1LI0NMSU):;8]K*RL:R1S0X,#7..#RV V63:;O0W:)
MS[?4LF#?6 R"WW@[JHU]U;<=2345JL=)6U-,TQNFJ,8 :<' [@"<+ T"V2'6
M]TBDCC@=U;^.*(^@T\;=AY!$KI-J6T0FI$M=&TTS^"4$'(=OL!C?D>65[6B]
MVZ[A_P!'539BSUFX+7#X'=4/3-OIKAKZ\BLA9,R)\KVL>,MSUF,D=_,I01MM
MO2'<XJ!@C8R&0M8T;>H'8Q[T0NEQU19K?4FGJZYC9FG#FM:YW#[\ X4A#<*2
M:A[9%4Q.I<<1EXO1 \SW+56C(ZZ>GK9*6T4ER+W8D?4/'$,CEN>_Q7E<[==K
M+IBHIZV(P03U3"&AX</5=D;'R;\DT-C0:NL4U0(([A'QDX!<US6D^\C"D+K=
M:*U0LEN$XAC>[A:2TG)Y]P5)U+9K73Z!BJ*>GA;.V.)S9FM <\N(SD]^Q)4;
MJ::6?H^L+YR2_CX<GF0 X#[@$&R:^YT=!1"KJYA'3G&'D$\^7(97A5W^UT=%
M!5U-8QD$[>*,D$EX\0,9^Y5SI >T:'I@2/3=$&^>V5%W'3U=<;+8;C;FQS24
M]+&# _'I8W!P=CYA$KM:+_;+O(Z.WU;99&CB+.$M./'! 4HJ3HF\4M5=*BEF
MM45ONC68>8F<(> =P1W%790"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("Q:NM9!Z(])_AX)<*GJ(\-]=W+R
M\U"$DDD[DHRO?74,B6LFD.[R!X-V7@23S)*X10PF9GV93*(B#*91$#*91$#*
M91$#*91$#*91$#*91$#*91$#*91$#*91$#*91$#*91$#*91$#*91$#*91$#*
M91$#*91$#*91$#*91$#*91$#*91$#*91$#*91$#*91$#*[MD>P^B]P^*Z(B6
M9#72-V?N/%9\%4UXYA0B!SF;L.Z-*9)CJ5E!!11UOK!*T;J1!R%+H$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MYXQA6%$%&9T?\75PU-XJI:&,Y;!C 'NW('R5@O>GJ2Z6>.W',,46.J+/W,#
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M[JN+<\SD@(C4>.TYJ'I(TGI^N=172\0QU3#A\4;'2%A\'<(.#Y%3MAO=MO\
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M?'4&FBB?(YK&-#6N)P",DEZ^C&-:QC6,&&M& / (I>(B=0Y1$11"W\XJ:/\
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M._\ 6N16:M[KTT__ $'?^M7KJZ;V8TX*4=T8047MFKO^V6?^ [_UKD5NKO\
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MZLJ?&4><0E,HH-U] _ZDGXK%DU*6Y_S<_-3XRK.6L+,F0J=/J]T8)[,#_O+
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M9R)&ARRVG?W*I=',QDLKX<D]3(6#/AL?S5N:,$KTJ3N'BY*>%YARB(K*"(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M5(J.K_[3H?>5(H"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@X+<KD;(B
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M.N9;:&6JJ'>A&W)6@=2:BJ;]7.FEE<6DYCCP &MSMR6P^FNJEI[!3PQ XEF
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MPJWGR]+'<->W6NE<VV0MI8>Y[_2<?@1LHF2Y:AJ"7.N$K0?[LG"F::@:&CT
MLYE$ -FA96S7M+>,&&D:UVJL==?H7!S;E4.QW.<<?BI>W:\N]"YK:^%M7#L"
MX>B0/ENI0T+2-VC*PZBUM<TC@&$C+:"V#!>/2[Z<U'0WV$]F<6RM]:)^ X?!
M33AG&WZ+1M=15-OG[7;WNBGC((#3C(\%LW1NHFWVU\9=PU;,"1G>#_C*Z\66
M+]/-Y/$G%7SCTLH8"-UV: !LN,\MUV');N&($1$2(B("(B B(@(B("(B B(@
M(B("(B B(4!$1 1<.SW%=<GQ0=T73B79NX*#E$1 1$0$1$!$1 1$0$1$!$1
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M<$_[RAYJ&6U:3MDE4'P5IKNNB QQQM(&_ >?J@X]R"]VK4\-PNAM[:&NAJ&
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MN#>V!CCR!:?Y*;I)XI6<4,C'AVXWYI$Q/I6U;5]QIDHB*51$1 1$0$1$!$1
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M<,;61L#&-&  , +IPXM=RX^1R(\/EPY=R/FN[-VA<D#"#DNIYXB(@(B("(B
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M^JJ[=62F9[IG-XVNPT M( QC@!&RK]IZ"M.T;WBKK+C7T^'!D$T@#&$@CBP
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M>M)6"]W"*NN]II*RJB8(V23,XL-!) QR(R3\U-1QLBC;'$UK(V@-:UHP !R
M")\M5U#LM;ZVZ']/ZINK[F9*JWUTAS*^F(X9#XEI!W\QA;(1%8F8]*7T?]'%
MCT099;:)IZV5O ^IJ' OX>?",  #(7-ZZ/;;=]<4&J*BJK&5M'U?!$QS>K/
M21D%N>_Q5S1$^4[V(B(J*+U%_H+?]H/P*E%%ZB_T%O\ M!^!2%J>TEIWU/\
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M&YTUWM\=72N#@\ N&?5..2^5(J>4.RTCR5\Z-]6R6"M%-7.<**79PY\+L_\
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M).VID>WJ'E[0TXVR0.\.0O6L1TRND+7UNT1'2&XTM;4259<(64\8.2W&<DD
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MVB(_+75K.),>:G _]FH>UL!DQRQNIAK0!E4M[?8X-VK%?PQNSNE=E>\5-U>
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M>='E!H>MNT]MJIY8Z\M_92 8B#2X@ \SZV-_!79$3-[3U(B(B@B(@(B("(B
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M'"L.;6=#+M)1Y;[C_-55U*<;-^Y>1ICW[8\DC<(\*PM5JU#;):EX=)44V>1
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M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1! :G]:/\ A_-0</K*<U/ZT?\
M#^:@X?64H35O[O@IRG]4*#M_=\%.4_JA0/5$1$HZO_M.A]Y4BHZO_M.A]Y4B
M@(B("(B B(@K&O8^LM].,9Q+^15)%,.\+8&KF<='"/\ YGY%57J?)<^2/J>K
MQ+:QHD4H\%SV0'N4MU/DN1!Y*FG1Y[10I\<@NS:92?4>7W+@P8Y;IHVJ6KK:
MZ>V\<8)=&[B"K=FN\,(:VKCXO:\BMHL@<X.#F@@C&"JW==%TU4YTD!ZN0[G
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MKL'#OYJ AU'#P@U# P9 R'YPI6*HCG8'Q.#FGD6[J8F)9VQ6KU,,SB R/%<
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M9LO&.17F]C,Y.5,]E:Z0$51(P$.RCI7//,[K-JHVG(:W)',=X5OZ,]"3Z@N
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MO[+[;>L?B.MC/#40\C&_O&"@GL!,! B!@)@(B!@)@(B!@)@(B!@)@(B!@+C
M7*\W2 ?^Z&]!V!VRJOKG5U%IFWE]0"^=_HLC:=\^*PM<Z\M^GJ=\4<\<]<00
MV)ASPG_6QR7SU?KU67RX25U=(72G9K2=@/)=.#CS>=R\WF\Z,,>%/;SO-SJ+
MQ<IZ^J>Z225Y(XC^[W-_!9&E[)4W^[PT=,,Y< ]QY-;S/^/-8EKMM5=+A'24
M$+Y99/W0,D'S\E])='^CX--6\-P'54G]9(1N?+[EUYLE<5?&KS.+Q[Y[^5_L
MG[!:Z>U4,=/2QL9&UH&&C&2!@G[E)[!=0W&P[EVQLO,F=R^DBL5C4.<!,!$4
M),!,!$0,!,!$0,!,!$0,!,!$0,!,!$0,!,!$0,!,!$0,!,!$0,!,!$0,!,!$
M0,!,!$0,!,(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B((
M#4_K1_P_FH.'UE.:G]:/^'\U!P^LI0FK?W?!3E/ZH4';^[X*<I_5"@>J(B)1
MU?\ VG0^\J14=7_VG0^\J10$1$!$1 1$05G7C^"WTYSC,OY%4<S#VBK9TGR=
M7:J0YQF;_P"Z5K?M(]I<^3]SU^'7>*$WU[O%=3*3S*ANU>:&KQWJCJ\4R*@C
MO43>;OV<!C,X[R.;EXFL\U#7N)]26319XF[EJK:9^S3#%/+ZX=*RIDN+?3:&
M1-Y8Y_%8!EF:USG./ T<P<[+QGJ)R> TKCW CDN*>BJJR0-G:(H@0<9YA8S2
M9]O5OR<=*QX1V254<D9BI^-[Y.1[E>;&74]MBCF]=H[E#T\4%,!U+&Y"RNU^
M)6U8U&GFYLUL]MRG#4 C=0MSM5/5N+XSU<A[\+IVL>*ZFL'BI94K:GI%?Y.3
M%Q#ZGB9\E8+12P6R$MB;AQYGQ6%VLGD=EP:G/,Y34+3%K3N4Z:P=Q*X-7X%0
M7:5U-2I1XQZ3IJ_,KCM7O4#VHCO3M94'A"?-5RP?FO-U4._90?:CXKKVGQ*G
M<&DRZ=O%G9WO 785CLXR.%0G:B.1"Z]J\TW"/!.=K<,[K@U?B2H,U7FNIJO-
M1M/@G'SMD:6O.6GF%6[C;9&2&2D(P>8)7N*D>.$-1_K$^Y1.I]K4FU/2)BAN
M(?Z#&MP>9/=\EZ?2E33O+)72-(\ ,*0[3L<O(7FZ9DFSV@CQ*KX5=$<K)'X1
MS[Q-42,$;'RN8X'#CAI^2V!7ZY=/IUUMM]M=332M#'28'"/$JH1RQQYX&M;[
MEZ"JRTDN5J_3Z<N>MN1,3>?24I9C#3,8XEV&\_->G:P!N3E0CJLGD=ERVI>\
MX8"X^04[(U'I."I#AZRX?5\+?64,>O )=!*//A.%XOG+F.:WT7#Q59F$XZQ-
MN_22EN46"US!-(3L#R"C'U%33/>6R$->=FM/+R4='<!3%XF:[BSZP!W6,^[Y
M<>HCD?+W9!P/N64Q,R]:ML-*)=U49#Z<H8!S)7-AJ2^ZS21$F'AP/?LHNEM_
M7%TU<XOD=W-Y!35)P4T8CI\-\U>M=./E<OYL>/V6,5(<!OE1MXI34.Z^ ALO
M+.5C]J]+;EXKNVJ(.%=RTW6=U14ETKHV&-_7$'P"\J&BJ;A5 RMX(>_).2IP
MU#7'+FKUCJML,P%$5B&]\^3)74ZC_9.4<C8(8XFC' ,;++;4Y[U714$<CDKT
M94'Q6FW+&/\ E8FS@<W8SLO&:X,B>6L#G/',!1,<CYYF01>O(<$GN"P[S4LI
MYW4E*<MC.'2=Y/@L[6UZ;<?C3FMXPF);Y+&TY9&2=N'B[E ,J)JBO?\ 1+9.
MM>?VD'CYC[UD65IEK(V/;EKN\\U[5%8S2NJ8ZV&+KHX@2YO$!ZW-4W,^W9?%
M3#$Q2-VA!R5$HED$S.KD8<.:[F%;="U4DUMD:\G@!&/O6%J6MM^K;C354%%-
M3N:,2%QP"-_$>Y3%O9%1PMCA&& +6,<5GIP9N7?DTCRKVG0[GE=V2.:TG._<
MHV.HSS60V88R>2G6G-;7K3O77'JGQP,?^W<,X\ H"X7LP2EG;7%P.[6L:0%'
MRD2ZQG9(_!+0&GQV"AX+?*RN,3V$OXL9*SM>?L]/C<6D]V76VWYIX6U3B6NY
M$-&<^:LI&,%A!!&<K76IJ04-O@.>&8GEE6?1-::NS,ZTY>W ^Y6I;\N7E8:5
MGYE/2P$/(SD87F]I+=L87JWT3@KL1ME:PXO+2-JZ3M,,D3V@QN"U[7Z;N$-2
M6TH:Z'D#D\ODMH/(:TO>[ 41)>: NZMDA<?]59SK?;HQVR1$^*(M%L%!;60O
MPYVY=\RO.KM=*]V7QQN/@0IV)\-1D1/!=X+K+#D;@<2M[]*:G?M5_H^"!KNI
MA8PYVPL2>#.<#*LU13C!437LZBFD?C9HR5&]0TI.I5R:-KINK;@O^Y>$]HJ^
MK<\0\;1[&ZZ4),[Y9 27.<3]Z]J>ZU=NJ@]CB1G=CAL0L?/MZWZ/Z/*/:!EC
M:<@C+@<$=X7%+5U5MFXZ65P YXW#N[?*O]PHJ345I=7TC!%<(FDN:W][;]%0
MS$U\66@X'-OFM(EPS'VM#86D*V2IM1J(']8X?UD)Y#GR5[T]>^I<UKG.?3GG
MGFSWK2&F+G)9KI')G]DX@.:/>MI.ZF4-GHW#K7#):#LX>"UK=P\CCQ+9\,T<
MK ^-W$PC+2.]>N50K%>74K@ /V?)\1_<_P ?DKO33QU$0DB>',/>%O6=O)R8
MII/;V&X1< Y7(.ZED!<'/<N40!GO1$0$1$!$1!QOGR3#O%<H@XP<>:ZAKN,D
MD87=%&AU#?%='1DQO;D'B\5ZHI%3O&A[1=FN[32QMDQLYF6X/PQE:>U_H26P
M/,L?[2G)]%XR,>6.2^C#SQCN6)6TL-;3F"JC$D9[BLLF*+QV[^%\2S<2VZST
M^01%EP<X %25-2T\X D:6_ZP[UNRY=%MJGJ'24\\L))SCF/P61:>C*UTKNLJ
MY):DC=K>3?CLN6.-.WU4_P!J,7R_4^32XL=0W+J=KWQ^/<N8;%<:A_!%3R//
M^J%]/4=-'20MB@C:R)O( ;+(P=RU@]ZV_2TT\N?[4<F9ZB&D-)]%=362,J;Q
MPPP@[MR>-WO'ZK<ULME-;*2*FHHFQQ1@  =ZS1R7*VICBD=/$Y/,R\JWEEG;
MC!RN417<KC!SY+ O]*:VS5U/M^TA<T9]Q4@L>XAQH*D,]8QNQ[\(K;U+YA#6
MP7*:/!P"1NEXC#X 0-UA724MN4K)LAP>[\5[OJA+3\+CN$?%<B(KFFOVE$0T
M !XP-\J6HX ,9"QJ>7)(SR6<V1K8SDHRFLUZ<U?"(SCN58EJ?VIP2L^[UX9&
M0TJM";C).436-I"><N"CYWXC<3XH^7#5'5,Q>YS!RPH;8<<VLQ;HUS)&D.:X
M$9P"L-SY'-QCT5D"G+G#.25F140QC!1[=;5Q5U*&#B'[*7M7$\[E=YJ 8PUN
MZ[6P=0_A<,%%,EHR4G2UVYA9A6ZV3AC<'*J-!,'84Y!)ANQ4QT\+-U;2R=:'
M#8KQGI&RQG+1E1]%*72 95B@:"W=:1&V=8\I[4RY4 A+B!\E$QY#B#W;JXW[
MA##NJ742\+R!NHF/%MBW-HC^6[>@,2.I+J\'T"YF!]M6GI3E=#HZLP2"X-:2
M/X@H;H'X3IJ=[1ASI,'X95PUE;_I33U93 %SG-R/@<_DL[ST^VXDQ$5F6AM-
M1M$3#C?&Y5RH6@ *BV2H=32.IYO1?&>$@^2MM)5@M:,KS;[WN7U>IO2)A9J0
MM W65VAK!WJO-K UO->,]S &,J8O$0Y_E3:=:6">O#1S*BJNY<]RJ[7W=H!]
M(*%?7U-;-U%%$Z:0]S0GU6]-JX:U]RL=9=L9'$57JV][N#7G.58[%T<W>Z@2
MW*3LD)P0, NQ\]EL*Q]'UEM;6.-.:B<#>25VZO3!:?;FR<[%CZI[:BLVF[YJ
M-Q?3Q=73YQUDF0W[@5L;3?19;Z-S)[J[MDXP?6<&CX# /R6PF-$;0U@  \ O
M49QOS753#6O;S,O-R9>GC3T\5+$V.GC9&P<FM& NM94P45.^:IE;%$WFYW(+
M!U'J"@L%#)4U\S6!HR&YW<? +YYUGJNZ:SJGM<>HM37YCB:-W#ED_>M7(E>D
M+I#JM2SNM]E?)3VX>L_8.?S\,^7>H335C#Y _A&3N3DDN\2O>Q6;):&L#1G<
M*VO,%KILD@ #.''"#WACAH8MF@#F .]1-9?*BKJ>QVJ-\U0=N%@!PO6QVFZ:
MRK28V/I[6#A\[A@GOPW/P\>:V]IO3UOT]2"GM\!9G'$\[N>?$H-;V;HTNERE
M;-J&K$,.<]5$X\1]^P_%9NO]*V736@[C+24;>O+"P2O<7'):[Q)PMJ#N54Z4
M+%-J'2%71TI_;8XVCQ(!_FIK[A6WJ7R0QW$[!P"INAR"SAWV"B7024M0^"<
M31/+'!35&0US3D87L8JQIXF:TQU*><PRTI:]F<C"J,M+)0UW&YIX"[.0?-7*
M.OA;&&N(67'!3UU,2[!"M-=SMS1:U8U/W9%@F9+20OCR7-Y8/XK=>GXZ&_6&
M%U730S'AX'\3!G.-UHB@IG6^K!@.(MR0?<MO]$U:RHHJV-FPC>#CWY_DN+ET
MUV]/A7^J:L>_=$UDKN.2W\=!,>1C<XC/N)6N[SI/66DW.FI)1<:)F3Z&2X-'
MCZ//'FOHE<>.=PN%Z;YPLG29U4O453GT\[=BQV%L>RZY;+PATF<\@<;JPZCT
M)8-1M<;E1 R.YR,/"Y:OO?0W<K8'RZ5N#GL&2VFFQ^.0@VY1ZAIIL<9+??A9
M_;J>1IWRWW+YM97ZIL#^"YVJH: <<4;"X'Y94W0Z^;@"4R,=X.!'Y(-S53X)
M">%S3GF,JLZ>(I>D2I@@PV*HIVO<!WD%YXO?LJM%KADHX:9L\TGA'&3^2N^@
M+-4LEGO%U865M1AK8S_U;!N!]Y078;K@N 1ARW.,>2YR@ Y"90G 74'/)!V1
M%U.4'8;IG9<-.V_-<.V!R@X=(UO/*[!P(R,X6)5U]+1Q&2IG9$P<R\X6N-7]
M*]#0.D@M#6U<XV#]^$?S5JX[6GIEDS4QQNTMD5M?3T=.^:H>&1,W+CR"T[KC
MI5#F24VG6N<.3JAP&![N:UQJ'5-VU!*YUPJ 69/#&P8:%! <7HANX[^0*[L7
M&BO=WC<CXG-I\<;VJYY:J1TU3*Y\SR7%SCN[*R['9ZR]US*2ABXI7<\YPT>)
M5BT9H&YZBE;)*Q]-1[<4SA@N'D"M]Z3TO0:>I!#00\.1Z3R<EQRM,G)BD:HQ
MXW!OFGRRHOH_T+3::HVN>&2UKP.LEW)!QR&?>5=6@CFN0/!<KS;6FT[E]#CQ
MQCKXU<;YYA<[HBJN(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@@-3^M'_#^:@X?6
M4YJ?UH_X?S4'#ZRE":M_=\%.4_JA0=O[O@IRG]4*!ZHB(E'5_P#:=#[RI%1U
M?_:=#[RI% 1$0$1$!$1!0NF"7JK+1'.,U&/_ +)6IG5'?DE;BZ4K8ZZ6FCB9
M,R'AGXB7=_HE4"DTG0Q;UE=Q_P #A_)<^3]SV>%;6*%:[5X.(^"X-3MOQ;\B
M5=745JIH^&F@B?YN6/);;54,Q,SJG?ZAY_<5G[=GDJ':,<\GW%.U>/%Q>]3%
M5I>F+B:6JX?X@3^2C:C3U1'P!D[7\7,AIV4Z6\ZZ[8YJ@!O@^\KTB,T^\3'/
M]P5CL]CM5#PR5KG33D9P&' ^Y3$EP8ST:1AC9RV8Y1VSF^U%?'4Q9+H7L"QG
MU(!])V/N6QXKIPLX9(Y'_P"XY>,SJ2J),E"7=V>$A-2CYC7@JV]QS\4-2/5V
M^:O1M5ND/^@2;^&!^*PZO3U-*T"&WR@@\R]JGQE'S84\U6VY#?BLNAIZJN<!
M30ND/OPKK26N*F8WJK2TO YR/:?P*DF27(-X8Z:*)OD?U4>,H^?"HPZ8N+@"
M\LCS[1RNT^DKF&YC?'(/(JRRT=?.XE[&D_X\UZ1TUQ:T-88VX_U"?S4Q6R)S
M5C[J%4V>YTP)EISL<9XLJ.<*AL@8^)P<>2VCV*Z')[0&$][6.7066O?(U[ZF
M1SF^##_)3X61\^OY4."PW>=H<VE<T$9!)YA2<&CZUS>*JF;&!W85Q%CK'DEU
M14DGPP/R7=NF)W;DU1/\3?Y*?ERK^HK^54_R<H0.%\TA>/ ?JO*KTBXMS1U8
MSX."NK-+R@>K4_;;_)>[=*3?W,A_B>U/ERB>56/NU9/IVZ1YX8A(!S+7+"%L
MN)JXZ<08)[R?>MR#2<A]:'YN:N?\CN)S7.@CXAWY"GY<J_K*_E0;7I:*(<=V
MJ0TCE$T9/S4G)!;X &PT\..[B )*N#-%Q\^KA!]R]6:-B'[M./'T2GRY5_65
M_*E=BM-0P]IBC8<<V#"CI].VI[B8JIS![B?S6RFZ.A!R>I^17L-*0 ;. ]RF
M,:)YE?RU(_2]&?5N(^+<?FL*.P1LK&QOJBZ GTB!W?-;L;I> 8_:._Q\%ZLT
MY"W/[63?P(_DI^6?KHAJF"TV&/&1+,X>\?FI2FDM=*WA@HFCPXF@GYK8G^3T
M./ZZ7YC^2?Y.P#E--\Q_)/EJ?K8:YDJV$GBB9P'N+0L&MMUJJV$N:87GO PM
MINT[$1_7RY]X_DNATXWZQ(?>1_)1\I:.;'Y:.K=,\0<:>KC>P;@."\[1IF2J
M<YTDT,3&[9',K=[M, G/6@D<LK&GTIQCTFT[_(M/\T^6G]96?<J)3Z=M5+'D
M\4[N\ G!^]=S9+95 LC@="?%6J71NQQ3,_W"!^)6%)I*6/)$=0WW2,5?ES^%
MZ\FGVE1[CI*L@)-(_K6#?&,*OU$-52DMJ8GQ$;<1W6SG6BN@/H3R^0>W/X!<
M/CKFMX9HXYA_K C\U'A9K'(K/W:M94\1.#[]UW;/CU<X\2KS/88;G74L,M ^
M+C< ]T;AR^]6EG1E8FMS(^JX0.]S?_2IK291;F5I^YJ-E4!WCS])>K*H;^D,
M'E@K<=NT=IV+T&TQ+L_]9C?[EG56B+)41\/9>K_@_P#96^6PCXA3?IH\W&2D
MFCG8<\.Q7LZF=5U1GA]-LOIX\2K1JKHVJ:6-TMJ)GBYNC)'%^2ULZHK+1.^*
M2.1G">1&"/YKGR8[/9X',QWB=3IL"W4PH(3550#"!L%3=2UXJGSRR$D//"SS
M4=4Z@,[?3,TA[FD8_)8]'!/6U0GJF\,;<<#01_CP5(BWK3><U:TM>)W*[6F4
M1V^(R['&^>X+/97M ];900F:&.DR7 >B,<EC]LF<X< ;P^[DK6R:GIC@X%LF
M.+3.EPIZUCP.%VZS63'8.YGY85&@J9'$<;2 >1'<I>GK'0N;%,[9W)RM6^_:
MG(X<X_JAQJJ&2&MBKJ3/$TC)'N7JW543HVRFC;V@#8[;GY+.ZQLL)BD&05"U
M.FHY7N?32N&=\''\DFJ,?(QQJ,L;AXUD]9<9^OG;G/)N<@!9MI=5PSAD7'&S
M.X#L!0K9ZFTU!CDWQMERSZF_NFIRW9CO$%9=P]&+4M7PI$:7ZR7;MG'!,?V\
M.YQWC_!"FXW<3-O5()"UKT?MF[=/52 CC&#GWC^2V!%*UKL Y"Z:S^7SV:(W
M]+SU!%)/9ZED!(>6#!!P0M10"5I'[8M=W;K=;",8[CS5 U9I:3KWU=$WB:1N
MT$96>2)GT[.!R:8MUR?=$TETK.L;'D"4#8MVRKO9ZSZ0I>-PQ(S:0>!6MZ /
MHYPXPRN>SDW&ZO6AZ:=D-5-4-+.N<"6GW)B\H]IY]L4QO'*6DBV*P*ZE$M/*
MPXPYN%.OC!')8LL7?A:3#AK;_,U/3/=:+I+'*W]FUY(SX94O='T58QLE-CCQ
MN"%8;]8X[@"\;2C<*FUMJK:<EO4&0=Q80%A:DQZ>QAYE+:\YUI[VNY/MHEZG
M<.&#OR4%;29Y:AW[N=L?!>KK;<JCB8V(QM=L22/YJ9H;4+?2]7C+CS*G'$Z[
M4Y.>EI_P^T'/3X)P%8M,WKL[12U3B&_NOSN%B5%/SV494P'?P5].;VVK"SM<
M(E@D E SGVAY^*D[#>)*2;@PXC]Z$GEYA:=MMYJK;(#&[+6D;%7NVWNEOD;0
M^3JJIGJD;95ZVF.G-GP>4-P4=3%50B6%P<T@+W:,%:]L=TEHYW!X =G,C.X^
M8\N>W-7JCJXJN(2PNXFD+HK.WC9,<XY9*+@E<@Y5F0B(@(B("(B B(@(B9&<
M=Z BQZRMIJ.(RU4S(HQS+CA4F[]*-GI)W0T+9:Y[3@]6QS0/B0@ORZ_!:DJ.
MD^[SO(MUHB:P^JZ8Y/W."PI=5ZPK&D-=14^3D.C:[/N]<HC>FYG 'N7)V;R'
MQ6D/IK6@_P#Q^,CW'^:]8M6ZRHSQ2LI*IG>'-=G_ (T3]FZ1A_)WP7)] ;#*
MUC;NE)D>&W:VS0.Y%[!D?(9*L5!T@:>K#@5_5N]E\4C?Q:A&YA;PB\::I@J8
MP^GFCD:>]KLKVR@(B("X>,L<,9V7*=R#2O23T>5$E4^OM3 ^-QR]@&"-EJ2K
M,U&_@J&.!8<8SOA?8>"1S5;U-HZV7V%[9XNKE(/[1FQ^_*/+Y?PVF;ZH]OEC
MM;7.+Z>3)_>:=L+I-<). C)^:L'2-H:KTS6F1K3)3N/HR;;[*FQO#V9^!\D?
M/YN+;CSXV<3RNFSQ$K$'$UV&KVG#FYP%VHWM<"7;$*%8]=/"1C^K)=LL6GA?
M(][FC( 4E5.;.YK&<E,4\$%);'\6\CAC"-L63Q5ZD8"!D;J<I:4$ X'R4?3T
MYX@K-0P?LAE2G/F\NT7/2-;N HVLI!P%S-G#P4]<SU*BW2M>TY.,HK@RVUTP
MJ*J,;AQ$JPTE8'C8JFUCBVHPTY"S;94NX@HVWRX(M7S7^AEP0588*MH9NJ9;
MYB6<E(/J"QNYP,*];/*M%JVZ>FH*L.!PJC+*2XK.KZKC)W7:QVBHO-Q@IZ2)
MSW.=O@; 84S;;T.%AM>T1$=OH+H.@,6C6.<,&1W%\UL C).V6D8*B])VH6>P
MT5'MQ1Q,#O> ,J7X?-4?64C58AIKI(T#5MK9KK8VAS3Z3XF[8QO_ #6NH;U)
M2S&*K:]CV[</?E?56#XJ$N^EK5=@[MU*Q[G<W#F5SWX\6>E@YUL?4OGYNH&E
MN[R/ +F.>NN4@;20/?GD<X6Z(= :;MY=.*%KG-W'%R7A&^.-SNR0QQ-)P&M!
M3'PXWVUS?%YB-5A2M-='5;<I.MN\_51Y'H#P6T+%IFUV6-HI*.(R 8ZQS07'
MXE2-MIC# ,G<X)RLW 6T8XJX+\C)E[F7+1Z(VPA]R\YYXJ>(OGD9&QHR7..
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M["BI&\J:+[ 64$4Z1Y3^6/V6F^KQ?8"[B&(# B:!Y-"]41&Y>8C8.3 /@N0
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MVRO!<R1H=[U$U]@#FN]$2,[L()^U:@M=TX>Q5T$KG#/ UP)"E5I>[Z-B+S)
M'Q2>1PLBU:EO^G<15+#<:)N <C]H /#D.2#<"*NZ>U=:KRQK8J@15'[T$OHO
M!_!6 >*#LGBB((O4-EH[W;WTM=$V1I&Q(SPKYIUUT=7'3]6Z6FBZRF))#F@X
M ROJE_JG'->;F!\9;(P.!'(HY\_'KGCQL^)'PS-/"^%S?$%1<_&R;JV @E?;
M<MAMTTO'+11N?XK073'HEUINIKZ&#_-7[M(Y#Q4:>9/PSY6YB=M?6.VY/'+N
M<=ZE)J'K)03ZO@NUEE:YF';.;LIEO">6ZEX>:?EWG:)IZ -/I 94BQ@8S "R
M.K[P%YR,.Z:<TY?.4)<Y&AQ,@R H&I>'N/5MP%8KA3CA<YW/.RP:>A,GI.;D
M*8AT4RQ2-*X^![R=MUPUCX90>$@*XFD<UOHO#?@L1X+,]8!(WO:[8J=0UCFW
MUJ(V\[74C#1DC<*T:?MXOEVIJ'B(Z\G?R )_)5.2G:8S/2<3BWUXO >2W%T(
M:9EDGBO4T@?"QI,(!W.1C?YE-=.G@4C-GB;PGZ/H<LS3Q32R3#P<"W\U==.Z
M5M-A8?HVCBCD/-Y&7?,J9W$>!XKT;G&XPJOIZXZ4F?& ?X*Y1$7$1<//"PD\
M@@K6K*\PM$#"07**T]":JN:';L8,E1U[J^UW6H<3Z(<6#PYE<4VKK5IRW2R3
M2B2L<=J>+TB[\AR\5M^VNW-$^5]-DR/9%$Y[W!K&C)<>0'BM>ZFZ3:&D>^DL
MC75]:-B8\%C?>?T5&O%WO6K9>*L_S:D_=@9MMY\_Q679[)#1M_9LRX\R5BZ8
M857)?M22%]YKI.SDY%/'(6Q@>! P#\0I:UV6GI( UD,;!C;A: I6GI>$<EGP
M4[CR01\5)P[D;KV%%Q]P4W341D.>$KO.(J.,F5PSX(C[H%T#*5I>X#(6O];Z
MC=&YU-3O(D)[CY*=UAJ6*FCDPYH=@@!:(O-X=+6SOSZ3W91AR<OC'TLJ2M,]
M6V'?JP=U+Q0\0+HO5 R J5;Y9#.>/F5>+%*',#7[D<D?+<VDQ;4RO71EJEMH
MN#6S.$<4AQ+RP!C;[UM*[=)UCH) P2OES^\S!'XKYVO%.8V<;,_!0DMS>R-\
M;W9/FCIXW/OBKX1V^O-/:NM5]/#053'R=[,C/XJ7N5;#04,U55/#(8V%[SG!
MP!DKX?L]RK:6ZP3T$ICD8X.\EL'5>M[KJ.@@I:EPA@B;PNQ_UAQC\OO5L=?/
MT]?%SZZ_Q.I172=JNMUO=@> QT</H1L/AD^E]ZB+59VQM#>9',GO7>/JF>BT
M^97I)>!#$1& <;;KUL6.N..W)FR6RS]*2;/';1DM&VZPZK4=54>A3Y Y;* F
MJ9*HDGF>0"F].6]AF:Z4N<\D8:W=3&34;4^3UJ?::T_0U=?*TR$EYY97T;T>
MV8V:PQ0R =:\![C\%6NC#3?!#VVJA<W/]7Q>'^,K931OG&-EYV?)YR]7B8O"
MO;LB(N=U"(B ND@R6KNNDAP6H?U8U=5PT<#IJE_!&WF5I;7O2C)4B2AL#G,B
M<WA-1D9/N*W1<:"GN%,Z&J:9(G<QR6J]3]$5-())K%(Z%P&T+G>B3\L_>M\'
MA$_4X>9&::ZQ^FE)I9)YG2U$CI'N]9\AR2?BNF>8P0?$]ZG;UI2]6=[NUV^7
M@&W'&.(*#)VX=L?(_>O6IXSZE\U:N2D_5#H'.&=R2>6^5R![(P>_97#2FD8;
MU2&I-:6XV+6_N_=Y+9>G.CK3C>'KHWU$@/[[L _+"QR<BM)UIU8>'?-WOIH:
M-CI3PQ,D>[R&58K1HB^7/A=!1.CC/[\@+?P"^E+9IZV6YH%'2LC'EO\ BI5C
M P8:T8]RY;<N?M#T,?PFL=VEI&Q=#LLH$EVK&X]B,EW\L+8%FZ/[#; TQVZ"
M61IVDE;QN'SSA7$<D7-;+:WW>ACXF+'ZAC14S(6!K&-#1R VPLAH ;MR7.$6
M?;HB(CT(B(D1<9'+*-.<J-P.41%((B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M((#4_K1_P_FH.'UE.:G]:/\ A_-0</K*4)JW]WP4Y3^J%!V_N^"G*?U0H'JB
M(B4=7_VG0^\J14=7_P!IT/O*D4!$1 1$0$1$!$1 QYH!YHB B(@(B("X(\UR
MB#@#'>N41 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!,;H
MB#JYF=\X5#Z1KB^!U-!Q%L>'.<.+AXL8^?-7UQP%5]1VBWW:J>VX$CA:.K=Q
M</#X_DJ9(FU=0Z.)>E,L6O'325XNU772EG6/;&!@,;D#"\(::;J07<7#X D*
M2J::GM]\GHZB1L@B/HN:<Y&/)+M=J8Q""A9OR)*\ZU9WJ7V^.]8B+XXZEXZ6
MJGT^IZ6:,NW/#L<=Q7T))!'64A9,QKV2LP\.&5H[H_M#[A>XG 'JX3Q./G@K
M?48X&!ODN[#757RWQ?+%\^XC31&LM+U-CJWNC:Y](\^BX @!0%#-V>7'$,M>
MW@(.YP5]&U]+!61.BJ(Q(P[$%4]FC+%!<1,UDFSLD%Q(!RH^3$3N&N/XQK#.
M/)&YG[LFZO;7:2@CJ(HGRRL&.L:#C!\_<JC%#04N&UEKC81R<UH+/PPMK1TL
M#J9D?"UT0& HVNT[3S,=U602/5)R"KVK,PX,&>E-Q+7=92VVH:>&CC#3R+0!
MC[E5+S:9:!O70<4E/XXQPK8%PTU)2.<Z+CA<>0!XFGYY4?UKH8G4]S@:YKML
MM!QCQ6$UF/;T\>>MJ_2H$,^XW&,<\K.AGQWY'D5E7W3IB:ZIM>9(#N6YW"KT
M,Y:0 "UPY@JNH;1$6A::">,3POE>WJL^ENK-JLVRDC@K+94P/XB&NB9(/$;[
M>]4!E0._A \%Q'3P&5LA:_C!XL<9QLKQ,?=ADQ6O.X7."H$C<CD<<U WZ]SL
MJS21YV\5[T]1L"3N?W5BW>E=4@SP8,OBJ6[].GCVI2\5O"-K;A4RT89)&T<+
MN(8/?OY>:D'W;Z0H(V2EIE8""[.<JNS%P]"8/SW@#FN(VO8/VL3XHNX@9RL-
M6EZT3@\NNDW:GFFN5/*#@YPMLM?Q9XN?=CO6H-.4T];=HL,=U,>^^RVK%+CT
M>0=W^"Z,43$=O&Y]XR9MU9F#G&,[<QONO,@\)R#\56:G4##4U#.N,-+ 2S+1
MESG#Y^!42[4A;)_F]5*1G]]H/Y)-XA2G"R7[725@&X];D!XY7>GH*.IM<@Z]
MD56PDCB=^7S4#;[^V;A;5$')'"_&-U(U]K@K!F3K&DG=S'85Z3$N;/AR4E%L
M_;0O<T@N!(.-QMYJC.JGOK:A[7;YVP>2V3#;HZ. PQ9X.0R<DK6-;&;1>Y!/
M&1#Q>_F%EEC\/3^'6KZO[<T]YKZ&<OAE?C.X=N"K+-5TE^MKZES&0UC&XR"-
M_P#&5&5+K=4P!\3L.QRW4%),(&N$9(8? K*MIKU+T,F&MX\Y]L.BB<65+78X
M^,[>:]Z.5]%70U+<C@YX[UVL3.L-1)OP\16344_/ SWX6U7FW]ZVV1#617&B
MIYQ_6  M<#D@[<_%3-CNSZ.;#LD?O1Y^\+5-EN\ELD+'^E"[U@1R5]H;C27.
M-O9WAD[1L3W*U;3$N+/A\H;0I:AE1$)(SQ-/GR7MGY*B62[2TDI#\8R.L;^8
M^]76DJ(ZB$21G+2NJ)B7CY,<TG3W0(BEF(B("(B M3],NEJFHEBOEHA<^>)I
M$[&-)<X8V.WN6V%U< 006AP.V$'RU07^.1F,\,@)XF$^D#[E(PWYK#N_[UM7
M5G158K[*ZIC;)1U9YOA?@$Y\#E:\OW0W?*0$V:K;5-[FO(!^9 08[-2-&X<3
M\4?J1KAC)^TJY)T=ZUA)#K<"1X2,_P#4C= ZS=L+;@_[1G_J03+[\#D];P_[
MR\7:@(/HO+OBN*;HIUE, 7QQ1 ^+VG\U+4?0M?IO]+KX8O=^@01 U%AV'%WS
M63!?PYV0\C_>4]_R&59:<WAF?<?_ $K$GZ$KQ TFCN<3SY_^R#VH]02, ,4C
MS_"5;;-J:8AO6.+AMS>M6W71FL+ WK'TG:81S,;F_AE8ULO\\$H95,="_8%K
MFX0?0L=727",'+0_X*.KK>UX) SX[?AX*@V:\/<X.BDYK8-DN4<[>"8@GD@I
MUWTY&^4RQ%T$H'HRQ^BX'WC<J3TEK&HM+VV[4CG&/B#65DCML<O2SR'GE6ZM
MH8WQ\;/2![LJN7&V,E88Y6M<#W$(-@4M3%5PMEII&2Q.Y/8[(*]LK34-#6V:
M9TEEKI*=QYQN]-A^#@?N4U9^D9\$P@U'2]G)/")XVDM/G@$E!LHC(PG#MC*C
M[?>;=<&!U)6Q29WYX/R*D001D'(0>?5'/KE8-\L]->+=)1UC&NC<-LMSPE22
MX?ZJ(\8GI\Q:XT;6:7N#Y6,>ZAD<>%[6G'BH2EJAG<X_!?5MPH*>Y4SH*V%L
MD9[BM8:AZ(H)"9+-.Z%W/A>[(_!'B\WX5&6?*GMK6.8.;L0O&>=K3PY])6=W
M1GJ)DW"V-KF#]\/;^&5BWKHZOM!2NJ !,UHR6@C*EXW]SYZ=J=72\<\;21@@
M[9\%[N<8QP@8/ER4/>VU%$YLDD3VNCV<".2V/T9Z<BU/4=J<\?1\3O2;G=QQ
MR\>\*85Q<"]LD5E7:*SW"XLXJ6GFF'_RXR[\%*6WHSOUTD(?"^!N?6F!;D?%
M?0U)14M%3MCI8&1QM&&AHW^:]I)1$TNY,&YSR 57TV'X;BQ?;TTYJ70UOTKH
M]U2][7U3>'B<6XXO$#=2'0"^1M%=J9SW&&*<\&^P'"S8*L]+6KY+Y<6V>W#K
M:>"0D@-_K'@[#W<UL[HQTR[3FG6,J#FMG/6SY/[VPV^ "O/K3DPUKEYLY,4:
MK$:G^5T'AC*1YP<Y1A!;D+IUG!Z[@J/;V]25YND(_=)7D^LIF@\4\0(\7@+R
M;7TF2&U4&VY],(,ICR<Y:0H_4=R@MMIJ)ZB5D36MYN(',X50U9TET%I?)36\
M&MK1L&M:>%I[N([9'N*U7J*XWK43C47B;]ES;#$ U@[O>?B5:M>U,D^-=N+S
MJF>K=)!; 6M)/%)G.?-9=CLC>!LTH,DCMR]V^?FH6!D-/%&'8&W(;Y5RH:OA
MA9U-(XG'^.]7S7BL:9<3';):9A)4M(&YP,!2=-#Z.P./<HF*Z%G]?2N8/'_!
M4[:JVEK2&PRX=[#AC\5A%J_:7;."\,FF@XB !LINWV\O;DC;W+WMU!Q8+VX
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M^3%-&8BXR<\ERK,A$1 1$0$1$!$1 1$0$1$#N58U1HFS:AB<*VD8V7?AEC:
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MK]U@<(YXVLD8'L[\KB"QVXR=9V=N5AT\V1C*D()BW&^RF(C[LK1:?4IFB9%
MT-AC:QH\%G,=L0.141%," <K-AE'BI83$_=F1G.5SA>,1W._->X17T\WM!!"
MP7Q8<< J2QNO M],J)6BVO;56I3,;Q,6NP6O<&_-<6RN]$B4XF;ODGF%*ZZM
MLD56RKB!ZLY+@/%5VD8Z649;@<\K+4[>M6:6Q+.P"> /;^]S6%44_/99%A8Y
MT<@!) .RS9X-SLM''-HB=0K,U/X@_)<4<\U!/Q1'92T\._)84L.YV4:3O:QV
M[4M+-&V&K&'>VXXX?<K);;AU1#X9AP<FR@[>XE:MEIP3CEA>]#75=&X!DG%'
MG=IY8\5>MM.;+ABS?=LNK*DADN&2]V^Q]RE<CQ6N+=+QTD<U*\R1'UAGT@58
M;=>7,:&2$R-]PRU;5M$O-R8)K/2S(O"FJ8I6Y8\;]Q7NKN:8T(B("(B B(@(
MB("(B B(@+C&XP/T7*(*AK70]!J6(R%O4UP&&3M&^WBM.UC;GI:Y"BO$;PP'
M$<_"0QV^.?+[^]?2*A]2Z>H=04$E-71!Q+2&OWRT^(P@U=9[X.$%KOO5VM%_
M)X07#'O6G;_9;GHRY&"IXI: NS%.T9'N.1[U+VF\!QX@_/%N<>*#=D5TAE9@
MXW\UBUW42,]'&?)4.@NA]HJ5;<BX <2:(CRGQ9E1$T.=C&%$U\U)2-)J:B&+
M^-X;^*PM4:CCLU%USLF=VT;?:/\ @*F62R5M_>;A>JES8WG+8_!OR5HAQY^9
M:D_*P1N5H-\M#GEAN-(WS,S?YKV/4OCXXI&R,]II!!4+7Z-L\D3FM8YCL;2<
M1Y_-4/MMRT9?HJ2JG=/;ICEKR,@<QWCR"C2/GYL?>:D1_29_\MC5=1'3Q.>X
MMP/$JCW6Z35DCN!Q$:R+Y<34O] G!P<=V,*&#2]X:P;%1K3LBU;1NGIT93];
M+EQ)4U04(&[FX\L+M0T@C;EXR5-45*]YXL;(G6W6"D:>;"/@L2_V(W2W.IXR
M(W#!#B/ Y5DBHB[F5[NIC&, 9W4Q.E;XZY(\94&+3=-:Z:%[@^2N+0/#/BKQ
MINV]3$UN,.YY&X436\4UZCC<-H\JZ6B$-;CN7#R,F[3#V?AW'KQL,3'W_P#V
MDZ:+A8 LH-^"\VMQR7LW<KGKZ6M.Y S*<&,K*AB+\876:(QDDK3PZVRC)WI$
M5T(>PDCU>["IS(A2WQ\!VCJ&D;[#.,_DKY, 00J9JF/JIXIV#=CV_P E2O4[
M=%9F])JK<H,=1(PC!:XC!YC=3^CZ\4MPZE[@(Y>\G RL+5%-U%='.P>A-Z1/
MQS^:BXI'1D.:?2!R%ZU8\Z/F[VG!FF&\Z&)KHSGN6%6-#9" HW3%Y[;;P_B_
M:M'"X?!9DSR]Q)*X<D167JX9FT[1EVC:ZG?MD;C??!\5KIUXN=OJIZ>EN%9"
MR-WHM8XEN#OR]Y6Q;K(&POSR#250(*854M14=SG[?#;\E'']MN7_ -&'5UZN
MDSFNENE>)#MQ<9 "QKUIZ:_4+ZB:ZNJJJ)I<T/=QGW<U)"E9R(0TA8!P.<W(
M)/#X+OB7DYL5<M9K;\('0+17026UT+A51N&'!V,CS&-^16R:*R34AC;*_A .
M,EOHJBV&$6"].K6./5O:&X R>_Q]ZVDV\4-PM<)<X.',M!P[O\U69<_!K>F&
M:9/<*CTA:PH-+@4U(7U-TG;B.%IW&<C/?X+RZ+K7+':ZZZ7<\%?7.XPU^Q8
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MS$R$D\O6P[/X!; !SA1:LU6I>+^G9$157$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1<.SC8H.4Y\BNA=CGL/%8M17TM.TNFF8QH\2B8B9],U%7JC5=!$>&!L]
M0?\ Y+01]Y"C9]17.?(@@BIV=SG'+OE@A1M>,5Y^RXY SEP6%5W>@I1^VJX
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M.GB:/!K $&KW:CN%4.&WV>JESR+\-'WD+T91ZSK&CJZ*DI8S_>N#B!\'K:
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MQ=L8Z*9KO59^[NHZKU)72QR0R3%X=NY[>0.=A^"YM6H7VJ3K6R1FIG]$-!
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M)//)/*]SI'G+G%=^+<QV\#DVI6=5>;CG=NZXSXG?N&%P.>"/<1WK-I+;7UA
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M"UJ3#OULE/41<,)D,<>#CN) _DN9KTV/>2E</'913=3P4SYY0\%\A&1[//\
MFHNX:OZQI# T_!,,^/32F.96,7MKAEM([!\ER;O(1Z%$XGY?FH6WZUIQ3M9.
MQC2 !R7>OUA#)3NCI2TR.&!CN6DY.FF/#-YUIZ56H^.K93 &&4[$]P5:NM]N
M@J'03L@C(Y$1C)^*P(X)KC52>D3(3N\=RGJBE;)2-@N1#W#U91S^*Y+7O&YA
MW?(C#,1:NXG_ (1-NKZLR,+JAI:]P9)&YHW:=CC;8JWV_3U761RLE<PQ;.CD
M!W;Y*N_0;'@-C#G/.P>.16S]-14MNLT-*'<50X'BX3DCFNCBS&3]SSOBE<6.
M-X+=H#Z=GLEOFBBC#L99D#(+QL ?BJW6U]9<ZALU34!V7 < QPM&/#GS5MJH
M8+?!4PU<;JALX<YSG#U1X^\<U!:.T^(KP\US&NA:.)E02.%S-OS./@NB]?)Y
M-+17]JL5U+)7WF6.>)_9V.P3C&W>05(:;T[27"I#X"]U-&2 V4D8(/B/BKKJ
M:"GN%L++;,UDT9_9C&"\CQ\E4[9JNJ-%4V]UKEIZC^K:Z)IP2#N[8>17/;%:
MDQITXN3?NJY72JH!0F",LA= .+A Y8Y;_!5NIG;=;M5TI> "QCV<QOPM_F57
M*"S7FLJ:>FC=)+&Y_%-*'<QX?=]ZL6HM.5S98:^C@G&,12<+L8&.?W!=$>6E
M,<4B^[L#45O-*Z*2221A:TM/#N"WNS\RHNCH*2ZU,DC:F2*:5HBRWU-L;D8\
ME)TM;<Y88&5$4=7UXQQO/&&CP5I=I*G?11]F#*4EO$X-:&[\SC[U$4;9.5JO
MRJ^_:,M&CO\ ,W5-RD=-4LB<QA!V(((Y8Y[E8^E[^+/<!1OIWEL!ZMKB#L.9
MS\5.V_55/!18#F<$8#0'GUL*DWJYS&MDKF5#)()GD]6T<M_?Y*9^E&"EN3;=
MT^S7%-J2":C93-?))Z'"_;/NP?Q4+05L5HOM/01]=)*UWILV(CW',J![+34>
MJ6QM9)#3R8EB>P8#>?YA2C&5K;S42MHGMC(SVD#+I?T5(M/M&;%2L^+:M'>+
M09ZBD>&,F;WAN2/BM=](<U5-7-;35($;'%K&\/I$'NY*'L45?25-1,XL>SC!
M+GG9PV[\J7U36R4U53RT-*VKGJ81P%F[6G ]+;S6/S_JTM&#Y<;H]Z;3%76/
M#^M;P!O[6-@P>+WD>&%'U5CJ#7L@@HPZ#BQ)(YV[ #CQ5UTSJ6(T?4SM#> 9
MGJ&\B?\ &%@W74]OI-4TD!=))33X#9&9X3G'/;S777Q]RRR7R_LU.D/=-+3/
MCD-?((+<#QMZK(< .[YK7U[%#605#:!TT9XQ& _G(W=;RDU)2W#KX&4SYF<'
M%@@D-'+P6LZBWVTUG;&R-%/!*&R[>BUV3@'Y%8YK4UTCC9)Q1UO;BUS06&.F
MC?&9)I?1>UFX#<'G\E>=$62VRS37!U&UG$<MD#G9X23S&<?<J9=I*BCJ8VVZ
MB!%1AO:\9 \ON\5/5.JI[#;::AH8&U-0X#K@S<CEN0._<KFX\S$S,NC-Y6C^
MK.UM:Y'AD5KG+*IG[1I=@Y9N/#W^:P=&OCH:T05K)&@D/>\$$%WXK'EOM/45
MU/4LK612OCX)&/=Z7%D[84Q))9[4P55SJV /&6QN/K+:W(K$J1@U'?M/W"YT
M%;;ZAD,PBE:P\+ ,'/O(5*TQJ'L\<O;^"&JB/""\$\0&<';;*Z.J+!<YI"ZX
MEID.6\6P;CWKBOME+)1.FRZH:W.<#*B.1KM-.-2T]I5CJ:YULE152-$+AQ$E
MQ&_ECN5?HM50QW&:FHZ%TU/N'2YW'F,E8[Z"E? SJJ@1ENY8]V%[PB.@I9:B
M"A:_AV/5 '/F<!<^;+Y0Z)X5\<[MZ95JHK2ZJJ+O/).R2(%SGR$G'D H^AJK
M)2U+ZEE5+,^5W&[ ._%W;A2&H:*MN.C7R4<1;USP7L:W<-P1^.%BV2VT=IM<
M,MX:R# #@Q[1EQQR^:RQ_3V36L5M*[T#Q-:XG4C&XW+FG )!)Q^2QF7FKM);
M''ES2_9H ./=^JI,]W=3UE1<*N1\-(Y@;!3YQGEOCX'N65IJZ5UPC';;?*T
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MY3^J%!V_N^"G*?U0H'JB(B4=7_VG0^\J14=7_P!IT/O*D4!$1 1$0$1$!$1
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MW<=RW.NK!;RJ^?\ B."<&;PG\"(BV< B(@(B((#4_K1_P_FH.'UE.:G]:/\
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MRNYB& !W<U[4%NBHXPVG;C PO;JB20.:TUIY]LGG,RCC$#G(W6-.UL4;GOV
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MH4';^[X*<I_5"@>J(B)1U?\ VG0^\J14=7_VG0^\J10$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MTC!IFYZLJ3(R*:*)YXGU$^03W;#?9;9L=NAL-HBH(972MCW+G=ZS99RT<+<
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MB B(@(B("(B B(@ZEH7FX>2]D08KSL00?)1EXH8[E2.CE;F7 X7CF"#E3;F
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M?SR,?JK!$>968R<MIW,!V6-?Y7M.2D_3+5,M-?+:[$M'))CFZ'+\_(+%AO\
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MDJN(VL:7EX)[@K#HNED%2^HDVRJTB8E;EWK>NH7ETF6CQ7#)"-BL<RC)W0R
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M):QY&07[=Y[UL*AJ+?<1P2N_K/5<5XW72SX8NMI2V2,_N@KGMCM+V*<ZE/\
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MPEIFG/HEH6-=CBGD_A*"P=$XQI&$CODD_P#,<KDJAT4MQHRE/C)+_P"8Y6]
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MWGP[$'!SY+!J;1056>T4=/)_$P(?=J%NKZ+&>OC./]98=QU-25M-) \F0/\
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MI)6PLP#S6Y&V*U-]6W4@]T07!L%I/.VTA_\ I-_DL_TL_EZ'_P"2XO\ 1/\
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M_6C_ (?S4'#ZRE":M_=\%.4_JA0=O[O@IRG]4*!ZHB(E'5_]IT/O*D5'5_\
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M5/=8J>]V22AAD(W<7![&D^M@@9'R61T@72VTFL+3!666&MG<V,LG=*6EF7D
M8 P0",[^*BNGAH%3978'$6R@GXM_FL?I._Y]6#_8P?\ F.1*WZHUP^WWUEDL
M]O=<+D<9;Q\+6DC.//;<\L*''2+>F7<6F73C?I(GAZKM'"2<9VVQR\U':LCJ
M+3TJ4U98^"MN$[>L-(=B/0+2">6[02-_RS)633E\N^MV:BOU-'01Q8+(6O#G
M$@8 VS[R2@V7$7.B8Z1O \@%S<YP?!:4U=7QVOI>=6RL?(R%T;N!@RYQZH8
M]YPMVK2^HI(8NFJ%]26B(309+N0/ W!^>$@3=+TG3P7:.FOUFDH(92,.<7!S
M >3B"!D>Y>O23=;;1ZBM4=;98;A*YC7,F?*6\(XR,8 P1W[J-Z>)8";1$"TU
M(ZQQ YAIX<9^(^XJ+Z26O;==+-FSU@HX0[/CQ;I"&R=>ZG=I:V05;*5M299A
M%PE_!CT2<\CX*JU_2?5]6:JV6*:6W,(#JF3B#2>\9 P-_$K(Z<_^;=#_ -['
M_ Y24$,<?1"6-:.$VDOQCO,9=GY[HEEV_6]OJM)37V1CXHX3P20YRX/VPT>.
M<C?S50?TDUEQH*WKK%,RVR1OA-1$7.$9((R3C!Y^2I],)#T85O!GA;=(R_W=
M6?SPMI:1FH?^2QCBZ/L[*25LV>YWI<0/G_-!6.B"XP6C3FH*^JXNI@<Q[@T;
MG8X \R=EG0=(]ZK(WU=!IF6:@8X@O:7.Y>8;A1W1)0TURTSJ&BKG<%/.Z-CG
M9QC(."">_.%C7"TZFZ/&/K+;7MGM?&.(?NY.PXF'EG89!^*#;MCKGW*TTM;)
M3NIG3QB3JG'):#RW]R]+G4NH[?4U,<#YW0QN>(F'=^!G 6#I&\?3VGJ.XF/J
MGS-/$P<@X$@X\LA8'2'J*736GS5TT;7U$D@ACX]VM)!.3\ 5 JL_2+?8:<UL
MFEY8[>,$R/+QM_%PX^Y35PU[#'HZ&_45*9@^80.A>_A+';YW /A]ZJ=P;J>Y
M:'J+Q=+]$RBFB+NS")OIM)P&Y &"?BH*'_HBG_\ TL/_ "PI0N%7TGU<E,*F
MU6*::DC:TS3OXN!CL#+<@8&#MDGX*WZ+U/!J>UNJHHC!+$[@EB<[/"<9R#WA
M1>DH(V=%<; T<+Z.5SACF3Q$_BJGT/"1VG=3-ASUAC 9CQX'X1*3K.D^::[2
M4MAL\EPBC)RYI<7/ YD  X'F57=+W!EUZ7HJV.-\0F<]QC>,.:>J((/N(*E.
M@=\ ==V$M%2>K(!YEHXLX^./N6/;WPR=.,CJ8M,?6OW;RXNI/%_]K*(;C5(U
M)J^\4-YFMUJT[/6.B <9?2+2",Y  _-7=:EM.I-2ZSOE73V>N@ME)""\?LPY
MW#G Y@DGY!1"5CT;KOZ;NLEJN- ZAN#0<-))#B.8P0"#Y>2YUIKV&P5[;=1T
MCJZX$#B8'8#,\AL"23X>:HVEXYXNE]D=76"MJ&22-DG#0T/(B.=AX<O@LBWO
MC@Z;)S<"&YJ) POY9+#P?B,?!2A;]*:RN5RNCZ.[V1]O:R%TSIGES UH\0X>
M?BHFJZ3JFJK98=.V2:NBBYR>D21X\+1L/>KCK>4?Y+W:&.1HJ'TDI:SB])P#
M3G ]RI_05)3_ $/<8FEO:NO#G#OX.$8^&>)$K%;=55%3HVMO=1;33R4X?B!S
MSZ?#S.<9&^1R[E[Z#U*[5%IFK7TK:8QSF'@#^+.&M.<X'M+TUK+'/HZ^=3(R
M3@IY&NX#GA(&X/FJOT'31MTQ7L=(T.95E[@3R:6-P3Y;'Y()33>M7WC55?9W
M4+8FTO68E$F2[@<&\L;94%1=*DU;3OCI;'+/<2[$<$3R\%N-W'#<_#"B>C*9
ME3TD7B>(\4<K)WM/B#("%Z= \;3<KM(0.-L+&@^ +CG\ B$G;^E=I;40W&TR
MQUK-HHHG$]8_..$@C+3\UZ6WI,J!>X:"^6=]")7-:"2X.9DX!+7 9'FH>EAC
M?TY/:YH+1,]^//J2<_/==NF< :JL[@/2,0W_ -\H+OK_ %8_2M-1RLI&U/7O
M<W!DX.' 'D5)7"].I-)OO(@#G-IFU'5<6!N <9QYJC].X/T;:3W=:_\  *8U
M%6P,Z)NL,K.&6ABC9OZSB ,#SY_)$H/4VHW:GZ+JZN?3"F+:ID7 '\7(M.<X
M'BK1T5DC0-L(&3B3;Q_:.6N*#_H8N/\ ^D!__35TTE=?H3HCAN(CZQT$<A:T
M\B3*X#/EDA!BU&O[^XSRTFE:CLL)(>]_&<8Y[@8[O-9+.D5M9I2JN-#;JA]9
M">KDA9Z8BRTD2../4V/=W8\U$6&KU7J>TU=T??H+?0QES2T0M.P&3W;#?O*@
MNCC_ )KZT_[D/^&1!E='>JKS1TTL,-JJ[JR6H!?4<3W"/( (V!]_Q6QM;:NI
M=+4L3I8W5%5-GJH&G&<<R3W!5KH+<W_)^XC(R*G)&>0X H#ID;*-:6UQD$3#
M P,D>,M:>L=DGW;%$)YG2/<*">G.H;!-1T<Y]&4<0('N(W]VRD-5=(#;;<X;
M;9Z%UQK)6M<.%QQZ0RT  $DD$'XJ'O.C=5WFA;'=-04-12M(E'$W !P=\AO@
M2N;OT=SU5/0U-IN43+O24\44G"\AKG-: UP<-VG&/NY(E8-)ZKNMTN[K?=;#
M-0O$9D,CBX# P.1'B1R*N1( ))P M8:!U9>1J4Z=U$!+..)HD..-KFC."1L1
M@<UL#4+9'V"YM@SUQII0S'/BX3C[U H]5TC559<9Z73%EEN3(?6ER=QX@ ;#
MPR=_!3FB-9P:E=/324[Z.X0#,D#CG(S@D';D>8(V6L>C.COE:RN9I^[T]"]I
M:98Y&@N>-\$>B=AO\U==(:-N=IU=)=;E<:2HEE8\R-CR'.+N_& ,94H=:SI,
M%)>;G;GVN26:GD=# (GY,S@[&",;;;]Z\[1TE3NOD5NOMH?0&5X8'$D%A/+B
M:X#;S4+I*-DG3+<B\ EDU2YOD<D?FN>F( :SLQ W,3-__J%!?M<:LI]+4,4D
MD1GJ9B1%"'<.<<R3W 9'S6MM8:SJ[WI=U-<K1-1=:]DD$V'<$@!Y;CPWR,K+
MZ;!PZDM#YP33=3O\'GB^XA6?I=FI':%)#XR))(S3X(WWYC_=RB7&D;W2:?Z+
M[?7UQ/5M:YK6M]9[C([#0H?_ )4;EU?;#IU_T;Q8ZWB=CG[?#C*K^I&2GHIT
MRYN>I$T@=[R7X_ K8!J*'_DEX^./L_T9P<QZ_!C'OXOO1"2;K"V.TH^_M<\T
MK1@QX],/SC@QXY(_%5-_2)>Q;#=AIP?1/%PB4S'QQSQRSMG&,JO:2M[:[HRU
M *NH%-3LG;(R1X):'M \/'8?%>MH=JB\:$ALM#:HWT,OHMJS(&^B'YQ@GQ'/
MP1*ZV/7#ZFP5EYN]O[%;X@.J>V4/,SLD%H&V^0!\5"CI)NSZ9UQBTW(ZU-.#
M-QNY9QGBX<+"UW8IK!T8VV@+^L=%5!\[F^KEP>?ED@+C3=CU1=M*4[*"_P!&
MVV30F/J"P'A!R'-/H\^?>B%_I=3TU=I*HOE"PO9#"^0Q/."'-&2T_P".]4^#
MI0J:ZC:+78IZFN&3)'&7/;&WN.PR<_!9=HT]/IOH^U'2U%3!4%\<SP822&_L
M\$'/?LO#H)B8+'<I0!QNJ0TGQ :"/Q*)2^@]=1ZFGGI*BE[)61,ZS =EKF@X
M/N(R-E$W'I,EEN4M)IRT2W$19S(.(\0',AK03CS5:L<;STA:JCI01(8JUL8;
MXY.,*8Z!Y(!%=X\M%271NP>9;O\ G^(1"SZ(US3ZDGEHYJ=U'<(P28G.R' <
M\';<>"Z6;6K[CK2KL)H6QM@=*WKA)DG@..6._P!ZIE YL_3>]] 08Q,_B+.6
MT1#_ +\KOI21L73+<Q(X-+YJAK<]YR3^2"X:TUJ_3EYHJ%E"VH%0P.XS)P\.
M7%O+!\%[:[UI%I?L\+:9U563@N;'Q<( SC)._?W*B]+U1%+K:UQ1O#GPQL#P
M#ZI+R<'SQ@_%77I T?%J@PN@JV4]Q@8>#BW#FD]XYC?O]Z)8=DUG>ZB\4E#=
M--3TPJ7<+9?2:&C&2=QO@#Q5^6H;%J346F=34EBU"[M44SV1M+G<3@'' <UW
M,C/<?N6WE T=66NDO'2Y6T5P+A322/+BUW"=H\C?WA;'TSHVR6.X]LMCY73\
M!9Z4H<,'RPM:W*S17_I8KK=/*^*.65Q+V8R,,SW^Y;"TOHRBTA/5W&&JJ)_V
M#FN:\#D"';8[_14HAB7O65[I[Q5T%JTU45/9G<+I3Q.#N\$8&V1CO67H?7$>
MHZJ>AJ:1U'7PM+C&79#@#@\P""#W*KZ=OFJM:U]8;?<H+72P8):V(.(SG W&
M3R.^0HWHX$C>E"L;-4BJE'7A\[1@2'.[OCS07'5O2#':+J;7:Z%]PKP0' $@
M-<?W0 "7%8MOU_=GPUO;-,U;9J>,/X8PX$Y.!D$9 YG._)5W1+XX>ENYBN(;
M,Z6H;&7^V7]WPRMM72:+L=7#UC.N-.]W!Q#BQ@C./#<(EIK0^KKW227.6"UU
M5X=42->\L+R(CZ1[@<9S]RVGJS5%+IJUQU58QSY9?1B@:<%QQOOW =Y5'Z!7
M#JKT,C/%"<?;6-TZM?\ 2%H>_)IS&\#'CD9^["(9C.E&O@ZJHN.GY8K?*?0E
M!<,CR)&'?<K=J'5D-OTFR^T$;:N&0LX&EW!D$XWV."/!1_2?443NCVH<Q\1B
ME$79^$C?T@1P_ 'X*DN;*WH2'6YX75>8\^SQ_P \HE8).E U$U%!:;8Z>21K
M#.YSCB-SL9:,#?'CLK3TAVKZ7TE7P-;Q2QLZZ/QXF[[>\9'Q6'T3TT4&AZ!\
M4;6OFXWR. W<>-PW^  5O.XW4"@]"]T[9I9]&]V9**4LQ_J.](??Q#X*MV ?
MY4]+557'TZ6C<7M/=AGHL^9]+YJ.BK7:'U3J6C82R.6"00>\^E&?@#A7#H4M
M79-.S5\C<25LGHG_ %&Y ^_B4H0&H_\ IJH?]K!_PA<5'_3H/]LW_P @+G4?
M_350_P"U@_X0N*C_ *=!_MF_^0$%^UGJ.LL7964%HFN,M22&]63AI'<0 2JW
M1=(]737:"BU)9I+>)B 'Y(X03@$@C<>8*Z:RU9>7:QCTY89(:60EC#,]H<2Y
MS0[O!  !'=E4[I*H[G17.WQ7F[MN-06%PQ&&=6,^7CC[DA+?J@-8WZHL%##-
M26V6X22R=4&1G'"<9&< GN/<IYGJCW+772+JZYVZ^4=ELACBJ)PPF9[0=W.(
M &=ARW.% Q_^4FXVZLA9J*P2T<$O)_I-<!WD C?'P5GUQJK_ ";M%+704S:M
ML\H8 7\(P6DYS@^"UCTGT-YH8+<+[>F7"1Y>6Q-C#>KY9.V,CX*>Z4_^CW3_
M /%%_P"45*&17])]7U1JK98II;<S ?4R<0;GO&0,#?Q*LENUQ;ZK24U]D8^*
M. ]7)#G+@_;#1XYR-UBT<$;.B+@:T<)M3GD>987$_,Y6JZ82'HQK"S/"+HPO
MQX=6?SPB5P?TDUEQM];UUBF9;9(WPFHB+G",D$#)Q@\_)>_0/_H%W_VL?X.4
MWI.>A'16PET8IV4DK9LD;.]+B!\\_BH3H'_T"[_[6/\ !R(;26'>*U]OME15
M14LU6^)N6PPC+WG.,!9B*$OG33];(=3U]7)I]UWEDZQSJ1[2_JR7[N(X3RY;
MCO6Q+KK^*TR4UHL=H=45;(VM= S(;$[&>  #)([^2ANBK_I$OW^SF_\ .:O'
MHY<R#I/NS*X@5+NO:SCYE_&"<>> 5*%HTOTABX7=MJO-O?;JUYX6<1."[N:0
M0"">Y5W6G_3!:/XZ?_B7CTJ.9-T@VJ.B(-4UL37<',/ZP\(/GN/F%[:T_P"F
M"T?QT_\ Q(E[]/7JV7WS?_<5LU/J^DTM:*(RQNJ*N:(=7"UV,@ 9)/<%4^GK
MU;+[YO\ [BC.D/$6M]/RUO\ H?44Y)=RX0\\7YH)R#I/K*6HA-\L,U+2S>K(
M.(''B X>E\%-:KUT+%7VQK*1E3;ZV-LC:D2XV)WP,;X!!^*P^FN:G.DX&N<P
MROJ&NBWW.SLD>6#]X5;U%:Y9^B&R5<C3UM&>+)[HWN('_P!Q$+MKW6?^2[J*
M.&D%7)4![RWK.'A:,;\CXGY+TFUE''H1FHA "7M $''^_P 7"6YQ[^[N5%TX
M[_+#6-$*D\<5):A')X$F/A/_ -J0_)5:IKZ@Z7@T[N9H[B\\ ]P 'VBY-#95
M]U)%<>CJ.[7:S130SSAK:9TQ&V2 [B R#L5ZNU;%8NCZTW.AM<;(9G]4VF$I
M 8,OWXL;^K]Z\>DZA9;>C:EHH\<-.^&/([\ C*K6H_\ H;T__P!Y_P#^J"<K
M>D^K=":JUV*::@8!UE1)Q!H=WC(&!OMN5;M+:JI+]8);F&FG;!Q"=CCGJR!D
M[]XQNHRS01LZ)0P-'"ZVR.(\RUQ/WE5OH=IHZW2M_I9G<$4SC&YW@"P@E$LZ
M/I#NMR;5U-CT^ZHH*7/'(^3!QSY>..X94EH?6E=JBM<P6AL-'&"))Q/Q<)QL
M,8'-4?0U7?Z.VW:WZ=H8KE2OE<T5(=PAKB,<0#B-B #NK]T8:7J--6NH[>YO
M:JIX<YC#D, !P,]YW*"2UO?I].6<7""C;5,;(&2-+^'A!Y'D>_ ^*]K%J""Y
MZ8CO+@(HNJ=)*W.> MSQ#/P*S;Y;H[M:*R@FQP5$99GP/<?@<%:'H[[/:=&W
MRP399.ZI;&!WM!R)!_\ 8 _WD&R--](0N5NN=QN%$*.@HFM]-LG&Y[B=F@8&
M_P#,*,'23=I:>2X4VFY'VJ,X=+QNY#OX@,!16I++):.B*WQAI$LM2RHJ?]YK
ML ^[T!\%ZZ5LNI[II6!MMOU(RVR1NCZ@L!+0<AS3Z//<_-$+[2:PMU3I26_-
MXQ3PM/61X]-K]AP^_)'S"J,'2/>JN)U91:8EFH&D@O87.Y?ZP;C[E):7T8VW
MZ6NUIN];3RP54@R^%^T;M@.??D#[E4Z^V:GZ.V&JH*YD]K+P".;<GEQ,/(GQ
M!^*)7/46OV6:T6V=]OD=6UT76MIG/QP-\7''W8^2\;+K2^3WBDH;IIJ>F;4O
MX6R^DT-',G<;X&_-8UVL\/2+IZV7**9E%<A&XAA.6D<1!![\9!P5#V34>H]+
MZDI+'J!PJH)GL8TN=Q.#7'A#FNYD9[CX=R"[ZWUC2Z7BA:Z%U36S;QP-=C;Q
M)[A^*KT72-74-93LU+8IJ"GG/HR^EL/'!&^._O5<Z5FSCI"H7"9L&8X>JFD]
M5GIGTCY [J8OFB]4WBD8R[W^AFIXSU@+V\(:<<\AH[D&!K=S7]+5C>PAS7/I
M2".1'6+<:TCJ&E?1=(VEZ65X?) RBB<X<G%K@"1\ENY!J#IV_P!/L_\ !)^+
M5=-9ZRIM,0T\74NJJZ=N8X&NQMRR3OW^6ZI?3M_I]G_@D_%JCNDEM0.D6B+9
MV4SG,@,,TGJQ[^L?(.R40M$'2-6T-=3Q:FL<MO@G]67?8>."-\=_>/!3FN=:
M0:8BIFLIS5U50"Z-@=PM#?$G=5:_:*U1=Z9@O%_H9H(CQM+V\(;MSR&A3>K-
M$,OUJME/VQD5THJ=L8<=VR   Y'/&1S1+RLVM+Y/=Z.BN>FIZ9M2\-;+Z30W
MO)W&^!D\UCT]SMIZ6'T;;+"VNXG-[;UIS_5<6>#&,XVRH:S:CU'I74=)9-0/
M[5!*YC&ESN)P:X\(<UW,C/<?#N2E_P"G5_\ M'?^04%UUQK6ETN(H>I=55TH
MXF0M=P@-Y9)5=I.DZIIJV&+45EFH89?5D]($#QX7#<>Y0^LRV#I?H):\@4W'
M3N:7\@WEGW<0*F>G26#Z#MT9<TU)J.)@[^#A.?ADM1"?USK :9I[?/%3-JXZ
MHNW$G#@  Y&QSS5<N/2?619JJ*PS/M7%PMJ9>)HDW[CC ^]072(V1FAM'MGS
MU@A.<\_4;C[E>=3P1Q]%4L36C@90Q8&/#A06#3-ZI]06>"X4K7,;)D.8[FQP
MV(4HJ#T*'_\ (Y^?K3_P:K\H2(B("(B B(@(B((N\>O'[BHY2-X]>/W%1RAR
MY/W2+#O%;1VZUU57<Y&144,9=,YXR WOV[_<LQ5[I!L#]3Z.NEGAE;%-4Q@1
MO=R#@X.&?+( **Q[[?.]<W0-98[JW3>DM15LC(Y"VX@.+(78)!.'8#1SW')2
M>CJR>I_HX:KAFD<^.FJ.KB!.>%I,3L#RR2?BI;2>D^DJETW/I TUNMUHF+VR
MUSG-?(&/]8-X7;YWYC._,+.TOT>ZBM_0]J;3]321BYUM1QP1B9A#F_L]^+.!
MZIYJ6\S'Y0?1;T9V?4W1S47:\FHEK7B5E,\3. @:S(&!R/I9.^RFOZ*E9-)9
M;]2/D<Z"">)\;2=FE[7<6/LA7GHIT[<M/]&\5HNL+8JYO798'AP])SB-P<=X
M4#T :,O>CZ:]LOU,R!U2^$Q<,K7Y#0_/JDXYA0K-MQ;MKO0%@I>DOI.U)5ZF
M=+-!"7R")LA;GT^%C<C<-:T=WDO?35@@TS_21I+5122/I8>,Q=8[B<UKJ9SN
M'/EG"FJW0>MM'Z]K[SH2.FJZ2N<\F.1[0&M<[B+'-<1R/(@\OBLO3.@-7TW2
M[0:FO[J:K8]KI*F>%[6B-QB<P,#>9 ]$9 1:;>^^M-XKY3Z#M%V[6%^O3+UU
MLE#2!KS R0L#WN<X-)(WV =\U]6+4'01HB^:2N-_EOE*R!E6(^J+96OXL%Y/
MJDXYA&=)U650Z,: :8Z?KE9+;+(* -ECX'.SEG"'M!\2#C=52.\T%[Z2;W<]
M7VJYWNG:][(:6D!/5@/PT'!&&@ \N96W+/HF^4W3K7:EFI6"T2\?#+UK23F(
M-'HYSS\E%W706KM(ZWKM0]'XI:NGK2YTM),X-QQ'B+2"0",[@@@CE[S2+1O_
M &0'0Y+-0]+4T=CMMTH-.U['CJ*N-PX,,XAD[C9P(!SG!4/T4:1H=7Z]U!2W
MDS26ZG?).Z!DA8)']86M)QX N6Z- S](%9>IJC65-04-M$!;'3TY:7.DXFX<
M<%QQ@.[^_DH#H;T1?-,ZNU%7WBE9#35@/4N;*U_%^T+N0.VR(FWMK"PZ*HJC
MIHK]*&:I;96RR&2)LA!DC8WC:PGOWQOY>*EIK'3:)_I!V6BL)DAI)7Q$1EY=
MAL@+7-R=R.?-7FPZ(OE)TY7#4D]*QMHF,G!+UK23E@ ]'.>::NT3?+CTTV;4
M-)2L?:J8P=9*96@CA)SZ).3S1/GW[^RJ]*W6ZNZ;;3I:MGECM<75M+&'&>)O
M&YP\R,-SY*.Z8-,4?1G>M/7G2+IJ21[GY892_P!)G">9WP0X@CDK_P!+/1Y=
M[IJ*AU3I":..\TO"'1/<&\9:<M<"=L]Q!V(^^NS:$UUT@:AMU1KUM+0VVB/]
M7$YI+@2"X-#2=W8 ))V[O!"MHZ[Z/Z1-GN]U=8;U2T4];:(8<SP1Y/5DGB)<
M!N 1@<7=CW+VZ'9^CRZZF@J;-;JBTWYD+VMI)9G2,=D>DYCB3DAN? X)V\+Q
MK^37M%=:2;1--15EN$ 9+33EHP\..XR6GECD>[DJ;H;H_P!35?24W5VJ:2AM
M75DR"FI2WTW\' -FD@#?)).2?>BL3].IE2J+1EDGZ?*C34M*YUG:78AZY^?Z
MCC];/%ZV_-;:Z1*716ENCVGL5\9/%:"__-J>!Q?,7!Q>>$D^).23R=CO"K&N
M=$:OM_2B_5VC8*>L=* [@D>T<#NKX'!P<1D$;Y![UWZ2=":NUIH^Q55;'2G4
M5&Z;KZ5CVM:YKW>CPG/#D!K>_O.Z)F=S&Y:MZ01I[Z'M]7IC2UZLO[48K*KC
MZN9N"1@EQ'%MD8/+*L_3O0P3Z4T=J"5KG76OI(FU$Q>3Q@1-=RS@;N/+Q4WJ
M[2723KC3T;+U3VVD[$YI@H87-#IW>J7EW$6C )VR/<K%TD='MUU%T:Z;M]"V
M/Z5M4,37P/> 'XB#7-#N600/)$^4;CM,V#1-BTUH^X5UFI'05-9:SUSC,]_%
M^S)Y.) W\%JKHIN]18NAK6UPHGEE3'*QL;QS87!K.(>8XL_!;)T/#KZHL]QM
M^K*.D@IFV]U-2B-S..23AX07$./=[E%=%W1O<J/06I+!J:%M*;D_T"R1LF/1
M&';'N< <>2*Q.HG<J_T-]%U@U1HPW>_MJ*FKJII US9G-ZL-.,[<R2"=\]RW
MO8+32V*S4=KH&EM+2QB)G$<D@=Y\SS/F5HK3>GNE?1-//:+#3T-50.D+V2ND
MC<UI/-S>(@C.!L0MX:6BN<&GJ"._3,FNC8AVB1F,%_?C  ^Y$9)W]VE_Z5Q(
MI=,D'!$E1O\ "-1O2IT9V>P]',%ZHG5!NL;HG5$\DQ?UY?LXD'D<G.WWJ2_I
M7_Z)IK^.H_"-8=_TETGZBME#IRM-%+9H2PLK ]K>-H&&E^_$<#NQS\>:+UG5
M8[=ND&Z5%X_HZ:?K:Q[GU#YXF/>[<N+.L9D^9X<K!Z4/^@;0W\47_E/5_P"D
M70-;4=%5LTQIR(5,U'+$?3>V/B#0[B=N<;EV<>:\=3]'=ROO0_9+&.JAO%M9
M&\1O>"USFM+7,XAD<G;'Q"(BT=?U>VNO_AV__A='^,2UZZ.XR?T9*46T2E@K
M7FJ$><]3UC\YQW<7#E2;M)]*%^T@--W5M'1VRDA 9E[#)4=6/V<9+7';(;N<
M>)RN;_%4:,Z#*?35XDGI+W7S2,@AI2)#(.LXB"0<<)! .^?2Y'<(1UU_*DZO
M.BY^CG3D.G(V.U*71MJ1&QW6$\!#P[N.7\./N7TOT?6:*Q:/M5&RCCHYNSQO
MJ(V#'[8L'&3YY"T900=(6B[(RO;I&Q10T,(<^I-/"9@QHW+BU_$3CF>:W9T9
MZJ.L=(TMVDIQ3S/<Z.6-IRT.:<$C/<=BB,GKKTU__2:L5ODTQ%?'PDW.*6.E
M9+QNP(R7DCASCGWXRJU5VRATAT(07^Q124UYN]/%2SU+97D\+SQ.P"<#/!C;
MQ6T.FW3=RU3HKZ.LL+9JOM,<G"Y[6#A =G<G'>%TCT,^[=$%'I:[XIJQE*QO
M$TA_52M.0=MB,\_(E"MM5C;7&G^BBQ5W1 ;S/UQO$E')5MG$I#6$!Q:WAY8P
M #G?GNI/H>O=7=.AC4])6R/E[!!411/<<D1F$D-SY'/PPHV#3/2O;M-S:2I8
M:*2TO:Z$5(E9D1N)X@"2' ')YMSNMAZ0T#)I;HRN=CAD94W.M@F,KV[-=*^,
MM#03W#89/F=D3:>NY:AZ$^CVDUS:JJ>^5M9V"BF,4%-"\- >X N=N#C]WDO?
MI3LK*OIIL=CAFE@IY:>EHR]CL.$1RQV_\.0MG= ND[OI'3UQI+[3L@GFJNM8
MULC7Y;P-&<M)[P5&ZMT1?+CTTV;4-)2L?:J8P=9*96@CA)SZ).3S0\_JGMK3
MILT;;]%ZAL?^3!GHS4L)_KG$M>UP'$'$Y'K?<L_IPZ.[-HS3MGK;*)V5)GZB
M9[Y"XR'A+N+R.6GECFKYTY:(OFJ[S8*BR4K)XJ0/ZXNE:SARYI',[\BI/IYT
MI=]6Z;H*2Q4[9YX:L2O:Z1K,-X'#.7$=Y")B_KM[:KN]B/1+02:UED=2W"C@
MXA$,RR2%@?Z'GD9R=O%:'UTS2\VF*>ITQI.^6W$K>&X5/$8I6D'8DN(R=B,>
M"V_TE]'EVU'T=:;HJ$1_2EJ@C:^![P _]FUK@'<L@M&.[FJ]?-)])6KM(1VR
M[T]NH:>WL88*:-S0^J>WT1Q$.+6@-+CW#/=X$4F(^Z%Z7*.&NZ*M&ZBJP^6[
MR0PTKYW/<>*,,>[<9QG.^>:VKT7:(L-DT];KW;:-T5RK+7'UTIF>X.XV-<[T
M2<#<=RAM5]'MUO70Y8['&V*.\6YL4G5.>.%SFM<US>(;?O<^6RS.BR'I IFQ
M6W5-'24]GI*+L\):YAD>YO"&9+7'DT'?9$3.Z]2UGT%72:RZ)Z0+C2_Z134T
M3XSC.'<,N#\#@J0Z%^CBS:TTS<+QJ-U34UDU4^)KQ,068#27^;B7'GGD%9NA
M?HZNMEM&I[=JJD;#3W2*.$!DS7ES<2!WJDX/I!0MGTETG:#[=;-*"CKK;4R%
M[)G.8. XQQ<+B.%V ,\QLBTVB9G4O;^C9<:NDOFHM-2SNFHZ4F2+)V8YK^!V
M/#BR#\%4^BK2-%J_7^H*6\F9]NIWR3N@9(6"1_6%K<X\ YRVYT+='E3HVFKJ
MV\3,FN]>1U@8>(1M!)QGO))R3Y!1G0YHB^::U?J*OO%*R&FK >I<V5K^+]H7
M<@<C9$3:.YA3=%VR/27](YUDM+Y&4#A(PL<XG+#3F4-)[\. ^2^D5J(:)O@Z
M?QJCLK/H;?\ ;=:W/^C&/U<Y];;DMNHI>=Z$1$9HK4?^@L_V@_ J1TYZG^/-
M1VH_]!9_M!^!4CISU/\ 'FIAT8O2TMY(C>2(U$1$!$1! :G]:/\ A_-0</K*
M<U/ZT?\ #^:@X?64H35O[O@IRG]4*#M_=\%.4_JA0/5$1$HZO_M.A]Y4BHZO
M_M.A]Y4B@(B("(B B(@*CZJZ.:*_766X=MJ*:IEQQX <W8 # V(V'BKPB"DZ
M6Z.;98Z]E;)-+6U49S&9 &M:?' [_>5[ZRT'0:EJF5;IY:6K#0PO8 X/ Y9'
MCYY5O1!KH]%%L=0]4^MJG51>'.J#C. ".$#PW^Y7*YV2EN5A=::OB=3NC;'Q
M X<.'&'#SR 5)H@H&G^C2EM%U@K/I*HG9"XN;"6 -)QC?QYKPDZ*J)M=)+1W
M.LIJ>0^E"S&<>SQ>'O!6QEAW:YTEIHGU=QF$-.P@.>6DX).!L!E!7[%H6WV/
M4'TG;Y)6-ZKJA =VC8 G//)QGXKPU9T>V[4%<:ULTM'5NQQOC +7X[R/'S!5
MIM5QI;K0QUEOF$U-)GA> 1G!P=COS"RD%(L'1[2VF"Y-[?43S5M,ZF<]P #6
MN[P/'XJ7T9IB'2]#/34]1).V63K"YX (. ,;>Y6!$%5TKHRGT]=JRO@JY9GU
M+2TM>T -R[B[DJM%T]1K%FH75<HF:YKNJ#1P^BT-Y\^Y6I$%7UIHZGU4^C=4
M54L'9@X#@:#GBQX^Y>>HM$TU[O-%<9:N:)]*QC&L:T$.X7%V_P U9JVJAH:2
M:JJG]7!"TO>_!. .9V4=2:EM%7:9[G3UK'4,#BV24M<T-.VVXSWCYH-4UD4&
MM];W!MQK*>TBDS$PD8?*&N(&<D#*C[]0?Y+7:@_R>O[ZZKD?O'$=VG(P#@D'
M.>16SI-.Z5U>TW.*&.HZQQ#IH7.C+B/$;;^\94A9-'6*S3B>@H&-G;RD>XO<
M/=DG'P4[0GFY+1Q#!QNJ=>^CZW7G4%1=*^>=W7,#3"W  (8&@@\]L95R10EK
MRU=%=MI+E'55=9/6,C<'-B>T ''+B/>/+93.J]&4^HKI25L]7+"^G:&AK&@@
MX=GO5J1! :RTS#JBWPTE1420-BEZT.8 23@C&_O64++&-,?0O6OZKLG9.LP.
M+'#PYQXJ56/4UM+2N#:FI@A<1D"20-)'Q05RQ:'H+98:ZTS2R5=+5NXG\8#2
M#@8QCPP"H6W]%%MIZSCJ*ZJJ*4'/4$!H/AQ$<_N5Y9=*"1[61UU*Y[C@-$S2
M2?#FLQ!3;5H"BH+%=+6*NHDAKRTN=@!S.'<84.WHIA=PQU%[K9*5IR(N$#Y9
M)'W+92(,6UT%/:[?!143.KIX6\+&YS_@K%U+8Z34-JDH*[B$;B'->PX<QPY$
M*41!KRV]%M! >&NN%764[0>"$^@QI(YXR=_DLQG1Y2-TL^R=NGZIU5VKK.$<
M6>$#&/#97=$$5;;-'0Z<9:&2O?$V%T/6$;X.=_O6!HK2<&E8JME/4RSBH+22
M]H&,9\/>K(B#7MTZ+;=57-]725M11LD<7.BC:"!GGPGN'S4A:.CZVVC4--=*
M":9G4MX1"<$$\!:23SR<Y]ZN1( ))P!S)7A35E-5<79:B&;A];JWAV/?A![K
M7M=T744ETEJZ&Y55$R5Q+HXP-L\P#W#RW5^GGBIXS)42LBC'-SW!H^97FZNI
M&T[9W54 @<<"0R#A)\,YQW%!5K3T?VVTWZDN=!+,PT[.'JG8<'DM(+B?$Y7?
M6&@[=J2H%5)))2U@ :98P"'@<N('G[U9I*VECA9-)50-A?ZKW2 -=[CG=>T;
MV21M?&YKV.&6N:<@CQ""FZ2T!2Z?N#ZUU;/63.C,6'M ;PGGD;YY>*C+CT46
MZ:L?-05]11L>2>K#0\-\@=CCWY6QT00>G-,T=DL3[4QSZBGE+C(9<>EQ#!&W
M=A5%W1+;^UN='<JME,X[Q #./#B_1;*1!4].Z&H+#?9[C032ALD1B$!W#0<=
M_,\OO7;16C*?2LU5)3U<LYJ&M:0]H&,$^'O5J1!58=&4\6LW:B%7*9RXNZGA
M'#NSAY\TU;HNGU)<:2LGJY874[>$-8T$'?/>K4B"(U1I^CU';#15W&&AP>R1
MAPYCO$?,JH6_HHMT+G]LKJFJ9PN#&8# TD8SWY(Y]ROETN%+:Z&6LKY1#31X
MXWD$XR0!L-^9"ZVFYTEWHFU=NF$U.XD!X:1D@X.Q&4%9AT%2Q:2GL(K9C#-.
M)S+PCB!]';'^ZI:VZ:I*32HL,SGU%)P.8YSMG$.<7=W(@G[E.(@US1=%5%!.
M1+<ZR6B+N)U.,-#\=SB.?R"GM-Z+H;$ZZMAD?-3W <+H7C9K?2]$'W.PK0B#
M6T?1/115G6172K;!Q ]5PC.,\N+]%;]4Z:M^I:-L%P8X.828Y8SA[#WX\O)3
M2(-:LZ*8#PQSWNMDI0?ZH- V^9'W*1O_ $>07.Z&OIKI5T<SF,8>  C#6AHQ
MC!Y *\H@J.D="T&G:U];U\U97.!'6R[<.>>!XGQ)*MR+I/+'!"^69[8XF N<
M]QP&@<R2@HMXZ,K=5W!]9;JRHMTKR7.;$,M!// V(^>%*:.T;!INIJ*EM;45
M=3.P,<^7 &,YY<_O7I3:ZTY4UK*6"YL?,]P8P"-^'.)P #C"LJ"JVK1E/;M5
MU5]95ROFG=(XQ%HX1QG)W35>BZ?45UI*Z>KEA?3M#0UC00<.+N_WJU(@@]6Z
M9HM34+*>MXV/C)=%*SUF$\_>#X*JTO11;64<\5375,\KV\,<F T1;@Y#?';'
MQ6QD00-)I:ABTK'8:KBJ:1K2.)VSMW%V1CD02JC_ ,D=#UW]J5?9N+/5\+<_
M/E]RV8B#7/2-+!I71<%JME'&::I)A/6 N &,DGQ<3OE5N+0UGBM#:I^K8(\L
MXR6\/#G'(#BR?Q6W[I;:.ZT;J6XT[*B!VY:\=_B/ ^85:CZ-M,,EX^P/<,YX
M73OQ^*D5[HE$U]TY=J"\\=7;N-K(^M)/,$N /,8PT^65D.Z*:>.1XHKS6T\#
MCO'@'[P1GY*=;J[2=E(MT-=3P-A/#U<,3BUI[]VC"M,$K)X8Y8G<4<C0YKO$
M'<%!!V[3%-0:5FL<$TQ@ECD8Z5^"[T\Y/+'>FC-,PZ7H)Z6GJ))VRR]:7/ !
M!P!C;W*?10*K9]&4]LU367R.KE?+4ND<8G-'".-V3NHJ^=&%MKZ^2KHJJ:@?
M(2Y[(P'-R>>!MCYJ_H@K.C]&6[3'624QDGJI!PNGEQG'@ .04;JGHYH+Y<WW
M"*JFHZF3!DX&AS7$=^-L'XJ\*+N^H+79YX(;G6QT\DWJ-=G?SVY#S*"I?\EE
MK:RE,=74B>)YD?*<$RG;8CN Q]Y4MK'1<&I*NGJS75%)4PLZMKHP",9)]^=_
M%6M$%'T_T<T5MNL=QK*VIN%5$0YAEV (Y$\R2/>KPB(*K3:,IX-8OU"*N4S/
M<YW5%HX=V\//FK2YH<TM< 6D8(/>N40:Y?T543:Z26CN=934\A]*%F,X]GB\
M/>"IFQ:%M]DU!])V^65C1%U8@.[1L 3GGDXS\5;404S5G1[;M05QK1-+1U;L
M<;XP"U^.\CQ\P5ZZ.T-2Z;JJBI%7-5SS1]4XR !O#D'E\/%6Y1-TU':;7<(:
M*OK!#53 &.,L<>($D#<#',%!3*CHFH'5DDE-<JJG@>3^R#02!X!WA[PKC?-.
MT%ZL[+=7L<Z*,#JWM.'L(&,@^*F$0:TI^B2@;.TU-SJIJ=IR(@T-^&=_N"MU
M_P!,TEUTZVS,<:2E9P<'5 'A#>0W4ZHF\ZCM5EGAAN=6())AEC2QSLC..X%!
MZ:<M,=CLM-;HI72L@! >X8)RXG\U)(B"GZQT'1ZFN$59-4RT\K(^K/5M!X@"
M2,Y]ZLUJH8K9;:6BI\]53QMC:3S.!S/FLI$%5K]%T]9JZ&_NJY6S1N8X1!HX
M3PC'-</T73OUF-1&KFZ_B#NIX1P[,X>?-6M$%-U?H&BU#<6U[:J:CK, .?&
MX.QR./'SRL";HMMLM+&U];5NJQ)QOJ7D.<_;U<'D%:ZK4=JI+O%:ZBK#*^4M
M#(N!QR7<M\8^]2R !@ *J:TT11:GEAJ))Y*:KB;P"5@!RW.<$?$_-6M$&O7]
M%MNEH71U-?5S5CG-/:GG) &?1 \-U.:DTC!?+%0VR:JEBCI"TM>UH)=PM+=_
MFK,B"*CLL;-,?0HE>8NR]EZS XL</#GWJ)L>AZ"V6&NM$TLE72U;^-_& T@X
M&,8\, JUH@UU;^BBVT]9QU%=55%*#Q=00&@^'$1S^Y6'1VEJ?2E/6-IZB6=L
MS@\\;1D8!Y8Y\U9%'WJ]6ZR01RW2J93QO=PM+@3D^X;H*-T46FM^DKQ>KG!/
M!+.\LC9,TM/I'B<<'_=^];)72":.H@CF@>U\4C0]CFG(<#N"%W05736C*>Q7
MZMND-7++)5->TL<T -XG!VWR7AJSH_MVH*SMHEEHZTXXI(@"'XY$CQ\P5<5C
MU-=24SPRIJH(7$9 DD#21X[E!4]*]'EML5<*Z2:6MK&[L?* &L/B!X^9*RKM
MHRGN6JJ6^25<K):<QD1!HX3P'(W4[]+VW_M"C_\ &;_-=S<J$1-E-;3"-Q(#
MS*W!(YC.4$'K72%/JH4@J*J6#L_%C@:#GBQX^Y>^I-*V_4%MAI*X/#H!B*9A
MP]FV/D<<E/-<'M#F$.:1D$'((6++<J&&1T<M;3,>W8M=*T$?#*"AT'1/;HJE
MDE=7U-7$SE%@,!'@3N<>["O-UM<%PLU1;7@1T\L1B 8/4&-L#RV^2Y^E[;_V
MA1_^,W^:S&/;(QKXW!S'#(<TY!'B@J^BM%TNEI:J2GJ9:A\[6MS(T#A SRQX
MY^Y80Z.Z :I^FC4S%W:.T]1PCAXLYY^_=79>,]734[V,GJ(8GO\ 5:]X:3[L
MH(S5M@BU':303S/A87M?Q, )VSX^]15?H:FK-)T-B=63-AI9.L;*&CB=ZW,?
M[RMR((JELT=/IH69LKS$*8TW6$#."TC/WJKFV,Z.]'W:HH7NK7N+7 3-  )(
M;OCNWRKZO.H@BJ8)(:B-DL,@+7L>,AP\"$&D-,Z/MEUM N-1J*GHI)2XNA86
M@1;G8Y=E2W11/50:ON-MI:^2NM44;CUF_ 2' -< >1._O5MDZ-],OE+^P/;D
MYX6S/ _%6*SVB@LU.8+92QT\9.3P#=Q\SS/Q4[&<J/>.CBW7/4+[I)42LZR1
MLDD#6CA<1C._GC[U>$4#'N%%3W"BFI*R)LM/*WA>P\B%K]_1331RO[#>:VG@
M>=X\ _>"/P6R$05BGT910Z1GT^VHJ#3S'B=*2./BR#MMCF JXWHI@?P1U-[K
M9:9IR(N$#'NR2!\ELI$%,O\ T?T-SBH&4E5/0=BBZJ+J\$<.<[]^<]^5XV'H
MXHK==8KC6UM3<*F)P='UNP#AR)YDX]ZO*BY-06J.\MM+ZV,7!V,0[YW&0,\L
MX[D&-JO2UOU-2LBKVO;)'DQS1G#F9Y^\>2J<715 2QE3>JV6F:=H@ -OB2/N
M6R4052\:*IKGJ>CO3ZN:.6F,1;&UH+3P.R,GS5K1$%6UGHVGU3-225%5+ :<
M. #&@YR1X^Y96JM)V[4M+''7![)8AB.:,X<WR\QY++L^H+7>99X[96QU#X?7
M#<[>>_,>84H@UO#T54_$QM7>JZ:G8=H@ W\2?P4]K'1L&I*BFJ'5M125$#2Q
MKHP",$Y]_P!ZM2(*+8>CBBM]UBN%;75-PJ(G!T?6[ $<B>9./>I"/1E/'K,Z
MB%7*9RXNZGA'#NS@Y\U:D05_5VD[?J>"-M:'QSQ9ZN>/UFCP\PJW:NBJVTU8
MR>OK*BN:P@MB<T-:<=QYDCRV6Q$05K6>DJ?5$%)%/424[:<N+>K:#G('C[E(
M7.S1U^G9+0^5[(WPMAZP#? QO]RE40:GUCIFILVDZ&Q69M76F>M,SGMC)X?1
MQ@XV R1S\%LNR4#;9:*.B8>(01-CXO$@;GXE9J("(B B(@(B("(B"+O'KQ^X
MJ.4E=V^H[PV4:H<V3]TB(B,Q$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1!K[I;Z/'Z^AMC([DVA[&Z0DNAZSCXN'_6&,</WJ^T\?4T\<><\#0W/
MC@+T1$[G6A$1$"IO25H&BUS0TL=14RT=72.+Z>HB&2W.,@CO&P[P=E<D1,3K
MN&H:CHIU#<X.QW[7]RJ[<<!\#(BTO'@27G/Q!6R]-V.ATY9:6U6N,QTE.W#0
M3DDDY))[R225)HB9M,B(B*B(B B(@(B("(B B(@(B("(B B(@(B((K4?^@L_
MV@_ J1TYZG^/-16I9 (((OWG/XO@!^H4MIT?L_\ 'FIAT8O2T-Y(C>2(U$1$
M!$1! :G]:/\ A_-0</K*<U/ZT?\ #^:@X?64H35O[O@IRG]4*#M_=\%.4_JA
M0/5$1$HZO_M.A]Y4BHZO_M.A]Y4B@(B("(B B(@(B("(B B(@*F=+_\ S&J_
M]I'_ ,85S5,Z7_\ F-5_[2/_ (PD#MT62,AZ/J&65P9&P2N<YQP  ]V25"5G
M2M%VF5EJM%1601>M*7\&WC@-.![UY6OK/^0Z;J<\752YQ[/6GB^[*SNA'J/\
ME:GJ^'KNTNZSQ]5N,^7ZJ18M':KH=44LDE('Q3Q8ZV%_-N>1![QYJNWKI/IJ
M:XR45HMTUR?&2USVOX6DCGPX!)'FJEH<N&M=1_1?]1V>JZO@Y8XO0Q]V%*=
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M!+:*U;2ZJI)GP1/@G@($L+CG&<X(/>-C\E$Z@Z0X:&[OM=IMT]TK(R6O$1P
M1S P"21W[*K]!PQ=[R&[ 1MQ]HJ T%%?I=07!MCJJ6GN'"[K34C)<.+?&6GO
MQE$-I:0UQ2W^MDH)Z66@N+ 3U,ISQ8YX.!N/ A6BLJ8J.DFJ:AW!#"PR/=X-
M R5K:TZ/U(-:4E\N]30/>U^9#$X@N'"6[#A Y+8USI(J^W55)4$B&>-T;R#@
M@$84):\_Y4I:A\LEMT[5U-)&<.EXSM[\-('S5MI=2LJ-(27X4<K(V0OE$,A
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MYJQ6.X,NUHI*^)A8RHC$@:>;<]RUUTU6U\+K;?:7T9H'B)[AW;\3#\#GYA1
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M]OK)ZZ>IC=#*&-$1: 1C.^05NRVTC*"WTU'$YSHZ>)L32[F0T8&?DM==!/\
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MBRJCT-=;]$ZEY]3U3<?Q<+_RP@P]&Z]N5)/<Y:FCK;J:A[7AK9'%L.[M@,'
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M6N_N8?D?YIH^79/(H'Z5KO[F'Y'^:?2M=_<P_(_S31\NR>10/TK7?W,/R/\
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M[.?!3_9![*=D'LH(#LY\$[.?!3_9![*=D'LH(#LY\$[.?!3_ &0>RG9![*"
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KH@XX0G"%RB#CA"<(7*(..$)PA<H@XX0G"%RB#CA"Y 1$!$1 1$0$1$'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g50309g16k00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g16k00.jpg
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M*"@H*/_  !$( K4%2@,!(@ "$0$#$0'_Q  <  $  @,! 0$
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MW X!,#@$%+K2D[W\I]R=:4G>_E/N5W X!,#@$%+K2D[W\I]R=:4G>_E/N5W
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MKW_N;?ZIWZD^->_]S;_5._4FC4<P93SL[HBX7\:]_P"YM_JG?J3XU[_W-O\
M5._4FC4<P93SL[HBX7\:]_[FW^J=^I/C7O\ W-O]4[]2:-1S!E/.SNB+A?QK
MW_N;?ZIWZD^->_\ <V_U3OU)HU',&4\[.Z(N%_&O?^YM_JG?J3XU[_W-O]4[
M]2:-1S!E/.SNB+A?QKW_ +FW^J=^I/C7O_<V_P!4[]2:-1S!E/.SNB+A?QKW
M_N;?ZIWZD^->_P#<V_U3OU)HU',&4\[.Z(N%_&O?^YM_JG?J3XU[_P!S;_5.
M_4FC4<P93SL[HBX7\:]_[FW^J=^I/C7O_<V_U3OU)HU',&4\[.Z(N%_&O?\
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MB(O<_,1$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%]'G7Q?1YT6'Q$1$$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$09JZ_P##EC^J
M?_O6%6:NO_#EC^J?_O6%4AMC_FCZ1^D"(BK$1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$%VR_SB@_ZB/_N"7K^<U_\ U$G_ '%++_.*#_J(
M_P#N"7K^<U__ %$G_<5/=M_U??\ 921$58B(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@+H7(?\ \6U'_1O_ .]BYZNA<A__ !;4?]&__O8N
M*_RR^A\+_P O#^KN2(B\;]%%IFL/YG#]8]BW-:9K#^9P_6/8K"2V&R^3A9)8
MVR^3A9)15*\>2?WM]JNJE>/)/[V^U74!8+7G_!MY_P"F?[%G5@M>?\&WG_IG
M^Q6GK##-?V:_I/Z/S0B(O<_,1$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0%]'G7Q?1YT6'Q$1$$1$!?>WL7Q9#3W-]?VSG\<STJ+;SV;.V,HZHIXJHI^;
M;Z7D]BI[?!4ZCO=-:7SC,<+V@N^W)&_V+5M36J*S75U)!70US QKQ-%V;]^.
MT^;'G\ZVKEL$_P +(C+M<R:9O-<,9=G\51Y);?37#6$+:MC9&0QNF:QPR'.&
M -WT9S]BSIF;<4R^MCX&%.8_H\*BTWB.*9F^W1J<E-/'$V22"5D;NQSF$ _:
MMHM&F:2MT%=+W)+.*NEEYMC&D;!'R.T8S_N/G6]Z8U+6ZAUA=[)=8H9;;LRM
M$)C'R UV!D^?=Q\_!5]+5'4.@=32TK62FCKY&Q;8VAD; :[[#@_8I-<]&V!\
M/P;S7Q7IM5UBUIB.MKN1ST\T! GADB+AD;;2W/BD%/-4$B"&24C>=AI=CP74
M[E<IM2<D-97W41RUE-4-#) P#_>T9W=FYQ"EOUVJ-&:-TY'8!%$:N/G9I3&'
M;9V6DYSQ+C]@5XYZ6]6$_#L.F]<USP<,5=/7UFUK7_=R,@AQ!!!&[!4K:6=T
MA8V"4O VBT,.0..%T;E6IX96:=NXB9#5UT0,S6C&3AI'AM$>"SW*=JNJTY=(
MH+7!3,FJ8 ^:=\>TYPR6M'V8/;GM3CF;6A*OAM&'.).)7:*+=(Z\73W<NN&G
M+A0VFWW":,&&M:YT;6Y+@!C>X8W9R"%AEV3E!U-=+=IC3\M).UCZ^F)J#S;3
MM98SB-W\1[%QM6B9F+RP^(9?"R^)P8<S/I%[_2)_GR;EH;1#M345352UHHX8
MI&Q,<8]O;<>T=HXM\5K%VH9+9<ZJAG_U*>1T9..W![?M[5VB'3=SIM&6*AM4
ME/#4Q3,K*@S/+<N!VMG<#YR!_:M1Y:[5T6_4]QC;B.LCPXCTV[O86^!7--=Z
MK/=G/AL8.5BN*;54VO/SO_YZ0JZ>Y-[A<K5+7UTW0(PPOB8^/:>\ 9R1D8"T
M1=8Y*[G6W1M^DN%3+4/BHV1L+SG9: [=_P#?:N3KJF9O,2\F<PL&G!PL3!B8
MXKWO[VFS*P6C.GI[M43<U&)1! S9R9G]KO/N 'G^Q8QD;WN#6,<XGL &<K:=
M5?Y6EM*T[/\ 3Z/+,<>=SI-_L"R-WO5;:=)Z8;;)332RT\ADFC #W 2'#=KM
M WDX^E+RXJR^'>8F;133$S[WF;>?/^FB$$$@C!'F7Q;[>97U=9I>XR=7]-JJ
M-QFDK6MYEY:7 .>",$X_'"L[=1C_ %-"?^B+W)Q+_11>8XO]?.(GY^6H6>@M
MM13R3W2[-HVM=LMB9"Z61_T@;@!].5>K=.T<(MM7!=.=M-9*834F$M="X=H<
MPGZ<]O8L1:WT$=8YUUAGGI\'Y-/(&':SVY(.[M6S:I-/6:2M]59<PVB"H= Z
ME>WY;9BW:+B[)VLCS[L<$F]TP:<.K"JF:8O'UOU^MK6^7JUB\VZ>TW2IH:H#
MG8'[)(["/,1]!&#]JI+:^4#_ #)K'4O_ -:HM5.^0^<NP1GP 6J+JF;P\^8P
MXP\6JFGH(B*L!$1!FKK_ ,.6/ZI_^]859JZ_\.6/ZI_^]852&V/^:/I'Z0(B
M*L1$1!;M=OJKI714=!"Z:HE.&M'M^@?2MSEY+KO' ]QK;:9F-VW0\Z0X#_TJ
M[R'1LZSNTP:'5$=.!']1._V!<[J*JHFJY:B:5YJ)'$O>2<DGM7%YF9B'TZ<+
M P<O1BXM,U37?WM:WVZH$72]&T]%9- UVI9:*"LKA+S<0F;M-8-H-]I)_!>M
M1QT>I.3OX1=!IZ.XT\NQ(8&[+7C:#?M[0=_!./U2/ATSA\7%_P N'BMX^O[-
M8UOI?X,5%'$*OI/2(N<SS>QL[\8[2M97<.4#4<5@K[01;:6KGFBP]\[=HMC!
M[&\"<G?] 6(U1I>W5'*C:J*.!D--5Q<]-'&-D.+=LG '9D- W+FFOT]7JS?P
MRG4JC GI-,6]?3BZ>KDR+L]->;?6ZUFTK)8K>+:"^%I$0#@YK22?P/9O^E8?
MD_LM+3<HUZMDL;*BG@AE:T2-#MVVS';Y\%7C]/6&/X7>NFFBN\35--[=)AS:
MCIIJRJAIJ6,R3RO#&,'G). %ZKZ.>@K)J6KCYNHB=LO9D'!^Q=5TMJ>AJ-6T
M-EMUDHZ>DAD>R.9PVI/DM=\K/F)Q]/:5K7*C?7UMYJ[:ZCHXFTM02)HV8D?N
MQ\HYW]J15,S:SC%R6#1EYQ8Q+S>W3TZ?SU:.MMN.@[K0:<%YF?3F#FV2.B:3
MSC0[':,8W9W[UC-&VKKK4M!1$9C?('2?T#>[\ NWFBN5=J6]4]=2EMCJJ-M/
M&_;:=XS_ +<Y'\;O-Y@E=?#+;X;\/IS.'557$^LVBWM-IF\^.F[A6G;'6Z@N
M H[<QKI=G:<7NV6M;Q/BL_?.3RZVNV2US9J2KAAWRBG>26 =IP0.Q:U)#66R
M[34L3I8ZR.1T!YHD.)R6D#&_?_[KH(#="Z'K:2ND#KQ=V$=&!SS3""W)^PG[
M=WF)2J9CHRRF!@UT5QBTS'#>]5_2/E%K=9ES!9"\6J>TR015;HQ/+$V8Q-)+
MHP[L#MVXXWX^E2:5IF5FI+73R@&.2IC:X'SC:&0LNZ47+E.8ZJ:V1DMT:QS'
MC(+>= #2#YL !=3/J\N'@Q5AWGK,Q$?O^S5$70:2[P.UIU*RU6T6E]8:4Q&G
M:7$%VSM;?\6?/V[E0M%H?TFY0T^GXKK'!4OB$DE0Z,M .,8#AGBIQ?-I_1WF
MU%5_68Z3UCZ7FS35LM/I3;$3)KU:(*J4 L@=.7'?V EH+0?M5C4]NEI;9SDF
MFH;:W; Y]E2Z0^?=@N/_ -A5=,T^G7N@DO-=51RA^3$V+_+.#NR\9(!\^ E[
MQ>"C+Q1B:>)$3]9FF/\ <1/\]U5^G:YC;J'AC:BVD&>#/R]G."X;L$#=G?YP
ML,NC6]];\;4L5U;'MUI?#,V(Y8Z-\9V<'SC&SX+GDS.;E>S.=EQ;E6F;N<S@
MTX<7IOUF/7Q_\G_3PB(NGC$1$%VR_P XH/\ J(_^X)>OYS7_ /42?]Q2R_SB
M@_ZB/_N"7K^<U_\ U$G_ '%3W;?]7W_921$58B(B B(@(B(-FTMHVMU'1RU%
M'4T438Y.;+9WEKB< [L \5DKIR:W6VT-355%9;MF")TKF-D=M$ $[@6]NY:I
M9?YQ0_\ UX_^X+<>6O\ XP9_TK/^YRSF_%:[ZF%1EYRM6+51/%3,1U^=_7HT
M%>HV.DD:R-I<]Q#0!VDE=6K*BDT-I*QR4=LHZJMN#.<EEJ&;7^T$CC_N 'FW
M*U<J.WT6I])WFAMU,QMU+&O@<SY,;G;!#V@8 < X^U-3PZ_"[>DU^L<-XMTB
MKI]>KE-UMM7::Z2CN$)AJ6 %S"0<9&1O&[L5-=(Y7KZ]]WJ[/T.D#&&-_2 S
M_-/R0<%V>S>L]IFGNU!26FFKK=IVBII-ECVU)#9YP3V@>E@C<?/VIQ^EY/PZ
MBO,5X.'5-J?>WFUI_P#7-=&V'X1WMEO-1T?:8Y_.;&UV#AD+'7:CZONM;1[?
M.='F?#MXQM;+B,X^Q=7M=NIK9RS204,38874YD$;1AK26;\#S#*YGJS_ (IO
M/_63?][E::KRXS.4IP,#U_-%4Q,_2R&"U3RV:IN9=''2PR-B!>3F1YW[+=V\
M@;S]"QZVO5'_ (?2FEZ2/<QT,E2__F<Y^,GZ@,*]<*^*R:<T[+0T%#TVHIW.
MEGE@;(2 \@8!&,]N3V[@G$RJRU-YB9MPQ$S][=-VC(MXNU+%67'3U92VFGFE
MN%(9):.,\U&][2X$C!&SV9W'S*YU+4?_ ,D4OWY__P#T3C6,A7,S$3T\5?*_
MM$_-IEDL]5>*B2.EYMK(F\Y+-*[8CB;Q<[S!6I['"VNHZ6GO%NJ'5#^;VV%^
MS&=V-HEO8<]HRLY8FT,/)W737!\[8IKBV)[(,;<H:S::W)W 9).=_8L7=;7;
MI+ R\V5U3'$VHZ--!4.#G,<6[0+7 #((!\R7]5_IZ:<.)M$S:\^OK:_M]ONP
ME?234%9/2U3#'/"\L>T^8A5UM7*'_FW"V5KO]6MMT$\IXOP6D_E"U5=1-XN\
MN8PXPL2JB.D"(BK$1$0$1$!="Y#_ /BVH_Z-_P#WL7/5T+D/_P"+:C_HW_\
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MU!9_FFW_ '9GN3J"S_--O^[,]RR2)>31P^V-F-Z@L_S3;_NS/<G4%G^:;?\
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M8V8WJ"S_ #3;_NS/<G4%G^:;?]V9[EDD2\FCA]L;,;U!9_FFW_=F>Y.H+/\
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M*.YRQVMTKR__ "!@'9<=Y9M;0"H<IESNU7>([$VRWZ33Q8'UU3;:?;?4@_\
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MU-'.W;CEC.0X?_?F\R"VB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("+F\
M^IM3CE,L%OJJ*"W6&NEJX&1/(DGGYJ(NYPD;F-)Q@#?CM[<+I" BTJUWR[7W
M5>IH+5+3Q6VT,%%%SL>TV:M+=IQ<1O#69:T@=N2L!JVKUCHRT17VLU+2W39J
M(8Y;;U>R)DP>\-+(G [>T,Y&2<X[$'5$6LZAMFIKA<@+5J"GM%M;&/\ 3HFS
M3O?DYR7G9#<8Q@9[50Y,[[<[J+]07F>"LJ+17NHQ701\VRH :'9+<D!PS@@;
MD&ZHM8U!:]47"YGJO45/:+:V,;(CH6S3/?OSM%YV0.S&!GM6MV"_ZFNVD-4Q
M055+/?;)62TL%9' !%6&,-?@LR0"<EIP=Q[$'2T6)TE?(-2::MMXI1LQ5D#9
M=@G)82/E-/T@Y'V++("(B B(@(B("(B B(@J4OE];_9[%;52E\OK?[/8K:$"
M(B B(@(B("(B B(@(L7J.*[SVTQ:>J:2EK7/:.?JHC(UC/\ <0T$9=CL!..*
MT^AN&HM/:]LMCO5XBOE'>(:AS)#2-@EIWQ-#B3L'!:0<;QG/G0=$18W4MX@T
M_I^XW:LR8**!\[@#O=LC.!]).[[5I=1J;4%MT=I]L[::HU9?IFQP1/;L0TY>
M"\[0&\MC8-_G)'TH.C(M<TM;[S2RRS7?4PO,;F;/-LHXX61OSV@MR>(P25K%
MFN6H];B:YVR_06&ROFDAH(V4K)YJIK'%IE<7G !(.&@=GG0=*10RQS.HWQQS
MAE08RULQ8#AV-SMGS[]^%R[6PUII;359=9=<05#X@&PT[;)&'32N.RQ@^6=Y
M<0.PH.KHM#JKU?-.W31[;[/#/27-C;?6ED8;S5:6[37M(_VN(<W'U%;X@(B(
M"(B B(@(B("(B"*L\DG_ *'>PI1^20?T-]B5GDD_]#O84H_)(/Z&^Q!*B(@(
MB("(B B(@(B("(M7O]KU1<+H\VS4=/:+:U@V&Q4+9IGO\^TYYP!PP$&T(M-Y
M+[_<;W;KM#>)(*FJM=QEMYK*=FPRI#,';#<G!WX(!QD*36M]KJ:]Z>L%E>R.
MX72=SY)G-#N9IHAM2. .[)R&C/%!MR+F]15:HONN]1VVSZCI[10VH4S6M?;V
M5!D?)&7NWEPQC=Q[5D-77B\Z7TE;J=E7!<M15]7%;H*F2#FHS+(XX>Y@)P&M
M!.,[\(-X1<\IJ_46EM6V2VZAO$=ZMUY,D#)S2-IWT\[6[8'R3@M< X;]X(&]
M9?E'O]=9;70P69L)NUTK8K?2NF&61N?DF1P\X:UKCCZD&V(N>T5PU!IG6-GM
M&H;O'>J"\ME9#4&E;3R03QMV]DANXM<W./."/'*:&OM;5W34%BO3VR7*T5(
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MH@TW0U.UM;4S-T-!IIHC#&S?^'$DN3DMQ%G#=P.\_8MR1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MCQ/8  23Y@%B=;<H%KTK,RFECGK:XEA?!3#)A8YP:'R'L:,D 9WDG<J5^_\
M$\LFEH9C_ETMOJZF('L,A+&'[=DE>N6F-C= 5\@8T2.GI YP&\@5,> 3]I\4
M&S:IOU)INR5%SKQ(Z*+9:V.)NT^1[CLM8T><DD!82SZRJ9;Y26K4%AJK+4US
M'/HW231S,FV1ES,L/R7@;\'Z=ZI\KFZFTJY_^@W4-$93YMG:=C/T;6RG*<<W
MC0K8_*#?8RW';L"*3;^S"":X:YJNL[E36#3M;>8;8[FZRHAFCC#7XR6,#CE[
M@#O \^Y7)-;VX6RP76)DDEINTK86U0P! Y^YFV/-EPV2?,5C>1[=:;^U_P#K
MMOM:)N.USGG^S"TZC@CJ?\.VH-HXIVNK9Z8\ RH>]A']S=R#MR*E99Y*FST,
M\W^K+!&]WUEH)5U 1$0$1$!$1 1$0$1$%:#RRJ_M]BLJM!Y95?V^Q64($1$!
M$1 1$0$1$!$1!\<=EI."<#.!VE:#7Z^N=OHI;I6Z-NL%DB^5)4/FB$S&>=YA
MVMH =O;G"W]<TY5;=JBILUUD974,NGHXW2U%#&PP5$L#1E[.>.T 2 >QHW;L
MH.CTTT=33Q3P/#XI6A['#L<TC(*P]+J."JU/<+/3Q/>+?"R6JJ2X".-S][8_
MI=LC:/F PK>FZRFN&G[964$9BI)Z:.2&,C!8PM! ^P+4N2 "6BU-62;ZBIOM
M89">T;+PQK?L:T(+VG-?6W4.JI[/:XJB6*.E=4LK2W9AF#7AAYO.]PR<;79N
M.%/J35DENO4%EL]IGO%WDA-2Z".5D38HL[.T][C@9.X#SX*QC(V1<M<,<3&L
MC9IPM:UHP .DMW )I_Y/+#JX2_ZCJ"B,6?0_S <?1M(,C;=<6^HTY=+M7Q3V
M\VISXZ^FG ,D#VC.SN.'9!&".W(5&W:[J376R.^:=KK/1W1XBHZJ:6-X<]PR
MUDC6G,;G ;@?/N7/]>Y<_E5='OI1/:.=QV;BWG/PV<K>^6<@Z4H1$1S[KK1"
MGQZ?/-QC[,HK8[5J&&MU!=;+)#)3UU!L2;+R")HGCY,C3PR"#P(6;6@WX=&Y
M8]*30[I*NWUE/-CSL9L/;G^XGQ6_(@B(@(B("(B B(@(B((JGR:7^@^Q*;R:
M+^@>Q*GR:7^@^Q*;R:+^@>Q!*B(@(B("(B B(@(B("QVH+Q16"SU-SN<O-4E
M.W:>0,D[\  ><DD #B5D5SKEI%7)0Z7@HC$U\U^I6[4P)C!^66[0':-H-.//
MC"#8-.WV\76K;TO3%5;*!["]D]14Q%_T!T;22TGZ]WG6?K*F&BI)ZJJD;%3P
M,=)(]W8UH&23]@6AU%5?]+ZGT_#<+V;S;[O4.I)(Y::.)\,FP7->PL ^3\D@
M@YQQ4_+A*^/DPO(C>6<[S,+G#S,?,QKOP)09&+6U!'I&EU!<HIJ*GJ\=&IW#
M;FFVB>;#6#M<X8(:/,=_G5W16HHM4Z=@NT---2LE?(SFIB-II8]S#G&[M:LO
M'30,A@B;$S8@QS8QG8P,#'#=N6@<E8D=R5RB#//&2N#,>ES\N/Q0>I.4IQI:
MB[4VGJ^HTQ3R.9)=&2,WM:[9=(V+.TY@(._@#N6;U)JZ.V2VRDM=%+=[E<FE
M]+34[VM#HV@$R.>XX:W!&_SY6N:0?3#_  _T[G%O1Q991)PW1NVOQRL5R=B1
MNL=)=+R''1L0CVO2$C-K[<;**W.T:P?<*.\L=9ZJGO=I:'5%L>]I>[+2YI8\
M?)<' '!XCS+.:>N])?[)1W2WO+Z6JC$C">T<0?I!R#](6IT!SRW77FOX&V.
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MT /@@=&^+<,9:U[';)W>96]*::HM-4M1'2/J*BHJI3/4U53)MRSO.[:<?JW
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MPY)(():"2 S?D=A0;?R*ZMFUCH*CKZ[^8P.=2U>[&9&8WX\V06GZRMZ7'/\
M"\UTFDK]7-:6T]9>)I80?.W98,^.[[%V-$$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$&J7[2E=<[G-5P:MOEMB>!BGI71"-F!C=M
M,)WXSVK6.3:._P!ZT_J&I@U/7/IJFK,%JK:J*.5[8HSLNE#<!IVSM8R-V =Z
MS?*W=:FFT]%9K2_9O%^F%NI2.U@?_J2?4UFT<^8X69=+9M$:4IHZJ9M':*&.
M.F$CP2&C<T%V!YSVGZ=Z#1K@;AI75>F*>VZKN5ZFN5:*>KM]:^.7,):XNF;L
MM!8&X!X;UU65XCC>\]C025PVXC2%+?\ 3QY*IJ7KZ6OB;.RTRE\;J3/^;SX:
M2W9 X[\XPNLQZGL\]SO5M;4[57:8VR5L?-._RVN:7#S8=N'8,H.9\FPGU+9;
M37UG*+<FW2J;SS[?%44^X;1PW8+"[&,+KUTK8;;;:NNJCLP4L3YI#P:T$G\
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MBNHV:X0W:T45QI3FGJX&3QD^BYH</P*MK5^2RFEH^3?3$%0"V5EN@VFGM&6
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MT#)XG"D1!\+0[&0#@Y&?,OCXV/+"]C7%AVFDC.R>(7I$$513P5#0*B&.4 Y
M>T.P?M4H    P B(#@' AP!!W$%1T]/#3M+:>&.)I.2&-#03]BD1!\#6AQ<
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MF,_/FGAY[O-@;7CVJ1\;'EA>QKBP[321G9/$+TB"&:EIYWM?-!%(]O\ "Y[
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MI7CR3^]OM5U4KQY)_>WVJZ@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M7/\ Z4$DS6OD\WR6DY/V+5N5K6E3H/3<5YI[6+C"*AL,[3-S9C:[.'?PG.\
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M+*9'%I: T8V>P;F-0<DUF;16Z_H-$:>T3;;K7V>A#&2W&I<V*"'9:X-QO+\
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MDYMT7,2/+CLEQ=_%VYR<@^9!P7EPK*9_^'[04+)XW2O%*YK0X$D-IW!Q^PD
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M%(W&S(T>?L'B[Z$1RW0VB;1K3EAY0XM0QS5-%1USY&THE=&Q[W2/ <[9(.0
M<;_.LEJ.>WZOY0+];;)HJS5TUG@%-5W"ZU3HVM8S+=S1V8WC:[<#S;EV73^C
MK/8+Y>+O;8)(ZZ[2<Y5/=(YP<[).X'<-[CV+ WWDATA>]1RWJOH)35S$.G9'
M.YD<QXN:..!G&,^=%?G&WU$LO^&6ZQ22.='#?V-C!.0T&-AP/HR2?M6S<JNC
M[1I/2^@+O9*<T]UDJ(3-5![B^5Y8'ESLGMVAG[5VYW)5I0Z;K+"V@D9:ZJLZ
M=)"R9P_S< ;CG<, ;AN63U-H:QZDMMLH+M3RR4UN>U].ULKFEI:-D9([=R%W
M*^7F 1<IVAZZLHA?*'$D74[,/DD<,DN##N/:WM]$!<]U)I:[:?T9K;4;K&+'
M3W2LBAI*=S6\]3T[GN+QD?P-=EC2!C/9V86^\MEJJ;IRB4+M4V2]7+1\%*>C
MFS4XDD;,[&UMG^(#=V9'8W'G5;DCT*Z75]YDI[)=K?H6JHS ^BO.YU2\EN_8
M\V,$@^;COW!@+3H34E33:/N]@T]9+4*-\,S+C37 ;=4T[/\ 'D[R>'TD?0NA
M:O\ \G_$OHE]/_K36^:.8#SL#9B,_;GP6<LW(KHVT7FEN5'25?.TLS9X(WU3
MW1QO!R"!G?@CSDKW8M)72IY6KMJ^_LBBAA@%#:H6O#R(_P#=(['83\K=_P Y
MX(.C(B(@B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@J4OE];_9[%;52E\OK?[/8K:$"(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B((JSR2?^AWL*4?DD']#?8E9Y)/\ T.]A2C\D
M@_H;[$$J(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@+3-8?S.'ZQ[%N:TS6'\SA^L>Q6$EL-E\G"R2QME\G"R2BJ5X\D_O;[5=
M5*\>2?WM]JNH".(:"3V!%XF_TG_4@\](C]+\$Z1'Z7X*DB"[TB/TOP3I$?I?
M@J2(+O2(_2_!.D1^E^"I(@N](C]+\$Z1'Z7X*DB"[TB/TOP3I$?I?@J2(+O2
M(_2_!.D1^E^"I(@N](C]+\$Z1'Z7X*DB"[TB/TOP3I$?I?@J2(+O2(_2_!.D
M1^E^"I(@N](C]+\$Z1'Z7X*DB"[TB/TOP3I$?I?@J2(+O2(_2_!.D1^E^"I(
M@N](C]+\$Z1'Z7X*DB"[TB/TOP3I$?I?@J2(+O2(_2_!.D1^E^"I(@N](C]+
M\$Z1'Z7X*DB"[TB/TOP3I$?I?@J2(+O2(_2_!.D1^E^"I(@N](C]+\$Z1'Z7
MX*DB"[TB/TOP3I$?I?@J2(+O2(_2_!.D1^E^"I(@N](C]+\$Z1'Z7X*DB"[T
MB/TOP3I$?I?@J2(+O2(_2_!.D1^E^"I(@N](C]+\$Z1'Z7X*DB"[TB/TOP3I
M$?I?@J2(+O2(_2_!.D1^E^"I(@N](C]+\$Z1'Z7X*DB"[TB/TOP3I$?I?@J2
M(+O2(_2_!.D1^E^"I(@N](C]+\$Y^/TOP5)$%WI$?I?@G2(_2_!4D07>D1^E
M^"=(C]+\%21!=Z1'Z7X)TB/TOP5)$%WI$?I?@G2(_2_!4D07>D1^E^"=(C]+
M\%21!=Z1'Z7X)TB/TOP5)$%WI$?I?@G2(_2_!4D07>D1^E^"=(C]+\%21!=Z
M1'Z7X)TB/TOP5)$%WI$?I?@G2(_2_!4D07>D1^E^"=(C]+\%21!=Z1'Z7X)T
MB/TOP5)$%WI$?I?@G2(_2_!4D07>D1^E^"=(C]+\%21!=Z1'Z7X)TB/TOP5)
M$%WI$?I?@G2(_2_!4D0>Z::,5U8<[CL>;Z%:Z1'Z7X+$P>657]OL5E"%WI$?
MI?@G2(_2_!4D07>D1^E^"=(C]+\%21!=Z1'Z7X)TB/TOP5)$%WI$?I?@G2(_
M2_!4D07>D1^E^"=(C]+\%21!=Z1'Z7X)TB/TOP5)$%WI$?I?@G2(_2_!4D07
M>D1^E^"=(C]+\%21!=Z1'Z7X)TB/TOP5)$%WI$?I?@G2(_2_!4D07>D1^E^"
M=(C]+\%21!=Z1'Z7X)TB/TOP5)$%WI$?I?@G2(_2_!4D07>D1^E^"=(C]+\%
M21!=Z1'Z7X)TB/TOP5)$%BKGC-+,-K_8?-]!2DGC%)"-K_8WS?0J53Y-+_0?
M8E-Y-%_0/8@R72(_2_!.D1^E^"I(@N](C]+\$Z1'Z7X*DB"[TB/TOP3I$?I?
M@J2(+O2(_2_!.D1^E^"I(@N](C]+\$Z1'Z7X*DB"[TB/TOP3I$?I?@J2(+O2
M(_2_!.D1^E^"I(@N](C]+\$Z1'Z7X*DB"[TB/TOP3I$?I?@J2(+O2(_2_!.D
M1^E^"I(@N](C]+\$Z1'Z7X*DB"[TB/TOP3I$?I?@J2(+O2(_2_!.D1^E^"I(
M@N](C]+\$Z1'Z7X*DB"[TB/TOP3I$?I?@J2(+O2(_2_!>F2L><-.3]2H*>C_
M -4_4@MHB("TS6'\SA^L>Q;FM,UA_,X?K'L5A);#9?)PLDL;9?)PLDHJE>/)
M/[V^U752O'DG][?:KJ O$W^D_P"I>UXF_P!)_P!2"@B(@(B("+1M4UE38^4/
M3=>ZIFZIN8?:IX2\\VR8_+A>&]FT2'-SP6/Y037ZBU?;]+VBOJJ(0T4]PJY:
M:9T3@2TQPMVFD?[R78_Y4'247(ZC4E?=N1NP1TE5-!?+O)!:>?:XB1DVWL2O
MSV@@,><KY5ZGN,G(BS8J)6ZBD>VR%X>1(*GG>9)VNW:P"[/:@ZZBY3>K:VNY
M3Z:RUU\NU+04U@CE;S%PD@YR03.9M.(/RG$=I.];-3!NDZ.C@M$5XO\ %6US
M8I)7U3JEU,'#!>7.)PP8&[Z4&X(M'Y4JNLGI;5IVSU<M)<KW4B(3PN+7PP,^
M7+(".S  ']RN<G5^?<]%P5-U>&5U"'TM>7G^"6$EKR?KQM?:@VQ%I-CUK77V
M:FJ+7I>X26.HD#&7"2:*/+,XYP1EVUL>?CCS*_RDWV?3NC;A740#JXAL%*#O
MS+(X,9X%V?L0;.BYC7VF4WRPZ8KKQ<Q206B>JDJ&5DD<D]0U\;=MSP<G9VG.
M SC>-V L31ZT-QL>DJ>[7;H,;:>&NNU9SIC<\;^:B!&_:E+2X@?[6GS%!V1%
MIG*%4S5&AY+]INO)FH&BXT[X)28ZAC-[F.P<.:YNT,<<'S+:+3717.UT=?3Y
MYFJA9.S/HN:"/:@MHB("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(M:O^DX[[<>D5UVN\=*V
M,-924M4ZGC#LG+R68<X]G:<#"#946A\E-QJ'V6]MKKA+6V^WW*>GI*ZI?M.D
M@9C>Y_\ NP=H;7GPM=IKW=;URF:3N@J*BGL%<^KAHJ0.+1-%' 3S[V^?:<<M
M![&M!\Z#KR+Q,QSXGL9(Z-SFD![0"6GB,[O%<GUY8I=):=;>;;J"^SZA940L
MA-16OD;62.D YHQ?P8()W #&/H0=;14KQ<([59ZVXU/^E20/G>!P:TD^Q:;I
M.S7*]Z"I)KG>KE35UU>+A4R4TNRYK'_*$+"<\VT-+1\G!W'B4&_HN:6ZDDTW
MRH6RSV>Y7&JH:NAFGKJ6KJGU @V2T1R O)+2YQ([<'"BUM\(:76FF:JHNQBM
ML]YCI8*&D)8U\9C>XNF/:YQ+<;/\( \Y*#J"(N8<MWPA@T]6U]#=C;[92-A<
M&4I+9YY'3-:0Y_\ M8 <X;O)[=R#IZ(L-J6QNOL,$#KG<*&G8\NE;12\TZ88
M_A+P-H#ZB$&91<YTH)++RD7>QT5QKJRRPVV.JE;5SNG-+.7D!@>XD@.8"[!/
MTK5[/?;#J5G6FL-5U-)-6R.=2V^GKY*:*DAVB(]OFR/EN #LN/\ N"#MR+S'
MC8;LG:;@8.<Y7,K5:Y==W?4M=<;K=::GHKA);:&&BJWP-AYH .DPT_*<7$]N
M>Q!T]%R!]\O,W)<R_=+E?>M-UDC:G8<6LJV0R%D@>T;CM1_*^APR,+K5)/'5
M4L-1"[:BE8)&'B",A!*B(@(B("(B"M!Y95?V^Q656@\LJO[?8K*$"(B B(@(
MB("*E>!7FV5(LYIFW MQ":G/-AW%V-^%I/)4;C%>=8T5VNM3<Y:6NB8)IS@9
M,+7.V6]C&Y)PT=B#H:+FVK[5I^CGKJK4.L;K35D@=-#&VZ&%T+23LB*%A&UV
M8&YQ)'G6R\F\]VJ=#V:;437MNKX 9N<;LO.\[)</,XMP3]*#9$7+=;Z@IJK6
M<MENE]ELUDM]/'+4FGF,4U5-*7;$8<WY0:&M).SO.5N>B.I^HFNT[<)*^@<]
MQ$LE4^H(=YV[3R2/J/8@SZ+1F5U5>.4^MIHIYV6W3U(QSX8WEHGJ9@2-K'\0
M:P;@?.[*U.Q6^IO_ ">2ZQJ=2W2FO<D<U6R6.L<RGIBQSL1<UG8V!L@$$$G>
M@[*BPNB[NZ_Z2M%UD:&25E+',]H[ XM&0/HSE<PNMPL=5RAZJAU/JRX6J.GF
MIX:2"&YR4S .9:7G#3C>X]J#M**A88*>FL])%0U<E93-8.;J))S,Z1IW@EY)
MVOK5+4NGNOG4S)KI<J2DBVC)!13\SSY.,;3V_*P-^X$9R@SB+E^GKA-IR\ZX
MI(*ZLN-EL])'51]+F,SH9=ASG1"0[R,-:<$[LK%26BZ4O)LW6HOMU?J1M(VZ
MOVJIYIW-QSAA,.=C8V<C<.W>@[*BK6RK;7VZEK(QAE1$R5H^AP!_]US/ECOM
MPJ;5>K7IVJEINK:-U9<:R%Q:Z+Y),<+2.QSC@G@T?2@ZJBYWK*NK++IS3FIX
M*J<,H'0"NBYPED]/+LL>7-["X$M<#VC!XKH?;V(/J(B B(@(B((JGR:7^@^Q
M*;R:+^@>Q*GR:7^@^Q*;R:+^@>Q!*B(@(B("(B B+1>5N*^OTS<9K1=&VVAI
MJ*>HGDA!Z1(]K26L:[L:TXWD;]V!VY0;TBU&KJ+L>2SI%F+YKR;4U\!/RG.D
MYL'._M=]?:5SZUUE$ZKTP[1FH+S<;[+51=8T]15RS 0YQ.9XW'$9'8-P.<8R
M@[>BIWBJ?16FNJXH^=D@@?*UGI%K20/MPN21T%2.3!NMFZFN?7W0^LC*ZK=T
M<NQM<QS.=C9_V8QG*#LZ+$T5[AFTI!?9AS<#Z)M:\>BTLVS^"YD^Y7IO)Y9J
M^>Y5--7:JNL#9Z@2'_P4$Q):V+.YF&-:,\7$]J#L:+F=73_ ;5^F8J"ZW"HH
MKO.ZCJ*.MJWU!+M@N;,PO)+2" #C<=H+<]9U;Z'1]]JXGN9)!0SRM<TX(+8W
M$$'CN09E%Q_DX&F*TV5S-:7.LO@BBEDI9+S(YLDNR"YO-DX<,YW;UV! 1:)J
MC2-.ZFNUWN>I+["]C))XY8ZYT,=(T D!K&8:0,?[@2?.L#6:MN\?)II(UE8R
MW7B]\W%-72@-Z/$&.?)-@[@[8;GZW(.LHM$Y/3I=]=4.T_J"MNE:V+$S:JOE
MF<6DCY>P\X&\?Q  ;\>=7N5*[UEGT?4/M<G-7"JFBHZ>3&>;?+(&;7U@$GZP
M@VU%S"[6N70=QT[<+==KM505=?%;Z^*MJWSMF$N0),.)V7!P'\..W"S%BK*F
MU\I-XL%3433T=;3-NM%SKR\Q?*V)8P3_ +<[+@.P9*#=T1$!$1 1$0%/1_ZI
M^I0*>C_U3]2"VB(@+3-8?S.'ZQ[%N:TS6'\SA^L>Q6$EL-E\G"R2QME\G"R2
MBJ5X\D_O;[5=5*\>2?WM]JNH"\3?Z3_J7M>)O])_U(*"(B B(@U?E,LDE^T7
M<J6DR*Z-HJ:1S>ULT9VV8^DD8^U83DACJ[G'>=5W:FDIJV\S@,AD:6NC@B;L
M,;@]F3MG[0NAH@XWI6Q5T?*Y6V^:GD;9K34U-UII"T[#GU+6 -'F^3F7Q22Q
M5WQS,M8IY.H36?"/;V3L"7FN;QGLSSGRL?2NR(@YM>=.4%]Y9#UU:X:ZB98&
M[!J(=M@DZ0[L)&,X)^PK8YIK+H>EM]'0VM]/3U]:VG9'04^6MD?_ +W@=@^3
MO*V9$'+W:?J-::^O%TGK[O:J2TAMMHI*.00ND.-J9V7-.1DM;D=NRJE)INKL
M5]U+IJ"JKJNBU';9)X*RK.V6U0:6/#G  9+2PY^A=;1!SG0&LJ"DLECT]<J:
MOHKY3Q14$E(ZCE.'M 9M!P;L[!QG:SC"M<M37,T4*X-+F6^NI:R1H&<L9*TN
M\!O^Q;XH:REAK:2>EJXFRT\[#')&X9#FD8(/V%!KVNK?8Z^P27"]4!N$-'$Z
M:(0EW..R,;+2P@G:W#'8=V5HT-E.E)-)WJ\P;(-3//<G0Q%[*9\D!9"T-:"0
MR-H$8\P^U=1L5LBLUHI+=323204S!%&Z9VT_9'8"?/@;OJ"OH.76^;J;D2O=
M56Q/IH9(Z^:""5NRYL<LDAB:6GLSM-W?2MUT-12VW1EBHJ@$3T]##'(#YG!@
M!'BI]06*COT5+#<><?3P5#*CF6NPR1S#EH>/.T'!QQ 650$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!<LY2]7?^=C3&W<+?0.8'W"X4])+*]S",\S$6-.'$'>[S#LWKJ:
M(.;RTMNUKHE^GM&UDMIHJ9T4<@FM\K6NBWGF\/V"0[&\@\<]JPNH+#J^/6NC
M&=?4,CHS5-AFBM!;'3#F<'::)"""-PWC'T]B[$B# #5-(*Z^4;J>NYRSPMFG
M?S!V9 6%V(S_ +C@=G%<TLNLK3=;\W4.K!<HYX"YMNMK;;4/91M.XO<0S#I7
M#SC<!N"[4B#7-;T[KUR?WN&B#W/J[=*(ALD%Q=&=D8.\$[MRUJ76[;-R46*[
M6^DEK9ZJEAA@CCC<]K)-C!+]D$AK2TYP,[L#M72%BM/6*CL%/44]MYQE--.^
MH$+G9;$YYRX,'F;G)Q])0:-R<7JP4]8Z(55QK]171X=5UL]NGB$KP#AH+F ,
M8T9#6YP/K65Y2H)9KKH@PQ22".^1O>6M)V6\W)O/ +>408B]WZGL]9:J:H@J
MI7W&H%-$Z&+;:QQ&<O/^T?2M>Y:X):GDTO$5/%)+*YT&&,:7$XGC/8%O"(,9
MJ"T]<T(INGW"@P\/YVAFYJ3=G=G!W;^SZ M-UK?9]!Z>HK=;Y+E<*ZL>YD=;
M5L?5=';G+I)-AI+L;0PW&_["NBH@YUR=W#3?1I;+:9KE45]6'S5575T,T3ZB
M0CY3W/>P#/ 9W#<%K-DN5!IKDWJ]&W.SUAO<<4U**.*B>\5KG%P;(UX;LD.R
MTY)W?8NUH@T[3->=.V_2.F;K%5RW.>B$9ECCVXF.BC&T'O\ -P'%8"SWNGT'
M=M36^^P5K8ZNXRW*AEAI9)6U#9<$L:6@X>' C!QVA=01!R%]/46#D)U#/=X'
M05UR955#Z=P^4R2I>0QF./RF[N*Z;IRD?0:>M='-_JT]+%"[ZVL /L4=\L5'
M>I+>ZX<X^.BJ!5,A#L,?(T'9+AY\$Y [,K*H"(B B(@(B(*T'EE5_;[%95:#
MRRJ_M]BLH0(B("(B B(@+1M P2Q:OUX^6*1C);A$YCG-(#QS#!D<5O*(.<ZC
MU/HBMFJJ>_VN6IKHMJ#F)[1+)*_!. P[!R#V@@XWY7W1-RJ])Z L$>I::XNJ
M:JJZ+%$&&:2!LCW&(2'.X-;@'AV+HJ(.9W"2ETARGW2_7FDF-!=:2%D5?'3N
ME%/)'EKHW;();M#9.>PX5[DQBDJ+MJR]PTDU':[I61R4D4T9C<\,C#7R[!WC
M;=OW[SC*WY$&@Z1/0^5+7-'-\F2J%)6PY[7Q\WS9(^@.;C[5J^JZ;2-1-=:7
M35EJJ_4L\DD8IHHZAE.R<D@RR-.(@&GY6UC?C=Q74:RQ4=5?J"\GG(Z^C8^)
MKXW8VXW=K'C_ '-R 1P(650:I:*BETC2:5TM)'5332T_1XYHHBZ,&)@VB\_[
M<^95KQKC3=%5UM#<X*SI3'&-T!MLLAGX;)#2'@^;>MT1!S70>D:N705+1UU3
M=K'FKGJH:>CJ.9DAB>]Q9$XX/8#G'F*:\U%4:/M=ML5NFN4U75!S776HADJS
M31Y.7NV&DO?OPT8QV9W#?TI$'-]*/TW<],7+2NG7U_.5%),9IZNCFC=*]XV7
M2/>]HVG$N!]FX+7ZC4<M1R8#1K+=<!JM]$VTNHS3/ :=GFS*9,;&QLY=M97:
M$0:Y27*GM=?;=*LCJC5BWA\=0(280U@V-[N.[L]ZYSJ716J+)R=:AIXM14M=
M%-%-/4,%J//U3W;W$OYP_*/9V'  &-R[2B#D^N8;C3\BKK==*N*LN-PZ-1TW
M-P<SDO>P-9LY.2 "<_1V+JT3=B-C,YV0!E8RYV*CN=UME?6<Y(^W/=)!%M?Y
M8D(QMD>=P&<<,E95 1$0$1$!$1!%4^32_P!!]B4WDT7] ]B5/DTO]!]B4WDT
M7] ]B"5$1 1$0$1$!:[RBQOFT#J..)CGR/MT[6M:,EQ,;MP"V)$&B:A@N[N1
MSF;$V=MUZM@:QL7R9, ,VPW@[9V@//E:9<3IRKALD/)];*JFU+3U,(C?%12P
M/@CVASO2'N: 6[.UD.)R3YUVY$&(H[]35>H[A96053:FBCCEDD?%B)P>,@-=
MYSQ_8KDVH[=I.ZTM;:]$V>IJKS6ET(:(ZAE+1N=D/F<U^(V;()(P,YQA=P1!
MKU[LQ^+^OLE%ESNJY*.'B?\ *+&_^RP%@K+'<N1NT37Z)DUHZ!!%4,,3GX<W
M##N:"<AX[1V8RN@+%6&Q4=B%:RW<XR"JJ'5)A+LLC>[^+8'F!._'9DE!S.PV
M.SWG6EEJ=+6ZL9:+6]U547&KYXF>39+8XHS,2X@%Q<<?)[/.M_AU515-/?9!
M1W LM,SJ>=IIB3(1VF-HR7CZEL2(.1:WO%KUM04-JTK25-5=NF02Q5 HI(A0
MAL@<Z1SWM&S\D$8&\Y6^56F!47]MTZ[OD6)&2=$CJ]FG.SCY)9CL.-XSOR5L
M*(.,:@U=;M1:FGH=0-N5+INW38%*RWSR&X2M/\3RUA B!&YN?E'>=V LUK9]
M-?J'2^I[?05%QMUJKS+-3&E>V3FL%A>(W .):[9=C&\!=-1!S."X4^KN4O3]
MRT_#4NH[73U(K*U].^%KQ(T-9""\ N(=\K'F4^KJE^M= 5E58*.L-7;ZYDT4
M%1%S;Y7P2AQ#1Y\@$#Z5T5$'++Y?8->7'3=LL5/7.%/<8;A7R3TLD3:9D67;
M#BX ;9=@ #/G65F/3>6ZF$.]MNLKS,X>9TLHV6GZ<,)6_+%6>Q4=JK+G5T_.
M/JKC-SU1-*[:<X@8:T<&M&X#S(,JB(@(B("(B IZ/_5/U*!3T?\ JGZD%M$1
M 6F:P_F</UCV+<UIFL/YG#]8]BL)+8;+Y.%DEC;+Y.%DE%4KQY)_>WVJZJ5X
M\D_O;[5=0%\<T.:0>PKZB"'HS.+O%.C,XN\5,B"'HS.+O%.C,XN\5,B"'HS.
M+O%.C,XN\5,B"'HS.+O%.C,XN\5,B"'HS.+O%.C,XN\5,B"'HS.+O%.C,XN\
M5,B"'HS.+O%.C,XN\5,B"'HS.+O%.C,XN\5,B"'HS.+O%.C,XN\5,B"'HS.+
MO%.C,XN\5,B"'HS.+O%.C,XN\5,B"'HS.+O%.C,XN\5,B"'HS.+O%.C,XN\5
M,B"'HS.+O%.C,XN\5,B"'HS.+O%.C,XN\5,B"'HS.+O%.C,XN\5,B"'HS.+O
M%.C,XN\5,B"'HS.+O%.C,XN\5,B"'HS.+O%.C,XN\5,B"'HS.+O%.C,XN\5,
MB"'HS.+O%.C,XN\5,B"'HS.+O%.C,XN\5,B"'HS.+O%.C,XN\5,B"'HS.+O%
M.C,XN\5,B"'HS.+O%.C,XN\5,B"'HS.+O%.C,XN\5,B"'HS.+O%.C,XN\5,B
M"'HS.+O%.C,XN\5,B"'HS.+O%.C,XN\5,B"'HS.+O%.C,XN\5,B"'HS.+O%.
MC,XN4R((>C,XN\4Z,SB[Q4R((>C,XN\4Z,SB[Q4R((>C,XN\4Z,SB[Q4R((>
MC,XN\4Z,SB[Q4R((>C,XN\4Z,SB[Q4R((>C,XN\4Z,SB[Q4R((>C,XN\4Z,S
MB[Q4R((>C,XN\4Z,SB[Q4R((>C,XN\4Z,SB[Q4R((>C,XN\4Z,SB[Q4R((>C
M,XN\4Z,SB[Q4R((>C,XN\4Z,SB[Q4R((>C,XN\4Z,SB[Q4R((>C,XN\4Z,SB
M[Q4R((>C,XN\4Z,SB[Q4R((>C,XN\4Z,SB[Q4R(,=34[#75@R=VQ[%;Z,SB[
MQ45+Y?6_V>Q6T(0]&9Q=XIT9G%WBID00]&9Q=XIT9G%WBID00]&9Q=XIT9G%
MWBID00]&9Q=XIT9G%WBID00]&9Q=XIT9G%WBID00]&9Q=XIT9G%WBID00]&9
MQ=XIT9G%WBID00]&9Q=XIT9G%WBID00]&9Q=XIT9G%WBID00]&9Q=XIT9G%W
MBID00]&9Q=XIT9G%WBID00]&9Q=XIT9G%WBID00]&9Q=XIT9G%WBID00]&9Q
M=XIT9G%WBID00]&9Q=XIT9G%WBID04ZNF8*68Y=N8?84I*9AI83EW\#?8IZS
MR2?^AWL*4?DD']#?8@^=&9Q=XIT9G%WBID00]&9Q=XIT9G%WBID00]&9Q=XI
MT9G%WBID00]&9Q=XIT9G%WBID00]&9Q=XIT9G%WBID00]&9Q=XIT9G%WBID0
M0]&9Q=XIT9G%WBID00]&9Q=XIT9G%WBID00]&9Q=XIT9G%WBID00]&9Q=XIT
M9G%WBID00]&9Q=XIT9G%WBID00]&9Q=XIT9G%WBID00]&9Q=XIT9G%WBID00
M]&9Q=XIT9G%WBID00]&9Q=XIT9G%WBID00]&9Q=XKU'"V-V6YSV;U(B B(@+
M3-8?S.'ZQ[%N:TS6'\SA^L>Q6$EL-E\G"R2QME\G"R2BJ5X\D_O;[5=5*\>2
M?WM]JNH"(B B(@(B(,<;W;QJ$6,SXNAINEB$L<-J+:V2X.QLG?YLY5756JK/
MI6EAJ+[5FGCF<61[,3Y7.(:7'Y+ 3@!I).,+5N5@=35NF]81[A:*P0UCO_Z6
M?_+>3QV3L'Q4$M-%J_E<K8YVB6UZ>MYIB/,ZIJ6_+\(L#^Y!NU;J&UT6FC?Z
MFK:RT"!M3TC9<1S;@"" !DYR-V,[U]EU!;(M-&_OJVBT"FZ7TC9)'-;.UM8Q
MGL\V,KC%HGDNFC=*:$JCSE3'>I+=6M/^ZGHWF1P^HM$0^U>*B20Z!')ZY[NE
M#4+;)V_*Z+M\^'_5S6Y!U&\\HNFK/44D%?6U#9JNE;61,CHIY7&)QP'$-8<;
MQV'!66TSJ2VZEI):FT2SR0Q/YMQEII(3M8![)&@GM&\+GNH[G56;ENADMUEJ
M[JXZ<$?,4CHVEC>DGY7RW 8W ?:ML O&J:*WU -RTM)25[99:>41R.JHFC>P
M[+B UV<9SYNQ!G-17NWZ=LU3=;Q4"GH:< R2%I=C) &X9)WD#<K=%50UM'!5
M4L@EIYXVRQO;V.:X9!\%RSE=U%9FZPTQ8+]614]LC>;I7<X"X/#,B&,@ Y!?
MDD?\B\\DVIFNT!J&WV287*HTZZ>*BP"3/#ASZ?=V[Q\G'_*@ZVB_/KKM55FG
MM)UMMUY=*R_W:KIHZRA@J(L@//\ G-;$&_Y>QOWD8&-_:NT:HK9+'HR[5L4C
MY):&@EE8]^]SG,C)!/TY""O4ZTL4%#75;JQSX*.JZ#(8X7O+I\@<VP ?+=D@
M8;G?]15BBU1:*S3]1>XJL-MU.)#.^5CHW0EF=MKVD!S7#!W$97/:.QSV_DPT
M!44%)/6]75-+<ZJ&!NW+*'L>9'-':YP=+M8[3A:K=;I5GKFFEMDXHZB[MNU5
M13?Y3GMD?'%2T\G;LF21O..!&0UOTH.Z5E\H:/3[[U4R2LMS(!4.DYEY<V,C
M.2P#:&[>1C(\_8KU-/%4T\4]/(V6&5H>Q[#D.:1D$'AA:WI6]5-YFO5GOU#3
M07"WN9'4,@D,L,L<C-IKFEP!P1M @CM!6(Y$9'LT9-;)'EXM%PJK<QQ.261R
MG9\ 0/L0;^B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@+6M1ZWL>GZYM#75$TE>YG.=&I*:
M2HD#/2+6-.R-W:<+95C-07:W:>ME5=KI*R"")@VY,?*=V[+1YW$DX XE!3IM
M9:?J=,R:@BN</5$>1)4.RW8(.-ES2-H.R0-DC.\*C9N4/3MVNE/;H*BJ@JZG
M)IVU='-3B? R=@O: [=YNU5.2RT5=):+M<;K2]&J+W<);GT)PWP-?LAC7?\
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MP$9E;+-0S0Q2-R!EKWM /:.Q9.^W>AL5KGN-UJ!3T< !?(07=IP   2220
M,G*U>W:FOE#JRW6/5=OM\9N<<KJ.IM\SWLVXQM.C>'M!!V=X/8<*IRC#I^N-
M 667?235L]=*WS.-/%M,!XC:<#]B#:-2ZILVF+2+E?JYE%2.P&F1KMIQ/F#
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M16VNN38JN1K"R,12/V@[^$[0:1O^M!6OG*'IVS7&>AJJJHEJ:< U#:6DEJ!
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MS"V1KF @AK@>T8(7VVZ:OE?JNWW[5E;;G/MD<K*.EMT;PP.D&R][W/.2=D8
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M.P_0B-*T5JV[WS5EVMUUM;+;3P4L-33PO),X:\N YS?@$AN=D=F<$E92BO\
M4LUW6Z>N4<+6OIFUMOFC!'.1@[+V.R3\IKL'=V@]FY8FR?\ QFU-_P#E='_W
M2+YJW'QKZ"YK_5YNOV\=WS3>WZ-K"#?D1$!$1 1$015/DTO]!]B4WDT7] ]B
M5/DTO]!]B4WDT7] ]B"5$1 1$0$1$&)U&Z]-HF-TY%0/JWR!KGUKW".-F#EV
M&C+CV#&1V]JUNUWW4-MUG0V#4QME6VX4\LU-4T,;XBQT>-IKV.<[=@[B"MON
M43*FDEI'54E,^H8YC9(7ADC=W:P\0N9TMM.D>56RPPW&IO,EZAFBF=<'":HI
MF1MVP6/ &&$[BW&,H+L>I=5WF.^W&QFR4MNM=5/3-@K&2/DF,7\1<X. CSYM
MQ^E;GI*\C4.F;9=Q"Z#IM.R;FG'.R2.S/G'TKD]OTFS7M#?=2279]HEJ:F2-
MU'3X;3@0O+1TIA_U''&79QN(71.3W44=XT58J^L;2T,U9'S;(&N#&N<TEN(P
M?,0W(' A!!>M07BLU/+I_2D-%TFEA9/6UM:'.B@#\[# QI!<\@$]H "V2R,N
M,=NC;>IZ6>N!.W)31.C81G=AI<2-V/.N:6O3E'=^4_6]-?*FK.T^FJ(:2.H?
M V1AB#><.P078+2WMP#GBL]R3U,[Z?4-":R:NH+==):6CJ)I#(XQAK3L%QWN
MV22,^Y!E(+_4UVO:FR4$</0;=3-EKYG@EW.R;XXV;\#Y(+B3GM W+$4>L[M5
MZ_M]J?9S0V>KCJ>;EJ@142NAV<N#<_)82[=G)/;N3DUQ\)=?<[Y3UP-K/;S?
M,LV/LQE2ZC_^+.C?^DK_ &1(,KJ%FK75S3IV>Q1T>P-H5T4KI-O)S@L<!C&/
MQ6)T)?=17/4U^MU[ZIEI;9S<1J*&.1@=.X;19\IQSLMQGZ2%G]:WZ/3.E[A=
MI6[;H(_\J/SR2'<QH^MQ 5+D^LKM-Z1@BN$@-=+M5E?,\XVIWG:D)/T=F> "
M#(ZE??&TD3--PT#ZJ239?)6O<&1,P3M;+=[CN QD=JU_3]^OE-K(Z;U.+?/+
M-1FMIJNA8^,%K7AKFO8XG!W@@@X6;U%J>VV.R-N<\W/Q2D,IHZ?#WU+W?PLC
M _B)_=8C1]FKNGUNH[^Z$Z@KHA%'3M?M1T4 .6P@CM.=[G><]G9O#;*^KAH*
M&HK*IXCIZ>-TLCS_ +6M!)/@%ING+EJ_4,='=V-M-LLU0YLL=+-%)+4O@)[7
M.#@UKBW>!@XR,Y5#5D.L:S0VJ(+S!9ME]MF$0MSY72.?CL(<!N(SV;\X6MWV
MVT-HY+Z35=DN]>^\QPP2T]5TQ[A.\EHYKFL[&R=[=@#=CZ$&[7N^WVNU;/I_
M2G5\+Z*G945M76L=(UA>3L1M8TC>0TDDGL5_0NH*J]07&EN\$-/>+74FEJF0
MDF-QP'->S._9<T@@'>L/I=_1>5G6$%5B.>OI:&J@:3O>QC'1NQQP[VJ/0M73
MNU7R@WAT\4=M=70P"=[PUFU%"UKSD[MQ.,H-EU=>:ZTT<3;1:YKC7U#BR)H^
M3%'@9+Y7_P"UH'VGL"J:.O5RU'R?4-V8*2*Z5=*9&@L<86R;\9&<[.0/.MBJ
M7!U'*YI!:8R01Y]Q6H\B_P#\+=-_]*/:4&6T-J#X2Z;IK@^'H]5ET-3!W4S'
M%KV^(W?00L^M!Y*<=+UOS7^A\(:C8_JV6;?YLK?D!$1 1$0%/1_ZI^I0*>C_
M -4_4@MHB("TS6'\SA^L>Q;FM,UA_,X?K'L5A);#9?)PLDL;9?)PLDHJE>/)
M/[V^U752O'DG][?:KJ O$W^D_P"I>UYD;M,<!VD(,>BGZ*_BU.BOXM00(I^B
MOXM3HK^+4&,K[91U\U'+64[)9*27GX'._P#EOP1M#Z<$^*]W*AI;G0ST5PIX
MZFDF;L212-VFN'TA9#HK^+4Z*_BU!J=KT+IJUOC?0VB".6.1LK)'%SWM<W.S
MASB2 ,G=V;U-J+1]@U'/'/>;9#4SQMV6RY<QX;PVFD''T9PMFZ*_BU.BOXM0
M:I7Z&TW7TU!!56F!T="SFZ;9+F&-OH@M(./H*FU#I&PZAEBEO%MAJ)HF[#)<
MN8\-]'::0<?1G"V7HK^+4Z*_BU!AZ6R6RDLKK12T,$-L=&Z(T\;=EA:X$.&[
MCDY^M6Z*FAHJ."EI8Q%3P1MBC8WL:UHP /J 5WHK^+4Z*_BU!3JH(JJFFIZF
M-LD$K#'(QPR'-(P0?L4%IMM':+=!06RGCIJ.$;,<3!@-&<^TE9/HK^+4Z*_B
MU!K[=,V9MBALPM\(M<+FNCI]^RTAVV#V^EO5R2UT4EUAN;Z=CJ^&)T,<Q_B:
MQQ!+?M("RG17\6IT5_%J#"6W3]JML5PCHJ&&..OF?/5,QM"5[_XB0<]O#L6#
MIN331]-6QU<%BIHY8Y!*P-<_8:X'((9G9&_Z%N_17\6IT5_%J"NYH<TM< 6D
M8(/G6MZ$L%3IFUU%I?-'-;H9WNH""=MD+CM<V_=VM)(!![,=BVSHK^+4Z*_B
MU!AHK%;(K(ZSLHH>K',<QU.6Y:X.)+LY[<DDK7;WHB$Z5JK#IMD%MI[A*T5L
MI<YTAB. _!.2YQ:-D9. #]"WOHK^+4Z*_BU!3I*>*DI8::G8&0PL$;&#L:T#
M '@I5/T5_%J=%?Q:@@13]%?Q:G17\6H($4_17\6IT5_%J"!%/T5_%J=%?Q:@
M@13]%?Q:G17\6H($4_17\6IT5_%J"!%/T5_%J=%?Q:@@13]%?Q:G17\6H($4
M_17\6IT5_%J"!%/T5_%J=%?Q:@@13]%?Q:G17\6H($4_17\6IT5_%J"!%/T5
M_%J=%?Q:@@13]%?Q:G17\6H($4_17\6IT5_%J"!%/T5_%J=%?Q:@@13]%?Q:
MG17\6H($4_17\6IT5_%J"!%/T5_%J=%?Q:@@13]%?Q:G17\6H($4_17\6IT5
M_%J"!%/T5_%J=%?Q:@@13]%?Q:G17\6H($4_17\6IT5_%J#7I=+V26S3VF6V
MT[[=/(Z:2!PRUSR[:+OKVM^54LFA=-62O;6VVTPQU;!ADSW.D<P?\I>3L_8M
MLZ*_BU.BOXM08>CLENH[O7W2EI&1U]<&"IF&<R!@PW/FW#@I+=:Z*VR5DE#3
M,ADK)C43N;VR2'<7$_8%E.BOXM3HK^+4%6:)D\,D4S0^.1I:YI["#N(6 T'9
M*O3=B%HJ:B.HIJ61[*.0$[?,9RQK\C^)N<;O, MIZ*_BU.BOXM08SJVCZV%S
MYAG3Q!T;GO\ =S>UM;/U9WK69>3#1DLLDDFGZ1SWN+G'Y6\G>3VK>>BOXM3H
MK^+4&M1Z0L,=-:J=ELA;#:YC/1M!.(9,D[0W\3G>LG=;;27:@EHKE RHI)<;
M<;^QV""/Q *R717\6IT5_%J"!%/T5_%J=%?Q:@QD%MHZ>XU=?# QE95-8R:4
M=KPS.R#]63XK"7'06E[C='7&MLM+-5O<'O<00V1P["YH.RX_205MW17\6IT5
M_%J##5=CMM7=J"YU%)&^OH ]M-,<YB#AAV/-O"QEZT-IN]5[ZVY6F&6JD ;)
M(USHS(!V;>R1M?;E;9T5_%J=%?Q:@TS5FD^MK!0Z?MPIJ&R<\SI<3&[),##M
M<VP 8&T0 3PSVY6U@!H :  -P 5CHK^+4Z*_BU! BGZ*_BU.BOXM00(I^BOX
MM3HK^+4$"*?HK^+4Z*_BU!CX/+*K^WV*ROL5#(V>9Y<S#\8[?,%-T5_%J"!%
M/T5_%J=%?Q:@@13]%?Q:G17\6H(%XFBCGADAF8V2*1I8]CAD.!W$$<%:Z*_B
MU.BOXM0:33<FND*:ICGBL5-M1NVV->Y[XVGB&.):/!7]0Z-L&H:J.IO%MCJ*
MF-G-MF#G,>&Y)V=II!QDG=]*V?HK^+4Z*_BU!K]LTQ9;7:*BUV^VT]/0U+7-
MFB8W_5#A@[1[3D;LDJO6:,T_66.CL]3:X7VZCQT>(EPYK'G:[.T#O[<K:.BO
MXM3HK^+4&O:<TM9-."7J6W0TKYL<Y(,N>_'8"YQ)(^U5=<Z>EOUNI74$T=/=
M:"ICK*.:0'9$C3_"[&_9<"0?K^A;7T5_%J=%?Q:@QEPH*>ZVR6BND$<U/.S8
MFB)):X><9W;E9$3!#S0&(]G9P#C=V*UT5_%J=%?Q:@QEHME'9[=#06RGCIJ.
M$$1Q,&YN22?Q)*I'3%F,MXE-!$7W=H97'?\ Y[0TM ._@2-W%;!T5_%J=%?Q
M:@T,<EFB@,#3M'CZW>];E#$R"&.*)H;&QH:UH\P&X!6NBOXM3HK^+4&M:BTA
M8=13137FV0U,\;=ALN7,?L^CM-()'T'<KS++;&67JAM!3"U\WS71>;'-[/#9
M[%E^BOXM3HK^+4&LZ<T?8-.3RSV6V0TL\K=AT@+G.V?1!<20/H&Y7K19+=9W
MUK[92LIW5L[JFH+<_P"9([M<<K,=%?Q:G17\6H,9%;*.*Z3W&.G8VNGC;%+,
M/XG-;G9!^K)\5A:+3]0[7-;J&XRQ/V:9M%00QY/-19VGN=D?Q.=CL[ !O*VW
MHK^+4Z*_BU! BGZ*_BU.BOXM00(I^BOXM3HK^+4$"*?HK^+4Z*_BU!3J?)I?
MZ#[$IO)HOZ![%9FHWOB>T.;ES2$AHWLB8TN;EK0$$:*?HK^+4Z*_BU! BGZ*
M_BU.BOXM00(I^BOXM3HK^+4&"U%IVTZCIHZ>]T,57%&[;9MY!8[B",$'ZBJ^
MG=(V'3LTLUFML-//*-E\V2^1PX;3B3CZ,K9>BOXM3HK^+4&H7/0&E[G7S5E;
M9J=]1,[:E+2Y@E/%[6D!Q^L%9.LT]::QUL-100NZLD$M& -D0. P-D#=N'F[
M-P6<Z*_BU.BOXM0:YJ/2=CU&^%]ZMT53)""(Y"2Q[0>T;32#CZ,X61M5MHK1
M014-LI8J6DB&&11-V6A9+HK^+4Z*_BU!J4&GZBBUW4WR@EB%'<*9L5? [(<9
M(_\ 3D;NQG!+2#C=@K-SVVDGN-+7S0,?64S7LAE/:P/QM ?7@>"R717\6IT5
M_%J#%W2U45U93MN-,RH;3S-J(VO[&R-_A=CZ%/6TL-;1STM5&):>>-T4C'=C
MFN&"#]8)5WHK^+4Z*_BU!JE=H?3=?:K?;:RT4\U#0-+::)Q=B('MQOSYO.O%
MET'IBR7&*OM5GIZ:LBR&2L+LC((/:>!*V[HK^+4Z*_BU! M8IM Z7I;LVY4]
MDI&5;9.=:X [+'^DUF=D'Z0,K;NBOXM3HK^+4&O:CTM9=2-A%[M\54Z'/-O)
M+7LSV@.:00#PRDFE[(_3;K ;;3BSN;LFE:-EI&=KS;\Y&<]N5L/17\6IT5_%
MJ"G%!%%3L@C8&PL8&-8.P- QCP5**WBU6$T.GX*>#F(BREB>2(VG?C.,G&5F
M>BOXM3HK^+4&M:'T^W3.G*:W&;I%0"Z6IG(P9IGDN>[[23CZ,+/*?HK^+4Z*
M_BU! BGZ*_BU.BOXM00(I^BOXM3HK^+4$"GH_P#5/U)T5_%JD@A=&\DD'=C<
M@G1$0%IFL/YG#]8]BW-:9K#^9P_6/8K"2V&R^3A9)8VR^3A9)15*\>2?WM]J
MNJE>/)/[V^U74!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 6F:P_F</UCV+<
MUIFL/YG#]8]BL)+8;+Y.%DEC;+Y.%DE%4KQY)_>WVJZJ5X\D_O;[5=0$1$&"
MN.HH*.YT]*YL@VG/:_,#R3AN1L8'RM_#*RM15"*W2588XM9$9=APV2<#.#GL
M*@K+125E29YV.=+A@#@\@MV7;0V>&_MQVKW>076BN#023 \ #S_)*#&"^U,-
M)#65]MYFAD#7&:*<2<V'=A<, XW[\964K+G0T3V,JZRG@>\9:)) TD<=ZUR:
MX,KM,,M=!'-/634S8"WFG!L>6X+G.(P -Z^W:JF;/6T#Y.9;' V.%K:8R/JL
MM.<'LQG=C[2@SDUZM\%R90RU,3*A[-L O &\@ =O:<[@IC<Z%M8*0UE.*HG'
M-<X-K/#"UVU2BCK;++5A[&26QD(<6G'.9:=D\"J5SK:BNII&/<65#:QG_A(Z
M8Y8&RC#G/^H9R,=N$&]*I27.AK)G14E93S2M&2V.0.('V*2X324]!4S01&::
M.-SV1C_>X D#[5J-+.:R[6B5TQJ&-9*)1%3&-D68S\G/;YNS/F0;3372@JJA
MT%-6T\LS>UC) 3X*6MK::AB$E94101DX#I'AH)X;UKNGZ@05U+04$_3: 1N
M<Z$M?3@=@+L '/9O *M71[*/4=+6UH/1!3/C9)LEPCD+@=^.S(&,_0@M7F]T
MUOLSZ^.6"5I $7^8 V0DX&#_ /?858H*ITEMZ342T\HP7;=,26%HX>"UF>)\
MFG+S)#"]M//6-D@9L$$MVF9<!V@$AQ6XRN;'$][P=EH).!G=]7G08JU7*NKQ
M3S]7LCHIV[;9#4 O#2,@EN//NW GM5T7&B-8:05<!JA_\KG!M>"URBEIHKI1
MLT[-4.ADD/2*;9=S3&8)+OE#Y!SC<,9SV*A;*;-/!05]?)!51U7.&'HN7&02
M9#@_&\'TN!0;?+=K?#,V*6NIF2N<6ACI0#D'&,9XJX\EK'$-+B!D =I^A:2R
MJHHZ+4E+/"YU1454X8P1%QF)&&@$#S'P[5M=&74=HA-627PP-YT@9.0W?]:"
MG#=:ME=2P7"@;3MJB6Q.9,)"' %V'# QN!["5F%JUIN5-<KI'65<CV2[V4M,
M8W?Y8/:YQQC:/@!NXK8;?615])'4TQ)B?G9)&,X./_9!CJ^[5=#MSSVX-H&2
M!CI.>!?@NQM;(&,;^.?H7FLO4\<M::6AZ1341Q/)SNR[.-HAC<;\ CSA8^KN
MU+<+DZ*LDDAH*63/-F)Y,[VG<3@?P ^;SGZ.T^K;;8[Y2S,E,]1(^6G:V-QY
MX/8  ,#MSD'@@SE35U+HX'6VE94ME;M[;Y>;8!YO,3OSP5#K^1])3.@HMNKF
MJ7TI@?*&AKVAQ=\K!R/D\/.H*VO?9K5;;<PEE4Z%L9F+'/9$&M +C@;SP'_L
MO@%A%KI8YGROIXI';,KFR-)D(^420!O.T>WB@SU#)4RPEU93LIY<XV&R<X,<
M<X"L+!Z6VO\ Q_-&<V[G1T4S%Q.-D;6-K?LYSC*SB B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B M,UA_,X?K'L6YK3-8?S.'ZQ[%826
MPV7R<+)+&V7R<+)**HWGR%Q]$@_BKP.0".PJ*JC$L#V'L<,*M:Y]J(P2'$L7
MR2.(\Q07D1$!$1 1$0$1$!$1 1$0$1$!$1!5M]$RB%0&.<[GIG3'/F+O,K2(
M@$ @@]AW+Q3PQT\$<,# R*-H:UH[ !V!>T0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%I6KG@W6)H[0?_8+<*J=E/"Z2
M0[AYN)X+GCYG7.\OD&]@W CS[]Y5A&[V7R<+(JG;(]B$95Q10]BQ5QIGM>)H
M26R-["%E5\<T.&"@PL-];'\BL9LN'^X;L^*L=>T/>I6VV.8'(6'FTZPDD-51
MF.O:'O4Z]H>]6!^#C>"?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7
MM#WJP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<
M;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO
MH,]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0]Z
MG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#WJP/
MP<;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?!Q
MO H,]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0
M]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#WJ
MP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?
M!QO H,]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO H,]U
M[0]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#
MWJP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<;P
M*?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO H,
M]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7
MM#WJP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<
M;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO
MH,]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0]Z
MG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#WJP/
MP<;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?!Q
MO H,]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0
M]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#WJ
MP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?
M!QO H,]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO H,]U
M[0]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#
MWJP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<;P
M*?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO H,
M]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7
MM#WJP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<
M;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO H,]U[0]ZG7M#WJP/P<;P*?!QO
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F!@<$P."(@8'!,#@B(&!P3 X(B!@<$P."(@8'!,!$0$1$!$1!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g50309g16k02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g16k02.jpg
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M*"@H*"C_P  1" +C X0# 2(  A$! Q$!_\0 '  !  $% 0$
M  8" P0%!P$(_\0 9!   0," @0)!0P&!@8&" 0'  $" P0%!A$'$B%1$Q05
M,3-!4G&1,E5A@=(6%R(U5G-UDI.4H<$(.$*QLK0C-F)RHM$T0U-T@I4W5(.S
MT_ D)4178Z/#X1BDPM0G149D=H3Q_\0 &P$!  ,! 0$!              $#
M! (%!@?_Q  O$0$  @( ! 4#! ,!  ,      0(#$002(3$%$Q1!42(R809Q
M@:&1L<'P(]'Q_]H # ,!  (1 Q$ /P#ZI
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M537&WRI+2U#-=CNOTHNY478J&'+BFD_AZF#/&6/RS0 5-
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MC>T@%0*>$;VD'"-[2 5 IX1O:0<(WM(!4"GA&]I!PC>T@%0/-=N]#U%10
M      !X]R,:KEYD /<C&YN7)#'6621<HDR3>>,8Z=RN?Y/4AE-1&IDB9(!C
M)3N=M>\JXJWM.+X L<5;VG#BK>TXO@"QQ5O:<.*M[3B^ +'%6]IPXJWM.+X
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M*^P:,+90U4[+]4U\_!.X"'7S17Y+JYZC$Z\N=4.)I.YB?]+8R1JMJZZ1\_\
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M*B\QZ./)%XW#Q<N&<5M2H !8J
M                           ^@OT><)OHJ"?$-;&K9:MO!4R.3:D6>UWK
M5$R]">DANBC1C48AJ(KG>HGP69JHYK')DZI]";F[UZ^K>GTI%&R&)D<3&LC8
MB-:UJ9(B)S(B&3/EC7+#?PF"=^9;^%0 ,CT0
M        P+C3I(QR)LUNO<IGE$[=:)WB!I;15JJJQ^QS5R5/2;QJYH1*9_%[
MVYJ;$D1'_E^1**5^M&B@7@ !3+T;NXMTG1+WE<W1.[BBDZ+U@7@
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MCE5WP7Y*J(N7JWG5&.1[4<Q45JIFBIUH!Z
M
M                                  >.\E>X]/'>2O<!",1?'%+\W^:D
MGM/1-[B,8B^.*7YO\U)/:>B;W$C8@ @43=$[N**3HO65S=$[N**3HO6!>
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M ,WC$>]? <8CWKX&$ ,WC$>]? <8CWKX&$ ,WC$>]? <8CWKX&$ ,WC$>]?
M<8CWKX&$ ,WC$>]? <8CWKX&$ ,WC$>]? <8CWKX&$ ,WC$>]? <8CWKX&$
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MS.(?H./^*(ZF<LMWZS.(?H./^*(ZF
M
M              *HND;WH4E472-[T V        !X[R5[CT\=Y*]P$(Q%\<4
MOS?YJ2>T]$WN(QB+XXI?F_S4D]IZ)O<2-B "!1-T3NXHI.B]97-T3NXHI.B]
M8%X                       '&K=^LSB'Z#C_BB.IG++=^LSB'Z#C_ (HC
MJ8
M                                               JBZ1O>A251=(W
MO0#8        'CO)7N/3QWDKW 0C$7QQ2_-_FI)[3T3>XC&(OCBE^;_-23VG
MHF]Q(V( (%$W1.[BBDZ+UE<W1.[BBDZ+U@7@                       <
M:MWZS.(?H./^*(ZF<LMWZS.(?H./^*(ZF
M
M                  *HND;WH4E472-[T V        !X[R5[CT\=Y*]P$(Q
M%\<4OS?YJ2>T]$WN(QB+XXI?F_S4D]IZ)O<2-B "!1-T3NXHI.B]97-T3NXH
MI.B]8%X                       '&K=^LSB'Z#C_BB.IG++=^LSB'Z#C_
M (HCJ8
M                                                   JBZ1O>A25
M1=(WO0#8        'CO)7N/3QWDKW 0C$7QQ2_-_FI)[3T3>XC&(OCBE^;_-
M23VGHF]Q(V( (%$W1.[BBDZ+UE<W1.[BBDZ+U@7@
M   <:MWZS.(?H./^*(ZF<LMWZS.(?H./^*(ZF
M
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MZV*CMU[M]552YZD44[7.=DBJN2(NY%4WP
M                                        "J+I&]Z%)5%TC>] -@
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MFB20T[&.3/8NU$S V0
M             !5%TC>]"DJBZ1O>@&P        /'>2O<>GCO)7N A&(OCBE
M^;_-23VGHF]Q&,1?'%+\W^:DGM/1-[B1L0 0*)NB=W%%)T7K*YNB=W%%)T7K
M O      !R[$]/CS$]]K:"TSLLEDIW\&E3FK7S[U14^%X9)Z5.JUYO=Q>_+'
M;;J(.-)H2EE3A*O%59)4+MU^"5=OK?F&X7Q_@Q>,V&\<N44>U]'.JYN3<C7*
MO^%R+Z%.^2L]K*_-O'W4Z.R@M4<KIZ2"62-8WR,:YS%YVJJ9Y%TJ7@
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MJ<;C\RG3YCX  <MH     B^#?CG&/TLG\K3DH(K@QS5O.,,G(N=U14R7JXK
M2H&]@
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M5%3K10/0 !QJW?K,XA^@X_XHCJ9RRW?K,XA^@X_XHCJ8      ,&[K<4I/\
MU.VD=5:R;*ISFLU>O:U%7/F,X 1?7QI_L,._;3>R:^QWC%]WI9IX:6P1MBJ9
MJ94?--FKHI'1JOD\RJU5-MB?%]LP^O!U#G352IFD$6UR)O7J0Y_AC2#'9Z>>
MGEMSY(Y:NHJM=LN2HDLKI,LLMN6MES[<CN*6GK$,.;Q/A<%N3)?4_P S_ITF
MS.Q M2[EJ.U-I]3X*TDDCG:V:<^LU$RRS-R:C#N(;??Z=9;?+FYOEQ/3)[.]
M/S38;<YF-=VO'DKEK%Z3N)<>TSP2-OU%.J+P<E/J-7TM<[/^)#GQV72576>N
MIELV<U;?$_I*>DH6<+,Q=[DSR8U>M7*B',+MAR[6C46X4,L37*UJ.3)S=9=B
M-UDS3//9D:<5XF-/B_&N RTSVS5C=;?TU)--%=FI;O>JGE&BIZREA@SU*B)L
MC4>KDR7)45,\M;:::TX6O%TF:RFH)FM5=LDK58Q/6OY':L'X>@PY:TIHW<).
M]=::7++6=_DG4,EXB-'@O 9<F>N:T:K7K_\ C&O6#[346:KIK?:[?2U#XU2.
M2*G8Q4<FU-J)LVHAP>>&2GGDAG8YDL;E:YKDR5%3G0^GB-8GP;;+^_AIFN@J
M\LN&BV*O]Y.9?WE6/)R])>WXQX7;C-9,7W1_<.!&WPK9Y;Y>Z>CC:JQJY'2N
M3F:Q.=?R[U0E51H^BI<2VJVRW!\D5;'/(KFQ(US.#U-G.N>>O^!TVP6&@L-*
ML-NAU=;RY'+F]Z^E?_*%ELL:Z/'X/P#/;)$YXU6/SO?^&F][O#;>AHZF!?\
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ME.4&=8Y)(KS020Y\(V=BMRWZR%EZQ:'B\!QF3A<T6I/3?6/E]*  QOT<
M      &MO5MGN+(FT]VK[:K%55=2)%F_T+KL=^&1$<76N[6>PSUM+BZ^.E9)
M$U$D;2JF3I6M7FA3J<IT C&DG^I]7\]3_P#?L >YBO\ EAB#PI?_  #9V2UU
M%MX;C%XN%RX3++C:1? RSYN#8WGSZ\^8V@
M            !5%TC>]"DJBZ1O>@&P        /'>2O<>GCO)7N A&(OCBE^
M;_-23VGHF]Q&,1?'%+\W^:DGM/1-[B1L0 0*)NB=W%%)T7K*YNB=W%%)T7K
MO     !\VZ3Z3%5SQE<XG4=]K+0R;***)DG!JW)/)V*WUY*?21JL57VFPW8:
MNZUJ.=#3M1=1O.]RKDC4[U5"S%>:STC:G-CB]>LZ?/EB6LLJM=3Z,Y*B5/\
M6U<$TSN_)4U4]2(=>T;XGOE^FK(;UA]]HB@8U8E6)[$?FJYHFLG5EU$%;INN
ML^;Z7#"/A5=BI*]WXHTFVC+'-?BZJKXJ^T<GMIV-<UV;EU\U5,MJ)N+<D6F)
MF8_MGPS6+1%;?TGP ,S<  #FFD[_ *1-&?\ O]1_W13IU_HZ3!U4_P#T>FQ'
M1R3+U(W-R9KZU_$EF(\+Q7N_8=NDM3)$^S3R3LC:U%217-U<E7J,S%-@H<36
M&LM%UC5])4MU7:JY.:J+FCFKU*BHBIW 173Y-'#HCQ&LN63H6L:B];ED:B?B
MI,;#$^"QVZ*9%22.GC8Y%WHU$4@D6C2MK*F@9BG%MPOEJH)6S04,L$<2/<WR
M5E<W;)EZ><Z2!$,?XMN6&'4*6S"USOZ5"/5ZT2*O ZNKEK9(O/FN7<I$O?7Q
M'_[K\3?47V#K@ X'HUNU3B/]("_5UQM%99IW65K5I*I,I&Y/B1%7-$V+SG=>
M+,WN.46+]9[$?T%'_'"=> L<69O<.+,WN+X L<69O<.+,WN+X L<69O<:[$=
M3':+%75ZYN6")7-1>97=2>.1N#1XYH9+EA*Z4L"*Z5T*N:U.=5:NMEZ\B8[]
M56>;5Q6FG?4Z_=\VU=1+5U,M14R.DFE<KGN=SJJED W/S"9F9W+98=NTUDN]
M/70*[^C=\-J+Y;.MOK0[)%:\28I:DESJ78>M$B9MI**1'U<K5[<W-'W,S7^T
M</HJ:6LJX::G:KIIGHQC4ZU5<D/JFEB2GI8847-(V(S/N3(SYO9]9^FK7Y<E
M9^WI_GJU=BPS:K#2+36BD931*NL[5VN>O:<Y=KE]*JJFITAT[4M=KR5?CBWI
M_P#FHR7D6TB_%5K^F;=_-1E#ZA(N+,WN'%F;W%\ 6.+,WN'%F;W%\ 0^^4[$
MT@X63-=M/6_NA)3Q9F]Q'+[_ -(6%?\ =Z[]T)*@+'%F;W#BS-[B^ +'%F;W
M#BS-[B^ +'%F;W#BS-[B^ +'%F;W$6PK3L7%N-$S796T_P#*PDP(KA3^MV-?
M]]I_Y2$"1\69O<.+,WN+X L<69O<.+,WN+X L<69O<.+,WN+X T^(K##>;+5
MT$CE;PS,FN[+DVHOBB'SC>+75V>OEH[A"Z*:->9>9R;T7K3TGU,85UM-!=H4
MBN5)#4L3FX1N:M[EYT]19CR<KR/%/"HX[5JSJT/E@FF ,&W.]2<H4T[:".G<
MCX:B:#A6ND1<T34S3--ZYDZP=A.QRWK$R36Z*5M%<D@@;(JN1C.+PORR5<E^
M$]R[<^<Z+&QL;&LC:C6-3)&M3)$0[MFW&H>?P/Z?G%DC)GM$Z]H0?A\9VS_3
M;-;KS$G^LMM2M/)]G+\'_P"8>MQW8X'(R^1W*Q2<V5SI71,^U3.-?K$X/'-1
MS5:Y$5J[%1>LH?3L"WS4%RITGMU9#5P+S202M>U?6AD\69O<1VX8 PS65"U+
M;7'1UB_^TT#G4LN>_6C5JKZS&]S6(K=ML>+:B5B;4I[O3MJF]VNW4D\54"5\
M69O<.+,WN(IRYBRV[+OA>.OB3GGL]6URY;^"EU%]2.<7:;2)AQTS8+A5RVBJ
M<N7 W6!]([/<BO1&KZE4"3<69O<.+,WN*X)HJB)LM/*R6)R9M>QR.1>Y4+@%
MCBS-[AQ9F]Q? %CBS-[B+Z3:=K<&U:HJ]-3?S$9+9'MCC<^1S6,:F;G.7)$3
M>IR72'I!MUPMU1:K9%)4(Z2-RU"KJL^!(U^Q.=<]7+JYSJM9MV9N(XO#PL<V
M:VG5>+,WN'%F;W'-;5I=II9VLN=M?3QJN7"12:^7>BHATJAK*>OI(JJCF9-3
MR)K,>Q<T5!:LU[HX;C<'%;\FV]'%F;W#BS-[B^#EJ6.+,WN'%F;W%\ 6.+,W
MN'%F;W%\ 6.+,WN'%F;W%\ 6.+,WN'%F;W%\ 6.+,WN'%F;W%\ 6.+,WN'%F
M;W%\ 6.+,WN'%F;W%\ 6.+,WN'%F;W%\ 6.+,WN'%F;W%\ 6.+,WN'%F;W%\
M 6.+,WN'%F;W%\ 6.+,WN'%F;W%\ 6.+,WN'%F;W%\ 6.+,WN/6T[&N145VS
M:7@         /'>2O<>GCO)7N A&(OCBE^;_ #4D]IZ)O<1C$7QQ2_-_FI)[
M3T3>XD;$ $"B;HG=Q12=%ZRN;HG=Q12=%ZP+P     0O3)!2U&CN[-KIU@C:
MC'->C5=D]'IJIDG4J[/1F30A53C?"]7=[AAZ^OA@E@EX-T=<Q."ERR5%15^#
MNY\CNF][CV5Y)CEU,]T"P=IFL]JPY06^OME:V6EA;#G3(QS7:J9:VUR99\YT
M+ FD"V8SJ*N&V4U;"ZF:U[UJ&M1%155$RR<NXSH;!A.:))(;58Y(UVHYL$2I
MXY&GNF*<$X+CFDIUMT52Y,E@M\;%D?ES(NKS?\2H=SRV^V.JJO/37/:-)T"U
M1S\9I()T:K4E8U^JO.F:9Y%TI:0          <AL7ZSV(_H*/^.$Z\<AL7ZS
MV(_H*/\ CA.O    -!=*?%#ZZ1UJN-FAHURU&5%#)(]-FW-R2M1=N?4AOS2X
MPOC,/6"IKW-1\C4U(F+^T]>9.[K[D)B-]'&3)7%2;V[0BF*KQBW#M'#/4W?#
M;EDGBBU%H)6N1KGHUS\N'S5&HJN7T(6J+%-UK9DBI\6X561=B(^VSLS^M.AR
M"Z7"JNE;)5U\SYIY%S5SE_!-R>@Q"^,,>\OE,GZDR<_T4CE_/=.;CAF3$-[G
M9AO@JV6%'<H5,#.!HTGSZ.)7.55=O1%5&KUIGDFHM6"[[=$>ZCH=:..:2!TB
MR-1J/8]6/3:O4YJH2[0YBF2"L98:MV=-+FM,J_L/VJK>Y=OK[R=:-OB2X?2]
MQ_FY3F;VITEIP^'<%XE7U%-UWWB/G_#68 T?QX?F2ON,C*BXY9,1B? BSY\L
M^=?23T%JJJ(:2GDGJIHX8(TS?)(Y&M:F]578A5-IM.Y>]PW#8^&IY>*-0ND6
MTB_%5K^F;=_-1F?[K<.?*"T??8_:(SC_ !-89[9;&PWNUR.;=Z!ZHRKC7)J5
M,:JNQ>9$1552%[H -+[K<.?*"T??8_:,JW7NU7.5T5MN=#62-;K.93SLD5$Y
MLU1%78!L :B\WUMKG9$ZW72KUFZVM24KI6IMRR54YEV<QK_=A'YBQ%_R]X%%
M]_Z0L*_[O7?NA)4<[NE^EJ,76*X16#$"TU)#5,E5:!V:*](]7).OR5-[[L(_
M,6(O^7O DX+%#4I64D50D4T*2-UN#F9J/;Z%3J4O@      BN%/ZW8U_WVG_
M )2$E1%<*?UNQK_OM/\ RD($J          $5P5\=XT^ET_E*<E1%<%?'>-/
MI=/Y2G)4      "W4T\-5"Z&IACFB=L<R1J.:O>BEP 1&?1WA[A73VRFGLU2
MY<^%M50^E7/TM8J-7UHI;Y%Q=;?BK$T%RB3FAN](BNR^=BU5]:M4F0 AONGO
M]NV7W"-6YB;%GM,[:MG?J+J2>#5,NVX]PU7U"4S;K#35B_\ LU:CJ6;/=J2(
MU5]1)S%N5MH;I3K!<J.FK(%YXYXFR-\%0#GNFR]R4UKI+;3/R2K57RJU>=C<
MLD[E5?P.+G1M*V#K?8(**KL=$VDI'N='+'&KM1KN=N357)N>WFRYCG)KQ?:^
M!\<M>>,M%O;6OVT'3M"-YEBNM1:)'JM/,Q98VK^R].?+O3]R',2=:&8HWXR:
M^2:)CHH'N8QST1SU7X.2)SKL52<GVRI\)M>O%X^3Y_KW_IWH &-^B
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M51U>S^@<O]F=JK&OK5%]!+:>>*IA9-3RLEB>F;7L<CFN3>BIS@7
M                               #QWDKW'IX[R5[@(1B+XXI?F_S4D]I
MZ)O<1C$7QQ2_-_FI)[3T3>XD;$ $"B;HG=Q12=%ZRN;HG=Q12=%ZP+P
M<CQSHADO%\JKS:;G&RKG?PCH*N%'QYY;\EV=Z*=<.(Z0-+5VMN(JZRVFFHZ;
MB\G!+53JKU79SHFQ$_$MQ<V_H49YQ\O_ ,C5K17/"Z+[J-'UKN=(SRJNCA1%
MR[2ZJ*B>MK3H>BV]82NZUCL*VUMOJ6L;QB/@$8N6:Y;4S14SSZSDW'*'$+M?
M&FD21T:[5IJ6FG5O\"-3ZJG5-$\."J=U;'@RIDJ:A&-XQ)*DB.5N:Y>4U$Y\
M^9"W)'T]>_\ .E&&?KC6M?G6_P"G1  96X          '(;%^L]B/Z"C_CA.
MO'(;%^L]B/Z"C_CA.O   !3)&R5$21C7HFW)R9FAOE]P[9':ERGI8I<L^#2/
M7?X(BJAB:2<1OP[A]TE,J)6U#N"A5?V=FUWJ3\50^>9I9)Y7RS/=)(]=9SG+
MFJKO52W'CYNLO"\4\8]';RL<;M^>T.S:-L18=CL5-;JFHIHJQ)9EU98]5%1T
MKW-^$J9<RIUF[@KL10*KJ;!M!'GULN3&Y^$9\]G6M#6*)Y9W6.ND61NHKZ9S
MES5N7.SNRVINR4F^+4;AG\.\<GB,L8L]8B9[3"8<L8K^2E-_S5O_ (9J,,+B
MVRT-13OPU22K+65-5K)=&IDDLSY$;Y'5K9>HZ""E]*CUMN>(IZV*.NP[!2TS
ME^',VXI(K$R[.HF?B2$                    !%<*?UNQK_OM/_*0DJ(KA
M3^MV-?\ ?:?^4A E0          BN"OCO&GTNG\I3DJ(K@KX[QI]+I_*4Y*@
M              1;2=_4RK^>IOYB,E)%M)W]3*OYZF_F(P)2       "F6-D
MT;HY6-?&Y,G-<F:*FY4(C4:/[9#,^IP[/68>JW+K*ZVR:D3E_M0JBQN^KGZ2
M8 "&<;QG9/\ 3:*CQ'2-_P!;1*E+4HF]8GKJ.7N>WN,VT8YL5QJVT3ZE]ON2
M_P#L5PC6FFS]#7Y:W>U50DQA7>TV^\TCJ6[4--6TZ\\=1&CV]^2]8&:"%^XJ
MIM7PL(WZMMC4YJ.I5:RE[D8]=9J?W7IW'ONEQ!9]F)<.23P)SUME<M0SO="N
M4C?4C^\"9@U%@Q-9<0,<MGN5/5.9Y<;7921^AS%R<U>]$-N   &%>*BNIJ-9
M+70LKJC61."?.D*9=:ZRHO[C1<L8K^2E-_S5O_ADJ $'M.*\1W6&HDI,*0*V
M"HEI7ZUT:GPXWJQW^KYLT4WMEK[W55;F7:R0T$",54E97),JNS39JHU.K/;Z
M# T<_%MX^FJ_^8>2H                         >.\E>X]/'>2O<!",1?
M'%+\W^:DGM/1-[B,8B^.*7YO\U)/:>B;W$C8@ @43=$[N**3HO65S=$[N**3
MHO6!>     "#SX?P-?L25\$M)15=Y;G)4LUG:Z<R9JF?I0G!P"DQ5;L):9L4
MUMVX;@96NA;P3-9=97,7>G4U2S'69WI3FM%=<W;;H=%@G %=45%/14%MJ)Z=
M=6:.*=7.C7-4R<B.V;47GW&QP=1X2H;E<:?"[*6.LBRCJV0N<KFY*J9+FN_,
MX[H[Q]9K!BK%%PK^,\7N,ZR0<''K+EKO=M3/9L<A(M!E;%<L<8RKJ;6X"IDX
M9FLF2ZKI'JF:=REEZ6B)W,J<>6DS7EB-SMVL &=L          !R&Q?K/8C^
M@H_XX3KQR&Q?K/8C^@H_XX3KP   <JT\0R+2V>9$7@FOD8O>J-5/W*<@/I_$
M]DI\06:>@JO@H_:QZ)M8Y.9R?^>;,^?L184NUAJ'LK*61T*+\&>-JNC<F_/J
M[EVFG%:-:?&>/<%DKGG/$;K.OXUT:$ENBF&27'5N6-%RCX1[E3J34<GYHGK(
M];+97729(K?2S5#U7+*-JKEWKS)ZSN>C7!JX:I9*FM5K[E.B([5VI&WGU47K
M7>O<=9+1$,?A/!9,_$5O$?368F9_9-0 9'WX                  !I;U5W
M^"J:RSV>@K:=6(JR5%P=3N1V:YIJI$_9EEMSZ^;8;H 1;E+&/R:L_P#SI_\
M^W-3:8L8T%WO==R#9Y.4IXYM3E=Z<'J1,CRSXOMSU,^KG)^ (MREC'Y-6?\
MYT__ /;DCHGSR4D+ZR*.&I<Q%DCCDX1K'=:([),T].2=Q>         $5P5\
M=XT^ET_E*<E1%<%?'>-/I=/Y2G)4              "+:3OZF5?SU-_,1DI(
MMI._J95_/4W\Q&!*0               :._X3L=_>V2Z6Z&2I9Y%2S..=G]V
M1N3D]2FHY"Q19MM@O[;C3IS4=[:KURW-G9D]/^)'DS $,3'7)JZF+K-7V14V
M+4ZO&:1?^U9GJI_?1I*K=<*.YTK*JW5<%73/\F6"1'M7N5-ADJF:9+S$5N.
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MC71[$3N-@ (2        $6TG?U,J_GJ;^8C)21;2=_4RK^>IOYB,"4@
M               .=Z;ZJ2'#--!&JHR>I1'^E$15R\<E]1P\^C-(]ADO^&9H
M*9-:JA<D\*=IR(J*GK15]>1\ZO8Z-[F/:K7M7)6JF2HNXU89CET^(_4..]>)
MYY[3$:4DBT>U4E)C.TOB545\Z1.RZVN^"O[R.G0-#^'IKA?F7.5BI1T2JY'*
MFQ\F6Q$[L\_#>=WF(K.WF\!CODXFE:=]P[H #$_20
M  /'>2O<>GCO)7N A&(OCBE^;_-23VGHF]Q&,1?'%+\W^:DGM/1-[B1L0 0*
M)NB=W%%)T7K*YNB=W%%)T7K O     !;G@BG:C9XHY&HN:(]J*F?K+A@W.\6
MVU+&ESN%'1K)GJ)43-CULN?+-=O.@C\(G4=V;JIJZN2:N6618HZ&DHFN;14L
M%.URYN2*-&9]^1SG &/HJVZ8E9?KY0-IX*Q642RR1QHL6L_R5V:R9(W;M,W
MF);A>,=XJH:BK9/;J-6+2HUK<D:JKM1R)FNS+G52R<=HVKC+6VM>[H( *UH
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M;_-23VGHF]Q&,1?'%+\W^:DGM/1-[B1L0 0*)NB=W%%)T7K*YNB=W%%)T7K
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M[7IVZOKI',^S:K6?X28@#76BQ6FS1ZEHME%0LYLJ>!L?[D-B
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M[3T3>XC&(OCBE^;_ #4D]IZ)O<2-B "!1-T3NXHI.B]97-T3NXHI.B]8%X
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MN)(> 6%=>FI'^5K=3WIU9=2<^?/EEM[DB(BJJ(F:@LOQ$VC4=%./@ZTG<SL
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M$]Z.56Q,SR1$V)GSKEFIU@   .0V+]9[$?T%'_'"=>.0V+]9[$?T%'_'"=>
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MC4&#A8QSS3.Y  9VL
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M XQ)VOP+0 N\8D[7X#C$G:_ M "[QB3M?@.,2=K\"T +O&).U^ XQ)VOP+0
MN\8D[7X#C$G:_ M "[QB3M?@.,2=K\"T +O&).U^ XQ)VOP+0 N\8D[7X#C$
MG:_ M "[QB3M?@.,2=K\"T +O&).U^ XQ)VOP+0 N\8D[7X#C$G:_ M "[QB
M3M?@.,2=K\"T +O&).U^ XQ)VOP+0 N\8D[7X#C$G:_ M "[QB3M?@.,2=K\
M"T +O&).U^ XQ)VOP+0 N\8D[7X#C$G:_ M "[QB3M?@.,2=K\"T +O&).U^
M XQ)VOP+0 N\8D[7X#C$G:_ M "[QB3M?@.,2=K\"T +O&).U^ XQ)VOP+0
MN\8D[7X#C$G:_ M "[QB3M?@.,2=K\"T +O&).U^ XQ)VOP+0 N\8D[7X#C$
MG:_ M "[QB3M?@.,2=K\"T --<Z3$%172RT&(FT=,[+4A6A9)J[$S^$JYKFN
M:^LC>(L"5^(FHEYO=+4N:F39%M;&O1-R.1R+EZR>@F)F.R)B)C4N36S0Y';Z
MOC$5WBE<F6JV>@;(UJIUZKG9+Z\^8FK+9BAC$:S%<;6M3)$2UQHB)]8D@$VF
M>\HK6M?MC2XV>5&HBOS7K7(]XQ)VOP+0(=+O&).U^ XQ)VOP+0 N\8D[7X#C
M$G:_ M "[QB3M?@.,2=K\"T +O&).U^ XQ)VOP+0 N\8D[7X%RGE>^3)RYIE
MN,8O4G2^H#,        /'>2O<>GCO)7N A&(OCBE^;_-23VGHF]Q&,1?'%+\
MW^:DGM/1-[B1L0 0*)NB=W%%)T7K*YNB=W%%)T7K O     !QC%FEVZV?%=?
M9Z.T4U3Q>7@V+K/UG[-R'9R)8GT=X;Q'+)/7T"1U<FUU1 Y8WJN]<MBKWHI9
MCFL3]4*LM;S'T3J7/UTH8R545<%2JO4O%YO\B9Z-\67S$E371WRQOMC(6-=&
MYT;VZZJJYI\+N.=7^CJ-'JO7#V/HM5G-;JEW".[M5J.3/O:WO)IH=Q[<<8\>
M@NE+ Q]*QCDFA16H_-53)47/;L+;UCEW6&?%>>?EM:=_PZ6 #,V@
M  XU;OUF<0_0<?\ %$=3.66[]9G$/T''_%$=3      !"]+>))<.82EDHWZE
M;4O2GA>G.S-%57>I$7UJA-#E?Z0M%+-ABAJHT58Z>IRDRZD<U41?%$3UEF*(
MF\1*K/,UQS,. .<KG*YRJYRKFJJN:JIX >D\1TW09B6>W8C;9Y9%6AKLT:U5
MV,E1,T5._++PW'T.?*^BJBEK<?6=L2+_ $4O#/5.IK4S7/PR]9]4&'B(B+='
MJ\%,S3J  SM8
M                                        7J3I?462]2=+Z@,P
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M;472=$265J?!8WL-]&?.O63< HM:;3N6JE(I'+4 !#H
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MJ9)UR.<B[]1-Q/2.Z/+=+;,&VN&J_P!+DBXQ49\ZS2*LC_\ $Y21
M                                          :C$.([3AZ!);Q6QTZ.
M\EJYJ]W<U-JD8I=+6%9YTB=55$**N2/D@<C?PS.HI:>L0XMDI6=3*? LT=5!
M6TT=11S1SP2)FR2-R.:Y/0J%XY=@
M       !>I.E]19+U)TOJ S        #QWDKW'IX[R5[@(1B+XXI?F_S4D]I
MZ)O<1C$7QQ2_-_FI)[3T3>XD;$ $"B;HG=Q12=%ZRN;HG=Q12=%ZP+P
M                  .-6[]9G$/T''_%$=3.66[]9G$/T''_ !1'4P
M<IK?_3+)46-NUUXQ--3/1.?@FRK++_@C<GK.GUE7344*S5E1#3Q)SOE>C&IZ
MU.3X$KJ2Z:1JS*J@=3T$E9- O")E+)43*B*SM9,C7F_VGI)U*-Q'1U[FYCT
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ME^;_ #4D]IZ)O<2-B "!1-T3NXHI.B]97-T3NXHI.B]8%X
M         '&K=^LSB'Z#C_BB.IG++=^LSB'Z#C_BB.I@   --B^PP8DP_5VR
MH74X5N;),L]1Z;6N\?PS-R"8G4[A$Q$QJ7Q_B*P7'#UP?1W2G=%(U?@NR^#(
MF]J]:&K1%541$S53[,K:.FKH5AK:>&HB7G9*Q'M\%,*@PY9;?,DU#:*"GE3F
M?'3M:Y/6B&J.)Z=88)X'KTGHY;H5P)54E6V_WF%T+FM5*6%Z9.VIDKU3JV9H
MB>G/=GV< SWO-YW+9BQQCKRP  X6
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M[W64FDG#MK9.UENJJ.JFG8K4VJQ&ZJZR[4RS7K(;AC#$6*\"8DH5D6"KCO\
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M2>T]$WN)&Q ! HFZ)W<44G1>LKFZ)W<44G1>L"\
M  #C5N_69Q#]!Q_Q1'4SEEN_69Q#]!Q_Q1'4P
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M,\/UEEM%74WI&)>KK5/KJQ&+K)&YW-&B]:-1$3OS)> !>I.E]19+U)TOJ S
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MJ3I?41_W5X=\_P!I^^1^T9-NQ/89ZMD,-[M<DLBHQC&5<:N<Y5R1$3/:H$C
M       /'>2O<>GCO)7N A&(OCBE^;_-23VGHF]Q&,1?'%+\W^:DGM/1-[B1
ML0 0*)NB=W%%)T7K*YNB=W%%)T7K O             !RO1#5TUBN6,L.7&>
M*FK::\3UD;)7(U9*>7)S'IGSILVY<VPZH:#$F#<.XFDBDOUGHZZ6),F22L^$
MB;M9-N7HY@(3HUJZ>Y8]TBXJCE9R.^2GI(JE5^ Y((LI'([F5N>6WF.D66ZT
M%[ML-PM-5%5T4V?!S1+FUV2JB_BBH*:TV^EM/)=-14\-NX-8N+1QHV/47G35
M39DN:^)Y8[106*UPVZSTL=)10Y\'#&FQN:JJ_BJJ! 6?K&R?_P",I_,G3#"2
MU4*7A;MQ6+E)8.+<8R^'P6MK:F>[/:9H A%RT3X(N5PJ:ZNP_!-5U,CII9%E
MD17O<N:KL=EM52;@#YUM&CK"DVGR]V&6S0NM$%H941TW"/R;(KHT5V>MG^TO
M7UG2O>:P!\FZ?[67VC0V+]9W$?T%'_'"=>"7/_>:P!\FZ?[67VA[S6 /DW3_
M &LOM'0 $.?^\U@#Y-T_VLOM#WFL ?)NG^UE]HZ  .?^\U@#Y-T_VLOM#WFL
M ?)NG^UE]HZ  .?^\U@#Y-T_VLOM#WFL ?)NG^UE]HZ  .?^\U@#Y-T_VLOM
M#WFL ?)NG^UE]HZ  .?^\U@#Y-T_VLOM'--/&CK"F'</V2HLMFAI)I[O!3R.
M;(]=:-S7YMVN7<A]%G(?TEVN=A?#NJBK_P"O:?F3^S($PWWO-8 ^3=/]K+[0
M]YK 'R;I_M9?:.@ (<_]YK 'R;I_M9?:'O-8 ^3=/]K+[1T  <_]YK 'R;I_
MM9?:'O-8 ^3=/]K+[1T  <_]YK 'R;I_M9?:'O-8 ^3=/]K+[1T  <_]YK '
MR;I_M9?:'O-8 ^3=/]K+[1T  <_]YK 'R;I_M9?:'O-8 ^3=/]K+[1T  <_]
MYK 'R;I_M9?:.:7S1UA2GT\8<L4-FA9::FVRSS4Z2/R>].$R7/6S_93KZCZ+
M.18D:[_\2^$G9+JI:)MN6S_7 ;WWFL ?)NG^UE]H>\U@#Y-T_P!K+[1T  <_
M]YK 'R;I_M9?:'O-8 ^3=/\ :R^T=  '/_>:P!\FZ?[67VA[S6 /DW3_ &LO
MM'0 !S_WFL ?)NG^UE]H>\U@#Y-T_P!K+[1T  <_]YK 'R;I_M9?:'O-8 ^3
M=/\ :R^T=  '/_>:P!\FZ?[67VA[S6 /DW3_ &LOM'0 !S2[:'L!PVNLEBPY
M3MD9"]S5X638J-7+]HAF@K1KA'$.C.UW*\V2&JKIG3(^5TCT5V4KD38CD3F1
M#N-[^);A_N\G\*G/_P!&QJMT/V5'(J+KS[%^>>$LWWFL ?)NG^UE]H>\U@#Y
M-T_VLOM'0 $.?^\U@#Y-T_VLOM#WFL ?)NG^UE]HZ  .?^\U@#Y-T_VLOM#W
MFL ?)NG^UE]HZ  .?^\U@#Y-T_VLOM#WFL ?)NG^UE]HZ  .?^\U@#Y-T_VL
MOM#WFL ?)NG^UE]HZ  .?^\U@#Y-T_VLOM#WFL ?)NG^UE]HZ  /G?27HYPG
M:L>Z/:"WV:&"DN59-'5QI(]4E:B1Y(N;LTYUYMYTCWFL ?)NG^UE]HTFE]KE
MTFZ+%1%5$KY\U1.;9$=;"7/_ 'FL ?)NG^UE]H>\U@#Y-T_VLOM'0 $.?^\U
M@#Y-T_VLOM#WFL ?)NG^UE]HZ  .?^\U@#Y-T_VLOM#WFL ?)NG^UE]HZ  .
M?^\U@#Y-T_VLOM#WFL ?)NG^UE]HZ  .?^\U@#Y-T_VLOM#WFL ?)NG^UE]H
MZ  .?^\U@#Y-T_VLOM#WFL ?)NG^UE]HZ  /G705HZPIB&R7^:\V:&JEI[Q/
M31.=(]-6-J,R;L<F]3I7O-8 ^3=/]K+[1HOT;&JW#V)]9%3_ -?5*[4_LL.N
M@<_]YK 'R;I_M9?:'O-8 ^3=/]K+[1T  <_]YK 'R;I_M9?:'O-8 ^3=/]K+
M[1T  <_]YK 'R;I_M9?:'O-8 ^3=/]K+[1T  <_]YK 'R;I_M9?:'O-8 ^3=
M/]K+[1T  <_]YK 'R;I_M9?:'O-8 ^3=/]K+[1T  <_]YK 'R;I_M9?:.>:9
M,!89PG!A2NP[:HJ&K??J:)TC)'JJMR>N6U5ZVIX'T&<D_2-:KK1A'515RQ#2
MKL3^S($PZV  @     #QWDKW'IX[R5[@(1B+XXI?F_S4D]IZ)O<1C$7QQ2_-
M_FI)[3T3>XD;$ $"B;HG=Q12=%ZRN;HG=Q12=%ZP+P
M    :W$=[H<.V2LNUVFX&BI6:\CLLUW(B)UJJY(B;U V0.<T>E%K:F@6^X:O
M-DMMPD;%35U6QG!JYWDI(B*JQY]69T8               $.Q)C:6V7E]IM6
M'+U>:Z-C9)%IH49"Q'<V<KU1N:^C/KW 3$$3P7CBEQ+7U]LEH*ZU7FA1KIZ&
MM8C7HUW,]JHJHYOI3T;T)8               ""7'2+&MWK+9AFQ73$-31OX
M.IDHT8V"%_6Q9'JB*Y-R9@3L&):*N:NME-4U-'-0S2L1SZ:945\:[ERV>!E@
M              &@QIBNWX2M<=7<&SS232M@IJ6G9KS5$KN9C&]:FDLVD-L]
M\I+1B"PW2P5==GQ-U8C5CG5-NHCVJJ(_+]E0)T              &@QGBZTX
M0MG'+Q.J*]=6"GC36FG=V6-YU7\$ZP-^#480OT&)\-6^]4D4D,%9'PC(Y<M9
MJ9JFW+9U$5K-(\[JNK99,(8ANU+22.BFJ8X4B:KFKDY&(]4<]45,MB =!!I<
M'XEMV++%#=;0]ZT\BJQS)&ZKXWHN3F.3J5#=             (1==)EBH<8V
M_#4+IJVX5,Z4\CJ=$='3/7/)'NSRUMB_!3-=FT";@U&+K]3X8PW<+U61R2T]
M''PCV1Y:SMN629[.LB-OTD7"LGIF)@+%,<4SFIPSX&:C45?*7X7-U@=%
M          8MSN%):J">MN53%2TD#=>265VJUJ>E2.8 QY;L;K=%M,%5'#0R
MMCUZAFIPJ.3-'-3/-$5-NW+G0"6@B.+<<06.\4UEH;97WF]U$2SMHZ-K<V1(
MN6N]SE1&MS3(81QQ!?KO5V>LMM=9[W2QI,^CK&IFZ-5RUV.:JHYN>S,"7
M  !X[R5[CT\=Y*]P$(Q%\<4OS?YJ2>T]$WN(QB+XXI?F_P U)/:>B;W$C8@
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MW0RL7)S57KV]>Y4)$0_11AJLPQA-*>[/C?<ZJHEK:O@US8V21V:M3N3)/$F
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M<4OS?YJ2>T]$WN)&Q ! HFZ)W<44G1>LKFZ)W<44G1>L"\
M
M
M       'CO)7N/3QWDKW 0C$7QQ2_-_FI)[3T3>XC&(OCBE^;_-23VGHF]Q(
MV( (%$W1.[BBDZ+UE<W1.[BBDZ+U@7@
M                                   6:JJIZ1B/JIXH6+LUI'HU/Q*H
M)HJB-)()62QKS.8Y'(OK0"X      P[O<Z.T4,E;<ZAE-2QJB.D?S)FN2?BI
M5:[A276@BK;=.RHI9<]21G,[)51?Q12=>Z-QO3* !"0%N:HA@RX>:.//FUW(
MF?B(:B&?/@9HY,N?4<B@7
M                       \=Y*]QZ>.\E>X"$8B^.*7YO\ -23VGHF]Q&,1
M?'%+\W^:DGM/1-[B1L0 0*)NB=W%%)T7K*YNB=W%%)T7K O
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M3NXHI.B]97-T3NXHI.B]8%X
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MP2S_  >[FS_$Z4#B+VKVE9;'6WW0Q[=14UMH8:.AA9!30M1D<;$V-0R #EV
M                                                  >.\E>X]/'>
M2O<!",1?'%+\W^:DGM/1-[B,8B^.*7YO\U)/:>B;W$C8@ @4R)FQR>@LT:_!
M<FY2^O,IB1NX.=<^90,P
M
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MNB^H.5+ONB^H2SD^/<G@.3X]R> $3Y4N^Z+Z@Y4N^Z+ZA+.3X]R> Y/CW)X
M1/E2[[HOJ#E2[[HOJ$LY/CW)X#D^/<G@!$^5+ONB^H.5+ONB^H2SD^/<G@.3
MX]R> $3Y4N^Z+Z@Y4N^Z+ZA+.3X]R> Y/CW)X 1/E2[[HOJ#E2[[HOJ$LY/C
MW)X#D^/<G@!$^5+ONB^H.5+ONB^H2SD^/<G@.3X]R> $3Y4N^Z+Z@Y4N^Z+Z
MA+.3X]R> Y/CW)X 1/E2[[HOJ#E2[[HOJ$LY/CW)X#D^/<G@!$^5+ONB^H.5
M+ONB^H2SD^/<G@.3X]R> $3Y4N^Z+Z@Y4N^Z+ZA+.3X]R> Y/CW)X 1/E2[[
MHOJ#E2[[HOJ$LY/CW)X#D^/<G@!$^5+ONB^H.5+ONB^H2SD^/<G@.3X]R> $
M3Y4N^Z+Z@Y4N^Z+ZA+.3X]R> Y/CW)X 1/E2[[HOJ#E2[[HOJ$LY/CW)X#D^
M/<G@!$^5+ONB^H.5+ONB^H2SD^/<G@.3X]R> $3Y4N^Z+Z@Y4N^Z+ZA+.3X]
MR> Y/CW)X 1/E2[[HOJ#E2[[HOJ$LY/CW)X#D^/<G@!$^5+ONB^H.5+ONB^H
M2SD^/<G@.3X]R> $3Y4N^Z+Z@Y4N^Z+ZA+.3X]R> Y/CW)X 1/E2[[HOJ#E2
M[[HOJ$LY/CW)X#D^/<G@!$^5+ONB^H.5+ONB^H2SD^/<G@.3X]R> $3Y4N^Z
M+Z@Y4N^Z+ZA+.3X]R> Y/CW)X 1/E2[[HOJ#E2[[HOJ$LY/CW)X#D^/<G@!$
M^5+ONB^H.5+ONB^H2SD^/<G@.3X]R> $3Y4N^Z+Z@Y4N^Z+ZA+.3X]R> Y/C
MW)X 1/E2[[HOJ#E2[[HOJ$LY/CW)X#D^/<G@!$^5+ONB^H.5+ONB^H2SD^/<
MG@.3X]R> $3Y4N^Z+Z@Y4N^Z+ZA+.3X]R> Y/CW)X 1/E2[[HOJ#E2[[HOJ$
MLY/CW)X#D^/<G@!#Y*V\2IDDB1I_98B&,EJJJJ37J'R2.WO55)TE!&G4A>92
M,;U(-B,VZR:F2JTD=)2-A3F,IC$:FQ"HA(B9
M
M
,             /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g50309g19r25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g19r25.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_X4^M:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 V+C M8S P,B W.2XQ
M-C0U,3DL(#(P,C O,#@O,C4M,3<Z-30Z,# @(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(*(" @(" @(" @(" @
M>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B
M"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN
M<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E
M<V]U<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B @(" @(" @(" @('AM;&YS.FEL
M;'5S=')A=&]R/2)H='1P.B\O;G,N861O8F4N8V]M+VEL;'5S=')A=&]R+S$N
M,"\B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]P9&8O,2XS+R(*(" @(" @(" @(" @>&UL;G,Z>&UP5%!G/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O="]P9R\B"B @(" @(" @(" @('AM;&YS
M.G-T1&EM/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM
M96YS:6]N<R,B"B @(" @(" @(" @('AM;&YS.GAM<$<](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]G+R(^"B @(" @(" @(#QX;7 Z0W)E871E1&%T
M93XR,#(V+3 S+3,Q5# W.C,U.C4R*S U.C,P/"]X;7 Z0W)E871E1&%T93X*
M(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C8M,#,M,S%4,#<Z,S4Z-3(K
M,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4
M;V]L/D%D;V)E($EL;'5S=')A=&]R(#(U+C @*%=I;F1O=W,I/"]X;7 Z0W)E
M871O<E1O;VP^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C8M,#,M
M,S%4,#<Z,S4Z-3(K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @
M(#QX;7 Z5&AU;6)N86EL<SX*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \>&UP1TEM9SIW:61T:#XR-38\+WAM<$=);6<Z
M=VED=&@^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FAE:6=H=#XX-#PO
M>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.F9O
M<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @(" @(" @(" @(" @
M/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G14%304))04%$+S=1
M07-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!04%"04%304%!04%%
M028C>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL04=404%!04%!9B]B04E1
M04)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+0W=O2R8C>$$[1$)!
M341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C2'@X9DAX.&9(>#AF
M2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[2'@X9DAX.&9(>#AF
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF+SA!04519T%6045!07=%4B8C>$$[04%)4D%135)!9B]%06%)04%!04A!
M445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W14%!9TE$05%%0D%1
M14%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!04-!44U$06=10T)G
M8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%54UP1VA">%=X46E0
M0B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-00TY546YK-D]Z3FAD
M55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y-"]0128C>$$[,4]4
M,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N9#1E6' W9D@Q*V8S
M3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[<6)N2C)E;C5+:G!+
M5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#04U$8E%%04%H141"
M0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T4TY#1E9*:6-V17I*
M1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H9UI*:EI&1VED:V1&
M53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&195U9P8EA&,658,5)L
M6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ
M;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ2VUQ<39Y=')Q*W8O
M84%!=T1!44%#15%-4D%$.$$Y56-V044K*S,X8U992BMC,VUV5B8C>$$[9DQN
M:W0W;E1#,$XS9'IP84QC0VA-46189&Y8<E$P:F]$,G)L,D=!;$QD>#E4:TU)
M5TAZ-S58=DI.4W9R=S9X96%T3VE7-U1+.6LP:R8C>$$[,&YQ:5--07DQ3%52
M9WA5=#)*2'EZ36U+1S%/=7A32D\U:VTQ,UHV5$9*0W-'<&$Y2TIM:%E'4TIO
M+S-5:D%S,49-;&8S6BM(9BMM428C>$$[0E!C1S1X2&9*=7IT9$Y9,T9V3F1A
M-4YE55E7<7=R3%%S<U-/95%+.'5+<TI#9CA!23,W8G!*.&MG1'9L.7%Y0TQ3
M2%%'93@Q,D%1<28C>$$[4%AM54\T63@Q2DE"031G4D9J.#9D<V0O2D9$=FLV
M97AT,$M.1F-A*W<U2WI2>5)Y9T=&55HU6#5!8D%+66TV1VEK;G=W,S=L35(S
M>28C>$$[5W=7*VQY>C(P2C%$6&5C>GAX<W%2=7I&-4A694UA,'%Z9F%O3S4R
M-V)T;G5#,$\K4S5,6%1'4TUI.#$V<F@R3$%-=S1,0UA6<6-2<R8C>$$[5UAX
M*WEF.$%**TIS*U,X23<U2W1X839%1W)(9BM915AN2%5&1UE"0V9J*TMI,6)I
M0U(X22M7044Y=U-9:G9K:&]6,'E/1T0V-60V-"8C>$$[:&MH.5-E-&\V:$=)
M:DDT<%$X;#)M3F51-D1R5#1J=C5-4EA5>59M='1(2D%H=F1F6C-6=VM42SE3
M=U)!:D1I=3E:0S-W*T9.-CE26B8C>$$[.&LX23<U26)864Q/,#!7-'5R4%5T
M5U<Y:'5K='A"9&5Q9S1&5S5K<T8T8V=Y9$]14'IP:&IU95%9-4)58D)L8D]0
M.$%N2#=Z=G(Y,28C>$$[<DYX-69V<FE7.7-Z8G1C5S5L674P3%)S;TE6;4YE
M1$(K;FI3;F9+.5)J049H=#!E5U)00V0S=DA)+WEN.% V-6AU=V)"0D92=4U6
M8R8C>$$[5%0V96=X5G)K9C54*T@Y8U9F2U U>&593EDQ4'IZ<61T97E/3&)4
M-6UG<S=5:VA%4DYG=UAP5B]T12LO:%1.:FAI0D5/;C%5>5IK2"8C>$$[;VQD
M:G%(:U%71G!&9F%49$YE4D-L,V-1,T9"2V95<E5)=TE8.3-69G5/4TEL9DY%
M6EDV,T)T16%B<%=J87I"95(V5'!.,TQC=WA1;"8C>$$[04I566E10U@Q5%%S
M:$EF-$M+<6LQ2%5D0T-33UI:4FI'5C!#;D8U-68P.$-'94QY9&5W;V)G>$9*
M6EI5:EEY1FMI4C)A471(*SAK428C>$$[0FHY<6Q+-TYY9TI(=F)$:FHO3DMK
M;6=E6#5:8FU/1'DO<45X9U-.-4DT-VU*-54Y9FU9-FA#97$P3D].4C%/,U4X
M4C<Q.$](.#!Q5R8C>$$[;2M8<E9Z83).-354=B]R='A%,4I&:V5,:R]Q0D$V
M;54X1E)A<4=,9$-4,G!2379.:DA'3U)I8F1A841P56QT03!V;'4O;F532T)H
M2B8C>$$[851$9S-Q<6E+45-:=51Y4U8R1D]V,F1S5$DY-E)J:E@P;&503#)L
M*V=05#AS86DX:GAO561P445$37=18V=$.$A+4D=!1$=T1#,R3R8C>$$[4$5E
M.5!H4B]M;&4R9V%.2U-L<#55,58O5$II235L<$1.-G9!<2]%8F9%<DE">#9J
M=6-(164X3#1C9C5P56PX=C)L<G!35#-8;&4Y3B8C>$$[3%IP>F5I5W%.1GEK
M2FQF9FEJ2V]!<#=D35!%4V5A4$1!1SA3;%0S+T%*04M+:6%894M76G96;&%D
M5%)A+T-554199T4Q0DHW6DMP9"8C>$$[-UAX674T<%9F6&QP838W4&1E6#5*
M-V4P:6U,-F9)>$M4;V=0=T5L4V9I*VY*9U=.,G%59TI81CEC95)T6'8X059V
M2T=K86QF269R9"8C>$$[,6)2=DTQ04]457!Z<'14;CER-F,Q=5%626@S5TM2
M35%3;FAK0VMC=F@U1V=*<#%08DE-,C V9E-F,6Y&570X>6583DLX>#908V%4
M<28C>$$[:UIK=&)G0W!5,&1'0G%R;S(Y1U4O=T)U,E-J27A.:&I/06M+3'I#
M>2]W0V-E6# V-6MM,'IZ4&-7:&M(06QB9%-X44]R.%=):U5-3R8C>$$[4T$Y
M379/;W9M2$9J;RM%,D-5>%@X;G9-<4LV<C4S=D9%:6Q:2U%!8VQ+:%-#9E8S
M,E5$22M-3S5N-$5V-7AC,S5/82LQ=$)B=#5W;B8C>$$[6F)A5C5O2$YP1UA2
M-44Y3G%-6DLP2SES9D=(8W9G4R]N3U@X;3EE5WE3>EAZ:$])54QL4TQ23U9*
M14--=DPQ2SA3<6IB2'AH,THX0R8C>$$[5E9X259V>4HQ2FU6>C5S;C5R2#93
M=CA!5E5$0U!I131G*W!50V='2'AX,TUF>34O;DEM6#AN4$UC<%5V-3)U>3!:
M5F\R*W)G1E=1<R8C>$$[5EI32F%G<5A*0D=$>&@S2CA#6#@T=$@X;69-0DYF
M.$%';#!+:TYT8G%"54QW<E%39GEI;5!J1'58=TIF>FET+S55<G)V1D8O>&QD
M8R8C>$$[63)6,$@Q6F1M43%5+W="-3%&8U!J1'58=TIF>FDQ2BM3;7534GE2
M=C5X=5-K;TEL2#%:9FE"57%A+W90-5=)>#A99'DK0DPK8U9E,28C>$$[+THO
M>D)B4EA%35AN0UE26$MS:VE'>FI)2$EH:7DO=E!H87%G.&AV9T]99'E2:&PO
M3U5.5B]*3%9D5W-)8DA54$YC;'A"07A:0S%N2"8C>$$[-FA*+VUK16Y.9T]W
M2G=J3T%B05EZ,#5K2TUM4R]L-RM6*VEE4S0U<$Q74C=V54QK0DHW>55"5'="
M<G=24CEL83=N8S$K-TE:37!K,B8C>$$[66-%8V9*;4]63GEH6F8S8B]W1$=7
M6"]I6GA65F8W568K="]X<6-66%EQ.#@X*V52+TE/=C8Y8FI6;UHT9%=M.4=)
M6$9Q-E)M55-E;R8C>$$[135"-F@K2&]N:U%V24-N8G!B1$Q+23)A8VU#37I:
M4W%0.&=0>39K-6-B:E5155!&=S!I<5%A03E':$(V2$HO;5I.6#5/0TMT=GE*
M."8C>$$[;%=V3#9R<4=Q46,V8R]3=593=$]L94U9<E-U039I4C=M43!S4GEV
M-6]U9CAN+TQK+W!E<G)/<TXV25%2+W=#;$%5.4TQ43=2:F1E>"8C>$$[-C10
M1U!C1U)W03E4.#%*9GE5.'%O,TID6#%H5V]G<4QU:'!&6# O.3$O<U902'=X
M.&,Y=U(K5VHS;C5U+W=#5DME5F518CE,-G9Y5B8C>$$[4V]B-C-U1DI$168S
M9E%K030K3V4T3"M7:C-N-7)O+WE9.'-X;VE2-GIR2TI'04DQ5SAO1D-G04)1
M23EQ0E(Y,E!J;G5#:E1J=E!Z8R8C>$$[=C5-958Q:U=187AR2$Y/2E5M-T)P
M-F4V9%DO,F4R4&IN=4-F>30W>C@Q-B]K.35B4S5&>75R-G-S>75:47=U14$U
M<U-X4$@P=5!6:B8C>$$[,G@X63EW5#1!=3=,;"]*-WDR='1086I73E<K<C-1
M26YI3GEP5F=X2EE535<Q95)R5')J-'@W9VIW0E97570O-D8W+TPS+VQO=B\X
M028C>$$[:V1(+T%.57-L*UIK=R]*=U9R4#AG=GDV=#=M3UIZ9#-+>&YK64IP
M:#9B53=.=U)'<#E/039I4VI2=T0P>49)6315:FA656A247-A228C>$$[07%Q
M<6EG04$V05I1-5-(,4@W14@O1V5,+VE72V]P3VXP;CE:>%9#-G)B,SEX67E1
M,D8S.5)U,DM'3S4T3$IX0W5#=S1/0W U2T-V,"8C>$$[-'%L=6MP<BMN3$9A
M-G!Q0V%N3$E*<%!8.451:T)744MV=T=H040K1F-65% V,4HT1#AC5F0Y86LX
M0BM/2W4K=%-E02](1EAF5W!0028C>$$[9FII<G9R56YG4'AX5C,Q<51W2#0T
M<3<V,4HT1#AC5F0Y86LX0BM/2W%D>G%,=U<X<S5J36=I4FY+4G%79'5)<E)2
M6&-N=&EQ5#-0;B8C>$$[94LS95I:9$]V*T5#:#-L5S%K9$M'3DI$47)8;TI.
M+V172'I.2VET1#@P=V%W,'EW451W;4%Q2%<T:6%):U!5<7DX=6])1F-65'I!
M<28C>$$[:%IF,V(O.$%'5U@O04EM8U966"LQ2"]R9CAA;D95<3@P95IR2'DU
M<&<Q1SEI;6QG37%1,&=#<W=:-C!*-7-I9U9&3W53:D=Z5$=5=28C>$$[15=Q
M6'5V4C)L.4):=F%83'9C3D-I>7AO1VI5>D=15EIG,G=J.4PT>C(U3#$S<$9K
M,6(Q;'5B,3!6=4IM02M*4W R:&I(4F=$:%98.28C>$$[1U@K531&9#9-=CA!
M2V-69#9-=CAP>%8S;WDO>6Y&6&5J3"]+8U9D-DUV.$%+8U9D-DUV.'!X5C-O
M>2]Y;D98;6UP-C=F4G<R9#%"9B8C>$$[,T4Q<S=82T=A2SAT;55M3U9X*W=N
M1G%B97=&0FMI2V$T5$UH6D9)2'E*-6HQ,E1Z9W1P<D=P>G1(3$90171V8S-&
M:$EP;5,T-'AQ128C>$$[='%-<CA72$4Y2%AE9W!G8DAS8TE):E5(631&42MO
M+UEG+S1Z>&8X045S5E4Y675R,C P93AU<DM.2F)Q,VIK;&EI:TI61TM68FE3
M3R8C>$$[;&%944XP13=*8F]F;E,P,515671,3G).0G%$5TU.+TUP-'1%:7I)
M:F-224-#.4,O1V]7;3)3;$-H8D=--TY,+T%$3G$P1VY7-3%-<"8C>$$[2F-1
M,C%T8U--;'-O:VM)5F]Q.%(P3DUJ15=756I1=&IF;$1Y-35G,%13-S(T;797
M=DPR.')C0T=3:7)8:E965E9J57A.+TYS=R]Y9B8C>$$[1V-P06YL5$-%4T)Z
M=%!D1C%+.&)38E-45UE46C-Z>$MB9TYU9V-J9C1W1D,O23 K;G)K5%8W37AD
M8G!R9U,W1EA9<3=&6%EQ-T953B8C>$$[<6QO.35P=#-A27E+.7A#.%-T279.
M05A5<4-Y,5AK3BML8U%X;D%3:5%E<D4Y5R],9&12;CED<G5&2DI9=E1U5DYU
M>DMZ96A(0T-V1R8C>$$[84UO<6U*6$%"<EAV:F%12T9)<GE6-4\Q1'DY9E1/
M,7I"2F$S4T%447A2>4E22D=W5TEQ6&MK1E!4-6-T<6QJ6&9&3$\X0W%&;"]D
M=B8C>$$[+W=!6EIF.$%I6GA65F8W568K="]X<6-666@K83AC8VYL54)J24A7
M-F=A3#!9:$Y*>D162$5&-'50=6584V\W-5II-71E6&MN1CDU9R8C>$$[;G1.
M6'1T3B]29#5C:31-871F47A%,C9E<'IQ>G8P54QW,S-R=4UR8D5483-*.5,K
M2FI+4V5S2U)U4C$Y1T]L4W90<FEQ=&%8-E0R<R8C>$$[37I,=TUQ2S552&Q4
M:TLP<E%F<7A65BMS>&4K2W4K<WAE*TMU*W-X92M+=2MS>&4K2W4K<WAE*TMU
M*W-X92M+=2MS>&4K2W%*:C X<28C>$$[14U#1D9:;593:3!$3U-7249/<$I.
M8U95,G,Y2&%F,3)T2510>E=4,51%:&9M9V]J8W%6-4M.9V4R2V\U5T1+1TA1
M-'%H9%(K>$(O>"8C>$$[;FDO-&QI<4,X,2MT+VA85B]26&TO=T)5=5!H<'EQ
M3T1C9T8W;6Y4,WE53UE9>C5&:%!K,DM+4'IH6GAT8E-'5S4X=C)K9#!'=$52
M028C>$$[:7A*+V538W<U86\T:T9+9$8W6F)0-F9I,5$K<C1*-7)/;#9(-5DP
M835A>G-18F(P6G!*;U-427HK<DY#2&\P:&,O=&)D:&Q)8DUK=28C>$$[1TI.
M6%AC:%!+2CAX,T=N,VPW<7DS;F\S440R-6E%4VYG14MS231'<3AF.$%K.$]V
M6$-71U!$2TE01DQI2BM!2'5:1&]&9C!88DQA>28C>$$[4U1"26PU5RMO:FID
M<E5B97%W1E%F;6AR-#!W1FY$2'=216)U=3E",DYJ8E<R=39N9')"939C6E)#
M=C<S:DI9=#9A9%DP6&MS63,K328C>$$[,5=V:E=U16Y::$$S3U=X2$PS2#-)
M*SDQ5S9S+W%:6%1M,4='-FY71C=I>6]W:5)G4UIP14\T454O6DQF<7%G5S)%
M,&U533%N35-S6B8C>$$[575U-U)K8UA8+U=5,%EF4TUI>59F5&HO04I2.7=X
M5C-P>"]Y:C=H:7)V5&HO;$@S1$9896Y(+TM0=4=+=3E/4"M59F--5F(Y3U X
M028C>$$[;$@S67$S:7%H6F8S8B\X04=76"]!26UC5E98*S%(+W)F.&%N1E=+
M9FUE3%5E6$EP<FU!6$UC1C5B>696+U<K<FPO:C0P1711>6UJ2"8C>$$[-THO
M0W57675B6&PU2G)F835Q3G1R5G9P.&5K>C-&=$]9=S$O1V8S8UEF;GE:.75I
M.%8W,3,V1&%T8EEH=%)U-VTQ=&14=C!I64='6B8C>$$[1TU255-/5D5C44E6
M5F-666HW4'A946=Q=FQY5G(W4610=3!I94I:;TDR.4]10EA5.%%#<D-P;U%C
M4TM+>$YI,'@K<GDK2#0T174K<B8C>$$[>2M(-#1Q-S9V3#1F:FER=G$X=F@K
M3TMU*W)Y*T@T-'$W-G9,-&9J:7)V<3AV:"M/2W4K<GDK2#0T<3<V=DPT9FII
M<4II57)'065O>"8C>$$[5D1A:CEI1"]!27IX9CA3>%9"*V%K.51Y<')+8B]&
M6C-12$5K2"LW8G=O8VQ(;4=-*U)96C5#849F3G1N16IC,R]W04TR2EEM;%5#
M*R8C>$$[;4%L2SAH,35E.69B3&-N3#1T5U!N+VUO+W=!+V%G,3="<#%P84QZ
M=&(V."]2*V]024=J-'AF6$DT2E-V2D-'265086A(:C!Y<4Y.>"8C>$$[2D95
M>F%),C!54U)2,%-/3E%Q2T]G54-G07E+5G-Y,FMW2'%52E@W3$%K371F-5=&
M0U!O>%9"4DA63&4X;FME-%<X<U=#96A">%9*;R8C>$$[>4LX+VDR5BM8=E0K
M<%-S;71T3'9B;4=E3V53,G5B9'I)>7=S65=C;%-O17E%9D=.-FIK4'=R:3%4
M>#A20G,W9FID5#$R2E@P;3=7-B8C>$$[:515<EE1>3AO5R]D5$93:#5"6%AB
M:U)S2T)F;FE/86-H<4I.5VAV3#EX<#!/:5=#5W,P;6Y1:4-0,&)7-%EY;V\T
M:6DK<$IU.4(O2R8C>$$[*TI.;&-:.4DR<$]0<E8Q2#EU3DHQ+VUI4$9J+T%,
M0GI19CA!0FY!>E%&.35U,'%Y,4A4-T<T67A3-F<P:5)M5EI%04U38S(K3&=5
M.28C>$$[=G1F2W5315-28D5Y04Y*=6QZ8GE)2%-26%)T=WEM;U P:DES;2]7
M:2]M1TMR63=U,FM:;&IL5C)1.%A#:T5G*T)P,'A65GA647-V-R8C>$$[="\X
M06I,3"]!351/2W%R+T%';R\Y8B]J531Q>% X,')C,TAL8C!M25=&<FU$,7HX
M46)H>C9*>&EU3GEA1&1A57)V;&U,;3$U4G-N1B8C>$$[-W%U=%%A=$9A5RMK
M3F175&U,;F9,36E"03=L6D-56590<&=!-T=P<C)Y='-3<GI.1$)F-EAF5W0P
M,#EP1SDO6BMO,&-N<$]&-3(T4"8C>$$[>&]32U5Y55141U%S3C,R<S)/:S94
M<#DS8U-T0F)4>5=K56I!<T%*1TMR53AE>DPX3%8R-DA%0S%-9T=39E=K.$1K
M5U1V<E-E0GA6,R8C>$$[,7!0031Q-S8P;F=C5F0Y851W3TMU*W1*-$A&6&97
M:SA$:7)V<E-E0GA6,S%P4$$T<7%O=UI1=S9(1E5,<5 R25 K33A8+T5S5E5T
M8B8C>$$[=$QM.#!/+W1,6E9A831H;&A66%!&5#9G2VYF:3E.:G152$1%-V]K
M3FMP.'4K54<P,B]S.51L;2\P:4Q38F942G)D4E9E55!%;'<T-"8C>$$[9R]:
M<#EG9G=Y57 S=#5S67=R9GE7*V,Y3FQV8C-24VIQ<3)T,&QX24<U8FA*;V=!
M3TI'.5-/=5)#6EDT>7$K;2]W054T>%I/>%8R2R8C>$$[;U,K,'5Y=EIB96%D
M0UIR4GI*8E-+>%5O>$9+:6AO9G R>%1B<')S,E54>3-R1#9V1T-Z6$E'>7%.
M>5I&2%0U:F(U66]214US33!#4R8C>$$[=W-S:TUQ:&\S6&175FA5165X1TMQ
M6#%#,U@K-7)B;G0V4C1R6'@T9EE**V$T<6=,,C Q2G16,'%4-GEP=%E:6E!5
M4VI+-T5W=49R428C>$$[.$<W.6AI,7DT=4E65F1F,DIG.6I:3WAD;TEZ261Y
M+T5C<2M03')81G-A*W!"9#1P<&]Z,U!->6)F2U@Q0FEQ0SAV,C%Z0F5A<#8K
M;R8C>$$[3F9E<&5C-'=Y>'(V4V5L1T)(.$%&854V;D-3>$%,2F-I>55,3"LW
M9B]J3$PO=T%43TMQ<B]A:B]!3F(O04DQ3TMS5B]-,U(Y5S%J>28C>$$[>BMJ
M.4UT9G)C,'1Z05I)=S!356I2*V).5UDX9'5).%1L;4EG1WDQ6EEK:6=M,35E
M95E5,6E',W1R0EID3F(P+U9V0S9!<4-7.50T4R8C>$$[-G1S2U5O<"]%.&$R
M,4PY46QT9G)O='11;%-!,TXS>D-",D%)=#=D2D]8<4%*5&EW431516=C,515
M-S%*8DM'87<U6#AB5%%-5W19>B8C>$$[3T](<4M347=+<G0Q3D-34$1&<FQL
M2$-*06-13F-V4'(W:UA$1'@U1WED6D58*SAT4V5,2EAP>$15-&8V<E5(>3=H
M=%$S;'I764YB,"8C>$$[.4QP1DYT23=33#E7;41*2U!39&M*-$]Q3E$X9D1*
M4T9&:D=6:3 S*W%V-&I)<VYF5E@X4FER=G%R*TEX5C,Q5B]%67$W-G$O:4U6
M9"8C>$$[.59F>$=+=2MQ=C1J1E9E3E-Q0E0R>%9$86HY:40O:E!&+WA,1E55
M;E0V5"MS-'%H.51K=C0Y4'5(,"M.6G(Q63).=D4U;W)/0G-$=28C>$$[=C9X
M.#A64V%D9%=U-7)"8GA93&$V651U24)-1EEH2FME3E%/379+:4MP8W(S.$)H
M5DU043%4+V952"])-2\X07%L9U9$0S9U1&9'>"8C>$$[+W="1BMS:&59:2MS
M2&U2*S%24%0U9D-#<$\S-U%W<6EF43%4+V952"])-2\K<5="54QB,VLQ>&18
M1G!%,6\Y>F)%0U=&8FYK-F=G8B8C>$$[<V]J<6]R56(K1T954S%T<51Q5F%#
M,UI71D=5>7-1465X+V191E%U;EA5;#1J<EHO535"8G-9;E-+-#4X3TI)04E3
M33AA9U9!.$U+;R8C>$$[<W<V;4)5>%%!1"]I-2\X07%L9U9#5V)Y86I'=#%!
M;&YC3$<W<$A+:R]Q54E013!:67I3;W=Q:4HO<G-%5%-Z:3)I:5=N2U(U,E92
M528C>$$[,$93639D8U975V-L.60R<U9Z06QU.%5Y:&Q:6GEW,R]!37!9>414
M1EA8;'IC869!8G$X*W)1=THQ6C=G;T-E>6=V1V]Q93(K2W!U:B8C>$$[;S9+
M-DU'4F=#<D$Q0D(S0D)'0E9'>2]U,R\T>7DO.$%%>FEQ<2\R;R]W1%<O=T-.
M5&EQ-T952G%,-F]P=&9Q0U)0>75%1C,V<$DT,B8C>$$[-4(U<VQ#4&I',4U6
M648U:CAI83$U;3AY;E4Q,4<Q:G1B12ML1F%55V8P-3921U)I4VY5:$%#<D1T
M-$A,0D]H5%1K=U)Y2#%J:6HS328C>$$[:VDP2%A9=$US8DM/*V%(-FXV5EI)
M6&IJ1&E-54LX0F)K0E0T8B]4:TQB;V=21D%B2W-+6%=P=V5T2&-2>D)'6EDU
M67)I2GEV8T984R8C>$$[,RM(:W9&=&II<4-S4$Q7<5=/;$IA6%9X1F1P1GEK
M;&YU6C=I:$I9<U-10W%G0W9F16QH:GAI06]86&UB461J;U=T,VUO;E9R3%8Q
M828C>$$[>65%,C8R,$XU8U11.#!K2D5O2F515DLW53=F4$1E,4UQ-G%M=F57
M9DUL,W!5.%@V8F)4,6](93=3959#:6]1-T5T455&0G9V:D=61B8C>$$[:D]*
M:TMU:UI:5W9M5S5T67 T<G5Y:U(Q2'A*3&1Y0V\R66,Q;DMM:#(R=TTQ,7I:
M96%)3&579')I>D-X27IT>6MV1D9&1F0R865G2"8C>$$[=6-644LK6"]!1$QD
M-G)A-GI"<6QV2F)P8GE24GA2>EAB44]*1U9U93!P-4@T979,1'AB53%M0C1G
M8C)R:VDW>5!Z9EI7<VLW-FY:428C>$$[=W@O6CE11E9Q>&]Q*W!+5#EP:4%/
M4G=.:E5Z*V%93%IB<697.5!I=&XT.$HS54Q',U W3D=/,WAD<U964$M.>$QA
M47DR=7)A-T)Q5R8C>$$[;UAT-T\Q;W9Q>&QU4$AM25DQ0C,T;VAF:4]I+TQ$
M23(Q-'A)6'A'.2]S5'959G-19CA:-'8K2EI&<U)39%!P4#9Z:7)E2W%%=&IA
M5"8C>$$[6&1V9'E2:')I,41I,VM.87 V9T%E;F)C1$969D953RMN5TPS.&5O
M3D-P=DEO>D9(3G9527AQ4C1F-2LK2V]J1E5$86%*<&1P9C-';R8C>$$[45%C
M8GDV<5HU:7I-5%=L86-I478R4C X0C19<7AI-#@X96%956Q(*T5R;W5J3T5:
M6D]56E9(-&AY94-K0F@X449/;5<X03<R<FI08R8C>$$[9TQ(>D)F84LP>C)0
M:VTW:6EV5V=K85I*0S=Y4UA%66M0<3AL3$M5:VLT2&,O1E4K3U!!3SEF15!C
M>FEW;695=$IH;'9B33)X=31G8B8C>$$[:7=N;S553U!I:F-D1#%O8W));W1G
M3F@R;&%0<&UK,G8Q5%1R9$Q7,C5&=E-46F%K069Q04="2W)F5TYP9C)C=&YD
M>&E7,FY8:$Q'4R8C>$$[44=5.6I3:'A6,6I9,FQH85(R;'!'26)E2452>&ET
M0E4Q4%=P-FY&5DQ69$@P>E9R55=U<%<V,TYU2%=14G979V1F<W-+14=O>%9%
M=R8C>$$[=WA147AW=W%%:6E52D=G-DMQ:6=!*U%X5E1S=C=T+RM-<W8O04)-
M-'%Q=CEQ4#A!,78X06I5-'%U>%8R2W%&<%E7;&]:>F)2:4TS328C>$$[<EA%
M.4-A3DMW05IQ13=6-&IP:7%V:7%%,'I33DXP=48T3E!G5S-H9"]584Y+.&58
M1E5Q05-A8DE/;4MO<#!6,%I'<GA914=H24Y$-R8C>$$[:F9&54IP96MA8G!6
M<V)85#1&=#1#>&-O<$HK2G5P,TI086U+<U0Q2'I,-3!E>G4W5UAY:DI-<VYQ
M>#AK=59+3D1Z-%9)465P5FM.828C>$$[1&9,94-093%C8W4U4G-V34AM9E-,
M4TLP<V9*8W$V8BLU*W%2>#-!<D=B:$),27-I;%=D9E1L:S1(86<S-D%9.$5E
M.65/6&-Y>4]"3B8C>$$[8C!+3U!79%!%279);$XS<#!R0U1G5%)U1$UT06%(
M=WES-T9S0G-)=7=S3%14-T]+>G,T>$9B46EK8UE*3D%453=K:VUP4&9!;&)Q
M5R8C>$$[;3)7<%=5;&QF4D-E,6PT*W!%4U%'-'-'1F%%2'%U2W!D<C)G0S@X
M='1P3FEK2VU.66MT5G516DDQ15)7;DQK2$HK154S>%9)9DQ(;"8C>$$[2%AT
M3S$V2S=V64Y+4S!J:FLT=%IX=4IH235.5'E93#EV;%4K1DM!1'%3<DQD4BMX
M0B]X;FDO-&QG5E=L95=/,VME1TPQ<%8U1DEU428C>$$[6&MA;F)K9&AI<41L
M=CE74E%5,'0U1TE5:T-A255*<%562DA3<"LW1E90.$%39715<61(:S9G544X
M1F%(=G5W1S)+<6E8*W).5&QP8B8C>$$[3%564#<V23!.854V-'%P9G!06$]3
M:CE$4%$O86(V>$1T*T]+=%!Q;79!:TQO<DY4;V9R14E",G(S3F-65D@Q1%=G
M1DMA55<K148Q328C>$$[.%E)2EEI9S9G,%56-FIW*U-Q-4PO5E1D3$4R;'-S
M2G!7-#EA27%!9716<GEQ4%E9<6U/2W5X5C)+=7A6,DMU>%8R2V]E>$E-5# S
M+R8C>$$[04AS=B]*=S1Q<E Y<5 X03%V.$%J531Q:#<K-'9915$R;&]B<W,Q
M2%533$=62#@S>&1C5E%W,417=5569$I)5C(T>4@Q-#9O3U9/4B8C>$$[2%%I
M;2MX>%9A*W!A,D-/3VIU=S)Q4E!#2T@V5#!X5G!T53%L559J;SAM-$IC0V%)
M;%15:6Q!9"]O>%9S-FYR;DIW3D=B:4$S0FIC428C>$$[:7!"4$=T0V%6>%9T
M9%(Q>'8K;%%6-F9A=4EU-3EU6&)&5GI8*W)H2D=';&QI<FM2<4IO*U1*54%.
M=E%#;S-P6$964#E*-C5X52]O6B8C>$$[*U(K,$)C43!(,#%'2W)X<4]S:TPO
M=4I92&M!=V%E3%I31%9H4W1A54<R2W10<4]T3$EY<G!$3V]&431N:4%*;T14
M8S$V;6XP67$P9"8C>$$[4S%W2"]J:G-256EO=4EU;$)1+V54.3)+='!Q3W1S
M4&DP:&MA;T%";FE);V5P2D)05$989G!,5W5)2C!H-C$S551W;G0W:UEQ;4U$
M>28C>$$[4$-J>7@K;$E25C1Y43-%*T92<V-642MO+UIT+RM-.%@O17-6465P
M96HY64Y0<C-,.7(V<GHT5B]66#59<6A09R]W0S%V+W<K1EAF0B8C>$$[+W="
M<F8O:#A69#A(+V$S+T%/2'A6,W=F.7)F+T%)9D989D(O,G0O*TAX5C-W9CA!
M83,O-&9&6&9"+S)T+W=$:#A69#A(+V$S+W=#2"8C>$$[>%8S=V8Y<F8O:#A6
M9#A(+T%'="\K2'A6,W=F.7)F.$$T9D989D(O,G0O.$%H.%9D.$@O83,O-&9&
M6$@P-D=V-EAP,RLS+T1&534P,R8C>$$[-G Y4F@K<58K<C K1&Q8;#$S-6-T
M-C$V,7=+<5A0<&5I,W$Q-&8U4$QL6'1X-"]&6#59<6QV.$%O=CA!>2\X02]4
M>&ER=CA!4F8X028C>$$[;"\X02MN:D989C9,+W=!=B]W1# X67$W+U)F*U@O
M.$$V94U69"]O=B],+R]!3E!'2W4O,%@O;"\O=T-N:D989C9,+WDO=T0O044X
M628C>$$[<3<O4F8K6"]!4#9E359D+V]V.$%Y+SA!+U1X:7)V.$%29CA!;"\X
M02MN:D989C9,+W=!=B]W1# X67$W+U)F*U@O.$$V94U69"]O=B8C>$$[+TPO
M+T%.4$=+=2\P6"]L+R]W0VYJ1E93,B]2+S%I4&PV+W$W*VHY6CE7;&8X;C%0
M:#5F:FER+R\R43T]/"]X;7!'26UG.FEM86=E/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+WAM
M<#I4:'5M8FYA:6QS/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N
M9&ED.C$W.&)A86%B+3(R83(M-C T-BUB-F(W+3-F,&%A83EB.#5E8SPO>&UP
M34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP
M+FEI9#HQ-SAB86%A8BTR,F$R+38P-#8M8C9B-RTS9C!A86$Y8C@U96,\+WAM
M<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M
M96YT240^=75I9#I&1$%&1$%$1BU"1D5&+30T,48M.#)&0BU%-T9#149!1$$S
M1$0\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-
M.E)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+WAM<$U-.E)E;F1I=&EO;D-L87-S
M/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N
M:6ED.C(Q-#DT9CDT+6-E9#,M.#<T8BUA,3,Q+3-F.#4S,C0V968V.3PO<W12
M968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^
M>&UP+F1I9#HR,30Y-&8Y-"UC960S+3@W-&(M83$S,2TS9C@U,S(T-F5F-CD\
M+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA
M;$1O8W5M96YT240^=75I9#I&1$%&1$%$1BU"1D5&+30T,48M.#)&0BU%-T9#
M149!1$$S1$0\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @
M(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+W-T4F5F.G)E;F1I
M=&EO;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @
M(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$
M/GAM<"YI:60Z8SEF9&9B9C0M,V1C-2TT8S$P+6$V-F$M-#8Q835C-35A,3AF
M/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M=VAE;CXR,#(V+3 R+3(U5#$Y.C$S.C0U+3 U.C P/"]S=$5V=#IW:&5N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!)
M;&QU<W1R871O<B S,"XR("A-86-I;G1O<V@I/"]S=$5V=#IS;V9T=V%R94%G
M96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V
M=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI
M9#IF-&$V-3$W,2TT8S4X+30U.6,M.#(R8BTU-30S.3)D-C(W-F0\+W-T179T
M.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P
M,C8M,#,M,S!4,30Z,30Z,3@M,#0Z,# \+W-T179T.G=H96X^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A
M=&]R(#,P+C(@*$UA8VEN=&]S:"D\+W-T179T.G-O9G1W87)E06=E;G0^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG
M960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O;2!A<'!L
M:6-A=&EO;B]P;W-T<V-R:7!T('1O(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YI
M;&QU<W1R871O<CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N
M/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W!O<W1S8W)I<'0@
M=&\@87!P;&EC871I;VXO=FYD+F%D;V)E+FEL;'5S=')A=&]R/"]S=$5V=#IP
M87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI
M9#IA8V,P,6%E,"UE,V8W+35B-#<M.#4Q82TV.#(U-C)A9# X,#D\+W-T179T
M.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P
M,C8M,#,M,S%4,#<Z,S4Z,30K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A
M=&]R(#(U+C @*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HQ-SAB86%A
M8BTR,F$R+38P-#8M8C9B-RTS9C!A86$Y8C@U96,\+W-T179T.FEN<W1A;F-E
M240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C8M,#,M,S%4
M,#<Z,S4Z-3(K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R(#(U+C @
M*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @
M(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QD8SIF;W)M870^87!P
M;&EC871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z
M=&ET;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \
M<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/E!R;VIE8W1#;V%G1FEG5&%B
M;&4S,$UA<F-H7VIS;F]W7W8R/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F
M.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @(" @/&1C.F1E<V-R
M:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @
M/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B/D9I;&4@3F%M93H@(" @(" @
M(" @(" @(" P,#$N86DF(WA!.U5S97)N86UE.B @(" @(" @(" @(" @.#,R
M-S$Q)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @(" S,2U-87)C:"TR,#(V
M(# W.C,U.C,Y)B-X03M%4U0@5&EM93H@(" @(" @(" @(" @(#,P+4UA<F-H
M+3(P,C8@,C(Z,#4Z,SDF(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N
M-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,C4N,"XP)B-X03M'<F%P
M:&EC('1Y<&4Z(" @(" @(" @($9L;W<@0VAA<G0F(WA!.R8C>$$[XH"B(#4Q
M(&AA:7)L:6YE(')U;&5S(&-H86YG960@=&\@,"XR-2XF(WA!.R8C>$$[XH"B
M(#$P.2!B;&%C:R!R=6QE<R!C:&%N9V5D('1O(&]V97)P<FEN="XF(WA!.R8C
M>$$[5&AE(&9O;&QO=VEN9R!C;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O
M8W5M96YT.B8C>$$[(" @(" @(" @($)L86-K)B-X03L@(" @(" @(" @0TU9
M2R8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TF(WA!.SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI!;'0^"B @(" @(" @(#PO9&,Z9&5S8W)I<'1I;VX^"B @(" @(" @(#QD
M8SIC<F5A=&]R/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @
M(" @/')D9CIL:3Y2=71H=FEK($UA;&QA9&D\+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R96%T;W(^"B @(" @(" @
M(#QI;&QU<W1R871O<CI)<T9I;&53879E9%9I84EN<W1A;G13879E/E1R=64\
M+VEL;'5S=')A=&]R.DES1FEL95-A=F5D5FEA26YS=&%N=%-A=F4^"B @(" @
M(" @(#QI;&QU<W1R871O<CI#<F5A=&]R4W5B5&]O;#Y!9&]B92!);&QU<W1R
M871O<CPO:6QL=7-T<F%T;W(Z0W)E871O<E-U8E1O;VP^"B @(" @(" @(#QP
M9&8Z4')O9'5C97(^061O8F4@4$1&(&QI8G)A<GD@,3@N,# \+W!D9CI0<F]D
M=6-E<CX*(" @(" @(" @/'AM<%109SI.4&%G97,^,3PO>&UP5%!G.DY086=E
M<SX*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/E1R
M=64\+WAM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/@H@(" @(" @(" \
M>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^5')U93PO>&UP5%!G.DAA<U9I
M<VEB;&5/=F5R<')I;G0^"B @(" @(" @(#QX;7!44&<Z36%X4&%G95-I>F4@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W1$:6TZ
M=SXX-C@N-S8P,S<V/"]S=$1I;3IW/@H@(" @(" @(" @(" \<W1$:6TZ:#XS
M,#0N-C(X-3$T/"]S=$1I;3IH/@H@(" @(" @(" @(" \<W1$:6TZ=6YI=#Y0
M;VEN=',\+W-T1&EM.G5N:70^"B @(" @(" @(#PO>&UP5%!G.DUA>%!A9V53
M:7IE/@H@(" @(" @(" \>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/D-Y86X\+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y-86=E;G1A/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D^665L;&]W/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D^0FQA8VL\+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI0;&%T94YA;65S/@H@(" @(" @
M(" \>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @(" @(" @/')D9CI397$^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<$YA;64^1&5F875L
M="!3=V%T8V@@1W)O=7 \+WAM<$<Z9W)O=7!.86UE/@H@(" @(" @(" @(" @
M(" @(" \>&UP1SIG<F]U<%1Y<&4^,#PO>&UP1SIG<F]U<%1Y<&4^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @
M(" @(" @(#PO>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @/"]R9&8Z1&5S
M8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $, !@0%!@4$
M!@8%!@<'!@@*$ H*"0D*% X/#! 7%!@8%Q06%AH=)1\:&R,<%A8@+" C)B<I
M*BD9'RTP+2@P)2@I*/_; $,!!P<'"@@*$PH*$R@:%AHH*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*/_  !$( FD'
M9 ,!(@ "$0$#$0'_Q  <  $  @,! 0$             ! 8#!0<( @'_Q !I
M$  ! P,! P4'#P<(!@<%! L!  (#! 41!A(A,0<3%$%1%5)487&1DA87(C(S
M-%-6<H&4H;'1TB,U0E5SD\$(-C=B=(*RLSAU=I7#TR1$5V2#HL)#8X3$\!@E
M)D6%AN%&H]1FI.+D\?_$ !H! 0$! 0$! 0             ! @,$!0;_Q  T
M$0$  @( !00! P(%! ,!     0(#$002%"$Q$T%182(%@:$R<9&QP='P!B-"
M4C/A\4/_V@ , P$  A$#$0 _ /5*(B B(@(B("(B B(@(B("(L-;504-)+55
MDS(*>)I<^1YPUH[24&9:J^:BM%BCV[O<::DR,ALCQM'R-XGY@N(\H'++5UDD
MM%I4NI:4>Q-6X?E9/DC]$?7Y%R"HGFJ9WS5,LDTSSESY'%SG'M)/%>FG#S/>
MSQ9.,BO:G=Z7KN6G2E,XMA=75>/TH8, ^F6E0O7UT[X!=?W<?XUYQ1=NGH\W
M69'H[U]=.^ 77]W'^-/7UT[X!=?W<?XUYQ1.GH=9D>CO7UT[X!=?W<?XT]?7
M3O@%U_=Q_C7G%$Z>AUF1Z.]?73O@%U_=Q_C3U]=.^ 77]W'^-><43IZ'69'H
M[U]=.^ 77]W'^-/7UT[X!=?W<?XUYQ1.GH=9D>CO7UT[X!=?W<?XT]?73O@%
MU_=Q_C7G%$Z>AUF1Z.]?73O@%U_=Q_C3U]=.^ 77]W'^-><43IZ'69'H[U]=
M.^ 77]W'^-/7UT[X!=?W<?XUYQ1.GH=9D>CO7UT[X!=?W<?XT]?73O@%U_=Q
M_C7G%$Z>AUF1Z.]?73O@%U_=Q_C3U]=.^ 77]W'^-><43IZ'69'H[U]=.^ 7
M7]W'^-/7UT[X!=?W<?XUYQ1.GH=9D>CO7UT[X!=?W<?XT]?73O@%U_=Q_C7G
M%$Z>AUF1Z.]?73O@%U_=Q_C3U]=.^ 77]W'^-><43IZ'69'H[U]=.^ 77]W'
M^-/7UT[X!=?W<?XUYQ1.GH=9D>CO7UT[X!=?W<?XT]?73O@%U_=Q_C7G%$Z>
MAUF1Z.]?73O@%U_=Q_C3U]=.^ 77]W'^-><43IZ'69'H[U]=.^ 77]W'^-/7
MUT[X!=?W<?XUYQ1.GH=9D>CO7UT[X!=?W<?XT]?73O@%U_=Q_C7G%$Z>AUF1
MZ.]?73O@%U_=Q_C3U]=.^ 77]W'^-><43IZ'69'H[U]=.^ 77]W'^-/7UT[X
M!=?W<?XUYQ1.GH=9D>CO7UT[X!=?W<?XT]?73O@%U_=Q_C7G%$Z>AUF1Z.]?
M73O@%U_=Q_C3U]=.^ 77]W'^-><43IZ'69'H[U]=.^ 77]W'^-/7UT[X!=?W
M<?XUYQ1.GH=9D>CO7UT[X!=?W<?XT]?73O@%U_=Q_C7G%$Z>AUF1Z.]?73O@
M%U_=Q_C3U]=.^ 77]W'^-><43IZ'69'H[U]=.^ 77]W'^-/7UT[X!=?W<?XU
MYQ1.GH=9D>CO7UT[X!=?W<?XT]?73O@%U_=Q_C7G%$Z>AUF1Z.]?73O@%U_=
MQ_C3U]=.^ 77]W'^-><43IZ'69'H[U]=.^ 77]W'^-/7UT[X!=?W<?XUYQ1.
MGH=9D>CO7UT[X!=?W<?XT]?73O@%U_=Q_C7G%$Z>AUF1Z.]?73O@%U_=Q_C3
MU]=.^ 77]W'^-><43IZ'69'H[U]=.^ 77]W'^-/7UT[X!=?W<?XUYQ1.GH=9
MD>CO7UT[X!=?W<?XT]?73O@%U_=Q_C7G%$Z>AUF1Z.]?73O@%U_=Q_C3U]=.
M^ 77]W'^-><43IZ'69'H[U]=.^ 77]W'^-/7UT[X!=?W<?XUYQ1.GH=9D>CO
M7UT[X!=?W<?XT]?73O@%U_=Q_C7G%$Z>AUF1Z.]?73O@%U_=Q_C3U]=.^ 77
M]W'^-><43IZ'69'H[U]=.^ 77]W'^-/7UT[X!=?W<?XUYQ1.GH=9D>CO7UT[
MX!=?W<?XT]?73O@%U_=Q_C7G%$Z>AUF1Z.]?73O@%U_=Q_C3U]=.^ 77]W'^
M-><43IZ'69'IN@Y:=*5+@V=U=29_2F@R!Z!<KM8]16B^Q[=HN--5X&2V-XVA
MY6\1\X7BY9*:>:FG9-32R0S,.6OC<6N:>T$<%F>&K[2W7C;Q_5&WN)%Y\Y/^
M66KHY(Z+59=54IPT5;1^5C^4/TA]?E7?:*J@KJ2*JHYF3T\K0YDC#EK@>L%>
M6^.:3W>[%FKEC=69$18=1$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1%S_E8Y08M(4(IJ+8EO-0W,;#O$3>_</L'7\RU6LVG4,WO
M%(YK-WK/6UFTE3AUSJ-JH<,QTT7LI'_-U#QG 7#M3<M&H+D]\=I$5KICN&P
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M[0.=YRT;MW'Q;_G6/)I36O2GJAL%Z9=+>P@2$, W%VSD$$YP< CJ5AK'%O\
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MY" 2UN=OB=PW KE2*\D[W$Z(RQRQ6T;TZ]R4WNTW#1-WT?>:Z.WOJBYT$\I
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M#9W'#&N!=@$]0(<=_B5FT?:-/\F<USO59J2CKN<A,5/# YI>YN0> )R3AH[
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M1NI+TV.L8+M7;%82:D<^[$V1@[6_?D;M_4HMIMM9=ZYE';*:2IJGY+8XQDG
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MF;D%24!$1 6M [H5;MKWK"< =^Y3:MYCI97CBUI(6*UQB.@A ZV[1^?>@E
M# W!$1 1$0$1$!$1 1$0>5.6^B=1\H]S)&&5 CF;XP6 'ZP51%WK^4C8'2TE
MOOT#,\S_ -&G('!I)+#Y,[0_O!<%7T<-N:D/B\13ER3 B(NKB(B("M')]H^?
M6=UJ*&FJHJ9\,)F+I&D@C: QN\JJZZW_ ":_YWW+^P'_ #&+&29K69AUPUBU
MXK*#>^2=]JM==6/U%;)32Q/D,3?;.V03LC?QW+F2ZEKC0EEHX;Q=(=96^IJV
MO?**)C6;9<7;V;I"<C/9U*RODMW)GR>66NI[325UWN08Y\M0W.-IFT=_' W
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MD)/-3<PT=@8-G^&?G76=;7:UZ-T]IRYP6*@JKG/ R)CY8P UH8TN.[KR1O\
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MNU%ND8DH)@>INT/FWI 450)F Y4I56QU)$KXR?:N(5I8<MRA#]1$0$1$!$1
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MQQ3#_H='$_8DDSO!\I[.H;RH?)EH^UZD;?+M=S-#:K<TR='@=ESAASL;1WX
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M61TL;Z1^R:>1AVHV!NRW+N!W <"5O;QJ/0NLM,V9NH;G64-7018,,4;LEVR
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M[I3C^N5>*??&%1;1^<I_EE7FF]R"LI#*B(HHB(@(B("(B H%M]]UWRQ_%3U
MMOONN^6/XH)Z(B B(@(B("(B B(@*E\INA*765K&R6P72 'H\Y&[Y#OZI^KC
MV@W1%:VFL[AFU8O'++Q1?+176.XRT-TIGT]3&=[7#B.T'K'C"@+V;JC3%IU/
M1=&O%(R9H]I(-SXSVM=Q'V+BFIN0VY4SWR:>K8JR'B(9SS<@\6?:GZE[:<16
MW]79\S+PEZ]Z]X<=162X:$U30.+:BPW#=Q,41D'G;D*!ZG+W^IKE]%?]R[<T
M3[O--+1YAJD6U]3E[_4UR^BO^Y/4Y>_U-<OHK_N5W"<L_#5(MKZG+W^IKE]%
M?]R>IR]_J:Y?17_<FX.6?AJD6U]3E[_4UR^BO^Y/4Y>_U-<OHK_N3<'+/PU2
M+:^IR]_J:Y?17_<GJ<O?ZFN7T5_W)N#EGX:I%M?4Y>_U-<OHK_N3U.7O]37+
MZ*_[DW!RS\-4BVOJ<O?ZFN7T5_W)ZG+W^IKE]%?]R;@Y9^&K+W. #G$@< 3P
M7XMKZG+W^IKE]%?]R>IR]_J:Y?17_<FX7EGX:I%M?4Y>_P!37+Z*_P"Y/4Y>
M_P!37+Z*_P"Y-PG+/POVE]6Z<JN3V/2NHY:^WB*4R"IHQD29<7>RXGKQC'4%
M]R:QTUIC2EUM&DGW.OJ;BPQR5%9AK& @M) W;\$]7E.["Y]ZG+W^IKE]%?\
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M$Q%#Z2_Q>9.DO\7F03$4/I+_ !>9.DO\7F03$4/I+_%YDZ2_Q>9!,10^DO\
M%YDZ2_Q>9!,10^DO\7F3I+_%YD$Q%#Z2_P 7F3I+_%YD$Q%#Z2_Q>9.DO\7F
M03$4/I+_ !>9.DO\7F03$4/I+_%YDZ2_Q>9!,10^DO\ %YDZ2_Q>9!,10^DO
M\7F3I+_%YD$Q%#Z2_P 7F3I+_%YD$Q%#Z2_Q>92HR71M)XD(/I$1 1$0$1$!
M$1 1$04C5/YY9Y3]@5FM'N0\BK.J?SRSRG[ K-:/<AY%4AL41%%1KE[QG^25
M]T/O*G_9M^Q?%R]XS_)*^Z'WE3_LV_8@S(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@+#6^\JC]F[["LRPUOO*H_9N^PH*
M/:/SE/\ +*O--[D%1K1^<I_EE7FF]R"LI#*B(HHB(@(B("(B H%M]]UWRQ_%
M3U MOONN^6/XH)Z(B B(@(B("(B B(@(B(--2:>IZ;5=PO[)9C55M/%3/C.-
MAK8RX@C=G/LCUK4W?1'=/U2MEOUYCBO;(HS'',-FE:S<1$""&[0R#Y2K>B#G
M5NY,ZJVT4%'0:WU+3TL#0R.*-T#6M:.H#FUT1HPT DG XGK7ZB B(@Y'<O\
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M1H#0 !@#< EM>RY-;[*;=*BZWK6-79K9=9;52V^CBJ)I88HY)))97/#6^S!
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M].U[8:J%D[&O&'!KF@@$=N]!,1$0%/@]R;Y% 4^#W)OD0?:(B B(@(B("(B
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M>&W/7FWL7S+&R6)\<K&OC>"US7#(<#Q!'6%](N;LY]IUH9RT:L:T!K1;*$
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MB W^L20!XR$&C@Y2@WH%1==-WFV6BOD9%3U]0V,LR\X9SC6O+F Y&\CK5_7
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M54K:?+X6VT1EXVANVN<./,N@:(@8=&6 D'\WT_7_ .[:M'RZ_P!$FIO[,/\
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MQ2%'MWO"F_9-^Q2$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M_HDU-_9A_C:K#H?^9=@_U?3_ .6U!'Y0KY'IW1UUN,@+G1P.$;0<9>00/O\
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M<M<,A<UFT!J"XVRGL%\U1'5Z;A<S;C91;%34QL(+8Y)-HC&X9(:"<>-=+
M & $$&\U-9241EMUO-PJ X 0"9L61UG:=N6A[O:G^)LO^\H%;$0<4HZFX5_\
MHR%]QMCK=.-.D"%T[)<MY\^RRW=UD8\2Z[S$G>_6N;S_ .DW3_[-'_/<NK((
M/,2=[]:<Q)WOUJ<B"DU<,GKFVP;._N15=?\ [ZG7'>53E#N%RN=?9[;-S%JC
M+Z:38XU'%KLGO3O&!Q'%=NJ_Z4;7_J>J_P ZG7FCE$T]5Z<U574U5&X122NE
M@D(W21DD@@_/@^->CAXK-IV\?&6M6L<K<:+Y2[S9;A"VX5<U=;20V2.9VVYK
M>UI.\$=G!>F8XW2QMDCPYC@'-(.X@KQUIZS5E_NU/;K;$Z6HF<!N&YHZW'L
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M:VCEENE'6ME@E<'8;$9"3CJ]ICYL+;\GUQT_)RIT'J/HC'1U5"[I39(R3#(
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MPIZK;A;]VHM,W.E:.-10XKH?+[#\H/G8M[E,H,%CU18[XXLM-UI*F5OMH6R
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MM%14L;1L'2(@UP,9P-^\@[]VY= IX8J:"*"GC9%#$T,9&P8:UH&  .H +[1
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M9)99#AK6CK*"2BIEKY2M.W"Y4E$V6MIGUCMBDDJZ*6".H=U!CWM )/4.M7-
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MFN':"$$A$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!:+65B&H;))1AP9,UPDB>>
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MCJW]K3?Y#59U6-.?SQU;^UIO\AJLZ B(@(B("(B B(@(B("(B B(@(B("(B
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M@6WWW7?+'\5/4"V^^Z[Y8_B@GHB("(B B(@(B("(B B(@(B("(B B(@Y3/\
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M%/7TQ#:B$'(&>#FGL.#Y,?.;BO./();+_+4W2OL5314L;6-@>ZLIWRL>2<X
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MSG-=,_ZOIF7_ ,>>/_T.53BUQR@11MCBY*Y&,: UK6W:(  =0&ROKU><H?\
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MS1N#APVL\55[MJ+4]GJZW3NI'6^LDN%JJY[=74,;HCSD49+F/82<;B""#_\
ML">_E5H^8EN45CO$VFHI3$^\LC88=SMDO#=K;,8/Z0':NB12,FB9)$YKXW@.
M:YIR"#P(7.M-Q4W_ -GZE9AO1SI\[?9O@)=]>5O^2M\C^372SIB2\VRGR3Q(
MYMN/J06A$1 5;Y1[]4Z8T1=[S0QPRU-'#SC&3 EA.T!OP0>OM5D5$Y=?Z)=3
M?V8?XVH,EE=RARU5'+<GZ3Z ]S73"G94"78/'9R<;6.W<MS=-9:;M37FY7VW
M4VQ*8'"2H:")  2W&<Y (R.K(6HTWHZJH9:"L?JW4=6R-K7FFJ)HS$_=P(#
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M%9D0<R];2YS6NGT_<-52U.DX', HC2-;-)$P@MA?-G>T8 W-!(&%TT
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MG<YW]6Y>A47*E^7>X\N^3'-]3$ZTXUI6U7K67*/%JV\VZ6V6ZC:&TT,P(<[
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M*J=50@O#FD\ "1GB"?J6NOFF.4/4>D(+3<Z>WQ1T)9S;&R#G:C9&R"YVT6C
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M-#3.Y\ROCIS(]CN<.RS&#C()WX/!?-GHYW72ADJ*>H+6UU3+M3QX."P;+C@
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MYS@ T=O9GYL+.^E>VQ:<C9 \.BFIBYH:<LPW>3V>-!9D1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 6&M]Y5'[-WV%9EAK?>51^S=]A04>T?G*?Y95YIO<@J-:/SE/\
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M^VZ[""WQ2U]14U,DWL@&T3VEN ,^Q#<XW\2MA)=J)ENCKG5#>C28V' $EQ/
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M\9)8XC>W(P<?,OM$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M8)#)L-YPC9+L;R.S/SE?2(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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=+F&=@3F&=@65$&,0L'4%]AH' +]1 1$0$1$'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g50309g36y62.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g36y62.jpg
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M#@\,$!<4&!@7%!86&ATE'QH;(QP6%B L(",F)RDJ*1D?+3 M*# E*"DH_]L
M0P$'!P<*" H3"@H3*!H6&B@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H_\  $0@"W0:$ P$B  (1 0,1 ?_$ !P
M 0 " P$! 0             &!P0%" (# ?_$ & 0  $# P$"! H8 @<' P0!
M!0 ! @,$!1$&$B$'$S%1%A=!4W%SD92QT0@4&"(R,S0U-C=25%9A<G2!DI.A
MLK/!TA55(T)U@J+"TR0X1$:$P^)B@^$E0W;PH[0F)V/Q_\0 &P$!  (# 0$
M              ,$ 0(%!@?_Q  X$0$  0,!!@((! 8# 0$      0(#$002
M(3$R,W$%$Q05-$%188&Q!E*1P18B<J'1\"-"X5/Q_]H # ,!  (1 Q$ /P#J
MD
M                                  (SK?6UFT=1)-=I\SO3^BIH_/22
M=A.HGQKN,7A/UM3:)T^ZJ>C9:^;+*6!5]&[JJO\ Z4W*OT)U3D.]W:MO=SGN
M%TJ'U%7,[+GN7[DYD3J(6;&G\S?/!1U>LBS_ "T\?LL75?#;J2[R/CM3H[32
M+N1(4VI53XWK^B(5W<+S<[B]7W"XUE2Y>59IG/\ "I@ Z--NFCEAQ:[U=R<U
M3EZXQ_NW=T<8_P!V[NGD&R-ZXQ_NW=T<8_W;NZ>0!ZXQ_NW=T<8_W;NZ>0!Z
MXQ_NW=T<8_W;NZ>0!ZXQ_NW=T<8_W;NZ>0!ZXQ_NW=T<8_W;NZ>0!ZXQ_NW=
MT<8_W;NZ>0!ZXQ_NW=T<8_W;NZ>0!ZXQ_NW=T<8_W;NZ>0!ZXQ_NW=T<8_W;
MNZ>0!ZXQ_NW=T<8_W;NZ>0!ZXQ_NW=T<8_W;NZ>0!ZXQ_NW=T<8_W;NZ>0!Z
MXQ_NW=T<8_W;NZ>0!ZXQ_NW=T<8_W;NZ>0!ZXQ_NW=T<8_W;NZ>0!ZXQ_NW=
MT<8_W;NZ>0!ZXQ_NW=T<8_W;NZ>0!ZXQ_NW=T<8_W;NZ>0!ZXQ_NW=T<8_W;
MNZ>0!ZXQ_NW=T<8_W;NZ>0!ZXQ_NW=T<8_W;NZ>0!ZXQ_NW=T<8_W;NZ>0!Z
MXQ_NW=T<8_W;NZ>0!ZXQ_NW=T<8_W;NZ>0!ZXQ_NW=T<8_W;NZ>0!ZXQ_NW=
MT<8_W;NZ>0!ZXQ_NW=T<8_W;NZ>0!ZXQ_NW=T<8_W;NZ>0!ZXQ_NW=T<8_W;
MNZ>0!ZXQ_NW=T<8_W;NZ>0!ZXQ_NW=T<8_W;NZ>0!M+9J*\VMZ.MUUKJ94ZD
M4[FIW,X4LW1_#K>;?(R'4<++G2\BRL1(YFIS[O.N["HG9*>!I5;IKXPEMW[E
MN<TR[BTMJ6U:HMK:ZRU39XN1[>1\:\SF\J+_ /J&X.(-':GN6D[S'<;5,K7I
MNDC5?.2MZK7)U4\!V)HS4M%JO3]/=;<N&2)LOC5<NB>G*Q?C3[TPO5.=?L3;
MWQP=O2:N+\8G=+=@ KK@
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M#^9QF ##P_F<,/YG&8 QAAX?S.&'\SC, ,,/#^9PP_F<9@!AAX?S.&'\SC,
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M#^9QF &&'A_,X8?S.,P PP\/YG##^9QF &&'A_,X8?S.,P PP\/YG##^9QF
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ME=] 8?9C48W"'Z &0
M                                            '+WDA-'/LNI'7NDC
M7^'7)RN>J)NCG_K(ORO1)_>YBICNJ_V>BOUHJ;;=(4FI9V[+FKRIS*B]147>
MBG)?"3P=W/1=<YTC'5-J>[$-8UN[XFO]R[P]0Z6FO15&S/%P];I9HJFY3PG^
MR$@ MN<
M                                   %]^1LT<])9M4UT:M:B.AHD<G+
MG<]Z?A3LN(EP3\%E;JJIBK[K')2V)JYVE39=4?\ I9\7.[N;^3J>CIH:.EAI
MJ2)D-/"U&1QL3"-:FY$0I:F]$1L4NIH-+,SYM?#W/J #GNR
M
M       &-/'LKE.13)/Q[=IBH!%ZB5;9<F85>)F7+>7<N=Z&^VFU,+7)U413
M2:J@XVTOD:GGX'-E3Z%W_=D]Z9JUEIVHON4\" ;V/+6(@/6 !\JCE1#ZT_I2
M'SJ?1(?6#TIH'L
M                                            #YU-/#54\D%5%'-!
M(FR^.1J.:Y.947E/H *AU7P%6.YR/GLE1+:IG;^+1.-BS\2*N4^A<?$5W<.
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MJ+E6[*6WHK-N<Q&>[\:U&M1K41&HF$1.1#] (%L
M
M    :B\L1UNKF=18GI]RD8T%/F--I<^=3E["$INWJ*L[6_P*0G0:KLIV$\"
MC@L=7HB]0'CBU7> /$ZY<A]X/2FGPFY4/O!Z4T#V
M
M
M
M
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MY<9:JIG>F[XS,
M
M
M
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M5=YW;21&[>.3*HB)DZ2.:_(S^V3J_M;_ ,XZ4,PQ(  P
M
M
M
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M=LO8^I:BM=S+OW+\7*>M1:A_AW\%CH(V5=3=:N."!NWA-A45[Y,IRHUB*O<
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MN$5'815RN.H;EFJXW7NQ0)$UULO=*LU'5([>LB-1^PY.IEBY1<_U50"4
M
M
M
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MN?Z.3G5RHB-^),\X&X
M
M
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M'V
M
M
M           1'A;]KB__ #?_ #(<@G7W"W[7%_\ F_\ F0Y!.CH^27%\2ZD=
M@ %MS0D?!O[/].?VA!^-".$CX-_9_IS^T(/QH:U\LI+?/'=VN #B/4@
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MC;N^CD,[45DI;_;O*%P65:19&221L=A)4:Y'(QV[T*JB91,9-DB83"<@'Z
M
M
M
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MQZELE%71ZMNR7*:21KH7),^38:B;T\\B8WDE=N*8YHE#;OU5SC8F(30 $2P
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M5<*R1S,;<?+Z)$5%YE3/,!N0
M
M
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M9?+*]&-:GQJNY /L#1=&.F?A%9N_HOW#HQTS\(K-W]%^X#GKR,_MDZO[6_\
M..E#FKR,CVOX1M6O8Y',=$Y4<BY14X[E.E3,$A1G"PDR:RJ.-SL+%'Q6?<[/
M4_O;1>9H]4:8H-1T[&5K7,EC]+FCW.;\7QI\1FF<-K=44SF7.YT-H-)DTA:D
MJ<\9Q*8S[G*[/^'!';5P86VEJVS5E5-6,:N4B5J,:O9Y<_<3]K4:U&M1$:B8
M1$ZAFJ<M[E<5;H07@_GBH:W74=;(R*6"\RU,JO7&S$^*-S'+\6RB[_B4]\#B
MI3\&VG(JAS8Y)H7/BC>N'.8KW.;A.KYU4^@W-]T?I^^UC*N[VJGJJAK49MO1
M45S47*-=A?/)\2Y0SJFRVZIKK=63T<3JFW;7E1^,<3M-V5V43=R;C5"K75%K
MO.D-":@H8+E;4L3V5"P.DB>M4G'*Y>(:F=ESE<]6H[X^12QM*4DMOTO9Z.IS
MQ]/1PQ29]TUB(OWH8K='V%+TMV=;(7W#C%E2617/V7K_ %FHJJC5^-$0WX'/
M<6F[8W@#@O3*=K;VU62QW%-U1$OEE&HC7\J(C=R(BX)S66&UZ:X1]%_P*AAH
M?+3:R"H6%NRL[6Q(Y-OW2HY,Y7*DV33]J2Q)9DH8OX6B(B4V_9W.VD_Q;SZ7
M6UPUKXJE&,2X4S)$I*AR96%SV[*N1 SE2-JTRW4=I2U]#]+5W."]/=5:@F6)
MS94CJ%5Z^>7C'9;YS85NS\>"QH(V7?A.1D3&I;]-4B,8UJ8:E3.G(B<GG8D1
M/BXP@[^#ZLJK ZWS:-I$U#(S9DO\EP1V9EY:A%3^D5<^>V<)S<A<-FM5/:J>
M1E.Q.-F?QM1+_6FEV417N^-=E *1L<LLUYEHM11+'H^745>Q7M>BMGJ^/58V
M3IU(^7"<BN1,[L&YU/015>O-6T53I^+44U30T_E3:?$B4+58YFPJR*FQE[5?
MEF5W\G(6A)IVT26RLMTEO@=0UDCYIX7)ELCW.VG.7XU7?V2N[CH^=]]NTUYT
MA!J?CILT55+6,;Q,"-1&PJUZY;LKM;VYSG/*!.]"V--.:2M5K5E.V:GIV,F6
M!B-:^393:=N1,Y7._E4C_!#+'#17^VS.1MSI;O5.JF*OGUVY%>Q^.9S53"]7
M!NN#NR5>GM)4=NN$K'SQK([98]SVQ-<]7-C:YV]4:BHU%7F/6I=%V#4<CIKM
M;HI*I8UB2H8JQRHWFVFX7=\881_3]53R<)VLKG%-&VVTM'2TU3.KD2/CF;;G
M9=R9:UR(O-D^]H9/K'45#J">-U/8K<KW6R-Z8?52.:K5J'(O(S9548G*N5<N
M-QEZ2T>VVZ.DTS>8Z&MMS5=&SBHN+XZ+.4XUJ83;YU3EY3[T'!_I:WUD%51V
M:GBJ('I)&]JNRUR+E%3>!7MVB>S75QT4UJ^5[Q=Z:[[/4=!LK)/]"R0(G]\)
M$[HX@T,K5\KQ7U;VU/ZOE7869&XYN/<J?06Z^TT,EXBNKZ6)UQBB6!E0J>>;
M&JY5J+S9'\)H/XS_ !;RK%_$N(\K>6,>?XK:VMG/-G>&<HKPT+__ ([N#7+B
M%\U+',O-&ZHC1_W*I@Z]M=)=^$C0]'<(DFHW07!9('>@D1&PJC7)U6YPN%W;
MD)MJ&TTU]L==:ZY%6FJXG1/QRIE.5/C3E3L&-:;,K*>T37E8:R[V^%T+:QK5
M:J[2(CG(F=VTC6Y^,,(/;+1!0:HUS9[-;U\I/I**H904LZTK>,=QB.5CFXXO
M*,;G&.0^MAL%73WFCF?IBY4S62HY9I-22SM9\:QJ]4=V"PH;?2PW&IKXH&-K
M*AC(Y94Y7M9G91>QM+W3*!E76H--S6.WZAOEEU3<*![GS7%T3TA?3<9L[T<B
MLSA=E$]%E#Y:EKY;E:N#:ZS0\1<*FZ4DBQIN5O&0OXQO8PJ]PD4^@=+SW"2M
MFLM+)/)*LS]K*L=(JY5RLSLJN=^<&3<+ ^X:LM=TJ9VK1VV)ZT],C=_'O396
M1R_$S*(G_J50RWX #
M
M
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M,  PG,,)S  ,)S#"<P #"<PPG,  PG,,)S  ,)S#"<P #"<PPG,  PG,,)S
M ,)S#"<P #"<PPG,  PG,,)S  ,)S#"<P #"<PPG,  PG,,)S  ,)S#"<P #
M"<PPG,  PG,,)S  ,)S#"<P #"<PPG,  PG,,)S  ,)S#"<P #"<PPG,  PG
M,,)S  ,)S#"<P #"<PPG,  PG,,)S  ,)S#"<P #"<PPG,  PG,,)S  ,)S#
M"<P #"<PPG,  PG,,)S  ,)S#"<P #"<PPG,  PG,,)S  ,)S#"<P #"<PPG
M,  PG,,)S  ,)S#"<P #"<PPG,  PG,,)S  ,)S#"<P #"<PPG,  PG,,)S
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MJJJ%>VWPO92TVQAK)'[GRJN=Z[*;*)U$5><#>
M
M
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M]8=K?^<=.
M
M
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M4]_Q>,,X>O(N^V7K#M;_ ,XZ<.6_(F-F9KO4[:M<U"4V)55<Y=QJ9^_)U(&
M
M
M
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M%O5RG\LU,:.15CSG".QU557+]/Q%F]33LYW*&EJJFO&_WYSV_P K$ !4=(
M KK5_!K/J#6,6HH-3W"W54$7%4[(HF/; F//*S:Y%7JKREB@"$Z<T?>[5>(*
MRNUM=KI3Q[6U23Q1HR3+51,JB9W*N?H,&306HV\9!2\(E[CH'JO]&^"*25K5
MZB2JFTG9+$ &DT=IBW:2LD=LM+).*1RR222NVI)I%]$][NJY3=@   !S'Y%W
MVR]8=K?^<=.',?D7?;+UAVM_YQTX
M
M
M
M               $/X8?:TU!\W_S(<:G97##[6FH/F_^9#C4Z.CY)[N)XGU(
M[  +CFA(^#;V?Z<_M"#\:$<)'P;>S_3G]H0?C0UKY926^>.[M< '$>I
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M.',?D7?;+UAVM_YQTX
M
M
M                                                         &.M
M=2-546J@14W*BR)XQY?I/?5/]HGC.7KYZ]7#YQ)^)3")XL_-Y6K\254S,>7_
M '_\=7>7Z3WU3_:)XQY?I/?5/]HGC.40/)^;7^):O_G_ '_\=7LK:5[D:RIA
M<Y5PB)(BJI]SF70WLQLOSN/\1TT1UT;+M>&>(3KJ*JYIQB<(?PP^UIJ#YO\
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M_..G
M
M
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M$3NDP YA\U!6_!>F[\=^P>:@K?@O3=^._8=/ ,N1/(X:C6@UGJ&N6W5E6M5
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M++=:6)SME'SL:QJKRXRJ\NY20E6>2)]AU#\^;^!YM1;BJJ(4+MZ;=$U?!O\
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MT5<W6=P96SOD:L#FR;>RW&].1.J9N;6SOKRULQ1M[K<Q\TT !770
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MGEVCEAY'5=:OO+EGAC]L>\_*C_+:0PF?#'[8]Y^5'^6TAAUK?)#R][J5=Y
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MXU3>UK*K4.VZW*Q/*LCX&Q;:YWJB(F53'T%CFMR)BK$I+,Q-$3&?J  T2@
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M4 PL1$1&(  &0            !O:7U/'\E#Z'SI?4\?R4/H0IXX  #(
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M[RP@   Y5\CG[8VK?D/_ #CHDYV\CG[8VK?D/_..B22G@BKXAGTJX@;]/A,
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M:=]4LC6J]KLMV&IG<J]5%+! (*JMJ<RMVZ(MTQ3'N  8;@
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M>OY76?9*2C@WL]QH=1<=64-1!%Q+DVY(U1,[@TN51L3O6F ##G
M                                 WM+ZGC^2A]#YTOJ>/Y*'T(4\<
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MFY4W\Q,"*:(TA8M/.FK+!(^5M2Q&J]9DD:J(N=RH2LCKQG<FM15%/\P #5(
M  :K4/J:+Y?Z*;4U6H?4T7R_T4TN<LK>A]HI:  %-ZL  $AT_P"HG?+7P(;,
MUFG_ %$[Y:^!#9ERWRP\GK>O7W1N^^KW?)0UYL+[ZO=\E#7E6OFEZ/2="CM
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M^ONC*=*=:=\7]'+M+E5:J;L?$I<(!#77-<YE9M6J;5.S2  U2
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M7?7;^TFP!YM?Q8EJH(K9;X*.!SW10MV6J]<KR]4RP CG>
M
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MTU7JJ[^7>:ZIM%)9;3'2V]CF0K,K\.<KMZI\?8-+F=F5O0X](I[M: "H]4
M#=:=JX7<;1M?FH9_2N9A=S5W(N>3E13[VR_6VZ5DU+0U/&SPHJO9L.3&%PN]
M4QRGQTS10M?-7(U?+#T2)5SNV4WIN[*J?:SZ;MUHKIZRBC>V>=%1ZN>JHN5S
MR=DN6\[,/)ZS'GU]VGN-7!65LSJ9^VV-RQ.7"IAS5PJ;_C,8R;C10T-;.RG:
MJ-D>LSLKGSSEROWF,5:^:7I-)T*.T  -5@,^U7RW4DT=NJ*E&5D[TXN/8<NU
MG<F]$QRHI@&=:M/6^NJ8;G41O6KIY$XMR/5$39WIN[*DEGF<[Q/H?6&SKK];
M:&Y0T%74\75S;.Q'L.7.TN$WHF.5"@ZSU9/VQWA4ORY:;MUQNT%RJHWNJH-G
M8<CU1$V5RF[LJ4'6^K)^V.\*EZW[WS;\1<MOZ_L^( )7F   7S!=J*T:;M<]
MQGXF%\,3&NV7.RNQGJ(O,9=9>[?1VR&XU-1L4<VSQ<FPY=K:3*;D3/(8C;)1
M7O3%JIK@QSXF0Q/:C7*W?L8ZG9,NOT];ZZST]LJ(WNI(-G8:CU14V4PF_L%>
M<OI%K&Q3V<?7!R/KZE[5RUTKE1?BRI\#[W!B1U]2QOH6RN1.PBJ? ZT<'GIX
M@ ,L)'P<U$5)K:T5%0[8ABFVWNPJX1$557<=2V^]V^XT$];1U'&TL&>,?L.3
M9PF5W*F>0Y9X.J:.MUK:::=%6&:;BWHBXRBHJ*=36O3UOMELJ:"DC>VFJ-KC
M$5ZJJY;LKO["%'5<T.OX?C8GNAW"5>*&\\&5]EML_'QQ\6UR[#FX7C&\Z(<T
M'2W"/8J&Q<&%^BMS'L9)Q;G;3U=OXQJ=4YI)=+R2K^(=2.P "RH!)^##V?V+
MYRW]2,$HX+O; L7SEIK7RRDM<\=W3U+?K;5766VP5.W6QJY'Q[#DQL\N]4P0
M[A9OUMETA?;7'4HM<UC46+8=NP]JKOQCD^,F-'INW4=ZFNL$;TK)5<KG*]53
MSW+N(;PM:;MT.E+]=XXWI6N8U5=MKC>]J+N[!S+>=J.[O7L>75VES6 #JO.@
M  M/@"NU%:[M<TKI^*6>.-D?G57:7:7=N3XR\[O?K;:)HHKC4\3)*F6(K'.S
MOQU$4HO@#LM%=[O<EKF.<M/'')'LN5,+M+XB]+YINW7NHAFN$;WR0IABM>K<
M;\]0YVHSMR[FBQY,*E\DJN_3J=7_ &A?RBDR[O),(FUIQ>JJ5"?EE(ENQTX<
MW6=:K_?<  F50M;@#N-+:JN]U-?+Q4"0Q-5VRKMZN7&Y$*I+5X!;52WFIOE)
M7-<^!8HG*C7*U<HY<;R&_P!.5G2=:E>;[W;V6=+JZHQ0+R2[#N?9Y,9Y?B-;
M<:^FN5%25=%)QM/)M[+]E4SA<+N7?RH;)^GK>^PI9W1O\HIC#=M<^BVN7LFM
MN%MI[3;Z*BHFN;!'M[*.=E=ZY7?V5.5=SLR]5X=CTBGZ_:6N !4>H  !OM/5
M<,M/+!&_,M.J+*W"^=VLJGW'TLU]MUZ69+94\>L6-O#'-QG..5$YE/.FZ&"*
M">I8U4EJ51)%SR[.43[CUI_3ENL*SK;8WL6;9V]IZNSC..7LJ7:.6'D=5CSJ
M^\N8^%2L@K]>W:II).,A>YFR["IG#&HO+\:*10E7"G0P6W7EVI:5JMA8YFRB
MKGE8U5^]2*G6M\D/+WNI5WD !NB?K/1-[)V%#?K;_$V6KRS_ +?A$XK8=[G:
MY<8Y/C./6>B;V3L*#3=N_C#+QQ;_ "]A%VMM<>AV>3L%/5>YT_#O^WT?.YWZ
MVQ54UKDJ<5[F*B1;#NJW*;\8Y/C*$+[NFF[=-7S7=\;UKFL54=MKC<W";NP4
M(06_>Y7XBXV_K^P "1YL  '05VO=OLT4#KE4<0V7.PJL<[.,9Y$7G0\WN]4%
MMM[9JVHXJ.H:J1.V'+M;L]1#U>]/6^^PTS;C&]Z0Y5FR]6XSC/)V$/.H+!07
M2VQP5D;W1TS56-$>J8PF"OO?2IQLN?P 6'S4  &^T+6T]OU-2U59)Q<$;9%>
M_"KCSCDY$W]4N:"]V^>TR7.*HVJ%F=J78=NQR[L9^XIG0U!!<]2TU'5M5T$K
M7HY$7"[F*O+]!<U-IZWT]CDM,4;THI,[35>JKOY=Y#7Q>P_#^/1JOZI^T(KK
MVYT=VT1+4V^;CH4J&,VME6[T7DWHG.5*6UKJT4EET+-2V]CF0K4,?ASE<N5[
M/8*E-Z.#D^/>U?2/W  ;N*$FX-O9E0?^Y^!Q&23\&GLSH.Q)^!QB>"SHO:;?
M]4?=;=LOUMNE9-2T-3QL\**KV;#DQA<+O5,<I$>$2_6VNLE904M2DE7#*WC(
M]AR;.R["[U3'*2ZSZ;MUHKIZRBC>V>=%1ZN>JHN5SR=DCFK=$0S4=9/9J9S[
MC4R;3]J7"*BNVG<JXY2"G.7N==3-6GN4TQF<2J $IZ =1>\6_;L\8Z =1>\6
M_;L\9/F'A_0=3_\ .K])18$IZ =1>\6_;L\8Z =1>\6_;L\8S!Z#J?\ YU?I
M+<\%%VHJ)U5254^Q454L;86;*KM+O3E1,)RIRE@5U^MM#<H:"KJ>+JYMG8CV
M'+G:7";T3'*A$=":(?25#ZJ^4JQU,,C'TZME14W95<[*\^.4EURTW;KC=H+E
M51O=50;.PY'JB)LKE-W94AJXO9^%T3;TM%-<8G?]Y+G?K;;*R&DKJGBJB9$5
MC-ARYRN$WHF.5!=K];;1/%#<:GB9)4RQ%8YV=^.HBB[Z;MUVKX*RMC>Z>!$1
MBM>J(F%RF[LJ+YINW7JH@GN$;WR0IABM>K<;\]0UWK^Y^WF^VZRK"ESJ>(67
M.QECG9QC/(B\Z'[>+W;[,R%]RJ.(;+G856.=G'+R(O.A^7_3ENORP+<HWO6'
M:V-EZMQG&>3L(?M^T];[[' RXQO>V'.QLO5N,XSR=@;S<72]V^U4T-17U'$P
MS>ENV'+M;L]1!<+W;[=005M94<533XXM^PY=K*93<B9Y!>=/6^\4E/35T;W1
M0>@1KU;C=@733UON=MIJ"KC>ZFI]GBT1ZHJ83";^P-YN*R]V^CMD-QJ:C8HY
MMGBY-AR[6TF4W(F>05%[M]/:8[G-4;-#)C9EV'+G/)NQD5^GK?76>GME1&]U
M)!L[#4>J*FRF$W]@5.GK?4V2*TRQO6BCV4:U'JB[N3>-YN?CKY;F6=+JZHQ0
M+R2[#N?9Y,9Y?B#;W;W6=;JVHS0)RR[#O=;/)C/+\0?IVWOL+;,Z-_E%,8;M
MKGT6UR\O*&:>M[+"ZS)&_P HKRMVUSZ+:Y>7E,[S<07RW3VF2YQ5&U0QYVI=
MAV['+NQG[C]H[W;ZRV37&FJ-NCAVN,DV')L[*97<J9Y#\I].V^GLDMIBC>E%
M)G::KUSOY=Y^T&GK?0V>HME/&]*2?:1[5>JJNTF%W]@;S<6^]V^XT$];1U'&
MTL&>,?L.39PF5W*F>06N]V^Z4TU105''0P^F.V')L[L]5.86O3UOMELJ:"DC
M>VFJ-KC$5ZJJY;LKO[""S:>M]GHZBEH8WMAG]&CGJ[.['@&\W/RSWNWWB.9]
MMJ./;#C;5&.;C.<<J)S*+-?+=>EF2V5/'K#C;PQS<9SCE1.93]L6GK?8XYX[
M?&]C9\;>T]79QGG[*GY8-.V^PK.MMC>Q9]G;VGJ[.,XY>RIC>;GY:+[;;O+-
M%;JGCGQ)EZ(QS<=3JH@ME^MMSK)J6AJ>-J(457LV')C"X7>J8Y18]-VZR3SR
MV^-['S(B/5SU=G?GJBSZ;MUHKYZRBC>V>=%1ZN>JHN5RN[LC>;B@OUMK[C-0
M4E3QE7#M;<>PY,;*X7>J8Y12WZVU5UEML%3MUL:N1\>PY,;/+O5,"VZ;MUNN
MM1<:6-[:J?:VW*]51=I<KN[(H]-VZCO4UU@C>E9*KE<Y7JJ>>Y=PWFXBOUME
MN[K7'4[5>U518MAV["97?C')\82_6U;S_"DJ?_J&<<5L.]SM<N,<GQB#3=N@
MOC[O'&]*URJJNVUQO3"[NP$TW;DO_P#&4C?Y>SG:VUQZ'9Y.3D&\W$M]ML5W
M;:Y*G%>Y41(MAW53*;\8Y/C%3?K;376.VSU.Q6R*U&1;#ESGDWXP)M-VZ6^M
MN[XWK7-5%1VVN-R83=V!5Z;MU7>HKK-&]:R)6JUR/5$\[R;AO-Q77VVT-R@H
M*JIXNKFV>+CV'+M;2X3>B8Y1<K[;;;6PTE=4\543(BQLV'+M97";T3'*+CIN
MW7"[4]RJHWNJH-G8<CU1$V5RF[LB[:;MUUN%/6UL;W3P(B,5'JB)A<IN[(WF
MXN]^MMHFBBN-3Q,DJ98BL<[._'411>;[;K,Z%+G4\0LN=C+'.SC&>1%YT%\T
MW;KW40S7"-[Y(4PQ6O5N-^>H+_IRW7UT#KC&]ZPY1FR]6XSC/)V$&\W/V\7R
MW6=D+[E4<0V;.PJL<[.,9Y$7G072^6ZUTT%17U'$PS>ENV'+M;L]1!?=.V^^
M1T[+A&][8,[&R]6XSC/)V$%YT[;[Q24]-71O=%!Z!&O5N-V!O-Q<+Y;[=005
MM94<533XXM^PY=K*93<B9Y#]K+W;Z.V0W&IJ-BCFV=B38<NUM)E-R)GD/RZ:
M=M]SMM-05<;W4]/L\6B/5%3";*;^P?M=IZWUUGI[941O6D@V48U'JBILIA-_
M8&\W$][M\%ICN<M1LT,F-F78=OSR;L9^X/O=O99TNKJC% O)+L.Y]GDQGE^(
M5.GK?4V2*TRQO6BCQLM1ZHN[DWA^GK>^PI9W1O\ **8PW;7/HMKE[(WFX;>[
M>ZS+=6U&;>G_ -W8=[K9Y,9Y=W((+W;Y[2^YQ5&U0LSM2[#MV-R[L9^X,T];
MV6!;,V-_E%<^=VUSZ+:Y>7E%/IZWT]CDM,4;THI,HYJO7.]<KO,[S<_*.^6Z
MLM<UQIJC;HX=KC)-AR;.$RNY4SR"WWNWW"@GK:.HXRE@SQC]AR;.$RNY4SR"
MAT[;Z&SU%KIXWI23[6VU7JJKM)A=_806O3UOMELJ:"DC>VFJ-KC$5ZJJY397
M?V!O-Q:[Y;KI33U%!4<;#!Z8[8<FSNSU4YA9[Y;[Q',^VU''MAQMJC'-V<YQ
MRHG,HL^G;?:*.II:&-[8:CTQ'/5<[L> 6+3MOL<51';XWL;/C;VGJ[.,\_94
M;S<6:^VZ]+,ELJ>/6+&WACFXSG'*B<RGY:+[;;O--%;JGCI(4R]$8YN.IU40
M_=/Z<MUA6=;;&]BS;.WM/5V<9QR]E3\L>F[=9)YYK?&]CYDP]7/5V=^>J8WF
MXME^MMSK)J6AJ>-GA15>S8<F,+A=ZICE%!?;;7W&>@I*GC*N':XR/8<FSLKA
M=ZICE46?3=NM-?45E%&]L\Z*CU<]51<KGD[(MNF[=;KK47&EC>VJGVMMRO54
M7:=M+N[*#>;BEOMMJKI+;:>IVZV)7(^/8<F,<N]4P(;[;9KN^UQU.U7-546+
M8=NPF5WXQR?&*/3=NH[S-=((WI63*Y7N5ZJB[2Y7<(--VZ"^/N\<;TK7JJJ[
M;7&],+N&\W'\>MO\8_A7EG_;\XXK8=[G:Y<8Y/C$M^ML5W;:Y*G%>Y41(MAW
M53*;\8Y/C'0W;OX]_&.+?Y>SG:VUQZ'9Y.3D$VF[=-?6W=\;UKFJBH[;7&Y,
M)N[ WFXJ;];::ZQVV>IV*V16HV+8<N<\F_&!77ZVT-RAH*JIXNKFV=B/8<N=
MI<)O1,<HJ]-VZKO45UFC>M9$K5:Y'JB>=Y-PN.F[=<+M!<JJ-[JJ#9V'(]41
M-E<IN[(WFXN5]MMLK(:2NJ>*J)D18V;#EVLKA-Z)CE%VOUMM$T,5QJ>)DE3+
M$5CG9WXZB*+OINW7:OIZRMC>Z>!$1BM>J(F%RF[LB^:;MUZJ()KA&]\D*88K
M7JW&_/4&\W%YOMNLJQ)<ZGB%ESL98YV<8SR(O.AZO%[M]F9"ZY5'$-ESL*K'
M.SC&>1%YT/-_TY;K\L"W&-[UARC-EZMQG&>3L'J_:>M]]9 RXQO>V'.QLO5N
M,XSR=A!O-Q=;W;[53PSW"HXF*;T#MAR[6[/407&]V^W4,%96U'%4T^.+?L.7
M:RF4W(F>07K3UOO%+3T]=&]\4'H$:]6XW8Z@NNGK?=+;3T-9&]U/3[/%HCU1
M4PF$W]@;S<_*R]V^CMD-QJ:C8HYMGBY-AR[64RFY$SR()[Y;H+3'<Y:C9H9,
M;,NP[?GDW8S]PK]/6^NL]/;*B-ZTD&SL-1ZHJ;*83?V%%3IVWU%DBM,L;UHH
M\;+4>J+NY-XWFX??+>RSI=75&*!>278=S[/)C/+\1^MO=O=9ENK:C-O3EEV'
M>ZV>3&>7XC\?IVWOL+;.Z-_E%N,-VUSZ+:Y>R?K-/6]EA6S-C?Y17**W;7/H
MMKEY>4;S<07NWSVF2YQ5&U0LSM2[#MV.7=C/W"CO=OK+9-<::HVZ.':VY-AR
M8PF5W*F>04VGK?3V.2TQ1O2BDSM-5ZJN_EWBAT];Z&SSVNGC>E)/M;;5>JJN
MTF%WF=YN+?>[?<+?/74=1QE+!GC'[#DV<)E=RIGD46N]V^Z4LU105'&PP^F.
MV')L[L]5.86O3UOMELJ;?21O;35&UQB*]55=INRN_L(+-IZWVBCJ*6AC>V&?
MT:.>JYW8\ WFXL][M]XCF?;:CCV0XVU1CFXSV43F/-FOMNO2RI;*GCUBQMX8
MYN,YQRHG,IZL6GK?8XIX[?&]C9\;>T]79QGG[)YL&G+=85G6VQO8LV$?M/5V
M<9QR]DQO-Q:+];;O-+%;JGCI(DR]$8YN.IU406R_6VZ5DU+0U/&SPHJO9L.3
M&%PN]4QRBQ:;MUDGGFM\;V/F3#U<]79WYZHL^F[=:*Z>LHHWMGG14>KGJJ+E
M<\G9&\W%!?K;7W&:@I*GC*N':XR/8<F-E<+O5,<HI;[;:JZRVV"IVZV)7(^/
M8<F,<N_&!;--VZVW6HN-)&]M5/M;;E>JHNTNTN[LH*/3=NH[U-=8(WI62JY7
M.5ZJB[7+N&\W$5^MLMW=:XZG->U518MAV["97?C')\82^VU;S_"O+/\ ]0SC
MBMAWN=KEQCDW\H@TW;H;Z^[QQO2M<JJKMM<;TPN[L!--VY+_ /QGBW^7LYVM
MM<>AV>3DY!O-Q)?;;'=VVM]3BO<J(D6P[JIE-^,<GQBIOMMIKK';9ZG9K9%1
M&Q;#ESGDWXP)=-VZ6^MO#XWK7-5%1VVN-R83=V!5Z;MU5>HKK-&]:R)6JUR/
M5$\[R;AO-R84WJ>/Y*'T/%/Z1'\E#V1)HX  #(     U5V]15G:W^!2#:#]"
MG8_1"<W;U%6=K?X%(-H/T*=C]$!"R4Y $Y !\IN5#[P>E-/A-RH?>#TIH'L
M "(<(U_TK;[3+;-6UC(X:Z-6\2C7/D<WW2(U%5,*FY>="7G.FI)=.5/#O?%U
MS,B6NFIV-A:_;5JOV(\-\[OQYY[NR2V:-J=_N^"OJ;DT4QC&^<;^#Y6#@DM>
MID?5:6UIQ] Q58K74SN-B1?ZKDVDY=_41%+OT+I.@T=8V6VV[;T5RR2S/]%*
M]<95>;D1$0H_0NHM+Z4X5[Q);;DV'3%138C<K9'-V_.+C&-K<NVB9ZA?&FM3
MV?4T,\MBK65<<+D;(K6.;LJN]/1(A+?FOA/!7T<6N,8BKAQ^S<@ JN@
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MP6=%[3;_ *H^Z\P 0OH0
M
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M$T,#-O:>[&$RQ40MT&-J4EKP.S:KIN15.Z<^[_  #5VP
M
M                              ;FG](C^2A[/%/Z1'\E#V0)XX  #(
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M0G-V]15G:W^!2#:#]"G8_1 0LE.0!.0 ?*;E0^\'I33X3<J'W@]*:![
M        >'PQ/7+XV.7G5J*1#A7M][N^D);/IN)..N,C*6>97M8E/3N7^D?O
M5,^=W83*[R9 ##LUMIK/::.VT+-BEI(FPQMYFM3"$&DU1P@0[=.[0$4]0BJU
ME1%=HDA=S.5%\\B?%REB@"&\%VEJW3=JN$UZGAFO-VK9+A6+#GBV/?CSC<]1
M$0R-=Z!L.N6T3=0P33)1J]8>+E='C;QG..7T*$J %4>9_P!!>\*OOM_C'F?]
M!>\*OOM_C+7 '*?D9H&4VOM401(J1Q0N8U%7.Y)<)X"^+1INW6FX5%;11O;/
M.BH]7/547*Y7=V2C/(X>V/J[Y#_SCHLEIX(J^+36[3=NM]WJ+E31O;5S[6VY
M7JJ+M+E=W9-#>8F4]TJ61IAJOVURO5=YY?O52;D(U&N+S4?W?PH;TPCJG<PL
MFUTW04]7<65,S566D\]$J+C"N147L[C2[1(M'+F6J^2W]3,QN:4\6=/INW37
MUEWDC>M:U45';:XW)A-W8/VMTW;JR\PW2>-ZUD*M5CD>J(FRN4W&X!IA+EI[
MEINW7*ZT]QJHWNJH-G8<CU1$V5RF[LJ+QINW7>NIZNMC>Z>!$1BM>J(F%SR=
MDW &#+3WS3=NO<\$MPC>]\*88K7JW&_/4/W4&G+=?E@6Y1O?Q.UL;+U;C.,\
MG80VX&#+47W3MOO<5/'<(WO;!G8V7JW&<<W8%XT];[O14]+6QO=#3XV$:]45
M-V/ ;<##&6HN>G;?<K736^KC>ZFI]GBT1ZHJ;+=E-_84^%WI8J*TT=+3HJ0P
MX8Q%7*HB)A#?&HU+ZEB^7^AI<C^65O0^T4HZ "F]6  #?6FFCK++4TLZ*L,V
MU&]$7&45,*?2U:=M]KMM30T<;VT]1GC$5ZJJY3"[^P>].>H7=L7P(;0NV^6'
MD]9UZ^Z$S6JELSUI*%KFPIYY$<Y7+E?C/!LK_P"N+ODH:TJ5\TO2:3H4=H
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MZ5DJN5SE>JIY[EW'[%INW17UUX9&_P O.555VVN-Z87=V#< 8,M.NF[<M_\
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MFD<[RK(K'/PBX3.3.&L3B5E UECBKDAXVXSN<]Z;HU1$V4^/XS9FB6
M   U&I?4L7R_T-N:C4OJ6+Y?Z&ESEE;T/M%*.@ I/5@  DNG/4+NV+X$-H:O
M3GJ%W;%\"&T+MOEAY/6]>ONC%_\ 7%WR4-:;*_\ KB[Y*&M*E?-+T>DZ%':
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MA7JXN7*JX]\@ -D0
M
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M YSN
M
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MMLO,U#!Q<^S_ $;<8SNWKOY1MRSY<+#Z;.A_A%3?4?\ M'39T/\ "*F^H_\
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M<$:1PQLCC3D:Q$1$^@\STT$[F.GABD<Q<M5[$79[&3Z@
M              J[@*]'KS_\EJ_\I:)5W 5Z/7G_ .2U?^4M$      B'#![
M5VJ?[/E_"IG<''M>Z7_LNE_*:8/#![5VJ?[/E_"IG<''M>Z7_LNE_*:!(0
M   J_AE]DO!O_;T?@+0*OX9?9+P;_P!O1^ $+0       !5W#-[(^#?^WXO
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M_P#,>3\@' #[4.F^TO\ S'D_      *O\D3[";?_ &O2?B4M J_R1/L)M_\
M:])^)2T       5?Y(KV#T/]K4OXU+0*O\D5[!Z'^UJ7\:@A:        *QN
MO^\18_[!F_-4LXK&Z_[Q%C_L&;\U2S@      5=P'^K^$+_\DJ?\I:)5W ?Z
MOX0O_P DJ?\ *!:(     1?A4]K/5?\ 9=3^4XE!%^%3VL]5_P!EU/Y3@/?!
MC[6VD_[)I/R6$E(UP8^UMI/^R:3\EA)0      5CP,>O7"+_ /D4_@0LXK'@
M8]>N$7_\BG\" 6<       "KN!CV1<)'_P"02^ M$J[@8]D7"1_^02^ M$
M    K&R_[PVHO[$@_&A9Q6-E_P!X;47]B0?C0LX      %7VG_>,OO\ 8,/Y
MJ%H%7VG_ 'C+[_8,/YJ 6@       "KK5_O&WO\ L"+\UI:)5UJ_WC;W_8$7
MYK2T0     "KN$+VYN#+LU_Y*%HE7<(7MS<&79K_ ,E"T0             #
M57;U%6=K?X%(-H/T*=C]$)S=O459VM_@4@V@_0IV/T0$+)3D 3D 'RFY4/O!
MZ4T^$W*A]X/2F@>P
M   >6,8S:V&M;M+E<)C*\YZ       /QS6O:K7(CFKN5%3**?K41K4:U$1$3
M"(G4       !Y<QCU:KVM<K5RBJF<*>@        !Y<QCU:KVM<K5RF4SA3T
M       #RC&(]7HUJ/5,*[&]3T         /*,8CU>C6[:IA78WJAZ
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ML[2[WJF4RO/G&XG!#-)TT\7"%KJ>6&5D,TE$L4CF*C9,4Z(NRO5PN[<3,
M   AVJ:/5&;E7T6I:2VT=/$LD$/E%LB*C6Y597N7/*B^AQA#<:+NTU^TE9[M
M50)3SUM+'.^-.1JN:BKC/4YOB*]UOJ2.\:EGL%VI+U3:;HW)Y:6"W3RK<7\O
M%HYC51(D_K+G+N3DRJV;8ZZFN5JIZJACFBIGMPQDT#H7-1%5,*QR(J<G,!G
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M<Y5GE=QJ[2955=R<O*A<]*DS::)*E['SHQ$D<QNRUSL;U1%5<)GJ94#Z
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MN_F)F5/3.MU\U=I%^D['5VYUMDDDK9GVY](D$*Q.;Q#E<U$<JN5NYN43&2V
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MR;**N]V%?C*\OQ<A-"'Z)IIX=4ZXDFADCCFN43XG/:J(]J4T*9:O53**F[F
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M=#;9<QOXN7,LJ\:NTBJJY7=ESD7/.976#S$CTC8DJM=)A-I6IA%7JX0]!@
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M\\C$5JKG98F5^6A8)&.#BR3V32T#;BNU=:Q[JVO?[JHD7:=W-S4^)J$G
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M
M
M
M
M                               U5V]15G:W^!2#:#]"G8_1"<W;U%6=
MK?X%(-H/T*=C]$!"R4Y $Y !\IN5#[P>E-/A-RH?>#TIH'L
M
M
M
M
M                  &JNWJ*L[6_P*0;0?H4['Z(3F[>HJSM;_ I!M!^A3L?
MH@(62G( G( /E-RH?>#TII\)N5#[P>E- ]@
M
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M+3.=IZ9VL>Z\]REU$=RB**IB)3V;DW*(JF,  -$H
M
M                                     U5V]15G:W^!2#:#]"G8_1"<
MW;U%6=K?X%(-H/T*=C]$!"R4Y $Y !\ZA,.0^T'I33Y5*>>0^L'I2 >P
M
M
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M826;<VZ=F9R  T2@
M
M            #57;U%6=K?X%(-H/T*=C]$)Q>7(VWUSUY$B>OW*0?0?H4['Z
M("%DIR )R #\J4W(HI7>=5O,>I4VHE5.4QHGX5')O0#- :J*F4Y
M
M
M
M
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g50309g62g77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g62g77.jpg
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M$Q0B(T)R<Y&2H<'1%3)28H+")"6B\#,U0__$ !L!  (# 0$!
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MIA1M(:;I'E1[7R-S3?8M(:"MX,72)?:%8*K[05O!BZ1+[0K!6&;B.3FDX#,
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M_P#V"[N@7?T>BR>UJWOX/HDD7S?\ORM%HB)2NG1$7(O&)K/9W%EQN$,4@_\
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M/DT;?\B_4?TS/H5D5\\65%2&F)V=NLLNK3.A>M=6:/Z$2$EU.Y\.?F#LQ^A
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MB.Z>(K1$ZVQ<?E^C?-&V9@OF[\/]*KD1%<N-17/H(HGQ6FYUC@0R>5D;?/L
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4(YV\JR."./N- 1$105J(B(0O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g50309g64w16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g64w16.jpg
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M?9J1HSUE7'N^*' D_("OV6N/J?,/1Z&.UI$1%RN\1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1!XYH<TAPR%R:UKJ9QE;G#>?K'>NNL%6P/B.1G'U(/*.<3,!!6PH
MU:9S#5RT[CY#B![.Q21ART%!ZM;C/(?^[;]*R5#ML1[SP7U"W9&!V\R@^P !
M@< B(@(B("(B B(@(B("(B B(@(B("(B JM_NC'N;H.G#>3J^,'V;)#_ - K
M25?=.]"ZMZ.JU[!EU++'/CU!VT_0XJ^+M>&6>-X[/RTB(O3>((B("W;$3\-6
M_C_\Q'^L%I+8ML[::X4L\@)9%*Q[@.> <J)3'E9_]TB3]W%#Q_\ [='_ ,V5
M=6E%LZ/NC*SWEMGH[E=;H6N,E2P.#0YI=@=P  &!S)RH5TNZKH-7ZDIJ^UQU
M$<,=(V B=H:[<'O=V$\,."[.G]<6"OT;3:;UO0U<T%&X.IZBE(W #. >(Q@$
MCMR%AQGA$.KG7U+3$^?$N[K"BLSK1I76U%9:.,U4[(JFA+?P,A<UW$@8!P6G
MV\,K=Z?M1MM]6VT?!5OJ#546152QYEBR]PPT]G+/O4'Z0]=TEXH;5:-.T<E)
M9[:YKXA-Y;W-& 2,G@ 3VDG*Z^OM9Z/U?;/#:FAN3+\RF,,(!'5L=Q(R=W$
MD]F?4HBD[B9A>V2LQ:*S]O\ MM=&]-?Z/2D<]'IBPNADD+Q<+F6M,C#R'?CG
M@\N*W.E"QV^VZTT574%)3TDM;4,Z]E. (RYKXSD8X?E'CV\%RAKC2EYT1:+3
MJBCNG7VQC&L92%H;+M;M&23VCGPX=A6EK/I ME_K=(U%-1U%,+5('SQ8!  =
M&<,.>/!AYX[$B+<MZ^Z)M2*:W]GO]T/_  _;_L<?UN6W_<V?PSN/^[W?\R-1
M?I6U/1:LU0+C;65#(!3LBQ.T-=D%V> )X<5L=$.K*#1^H*NNND=3)#+2F%H@
M:'.W%[3QR1PPTJTUGTM>[.+U]?EOMMLZYTE8[90UU?0ZNI+A6"7]YQL:''+^
M/$//+/=V*=Z+I+[0VFSPU.E-.TE&\,9-+6EC9ZAI/E8['8[#GBJ*JYQ)<)JB
M,<'2F1H<.\Y&5;VHND/2%^?;;Q<+;<Y;Q0-!BI0\-@+\Y\8YXC/JR>T)>MM1
M'E;%>FYMX_S]VW<]"6BHZ;8+:RF;%;'THKI:=GBM)&1M '($@' ]:XFN->T$
M<U[L%'I>TQTL1DI(9A$T/8X$MW@8QV$CNX<5COG293OZ2Z#4UJIIS3Q4S:>:
M&8!KGC+MP&"?2!![PO-5W[H\N<=SN%):KG\,UC'EH?XL;)7 ^.0'XYG/;[%6
M(G<<H6M:NK<)B._\)C9]00V[H+CN<5FMSVQ2"-U-)'NCD(D#-[@>;CSSWJ-=
M%5MM=ZK-4:JO%MIY(:%IGCHFL'5-)#GG#3PX!H ![_4M'1>M-/1Z#GTOJNEK
M7TQE,C'TN.(W!V.8(((]:TM$ZXMVEM07AD%#/-INX98:=Y!E:P9#3Q."<.((
MSV\^"<)B+1$=SU*S-)F>VOY3&R3VOI/TOJ".IL=#;KA;XQ)3STS TC(<6@G'
M++<$<N/8EH&G[)T06+4%TLE-7U4,CQ$TM:WK'E[P-YP<@ $\<\@N+4:ZTMI[
M3ESM^AK?71U5Q;MEGJCP8T@CAQ)) )Q[<Y*XETUA;ZKHGMFF8XZD7"FGZQ[W
M,;U9&YYX'.?RAV)PF?TV>I6/,Q,Z_OV175%V;?+]5W%E)%1MG((@B\EF&@<.
M [L\E9NG'?=5T'W:UN\>LLK_  B(<SL&7CZ.L'R*GE-.BK5M/I.^5$MRBEFM
MU53NAGCB:'$]H."0#VCGR)6MZ_3V]F&*_P!?U>Z6Z_=]R_1%IW3K/%JJ_%34
MCMQY9!_K.:/ZJR=(?^ O2'^MB_Y4BA'2CJN/5VJ'5U(R6.BCB;# R4 .#1Q.
M0"1Y1/;RPNEJK65NNW1K8=/TT54VMH7L=*Y[&B,@,>TX()/-P[ LXI.J_JUG
M)69M$3VUJ$EZ:?X :&_V=O\ RHU#>AK_  E6/_6/_P"6Y;O2'K*W:BTOINW4
M,54R>W1!DQE8T-)V-;XN''/%IYX4?Z/[S3:>U?;;I7-E?3TSG.>(@"XY8X<
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M@GE%TJZCIZ*"FF\!K1 T-CDJJ</>T#EQR/EYJ-ZGU+==35S:J\U3IY&C:QN
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M]+'>+UV\3-BG%;0B(M&0B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MU0_RY3Z^X=P__FI&. X(N;)FM?M[.S#T]<7?S(B(LG0(B("(B B(@(B("(B
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MUT5/21=K88PS/MQS6ZL;]1-NT=G3BZ.M.]NXT!K0&@ #@ .Q$1<[L$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$'"U?\ BJH^*W]98=,>9:LVK_Q54?%;^LL.
MF/,M02-$1!CJ/-.7L'F6^Q>5'FG+V#S+?8@^T1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!>/\ (=[%ZO'^0[V((-<?
MX2'XK?J4RH/,-]BAMQ_A(?BM^I3*@\PWV(@J?.,]JV%KU/G&>U;")$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MU-;YZIC)*^5IX2S-)R(P?)8>?,]@5VO:U['->T.:X8((R"%SO@"S_P"2;?\
MHS/L0<._W?1%8+6[4%58IXZACIJ&2MZMS'MX N8YW#M'(J)Z(9:']+UQFT,*
M<6$6P,N#J( 4KJKK!LV[?%+PS.<=GK5G5%KM]32QTU10TLM/'Y$3X6N8WV C
M 6>EIH*.!L-)!%!"WDR)@:T>X(,JX-VT?I^[UKZRY6FFJ:EX =)(W)( P/H7
M>1!4?02YPL>H8-[S#3WRKAA8YQ(C8"W#1GD/4K*5:=!?XKU5_2&L^MJLM 1$
M0$1$!$1 1$0$1$!$1 1$0$1$'R\X'!?&X]Z^W\EC4PK+W<>]-Q[UXBE#W<>]
M-Q[UXB#W<>]-Q[UXB#W<>]-Q[UXB#W<>]-Q[UXB#W<>]-Q[UXB#W<>]-Q[UX
MB#W<>]-Q[UXB#W<>]-Q[UXB#W<>]-Q[UXB#W<>]-Q[UXB#W<>]-Q[UXB#W<>
M]-Q[UXB#W<>]-Q[UXB#W<>]-Q[UXB#W<>]-Q[UXB#W<>]-Q[UXB#W<>]-Q[U
MXB#W<>];- <R.SW+56U0><=[$E,-Y$156%X_R'>Q>KQ_D.]B"#7'^$A^*WZE
M,J#S#?8H;<?X2'XK?J4RH/,-]B(*GSC/:MA:]3YQGM6PB1$1 1$0$1$'CFAS
M2UP!:1@@]JK;I<AME)H1VE+7;J9U?=AX+;J"&,- ?GC)@#Q6L'C%W9CUJQ:M
MTS*29U+&V6H:QQC8YVT.=C@">S)QQ51:7H]=VNZ5MYNND:.Z7ZKRUU6Z[L8V
M*+/BQ1,V'8P=O$DGB2@[&M+1>H+QH:JM]GDOT=H9.*A@FCC+GNA$;7$R$#F7
M'M7:T=JNGN5XK++666HL5[IXFSOI)@PB2(G >Q["0YH/#VE9[K==54U/;YZ'
M3--6F6+-53"X-C?!)W-<YNUXY\>"YNEK+>Z[6U1JS4U-36Z440M])00S=<61
ME^]SY'@ %Q(& . ""=J.5FMK'1U4U-//5B6)Y8\-H*AP!!P<$,(/M"D:((OI
M765!J@7-UI$VR@JWT<AFC+"7MQD@9SCCVX/J7=\)?W-57=#7XQZ0OZ3UGUA6
M4@S^$O[FIX2_N:L"(,_A+^YJ>$O[FK B#/X2_N:GA+^YJP(@S^$O[FIX2_N:
ML"(,_A+^YJ>$O[FK B#/X2_N:GA+^YJP(@S^$O[FIX2_N:L"(,_A+^YJ>$O[
MFK B#,:IPYAJ\\+=_-^1:[U\*=*S+;\+=_-^1/"W?S?D6HB:-MOPMW\WY$\+
M=_-^1:B)HVV_"W?S?D3PMW\WY%J(FC;;\+=_-^1/"W?S?D6HB:-MOPMW\WY$
M\+=_-^1:B)HVV_"W?S?D3PMW\WY%J(FC;;\+=_-^1/"W?S?D6HB:-MOPMW\W
MY$\+=_-^1:B)HVV_"W?S?D3PMW\WY%J(FC;;\+=_-^1/"W?S?D6HB:-MOPMW
M\WY$\+=_-^1:B)HVV_"W?S?D3PMW\WY%J(FC;;\+=_-^1/"W?S?D6HB:-MOP
MMW\WY$\+=_-^1:B)HVV_"W?S?D3PMW\WY%J(FC;;\+=_-^1/"W?S?D6HB:-M
MOPMW\WY$\+=_-^1:B)HVV_"W?S?D3PMW\WY%J(FC;;\+=_-^19Z:4RAV<<.Y
M<U;UO\E_N328G;:1$4)$1$$0U?YZE^.Y=VR^8"X6K_/4OQW+NV7S 4H=)?$W
MFG>Q?:^)O-.]BA+YI?,A95BI?,A94!$1 1$0%R]2V@WRTRV\5]70LE+>LEI'
M!DA9GQFAV#C(X9'%=1$%;=!M%3VVVZKH:&(14M-J&KBBC!)#6M$8 X^H+=UI
M8]&V#3%\K[G9K>65(D?*70A\M1,_.&M)\;<7'@!R[,86UT9VFNM+=4_"%.Z#
MPN^U57!D@[XG[=KN![<%0E]3JBNUI+>-1:)NM=!0RD6FDAG@ZF$<NN=E_C2'
ML.,-'+CQ06#T7T%PM?1]8**\EYKX:1C90\Y<WN:?6!@>Y;MZU1:K-5-IKA+4
M,E<P2 1TDTHP21S8TCL/#FMG3]?57.V1U-=;*BUSN)!IJAS7/;@X!):2.//F
MNB@BMHU[9;MJ5UDH75;JMM)X8724[XF[-^S'C@.SD]V/6I-U\?I?0JNG_P 8
MN7^C0_M"L-!O=?'Z7T)U\?I?0M%$&]U\?I?0G7Q^E]"T40;W7Q^E]"=?'Z7T
M+11!O=?'Z7T)U\?I?0M%$&]U\?I?0G7Q^E]"T40;W7Q^E]"=?'Z7T+11!O=?
M'Z7T)U\?I?0M%$&]U\?I?0G7Q^E]"T40;W7Q^E]"=?'Z7T+16+)SS*0B9TZ?
M7Q^E]"=?'Z7T+F9/>4R>\J=(VZ?7Q^E]"=?'Z7T+F9/>4R>\IHVZ?7Q^E]"=
M?'Z7T+F9/>4R>\IHVZ?7Q^E]"=?'Z7T+F9/>4R>\IHVZ?7Q^E]"=?'Z7T+F9
M/>4R>\IHVZ?7Q^E]"=?'Z7T+F9/>4R>\IHVZ?7Q^E]"=?'Z7T+F9/>4R>\IH
MVZ?7Q^E]"=?'Z7T+F9/>4R>\IHVZ?7Q^E]"=?'Z7T+F9/>4R>\IHVZ?7Q^E]
M"=?'Z7T+F9/>4R>\IHVZ?7Q^E]"=?'Z7T+F9/>4R>\IHVZ?7Q^E]"=?'Z7T+
MF9/>4R>\IHVZ?7Q^E]"=?'Z7T+F9/>4R>\IHVZ?7Q^E]"=?'Z7T+F9/>4R>\
MIHVZ?7Q^E]"=?'Z7T+F9/>4R>\IHVZ?7Q^E]"=?'Z7T+F9/>4R>\IHVZ?7Q^
ME]"=?'Z7T+F9/>4R>\IHVZ?7Q^E]"=?'Z7T+F9/>4R>\IHVZ?7Q^E]"=?'Z7
MT+F9/>4R>\IHVZS'![<M.0O5AHO,#WK,H6$1$'"U?^*JCXK?UEATQYEJS:O_
M !54?%;^LL.F/,M02-$1!CJ/-.7L'F6^Q>5'FG+V#S+?8@^T1$!$1 1$0$1$
M!$1 1$0$1$%1=!?XKU5_2&L^MJLM5IT%_BO57](:SZVJRT!$1 1$0:<MTH(J
M@T\M=2LG! ,;IFAV3RX9RMQ5J\P2:DU?3RZ>FN\DL\36[8F%@_ ,X%[B-JV9
MZZXV&ATW8)*J>.I-(7U-33TSJIX# T;6M /:[&XCD/6M.'V8QE\[_P [K!6"
MLJX**G,]7*V*$%K2]W+)(:/E) 4/H[_5NL=0+E6ST,[:SP>GJ74#A+4LP' M
MA(SNQD<!CAG"X]TO514Z9U%!<)YIHZ"JHRR:>F,$A8Z2-WC,P.7'C@9"1CG:
M9RQ$+/10ZAO-WN]DNUVM0C)#7Q4-"YHW->PD$R9XAY/Y.0 ,9YK:TA<#635#
M);Q45<[&MZRDJJ5M/+">\@ '!]X]959I,+1DB9B'>KJ^DH&-?755/3,<=K73
M2!@)[ADK8:X/:'-(<TC((.00J^UW/.[44<EGH!<JNAHY!5121A\<4<A&' 9X
MO\0^*.)&>2[FBZ^VMH**SVJJ?6MIJ*.0U 'B[22T ]SB6GQ>P!3-/IVB,F[3
M5)D1%1H(B(/E_)8UD?R6-6A61$1$"(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@+:H/..]BU5M4'G'>Q)3#>1$55A>/\AWL7J\
M?Y#O8@@UQ_A(?BM^I3*@\PWV*&W'^$A^*WZE,J#S#?8B"I\XSVK86O4^<9[5
ML(D1$0$1$!$1 1$0$1$!$1!4?0U^,>D+^D]9]85E*M>AK\8](7])ZSZPK*0$
M1$!$7-O5YI;.RG-6)W.J).JB9#$Z5SG8+L -!/(%(C?A$S$=Y=)%S+->Z*\=
M>VC?)UL!#9H98G121D\LM< >/85TTF->2)B>\"(M&T7*&Z4\TT#7M;%/+3D/
M !+HWEA/ \LC@FC?LWD1:UQK:>W4,]962"*GA:7O>1G ]@YHGPV47+LU\I;M
M+40P,J(:B -=)#40NB>&NSM=@]AP?D744S&O*(F)[P(B*$B(B#X>OA?;U\*T
M*3Y$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0%O6_R7^Y:*WK?Y+_<DIJVD1%581$01#5_GJ7X[EW;+Y@+A:O\]2_'<N[9
M?,!2ATE\3>:=[%]KXF\T[V*$OFE\R%E6*E\R%E0$1$!$1 1$0$1$!$1!54_^
M,7+_ $:']H5AJO)_\8N7^C0_M"L- 15[JDV@Z^V7Z*2:#X+88V,BDD.[K7\0
M& D'"]I+S5:;TE ZJ!B=55[X*(7%Y!AA<YQ892>/!H/#GR"OP[=F7JQN=^RP
M5\O<UC2YY#6M&22< !0^R:J?6F[4SZRU32T<+9HZR)Q;3N#LC#\DEI!''B>!
M"T3J2:X4U^MLU5;JYK;7)4,J*$.:T<"TM(+G>HY!3A*?5KI/VN#FAS2'-(R"
M.((7JA^C[Y+=*6".ULBEM]#3,BGE)RZ28,'X-G'@!VN/?@=Z^]'WVOO4C7U%
M5;&D-)GH61O944[NQKMSN/K.T#N2:3&R,D3K\TM10OI+FC;#:HC"^O=X3UKK
M;&"754;6D.X#L;D.X\. '<LN@:NEIK)00&KB<^X2334T$;G/;$S.XQ D?D @
M'../!./T[.?U<4O11KI"JJ^BTU)-;)F0S=="PO<"3M=(UO#!'>/=E8KG=+Y2
M7&TVN%EOFK:V.=SYBU[8X]A;@[=Q)&'8QGB<<0%$5W&TS>(G25(HE!=+_<)Z
M^.V"V#X.<()73,?^Z)@P.>&X=XC?& !.XK+0:G=7S::-/"UD%UBF?('\71EC
M0< ^W(3A)ZD)0O"0 23@#M45NNIYZ :H=X/'*VTQQ.B R"XO9D[CW ]W8M6*
M[W:6\36VIJK54TYM[ZM\E+$\$?DAN2\@<\@]H!X!3%)1.2/"9QO;)&U\;FO8
MX9:YIR".\%?2KO3-TO-LTGIFIFCH76V5M+2F(!W7-:_:QK]V<'B0=N.1YKJ:
M5O\ <+Q6[:B>VP.:YXFMQC>VIA R!DEW'LX[<<>!2:3&RN6)U"8+$>:RK$>:
MK"TO$1%*!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$'2HOWN/:5F6&B_>X]I6957@1$0<+5_XJJ/BM_66'3'F6K-J_\55'
MQ6_K+#ICS+4$C1$08ZCS3E[!YEOL7E1YIR]@\RWV(/M$1 1$0$1$!$1 1$0$
M1$!$1!4707^*]5?TAK/K:K+5:=!?XKU5_2&L^MJLM 1<N[7ZW6FJHZ>X544$
ME4YS6=8]K0,-+B22> X8SWD!9YKI;X0#-7TL8):T;YFC)=Q:.?;V=ZG4HY0W
M46G67.@HIHX:RNI:>63R&2RM8YWL!/%;#9HG3/A;*PS, <Y@<-S0<X)'8#@_
M(HT;AIV^UPT-?<JN)\CI*^1LL@<1AI:P,&.'<T+#>[+'<Y:6H94ST=;2EW4U
M$&-S0[RFD.!!!P.!'8%N27"CCI'U4E73LIF$M=,Z1H8T@X(+LXY\%R+OJBB@
MM,]7:ZNCKI(GQ LBG:_ ?(UF3M)])6C<SV5GC$:DJ=-R5,-(Z:[USJ^EF=-#
M6%L>YI<W:6[=NW;@GACWK&W2%*:>XQS5E9/)7R0RSRR.;N+HW C&!@#Q0,8Q
MCEA=JCN5#6R21T5;35$D?![8I6O+?: >"^8;M;IJUU'#7TDE6W(,#)FEXQS\
M7.5/*QQJTWV&-M=7U=%5U-')6L:)1"6XWCE( 0?&QP/81S"6JQFCN4EPJZ^I
MKZUT0@$DK6-#(\[L ,:!SXY*RW>_6ZT5-'!<*J*!]4XM9O>UH&&DEQR1@<,9
M[R%GJ[K;Z-L1K*^DIQ+YLRS-9O\ 9D\5'U&J[_1SKEIXU%UDN-!<JRW54L;8
MIC &.;*UN=N0]I&1DX([U\Z=TM26"KJ)Z"HJSX2,U#)7APEDR3UAX9#N/9@>
MI=\$. (((/$$*,-U'<IZNXLH+$ZJ@HJAU.][:IC7.< "<-<!V.':IB;3&D3%
M:SN4H1:%CNM/>;<RLI-X826.9(W:^-X.'-<.P@A<J]:@K[6VKJ7V25]LI.,L
M_A# \L'$O:SCD =Y!X<E6*S,Z6FT1&TD1<*YW>Y0O<ZVV5]93,C$AF=4-B#P
M1G#!Q).._"Z-HN$-UM=)7TN[J*F-LK-PP0",\?6FICN1:)G3:?R6-9'\EC4P
M2(B(@1$0$1$$+U90U-/<;6ZGO-UB;75XADC9, UK2Q[L-&WAQ:.];U1=9;-6
MTUDI*:MNU9)"Z=CY9F@X#L'>X@  9YX[@M[4-MGN%19GP%@;25S:B3<<>*&/
M'#UY<$?;9SJ^*Y@L\&;0/IB,^-N,C7#AW8!6FXUW9<9B9TPUE]J6W#X/M]L=
M65L<+9ZAO7-8R$.R "X\R<' QV=B^;1JB"YUU'2Q4\L<D\4SWB0@&%\3VL<Q
MP[\NY^I?%90W.@U!57.TP4]6RLACCFAEF,1:YF[:X':<C#L$>H+E4>G;M::N
MBN=,VEK:[-2ZKA,IB:3,]K_$=@^26@<1Q":KI$S:)=>KU1#34UWE?32N-!4L
MI QI&97O#-N.[B\#BN==+_7RT]\MU1;O JB"VR5/6LJ0_@6O#2W !SEI]BYE
MZH:ZDL%\BN3:8UE\KV,IVQNW,8YS&!H+B!C&P^-CL! SP7U205$,]QL4]OIX
M[C<[?*6U+:^2J<=HV@/+QN:W+^'9S5HK"LVM,Z_SW=6R:CJF4EC;7VR>*EK6
MQPQ53I6N<YY9D%S>8#L'!R?7A;M%J&IN%RJ8*"V&6EIJDTLTQJ&M<UP.'.V<
M]H]N3V!*RSU,UMT] PQ[Z"H@EER>&&,(..''B5SKK9KC7WJ*HAMM%0SQ5+7?
M"4-2>L?"UV=KF!HW$MX8)(&57Z96^J$AOUUCM%&R9T4D\LLK8(88\;I)''@T
M$\!VG)Y %:ENOLLMPEM]RH'45:R'PAC.M$C9(\X):X=H.,@CM"^]46R>XTM*
M^B=&VLHJEE5")<ACW-R"UQ'$ AQ&>Q:E%;[E6WUUUND,%*8J5U+!3Q2F4^,X
M%SG.P/1: !ZU$1&EIFVVI1ZREJ*"WW)]GGBM56^./KW3-+F.>X-!+.>W<<9Y
M]N%\2WE]IOFJ*J<2S4M.ZCW-#^$3'-PYX'JYGV+,W3U8-"VRT9A\+IS3%YW'
M;^#D:YV#CN:5NQ6?^^FHIJ_JC0W&.)F"[\EL9:[/=S5OI[J_5V_SVENONK!?
MX;5'$9)'T[JF20'A&T.#6Y[\G./85HUU_J67NHM=NM<E94PPQSN<9FQLVN+A
M@D]OB\L<?5A<SHQI)C:YKE62]?+4%L$,N/*@B&QA_K8<[^LO))+G#KZ\26NF
MIZH"BIFR12S&(Y+I<$':>6#D>OU*.,;F#E,Q$_=T1JN!]GI:N"DGDJZF<TD=
M'D!XF:7!S2<X &UQ)[@OJ+4O5-N4=UH9:.KH:?PM\37B421<?&81C/%I&#CB
MN;%IFX4ULH)XI*>2\4U=)<'M)+8I'2;@]@."0,.P#CF.2WJ*@NLMUKKS6T]+
M%5&D%+34@F+VX!+B7OV]IQR!P!VIJI$V]V"HU'=#IRNN<5H8R-E(ZIAD%4R0
M' SQ [AQX9Y8RNUIVKK*ZU03W"E%/*YK3@2!^\%H.[ARSQX*+P:9K9Y;GU='
M2V:FJZ&6F?3P3F1DDKQ@2%H:&MQQXCB<J3Z<%=':H8;G314\T+6Q 13=8'@-
M W<AC/'@EM:[)IRWW<"W4E7>+GJ!SKS<J4TU<8(6P2-V-:(XW>26D'BXKJZ0
MN-574=9!<7,?64%4^DDE8W:)=N"'X[,APX=^5SZ:DU!;;A>3;Z*WS15M6:B.
M::J<S9EC&X+ PY\GO[5U],VAUHH963SBHK*F9]342ANT.D=SP.P   >H);6B
MD3MQM9T]106ZX76.]W"*I:/W) PM$>_DV/9CQ]SN'')XIK*OGHVV:2X5<]!;
M9'%M9)2GQVR%HV#/$AN=V2/5V+XK*+4$NI'UTMNH*RGIW$4,;ZUT8B'(O+>K
M.7GOSP' =I.]=J"Y2W.TW>"EI9YZ:%\<E)),0&N?MRYC]IXC:1Q R">2F/;:
ML[G>GN@ZJ>MM$T\E3+54CJA_@<TV.L?#PP78[<[N?'&,J1KA:5ME30&Y5%8R
M""2NJ.O\&@<7,B\5K>>!DG&2<#B5W52WEI3?'N(B*JXB(@(B("VJ#SCO8M5;
M5!YQWL24PWD1%587C_(=[%ZO'^0[V((-<?X2'XK?J4RH/,-]BAMQ_A(?BM^I
M3*@\PWV(@J?.,]JV%KU/G&>U;")$1$!$1 1$0$1$!$1 1$05'T-?C'I"_I/6
M?6%92K7H:_&/2%_2>L^L*RD!$1 42UV:IMPTP:!D+ZGX0=L;,XM8?P$O,@$\
ML]BEJP5%)!4RT\D\37R4[^LB<?R'8+<CW$CWJ:SJ=JVCE&D.NM-=;1:-2Z@J
M)8#=I:,,C93-.R%K [!R[BX^,3DCL'!:]FHZ^VUE%<V0&GMK('OK9'7%U3X0
MW9N#]I'E9&<CL)4_<T/:6N <TC!!&00N10:9L]OJ#/1V^&*3!:,9PT'F #P
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M-44/7&!TFUS)0W=L<UP<TX[>('!:\5HJI;I:[C<*N&2IHXIHWB&$L:_K"W!
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MCS40F7B(BE B(@(B("B^M:V]VFAJ+C;JF@%-$&#J9J9SG$EP:?&#P.WN4H7
MUY33UFE:V"EB?-,XQ[6,&2<2-)X>P*U?*E_PSH?=7V*!AU-7TSWSR%D+J>F>
MP$AI.W&YQ).#COX#FMBHU%0T]#2U,XJ6&J);# :=_7/(Y@1XW=F>2UM24<M3
M>M-R,@=+%!6/DD<&Y#!U3P">[B1[UBU#'/1ZDM=X;2SU=+##-3RM@9O?&7EA
M#PT<2/%(../%3$1*NYC;>I=26RI93NCG>'35'@H8^-S7MEVEVUS2,M. 3Q6W
M)<Z2*LGI99@R6" 5,FX$!L9)&XGE^25!*JDKY;I)J%MMJQ3?"5/,*;J_PQB9
M$^,R;.>27CASP%NU$S:NZ7ZX7*BJ*2T/M+:?K*EIBWC=)NX<V^5CB,^KDIX0
MB,D^[MT>K;;5UE+30MKNLJAN@+J.5K9&\/&!+<;>(X^M<O36LZ:2T4[[M-,9
MS*^*2<4S^J8[K'-:USPW:#C;V]O%<K2E2^.LL+M1-N\=5'%X+2^$4C8HFR.:
M,C<TDEQ#< G'LRMKX+K!T4U%"*27PQQD(AV>.<SEPX>SBK<:QV5B]I[_ .>R
M37'4=!0UDE*\54T\30^5M-323=4#R+BT'&<'UKISU$-/2R5$\C8H(V%[WOX!
MK0,DG/)0[5;70W&KJ;/!>8+T8VADE- 7P5) \5K\Y9@9QDX([UV-56^LNVCZ
MND8U@KI8&G8#XI>,.+<]QQCWJG&.S2+3W9;9J6W7&KCIH75$<LK2^$3T[XA,
MT<RPN W>Y:]1K&SP.J Z6H<VFD=%421TTCV0.:<'>X-PWB/DX\EH33SW^\6/
MJ+;74C*&<U-1)4PF,,_!N;U;2?*)+NS(P%\T=NJ6:6U9 ::035517/C9MXR!
MV[:1WYX84\8]U>5O9OW"]NHM2MCDE_O8VV2UCPQFXY:]HW# R>!/ +JSW:CA
MCH'NFRVN>V.GV@NWEP+AR[, G*X-OH*@:CM4DU._J&68P2.<WQ0\N9XI]> >
M"YFCZ*H=J-]%4 NI-.!\%,XG.\RG+?>V+:W^LFHT1:=_JE=VOM!:JB"GJWR>
M$3M<Z&*.)TCI-I&0T-!)/C#A[>XKREU!;:FV5->VHZNGIB6S]<QT;HB.8<T@
M$'B.&.U</4]4:+7%@G%+-4M;2U6YL+-[VC,8W!O,^[C@KGU5KK[M0ZDKH:*6
M(UE332T]+.-CY6P%A.0>6[:0 >X92*QJ-DWG<Q'^=DJM>H:"Y57@T)J(J@LZ
MQD=13OA+V>DW<!D<1R6*EU1;JJ4MIFULL?C!LT='*Z-Y;G(:X-P>1Y<^S*YW
M6SWW4UFJ8*"MI:>WB:2:2JA,1)>S:&-!XGGDD<. XK1M GI;U1Q6"GN]/0OE
M=X725D!;!"P@DNC<[D=V/%:2#D\DXP<Y=_2>H8]0T J(Z:I@/'A)"]K2-Q P
MX@!QX<<<EIUU?>JC555;+5/0P14]+%.344[I"XN<\8X/;@>*O>C\RTUE9;*N
MDJH*FD<\/,D1#'9D<06NY.&".2UJNIFM>N*ZK?;KA4T\]##&Q]- 9!N:^0D$
M]G,)J-SHW,UC;J:=N]35U=?;KI!%#<:(L+^I),<C'@EKVYXCD1@\B%ENS+V^
M<_!E3;Z:F8S.Z>%TKGNX\#AS0UO+CQ*TM,TE9->+I>KA3.I'5;8X8*=Y!>R)
MF[B[' $EQ..S@M'5]=5SW!MJ\ N?P46!U3/2P.>9@?\ LFD<AZ1Y]@[TU]79
M._I[ON;5%4_1MLNT44%/-6R1Q/?-DQ0;G$&0\02WAPXCF.*WM-W.MJ;I<K?6
MS4M8*1L;A5TT98TEV<L<"YV'# / \G!:.H0^OT[;VTEOK66P3M95T38C'*:<
M!PVAO/&=N0.);E-'4G@]XKS:Z*JH+$Z)A;!.PQ@SY.YS&.XM&,9Y E3J-2B)
MGE"7HB+)L(B("(B B(@Z5%^]Q[2LRPT7[W'M*S*J\"(B#A:O_%51\5OZRPZ8
M\RU9M7_BJH^*W]98=,>9:@D:(B#'4>:<O8/,M]B\J/-.7L'F6^Q!]HB("(B
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M'UX'%)F-%:S$]_#C_<)I3^3EI_16?8H[HS1NFZEEZ\(L-MEZNZ5$3-],T[6
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M23J#Z2# BS]0?23J#Z2# BS]0?23J#Z2# BS]0?23J#Z2# BS]0?23J#Z2#
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M?H7?J])Q5-7-.;Q?(C(\OZN*N<UC<G. .P>I21$-H#KK3INM7,R@TU#45L\
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M,AQ/$X )/><!=?HPIY]-=(=]TK%7S5MNAIF5#.M/D/.SLY#R^SN"FW+C._\
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M/41MEC>.3FN&0?D*SJC)BGYA8EEGYA8E:%)\B(B B(@(B("(B B(@(B("(B
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MX7Q.K#WG@<<3AP5WHB=JEU-I#55%J[4MUTFRVU<&HJ1E/.VLE<QU,]K-@>,
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M<P(B*C41$0$1$%7=!W[]Z1/Z4UGUA6BJNZ#OW[TB?TIK/K"M% 1$0$1$!$1
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M7&@ME3U\M UKIGM:>K\8N'BNY.P6.!QP!&.]<?2MBN5!=FSUE&V&(,<-PO\
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MVBFAG8Z(->P$$9E8#V]Q(068BBWWO=)_Y"H_D/VJ3011T\$<,+0R*-H8QHY
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M#APSSYK6\1Q\:88IGE$;F86BB* ZUZ2(-/7>"VT5NJ+E4"I@@JY&GJXJ02N
M;N>0<N.X$-'9Q)"YG:GR*/=(&HWZ5TK57:&D%;-$^*..G,G5]8Z25L8&[!QY
M6>78M73UVU=5W-D5\TQ1VZB+275$5S$[@<<!LV#.3ZT$K1$05=_<_P#XGU7_
M $BK/K:K157?W/\ ^)]5_P!(JSZVJ?:EO,%AL\]?4@N;&,-8#Q>X\@B?+D:H
M_ACHS_::G^S2*5+\]W775XN%VI*\OBB?1O<^G8R,$,+FEIY\_%)'%6CT=:R^
MZ6*6GK(V17"!H<=GDR-Y;@.SCC(]85IK,+3CF(VF:C.B//:E_P![S?J1J3*,
MZ'\]J7_>\WZD:JHDR(B B(@(B("BFK/W7JC25N_)\*EKY!WMAB('_'+&?<I6
MHK2?NWI-N,O-EMML5.T_SYI'/>/DBB^5!*EHWZW1W>QW&VS>;K*>2G=['-+?
M^JWD0</0MQ?=='VBLG_?#Z9C9AW2M&UX]S@X+N**:%_<=9J6T'@*.Y/FB'^C
MG F&/5O?(/<I6@QS^2/:L*S3^2/:L*M"LB(B($18*RKAHX3+.[:WD.\GU(FM
M9M.H\LZ+F4-ZI:N81,+V//(/&,KII$Q/A:^.V.=7C0BJ"U7C6FO;I?:K3-ZH
MK)9[96/H:=DE&)W5+V8W%Y/DCB.7?RX976O?2G266OKJ'X+NEV^"&,^%*RBA
M;U5.2./-WM..SCW%%-+)14Q<ND*LINE6,6N*Y7JSU5A95TU#1-!WO<\$2<<8
M\4'GW@<U*/OJ60Z$HM3LAK)(JR;P6"C8P&>2?)'5@9QG@3G/+Y$-)^BK=O2S
M;HK-?JJX6JY4-?96QOJK?.UHEVO<&M<TYP1XP_\ X(7%OG3%5QU%D%GTM=74
MUPK6Q12U4.SPJ+'.$%P\8Y&">&/:AI<2*+:SO5;0]'%UO-)')15\5O=4LCF:
MUSH7[,X<.()!X'F%571[TBZBN.JM+T)U!0ZACN<+I*ZGCHA"^@PP'BX<#@G'
MNY<0AI?R*G]<](MS@U[8[1ITM;;&72"@N-26!PDE><F%I(_):/&(X@N X*Q]
M+7M]]M\M3+:[A;#'.^'J:Z+JWN#?RP/1/8?44-.RBK&+4%\%EI]727%IMLUP
M;";;U#-C:9U1U+7!^-_6#(?G..8PIAK"1]/;V5#M01V&CC=^'J71QDD'@ '2
M9:WCW@Y]2&G>117HXNU9>+#-4UM0*R)M5+'25@C$9JH ?%D+1P&3D<  < XX
MKFNZ2J5M*RM^!+PZVNJG40JFQQD&</+ T-W[CEPP#C&2.// TGB*'.UY3T\5
MP9<;5<:2X4CZ=G@3^K?),9W%D6PM>6G+@1Q(Q@Y6]I[4[KM=+G;ZBTUENGMP
M89S421.;XXRW!8\YR,G.,<"AI(T556+6E2+[/=+W6N99JB@EK*.G#!GJS4".
M': ,N>]H! XD[\*17+78HF5>RPW2>2AHV5M=&PQ!U*QP<0UV7@.?AKCAN>7-
M#29HHY>M3"W:%J=1&DD!92^$1T\CFY)(\1I+21Q)'(GFN!>?NJTYIZ?4%7?6
M5\E'%X35V_P2-D+HQQD;&X#>"!G!).<<1Q0TL)%#-97>]4=;8)K9)2PVFHK:
M6&9SFE\LW6/P6@$8:W;QSQ))[,9.>YZ@FL^L:B"X3 6E]I?6Q9:!L?"_\+QY
MG+7L.#W%#26(JHM>L;_+H>ICKWQQ:I=6TU)%B-N&^$]6^,[<8.UDC@?]65,[
MQ<ZO[KK)9:"01B2.6MJWEH)ZF/:T,&>1<^1O'N:<(:21%"8.D&GFABJQ9[HV
MTNJ_ GU[FQB-DO6]4,MW[BW?@;@,<?:NK5ZHBIJJ6 VF^2&-Y9OBH)',=@\P
M0.(]:&DA15KJ;4,\&L*^CJM426"WP4U.Z(^"1O:][R_>7/>PAH #!S 4DL5U
MJONKNMFKIVU+&P0U]',&M!="_<QS3C@</82#W/'<AI)D1$!9H.3EA6:#DY)3
M#(B(JK"\?Y#O8O5X_P AWL00:X_PD/Q6_4IE0>8;[%#;C_"0_%;]2F5!YAOL
M1!4^<9[5L+7J?.,]JV$2H<3ZK@Z4-8'1E)35,IDCZ\3EHP,>+C<X>M=SX0Z7
MO\CVSY\?_N*R;?8K=;[K7W*DI^KK:[!J)-[COQRX$X'N736TY8^SGK@F/-I_
M9@H#.ZAIS6-#:DQM,H;R#\<0/>H)TC]&D.K[A%<H[@^EKHHA$T/B$D3@"2,C
MG^4>_P!BL)5'TP-UK47N"GTVRY&TFG:9/ R&$OW.R-XX\MOJ5<>^7:=+9M</
MJC:)W6WLT2YK=5Z9T]=*<D 34L_4RGU[">/N;CUJZ.C^KME=I*@J;#2.H[<\
M.ZN!PP6>.0>T]N>U4I9;)<+;)UTW1O47&ISDRUU2923ZVX#?H5YZ0GJ:G3U)
M+76QMJG(<'4;>46'$#L', 'WK3+X9=/^*?\ C^^H=A$1<[K$1$!$1!5W0=^_
M>D3^E-9]85HJKN@[]^](G]*:SZPK10$1$!5[TH:FM7P)6VAE4)*YSX\L8"0W
M;(UQR>0. >"E^J*N6AT[<JJGSUT5.]S".PX.#[E^9G.+G%SB2XG))YE6K7;3
M'3EY?I^SW6BO%&*JVU#)X2<9;P(/<0>(/M6ZJ/Z&:R:'5+Z5CCU-1"[>WLRW
MB#]8]ZO!1,:E6]>,Z$1%"HB(@.(:TEQ  XDE1/H\!KJ6XZAD!WWFI,\6>RF9
MXD(]A8W?[9"LO2)42_ +;72/+*V\3-MT3F\V!^>L>/BQB1WN"D5)3Q4E+#34
M[!'#"P1L8.36@8 ^1!E1$0%P-<VN>Z:=G;08%RIG-JZ,GLGC.Y@]AQM/J<5W
MT0<NSW2"]66@N=+GJ:J%LK0>;<CD?6#P/K"VE%M-_P!Y]2WFP.\6!SC<Z(=G
M5RN/6L'Q9=Q]0D:I2K0K/D1$1 B(@(B("(B B(@(B("(B B(@(B("(B B(@(
MB("(B B(@(B("(B B(@(B("SP^0L"SP^0DIJ^T1%581$01#5_GJ7X[EW;+Y@
M+A:O\]2_'<N[9?,!2ATE\3>:=[%]KXF\T[V*$OFE\R%E6*E\R%E0:MVCGFM5
M;'1N+:E\+VQ.#MI#RTX.>SCA?F^I&L[/.YFJ;QJ6VP@X\)BW5$7O<'@?)E?I
M*XU3:&WU56]I<R")TI:.9#03CZ%1M9TQW*\2/AMC;79:<\.OK7NF=\C6G]4K
M?#R[ZAR]1Q[;G4NUT>4,M9>:.LINDB:[PQ.W/HGE[72#!X%KGY^A6^]P8QSC
MG &3A45T?6O3#]945QJ-5QW&^.D+HX*:D,$;G[3S\7!X9]%7I*7")YC&7@':
M#VE5R^5NG_#_ -[4[K/6&BM1V"V7&^VVZSTWA$T,+688YKFAFXG#QP(+>T]J
MB5'<^BTU< BL5[$A>W:3+P!SP_[13$WCI0+0TZ0M):"2 0W S_XJ^J>Z])9G
MC$ND+0V,N&YP#<@9XGSJUCM&O[L+;M.YC_\ E;RJ_3M)JS15/<;50Z:BO5-+
M63U5/6QUT<.X2/+L3-?QR,XR,Y&%:"+E=Z+=&6G:G2^D*6VUTD3ZOK)9Y1#D
M1L=(]SRQF?R1NPI2B(*JG_QBY?Z-#^T*PU7D_P#C%R_T:']H5AH"(B#6N%6V
MAHY:E\4\S8QDL@B,CSQQP:.)7!^[*F_R1J'_ ,JG_94G1!$J/7EOK:6*II+;
M?IJ>5NYDC+7,6N'>#M4@M-P9<J05$<%7 TN+=E5 Z%_#^:X X7%Z,/\ !_8/
M]D8I.@(B("(B B(@B_21^%TN^@;Y5QJ8*''>V25K7_\ !O/N47F_<UJK+F.'
MP;J@SD]T;I!%(?F2./N4HU+^ZM7:5H>;8Y9Z]X]4<18/^*9I]RYELMWPOIC6
M=N[:JNKH0>XN& ?<<%!.T7*TI<?A?3-JN!\JII8Y7#N<6C(]QRNJ@+$>:RK$
M>:F%9>(B*4"QU,S:>FEF?DMC87G'<!E9%X]K7L<QX!:X8(/:$%%7+5UYK:UT
MXKIX&[LLCB>6M:.[ Y^]6AT?WR:^60R5>#4POZM[@,;^ (/MXJ*7+HSJ36N-
MNJX!2N.0)<AS!W< <_0IWI>QPV"UMI(7F1Q.^20C&YQ[<=@X!6G6F^2U)KV1
M/I]GJZ?HJO;Z%SVN(C9(YG,1ND:'>X@X/J)6M74^G-)Z EONDZ"U^'TMM<^D
MJ(V-,CP6C+B1Q=WG/K5C55/#5TTM/51,F@E:621R-#FN:>!!!YA1FR='>E+'
M6RU5KLM/#/+&Z)Y+GO!8[@YNUQ(P>["JQB5=:=O5]M5_T2*C4DU[@U+222U5
M/*UF('",.#F;1P )(Q_-/NB.C:F^Z=Z-=*WZ@OM2RGDNPH_@[8WJ3&Z1^[/#
M)<2#Q[B,<E?&GM!:8T]7R5MFL]/353VEID!<XM!YANXG;[L+*W1>GFV.DL[;
M9&+;23BIA@WNPR0$G=G.>;CV]J&U<ZINU[N^M=7T5/J.:Q4NGJ%E13QPAHZ]
MQCWE[R>;0>&/6/?S:#4VJM77?1]#37F2T&ZV=\M4^.)KO&9(\%[ >3G!@X]@
M<5:NI=#::U+615=\M,%54QMVB0ES7$=QVD;AZCE;T>G+1'=**XQ4$4=910>"
MT[V9:(HO0#1PQQ[D-JLZ*;96CI-UB^JU!7SOH:F&.1C]@%6.K>UID&/R<<,8
M7WTXT\]5KS0,%)2VZKG>ZL#8;B,T[_%9Y? \/^N%8YT;8/NH&HA;8A>1_P#,
MAS@2=NW);G:3CAG"]U1I"Q:I-,;_ &Z.M--NZK>]S=F[&?)(Y[1\B&U5=$%%
M1SV?7-IKJ.VR5HN!+Z1V#0=9Q,;8^?B[F\>W "T-+VZH&OM36ZHKJ72U]=%3
MRA]H:SP1L+7-&W#L>.XEO/';PXX-NMT'IANGY+(RS4S;7(\2/A;D;GCDXN!W
M$^O*U*?HRT?3VZ6ABL5.*:61LL@+GESG-.6Y<3NP,GAG'%#;[Z2VA]HM<4P#
MJ26[43*D.\ET9F;P=ZB[:"O*%K(>E*Z,I@&QR6FGDJ T8'6"60,)]>T$>P!2
M6XT-+<J&:BKH&3TLS=CXWC(<%S:72MFI;=7T,-&?!Z]I95%\KWOE!;MPY[B7
M<N X\.Q$(%K:AN%HT[K@36NGJZ>X.DJXZ]T[6EF8VM8TM\K>US1LVYR=O$<5
M*M:UESH-&TCZ.J--<7U%% Z;:'8+YHV.X'@?**Z<FE;/+7PUDU*^66'88VRS
MR/C86 !I$9=L!  XXSV\UTKC04UQ@;#6Q"6)LC)@TDC#V.#FGAW. /N0V@L-
MNNTNL+C8_NHNPHHJ&&L8_$77"1[Y&8W;/)'5YVXYGNX+@1:DO-VH;.ZIK+K'
M)5V!E7 +3 'NDJB2'&0!IVM\WC.&\7<>'"V64%,RY2U[8@*R6)L#Y,G)8TN+
M1W<"YWRJO[KH9S+N74]EH[E;(J6.FH(9*^2F-&UN=S>#3N!.#G.>&$3$MJZ0
MUM59=*Z:N<LDU?<"R6XE[@3U<0$DP) Q@OV1^QRXG1U=JRIKX+-UDEOI8*BO
MJ8BYH_OB_P +FRQKNQC-PW#RB3W YG.D-/&T6VWFXR^%W:"F-,^J+W.\0O+M
M@+CD@<!D\2&C*R5^F:&2T"DH864TT$DM31R\28*AY>[K!QSY3W$CD<D<D-H-
MHJKOEYK[!4NK[V\?A7W821-92A[<@-B=MPYN\8\0G+>).5(M4QQ5/2%I*GN#
M6OHNJJY8F/XL=4M$>S(/ D,,A'O[EP]/Z(KZ*MLKH;?36J2BE;+5UD%QEF=5
M  [F]66@8>3DYY=@5@WJST%ZI!2W2E940AP>T.R"QPY.:X<6GU@@H(U<XH8.
ME*Q&A8QL]30U0K@P8WPM,?5EX]3R0">\K'#3TU\U5:C9J:*&TZ?DES4Q,#6R
M2ECH^ICQS:W<2XCAD <P<;NFM'PV&ZWB2"7KJ*X!O"8N?41X&"SK22YS.T \
M02>*V+5HBP6J6GDM]'+ 8#F-HJIBUO\ 5+\>["(5W/;/AFLJ>C]Q+(::NK*Q
MV/R(',#X?DDJ6X_U?J4@Z.KC)J?4,MXJ&D26^V06]X/Y-0X[YQ[BV,*=16JA
MBN\]TCIF-N$\389)QG<YC22!]*6NTT-J%4+=3,IQ53OJ9MGY<KO*<?6<!$[5
MR^MKJ;1NI+M;ZGP>ZU6H!!UQ:'%C161T[6D'LZL<O6>]=?K+G:-2UMLCNUQK
MHI;6:QAEBCEECE;(&G8 UH((=Y)X<."[=-I>G9/=XZ@MGMM?51UPIG CJIVE
MKBX.!X@N8QV._//*[!H*8W,7 Q#PP0F 2Y.>K+@XM[N8!0VB^EZV[SW5K*^:
M[/@V.)%3;60,S\8.)7*LU/<M'QZ>LUVCM5?05;_@\2P1.9,'ECW;G!Q(<#M.
M<8QGM5BO8U[',>,M<,$'M"CM/I"V6]SZFTP=5<61/933U,LE0("1C+6O<=H[
MPW&1P1#7Z+GN^XVG@<XO923U%)&XG.8XIGQL_P"%H'N4K7.TY:8;%8Z.V4[G
M/93QAID=Y3W<W./K)))]JZ* B(@Z5%^]Q[2LRPT7[W'M*S*J\"(B#A:O_%51
M\5OZRPZ8\RU9M7_BJH^*W]98=,>9:@D:(B#'4>:<O8/,M]B\J/-.7L'F6^Q!
M]HB(./JR[362RS5M-;JFX/80.IIAE^#^5[ J?T1TLU5OT]#3W.V76ZU37/+J
MK=NW NX#)'9R5[NSM.WB['!4[2W+I2M].YE)I.SP1;G/+(@T DG).!-S)6V/
M4Q,3'\N?-RBT3$S_ $VD?1!77FZ4=ZK[PRLCIZBM<^CCJG.+F1GCM;G\D<!W
M<"I9J:Q4>H[/-;+D)#2REI=U;MI\4@CC[0H]T5ZDNNIK16U-\CI(:B"I=!U4
M#7-<PM R'M<20<J:JEYF++XXB:1'E0VH=.=%M@N+Z"XUM>*N/&]D;W/V>HD-
MQGU*2]$L6AX[W5G1\];)6>#GK1.'8ZO<WED#CG"B+K]I;372)JMNH+8+LVHJ
MM\<IIVR&%V27,VOP.9YCN5A='6JM)WVZU-/IFT"AJF0[Y'^"1P[F;@,9:<GB
M1P6U]\?=S8N//MJ/]U@*O^FP :6MY YWBAS^?:K 7(U1I^EU)00T==)/'%%4
MQ533"X [HWAS0<@\,CBN9W-?7&FVZJL)MKZR:B_#13MFB:USFNC>'C@X$'B
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MC1R( &.)[QCBHA>WUERU-<WW5UBBFHJ&&CN,,]SFHXJEV#)N&P R1EKP,/&
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M1@C(!)QDCN&<^Y=6VBG%OI10X\$$31#CELP-O/U86CJ2E==K/<;51U<4%9-
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M]YPUK0,DDGD $'5W-](?*FYOI#Y5#_NTTO\ RCLWZ;'^TGW::7_E'9OTV/\
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ME!FZ/J22CT59HY_/NIF33?ZQ_CO_ .)Q6'0GD7[_ 'O4_K!29K0QH:T - P
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M@N-CK_"J&H>'$@R,<<MD ['#M]O-6X[AM7%.MOTPBT[-7QW2U4M=",,GC;(
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M25=\E!QNHV 0 ^N9Q$?R$GU(/=)?C_6/^\X_[)3KMW2Z4%II34W2LIZ2 ?\
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M)'6-_=#]S0][@3S.7'AA3W4,;+WJZTV:1C9:.C8;G5L<,M<>+(6$=N7%[O\
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M-ODZDN/>]OD/_K-*^?NZL7;-7#XUNJ1]<:PU>HZ&[P&*V32O#2#)OADC]GE
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M?JY7;I[704_[WH:6+XD+6_4%MC@."",_=S8W>9DKY_\ 46ZHD_5C*?=E3/\
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M[1G(]V1\BMQ;VPZKM=</D+[7Q#Y"^UFS@1$0<+5_XJJ/BM_66'3'F6K-J_\
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MTD%YK1'2%P(9MQUKL\&9[ >_W+]1@!H    X !?E=I((+201RPKZHM47-]'
MV/2E]J)Q&T/>[J(6EV.)\>4'&?4IS3,ZF67P+K+]1%Z7CO&NZ7HHM\+:JF_>
M^EZ6'UU=S#?U&/6O<:/5]VHI:6I^ :2&48=U<E3(X<<\'-,1'N(6#Z!L=*7^
M#O47^Q2?4I2JJFZ**JMB?'7:CG;$\8='3^$ $=WX2H?GWA;5-T1TC';JC56K
M9SVCX2+&_(T9^E$]EEK3NM'05U$^"[4]-44A(+HZEC7L)'+(=P4>I] VB.%D
M4U1>JIC1@">[5+A\F\#Z%FCT#I1CP]VG[=,\?E5$(F/RORB$+Z1H-(T-D=%9
MK3IZ2LE>(W.AIH7.B;@DG@.!.,#W]RJXQL,?5EC>KQC;CACNPKRUYHVGJ]/;
M+%04U/40/$C8X(FQ]8,$%O #CQR/8J7;153JKP9M-,:C.WJ@P[L]V.:Z,6M/
MC/C\99ZF-[XZ[?Y]UN]%%JT_>=/MFJ-/6?PZCEZLRBBC#G8P6NSMY^OU95GJ
M)=&.GYM/Z<$=8-M74/,TC/0X !OR#Y2I:N>VMSI]7T'J?+T]7\6NXB(JNM$-
M7^>I?CN7=LOF N%J_P ]2_'<N[9?,!2ATE\3>:=[%]KXF\T[V*$OFE\R%E6*
ME\R%E0%76O\ 2=^GU)2ZDT=60P7.*'P>6*7&)&9)X9!';R/<%8JI_I/JKY=-
M85%GM5WGM=-06I]P/4N<UT[AGAEI![AZN*TQ;WV8YM<>[;TWI/5UTU=;[YK>
MKIPRW!QIZ>';Y1'\T8 [<Y)X *T:D2&FE$)Q*6$,/<<<%1.B6W&AU+H^JN.J
MKA<*.[Q.>V$5+R&2AH\21I<<C)QGO"OI3EWM&#4UE^<J'I*OUBCLUNN;+EX1
M1U,GAPF <^I9D;6 N&1CB%-(.FNBFGCC%AN0+W!N26\,G"L^MMU)72TLE73Q
MRR4LG6PN<.,;^60MI3-Z3_ZHKBR5\7_@1%H7V\4%AM51<[O5,I:&G;NDE?D@
M#..0XDYX8'%8NAOHL%!5P5]#3UE(_K*:HC;+$_!&YCAD'!X\BLZ"L8O\9";^
MC(_M*LY5C%_C(3?T9']I5G("(B"*7O\ OAK[3]!SBH(IKG*.S=CJ8O\ F2G^
MJI6H79:*'4%[U=5U76&FDGCMD9CE=&[9 W+L.:01^%DD' _DK:^X&Q?_ +U_
M\VJ__<0>]%?^#K3W^QL^I=G4-JAO=CKK94DB*KA=$7#FW(X.'K!P1ZPHY;>C
M73]OH(*2(W9S(6!@)NE2W('J:\ >X!2BTVZGM5#'24?7=2PDCK9GRNXG)RYY
M+CS[2@YNA[K-=]-TLU: VX0[J:L:/R9XW%DGN+FDCU$+NJ)4/]YND&MH_)I+
MW#X;#W"HB#62C^LSJG?U7%2U 7DCVQQN>\AK&@DD]@"]4<Z1JJ2DT->WP'%1
M)3.@A/\ I)/P;/\ B<$&'HP8XZ*M]7(");@9+B_//,\CI?J> I2L%OI8Z&@I
MJ2$8B@B;$P>IHP/J6= 46T!YO4/^^:K]8*']+W2=4::K1:+&V(U^P/FFD;N$
M0/)H':[''CPP1[H'T>=*U?9[H^&\B.HM];4NFGD# U\;WGQGC' CO&/8M8PV
MFO*'/;J<=;<9?I5%XUP<T.:06D9!':O5DZ$4Z2_P&G([F/*M=93UQ/<QD@ZS
M_P!,O4A/,KXOEO9=;+<+=-YNKIY('>QS2T_6N-H:O?<]'V>KG\^^F8)L]DC1
MM>/G J81+N(B*51$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!%'[EI
M&U7&MEJZKP_KI,%W57"HB;P&.#6O '+L"B\^DK8W7E#;VR704<EMGG='\*5/
M%[98F@YZS/)SOE060BX%LTC:K;715=+X?UT>=O6W"HE;Q!'%KGD'GVA=] 1$
M0$11Z]:IIJ*L-NMT$MUO.,BBIL98#R=*\^+&WUN.3V H.]+(R*-\DKVLC8"Y
MSG' :!S)*A]5?*C5$4M#IBD946^4&.>Z5.6T^T\"(@/&E//B,-_G'DLL6F*J
M\R-J=95$=6T$.CM<&121'LW \9G>MWB]S0I:UK6-#6 -:!@ #  0\/SYJ32E
MSL4TOA$#Y*1I\6I8W+",X&3V'EP*GO1?I&JMM1)=+I&892S9#$[R@#S<>[NQ
M[5WND_\ @-<__#_YK5*5;DUMEF8TSP^0OM?$/D+[6:L"(B#A:O\ Q54?%;^L
ML.F/,M6;5_XJJ/BM_66'3'F6H)&B(@QU'FG+V#S+?8O*CS3E[!YEOL0?:(B#
MB:ITK:-40P17NF=4,@<71@2.9@GGY)"COWHM&_Y+?^DR_M*=3/ZN&1X:7%K2
M[:.9QV*D=.R=).M*%]XMU]HJ&CEE<V.%P V@'&  P\/:<K6G*8[3J&&7A$]Z
M[F5KZ7TQ:M+TTU/9:<P13/ZQX,CGY.,?E$KM*,:"MVH[=0U+-67."X5#I Z)
M\7)K<<O);VJ3JEO/G;6FN/:-*&Z1['IB'6%547?5M=#<JA^[J(83(86GR6Y'
M(8Y#N4RZ.M,6[3>J;E3T^H*FX7"*G#)J69I'5M<6N#O7R'+O58](^+'=-44E
MUM;W5=QKF55'<"T$=4';BP$\N'#AW<58/1O6SZJU_>-50T4U):W4C:.$RC!E
M((.>[AM[,XR%T6B>'GLXL<U]3QWW^?YK41$7*[Q$1 1$05=_<_\ XGU7_2*L
M^MJQ:;@95].^N&3QMDABHH&.:\9!$L4.01Z^J67^Y_\ Q/JO^D59];5\Z;O-
MEM_2QTA5%?=[=3&1U#"WKJEC,ED)W 9/83@]Q1*/ZTZ/=*Q5=?\ !K:Z"II9
MJ'KHFO!A#:BH$>!D%V=NXXSPRWV*Q8>CG3=+30QT%'+0SQ##*NDG?#/[WM(+
MO8[(]2@UTU)8ZFDU55_#5M,E1?J%L3?"F9,,,E,-P&>(R)#GEC)5E?=EIC^4
M=F_3HOVE:;VM&IEG7%2L[K"J>ES4.H='QP6>EU!-5LK(R_KI8&LJ(F@XP)&8
M!SQX[01CGQ5*Q7"LBJ_"HJNH959SUS9"'Y[]V<K]$=*NEH>D&U07'2U=1UU9
M0ET>(9VO;(TX)9N!P'#@1GO5"U6FKS254E-5VVI@EBZLR=:S:U@>\L8YSCP#
M2X$ DXX'N79@FL4>=U5<DY/R]GZ*Z$M7U>J-/5$=S?UE=0O;&Z7'&1K@=I/K
MX$>Y6*H1T2:,?H[3\D58]C[A5/$L^PY:W PUH/;CCQ[R5-UR9-<IX^'H88M%
M(Y>11.K_ +U=(]%4#A3WJD=22=W7PYDC]Y8Z;Y@75O='>JF:-UGN]-01AN'M
MFHNO+CW@[VX]BKKI-^';=:H)*C5-LEN5+,RLHZ<6PL<^1A[2)3AI!<"2.1(5
M&L1M,;)^[.D'4E7S;1P4UO9ZG8=,_P"B6/Y%*U471Q)>KE%<GTFJK=%7559+
M530/M9<[&[8UWG1P+&LX#..65+;E57G2]ENEYOMZHZZCHZ227J8Z#J"7@9;X
MW6.YGAC':A,:?.GZJG?>=5ZDKIHX:.&44$<TCL-9#3@[SD\AUKY0?BA?%%33
MZUJH;C=(9(-.Q.$E%0RM+75;AQ;-,T\F]K6'U.=QP!Q- 6"JO=CL[KW&^*RT
MC&RP4<@PZMG)W.J9AZ)>2YK#W[G<< 2NIUA34]1+"ZTZ@>8W%A=':IW-.#C(
M(;@CUA$)+@(HA5=(%MI&L=4VW4$39)&Q-+[3.-SW'#6CQ>9)  6;[MJ7_(^I
M/_**C]E!*5Y(TN8YH<YI((W-YCUA:=GN++I1^$14]93MW%NRKIW0OX=NUP!Q
MZUMR.V1N>0XAH)PT9)]@05<W3E59-9.M_P!TM\BH;PQU5#(UT )JF>=:[\%C
M+F;7# 'D/YKM7#1+KA3B"MU-?Y8A(R4-+X!XS'![3PB['-!]RYVN=0,NMDS;
MK1J%MTHY6U=$YUIG ZYG$-)V\G#+#ZG%;%#TEVBKIZ&1E#?-U8TF%K;;,[>0
M,N#2&X.,'..Y3"LNE]R]7_*O4/SJ?_V5OV>SSVZH?)->KI< YNT1U9B+6\>8
MV,:<^_M7.^[2E_R1J+_RB?\ 94@H*EM91Q5#(YHFR-W!DT9C>/:T\0?:I0S2
M2,B87R/:Q@YN<< +6^$J'^.TWYUOVK+5TM/6TTE/6015%/(,/BE8'M<.X@\"
MN/\ <=IG^3EF_08OV4'+%PH_OEN?X73[/@@#=U@QGKCPYJ3_  E0_P =IOSK
M?M7,^X[3/\G+-^@Q?LI]QVF?Y.6;]!B_90=T$$9!R%RKWIVTWUT+KO00U;H0
M0PR9\7//Z@NJUH8T-: UH&  , !<N]V2*[NA,M;<J;JP0!1UDD =GOVD9Y=J
M#E_>^TK_ )#I/D/VJ/:"T/IJJTVR6HL]-))X55-W$'DVHD:!S[  %(ON+IO\
ML:B_\VG_ &EKT&@*"AIA!3W;4+8PY[\"Z3-XN<7'@"!S)1.W9LFFK/8Y99;3
M;X:621NU[H\^,.Y==<*U::@MM8VICN-XG<T$;*FX2S,.>]KB0NZB$7UI^,](
M?[X']FJ%*%%]:?C/2'^^!_9JA2A 1$0% KM"^&XU#9 <EY<#W@G(4NO-1<*>
MF:^TT$-=.7X='+4=0 W!X[MKO5PQVJ.5L^HZQH%1I2WN(Y'X6P1[^J5+UY0Z
M^CZF.GO,S':7):"X@-!)/  *;6*CJZ*E='6UGA(+LQ@QAAB;@>)D>5@YX\\?
M*H'I6NU$ZXWP,TW0S.HZ[P=NZY;>J'4Q/V@]5XWED[N'E8[.,LHKCJ62KA95
MZ>HX*=S@))6W/>6-[2&]4,^S(44IQ\M>MZN,^JUCM"1(B+1YZ,VG_"%J/_8:
M']:I4F49M/\ A"U'_L-#^M4J3("(B HOJ3^&.D/]=4_\ARE"B^I/X8Z0_P!=
M4_\ (<A"4(B("+0O-L9=:5L$M36T[6O#]])4/A>>!&"YI!QQY>Q<;[BZ;_+&
MHO\ S:?]I!YI#^$.M/\ >D?]CIU*5$*?0-OIY:B6&YW]DE0\22N;=)@7N#0W
M)\;B<-:/8 MVCTG3TM5#.VZ7V1T3@\,EN<SV.QV.:78(]102)?,C&R,<R1K7
M,<"'-<,@CN(7TB"$4/7Z3JJJVT<D=1:0 ^DBD)WTA.<Q9[6<BWCD9QR 6;2=
MSCLM(*%S"ZG,TLV_/C R2.D=[1EY]W>M6\M>RZ5(DYEY(]AY+27/-YV^@P]%
MAG%&XW,QY6BUP<T.:06D9!':O5IV9CV6JE;)G<(QD'L6XMH>):.-I@7C_(=[
M%ZO'^0[V(J@UQ_A(?BM^I3*@\PWV*&W'^$A^*WZE,J#S#?8B"I\XSVK86O4^
M<9[5L(E&.D+3@U18A20U8I*V"9M3339\B1N<9[>T^SFJP@Z/-:W"IKZ:\7FB
MAH+C,R6NDB<"Z;;RP T?)P"\Z1>B^]5VJ:^]4<,5PI*E^\T\4_53#@!C+ACL
M]?L4<H[!HF&=M-J>/4UAJCV5(:Z,^QPCR?;C"ZJ1JO:?X<&6=V^JNOWUO^'Z
M5HZ>.EI(:> ;886-C8.YH& H9TNZ=L]YTQ/67F22!UOBD?#.PD]678YM_*!(
M;P^D*7VN.&*V4D=*\R4[(6-C>3G<T-&#\BY^L[,=0Z7N5J;((WU,1:QQY!P.
M6Y]60%SUG5MNR]>5)C2JZ#HCTO)IB"\2W"[2PFE%2]T6T;AMR2UI9NQSP.:L
M[0/P.-)6\:;+C:@TB(NSN/C'<3GMW9RJPBK>DZCL;=.LT_3O#(?!658P?$QM
M!SOVYQVD>Y67T=V"73.C[?:ZE[7U$37.D+3D;G.+B![,X]RUR;UWG;##$<OI
MKKLD:(BP=0B(@+3NU%)7T9@BKJJA<2#UU*6!XQV>,UPQ[EN+GZBND=EL5?<I
MF[F4L+I=OI$#@/><#WI$;1,ZC<J1Z/**6FI.D:H&IKG0R4M]KFLVR0#KWM&0
MYVZ,Y<3SQ@=P"V+K\(O%#7_=%>:BMHK-%61#=!^_:HB*%C?P7 '\(#G)P1Q'
M;5=10SW*NK*^J<R*:LGDJ9&L;PWO<7...SB5+.BMTE'K.T4-?*Y]NEJFRAH
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M\?<HK'*=//ZOJ/EL-LNMZAS-9:_LUQ%#34?A$C:>XTU2^;J\-+(Y6N=C)SG
M.."LJSW2CO%"RKMT[9X'<-P[#W$<P?4ORPK-Z"ZJ=MZN%*"33OI^L<.P.#@
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M B(@(B("(B B(@Q3\PL2RS\PL2M"D^1$1 7A(&,D<5\5$G5022;2[8TNP.W
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MK(ZJ9CF0QG<-PQN/9A85WM]#GMC]&=^-)=2T\-)314]+$R&")H9'&P8:UH&
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M&C.%"]'#4[]-VRTT[;=:F4-+%325$KC4RO+6AI<R,8:!PX$N/K"SL:UC&M8
MUK1@ <@%D97&V[JS9+((6E[HXF[GO &2&CM)[!WK&,D[>S?X92,<ZGNZ=/HR
MW/F947J2IO=6T[A)<']8QI[VQ "-ON;GUKL7.Y4%FHC47&J@HZ5G#=(X,'J
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MB+MQ9!&&-)[\ <^ 6629FWU/1Z+-BS88OB\.EUK._P"A.M9W_0M5>.<&C+B
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MWT])Z,M3Y,LOKV#,8]9D]2ECWL8,O<UH[R<+2M=!2V2S045(PLI:2(-:"<G
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M74K?C2M'_5!572A9**SU+[BVMIX6U+BXTSSXY=VE@',?4N;T=V>AU)7!SZ^
MQPG<^F!(E>!ZCV=Y5?:TO4U_U+75T[RYKI"V(9X-C!(:![OIRN?:+C46FY4]
M=12&.H@>'M(^H^H\EV1@^GSW<G_Z-XG41V_E^PP   !@!>/:UXP]H<.XC*BM
M/KZQ5$$;Z6>HK)7M!,=%2RU!:2.1+&D CUE9/NDN=3^+=*W1X].KDBIF_(7E
M_P#PKC=;=NMEH>I?44]!2MJV<1*V%H?CMP<9Y94?73W:QJN4=AMK3WNEJW#W
M8C'TKAWBT7.@K[.ZKOCY_#JYM-*R&DCB8&F.1Q+00XYRP<R5G>G+O#TNBZRN
M"LTO'9TJ&WNN+GQ=?44[ ,F:G?L>WV.[/LRM*Y.H[.XMEZ1:JD>.453-2R$^
MK#H]Q^5=@Z&L4KW/K:>:N<XY(JJB21A_\,G8/<%U[;9;7:VAMLMM'2 =D$#8
M_J"M2O&-.;JNH]?)RCP@'W0WD_B>\55W[O\ X<E+3_X@?&SZ53NNGW.75%=+
M?('05\A:]["T-P-HVX <X 8Q^4?:OU@HCK[1UFU)3-GNDO@<\+<-JVN#<#N=
MG@0M\-XI;N\[J:<Z=O9^7U^C>A^R4L6F**OJ;2V*YN;@54P:]\D9XM+'9):W
M:0,<.1X=\$Z,=$VJZ7^Z-NDKJB*@GVT\>0UM0T/> \CF1AK3P/Y7RVM)H>RL
M>9+;%46F4G.ZVU#Z<9];&G8?>TJ^;)%HU#+I,>MVVDR\<T.:6N&01@A1CX*U
M-0_B_4$-<P<H[G2 N_.1;/E+2GP[?:+\:Z:EE8.<UKJ&5#?;M?L?\@*YW:^Z
MVRS1N<Z##XN?$X("^M*T\5;14=UC?OIZB)L\' C+7#()SRX'DOANMK!*'03U
MPH*ES2!#<(W4KR<<@) ,^[*^^C8@]'NF<'/][:?_ );52*1$[=MNNS6IPF4C
M1$5W$XU\AU!)41FQUMLIX0WQVU=*^5Q=GF"U[<#&.Q1J2P:S?J."[&[6#K8J
M62E \!EQASV.Y=;_ #.>?=W3N>:."&2:9[611M+G.<<  <RJ[N'2C!'4N90V
M]\\(..L?)LW>P8*M%9MX<O4=;AZ6(]6VMI!3TVLA41&HNEA="'#>UE!*'%N>
M(!,IP<>I2=<'2FJ*+4<+S3AT51&,R0O/$#O![0N\HF-=I;8LM,U(OCG<2*-S
M:TM$,TD3V73<QQ:=MJJG#(..!$>#[0I(BAHKO1^JK?;Z&OCJX+M&^2XU<[!\
M%51RQ\[W-/"/M!!4NLNH*&\2R1T3:T.C;N=U]%- ,>HO: ?8%UD0%SKU>*2S
MQ1OKFU)9(2T=12RSGWAC3CWKHKQS@UI<X@- R2>Q!6]XU-:6W&U"BI[IU$U2
MYM5FUU0VQ]4\@M!CY[PP<,\">':.[3:PL5-'LABNK6_[IJN/_IJ%ZDZ2+I/7
M21V(PTM&PX;+)'O?)Z\'@!ZN?U+NZ UU476M;;;TR$5+P>IGB&UKR/R7-[#C
MM' ^KMOZ,Q&W)'QK#GOZ'J;G^%I6YXDHXWMSM<,C((/R'DME8:+][CVE9ED[
MH$1$'"U?^*JCXK?UEATQYEJS:O\ Q54?%;^LL.F/,M02-$1!CJ/-.7L'F6^Q
M>5'FG+V#S+?8@^T1$&C=;/;KNR-ETH*:L;&26">(/#2>[*YWW%Z9_D_:OT5G
MV+OHIBTQX5FL3YAI6JTV^TQ/CM=#34<;SN<V",,#CWG"VIXHYX9(9V-DBD:6
MO8X9#@>!!':%]HHVG41V5M7="^E*JJ=-&VMIFN.3%#,-GNW D?*ICI?35JTQ
M0FDLU*((W'<]Q)<YY[W$\2NPBM-[3&IE6N*E9W$"(BJN(B("(B#\4WM\\5UN
MU(Z9YI_A*IG$>?%#G/.3COP!\BZ%BIVLI>NP"]Y/'N&<+0O<-1)<;M6OA<*8
MW.IIFR=A>UY)'MPX+H:5%172B@I:>:>;BYC8F%QQV\EZ-=<(T^6^+4RWI:*^
M=_PZ;'.8X.82US3D$'!!5]Z&N3+MIJDJ:ML7A !CD) &XM.,^\85+4EAN51<
M*:B\#FAGJ'ED?7,,8) +CQ/< 3[E8#^BR"E#*FC;:Z^J+6]=!=*)DL4C@,':
M\#>SY7#U+FS3&F?^G<.:N2UIB8KK^7:U+5115LKY9&1PQ@-!)  &%Q*6[T%5
M+U<%5&YYY-S@GV9YJ$ZN>8KCX VU4]GCI0&FBIG QM<>)<"  <YSR'RY7#!(
M((."%E7IHM&YEZ_4?ZPOTV;T<6.)K7M._,Z\Z^W\OTC8'N?:X=W9EH]@*Z"C
M?1Y6OK])44LOG&AT;CZ1#B,J2*FN/:7JQGKU$>M3Q;O_ %%^2=>U-35ZRO4E
M:7&854C,._):UQ#0/4  OU56W.@H7M975U+3.<,M$TK6$CO&2JWUYI/2NJ*L
MUT&H*"@N#@ ][9XWLDQR+F[AQ]8*VP7BD]W/U6*V2OTJ :XM<'-)#@<@CF%^
MO=+U,]1I>UU-><5$E)')*7<.):"252FA-#:>JJ.BNEWU'1[BYLG@A?&T8:_B
MU^79(('<.:LW5=UI;U#2Z<LM=!-/='&.9U-*UQAIFC,KN!X9;A@];QW*V?)6
M^HA3I,-L>YLV-%--VJZ_4\P.*\B&A!_)I&$["/CDN?["WN4L6."*."&.&%C6
M11M#&,:,!H P %D7.[!$1 7Q*SK(GLR6[@1D ''RK[1!5++)<=)7*EM<FJKK
M3:?J?%HYQ'38@FR28G[HB UWY&, 8+<<L_-/7RRZEJ:)VO:\4+:>-T4_5THW
MRESP]N[J<8 ##_6YE;/3/<IF-H;;&2V&0&:3^=@X:/=Q/R*K%O3'N-R^;^(_
M'+=-GG%CK$Z\[7J-.70@$:QO1!_T5)_[*D%#!)34D4,U3+52,;ATTH:'//>0
MT ?( JUZ/=4UD-H?0,MMPND\3OP(@:-K6GL<]Q#6C/+)SW#@I1U&K+IY^JH;
M% ?R*9OA4^/CO 8T_P!1WM6<QJ=/9Z7J(ZG#7+';:2U-1#2P/FJIHX86#+GR
M.#6@>LE1MVM**J<6:?I:V^2<MU%'^!SZYG$1_(XGU+)3:+L[9VU%PCFNU6TY
M$URE-06GO:UWB-_JM"D;6AK0UH :.  [%#H1?J-673S]30V*G/Y%,WPJ?'QW
M@,:?ZKO:LM-HNT-F;47&.:[U33D37*0U!:>]K3XC?ZK0I(B#QK0UH:T -'
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M&/T1'I&R.%=-;+CX%#UTE#)- XR;!N+@SQ7'.>8*L3[@[</-U%[C^)>:H?\
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M9WJ7ZCZ,[Q3UTC[%'#5T;SED;Y0R2/U<>!'KSGZUW>C_ $!66RM;<KWU(J&
M]33QNW!A/#<YW:>X#A_TZIO&MOB\'P;JHSQ%HU$3Y6G1?O<>TK,L5(TMA /-
M95QON8$1$'"U?^*JCXK?UEATQYEJS:O_ !54?%;^LL.F/,M02-$1!CJ/-.7L
M'F6^Q>5'FG+V#S+?8@^T1$!$1 1$0$1$!$1 1$0$18:V%]1230Q5$M,^1I:V
M:(-+XSWC<",^T$(/SQH>VTUQI;R*R,R-@O\ 7R-8[R7;BP9([<;3\JG5%NMT
M<K;9LI'/!&8XVX![#C&"JZT9>8[)1WBFK343S"[56UQ: Y[=_EGD.)W<A[@I
MC9;Y2W><04^]M0[R8WCB[V*EJW\^ST.EZ_X?,QT\WKSGV_/[?].])IF]7&>V
MW"35+S+2ETL)\ C&"YA:<C/'@2LURH-1T-%+4_='4U.S'X*GM<3WNR<<!GCW
MK:^YJO/&/5-YIFGE#"RF+&>H;H2<>TE22%ACB8QSW2.:T O=C+O6<8&?8KPX
M;:BTZ\*5U9;J^[U%-4T]KO<M:Y@CJ))J$1!Y')V&D@<,#'J"X;]+WQ@!=:*\
MMW '9"7'VX7Z)1:5RS$:>)U'P/I^HRSEF9C?F(5=I;55?IZU> W;2=ZCHZ1I
M+:REIS()!G)+F'QFGCQQN'K5B6FZT%WI!4VNL@JZ<\-\+PX ]QQR/J*W5P+M
MI.V7"K-;&R6@N9_^=H7]3*?C$<'CU.!'J6;UZ4K2L5K&HAU*RVT-:]KJVBIJ
MAS1AIEB:\@>K(6O\ 6?_ "3;_P!&9]BXKJG4UA8YU9%#?Z!@R9H-M/5,:.TL
M)V/]H+?8H)J+I&N=95O%ID\#I <,\4%[AWDG./8%:M)MX<?6_$,715BV3W\1
M"U#8;, 2;5;@!S)IF?8H]H"W4E55W#4T-'3P,KB(:$1Q!FVE83M=P'-[BY_L
M+.Y0:CU?=KW2FPU]4P1W![*=]7C:^.-S@'@8X9+<@'L)SV*ZJ>&.G@CA@8V.
M&-H8QC1@-:!@ ):LUG4K]'UN+K*<\3(B(JNL1$0$1?+R6L<YK2X@9#1S/JXH
M(GTB:7=J&ABDI"UM;3YV!QP'M/-N?<,*I(M,7B6Z/M[:&3PMC&R/82!M:XD!
MQ.<8):[CZBKB?J"ZX_@A>/S])_[RXM/67N/5M==3I.Z=1/104S6B>EW!S'RN
M)/X;&,2#Z5K3)-8T\?K?@V'J\GJVF8GWU[NWHC3PT[:.HD>U]3*[?*YO+/8!
MZA]JD"CGW077^2-X_/TG_O+NT4TE12Q2S4\E+(\9=#(6ES#W$M)'R$JLSON]
M'#AKAI&.D=H9D1%#01$0$1$!$1 1$0$1$!$1!@KHIYJ26.DJ/!IW##)M@?L/
M?@\"HO<-,7FXTSJ>NU&V>%W-K[=$?>./ J7HB)B+1J8W"M+=T7ST54Z=M^:]
MP=NC#Z!C@P8'820>.>*DOP-J/^51_P#+XE)D4S,SY9XL./#&L=8C](T\8"&-
M#G;G <3C&5ZB*&HB(@(B("(B B(@(B("(B B(@+:H/..]BU5M4'G'>Q)3#>1
M$55A>/\ (=[%ZO'^0[V((-<?X2'XK?J4RH/,-]BAMQ_A(?BM^I3*@\PWV(@J
M?.,]JV%KU/G&>U;")$1$!$1 1$0$1$!$1 1$05'T-?C'I"_I/6?6%92K7H:_
M&/2%_2>L^L*RD!$1 1$0$1$!$1 1$0$1$!$1 1$0?#U\+[>OA6A2?(B(@^)I
M!%"^1V=K&EQQZE1-UU3=KA7/J#6SPC=ED<4A:U@[ ,?6KY(!!!X@JM;KT:.D
MKGOMU9''3/=G9(TY9Z@1S5JZ:XIK&]N_T<7RHO-GD\-=OJ*=^PR8\L8R"?6M
M+IN-6.BS4/@&_K>H&[9SZO>W?[MN[/JRI%IBQP6"V"D@<9'$[Y)",%[N_'8/
M4NJ]K7L<Q[0YKA@@C(([E$J6F.6X5E17#3EKZ-H:[2S;2^Z4MJ?+1M8(S-O$
M)+N'E$\"7#VY4,TM>*^WW7H_K*35-?>*G4!+;E13U E8S(!):W\C:2?F^T*X
M;3HO3=HN)K[99*"EJR".MBB (!X''=D=R^[1I#3UGN,E?:K-0TE8_(,L4(:X
M9YX[O<H1M^=+*VYV3HN9J>VWVYT\]/>#$RDCEVTY87^-N9CQB3VD\N"L'6=;
M4W;I)O=IN&I:ZP6ZVVQM52"EJ!!ULA&2]Q_* )(QZO:K-^Y2Q?!!M?P31_!Q
MEZXT_5C9OSG=CORO;_I:Q:@DADO=JHZZ2'@Q\T8<6CNSW>KDFC:D;5?-2:KF
MZ/*.:^5]M?=:.K9534YVND;&YV'@<@XAGE8X9)"ZO1]98Z3IEU13U6H;L^6W
M^""+KZP;JO,7*48\<#(P.S*N'X#M8K*&J%!3"HH6&*E>V, PL(P6M[ACAA8*
MC3%DJ+[%>IK72ONL>-M48QO&!@<?4."&U:]//6_=+H+P:6ABF\+GVOKAF!IV
MLXO'<N;T1/H8JOI!I;H^T/F=41==4,+?@Z0NW"-K6D #QLY&3GVA6_?M.6?4
M#86WNVTU<V$DQB=@=LSC./D"Q1:3L$5FFM,5FH&6V8YDIVP-#'D<B1CB> X^
MI#?92%!$R3I#OM'J"]T=KN,UMB++K8JAL$$$39&>([(X.<0WB2>&!VJVNDP
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M]/Z)U)H2KTK0.MM357V"FF?%42GK(CDEAW./ X";(A>2(BA(O'^0[V+U>/\
M(=[$$&N/\)#\5OU*94'F&^Q0VX_PD/Q6_4IE0>8;[$05/G&>U;"UZGSC/:MA
M$B(B B(@(B("(B#EZGOU!IJS3W.ZR.9318&&-+GO<3AK6M'-Q)  7%T]KJEN
MMYCM-;:[M9KA/$Z:GBN, C\(8WRMA:X@D9&6\PN7TM#?<M!Q2_O=^H8"_/(N
M#)"T?*G2G^#U%T?31?OD7QL;2.?5NBD#_=@!!82(H3J_5>H[/=S2V?157>J7
MJVN\*BJV1MW'.6X(SP_ZH(ST-?C'I"_I/6?6%92H#HSU3J:CJ]8OM^AZRX&I
MOM3/.UE6QG@TI(W1'(XD=X4W^[;6O^;*X_I\?V(+(15O]VVM?\V5Q_3X_L3[
MMM:_YLKC^GQ_8@LA%4TW2AJ2&^4]GEZ/:YMSGB=/%3FO9N<P'!=Y.%T?NVUK
M_FRN/Z?']B"R$5;_ ';:U_S97']/C^Q/NVUK_FRN/Z?']B"R$5;_ ';:U_S9
M7']/C^Q<ZFZ4-255YK+3!T>US[C1L8^> 5[,QM<,M)\7'%!;**M_NVUK_FRN
M/Z?']B?=MK7_ #97']/C^Q!9"*M_NVUK_FRN/Z?']B?=MK7_ #97']/C^Q!9
M"*IK1TH:DO#ZYEMZ/:ZH=13NI:@-KV?@Y6\VG+>871^[;6O^;*X_I\?V(+(1
M5O\ =MK7_-E<?T^/[$^[;6O^;*X_I\?V(+%>OA5T_6VM,$GHSN( &3^[X_L6
MA8>DO4U_M4%RL_1Y755#/NZN9E<P!VUQ:>;>\$>Y3$JS$K415U]V>M?\V=Q_
M3X_L3[L]:_YL[C^GQ_8IV:E8J*NONSUK_FSN/Z?']BY]ZZ3=2V2"":Z]'M=3
M13S,IXW/KF>-([R6\&\SA-FI6JBKK[L]:_YL[C^GQ_8GW9ZU_P V=Q_3X_L3
M9J5BHJZ^[/6O^;.X_I\?V)]V>M?\V=Q_3X_L39J5BHJIKNDW4E!=+?;JSH]K
MHJVX%XI8C7,S*6#+L>+V!='[L]:_YL[C^GQ_8FS4K%15U]V>M?\ -G<?T^/[
M$^[/6O\ FSN/Z?']B;-2L5%77W9ZU_S9W']/C^Q<X=)NI/AXV7[WM=\*"G\*
M\'\.9NZK=MW>3C&>";-2M9%77W9ZU_S9W']/C^Q/NSUK_FSN/Z?']B;-2L5%
M77W9ZU_S9W']/C^Q/NSUK_FSN/Z?']B;-2L5%5-OZ3M27"Y7&WT71[72UEO<
MQM5$VN9F(N!+0?%[0#R71^[/6O\ FSN/Z?']B;-2L5%77W9ZU_S9W']/C^Q/
MNSUK_FSN/Z?']B;-2L5%77W9ZU_S9W']/C^Q<^R])FI;W3S3VKH]KJF&*9U.
M]S*YGBR-X.;Q;V)LU*U45=?=GK7_ #9W']/C^Q/NSUK_ )L[C^GQ_8FS4K%1
M5U]V>M?\V=Q_3X_L7/OO29J:PVN:XWCH]KJ6BA+0^5]<PANYP:.3>TD!-FI6
MJBKD:TUJ0".C.XX/_P"?C^Q>_=GK7_-G<?T^/[$V:E8J*NONSUK_ )L[C^GQ
M_8GW9ZU_S9W']/C^Q-FI6*BJF[=)NI+1+0QW+H]KJ=]=.VFIPZN9^$D/)HPW
MFNC]V>M?\V=Q_3X_L39J5BHJZ^[/6O\ FSN/Z?']B?=GK7_-G<?T^/[$V:E8
MJWK?Y+_<JL^[/6O^;.X_I\?V+=TKTAW6HUG0:<ONDJFS35T4DL4DM4V3@QI)
MX >K'-1*8A:"(BA(B(@B&K_/4OQW+NV7S 7"U?YZE^.Y=VR^8"E#I+XF\T[V
M+[7Q-YIWL4)?-+YD+*L5+YD+*@(B("(B B(@*'WSI'T]9KG54-3+632T@!JW
MTM)).RE!XCK'-!#>'%3!5WT(QLGTC<JF9K7SUUVK9:DD>4[KG-X^X!!/J*J@
MKJ."JHYF34T[!)'(PY:]I&00>Y9E7W00XCH]AIP28:6LJZ>$G_NVSOV_)R]R
M[NMM:V;1E/2SWV6>..I>61F*%TF2!DYVC@@BL7^,A-_1D?VE6<OSK'TKZ6'3
M3+J U%7\&FQBC#O!7[NLZ[=C;C.,=JG/W]M$?QNO_09?L1*T457??VT1_&Z_
M]!E^Q/O[:(_C=?\ H,OV(A:**K7=.^AV@EU97 #F312_8O1T[Z'(!%77$'M\
M!E^Q!:**KOO[:(_C=?\ H,OV)]_;1'\;K_T&7[$%HHJN^_MHC^-U_P"@R_8O
M#T\:&#@#65P)Y T4G'Z$%I(JN^_MHC^-U_Z#+]B??VT1_&Z_]!E^Q!:**KOO
M[:(_C=?^@R_8GW]M$?QNO_09?L06BBJW[_&AM^WPVNW8SCP*3./D7OW]M$?Q
MNO\ T&7[$%HHJN^_MHC^-U_Z#+]B??VT1_&Z_P#09?L06BM4\RJX^_MHC^-U
M_P"@R_8M?[^FB'.<&UE:2.8%%)P^A3")A9Z*L?OY:*_C==^A2_8GW\M%?QNN
M_0I?L4JZE9R*L?OY:*_C==^A2_8GW\M%?QNN_0I?L0U*SD57MZ=-$/&6UE:X
M#APHI#_T7U]_+17\;KOT*7[$-2LY%6/W\M%?QNN_0I?L3[^6BOXW7?H4OV(:
ME9R*L#TY:) R:NN _P!BD^Q&].>B7 %M96D'D112?8AJ5GHJQ^_EHK^-UWZ%
M+]B??RT5_&Z[]"E^Q#4K.15C]_+17\;KOT*7[%\NZ<]$-:2ZLK0!VFBD^Q#4
MK015A]_+11Y5==^A2?8O?OY:*_C==^A2_8AJ5G(JQ^_EHK^-UWZ%+]B??RT5
M_&Z[]"E^Q#4K.15>[ITT0W&ZLK1DX&:*3G\B^OOY:*_C==^A2_8AJ5G(JQ^_
MEHK^-UWZ%+]B??RT5_&Z[]"E^Q#4K.15C]_+17\;KOT*7[%\GITT0'!IK*T.
M/(>!2<?H0U*T$58_?RT5_&Z[]"E^Q/OY:*_C==^A2_8AJ5G(JQ^_EHK^-UWZ
M%+]B??RT5_&Z[]"E^Q#4K.15?]_31&[;X96[L9QX%)GZE]??RT5_&Z[]"E^Q
M#4K.15C]_+17\;KOT*7[$^_EHK^-UWZ%+]B&I6<BK'[^6BOXW7?H4OV+Y'3I
MHAQ(%96DCF!12</H0U*T$58_?RT5_&Z[]"E^Q/OY:*_C==^A2_8AJ5G(JQ^_
MEHK^-UWZ%+]B??RT5_&Z[]"E^Q#4K5A\A?:X^D=0VW4]CANEFJ.OI)20'8((
M(.""#Q!]2["JO B(@X6K_P 55'Q6_K+#ICS+5FU?^*JCXK?UEATQYEJ"1HB(
M,=1YIR]@\RWV+RH\TY>P>9;[$'VB(@(B("(B B(@(B("(B B(@J[^Y__ !/J
MO^D59];5:*BG1WI-^DJ*[P25;:HUURFKP6LV;!)CQ>9SC'-2M 1$05?TQ?PJ
MZ-O]^-^I6@N#J32U%J"OLE96R5#);15"L@$3@ YX['9!R/9CVKO("(B JQZ/
M/\,?2G\:V_\ (>K.7"LVF**TZEO]\II*AU7>C :ALC@6-ZIA:W8  1P/')/N
M0=U$1 1$05CT!_BC5G])*WZV*SEPM(Z7HM+4UPAM\E1(RMK9:^0SN!(DDQN
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M1/Z4UGUA6BJNZ#OW[TB?TIK/K"M% 1$05??/\8C37^Y:C]<JT%6EZIIW=/\
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M-^+6NHGRR.<1-+4<VO;D9'$@@#V7%?+K5Z<TO9+':IFU^HZR&.BHWNXASFL
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M;C&\@#:[&<<P<<%.4!$1 11G4UXU);ZYD5BTL+O3&,.=.;C'3[79.6[7 D\
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MZW-E+5:2O5LB<"34U1BZMN!G!VO)X^Q!*T1$'S-%'-$^*9C9(GM+7,<,AP/
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M>"TORUQ<X '. WBK*1!6EPTG<].#2%RT[3BZU-AHS;JBF=((GU,#FM!<QSN
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M3-1S@NC>6.9D D<G $<0>86EJ[3U/J>T"WU<LL40GBGW18SF-X>!Q!X$A=I
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MVK@J))KI+U43HP-K3N:WQLD>D.653A9IZE?.TD1074W27;+)?S9XZ*ON-9&
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M(5I^&K)0-CJ71W>-LE+5;1U9W9 :>.0<C&,<R%'IV^R_JT^Z8HHM7:WMU)K
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M)=>>B2CKZ>H'W035/@1>&-)W@[B[;C'%NWLYN5N6&*LALU$RZ3]?7B)O7R8
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MLUP/45\#8V[0]KRUS@2,C(R0,_DK3LO1]J^WV*[:>CI[,REJW.<ZX.)=*X8
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MS'1BG-+3!XPZ5A<'.D([ <# [LGM7S [X=O])74XQ;K<9!'-_P!_(YI8=O\
M, SQ[3RY()(M6HN%+3UM+23SL94U.[J8SS?M&3A;2K>]U%1<+A=;A26ZMJ)*
M-[(Z&>)K3&TQ.W/SEP/%V6G / ()]75T-$ZE;.7 U,P@CP,^,02,_-*6NNAN
M=!#64I<89F[FEPP<>Q<*^U<5?!IBKISF*>X0R-/J,;RL_1__  .M7^J_ZE!(
M%\F1@E;&7M$C@7!N>) QDX]X^50@&JK-/W.^NN=7!60/J'11MDQ%$(G. 86<
MCG:,YX\5G$'PCK&W5$LM5"Z6UF8LCF<T-.]G#@>7>.U!*:&NAK34B N)IYC
M_(QXP )^L+94%IK?)/#JBJ;7UM.Z&LF=$V"4L:UP8TY('E=G Y'!?59<:^X5
M%DI6LK)&3V\5DS:.9L+Y'':/*+A@#). >T()PB@KS>FP6BCJZBJHWS7&2$/,
MC'RN@ZMY&XM)!=V9[P"I)<K?4,TY44EMJJD53(R897RESR\'< 7'B03P]B#K
M(HK;;R;S=:.>"5T5#347A-2 < R/X!COBAKS\BYK:Z;PZT5U%\+MI:RK:SK*
MN=ICEC>'' CW9'($' Y()G05T-<V=U.7$0S/@=D8\9IP5LJ#15$U-1/,$KXR
M_49C<6G&6F;!!]176N5PGIM4/9&]SXX[5+4=3G@YP>W!QW\P@D:*!V WN<6B
MOCCN+W3N8^JDFJHW0/C<.);&'>+C((P >'%;5K\(H+O R_2W(54TSFQ3MG+J
M6?.2UNP<&''80.7,H)DBY]_K(:&U32U#YV-=B-I@\X7..UH;Z\D**055;1W"
MZ4V;C!$;6^I8RLJ!,]KP<!S2'.QSY9[$$[10&H=7T>G[/.RMKZFLNKX(YBV8
M#:US"XB,.(:TG&W//CWKN:8BN<%=6,JH:R.WEC'0BKJ&32-?QW .#B<8VGB>
M]!(D4;U.Z>2^6&BBK)Z6&I?,V7J7;2\-9N SV<N?/N7#N,]?1W*HM%'<JKJQ
M54?5S2/WR1"4O#FDGRO)!&<\T%@(HCJ+PFVQ6FVT,MPG%74.$CQ4#KG -+MH
M>\C&2.\< <+)9ZB[6UM;X5;;G44ID9X-&Z:*:9H+3NRXOXM! QDY\9!*EK6^
MNAKXY7TY<6Q2OA=D8\9IP?I"C[C->M1RTLT];14]/1Q3-@CEZIY?(79+BT\=
MNT#&2,]ZY%!/4TVGV4T-6]KZJ]24LE4W&\-,CLN'8"<8SZT%@(HQ RIMVHC;
M*6LJ)H:FBDF;X3(93#(UP =D\<'=R]2YE'5U%F@G^$OA,7B.CEE:)J@RT]2Y
MC<DLXX'+EAN 4$Z7S)(R/;UCVMW$-;N.,D\@/6H381>G36FK9%<GMFPZKDJ:
MJ-\3V.;G<U@<=N#@C '#FNCK:F%1-8099XP;@QAZJ0LX%CSGAV\.:"3HHI44
ML]5JLVWX1K8J&&@BD+8IBU[W;WC)?SY#CWX"R=3+>-17:FFK:RG@H1$R)E-,
M8\ES-Q>2.)YX&>' \$$G10O2-UK:Z[TK*NH=(T4,P/8V1S*C8),<LD#Z5BK+
MC6_ ]^ECJIMD%UZI[F.\=D.6!S8\]O$X [3PXH)C<*N*@H:BKJ"1# PR/(&3
M@#)6:-XDC:]ODN (]Z@%933?!6J:AK[I\'> EE.VMEDSNVNWD-><X\GB?7A=
M)L%1:JO3TC+A63&KD$%0R64NC<#$YV0WDW!:,8P@EZ*&M-107LOODMR#9JO%
M-40SDTY:YWB1N8/)[!Q!R>U3) 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$&O744%="
MV*J9O8V1DH&2/&:X.:>'K 6PB(.<;)0&S_!9@S0X(ZLN/#CNR#G(.>.<KH,:
M&,:T$D 8R3D_*B(/5&-64L5;>].05#2Z-T\N=KBT@B)Q!!'$$$ Y"(@Z=-8:
M"GHZRF;$][*P%M0^25SWR C'%Q.>7KX+8J;;25,5-'/$'LIG!T;23@$-+??P
M)YHB#1I-,6NFDIWQQ3.-.X.@$D[WB+'8T$X ]2Z4-%!#6U-7&S$]0&-D=D^,
M&YV\.0YE$0:WP+0_!9MW4GP0OZS9O=Y6_?G.<^5Q6RZC@=7QUKF9J8XW1-=D
M\&N()&.7-H1$'+^Y6T[CF"4Q]9UK8C.\QL?NW;FMS@'/<._O6>ML%!5UCJI[
M9XYW@"1T$[XNL Y;@TC/O1$'S7:<MM;4RS312@S8ZYD<SV,FQP&]H(#O>MYU
M#3NJZ>IZL"6G8Z.(@D!K78R,<OR0B(-6*Q6^*.&.. MCAJ#4QM#W88\@@D#/
M >,>'+CR7V+/0BTQ6T0GP.+9L9O/#:X.''.>8"(@^+C8Z*OJA4RB:*IV[#+3
MSOB<YO<2TC(]J5-BH:CP,N;,Q](W9%)'.]CPWAD%P.2#@<T1!D=9Z%]/6P24
M[7PUKS).UQ)#W$ 9]7DCEW+69IVB;3NB$M?ASFN#S6RES2 0,.W9 XG@B(,=
M7IRF?9JFWTSGQ,J9&OGD>YTCY '-W9<3DDM&/4NVYC7,+"/%(QCU(B##04D-
M!104E*S9!"P1L;DG#1P R5SJW3=NK*V:JF94":8-$G5U,D;7@# R&N /!$0=
M&AHZ>@I64U%"R&!@PUC!@!9T1!X[R3[%#-$6"WSZ=M-5+'(YP:)>K,S^JW@G
M#MF=N?7A$02R&B@AK:FKC9B>H#&R.R?&#<[>'(<RM&73UNDI(*8121L@D=+$
MZ.5S'L<XDN(<#GCN*(@1Z=MD=-/ VG/5SR,EDS(XE[V$$.))SG('M[5O2T<$
MM;!5O9F>!KFQNR> =C/#EV!$08FVND;%71"([*USG3C<?'+FAI]G #DL-;8Z
M&K92-D;*QU*W9#)#,^-[6X (W-(." $1!\MT]:VV^>B;2@4TTG6O;N=G?@>,
M#G(/BCB#SXKS[GZ T3Z645$S'/$FZ6HD>]KAR+7$Y:1ZB$1!GMUGH[>R<01N
M>Z?SLDSW2/DP, %SB21CL6G3Z6M4$D#F0S.$#Q) Q\\CFPD'(V-)P/<B(./9
M*J#4VK9+BR#JX[0U],W?Y;Y''!/#AM !Q\8J3Q6VEBAK(F1X95O=),-Q\9SA
M@GU<!V(B#5J-/6^84OB31.IHA!&Z&=\;NKX>*2T@D<!S62FL5NIHZ>.GIQ&R
MGG=41-#CAKR"">?<X\.7%$0;4-%!#6U-7&S$]0&B1V3XP;G'#D.96NRS4+*.
MBI6PD04;VR0-WGQ7-S@YSQYGFB(,5+8*"DK?":9L\1W%_5-G>(MQSD]7G;VG
ML7C=/4 JVU#A4R%DG7,CDJ9'QM?G.X,)QSY<."(@S6"V_!5LCIC)ULFYTDDF
M,;WN<7$X]I6Q3T4%/5551"S;+4N:Z5V2=Q #1[. [$1!BNMKH[K#%%<(1-''
M*V9H)(PYO(\/:LLM%!+6T]7(S-1 US8W9/ .QGAR[ B(-9UDH'6J2W.@S2/<
M7EF]V=Q=OR#G(.[CZEY;['0T%6:J%DKJHL,9FEE?(]S20<$N)[A[/>41!TD1
M$'$J-*VFH?4==!*Z.H<7R0]>\1EQYNV9P#Z\<^*SW&Q4-?5"IE;-'4;=AD@G
M?$YS>YQ:1D>U$09*ZS4=;)322ME;+3 MCDBF=&X XR"6D$@X' KYJ;';ZFDK
M::>#=#62=;.W>[QG<..<\/)'+N1$'W6VBCK*"&CFB(AA+3%U;RQT9;P:6D'(
M(6&FT_;:=E6UL!?X7&(JATDCGNE:-WE$G)/C'C]@1$'AT]0.MS**1L\D+'B2
M-TD[W/C<!@%KR=S<#N*^A8:$V^:BF;-40S$.?U\[Y'$CD0XG(Q@8PB(%OL-#
M0U@JX63/JPPQ==-,^1Q:2#@EQ/#@/9Q[RMRKHH*N2F?4,W.II>NB.2-KL$9X
M<^#BB(/BZ6ZFN=,(:QCG-:\2,+7ECF.')P<#D%:U)8+=3"JV0%YJHQ%.Z5[I
M#*T9\HN)SY1__@(B#'!IRW14U13%M1+3S1]4Z.:HDD:&=S0XG'N7W)8*&6BB
MII?")!"_?'*ZH>96.[P_.X?*B(/J*Q6^.VU5"(7.@J@>O+I'.?)D8)<XG)./
M6NDQH8T-;R P$1!IW6UT=UBBBKX1,R*5LS 21AS>1X+++102UM/5R,S44[7L
MC=D\ [&[AR/DA$0:T=EH8X:6*.)S8Z6=U1$!([@\EQ)/'CQ<[@>"V;A107"E
M=35;-\+BUQ;DCBUP<.(]8"(@V%QAIJUBJ$W4R8$G7"'KG]4'YSNZO.W.>/+F
MB(,EPL%%7SR25)J2)0!)&VID;&\ 8XL!P>'JXK*;/1_"3*]C)(ZAK0P]7*YC
M7M&=H<T'#L9.,A$09+I;:6YT[8:R,N:QXD8YKBQS'#DYK@00>/8L-OL=!02S
MRP1.,L[!',^61TCI ,XW%Q.>9]W#L1$&*ATY;:*IBFABE)ASU+))GO9#GAXC
M22&^Y>RZ>H):LSRBHDS)UW5/J)#%OSG.S.WGQY81$'E3IVWSU<E3MJ(I)3NE
M$%1)$V0][FM(!*QZX_@?>?\ 9)/U2B(/JU:?M]+)3U44<AEC9B(23/>V+(X[
M&DD-]R^JG3MOGJY*G;4122G=*(*B2)LA[W-:0"41 J].6VKJIYYHI"9\==&V
M9[8Y2!@%S <'AWA;4%KHX98Y(X?&CIQ2MRXD=6/R<'FB(,ENH8+=1LI:-I9!
M'G8TN+MHSG SV>I<VJTK::EU3UT$ICJ"72PB=[8W./-VP'&>W..?'FB(.DVA
MIVUXK S]T"'J-VX^1G.,<N:TZVP6^LK7U4T<O62-#90R9[&R@<@]H.'>]$0?
M3[#;7TUOIWTP,5 ]LE,W<?$+>7;Q]ZS,M=&R[ON;80*Y\74NDR>+,YQCEV#B
MB(/66RE935<#8R(JMSWS#<?&+_*]F?4LIHZ<T'@3HFNI>KZHQNX@LQC!]R(@
MYM)IJVTM13SLCF?+3G,+I9WR=6,$8;N)P,'E[.X+XETK:972]9!*Z.5YD,/7
MOZL/)R7!F< YXY 1$')HJF#4NLS(V'8RQ.EA)?Y4DI.W(Q^2 TGOR0IDB(->
M:C@FJZ:ID9F:GW=6[)&W<,'AV\%K7*S4EPGCGF$K*AC2QLL$SHG[3QVY:1D>
MHHB#7BT_305EMDIL14]%UKVQ<27R/ &\N)R3C=SX\5T+C0T]QI'TU9$)(7XR
MW)'$'(((X@@]H1$&G16"WTE2:AD<LE0Z,PNEGF?*YS"02TEQ/#@/I[RL$.F;
M51]5*V&9_@IZR$23O>(L=C 3@#U(B#EZ-G@U#=JS4L</5,=&VCA:[R\-.7.=
MV9)('#L"DMVMM-=J"2CKF.DIY,;FAY;G!R.((/,(B#0CTS;V,E9FM>R6-T3F
MOK9G M(P>!<O:#35OH)87TQK6]3C8PUDSF#'(;2[&/5A$0="EH8*:>JFA#A)
M4O#Y"7DY( '#/+@.Q>V^B@M]''2TC-D$8(:W)/,Y/$\3Q)1$&M%9:"*FI*>.
M$B&DFZ^%N]WB/\;U\O&/#DMFW44%NHHJ2D9L@B&UC<DX'M/%$0<^ITU;*FID
MFEADQ*_K)8FS/;%([O<P':3P[1Q[5LW"T4E=4T]1,)6SP ADD4KHW8.,M):1
MD<!P*(@R16ZEBBK(F1X95O=),-Q\9S@ 3ZN [%KU5BH*FEI('Q/:*1H; ^.5
MS'Q@#& X'/(#MXHB#ZALU'$VE&V5YII3-&Z29[W!Y!:2222>!/-=%$0:-MM%
M#;6U3:.G;&VID=+*,D[G'GS[/5R6G2Z7M=,^!T<,KO!W!\#9)WO;"1Z )P![
M$1!LS62@FHJBDD@S!/*9WC>[/6%V[<#G(.>/!?-OL5#059JX62NJC&8G333/
MD>YI(."7$]H'L]Y1$&.CT[;Z.I9+3-J(VL<7MA;42=4T]X9G;[L87M-IZ@@J
MHIP*F1T3BZ)LU1)(R,\LM:XD \3[$1!NW*AI[E1OI:R/K(7X)&2""#D$$<00
M1G(6E3Z>MT#YGB.626:%T$DLLSWO>PXR"2<]GN[$1!LSVJBJ+8RWS0!](QK6
MM82<MV^20>8(P..<KRV6N"W=88'U,CI,;G3SOE.!G &XG',\D1!Q=4TD-=J+
M3L%0'&-SISXKBUP(CR"".(.>T+ITVGK=!&&MA>YW7MJ3))*Y[W2-\ESG$Y..
MX\$1!M7.W4MSIA!6Q[V!P>TAQ:YKAR<UPX@^L+RV6Z&W,>V!]0\O.7.GF?*X
M^]Q*(@Q7*RT=PJ(ZB=LK*AC2P2PS/B<6YSM):1D>I?++#;66N2W-I6BC>\O,
M>3P<3G(.<@YX\.2(@]H+'1477NB;*^6=O5R2S3/D>6^CN<20./(+XHK!0TE2
M)VBHFE:TL8:BH?+L:>8;N)QE$0>4&GJ"@J&2THJ&-C)+(O")#$S/<S.T<^Y;
M=TMU-<Z805;'.:UXD:6/+',<.3@X'(*(@\IK;34U2*B-KS.(6T_6/D<XEC22
M <GB<D\>:P7*Q4-PJ/")VS,GV=6Y\,SXB]OHNVD9''M1$'Q4:>MLT=*UL+X/
M!6&.%U/*Z)S&GFW+2#@X7!U?;J*S:<<*> MMAJFS5L+7G=*W&.!/(Y##S'(\
M>*(@TM'"BU!45SZ!E5%97TQIYJ:HJ'O,CW'RADG;@ C(/:IO/04TQI#)'DTK
M^LA\8C:[:6Y]? GFB(-,:>H/#&U#Q4R%LG7-CDJ)'1M?G.X,)QSY<."W:"A@
MH(Y&4S7!LDCI7;G%WC..3S^I$0;*(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
C B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g50309g77z52.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g77z52.jpg
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M!6 # 2(  A$! Q$!_\0 '  !  (" P$               0&!0<" P@!_\0
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MQ9&U@^*/M7)$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!",\41!T2T[3O9N/]%#<'QNW
M;B/ LFNN:(2-_P#$.""-350>-_%3&G*P=9F!W/-&[.'C_JI]%4B1O$()R(-Z
M("C5;N#!Z5)40_'JL>=!)B9L1@=JY(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@A5\+7 @CXKQ@K!VNH=',^)Y.TQQ:>TJR50S"?-O50KG<Q>WXW![6N_H
M1_T2!<('[3 NQ0+=)M,"GA /!1(_UH^DJ6>"B1?K1])02T1$!$1!H_6>M=06
M_5%RI*.XNCIXI2UC.;8<#[0L-^D'4_UJ[V4?X5&Y0_[ZWC^.?N5=7933%H]'
MSO,YS,4XU<1B5>\_>=5K_2#J?ZU=[*/\*?I!U/\ 6KO91_A5417IIT:/'9G<
MJYE:_P!(.I_K5WLH_P *?I!U/]:N]E'^%51$Z:=#QV9W*N96O](.I_K5WLH_
MPI^D'4_UJ[V4?X55$3IIT/'9G<JYE:_T@ZG^M7>RC_"GZ0=3_6KO91_A541.
MFG0\=F=RKF5K_2#J?ZU=[*/\*?I!U/\ 6KO91_A541.FG0\=F=RKF5K_ $@Z
MG^M7>RC_  I^D'4_UJ[V4?X55$3IIT/'9G<JYE:_T@ZG^M7>RC_"GZ0=3_6K
MO91_A541.FG0\=F=RKF5K_2#J?ZU=[*/\*?I!U/]:N]E'^%51$Z:=#QV9W*N
M96O](.I_K5WLH_PI^D'4_P!:N]E'^%51$Z:=#QV9W*N96O\ 2#J?ZU=[*/\
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M1G^I5;U13-AU-=X*6(-BBJI6-8QNYH#B  ML:2TZ=.\H]PCB:115%(Z6G/@
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MZFJ<U,9?PT1Z15>_]K/0^D]7VR[6:EJZZLHZ>N8TQRMEE:QP=NR1D\#@'_\
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M<E5-(&4\<9E>\\ T#)/8@[D5+T[RGZ0U%=H;99[N)ZZ;/-QF"1FU@$G>YH'
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MN]:[J+U1M8YII'T#(@XD;CM!QX>A7Q$!:=D!T/R]/JY_[.RZMA;$).#65;,
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M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$7QSVLQMN:W)P,G&2OJ
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M*#+.^$5I85G-BWW<T^<<_P VSMQMY5MUM>[?J'D>U!<[/4LJ:.>W3%CV[O\
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MX!_6WS(*E\':RSVCDSI)JUI;5W.9]PD!&_X^ WM:UI^U;+7QC6L8UK&AK6C
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MN<_SK_2N" B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MN_JK:TAS0YI!:1D$>%>-]>U?)I4:;=%H^U7:GND;V[%3+M&-[<_&#LO/@X8
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MFU5,9TBFZ^=9O 'I&6_\2N2TMROZAY01=J[3^EK#+-;JF%K&UT5,]SAM-^.
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M#L< 1L[_ $KTJB+=Y7Y0]:ZEY3])NBM^F*BDME YM353!QDYQP^* T[(\8G
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M[WWEM[Y9;/5TU'425$\C^:<8XR]CL#;( XD!>IT17F;E&H:N3X25IJ(Z6=\
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M"(TMPA>PEM7#NQPX.&!O\PZM]U0:CM7+-IFGBI:"@T_J&F@9LPQ1MMP:Q@X
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M"PV3YMJSK>"P5D^;:LZW@A >"B1?K1])4L\%$B_6CZ2@EHB("(B"!/\ .O\
M2N"ZZJ685$@;3[3<[CM@975SU1Y*?:!!)11N>J/)3[0)SU1Y*?:!!)11N>J/
M)3[0)SU1Y*?:!!)11N>J/)3[0)SU1Y*?:!!)11N>J/)3[0)SU1Y*?:!!)11N
M>J/)3[0)SU1Y*?:!!)11N>J/)3[0)SU1Y*?:!!)11N>J/)3[0)SU1Y*?:!!)
M11N>J/)3[0)SU1Y*?:!!)11N>J/)3[0)SU1Y*?:!!)11N>J/)3[0)SU1Y*?:
M!!)11N>J/)3[0)SU1Y*?:!!)11N>J/)3[0)SU1Y*?:!!)11N>J/)3[0)SU1Y
M*?:!!)11N>J/)3[0)SU1Y*?:!!)11N>J/)3[0)SU1Y*?:!!)11N>J/)3[0)S
MU1Y*?:!!)11N>J/)3[0)SU1Y*?:!!)11N>J/)3[0)SU1Y*?:!!)11N>J/)3[
M0)SU1Y*?:!!)11N>J/)3[0)SU1Y*?:!!)11N>J/)3[0)SU1Y*?:!!)11N>J/
M)3[0)SU1Y*?:!!)11N>J/)3[0)SU1Y*?:!!)11N>J/)3[0)SU1Y*?:!!)11N
M>J/)3[0)SU1Y*?:!!)11N>J/)3[0)SU1Y*?:!!)11N>J/)3[0)SU1Y*?:!!)
M11N>J/)3[0)SU1Y*?:!!)11N>J/)3[0)SU1Y*?:!!)11N>J/)3[0)SU1Y*?:
M!!)11N>J/)3[0)SU1Y*?:!!)11N>J/)3[0)SU1Y*?:!!)11N>J/)3[0)SU1Y
M*?:!!)11N>J/)3[0)SU1Y*?:!!)11N>J/)3[0)SU1Y*?:!!)11N>J/)3[0)S
MU1Y*?:!!)11N>J/)3[0)SU1Y*?:!!)11N>J/)3[0)SU1Y*?:!!)11N>J/)3[
M0)SU1Y*?:!!)11N>J/)3[0)SU1Y*?:!!)11N>J/)3[0)SU1Y*?:!!)11N>J/
M)3[0)SU1Y*?:!!)11N>J/)3[0)SU1Y*?:!!)7UGRF^E1>>J/)3[0+ZV:HVA_
MV4\?I @S2*'TBK\A/M6ITBK\A/M6H)B*'TBK\A/M6ITBK\A/M6H)B*'TBK\A
M/M6ITBK\A/M6H)B*'TBK\A/M6ITBK\A/M6H)B*'TBK\A/M6ITBK\A/M6H)B*
M'TBK\A/M6ITBK\A/M6H)B*'TBK\A/M6ITBK\A/M6H)B*'TBK\A/M6ITBK\A/
MM6H)B*'TBK\A/M6ITBK\A/M6H)B*'TBK\A/M6ITBK\A/M6H)B*'TBK\A/M6I
MTBK\A/M6H)B*'TBK\A/M6ITBK\A/M6H)B*'TBK\A/M6ITBK\A/M6H)B*'TBK
M\A/M6ITBK\A/M6H)B*'TBK\A/M6ITBK\A/M6H)B*'TBK\A/M6ITBK\A/M6H)
MB*'TBK\A/M6ITBK\A/M6H)B*'TBK\A/M6ITBK\A/M6H)B*'TBK\A/M6ITBK\
MA/M6H)B*'TBK\A/M6ITBK\A/M6H)B*'TBK\A/M6ITBK\A/M6H)B*'TBK\A/M
M6ITBK\A/M6H)B*'TBK\A/M6ITBK\A/M6H)B*'TBK\A/M6ITBK\A/M6H)B*'T
MBK\A/M6ITBK\A/M6H)B*'TBK\A/M6ITBK\A/M6H)B*'TBK\A/M6ITBK\A/M6
MH)B*'TBK\A/M6ITBK\A/M6H)B*'TBK\A/M6ITBK\A/M6H)B*'TBK\A/M6ITB
MK\A/M6H)B*'TBK\A/M6ITBK\A/M6H)B*'TBK\A/M6ITBK\A/M6H)B*'TBK\A
M/M6ITBK\A/M6H)B*'TBK\A/M6ITBK\A/M6H)B*'TBK\A/M6KZ*BJ)&:(@=?.
MM02T1$'"?YEWH5$U+^W(?X(^]RO<_P R[T*B:E_;D/\ !'WN2!8;)\VU9UO!
M8*R?-M6=;P0@/!1(OUH^DJ6>"B1?K1])02T1$!$1! G^=?Z5P7.?YU_I7! 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0%]9\IOI7Q?6?*;Z4&11$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MKY"3)/7QBHE>3Q)<X''V85.Y&*9EFY4.4"PV4N[WJ62*2.+:+F0RN'QFM_\
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M8_3MUAOEAMUUIMT-;3LG:.H.:#C[,X600$1$!$1 1$0$1$!$1 1$0$1$!$1
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MSS.GV9)'1/A>_.T 0T@M.3NW;CC>L?J'D&U/>8(:^OU%35U^D>>DOJ7OYL,
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MK=IO5-&RV;1+ 9'-V<\3LECMGKW%!:/@\Z*O^C*2]PZAA9"VIDB?"UDS9 2
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M4-+%0T5/24S=F""-L4;>IK1@#L"[T01$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M>9D;C8.';RT#<?.NO67*%IK1\L<-]N+8JF0;38(V.D?CK(:#@>G""PUURH:
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M8C4O!W$<XXO /GV2 B+ZB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B#A/\R[T*B:E_;D/\$?>Y7N?YEWH5$U+^W(?X(^]R0+#9/FVK.MX
M+!63YMJSK>"$!X*)%^M'TE2SP42+]:/I*"6B(@(B(($_SK_2N"YS_.O]*X("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(*CRJ:3DUGHNML]/4-IZAY
M;)$]^=G;:<@.QX#P\W%:MTRSEBTG98+%0:?M572TP+(9Y)&$AI)/$2-Z_",K
MT B#3/)QR;7]NN9=::[JJ=]U()BIX""&N+=C+B!@8;N &>O/7N9$0$1$!$1
M1$0$1$!$1 1$0%KSE=DUXR&VCD]C:\OYUM63S66_)V".</\ O</M6PT0:=Y$
M>2^NTQ<*S4&J)62WRJ#FM8'[?-!QR]SG>%Y/5X,[SE;B1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!?6?
M*;Z5\7UGRF^E!D41$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$%4O.BX*W6UJU11U<E#<J-AAFV&!S:J$_X'CS;\'P?8%:T1 1$0$1$
M!$1!5-=:,AUD^U07*LE;:Z2H%3-1L:,53A\D/=XHW[O#GT*U@!H    W !$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0<)_F7>A434
MO[<A_@C[W*]S_,N]"HFI?VY#_!'WN2!8;)\VU9UO!8*R?-M6=;P0@/!1(OUH
M^DJ6>"B1?K1])02T1$!$1!B:H5/2)-@P[.=V0<KJQ5^-!V%3)_G7^E<$$;%7
MXT'84Q5^-!V%2401L5?C0=A3%7XT'85)1!&Q5^-!V%,5?C0=A4E$$;%7XT'8
M4Q5^-!V%2401L5?C0=A3%7XT'85)1!&Q5^-!V%,5?C0=A4E$$;%7XT'84Q5^
M-!V%2401L5?C0=A3%7XT'85)1!&Q5^-!V%,5?C0=A4E$$;%7XT'84Q5^-!V%
M2401L5?C0=A3%7XT'85)1!&Q5^-!V%,5?C0=A4E$$;%7XT'84Q5^-!V%2401
ML5?C0=A3%7XT'85)1!&Q5^-!V%,5?C0=A4E$$;%7XT'84Q5^-!V%2401L5?C
M0=A3%7XT'85)1!&Q5^-!V%,5?C0=A4E$$;%7XT'84Q5^-!V%2401L5?C0=A3
M%7XT'85)1!&Q5^-!V%,5?C0=A4E$$;%7XT'84Q5^-!V%2401L5?C0=A3%7XT
M'85)1!&Q5^-!V%,5?C0=A4E$$;%7XT'84Q5^-!V%2401L5?C0=A3%7XT'85)
M1!&Q5^-!V%,5?C0=A4E$$;%7XT'84Q5^-!V%2401L5?C0=A3%7XT'85)1!&Q
M5^-!V%,5?C0=A4E$$;%7XT'84Q5^-!V%2401L5?C0=A3%7XT'85)1!&Q5^-!
MV%,5?C0=A4E$$;%7XT'84Q5^-!V%2401L5?C0=A3%7XT'85)1!&Q5^-!V%,5
M?C0=A4E$$;%7XT'84Q5^-!V%2401L5?C0=A3%7XT'85)1!&Q5^-!V%,5?C0=
MA4E$$;%7XT'84Q5^-!V%2401L5?C0=A3%7XT'85)1!&Q5^-!V%,5?C0=A4E$
M$;%7XT'84Q5^-!V%2401L5?C0=A7UHK-H8=!QZBI"^L^4WTH.W%P\:E]5WO3
M%P\:E]5WO4Q$$/%P\:E]5WO3%P\:E]5WO4Q$$/%P\:E]5WO3%P\:E]5WO4Q$
M$/%P\:E]5WO3%P\:E]5WO4Q$$/%P\:E]5WO3%P\:E]5WO4Q$$/%P\:E]5WO3
M%P\:E]5WO4Q$$/%P\:E]5WO3%P\:E]5WO4Q$$/%P\:E]5WO3%P\:E]5WO4Q$
M$/%P\:E]5WO3%P\:E]5WO4Q$$/%P\:E]5WO3%P\:E]5WO4Q$$/%P\:E]5WO3
M%P\:E]5WO4Q$$/%P\:E]5WO3%P\:E]5WO4Q$$/%P\:E]5WO3%P\:E]5WO4Q$
M$/%P\:E]5WO3%P\:E]5WO4Q$$/%P\:E]5WO3%P\:E]5WO4Q$$/%P\:E]5WO3
M%P\:E]5WO4Q$$/%P\:E]5WO3%P\:E]5WO4Q$$/%P\:E]5WO3%P\:E]5WO4Q$
M$/%P\:E]5WO3%P\:E]5WO4Q$$/%P\:E]5WO3%P\:E]5WO4Q$$/%P\:E]5WO3
M%P\:E]5WO4Q$$/%P\:E]5WO3%P\:E]5WO4Q$$/%P\:E]5WO3%P\:E]5WO4Q$
M$/%P\:E]5WO3%P\:E]5WO4Q$$/%P\:E]5WO3%P\:E]5WO4Q$$/%P\:E]5WO3
M%P\:E]5WO4Q$$/%P\:E]5WO3%P\:E]5WO4Q$$/%P\:E]5WO3%P\:E]5WO4Q$
M$/%P\:E]5WO3%P\:E]5WO4Q$$/%P\:E]5WO3%P\:E]5WO4Q$$/%P\:E]5WO3
M%P\:E]5WO4Q$$/%P\:E]5WO3%P\:E]5WO4Q$$/%P\:E]5WO3%P\:E]5WO4Q$
M$/%P\:E]5WO3%P\:E]5WO4Q$$/%P\:E]5WO7UHK\C:=2X\.&N]ZEH@(B(.$_
MS+O0J)J7]N0_P1][E>Y_F7>A434O[<A_@C[W) L-D^;:LZW@L%9/FVK.MX(0
M'@HD7ZT?25+/!1(OUH^DH):(B B(@@3_ #K_ $K@N<_SK_2N" BZ:MTC*69T
M VI0QQ8,<78W+S=>^4OE9L= ZMN]DIZ2D:0UTLM&0T$[@/E(/2Z+S19.4KE9
MOE RNM%DIZND<2ULL5&2TD'!_P 2LW+?RG:BT5=;12VIM&!4T8FE$\)<0_:(
M.-XQP1;-XHO/+-8<M+BW_P!FHMD^'HG_ .6O0C2=@%VXXWHCDB\N:BY=]41W
MVYOLL=$ZRT]48HG/@+LMR[9R[/%P:2O2UEN,%WM%%<:0YIZN%DT9\SAD?>@F
MHO,<7*[RAW34U?:=/T5#62P2RAL;*8EVPUV,GXWH6QN2V_<HESU%+!K2SLHK
M:*=SFR-@V,R;3<#.T? 7(6;61=%764U&P/JZF&!AX.E>&C^JY4\\-3&)*>6.
M6,\',<' _:$':B+SQWT7W_TE.XW=:M[E=*V.B<Z>;QS&<;/#CO0>AT7&1[(V
M.?(YK&-&2YQP NFDK:6L#C1U4%0&[B8I _'8@D(OCB&@EQ  XDJ)3W.@J9C#
M3UU++,.+(Y6N=V H)B(L5=;C3FW7)E)60NJH:>1VS'("]A#3OP#D(,JBT'\&
M#4MZO]9J%M[NE97MAC@,8J)2_8R7YQGKP%9+!;]>,Y7:RIN-WADTP9)2RG$[
M7 QX.PT1\0X?%R?,=Y0;81=8FB,IB$C.='^#:&>Q=3*^CDJG4S*NG=4-XQ"0
M%X^S.4$E$46JN-%22-CJJRFA>[@V25K2?L)02D70RKII'!L=1"YQX!KP25WH
M"+7^G^4Z@O7*%=M+PT_-MM['N-8Z8;,CF.:US0W'6X^'_"K]&]LC Z-S7-/
MM.04')%%=<:)M2*9U93"H/\ [HRMV^S.5*0$7172NAHJB5F-ID;G#/6 2O,>
MG>5[E,U'+-%8K=15TD+0^1L5*26@[@?E(/4:+S_I_ETNMLOC+5RB6/N>7$!T
MT<;XW1@\'.8XG+?.#]A6_8I&31,DB>U\;P'-<TY#@>!!0<T4:KKJ2CV>F54$
M&U\GG9 W/HR5WL<U[ YC@YI&00<@H.2+HJZRFHV!]740P,/^*5X:/ZK[2U,%
M5$)*6:*:,_XXWAP[0@[D5"Y2^4FCT/76BCEHW5E3<'D;#90SFVY VCN/A/\
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M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!PG^9=Z%1-2_MR'^"/O<KW/\
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M0=&B>[=M2 9#CZ7#)]*#S)HN'2VJZFYW7E-U15P5LC\1-;M%[MV2XG8< !G
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M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("^L^4WTKXOK/E-]*#(HB("(B
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MM9) 1$0$6*K]16FWSF&KKX8Y1Q9G)'IQP4^CJX*VG;/23,FA=P>PY!0=R(B
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M14]9#20TE4^)C^8#W/QP&\X '7QWKNCBK;Q?:&KJ**2BHZ';<ULSFE\CW#'
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M" #M;NK)/G71;*J\6>DCH*RU35H@&Q%44SVX>T<,@D$'"D5$-96W?3]:^C=
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M*WQW*"2$0S0$-VFD'(>W:W'JP@QM5J>LI+==XQ4TU74T8BDBJ(@-F1CG@$$
MD CA]JG7:JO=IH!=:BLIY(F.89J1L& UKB 0U^<DC*Z;M1S7+3MRAHK%T&5_
M-B,'FVNDP\$[@=V /"5EM94517Z9JZ6DC,D[PS98"!G#@3Q]"#%7.&XRZY@C
MI[@R'_L;WQY@#@QNT 1C.\G WJ5?KG5TUSH:#IT-!%+$7.K)(@X/>#C9 )P.
MO>NR\15=+J2DNE/1RUD(IWT[V1$;;27 @X)&0I-VJI=ED4UDFK::6,.<&[#M
MEWBEI/\ 5!\93WL"DV;C2SL$VU*_F=DOBP-PQD9X[]W@6:5,L+ZRT5T%$VCY
MF&X5#WQ4SY-HT\36C)W9&\^!7-!KVK)HM5W*[MW-I*N&.;^%)&&DGT'!69UD
M>GRTUK8<LV'UD^/$8/B@^8NQV*13VE\]=J1E7$6TU<6-8[(.T.;P2/05$TW:
MKA%;KC-=6YKY8A31C(/]FQN&]I)*(Z:2[/M>B[((#"VHJ6LAC=,<,9D;W.\P
M"[(KY+;[G2PU5UI+G35(<"^)K6OB<!D;FDY!PN,MBJY-+V5@IXWUM 62&GE(
MV9,##F$\-_6I=&QE7,(7::-&US7-?.]L0V-Q^3C>>I%=5NJ+[<[=W5AJ:>*.
M0%\-$8<AS!G <_.03YEA:??R>V'JZ9'_ ,URS-HDN]LMC+2;6^6>$&.*I;(T
M1.;X''?D8ZL>!0^Y%PAT1:Z04KI*NFJ&2/B:YN<"0GCG'!$66]VBDN5OFAGA
MCSLG8>&@.8[P$'P*H27/GK'I*ON+R0*C^T>07$[(<W.!O/!9RMJKY<H)*2DM
M9H!*-AU343-.P#Q(:TDDI5V5].W3M/0QE\%#."]V0,-V3EQ])/\ 5%0GU%)?
M-1VR2R1EQHY"^IJ!$8PUI;\@Y ))ZESU''!>[\VUU$K&4U+3NED+G ?VCP6L
M^T ERR%SHJFDOU-=;;"91*.8K(FD N9_A>,^%OW*/9-/05$,]9?:"&2OJIG2
MN;*T/,;<X:T'S !!.TA7NK[' Z8@U$.8)M^?CMW'MW'[5,NDE=&QAMS*5SB?
MC=(D+1CS8!6,M%LDM.H*QE)3AEJJ8VR-V,!L<HW$8\XWK*W&VT=Q8QM=3QSM
M8<M#QG!00J2>].J8Q4Q6P0D_&,<SR['F!:ONK_[KW7_+O^Y<Z;3UII9V3T]O
M@CE8<M<UN\%<M24\M78+A3T["^:6%S6-!QDD(,-HL] GJK4_<PL964_^X\#:
M \P=GM6(BS6ZIMEW=O;55DD<'\*-A (])VBLKJ*TW&2@MDUJ;BOBBZ-(,@?V
M;VX)^PX*EUEIDAK-.,HXBZFH7.#W9 V6[& 3Z2B(]9>9JN\5E)3W2DMD%(0P
MR2AKGRO(R0 XC "BQ:GK*BD91TYII+H^L-()F[XB ,\X!GJ\"[JBW26Z]5]2
MZT,N='6.$@+6L,D3\8(P[B#QW+[64-5/3T5PM]I91U-'4F04I<QIE86X.\;@
M?3U(KHO,5SI[G88Z^KCK(75S7"01<VYK@#NP#@@@GL4JLU!+;ZK4CY&,D91\
MP(6 8+G/;P)\._"^5YN=WK[3(VV34U-3539).>>W:.XC( )W#_J%UW"PU=?4
MZE:&\T*KH[Z:1Q&'.8W^F\8096VTM[;/#-7W*![#ODIV4X &[@UV<\>M=5YD
MK8JB5S;Y0T,>,Q121-).[_$7.Z^I=UMNEPGFA@J[-40._P#>RF1AC;NXC!R=
M_P!ZP=OHZNAFKHI['TVNFG>]E8\L+'-)W9).0!U (/E/<7W:NT?6RM:V24U&
MT&\,ANR<>;<KLJ79+-7TK-+MF@(-&^IY\@C#=K:V3Q\*NB"M:9C8^[ZBVVM=
M_P!K'$9_P!=4L$=IUK0=!:(HKC%(V:)@PTN8,AV.O?A<:1URM=UO#H[1/51U
M-0)(WLD8T$;('A.5+M=OKZN]"[7AD<#XXS%3TS'[?-@\7.=X2>&Y!CJ6_P!=
M):J2*G;";A65<L$;G-PQC6N.7$#C@+-04=XBAJ!/=HIG.9_9NZ*&[#O"<!V_
M<L!2V6Y4UMH*F& &MHJR:40.>!SD;R<@'@#C"LMMKZFN=(R>VU%&P-^7,YN\
M]0 )[4%1M<URH= NN K8Y(A"XL@= -Q,G$NSO\/@\*LM\N=330V^GH6QFNKG
MB-CGCXK !ESB/#@>!5]E'<^\VIL3K9-TB.-S6RAS>;D^/D8.<\#U>!9V_6^J
MD9;*RA8V2KH'[8B<[9YQI;AS0? 41T255TLU?0LN-7%74=7*(-L0B-T;S\G@
M<$'"XBKN]PO]VH*2IAI:>D,9$QBVW?&8#L@9QQR<GS)4,KK]7V\2V^:AHJ2<
M5,CIW-VGO;G9:T G=D\5.M%'/!?[[42QEL-0^$Q.R/C ,P?ZHJ#05]SFCN=#
M-64L570RM::IT7Q7,<,@[.< _;A+/=:@:@%NFN-+<HI(#*V6)K6N8X$ M(:2
M/"L1=+-7G5-37R4#JRV\^Q[J<.;_ &O]GLAV"<'9/@*REOHZN74]-7]S&T-$
MVGDB#,M#\Y!RX-W#/@&_@B/HK+Q<+[=;?15$-+!2O9_;NBVW .8#L@<#OR<E
M3K'7U1N=RMMRD;)/3ELD<@:&[<3AQQYB"$LM'44]^OM1-&6PU$D1B=D?& 9@
M_P!5B]>13P2T=9;R!5S[5O(S@N$@..PC**RVF*^HNE/55DI'1GSN;3 #']FT
MXR?205AK937%VM;L>Z$8+&P&3%/\MF_XH^-\7=X=ZM5MI(Z"@IZ2'YN%@8//
M@<5C+=1U$6J;O521D4\T<+8WY'QBT'*#IJ*RX7&]U=OME1'20T;6<].Z/G'.
M>X9#0"<8QX5B;CJ*Z6R1]#,(9ZZ*HA#7L;LB>-^?!OV3D863FAK+1?JVNIJ.
M2MI*YK#(V)P#XWM&,X)&00L576BYW&O;=)J0Q2.JJ<,@VP71PL))<XYQG)S@
M(+3:8+C%SKKG615#GX+61Q;#8^.0#G)\''J6&UU-%3NL<U0<1,KV.<<$[L.\
M XJTK":EHJBKJ+,ZGC+VP5K)9#D#9: <E!AZBII+[?[6;)&724<PEJ*@1&,,
M9@_%)(!.>I=TUYGKKE70T]VHK9!22&$<ZUKGRO'RCAQ&&@[E.NU#4T][I+K;
M8C(YV(*N)I VX_ [?X6K'=SI+5<[@Y]E;<Z2JF-0R1C6%\;G?*:0[P9X80=L
M6IYN]*ON+HXI*NC>Z%W-G,;G@@!P_P##O!77<Y;W0/M>;O%(*R=L#@*9OQ"X
M<6[]X]*E7&=E/I:JVZ".WR5&8HJ?8:_;>[<W+6[B3U+"T'_J""GK*_3D\;*=
MK6NJ35B8QYW$AI.[[$%FT]7U%957:*I<UPIJHPL(;C=L@K#72OGK=/:K9.6E
MM-(^&/ QAH /_52:4U]GNMT,=MFK:>LE$\4D#F[B0 0X$C'#BHD-JN;K!J2.
MII@VKK97R1QL>"#M-&X'S</L09:H-4VWT!ANE-;X.9;M/EC#G$X'#) PNO3M
MRJ[E37*G-53R5%++S;*N-FTQX(R';(.,_:L<:&II+T:JLM#[E$ZFBCAV=AW,
M.:W#AAQW9._(62TI0U=+57:6LIHZ<5$S9(V1D%H&SPW=7 ^=!A=.UM9:M'FZ
MU%8)Z9C9"VFYD EYD('Q\^%QZO"LC6RZ@MEN=<ZBKIJ@1-$DU(V#9 ;X0U^<
MY ZU#H[76S::J-.U5'+$YNV8ZO::8G?'VVGCGCCP*7<)[S=+5);#:9*>HG;S
M4U0^1IB:#N<X8.3NSNP@[;K=J]]VME+:3%L5M.Z0/E;D,X':\^[.[K(79#57
M&VWNAH[G5LJJ>KC>ULHB$>)0<@;NMO\ 5<G6R6+45GDAC)I*6E?"Y^1N. !]
MR[-90<Y8IJAC@R>C(JHG'P.9O_J,C[4'.FN%15:GJZ6%S>A4<+1)NWNE=O S
MYFKHUK4EMLCH(Y R:X2BG#B<;+#\MWJY[5V:.IGQ6CI-0,5-<]U5+YB[>!]@
MPNFIM!NNI)9KG2MDM]-"(X&R8<U[W'+G8\V -Z#JTNZ&@N]RL\#V& 8JJ8-=
MD!CMSA]COO7?75MPK;Y+:[5-%2MIXFR3U#X^<(+ODM:W..&_)737V*.@N%MK
M['11QR12[$\<0#=N)PP3Y\;BN59!76O44]RHZ1];35<3&31QN >QS=P(!.\8
M08ROIKP-3V>"6[1.E,<Q9(*4 -W#.6[6\D=BR]YJ:VFJK+2Q31NFJ#(Q\KHQ
M\H1DAP'@WJ)7.N,URM=W;:I]FGYV-]/ML,FRX##N./ =V5.N5/4UMRL%4RG>
MQD4CWS-<1F/+",'?U[MV4'31Z@=WH2W.K %53L<R5F,?VK3LX^TX[5U"KN?3
M;12331,JJBDDDDD,(.R\8.X;N&<?8HU;8ZR34;H8X\V:IJ&5LSLC >T'+<<3
MM$-*R];1SR:IMM4R,FGB@E8]^1N)QC[D&,Y/8JYUFIJB:N:^F>93S/,@':YQ
MV3MYZ\GAX5TC4=1#:Y#FG;537&2DB?( UC #\IW7@*=H]E;;:5MIJZ"9HA=(
M14AS3&YI<7#PYSOX86,.GZU]L<_HT;ZFGN4E5'!*1LS,)X=0R.M!,I+Q44EY
MHJ2>Z4=S@JRYFU$UK71/ R-S2<@K[)<JZLOU;0LN<%L= X-AB?"'NF!&=K+B
M,CS!2K6X25L0&FNAXR73O;$-@X\&-YWKKOKW5AFI:S3D]8T$B*1KHR#U':)!
M:@R5)#=67!CJJIIY*,0!KFL9LN,N?E>C'G635:TG4UT4G<BL D=14S#--M$G
M;<20WSX;X594!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$'"?YEWH5$U+^W(?X(^
M]RO<_P R[T*B:E_;D/\ !'WN2!8;)\VU9UO!8*R?-M6=;P0@/!1(OUH^DJ6>
M"B1?K1])02T1$!$1 1$0$14/1%TJZ9U/%<YY)J:X.>:>61Q)9(UQ!C)/6 "$
M%\18*FFE.M:V$R/,3:.-P9M'9!VCOQUK)W&NBM\ FG$I87;/]E&Z0Y]#03X$
M$I%AH=1T,TS(V1UNT]P:-JDD R>LENY9.MJ&TM'/4/!<V&-TA XD $_]$'<B
MK7?5M4(KX;5726\-VGSC9&!X<-)R0.OS+*27>!M7:X&!T@N >Z)XX -9M9/I
M"#(HH-9<HZ6YV^B>QSGUA>&N'!NRW)RL<=1F6JJZ:AMM55STLA9(&%K0 /#D
MGP[\#CN09]?"X#&2!G<,JN0:I%93F6VVNMJA'\\ &LYIPXMWG>[S#/$*#J6[
M4U5;=/7.+;=3NKXY,!N7;@[(QUY&$%R18."_D5T%-<+?54/2#LPOE+7->[Q3
MLDX/F*[*V]F.ODHJ"AGKJB)H=*(BUK8\\ 2XC>>I!F$5?EU70Q6^"L>R9K))
MS3/86_'B> 20X=>[P=862M5;/6LD?/03T8!&P)BW+AUX!W>@H)R+'7B[16P0
M,,<L]3.[8A@B&7/(X\> 'A*Z*"^<]6]"K**HHJPL,D<<A:X2 <=EP."?,@R[
MGM:0'.:">&3Q7U46VM%UU5<Y+A9Y9]F2.-KI7,(I@&YX;7A._=E6V]7&.U6R
M>MF8Y\<0!(;QWD#_ *H)J*O2ZG$+65%1;JR*VO( JW!N,'@XMSM 'K(4FOO%
M332S"&T5E1#",NE:6 $8SEH)R[[$&818JHOM+%I_NPP/DI2QKP!N."0/Z94&
MJU#4&VUE526NK,$<+I(IW;+0_ ^5@G./#Z$%C14YUV?5:?H9+O15L;7.I\3,
MD:WG7DC>-D[AX<;N*S]YN\5LYAABEJ*FH<6PP0C+GD<3Y@/"4&215FKN7/SV
MT7*W5U')TQC8ASK<.<0=YV3O&[>%.NE]CH+E'0"FGJ*F6(R1LB .UOQC>=WA
M.3NP$&818FUWH5==)0U5+-15K&<YS4N#M,SC+2"05T5]^GH^?D?9ZYU) 2))
M\L&X<7!NUDCPY09U%@ZS4=/!5TU-#3SU4M3 )X!$!\<$\-YW;M^2N5!?345-
M323T%33UT,7/"!Q:3(WAEI!P=^[B@S2*M:3O==<VOZ30S",S2@3[3-E@!.&X
M!SNX9PNYNHI9S))06FLJZ2-Y89F.8-H@X.RTG)09]%\:<M!((R.!XA56WWZ@
MMEFI9&15CH:BIDA:''G'[67=N2,#TH,Q=K0VOJ*>IBJ9J6L@!#)HL9P>((((
M(4-^G99I6U%3=:N:KBSS$CFL#8B>)# ,$XW;USI[^XW"GI*^W5-$ZIR(7R%K
MFO(&<'9)P?,LS.\QPO>V-TKF@D,;C+O,,[D$&S6N*U13GG9)YYG\Y-/*1M//
M_0#J61!R,C>%1X[U77+3%XZ50S!CHJH<_M,V6 !V&X!SNX9PI=NU&ZEL-'.;
M76OH(H&-?4C9 W  D-)VB//A!;46,N5Y@HXJ;FXY*J:J^8AA +I-V<[]P 'A
M*XVN\"LK):*II9J.MC8)##*0=IA.-II!((R@RJ*!>;I';(8G/CDFEFD$4448
M&T]Q\&_<.'%<;97U-5*^.KME11EHV@Y[F.:[S M)WH,BBKTFI@6SSTENJZJA
M@<6R5,>SL[N):"<N ZPHM3J.I=?Z2&WT<U3224SIFAA8.=!+<.&3N WC?@[^
M""UHN,3B^)CG,+'$ EIX@]2Z+G5MH+?4U<C7.9!&Z0M;Q( R@DHJW)JK8I17
M"UUIMN 34X;P/^+9SM8\^%81*PP\ZT[3"W:!&_(0<T6$[YZ#Z.N_DY?PK+4=
M0RKIF3Q!X8\9 >PM/V@[P@[46!DU'M5]70T5OJJNJIGAKVLV6MP0#DN) ''A
MQW%<X=1026BNKG031OHBYL\#P ]K@,XZOM09M%!K+E'2V:2XN8XQLAYXL''&
M,X4.XZAAHI*",T\\LM;&7Q,C )) &[^O'AN*#-(=PR57!JC9JG44]KK8[B0'
M1TPV7&0'.\.!P ,;\E=C+P+A1W6EFI9J2LIX"7Q2X.XM.""#@A!GP00"""#X
M0BIFGK^^ETS0O9:ZR>D@@:V6=FR ,#?AI.2!UK/UM\I::AIJF/;J>E$"GCB&
M72DC.[/#=QSP091%B;;>NDUQH:RCFHJS8YQL<I:X/;G!+7-)!QU*+)J5IK:J
MCHJ"JJZNGDV'LCP !@':))P <X'AW%!8$734U,5+1R5-4X111LVWD_X0L'WT
M<W"RJJK76T]N>1BI?LD '@7-!R!YT%B<0T$N( '$E?&N#F@M((/ A4[6=0^>
M[V>B=03U5(^1SRQKFAM00S( R?!QWX5HM<$5-00QP4PI&;.US(Q\0G>1NW<2
M@E(J[%J9U49Q;[75U3H)'1R[):T-+21Q)WDXS@+(4=XAK;0;A213S-&086M_
MM X'!;C/%!DD6$IKZ\W"GI*^W5-$^HSS+I'-<UY R1EI.#A=5-J45D[X:"WU
M50^*5T4Q;LAL>'$9))W\,X'@06!%5[-?:^KO-P@DMM08&3MC'QHQS V1G:W[
M^O=E2XJVBI;Q?)9731NIXXGSO>_+,;)(V1X/^J#-&&(SMF,;#,UI:'X^, >(
MSU;ES6%MUZJ*V:'9M%;'2S?)GD+ ,8SDMSD!0Q=Z*ULO=665);#5-9-M/VAD
M[(RT> ;T%F15]VI>9=%)66VLIJ&9P8RIDV<;^!<T'+0?.LA<Z^>E?''2VZIK
M'O!.8RUK6^ESB-Z#((L=9KM'<X9R(I8)H'F.6&4#:8X>C<1YUBJ;59K:(5=!
M::VHIV@F1S=D;..(&3\8^A!9D5/AU34U=[C;;[?4U%&^DYYK 6-<[+P-O>=P
M&",9^Q9FX7HT];'14U%/5UKXN>,3'-:&,SC)<2!Q09=%%MM5)5TYDGI)J1X<
M6F.7&?2""00NJBND5567"F+'1R43PU^UC!!&0X>;"">BPMFU%272V55;&U\<
M5.7;8?QP&[6?00HL]SIZF:P53Z>K$U0))((V/ _P9PX9P<CAZ4%D7P.!S@@X
MW''@5:TM>ZZXR3MJ*"<1])D8)=IFS$!P:0#DD<,^=0;+<I:6Z7^&EH*BMF-:
MY[FQEK0UN -[G$#?@[O,@NB*!9;I%=:5\T3)(G1R&*2*08<QXX@KIN=Y%+6,
MHJ6EFK:US.<YJ(@;+<XRXD@!!E46$9J&)ULKZKHL[9Z'Y^F=@/;X>O!&-^5+
MKKM34ED=='$OIQ&)&[/%V<8 ].0@R"+#U=\YJ:"EIZ*>IKI(A,Z!A:.;;_XG
M$@#?N4>355)%;IZJHAGA?3S-AGA>!MQEQX^<>'(XH+ BP'?&8IJ?IELK*6EJ
M'B..>39QD\-H Y;GSJ-4WVOCU5+10VZHF@CIML1M<P%QV\;>2>'@QQ\R"T(H
M-MN#JV:LC?25%/T>3FPZ5N!)YV]84#45ICJ(*JLZ5712LA<0V*H<QN0#C<$&
M=15;1]K:^V6VXRUE?).^(/<U]2YS"2/%)PH-'!35UWO7="Z54!BJBR-C:PQ@
M-P. R@NZ+!UU3%8],S34LTE1LM(A<^3G'/>XX:,^'>5&T<^II)*NT7&9\U33
M[$K9'NR7L>-^_P SLA!945(HX*:NN]Z[H72J@,5461L;6&,!N!P&5;;7!%3T
M,<=//)/$,D222<X3O\;PH)2+%5M^I*.I?!,RK+V8R64TCV[QG<0,%=]LN<%Q
MYSH[9V\WC/.PNCX]6T!G@@G(JWJ"\UM#?+724M'--',7EP:6#G<,/Q1D[L;B
M>'!3+E?8K924<]?3S1=(?L; PYS#@G!QQX8W=:#,(L-W=YBW35EQHJBC8QP:
MQC\.?*3P  /$]2^4E]+JZ"EN%OJ:%]1GF72EKFO(WXRTG!QX"@S2Q#+)M79M
M=6UD]48BXP1/#0R+/4 -YQNR5TU]^GH^D2.L]<ZD@)YR?+!N'%P;M9(\.5U:
MIO<U%:*:IML3Y14/CV96[. TD;MYXD;@@L2+ 5&I#2.I8ZRVU<4]2Y[8HALO
M<XM ZCC?G^F]=??1L51HZFUUL5P< Z*G&RXRC?O#@<#&-^2@L:+$VJ]MK*BI
MIJJFEHJJG:'OCE(/Q3_B!!P0H1U2WF#6"W5AM8..EX;C&<;6SG:V?/A!8T6*
MO-\I[6RC?*R25E4_888AM$G&1@>'/#[5!FU-+3RMAJ[160S2M)@:7,(D(&2,
MAV <;]Z"QHJ_H^[5MSMU.^MHY6[4>WTDEFR\Y\ !R.SP*P((-XMD-UI!!.Z1
MFR\2,DC.',>.#@L?)IZ2K#8[I=:NLI@03"6L8U^#D;6R 2%PDU,"V:>EMU74
MT$!+9*F/9V=W$M!.7 =8795:EIXZJFIZ6">KEJ8!/ (0/C@GSD8Z\E!G45<B
MU09)Y*,6NL[IQ\:7XOR?&VL[./M4RW7ZGJ:6MEJ8Y*-]$<5$<V,LW9SNX@A!
MET5>9J8 0355MK*:@G<&LJ9-G&_@7 '+0>LJ5>;[!:JNFIY89I9:AKC&V)N2
MXC'Q0.LY09=%A)K\^""E$]NJ&UU2]S(:0.:7.P,DDYP!CSKKH]0R2W.6BJ;;
M/2OA9SLSY)&%K&;_ (VX[QN\"#/K$7>RFZS-;4ULXH=Q?2L#0UY!SO.,X\V5
M#[Z6B!M8^W5C;62 *LAN,$X#MG.UL^?"G7F]P6IU&)8Y9>E.+(^:&T2<9 QX
M<[A]J#*@   # '@15JIU/+2N,-5:*N"H?&Y\#7.81)LC)WAV!@;\+OTC=*RX
MVVG?6TDS"80[I#BS9D/F .1V(,\BX3/YJ%\FPY^RTNV6#+G8\ \ZPC=0OCJ:
M9E?:ZNCBJ9!%%+(6$;1X!P!);E!GE\!!S@@XW'"PM1?ST^>EM]OJ:YU.0)WQ
M%K6L/4"XC)\P6$T_>H:2.Z5CXY33SW7FR2,&+:#1EP/#!W%!=D4"[W..VMIM
MN-\LE1,V"-C.))\/H"B55^(K)Z:WV^IKW4^Z9T1:UK#QV<N(R?,$&:15^;5=
M#'34%0&3OCJR]C0UOQVO:/D%O7G=Z5SDO\D-/$:BV54=5/*8H*;+2^3 SG.<
M >DH,ZBQ]LKZBJ=*VKMT]$Z, YD<US79ZBTGJ6-=JAIADJX;=636R,D.JV[.
M, X+@W.T6^?"#/QPQ1OD?'&QKY#E[@,%QQC)Z]RYKA#*R:%DL3@^-[0YKAP(
M/ K#U-^(K*BGM]OJ:\TQQ,^(M#6'Q07$9/F"#-HL+:M1TERK8Z>!L@YV S,<
M\8SAVRYN/ X'B%(?=X&76:B<".8I^D32DC9C&>!\^!GT(,DBKHU2T0LJY;=6
M16QY %6[9Q@G <6YV@WSX7;4:A:VYU5OI*&IJZN#9);'LAI:YH.=HD #?A!G
M46 ;J+G;7<)H:*H;64>6RTS]D.:<9!SG!&-Z:;O%14V:.IN5-+"QE.)7U+RW
M9DW9) :<CKX(,^BP5%?:BK,$D=FK>ASD;$Y<S@>#BW:R!X5G4!$1 1$0$1$!
M$1 1$0<)_F7>A434O[<A_@C[W*]S_,N]"HFI?VY#_!'WN2!8;)\VU9UO!8*R
M?-M6=;P0@/!1(OUH^DJ6>"B1?K1])02T1$!$1 1$0%3M.VR.[:#AI9"6/+Y'
M1R#C&\2.PX*XKXQC8VAL;6M:/ T8""EZ1K*BLU37=.C,=9!2,@G'@+FO.\>8
MC!^U6NXP5%1 &4E6:23:R9!&'Y'5@J0(V"1SPQH>[<7 ;S]JY(,-#;;JR5CI
M+X^1@<"YG1HQM#JRI=^_8=Q_RTG^DJ<C@'-(< 0=Q!\*"NTX Y/6@# [F?\
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MHT'/\_S$7/?2; VNWB@HKA_^B, _1 ?_ ,U6Z^1E^G;A'$W+C2R-:T#C\0X
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M 'FQX1X=ZD58'?W;SC_[%+_J"S<=/34[08X88FLR1LM#0,\5V;+"X2;+2[&
M[&_'I05*Z0256J;M!#\[+9RQOI+G +&6MMLGL$<%?J&KI=F+F9Z22=C"P@8+
M=DMSA; V&[>WLMV\8VL;\=2ZI*.FDE$LE/"^4<'N8">U!6[W#%#-I2&%Q?%'
M4M:QSN) 8<%=VL&EU;8PT9)JG >S<K&YC'%I<UI+3D$C@?,OKF-<6ES6DM.0
M2.!05S05=2RZ>H:5E1$:J*,A\.T-MN#@Y;Q'@4Z.UUC*A\CKO52L(=B%S6!H
MR#C>!G=G^BR+*>&.5TL<,;97?*>UH!/I*[4&NM/1T<5G%)<;]5V^H@VHYJ5T
M[(PW>> (W@\?M65LU-34NJ+=#12.EIF6H\T]QR2TR9!_JK5-24T[P^:GAD>.
M#GL!([5V"-@>'AC=H#9!QOQU(*]1#_V\N1_^YQ?ZBL/=Z6:MEUM!2M+I7-IB
M&MXNPP$@?8%>0QH>7AK=LC!=C>0OK6-:YSFM:'.^40-Y]*"BB.S7.V,CJ=2U
M;HI0T&GDG8' Y&&ENSG(*R]U:._2P9&<0U&,_P"Z%G324HF,YIX1+QYS8&UV
MKM#8WEL@#7$#XKN/84%7US(VCFM%<R84\\506-G>W:8QKFG:VAQ.<*%$RGNU
M/>9(+M3U]UJ*1T+60MV U@!^*&DD[R=Y67O%!6B^T]SI:>&M9' 833ROV"TE
MV=MI((SX%PI;=6UE^I+E6TM/0LI&O#(XW[;WEPQ\8@ 8'4@P-"VTU5ACBK=1
MU<#>:$<U+).QI80,%NR6Y6:O,+(KMI6%A+F1RO:TNXD",X/]%8'T=,^;G7T\
M+I1_C+ 7=J[G,:YS7.:TEN]I(X>A!5=:L<^Y65C 2YQG  \),14K0]=2SZ>H
M*>*HB?410 /B#AMMQN.1Q&]9]S&N<USFM+F_))'#T+A'3PQ2/DCAC9(_Y3FM
M +O24&-U97U%ML-3548'/,V0'%NT& N +L>' WJJWJ2F<^U-AO4]SG-9"YX$
MC7,:-KY1#1AN\@#/6M@D @@@$'<05TQ4E/"TMBIXF-)VB&L &>M!6-.W"DM5
M5>J2Y5$5+/TV2<<\X,YQCL$.!/%=%@IHKW:]2PAI;%55DA87#'%K2UV.PJWS
M4T$[FNFABD<WY)>P$CT978UC6EQ:T N.3@<2@I>F:F6_7:DFJ6N'<JGYN0.\
MH<2UW]&_U46W10TMSN]-<;U56R<U3YFMYUL;)&.WAP+AO/7O\"OK(V,+BQC6
MEQR<#&3UE<*BF@J !40Q2@<-M@=CM04J*DH:>Y:=%OJG5<$E9/*97N#LOV-^
M\ #B%8=21VN:.GCNM4*5^V703<[S;F.'A:[P'>LL(8P& 1L&Q\G#1\7T=23P
MQ3LV)XF2,\5[01_5!5;/5U57-=;7'7LN5.RG_LJL 9:YP(V'$;B?#E8BR,M[
MK$RFN&H*NBDC889Z229C-@\" TMSCM6P888X&;$,;(V>*QH _HN$M)332"26
MGA?(.#G,!(^U!U6B"&FM=)#2O=)3LB:(WNXN;C<>Q4NV104MPNM-<;U56R?I
M4DS6\ZV-DC''(>"X;^WP*_KJJ*:"H %1!%+CAML#L=J"F3T=';+717>TU+ZJ
M*DJW2R2EP<7,>=F3> /3]A7924<]STO?*YC2:JZ;;XV^'FP,,;V#^JN7-LYO
MF]AO-XQLXW8]"^M:&M#6@!H& !P""@4S;166-D=;J2KCC,89+323L:6D#>W9
M+<[BLWIV)L6J-0,;DAC:5H)XD"-9YU'3.FYYU/"9?'+!M=J[@QK7.<UK0YWR
MB!O/I052)CI+KK)C 7/=%$ !X3S)4G2MPM\VE:6)U1 \0T@$\>T"6 -P[:;Q
M5B:QK7.<UK0YWRB!O/I77'301/>^.&-CW_*<UH!=Z>M!2S506=])WO7AM7!+
M,R,6\R"7XI._8/RFX\^Y6ZVW&EN44DM%*)61R&)Q (PX<1O79#1TT,ADAIX8
MWGBYC "?M7;%%'$"(F-8"2XAHQDGB4')$1 1$0$1$!$1 1$0<)_F7>A434O[
M<A_@C[W*]S_,N]"HFI?VY#_!'WN2!8;)\VU9UO!8*R?-M6=;P0@/!1(OUH^D
MJ6>"B1?K1])02T1$!$1 1$0?'@N:0'%I(QD<0L/IJ/F3=(N<ED#*L@.D=M./
M]FP[SZ5F5U04\4#IG1-V3*_G'[SO=@#/8 @Z;E7Q6^ 2SMF<TNV<11N><^@#
MS*!#J2BFFCB9%7!SW!H+J20#)ZSC<LA<8*FH@#*.L-)('9+Q&'Y'5@J!#;;J
MR9CI+X^1C7 N9T:,;0ZLH)UW<YEIK7,):X0/((."#LE5&YU]5%R:P/8V>226
MF8'SAX^)D@$DDY.<XW95MO7['K_X$G^DJIU_^RB/_+1?ZFH+!IFC@I:1SH;5
MW.>[#7-):7/ &XDM)ZSYUWW*OJ::9D5);*BL<YNT7,<UC!YB7$;_ #+(1_-M
M] 52K;CSVH;A27"[FUTM,UAB8US8S-D9+MIPWXX8"#/66Z1W6GDD9%)#)#(8
MI8I!\9CQQ&Y=5ZO<-JJ:."2&::2JVQ&V(9)<W&[[<K$Z!<UW=IT;YI&&L):^
M;Y3ALMPX^D;TU95146I-.5%1NA8Z?:=C.R"UHR?,,H,C0WTRW)E!7T,]#4RM
M+XA(YKFR <<%I(R.I<KA=ZNFFF;#9ZRHBAWOE:YC01C/Q03ERQEQK*>[:GLD
M5MFCJ33/?/-)$X.;&W9P 2-V\^!0*:Z-K8*R>Z7J>EJ&2OC;00.:QS<' ;C!
M<XE!FZG5-%##;I61SRLKV.="(VY<2,?%QUDG"A7B_P!S@CMVQ:JB!\]6V-S7
M/C.TWQ1OW$_TZUB-.-R[1(<-X95\>O!6?UL]L++/42G9AAN$3Y'G@QN_>?,@
M[;W51OLU/+<J6J@VJB-O--D >UVW@$EIQCPKMK;Z8Z^6BM]#/7U,(!E$9:UL
M>> +G'&?,H>KZB"JLE-+2S1S1&LA ?&X.!^./"%T6>NIK1?+Y372>.FDGJ.D
M1/F<&MD80.!.[=C""?<JJ*5EEEKJ:JAEEJVAD8> 6/P<;6#@C<N(U(Z>IJZ>
MWVRJJYJ65T<H:YK6C'AR3X=^[CN73J*IAJW:>GII&RPON#-E[3D'<X*'IJ[4
M-%<=00UM1%3.-?)(UTK@T/&X8!/$C'#SH,_;;S#<+;-5P0SET)<V2GV?[1KV
M\6XZU%CO\C*RF@N-LJ:)E2_FXI'N8X%W@!V2<$JNLN-12VN^7>@_LX*NM:(I
MG,R&LW-,N/"%\NLE,ZOL;::\5%SDZ?"Y_P#:-?&P9XG9& 3G=]J"P-U(ZHJ*
MNGMULJJN:EE=%*&N:QHP<9VB<;]^[BH]TU*]VE:NX6ZGF$\9=$]KPT&!XW$N
M!._&[AGP+MT8!SE^.-YN<W_RK"2L=)IG6+6-+CTV8X'FV24%OL]745=/M55%
M+2N &.<<UVWNXC9)77=;NVAJ(:6&GEJZV8%S((L [(XN))P NVSU])74<;J.
MIBG#6-VN;>"6Y'AZE6=0Q,@UA%4UM;4T-)/2\RRHB>& /#B=EQ(( (WH+!:K
MP*]]3 ^FEIJZGQSE/*1G>-Q!&X@]:Z&ZDI.XTU?(V2-T+S$^G(_M!)G 9CK*
MCV"GM;+G55=)=Y*^H$(9*Y\S9 UF<C>!YBL!4;51=7ZIAI0^V02@&/!VI6M!
M:9\<,C.[S!!9ZW4 I*NFI'452^LJ(>=9"S!.<XV2<X&-Y)X;EV6N]BKKY*"K
MI)J*M8SG!%(0X/;G&6N!P5AKC<Z2GUG;*N65G19:%P$W^%H+A@D^ >#/G7:Z
MHAN^LZ1]ME;-%1TT@FFC.TT%^YK<C<3X4$N34I<)YJ*VU=710.+9*B,M W<=
MD$Y<!YE]J=44D<]-%!#/5/JH!/ (ADR9.,>;PDYX8*K.G(J.GM70[E?:NW55
M.71RT[JAL;1O.]H(W@C?]JR-FI:2EU1:XJ"1TU*RV/,3W')(,F<\!UH,I)5L
MFNMC-=25--62F?FX^=!:S W[6#@Y'!)-2EW/RT5MJJNB@<6R5$9:!NX[()R[
M'F77?P3JS38!P3TD9_\ PPJ_IR*CI[6:.Y7VKMU53N='+3NJ&QM&\[V@C>"#
MG[4%NN-_HZ*T07(ETE),Y@#F#@'>''FZE&[XGQ5%.VNM=724U3((HIY"TC:/
M . .6Y\ZQ=[I:6ETC:X*"1TU(*J'FWN.2YI?G_JLCKK]E4O^=@_U()=SO8IJ
MX4-'23UU;L<XZ.(@!C>MSB<!=,NH'QMIXC;:HW&?:+:0%NT&@X+B[. WSJ##
M5P6C6-V-RE93QUL<3X)93LM(:TAS<G=G/@6/ND])-JF&O=<Y:>WSTW,,JZ>0
M!G.->26EV",>%!:+1=VW"6HIY():6LI\<[!+@D \""-Q'G4)NI#.^:2BME75
M44+BQ]3&6@$CCLM)RX#S+A8:2VFY5510W:6X59A$3W.F;(&MSD;P.L*%I"[T
M%LTZRBKZB*FJZ0OCEA>[#R=HG<.)SGP()G)XX.TO YIRTR2D'_\ $<N^?4)[
MI5=OHK?4U=73%NTUA:UN"T'.T3@<<8XKHY._[K4^6EG]I+\4C!']H[<ONGQ_
M[5:F/AYR#_EH%-J@UK7MM]JK)ZF(EL\1V6<T02,$DX)W< I+-241L8N;A*V,
MNYOFBW^TYS.-C'7E1M(C_MFH?_,'_P"D*NL:YEH%9L.?!1WQ\\P:,D,#B"['
MFSE!:(=0/954\-SMM30-J';$,DCFN:YQX-.R?BD]17VNU"RGN<UNAHZBIK6-
M:]L<>/C YWY.X 8XGK"QNJ+C1W>GHJ"UU,554S5,;P(7!W-M:<EQQPP%,MX'
M?S=CC>*6$9^TH)-7>W0&E@90SS7&>/G.BL<W+!X2YQ. ,[LKOL]V9<9*B!\$
MM-5TY E@EQEN>!!&X@]:KE]B93ZQ$]=75-!2U%*(XZB)X8W::XDL<2"!UK*:
M=I;:+E5U-#=);C4F-K)7.E;( ,G&\#S% U3=ZRW5-LBHZ6203U#6N<TLP\;_
M (@R>)QQX>=0]953C8*&IJZ>2F+:V)SXW$.<T!Q\4D'<%(UH]L$EDJ9B&00U
M[#(\\&C#AD]07#6,\%7::"2GECFA=7P@.8X.:?C8.\()0U"^.IIF5]KJZ2"I
MD$44TA:07'@' $EN?.IMRN%333-BI+94UCBW:+F.8Q@\V7$;_,L=KG]GT/\
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MW3H/]2#N@U _I]-35UMJJ)M42V"20M(<<9P0"=D^8KE57YW3IZ6VV^HKY*?
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M SU^E=RK>G]127.[U5-+$QE.X.?1R-SF5C7%KB=_6 ?04%B8QK-K8:UNT<G
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M(.;8HVN#FL:"UNR"!P'5Z%]V&[>WLMV\8VL;\=2A27>W1U?19*ZF;4YQS9E
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M@<704\4;CQ+& $]B[ QK7N<UK0YWRB!O/I7)$'":*.9A9-&R1AXM>T$)##%
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M9!!XA8>ATY!131.@K;B((CEE.:@F,>;'''FR@A::@BJ[M?ZBKC9)5-JS"-L
MEL8 V0,\ =ZKC(8SKAMIV0;0*QTHB_P<YS6=G'#CX%=:^PT]56.JXIZNCJ7@
M-DDI9=@R <-KB#Z5P=IJW&W-HQ'(T-DYX2B0\Z)/'VN.4&-U!24T.J-.311Q
MQS.F>T[( V@&>'T?]5!M8KZB]7Z:&AH:J051A+JF4M<U@ V6@;)W8[5GX--T
ML=73U4L]94U4#MIDL\NT1N(QPQC?X%SK[!355:ZKBGJZ.I> V22EEV"\#AM#
M>"@K]525]FT+>8YN;C<9'.B9"\N$<;W#+0<#AEREZJMEOBT14-B@A:R& .B>
M&@$'=@Y\_P#7*S]+;8(;>^CD=+4Q29$AJ'E[GYXY)6+.DJ)],ZFFJ:^6DV2U
MD$DY+(^K \W@SG"#-6[]0IOX3?N6"Y/R&Z.HRXX#><SGP?'<K%#&(HF1MSLL
M:&C/4%@^]:C;)*(ZBMCII7%[Z5DY$3B>.[C@]64&"L-KFN>BK,^D?#SU-,^9
MC)V[4<GQWC#NWBL]8Z]LERGHZNVLH;DV(2.V,.;(S.,AP\&? 5VMT_316RGH
M::HJZ:.!SG,=#+LN&2203X1OZEW6NS06^HEJ!+45%5(T,=-42;;MD?X1X /0
M@H]MIHZNRZ3AG:'Q.K9=IIX$ O.#YMRLE]IX:?46G98(F12&9\9<QH&6[!W'
M'@4^ET_1TT-!%&9=FBD=+%EWA=G.=V_B5,K+?#5U-'/+M<Y2O,D>#@9(QO05
M2C>ZDN.H:0VR2Y2S3E_.1!I;AS?BQO)(QC_JK%I:@EMEAHZ2H+3-&SX^SUYS
MC[.'V*GTIMDDM547^LK**[22.YV&(OB& <-P&CXVX#?O5FT9TON7,:MU0Z+G
MW]&-3\X8=VSM9W]?%!&?!"_E"(?%&X&V%Q!:#D\Z-_I7&^4D-5K2QQU$;9(V
MPS.V'#()&,9"RMTLD%PJH:HS5--4Q-+!+3R;#BT_X3N.Y=[[;"^X4M8XR&>F
MC=&PEVXAV,YZSN08>I@BIM<6UT$;8S-2RMDV!C: +2,K"Z9BN%9;*J46VW51
MJ9I.??43$/)VB-DC9.,#@,JZ36^&6Y4]<_:Y^!CF,P=V'8SGL6/J--TSZJ:H
MIJJNHGS':E%+-L->[K(P=_H0=VEJ*JM]BI:2O>U\\0+<M<7#&3LC)\V L!=J
M!UQO6H((MTXI8)(2.(>TN+?ZC^JMU'3MI*:."-TCFL& Z1Q<X^DGBNN*@ABN
M517-VN>G8UC\G=AN<8[4%:HJ]NI;E:2SYBEAZ9./ )CEK6^D':*KFF^E33V2
M&&GIZD14<LL<=0\M9MF9P+AN.2  MA6JSTEK=5NHV%IJ93+)DYWGP#S<>U0^
M]B@%OI:5AGC-*7&&9DFS*S)).'#TH(]DMMPI[_5UU13TE-!/ &NBIY"X.D!W
M./Q1X,A=&AZ.FJ].NGJX8IJBJEE=4&1H))VR,'/F 6;M=K;0/D?TNMJGO &U
M4R[>!YAN 4.33-(:B:2&HK:>.=Q?+!!.61O)XDCP9\Q""IM:UG)?6MC.TQM0
M0T]8YX+8D\T=/3OFG>UD4;=ISG'  "Q9T[0]Q);4T2,HY'EY#78(^-M8!QPR
MN@:4H7N;TR>NK6-.1'4U+GLSZ/"@JK(IAHNT&/\ LGS71DD.TW(:'/=LG'5X
M5EY(JMVJ*"EU#5MF@']O2<U&(V/E;X'<3D#>-ZLMPMM/714T<P<UE/*R9@8<
M8<WA]B7:V4]T@CCJ-MICD;+&]APYCAP(*"MU=36U>KY)Z"@%;#;8S" 9A&&R
MOWN.2#G=N7?HN:>FJKC:JRGZ-(Q_288ML/#8WG@".(!^]9ZUVZ&VP21TY>><
MD=*]SSESG..\E);=!)=(+@=MM1$QT8+3@.:? >O?O08GE!_NO4?Q(O\ F-6>
MJ9XJ:GDGG>&11M+G./  */>+;#=:"2CJB\1/+22PX.X@C?Z0L8-*T+WM-9/7
M5K6G(94U#GMSZ.!^U!6;9&^.QZ5+VE@DN7.-:? TEY']-ZS>CJ:"K9=*NJBC
MEJY*R5DCI&AQ: <!N_P >!9ZMMM/6.HW2APZ+*)HPPX&0"!]F]0:O3E--62U
M,%36T4LV^7HLVP)#UD;]_G00K_3PC4NFF<S'L;<S<;(Q@1[AZ%VT;6LUU6-8
MT-:*"/  P!\=RGW"R4U=2TL,DE0Q]*089F28D:0,9VO#GPY7.AM,-)6&J$L\
MM081 Y\K]HN:"3D[N.]!AM'TT%4V[5-7%'+5R5LL<AD:"0 <!N_P8\"PE4!%
MI#55-"?^R4]6YD(\#1M-):/,"5:ZS3U-/5RU,-164<LV.=Z+-L"3SD=?G7:^
MPT)LC[4R-T=(\?&V7?&)SG.3X<H,-JVVTE+HF<04\;'0,8Z-X: X.#AOSU^=
M?8:R2[P5<]!::%U*XN9)453]DS;(P3@-)QN\)5AN=OAN-NEHJC;YF1H:[9.#
M@$'_ *+&-TM1,?((YZUE+(XO?2MF(B<3QR..#U9P@K^TY_)&"7$GF0 ?1+@*
MPUNGJ673LM!2PQQO=%AD@&';8W@D\2<@$J2;%1]P3:!S@HR,;G?&QM;7'TJ5
M<*ZEME+SU;*(H00W:()W_8@JC:XZC=8*-PW[ZJL;U&,[.#Z7JZJL:-HAS]SN
MQ@=#TZ8NB8X8(C!W''@VB2>Q9"QVZ6EK;K5U..=JY\M .<1M&&_]3]J"'J]I
MI'6^\,&^AF EQX8G_%=_T*C,>^NO=YN</QFT$#J6FQO!DQM/(\^<!6>LIHZN
MDFIIV[44K"QP\Q&%'L]LI[30,I*0.YII)R\Y<23DDE!2[/;Z^NTDR"&W6V6*
MIB+C.^<[9<<_'/Q?E ^?P*7;+;SNKHH[J&5$]-;(MH'XS3("1M;^)X]JS'>O
M2L>_HE9<*.%[BYT-/.6LR>.!C=]BR%/:Z>"X&M89#,8&T_QG9&RTY'V^=!BK
MM::J*[QW.V0TM060<PZEF^*,9)RQW '>H%WKJ>NT/>#3TO1)(BZ.: M +) 1
MGAN/@WK/W&SMK*GGVUU?2OV0TBGFV6D#K!!&=_%<&V"B;9ZBV@2\S4$NE>7Y
M>]QXN+CX=P08JUQ1U>L;@:QC9'4U+ *=KQD!K@2X@>GPK[2QLI-97.GHVAE/
M)0MFE8P8:)-H@''@)"RUQL=-6RPS<Y44]3$W8;/3R;#]GJ/@(]*YVNSTUNCG
M$)EDEG.99I7[<C_!O*#!:.ME&[1,/.4\3S/$]TCG-!+MY\/F&%D]$.<_2EL+
MB2>9 R>H$@+(6ZWPT%MCH8-OF(VE@VCDX/\ ^=<K90Q6V@AHZ?:YF%NRW:.3
MA!B[U<9YJ@VFT$&N>W^UEXMIF'_$?_%U!=5WCI[%I/HD5.VHB ;3LCD.Y[G'
M&7?:<E&:3I8I9I(:^Z1&9YD?S=26[3CX>"R#;+3&URV^J?45<$ARXU$A>[P<
M#X,8056KM-3IV*BN-76&Y4](YK7039Q%M' ='OXC.[.=RM>HXW2Z?N3(P2]U
M-( !X3LE1(]-4W.PNJ:NOK(X7!\<51-M,:1P.,;\>?*G2VR&2[PW%SYN>BC,
M08'_ !"#UCK08V*>+O";-D<T+=_]/&/^BFZ68Z/3=K9)D.%-'D'P?%"A'2=
M26<[5BC+]LT8F/,YSGY/5GP9PK     , ("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B(.$_S+O0J)J7]N0_P1][E>Y_F7>A434O[<A_@C[W) L-D^;:LZW@L%9/F
MVK.MX(0'@HD7ZT?25+/!1(OUH^DH):(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@X3_,N]"HFI?VY#_!'WN5[G^9=Z%1-2_MR'^"/O<D"PV3YMJSK>"P5D
M^;:LZW@A >"B1;JK[2I9X*&\[%1GSY03$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1!UU'S+E1-2'-]C'5"T?U<KS5NQ'CK*U[<I>D:@J"W>UA#!]@W_UR
MK M=D^;:LZW@L+96XC:LT."A HE4W?E2UU3,VFE IG[<>#Q&Y=JQL4A8_P#\
M0_JLA&\2-RWL0<D1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$11:JH:UK@'  #XS
MO  @@7VO;24DU02/B##!UN\"I%EB=),7NR7$Y)ZSO7._7(W6L$<)/1HC\7_Q
M'K67L-'C!(__ +WJHLEKCV8QZ%DAP712LV6!=ZBB(B"!60D_&;N(\*BQ5>P_
M9D/-OZ_ 5F'-!"QM;1"0'<@EQU(/RQCSA=S9&'@X*K215=*X\Q(_9\4C(74;
MQ5Q;I:5K_P#=);_T*"W[0ZPFT.L*FG4;AQH7^O\ DN/?*[R%_K_D@NFT.L)M
M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT
M.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D
M@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%
M_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?
M*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K
M_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[
MR%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I
M??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M
M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT
M.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D
M@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%
M_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?
M*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K
M_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[
MR%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I
M??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M
M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT
M.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D
M@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%
M_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?
M*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K
M_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[
MR%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I
M??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M
M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT
M.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D
M@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%
M_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?
M*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K
M_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[
MR%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I
M??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M
M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT
M.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D
M@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%
M_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?
M*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K
M_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[
MR%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I
M??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M
M#K"I??*[R%_K_DG?*[R%_K_D@NFT.L)M#K"I??*[R%_K_DG?*[R%_K_D@NFT
M.L)M#K"I??*[R%_K_DG?*[R%_K_D@NA<T<7#M7!T\;?#D^94QVII,?$H'9\[
M_P E#J+[<Y@1"QD(ZVM)/]4%ON%RBIH2^HE;%'YSO/HZU2+Q>9KHXP4X,=+G
M>/"_T^;S+H%%4U4O.5#I)'GPNR5F+=9R""6GL51"M%N)P2%<[=2\VT;EQH:$
M1M&[^BRC&!HW*#DT8"(B*(B("^$ A?401Y:=KO % FMS79^*.Q9=,(*X^T-.
M=P[%U=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)
MLA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0
M[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=
MB=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6
M.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]
MD)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV
M]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>
MH=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA
M!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%
M9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=
MQV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X
M[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)
MLA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0
M[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=
MB=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6
M.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]
MD)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV
M]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>
MH=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA
M!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%
M9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=
MQV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X
M[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)
MLA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0
M[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=
MB=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6
M.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]
MD)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV
M]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6.X[>H=B=QV]0[%9]D)LA!6!9V]
M0[%V1VAH_P ([%8]D(&A!B8;:UO^$=BG0TS6> *2!A$'QK0%]1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
B$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g50309g84u21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g84u21.jpg
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M#@\,$!<4&!@7%!86&ATE'QH;(QP6%B L(",F)RDJ*1D?+3 M*# E*"DH_]L
M0P$'!P<*" H3"@H3*!H6&B@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H_\  $0@"]@9= P$B  (1 0,1 ?_$ !P
M 0$  @,! 0             ! @8$!0<#"/_$ %T0  $# P$#!@@)"00(!0,
M"P$  @,$!1$&$B$Q!Q,605&1%!4B4E-A<9,R,S158H&AL=$(%T)4<G."DL$C
M-Y32-G1ULK/"X? D-4.B\256@R8X=L,H1F.$E:.T_\0 &P$! 0$! 0$! 0
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MRCZ3=2W&[W:=K9W8;L2M?&'<=DLQLC=GJQN7MVA+\_4>CJ"ZR-:R>:-PD#>
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MLT\+Y=G.-K9:3C/U+IN3^DOM%8.:U14BHN/.N.V'[7D;L#./:NPU3_HQ=_\
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M4(*."J@X*H*J%%0H"(B+&2HX**C@K$%0HJ$!$1!0JH%4!9#@L5D.""A50*J
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M$1!$1%CR[E'L5MLEML8ME*R U&H:>65PR7/<2\[R=_7N'4O45H/+%_Y=IO\
MV[2_\ZW>OJHJ&AJ*NI<6P01NED<!G#6C)./8%TRW<8Y823++^SC7V[45AM%1
M<+A(V*F@;D]I[&@=9/ !:QR06RJM^E9)ZZ(P37&JDKN8(QS37XV6X]@S]:T2
MDUQIW4E^%UU9<A!0T<A-OM9BD> 1_P"K+AI!=V#>!]_J^F=4V?4S*AUCK!4M
MIRT2'FW,V<YQ\(#L*N6-QQUIG#/'DRWO]G2Z_NE=9+UI>MAJ7LMLE;X)61;M
MEPD&&N/LP2NBY6-3W>W7BEIM/S.9XOIC<JYK0#MQ<XUH:?\ W'V+9^5.UF[:
M#NT,8//Q1>$1$<0Z,[6[UD CZUK?)E!TLI-1WZYL.S> *)K2.$3(]EV/:2>Y
M7#6NJ^C.?5<KA+Y_^_X=KKN^5,C-+T=AJGPS7BLC(E9C/@X&T\CZBU<?55\K
M;AK)NFK;=H[/3P4XJ:VL.SSAR?)C9M;@<$'/X;]6Y*&5=SU?34]Q:[.EJ*2B
MR?2NE<T$?_C&/J7.UG;[79^4>2\ZIMK*NPW&F9$:A\)D;33-P!M < 0/M]16
MIC)>EGKN6/5Z6_\ OW=G:KO6Z>UM;+-47WQY:[JR0122ECI:>5@S@EO$'=Q[
M?5OY.K+Y6U^L8],VVZQV>"&G\)K*T[.WO.&QLVMP)R#G\-^.F:CD\J-04L.G
M*6@DN0VGQOIZ9PYO ))+L8'8NFUM;[9:.49UZU1;6UE@N%,V%T[H3(VFF;@
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M]09-.UL!.>:J<CU!S1^!7HJ\6<UE8_I'P'->;X;#DOG8(B++V"(B!U**]2B
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M%4%'!50<%4!9#@L5D." B(@H54"J(!9!8A9! 1$5!4<%%1P4BJ%5 JB"(B+
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MGLWKB^.[5\YT/^(9^*NJFX[!%P([S;)'M9'<:)SW$!K6SM))[!O7/4T;1$1
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MH*C@HJ."D50JH%401$18!9!8A9!!41$!4<%%1P0$1$!:IK+1%!J-IF^37 #
MG8/A>IPZ_;Q6UHK+9WCES<''SX7CY)N/SCJ#1]YL;G&JI'20#_UX07LQZSU?
M7A:\OUBW@NIK]-66O<75=KI)'GB_FP''ZQO7:<WO'YOG_P#C<MWPY_VO^?\
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MFKY/KO3@X,U3+&#V9B8%I?([=J;3&LJVGO<C:,21.IW/EW!DC7 X<>H;CO\
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MW)O0V^I?-35$L$AVFDM?%MN<X$=A <%][1R?:9M-2VHI+7&9V'+7S.=)LGM
M<2,^M=9RU72LM6BW.M\CXGSSM@?(PX<UA#B<'JSL@?6I<IE)QX+,;AODS:1-
MR6TX$C[]JZF97NR</(.#ZRYP)[E\N1*^5U-JB6Q35+IZ)['[+=O::Q[-^6GL
M(!^Q<?D]TWI&NTY+=-2W%GA >[;B=4"/8 X;OA$GBN!R.F(\I<1IFEL!;-S8
M/$-V3C[,+M>^.4O?3ACVRQLFMMC_ "A99(JZQF-[FG8E.XXZVKA4>C]3Z\?!
M?;K60102D/ABE<[X&?T6@$ 'O/%<K\HGY;9/W<OWM7JFC=VD;'_J,'_#:N?7
M<./&QTF$SY,I7DG+U:ZN"NI[C/<9)J:H?L0TI;AL&RT9(W[\G)X+E\G/)W+)
M'9-0>-R&!S*CP?F3U'X.=KU=BYOY0[3XIL[L' G>"?X1^"V#DTU%9QH^RT;K
MG2-J]D0<PZ4"3;VL ;/%.K*<4T=.-Y;MO74OSURW3R5NO&4A=AD,,<3!U#:W
MD_;]B_0O4O!^7JU34VH:2[1M=S%1$(R\?HR-SN[L8]A6/A_];?Q'^A[?;J.&
MW4%/1TK R"!@C8T=0 7W6G:<Y1+!<[5#/5W&GHZK8'/0S.V"UW7C/$>Q=S8=
M26J_35<=HJQ4FEV>=<UI#1M9Q@D;_@G@N>6.4\XZ3+&^5:)^4#0-ET_;ZX#^
MT@J.:S]%[2?O:.];GH&N=<M&VBJD.U(ZG:UQ[2WR2>\+5^7J=L>C88B1M2U;
M ![&N)/V?:N]Y+870:!LS'\3$7_4YQ</L*W?_JG[N<_^V_LVI0JJ%<79$1$0
M*BI400HA1$0J*E1$"HJ5$&Q0?$1_LA9K"#XB/]D+-5[)Y"(B*+SK7/Q=+^^/
MW%>BKSK7/Q=+^^/W%!L>E_B0MB6NZ7^)"V)!QZ_Y))[%\[5\E_B*^E?\DD]B
M^=J^2_Q%!S$1$!$1!T^HO@0>T_T73+N=1? @]I_HNF0%0HJ$%'!50<%4%5"B
MH4!$1%C)4<%%1P5B"H45" B(@H54"J LAP6*R'!!0JH%5!XOJ:OCM6N;I4-T
MDZYS\XTBHEVW-^"/@MV=D?:5S!RHWT# TK*!_P#D_P J]<"J[>)C?.//X.4M
MZ<M?VCI-&WBHOMBBKJRC-%,]SFF$YW8.,[P%S;[;8KQ9ZRWSG$=3$8RX?HD\
M#]1P5SD"Y[[[CM)VU>[\_6:MU-R:U]9326TSTTQ'%KC&\C@YKAZNI<W1]CO6
MKM<,U!>*9]/3,F;.][F%@<6XV6,!WD;AO[!VKW5%V\?SNN[SSX;6I;VGHH6I
M<JMI==]$U\<49DG@Q41M:,G+3OP/V2Y;:%5QQO3=O1ECU8W&O!>1VT5T^LZ>
MIKZ:>.*AIGEAEC+1D^2!O_;)^I7ECM%=#K.:JM]-/)'6TS=MT49<,_!(W>IH
M[U[R%5V\:]75IY_EIX?1MJ')+:'6C1%$R:,QU%075$C7#!!<=V?X0U:3RIZ1
MNU-J5FIM/PR3G:9*]L3=I\<C,8=L]8.!]J]F5'!8QY+,KDZ9<..6$P]GC4?*
MU>WQ-A9IHOK<8)!>03^QC/U96Y7"TUVLN3IM-=8Q2W2=@EV7,+1'('$M!'$#
M&[ZUNB!+G/\ IFC'BR[S/+;P#2^H]1\GK)[97V26>F,A>UKPYN'<"6O ((.
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M\?#N75:EUK?-24<=+=ZIDT,<G.M:(FLP[!&<@=A*UCCGU;R8SSX^CIQV_0-
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MSQRLR23=;MMNHYU;7TM#025M5.R.DC;MNE)RT#MW+I[AK;3EOJ13U=WIF3$
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M/3L?5TH<(93Q9M#!Q[0G7_R>%>^OI]GF=ZMM,>5>M9=KC76V*X4L;J6:GJ#
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M?(X^[\8]%M0?,5U_P<GX)T6U!\Q77_!R?@OV<B?,WV7Y''W?C'HMJ#YBNO\
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M((P03Q(W[]Q+A=;>CE1>%57*CK^LAK+E9=&QQV:E+B]U4QY?AN=K])N<8.<
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M2GDK Z5Q+B^=S'8/Z(V0  ."VWERTK:M'\BLUML4+X:0W&.8M?(7G:.X[S[
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MZ>N4%FL5!!<I('MII3M ,D(\DYWXWJM]4F5='^3+=:&30_BN.JC=<(9I9I(
M?*:PD ./J7L*\6T_IV7DIY*[U=:J&C9J*.)[14Q';!#G 1@Y SAQ&["WSDJK
MKS=-#V^XZCE;)758,PQ&&8C)\C</5@_6HSE-[L=QJ:_6_35FJ+I=YQ#2PC>>
M+G'J:T=9/8O'.3>U7/7W*&_E O%.:.V0^300NXOP"UOM R23UNX<"N9RR\GV
MK]9:DAFMU51&T4[&\Q!/*0&O_2);LD'/KZER-.V3E:I+I;6W"]6LVJ*:,30Q
M,C']B"-IK0(ACR<C=A%DDG:NBY"M_*YKET_RC;FSGC\?O^W"<F_D_E':L$'Q
M9;4;>.&><9G_ -R[G5?)WJ>VZZJM4<GM=2PS5K2*B"? PYV-K&0002 [?O!7
M.Y-^3J\:8HM0W:NKH)]5W.&01R-.61/.7 DD;R7X)W8W=:%L[U].6?77B^F=
MI;3\;JW45R9S'-1#:,+'C!)^D0=PZN)]?PL_)E6V[D:N.FJ>> 7BXXFF>\GF
MVO);Y.0"<!K,9[<E:78^3'E,L=WJ;I;KE:F7&ISSM3(\2O=DY.]\9QGKPM[H
M++RF2Z6NL%ROU$V].EA?0SLV0UC6DE[7;,8X[N(*':34K0+E;>4KDMTO3545
MYH);/1N#330M#PS;=GRMI@)!<[B#G>O1*_3]OY8=$:?N-PEJ:%V#-BG(W./D
MO;O!W9;N*U2\Z+Y4M7T\=KU+=[;%;-L.E='LY?@\<-:"?82 MMUAI34U#I*P
MV?D\N I&T)V)B]X8Z08W.)P>O)(]:);Y=^[T2DIV4E)!319YN%C8V[1R< 8&
M>Y?5?*C;,RD@;5/;)4"-HD>T8#G8WD?6OJCD%14J(C8H/B(_V0LUA!\1'^R%
MFJ]D\A$1%%YUKGXNE_?'[BO15YUKGXNE_?'[B@V/2_Q(6Q+7=+_$A;$@X]?\
MDD]B^=J^2_Q%?2O^22>Q?.U?)?XB@YB(B B(@Z?47P(/:?Z+IEW.HO@0>T_T
M73("H45""C@JH."J"JA14* B(BQDJ."BHX*Q!4**A 1$04*J!5 60X+%9#@@
MH54"J@!50*J@@1 @J(B04*J!5 "J@5054<%%1P2"H$0(*B(@JH45""JJ*I "
MJ@504<%5!P50%D."Q60X("(B"A50*H@%D%B%D$!$14%1P45'!2*H54"J((B(
ML L@L0L@@J(B J."BHX("(B B(@R;P54;P51!$1 1$18(B("(B#)O!$;P1$$
M1$6"(B B(@(B("(B B(@(B("(B B(@(B("BJB)!$1%$1$$1$1!$1!.I17J40
M$1$!$1 1$0.I1:CRO76MLG)O?;C:YW4];3PAT4K0"6G;:.O=P*ZSD6U'<+WI
MVKH[_-SU[M52ZFJ9" TR-/E1R8'46G=^R@]!47BWY0>MKW9704&E:UU)44M.
M;A72M:UQ;$9&Q1MW@\7.)^H+T^^:DM6G+1%7W^OAHX'!K0Z3B]Q'!K1O)]0"
M#NE.I:_I76=@U5S[;#<HZJ2#XV(M='(P=I:X X]>,+CZFY0-,::K? KS=HX:
MS9#C QCY7@'K(8"1]:B-G1=;IZ^VS45M9<+)6PUE(XEHDC/ CB"#O!]1WK6Z
MSE5T724E+4RWZ!T=2PR1\W&][BT$M+BUK26C(/$#@J-V1<"QWBWWVVQ7"SU<
M571R_ EB.0<<1ZCZBNOU=9KI>*>GCL^H*BR21O+GR0P,E,@QP(=P1'?J+Q#E
M"H=8Z8M]"*+7]PK;I<*N.CHZ4T4+0][CO).#@ 9.?8O:J5DD5-#'-)SLK6!K
MY,8VR!O./6AI]46FZCT]J:\WF0T^JI+19FL;S<%#3-YYSL>472.SU\,#[LGI
MM$W2]VOE&N6CKS=3>J=E VX4]9)&UDL8+PTQOV=Q._(/XH:>E(N'=[E26>VU
M-PN4P@HZ=FW+(02&M[<#>M7K>5'1E%<115-^IFS9#20U[F-)ZG/ V0?:=W6@
MW,J+3[SRFZ/L]Q=0W"^4[*EI >&-?(UA/ .<T$#ZRMH-=2BW^'&IA%%S?/<^
M7CF]C&=K:X8QORB.0HM+H.5/1=?<64--?J<SR.V&%['L8]W8'N :>];->KO0
MV2A-;=:AM-2A[8S(X$@.<X-:-W:2 AISD6ES\J6BX+F:"6_TPG#^;+MEYB#N
MSG,;'VKA:[Y3;7I;4-FM<M3!M5$V:QSFN=S$.P2'>3UD[...[.Y#5>@J+R;E
M0U-2W/3^D+G8;B\T4NH::-TS"Z(.:"\.!S@XW;\[ELU)RH:-J[JRWP7ZF=42
M/YN,EKQ&]V<8:\C9/U%#3<T6O:HUG8-+OACOERCIIIAF.$-=)(X=H:T$X]>%
M]M+:JLNJJ::>P5S*N.%P9)AKFEA/ $. (1-.Y3J1.I$1$1 1$1$1$46"A54*
M1$*BI40$1$1$1$!$1!"L5D5B@A1"B B(B)U**]2B HJHB/E4T\-3"8JF*.:)
MW%DC0X'ZBLF-:QC6,:&L:,  8 '8LBB H55"@B(B(%14J((40HB(5%2HB!45
M*B#8H/B(_P!D+-80?$1_LA9JO9/(1$11>=:Y^+I?WQ^XKT5>=:Y^+I?WQ^XH
M-CTO\2%L2UW2_P 2%L2#CU_R23V+YVKY+_$5]*_Y))[%\[5\E_B*#F(B("(B
M#I]1? @]I_HNF7<ZB^!![3_1=,@*A14(*."J@X*H*J%%0H"(B+&2HX**C@K$
M%0HJ$!$1!0JH%4!9#@L5D.""A50*J %5 JJ"!$""HB)!0JH%4 *J!5!51P45
M'!(*@1 @J(B"JA14(*JHJD *J!5!1P54'!5 60X+%9#@@(B(*%5 JB 606(6
M00$1%05'!14<%(JA50*H@B(BP"R"Q"R""HB("HX**C@@(B("(M>O.H&P%T-%
MA\@W&0[P/9VJ6R>;KQ<.?-ETX1WTL\5/&7SR,C;VN.%U<^I*",D,,DO[+?QP
MM-GGEJ)"^:1SWGK<<KYKG>2^CZG'_#,)_KNVW'55/U4\O>$Z54_ZO+WA:BBG
M77;\/X/;[MNZ54_ZO+WA.E5/^KR]X6HHIUU?P_@]ONV[I53_ *O+WA.E5/\
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MO;;186VW1]+86U#I&040HQ,6X) 9L[6,_7A=-1<G]N;R<0Z.N4CZRBCB,?/
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M:N[EB?06:6.,NJ-O.7C@T'<59)8G-S9\?))+._IK_EK:(M@;!1PVB"JG@#W
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MII)KQ2T\CF?I1N+MII]1PC.F](O->5B\WZW:ET;1:;J6PS7&>H@>V09C.6-
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MVW"ADJ8#6EIEBD8=XVP!D$??ZM^OZ+J*K6$<INFNKK:]3B5[9+7$YD+:<AQ
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MC#L@8/LRMQ1=O!=.24L.A&:?M.@;BW4SZ0TTTE5;A'&)BW#I7SNXC.2,9)W
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M:J:@U%R>7$7FGC;%**:SLG9,YHQM,>-Q!QGZ_K7JUD+#:*-T5";>QT37BE+
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M@J!$""HB(*J%%0@JJBJ0 JH%4%'!50<%4!9#@L5D." B(@H54"J(!9!8A9!
M1$5!4<%%1P4BJ%5 JB"(B+ +(+$+((*B(@*C@HJ." B(@(B(,F\%5&\%401$
M0$1$6"(B B(@R;P1&\$1!$1%@B(@(B("(B B(@(B("(B B(@(B("(B HJHB0
M1$11$1!$1$01$03J45ZE$!$1 1$0$1$#J45ZE$!151$%.I53J4$1$5!$1$%%
M5$!$1!$1$$*BI41!151$$1$!151 1$08IU(G4B(B(@(B(B(B*+!0JJ%(B%14
MJ("(B(B(B B(@A6*R*Q00HA1 1$1$ZE%>I1 4541$*(40%"JH4$1$1 J*E1!
M"B%$1"HJ5$0*YMIAVYC(?@LX>U<6*)TL@8P9)7>T\388@QO5U]J.G'CN[?1$
M15Z1$1 7G6N?BZ7]\?N*]%7G6N?BZ7]\?N*#8]+_ !(6Q+7=+_$A;$@X]?\
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MSM7R7^(H.8B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B O.M<_%TO[X_<5Z*O.M<_
M%TO[X_<4&QZ7^)"V):[I?XD+8D''K_DDGL7SM7R7^(K[U3=J!X[05Q+.[,<C
M.PY0=@B(@(B("(B B+6;6*^_4[K@;E/1TTCG>#Q0-9N8"0'.+@<DXSA!LR+I
M+-75DC+C1U/-SU]"[9#O@"4%NTPGLSP*X5)/=I8=0T\M4UU; &\R8F -8XQA
MV!GB,G&]!M"+4;U?*M]DM<UJ<!4U$9J7[@?(8S:>/K.!]:[.>X25-XL\%%*1
M#-$^JEP!OCP T?67#N0=VBXM?7PT+&NG$Q#C@<W$Z0]S0<+YT%UIJZ5T<#:@
M.:-H\Y3OC&/:X (.<BZZXW6.CJ8J:.">JJI&EXA@ )#1NVB20 ,^M? ZAHV6
MNHKI6S1MIGB.:)[</C<2!O&?6#N/!!W"+J::^,EKH*6>CK*5U0#S+YFM#9,#
M)&XD@XWX("C+ZR:J?%24594Q1R<T^HC:WFVNS@[RX$@=9 0=NBZ1FI*=QCD\
M&JA122")E66CFR2<#KS@G=G&%V-QKXJ".%\[7EDDK(<M'P2XX!/JS]Z#E(NO
M;=Z9U[=:AM^$MBYW./)ZMV>W!!]B^!U!3&CCJ(XIY#+,Z"&-C07RN:2"6[\8
MW$Y)"#MT73C4-*V"I=415$$\#FL?3O:#(7.^"&@$@YZL%?:WW9E75OI9::HI
M*IK.<$<X;ES,XR"TD'>@[)%K.G+N([';6U#IJFLJ7R-:P':>0)'9<<G< .LK
M.PW4"Y5E%4NF=)+6SB%SCEH# T[ W[MQSCVH-C1=747J*.>JBBIJJH?3.C9)
MS+ [>_LW]0WGVK[7RO%KM-56ENWS+"X-[3P [\(.<BU]MLO#J43.O,K:XMVN
M;$;.9!\W&,XZLYROM0U%1?;)1U%/4NH72?';# YV1D.:"=PWCC@H.Z1:O%+<
M1X^H(:V2>2EB:Z"=S6[;7EI.P<#!X#JZU\;W?*M]EM<UJ<!45$9JG[@?[-C-
MI[?K.!]:#;D723W"2IO-H@HI<02Q/JI< ;X\ -'UEP[ES*Z[4U%,(IVU)<1M
M?V=/)(,>UH(ZD'/1<:@K8JZ)TD E#6NV3SD3HSGV. *X-3?61U,\-/1UE9X/
MNF? QI:PXSC>1DXZAE!VZ+J*C4%'%%021MFJ!6@F 0LR7$#...[_ +SA9T=[
M@F-6VIBFHI*5@DE9. "&'/E @D$;B@[1%UEMNYKWMV*"MB@>W;9/*UK6N'LV
MLC/K"X[-24[S')X-5"BDD$;*LM'-DDX'7G!.[.,(.[1?"NJX:&DEJ:E^Q#$W
M:<>*Z>?4\%*PNK:&NICL&1@D8W+V@C)&''@#D@X.$'?HN'5W"&FGHH2'/DJW
M[$89@\ 27'U #[5UXU)3'$O@]5X"9.:%9LCFLYQGCG&=V<80=XBZ3I%$^>IB
MI:*MJ74SW1S&-C<,+?62,Y[!O7)EO5*RU4]>T2215!8(FL VG%Y  QGCO^PH
M.R1==J&O?;+-5U<43I9(HRYH&, XXG>-W:OE:[RVLJ12S4M135',B?$H: YN
M<$C#CUH.V1=+!J6AGL]3<HQ,8('[#F[(VG'=C SUY&/:OK5WID-8^EIZ2JK)
MXVA\K8&M/-@\,DD#)[ @[5%QK;6PW&C94TSB8W9&'#!:0<$$=1!7$DO=-'27
M&=[90*&0QR-P-HG=C9&=^<C"#M$742Z@H8J.AJGN>(:MI>PX'DM#2XEV_J ]
M>]*.^QSU-/#-25=+X0"8'SM $F!G&XD@XWX.$';HNGJ[_%!-4LBI*NICI=T\
ML+06QG&2-Y!) WD %<2GNT,=WNU3-5$T#*:GD9O);Y6U\$=IW>W<@V-%T\E]
M DBABM];+4OB$SH6A@=&PD@;67 9..&<KM*:4S01RF.2(N&=B08<WU%!]$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!><ZY(V*3U
MS$_85Z)([8C>[L!*\RUG+MUU# .(#GGZ]P^XH-NTO\2%L*Z#3+<0!=^@CAEI
M754Q\'KRT[FN./P7;+K+G%_Z@ZMR#LT7&H*@3P[SY;=Q_%<E 1$0$1$!:I;Z
MR33%NDHZ^BJY*>E+C%401[;71Y)&=_DD9P<]BVM" X$$ @[B"@Z/3$,LAK;I
M4-#'W![9&,#@[9C:W#,D;LD;_K7UM,$L=\ODLD;FQRRQ&-Q&YP$30<?6%SZ"
MBIZ"G$%)&(H020P$D#/9GA[%R$&J:7M513W6O%7$6TM,'4]+M#<YCWN>2.]H
M^I9:.MM525=:ZM8X"G HZ9SOTHFN<01ZCEO<MI1!QJZD-6QK6U-13[)SF%P!
M/MR"OG0T#J65SW5M949&-F9X('KW ;US40=#7B:@U$+B*::HII:80.YANVZ-
MP<2#L\2#D\.Q=76T-766V]U7@DK'5TT!C@</+V&%HR0.!."<=BW)$'47F"66
MZV22.-SF13O<]P&YHYMPR?K(776ET]MHI+14T-8YQDD:R>&/:8YKW$AQ=G=C
M:WY[%M"(-&MMMACHJ>W7*W7=\T>S&[8ED= [!W.'E;(' XZNQ;1J*C=7V2LI
MX_C71DQ_MC>W[0%V*(-)EHKDVT"[QTK_ !N:ITYAQY08X&/9^INR?J7(N%DD
MIJ&Q%D51-'0-+)F4\A9(=IH!<T@@G>.&=^5MR(-(K+1%64SJFWT5S$T,\4KQ
M42O;),UNUY+"YV00'$]2[:Q4]&ZXFHBH[K',R,MYVM<\@ D9:-IQ[.KL6PH@
MTC3]LK+-#27%L,\KY"Z&JIW#+V,YP[+F#B,<2.O.5]JFCFI[7=:UT9CFI+B^
MMA+MVTT8S]1;M!;BNONEJCN98VIGG%.,;<#' ,DWY\K=DCZT'5VJ<VNS4]34
MQ.?5W*I#W,'':D.X?PMQW+M;_0&Z6:KHVN#'2LPUQX!PWC[0%S'Q1O,9?&QQ
MC.TPD9V3C&1V;B>]9H-:GU+-24L;*NV5<=P>1$UI:!$Z0\,29Q@]Z^<C:ZP:
M;HJ*C@EJ*M^1)+%'MB(DESG8Z]Y. MCK:2"MIGT]7$V6%XPYKN!7TC8V.-K&
M9V6@ 9))Q[2@Z?34D,<+J6"BKX,9D?+51[)E<3O).=Y*Z[2]JJ*>Z5XJXBVF
MI@ZGI=H;G1N>YY/VM'U+:T0:MHVVU5)5UKJUCFBG HZ9SOTHFN<01ZCEO<N[
MK;>ZJF$@KJR 8QLPO ;[=X.]<Y$''H:4TL3F.J)ZC+L[4S@2/5N W+HJ26HL
MM1<HI*"KJ6SU#ZB%\#-H.VL>23^B01UK940:G;;554<FF62Q$F U#YBW>V,O
M:X@9]IPOK>K745]QN\<;"UM1;6PLD.YI?MO.,_6.];.B#IJ"O?6P"CFH*VEE
M,1:]SX\,8<8W.S@^K"U^VVV&.BI[?<K=>'S1[,;@R61T#L'<X':V0.!QU=BW
ME$'4ZJH);C8JFGIQM3$M>UNUL[1:X.QGJSA=704-!6U48EM]W#VL>,UCY',9
MM-+7#RG$'(.-V5M2(-4TU;ZUU6XW-CV"@@-% ]W_ *GE',@]K0P=ZZ^W6N&"
M@BMMSM]WEE9_9NYJ60P/ .YP\K9 X'!QA;VB#I]-T\E.+ISL;H^<KI9&[0QM
M-.,%=-;*.3I*;<X9H+;(^KC[,R#R&_PDR?8MNF89(7L#W1ES2T/9Q;GK&>M<
M6UVV*W,EV'RRRS/VY9I7;3WG&!D^H;L(/GJ.FEK+#<*>!NU++ ]K&]IQN"UZ
M\-K:VBH:FVT=5'5,:^C>V6,L<&R,P7>L-< <K<D0:?566>&]T=+2PN-LEYF2
M9W4TP@X!]N&=RYS7S6B]7.62CJJBGK',EC?3LVR"&[):X=7 $'AO6Q(@ZC3%
M)/2T$SJIG-35-1)4&+.>;VW9#>Y=9<K94R:H8V.)QM]4Z*>H?U!T6U@'V^1W
M+:D0:'-I^NJY+G1&,LIZ:*5M$YVYKC(\/P#ZL;/UKL;734LU91\];[RRHB=M
MYJ)9'1QN ._)=@]8W9XK:T0:6;>VBKKDRNI+K,RHJ'S1OHY)-AS7;]DM:X8(
MWC>%@_3TLMPFFHHYJ;P6"G=1LEWL+VAWDNXY(&[CNRMW1!JUQDAK6T]146V[
M4]=S7DRTT9VV')RS(X[QUC&]=E;*NNBHK7%<:::2JG!$LC&C$>!D%^.&=W#K
M7;H@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(BCG!K
M2YQP!O)0<2Z2[$&P#O>?L7EE1+XSU)/(PYC8>:8?4,_URMHUI>C2TCS&<5$W
M]G".L=KOJ^\A='H^VG#7$(1O]EBYN +M%\:6/8C 7V0%\YF!["#O7T1!T9+Z
M2HRWJ^T+MZ:H9.S+3O'$=B^-93"9A!X]JZ4ROI)?+);C@\?U0;*BZZFN37-'
M.C^)N\%<^.1D@RQP=["@R1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$) &2<!<6:NACR =MW8U!R
MG$-!+B !UE:_?[S#2TKY97[,#.]YZ@ NMU#J>GHP6S/VYOT8(SO^OL^M:2[P
MV_5@FJR P? C'P6#_OK0(S47VZFJG&&[@QG4UN>"])T_;Q! W=U+K]/65L+6
MD@;L+;(6!C<!!F!@(B("(B N)5TC9F$."Y:(-4J[;44[G.I7N:..SQ'<N ;E
M54Y_MZ7:Q^E&2/L/XK>',#AO"X4]OCE!RT=R#5VZHB8,.\+9ZBW/]4.KZ<?^
MK4^[*[6>P1/)P!W+B/TU&2?)'<@XG3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/
M-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[
MLKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F
M]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.
MY.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*
M;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@
MX_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=
M&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^
M[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#
M/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3
M[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"
MF]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:
M.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,
M*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<
M@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD
M=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4
M^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C
M#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM
M3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3
M"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>
M:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=
M,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'
M<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LK
MD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+
M4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.
MC#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;T
MM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_
M3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&
M>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*
M=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-
M'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[L
MKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]
M+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y
M.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;
MTM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X
M_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&
M&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[
M*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/
M-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[
MLKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F
M]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.
MY.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*
M;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@
MX_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=
M&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^
M[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#
M/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3
M[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"
MF]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:
M.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,
M*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<
M@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD
M=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4
M^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C
M#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM
M3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3
M"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>
M:.Y.C#/-'<@X_3"F]+4^[*=,*;TM3[LKD=&&>:.Y.C#/-'<@X_3"F]+4^[*Q
M=K"FQ\95'V,*Y71AGFCN0:98/T1W(.GJ=7!V>8HZB5W;(=D?U755-RO5QRQA
M\&C/5$"#W\>Y;G'IR,<6CN7/IK+%'U#N0:%:=,O?)M2-<23DD\3]BW:T65E.
MT9:NY@I61#< %R  ."#"*,,& %]$1 1$0$1$!$1 1$0%-D(B!LA-D(B!LA-D
M(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!L
MA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(
MB!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA
M-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B
M!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-
MD(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!
MLA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D
M(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!L
MA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(
MB!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA
M-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B!LA-D(B"@ <$1$!$1 1$0
%$1$'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g50309g89f01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g89f01.jpg
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M#@\,$!<4&!@7%!86&ATE'QH;(QP6%B L(",F)RDJ*1D?+3 M*# E*"DH_]L
M0P$'!P<*" H3"@H3*!H6&B@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H_\  $0@&? 8D P$B  (1 0,1 ?_$ !P
M 0 " P$! 0             $!0,&!P$( O_$ &(0  $# P$#!PD& @4(!P4
M$P$  @,$!1$&$A0A!Q,Q4522DQ4R05)387&1T0@6(E6!H3.Q(R0U0G,V-V-R
M=+*SP1<T.&)U@O E=J*TPN$80X/Q)E:$E,/21"<H187$Q>+_Q  : 0$!  ,!
M 0               0(#! 4&_\0 -Q$!  $# 0<"!0(& @(# 0    $" Q$$
M$A,6(5*AT04Q(D%187$4@08R,Y&QP31"%? CX?%B_]H # ,!  (1 Q$ /P#Z
MI1$0$1?E[VL'XCA!^D4=U4/[K<_%?C>7=002T4/>'=03>'=003$4/>'=03>'
M=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=003
M$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>
M'=03>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=03
M>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=0
M03$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=003$4
M/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=
M03>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'
M=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=003
M$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>
M'=03>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=03
M>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=0
M03$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=003$4
M/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=
M03>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'
M=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=003
M$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>
M'=03>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=03
M>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=0
M03$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=003$4
M/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=
M03>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=03>'=003$4/>'=005#
MNH()B**VHZPLK)@4&5%X'97J B(@(B("(OS(_882@_$\W-C XN_DH\<3Y3M$
M\.LI PRO)=T>E31PZ$&-D#&^C)]Z_>PWU6_)>H@\V&^J/DFPWU1\EZB#S8;Z
MH^2;#?5'R7J(/-AOJCY)L-]4?)>H@\V&^J/DFPWU1\EZB#S8;ZH^2;#?5'R7
MJ(/-AOJCY)L-]4?)>H@\V&^J/DFPWU1\EZB#S8;ZH^2;#?5'R7J(/-AOJCY)
ML-]4?)>H@\V&^J/DFPWU1\EZB#S8;ZH^2;#?5'R7J(/-AOJCY)L-]4?)>H@\
MV&^J/DFPWU1\EZB#S8;ZH^2;#?5'R7J(/-AOJCY)L-]4?)>H@\V&^J/DFPWU
M1\EZB#S8;ZH^2;#?5'R7J(/-AOJCY)L-]4?)>H@\V&^J/DFPWU1\EZB#S8;Z
MH^2;#?5'R7J(/-AOJCY)L-]4?)>H@\V&^J/DFPWU1\EZB#S8;ZH^2;#?5'R7
MJ(/-AOJCY)L-]4?)>H@\V&^J/DFPWU1\EZB#S8;ZH^2;#?5'R7J(/-AOJCY)
ML-]4?)>H@\V&^J/DFPWU1\EZB#S8;ZH^2;#?5'R7J(/-AOJCY)L-]4?)>H@\
MV&^J/DFPWU1\EZB#S8;ZH^2;#?5'R7J(/-AOJCY)L-]4?)>H@\V&^J/DFPWU
M1\EZB#S8;ZH^2;#?5'R7J(/-AOJCY)L-]4?)>H@\V&^J/DFPWU1\EZB#S8;Z
MH^2;#?5'R7J(/-AOJCY)L-]4?)>H@\V&^J/DFPWU1\EZB#S8;ZH^2;#?5'R7
MJ(/-AOJCY)L-]4?)>H@\V&^J/DFPWU1\EZB#S8;ZH^2;#?5'R7J(/-AOJCY)
ML-]4?)>H@\V&^J/DFPWU1\EZB#S8;ZH^2;#?5'R7J(/-AOJCY)L-]4?)>H@\
MV&^J/DFPWU1\EZB#S8;ZH^2;#?5'R7J(/-AOJCY)L-]4?)>H@\V&^J/DFPWU
M1\EZB#S8;ZH^2;#?5'R7J(/-AOJCY)L-]4?)>H@\V&^J/DFPWU1\EZB#S8;Z
MH^2;#?5'R7J(/-AOJCY)L-]4?)>H@\V&^J/DFPWU1\EZB#S8;ZH^2;#?5'R7
MJ(/-AOJCY)L-]4?)>H@\V&^J/DFPWU1\EZB#S8;ZH^2;#?5'R7J(/-AOJCY)
ML-]4?)>H@\V&^J/DFPWU1\EZB#S8;ZH^2;#?5'R7J(/-AOJCY)L-]4?)>H@\
MV&^J/DFPWU1\EZB#S8;ZH^2;#?5'R7J(/-AOJCY)L-]4?)>H@\V&^J/DFPWU
M1\EZB#S8;ZH^2;#?5'R7J(/-AOJCY)L-]4?)>H@\V&^J/DFPWU1\EZB#S8;Z
MH^2;#?5'R7J(/-AOJCY)L-]4?)>H@\V&^J/DFPWU1\EZB#S8;ZH^2;#?5'R7
MJ(/-AOJCY)L-]4?)>H@\V&^J/DFPWU1\EZB#S8;ZH^2;#?5'R7J(/-AOJCY)
ML-]4?)>H@\V&^J/DFPWU1\EZB#S8;ZH^2;#?5'R7J(/-AOJCY)L-]4?)>H@\
MV&^J/DFPWU1\EZB#S8;ZH^2;#?5'R7J(/-AOJCY)L-]4?)>H@\V&^J/DFPWU
M1\EZB#S8;ZH^2;#?5'R7J(/-AOJCY)L-]4?)>H@\V&^J/DFPWU1\EZB#S8;Z
MH^2\,;#_ '6_)?I$&%].P^;^$J+)&Z,X/#WJP7CV![2TH*^.<L?LN4V.0."K
MJN$EKFCSV\05AM]7M  ]*"[1?B)^TU?M 1$0%&K'>:W]5)4.J_B?H@D4[=F(
M>_BLB\9YH^"]0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M$^_VIOS:7N,^B;F3B33]-7;R^C$7!]+:UU#6:DM=-4W.22"6IC8]I8W\32X
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M)]V0/FNCZBLVKJJZR5%@OK!;YL.8UTF-CAT##3D+A2SQ5E3#'L15$S&>JUY
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M=(Z8J]3U4T-%+3Q<RT/>97$<#U  DI%><YY8;+_IU5$T;F=N*_;ECV^RA1=
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M=I66I9+3FHI*C!<UKL.:X>D?/H^"O:;E&MMLN#'V2P14M,\DU!&&R2<#@#'
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ML8/ \"" /DK-,[&(:-/K:(UU=RY5\,[41/Y]FE.<7><2?B5<:-G93:KM$LI
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M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("+]1,=+(R.,;3W$-
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MCU@M-JI!+532-R&O>7#/O*SIC%4O,U5^FYH[-&UFJ-K/]^3L'(DX2:;N\$9
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M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$$NT_P!J4?\
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MP?E5+W4^Z-@_*J7NIOH.&[_7'?P^>D7T+]T;!^54O=3[HV#\JI>ZF^@X;O\
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MP?E5+W4^Z-@_*J7NIOH.&[_7'?P^>D7T+]T;!^54O=3[HV#\JI>ZF^@X;O\
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MP?E5+W4^Z-@_*J7NIOH.&[_7'?P^>D7T+]T;!^54O=3[HV#\JI>ZF^@X;O\
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M ,!VR3G;) !!XD+I7+W_ )I-1?X<7_&8N&:2U+K&IY+1I33NE*FJI*ELT/E
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M:?R?7C3EH^T/75-)74=/8A$ZGI90_P#HR.;8UH!]/0@^L'.#&ESB&M R23@
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MQI=354+X9 #@EK@0?V*X':M#<J&AH[A:=(55#56FJD+V3/<UKHR1C:P[S78
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MYU5<9K_KRNL;WS-%%'%SKFO+G$!K6M(#0.'S^*^F=1:PTYHRGIH+_>&4[^;
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M0TECW8P79'$9'2,$'YH.*:NM&KK)5WS4-/IF33=LK*?=ZB*"1IC8U^RT@8/
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MDMHIVU;*F&5X_N%S0-EWN4[5>N)K=J&+3VG;+-?;ZZ'>)8&3-ACIXLX#I)'
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M5/3MDYLDNZ7$X/ <,\/2%*UY=;A9=*W"OM-O-?50Q.<(Q*V,, :27DN] QG
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MD# YQZ&@GTGJ7*.6/5^I;?R9P5E-9JJUU=6Z-M1(VL:'T1YP8:"WBXNQC(X
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M>O>6.P:/O7DF6&KKZ]F#*RE:W$61D DD<<8. N??:$BCCY6-%3,8ULKS$'.
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MYKISMG;VL>GF\9]R*Z)>^6C35DOEWM5QCKHZJW</PQM<)W9 V6?BZ?Q9XXX
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MJ*6X1M#!4TK@USFCH#@00<?/WK%R?<DVG]%5[KA2&IK;D06MJ*IP)C!Z=D
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MTK;]^I.TP]\)OU)VF'OA!K7*1H:BU[::>VW2MKJ:EBEYXMI7-;MN (&UM-/
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MJ(,6ZP>PB[@3=8/81=P+*B#%NL'L(NX$W6#V$7<"RH@Q;K!["+N!-U@]A%W
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MCB\P+7+)Y@^ 6QQ>8$(?I$1 4*I_B?HIJA5/\3]$$QOFCX+U>-\T?!>H"(B
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M8I&,VF@QPL):0#G)R   <DX4*V?]E]W_ +OR_P##<J!L$=1<>09DS ]HI'O
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MHFT\C,NAFO$XD'6TQF3:S[L(-LO6N+Q?-24FGN3^.B,\E$RX55PK0YT=/$\
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MAY<UCQY[0&CB&G@7$@90P[.BT[DSU)>]2VRKFU#8)++44\W,ADA<#)P!)#7
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M<&07.LV>8@,;R7[3BUO$# R01Q*YW:>5J[V_4UOL^O=-&S>4"&T]0R3:;DG
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M(+1_?<[C@<1CAQ0= 1<DTERAZSK[U%2WS0M324LL,DPF;MMP&L+@/Q#!<2
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M(X](0=J1<+I^6;46H;A<!HG2!N-#1$;;WRG;().#LC&,X/ 96SW_ )49=/\
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MCDAU!>+FYS:6EN+W.#1ESB8X@&CWDD#]47#Z"1<''+/JDVHZA&B#]V0_'/\
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MURR>8/@%L<7F!"'Z1$0%"J?XGZ*:H53_ !/T03&^:/@O5XWS1\%Z@(B("(B
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M?2OH34NFK/J:ACH[[015E/&\2,:\D;+L8R""".!*Q5&D;%4Z>AL=5;89[5"
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M1 1$0$1$&*J_@GXK1M2_VU%_A-_FY;S5?P3\5HVI?[:B_P )O\W) N;)Y@^
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MADHG\W4RVZG#XHGCI;M$C+AU!4'((:@VS7N*F.KJO+M5B>)FPR1^RW\36Y.
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M93;Y"8J@315$6ULDM=@8(/H]Q6V:AO%'8+)6W6YR<W1TD9ED<!DX'H ]))P
M.LH+!%RJ;E$U72V;[QUFB>;TX&"9^*YIJF0'CSACQCHX[.<CTK9M7:PDM.CZ
M;4UGM_E:V$1SS\W)L/;3.&3(T8.T0""0<</3P0;>BTC4_*!3T5/8(].P,O-R
MOKV[C3LEV&NBQETKG8.RUHZ>'\BM.NNI=9MY:G4-#9*><06E[HJ-]QV(Y(S,
M!SY.R0''9 #<9 ]*#M"+E]RY3;E1:F=IIFFG56H'4<$\5-!4@M,CP2\.>6@-
M8S'G>GAP5K<];7#3FDZ>NU/9A'?*JI%)2VRBG$IGD<?P .]&>DGT?L@WM%S4
MZ^O]CN-M9KC34-LMUQG;315E+6"<0RN\UL@P,9]8<%Y4\HMVJ=87W3&GM-[_
M '*VO9_2250BA$;F!VV]Q' Y. T9)XGAA!TM%R>AY4;W476KTV[2,GWPIW F
MD;5MW?FB,\\9<<&\1PP220.O%WH[6]RKM656F-4V5MIO$=,*R$PU FBGBVMD
MEIP,$'T>X]2#<;;=*"Z-G=;:RGJVP2N@E,,@?L2-Z6G'01U*8N?<G-YAK;/J
MN:P:>I:2HI+O4T^[Q2A@JY6;/](YVS^$NR/0<86BZ!UKKAFG]371FG(+K!#<
MJN64ON6RZ+9 )B8W9.0T#ACIST(.]HJ33.HZ.^Z1H=01N;%25%,*A^79YKA^
M($_]T@@_!0N3;5$^L=,1WN:@W&&HED%.PR;9?$UVR'G@,$D'A^Z#:$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MUI043"RFI=0U,,3222&M# !D\3P"ZP@J[IJ.R6F=L-UO-MH9G<6QU-4R)Q^
M<0I3KE0MW7:K*8;T<4^96_TWI_!Q_%^BX7HY^D++<-54W*;3T#-1.K9JB2>Z
MPA^\4Y/X#"7 Y&/[K>/NZO+'I*JK^2+5#H*>IH*:.X37;3L<N6RTS&?BC+0>
M+=K! '_>)].45W]%0: OWWFT79KR0!)5TS7R = ?T/ _\P*OT01$0$1$!$1
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MJ:@H(A#24T;8HHP20QH& ./'H1'-](_Y^]??['0_\,+SD^:/^FOE0=@9'DX
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MPX @?$(/QL7'VM-W#]4V+C[6F[A^JAZ=U59-1SU\5BN,-:ZA>(Z@Q EK''.
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M.6%[9(I&AS'M.0X'B""OGC2NDK2_[-.HJ:@NE/=7RMEN$LL(<&Q31M:X, <
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M,E/BIBARYT6T,&-Q ."!LD'H]"^L$1<OFZ@I;[RK<K-HU!462IM5DM?-G:J
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M3R@![VC@,X].,#/N5DBN5\HO*=>-%ZF-']TJRZ6ET+'LK*?;;AQSM-)V2#C
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M=WW?53T00/)%'[-W?=]4\D4?LW=]WU4]$$#R11^S=WW?5/)%'[-W?=]5/1!
M\D4?LW=]WU3R11^S=WW?53T00/)%'[-W?=]4\D4?LW=]WU4]$$#R11^S=WW?
M5/)%'[-W?=]5/1! \D4?LW=]WU3R11^S=WW?53T00/)%'[-W?=]4\D4?LW=]
MWU4]$$#R11^S=WW?5/)%'[-W?=]5/1! \D4?LW=]WU3R11^S=WW?53T00/)%
M'[-W?=]4\D4?LW=]WU4]$$#R11^S=WW?5/)%'[-W?=]5/1! \D4?LW=]WU3R
M11^S=WW?53T00/)%'[-W?=]4\DTGJ/\ $=]5/1!!\DTGJ/\ $=]4\DTGJ/\
M$=]5.1!!\DTGJ/\ $=]4\DTGJ/\ $=]5.1!!\DTGJ/\ $=]4\DTGJ/\ $=]5
M.1!!\DTGJ/\ $=]4\DTGJ/\ $=]5.1!!\DTGJ/\ $=]4\DTGJ/\ $=]5.1!!
M\DTGJ/\ $=]4\DTGJ/\ $=]5.1!!\DTGJ/\ $=]4\DTGJ/\ $=]5.1!!\DTG
MJ/\ $=]4\DTGJ/\ $=]5.1!!\DTGJ/\ $=]4\DTGJ/\ $=]5.1!!\DTGJ/\
M$=]4\DTGJ/\ $=]5.1!!\DTGJ/\ $=]4\DTGJ/\ $=]5.1!!\DTGJ/\ $=]4
M\DTGJ/\ $=]56ZZU/3Z3L$M?-&9ZA[A!24K3^*HG=P9&WXGIZ@"5'Y,M3RZQ
MT3;K[44S*:2JV\Q,<7!NS(YO2?\ 5077DFD]1_B.^J>2:3U'^([ZJNUUJ:FT
MCIBLO%6QTO,@-BA:?Q32..&,'Q./@,E?BNU/!8-)0WG5QAMKS&TRPL<9,2.&
M>;9PRYWHX#T'T(+3R32>H_Q'?5/)-)ZC_$=]5J7)EKRHUG6W^"IL\MJ-MEB8
MV.=^97->TN!>W'X3@#AQZ5?ZPU3:])VO?;O,YH<[FX88V[4L\AZ&,;TDG_\
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ML8!C8G8=EXQZ,D9QU$+5>3W6$-+4ZYEU3?(H::FU!44U,ZMJ UK&-QAC-H]
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MAO',CN&SD>\YX#]0V]%H];RK:0I8PXW1TTADDBYB"FEDE!8[9<2P-R "#Q/
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MV[55K-PL[YGTPD,69871':&,\' 'TCB@N41$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MNX#T$D__ (%R6+_LL3?^)_\ ZP+>J?2-KUER(Z1MMPN<5MK!$)*.61P_$_\
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M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M3!F?Q8<<X4Q 1$0$1$!$1!BJOX)^*T;4O]M1?X3?YN6\U7\$_%:-J7^VHO\
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MRWB3'/55,TRXZ.<'X7__ ! K8T!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$08JK^"?BM&U+_;47^$W^;EO-5_!/Q6C:E_MJ+_";_-R0+FR>
M8/@%L<7F!:Y9/,'P"V.+S A#](B("A5/\3]%-4*I_B?H@F-\T?!>KQOFCX+U
M 1$0$1$!$1 1$0$1$!$1 7(M+VNWW/ERY21<J&EJQ'';M@3PMDV<P#.,@XZ
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M>>9'G8>UV<.:#Q'$$$<?1UKCSKU<;)]H/4DUBMCKG=9WRP4U/G#2X[)RX^J
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MNA=M.?G& WI]!7%[]RAZXU#R>7>LNVF8&Z;KH71,JZ<%KHCG <07$N;M#!.
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M.9FGIWQMQY[87$R.'6!M=/\ W3U+Z7N7)_I.Y7!U=7:?MTU4YVT^0Q ;9ZW
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M:X-:T$>C\+0<>];+:.3C1]HK&55OT[;HJEARR0Q;1:>L;6<'X+;$5\_\JO\
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MT, +><CVG9/IXK>URO0'^?'E-_U;?_P4&^5VJ+%04U345MYMT$---N\SWU#
M(Y<9V'<>#L>CI6>2^6J.SLNTMRI([8]@D;5OF:V(M/0=HG'%<CY-M+VR]<I'
M*#7WBFBKA275S*>"H:'QQN<,O>&GAM$!HSCH"G:DMM'?.6VP:;KZ:%UBM=H=
M7Q4)8!"^7;+!EG00T 8'1P/64'1[#J>Q:@,C;'=Z"O=&,O;3SM>YHZR <@*3
M67JUT-1+!6W*CIYHH-YDCEG:QS(L[/.$$\&YX9Z,KEO+-::#3+],ZGL-)3T%
MTIKK!3N=31B/GX9,AT;@W&UG'I]ZQZHL5%?OM(VN"Z0LJ*6#3PJ'02#+)"VH
MD#0YO00"X'!]("#IEBU58;_+)%9+S;Z^6,9>RGG:]S1UD YQ[U<KD7*#:+?9
M>4GD[N%HHZ>AJIJZ2EE=3QB/G(RSS7 =/I^:Z#KNX3VG15^N%(<5%+0S31'J
M<UA(/S0?FLUEIJBNGDVKO]KAK\[/,253&O!ZB">!]RUCD7N==<X-7FXU<]4:
M?4-73P\Z\NYN-NSLL&>@#/0HW))HG3[^3&TNK;71UTURI6U-7-41-D?*^0;1
MRXC/#./T6BZ,J9])\CG*8ZV2OY^AN]7!#-M9<.$<8?GK&<YZT5VFHUIIFGNG
MDV?4%JCKP[8,#JI@>'>J1G@?<M+Y;=7>3!9+'07^GM-3<:^.&LJ6S,;+2T^,
MN?Q/X?1^(K4++01OY.X+,.2VOJ6U%&-NMVJ<OED<W//;1=M9R<CJX!8:BR5,
M5HY)X]56R%MY==135?/QL?))&W::P/=QVAL!O22@WRVT9MT-BDL'*(ZKM]7<
M@7ON=7'5FL8.!@A?UD@]'')]V%O%]U#9K!&Q][NE%0-?YF\S-CVO@">/Z+GG
M*S24U#>^36GHJ>&G@;?X]F.%@8T9XG '!1.3BU4.J]=ZZONH*6&OJJ.YNME*
MRI8)&T\4? ;+3P!.>GX]9R1OEVO=+=]&7*NTWJ.VTX;&YK+GSC)(:=X]+CG
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MZ,43K=!!>'NCH2X.%-M-XL!;PP,#HX(.O(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M1 1$0$1$&*J_@GXK1M2_VU%_A-_FY;S5?P3\5HVI?[:B_P )O\W) N;)Y@^
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MF$%'O]-[7]BF_P!-[7]BKS"804>_TWM?V*;_ $WM?V*O,)A!1[_3>U_8IO\
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M"(B B(@Q57\$_%:-J7^VHO\ ";_-RWFJ_@GXK1M2_P!M1?X3?YN2!<V3S!\
MMCB\P+7+)Y@^ 6QQ>8$(?I$1 4*I_B?HIJA5/\3]$$QOFCX+U>-\T?!>H"(B
M B(@(B("(B B(@(B("YMHFVUU-RQ<H=;44=3%153:'=YWQ.;'-LQ8=L.(P[!
MX''0NDH@T_E?HZFOY,]14M#3S5-5+2EL<,+"][SD< !Q)6@:@H=04&H>32[6
MRQUM<+3:G[Y"R,AP:8V,<SCPYS!)#2026X7;T0<7UI<JWE0-KTY9[!>J.@WR
M.HN-;<:0T[(XF')8W/G.)]'N^)&Q5=NK7?: H;BVCJ#;VZ?= ZJ$3N:$G/N.
MP78QM8XXSE=&1!SGEXMU;<]'4<%MHZBKF;<Z:0QP1ND<&AQR[ '0.M.6ZW5M
MRMFEV6ZCJ*MT.H*2>401.>61MV\O=@<&C(R3PXKHR(-/Y7Z.IK^3/45+0T\U
M352TI;'#"PO>\Y'  <25>:5BD@TQ9XIF.CECHX6O8\8+2& $$>@JT1!Q=MVK
M=)<L.N;A/IC4EQHKBRB;3S6ZWNF8[FX '?BX#I..&>(*_>HF:EY5MWLSK!7:
M=TKSS):ZHN.&5%0UIR(VQCB.(!R>H=6#V5$'YBC;%&R.-H:Q@#6@=  Z N6:
MQ@N6E.5&GUG1VJLNEIJ[?Y/KXJ*/G)H2'[39 SI<. 'NX^Y=51!Q'5ERN^M-
M6Z'K+5IR\P62WW:-\U15TIC>YQ_O!G$B-H!R\X&7 +9(;;7#EYN=Q-'4B@?I
MX0-J>:=S3I.>!V [&-K'''2NE(@YY]GZW5MJY*++1W2DJ*.KC=/MPU$9C>W,
MSR,M(!&00?U7XY#+=6VRP7V.XT=12227NJE8V>)S"YA+<. (X@^@KHR(.-4.
MC:Z^T7*O:JJGGHQ=:\NI)IXW-9(0T%K@2.+=H#B,K'8-3TEHM%+;=3\G=V%Z
MI8VPR;I:&U$<[FC&VQXX'.,_JNTH@YWRCTM1=N1:ZPVRS5--4U-(UT=NCA_I
M6$O!+=AGIZ<@+==/1OBL-MCE8YDC*:)KFN&"TAHR"%/1!SG[0ENK;KR57:CM
M='45M6]\!;#3Q.D>[$K2<- ). ,IR]6ZMNFB8(+;1U%9.+C3/,<$;I'!H?Q.
M ,X'6NC(@USE(IIZSD^U-34D,D]1-;:B..*-I<Y[C&X  #B23Z%SR^:;O?W!
MY.KQ::"2>\Z;BIYI+>\;$DC#$ULC #T/_".'Q]/!=F1!S"NU[]Y;1<K30Z6U
M1%55-#4,<ZIM[HV1.YEY#7'/$DX: ,Y)"V#D@HZF@Y--.TM=3S4U5%2-;)#,
MPL>PY/ @\05MZ(.)0T9Y/]7:C\L:5J;U8;M5NKZ:MHZ,53X'O\^-[>D#/0?J
M<;]H2ZT5X=736W3%=9(HPUK9JRA;3&?.<[+>D@8'3UK;T0<!Y.JD:0IKA0:B
MT5>;CJN2KE>^KBM_/BLVG?A<)CP#?B<#IZU;<G-7>-$Z>U%57W3-TFGJM032
M24]OIS*6,>QKN<8.&W&"-G(7:$0<,;34^HN4C3EUT3IBZV:2FJ#)=*^:C-'%
M+!CC&6G&VX]'1G_E9:FM<^E.4VY:FFTY-J"PWF")E2*:G%1-2S1C9#@P\2TM
M'H_Y#/840<PI)[5KB@O-FMFE+C:(ZFWS1>4:NVBF8'. :&M_O$_BS\&JNT3K
M2YZ;TS0Z<O>DM0R7RWQ"D8*6DYR&H#?PL<V7.R!@#)/0NP(@YCR!VR[VRQZB
M9J&BDHZZ:]U$SFN:0U^T&?B83YS2<X<.!73D1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 7XJ(S+!)&UY87M+0X=+<CI7[1!Q;DZO]3R=:8CTQJ'
M3%]-712RAE3;Z)U1#6!SRX/:YOIP<8/4/@-BY(+1<H:W55^N=O?:F7RM;404
M$F ^)C6D;3P.ASLY(]RZ.B#EG+.?)>H] :DDX4MNNAIZA_HC9.T-+C[AL_NI
MW+/J/4-GM-+1:5M-TJJJO<YDM;14CJ@T<8QEP:.EYS^') X%;GJ6R46H[%6V
MBZQ<Y1U49C>!P(ZG ^@@X(/6%ELM";9::2A-5/5[O&V(33D&1X P"X@ $X].
M$')]&:LH-)V:.VVO0&NPW:VYIY+43)/(?.D>[:XN*WG5FLGZ;N$$4^GKY744
ML0?O=OIN?;&[)!8]H.1P .?>ML1!QG4=7<.4Z^:9I+38+M;[5;+C'<:FXW&G
M-/\ P\X9&#Q<3GYX6_Z.U-5W^XW^FJ['66QELJS312SYQ5-X_C;P'#@#PSP<
M.*V=$'.'<J@AVX:S1NKHJYI+>89;C('G_NO!P1[U2Z=BN&EM(:]UGJ6G%NK+
MLZ2K;1%P)A:&EL3''UR7?N/3P'850:PTM1ZKIJ.DNDL^XP5#:B2FC(#*@MXM
M;)PR6YXX&,H*GD5M,MEY+M.T=0TLFW;GGM/2#(XR8/O&TMU0# P.A$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$08JK^"?BM&U+_;47^$W^
M;EO-5_!/Q6C:E_MJ+_";_-R0+FR>8/@%L<7F!:Y9/,'P"V.+S A#](B("A5/
M\3]%-4*I_B?H@F-\T?!>KQOFCX+U 1$0$1$!5M<R5U02RIEC;@?A;C"LE"JO
MXQ^""'S51VV?]DYJH[;/^RS$AHR2 .LKQLC''#7M)]Q08N:J.VS_ +)S51VV
M?]EG1!@YJH[;/^R<U4=MG_99T08.:J.VS_LG-5';9_V6=$&#FJCML_[)S51V
MV?\ 91:.]VJMN53;Z.Y4<]=3?QJ>.9KI(^./Q-!R.*L4&#FJCML_[)S51VV?
M]EG1!@YJH[;/^R<U4=MG_99T08.:J.VS_LG-5';9_P!EG1!@YJH[;/\ LG-5
M';9_V6=$&#FJCML_[)S51VV?]EG1!@YJH[;/^R<U4=MG_99U^)I60POEF>UD
M3&ESG.. T#B24&/FJCML_P"R<U4=MG_91+)?+5?8))K+<:6OBC=L/?3RAX:<
M9P2/2K)!@YJH[;/^R<U4=MG_ &6=$&#FJCML_P"R<U4=MG_99T08.:J.VS_L
MG-5';9_V6=$&#FJCML_[)S51VV?]EE>YK&.>]P:UHR23@ =:@V>\VR]0/GL]
MPI*Z%CMASZ:5L@:[J)!Z4$GFJCML_P"R<U4=MG_99T08.:J.VS_LG-5';9_V
M6=$&#FJCML_[)S51VV?]EG1!@YJH[;/^R<U4=MG_ &6=55PU#9[=<Z:W5]SH
MZ>OJ=GF:>64-?)M.V6[+3Q.2,?%!.YJH[;/^R<U4=MG_ &6=$&#FJCML_P"R
M<U4=MG_99T08.:J.VS_LG-5';9_V6=$&#FJCML_[)S51VV?]EG55;]16>Y7&
MIH*"Z4=36TVUS\$4K7/CV3LG: .1@\$$[FJCML_[)S51VV?]E%L][M=Z;,ZT
M7&CKFPNV)#3S-DV#U'!X*Q08.:J.VS_LG-5';9_V6=$&#FJCML_[)S51VV?]
MEG4>OK*:WT<M77U$5-2Q#:DEE>&,:.LD\ @]YJH[;/\ LG-5';9_V7YMM?27
M.BBK+=50U5+*,LFA>'L=Z.!'#I4E!@YJH[;/^R<U4=MG_99T08.:J.VS_LG-
M5';9_P!E%O=[M=BIV3WFX4M#"]VPU]1(&!SL9P"?3@%38)HZB".:![9(I&A[
M'M.0YI&00>I!^.:J.VS_ +)S51VV?]EG55]X;.+YY&\IT?E;L?.CG?-VO-Z?
M-X_!!.YJH[;/^R<U4=MG_91:.]VNMN53;J.Y4<]?3?QJ>.9KI(^./Q-!R.*L
M4&#FJCML_P"R<U4=MG_99T08.:J.VS_LG-5';9_V6=$&#FJCML_[)S51VV?]
MEG55)J&SQ7IEGDN=&VZOQLTAE E/#/!O3T<4$[FJCML_[)S51VV?]EG1!@YJ
MH[;/^R<U4=MG_99T08.:J.VS_LG-5';9_P!EG1!@YJH[;/\ LG-5';9_V6=$
M&#FJCML_[)S51VV?]EG1!@YJH[;/^R<U4=MG_99T08.:J.VS_LG-5';9_P!E
MG1!@YJH[;/\ LG-5';9_V6=$&#FJCML_[)S51VV?]EG1!@YJH[;/^R<U4=MG
M_99T08.:J.VS_LG-5';9_P!EG1!@YJH[;/\ LG-5';9_V6=$&#FJCML_[)S5
M1VV?]EG1!@YJH[;/^R<U4=MG_99T08.:J.VS_LG-5';9_P!EG1!@YJH[;/\
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MNY?+10S7RFJ+74[]05.ZP0,D#C4D.>TNSC\(&R.OSATK7.1K_M!:X_\ SO\
M^88L'(51T]1RUZRGGB9)+3OJ71.<,[!,^"1U''#/O*#?:WE8J:;2UAN<6DKG
M55EW$O-TD#MOFRQY;@N#<Y(P?-]/N7XT9RPQ7C5,>G;]8:VPW2;A$R=VT''&
M0#EK2,CHX8*H>4O7>HY.5&ET7IZXT]EB=S8DK98VN)+F;><NX 8P !@D^E:)
M<8*FEY?M,4]=J,:AJHJBF;)5"-K-@[9/-X:2.&<_^9!L_*MRI7:CY2;3;K12
MW6&EMU3B>G ,;KB=L AHX[3#LD ^G)70ARJ4='H>34>H;576DBH--%12C^FF
M=@$;((;PZ>/1P*YSRR31TOV@]&SU,C8H&"D<Z1YV6M J'Y))Z OU]JV5M?:M
M/5=!415-##43PRNA>'M;*6L+02.@X!X(+FB^T! VHIGWO2UQMUKJ3_15FV7A
MP]8 M;D? G]5UB_7^"V:3K+]"T5=+!2FK8(W8$K W:&#[QZ5R/[0.HM.W#DH
MI8K;6T<[IY87TD43VN<QH!R=D<1AN1^N%=4T%13_ &:'QU@<)A8Y#AW2&EI+
M1W2$%54?:$MSZ"@=:[%5UMQJ YTM*V79$&'%H!?LG)( / =!'%;CR6<I5+KX
MW.*.@EM]30ENW#+('EP=D9Z!T$8/Z+6?LKT=/%R>U-4R)@J9JV1LDF/Q.#6M
MP,]0R>'O*T;6=7-R4<L-VN5&PMHKQ0S2Q #@)'M) _25H/N#D'6](\IL.J-=
MW33MOM<O,V\R<Y7&8%A#';.0W'I/1QZ.*Z&N*?9KL\%AT)5:ANLL5.^Z3;1F
MG>&@1-):W)/6XN/OR%V:EJ8*NG9/231SP/&6R1N#FN^!' HCFW+UK6JTGI22
M*VT]8*ZM:61UD3/Z.FX@$N=Z'$'#1U_!:WR><H-TO^CY;3<[+<RYMJG>Z[SE
MQCF(:?26^G/7Z%?_ &E@3R4UV!T5$&>^%^>3JZ4$O(E1TD==3.JA:YFF$2M+
M\AKLC9SG@BN1<B?*']S]-7*DHK)77FX35//F&G! CC#&C:<X-=Z?=Z/0NX<G
M?*K9]866Y5SXW6U]M9SE7',\.#&8)VPX=(X'T \/@M'^R1!&-.7Z<-'.OJV,
M+L<2 S('_P 1^:YM8:6>:AY68*!IVVQ;6RP?W&U.7?\ P@H.H5'V@HGR5$]K
MTI<JRTP.Q)6;>R&CK(#2!^K@MZ_Z2;54\G-7J^UQR55+3-_I*<D,D:_(!8[I
M (R#Z>"T/D;U'IVBY#ZF"NK:.)\#*D54$DC0]Y<7$?A/$Y:6@=?0M!Y.H*AG
M(+R@3/#A2R/B;'GH+@6[6/FU!TJ/E\MU946>EM%EJJRKK"P3LYW9;3%SMG!.
MR=HCIZ .(X]6Z\H^N)='MH&4U@N%XJ:USFQ,I1P!;C@2 3GCPX'H/4M<^S-1
MT\')?2U$43&S5$\KI7@<7D/+1D^X *CY4-=ZC/*=1:-T]<::S12",25LK&N)
M+QM=+L@ #  '$GTH+S1_+%%=M4PZ>U!8*VPW.?A$V=Q<'$C(!RUI&?1P(*LN
M4OE6MFB:Z"VMHY[G=YFAS:6 [.R"<#:=@\3Z  3^V>*W:"JI>7K2M/7ZD&HJ
MJ*HIFR5(C:SFSSI/-X:2.&<_^975RJJ:T?:J-7?I&0TKBTQRS'#&[5-LL.3P
M VN&?0?@@Z+I#E&DUA!?*&[:5KK8*6B?-,R9YP]A!&SQ:T@D;6.'H*K?L^7/
M38TK?*NRV^>TT<$^W4OJJGGB0&9SG P ,K?[K?;57VV[T5#<:2IJV4,LKXH9
M6O+6[)&3@\.)"^>N2J*>;D)Y064H)ESG Z=D,!=_\(*#=ZCE^9/55'W?TG<K
MI00'#ZD/+,#K+0QV!\2%U_3=T\M6&WW/=I:45<+9A#+C:8'#(SCW+D?V:]06
M*BY.7T]1<**DJH:F1]0V:5L9.<8=Q(R,8&?<NS4%93W"BAJZ*9D]-,P/CD8<
MM>T]!'N1'.M:<IUPL>HZBS6G1MVO$\#6O?)%D,(<,@C9:[(]'''$%3^2_E,H
M->&LIHZ.>WW.C ,U+,=KAG&0>&<'@<@8X+F=EUEJSE!UE>J*DU/3:8ME#M.:
MWF6.>6AVR/.XD\,DY '4H/V=';7*]JEV_>4,P3_UO9#>?_IV?TF!T;73^J*W
M*7EWHFUUTMT&G[A572EJ33P4T#MLU&R7!SL@?A V1Z"?Q>XJYY,N5NCUI>*B
MSU-LJ+5=8FN>(97[8<&G#AG (<.HCK6@?9^AC?ROZVF<T&2,SM:3Z,S\?Y!?
MJT-#/M9UP8 T$/.!UFE!/[H-_P"4[E:H=$W.GM4%OFNMVE:'[O$_8# 3AH)P
M3M'T #_DN.:HU8S5_+-H:M-OJ[;4P5-'3STE2TA\;Q4[74,@AP] ^"NKE44U
MJ^U7O5]D9#2N+3%+,<,;FFV6')X>=PSZ"OWRL7&W7#E\T0;;405$D511LG?"
MX. =O.0TD>G!_<(/H2]5PMEGKZ]S#(VE@DG+ <%VRTNQG]%QMOV@:>JM8GM6
MF+C6U; Y]1"Q_P""!@Z'.>&GI^'#K75M;_Y%W_\ \/J/^&Y<E^RA3Q'1-\E+
M&E\E:8W''2T1M('_ ,1^:"5!R_T%=:HWVG3USKKN2[G*"+B(VC'XR\ Y''U?
M0<XX9VSDIY3:#E BK&0T<M#74FR98'O#P6G(!:[ SQ''@,<%S3[(T,?.ZLEV
M!SC33,#O2 3*2/V'R3D!:V/EBURQ@#6-,X '0 *A!NFJ.6*&AU+46'3-@KM1
M7"FR)Q3$AK"/. PUQ..@\ ,J]Y-.4>W:Y%9!%33V^Z49_K%'/YS1G&0?2 >!
MX @^CH7SWR94-Z=KK45OHM4Q:<NW./$AGB:XSD2'::"[T@\<>G]%U'D]T'46
M?6E[NTFK:&\7:IHI6S10-#9 YY!#W 'AQ;U(,MTY>*2/451;;%IZOO,%,XB6
MHIW<< X<YK0TY;[R0M1Y *VGNG*UK2N@#GTM7#43L#A@ECYVN (]!P5D^RO=
M+7;&ZDI[E4TU'7ET;OZP\,)8W:! )ZB>/Q7O(944M7RQ:YJ+<6NHY8JA\+F>
M:6&=I!'N0;3]G"LT[5Q:B^[-GJK;LR0\]S]5SQ?G;V0. P!^+YKV[<M-QI9Z
MYU)H.\ST%%(^.>ID<6!FR2'9PQS1C'K+2OLYW8V'2/*#=FQ<\ZBABG;'ZQ:V
M4@'W<%^K/?M5ZTT9?;_=]<TUHH8!+%N,=/'^/\&=GI! =G Z24'8K#RE62[Z
M#J]5M,T-%1APJ(G@&2-XQ^'@<$G:;CKR.A:-!R[U4\!KX-#7>2R[1;OK'EPX
M'CT,V<^[:5#]G^BM=RY)M5T5_G93VR>J$<TSGA@CRQF';1X @XZ5276/4_(R
M*:KT_J6CNFGZB;#*<O#@XX)XQY.,@><P_''!!957+%>I>543TEJO3[;!"8A9
M<%DKSLD[;V 'CDY]/ !=1UI>Z.[<C-==M0V6K9230M?-;WR&*5O]* /Q8X$$
M!W0N4:2O5//]I#RK6N911UM,V8"9X:&F2D8X-R?BNL\M]3!6<CVH)Z2:*>%T
M;-F2)X<TXF:#@CAT@H-&TMRL:<T=IK35%366KI;561RR[9J.=?%B5[23P_$2
M6YX8Z5.CY?Z>"[4T-YTQ<K;;J@@Q54SOQ%A/G[!:,CKPX_JN,0P1U(Y,8)FA
MT4KBQ[3T$&M>"%UK[7#&^0=/NV1M"ID /4"T?0(.QZLOS-.Z;K+P:2HKHZ9@
M>8J8 O<"0,C)Z!G)]V5RJ3EVJ+?-32:AT3=K7;9W894R..2.L-<QH/#C@%67
M+!KJY:)T%8Y+*V,5M:UD0FD9M")HC!) / D\,9X=*Y3RO17MNA[15ZAUM#>)
MJV1DS+=%$P-9ECCMAS3Q SCH'G(0WS[5%3%6<G]BJ:9XD@FK6R1O'0YIB>0?
MDNO:-_R1L?\ L,'_  VK@O+=_F+T'_JTW_RQ7>M&_P"2-C_V&#_AM1'/]=<L
M])I[4[K!:;-57NXQD-F;"_9#78SLMPUQ<0.GAP^:YOI._0ZF^TQ17:G@GIFS
ML(=!.W9?$]M*6.:1[BTJ5R55E':.7_5S;[-%3U$LE4R&2=P:"XS!W GK;DCW
M+/25U!</M70SVJ6*:$AS72Q.#FN>*5P=@CIZ,?$%%;+R;UFFY>6G5<-LLU32
MW:,5!GJI*K;C=B5H?LLQ^':<0>DXPO:CET-7<JR'2VD;G>Z6D=B6HA<1@9(V
MMEK'8!P<9(6O\D6/_MA];YZ-FKS_ /I#%6:@TC4Z*;7ZMY,M74IMH_I9:=M0
MTD-SYOI;(!G@" ?B4':*7E"MPY/FZMNU-56VC(/]!, 9'.#BT!HSQR1PSCKX
M!<^C^T'&#'556DKG#9I'[#:T29S\!LAI/NVEK'*5J:Y:YY![5>*J 1RP701U
M7- ACL,>T/QZ!EP'Q*V?5FHM.S?9RAIX:VC?(^WT\$=,V1I>)F[&1L].002?
MAE!O6MN4FWZ<T50:FI('7.AK961Q<W)L9#FN.>(/1LX(ZU2V'EEH-1:WHK#8
M[745--.2U]>Y^PUA#"XX;@Y'#'$A<DO\%1!]F*P;R'-#[J7QAWJ'G<?H>)_5
M?0O)11T]%R<:;CI8F1-?00RN#1C:>Y@<YQ]Y))0:KR@\L='IC48L-MM%3>KH
MW'.QPOV PD9#1AKBYV.. /3TKF%JU%%JC[1UDND--44CG@,EIJANR^)[87M+
M3\OW4_0]726C[2NI#?I8Z=\KZEM/).X- <YS7-XGHRS('QQZ5FN5?;[C]J:U
M36N:&=C0UDLD3@YKI!"_/$=.!@?H@WW6'*]!:=2R:?T_8ZW4%VA_C1TQPUA]
M(R XDCT\,#K6"V<M=MK-/WRKFM=5276T,$D]MF> XC;##AV/07#.0"%Q_2%'
M=_\ I:U/14FI8].75\\X,L\8=S_]+DL!=Z3P=[P%:ZPT'46NDU1?+AJ^@O%S
M?0_UB&%@;(X%\;0YP!X#('H0;[#R]6ZNK+-26BRU5955IC;.WG=EM,7.V<9V
M3M$=/0![U><H7*Q3Z6U##8+=9ZN]7F1H<:> [.,C(' $DXXX Z%&^S11T\')
M;13PPL9-4S3.E>!Q>1(6C)]P "J^570%'J351NNGM24UKU52L9MPOGV2<#\#
MN!VF'!''!!"#;>3C7M3J^KKZ2NTY<++5436ND;4\6_B)P.(:<\#Z/1TK>UQ3
MD&U]?KY?+MIK4SXJNIM['.;5QX).R\,+26\'=(((ZCTKM:((B("(B B(@(B(
M"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@*Q9
MYH^"KE8L\T?!!ZB(@(B("(B B(@(B("(B B(@(B("(B B(@+4N5F^56F^3J^
MW6WG9JX(,1.QG8<YP8'?IM9_1;:J_4%MHKQ8ZZW75H=05,+HY@3LX:1Q.?1C
MISZ,(/E?3?)=%J+DFK==55^K?+H9/5L<Z0%HYIS@0\G\6T=DG.1C(7:/LYZL
MK=6<GC);K*Z>MH:AU(^9YRZ0!K7-<3Z3AP&?3C*Y+JOD^L&C-.W%\W*%/56H
MM=)!9H90#4RX_ '!KR",XR[9' >A=,^RW9)[3R8MGJHW,=<:I]6P.&#S>RUC
M3^NP2/<456_:3O%95S:<T/:IC%-?*EHG<WV>V&M!]Q<23_J*VUUR/OU&RPVN
MAOU3;=-6^#F9:&,9#R.AX]!<>.2[..D=)6M<IW]#]IC0LM3_  'P1L9GHVN<
ME _<M6Z\M'*C2:!M@IZ7FZF_U+?ZO3D\(QT<X_W=0])_4@.-ML;N3#EYT]9M
M(W2KJ8*PP"JAD<"=E[RUS'AH .&C:!QPR#[UMO+EJ6X7K7M#H2VW<6:W<SS]
MSK"_8#6[)>0XY'X0P9QD9+@"LO(Q9]/VBX2:GU;JJSU^KJ\DX-?$_=]K@0,.
MXO/1PX <!PZ=1Y2;5:__ +9B)NL#S=CKQ#(7/<6,<T1;+0YWH;SC,%!O/(_H
MGD\H=3PW+2>IY[I=J1C]J-T["'!S2TNV-D'''I!ZEV6]3[K9J^HSCFJ>23Y-
M)7R_?Z&R6;[1&E8>3\PM8Z2#>8Z23;C:XO<)!D$X_H^D+Z&O^K=+4M75V2]7
M:BCJ#3/?/3228=S6P2[./^[DXZ<<4'R1R6Z4TAJ*V5,^K=5^1JIM1S4,7.L;
MMMV0=H[0ZSC/N7U3I_0UH@Y,8])LJ77"T202-;4.+7%XD>YX<".' NR".H+F
M&MM#\D5-H6Z5MLJ+?%4,IWR4TT%Q=*]TN"6M#2\[63@8QZ?1TJY^R9-6R\F]
M2VK<]U-%7O;3;7H;LL) ]VT3^I*#\_9GOE:VCOVC[O(7U=AJ3'&7'CS9<YI:
M/<'-/Z."[8N <CW]-]H/E$FI_P#J[>=8['1M\\W_ )M<N_H@B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B(,55_!/Q6C:E_MJ+_";_-RWFJ_@
MGXK1M2_VU%_A-_FY(%S9/,'P"V.+S M<LGF#X!;'%Y@0A^D1$!0JG^)^BFJ%
M4_Q/T03&^:/@O5XWS1\%Z@(B("(B H55_&/P4U5M=)(VH(;3S2# _$T9""LU
M+8Z+4=DJK3=&/?1U( D:QQ:3AP<.(]X"P:;TS;-/:=98[= ?)K \<U*[;R'D
MEP.>D')5GSTW8ZCNISTW8ZCNH-0L')AIBQTERHZ.CD?0W%H;44T\KI(WX.0<
M'H(]!'%4'_0)HC>N=W6MV,YYG>G;'P];]UT[GINQU'=3GINQU'=0RU75_)QI
MW5=!;J2Z4THCM[.:IC#,YIC;@#'ISP:.G/0HVB^2O2VD+@*^UT<CZYH+63U$
MAD<P$8.ST <.&<96Y\]-V.H[J<]-V.H[J#YIH=/VW4_VBM46N]4XJ*.5LQ+<
MEI:0&$.!'$$+M.AN3/3>BZJ6JLU+(:R1NQS\\FV]K>IOH'Z#*V*.CIXJU]9'
M9@RK?G:G; T/=\7=*E\]-V.H[J&6NV'0ECL6I[C?[?#,VY5^WS[W2ES3MO#W
M8'0.("::T)8].7ZXWBUPS,KK@7&=SY2X':=M' /1Q6Q<]-V.H[J<]-V.H[J#
M4=<\F6F]:5D59>::45D;=CGH)-ASFCH!Z0>GJRL%OY)](VZJM%30VYT-1;).
M=AD;*[:<[(.7G^]Q'I6Z\]-V.H[J<]-V.H[J#6==\GU@UN*<WRFD,\ +8YX7
M[#V@](ST$?$+\V?DZTW:])U&G(Z$SVJHD,LL=0\O+GD ;6?0?PC&,8PMHYZ;
ML=1W4YZ;L=1W4'.+5R':)M]Q95BAGJ2QVTV*HG+XP?\ 5](]QRN@7FV4UWM%
M7;*UA-)51.AD:T[)V2,$ CH6?GINQU'=3GINQU'=05.D-,6O1]F=;K+')'2"
M1TQ:]Y>=HXSQ/P"^>>5#4]-RP7W3UDTA05,DD;W&2IFCV2P.P#T$X: ,DGW8
M]_TWSTO8ZCNJ-1TL-#M[E:-WV^+N:A:S:^.$&A\K&CKE<N36BTQI2GC<V-\$
M3@^0,#88P>/'I.0U;UIBT0V#3UNM--QBHX&0@^L0.)_4Y/ZJ9STW8ZCNISTW
M8ZCNH(]]M%#?;34VRZT[:BBJ&[,D;N&>.1Q'$$$ @]86EZ8Y(-*Z<KIZNWPU
M9FEA? 3+.7!K'C#@.CT'TY6^<]-V.H[J<]-V.H[J"CT3HRSZ+HJBEL,4L4,\
MG.O$DA>2[&/3[@L&F-!6+35TN5PM=/*VHN.=XYR0O:[+BX\#T<25L?/3=CJ.
MZG/3=CJ.Z@YO<.0W1%;<75>XU$ <[:=#!.6QD_#T#W A;A4:0LLNDI--,HVP
M6=[.;,,)+>&<]/3G(R3TE7'/3=CJ.ZG/3=CJ.Z@KM)Z=M^E;)#:K/&^.CB<Y
MS6O>7G+B2>)]Y5'KGDTTWK2JAJKS32BKB;L">"38<YN<X/H(XGT+;>>F['4=
MU.>F['4=U!I5OY)M(VZHM%116YT,]LEYZ&1LKMIS\@Y>?[W$#IZ%8:XY/M/:
MT$3K[1E]1"-F.HB>62-;U9'2/<<K9>>F['4=U.>F['4=U!J&CN3'3>DHZX6F
M"HYRLA,$TDLQ<XL/2!T ?)6.B]$V71U#54=D@D93U+]N5LLADR<8]/N5]STW
M8ZCNISTW8ZCNH.:W#D+T165[ZD4533ASMHPP3EL?Z#C@>X$+HUJM]-:K;2V^
M@CYJDIHVQ1,R3LM:, 9/$K)STW8ZCNISTW8ZCNH.?WOD7T;>+W-=*JBG9-,\
MR2QPS%D;W'B20.C/N(5]IW06G].WZIN]EHMTJJB$4[FQN(C#!L]#>@>:/W6Q
M<]-V.H[J<]-V.H[J#7=,:$L>FKU<;K:H9F5E>7&=SY2X'+MHX!Z.*0Z$L<.M
MI-5LAF%YDR'2<Z=GS-CS>CS5L7/3=CJ.ZG/3=CJ.Z@U?77)WI[6SH9+W2O-3
M"-EE1"_8D#<YV2?2,D](X9/6J^AY(M'T,]HGI+<^*>V2B>&5LKMI[PX.!>?[
MW%H6\<]-V.H[J<]-V.H[J#RXT<5PM]31U()@J(G0R '!+7 @\?@52Z+T=:-&
MVV>@L44L=/-*9GB20O)<0&])]P"N^>F['4=U.>F['4=U!KVB-"V316_>089H
MM\+#-SDI?G9VL8ST><5YIK0ECTY?KE>+7#,RNN!<9W/E+@=I^V< ]'%;%STW
M8ZCNISTW8ZCNH--UGR5Z5U=7&MNE"^.N< 'U%-(8W/QT;7H)]Y&5+T+R>Z?T
M2:A]BIY6S5#0V6664O<X#B!U#] MGYZ;L=1W4YZ;L=1W4&@WWD;T=>KY)=*N
M@E9/*_G)HX9BR.5WI) Z,^G&%=:=T!I[3M[KKK9J,TM361\U(UCSS8;D'#6]
M XM"V3GINQU'=3GINQU'=0:UI'D^T_I2EN5-::5^[W$!M3'/(9 \ .&,'T8<
M506[D1T30W=M>RWS2EC]MD$TQ?$T^C\)Z1[B2%T3GINQU'=3GINQU'=0:K;.
M3?3=MTY=+%34D@MEQ?SD\1F=Q/#H.<CH"UZW\A.B:.L94.I*NI#3M"*>H)9^
MH &1[B5TOGINQU'=3GINQU'=0RTK67)3I;5MP977*DEBJFL;&9*:3F]IK1@
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MDKFTM\FM+'%OE*.W2&F)SC@\^_@@Z0BIM-:CH]068W2EBJZ:C!/XJV!T!+0
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M&R6E^WM9Z<^A7U7_ -4G_P!1W\D'+OLQPTT?)-0OIVL$LL\[IR!Q+Q(0,_\
ME#54Z2O5%I+5O*]<'-=Y&H9Z>H+(ATS.8[;:WT9+L!5?(EHNOK>36VW#3^J;
MC8Y:PR[U'%&R:.0ME<T/#7C\#MD 9!] 73+-R<62VZ-N.G7[Q50W+;?6U,S\
MS3R.Z7EV.D<,=6/3QR5JU]NFNKYR?W2X2VW3ELM%3;I93!4S2S3B$QD\=D!H
M=L__ &5JUC<7,Y!RXDG8J1Q]T;5O5-R6U4EM9:+SK"[W&P1L$;* L9%EH&&M
M>]HVGM'#APZ K&BY.*2E;HL-KYW?=@2"'+!_3[;0#M=71Z$%'R.TD(UWRF5?
M-MWAUVYK;QQV0"<?,K/0,;']HZZ<V WG=.QO?C^\X3  G]  MMTKI2#3MTU!
M6PU,DS[Q5[W(U[0!&<8P,=(7L6EH8]?3:I%3(:B6WBWF#9&R&A^WM9Z<^A$;
M$B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("YQ
MK7DKAU//63OU+?X73NVVTSJ@2TC".@<RYN"WAT96]WF@%SM570FHJ:45$9CY
M^F?L2QY_O-=Z".M:%)R>ZCFA=23\HU\=0.&RYC8(FS%O5SN,_J@F<B6H:C4&
MBOZ[!30U%NJ9+>XTK R)_-X <QHX 8(X#AP]"JKYAWVBM-B;S&V6=T.?7+W
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M+.-C&SQ\_)X^A;O5:PT_27&MH*J[T<%711\]41R2;)C9PXG/#^\WYA<5N/\
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M"".MI725P#D:_J?+[RB45/PIGF24@= <)AC_ 'W+OZ((B("(B B(@(B("(B
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MCT[+MM,;HRUX:[.T -DEN<G(#P.)75N2_0])H'2[+31S/J9'2&>>=S=DR2$
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M89Q2T3YFLVV![>+?<?YH-UW2G[/#W FZ4_9X>X%K^CM<Z?U>:AECKN<J*?\
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M+OPQAQ R<;1..C ZT%_JS4NK'\K3M)Z:J*>**IM;*@33Q->VD/..#Y<8RXX
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M%\]?9BU!?[OJ35-/J*[UM>^G8P!L\[I&L=MN#MD$X'1Z%V/7^JZ+1FEJR\W
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M"(B B(@Q57\$_%:-J7^VHO\ ";_-RWFJ_@GXK1M2_P!M1?X3?YN2!<V3S!\
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MVW^XW:OO5W8"(YJH\&DC9STDDXX#)X(.;Z&MM+<OM,:CWV".9M-)4SL;(T.
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MN"+[+KY'RL##:9H<Y_ODN:!\=H@+8=,<DEGLVCKQINHJ:BNH;D\22.> QS"
M,%N/2" 5K=K^S[:J=SHJZ^W.LMP)<RDX1L#B,!QP>)'3P 02?LP,9)R73,D:
MU[#72Y:X9!_"Q:I]E.G@GK-7">&*0M=!@/:#CC+UKLG)QHVGT-IYUIHZJ6JB
M,[I^<E: <N &.'P6@7#D#MTE[JZVUW^Y6VGJG%TE/ !T$Y+0[(_#[B"@TZ^6
M:BO_ -JA]ONL(GHWEKWQ.Z'[%(' 'W9:,A3?M46VAM=CTY!;**FHX343N,=/
M$V-I.RP9P .. /DNGP\FM%%RFMUF*^I-4UNSNY:W8_@\UT]/1Q67E1Y.Z3E
MIK?#6UT](*-[WM,+0=K: ''/P0<S^U1&P:4TS(&-#S*078XD<V/2NXZ=IX(K
M-0N@BC874\>2QH&?PCJ5'RA:#MVMM.PVJX2RPFG<)(9XL;3' $=!Z00>(4#D
MRY.1H>6JD-[K;FZ:-L36SC#(FM.0&C)Q\T1\M:HDJ&7[7HIR[FWUTC9L>IO)
M/'_S!J[DZTV#_P"UG$V[4F/)@FY[8;M;SU[73M;?#]EL]IY(+-1WC4=;65$U
M=#?&R-GII6@-;MR"3+2..00,%:S_ /:\6WG>9^\=U\E;>WNF&]/QZ,^_915G
M]FF6HDY*"VH+C''4SM@SZG \/_,7+2?LH6FBJZG4U95TT4T\/,Q1ND8';#7<
MX78SU[(^2^@K)9J&R66GM5KA$%%!'S<;!QP/22?22223UE:MR7\G-'R?LN;:
M*NJ*O?G1N=SS0-G8VL8Q_K(.6<B,$5%R_:UI*5@BIHHZMK(VC#6@5,8  ]P7
M5N6R2:/DKU(ZF)$F[;)QZI< [_X25CTKR<4>G=>7G5$%?435%S$H? ]H#&<Y
M(V0X(X\"W"W.OHX+A0U%'61-EIJB-T4L;NAS7#!'R*#B7(C9[!5<B-?+64U)
M(9=YWR21@+F[(.,D\1ANR1U9RM(Y,/\ ,+R@_P"L/]UJZ);_ +/]GI+G([RS
M<WVF1X<^WAVR) .AKW#I'Z ^]7^G^2:WV71E]TY!<:J2GNQR^5[6[4? #AZ#
MT(-'Y.=)#6OV>F6<5(IIWU<DD,CAENVUY(!'41D?OZ%KT6I=5<E8M]CUI9:&
MX6B,DT4VPUQ86G(=&_TEI(.' .Z.(76F<E% SD[CTDVZ5K88JC>HZI@:V1K\
MDCT='%4E#R%TDESI:G4FI+K?(J5V8X*AV&X]4DEQQP&0,(-2^RI1V^X3ZFJ+
MA%#4W+,7&9H<X,=M[1&>LXS^B<C;8Z3E_P!54MF#6VL-J061^8UHE;C'HX'@
M%NFJ>0ZU76^3W6S72MLE14$NF93#+'$^=@9!&?2,X]RVGDVY.[/H*DG9;#+/
M5U&.>JI\;;@.@#' #W?/*#C?*5:J6]_:3M-NN,?.TD[8!(S.-L!KC@^XXPLG
MVI;926B@TS2VJAIJ&A?).Z1E-"V-KG@, ) '$@$X_5=8N?)Q1U_*11ZP?7U#
M*JF#0VG#1L'9:1Q/3Z5:\H&C+9K>Q&VW;G&!K^<AFB(#XG@$9&>G@2"$,N7_
M &BK/8:/DKMLENIJ2+FIX64;XF %S"UV0".D$<?T!7/.5A]0_37); =C=?)4
M98)3B,O.P';7NQLY]RZ=!]GZU.M,M)<+[<ZN4 -II'8#:8;0)V69(X@86YWK
MDTLM[T3;--W,S21VZ%D5/5,PV5A:T-VAPQQ XCH^00<LUSH3E(UG1T,=TI=-
M0LHCF&2E>8RUN/-SQ_#T</<HWVF:9\]\T32UCB9)(G12N!Z27,!/\UM]!R&B
M*:F96ZPO=5;Z=[7,I-K9: TY XDC'#J6U<H?)Q1ZUNUHKZNOJ*9]N)+&Q-!#
M\N#N.?\ 500-><E-GO.BS9K#2T-IJ6/8^"5L(&VYH/X7N VB"">/$YX\5S&T
M:LU'R;W.S:>Y0++15=KB<UM'4\VUSXFM( ?&\<#LY' @.Z.(7<>4+2$&M+''
M;YZVIHG13MJ(YZ<@.:\ @=/H_$>I:/:>0^C9>:2X:BU#=+Z:1P=#%4G\(P<@
M')<<9] P@Z^B(B"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("L6>:/
M@JY6+/-'P0>HB("(B B(@(B("(B B(@(B("(B B(@(B("@:@HJ6Y6*X4%PE,
M5)5T[Z>5X<&EK7M+3@G@#Q4]5>J;)3ZDT]<+/6OECIZR(Q/?$0' 'TC((_9!
MP#E Y ]-Z=T1<[O0WBY,JZ*!T[75,D9CD(Z&X#003T#CTGTK?OLT7RXWSDSB
M?=II)Y:6JDIHY9#ESXVAI&3Z<;1'Z+6A]G&CD<R&KU9=IK>PY%/L@8^!)('=
M79],V&WZ:LE+:;/ (**G;AC<Y)).22?22<DE%<3Y3</^TSH5E3_ $$;F9Z-K
MG)2/W#5W]<5^T=IZX'R!K&Q0/GK[%4-?)&QI+G1[0<#@<2 X<?<X]2ZY8;I!
M>K-1W*E#VPU,39&M>,.;GI:1Z"#P/P1'SU]E;_+;6WQ;_P 5ZKN5K5YK.6""
M*_VBOK-.V"3^BI(&9%1+@';<3P(SCAU#'I*[)R;<F-%H6[W>X4=PJ:I]RQML
ME:T!F'%W#'Q70$5\><GNO(J;ESN=^=;*Q[+K(^%M.,;</.2,P7>X8XKZ^-3
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M/X0".E!M"+3;G->=-NIJJHN8N-"^9L4L<D+6.;GT@A;/<[G1VN 35]0R",G
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MDC&TG*-3[LT,WNC<9FM& X@G#C[^ "R#3E;27*ON%LN38JBJE+G,DBVHRWT
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MTQ=:>VZ+?OS75$#*E]+#&&[1ER>#0#T^E2K=:+SY%IJ>AO#(J.6%I&W#M21
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M[C<J>6G8#F.*#9+SC@2<\.O@@U>;_J.NO\3_ )+:--T%(-+4-.(8W0RT['2
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M&\(M<=K"WL<QTL-=%2O<&MJI*<MB.>@YZOT5O=+E2VRC-562AD60!@9+B>@
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MHP@V33=S-XLM-7NB$1F#OP!VUC#B.G]%9+0=$VVX7#3-*[RK/14[=IL,=.T
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M2L=3T])3LC#MD. E=QVL'IP,A!LZ+0[S53V.*.LIM1NKI62M$M-*]A#VDX.
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M-^A=+-J&HI;EM.#J2,-:(L$X&P1D_%2KE<:B6\LLQN[**.F@:^IJCLL?*\]
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M,,#"^62![6M'220<!6"(-0N]LK9-(V9M/ 7U="Z"9T!."[8;@M^*V&T5\E?
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MVMK/ >G"BUVGZJEY/9[;"TU%:_#WAG]YQ>"<? ?R6Z(@BU,;W6J6-K27F$M
M]^ST+518JV;15JAB8(KG0O;/&R3A^)I/X3\UNB(*"AOE=45$,$MBK87N($CW
MEO-LZR#GBHE5!7V34-9<:*C?745<UO/1Q$<Y&]HP" >D?5;4B"KM%SJJ^=XD
MM=31P-;D25! +CGHV1Q_53:YCI*&H8P9<Z-P ZS@K.B#5+?8IJOD_CM-6TP5
M#HB,._NN#RX9_7"]BO-ZBH6TC['4ON+6; D#F\RX]&UM9Z/3A;4B#2[AI^II
M>3V6V0--16NV7O#/[SC('''P_P"2W*($1,!Z0 OTB#'4PMJ*>6&3S)&%CO@1
MA:G9ZFYZ>HVVVKM-56QP$MAJ*7#@]N<C(SP*W!$&FWZ*X5TEFNDEJD?'2RO=
M+0E[7/(/!KL=!(QG"\NIN=ZK+1+%;)J:CI:V.1PF($CN/$[(/  9^:W-$&HQ
MQU^G;Q<9(:":NMU;)SXW?!?&\](+3TA3+G)67C2ER;Y/GIYY&.9'#(07N&!@
M\.CT\/<MB1!#M$3X;/112M+9&4[&N:?00T A5FA:.HH=-4]/5Q.BF:Z0ECND
M9>2%?H@@W>LJ**!DM-0RUOXL/9$X!S1@\0#T_#WK6C!/=]1VZMIK1/;Q3O+Y
MZB<!CI!CS< \?BMS4>X-JG4D@H'Q,J>&PZ4$MZ>.0/<@T:X6V1^LC:8\&@JY
M67&5H]&SD.!'4YV/V6WWBX5- Z$P6VHK8G9VS 1M,Z,?A/3GC\E'L-GFHZNJ
MK[C4-J;A4@-<]C=EK&#H:T=2ND&H6JCFJ]5LND-LDME,R%S)>= :Z=QZ,M'5
MTY7N:VRZGNM2+;4UE+7"-S'TX!+7-;@@@GA\5MR(-1I67#3=PKQ%;YJZVU<Q
MJ&&GP7QN=TM+3TC@KZSU]37ME?46Z:B8T@,YYPVG]? ='H5@B#7]&T=11Q74
M543HS+7RRLVO[S3C!7NGJ.HI[W?YIXG,CGG8Z)Q_O -Z0K]$&OV^CJ(]9W:K
M?$X4TL$362'H<0.(7[U9;*BN@I*BW[)K:*83Q-<<!^.EN?1E7J(-0NU;=;Y;
MY+;36>JI'SC8FFJ" R-OIQ@_B4F]6J42Z:BHXG20T4[ \C^ZQK0,GY+9D05>
MIJQE%9*I[I1%(]ACB);M9>X$- 'IXK3K1!-::6">31NU+"P%T_/-<\D=+MD\
M05N.HK0+Q0LA$SH)HI6SQ2@9V7MS@X]/2H$M#J.IA=3S7*AAC<-ETL,#B\CW
M9. 4$;46WJ72E-4VJ,S,,K)S X[)D:TG:8??G^2B:CEN=\L$]#;[+44K &EW
M/AK<X(.RQH/'X\!@+;+300VNW045-GFH6[()Z3Z23\2I:#7(J*I&N&5AA=NP
MMHAYST;>WG'R6345'45%XL,L$3GQP5#G2.']T8Z2K]$!$1 1$0$1$!$1 1$0
M8JK^"?BM&U+_ &U%_A-_FY;S5?P3\5HVI?[:B_PF_P W) N;)Y@^ 6QQ>8%K
MED\P? +8XO,"$/TB(@*%4_Q/T4U0JG^)^B"8WS1\%ZO&^:/@O4!$1 1$0$1$
M \!DJ-#7T<\IB@JZ>20=+&2 GY K7];N?436>U"1T<%=4;,Q:<%S&\2W/ORK
M:DL%JHYH9J6@IXI8O,>UN".&.GT]/I00K+6U$^J+_32RN=!3\SS3#T-RTDX5
MOO\ 1\_S&]T_/9QS?.#:S\,K6K7-!3ZHU9+5O:R!C8"]SN@#8*J+JVR2Z>JQ
M;;!5\V(7/BJQ3;(! )#MMQVL(.@U$\-/'SE1+'$SUGN#1\RO*:I@JF%U-/%,
MT>F-X</V6BST]3.RQW>LH'W:B% QLD(_$YCR 2\-/G*_TU)9*D54MCBBIYR
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M*_1%NMI)%745++?(/2W8=Q/R ^:#?)ZVEIV,?/4P1,?YKGR!H=\,]*S,>U[
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M)&QRN@:6NA)Z#QZ0MK6N<HFS]SKCM=3,?';:KZDVMUAV_.V!GXX0941$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$&*J_@GXK1M2_VU%_A-_FY;S5?P3\5HVI?[
M:B_PF_S<D"YLGF#X!;'%Y@6N63S!\ MCB\P(0_2(B H53_$_135"J?XGZ()C
M?-'P7J\;YH^"]0$1$!$1 1$04VI[1)=*>G?23-AKJ6430/<,C:'H/N*_%NGU
M!)5Q,KZ*AAIQGG)&2EQ=P_NCT<<=*O$0:C<-,U-=-J4.DCCCN AYEV<X+./$
M>@9 7M12ZBN-IDML\-%1QF(QOF9(7EXQC#6XX9]_H6VH@UNGCOMLH+?3TE+1
MU,45-'&]KI2QP>!@X.,$="_5EM=>+Q6W>X-IX:F>(0LAA)< !QRX^D\ MB1!
MJ]4[4M51S4<MOMN96&-TW/$LP1C.SC*NK'0>2[12T6WSG,L#2[K/I4Y$&K.M
M]VM=^N-;;(*:K@KMESFR2<VZ-S1CIP<A9;):+C!J.JN=QEA>:BG#"(L@,<'>
M:,](P!QZULB(*2U6RHI=27NNEV.8J^9YO!X_A:0<A*JV5$NK:*XMV-WAIWQ.
MR>.2>'!7:(-69;KO9;E72V>*FJZ*LD,QAED,;HWGI(.,$%?NRVBY0ZGJ+K<I
M('<_3<V6Q$XC=M##1GI&!T]9*V9$%;J&U,O-JFHWO,;G8<R0?W' Y!5/41ZH
MJZ)U!)'01%[>;?6-D)RWH)#<=.%M2(-:O&GGNTY0VRW;)%-+&[+SC(:<D_$]
M*M[]2R5MEKJ6#9YV:%T;=HX&2"%.1!K-;I^HGL-GC@F9#<[:R,QO/%FTUH!!
M]QPI=MGO\M7&VOHJ*"G&><>R4N<[APV1Z...E7:(-8EMETM5VK*RR-IZBGK'
M!\M-,XL+7^LT^]6MGDNLIF==H:6!O#FV0O+W#ISM'HZNA62((5\I9*VS5U+#
MCG9H7QMVC@9(("K9[":S25/:JEXCGCAC D;QV)&@8(_4*_1!JM1'JBLHG4$L
M5!#MMYN2L;(3EIX$AN.G"RWC3[W:?MUMMVSBEFB?EYQD-SD_$Y6RH@+#6TT=
M91STTXS%,PQNQU$869$&J4$.I+12LH88**O@B&Q%,Z4QN#?0'#'H]R]K[9>3
M<;=>(F4<U?#$Z*:#:+6$$DY:3Z>/I6U(@U1]KO%?>[7<J_=HF4LCL4\;B[9:
M6\27>DYQ\D@MMXL575^1HZ:KH*F0S"&5Y8Z)QZ<'H(6UH@UR_6^YWC24]).R
MF9<)2T[+''8 #P>D^X?-75;"Z:W5$#,;;XG,&>C)!"DH@K-,T4MNL-%25.SS
MT3-EVR<C.2M:JV5QY0:N6UNB,\5&PF*7(;(TGB,CH/01\%O"KHK4R._3W02N
M,DL(A+,<  <Y05-/;;G<[Y2W"],@IX:,.,%/$_;)>?[SBIEJME12ZDO==+L<
MQ5\SS>#Q_"T@Y"NT04>I+145LM'76V5D5QHW%T1D'X7@C!:['H*\HZC44M3$
MVIHJ"G@#ASCQ,7DCT[( Z?BKU$%)?+9/6WBRU,.QS5)*]\F3@X( &%BOEIK#
M=8+O9GQ"MCC,,D4V0R5F<XR.@Y6P(@IK;/?9JMN_T='34H!VMF4O>XXX8X8"
M_.CK946FRMI:O8YT2/=^ Y&"<A7:(*2GME1'JZKN3MC=I:9L3>/':!ST+]:F
MM$ET@IY*2805U)()H)'#(SZ0?<5<H@U^GJ-2R2Q,FH;=$P.'.2\\YP(SQV6X
MZ?BOWJ2TU-744-PMDD;+A1.)8),[,C2,%IPKU$&FWRVW^_4;(ZB*DI&12-D$
M39"\R$'TG&  ">'6MR1$&K6^@N]HNU<*2"FJ*"LJ=X+W2%KH]KSN&.*D7JTU
MHN\5WLKX=[;'S,L,V0V5F<](Z"/_ %[]A1!3VR:^358-PI*.FI@#D,E+WD^C
M'HPOQHRV5%HT_3T=7L<\PO)V#D<7$_\ -7:(*2CME1#JNX7%^QN\\+(V8/'(
MZ<A>OML[M7Q7(;&[-HS >/XMK;ST=6%=(@I;G;9ZG4EEKH]CF*03<YD\?Q,P
M,#XK/:_*OE&X^4>9W/;&Z['G;/'.?V5FB"DU3;*B[QT=)'L"C,[7U63@EC>.
MR!Z<G^2NP,# Z$1!ICM*5+J.YT+)610&J%702 YYM_201Z!Z%GKZ?4EUMD]!
M4PT-*'QEKYF2%Q?PZ ,<,^G/H6V(@IH;09=)QVFKV=K=1"XCB X-QD? \5$T
M;9JRW-JJB[/9)6S;$>TPY 8QH _7IRMD1!K-3;+G;;S57"QBGFBJ\&>FF<6_
MB']YI_\ 7TL[1)=I7RNNL%+3QX'-LB>7NSZ<GH5FB"DT];*B@KKS-/L;%54F
M6/9.?P^]9+G->H:O-OI*2JI2T?A?*8WAWIXXQCH5NB#3'Z5JKJ;G571T--55
M08(FT^7"(LXAQ/I/_)3HIM5,C$+J.VOD QO!F<&GWEN,K940>,VM@;>-K'''
M1E:Y<;7<:2]RW6R&"1U0P,J*:8EH?CH<".@K9$055HEO$T[W72FI*: -_"V.
M0O>79])Z,8RJK65AK;E/!46J2..<QOIIB\XS$[Z<?FMJ1!KMWL$FQ;9[-)'#
M66YNQ")!^![,8+78]RRT51J&:JB;545#3TX/](X3%[B/^Z /YJ]1!25MLJ)M
M5VZXLV-W@ADC?D\<GHP$U1;*BY"V;ML?U>LCG?M''X6YSCW\5=H@UR^6ZX-O
MU)=[4R&>2.(P20ROV,M)SD%?IU5J6-Y/DZ@F8X AK:@M+#CB"2./'J6PH@HM
M+VJHH'W"JKC"*FMEYQT<.=AF.@#/2>/$J](!!!X@HB#5-(:;J+1<:J:J?&^)
MC3#2!IR6QEY<<]1R0OS3::J(M8ON!?'Y.#WU$<>>(E>T-<<?H2MM1!JS;;=K
M+7UDEE9355%52&9T$KRQT;ST[)Z,%7-G?<Y&2NNT5-"21S;(7%Q ].T3_P E
M8(@I-)VRHM='5Q56QM2U4DS=DY_"[&%@N]JKHKRV[V5T)J#'S4\$Q(;*WT$$
M=!_]?'8D05%JFO<U5FXTM'34P:>#)"]Y=Z/=CI5E64\=7234\PS%*PQN'N(P
M5E1!J=OI]26>D;04T-%6P1?AAG?(6$-] </=[ED-MNULN4]?:V4M0*QK75-,
M]Y8!(!Q<QW4>/2MH1!KUIM==+>G7>]&%L[8^9@@A)+8F^DDGI)4:*W7>R7"M
M=:(J:KH:N4S<U+(8W1//3@XXA;4B#6K':+C!J2KN=RD@>:FG#"(LX8X'S1GI
M& ./6L-);KS8)*B&T14U9;I)#)'%+(8WQ$](ST$+:T0:W<;5<KW971W TU+7
M,F$U,827!A;T;1/2>GHZPHUPIM27>UST%3#0TH?&6OE9(7&3W 8X GISZ%MJ
M((=EIWT=HHJ:;'.0P,C=@Y&0T JOU5:JBXP4DM!)&RMHYVSQ<YYKB/05>(@T
MR_V_4.H+5+2SPT=&P8=LME+S*X'@,XP!Z?3T!7EQDO-/)%Y-IJ2I@V 'LDD+
M'AWN.,8PK=$&DU^GKI=/*=95LI8*JHI1310QO)&-H.RYV.)X*XOUJJ*[2+[;
M!L;R8HV?B.!EI;GC^BOD01Y87.M[X1C;,18/CC"TNXTE13:5M>F^FYU&0T,=
M^##7;1VCZN%OBJ[W98;JZGE,LU/54Y+H9X78<W/2/>"@H:JLU'9**2LJ*2SO
MI8@#(RGVV.(]V>"VZEF;4TT4[ 0V1@>,].",JADTR^LV67:[5M;3@@F$[,;'
M8];9'%;"UH:T-: &@8 'H0:S5V^ZT.HZJY6J&GJHJN-K)(Y9-@M<W@"#CH4N
MQVVJI;Y>:RI$896&(L#79\UI!_=7B(*2>V5#]7TUR;L;M'2NA/'\6T7$]"@M
MMMVLM?6265E-5455(9G02O+'1O/3@]&"MI1!7V=]SD9*Z[14T))'-LA<7$#T
M[1/_ "6#5UNGNNGJRBI=GGI0W9VC@<' _P @K=$&O:MLU1<[5 *![8Z^F>U\
M3R<8]!&?A_)?BYV"0Z)-FH=CG1&Q@+C@$AP+C^O$K9$04=^LLEQM](*>805]
M(YLL$A&0' =!]Q6*"HU,^2..6AMT0!&W+SSG CTX;C/S6PH@U>2VW6TWFMK+
M-'3U--6D/E@E>6%K^L'WI;;3=/O2V[W)]/AU,8C'$3B/B"&C/3Z23UE;0B#4
M(J"_6Z]7:IM]/0RPUDK7@S2D$8!'0![UGBL=QN=?3U6HZBG=%3NYR*DI@=C:
M]!<3Q*VA$%)6VRHFU7;K@S8W>"&1C\GCD]& L>I+34U%70W*U%C;A2OQ^,X$
MD9Z6D_\ KTJ_1!1Z?ME3!<;I<;@&"IJY &!KMK8B:,-&>OK^"_6K;5-=+='N
M1:VNIY6SP.<< .!Z_AE72(/S&7&-ID :\@;0!S@K59Z"]T>I;E7VR"CFAJVQ
MM'/2%I&RT#T#KRML1!JKK)=+S4POU%44S:.%P>*2E!V7N'1M$_R5A7VV>?4]
MJKX]C=Z:.5K\GCEPP,!72(->OEIK?*\%WLSX=\CC,,D4V0V5F<XR.@Y4>XT-
MYOUGKJ.X04E&'M:8=B0O.V' \3U<,+:405=EDNLD;VW:EIX"UH#712;6V?2<
M8X#H5%2:6J?NI2T4DK(+C2SFHAE;^)K7;1(S[L%;BB#4Z^EU%>*0V^KBHJ*G
MDPV>>.0O+F^D-;CAGWJ;>+-),^Q,H@P04%0Q[@XXPQHQPZU?H@I]7VZ>ZZ>J
MZ*EV.>EV=G:.!P<#_P E!NUKN$=ZHKM;&03RPT^[R02NV<C).6GKXK9D0:KY
M+N];?[7<[ANT3:9SQN\;B[8:6D9VO22<?)3]+VRHMHN>\[']8K))V;)S^%V,
M9]_!7:(-:Y06M98#6->(ZFCE9- [_O[6,?KE9[+3^0-) S?Q8H75$Q/I>07'
M/\OT7M1IX5ES;4U]=4U%/')SL=*[ C:[T9QTX]ZNY&,D8YDC6O8X8+7#((05
MFE9JVIL-)47-X=4S-YPX:&X!.1P'NPK5  T    <  B#4*#3%3!J<SO?&;5%
M-)4P1@\1(\ 'AU#!PL[[9=;1=*RJLC:>II:Q_.R4\SBPM?Z2T^];0B"NL[[K
M)SKKM#2P XYMD+RXCISM$\.KH473%LJ+;Y5WG8_K-=)4,V3G\+L8S[^"NT04
M]QGOD-8[<:.CJJ4@;.U*8WM/ISP(PM=K-,7*MI[A4S;LRMK)X7F&-QV&-9[\
M<25O2(*G4MH-VH8VPR\S5P2MG@E(R&O;T9]RJ:^FU%>*1UOJXJ*C@DPV:>.0
MO+F^D-;CAGWK;$04%WLLDTEB91!@@H)V.<''&&-&.'65GU?;I[KIZKHJ38YZ
M79V=LX'!P/\ R5PB#\Q-+8F-/2  M)AMVI8[S/<I::W5-0[\,3I978A9U- Z
M/BMX1!4VE]WF=,R\T]'%$6X;S#RXD^G.54VRCOUAI=PHJ>DKJ-CG<S(^4QN:
M"2<.&./3Z%MB(-2CM5\H:*MJZ.6EDO-;.V27A_1M8,@-&>I6VH[5)=*&'F)6
MPUU/(V>"0C@'CT'W%6Z(-3J[?>[Z8*6[Q4E+0,D;),(I"]TV.@#J"VQ$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$&*J_@GXK1M2_VU%_A-_FY;S5?P3\5H
MVI?[:B_PF_S<D"YLGF#X!;'%Y@6N63S!\ MCB\P(0_2(B H53_$_135$JAT%
M!*9Q8WX+U8J5VU%CTC@LJ B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@PU7\+]5HNI' WQ@']V-H_<K=J
MM^2&]7$KG=5/OEZGE:<LV]EI]PX?\E8&TV3S!\ MCB\P+7[,W#!\ M@C\U0A
M^D1$!8*AN6K.ORX9""##(6.R.CTA3VN#FY:<A5E0UT;MIH^(2FJ03_1NP[TM
M*"T11V50_O CX+][Q'UGY(,J+%O$?7^R;Q'U_L@RHL6\1]?[)O$?7^R#*BQ;
MQ'U_LF\1]?[(,J+%O$?7^R;Q'U_L@RHL6\1]?[)O$?7^R#*BQ;Q'U_LF\1]?
M[(,J+%O$?7^R;Q'U_L@RHL6\1]?[)O$?7^R#*BQ;Q'U_LF\1]?[(,J+%O$?7
M^R;Q'U_L@RHL6\1]?[)O$?7^R#*BQ;Q'U_LF\1]?[(,J+%O$?7^R;Q'U_L@R
MHL6\1]?[)O$?7^R#*BQ;Q'U_LF\1]?[(,J+%O$?7^R;Q'U_L@RHL6\1]?[)O
M$?7^R#*BQ;Q'U_LF\1]?[(,J+%O$?7^R;Q'U_L@RHL6\1]?[)O$?7^R#*BQ;
MQ'U_LF\1]?[(,J+%O$?7^R;Q'U_L@RHL6\1]?[)O$?7^R#*BQ;Q'U_LF\1]?
M[(,J+%O$?7^R;Q'U_L@RHL6\1]?[)O$?7^R#*BQ;Q'U_LF\1]?[(,J+%O$?7
M^R;Q'U_L@RHL6\1]?[)O$?7^R#*BQ;Q'U_LF\1]?[(,J+%O$?7^R;Q'U_L@R
MHL6\1]?[)O$?7^R#*BQ;Q'U_LF\1]?[(,J+%O$?7^R;Q'U_L@RHL6\1]?[)O
M$?7^R#*BQ;Q'U_LF\1]?[(,J+%O$?7^R;Q'U_L@RHL6\1]?[)O$?7^R#*BQ;
MQ'U_LF\1]?[(,J+%O$?7^R;Q'U_L@RHL6\1]?[)O$?7^R#*BQ;Q'U_LF\1]?
M[(,J+%O$?7^R;Q'U_L@RHL6\1]?[)O$?7^R#*BQ;Q'U_LF\1]?[(,J+%O$?7
M^R;Q'U_L@RHL6\1]?[)O$?7^R#*BQ;Q'U_LF\1]?[(,J+%O$?7^R;Q'U_L@R
MHL6\1]?[)O$?7^R#*BQ;Q'U_LF\1]?[(,J+%O$?7^R;Q'U_L@RHL6\1]?[)O
M$?7^R#*BQ;Q'U_LF\1]?[(,J+%O$?7^R;Q'U_L@RHL6\1]?[)O$?7^R#*BQ;
MQ'U_LF\1]?[(,J+%O$?7^R;Q'U_L@RHL6\1]?[)O$?7^R#*BQ;Q'U_LF\1]?
M[(,J+%O$?7^R;Q'U_L@RHL6\1]?[)O$?7^R#*BQ;Q'U_LF\1]?[(,J+%O$?7
M^R;Q'U_L@RHL6\1]?[)O$?7^R#*BQ;Q'U_LF\1]?[(,J+%O$?7^R;Q'U_L@R
MHL6\1]?[)O$?7^R#*BQ;Q'U_LF\1]?[(,J+%O$?7^R;Q'U_L@RHL6\1]?[)O
M$?7^R#*BQ;Q'U_LF\1]?[(,J+%O$?7^R;Q'U_L@RHL6\1]?[)O$?7^R#*BQ;
MQ'U_LF\1]?[(,J+%O$?7^R;Q'U_L@RHL6\1]?[)O$?7^R#*BQ;Q'U_LF\1]?
M[(,J+%O$?7^R;Q'U_L@RHL6\1]?[)O$?7^R#*BQ;Q'U_LF\1]?[(,J+%O$?7
M^R;Q'U_L@RHL6\1]?[)O$?7^R#*BQ;Q'U_LF\1]?[(,J+%O$?7^R;Q'U_L@R
MHL6\1]?[)O$?7^R#*BQ;Q'U_LF\1]?[(,J+%O$?7^R;Q'U_L@RHL6\1]?[)O
M$?7^R#*BQ;Q'U_LF\1]?[(,J+%O$?7^R;Q'U_L@RHL6\1]?[(:B/K)_1!E7X
MED$;??Z L#ZD]#!CWE:]>M0048<R(B>JZ-D'(;\3_P D'FJ;IN=*8HW?UF<8
M&/[H])6MV> E[>'I"BM;/6U3IJ@E\CSDDA;/:*+9V>'5Z%475KBV6MX=2N&C
M 4:DCV6C@I0441$0$1$&*:,."I:ZB))<W@1T$!7ZQOB#@<A!J<E17T^=F3;
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>/FF]03FF]061$'X$8'H7Z#0%ZB B(@(B("(B#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g50309g89f02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g89f02.jpg
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M#^"S_2%%O/\ +I?P_NI4'\%G^D(/:(B#BW3K_/K?_NW_ ,17-%TOIU_GUO\
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MH/X+/](46\_RZ7\/[J5!_!9_I"#VB(@XMTZ_SZW_ .[?_$5S1=+Z=?Y];_\
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M'_I[5H--Z4N-^KJFEIVQP&E_COG):(^)&#PSG@?@KQQ/NX6V.XI:*6I.9Z-
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ML=BTA<;O?*NTM,-/5TK2Z03$@<' <, ]X6/3&EZS45RJ:*CE@CE@87N,I(!
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M_P#=O_B*YHNE].O\^M_^[?\ Q%<T7LT_Y8?SSQ?_ #FI]_Z"(BV^:(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B#-24\E550T\#=J65XC8.\DX"[1JZ?3%
MJH[78KT^L_ZG$R2,4W#CQ <?;P)_%<6IIY:6>.>GD?%-&=ICV'!:>\%>ZZMJ
M:^H,]=42U$Q !?*XN<0.7$K%J\4O?M=Y&VT[Q%<VMCKTPZGTE,I+A%IW5%+E
M](9&1RN(X[.UM#(]F'!2>D*Q7>YZRL]=;8WRTC61XF8X;,1#RXD]PP0<KDYN
ME<;<+>:RH-"#D0;P[ XYY<N?%9A?;J+?U$7&J%'C&YWIV<=V.[V+,4F'KOXE
MI:DWXZS^+AF<=X_I+O0D:=:WBF8\,JY;;$8B>?!T@)^+FJJ=&MCNMGH-1&Z4
M\E.V2'#6O/WB [)'LXCBN6R7BY25\=;)7U3JR,;+9C*=MH[@>?:5FDU%>99W
MS/NE897LW;G;UW%OA]WL4\N<8=I\7TK:D:EJSFLVQSC_ *NZ[Z2_[(-2?^.[
M_EC4RJM]7>.AZSP6R!]3,R;:<R/B0 Z0']2%S*"Y5L%#+10U<\=)*<R0M>0Q
MQX<QR/(?!9[;?;K;(70V^X5-/$XY+(Y"!GOQWK4TGJ\VGXAIQ6*7B<<'#./O
MG*_:?B?!T1:DAE:6R1U+F.:>PC=@A9;+3RWGH>FH+0-Y613'>Q-.'._Q-K^V
M/@N;MNMP;23THK:@4\[B^6/>'9>X\R1VG@%YMMRK;9,9;?534TA&"Z)Y;D=Q
MQS3@E*>(4B:Q-9QP36>_.>L.JBFFLW1G;Z&[MW57+6Q[J)Y])O\ BAW]@3^*
M@]*LKQTA64!Y 8R%S>/([UW'] N=5UUKZ^I945M943S,^X^1Y);[NY?*RYUU
M;5,J:RKGGJ& !LDCRYS<'(P3[4BF)RUK>)4OI^56LQ$<,1]JYZ_+HO250Q7+
MI,M5%/(8XIXHHW.'/!>[E[59K79J:TZSIZ6VZ:W=+"W)N<DCCQ+3RSPSDXQ[
MUQ*NN-97U#:BMJIJB=H#1)(\N< .(&2IE1J2]5#86SW6M>(G![,S.X.'(^\=
MZG!.,9=*>)Z-=6^K-.<VB8Z?'/./TYNLV+_:'I!_TM_Y)%Q!;".]7..6JDCN
M%4V2J_CN$I!EY_>[^96O6JUX7BWF[KN*UK$8Q-OWG+IW19_LCJ[_ '?_ /IO
M6EZ(/]N:3_PY/^0JKT=RK:*">&CJYX(IQB5D;RT/&",$#GS*QT-94T%0V>BG
MEIYV@@21N+7#//B$X>OU;IO:U\CE_A]?KSRZGK)^N*F6[4L=*Y]H>Y[6D,CX
MQ9..//E^*V.IW:;LMBM.GK^ZJ(AC;*&T_:X9!<?>2XKEIU5?R.-YN'Y[OW6N
MKZ^KN,^^KZF:IFP&[<KRXX[LE9C3GW>J_BE(X[4B;6MR_%SB(SG#IO2I%37O
M3%JU#;2]\+"87.</2V22!GW.:1_Q*QWN?4D&G-/^2T6\<:9N^]%CL#8;L_>_
M%<2;=*YMN=0-K*@43CDP"0[!XYY<N?%3(M3WR*)D<5WKV1L :UK9W  #D!Q3
MRYZ+7Q33X[WF)B;Q&<<N<>\?=BU*+A]N59O3"RX.<'2MP!Q(![.'+"UBSUE5
M45M2^HK)I)YWXVI)'%SC@8XDK ND='Q=2T6O,Q[S[]?U$1%6!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!U+HFWDFE
M=3PT!Q<71_X>R<.R6.#<?CE2-&4=RH^CO5#;E#40L=%(8F3M+3_#.T0#V<ES
M.T76NL]5UFV5,E/-C!<WM'<0>!'O4^IU;?:KK0GN4SVU3-U*TXPYO'AC&!S/
M+O7*:3,R^UM_$-*FG2+1.:Q:.6,<\\UO@_[#JC_>!_YK5OZ*2/5[Z>VZHLE?
M176!AW=6QKF@8'$AW9G'(Y"Y(+S<&V=UJ%2_[/<[:,.!@G.<]_,+;'7>I>K[
MG[6FV,8SLMVOFQG]4FDM:7B6E7AB\3B*UB8Q$Q.,]Y^O*5\TC;Y:33>L[9;9
MC-<89Y(VO8</>-G#?Q.'?BJ=I"AKK=J>R37JFJ:>CZULLZPTL&V1PP#[<<57
M;7>+A:JQU5;ZN6"=WWGM.=KWYY_BL][U'=KX(A=*U]0V,Y8"T- /?@ *\,\_
MJXVWNC:M)Q,6ITCVZYY^[I=9;KV[I@BJF0U1H]MI$P!W8BV/2&>7//#O*S6.
M2&3IINYIBTM%.6N+>6T!&'?KE<Z9K;4;*,4K;M4;H#9["['^K&U^JU=JNU=:
MJQU7;ZE\-0YI:9!@D@\3S]RG!+O/B>C6\36)QQ\<YQ\0Z/T;U<\_2;>C+*]V
M\;-M G(.)!CX+/T=-=)%KB&(%TCB0QC>9)WH& N:6Z]7"W7"6NHJI\-5('!\
M@ R<G)Y^U>K7?;G:ZZ6LM]9)#42YWCA@[63GB#P/%)I,Y<]#Q*FGP<43.)M,
M_:T87?H=I*JCUE-'74\T$CJ)S@V9A:2-MO'![.!6RT;-)3Z0UK+"\LD9),YK
M@<$'8/%<_.J[V;JZY?:$G73'N3*&MSL9SC&,8RHU-?;E34E92P5;V05A)G8
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MZS%)Z2]E_$].E[7T:SFUHF<SVG.(Q]79+=IZ\Q=+,]RDAD%#O))-_GT7,+"
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M^%VVID;'K/2-%+(U]=!2S&8@Y/&,#)]Y:5Q_7L\L^L+N9I'/+:E[&[1SAH.
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M#P]J^VVH@J>FRL=3.:YK8"QSF\BX,:#\#P_!<PAU)>H:,4L5UK64X&R&"9P
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MV!)O,Q+>EL-.NII5FV9OB<8Y8GOS<UJ6,943-@>9(6O(8_&-H9X''8O#F.:
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MM,=S8X#@YO;@\CQ"B56C[/4MO[9H9"+X&BMQ(1M[+=D8\/#N043I-MU)3?\
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MAF'1O>TCDX'!&/;S7G3&J;OKZ]T5+2B>T4UG]*];! <^I!+13M/'T,M+B>[
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MB%/4T;I*YV]<!LDL#'%I:[F,<.*O6KO(6ELEFM.I:&:GM\=.UU"]\$Q-.
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M'LV3MD@ N)/,E!V%%RO4NO:VEZ*=.W9D\=)<;T::G-28]MM.9&Y?*&]N UQ
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MTN:<TU<AO;/2T,MVFIG?<J) _=L#AVAIXX]I5UT+?9=3Z3MMZGH30.K8]ZV
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M2G:.0#QV0 "BNAHB(@B(@(B("(B#5ZEOUOTW9Y[G=YQ#2Q#NRY[CR:T=KB>
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M!@G#P<L(#O2P#D \CQ%??:[[H;0 JJ#I-I.IT%*7T],Z@@=%+@$B-K\[9R>
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MFL<2,/8<M/ ]A2[V>@O HQ<J9L_4ZEE7!DD;$K,[+N![,GGP1%)LW_;QJ/\
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M(,<#G.%"TSH73NF:Y];9Z Q5;X]T9I)Y)7;&0=D%[C@9 Y=RLR"GV2+7K;I
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MU*@_@L_TA1;S_+I?P_NI4'\%G^D(/:(B")6??'N6!9ZS[X]RP("+YE?4!$1
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M>*5\+MB5K'AQ8[GAV.1]A69 1$0$7S(SC*^H"+XOJ B(@(B("(B B^9XX7U
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M^"BB<-HND:PAI<<   DEQ[ 5<+'K.JFU)%8=26.2RW&IB=-2?]9;415#6_>
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MS-15<0S42,;LC8(!:UP:>)/,+H^HZ"EMF@+Q1VZGBIJ6&W3MCBB:&M:-V[D
MBN4Z&L71G6Z2LLUXN=!]JS4T;JALE[>Q^\(&06[T8.>S"[LQH8QK&\&M& N*
M]'VH>C:FT78H[I-I]MQCI(A/O:=AD$@:,Y.SG.5VIC@]C7-.6D9![PB/2(B
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MSTC:FHJXWS0$"0-,/I!I/(D9&>S*(L=+KJDJJB]ST].]]BM$3W5%TVO\-\C
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MPLV(8V1MR3AC0!D\25Y;30,G=.R")L[AAT@8 X^\\UF1 7EC&L;LL:UK>X#
M7I$'EK&-9L-:T,QC9 X*C:OL%W\KK1J.Q4U%<#0TTE,Z@JI3$!M$'>1NV2 [
MA@Y')7M$'/&V+4&I-662[:@H;?::2T/?+%#!.:B>9[F[.'/V6AK>.<#.5T%C
M6L:&L:&M'( 8"](@\M8UI<6M +CDX'-4356G[O%K:WZGL-'0W$P4CZ1]#4R[
MG9+G;6]C=LD!W#!R.2OJ(.>P6*_Z@UC9;YJ&BM]JIK1O70P4\YGFE>]NSZ3]
MEH#0..!GBNA(B#2ZHTS:]2VNIH;K2QR,F9L[P- D8>QS7<P0>(32ELK[78H:
M"\W,7::(; J70[MSV=@>-HY/M[??Q.Z1!@ZI3?T\/R!9=AFQL;+=C&-G'#"]
M(@^- : &@ #@ %\8QK!AC0T<\ 87I$!$1 1$0864T#)W3L@B;,_@Z0, <?>>
M:]F*-TK971L,K00UY R >8!7M$$::AI)Y1+-2P22#D]\8)'XE241!YV&[>WL
MC;QC:QQPFPW;+]D;1&,XXX7I$&@UU89-1:2N]JI9Q2U%; 8Q-CMY@'''!Y'V
M$JJS0ZUJM.NL+--V&C:^GZJ:DUI? UNSLDMB$>>7($KI*(-1I.R1:>T[;;7&
M_?&CIV0;XC!?@<_9Q[%M2QKG-<YH);R)')>D05GI&TY+JG2%QM5)-'3U4[6[
MN1XRW(<';+L<=DXP<=A5<NU/K2]Z?J+"=.V.VQ5$)II*EU:98V,(P2R(1@YQ
MR!/#@NDH@@6"VLLUCM]LBD=)'1T\=.U[N;@QH;D_!2JB"&HCW=1%'*SGLO:'
M#X%9405'3.CW::U!<*BT5^ZL=:=ZZUNBRV*8\WQNSZ(/:W!'Z8MCVM>TM>T.
M:>8(R"O2("\M8UI<6M +N)('->D0>=ANWM[(V\8VL<<=R](B B(@(B((=9;*
M"M$PK*&EJ!,T,D$L37[;020'9'$ D\#WKU;K=16RF%/;:.GHZ<'(BIXFQMS[
M@ %*1!@IZ2GIA**>"*(2O,D@8P-VW'FXXYD]Z@TFF['1UG6Z.S6V"KSG?14K
M&OS_ *@,KGVG9-9:GJM23T.K(Z"*@N]10PT[[;'*W9806Y=D'_-C\%J[KK2]
M5^BV&ID%%>;?J2&U5CZ-[FLEP\9+>.=EP(R$'7KG:Z"ZP"&Z4-+6P@Y#*B%L
MC0?<X%>K=;J*V4^XMM'34D&<[N")L;<^X !0=2:EM.FX89+S6"G$[BR)H8Y[
MY".8:UH)/P6DJNDC3HTS<[Q15PJ&T+2'Q;M[9!)LDM8YA&T,XYD8Y]R"P,T_
M9HZV6LCM-O;5R@B2=M,P/>#SR[&3E0Z?3%+!JT7UK@'QT#;?3T[6!K((PXN.
MSCOX#V *+H;6=NU3:8)X)@*L4L<]5'NWL;$YS<D!S@ 0#GB">2Q4/2/I2NN4
M5#37>-TLTFZB>8WMBD?X6R$;#C[CQ06N:*.:)\4S&R1/:6O8\9#@>!!':$AB
MC@A9%!&R.*-H:QC!AK0.0 '(*E72X5<?2_8Z!E3,VBEME1*^ /.PYP>T!Q'(
MD+:ZCUK8-.U;*2ZW 1U3F;S<QQ/E>&>(M8"0/:4&]IZ6GIW2NIX(HG3/,DA8
MP-+W>(XYGVE0ZVPV>OK&5==:K?4U3,;,TU,Q[QCEAQ&55-5=)MEM%!9*NCJH
M:R&YU44;7QASVMB+L/?Z(YM /H\\]G-6VR7>BOE *RV3.FIBXM#C&YG$<^#@
M"@]W.U6^ZPMANE!25L33D,J(6R-'X.!7VAMM%;:1U/;*.FI(>)$=/$V-N?<
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MO$9W;"7-<3C!',8SQSR03418NL1F*61CMX(MH.#!M'(YC'?[$&5%YB>)8F2
M.:'-#L.&",]X["O2 B(@(B("*!0W-M;4S1P4\^ZB<YAG( 8YS3@@<<\_9C@5
M/0$1:>#4EOE<STIV,>_=MED@>V-SLXP'D8Y\.:#<(B("(HU361T]524[PXOJ
M7.8P@< 0TN.?P!0241>(I8Y3((WM<8W;#\'D< X^!"#VB(@(BB7&X4UNBCDK
M)!&R201-.,Y<>2"6B+P^6-DD<;GM#Y,[+2>+L<3A![18J:<3L<YK)&AKW,P]
MI:3@XSQ[/:CYPRHBA+)"Z0.(<&DM&,<SV<^"#*BCOK(@P/9M2M,NY.[:78=G
M!SCD >9[%(0$1$!%JZN^T=+53P2BI+H,&5S*=[VLR,C) ('!3HJN";<[J9C]
M\S>1X/WF\.(]G$?%!F1$0$1$!$7ADT<CI6L>'.B=LO X[)P#CX$?%![18Z68
M5%/',ULC \9#9&EKA[P>2^"<&J,&Q)M!@?M;)V<$D8SRSPY(,J(B B+P)8S,
M80]N]#0\MSQ )(!_0H/:+Y(\1L<]WW6C)6JH]0T%4^%K3/'O_P"$98'L;)PS
MZ)(P4&V1:7REH]]N>KW'>[.WL=2EVMG.,XV>65N6G::",C(SQ&$'U$6LK+Y2
M4E7+3R"I=)$UKI#% ^0,!S@DM!QR*#9HL=-/%54\<]/(V2&1H<US>1"R("*#
M<KDRBD@B$,U1/.7;$40&2 ,D\2  .';VJ:TY:"01D<CV(/J(B B*-/61PUM+
M2O#C)4;>P0. V1DY0246KN-\I;?,8ZB*L^\UH<RF>YI)Y . P3QQ[U-H:IE9
M!O8XYXVYQB:)T;O@X H,Z(B B(@(M6;[1]9?"QM3+L/W3Y(J=[V-=RP7 84F
M>XTT%?344LH;45 <8VXYXXGW():+6UMYIJ2L-*^.JEF#!(6P4[Y,-)(!.R#C
MD5/IY1/"R5K7M#QD![2UP]X/$(/:(B B(@(L3I@VI9!L2%SFEVT&G9&,<">0
M/'E[UE0$1$!$1 11IZR.&MI:5X<9*C;V"!P&R,G*DH"(B B(@(B("(B B\/E
MC9)'&][0^0D,:3Q=@9.%[0$6HJ]04E+4[B:&NWA>6-V:20AY&?ND#CP!/!?#
MJ&D$AC$%>Z0-#G,;1R$M!SC( X<CS0;A%@?511T3JN4NCA;'O7%[2"UN,\0>
M(/L4=]VI&6@7(R.-(6AP<&DG!.!PYYR>2">BA6^Y15TCF1P5<9:,YGIWQ@^X
MN RIJ B+Q#*R>%DL+P^-[0YKAR(/(H/:(B B\/EC9)'&][0^3(8TGB[ R<+V
M@(B("(O#98W2OB:]ID8 7-!XC/+/P0>T1$!$1 1$0$1$!%X?+'&^-CWM:Z0E
MK 3Q<<$\/P!7M 1%&K:R.D=3"4.._F$+=D<G$$\?9P0241$!$1 1$0$1$!$7
MB66.+8WCPW;<&-R>9/((/:(M7<KW2VZ0LJ8JO +1MLIGN9D\ -H#&<D!!M$6
MG=J*D:YC#!7[QX)$?4Y-O QD[.,XXCBMA!5QRT?6B)(H@"X[YA8X <\@\1R0
M2$4!EWHWV<W1LI-&&%Y?LG( X'AS[$H+I%6RF.."LC(;M9FIGQM^+@!E!/1%
M$HKA35LU5%32A\E,_=RC'(__ (Y^!02T1$!$1 11IJR.*NIJ1P=O)VO<T@<
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M,;(QS'M#F.!!!Y$+$*6GVX'"&/:IP6Q'9&8P1C [N""F2&2CM$U-1@,A?=C
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M S@?J?B@T\3@W6%87$ =1BY_ZWK2U4P?676IHGGJSZRBCVV'T7O#P'X(Y\"
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M]ZA-147^CHFQME@,#Y1$^H="'O#@.8!S@=GMSV+<TEIM]'4&>EHJ>&8Y]-C
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M$=N!C/);6PT5927&8OCB@HWQ#$+:ETWI@_>&T!C(/'W!;6GM]'3TSZ>"EA9
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MIZ>2>0S,>_?9C:8RWB"!Q:0[/P7FMO%Q=2;$4<$57%7QTLOIDM.2TC'#D0X
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M*!@G#=W12TF=G.=L-&US[-GE[4'RGNM<*BWFLI8(Z:N.RS8D)?&=DN&UPQQ
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MXY.,C [UN;C%5RQM;2/I@.(>V>,O:X?@0@U]QO4E!248J.IMJJEY:UQFV80
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M%KB<9 P>2ET]H,+K.=\#U"$Q'T?OY:&Y]G):G5%)N(ZLR2L9#<JB(/ED;ED
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M1M;_ '!62PT\M%8:&GF:-_# UCF@_P"8#EE! J);E05MOWU<RIZS/NG0"$,
M&"2YISGACM)4"W7BMFJJ,&K9)5R3EE10"( P,XY.>8QPXG@<\%FH&78ULE57
M6QQJI/\ #;(*AA;3L)Y-'ZD\RL-):*ML5NI_L^."IIIFODKQ(TE^#Z9'^8E_
M:#PX^Q!NKU4U#:BAHJ.00S53W RENUL,:TDD \,\AQ[TLU34.J:ZBK)!-+2N
M;B4-V=MCAD9 X9YCAW+!<8JZ6LAJXJ1I=13$,9O1_CQN9@D>$@GD>Y9K+35
MJJ^NK(Q#+5.:&Q!P<6,:,#)'#)XG@@VJ(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@^/^X[W*@TG\YD]X_L%?G_<
M=[E0:3^<R>\?V"L(O-)_""S+#2?P@LRBH=W;M6^8#NS^JD4S@ZGB<.1:#^B^
MS-#XW-/$$8*@6J;=EU)*</9]PG_,$&R1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M!XF<&PO<>0:2J%0G:O$I'80/T5FU-<HZ.C>S.7N'$?\ I^*K6FX'R3&5_P!Y
MQR2K"+S2?P@LRQP#9C'N6111:NY4A>-MG!XX@CL6T7QS0X8*#01WJ6F]"J9M
M ?YN167RDHQS./\ B"EU=O9,#EOZ+436"-Q/H_HJB9Y2T7B'S#]T\I:+Q#YA
M^ZUOD\SPGX)Y/,\)^"#9>4M%XA\P_=/*6B\0^8?NM;Y/,\)^">3S/"?@@V7E
M+1>(?,/W3REHO$/F'[K6^3S/"?@GD\SPGX(-EY2T7B'S#]T\I:+Q#YA^ZUOD
M\SPGX)Y/,\)^"#9>4M%XA\P_=/*6B\0^8?NM;Y/,\)^">3S/"?@@V7E+1>(?
M,/W3REHO$/F'[K6^3S/"?@GD\SPGX(-EY2T7B'S#]T\I:+Q#YA^ZUOD\SPGX
M)Y/,\)^"#9>4M%XA\P_=/*6B\0^8?NM;Y/,\)^">3S/"?@@V7E+1>(?,/W3R
MEHO$/F'[K6^3S/"?@GD\SPGX(-EY2T7B'S#]T\I:+Q#YA^ZUOD\SPGX)Y/,\
M)^"#9>4M%XA\P_=/*6B\0^8?NM;Y/,\)^">3S/"?@@V7E+1>(?,/W3REHO$/
MF'[K6^3S/"?@GD\SPGX(-EY2T7B'S#]T\I:+Q#YA^ZUOD\SPGX)Y/,\)^"#9
M>4M%XA\P_=/*6B\0^8?NM;Y/,\)^">3S/"?@@V7E+1>(?,/W3REHO$/F'[K6
M^3S/"?@GD\SPGX(-EY2T7B'S#]T\I:+Q#YA^ZUOD\SPGX)Y/,\)^"#9>4M%X
MA\P_=/*6B\0^8?NM;Y/,\)^">3S/"?@@V7E+1>(?,/W3REHO$/F'[K6^3S/"
M?@GD\SPGX(-EY2T7B'S#]T\I:+Q#YA^ZUOD\SPGX)Y/,\)^"#9>4M%XA\P_=
M/*6B\0^8?NM;Y/,\)^">3S/"?@@V7E+1>(?,/W3REHO$/F'[K6^3S/"?@GD\
MSPGX(-EY2T7B'S#]T\I:+Q#YA^ZUOD\SPGX)Y/,\)^"#9>4M%XA\P_=/*6B\
M0^8?NM;Y/,\)^">3S/"?@@V7E+1>(?,/W3REHO$/F'[K6^3S/"?@GD\SPGX(
M-EY2T7B'S#]T\I:+Q#YA^ZUOD\SPGX)Y/,\)^"#9>4M%XA\P_=/*6B\0^8?N
MM;Y/,\)^">3S/"?@@V7E+1>(?,/W3REHO$/F'[K6^3S/"?@GD\SPGX(-EY2T
M7B'S#]T\I:+Q#YA^ZUOD\SPGX)Y/,\)^"#9>4M%XA\P_=/*6B\0^8?NM;Y/,
M\)^">3S/"?@@V7E+1>(?,/W3REHO$/F'[K6^3S/"?@GD\SPGX(-EY2T7B'S#
M]T\I:+Q#YA^ZUOD\SPGX)Y/,\)^"#9>4M%XA\P_=/*6B\0^8?NM;Y/,\)^">
M3S/"?@@V7E+1>(?,/W3REHO$/F'[K6^3S/"?@GD\SPGX(-EY2T7B'S#]T\I:
M+Q#YA^ZUOD\SPGX)Y/,\)^"#9>4M%XA\P_=/*6B\0^8?NM;Y/,\)^">3S/"?
M@@V7E+1>(?,/W3REHO$/F'[K6^3S/"?@GD\SPGX(-EY2T7B'S#]T\I:+Q#YA
M^ZUOD\SPGX)Y/,\)^"#9>4M%XA\P_=/*6B\0^8?NM;Y/,\)^">3S/"?@@V7E
M+1>(?,/W3REHO$/F'[K6^3S/"?@GD\SPGX(-EY2T7B'S#]T\I:+Q#YA^ZUOD
M\SPGX)Y/,\)^"#9>4M%XA\P_=/*6B\0^8?NM;Y/,\)^">3S/"?@@V7E+1>(?
M,/W3REHO$/F'[K6^3S/"?@GD\SPGX(-EY2T7B'S#]T\I:+Q#YA^ZUOD\SPGX
M)Y/,\)^"#9>4M%XA\P_=/*6B\0^8?NM;Y/,\)^">3S/"?@@V7E+1>(?,/W3R
MEHO$/F'[K6^3S/"?@GD\SPGX(-EY2T7B'S#]T\I:+Q#YA^ZUOD\SPGX)Y/,\
M)^"#9>4M%XA\P_=/*6B\0^8?NM;Y/,\)^">3S/"?@@V7E+1>(?,/W3REHO$/
MF'[K6^3S/"?@GD\SPGX(-EY2T7B'S#]T\I:+Q#YA^ZUOD\SPGX)Y/,\)^"#9
M>4M%XA\P_=/*6B\0^8?NM;Y/,\)^">3S/"?@@V7E+1>(?,/W3REHO$/F'[K6
M^3S/"?@GD\SPGX(-EY2T7B'S#]T\I:+Q#YA^ZUOD\SPGX)Y/,\)^"#9>4M%X
MA\P_=/*6B\0^8?NM;Y/,\)^">3S/"?@@V7E+1>(?,/W3REHO$/F'[K6^3S/"
M?@GD\SPGX(-EY2T7B'S#]T\I:+Q#YA^ZUOD\SPGX)Y/,\)^"#9>4M%XA\P_=
M/*6B\0^8?NM;Y/,\)^">3S/"?@@V7E+1>(?,/W3REHO$/F'[K6^3S/"?@GD\
MSPGX(-EY2T7B'S#]T\I:+Q#YA^ZUOD\SPGX)Y/,\)^"#9>4M%XA\P_=/*6B\
M0^8?NM;Y/,\)^">3S/"?@@V7E+1>(?,/W3REHO$/F'[K6^3S/"?@GD\SPGX(
M-EY2T7B'S#]T\I:+Q#YA^ZUOD\SPGX)Y/,\)^"#9>4M%XA\P_=/*6B\0^8?N
MM;Y/,\)^">3S/"?@@V7E+1>(?,/W3REHO$/F'[K6^3S/"?@GD\SPGX(-EY2T
M7B'S#]T\I:+Q#YA^ZUOD\SPGX)Y/,\)^"#9>4M%XA\P_=/*6B\0^8?NM;Y/,
M\)^">3S/"?@@V7E+1>(?,/W3REHO$/F'[K6^3S/"?@GD\SPGX(-EY2T7B'S#
M]T\I:+Q#YA^ZUOD\SPGX)Y/,\)^"#9>4M%XA\P_=/*6B\0^8?NM;Y/,\)^">
M3S/"?@@V7E+1>(?,/W3REHO$/F'[K6^3S/"?@GD\SPGX(-EY2T7B'S#]T\I:
M+Q#YA^ZUOD\SPGX)Y/,\)^"#9>4M%XA\P_=/*6B\0^8?NM;Y/,\)^">3S/"?
M@@V7E+1>(?,/W3REHO$/F'[K6^3S/"?@GD\SPGX(-EY2T7B'S#]T\I:+Q#YA
M^ZUOD\SPGX)Y/,\)^"#9>4M%XA\P_=/*6B\0^8?NM;Y/,\)^">3S/"?@@V7E
M+1>(?,/W3REHO$/F'[K6^3S/"?@GD\SPGX(-EY2T7B'S#]T\I:+Q#YA^ZUOD
M\SPGX)Y/,\)^"#9>4M%XA\P_=/*6B\0^8?NM;Y/,\)^">3S/"?@@V7E+1>(?
M,/W3REHO$/F'[K6^3S/"?@GD\SPGX(-EY2T7B'S#]T\I:+Q#YA^ZUOD\SPGX
M)Y/,\)^"#9>4M%XA\P_=/*6B\0^8?NM;Y/,\)^">3S/"?@@V7E+1>(?,/W3R
MEHO$/F'[K6^3S/"?@GD\SPGX(-EY2T7B'S#]T\I:+Q#YA^ZUOD\SPGX)Y/,\
M)^"#9>4M%XA\P_=/*6B\0^8?NM;Y/,\)^">3S/"?@@V7E+1>(?,/W3REHO$/
MF'[K6^3S/"?@GD\SPGX(-EY2T7B'S#]T\I:+Q#YA^ZUOD\SPGX)Y/,\)^"#9
M>4M%XA\P_=/*6B\0^8?NM;Y/,\)^">3S/"?@@V7E+1>(?,/W3REHO$/F'[K6
M^3S/"?@GD\SPGX(-EY2T7B'S#]T\I:+Q#YA^ZUOD\SPGX)Y/,\)^"#9>4M%X
MA\P_=/*6B\0^8?NM;Y/,\)^">3S/"?@@V7E+1>(?,/W3REHO$/F'[K6^3S/"
M?@GD\SPGX(-EY2T7B'S#]T\I:+Q#YA^ZUOD\SPGX)Y/,\)^"#9>4M%XA\P_=
M/*6B\0^8?NM;Y/,\)^">3S/"?@@V7E+1>(?,/W3REHO$/F'[K6^3S/"?@GD\
MSPGX(-EY2T7B'S#]T\I:+Q#YA^ZUOD\SPGX)Y/,\)^"#9>4M%XA\P_=/*6B\
M0^8?NM;Y/,\)^">3S/"?@@V7E+1>(?,/W3REHO$/F'[K6^3S/"?@GD\SPGX(
M-EY2T7B'S#]T\I:+Q#YA^ZUOD\SPGX)Y/,\)^"#8G4M%C[P^8?NM?7ZL8&EM
M*TEW_=XGX\E\\GF>$_!98; P'BW]$%;;'572I$DX.SG(;W*Y6:@W#!P4BCML
M<('H_HMBQH:,!!] P$1%%$1$!,!$0,#N3 [D1 P.Y,#N1$# [DP.Y$0,#N3
M[D1 P.Y,#N1$# [DP.Y$0,#N3 [D1 P.Y,#N1$# [DP.Y$0,#N3 [D1 P.Y,
M#N1$# [DP.Y$0,#N3 [D1 P.Y,#N1$# [DP.Y$0,#N3 [D1 P.Y,#N1$# [D
MP.Y$0,#N3 [D1 P.Y,#N1$# [DP.Y$0,#N3 [D1 P.Y,#N1$# [DP.Y$0,#N
M3 [D1 P.Y,#N1$# [DP.Y$0,#N3 [D1 P.Y,#N1$# [DP.Y$0,#N3 [D1 P.
MY,#N1$# [DP.Y$0,#N3 [D1 P.Y,#N1$# [DP.Y$0,#N3 [D1 P.Y,#N1$#
M[DP.Y$0,#N3 [D1 P.Y,#N1$# [DP.Y$0,#N3 [D1 P.Y,#N1$# [DP.Y$0,
M#N3 [D1 P.Y,#N1$# [DP.Y$0,#N3 [D1 P.Y,#N1$# [DP.Y$0,#N3 [D1
MP.Y,#N1$# [DP.Y$0,#N3 [D1 P.Y,#N1$# [DP.Y$0,#N3 [D1 P.Y,#N1$
M# [DP.Y$0,#N3 [D1 P.Y,#N1$# [DP.Y$0,#N3 [D1 P.Y,#N1$# [DP.Y$
M0,#N3 [D1 P.Y,#N1$# [DP.Y$0,#N3 [D1 P.Y,#N1$# [DP.Y$0,#N3 [D
M1 P.Y,#N1$# [DP.Y$0,#N3 [D1 P.Y,#N1$# [DP.Y$0,#N3 [D1 P.Y,#N
M1$# [DP.Y$0,#N3 [D1 P.Y,#N1$# [DP.Y$0,#N3 [D1 P.Y,#N1$# [DP.
MY$0,#N3 [D1 P.Y,#N1$# [DP.Y$0,#N3 [D1 P.Y,#N1$# [DP.Y$0,#N3
C[D1 P.Y,#N1$# [DP.Y$0,#N3 [D1 P.Y,!$0$1$!$1!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g50309g89f03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g89f03.jpg
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M 0$!              4! P0&!P(("?_$ %X0  $# P$$! <*# ,$"0(#"0$
M @,$!1$&$A,A,0<405$5(E)A<8&1%A<R,U-5DI2AT2,T-4)45G*3L;+!TF)S
ME0@D-N(8)72"HK/3U/ WX4-$=8/"\5=C)V2CI/_$ !H! 0$! 0$! 0
M       ! @,$!0;_Q  X$0$  @( ! 0#!P0" 00#     0(#$002(3$3%$%1
M!6'P(C)2<8&1H2.QP='A\4(&%3.")%/2_]H # ,!  (1 Q$ /P#ZI1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%C7&
MX4=MIG5%PJH*6 <Y)GA@]I6D]*/2+3:/IQ2TK65-XE;ED1/BQ#RG_P!!VKYJ
MOU]N5_K75=WK):F8\ML\&CN:.0'F"[X\$WZSV>7-Q5<<ZCK+Z8KNEK1]*\L%
MS=.X<]S ]P]N #ZEB>_-I'](J_JY7S B[^6H\GG<GR?3_OS:1_2*OZN4]^;2
M/Z15_5ROF2.GFDADECAD?%%C;>UI+69Y9/8O!:0,D'">7H><R/I[WYM(_I%7
M]7*>_-I'](J_JY7S!@XS@X3!QG'!/+4/.Y/D^G_?FTC^D5?U<I[\VD?TBK^K
ME?, !(R <(GEJ'G<GR?3_OS:1_2*OZN4]^;2/Z15_5ROF#! Y(01S&$\M0\[
MD^3Z?]^;2/Z15_5RGOS:1_2*OZN5\P(GEJ'G<GR?3_OS:1_2*OZN4]^;2/Z1
M5_5ROF!7GTE1'2QU+Z>9M/(2&2EA#'$<P#R/)/+T/.9'TS[\VD?TBK^KE/?F
MTC^D5?U<KY@1/+4/.Y/D^G_?FTC^D5?U<I[\VD?TBK^KE?,U725%'(UE73S0
M/<T.#96%I(/(X/8K*>7H><R?)]/^_-I'](J_JY3WYM(_I%7]7*^8$3RU#SN3
MY/I_WYM(_I%7]7*>_-I'](J_JY7S B>6H>=R?)]/^_-I'](J_JY3WYM(_I%7
M]7*^8%E1VVNDHG5D=%4OI&_"G;$XL'I=C">7H><R/I7WYM(_I%7]7*>_-I']
M(J_JY7S"&D\@3Z%0@@\1A/+4/.Y/D^G_ 'YM(_I%7]7*>_-I'](J_JY7S B>
M6H>=R?)]/^_-I'](J_JY3WYM(_I%7]7*^8$3RU#SN3Y/I_WYM(_I%7]7*>_-
MI'](J_JY7S F#C..">6H>=R?)]/^_-I'](J_JY3WYM(_I%7]7*^8 "1D#@%7
M9/#@>*>6H>=R?)]/>_-I'](J_JY3WYM(_I%7]7*^8,<<*H:X\@?8GEJ'G,GR
M?3WOS:1_2*OZN4]^;2/Z15_5ROF @@X(PB>6H>=R?)]/^_-I'](J_JY3WYM(
M_I%7]7*^8$3RU#SN3Y/I_P!^;2/Z15_5RGOS:1_2*OZN5\P(GEJ'G<GR?3_O
MS:1_2*OZN4]^;2/Z15_5ROF#!QG'! ">03RU#SN3Y/I_WYM(_I%7]7*>_-I'
M](J_JY7S#LG.,'/<J)Y:AYW)\GU WIETB2 :FK'G-.Y3]DU[IB]2-CM]XIG2
MNX".7,3B>X!X&?4OD!%)X:OHL<;>.\0^YD7R[T=]*-TTU-%2W&22OM&0#&]V
M7Q#O83_*>'H7TQ:KC2W6W05UOF;/2SMVV/;VC[_,O-DQ33N]V'/7+'3NRD1%
MS=A$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!%J.OM>VO1U,.M$U%?(,Q4D;L.=YW'\T>?V K@FI.E?5%YE<(:TVZG/P8J
M3Q"!YW_"SZPNM,-K]7GR\33'TGN^J47Q1/>KI4/VY[E6RO\ *?.]Q^TJWX3K
M_P!.JOWKOO77RL^[AYZ/POMM%\2>$Z_].JOWKOO3PG7_ *=5?O7?>GE9]SST
M?A?;:+XD\)U_Z=5?O7?>GA.O_3JK]Z[[T\K/N>>C\+[;1?$GA.O_ $ZJ_>N^
M]/"=?^G57[UWWIY6?<\]'X7VVB^)/"=?^G57[UWWIX3K_P!.JOWKOO3RL^YY
MZ/POMM%\2>$Z_P#3JK]Z[[T\)U_Z=5?O7?>GE9]SST?A?;:+XD\)U_Z=5?O7
M?>GA.O\ TZJ_>N^]/*S[GGH_"^VT7Q)X3K_TZJ_>N^]/"=?^G57[UWWIY6?<
M\]'X7VVB^)/"=?\ IU5^]=]Z>$Z_].JOWKOO3RL^YYZ/POMM%\2>$Z_].JOW
MKOO3PG7_ *=5?O7?>GE9]SST?A?;:+XD\)U_Z=5?O7?>GA.O_3JK]Z[[T\K/
MN>>C\+[;1?$GA.O_ $ZJ_>N^]/"=?^G57[UWWIY6?<\]'X7VVB^)/"=?^G57
M[UWWIX3K_P!.JOWKOO3RL^YYZ/POMM%\2>$Z_P#3JK]Z[[T\)U_Z=5?O7?>G
ME9]SST?A?;:+XD\)U_Z=5?O7?>GA.O\ TZJ_>N^]/*S[GGH_"^VT7Q)X3K_T
MZJ_>N^]/"=?^G57[UWWIY6?<\]'X7VVB^)/"=?\ IU5^]=]Z>$Z_].JOWKOO
M3RL^YYZ/POMM%\2>$Z_].JOWKOO3PG7_ *=5?O7?>GE9]SST?A?;:+XD\)U_
MZ=5?O7?>GA.O_3JK]Z[[T\K/N>>C\+[;1?$GA.O_ $ZJ_>N^]/"=?^G57[UW
MWIY6?<\]'X7VVB^)/"=?^G57[UWWIX3K_P!.JOWKOO3RL^YYZ/POMM%\2>$Z
M_P#3JK]Z[[T\)U_Z=5?O7?>GE9]SST?A?;:+XD\)U_Z=5?O7?>GA.O\ TZJ_
M>N^]/*S[GGH_"^VT7Q)X3K_TZJ_>N^]/"=?^G57[UWWIY6?<\]'X7VVB^)/"
M=?\ IU5^]=]Z>$Z_].JOWKOO3RL^YYZ/POMM%\<6O6>H[8]KJ*]U[ WDQTQ>
MSZ+LC[%U;0_3:9)HZ35D+&-=P%; W '[;/ZCV+%N'M'6.KI3C*6G4]'<47B"
M:.HA9+!(R2)X#FO8<AP[P5[7!ZQ$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$) &2<!675# <#+O0@O(L?K#ODRF_=\F4
M&0BQ]^[Y,IOW?)E!D(L??N^3*;]WR909"+'W[ODRF_=\F4&0BQ]^[Y,IOW?)
ME!D(L??N^3*;]WR909"+'W[ODRF_=\F4&0BQ]^[Y,IOW?)E!D*+U1>8=/Z?K
M[I4\64T1>&^4[DUOK) ]:S-^[Y,KE/\ M%7.2/25%1M!:*FJ!=YVM:3CVD>Q
M;QUYK1#GEOR4FS@=XN55=[I4W"OD,E34/+WN/?W#S#D!W+#1%]+L^',[ZBZC
MHC0UGNFB_#-3%=+G5;YT<M+;7QA\#1GCLNXN/ ' [QP7+EO.A]8VC3,=/4&Q
M337:#:Q4QUSXFR@DX#V 8(&<>I8R;U]EUPS6+?:[,S3-"'Z%UY)2UEPIZ:G=
M$&TY+0)&[;@!(-G.0!V$+LKFUS9K4^>6V^Y>*U-DKX)XP^0X:[Q@,$X^#YN!
M7!H-;R"U:LIIZ)KYK]*)72,?LMA(<7'#<'//O4E/TFU'NHL]WI:'=,HJ)M#-
M3NEVA41@G.3CAG/GP0%RMCM:?KV=\>6E([_6Y;GT<W"S4NB;QUN!O@2NO3Z0
MA_#=Q2, :3Z/%]'-0UUT[-ICHXUG;*D;1BN$!BD(^'&2W9=ZQ]N5J%QU922Z
M8N=DM]K=2TU7<!7,S/M[H;(&QC9&1PX'N4K<.DN2Z:&@T]<[>9Y&&)LE6)L.
MD8QX(!&SSP,9SYU>2V]_-/$I,:GTAT30-H=;M(V.R3VZ::'4$51+6SMA+FPA
MS/P>78X9&/6N!72AEMMRJZ&I&)J:5T3QYVD@_P %NM_Z4KW6WV.LM<]1;:&(
M1M911S$LPWL/ 9SZ.7!:]KF_0ZEU)4W:"BZEU@-+XMYM^,!@G.!SP%K'6T3N
M?5C+>EJQ%?1V^S:;H[QI31==6QMJ6VV@DG90M(#ZJ3#2UN#S QQ]([%H5KHZ
M/7,&J=3:LJ*R V]T3A'2[/BQDN_!AKASX #B.)R<J'EZ0:F.GTF*"FZO46%K
MFB0R;0G!V001@8! (YGFK]QU_234NJ8**RFE;?1&YXZQM")[22YP&R,[6<X[
M\K,4M'U\W2<F.?KOT4UEI&UQ4.FKCIB2K-->B8VQ59!<QX<&\QYS]BV-W1[I
M>6^U.DZ6MN?NCAI][UEX9U=S]D.V<<\8(^]:-==6OK-,Z=M4-,8);.Y[VU D
MSMESMH'&.&/25M+^E2F%5->(-.PQZGF@W#J[K#BSD!M"/&,X [>SFK,7UT9K
M;%N9GY?\L*U:7T]:]'4E^U>^Y2=>G?#!3T.P"T-)!<2[GQ:?L6XTVE&:LZ.M
M,4EMDEAM,-953/FFP7L@$DF,@<W$8X#M6B6/6] S2\-AU-8Q=J2FE=-3N;4.
MA>PDDD$@<1DGVK(;TFU-%;+3262C-O;05DM2&MF+F/8][W;HMP,@!V.?GX):
MMY_=:7QQ'7MK]?1 R6#P[>ZR'1-#7U=%!C&]+72$<MHX P#W+8;5I&R6S1LE
M[UDZY,DDK'445/1[.TQS<AQ=M<\%KN&>SSK6M1:@967^JN5C@GL[:GQI(8J@
MD;7:00!P//'?E3%BUQ30Z6EL>HK.+Q3"<U4#G5#HW,D.<Y(XD9)]I6IBVNCG
M6:;G?_#?M:Z7IM4])-'!453XK;2V2.JFE8/&,;7.'#/(G(^U:A7Z8TQ6:<@U
M)8I;G':X*YE)70519O TD9<P@$<G#GGGYE2?I1G=K&FOD5LA9&*$4%12&3+)
M69).#CQ>)&.>,=JCM2ZSHZO38L&GK,VTVQT_6)FF<S/D?V<3R' >P+%:WC4.
ME[XYW/U\FXTW13:QJ&]4=;55<=(R2*"VR![<R2/C<_#CL\<8QPPM8J=&4%%0
M:,96OJFW.]5($[ X!L<)D#1@8R"0X<3GD>"NW/I.J:VBTW"VBW<MIGBGEEWN
M>LNC:&C(QPR,]_-1^J==.ONLK7>^H[B"WF'=THDSP8_:(VL=I\RM8R>J6MBU
MT^O^NS;G]'^E)KQ?M/T-7=3>*"G?4MFDV-S@8(9@#)QM-!/#MPN>:#TZ=4ZH
MHK3O3"R4ETD@&2UK02<>?ACUJ?HND(4VM[WJ#P:7"Y4SZ?<;[&[VMCCM;/'X
M'=VK5]*7VITU?J2ZT0:Z:!Q.P_D]I!!!]()6JQ>(EBUL<VCVW_#=;EI/3-RT
M]>Z_2L]S;-97M%0RKV")F$D;3<<N1/'NY+8>DFZV^@Z--/4%MGNT,=71 T\8
M<QL<C,L+M^!S."<8X9*U*^:]H9;%<K=IVPLM7A1X?6RFH,I?@YV6@@;(Y^T\
M%"ZJU0+[9M/T I-QX*IC3[>\VM[\'CC Q\'S\UF*VF8VW.2M8F*]YC_/^G0.
MA<US="ZH?:*BEI:\30[J>J($;._)((Y9'I4(^UUFH->U<.J(JJ]3Q4[276/=
MEI.!LY<0&@8)R>]:U9M4"W:,OEAZIO#<G1NWV\QN]AP/P<<<X[PLG0>KX=-T
MEXH:ZWFNH+G$V.5C)C$\8VN3@.7C%7EF)F82,E9BM9GI_P!MAU=T<T]+=],4
M]J=54K;T\QNAK"U[Z=P+<\6\",.^Q1FLK=HNSU-1:Z)U\DN-)4-BFF<8S&X
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M@C#FPQ'&/:!]);_IYC?#'1?XHXVJ?/#G^"8N0=(VL7:QNE-4-I!14]/%NXX
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ME!)75,<Q:Z:+8+<L!'#\X=_(\UI.B-84]AM-WM5RMIK[?<FMWC63F%X+<_G
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M*:ZUE''/30^+L1D\R]V!D$AV .Y1]_UQ0S:<J[+IRQ,M-+6RB:K<9S*Z0@Y
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MMB-Y<TX).1GD./+CZ5JZ[4WK[7=Y\G+S3R]A=?\ ]GO5<E%>7Z?JI":2LR^
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M%9ZPQ.L,07D5GK#$ZPQ!>16>L,3K#$%Y%9ZPQ.L,07D5L3L/:O8<#R*"J(B
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MX=X3Q?>$\#VGZUMP_!QG'!95IH)KI=*2@I=G?U4K88]HX&TXX&2NZ4U3/?\
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M$2 50J*H051$1($1$41$0 JA4"J$%41$!7*7C-ZE;5RD^-]2#,1$0$1$!$1
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M9?-L7UF/^Y2WAS&HEJOC5G<UF?K3.Z8F6%L%J=0Q6Z"^NVC716^7>1-'9DX
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M1]NAJ[Q6RTU'5/BIHG@/#3M$;?;@]P^Q8M_-K<ZY6Z*AH&8H#.V=C&Y#B2W
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M0$1$!$1 1$0$1$!$1!?;\$>A55&_!'H55EH1$01>H_R95?Y+_P""A])_%-]
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M2N\*QVYM*987U66O#@#M,VCQ+3P/%"$]0W]U5!%4&V5L=-,Y@ADPUVV'' )
M)(';D]BG%H\;)+=I6PR4U55;51/2!^U*2 #C+1W-\RSZ>&6_76ZFHK:N"FI)
MNKQ14\ICXAH)<XCB>)X(-AZTWK_5-W-M;K>[S8\3&<8VN_S+)"U6IK)K;J"=
M@FFE@IK.9MA[R=IS7_"/>2!S4)%57!UJ@KZ47Z:ZN#)>+'=7?D@EH;RV<$X(
MXH.BHM49!/=-4WFFFKJN*C@9 X10REGC.:>T<0.!X#FL3PI6VZP7N-E0^::D
MK!2P33':< XLP2>W&T4&[*H6N5&G98[?4]5NES=6.B(:]]2X@OY@XY#B.SL*
MQ)+M+=Z.PP4DCX9ZUX?4%A+2QD?Q@SV>-XJ#9ZRJ;2[G:CFDWLK8ANV;6R3V
MGN'G60H/54\L#;3N)7Q[RX0QOV3C::<Y!\RP[G'45NL8Z$5M3!1FAWLC(7[)
M<1)@<>SGS''@D#:%@W*XQT$E$R1CG&JG$#=GL)!.3YN"T^LK*VV55QM-+6SN
M;)44L,$TSMM\(EVMK!//X/#/+*RKS:S;[EI\QUE7-$ZN:',J)3)XVR[#@3R[
M>7#B@W0+T%K^GJB::\W^.65[V15+&QM<<AHV <#N4#35U;75S;6*V>)E3<JP
M/F8[QVQ1D$,:3RYCER0;\BU/4(DT_9VQT-37R25E5' 'OD,SXP<YV,]N <><
MK'ML]527FFZG#>W4+V2"I%>'.#2&Y:YI/(DC![.*#;ZN<4U+-.X$MB8YY YD
M 9_HO%MJFUU!35<;2UD\;90UW, C/%:=34=3<])3W>>Y5@K9X))@ULI$31@X
M9L<L8X'M6S:4_P"&K3_V2+^0(,RBJFU;97-CFCW<CHB)6;.2#C([QW%9*T&J
MKJ\V2H,%9+'.;V8&2;6=EN\P!Z/-R4G4TTMEO=G=3U];-'5S.@FCJ)C(UWB$
MAP!Y$$=B)#:T1$41$0 JA4"J$%41$!7*3XWU*VKE)\;ZD&8B(@(B(+"HJJBT
MRA-:UMTMVE;G6:?HQ6W6&(N@@()VW9[AQ.!DX'/&%R&VWZZ:KL=+6ZDI;,+A
M&7-+*:F=+5T^'$>-&7XP<9V3G]E=>UO=+A9M*7.XV:@-PN%/%MQ4P!.V<@<A
MQ.!DX'$X7'+9J6LU1;H:Z_=0I[L7.#Z"*(4KX0'$9=,[+VYQG (=YBNF/NY9
MONNKV>,632<,E-' Q\KFOD<(I(XVE[@"\QN.TT <2.''/+B5'-W5PK6U6HZK
M?4['$PP11/$#6[1:V1_/ =@XR<$9XX) V.TU9J-,P5%O,50_J_X+9F=(Q[@,
M ;;L%PR,;1XGFH UE$^X[F^OJVMEC:&3S1OIFR8R3&\# (:>()X>,1GO1ZI/
M:&YQEI8TQD%F.&SRPJK7#H^V-)?0/JZ%[N)?33D$^LY61;K7<J*K8?#$E32#
M@89X]IQ\^WG.5G4>[I$SZPTO7MK@BOVV*6"5M0!*]LE))('NY9DFV@&M&/@M
M.<<P1P6#8.DZCHM:T&DGTM%4U%9C_>;3'L01.+>#<$DNQCB[ACNX*7Z2JFG?
M=*>!\L&8H]J0.JO&8"3Q,#QL/'GXGLPH?1'2':9=<P:6>8:ZL='_ +M6TUO%
M.QGB%[F'QL\AS#6C(QA;M]V'*FO$G3KRU6JU)<9KY<+;8K3#6/M^QOW3U8AR
M7-V@&C9)/#M. MJ6@ZSBH*JOJ"ZPWP7:%FS3W"WPEI=PR,2-., \,.X+-(B9
MZMY)F(Z)<U<;]96B*KH'Q7&2W2R[8J"1$-IFTPM'!W$CQO,M LL%C?HRJN5Q
MO512WAKZ@MD9<GMD#FR/# (]K!Y#ACBMNL]#>/=-IRJN\3GU$=HDBJIFCQ1*
M7,."1PSP/+N*BK)HLU.A<&B90Z@BJ9:FGJ'Q!LC9&S.<S)QDM(P./85N)B/7
MZZN,Q-I[>_\ A8U(;[<K5H9@JI:.]3ATCC\':E;"7@/'<2!D><J3U!J$WGHW
MEKH-NEK&5$$-3$"0^&43L#V'_P"<05E3.N%YN&BKA-;:FFDBFF=5QO81N3NG
M-X^8GD>W(45TCZ=N,=5)5V"G?/!<Y(&5]/&,X<R1KFS >AI:?2"D:F8B?KJ3
M$Q$S'UT2/2(*Z\U])I^SU$D%2V&2X2R1NP1L MB:3W.D(]35L^EKLR^:?H+B
MP;)GB#GM\EXX.;ZG CU+5;5I5M^N-UO5\;<*:HJ:@Q4\<=1) 6T[/%9D-(YX
M+N/>L_1%LGT]=+S9VQ3FU;QM71S/)</''CL+CVAPSW^-E9G6M>S=>;FYI[2]
M6^:6[=(-S+I'BCLT4<$<8<0UTT@VG./>0W9 SWE5Z-YI)K;=S-(^0MNM4T%S
MB< 2<!Z%;TP>I:[U712\'U)@KH<_GL+-AQ'H<W'K43I:[U6GV76DJ]/7V9S[
ME43LDIZ3:8YCGD@@EP5UN-1\B)U.Y^:FO'W9FMJ">R2R.GHK?)6=5#CLU+6R
M-:YA'>6N./. I&^7F*Z0:-K[9._JU7<XSXIQD;N3+7>@C!'>%FLAJ*C7UON(
MI9XZ5UHD8YTC,;#W21N#'=SL \/,5KEUT[<;;K2U-ME.^:PU%Q;7O#!D4DH:
MYK_0UVT#Z058U.H2=QN8]96+/;K/7C4]9>[E4TD\-VJHV3MN$D)B8UW# VMG
MAD]B]:9N5R@CT?>+A/,\7/;MU2'Y&\XO,$N.QQ#>)[0Y2VD-*4+ZJ_5=YLM,
M^JDN]3)#+4T[7.=&7 M()'+GA9>M\55[TG:X1^%-P%80/S8X6N)/FXN:$F8F
M=)%9B.;Z[MP1$7%Z1$1 1$0$1$!$1 1$0$1$!$1!@Q7.&2^5-J:R03P4\52Y
MQ V2V1SV@#CG.8SV=H6<M&KZ&YU?2-<3:[IX.V;72[9-,V;;_"U&.9X8_JI'
MP+J;];!_IL?WH-H1:OX%U-^M@_TV/[T\"ZF_6P?Z;']Z#:$6K^!=3?K8/]-C
M^]/ NIOUL'^FQ_>@VEO->UKELM=^@KHI*W48JJ=I\>'J+(]L8\H'(6QJ HBX
M:BH*&Y.H9>LOG9$)Y-S3OE$3"7!I<6@XR6.P.W"EUS/5=DE\,:PKJ*BJ#52V
MVD;!-$UV7OWDVV&D<SC8R!RX=Z#IB+F-937@ZNK)J*&O;9G23-I&NSLMN&[P
M)2W&=P3D#/B[>78P05@:5MUU99[I);JNJCO!LTD3J9]!40$U>/%D?)*]S7R!
MV1EO/.>0"&G4G7&F;=X[87GKDD#JEK=DXV&N:TG/+FX<%EKFVBZ.C;K:DJ;1
M07.GI&V>2*9]7!-&-]O8C@[P<7X!R1SQS.%TE 7@\RO:UFLM.H9:N>2GU,((
M7/)9%X/C=L-R<-R3QQWJP-B1:OX%U-^M@_TV/[T\"ZF_6P?Z;']Z#:$6K^!=
M3?K8/]-C^]/ NIOUL'^FQ_>@VA8#;K"Z_P MI#).L1TS*HNP-G9<]S0.><Y:
M>Q0W@74WZV#_ $V/[U@6"FKJ7I%KF7.X=?F-IA(EW#8L-WTO# ]?'SH-W1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1!?;\$>A55&_!'H55EJ!$1!%ZC_ "95?Y+_
M ."A])_%-] 4QJ/\F57^2_\ @H?2?Q3?0$&V=BQZ7XR7TK([%CTOQDOI09"(
MB B(@(B("(B B(@(B("AM1726W.I&Q.@C;,YP?+.USFM &>3>]3*QJV.K?L=
M3J8H<9VMY"9,]V,.&,(+?7F0V=U=/)'+''"97O@XM< ,DMX_U4>=3TP#\TE>
M"R,3.!@__#.?'Y\N'I\RR&69K-.26ELQQ)"^,R[(YOSDX])/!>Y[6)9ZF3>[
M.^I!2XV?@X+O&Y_XN7F06KA?Z6C+ANYYPR)LSS"P$,:XX:3DCG@K"N=]GAK-
MF)L<=-%44\$KY!QR\Y>,YP,-+?65%7J@J&W0OCADD=34T44#32OECJ"W)\8M
M(#>/E9QS4R=.MJK/!2USVND=4BKJ/%R)';6TYO/EV>@(,SPW3NI(*B.*H>VH
MEW4#0S#I>!.0">6 3DXX!([W3.LS[F]DT5,S.0]OC<#L\@>_@H>^6N>.V4%$
M99IJ>*H+A.V%TCXF!IV6D-.T>>-H84A9(*F33W5Y(H8#ES(P^ [+F9X%T9=G
M)&<C/:@S8+I'(^G8^"HA?.YS6-D:!\%N2>!/#"Q)+^P5U-3PTM1*)9)8G.:T
M>*8W;)[>6?L5FET]+21P&FK(V2PSOF8-R3$T.9LE@9M9 [?A<U[IK'/3BE>R
MN:ZHAEFE<]\.6OWA)<,!PQ[4&<RZ1NN+:-\%3$]Q<&/>S#7[//!RL*6_QRT,
M\]'',(F_ J)(LQ/\<-X<03S\RM6O3?4KC#5.J(I'1F0[0@V9)-O/PWY)..SD
MKL=CF;:S;36L-&T!L7X'QV@/#@"[:P< 8Y!!6?4M)#+*QT%8YL<QIR]D66[S
ML:./$GACTA>GWMCX87Q-?"XUC:21DT?C-<>S@>' @YX\U5ED#1*-^3MUXK?@
M<N7B\_-S5*BR;QSWB8Y-<RN V>UK0-CGV[//SH/5'?J>KK8*>*"I&_#W1R.8
M QS6G!(XYYX[.U2ZTC2M)54MSIW]5<#*)#4;RF>SJ^27;+7D[)\; \4<1Q6[
MH"(B B(@(B("(B B(@+7K_<JBDN+(Q4FDI!!O'3=4=,T':QQ(X 8[UL*CKK0
M5%<'QQU[Z>"2,QR,;&UV0<Y()Y'!P@]W.XLM]NZV6/J&Y8T"+!+RYP:,<?.%
M'^Z,,=(*BWU4+8)&15#G%A$1>0&\G>,#M#ERRI"HML4MO@HV.,<4+HG-[>$;
MFN _\.%CUUD951U['3.;UN6*4X'P=C9P/7L?:@LU6H6Q5CH(J*>9K:AM*Z0.
M: )' '&"<\B..%A/U!)'5QU,\K8[:^:9C &Y+VL:!GO)+\X \RP*FWW1U]K*
MB&G<RIEG#8Y# Q[&1##=L/)R#LY.!VJ?GT[1STM!32MVZ>DC=&UI'PLMV<Y[
M#VY[T"LOAIHX ZAJ'5$D+YS#M-!8QN,DDG&>(X#*]U-[CIK/2U\L$@%06!D9
M<T$%W$9<3@</.H6_6RK?-;8YFS5D5-$X;YM.R4O>2!AS7''(#CWJ<BIJVJLE
M-%5OB@JMEN^:(VO8>'%I!X>SU(+U+<-[514TE/)#,^$S%KG-. '8QD$CMRL"
MWWV6NN%+'#1/ZM/2MJ-X7-RW)[1GEV+S#IUU-%3-H[A-"^*)\)?L-.TUSMK@
M.3<'ECD%[AT^V&*GCCJY6MCI.IOPT9>SO![#QYH/=+J""22K940R4YIHC.[:
M<Q_B#.?@DX(QR*&ZSR1TDCJ6>C;-4,8W>ACB]K@3R#O%Y=O$*Q0:9BIXYHY:
M@RQR4II"UL;8P&'MX=O/BLF*TS[NG955\E0*>5DD>U&UI\4$8..><\_,@Q(-
M3[\0;JUUKA4%S8#EF)"T^-^=P' G)[E=-^C=%157X6*!\<\DD;F N&['C \>
M!!!Y<UDTEG93MMP$KG=3V]G(^%M CC[5BU5FD@H,T3M[4P,J#$QV 'NE).">
MSB4&1:;RZX5CX#134^S"R?:>YA!:[.SR)YX/L4LM7TA1U5#,Z$0.91"$ OE@
M9%(YX.!\$G:&,\3YL+:$!$1 1$0$1$!$1 1$00=3>I6WQ]OAZ@-C8SOZDL>X
MNSP:W9.<#^*DKC<*>WQQOJG. D>(V!K'/+G$$@  $]A49?+96W,S4V*)E)(6
M_A2UQF:!@G'9G(.#GAZE(7*D?52T#F.:!3U F=GM&RYN!]((,:DU#;JJ:.*&
M27:>\Q N@>T;8SEI)& [@>"]QWRADK8Z5CY3+(]T;#N7[+G-^$ [&#C!SQ6)
M3V6:,-S)&<7*2MX9^"[:P/3XP6KP0U=14N; P-GJIIVMC<)0ZC:\NVGX^ #C
MVDH-EI=1M>]LM2UD-$^&29C^+G.:) UIQ_B!SCSA9]?>Z*@_&73-Q&)78A>[
M8:3@%V!PX@\^Y8%TTX*JHI9*>1L/4X-BF/$[$@<TM)'(C#<'TJ%U)UB2[RNG
MC;^"I8VNA_"EM4[)=LMV.8SPP?8@VZLNE-2-@WQEVYP3'&R)SGG R?% SP51
M<J78G<7N @A;/(',(+6$$@XQ_A/#FL*]T-1=**G$<-,),;1WSGM=$XCFUS>(
M(XK"K++=#%4QTU73R&JHV4TTLP<';30X%PQSSM'_ .Z#/IK_ $L]=64S8ZC_
M '9@>7[EY!!;GN[N7?V*ZR]T+J>JF?*^)E, 91+&YCF@\N! /'L4=+9*YIN
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M9"UU(V1H9C@[; '/S84@.2\;QFWL;;=OR<\59I9Y7RU+9X!%'&_9C?O [>#
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MW!75%QFEGD:ZJ$.R6#!B='G9<#WY*\&P5515451<KJ^I?22B6-K86QM/ @Y
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M>E^,E]*R.Q8]+\9+Z4&0B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M?01A%:57;?N L.Z#3)MTNR'<LY&,^93;+;<JZY4E3>)*1D5(XR1PTVT=IY&
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M(@(B("(B B(@(B("(B B(@(B(+[?@CT*JHWX(]"JLM0(B((O4?Y,JO\ )?\
MP4/I/XIOH"F-1_DRJ_R7_P %#Z3^*;Z @VSL6/2_&2^E9'8L>E^,E]*#(1$0
M$1>)Y8X(9)IGAD4;2][CR: ,DH/:+2#TE6MX=+26V^U=$T\:R"@>Z''?G@<>
MI;59KI1WJVPU]MF$U++G9?@CD<$$'B""",+4UF.[-;UMTB6:B\R[>Z?N=D2;
M)V=KEGLSYEQ@7;4&GK-TJ3W"Z]>NM V%T4S6;$<3GT[78C9DX#2[AWXR>)66
MG:47+;?1773.M(K+8[K45W7[2ZJ(N]1).P3QRQM=(#DN&TV1V0.&0%G:=UG>
MI]75UDN]-;P:>!THDIMH9(DV".)/#V)$;)G75T1%%>$Y/DVIX3D^3:M<DL>)
M5*HHKPG)\FU/"<GR;4Y)/$JE44=37!\I?EC1LD*_UIWDA9;CJRD6+UIWDA.M
M.\D(,I%B]:=Y(3K3O)"#*18O6G>2$ZT[R0@RD6+UIWDA.M.\D(,I%B]:=Y(3
MK3O)"#*18O6G>2$ZT[R0@RD6+UIWDA.M.\D(,I%B]:=Y(5VGE,FUD 80741$
M!%B7*=\,;#&<$G')1_7ZCRQ]$+45F6)O$=$VBA.OU'ECZ(3K]1Y8^B%>24\2
M$VBA.OU'ECZ(5VDK9I'2->X>+C'!2:S#5;Q;I"61876)/*^Q.L2>5]BRTS46
M%UB3ROL3K$GE?8@S46%UB3ROL3K$GE?8@S46%UB3ROL3K$GE?8@S46%UB3RO
ML3K$GE?8@S46%UB3ROL3K$GE?8@S46%UB3ROL3K$GE?8@S46%UB3ROL3K$GE
M?8@S45BFD<\NVCG"OH"(K%=(Z*F<]APX$)'5)G75?10G7ZCRQ]$)U^H\L?1"
MWR2QXD)M%"=?J/+'T0G7ZCRQ]$)R2>)";11-+632ND#W#Q<8X!9&_D\K[%B8
MTW$[ZLY%@[^3ROL3?R>5]B*SD6#OY/*^Q-_)Y7V(,Y%@[^3ROL3?R>5]B#.1
M8._D\K[$W\GE?8@SD6#OY/*^Q-_)Y7V(,Y%@[^3ROL3?R>5]B#.18._D\K[$
MW\GE?8@SD6#OY/*^Q7*>5[I0'.R$&4B(@(B("(B#7]7?DVH]+/Y@O6F_Q=OH
M"\ZN_)M1Z6?S!>M-_B[?0%43R(BBBB[I^,-_9_J5**+NGXPW]G^I08:(B B(
M@](B*0HB(JBH1 BBJA%1SFL87/(:T#)).  L1EUMSWM8ROI'.<< "9I)/M1&
M8B(BP*HY*Q4U4-,Z$3R!AF>(H\_G..<#["KXY(*HB*H(B("JJ*JBP(B*H*H5
M%B276WQ/='+7TC'M.'-=,T$'N(R@S$7F-[)(VOC<U['#+7-.01W@KT@*H5%4
M(*HB)"B*V^:-DD;'R,:^0D,:7 %V.>!VI--'!$Z2>1D<;>;GN  ]91%P+T%8
M;4P&*2431&*,D/?M##<<\GLPKK'![0YI#FD9!!R"$'I$1(!5"HJA!5$1$@1$
M11$1 "J%0*H051$0%<I/C?4K:N4GQOJ09B(B B(@L*BJJ+3(B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("\R2,B;M2/:QO++CA>E':AM,%[M%105(\65OBNQQ8[L</0588O-HK,UC
M<LKKE-^D0_3"]1U$$CMF.:-SNYK@2OF*YT,]MN%11U;-B>%Y8X?U'F[5U[HA
MTWU&W&[U;,5-4W$0(XLC[_7_  PNEJ16-[?%X+XOEXK-X/AZUWZ]OX;O=JUU
M#3L?'#OI))6Q,9M;.2XXYX*NT,M3+&XU=,VG>#@-;)MY'?G 5B]MI'4K1<(9
M)8=L'$;'/+3QP?%XK#TXPMJ*XP,J&6XEFX;,' YP=H@.XAO+[5R?=9\MTH(I
MQ#)6T[)2[9#'2 '/=A>J:Y452913U<$IB&7[$@.R.\^9:]54+WV34K>K.=)-
M4/+1L'+QLMP1WKWJ6FC$CBYACIQ;IXBYHP <LV6YY<>P()NENMOJIA%35M/+
M*>(8R0$GU+%?>";W'0Q0@Q[S=/E)_.W9?@#S#9]JC+/6CKAJ:YTHK>J;+(!2
M/B#FM\8XVL[1]'L5JHM5;+1VJ..1\%9-)+-/,UN=VY['$Y[N8:@V2:YT,,>\
MEJX&,VS'DO&-H<QZ0KM)5T]9$9:2>.:,'&U&X.&>[@M2EJ7T\UIZO3.IJNG9
M+#)"('2M8WAEP:W!() P[SG*G],]7;:8XZ65TK8W.:\O86$/R206GEQ/)!DQ
M7*AEJS2QU<#Z@$C=MD!=D<QA7154Y@;.)HS"XAH?M#!). ,^G@H"UO=37&&E
MM_6)*-SWF2*>G<SJ_,Y#R!D9X8.>?-84;Y&V&EMO5:HU<55'O!N7;+6B8.VM
MK&",=Q[4&P4]\MT\M5&RKA#J=Q#]IX'  $N''EQQGO!61!<J*>GDGAJX'PQ_
M#>)!AOI/8M?EJ:B@-VBB@EWTM8)0[<.D:(B& O&!@D8/#GP6%+!435U34[NK
MJJ9KZ:1YD@V#*UKGYPT 9QD'!&>'H0;0VZ4\T<,E%/3SQOF$1<)0 "1V=Y\R
M]S72@@EW4U;3QR;6QLND .>'#[1[5'7&9MP9;I*2*9S65T9<70N80 #DX(!Q
MQ'%8E31O=0:J_P!W<9)G.V/$XO B;C'?QSZT$VVZ4DHJ!2U5/-+"TN<P2CAC
MO[AYUX?=Z&!D76ZRFAD>P/V3*.WS]WG45=:1X=1B"!VRV@J(_$9RRUN&_9R4
M,> K:5[I64LU/ *E[:5\Q:X, < 6_!( ' @XSE!NM7704UNDK7.#X&,W@+..
MT.S'?E8,ETJW53:6FH&R5+86S2M?/L-9M9 :#@Y/ ]F%XU)(R;3CIX3O( 8I
MLCCE@>UQ/L!5N^F@?.'2MK65;6?@IZ6*0N(/8'-!!]!X(,F>Z3BHCI::BWM;
MNQ+*PRAK(@>678/'(/(=B]PW&85=-3UU**=\X?L%LFV-IO9R',<1Z"HFVS5=
MMJC57:"9W7*>+>211E^[D:""'!H)&00>[.5EW&H96U-DW D#G51D&VPL=LM8
M\.." <<1[4$ZB(@(B("(B B(@OM^"/0JJC?@CT*JRU B(@B]1_DRJ_R7_P %
M#Z3^*;Z IC4?Y,JO\E_\%#Z3^*;Z @VSL6/2_&2^E9'8L>E^,E]*#(1$0%CW
M&&2HM]5!"]K)98G,8YPR&D@@$CM60K%?3"LH:FE<]S&SQNC+F\P"",CS\4A)
M<"O-XU5IBX,I-0:IE$9.PU]N,$[AZ8CLN 7?:!K&T<6[QAS0XG9V=HGB21WG
MFN$36316D;O44HUM=Z"X1'9EW$;BX''+:;&?XKO-(6NI82Q[I&EC2'NYN&.9
M7;+K4:>?A][G<_SM=4"[2EMDFU$^H;),R_!K:R*1PV2&Q"+#<#(\4=YXJ>1<
M7I:QI;1=%I^O?6MKKE<:PTS*-DU?,)'10M.0QN&C S@G.2<#BM-HZ2>FZ6[F
MZ=E8ULU#))'UB.F:"TS\V;GB6^>3Q^]=97+Q2MINEBL<VV04.]MSWE\;PXU&
M9_C'8 P3W'*U7NS?[LMK1:[KB^RV&TMFIF-=/+((V[8RT<"23Q'<N?V?6E[9
M7,?-/UJ%OPXGAK01Z0%WUTV^/G^(X\.:,$Q,S/M&W8D45[H;9L2NZSXL36O?
M^#=P#L8[/.%<CO5ND,@%7&W=AKG;?BX#AD'CZ0L[?0CKUA-4.U^$SG&1A92B
MJ&XT@-0'5<'X-HD<-X/%;CF>X<0KXN]N.SBNICM-+Q^%'%HSD\^7 ^Q<9[O3
M7LSD6#X6M_B_[]3>,PR-_"#BT9R?1P/L1EVM[Q$65U,X2N+&8D'C'AP'>>(]
MJBLY%@QW:WRF,1UU,\R.V6;,@.T>X=_,+SX:MFPUWA"EV7$M:=ZW!(QD#CYQ
M[4$@BP7W:W,+P^NIFEC]V[,@\5W'@?/P/L1UVMS&O<ZNI@&/W;B9!P=QX'S\
M#[$&<BPYKG0P2RQS5E/')$ Z1KI "T'&">[F/:%Y-VMX#R:ZFPQH>[\(/%:<
M8)\QR/:$&<BPV7.AD+PRLIW%D>]<!(#LLP#M'S8(.?.O(N]N.SBNICM-+V_A
M1Q:,Y//D,'V%!G(L'PM;_$_WZF\=AD;^$'%HSDCS#!]A5QEPHWLA>VK@+)CB
M([P8><XX=_%!E(L5EQHI"P,K*=Q>[9;B5IVCW#CQ/$>U>?"=!LAW7J79<2T'
M>MP2,9'/SCVH,Q9-%S?ZE&/N-$PO#ZRF:6.V'9E:-EW'@>/ \#[%(VY[) ]T
M;FN;G&6G(R"01[4&6B(@C[Q\5'^TM:U%(^&P7*2)[F2,II'-<TX((:<$%;+>
M/BH_VE%+M3L\V>O-$U]WSQ3U$[:B-[)Y&/#P0X..0<\UV:EOE<YE.)[3.'O@
M=(]P#@ YNUXN".&=D8X_G#FLF#3-GIZ_KD5!"V?((.#AI&,$-Y \.8"F%NT[
M?*^%\#;@XM&2=S/YH"&^UDDU&QUGJ6-GQMN.<1>,6\?%[AGLYJ[;;_7.EA#K
M+5AL\VZ<3M8C'B^,?%Y>,?8II7Z!K@Z5Q^"< +G?L^QCGJAZ?45;*RD<^QU4
M9FG,3@=K\&WQ?'/B\O&/T2O,NI*QL-5)'8ZMXBF$;!AP,C3M>.!LY \4?26S
M+"I[K;ZF9L5/7TDLKN3&3-<X]O(%<G2;1'290]1J.NB-5LV*KDW,XB;C:_"-
M.UXX\7EXH^D%>EOM6QMS+;/4N-(]K8P,_AP7$9;XO8./#*E;G7TULH9:RMDW
M=/%@O=LEV,D <!QYD+0;UTNV6VVFHK&4-RJ'Q#A"V-H)X'B3M<&@@ GB1G.#
M@XL1,]7+)Q.+'>,=[1$SVA.W'5LMOCEDJK7)%&V&.1KY'E@<]VSE@);S&T?H
MG@L:CUVRNEFCH:!U0^.%LH;'+ESCXH<T#9SP+CQ\RY735VO=8Z=J+_J*F9!9
MOP<M+3PM#!LX(=(&DEY' '+CR=EO#*P[>S45-%+=M*T+ZFMH 9@#'M,<&XVV
M]F26DC9!VCGAQPMQ2)KM\SB/B>7%QE>&BFXG77\_7]'=9[Y5QNI0VSU+Q-3F
M=Q&?P;MDG8/B\^&/7R5J#4-;(^ .L=4P20OE<3M>(6[>&GQ>9V1](+1M#=--
M%=J6KI]0V^IMUYH@ULL+(W%LCN3L9^ 0<^*XYQVGCC9ZCI0TK26SKUPN#Z.+
M;$9;) ]SPXYQP8'9X-/$<N&<96-3K;ZD\1BC)X,VCF]O5(P:CKI)J%CK%5L;
M4$![CM8BR\MX^+W#/9S2#45;(ZG#K'5,$LYA<3M>(WQ?'/B\N)]BYU=_]HK2
M],RH;;:&YULT;MF,N8V*.49QG:+BX#'$9;GO [,%FO\ I3U+/7#2^CX:*D:Q
MH8:YA9*S:;C:#I'L:\Y!/!I X9![8[:=3I]15LL5,YUCJF&6<PN:=KQ&^+XY
M\7EXQ]A47<^D*"TT;YKO1LH'EX9#'55 B,PX[1;M 9V?%SC/P@M"IM$=+-]G
MBJ+_ *T%J!A V*-YVFNSG9<R,,83Q.7!QY <1ROV+_9UT_!% ^]W*XUU4U^U
M((G-BBD&<[);@N (X'#L]V$&T7/I%DZP&6J"EDA\8B9TAD;(WA@MV2.!])63
M9M>23V>KJZZEBWL19L,B<6A^UV<<X( )RM<U#T7FW/IXM(41ZALG,+J@$QNS
MDX+SD@YSS/'/(86T]&.F*VPPU<]RV8YJC9:(00XM#<\20<<<\ETF(Y=[?(Q\
M1Q$\9..<<Q7KUWT]-3VU_P!_)F^[*)DSQ/1R-C92QU)<QX<?'#?%P0/+YY[%
M?]V%!^'_  -5^!IV5#O%;Q:[9P!XW/QQ]JV1%S?76[%<8JX-=$V1HDA9.-H#
MX+B<#GSX*66-1<W^I9* L6Y_B;_2/XK*6+<_Q-_I'\5:]TMVE"(L"_W%MJL]
M56N:7;IN0 ,\2<#M'#)"Y;!K^]-KFRS2QR0;>70"-H!;W XR/-Q]J]$1M\?B
M_B.'A+13)O<^SL**(CU';'T'7#48AVA&3L.X.(SCDKK[[;F2OC?4AKF2-A=E
MK@ XYP,XQV'CR6=P]\1M,T&=J7.<<,+,452U]'$VIDEJH&QL<UKG&08:>(P>
MY9<EPHXC.)*J!FXQO=IX&QGEGNRN,]WHKV92+&-?2!\C350!T;0]X+QXK3R)
M[AQ5>N4H)'68<AF\/CC@SRO1YU&F0BQ(;E0S.<(:VFD+02X-E:< <R>*LW"]
MVVWTHJ*JLA;$1EI:[:+AG' #B>/<B3:(CFF>B14)JG4E%IRECEK=M[Y21'%&
M/&=CF>/8.'M6M:BZ4+=;J)C[3;KE>*Z1^Q'2TT#@[/>XD<!P/$ K4)+7K'5]
M*VZ7\V>FD>=FBH()AMAOYP+LD%W+AGOY<EJL1O5GCXO/D\O;)POVK>GK^;HF
MF=<VV_5G5(VRT]01EC9<8?Z"#S\RVM<5L/1_)6;;KU7-H*5VU"'4U2S>[9&
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MZ4-=RVN60<9Y]P!)X:Q7ZQOM=;:R@DN,M/#5^+))3M:V1K>T-/9PX=_G7;]
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M!B=5=Y34ZJ[RFK+1!B=5=Y34ZJ[RFK+1!B=5=Y35[A@<R0.)&%D(@(B("(B
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M()SR!XX[<!9$%7#/4U,$3]J6G+6R#'P21D?852DGEF=4"6F? (Y2QA<0=XW
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M'C.,@C!5Y$28B8U+2[)T76]]<Z6IK9Y8(G@[D,#=KM )[O5[%U0 -    '
M+ M#RYDK=D#9<.('-9ZY6M,SU7A>$P\-6?"KK8B(LO4(B("(B B(@(B("(B
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M%M#[-2/OL=V(?UID6Z SXN./''?@D>A4IK+24UZJKI$']9J&ACP3XHY<AWG
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MZ/FGHOL'2!1NJKAI6EHZ3>,$3C=FO9'(W.<M &21CGRXE;Z9>FFG<UVXT?5
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M?;RT#4?1/IN]W"2L<VIHYI#M2=5>&M>>TX+2 ?1A=\.2*;B7EXG#;+J:N":
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MWA(<'$<,\T-.KHJ,VMANWC:QQQRRJH"(B!D=ZLUE5!1TLU352LB@A89)'N.
MUH&23[%I&O;!6W._4<5) ]]!=8.H7-[3C8A9()!GTMWS/3(%"V736IZQN_K6
MTC9(9XJ:6*L+L54=,P")^6Y\4R.EDQV^+YP0Z79KE37BUTMPH7.=35+!)&7-
M+20>\'B%F+6>C6DN-#HJUTMXACAJHH@W=LSEH[-K/:MF0$1$!>)9&11/DD<
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MJ#0"(D\6AP:\NQ@@\"W9/+GQX=M1%;WF_=G'BKCC51$18=!$1 1$0$1$!$1
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M%35>Y^U3[B)TFZANTKI'[()V6CJO%QQ@#O03J*(9)JAS [P)91D9P;Q+D?\
M_*L>XUFJ**CDJ/<]:Y]C'X."[2N><D#@.J^?/H03Z*)VM4?,MD_UB7_VJA=5
MZDOVFJ"GJZZPVN2.:JBI&B&[R$A\CMEI.:8<,GB@W!%$[6J?F:R?ZQ+_ .U6
M-65FJ:9U,/<_:Y=]*(LQ765VQD$[3O\ =>#>'/SA!/K)HN;_ %* VM4_,UD_
MUB7_ -JKE!6WV"ZTE/<K-1QTU27-,])723[HM:7#:!@8 #C&<\R$&R(B(,2Z
M?B;O2%"K8:B%L\18XD ]RQ?!D7EO^Q=*VB(<KUF9Z(A6:RJIZ*G=45D\5/ S
M&U)*\,:,G R3PYK6K4_4%UU[K&VT5TH8*&UR4K(8ZFB,I&W"'G!;(P\\\\^I
M8_2=I"^W70MVIJ^[V^2F$8F>RFMTC)'[#@_9:XS. )V<9V2KSPD8Y;FKELGB
MEFJHXWQN?$YK7AIR6DC.#W'!!]:DA;(@/AO^Q<WTS!>I>D77]):;C0T]+!54
MCRRJHW3$N=3,R06R,QP:.!SR[..9:T3#5*3$[ET5%$^#-4_/-D_TN7_W"PK9
M3ZNJQ5;ZOM%/N9WPMV[7-^$:.3Q^'' __"N;HV-%$^#-4_/-D_TN7_W"QJ"C
MU94P.?+<K- X2R1AKK7+DAKW-#OQCDX .'F/:@GT43X,U3\\V3_2Y?\ W"PK
M-3ZNK[93U517VBDEE;M.@DM<VTP]QS./X(-C10M1;]514\LC+K99',:7!@M<
MN7$#E^,*U;:35E7;J6IFN5FIY)HF2.A?:YMJ,D EI_W@<1RY()]%K=]@U=;K
M)<*ZFKK16STU/)-'31VN;:F<UI(8,3DY)&.1Y\EE0V[54D,;W7:RL+F@EIM<
MN1YOQA!-(M<O%/JZ@ML]33U]HJY8P"V&.US;3^..&)S_  6;X,U3\\V3_2Y?
M_<()9%SSI,GUA8=/T]72WVUQO?6P4Y,-L<#B1^Q^?*\8&0>6>',+;/!FJ?GF
MR?Z7+_[A!+HM8N\>KZ&2W-@J[35"JJFT\A9:YOP+2UQWCL3G@"T#L^$.*D?!
MFJ?GFR?Z7+_[A!-TOQP6:M6IFZBH+U;65M1;ZVCJ)'QRFFH9(C$!&YP<7&5X
MP2T#B.U;2@+%N?XF_P!(_BLI6ZB(3Q%CB0#W*QTE)C<->12_@R+RW_8M*A@O
MU?K'4-);[K1045#U=D<531&8@NCVB0YLC#S/(YY+KSPX^'*>6&VYT#J'KK:V
MF=1YQOQ*TLSG'PLXY\%7P%J;YZLW^ER_^X7,9](31?[/MO%O-8Z6,"NFA)XD
M.<7/! '$-VLX_P .>Q6MHF8AF]9K6;+721K&'4]II],:1JQ)4WBICIIY]AS!
M%"3XV=H#.> X=FUWA=AT_::6Q66BM=OCV*6EB$3!YAVGSD\3YROD*WT]15UL
M%/0L?)52/#8VQ_"+L\,+ZTAM6JVPL#[S9=H- .;9*3GT]8XIFQQ2>B<+FG)$
MQ,=DRBUBS1ZOKVUIJ*RTTFXJI*=@DM<WX5K3@2#,XX.[.?I*D?!FJ?GFR?Z7
M+_[A<'J2R+7+13ZNKJ-TT]?:*5XFEBW;[7-DADCF!W&<<'!H</,X<^:S?!FJ
M?GFR?Z7+_P"X02R+7++3ZNN%HHJRHK[1233PMD?3R6N;:B)&2TYG'$<N065-
M;M5,B>]MVLKBUI(:+7+Q\WXP@F46OVJEU;6VRCJIKC9Z:6>%DKX'VN;:C+F@
MEIS4#B.7(+Q>J?5UOL]?64]?:*R:G@DF93QVN;:F<UI(8,3DY)&.1YH-C11'
M@S5/SS9/]+E_]PH_4$>K[7:*BLI:NTUTT6SLT\5KFVGY<!PQ.>0.>78@V=%$
M^#-4_/-D_P!+E_\ <+6]?7#5>EK VXMN-DJ":F"GV/!LK?C) S.=^>6<H-Z1
M1/@S5/SS9/\ 2Y?_ '"PKC3ZNI9:%D5?:)Q45 A>YMKF_ MV'.VS^'/#+0.S
MX00;&JQ_#;Z0HCP9JGYYLG^ER_\ N%89[I*'4%H@K9:"NH:I\C9GTM!)$8-F
M-SFDN,KP 7 #B.U!MZ(B B(@(B(-?U=^3:CTL_F"]:;_ !=OH"\ZN_)M1Z6?
MS!>M-_B[?0%43R(BBBB[I^,-_9_J5**+NGXPW]G^I08:(B B(@](B*0JCFAS
M2UPR",$*%]REB^:Z;Z*FT6HF8[.5\6/)]^L3^<*C@$0(LNJU62314LDE-!UB
M9HRV+;#=KS9/ +6[A'7WV:AC=:7T0@J&3.J)I&$M#3DAFR223R[EM$DC8HGR
M2.#6,!<XGL [5;I*F"LIV5%+*R6%XRU[#D%$0$+;C:;O='0VZ2L@K)6S1OCD
M8W9.R 0[:(QRY\5A,LMR=H^Y4<L48KI:IU0UH>-E_P"$#^![,X[5LXN5&6L<
M*F/#YNKM.><G'Q?3P*O5=3#20.FJ9&QQ-P"YW(9.!]I"+#5;G%6W"X4=9666
M>>BC8YCJ)\D9+9,C#R-K9<.8Y\%:@T[555)J&%]+#;VUPB=3LC(+6%H/ X\X
M&?3PRMGN5UH;8(S7U4< DSL;9QG'/^(5RW7&CN,;GT-5#4-;P<8W@X]/<JC!
MH*^Y5)$%9:):=VP1)+O6%F<?FX.3D^91-KM%=!2:69+!LNHGR&<;0\3+7 =O
M'B1R6WJCB&@EQ  [2@B.IS^Z_KNQ_NW4=SMY'P]YG&.?)1E?::V6GU4V.'+J
MW9W'C#Q\1@=_#CWK:U&5]^M=OJ#!6UT$,P .P]V#@H-9NT,U7?X6T5'+5.HJ
M40U&XJ.KN:YV" 7_ )PQV#O4]I6JA=!44$5 ^@EHG!LD#G!^-H;0.T.>>>53
MP717*4W*@K*F$U+1M24LNR)0. )'$<.65(6NV4]MCD;3!Y=*[;DDD>7O>[O)
M/-"&JFU576;FRKLK*^JJ)GF&LF>QS&1GX(XG+=GN 5ZFM=QMU-8*N&EW]11T
MYIZBG#VAQ:X#BTDXR"._BMQ1!KENAN%3JHW*JHC2TO4C QKGM<\';!\;!X9X
M]_)6J"U5D6@*BW/AQ6.@G8(]H<2XNQQSCM"VA8/A>B\(1439@ZI>]T8:T9PY
MK=H@GLX((Z\6^JJ-/V^FABVIHI:=SV[0& UP+O9A1KK-7FVF(0?A/#/6L;3?
MBMYG:Y]W9S6Y(@A[[1SU5PLTD$>TRGJC)(<@;+=APS[2%A4=-64#KW(ZW&K9
M4UFVV(/8-N,M )XG'9R.%LJJ$&H6NT5#JJY&FH7VNWU%(Z(4\D@(=*?SPUI(
M:,</.L=UKKZ_3MOI)[6&U%K=$X1SO8Z.IV06EH()QD=I"WA$&MV6EA%9MQZ9
M9;G-8?PY$0(/+ V23W\>"N6.TRC1D=KK6F*5].^%XR#L[6>[TK8$0:1;;7U:
M"GI*O2=-/41@,=4LW6[>!PV\GQO/C&5)QQW"SWFY2T]ODKJ2M>V5IBD:UT;P
MW9(<'$<#@'(6R!>@@@M(T=;207(W&)L4U16R3AK7!PV7!O(^HCU*S70UM'JL
M7&GH9*RGFI!3N$;VAS'!Y=DAQ'#!6QH@UM\-=:+[<*REH7UU+7!CG-B>UKXW
MM&SR<1D$8[5E:9H:F!]PK:]C8JFNFWIB:[:W;0 UK2>TX''"FE4((*INES!F
MA;I^>5V2UCA/'NWCL)).0/-A9&E;;+:;#244[VOEC:2XMY DDX'F&<*61$@1
M$11$1 "J%0*H051$0%<I/C?4K:N4GQOJ09B(B B(@\O;D<.:M*^J%H/,*Q*:
M6$5W=CO*;L=ZNTTM(KN['>F['>FS2TBN[L=Z;L=Z;-+2*[NQWINQWILTM(KN
M['>F['>FS2TBN[L=Z;L=Z;-+2*[NQWINQWILTM(KN['>F['>FS2TBN[L=Z;L
M=Z;-+2*[NQWINQWILTM(KN['>F['>FS2TBN[L=Z;L=Z;-+2*[NQWINQWILTM
M(KN['>F['>FS2TBN[L=Z;L=Z;-+2*[NQWINQWILTM(KN['>F['>FS2TBN[L=
MZ;L=Z;-+2*[NQWINQWILTM(KN['>F['>FS2TBN[L=Z;L=Z;-+2*[NQWINQWI
MLTM(KN['>F['>FS2TBN[L=Z;L=Z;-+2*[NQWINQWILTM(KN['>F['>FS2TBN
M[L=Z;L=Z;-+2*[NQWINQWILTM(KN['>F['>FS2TBN[L=Z;L=Z;-+2*[NQWIN
MQWILTM(KN['>F['>FS2TBN[L=Z;L=Z;-+2*[NQWINQWILTM(KN['>F['>FS2
MTBN[L=Z;L=Z;-+2*[NQWINQWILTM(KN['>F['>4V:6E=C;CB5Z:T#DJJ;6($
M1%%$1$$7J/\ )E5_DO\ X*'TG\4WT!3&H_R95?Y+_P""A])_%-] 0;9V+'I?
MC)?2LCL6/2_&2^E!D(B("(B M5U5I%]XNM-=;;>*RSW.&!](9Z=K'[R%Y!+2
MUX(R",@CB"MJ1!K%)HVCI;/!9HJFJ\",H'T#Z(EI;*'<#(YV-K;XGD0.)X+&
MTKH@66ZQ5]=>*V[3TM+U&CZRQC>KPY!(\4#:<=EH+CQX+<$01-FL4%JNEZKH
M99'R72H942M=C#"V-L8#?-A@/%2R(@*)M-@H[7>+Q<J7>]9NLD<M1M.RW+&;
M V1V< JV>[FXW"[0=7W<-'4-@BGV]IM1F)CW.;P_-<XM.">+3Z%<U#=HK)9J
MFXSQ33,A Q%" 7R.)#6M:"0,DD#UH)%' .:0X @\"#VK7K1J=E;5VVCJ**>D
MK*R*IDW;G->(W02-C>PN:>>7#!' X/%9>JKW%IVPU5UJ(9)8*;9=*&8RUA<
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M'U;X75<CXHW;+MGF=N1K!Y\K?-&4%=;-+6RDN]9+6W&.$=8GE=M.=(>+N/:
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M %M=9["VD,<-?="6F0MVFQAH)>X#M/#@%,Z=MLELHYX9GL>Z2HEF!;G&'.)
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MI!F(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MG_E0=+1<T]]$_- ^L_\ *GOHGYH'UG_E0=+1<T]]$_- ^L_\J>^B?F@?6?\
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MH?2?Q3?0$&V=BQZ7XR7TK([%CTOQDOI09"(B B(@(B("(B B(@(BQZNNI*,
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M%\C@T<N\H,5FE+L;I34$U.V&>H!+-MX(P.9.,J7DZ/+C''*]]?;&LB^,)E<
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MTB#<)M78J+F^DWL,$G&EIP!LL<?A//<>9 '#)SV+%UC?:6\QT8IFS QESCO
M!L AN&-P>0P?:M91 1%Z8USWM:QI<YQP !DDH);2%(ZMU+;H6#.)FO=^RT[1
M^P+OBTOHZTN^T4[ZVN9LULS<!AYQL[O25NBBB(B B(@(B("(B B(@(B("(B
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MMKZ=C;G#4&JK(I68>,0,&SG:.?%'BD]G%W+F5SK5E]JKG>Y'R2LDAIIG"G#
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M5T5OL+J40R5=M#0Z-[RUK_P>R[#L>S@J+UWJ:FEW+9;Y;Z+$8VG2Q#:D?VD
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MD-O1:GIC6<=^N#(H[=44]'4"<TE3(YIWVYD$<F6@Y;XQX9Y@'DML0$1$!$1
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M+G?*BVR]9D>8SNPV1KCD.:7-.<CSH-QJ[K!3T\$T<=15-G&8Q31&3:&,YX<
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M+8*/\5B_9"U];!1_BL7[(6+]G3%W741%R=A$1 1$0$1$!$1 1$0$1$$7J/\
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M/9G&TTC*U&W-DJ.CBHI8XW.JH:>6F=$T9=MMR,8[^7M6WO<UC"Y[@UK1DDG
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M4WXFGZW00-#Y"V79E'X-OE#O]"#.W$GD_:FXD\G[5'T]3?\ :9OJ"GV3/L.
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M=YUDZS8\6R"LC:7FAJ8ZIS1S+6GQOL)*".U:*"DNNG&UL+#0QF9IC,1D& P
M#9 .>SL6?15% ^CJI--QT5-*W9$CY:9T+,<>?!I/:K]?225MYL==3%KZ:#>O
M>X.['LPTCO5O55OJ*WJ$D$$=7'3S;R2ED<&B48('/AD'CQ0ACVR^RBY5=)75
M-%5,AIC5">EX  '#FN&3Q[>:NVBIOERAIZX&@IZ2;#VP.8YS]V>1+L@9QYEC
M4=GJJB\U%35TD%'234+Z7=1.!+<N!XX &2,\NX+(LGAFWT]+;IJ"&:*'9BZV
MVH !8. .SC.<=GVH(ZQ7"XTT-[KJ^HIY*2EJI]ZQL;MLEK1@,)=@#EPP5E37
M.]T5L;=JQE$ZDPV26FC:X2,8>YQ."0#QX*D5HK1X9MDU.UU#<)I915-E&6;;
M>19S)! 5*FEOE?:!9ZFD@B:YK8I:P3;0<P<RUF,Y(':@RKE=;@;[#;;6RG=O
MJ7?[V4$AGC8R0#Q[.'>>:D+A;Y+C89Z&M?&Z:6(M<]C<-VNP@>G!5EEOE9JB
M.L:T=590FG!SQVML'&/0%,(-.J+Q-4Z'BV"1<:G%!L]HF)V'?P)65)2QT.H]
M-TL(Q'#33QM] :P+Q3Z?J&:M?5.+?!;7NJHV9X[]S0T\/43ZU*UU#--J.UUC
M -Q3QS-><\07!N.'J*"(TN^HCTJ]U')312"JFR^HSL-&\=D\"/XK)L]XJZBX
MUMNDGH*J:. 30ST^0PY)&RX9."#CD>2C!8*^*@MP?2Q58IJN>:2D=( V0/)V
M3D\,C.<%2%LM]PBOE3<7T=-3,?2;J*"-X.'!V0'$#M[P@RJ^YUULLE*ZJB@E
MND\C*=K(R1&9'$XXGCC RL6]LNK--7GPG/1RQFD?LB")S"'8/>3D+(N=#<+I
M9:*1[(:>ZT\K*EL>UEFVTGQ2>X@E4K?"UULURI)[8RD=)3N9&34-?M/(QC@.
M \Y0>/"-:^:@M=J$#9NJ-GEFG!<UC>0 :",DG/:HC4MWNL=INM#.^GBK*=L;
MS+$UP$L3W;.6C.6G/ \U+RV^OH:^DN-! RID%(VEJ*<R!A(!R'-<>&0<\UA7
M"PW"[4UWJ:IL5/6544<4$ ?M!C6.VL.=CF3W<D$A?*.LGTS6]>E@=60@U$$D
M#"P,<P;3>9/'(/J*]W2NJ)]%RW"C>R*5]$9\N!. 6;1Q@\^Y6[U<:IFEZV2L
MH^K5<K33Q0B02%[GC9;@CSD\/,LWP6XZ5-J:\!YHNK;1Y9V-G*""N KO>\K'
M5\T$H=1,,>[8YI V1\(DG)Y=RRIKC>;=34595MHC1R21QO@8UPDC#R #M9P2
M,C/ *LE'=*W1]5;)Z)D%2VF;!&=\'-D(&,^8<.WO6?J*WSUUFBIJ=K3*V6%Y
M!..#7@G[ @P[=<KQ<Z^MCIVT<%+1U;H72/:YSI ". &>!QV^?DJ4MQO5VBGK
M+5U&.D9(]D+)V.<Z;9)!)((#<D'' J0T]0ST)NG6 !OZV2=F#G+3C'\%&T-/
M>;)3S4%!10U=/O'OIYG3AF[#B3A[2,G!)Y<T%UNHGU%)8:FFB:UEPJ!#(U^2
M6<'9 \X+5(UUPEI[]:J)C6&*J;,7D@Y&P 1CVJ'ET_54=CL\-"65%5;IQ4%K
MW;(E)VMH ]GPCA71!=*O4-NN5;2Q4E)21R@Q[T/<-IH\8XX=@X!!AU-]O$EF
MN-WHWT$5-322,;!+&YSG!CL$EP<,$]V%;L[KQ-J.]"EDHVRO93/EFDB=LC\'
MP#6;7\3V>=85#15%6ZKNT=DIJZFJ9W5,1FJ-T7,[,Q@%N>',\3S*V+29?6U=
MPO C,=-<&0/B!.2-EA#@?6@M1ZDG@L-PJ:V"-U;1U!I"R(D-EDR TC/$ [07
MN:X7BTR4DUV-%-23RMADZNQS70N<< Y).T,\#R5J33U346V]P.<R*6HKC54S
M\Y QLEI/K:O=737>]NI*:OH8:*FBF9-.\3B3>;)R&M ' $]I02>G;C-<:.JE
MG:P.BJ986[ (&RUQ [>:UFONMTN%ATY60RT\#ZJLC:\!CL;6T['YWP>'$=O>
MI*AIKS:S7T=+10SQ3U$DT529PT,#SGQFXR<>;FK#;%<(=*6:FCCCDKK?4,J#
M$7X$FRYW .[,@JHVJB%0VF8*U\3ZCCM.B:6M/'A@$D\L=JOJQ12334K'U5/U
M>8YVHML/V>/#B.')7U%$1$ *H5 JA!5$1 5RD^-]2MJY2?&^I!F(B("(B K=
M2"::4-C;*=@XC=R?PY'TJXL*\U-'3V^47&LAHX9@8M[+*(QD@\B3SY^Q(2>S
MF6@K(WW2LND%UM%LC$CHWVJTU#I&2OV2=E^7;)<!QPUO8NM+CNB-/"EO]%%)
MJ/3M11T\[)X8:&0;Z9[(3$TD9P/%RXXSDY78EUR]W+!]WL(B+D["(B N=-;"
M.F*@,<=W;(:.MVW5;Y# [QH/B0XEH'?L@=BZ*M'JV7)O2K975M1224;J*NZL
MR*%S'L&U3YVW%Q#NSD @WA$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1!;J/Q>7]D_P4&IRH_%Y?V3_!0:Z4<<G<6DW?
MH[H*VN?44]1+2B1VT^-K0YN>W'<MV1=(F8[/)GX;%Q$<N6NT?8;/2V2@;243
M2&9VG.<<N>>\J01%'6E*TK%:QJ($1$:$1$&%=;717:GW%PIV31@Y&>!![P1Q
M"Q[+IZV69SG6^E;'(X8+R2YV.[)4JB;<IPXYOXDUCF]]=1$1'47F6-DT3XY6
M-?&\;+FN&01W%>D1.[7Z;1UBIJP5,5 W> [0#G.<T'T$X6'TE6F"XZ:GF=1P
MSU5-LR1/=&'/C <-HM/,<,K;$/$<5=N$\-C\.V.D<O-$]GS6NY='U'U+2="Q
MT#(9'ATC@U@:7;3B03WG&%DC2]D%7UD6VGWN<\N&?V>7V*96K6V^;\,^&7X.
M]KWMO?3HU^?1MBFJS4OH&;9.T6M<X-)_9!PMZH6,BHX&1M:QC6 -:T8 &.04
M*IRE_%H_V0N-YZ/M</AQXYF:5B-^T+B(BYO4(B("(B B(@(B("(B B(@B]1_
MDRJ_R7_P4/I/XIOH"F-1_DRJ_P E_P#!0^D_BF^@(-L[%CTOQDOI61V+'I?C
M)?2@R$1$!$1!RS4&E-52OU%;+;X,FM-ZJ-^Z>H>X209V<C X<-G@NH4\>Y@C
MC+BXL:&[1YG YKBFJ==WVVZRN]$ZKG@>ULL-!11TH?M.\3=/R0=K;R[T8\X7
M:J8R.IXC. V4L!>!V''%=<D3$1MPPS69GE<'J8;!/?:6CLUWN^XBK-W4;N@W
MC'D5!D:!)PV=ESB-KCP\W/OBX!I*]PT]TDII-75EN>^YR8MT%"7PG:EY-=V!
MWJQE=_5S=-0SP^IB9^O[H:\6%ESOEAN3YW1OM,TLS6!N1)MQ.CP3V8VL^I85
M[TU679MQ:^_UU.)9H9Z(T[6M-$^,=AQX[7'B0[/,A;,BXO2US2>ES9*RYW"M
MN,]SNUQ<PU%5*QL?BL!#&-8T8:T GOR22M<T0*(:CU +9<:NX0;NF_#54SI7
MY_"9&7<<>;SKHRTBQ25\FK[^ZZ4U+35&XI0&4U0Z=NS^%P=IS&'//ACUH-E1
M$0%C7*A@N5!4458POIYV&.1H)&6GGQ"R40[OE>OT-6T>O:/2;JND=7U<3IX7
M^,&F,;9R>' XC=PX]G%?1]'IZCCTA%I^HC;)1FCZI.&98) 6X>>!R-K)//M7
M'])6N*O_ -IO4U9-)()+;%O8FM(PXNC;&0?-AY/#'%=Y72^6U^DN.+!3%,S5
MK%ET)IVR1316NW-IHII8)GL9([!?#C8.,]XR>\\\KSI;06G-+7.JK[#;^J5-
M2TLD+97ENR7;6 TG &0.06THN;L(B("(B#BW^U9_P+:?_P!5C_\ *E7:5P?_
M &F+>;OJ#H^MF^W(K:R6GWFSM;&V^!NUC(SC/+*[P@(B("B-3Z>MVIK6ZW7F
M.2:B<YKWQ,F?&'D'(#MDC(S@X/#("ET0:;7=&6DZZS-M4]J;U!E0ZJ9$R5[-
MAYSD-(.0WQCXHX#/):=K2'3.GM445316MU7>:,1.VZBIE=%#L1AD>&%V"\-#
M3G'GXDKL:XKT]4\%A=#J&;:ZO4O932-9Q=O-EQ!P>&-EF/5YUNFM_:?/^)VX
MFN#_ /%^]O\ CY.BZ(U3'J:EG<*=T$]/LB0;66G(YCU@\/1Q7+.BZKGNG^T1
MKNMD@V6112TA<P'9&[ECC;D]Y$1/J/<ND=&NFYK#:I):TEM76;#WQ9!$0 .&
M\.9XG.#CN[SHW05_]1NE;_\ 5!_YU0I;6^CMP,YIX>L\1]_U_?\ T[C1?"=Z
M%E+%HOA.]"REEZD#KK_A2O\ 0S^=JFH0#3L! (+1D'T*%UU_PI7^AG\[5E7B
M&KGLDC*"1K)3"1@LVB[Q3P'$8/GXH)*2-DD3HY&M=&X;+FD9!'<HQUHM,$)@
M?!$QD[FM >\Y<1DM ).>''&.2K(*N"P3[^H'6!$=F2*$Y9PX>+DY(6N4%=/+
M-3,,SY&BK8TR-E,D;@8WY#20".0R#G&0@FX&Z?J864,$M%*S;WC8F2@G:[QQ
MSE5CMEB%,Z9D=,Z#XLO,FTT9.-D$GAQQP[U T\-3%;[!+<)VOMN8G?@X0UT3
ML#8VCDY&>!/!88@GH]/QR0M<^EK9FB5OR<C9N#O00,'SX5&Y,MUJCD%*(H=Z
M6/.[+LO+78#B<G)S@#/F64ZAIG->'0M(>QL;O.UN<#U9*U&1]4:B34+(&F%E
M1D/VSM&G&6$;./2[FMV:0YH<T@@C(([5!%76SMJH\4^XC<93,\21[;7N(QD\
M00>7$%95GH1;;=#2-?M[O.7;.SDDDGAV#)68B B(@(B("(B N5:]L6F[;='5
M5PMVI:R6L+YWNM[GO8PYXY\8!O/DNJKG'2M>A;*R@CCU!<K=.^-SNK4%(V=T
M@S\(Y(P!R73%OFZ.6;7+N4YT8RVN;2L4EABKHZ!TK]D5IS(2#@\<GAD=ZTK4
MNF*>FU%+7:<H])55+/3;AU-6EK1$_))> .9.>?-;AT4,HV:1CZA)7RL=/(^2
M2NC#)'R$Y<[&3@9\ZT765BM--J9UKLM@T^R1E-UJ66Z3R1B0DD!K,.&>1SZ>
MQ;K]^7*_7'7HZ9H.V26?2%KM\U1%4R00[)EAXL/$G@>T#EGMPLG5%R%HL=17
MNH)Z]D!8Y\$#-MY;M %P;CCLCQL>98N@*F"KT=:IZ2C;10NAP*=IRUA!((![
M1D'![E/KC;O.WHIKEC3Y^J:6I?-J2YVIMTO5EBK[7<75-5"\SRF*7,K(\M:7
MM8P XQPXA;=8J&VZIU=JW44UIEK;5N::"EWM.YIJ'QL>9"QK\'\YK<\ 2%U-
M6:W:ZG/L3BG=L'$Q (C./A8/#ASXJ--+Z/FQ14=W924DE# +C+LT[VAIC&&\
M" 2 MIVG>4?:M9T-M;J\[RK;6.\)2YG:T /X-XX'!;*@KM.\H^U-IWE'VJB(
M*[3O*/M3:=Y1]JHB"NT[RC[4VG>4?:J(@KM.\H^U-IWE'VJB(*[3O*/M3:=Y
M1]JHB"NT[RC[4VG>4?:J(@KM.\H^U-IWE'VJB(*[3O*/M3:=Y1]JHB#YGZ=M
M2=0U-J&W36K?2RFGE@N&<F("'9W?$?!\:3N.7DCB 5SBXZ\ND]WM^HWU.]O;
M'AS]LM=&-VTLC\3&<X<XY).22MV_VAH7RZ[KBR,2[O<2&/R@(QD+C]R9)-7E
MPIW0F8C88[@>[[2%UM34;<<>3FM,>TS]?Y=%T#K>KL=5)9Z&BMEVI+NYS)15
M,:"7/QDN+0'8SQ+3D8X#!7UMI^BDM5AMMN?4.G=24T=.93D%Y8T-VN9YXSS7
MQ#H\LJ=0V@T4)IY(ZAF^<TY:6[7+!.3G[%]V+-XB.L-4M,[B?1E49)#\DGDL
MA8]%R?ZED+#H(B("(B#7]7?DVH]+/Y@O6F_Q=OH"\ZN_)M1Z6?S!>M-_B[?0
M%43R(BBBB[I^,-_9_J5**+NGXPW]G^I08:(B B(@](B*0HBIV+3K+5S35<4=
MUNU;277>>-22,8V)XS\%F6^,".T'*J-Q:]CG.:US2YN-H \1Z5Z6FV:EG%XU
M#+X1K"8)FG9\3$GX,$;7B]G+AA9T5PJG:!Z^9CUOJ1EWF!G:V<Y[E-*V4+$Z
M] ^Z/MQ#C.(1,01XNR3A04U76U]9:K;!5/IM[1]:J)HP-LC@ &Y! R3W+#CH
MZZ/5%RIV5TCZ@VP=7G>UNV/'.-K P>/FY(C<HHV11MCB8UC&C :T8 'F"]+5
M)KW45M@M0HWF*XUTK8'$ 9C+3^%.#W;)]H6UHL"J.2HJCDD"J(BJ"(B JJBJ
MHL"(BJ"J%15" B(@\211R%ADC8\L.TTN&=D]X[BK@5%4(*HB)"B(B(!5QD$'
MDJ!>@@@O<K; UT;6U3*9Q)-.VID;%QY^*#C'FY*:@BC@A9%"QK(F -:UHP !
MR 7M$!5"HJA!5$1$@1$11$1 "J%0*H051$0%<I/C?4K:N4GQOJ09B(B B(@+
M#NMNH+E2[JZTE-54[#O-FH8'M! /'!\Q/%9BL5[(I*&H94NV8'1N$CLXPW!R
M?8D)/9HVG+QT>5-^IZ>PPVWPGM$1.@H2T@@')#]C X9XY70%QK2G@6IU99O
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MCO&>6WVJ36:SJ5K:+QNKTB\[QGEM]JHZ:)H\:1@]+E&GM%COKZ1GPZJ!OID
M6,^^6F/XRZ4+?VJA@_J@D44-)JO3T?QE^M+?VJR,?U6B=)/2S1V2GA@TS/0W
M*MF!)E9*)8H1RX[)XN\V5JM9M.H9O>*1S6=41?/6D>FNZLNL46HV4\]!(X-?
M+''L/BS^=PX$#NQGSKZ!CJ(96!\<L;VGD6N!"M\<T[L8LM<L;JN(O.\9Y;?:
MF\9Y;?:L.KTB\[QGEM]J;QGEM]J#TB\[QGEM]J;QGEM]J#TB\[QGEM]J;QGE
MM]J#TB\[QGEM]J;QGEM]J#TB\[QGEM]J;QGEM]J#TB\[QGEM]J;QGEM]J#TB
M\[QGEM]J;QGEM]J#TB\[QGEM]J;QGEM]J#TB\[QGEM]J;QGEM]J#TB\[QGEM
M]J;QGEM]J#TB\[QGEM]J;QGEM]J#TB\[QGEM]J;QGEM]J#S4?B\O[)_@H-35
M1(PT\N'-^">WS*%R.\+I1QR=Q$R.\)D=X6W,1,CO"9'>$!$R.\)D=X0$3([P
MF1WA 1,CO"9'>$!$R.\)D=X0$3([PF1WA 1,CO"9'>$!$R.\)D=X0%.4OXM'
M^R%!Y'>%.4OXM'^R%B_9TQ=UQ$1<W81$0$1$!$1 1$0$1$!$1!%ZC_)E5_DO
M_@H?2?Q3?0%,:C_)E5_DO_@H?2?Q3?0$&V=BQZ7XR7TK([%CTOQDOI09"(B
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M?G\)D9DXX\W)2.A**Y2:@U+J"Z4$EM;='4[(*29S72M9$PMVG[)(!<7'@#P
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M(@(B("(B B(@#FMAI?Q:/]D+7AS6PTOXM'^R%B_9TQ=UQ$1<G81$0$1$!$1
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M^T#<ZZDUY<F6_K;HQ20[]\3C&8SAQ:-H<3'S<1P&2<]A7#72N$F<AX;D-SQ
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MJ2W4KZFX54%+3,^%+/(&,;Z23A!D+!K+735=RM]=,'&>A+W0D.P 7MV3D=O
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M%41$2!$1%$1$ *H5 JA!5$1 5RD^-]2MKW2G$R#-1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M&.Q5&:B(HHB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M/RY_=.^Y/=10_+G]T[[EX\ 1^2G@"/R4'OW44/RY_=.^Y/=10_+G]T[[EX\
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5("(B B(@(B("(B B(@(B("(B#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g50309g89f04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g89f04.jpg
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M 2(  A$! Q$!_\0 '  !  (# 0$!              ,&! 4' @@!_\0 5!
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M!!SEO!3]2H8O$F/+HVN\IJ* :]KMRGHQ):=6^-&JGFGJO'5DFQW]P,T!%R@
M*N$55W(00)KN65WV'JI7$2^G82,358B<$ _0
M
M
M       #67:!4C62)/';M3']C9D=0F87>C:!BVNJ2>%%SDSBKV>;DJ^H@Z&R
M*B=62T-VH!!5_%IUDZ$%7Y"=9.@
M
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M;XI_4!3:1RII!5I_G_ N4?D(4NE^457]?\$+I%Y"%(15?D)UDZ$%7Y"=9.A
M
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MU7?L:VG54;_G9M1>Q7&B_1S4YV=7"7)HKY?27T> #@>L'F;XI_4>CS-\4_J
MI=+\HJOZ_P""%TB\A"ETORBJ_K_@A=(O(0I"*K\A.LG0@J_(3K)T(
M
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MR$ZR=""K\A.LG0@
M                         !IM)M);;HY2I+<9L/<G[.%FU[^I/Q786(SX
M87+E-NF:ZYQ$-R#A5_[J-XKW.9;49;X.C536D5/2Y=WV(A3:R[7"M<KJNNJI
MU7^)*YW]U-L69GR\&_\ U%8HG%NF:O\ SW_A]3@^48JJ>)VM%/*QW%KU12PV
M?3K2"UN;R=PDGC3_ .G4_M$7MVI]BH)LSZ2UV_ZDMS/]RB8_2<_P^C04+1#N
ME6^\/92W)J4%8[8U5=F-Z^A>A?0O:7TU33-/:7O</Q-KB:>>U5F  $;P
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ME%5_7_!"Z1>0A2$57Y"=9.A!5^0G63H0
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MZGC=03O3FZ0^*]C47.W9U<>DV])1PTL,,<;<\C&D3'NVNU4Z,[S(
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MK-^<G:<F TWW-9^5UI%1=RY!R>.1\:YC>YB\6K@W%NTDKJ5R)*_G$72V3?\
M8N\QGAYCQ+*GBZ9_%&'0 85JN=/<H=>G=XR>4Q=[3--$Q,3B77$Q5&8  10\
MS?%/ZCT>9OBG]0%+I?E%5_7_  0ND7D(4NE^457]?\$+I%Y"%(15?D)UDZ$%
M7Y"=9.A
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MOZ_X(72+R$*0BJ_(3K)T(*OR$ZR="
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MI?E%5_7_  0ND7D(4NE^457]?\$+I%Y"%(15?D)UDZ$%7Y"=9.A
M
M 8-ZM5+>;;-0U\>O!*GVM7H5%Z%0^?-,=$J_1FK5L[5EHW+^RJ6IXKO0O!?0
M?2)'4T\-5 ^"IB9+"],.8]J.14]**9T5S2\SXC\,M\=3F>U4>)_E\G@[9?\
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M5):F)F&-<G'<F[/9N-Q3U,%3K\WFCEY-RL?J.1=5R;T7T@2@
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M_!"Z1>0A2Z7Y15?U_P $+I%Y"%(15?D)UDZ$%7Y"=9.A
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M6S7BF=;H()N29)*[XQ%78O\ ;BG8;ICVR,:]CD<QR91R+E%3B!^@
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M]T7SW_=4=6O<Z%O9K?!"C_CU':WW#P0H_P"/4=K?<;+OW1?/?]U1W[HOGO\
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MBE@9&O2J)E5^W>0LO%$]<<KJ];50S8I8Y6ZT3VO;Q:N3&:ZI\RSIMT4^(>P
M8LP  #S-\4_J/1YF^*?U 4NE^457]?\ !"Z1>0A2Z7Y15?U_P0ND7D(4A%5^
M0G63H05?D)UDZ$
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MH](ZU6,2FC7"N3+U3AP ANEZ<YSHJ-<-38LG2O4:1SE<Y5<JJJ[U4_ 5
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M"Z1>0A2$57Y"=9.A!5^0G63H0
M                                     ""MJHZ2!9)5V="=*KP%951T
MD"R2KLZ$Z57@5"NJY*R=9)%V?NMZ&H!8K5=FU;UCE1&2Y\5.A4]YM"@HJM5%
M1514VHJ%GLMT2I1(9U1)DW+\[]0-N                       "K:=VFNN
M=$V&U4\"S2>+-,Y4:[41<ZN=^%7"_85G131W22P75E0RFC? [Q9HTF;XS>W>
MF]#IX    4FX2K/6SR*N<N7'5T%V*$_*/=G?DL(_     &MTC:Y]EJFL:KG*
MB81$ROE(:ZOJ5KK*^"ECGY1C6J]JL5-9$QE$XEC %8I:6.LK*Q**!\-&^FY-
M<L5J*_HV>@PF)5I3)<.2DY>+5@:W57.KJ*BKVJ70 5:X44E/1VIF%Y&)%Y7]
MGRB-<J9RK>G;DABH6ODM\>9)J=T\BK^R6-$1439C@6\ :AD"2WIC6QZM-11X
M8F,)K.X=2&#-%)R6D'B.\=R:NS?U%E %:AH61UUKU(,-DIW)+XNQRZO[Q^Z/
MS0T-ME62GD;419Y3$2ZRIK;-O26)SFM\IR)LSM4_=9N$7*87IR!KK^BRV2IU
M&N57-3"8V[TZ#7(Y]QJ+8R""9K*9R/DD>S539C8G'<6,\/EC8Y&OD8UR[D5<
M*H%/6!W)N@YO+WTYSK)+J+NSOUN!E5+$COBOIXUG?),FO')"N68_>:[@6A%1
M57"HN-B^@_0*;04KTJ8F5#WQ53)]9<4ZJYVW?KYW&[TJ8Y]FD:QKG.UF[$3*
M[S;@"NWJI6XV]6TD<^(Y&ND1T:[6[>CIZCQ04$=52W%D<JO;,UN$Y!8FHY,X
M5$_N64 5*.&LKZ.MJ71O;.V%L#&JF%7&%=V_B362!O.'21R.UD@5KHTIEC3[
M5SM4LX UFC37,LE,U[5:Y$=E%3"^4ILP    &WT9E5E:Z/HD;_5/]J:@V%@1
M>^L./\W]E MP (H>9OBG]1Z/,WQ3^H"ETORBJ_K_ ((72+R$*72_**K^O^"%
MTB\A"D(JOR$ZR=""K\A.LG0@
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M\S?%/Z@*72_**K^O^"%TB\A"ETORBJ_K_@A=(O(0I"*K\A.LG0@J_(3K)T(
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MORBJ_K_@A=(O(0I=+\HJOZ_X(72+R$*0BJ_(3K)T(*OR$ZR="
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ME')5A[5BYU*(J  :VT
M           #S-\4_J/1YF^*?U 4NE^457]?\$+I%Y"%+I?E%5_7_!"Z1>0A
M2$57Y"=9.A!5^0G63H0
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M)#2JB3KPDRY=9"J@O+&<L8KJB,,BY57/KA4U7(PP<M(Z3DH&ZK&97.&IT(G
MQP#)B        MW<DG=3]T:Q/8N%6?47J<U6K_<^N#Y2[B= ZN[HUKPF64^O
M.]>"-:N/_DK3ZM.'B?Q/4X'\$_J  YW8
M                         !YF^*?U'H\S?%/Z@*72_**K^O\ @A=(O(0I
M=+\HJOZ_X(72+R$*0BJ_(3K)T(*OR$ZR="
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MN9(U6O:JHYJIA45.A3\/H+NP=RY]TFFOFCD2+6N\:II6[.57Y[?\W%.GKW\
MFBDAE?%,QT<C%U7,>F%:O!4/2HKBN,P\:[:JM3B7@ &;4          "^7NY
M4T=PN5Q<]70WFSL9"K4SB7]FCV+PPZ-W].)B5>DU)7Z#RT56V3OUKP1+*B9;
M-#'K:BN7YS4=J^E$;P*<##DALFY/=NI-(IWTSH%H;2C7,5FLV@B1Z)C&4=JY
MSZ3<TETMUKM5? R\UMR@J*5\$-#) K&-<[<]V7*B*U=J:N5SP*8"S3"17,+'
MIHYL/>:W(Y'2V^@9%-A<ZLCGOD<W[.41%]**5P L1B&-4YG( "H
M'5.Y5W+:F^3PW._POI[2U4<R)Z:KZCALZ&^GIZ.)C55%,9EG1;JN3BE=?^'G
M19]NL]1?*R-6SUZ(R!%3:D*+G/\ Y+_1$XG73S&QD4;8XFM8QB(UK6IA$1-R
M(AZ/-KJFJ<R]JW1%NF*8  8LP
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M9_ %/_B&+U1?SCX I_\ $,7JB_G.F>&/^A]K^@\,?]#[7]!F][P<O#>\N9_
M%/\ XAB]47\X^ *?_$,7JB_G.F>&/^A]K^@\,?\ 0^U_09O>\'+PWO+F?P!3
M_P"(8O5%_./@"G_Q#%ZHOYSIGAC_ *'VOZ#PQ_T/M?T&;WO!R\-[RYG\ 4_^
M(8O5%_.9%+W VH]%J]('.9TI%2X7M5R_V.B>&/\ H?:_H>X],8U7]I1N1.+7
MY_ F;WO!%/#>\L'1?N7:,Z/R,FCI'5M4W:DU6J/5%]#<(U.O&2\&KM]^H*U4
M:R7DY%W,D355?P-H<]?-GYG9;BB(^3P  Q9@
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MUN>EOZ?B60\^JGEG#UK=<5TQ5  #%F
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MZ'Y[$53I!R<1^)Z'!_@D !SNL
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MYZLO6LV^G1@ !@V@
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MESS0'N;<UDCN&D+6NE;AT=+O1J\7\5]&XZD :*JIJG,OJ>$X.UPE'):C^9
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MT<;N6\QJ_-9_Y:CF-7YK/_+4ZD!J9V-'&[EO,:OS6?\ EJ>H[;6R+AE).O\
M^FIU #43LNCC=1K?HK5S.1:I6T\?#.LY?L+=;;?3VZ'DZ9F,^4Y=JNZU,L&J
MNY57Y;[=FFWX  :VT
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M/,R>%DL:Y8Y,H2$4
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MI0SJNU-DD@EIY5@EB9R:+JHY%;P5%/4EM66.C22=7/IY$DUM1$UESP3<!L0
M   &]T8J51\E,Y=BIKMZ^DL)3K*Y67.!4Z78[4+B18
M                                      #S-\4_J/1YF^*?U 4NE^45
M7]?\$+I%Y"%+I?E%5_7_  0ND7D(4A%5^0G63H05?D)UDZ$
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MM^0-C23MJ::.9B*B/3.%Z/02F%9VJVW1*Y-57:S\+T(YRJG]S-
M    ,ZQL5]SAQT*KE^Q"X&BT8I5:Q]2]/*\5O5TJ;TBP
M                                        'F;XI_4>CS-\4_J I=+\
MHJOZ_P""%TB\A"ETORBJ_K_@A=(O(0I"*K\A.LG0@J_(3K)T(
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MB(U$1$W(@'Y&QL;&L8B(UJ81$Z#] (H
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M-'Z.VSQ%-WMXEO  :G0
M
M      >9OBG]1Z/,WQ3^H"ETORBJ_K_@A=(O(0I=+\HJOZ_X(72+R$*0BJ_(
M3K)T(*OR$ZR="   !S;NZ:5/L&B[:*BD5E=<56)'(NUD:)XZIZ=J)]J\#I)\
MR_\ $)7NJM/G4RKXE'31QHGI<BO5?_DG8;;%/-7W<_$US1;G#F8 /1>.
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M%_JBF\/,F,3A[L3F,@ (H
M
M     >9OBG]1Z/,WQ3^H"ETORBJ_K_@A=(O(0I=+\HJOZ_X(72+R$*0BJ_(3
MK)T(*OR$ZR="   !\M]WFG=#W2:][MT\4,C>K41O]VJ?4AQ7_B0T>?/1T%^I
MV*[F_P#RU0J=#57+%ZD7*?\ DANX>K%;FXNGFM]O1P, 'H/(           ,
MBW451<:R.EHXUDGD5=5N43<F55578B(B*JJNXQRRZ%9;#I&^/X]EIEY/BF7Q
MM=C_ ,%>29Q#*F,SAJ:ZT5U#045;54[F4M:USJ>7**CT:N%W<%XD%?15%OJ5
MIZN/DYD8Q^KE%\5S4<U=G%%1?M+]SN"HM5@L%SD;'0U]L:L4SMU/4)/,C).I
M?)=Z%ST(8^DBP6S3VLBNJPQ+%1TT3DFI4J41Z01(J:N4V[%VY_N817.<,YMQ
MC,?93;5;*JZ3NAHVQJYC==[I)6QM:W*)E7.5$1,JG2959HY=*1\[9J9%Y*!*
MI71R,>UT2KJZ[5:JHYN>E,XZ3:7%:6X5]/);Z-+E3P-5T\5'1+2X1=B95JNZ
M>GWEJB8GA+HSJT[Z*EFME1&ZWRKET$.K-K*Y5VJCO&?E4Z>"()JF%IMQ+E8
M-C2            ;?1&R3:1:14-KIT7,\B(]R?N,3:YWV)DDSCNL1,SB'U3W
M,J=U-H!8(WIARTC'X^LFM^)9CQ3PLIX(X86HV.-J,:U.A$3"(>SRYG,Y>]3'
M+$0  B@
M                                                  !YF^*?U'H\
MS?%/Z@*72_**K^O^"%TB\A"ETORBJ_K_ ((72+R$*0BJ_(3K)T(*OR$ZR="
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M:.I1N="Y],N<@Z-\#6EWF])ZPT? UI=YO2>L-'4HW.A<^F7.0=&3N,Z7*O\
MT](G_P"X0W=F[A-VFD:MWN=)2Q=*0(Z5_P#5$1.U1-VB/58X>Y/_ ,N1TE--
M5U,=/2Q/FGD<C61L;K.<J]"(?3G<?T 31*WOK+BC77BJ:B/QM2%F_41>/%>K
MAMWFAF@=CT29K6ZG62K5,.JIO&D7T(NYJ>A,%I.6[>Y^T>'=P_"]/YJO( #G
M=@
M                                                !YF^*?U'H\S?
M%/Z@*72_**K^O^"%TB\A"ETORBJ_K_@A=(O(0I"*K\A.LG0AJD_9]2DK%UFH
MO%"#]
M
M                                     /,WQ3^H]$<ZXA=V 4VE^457
M]?\ !"Z1>0A2+6_EKW52-VM61R(OH1<%WC\A"D/R5NM&J$=(_+58N]-Q/T&!
M5(Z%_*-SCIP09X,>GJF2M155.LR$V[@
M
M                                                           !
M51$RJX0 :72:Y)0T$CFK^T7Q6)Q<ONWF1=;M3T$"OED1J='%WH1"E*^HOEPY
M65JMB;L8SYJ>\#::)4BHU'NSM+FU,(8%JI$IX43!G@#\>U')A3] &HK*!Z*K
MZ>1S'>@U[ZRX4RX5D<B<4RU2SGAT3';T0"INOU<W_P"Z^T7W'YX05WFGM5]Q
M9UHXE_=3L/SF,7!.P"L^$%=YI[5?</""N\T]JON+-S&+@G8.8Q<$["HK/A!7
M>:>U7W#P@KO-/:K[BS<QBX)V#F,7!.P"L^$%=YI[5?</""N\T]JON+-S&+@G
M8.8Q<$[ *SX05WFGM5]P\(*[S3VJ^XLW,8N"=@YC%P3L K/A!7>:>U7W#P@K
MO-/:K[BS<QBX)V#F,7!.P"L^$%=YI[5?</""N\T]JON+-S&+@G8.8Q<$[ *S
MX05WFGM5]P\(*[S3VJ^XLW,8N"=@YC%P3L K/A!7>:>U7W#P@KO-/:K[BS<Q
MBX)V#F,7!.P"L^$%=YI[5?</""N\T]JON+-S&+@G8.8Q<$[ *SX05WFGM5]P
M\(*[S3VJ^XLW,8N"=@YC%P3L K/A!7>:>U7W#P@KO-/:K[BS<QBX)V#F,7!.
MP"L^$%=YI[5?</""N\T]JON+-S&+@G8.8Q<$[ *SX05WFGM5]P\(*[S3VJ^X
MLW,8N"=@YC%P3L K/A!7>:>U7W#P@KO-/:K[BS<QBX)V#F,7!.P"L^$%=YI[
M5?</""N\T]JON+-S&+@G8.8Q<$[ *SX05WFGM5]P\(*[S3VJ^XLW,8N"=@YC
M%P3L K/A!7>:>U7W#P@KO-/:K[BS<QBX)V#F,7!.P"L^$%=YI[5?</""N\T]
MJON+-S&+@G8.8Q<$[ *SX05WFGM5]P\(*[S3VJ^XLW,8N"=@YC%P3L K/A!7
M>:>U7W#P@KO-/:K[BS<QBX)V#F,7!.P"L^$%=YI[5?</""N\T]JON+-S&+@G
M8.8Q<$[ *SX05WFGM5]P\(*[S3VJ^XLW,8N"=@YC%P3L K/A!7>:>U7W#P@K
MO-/:K[BS<QBX)V#F,7!.P"L^$%=YI[5?</""N\T]JON+-S&+@G8.8Q<$[ *S
MX05WFGM5]P\(*[S3VJ^XLW,8N"=@YC%P3L K/A!7>:>U7W#P@KO-/:K[BS<Q
MBX)V#F,7!.P"L^$%=YI[5?</""N\T]JON+-S&+@G8.8Q<$[ *SX05WFGM5]P
M\(*[S3VJ^XLW,8N"=@YC%P3L K/A!7>:>U7W#P@KO-/:K[BS<QBX)V#F,7!.
MP"L^$%=YI[5?</""N\T]JON+-S&+@G8.8Q<$[ *SX05WFGM5]P\(*[S3VJ^X
MLW,8N"=@YC%P3L K/A!7>:>U7W#P@KO-/:K[BS<QBX)V#F,7!.P"L^$%=YI[
M5?</""N\T]JON+-S&+@G8.8Q<$[ *SX05WFGM5]P\(*[S3VJ^XLW,8N"=@YC
M%P3L K/A!7>:>U7W#P@KO-/:K[BS<QBX)V#F,7!.P"L^$%=YI[5?</""N\T]
MJON+-S&+@G8.8Q<$[ *SX05WFGM5]P\(*[S3VJ^XLW,8N"=@YC%P3L K/A!7
M>:>U7W#P@KO-/:K[BS<QBX)V#F,7!.P"L^$%=YI[5?</""N\T]JON+-S&+@G
M8.8Q<$[ *SX05WFGM5]P\(*[S3VJ^XLW,8N"=@YC%P3L K/A!7>:>U7W#P@K
MO-/:K[BS<QBX)V#F,7!.P"L^$%=YI[5?</""N\T]JON+-S&+@G8.8Q<$[ *S
MX05WFGM5]P\(*[S3VJ^XLW,8N"=@YC%P3L K/A!7>:>U7W#P@KO-/:K[BS<Q
MBX)V#F,7!.P"L^$%=YI[5?</""N\T]JON+-S&+@G8.8Q<$[ *SX05WFGM5]P
M\(*[S3VJ^XLW,8N"=@YC%P3L K/A!7>:>U7W#P@KO-/:K[BS<QBX)V#F,7!.
MP"L^$%=YI[5?</""N\T]JON+-S&+@G8.8Q<$[ *SX05WFGM5]P\(*[S3VJ^X
MLW,8N"=@YC%P3L K/A!7>:>U7W#P@KO-/:K[BS<QBX)V#F,7!.P"L^$%=YI[
M5?</""N\T]JON+-S&+@G8.8Q<$[ *SX05WFGM5]P\(*[S3VJ^XLW,8N"=@YC
M%P3L K/A!7>:>U7W#P@KO-/:K[BS<QBX)V#F,7!.P"L^$%=YI[5?</""N\T]
MJON+-S&+@G8.8Q<$[ *SX05WFGM%]QCS72ZU&4C9'#GI1%<O]2W<RBX)V'IM
J)&W]U.P"DTUDGJIN5JY'2/7I<N2U6VV,IF[$-DV-K=R(>B*(F$  '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g50309g89f05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g89f05.jpg
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M8/V%6;-^3HOI^TH,Q$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0" 00=P=
MERZ].-%J)F/SF8/O!(_HNHKD^NW<.H*?'C)]J#H=DGZR'^_:MJHWI9_%!_?M
M4D0$1$%BM_RDO[)^PJU9OR=%]/VE7:W_ "DO[)^PJU9OR=%]/VE!F(B("(B
MB(@(B("(B B(@(B\XAXH/47G$WQ3C;XH/47G&WQ3C;XH/47G&WQ3C;XH/47G
M&WQ3C;XH/47G&WQ3C;XH/47G&WQ3C;XH/47G&WQ3C;XH/47G&WQ3C;XH/47G
M&WQ3C;XH/47G&WQ3C;XH/47G&WQ3C;XH/47G&WQ3C;XH/47G&WQ3C;XH/47G
M&WQ3C;XH/47G&WQ3C;XH/47G&WQ3C;XH/47G&WQ3C;XH/47G&WQ3C;XH/47G
M&WQ3C;XH/47G&WQ3C;XH/47G&WQ3C;XH/47G&WQ3C;XH/47G&WQ3C;XH/47G
M&WQ3C;XH/47G&WQ3C;XH/47G&WQ3C;XH/47G&WQ3C;XH/47G&WQ3C;XH/47G
M&WQ3C;XH/47G&WQ3C;XH/47G$/%>@@\D!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!<DZ0/R_3>^3[5UM<DZ0/R_3>^3[4$RTE^(_OVJ4J+:2_$?W[5*4!$1!8K
M?\I+^R?L*M6;\G1?3]I5VM_RDO[)^PJU9OR=%]/VE!F(B("(B B(@(B("(B
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M/J<T[&"26&C8.%KVL)XL#'#W$ '.<;E=0Z&]93:TTB*RN:QM?3RFGG+!@/(
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M[JYXRQV.%F^".2+3J(W"/ZUU1J?4G2:[1FDJ\6R&G;^'J0/2)#>)Q)Y@#(
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M1B2*(L#"T'Q#<@?0N7?X:;166_3]X9=;?/2R.JFEC:F$L)' -QQ!=E: T -
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MR?[W70H3EBY+HAWHM_OQ75Z3\4I=:\B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M%)!4NIGEL8F8'AI=([) /?Z//VE9?1+30V_I[U;1T;&PTS(Z@-B8,-:.M9@
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M41"+,S6C@;G)QCQ('P4_1#JE"[=T?TE#TAUFK65M0ZJJ6N:Z M' ,M V//\
M-4T1$1,[$1$0+5ZH_P##UQ_[+EM%J]4?^'KC_P!ER+5\HUHCDWZ?]UUBC_%!
M<GT1R;]/^ZZQ1_B@I=:\B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MC>!0S$9# #N&[\EK] 76EO>K>DFX6]SW4TT5,6%\;F':%X.6N (W!72-(_\
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MWJ9CSIT5$14>B(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M_4U_J\VEK;7:&FHO51Z+&,'$8L\B1X^ ^D^VYT<:4=IV@EFK7<=RJ\.F.<\
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M@\U$QKRM$Q,;ARVMTFTN.(A\ M>[29R?P7U!=>= T]RM]C9X!0ER3S3/JA\
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ML9=C. !W#<GO._-%9M$UU+!Z??\ RFOW_P"8_P#L\:YO?/\ [5RU_P#<;_\
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M><U^_P"G_P!/[T/2LZ(BYWYS7[_I_P#3^]/.:_?]/_I_>AZ5G1$7._.:_?\
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M4K]TZ)U%=RHZ^1@/#(1X'*.O<_"8HF .(^5X>U<5U97WFI$E=2UKV@.QP,.
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MR,E<UPQC?"ZI8=0U,M*SJYB0WF';D^Q89\/I=X\.OB9_U':?+HZL5QD%',8
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MI.$1N<2P9[L[**5/%Q</&>>_O6^L=/1UNH*".KGQ'D!Y<=O<NOM7[M[<%?\
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M\\@?["DTG*(TY&4141$0$R@]Z(&4[E05;JIVP0.D<< #*1W[0B9U&Y>U%1'
MPND< /:HW<M3;%E)'Q'YV5I[I=)*^<AKRV('8)30LQG 713%K\G#DY.YU1B5
MMTN$H),SVY^:<+35%QKHVN(J9,^TJ05P8UNP"CU8T.+O:M?3KIQ6R7^63:*I
M\\!,CRY^=R2LF2;FHS353J&I()/ 5M):^)T7$"/BN3)28G<,]SI753AC'..!
M[5#;Y= XN8T_!7[U<I'\3( YWNW4>@@FJ*@<0)(]BS6K37>R>]&MB943"X7
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M"M91P.?(0".Y-(F8B-RO2RLB:7/. .]:.OU-2T^0PE[AX!:"NKJBXR'TB(O
M=ZPGT7"WBP%T5Q?+AR<N9_!M'ZTD!]&GV6GOVIY[G3=3#'P;[K!FC#7'*M\+
M? +6N*L=X<E^5DM'3*ND<YK6\7-;".K(&,K7B1K=LA7,CGE:ZVYX[=V1/.7
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M/JJ6GX6SL#VC8NSNL*NO$%TJ)'&9I8/DQD\ETXIC)WAQ\FEL$3U-%<[MU<9
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M5TIXVX&[@.Y;_3=T9=;;%,#B3&'M[P5[AKB<;<*B<Y?I>^&IB:?)M6[\(>?
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MYIVPI'5PMJ&]; ]I/L[US(,:0 SF.]7J2NK:5_\ R\KFM'=S7D1R8F>[Z:W
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MAN _&QQE4VNY"L?-#+"ZGJH2!)$XYQGD0>\+"AO<U6^>*BH'32Q2.8_,@:T
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MG3V[.N&FTQ=@VI;$YV1@X 4\:<@%1G3^F([=,99B)'C8'FI,J@B(@(B("(B
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MU%5O+@VG:%?'DY%8G5?,S/\ =%Z4G7[)=Y9D#<\#\> ;G95,O<;".M:\!W+
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MMMN$DD^>KE.25O'>'#$1O<>72;5>I6L8VK)D:1CB]JUO2E<*Z@L0?;I>!KG
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M@B<66=1'NQY..<DQ>(3S_#==YZ[2E135#N)M-(&L/L(77E >A[2L>E; ^#M
MFGF<'O[L'P4OK+E%3O+<@D<SX*EYK:TS3O#2(U&I9Z+$H*YE6TX(!!QC/-9,
MCQ'&Y[N30253:52+6T]XCJ.K,=)6EDF,/ZD\.#WY\%==<&MD@8Z&5IFE=$.,
M8Y [^XX649Z3&XEI.*T=M,U$1QP"<$X[@M68BMT\O70,DX'Q\0SPO&'#WA7%
M$3N-P3&NPB(I!$1 1$0$1$!$1 3DBHD>&@Y.$%1=ME6738/-:FKNAXBV YQL
M2M?(^61W$Y[C]*I-M-:XIE('5\+3Z3P%1Y3@SL\?!:$,SS57![%7K:^A'RD
MK8G8],*\V9I'HNRHT&D<EX'2L.6O(^E3%U9P?NE+9 54""HY#<IXMI&AX\5L
MZ:XQ28 .#X%6BT,IQS#8HJ&O#AL56#E64$1$!$1 18E96LIR!CB<>[.%B,O&
M3Z4'"/'C"#;(L+RE3@X+CGV#*\EN4+6!S"'9[LX*#.6NN0I7@NGABD<.1>P%
M8\U[8QF71X_^2T<MQ?<:@QQ8#1S+>Y8Y[Q6N[-<59M/9?=4F0NCI8A$QNQVP
MU:RIN$-(XLIP9:CO<>2P[G=6B3L5&\!N</?[5F6NAC(!=@D_*)7FTK^I[SX=
MFNB&.V&KKR'3O/T<EBUFFI,=9",OYN#CS]RESY*6CA)<YK6M&Y<>2B%PU3/7
MS]DLL1D.<.G_ #6KNQ8ZX_QAG/7;WTUD5.Z.8Q3-P[.#E;VCHF8+>\*S#;GM
M@,D\AEGYEQ6932;9[^]=,0Y)F8E4ZB9R(5GR9&<Y P5L&.#MSS5U2CJEIW6Q
MH:0 M5=+7F%W" T@*6XW6-4MR",*DXZSYA:N3IG<N+R5MRH*Z0TU1(WA/(\E
MO+;TAW2FPVMBCF8.9 W4DK=.05DSG?)<3OA8QT33$;R.^"X,W%BTO?KS>+?#
M'5&GD.L-/7/T;C2F-QYDM6RH*6P2R<=MKC"3OP\6Q6FJ-"TAC/#(X'W*+W/2
M%93.)II'./<&[%8SQ;T[Q.H12>-GG5+:=?@@G Q!6QN'M*P+M1ULL+@^6,@<
MU#[#9ZJR6MU775,QD<,ACBHU/J&Z27!W:Q-%2.]%K\E98[9I[0PMAK7?=T>P
MU#X'FGJ)&ES3Z(]BN7WJ*5[:F<.ZK/(+F=7>FVVJBF;,Z61I!P#W+ID;H=2:
M=:6D<,T>Q'YKL+T:??CZ9<F7%;':+S'9ASZSACCX("V-F.96/2:[H:=QD+GS
M2'F6A<RJ[5/;ZZ2FJN/C:< GO67#2@ 87/2D8WN8>!3+7JVZ-+TGX)$%*_'Z
MRP9>DJM<3U5/&/>/O4.$ QR7O4M"MZEM]F]?IF#WCND[ND6Z;XAA'T+JW1O=
M9KSIEE74AHD,KVX'L*X"8VX*[CT/@#1L8'KY/M6V"\S?4O/^J</%@P[I&IVF
MJ(B['SHB(@(B("Y)T@?E^F]\GVKK:Y)T@?E^F]\GVH)EI+\1_?M4I46TE^(_
MOVJ4H"(B"Q6_Y27]D_85:LWY.B^G[2KM;_E)?V3]A5JS?DZ+Z?M*#,1$0$1$
M!$1 7CODGW+U>.^2?<@TK@,E J7'<JG*HV7,KS(5&4R@KXEYE49*\R4%S*95
MO)3=!47)Q;JGWH.:"O*\3(3(0AXB]R$R$3I3NFZJ1#2G)&^%:J6];&X#Y0W:
MKV<=RHV&".81&FM:_&W>K@=LJJJ'AR]@]$\_858:[;<J4+P*]R5;:5[E%5>=
ME07+QQ5I[N:)4N=S/>MK3.XH6'V+3..>1YK;49_Y5OB%$K59.!Q8[E[PA6]\
M93B4+:5A_#RV7CW!P.4]'Q5)QCFIB(MY1WJU=;1B88P#[PH]6V"F>\F-AAD[
MW,V4Q<,\N:Q*BF$F2=CXA5^ZOB5HFD]KP@TUJN,.33U E8.Y^Q6FKF5[01+2
MR9\6C(709('L<<.R/K5O\TM>W/M*F,]ZL[</#D\.1FEEDJ1UX+&D\RNQZ*KK
M'9[;'$*R+K2 7'*Q#3TKF@.B83XEH5DVZA)&88O;AJM.>9@IP:T[PFGG1: -
MJV(__)8\VL[/$<=I#CX-W42CMEOP1V9FW>5=90T3-VT\6?V52,C6./'RW%3T
M@4;<BEIIYS[ M?+JR[UQ(HJ(4[3^=(?N5#6PL'H,8WW-"KZX8X1R]R3>?9:,
M%8\M?-2W*M>'7*XRN83DL9L%E4M!2TN3#$W/>YVY*O N<,-S]*NQTSGN],G"
MKN5XZ**&-=*2(QCVK9T4/5M ^M4Q0< P!@+,8, *VF5LGPNM! .%YPA5-< "
MO.(*85T86LU#=V66CBJ)(G2B29L(#3C!.=_J6S#@HITE1.J;'31Q-D<35QYX
M!D@8=NKTB)G4N3FY+8L%[X_,0V]PN[*.[6Z@=$YSZTO#7 [-X1G=8E@U+!>+
ME743(7Q2TI/RB#Q@.+21]./BM'46,6S5^GW035U2QSI>-T\AD#,-VWQMG*TI
MBKK;%-<Z*GE=.ZLJJ5S0TY+7C+'>X.&5>*5F'EY.=R,>29M':)[QY[:K[_SG
M?^$UL&IX+S6UU/3PO:*7_P!0D8>,D9'P6NIM<Q/@AJ9[75Q4,LG5"HR'-#LX
MW5O2EM-KU!<Z8,<&1T<#.+&SG</I8/ORH9;Z9[K7114L%SDNL=0'M@?&33@9
MYD$8'O5HI69EAEYW+QTIN?N^[?:/:8B(_P#KS\NS2R,AB?)(0UC&ESB>X#FH
MY:=7Q5U92Q/H:FF@K"X4T\F,2<//;N65=J"ZU;JQD=="**:%\8@ZGTLEA'R\
M_.W40M)FKY=,6]M)4Q36V1SZDR1EK6 ';?VX5*UB8[N[E\K-3+6M(F(_E'W=
MXC]_:9GVG^R1U>LX*>LJ&]CJ'T5-,()ZMN.%C^7+F0%[5ZN['4?\S:JV.AZ[
MJ>U/  SG&0.\>U12X1U%/;[Y8>R5#ZRLK^M@<V,EKF%S3GBY?F_6LBJN\=PN
MD,=SAK6VR@<.KB9 YQG>W;B=[/ *_1'PXI^H9HW$WU/\HU$[G<3^T1$3\]_W
M=++MEZP@;XSC?"M-)<,@;8RKD;3PN)VR,+GWW?1Q&WS9TA3>4+[72P,X,/(X
M,\]U$K93/[5Q/R?U5TWI3TX;;=GU#'!L=02X8]ZP-(Z*N=XC=(T-9#^:\@[K
MHKK79MK7='J:WU-1/P0QND+CLT#==-Z.](W.CNU-7U#.IB:2,.V*E>BM(LL7
M62U!CFF=R)'+W*5[\&02 >Y4ODWVA%\L1Y:N_4O6F.9[2X-V(.^RAMZ,+:>5
MS6YV.P71R6O:0_=I&P\%"[K;^.LJ6L;AA[NY;X<D3'2\;FXM??"+62M@93LA
M$_X1Q.6D8X5?N%JD@<VKI7F.1OI!S=EA7FR<+3) ."1N^RS[?7R2T+8:OT7\
M.V>\+?7\,N&)F)ZH3_25R-PM4<\N>M_%OWYD=ZW9PXKF&F+^^T51HIHAU$S\
MMDSR.5TMK@6@M&Q[_%<&6NK/;X^3KHK( 7F53Q9R.]>#*IY;[7 O<XY*WE>M
M([U K#EX2<[(".:IDE:&DCDF]$5VK+P![5K+E)33@PR1MF;W@[A8U95R2.+8
MLM;R)\58CR.7/ORJ]<Q&H:UQQ/Y0CM]LCNK,ULC;#(T[-;R<%&I*NKF IJVF
M<7\AQ#DNEM&2-CCP*L5]-&^"3AC9UA&QQDK6G*FL=+DY' K,3:J$/L+XJ)T]
M"3VC&2!W*Q37"YQ1$S4\CPWO:-E(;96\+RQW,>BX+8TCH>W&)O#U;QG'M5;6
MFW=Y6+#%K=%NTHJR\U4V&14LSG'8#"F-EBE901FI8!*1DMQ\E9L=/&TD\#=N
M6&@%7<!93:?#VN+PXP?=M;X =SN?$JG@ 5[&RH(5.EW;T\IZV2G=PG);GDM]
M3U(?&",'/>H\6CBR5E6N8B8Q?FG<+6L_PN?)3?W,V]VR&\VV:DGV#QL[O!4*
MTMT545JOWE.LG[9(TYB:YN.$YYKH,9\5<<0>1P5M%YK&G).*+3U2N!W=X;+U
M6,X58>,*F^^VFNRZ''&$!/?R5L/'BJLJ=JZA4YK7-(<UI'@0M95V*WU0=Q0-
M:X][=ELD&%&HGRM6UJ_C*'UFCG@N=23C'<UP6@K;374;CUT+G ?G-&0NH-R.
M3L>PKTAKFX> ?>LK8*RZ:<R]?/=R NQSSE>M((73*RQT%6"9(6!WBW9:&LT8
M,$TD_P#\7+"W'F/#LQ\VD^4/QS6#6',@6_K[)6T33QQ%P\6C*CU<"UXX@0?
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MO4;N(<78R2,A=%9BT;APY*32=3Y2%E:7TP=*<GA!'L"VFCZ7KZB2JD9Q-(]
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MS;%]2SXOW<B$573.X*BG>T^[.5(-'6V8W UDL9: , %3IT3'<V-/O"J:P 8
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M>J@5:XDXDV:*@99(,9!;@KAVJ+*^*KG.X;G;9=QC](@$X(."?%:J_6F*Z4?
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M.#"&@!91Q:PZ9^HVFO9I9GP6V'@BQQ<B?%*"CEKY&S2'$(.0WQ6$Z!S[@'R
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MQA62>!X<#@@Y5YY 6IN=3PD-C(XB< *)F,?>R8B;=DFCN$;&![G -/BM!62
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MMFDZBAO.KZ^6HA,5ZZOJ@,YCX8RT\7TGN48N>GJ"FZ,:#359>8XKE0%LL-3
MTO:V5KBYIQX;X6P?0WBY'_G:V4,/YC#@+-H=+018+F<;N\N"B;S+6O&K7RY[
MJ>JU9J^QS6FXU5 VG(!S10/:9G Y'&7'89P< =RW%ZHM0WQVGB9((&VJ9DS=
MMSPMQLNC4UHCC&S&@>Y9T5!&!R"KU2O&/%#E^I-+W>_,M_6U^335D=2>/EAN
M<XQW[KS4^B:R[4$4$%66N9/'*3(21AIS\5TRKJ:6C&)""X=RU[KY3@X9'D*(
MM,+=^^H\HXRW76E]*FKYACQW5^.]:CHG>EU52T?/&#]2W\%UHYCPD%A6?V2&
M:,.: 0>\*-IF=_E#0TVN(P VZ4LL#N\L&6K>VV[VZX#_ )6I:3X'8K$JK,R0
M$%C7#W+05VEHG.XHN*-_BS8J8G2DXJ63SJS]"I+<+GT$E]M!/45#JF(?F2[K
M:46MHFG@NM*^G?R. 2U:>JQGB^\)8T YPO6X*L4=QHJU@?1U$;QX-*ONRX9Y
MM"O6\2QMCFKWZ45&4RH0N(J$RH0J.5Y@KS*]RB7N"J<KW*9"#UI"]R/%4Y";
M(*N(*H;JWLFZ"X O<%6]QXIDJ1Z0<I@IE,J$ R%Z,A,[*GB0590%>#=>X1+U
M%XO0/:@][EXO"<)Q*4*@<+TY+01\H'O\%0"JB<M \%,>4>W=P_7ED?<=83.K
M<QT[=V9VR-U!;O:'&J>RE'X%A[^]?4%7;Z>N;_S,+) -@7-R0HGJ;35+VR.1
ML0CIR.%W", %>CQ\]9[2\;F<2U:S>KA5IJ8HJGL5;"V&-W)WM4JCI:S2]=3W
M.W2'JB0X[Y#@O=8Z8$?& /1(RUX6HI;Y4PZ0GCJ(^NZIW QQWW79>*]/=Y>.
MU^KU:^8?1-GKV7BUT]6S'$]@=[O$*S4P$O)8,.7!]%=+%58*%M%76T21%V0\
M.(("[!I765HU33DT<X;.W_T''#EXV3!.YE]/@Y47B/GW9S26G<85UD@!6;+3
MA[!LL)U.6N]'*Y8I,/0C)"L2> 3C5G@D;R&4ZN0]RE/7"]QKSK!XJAD#_'"N
MLI,G?)4Q")O"V7@G;<JIL+W'?8+-BI6M&PPLAD>/:IZ6=LGPQJ:G#1L%G1,
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M[3L* >2+I/\ YBNE=GP.%[%I5KW9GDF?[W%)NG]-K\I3"HOUKIQ^$KH<^#7
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ME%L\1'3,-,7$G<7K/EM-.UQN-DHZJ1I;))&"X>W"V!:T\PK<$;88VQL #6C
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M,$ ZXG)<3E;.JNK&0NW  "QC#-MVO+TH^H?IZ13CQW^7*ZBDDH*KLLC/PG<
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M0$1$%BM_RDO[)^PJU9OR=%]/VE7:W_*2_LG["K5F_)T7T_:4&8B(@(B("(B
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M:,SI+KJVEH(8Z-DA9*<2.8.2UVC](=? VJN@(!.6PG_==">QKQA[0X>T*H
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M;XSU$;&9YD#<K+'QIZYGV<N+ZG''IV\RC5FTNV)S:BXG+AN&=P6QN]SAI8"
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M6$]_<MG':8(YH?*-3Q!PR"7++L<%!<(ZC\.)'-)QQ<U#M16VLJ+EZ,DAIF#
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M[:U^T!FJ:H9.:F3EX1M\5N()Z*TP]5UPXB<NQN2H]3R/,3I9'.B;)S(^5)[
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M17,AU3+<1%#+&'/@-,&!PXG ?*VP3E6?.35_Z1'_ ']"J9J;6#<_\Q"<^/\
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M/V%6K-^3HOI^TH,Q$1 1$0$1$!$1 1$0%RK5@XM:R#]0+JJY;J<9UO)^P/\
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MF-;&P-:-L!;2"'V*[# ,#;<K+BBPJQ&GJ6OU=EN.(9"HZ.AB\W<?KC_=9S6
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M&WM$;''VA:JX/Q.5&[[J=M*>HA)?-CEX*MK16.[7%AOFMTT3:6OHJ)KB&QM
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M)^Z.T)\,)O9(_1+GU+W'T6\F++_YES0UI93Q^#1O\5ATY;3DT58WJ^)V8Y/
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MK1I^BM7&8&ESSR+CG"SJBFCJ8S',QKVG8CP7G6X4Y77^HBO9S"HJKE23"*:
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M,"0RF=J@%4HY5ZXTQ15<M+5WVWPU$+S')&^8 M<#@@K;6J[6^[P&:U5U+61
MX+H)6O /@<'93J5>J)[,U$1$B(B B(@(B(/>Y8/1_P#EJ[_MC_=9W<L'H_\
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MCA5#FK)X506[JLK1+&<T@' R5SNDM=;=[Y4&MC<R-KSQ.\1G8!=,X<JG@&^
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MT.:06GD0@]1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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ML\ G9V> 5Y$%GL[/ )V=G@%>1!9[.SP"=G9X!7D06>SL\ G9V> 5Y$%GL[/
M)V=G@%>1!9[.SP"=G9X!7D06>SL\ G9V> 5Y$%GL[/ )V=G@%>1!9[.SP"=G
M9X!7D06>SL\ G9V> 5Y$%GL[/ )V=G@%>1!9[.SP"=G9X!7D06>SL\ G9V>
M5Y$%GL[/ )V=G@%>1!9[.SP"=G9X!7D06>SL\ G9V> 5Y$%GL[/ )V=G@%>1
M!9[.SP"=G9X!7D06>SL\ G9V> 5Y$%GL[/ )V=G@%>1!9[.SP"=G9X!7D06>
MSL\ G9V> 5Y$%GL[/ )V=G@%>1!9[.SP"=G9X!7D06>SL\ G9V> 5Y$%GL[/
M )V=G@%>1!9[.SP"=G9X!7D06>SL\ G9V> 5Y$%GL[/ )V=G@%>1!9[.SP"=
MG9X!7D06>SL\ G9V> 5Y$%GL[/ )V=G@%>1!9[.SP"=G9X!7D06>SL\ G9V>
M 5Y$%GL[/ )V=G@%>1!9[.SP"=G9X!7D06>SL\ G9V> 5Y$%GL[/ )V=G@%>
M1!9[.SP"=G9X!7D06>SL\ G9V> 5Y$%GL[/ )V=G@%>1!9[.SP"=G9X!7D06
M>SL\ G9V> 5Y$%GL[/ )V=G@%>1!9[.SP"=G9X!7D06>SL\ G9V> 5Y$%GL[
M/ )V=G@%>1!9[.SP"=G9X!7D06>SL\ G9V> 5Y$%GL[/ )V=G@%>1!9[.SP"
M=G9X!7D06>SL\ G9V> 5Y$%GL[/ )V=G@%>1!9[.SP"=G9X!7D06>SL\ G9V
M> 5Y$%GL[/ )V=G@%>1!9[.SP"=G9X!7D06>SL\ G9V> 5Y$%GL[/ )V=G@%
M>1!9[.SP"=G9X!7D06>SL\ G9V> 5Y$%GL[/ )V=G@%>1!9[.SP"=G9X!7D0
M6>SL\ G9V> 5Y$%GL[/ )V=G@%>1!9[.SP"=G9X!7D06>SL\ G9V> 5Y$%GL
M[/ )V=G@%>1!9[.SP"=G9X!7D06>SL\ G9V> 5Y$%GL[/ )V=G@%>1!9[.SP
M"=G9X!7D06>SL\ G9V> 5Y$%GL[/ )V=G@%>1!9[.SP"=G9X!7D06>SL\ G9
MV> 5Y$%GL[/ )V=G@%>1!9[.SP"=G9X!7D04-B:.X*H #DO40$1$!$1 1$0?
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g50309g89f06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g89f06.jpg
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M 2(  A$! Q$!_\0 '  !  $% 0$               $" P0%!@<(_\0 71
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M4D3F=_4*VP-/W?4TZY5=.J)TF[#-IJZ*=/F.3/F7:!E@A'(I(
M"'*C6JKE1$3:JARHUJJY41$XU534/?)=9UCB564K%XW=("N:NFJI%AM[>+ED
M7D+M+:XHUUSKOTJ\:J[89D$+((T9$U&M3UEP B(B9)Q(
M
M
M
M
M                                        J(J9*F:&NJK5%(NN!=ZD
MY,MAL0!HV54]))O56WS.Y%-I!.V1$5%VERH@CJ(U9*W-J^HT4C);;-I<JNA=
M]%Q4="BY@PJ6I:]J<:=9FHN:$4      "Q73I34KY.5$R3S@8-QE?55*44"\
M6V1W,;&GA9!$V.-,FIZS#LU.L<"S2<<LOSE5>8V
M
M
M
M
M                                          +=1 RHA='(F:+ZO*7
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MWP5=V"?$._=AWP5?V"?$?-P+Y>B><U'TEW[L.>"K^P3XAW[L.>"K^P3XCYM
M\O0\YJ/I+OW8<\%7]@GQ#OW8<\%7]@GQ'S:!Y>AYS4?27?NPYX*O[!/B)[]V
M&_!5_8)\1\V >7H><U'TGW[L-^"K^P3XAW[L-^"K^P3XCYL \O0\YJ/I/OW8
M;\%7]@GQ#OW8;\%<.P3XCYL \O0\YJ/I/OW8;\%<.P3XAW[L->"N'8)\1\V
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M[H  ;G.
M
M                                                    .ELW^71_
MC[5,TPK-_ET?X^U3--,^KY'J?XU_SG_D !&@
M
M                                   ![WN2XC=>;&ZDJGZJRBR8KE7C
M>Q?HKY^)4_!.<[D^?-R:X.H<:4C,\HZIKH'^7-,T]:(?09R:E<6??_8O53U'
M2QN]:]@ &MZP:'%C<Z=B_P#*]/4;XT>*_JK/,[V%A&EP_)Q-0[&F7-B'"X><
MN;?[Y3MZ/Z (9  (HNQ35V+94_?-HNQ35V+94_? V@    #XRQJ]TF,;Z]ZY
MJM=/_P!1QIC;XQ_*Z^?MT_\ U'&H/5KZ0\&WK( "L0
M   !D4E#5UFKN.EGJ-&6K>HU=EGLSR,=45%5%145-J*
M
M
M     =+9O\NC_'VJ9IA6;_+H_P ?:IFFF?5\CU/\:_YS_P @ (T    EJ*YR
M(U%557)$3E-Q\E[]]C7#_P"W=[B9B&=-.]_NQ,M,#*KK=6V]R-KJ2HIG+L26
M-69^;,Q2I:LUG$P  ,0     !4QKGO:QC5<YRY(B;54V_P E[]]C7#_[=WN)
MF(9TT[W^[$RTP,RNM=?09=W4533(O$BRQ.8B]:&&5+5FLXM& &_LV%;A=[+6
M72D= E+2ZM\UOR=\UJ.7),N930$SEE?2O2(M:,1/H  K6
M
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M7;%SY438OG,*;]_?W_+ALU/#\/$>[Y\_\O/@ =3A
M
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M:CLU>J?I+R9KY"TK:)S+7U_6]-?0V:,5S';TGT]<UX[\M& #<^=
M
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MF.N-;4U;F)DU9Y72*U/)FJY"NEMMFOH7U]]-MO5B  VM
M
M
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MBM:^D0  S<
M                                              #;X0_*JS_MD7\:
M'TZ?,6$/RJL_[9%_&A].G/K>L/L/_&OX5_S_ .@ &A]*&CQ7]5;YG>PWAH\5
M_56^9WL$)+FL/;6_WRG<47T#A\/;6_WRG<47T"D,D $478IJ[%LJ?OFT78IJ
M[%LJ?O@;0    !\88Q_*Z^?MT_\ U'&H-OC'\KKY^W3_ /4<:@]6OH\&WK(
M"L0
M
M                                               !TMF_RZ/\?:IF
MF%9O\NC_ !]JF::9]7R/4_QK_G/_ "  C0
M
M                                  V^$/RJL_[9%_&A].GS%A#\JK/^
MV1?QH?3ISZWK#[#_ ,:_A7_/_H !H?2AH\5_56^9WL-X:/%?U5OF=[!"2YK#
MVUO]\IW%%] X?#VUO]\IW%%] I#) !%%V*:NQ;*G[YM%V*:NQ;*G[X&T
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M$$H    J*2H   *DV )L %0 ) E-@"; 6 " (!( $ 2A!* 2$ 0"24V$$IL
M%125 "4V$$IL   "4 0 5  @D( A1)*$$H($@  5)L*2I-@   "HI*@@$ 0I
M"I $!  !2 J*2H0"$D(20  " E-A!*;!"I0DA"00   A)"$@     $M*BEI4
M$     (  %     %3=@#=@"  !   H                          !!)
M2  !0  <38?SHXE_9X/X6G:G%6'\Z.)?V>#^%IVIE9Q=#]RW]5O\I  8NP
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M7#.Z-B#AZV-O54C[?4/1KLX6-16JJMU9HB+Q+[#932M>,PTZFO73M%9>[IL
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MA25)L    5%)4$ @"%(5( @(  *0%125" 0DA"2   0$IL()38(5*$D(2"
M $)(0D      EI44M*@@    !   H     J;L ;L 0  (  %
M               ()("0  *  #B;#^='$O[/!_"T[4XJP_G1Q+^SP?PM.U,K
M.+H?N6_JM_E( #%V   A2"5(        541%55R1.4 .0M0U,$ZJD,T<BIM1
MCD7(N\@2)B?1 !0R6.17)&]KE:N3D:N>2^4"L@D@ 1R!SFL:KGJC6HF:JJY(
MB%N&>&=';S+')EMT.1<B)F/16 "J  (  "   '(!R 0  (4@E2 @020$
M $   1R$D<@1 4!0(    !$* H   BH4@E2 B     1      4E12!!"DD*
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MI!*D!   0  (4!0$1R$$\A 0()( N4WUB+[Z>TZ$YZF^L1??3VG0EAOT?20
M!N#1XK^JM\SO8;PT>*_JK?,[V"$ES6'MK?[Y3N*+Z!P^'MK?[Y3N*+Z!2&2
M"*+L4U=BV5/WS:+L4U=BV5/WP-H     T&(/KC/U:>U36FRQ!]<9^K3VJ:T
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M*;!"I0DA"00   A)"$@     $M*BEI4$     (  %     %3=@#=@"  !
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MN,SQ& @D@Q=8     @  ".0DCD"("@*!     (A0%   $5"D$J0$0    "(
M    "DJ*0((4DA0     (A2"5( $$D%0()((   A2"5("   @  0H"@(CD()
MY" @020!<IOK$7WT]IT)SU-]8B^^GM.A+#?H^D@ #<&CQ7]5;YG>PWAH\5_5
M6^9WL$)+FL/;6_WRG<47T#A\/;6_WRG<47T"D,D $478IJ[%LJ?OFT78IJ[%
MLJ?O@;0    !H,0?7&?JT]JFM-EB#ZXS]6GM4UH ( @%2$D(2 0DA"2"4 0
M"4()0*DD@DJ!*$$H    J*2H   *DV )L %0 ) E-@"; 6 " (!( $ 2A!*
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M  ,"NL]MKYDEKK?25,J)I1\L+7JB<V:IY3.)(#"*UB9F(]0CD)(Y",D  H
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MJJKQJJ@ [7F@
M                15145%R5.4 #O,+7CN^%8*AW^TQIMZ:<_G-\>64-3)1U
M44\2_/8N?G\AZ?2SLJ:>.:-<V2-1R'%K:>V<P]+IM7?7$^L+A!)!I=$  "@
M XFP_G1Q+^SP?PM.U.*L/YT<2_L\'\+3M3*SBZ'[EOZK?Y2  Q=@  (4@E2
M         Y .0"   ()("!'(21R$$  H  (  "   '(!R 0  (4@E2 @020$
M     $   1R$D<@1 4!0(    !$* H   BH4@E2 B     1      4E12!!"
MDD*     !$*02I  @D@J!!)!   $*02I 0  $  "% 4!$<A!/(0$""2 +E-]
M8B^^GM.A.>IOK$7WT]IT)8;]'TD  ;@T>*_JK?,[V&\-'BOZJWS.]@A)<UA[
M:W^^4[BB^@</A[:W^^4[BB^@4AD@ BB[%-78ME3]\VB[%-78ME3]\#:
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MF>1#45SD1J*JJN2(ATUK8RC5]&F2SK$Z29W,O(WUB]ML&GI[Y<P #)K
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MBWW1N=!60S\JM:[YR>=-J$FLQZPWZ75Z&MVT[Q/]V<I!*D&+H""2"H$$D$
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MYSQUF,H=5+!,B?0<K5_'_P#D<F=VC.:0\OJ(QJ2  V-(
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MTDUM,3*UO2MHCW0M5E,ZEFWM[V/7+/-BYH60#;#GGY
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M5-.*OA^N^U-;JYF,XKQ_OD !L>6
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M*CEK8&YM7_>HG(O.;]"^)VRY>JT]T;H]SF0 =;SP
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M(G/M1O\ W>H\G.K1KB,OB_M_JYU-;P8]*_\ ( #<\
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M ( E""4 D( @$DIL()38 *BDJ $IL()38   $H @ J !!(0!"B24()00)
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M$%W;W+GW'3(K(E7]-5VN_').HY0SIG'=Y_7SI3U%_ ^[GM__ 'Y@ ,G&
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M0! 0  4@*BDJ$ A)"$D   @)3802FP0J4)(0D$   (20A(     !+2HI:5!
M    "  !0    !4W8 W8 @  0  *                           020"
M    !YM!7K;]TR_RY:FJV)KD\F]L/0Z6HCJH6RPNU,=RGE]Q_.!B#S1?]-AM
M;3=)+;/FF;H5^DS/U^<RLX^C^Y;^JW^4O0 6:2IBJX&RP/1S%YN0O&+K  !"
MD$J0         '(!R 0  !!) 0(Y"2.0@\$W6J1:;&=3)EDVHC9*WJTKZVJ<
M:>Q[M5H6>V4MTB;FZF=O<N70=L7\%_B/'#MTYS5^??:VA.CU=XY[_J  S>:
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M)0*DD@DJ!*$$H    J*2H   *DV )L %0 ) E-@"; 6 " (!( $ 2A!* 2$
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MF?F/*IN4S+'>9K34YM^= [+6S^:>4Q=;U %BAJX:VF9/3/1\;MBE\@A2"5(
M        #D Y (   @D@($<A)'(08]PHX:^AGI*INN&9BL>GD4^;\2V6HL-W
MGH:E%70N;'Y<3V+L<G][<SZ7.=QMA:GQ-;M[<J15D6:P39;%YE\BFW3OMGN\
M?[7^SO.:>ZGWZ^GS^3YU!F7:VU=IKI*2OA=%.Q>-%Y4YT7E3RF&=;X:U9K,U
MM&)@  8@
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M2-:F2(G,5*0:;6FT]WO=-TFETM=NE&/^0@D@CH""2"   (4@E2 @  (  $*
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MKS.,=W! ['$.YS?K!:9KC<64S::+2CE9,CEXU1$R3SJ<<6+1;O#&U)K.+0
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MI!*D!$     B      I*BD""%)(4     "(4@E2 !!)!4""2"   (4@E2 @
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MV%KT^+)SJ"95?32KRMZ*^5/<O*<N>E$Q:,P\6U9K.)  5B
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M;N>);1?&6J"T5T=4^G=(LF]HN29HW+CRR78NP\G-NE,S7][U<^O%8U)BOH
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MY"O 6#=XWNY76-=^VQ0NV-_YE\OD/0B  "    Y .0"   ()("!'(21R$$
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M9[8S$X]&-W!2\(]W;RWNO>]ZWWETYYY&2 $BL1Z(  4   I*BD""%)(4
M "(4@E2 !!)!4""2"   (4@E2 @  (  $* H"(Y"">0@($$D 7*;ZQ%]]/:=
M"<]3?6(OOI[3H2PWZ/I(  W!H\5_56^9WL-X:/%?U5OF=[!"2YK#VUO]\IW%
M%] X?#VUO]\IW%%] I#) !%%V*:NQ;*G[YM%V*:NQ;*G[X&T     :#$'UQG
MZM/:IK398@^N,_5I[5-: " (!4A)"$@$)(0D@E $  E""4"I)()*@2A!*
M *BDJ   "I-@"; !4 "0)38 FP%@ @" 2 ! $H02@$A $ DE-A!*; !44E0
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M @  0I!*D! @D@(     (   CD)(Y B H"@0    "(4!0  !%0I!*D!$
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MIL   "4 0 5  @D( A1)*$$H($@  5)L*2I-@   "HI*@@$ 0I"I $!  !2
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MB#ZXS]6GM4UH ( @%2$D(2 0DA"2"4 0 "4()0*DD@DJ!*$$H    J*2H
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M2HGSHUVIYN=#8D5+2HI:5!     "  !0    !4W8 W8 @  0  *
M                  020"     !Y3<./=!O^7-%_P!-AV&'K)H5M56-^?\
MH1JFSRJ:FST\<VZEB+?6H[1%"]$7G5C4_D=V96<?13FEOZK?Y2  Q=8  (4@
ME2          Y .0"   ()("!'(21R$$ '*X^Q;%AJ@1L6F2XS(N]1KL:G2=
MY/;UF41,SB&K6UJ:%)U-2<1#,Q5BJW8<I]56_74.3..G9]-WE\B>53QW$>/+
MS>G/8V=:.E79# JIFGE=M7V>0YJNJZBOJY*FLE?-/(N;GN7-5+!U4TXJ^(Z[
M[7UNJF:UG;7C_:5XUS4@ V/(
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M5L<\?(N3DZ2<J >FM*BU3RLFB9+&N;'HCD7R%T@     0  *     *F[ &[
M$  "  !0                          ""2 D  "@  XFP_G1Q+^SP?PM.
MU.*L/YT<2_L\'\+3M3*SBZ'[EOZK?Y2  Q=@  (4@E2          Y .0"
M ()("!'(21R$&)=J^&UVVIK:IV4,#%>[R^1/*NP^;;[=:B]76HKJMV<DKLT3
MD:G(U/(B'IV[9=EBHZ*U1NR69=^E1.BG$U.O-?P/(3JT:XC+XW[?ZN=35\"/
M2O\ R  W/G@
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M@_A:=J<58?SHXE_9X/X6G:F5G%T/W+?U6_RD !B[   0I!*D         !R
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M)(0D A)"$D$H @ $H02@5))!)4"4()0   !44E0   5)L 38 *@ 2!*; $V
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MNZ:CKJ.FCJ)GT\L#=&>C4UR?@(9Z.W1S+2ROJ*B1BL1RMTM:BFH
M        &ZPA_GD7W7>P] .'P1$K[I))R,C7K54_J=P0     (  %     %3
M=@#=@"  !   H                          !!) 2  !0  <38?SHXE_9
MX/X6G:G%6'\Z.)?V>#^%IVIE9Q=#]RW]5O\ *0 &+L  !"D$J0         '
M(!R 0  !!) 0(Y"2.0@\!W5Z5:;&M8[+)L[62M]%$7UM4Y ]=W;;2LE+176-
MN>]*L$JIS+QM7KSZSR([=.<UA^>_:NC.CU=XYG/Z@ ,WG
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MS.<X;3%2H[$MV5JHJ+52Y*GWE-6 91V<FI;?:;<@ *P
M  /:=RVF6#"<3U3+?Y7R>O3_ -IXW3025-1%!"W5+(Y&-3G55R0^B+51LM]M
MI:./C;!&UF?/DFTT:T]L/?\ L#1FVK;4]T1C]64020<SZP  $*02I 0  $
M"% 4!$<A!/(0$""2 +E-]8B^^GM.A.>IOK$7WT]IT)8;]'TD  ;@T>*_JK?,
M[V&\-'BOZJWS.]@A)<UA[:W^^4[BB^@</A[:W^^4[BB^@4AD@ BB[%-78ME3
M]\VB[%-78ME3]\#:     -!B#ZXS]6GM4UILL0?7&?JT]JFM ! $ J0DA"0"
M$D(202@"  2A!*!4DD$E0)0@E    %125   !4FP!-@ J !($IL 38"P!CW"
M#NFCEB3:J<7G389 0#A=A!M+]1K3U*RL3_"D7/S+RFK*@
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MV>#^%IVIQ5A_.CB7]G@_A:=J96<70_<M_5;_ "D !B[   0I!*D
M!R <@$   020$".0DCD(,.[V^&ZVRIH:I,X9V*Q?)S*GE1>,^;;W:ZBSW2HH
M:MN4L3LL^1R<CD\BH?3IR6Z!A&/$E"DD&F.Y0I_A/7B1Z=!WDYN8W:5]LXEX
MOVQ]G3U>GOT_O5^L<?Z>  OUE+/154E-5Q/BGC72]CDR5%+!U/AYB8G$@ "
M
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M9M7Z+N14.R+=1!'41+',U'-7U"!PX-K7V::!5=!G+'Y/I)^!JU147)4R4J(
M                  NK/*K=*RR*WFU+D6@ +C)I6)DR1[4YD<J%L 2JJJYJ
MJJOE)1[D141RHB[412D 5->YN>ERIGS*&N<U<VJJ+Y%*0!4CG([4CEU<^9#E
M5RYN557G4@ 2URM7-JJB^0KWV3PC^M2V *E<Y79JJJO/F5;[)X1_6I; %3G.
M<N;G*OG4(]R-THYR-YLRD 2BJBYHJHOD*]]D\(_K4M@"7.5RYN557G4@
M               ;2UV2KKU16L6.'PCTR3\.<# IH):F9L4#%?(Y<D1#T"QV
MMELI=/$Z9_&]_/Y$\A7:K73VV+3"FJ1?I2.VK_0SR*EI44M*@@    !   H
M    J;L ;L 0  (  %                           ()("0  *  #B;#^
M='$O[/!_"T[4XJP_G1Q+^SP?PM.U,K.+H?N6_JM_E( #%V   A2"5(
M   #D Y (   @D@($<A)'(00 "CG\683MV)(/]J:L54U,HZAB?.;Y%YT\GL/
M&\1X'O-D<][H%JJ5-D\"*Y,O*FU/9Y3Z$!LKJ35Y76_9.AU<[I[6YC_M\I@^
ME;IAFS71RNKK;3R/7:]&Z7+_ .Y,E-!-N98=D559'4Q>1DR_S13;&M'O>#J?
M^/=16?W+1,?H\)![AWK;!TZ[M4^$=ZVP=.N[5/A+XU6KV!U?R_5X>#W#O6V#
MIUW:I\([UUAZ==VJ?"/&J>P.K^7ZO#P>W]ZZP].N[5/A'>NL/3KNU3X1XU3V
M!U?R_5X@#V]=RZP].N[5/A([U]AZ==VJ?"/&J>P>K^7ZO$0>W=Z^P].N[5/A
M'>OL/3KNU3X1XU3V#U?R_5XB#V[O7V'IUW:I\([U]AZ==VJ?"/&J>P>K^7ZO
M$0>W=Z^P].N[5/A'>OL/3KNU3X1XU3V#U?R_5XB#VWO86'IUO:I\([V%AZ=;
MVJ?"/&J>P>K^7ZO$@>V]["P].N[5/A([V%BZ==VJ?"/&JGL'JOE^KQ,'MG>Q
ML73K>U3X2.]C8NG6]JGPCQJGL'JOE^KQ0'M?>QL73K>U3X1WL;%TZWM4^$>-
M4]@]5\OU>* ]K[V-BZ=;VJ?".]C8NG6]JGPCQJGL'JOE^KQ0'M7>RL73K>U3
MX1WLK%TZWM4^$>-4]@]5\OU>*@]J[V5BZ=;VJ?".]E8NG6]JGPCQJGL'JOE^
MKQ4'M2[F5BZ=;VJ?"1WLK%TZWM4^$>-4]@]5\OU>+ ]H[V=CZ=;VJ?".]G8^
MG6]JGPCQJGL'JOE^KQ<'M'>SL?3K>U3X1WL['TZWM4^$>-4]A=5\OU>+@]H[
MVECZ=;VJ?"1WM+'TZWM4^$>-4]A=5\OU>, ]G[VECZ=;VJ?".]I8^G6]JGPC
MQJI["ZKY?J\8![/WM+'TZWM4^$=[2Q].M[5/A'C5/875?+]7C /9N]K8^G6]
MJGPD=[6Q].M[1/A'C5/875?+]7C0/9>]M9.G6=HGPA-S:QHOTJQ?_P"ZGN'C
M5/875?+]7C1?I*6HK)DAI(9)I5V-C:KE]1[728#P_3JBK1NF5/"R.7U9Y'04
M='3446]T=/%!'T8V(U/48SKQ[H=&C_X_J3/_ +;1$?+O_IYGAG<XED<R>^NW
MN/:E.QV;E^\J;/P]1Z;2T\-)3L@IHV10L3)K&IDB(7E(-%KS;U?0=+T6CTE<
M:<?W]X0201U!!)!   $*02I 0  $  "% 4!$<A!/(0$""2 +E-]8B^^GM.A.
M>IOK$7WT]IT)8;]'TD  ;@T>*_JK?,[V&\-'BOZJWS.]@A)<UA[:W^^4[BB^
M@</A[:W^^4[BB^@4AD@ BB[%-78ME3]\VB[%-78ME3]\#:     -!B#ZXS]6
MGM4UILL0?7&?JT]JFM ! $ J0DA"0"$D(202@"  2A!*!4DD$E0)0@E    %
M125   !4FP!-@ J !($IL 38"P 0! )  @"S/1T]1GOT37+SY9+UEXE -3)8
M:9WT'2,_',M?)Z/QA_HF\" :3Y/1^,/]$?)V/QA_HF\)38!HOD['XP_T2?DY
M'XP_T4-X5 :'Y.1^,/\ 10GY.1^,/]%#>DIL T/R<C\8?Z*#Y.1^,/\ 10WP
M T*8;C\8?Z*$_)N/QA_HH;Y !H?DU'XR_P!%!\FH_&7^BAT &1H/DS'XR_T4
M'R9C\9?Z*'0! -!\F8_&7^B@3#$?C+_10Z E CG_ ),1>,O]%!\F(O&7^BAT
M("N>^3$7C+_10GY+Q>,O]%#H"I-@'._)>+QE_HH/DO%XR_T4.B '._)>+QE_
MHH3\EHO&G^BAT)4$<Y\EHO&G^B@3"L7C3_10Z,(4<ZF%8O&G^B@^2D7C3_10
MZ1 0<W\E(O&G^B@^2D7C3_10Z0%'-_)2+QI_HH3\E(O&G^@AT94!S283B\:?
MZ"$_).+QI_HH=(A('-?).+QI_HH/DG%XT_T4.E!!S7R3B\:?Z*#Y)1>-/]!#
MI24V%'-)A*+QI_H(/DE%XV_T$.F0D#F/DE%XV_T$'R2B\;?Z"'3@BN83",7C
M;_00NQ83I&K_ (D\S_(F2?R.B0DHU]'9J"D5%BIVJY/TG_.7UFP (   EI44
MM*@@    !   H     J;L ;L 0  (  %                           (
M)("0  *  #B;#^='$O[/!_"T[4XJP_G1Q+^SP?PM.U,K.+H?N6_JM_E( #%V
M   A2"5(         #D Y (   @D@($<A)'(00 "@  @  (   <@'(!   A2
M"5("!!) 0     0  !'(21R!$!0% @    $0H"@  "*A2"5("(    !$
M !25%($$*20H     $0I!*D ""2"H$$D$   0I!*D!   0  (4!0$1R$$\A
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M6E12TJ"     $  "@    "INP!NP!   @  4
M   @D@)   H  .)L/YT<2_L\'\+3M3BK#^='$O[/!_"T[4RLXNA^Y;^JW^4@
M ,78  "%()4@         .0#D @  ""2 @1R$D<A!  *  "   @  !R <@$
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M"4V"%2A)"$@@  !"2$)      ):5%+2H(     0  *     *F[ &[ $  "
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M 2  !0  <38?SHXE_9X/X6G:G%6'\Z.)?V>#^%IVIE9Q=#]RW]5O\I  8NP
M $*02I          <@'(!   $$D! CD)(Y""  4  $  !   #D Y (  $*02
MI 0()("     "   (Y"2.0(@* H&BM5FEH\2WBY/EC=%6I'H8F>;=+<ES-X
M69RPT].NG&*\S/ZSD !&2% 4   14*02I 1     (@     *2HI @A22%
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M?05:11LJEW]42&3+)OE,*Z,N'<S6S4J04S%S1L:)I1>=<@-0
M %4;W1O:]BY.:N:*G(I2 /2+=4I5T44Z?IMS7R+R^LR#08-FUT$L2K_NW\7F
M7^U-^0  4@*BDJ$ A)"$D   @)3802FP0J4)(0D$   (20A(     !+2HI:5
M!     "  !0    !4W8 W8 @  0  *                           020
M$@  4  '$V'\Z.)?V>#^%IVIQ5A_.CB7]G@_A:=J96<70_<M_5;_ "D !B[
M  0I!*D         !R <@$   020$".0DCD(( !0  0  $   .0#D @  0I!
M*D! @D@(     (   CD)(Y B H"@0    "(4!0  !%0I!*D!$     B
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ME%52<BN:WJS]YTI  !2 J*2H0"$D(20  " E-A!*;!"I0DA"00   A)"$@
M   $M*BEI4$     (  %     %3=@#=@"  !   H      M5=3!24[YZJ5D4
M+$S<]ZY(A5#+'/$R6%[7QO3-KFKFBH!6                  !!) 2  !0
M <38?SHXE_9X/X6G:G%6'\Z.)?V>#^%IVIE9Q=#]RW]5O\I  8NP  $*02I
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M;?G/7R?U Z[#=-W-:8D<F3I/\1?QV>K(V9#41$R3B0D@  I 5%)4(!"2$)(
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M?SHXE_9X/X6G:G%6'\Z.)?V>#^%IVIE9Q=#]RW]5O\I  8NP  $*02I
M     <@'(!   $$D! CD)(Y""  4  $  !   #D Y (  $*02I 0()("
M "   (4DA0B H.<QAB2*R4RQQ*CZZ1OS&[4;Y5"J<88GAL=-O<64E:]/F,S^
MAY5/'*RHGK*A\]5(Z65ZYN<[C52]6335E3)45+U?+(NISEY2SH*SB,-_@W$\
MUBJ-[F5TM"]?G1]%>=#V.DJ8JNG9/3R-DB>F;7(I\^Z#I,'8DFL=0D4JJ^A>
M[Y[-JM\J"4FN7L2@M4M1%5TT<].]'Q/3-KD+I&L !%0I'(2I'($0    "(
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MVEZIISR1>(S>';AX=/03W&K &1)5S/J^Z7.SFS1VK)-J;#,X=N'AT]!/<:L
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ML/YT<2_L\'\+3M3BK#^='$O[/!_"T[4RLXNA^Y;^JW^4@ ,78  "%()4@
M      .0#D @  ""2 @1R$D<A!  *  "   @  !R <@$  "%()4@($$D!
M  !   $*2:'%%_BM%.K8],E6Y/FLS^CY5 HQ7B**S4ZLCR?6/3YC.;RJ>25D
MTM9423U#U?*]<U<IE5<LU74/FJ'J^1ZYJY2UO:F40SB,,30-!E[VHWM0K$T#
M09>]J-[4#<82Q%+9I]ZES?1O7YS>CY4/5J:>*I@9- ]'QO3-'(>([VIT&%;]
M+:)M[ES?1O7YS>CY4)AC,/4P6J>>.IA9+ ]'QN3-%0NF+!"D<A*D<@1
M(@     *2HI @A22%      B%()4@ 0205 @D@@  "%()4@(  "  !"@* B.
M0@GD("!!) %RF^L1??3VG0G/4WUB+[Z>TZ$L-^CZ2  -P:/%?U5OF=[#>&CQ
M7]5;YG>P0DN:P]M;_?*=Q1?0.'P]M;_?*=Q1?0*0R0 11=BFKL6RI^^;1=BF
MKL6RI^^!M     &@Q!]<9^K3VJ:TV6(/KC/U:>U36@ @" 5(20A(!"2$)()0
M!  ,6:WT\V:N9I=SMXC*)0*U#[*W]"94\[<RC@1_AF]1NR2HT? C_#-Z@ED?
MX9O4;PE -'P&_P ,WJ' ;_#-ZC> #1\!O\,WJ' <GAF]1O"H9,-#P')X9O4.
M Y/#-ZC? #1< R>'9U#@&3P[.HWZ; !H> 9/#L]$< R>'9Z)T &1H. )/#L]
M$< 2>'9Z)T"; ,CG^ )/#L]$< 2>'9Z)T 0#G_D_)X=GHJ/D_)X=GHJ=" .>
M^3\GAV>BI*8?D\.ST5.@)0#GOD])X=GHJ$P])X=GHJ=$$ Y[Y/2>,,]%1\G9
M/&&>BIT1*;!D<Y\G9/&&>BI/R<D\89Z*G1%0'-_)R3QAGHJ/DY)XPST5.D)3
M8!S7R<E\89Z*CY.2^,,]%3I0!S:8;E\89Z*CY-R^,,]%3I4 '-?)J7QAGHJ/
MDU+XPST5.G R.9^3,OC#/14?)F7QAGHJ=.$ YGY,R^,L]%0F&)?&6>BITY*#
M*.7^3$OC+/14?)B7QEGHJ=2 KEODQ+XRST5)^2\OC+/14Z@J38!ROR7E\99Z
M*EV+"R9_XM4JIS-9_4Z4 :RDL5#3JB[VLKDY9%S]6PVB(B(B(B(B<B$%00"
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M%K0    "(     "DJ*0((4DA0     (A2"5( $$D%0()((   A2"5("   @
M 0H"@(CD()Y" @020!<IOK$7WT]IT)SU-]8B^^GM.A+#?H^D@ #<&CQ7]5;Y
MG>PWAH\5_56^9WL$)+FL/;6_WRG<47T#A\/;6_WRG<47T"D,D $478IJ[%LJ
M?OFT78IJ[%LJ?O@;0    !H,0?7&?JT]JFM-EB#ZXS]6GM4UH ( @%2$D(2
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MJ$G%89O;J56TM6[.'8UR_H_T.T:Y'-1S516KQHJ$5(       !!) 2  !0
M<38?SHXE_9X/X6G:G%6'\Z.)?V>#^%IVIE9Q=#]RW]5O\I  8NP  $*02I
M        <@'(!   $$D! CD)(Y""  4  $  !   #D Y (  $*02I 0()("
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MY?T?Z&JWL;V!Z(BHY$5%S1>4'+V.ZK!E!4*JQK]%R_HG4(J*B*BYHI%
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MT.Z!^5M?YV?P-.>/:TON5_*'S6O_ !;?G( #8U
M
M                                           *   =+@-,[I)]PYHZ
MC<^3.ZR?<-.O_#ET=+_&J[O2@TH9&GR#3Y#R'T#'TH-*&1I\@T^0#'TH-*&1
MI\@T^0#'TH-*&1I\@T^0#'TH-*&1I\@T^0#R?$W%?JW[_P#(UAM<4\6(*[]9
M_(U1[6G]R/R?-ZO\2WYR  S:P    $
M                                  @  4  '=[GJ9VZJ_6_R0ZO2<QN
M<)G;:K];_)#KM)Y'4?Q)?0=)_!JL:1I+^D:32Z%C2-)?TC2!8TC27](T@6-(
MTE_2-(%C2>47W_.*S]8IZ]I/(K__ )U6_K5.SHOO2\[[1^Y'YM> #T7D
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M,@+.D:2]D,@/'L5_E%7_ *S^1J3;XM_*.O\ UG\D-0>WI_<C\GS>K_$M^<@
M,VL    !
M            (  %  !Z'N:)G;*O]=_VH=AI.2W,4SM=7^N_[4.RR/'ZC^)+
MZ#I/X-5K2-)=R&1I=*UI&DNY#("UI&DNY#("UI&DNY#("UI/'<0_YW7?K5/9
M\CQC$?\ GM=^M4[>B^]+S?M'[D?FUP /1>0     @
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MV0R \5Q?^4MP_6?R-.;G&7Y3W']9_(TQ[>G]R/R?-ZO\2WYR  S:P    $
M
M  @  4  'I6Y:F=JK/UW_:AVFDXW<J3_ .DUOZ__ +4.WR/'ZC^)+Z#I/X-5
MK2-)=R&1I="UI&DNY#("UI&DNY#("UI&DNY#("UI/$\2?Y]7_K7'N.1X?B;_
M #^O_6N.WHOO2\[[1^Y'YM8 #T7D     (
M                #98:_*&V?M,?\2'NYX1AK\H;9^TQ_P 2'NYYW6_>A['V
M;]RP #B>D&CQ7]5;YG>PWAH\5_56^9WL$)+FL/;6_P!\IW%%] X?#VUO]\IW
M%%] I#) !%%V*:NQ;*G[YM%V*:NQ;*G[X&T     >+[H'Y6U_G9_ TYXZ'=
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M "HN/ZS^2&E-UC3\J+E^M_DAI3V]/[D?D^:U?XEOSD !FU@    (
M                                                       !   H
M  /3MRA/_I-;^O\ ^U#N,CB-R;_*:W]?_P!J'<Y'C]1_$E]!TG\&JG(9%60R
M-+I4Y#(JR&0%.0R*LAD!3D,BK(9 4Y'AF)_R@N'ZYQ[KD>%8G_*"X?KG';T7
MWI>=]H_<C\VL !Z+QP    $
M     !LL-?E#;/VF/^)#W<\(PU^4-L_:8_XD/=SSNM^]#V/LW[E@ '$](-'B
MOZJWS.]AO#1XK^JM\SO8(27-8>VM_OE.XHOH'#X>VM_OE.XHOH%(9( (HNQ3
M5V+94_?-HNQ35V+94_? V@    #Q?= _*VO\[/X&G/'0[H'Y6U_G9_ TYX]K
M2^Y7\H?-:_\ %M^<@ -C4
M
M                          H  !V>Y9_GDOZLXP[/<L_SR7]6:=?^'+HZ
M3^-5ZL #QWT(          /$<:?E3<OUO\C2&[QK^5-R_6_R-(>WI_<C\GS6
MK_$M^<@ ,VL    !
M                    (  %  !ZAN3?Y16_K_\ M0[DX;<F_P HK?U__:AW
M)X_4?Q)?0=)_!J  TND        /"L3_ )0W#]<X]U/"L3_E#</USCMZ+[TO
M.^T?N1^;5@ ]%XX    "
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M6'MK?[Y3N*+Z!P^'MK?[Y3N*+Z!2&2 "*+L4U=BV5/WS:+L4U=BV5/WP-H
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M7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON'
M-5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD
M/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L
M^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X
M:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#
M?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X
M2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6O
MN' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :
MKPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4
M-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7D
MV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K
M7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON'
M-5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD
M/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L
M^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X
M:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#
M?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X
M2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6O
MN' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :
MKPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4
M-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7D
MV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K
M7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON'
M-5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD
M/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L
M^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X
M:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#
M?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X
M2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6O
MN' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :
MKPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4
M-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7D
MV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K
M7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON'
M-5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD
M/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L
M^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X
M:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#
M?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X
M2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6O
MN' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :
MKPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4
M-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7D
MV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K
M7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON'
M-5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD
M/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L
M^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X
M:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#
M?7DV6X:S4-1L^ :KPD/6ON' -5X2'K7W#?7DV6X:S4-1M&V"H_2EB3S*J_R,
MB+#[<_\ %G5?(UN0WU6-.S1ZC/H;;/5*CE3>X^DY-OF0WM-;*6GR5D2.=TG\
M:F886U.&RNERL4E+%2QZ(D\ZKM4O@&ENB,      :/%?U5OF=[#>&CQ7]5;Y
MG>P0DN:P]M;_ 'RG<47T#A\/;6_WRG<47T"D,D $478IJ[%LJ?OFT78IJ[%L
MJ?O@;0
M
M
M
M
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MS<8&8              %MD\3YI(F2L=+'EK8CD56Y[,TY +@
M       L4]93U$T\,,K7R0.1LK4_15>-$4O@
M
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MYW$W/U@7L+_E#B;]HC_A.E.:PO\ E#B;]HC_ (3I0
M
M                                                       :/%:Y
M4K?NO]AO#F\92HVG5.:-WKXBPC18>VM_OE.XHOH'$8>3C3^^4[BC^@"&0 "*
M<AJ$7N>^(J\396Y?C_:&W-5>HEWMLS/I1KGF(&U!:I9DJ*=DK?TDZE+H
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M68[#:8ITFCMM&V5%S1R0MS1>?8;( "U'3PQSRS1Q,;-+EK>C4179;,UY<BZ
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M))5SD<UJ(KUYUYRZ
M
M                               #B,9U.N5[$7:Y&)^'&OK.QK)TIZ:2
M1>1.+RKR'FUQE6JN:MSS2/BS\O*6$;?#\>67]\IV5*F3$.>LD&34.DB3)H(5
M@ BA:G8CV.14S14+H5,T TMME6CJW4TB_P"&]<V*O.;HU=TI=];FG$Y.-%*K
M57;\W>9URF;Q<?Z7]2I#9  B@
M
M
M
M
M                        &IOET920O8UZ([+YSNBGO U>++JD;%9&N>E<
MF^5W]#FK+3+))J=QJO'F6'O?<:O6J*C$XFMYD.JLE#H:BY<A4;BV0:&IQ&T3
MB0M0,T-R+I%     %$C-2*:6OI%1VN/-'IL5#>EJ:)'M UUONJ+E%5_->G$C
M^1?.;9%S3-.-#0UU!M<WB4Q(*ZHH5TY_,Z*\:?T*CJ0:RFO,$B)OJ+&O/M0S
MXJB&7_=RL=YE(JX
M
M
M
M
M      !:EJ(8O]Y*QOG4"Z%5$155<D0U55>Z>%JJSYV7*OS4.7NF)'SYLB7?
M/(G$U/>7"9=#>+Y%31.2)Z)EQ*_W<YPU5437*;8Y(D7-&\_E4AL%16RZYW*Y
M>1.1/,=!:[3EDJHG4!;L]NR5%5%.MHJ=(VIQ%%'2)&U.(SVIDA%2G$@
M     H>Q')L-?54*/1>(V85,P.1J;8YJJL:JU?(I@R,JXMFEWG0[=\+7)L,6
M6B:[D+E,..[NK(^+>^IRH4K=:Q/_ "W=HIU+[8U>3U%EUI;S>H9,.;X6J_!N
M[11PO5]!W:*=%P2WF]0X);T?4##G>%ZOH.[11PO5]!W:*=%P2WH^H<$MZ/J
MYWA>KZ#NT4<+U?0=VBG1<$MZ/J'!+>CZ@.=X7J^@[M%'"]7T'=HIT7!+>CZA
MP2WH^H#G>%ZOH.[11PO5]!W:*=%P2WH^H<$MZ/J YWA>KZ#NT4<+U?0=VBG1
M<$MZ/J'!+>CZ@.=X7J^@[M%'"]7T'=HIT7!+>CZAP2WH^H#G>%ZOH.[11PO5
M]!W:*=%P2WH^H<$MZ/J YWA>KZ#NT4<+U?0=VBG1<$MZ/J'!+>CZ@.=X7J^@
M[M%'"]7T'=HIT7!+>CZAP2WH^H#G>%ZOH.[11PO5]!W:*=%P2WH^H<$MZ/J
MYWA>KZ#NT4<+U?0=VBG1<$MZ/J'!+>CZ@.=X7J^@[M%'"]7T'=HIT7!+>CZA
MP2WH^H#G>%ZOH.[11PO5]!W:*=%P2WH^H<$MZ/J YWA>KZ#NT4<+U?0=VBG1
M<$MZ/J'!+>CZ@.=X7J^@[M%'"]7T'=HIT7!+>CZAP2WH^H#G>%ZOH.[11PO5
M]!W:*=%P2WH^H<$MZ/J YWA>KZ#NT4<+U?0=VBG1<$MZ/J'!+>CZ@.=X7J^@
M[M%'"]7T'=HIT7!+>CZAP2WH^H#G>%ZOH.[11PO5]!W:*=%P2WH^H<$MZ/J
MYWA>KZ#NT4<+U?0=VBG1<$MZ/J'!+>CZ@.=X7J^@[M%'"]7T'=HIT7!+>CZA
MP2WH^H#G>%ZOH.[11PO5]!W:*=%P2WH^H<$MZ/J YWA>KZ#NT4<+U?0=VBG1
M<$MZ/J'!+>CZ@.=X7J^@[M%'"]7T'=HIT7!+>CZAP2WH^H#G>%ZOH.[11PO5
M]!W:*=%P2WH^H<$MZ/J YWA>KZ#NT4<+U?0=VBG1<$MZ/J'!+>CZ@.=X7J^@
M[M%'"]7T'=HIT7!+>CZAP2WH^H#G>%ZOH.[11PO5]!W:*=%P2WH^H<$MZ/J
MYWA>KZ#NT4<+U?0=VBG1<$MZ/J'!+>CZ@.=X7J^@[M%'"]7T'=HIT7!+>CZA
MP2WH^H#G>%ZOH.[11PO5]!W:*=%P2WH^H<$MZ/J YWA>KZ#NT4<+U?0=VBG1
M<$MZ/J'!+>CZ@.=X7J^@[M%'"]7T'=HIT7!+>CZAP2WH^H#G>%ZOH.[11PO5
M]!W:*=%P2WH^H<$MZ/J YWA>KZ#NT4<+U?0=VBG1<$MZ/J'!+>CZ@.=X7J^@
M[M%'"]7T'=HIT7!+>CZAP2WH^H#G>%ZOH.[11PO5]!W:*=%P2WH^H<$MZ/J
MYWA>KZ#NT4<+U?0=VBG1<$MZ/J'!+>CZ@.=X7J^@[M%'"]7T'=HIT7!+>CZA
MP2WH^H#G>%ZOH.[11PO5]!W:*=%P2WH^H<$MZ/J YWA>KZ#NT4<+U?0=VBG1
M<$MZ/J'!+>CZ@.=X7J^@[M%'"]7T'=HIT7!+>CZAP2WH^H#G>%ZOH.[11PO5
M]!W:*=%P2WH^H<$MZ/J YWA>KZ#NT4<+U?0=VBG1<$MZ/J'!+>CZ@.=X7J^@
M[M%'"]7T'=HIT7!+>CZAP2WH^H#G>%ZOH.[11PO5]!W:*=%P2WH^H<$MZ/J
MYWA>KZ#NT4<+U?0=VBG1<$MZ/J'!+>CZ@.=X7J^@[M%'"]7T'=HIT7!+>CZA
MP2WH^H#G>%ZOH.[11PO5]!W:*=%P2WH^H<$MZ/J YWA>KZ#NT4<+U?0=VBG1
M<$MZ/J'!+>CZ@.=X7J^@[M%'"]7T'=HIT7!+>CZAP2WH^H#G>%ZOH.[11PO5
M]!W:*=%P2WH^H<$MZ/J YWA>KZ#NT4<+U?0=VBG1<$MZ/J'!+>CZ@.=X7J^@
M[M%'"]7T'=HIT7!+>CZAP2WH^H#G>%ZOH.[11PO5]!W:*=%P2WH^H<$MZ/J
MYWA>KZ#NT4<+U?0=VBG1<$MZ/J'!+>CZ@.=X7J^@[M%'"]7T'=HIT7!+>CZA
MP2WH^H#G>%ZOH.[11PO5]!W:*=%P2WH^H<$MZ/J YWA>KZ#NT4<+U?0=VBG1
M<$MZ/J'!+>CZ@.=X7J^@[M%'"]7T'=HIT7!+>CZAP2WH^H#G>%ZOH.[11PO5
M]!W:*=%P2WH^H<$MZ/J YWA>KZ#NT4<+U?0=VBG1<$MZ/J'!+>CZ@.=X7J^@
M[M%'"]7T'=HIT7!+>CZAP2WH^H#G>%ZOH.[11PO5]!W:*=%P2WH^H<$MZ/J
MYWA>KZ#NT4<+U?0=VBG1<$MZ/J'!+>CZ@.=X7J^@[M%'"]7T'=HIT7!+>CZA
MP2WH^H#G>%ZOH.[11PO5]!W:*=%P2WH^H<$MZ/J YWA>KZ#NT4<+U?0=VBG1
M<$MZ/J'!+>CZ@.=X7J^@[M%'"]7T'=HIT7!+>CZAP2WH^H#G>%ZOH.[11PO5
M]!W:*=%P2WH^H<$MZ/J YWA>KZ#NT4<+U?0=VBG1<$MZ/J'!+>CZ@.=X7J^@
M[M%'"]7T'=HIT7!+>CZAP2WH^H#G>%ZOH.[11PO5]!W:*=%P2WH^H<$MZ/J
MYWA>KZ#NT4<+U?0=VBG1<$MZ/J'!+>CZ@.=X7J^@[M%'"]7T'=HIT7!+>CZA
MP2WH^H#G>%ZOH.[11PO5]!W:*=%P2WH^H<$MZ/J YWA>KZ#NT4<+U?0=VBG1
M<$MZ/J'!+>CZ@.=X7J^@[M%'"]7T'=HIT7!+>CZAP2WH^H#G>%ZOH.[11PO5
M]!W:*=%P2WH^H<$MZ/J YWA>KZ#NT4<+U?0=VBG1<$MZ/J'!+>CZ@.=X7J^@
M[M%'"]7T'=HIT7!+>CZAP2WH^H#G>%ZOH.[11PO5]!W:*=%P2WH^H<$MZ/J
MYWA>KZ#NT4<+U?0=VBG1<$MZ/J'!+>CZ@.=X7J^@[M%'"]7T'=HIT7!+>CZA
MP2WH^H#G>%ZOH.[11PO5]!W:*=%P2WH^H<$MZ/J YWA>KZ#NT4<+U?0=VBG1
M<$MZ/J'!+>CZ@.=X7J^@[M%'"]7T'=HIT7!+>CZAP2WH^H#G>%ZOH.[11PO5
M]!W:*=%P2WH^H<$MZ/J YWA>KZ#NT4<+U?0=VBG1<$MZ/J'!+>CZ@.=X7J^@
M[M%'"]7T'=HIT7!+>CZAP2WH^H#G>%ZOH.[11PO5]!W:*=%P2WH^H<$MZ/J
MYWA>KZ#NT4<+U?0=VBG1<$MZ/J'!+>CZ@.=X7J^@[M%'"]7T'=HIT7!+>CZA
MP2WH^H#G>%ZOH.[11PO5]!W:*=%P2WH^H<$MZ/J YWA>KZ#NT4<+U?0=VBG1
M<$MZ/J'!+>CZ@.=X7J^@[M%'"]7T'=HIT7!+>CZAP2WH^H#G>%ZOH.[11PO5
M]!W:*=%P2WH^H<$MZ/J YWA>KZ#NT4<+U?0=VBG1<$MZ/J'!+>CZ@.=X7J^@
M[M%'"]7T'=HIT7!+>CZAP2WH^H#G>%ZOH.[11PO5]!W:*=%P2WH^H<$MZ/J
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M>+-IU<5N:WD,J*E:WD U%%;$;R&WIZ=&)L,AK$;L*B*(F0
M    9(1I0 !I0:4  :4&E  &E!I0 !I0:4  :4&E  &E!I0 !I0:4  :4&E
M &E!I0 !I0:4  :4&E  &E!I0 !I0:4  :4&E  &E!I0 !I0:4  :4&E  &E
M!I0 !I0:4  :4&E  &E!I0 !I0:4  :4&E  &E!I0 !I0:4  :4&E  &E!I0
M !I0:4  :4&E  &E!I0 !I0:4  :4&E  &E!I0 !I0:4  :4&E  &E!I0 !I
M0:4  :4&E  &E!I0 !I0:4  :4&E  &E!I0 !I0:4  :4&E  &E!I0 !I0:4
M  :4&E  &E!I0 !I0:4  :4&E  &E!I0 !I0:4  :4&E  &E!I0 !I0:4  :
M4&E  &E!I0 !I0:4  :4&E  &E!I0 !I0:4  :4&E  &E!I0 !I0:4  :4&E
M  &E!I0 !I0:4  :4&E  &E!I0 !I0:4  :4&E  &E!I0 !I0:4  :4&E  &
ME!I0 !I0:4  :4&E  &E!I0 !I0:4  :4&E  &E!I0 !I0:4  :4&E  &E!I
M0 !I0:4  :4&E  &E!I0 !I0:4  :4&E  &E!I0 !I0:4  :4&E  &E!I0 !
MI0:4  :4&E  &E!I0 !I0:4  :4&E  &E!I0 !I0:4  :4&E  &E!I0 !I0:
L4  :4&E  &E!I0 !I0:4  :4&E  &E!I0 !I09( !.0            #_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g50309g89f07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g89f07.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_X4]<:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 V+C M8S P,B W.2XQ
M-C0U,3DL(#(P,C O,#@O,C4M,3<Z-30Z,# @(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(*(" @(" @(" @(" @
M>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B
M"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN
M<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E
M<V]U<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B @(" @(" @(" @('AM;&YS.FEL
M;'5S=')A=&]R/2)H='1P.B\O;G,N861O8F4N8V]M+VEL;'5S=')A=&]R+S$N
M,"\B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]P9&8O,2XS+R(*(" @(" @(" @(" @>&UL;G,Z>&UP5%!G/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O="]P9R\B"B @(" @(" @(" @('AM;&YS
M.G-T1&EM/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM
M96YS:6]N<R,B"B @(" @(" @(" @('AM;&YS.GAM<$<](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]G+R(^"B @(" @(" @(#QX;7 Z0W)E871E1&%T
M93XR,#(V+3 S+3,Q5# Y.C0Q.C,T*S U.C,P/"]X;7 Z0W)E871E1&%T93X*
M(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C8M,#,M,S%4,#DZ-#$Z,S0K
M,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4
M;V]L/D%D;V)E($EL;'5S=')A=&]R(#(U+C @*%=I;F1O=W,I/"]X;7 Z0W)E
M871O<E1O;VP^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C8M,#,M
M,S%4,#DZ-#$Z,S0K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @
M(#QX;7 Z5&AU;6)N86EL<SX*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \>&UP1TEM9SIW:61T:#XR-38\+WAM<$=);6<Z
M=VED=&@^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FAE:6=H=#XW-CPO
M>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.F9O
M<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @(" @(" @(" @(" @
M/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G14%304))04%$+S=1
M07-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!04%"04%304%!04%%
M028C>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL04=404%!04%!9B]B04E1
M04)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+0W=O2R8C>$$[1$)!
M341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C2'@X9DAX.&9(>#AF
M2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[2'@X9DAX.&9(>#AF
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF+SA!04519T%4045!07=%4B8C>$$[04%)4D%135)!9B]%06%)04%!04A!
M445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W14%!9TE$05%%0D%1
M14%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!04-!44U$06=10T)G
M8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%54UP1VA">%=X46E0
M0B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-00TY546YK-D]Z3FAD
M55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y-"]0128C>$$[,4]4
M,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N9#1E6' W9D@Q*V8S
M3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[<6)N2C)E;C5+:G!+
M5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#04U$8E%%04%H141"
M0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T4TY#1E9*:6-V17I*
M1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H9UI*:EI&1VED:V1&
M53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&195U9P8EA&,658,5)L
M6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ
M;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ2VUQ<39Y=')Q*W8O
M84%!=T1!44%#15%-4D%$.$$Y56-M4#)2565*3DU69%8O069F+R8C>$$[04=9
M<7=0.$%/;GI(-6@P1'E98GI2;4U-.'1Z2$).8V]/5%)23W)K<TMI:3%:5E=V
M=C0U9&=I1$QD>#E43U595TAJ5VHK969-1C=A2R8C>$$[,3<U-75T3W5Y6F%X
M>4DX:4%)1DUF>$IV5GE33VTQ37E:67=0-%A$:&U*1S@V2TIF>F9R0TQ%=R]-
M4V513SAA4TM)<&=Y0C8X;C=G<28C>$$[:'!8=C1$0G=$*V%Y.%$O>B]S6%0K
M9$Y11#)Y=V9M0F5-2C%,>74X5'%)9F=C:$AP56QU86]V=S=5879B2&<O;W!/
M6"MM<7(U;3%D-R8C>$$[6G!K+TUM565M5T5G:VID5#%):C1P>4QT>30W:T0T
M86EU,BM00U U<3A:+VYO1%%F>DPX*WAE8C=+,G1.875.6F=E-6II5TM287)/
M:B8C>$$[<T%2=U!)<6%(<V1V2$1,1DAH-54Q=WIZ-'=!8D0V9W$O9U!V+W-Z
M061Q-G(K02LO*WI&6&-X=EA9:G%-5F1Y4#AP+T0K=4MU-4@K528C>$$[+V@O
M6$989U U,2]M0C4R,')Z9S)M,D8U3G!U;G=W>'9"-E%#97)Z5W)U6'!6<4Y6
M971"5'AR;5IG>'A-8DQR=%9M;D=61%E*3VYM-R8C>$$[535);&Q8.'AR:4Q9
M8S1:25I42GDU:%=P>'%V1VA,1#1T-F1S;'=$*V%J>$0O4&1B96-D4BMS:4\V
M+TU3-E=!:%-*;V]*1W!6-4991B8C>$$[5TLW:%92='8U<61S5$%F>E9'5'9M
M<'(U,3%6-4I62&XK.&I22D573C-I8VPP2TUZ=4%$=%)U0V=%,4Y4-&)V05 U
M<2M,+U1B;C@T828C>$$[,DQ/85<S+TU#-6MN:E=2,6=A3FLU0D901F5435!I
M9&A18U%E=%149D512#@Q5&M.8E1:;BM1=FYB>F1R;"]Q5FQQ,7A,<49L1$-S
M<28C>$$[6$5O0F%/57-&-&,V1#=3,4Y$-&)D.'(Q14EI<6)D2FQL2S=E>F-J
M+T%#;CA0-C5I=6$Q>5 X:"]$*W5+=5=25U975&--2VIT:7)D6"8C>$$[.$(Y
M+SEM2W9-9GHR.#$K6B],*VA70C!A4G)68G5::W5B,DU66D%I:&M135(X4%!C
M,38O1&PK;F=*2&1X9%AK;$=/>GIG*V)T4V%2:B8C>$$[2"M9.7ES26565CE3
M0UAM46I!23%&2D9(0G%.*S(O:&PO05 U<FHK2B]4*WA3:C@T-C(P:E)V.$%M
M1D]V=TLV5&5N354S4C):1T9/6"8C>$$[24UQ<G-+8CED<V5!9GI6.%$O>C)N
M.#8V<VHR+R])44QY4T]8*RLT=T]':2]D<W@U0711+T5!=G=K.6$T.$$O;7(T
M<"]N+UEU=5!/;28C>$$[<DIC2VM8;BLV:VA,=TMZ*VY)0W%/-T-:-E5O9E15
M2U%!8718,GA%0B].53549C%R:C5W,5)A,2]-4S5B:E-P5T=3:#9!.$MN96Y+
M=28C>$$[.4YH:G=$*V%V:4@K97EZ.'!F3B]M=38X.%A7:51A<S-M1%-H8F5S
M.31W,FIA:6M&5S-05G5"1F%6-F1-<GI106ID55<S5#5*1UI&."8C>$$[464Q
M,69W2#,O=T)M67)M=$8K3D]E,5111W4Q5&ER8610<% V>FEQ0FDQ+U)P3&EA
M,U<X:D4Q=E@Q,%DX4VQ(84TQ-54O85$T<6<O328C>$$[;FUN>7)O<5%W83ED
M>%%2,W=:66\U;%HQ:T-S:4U+0E=(,G!61R]J:499=$8U;B])*V(K-EA3;BM'
M3U0T8DE(-%IO>$MH,FDW;W=0="8C>$$[,WE81DQV63A%935/3D1T+WEV,39.
M-61(=$Y*=F\T=W)/,$YV07=!:W)W2BM(=GA.365-.38X164U3E X2654+T%0
M<7DV9CA!.4ES2"8C>$$[+TY/4$=E.65#4&,W+T-(:R]W1#9S=6XO05!33$(O
M>E1J>&YV6&=J,TLY;&](;#9X;44Y;'!T<&%Z9T5#5T='2TXV2%DO17%G-$1)
M;"8C>$$[4D5"34]3*TEW36YC;#A2:7%M9C<U=FMN+T5J:7%Y.#%(5#=*5F$Y
M=6]B6EAQ14TP:7AG,$945&M25V=X5EID-G1P;&YA,T8S8S--8R8C>$$[9'9A
M2U=U<$-W<$=&-FQQ9$M9<7AF55!04#5586=O1V\V;'!L,DE:1FE68F=*259K
M;$I#9TLT3S=&0U!M2V1C24I#0T%E838Q9CAO-R8C>$$[=3=7>G0Q,$XW,3)+
M2F%C3%9::7=.2T-*9TA0,UEE2UAE:F=J,TIZ+T%)43AN+SA!5FPP+R]P1F<O
M=T-A8V5-.38X164U,RM%4$HO+R8C>$$[049:9% O-E)94#A!;6Y(:E!E=D)(
M=60O:$1Y9B]W0E=85"\K:U=$+T%*<'@T>C-R=U(W:V9:5T]M,D50;S).=D1A
M43$U96Y!:7AR6"8C>$$[>#1Q04U"2DM10452>5AX1T),64E05$952'!V*S@V
M+S8P=CA!>6-/2W18=70V6EDS549R9%1E;%!C,$5#;%A)671):U$K24%R.756
M4B8C>$$[,3<T<7%31%1T471N:&M%3C-B4#A-:V)C6EEZ4VAO=TY18U9+02]W
M:#50.$$K<DQP+W=$,&EW9C@P-4QJ4&5X-$DY>G8X2654+W=$<28C>$$[>39F
M+T%.27-(+TY/4$=E.65#4&,W+T-(:R\X039S=6XO=T133$(O>E1J>&YV6&=J
M,T\O=V@U4"]!3W),<"\X03!I=V8X,#0X6C<Q-"8C>$$[23EZ=CA)950O=T1Q
M>39F+T%.27-(+TY/4$=E.65#4&-J8D149$LP-4=J,"LQ9W,P8S%D64DP:4))
M-VM)0F=*2E-!0GE26$IF15E%<28C>$$[3C4O8W(O>&QI+S5/<FEQ:'%'<V%D
M<&%7-U@P<&E7-W5&=%E$=V1W6EI#94E004YX2'=N-&UO0C-/14%L0FM!<%@R
M;39D8E=/;WHR.28C>$$[<D1$4$Y$35I:630Q5C-,0FU9<W=!2G%X<6$Y.$-5
M;3AY>#-J,V5I+U8U-WE&4F9+6C%S=W!2,#1-94TO3"]D9FHO5VU4:65B4FUM
M628C>$$[;4]X,U!4.5!K=W4Q.'<V>C96;D4K=6%M2&Y5,&AL,&Q5;65J02]!
M>$I(2V@W:S=:1G540S(Q=E5W-D(Y53%344YE*VYX9E-W:CA7.28C>$$[04%D
M04)%2VUJ8V%N-"MT0FER96PV,7$P;#='<VUR-FI-:C--2SA*3DM70D-P;&E2
M:#9H0S!1,4MK,7)V559!,U9:+VEL,DMU>%9F1B8C>$$[+V5,.#A#;V<O=T(X
M,WE4+T%):V-663-O,35P=FTX86=.4S R3GAP1V]81FQ$-FES-DU)>48U:FUQ
M8FMD44LP.&-N2TY5=VA0:78S;R8C>$$[,U<T+U5B55DV;&56:V]$2V=L64=S
M,4-S8D%H>4]Y:V(U14IK84),>E,R:U,R<S=70V)6941$5%9U6FMU9$9$8W!6
M6G%45%-O<V=50B8C>$$[9'%B+T%!+T9Y,WE5=6)6<#4X94U3,S-(6%EO=7DQ
M1TXU,G55,5=-4TDW0TYX;W)+:2\V4$DO1DI31EIJ>F\V,#9S3TA5-49U4FPO
M-28C>$$[;G52-D1X*UIM=#%:;41!-E),3%AI2D%3,41S;DID<64S:G5Q>3=Y
M,V1Y6&5J451Y6%)V6%EY03-,4F5G5S1Y374X6#=*5VY%+TQ&2R8C>$$[6EEQ
M-T9867%I-V(K-BMN07%66&5O4V%B-6)V=%)J45-35U5&-6-*1WAO<D=)<S1"
M4%E';5-!<S!X:V%&<G1!;G0Y8S!F4SEA=3=&228C>$$[-WEA0T]596]I;&\R
M241(,#).5'@U8G%A.4M(1U%O,'-4671E;BLY;#DO>&U8+VMZ2&=:2W5+<&)B
M-GA&2G)&-UE/-%0V<TE19V13;B8C>$$[2C515V]R:S!F86Y163 Q>'E!>4UD
M+U-I,&QM3C=,15-V<$I':G%!1'EQ-5EB;710,E!$1G-7;T0K:W!V:6%G:6IO
M=DDX45=:-FYJ5R8C>$$[;&9H1TMO;&E1<$E"66=B055Q9G9X5EIB>DQ00DA-
M<6Q6:U5-;V%L84561F%%-'%V>%98=68Y-5DO=T18:"\U3TQG5FE0-6Q1=S-8
M*R8C>$$[1V)/5E9D2DYC=%I(5U%)54M+>DEY;FMY;7 Y5&)J52]2;'5082]C
M,#529&4Y3C=R>D-L>DAQ;&XK:C<K05<X330K<WI7>G)$259,4B8C>$$[+W4R
M1E,Q86-G854T-S55,TIP-D5V.'5+=$Y&27%L:7!O0E4P,U S1$96:U%A94):
M67$X2D8U23%+1V@V1VI$.5EX5E1S23=M4W=T,R8C>$$[:TIE4U-.5UIZ>$)*
M658V04%F:&A6,6I(8W1!5$E427=K;%1K94E.16M:4CEK061":7$K5G9394I(
M5G55>F-)-DM70DY#9'E!44YH,R8C>$$[>%96.4-8*UA!<39/1U%/<$LW031Q
M<6XK*V(U2B]W05-/2W-7+TQ14FY43E5M4U):1W5.575:-6EJ:'=*2D%J3TYN
M;30P4%%&<3 S228C>$$[1F%#>DIZ*T18:35(,W U3B]W06178B]J0D0O>$]8
M2S)X8F141T,R;&U#.&I%:E!X<E-V159P5VAW<6PU,64Q:C%P-TLT=3%I;$9T
M2"8C>$$[34Q9;%%M-TUR34A+<50P2&8V36%A+T9J>#A&*W%R4F8Q,41E43(V
M1DA%,&)Y:&<K+T9#;S)503%(>&IE=4Q0:48Q,61+0V119TA*9R8C>$$[;VIL
M8FE'24))6D%+9T=H*S!E=4M55&EQ>4-E3UI3,&13;UIK3E9:9#%.1#EO1'9I
M<2]&55AB9C-8,#1&63DU:6)J-4HQ5W)"1F$R=28C>$$[,&MC,3)2,EI83WA8
M8TM45&-E-7EC3UE95"MK<DY&,6PW1%-03&1J1' Y>&51,TYL87(Y8G1L85-'
M26-9,$)D>C)O,TMV5V<S=U,U;"8C>$$[34]15%<P4V%7-'9835IJ2FU(=T]6
M<B]C>"]Y;&@K3U):24QZ33$W8C9C4'%V1#9Z2DQ%<4)P1$5/2FM8;5-Y.4)X
M-C11,354240P:28C>$$[>6IO9$AJ:4UH0VQJ2V]36&UX64U!4V9S:SAD>7A*
M;TXX1%EL,$=K0TA88G57,&TT>D=#14YA<S5A24M'9EE2,2M$-D]L96TK1S)O
M628C>$$[9TIM5SEN-69*=5!63$YD8W5B2S1K5T,X4S)I:V%*>BMY2&LS5G9S
M=#EO53<K,DY+37-E4&<O:7$P6DYE=W=X4$Y)<W=J:E5U-3E#628C>$$[,$-I
M<"]9>%IY:T%,2S-15U<W,%=X=5E$>6EK:%%Q4T-P,E5!-T@S>$M-95%4:4I$
M:U5D.5=L.79V=TTQ.3!#3&%-2'%*25(O>5581B8C>$$[5T\K8WAF9E=V3')7
M='A,06\Q5TPV>C9C:VMA3D95;&QK.4TO14=P5&EW<'9U44US:#$Y>EA0<#<R
M439N+W=!8S(W+S1W>68X4D]6="8C>$$[:4IX5DIB*S5V,S%T<E,R<D)'3$M2
M,G8R9FQ':VAD45 S3F5,36<K3&9S8TQ627E*-%%.<34K9G58-E!9>5,V3EIR
M8S-K;'=$06=9;R8C>$$[4D5P4$5$67A"5R\T8D9L1THT84IS=3!B5&UT3D=S
M-')'6FM2244T>%1%>7!5<4-D>659*VAQ1'=X2TUE35%I26IK1FUG6&UQ='!O
M828C>$$[.'1&3G@V,7=S9W1N1$M(5V0Q8BLY.4]G<4YT>FE6>$=80T]+=4QY
M5F(S5CE/4RLP,D=76#!:6C5Y<TM3<3A28RMK-&]V34Q89&=.=B8C>$$[15DP
M<W-S66M!;6EE4V$T1W@R2W%2+W9M*U-F.%-/2W-$.&LV;&,V9F]6.#%N679Q
M1$A5-V]3>'=55&DO2E!H5E%'-&EJ9G1T<U)V5"8C>$$[=%IK-71E4&PX5U=U
M6C,Q5S1P03E&:&E!2DMB+T%">3=J-'5N>GET<U,O>D%Z>F%F95=%6DUD=SA$
M3DIW9$$X8UI"2$TP86]R,$AI8R8C>$$[26$X9T5W63-2<G!Z0S9W='!99%%:
M26):<$EJ8E%K,U)E3FYC,65J36$O15<W;D9L155U;C!*6DY4:79L<VQ35D5K
M53-#1D5L1%-&5"8C>$$[545D9G,Y>C-X=$)X>$UH2W9514AE4S,P2&U,5%E:
M64AM36M&>4DO5&M60S-%>$U3,%IC2S-';C0Y359-:4I!5GI45#8V;S-E2U=*
M9B8C>$$[-35536%J-7,O1F9X>%IQ3VDS560U85-3,FQ*-#%U2C!:-#)29T=%
M<D5I=DPS>$Q$2&MJ35A%,FHO5'50.3AT.39F.$%.5T)M:3=C328C>$$[26AY
M57%A.414*T)/2W-C.'EE;B]!24DQ6#%!4%0K<C-266Q"3%%":CA806Q195!8
M<FLT8W=W;CE*5%!Y<UEJ-5HP9WA!:4PV;F(K;B8C>$$[5V<K2#!L-"]:3$1P
M-$A"3&U5>#5"1C)N.2]E+SA::"]Y6FIY3$I#-E9A,TLS;6]88SDP,7I(3DU6
M=%DS5E%)630O:%I&<"]L9R]/9R8C>$$[=W1525-"2DIU>G0U23EB:4IP,V="
M4'%2:%=C1E=!;S%A55EI:#9(<&=B5E1&541$2S4Q>39I-$M%5S)T,CE4;#A2
M-5!-04].4#AK.28C>$$[.%92<DUQ<5=99TM"56LW04%9<6PR;7 O=4]T8FDP
M2W1Y:&I,;T-/16YW059Q3VIE+W="0C=55E(X33!C>3AK-T=J2V1M52M"2%DT
M<28C>$$[<#-V.7EV.$%X;&DO-4]R:7)%=GI"9W5:8G)Y=3!B:$E&,6TS.69L
M2D9'1T)F6E S:DE8-550=W)5;G=Y,T@Q.7I6;#9E.4XW>34X=R8C>$$[96QQ
M2U0R:TET170U:D9.>C1L:GIK0VEG.5$O,U!!;6](>%8K:7!T4E8Y<3$Q83)C
M,7ET<4IJ0VI/26MK;WI&4EAI2W%"=FA9>FM10R8C>$$[44PX:U!:,TY$2$Q*
M8E%R<6MS6FMD6&M(<6=046QA:%=01E129'%J8D9-5%E613%T,W0T;64S47E4
M>'$O,6186C(T=4\T1694=%4W628C>$$[17574RMA25)*1$A:,C1&0D9%.4A!
M.$]15&EV*WA(,#164VYY;'!Z-EIO8U9N6GAZ,F--571X-F-5,'!D*T14=396
M.59*86).,G!8=B8C>$$[:&MB3G-9:6A33W9*=%)E5S!%.$9R8T0Q5S1G;&M!
M<D1)1#%75W118T-31G<Q0SEG24M7>GA*,F=K3%1+4B]K;4I:1U0V9'9!67!1
M.28C>$$[.35L:65/0T]S8V-R6%9V1E%82E=V<5-H84MY3%(V9VXT9D1E;4Y-
M6E1!-6UM44@K*V(U2B]W05-/0FMX5#AS<DYB4%,Y5'0P16]34"8C>$$[57!W
M<&U1>$TQ16IQ,T5S*WA0>2M75UI$6F$X66](,W-N:B\T-E4O+T%":&@O=T-*
M4S57,DI#.3EP4S9D<EAM2UEW,GA22EE'=F\S0B8C>$$[+V0R=TMJ.31O5G$K
M<%=N9F]01$I!13=.369$<WI&9#$K-5=S.5=V-VI84VUN,DEU3DIK<UE:63E5
M:VXT<7@U=GA65DMU-T)L3E$K3B8C>$$[8F5B6EIV>51J,&(U+W=#.'521T]W
M:%%!+TEM5#%++V--:7E382LX=6%28V5A9$QV3&E*<&)U,71R=')E-&%35&UH
M3'=+4W!$0VUZ2"8C>$$[2D-2<6U*:4-B5&XV=&-P+V,S3%4V0DI616EG9DUC
M2% P=&M74UA73G9D4E)/.%5#<DHV,#E8='E">E!R4'4X5#A&<"]S*UAG8U5!
M028C>$$[8VM81G)&=7)#3SA"<S5U9SE91EDR23=*27=#<V992#A..%5T85AF
M>5A6,W%58E11>7@R:S924D-)14UQ=$)(3BLX4$XV:RMR='-.<R8C>$$[2W!8
M<CEQ=#$U3C%/0B]52W9"9&)1<5AK3DA*;W%I:$I.2UE92&1J35=#-U)2<F-8
M;'9Y-TAP:V-F;W)B,FMD,FPV2%=:26Q735-(628C>$$[+V(T0F="+TY4=&I,
M;59H>4-,835V;%A5,4-X4E-C:E-1>4YX52MG;$=*-'%A1$%K,U=Y55A(;4,K
M.'5E5DQ7-'9K.6$T57=X>D]Q4R8C>$$[>74P:S!G1$5X9V-Q+T53870Q*S=#
M23)7=4I-66II3FQ&5W0W-6YK,7951$I&85%7;G R+S%.5'IE5&HX9DPQ0T-&
M<GIR,"](<FEA<"8C>$$[<T8R;4AQ-G,O=T)U4D9P,#E(-&$O=T-T-FEY+VA4
M27!36DE,;4AZ5F18>C9R2T=K<S1)4'%B5%)#36-:2D<U:%!2*S%V-&9R,FQE
M,28C>$$[36$S=$YL,5,O5V@Y5S!L43=+0S51;7!O4&I(258K4S1'4W K;&12
M04(K;W))1T91.$UY<W1$-W5)>BM'0E9'8E935T5O45<X;T9#."8C>$$[=G%)
M:$@X<D9K5E0W8B],=E5Q:'9+*W1X83$U86@Q0TPW16PP5D$Y650P-%A81VYQ
M0717;$M94TM,5FAY8V-B<79X-4E,.'=P:$@O:"8C>$$[<&%R>6TQ,C!I2VM6
M2E)M8FU/:F4R+S0U3$@Q.7DU1%9E.6LK<F8X04A+=E K345V+T5$;&)A:U!M
M17EI6%0S*W-#,W192G9R3C@W328C>$$[15%147)5;#):,%5+2$LQ-BM08D-'
M=DE*5TM.0SDO8VAP<E=B53E7*W-M.&TO47,Y:DI%='1!<$-V>F14-GDS0T1L
M.&$O6E94,$%0928C>$$[;4<V6E9:.&MW.'4V9&(V9&]L;%HR-DUI4E%O<$5N
M3&YY0V=%=5<K2W4R2DYL35)1<$UC0UA9<7-K9VAK6DAK:E8R:E!+3FU!2E4K
M2R8C>$$[:SE-5E@T<6Q8;4A43&4K:7-X3&%P8W9$95<X<V9)33-(:$MR3V9H
M5B]W0FM%1W4R24Y-2C0T>35I-EI!9C<U=FMN+T5J9UIS4R],0R8C>$$[5G!T
M4#%U67A00W-U<S-R<$A)<7%1<DUP5VY!0E-+9'A8-35:;#5J,TY73&MF95=5
M;U%.4G5#5%%#0T5K;B]7;'ET=%EL<'0Y6C-C5B8C>$$[-359=$9I;6Q&<3$W
M9')#=D)'3C!Z:W<P23E0-UHT=#AF5%DU2VIZ831#23E)1F9T6EI"1DUT-#!G
M:E9,9#19,%9E6'AQ>49Z>#1G1B8C>$$[869(,F))=&E+>%91;'-B5U<V:'5P
M27<Q>$%'14UL5%91.4]1,E!E9WA66'A66D9"1$-P5T=.63%*3$5)06],2&-N
M8G5C5F)K:FIK428C>$$[<$EO9$<V<5)567%K2&QJ4DED3C%06#59;V=G=DQX
M2D]14TY3,4E).7EY:W,R-5 R.2LO56Y*13(Q63A::5I%;3=0>54O34IF+T)'
M<R8C>$$[0DDR;60W4SE263!53WI&*V%G0D153C$V65EF54=5+W!+3SAN<DEV
M;$Q21FM6;&M7=W11-G5V0F=20W11>3=C5#1J0E!M57<K:TE85R8C>$$[2C1R
M93$Q;5=69VE,549M3D9(2T--0W W0W V-$%K<$PU5W9.4SAW>%AE;S-C<2]O
M-E-:2F1&845';VE!1&-J-FM91$AK2U8K63(W>28C>$$[:TM9=TI/+U1O>6A9
M23%M95E6.5-12W)%<WA&1G)39TIO3W V6D9M=GA6:6XU;E=&=F5E5DI22VQO
M-U%44E-W+UAZ24E1+TQH6#DP428C>$$[,65,;6U39T)E-U1Q36]X=TUI45!E
M=W4X,%!1<DLY9W0T3DLP2V%/,W59:V=186TX13AA<DMH-3A'8SAM56YK1C5B
M,$AJ:U<P2G U928C>$$[:G-T3&8V-7!T=&]D=F-,0VM*;&HQ2C564DI*,%9Q
M:'%G5F]&540Y=6<U8C=+<'!D961D6FIL;455;6@K:VAP1S!M;VA345$Q0S-W
M,"8C>$$[,W P>%9L5VA714YJ-6-T25EL:5)8:U-C<D)5>$)P-7A+,T%K=%9E
M5&UH-S1K<4%J<B]29$TQ3G)2-S9(,6US8F=85G%E5')W;6I9;"8C>$$[6"M%
M:71003=9:5)#;4E03DQD6'1R=7IS=%1V<B]76%14:&)45E0P5G!'1V0S-6MH
M6D=B9VIH3FPV1'5C0U5S,6XX=G!.93%/1S9U.28C>$$[8G58,&A556I4,5-%
M0G=664]R3G=(=T]'1E)3<"MG56U*53!N1DEZ<VXP,7E484<Q<S=854Q84DE,
M-E=.;'1';&ET9VME,$U,4GA!<28C>$$[,W!C048U,&]46#AC:F)A;4@V3&8O
M;'1N*S9(+T%+<#1%;TQ29E$Q6%-R6%5,5%4U8FE#-%%-:WE,1W%T,DI!94I7
M<%5(<4U69&5#1R8C>$$[,G9R0WIK,4M:2G(K4C0T15I)>GI-8U13<W%S26EO
M24,Q*TDY06-64G8V3&8O;'1N*S9(+T%+<#1Q;"MI>3)U<E%44S)M<%1Y:4-:
M;R8C>$$[6D-),6HT<T%(0VM347%A:$A7=G9T:%8R<UAD;&]K5G9C,S)P4WA2
M>51X>$M8:E8P2DQ62W-9;VE6<6]/-6]09D%Q8VXK*V(U2B]X228C>$$[-'%H
M3EHP+U5B,D)%<V119E1P5F%R4V]I>6-L<%-L1W S-S1Q;%=R5U0V>%!R1VLR
M5W145V0V26)C5$=/3E,P2WE0238Y55-O9%%6,B8C>$$[979J:$)P<GEW36]K
M03A*-S(Y3#AU6&5I-F9D>GIA>F-89#8O<E146&MQ4DMP0EIP1D)J4D=&17(R
M2'DX34I.<V]G9V)M,#%S-EAL<"8C>$$[0F0R,2].2F(S36%Y=WEC66AY4C%$
M2V%'24AC2'9K5U-J4$])9%9T3E!F57!&;G4T<#5)66EK9DHO44UF26AH1G@K
M2#%/:$Y4,C9(1B8C>$$[55HY56XO-6):=G5H+W=#<65+;U!2-V=A;EE*93(R
M;WI3=U-V24DS16%*<VMJ2E%R2D5R06IJ43%'2W%E<#,X1VXS3FQ"8S9N3$4Y
M-28C>$$[2G=J5F\P4$MR3$5!0W-204IL;6I(>&9W>%9-4'%K+R]!0S)Z9F1$
M+T%.53A645=I6&1T3F,V;DA&95!D4W<S05=:2D4T3D<S<$E+528C>$$[.4]+
M=E1Q2VHS<EA&559P;BLX-B\V,#,O04-C3TMR9%(P*S5U<')74T,Y:W120DMS
M:W%*=7-Q2W=9;S(T-C!P6$95:W9.0G-D96XQ1"8C>$$[5#4Y4G9!,6YD=U-Z
M0TAH1CA1:%(P570V5D=&2TAB,C<T46%A<W5)5$%"=EDS<V%2;#5:4F%0;W)Z
M9EA*,71D4&E$3E));F(P67%&9R8C>$$[<4I&=65!;T%":3)O.&%A4T%2951%
M2&-%0T@O<6YG5D)H62\P=RMM;2MN.68V=71Y<V9#4%I/8DE7-2ML>#8P,G)8
M1E9A*S!N;EIZ2R8C>$$[,7I)+W=-47)P0S8Q07%+<C9:<G9I9V=%555S:#AR
M95=.8G,W8E5Z06LX9#))<C9'5U<S='A)4S-'5TYZ>6@U0G%H5'9V:%-P6&UI
M928C>$$[6$QF5DQ$5$IO,4)V5FQ70U V<F)L0U5!96Y,,&5);T$R,W9I<4]0
M:VY10U=*=&]I5TI::6)E,3-*1D-4*S4Y.$9Q,V]U<%=6+V]K8B8C>$$[,F)-
M,$55.&-3.#1Z0U954TEY3'=+<%-I379B0W%E2C K:R]R3T)5<#@T>6%N2#54
M,6PY2VEA9E5X6EA!<TEK2$IM;DU40TE!8F9T,"8C>$$[>55+<U=I5C%S:CE0
M;'5*=%!T<&)H1$AC4U)).#!:2$5Q-TM#>6MD<4A!56]J07$R44]9,D-.>&-G
M:%<V,$Y.:FER1'AO=C5N;W-!2"8C>$$[;4\Q;$M-;G)&-U)&3&<W4'5O<'18
M:V]!,TEP541,3TM08S%C32LY6'1T2B]-3U!53&-Z83=B5#9E<D)R:%1B2W-R
M2TIA;$)X1E!I:28C>$$[2E=V66IV6$5M3F-K,4LK8DLX<F)(67$W1E9):V5U
M=S<X62\K2DA&5EA&56<P<30Q>51Z:'(P5C-B=$AP5556:W5L>CA31FM01U)P
M+R8C>$$[:7)U5F1W36MA;TE4+TEP9&EQ4F$U<"]M,F9525IT2#%A2WET151J
M3F%Y=TQ+2&5P*TQL<W<R239(=&LT:V11>&M$97A3>CE#+VU7628C>$$[:R\U
M,DLR5U=.<$LP=$5+>4EY4BMN>49+<59C4V9:4%%J<FAU4&-W-%HY-F9E6')F
M6#1.4$-A-V1X6'0X5S5'4T-0,&\Q0E5F04(S;R8C>$$[,60X:DMR,EIX0G)D
M37-I>61I<G-6465M+W=#.#8O-C!V+TIW-'%J3599+S54=61C;G5D9D]Q,C=1
M0DY5;%14*U-L5F4P4TM*23-7<"8C>$$[3F525FI8>'E5<3)P05I":U5U>%9J
M;7$V6#4R;#%+96943F%H=')'4D%S3G!.8DQ*-F)C44,T8V-74'A!;6A09DIG
M>')C34-*6'-50B8C>$$[3F\O-6]E:7)W*UE,4#9W<UI2;W!,5E1'>FE6>4I/
M4V=-0UEI9TEP4V].2UEB:#--94=F97EN5$ER*TMX:&HQ0V1B;3A51514;VYP
M<28C>$$[>'%A14PR,GE".&UW26Y!;#)+;V4K245+5DY+>7=G9CAJ5GA61%AN
M<2MQ9G$O=T)A-B](-DAP8V$O=T108B]J6$961"]!12\O04Q72"8C>$$[+U1P
M:%8S*VXO=T1A=R\V9$U69"]P+SA!,G-0*VY41EAF-F8O04YR1"]P,'A6,RMN
M+W=$87<O-F1-5F0O<"\X03)S4"MN5$989C9F+R8C>$$[04YR1"]P,'A6,RMN
M+W=$87<O-F1-5F0O<"\X03)S4"MN5$958EDK;#95;&95.5-V-S<Q+W0Q<'0P
M*T=L3VY(8D%R56YQ8WIX*W-C928C>$$[,TAH5"]H=#A65R]V=BM8<B]K;&ER
M=C,S+TPQ+WE3>%8S-S<O04IE=BM35TMU+V9F.'98+T%#4WA6,S<W+VPV+S5*
M67$W.3DO>3EF."8C>$$[:W-69"LK+S5E=CA!:VQI<G8S,R]!0SEF.&MS5F%0
M<5503#8Q>'!V+T%(9E0O62]&.3)+<6IF5B]Q8V8Q9FYX-"]U4%)P>7!4='DR
M+R8C>$$[-$Q&548O<"\O87<O-F1-2W4O,"\O=%EF.4]M2W4O,"\O=%EF.4]M
M2W4O,"\O=%EF.4]M2W4O,"\O=%EF.4]M2W4O,"\O=%EF.4]M2R8C>$$[=2\P
M+R]T668Y3VU+=2\P+R]T668Y3VU+=2\P+R]T668Y3VU+<F]E4#%M2#8U.6%R
M>2]C9E=05#E0;E$O-S4R<C1C=F]X5B\O,E$]/3PO>&UP1TEM9SII;6%G93X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L
M=#X*(" @(" @(" @/"]X;7 Z5&AU;6)N86EL<SX*(" @(" @(" @/'AM<$U-
M.D1O8W5M96YT240^>&UP+F1I9#IB,S T8C,T."TQ8S<V+6$X-#0M.6$R,BUA
M,#8U839E-# T9#$\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-
M33I);G-T86YC94E$/GAM<"YI:60Z8C,P-&(S-#@M,6,W-BUA.#0T+3EA,C(M
M83 V-6$V930P-&0Q/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP
M34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z1D1!1D1!1$8M0D9%1BTT-#%&
M+3@R1D(M13=&0T5&041!,T1$/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^
M"B @(" @(" @(#QX;7!-33I296YD:71I;VY#;&%S<SYD969A=6QT/"]X;7!-
M33I296YD:71I;VY#;&%S<SX*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F
M.FEN<W1A;F-E240^>&UP+FEI9#HW9F%C,&0S.2TU,3EE+3,V-#@M83<Q92TX
M-SDY,S$X,&4U8C4\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS
M=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z-V9A8S!D,SDM-3$Y92TS-C0X+6$W
M,64M.#<Y.3,Q.#!E-6(U/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @
M(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z1D1!1D1!1$8M0D9%
M1BTT-#%&+3@R1D(M13=&0T5&041!,T1$/"]S=%)E9CIO<FEG:6YA;$1O8W5M
M96YT240^"B @(" @(" @(" @(#QS=%)E9CIR96YD:71I;VY#;&%S<SYD969A
M=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*(" @(" @(" @/"]X;7!-33I$
M97)I=F5D1G)O;3X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @
M(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C
M=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.F,Y9F1F8F8T+3-D8S4M-&,Q,"UA
M-C9A+30V,6$U8S4U83$X9CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.G=H96X^,C R-BTP,BTR-50Q.3HQ,SHT-2TP-3HP
M,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W
M87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@,S N,B H36%C:6YT;W-H*3PO
M<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A
M=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II
M;G-T86YC94E$/GAM<"YI:60Z.64W-3(T-S8M,&0P-2TT-69C+6)A-V0M9C,W
M,F4V-C4Y.&4U/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z=VAE;CXR,#(V+3 S+3,P5#$T.C$T.C(U+3 T.C P/"]S=$5V
M=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N
M=#Y!9&]B92!);&QU<W1R871O<B S,"XR("A-86-I;G1O<V@I/"]S=$5V=#IS
M;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E
M9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A
M;65T97)S/F9R;VT@87!P;&EC871I;VXO<&]S='-C<FEP="!T;R!A<'!L:6-A
M=&EO;B]V;F0N861O8F4N:6QL=7-T<F%T;W(\+W-T179T.G!A<F%M971E<G,^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T('1O(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YI;&QU
M<W1R871O<CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A
M=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II
M;G-T86YC94E$/GAM<"YI:60Z8S R,S9E9&,M-#,R-2TW8C0X+3DV,V(M8C,T
M,V,P-C1D,S9D/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z=VAE;CXR,#(V+3 S+3,Q5# Y.C0P.C(S*S U.C,P/"]S=$5V
M=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N
M=#Y!9&]B92!);&QU<W1R871O<B R-2XP("A7:6YD;W=S*3PO<W1%=G0Z<V]F
M='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^
M+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$
M/GAM<"YI:60Z8C,P-&(S-#@M,6,W-BUA.#0T+3EA,C(M83 V-6$V930P-&0Q
M/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M=VAE;CXR,#(V+3 S+3,Q5# Y.C0Q.C,T*S U.C,P/"]S=$5V=#IW:&5N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!)
M;&QU<W1R871O<B R-2XP("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z
M8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @
M(" \9&,Z9F]R;6%T/F%P<&QI8V%T:6]N+W!O<W1S8W)I<'0\+V1C.F9O<FUA
M=#X*(" @(" @(" @/&1C.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*
M(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CY0
M<F]J96-T0V]A9T9I9U1A8FQE,S!-87)C:%]J<VYO=U]V,CPO<F1F.FQI/@H@
M(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @
M(" @(" @(#QD8SID97-C<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M<F5P86ER(CY&
M:6QE($YA;64Z(" @(" @(" @(" @(" @9S@Y9C W+F%I)B-X03M5<V5R;F%M
M93H@(" @(" @(" @(" @(#@S,C<U-"8C>$$[3&]C86P@5&EM93H@(" @(" @
M(" @(" @,S$M36%R8V@M,C R-B P.3HT,#HS-R8C>$$[15-4(%1I;64Z(" @
M(" @(" @(" @(" S,2U-87)C:"TR,#(V(# P.C$P.C,W)B-X03M38W)I<'0@
M5F5R<VEO;CH@(" @(" @(" R+C8F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ
M(" @(#(U+C N,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K
M)B-X03LF(WA!.^* HB R,S @:&%I<FQI;F4@<G5L97,@8VAA;F=E9"!T;R P
M+C(U+B8C>$$[)B-X03OB@*(@,3@X(&)L86-K(')U;&5S(&-H86YG960@=&\@
M;W9E<G!R:6YT+B8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.SPO<F1F.FQI/@H@(" @(" @
M(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z9&5S8W)I<'1I;VX^"B @
M(" @(" @(#QD8SIC<F5A=&]R/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @
M(" @(" @(" @(" @/')D9CIL:3Y2=71H=FEK($UA;&QA9&D\+W)D9CIL:3X*
M(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R96%T;W(^
M"B @(" @(" @(#QI;&QU<W1R871O<CI)<T9I;&53879E9%9I84EN<W1A;G13
M879E/E1R=64\+VEL;'5S=')A=&]R.DES1FEL95-A=F5D5FEA26YS=&%N=%-A
M=F4^"B @(" @(" @(#QI;&QU<W1R871O<CI#<F5A=&]R4W5B5&]O;#Y!9&]B
M92!);&QU<W1R871O<CPO:6QL=7-T<F%T;W(Z0W)E871O<E-U8E1O;VP^"B @
M(" @(" @(#QP9&8Z4')O9'5C97(^061O8F4@4$1&(&QI8G)A<GD@,3@N,# \
M+W!D9CI0<F]D=6-E<CX*(" @(" @(" @/'AM<%109SI.4&%G97,^,3PO>&UP
M5%!G.DY086=E<SX*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE5')A;G-P
M87)E;F-Y/E1R=64\+WAM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/@H@
M(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^5')U93PO>&UP
M5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^"B @(" @(" @(#QX;7!44&<Z36%X
M4&%G95-I>F4@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" \<W1$:6TZ=SXY-3DN-S8P,S$U/"]S=$1I;3IW/@H@(" @(" @(" @(" \
M<W1$:6TZ:#XS,38N,# P-S4W/"]S=$1I;3IH/@H@(" @(" @(" @(" \<W1$
M:6TZ=6YI=#Y0;VEN=',\+W-T1&EM.G5N:70^"B @(" @(" @(#PO>&UP5%!G
M.DUA>%!A9V53:7IE/@H@(" @(" @(" \>&UP5%!G.E!L871E3F%M97,^"B @
M(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/D-Y
M86X\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y-86=E;G1A/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^665L;&]W/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D^0FQA8VL\+W)D9CIL:3X*(" @(" @
M(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI0;&%T94YA;65S
M/@H@(" @(" @(" \>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @(" @(" @
M/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<$YA
M;64^1&5F875L="!3=V%T8V@@1W)O=7 \+WAM<$<Z9W)O=7!.86UE/@H@(" @
M(" @(" @(" @(" @(" \>&UP1SIG<F]U<%1Y<&4^,#PO>&UP1SIG<F]U<%1Y
M<&4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI397$^"B @(" @(" @(#PO>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @
M/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_;
M $, !@0%!@4$!@8%!@<'!@@*$ H*"0D*% X/#! 7%!@8%Q06%AH=)1\:&R,<
M%A8@+" C)B<I*BD9'RTP+2@P)2@I*/_; $,!!P<'"@@*$PH*$R@:%AHH*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*/_  !$( C$': ,!(@ "$0$#$0'_Q  =  $  @,! 0$!            ! 8#
M!0<( 0()_\0 9!   0,# 0,&!@L)#@,## $% 0 " P0%$082(3$'$Q1!47$5
M(E)A@9$6%S(S-562DZ&QT38W0E1S=92SP0@C-#A65V)R=(*TPM+B)**R4V.#
M)29#162$E:/#Q.'P1-,G=M3Q_\0 &P$! 0 # 0$!              $" P0%
M!@?_Q  Q$0$  @( !@(! @8" @,!     0(#$002$R$Q405!%&%Q(C*!D:'!
ML?#1\09"X2/_V@ , P$  A$#$0 _ /5*(B B(@(B("(B B(@(B("(B B(@(B
M("(B B^/>UC'/>X-8T9+B< !<VU1RQZ>L\KX*'G;I4-W'F"!&#_7/'T K*M9
MMX87O6D;M+I2+@,W+W7EY,%CI6,Z@^=SCZP L?M\W3XFHOG'+9T+^FG\O%[>
M@D7GWV^;I\347SCD]OFZ?$U%\XY.A?T?EXO;T$B\^^WS=/B:B^<<GM\W3XFH
MOG')T+^C\O%[>@D7GWV^;I\347SCD]OFZ?$U%\XY.A?T?EXO;T$B\^^WS=/B
M:B^<<GM\W3XFHOG')T+^C\O%[>@D7GWV^;I\347SCD]OFZ?$U%\XY.A?T?EX
MO;T$B\^^WS=/B:B^<<GM\W3XFHOG')T+^C\O%[>@D7GWV^;I\347SCD]OFZ?
M$U%\XY.A?T?EXO;T$B\^^WS=/B:B^<<GM\W3XFHOG')T+^C\O%[>@D7GWV^;
MI\347SCD]OFZ?$U%\XY.A?T?EXO;T$B\^^WS=/B:B^<<GM\W3XFHOG')T+^C
M\O%[>@D7GWV^;I\347SCD]OFZ?$U%\XY.A?T?EXO;T$B\^^WS=/B:B^<<GM\
MW3XFHOG')T+^C\O%[>@D7GWV^;I\347SCD]OFZ?$U%\XY.A?T?EXO;T$B\^^
MWS=/B:B^<<GM\W3XFHOG')T+^C\O%[>@D7GWV^;I\347SCD]OFZ?$U%\XY.A
M?T?EXO;T$B\^^WS=/B:B^<<OK>7JY!PVK+1D=8$K@G0OZ/R\7MZ!1<CT_P N
M5GK)&QWBAJ+<3NYQKN>8._ !'J*ZG;J^EN5''56^HBJ::09;)$X.:5KM2U?,
M-M,M,G\LI*(BQ;!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1%^)I8X(GRS/9'$P;3GO. T=I)X(/VBYAJ7EHT_:Y7
MPVV.:ZS-W%T1V(L_USQ] (5/EY>K@7DQ62E:SJ#IG./KP%MC#>?IHMQ..O;;
MOZ+S[[?-T^)J+YQR>WS=/B:B^<<KT+^F/Y>+V]!(O/OM\W3XFHOG')[?-T^)
MJ+YQR="_H_+Q>WH)%Y]]OFZ?$U%\XY/;YNGQ-1?..3H7]'Y>+V]!(O/OM\W3
MXFHOG')[?-T^)J+YQR="_H_+Q>WH)%Y]]OFZ?$U%\XY/;YNGQ-1?..3H7]'Y
M>+V]!(O/OM\W3XFHOG')[?-T^)J+YQR="_H_+Q>WH)%Y]]OFZ?$U%\XY/;YN
MGQ-1?..3H7]'Y>+V]!(O/OM\W3XFHOG')[?-T^)J+YQR="_H_+Q>WH)%Y]]O
MFZ?$U%\XY/;YNGQ-1?..3H7]'Y>+V]!(O/OM\W3XFHOG')[?-T^)J+YQR="_
MH_+Q>WH)%Y]]OFZ?$U%\XY/;YNGQ-1?..3H7]'Y>+V]!(O/OM\W3XFHOG')[
M?-T^)J+YQR="_H_+Q>WH)%Y]]OFZ?$U%\XY/;YNGQ-1?..3H7]'Y>+V]!(O/
MOM\W3XFHOG')[?-T^)J+YQR="_H_+Q>WH)%Y]]OFZ?$U%\XY/;YNGQ-1?..3
MH7]'Y>+V]!(O/OM\W3XFHOG')[?-T^)J+YQR="_H_+Q>WH)%Y_9R]7$.&W9*
M1S>L"5P/[5:-.\M]DKY&Q7>DGMCW;MO/.QCO( (]2DX;Q],J\3BMVVZPBPT5
M73UU+'4T<\<]/(-IDD;@YKAYB%F6IO$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1?B:6."%\L\C(XF#:<]YP&CM)/!!^
MT7+]2\M-@M<CX;9'-=9F[MJ,[$6?ZQX^@$*H2\O5P+R8K)2M9U!TSG'UX"VQ
MAO/TT6XG'7MMW]%Y]]OFZ?$U%\XY/;YNGQ-1?..5Z%_3'\O%[>@D7GWV^;I\
M347SCD]OFZ?$U%\XY.A?T?EXO;T$B\^^WS=/B:B^<<GM\W3XFHOG')T+^C\O
M%[>@D7GWV^;I\347SCD]OFZ?$U%\XY.A?T?EXO;T$B\^^WS=/B:B^<<GM\W3
MXFHOG')T+^C\O%[>@D7GWV^;I\347SCD]OFZ?$U%\XY.A?T?EXO;T$B\^^WS
M=/B:B^<<GM\W3XFHOG')T+^C\O%[>@D7GWV^;I\347SCD]OFZ?$U%\XY.A?T
M?EXO;T$B\^^WS=/B:B^<<GM\W3XFHOG')T+^C\O%[>@D7GWV^;I\347SCD]O
MFZ?$U%\XY.A?T?EXO;T$B\^^WS=/B:B^<<GM\W3XFHOG')T+^C\O%[>@D7GW
MV^;I\347SCD]OFZ?$U%\XY.A?T?EXO;T$B\^^WS=/B:B^<<GM\W3XFHOG')T
M+^C\O%[>@D7GWV^;I\347SCD]OFZ?$U%\XY.A?T?EXO;T$B\^^WS=/B:B^<<
MGM\W3XFHOG')T+^C\O%[>@D7GWV^;I\347SCD]OFZ?$U%\XY.A?T?EXO;T$B
M\^^WS=/B:B^<<GM\W3XFHOG')T+^C\O%[>@D7GWV^;I\347SCD]OFZ?$U%\X
MY.A?T?EXO;T$B\^^WS=/B:B^<<GM\W3XFHOG')T+^C\O%[>@D7GYO+U<LC:L
MM&1V"5P5DL'+G:*N1L=XH*BWD[N<8[GF#SG !'H!4G!>/I8XK%/;;KJ*+;+A
M1W2CCJ[=4Q5--(,MDB=M _\ Y\RE+4Z/(B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B OCW-8TN>0UK1DDG  7U<XY>+^^S
M:*?34[RVHN+^C@CB&8R_Z,#^\LJUYITPO>*5FT_3EG*WRCU&I*V6VVF9T5EB
M=LY:<&I(_"/]'L'I/FYFB+TJUBL:AXM[S>>:PB(LF BS45.ZKK(*:,@/FD;&
MTNX DXWKITO(?J)F0VNM+Y<9$8E>"?6Q8VO6OF6=,=K_ ,L.5HK7IW1=5<-=
M1Z8N;W6^J)>)'%@DV=EA>-V0"#@;\]:T^I[4+)J"X6P3<^*29T7.;.SM8/'&
M3A(M$SI)I,1N6L1$63$1$0$1$!$5AT1I2KU?<Y:"WU-+#4,B,N*AS@' $ XP
M#OWA29B(W*UK-IU"O(I]'::NKOL5HC9BMDJ!3;+NI^UL[^XJXUW)7=J2.\D5
MUNFDM4(FJ(HWO+@"TN&,MXX!4FT1Y95QVMWB'/T5KT-H2Z:R97/MDE/&VDV=
MHSN(VB[. , []RC:+TC<-6W::WV]T,,L,1E>Z<D- ! QN!WY*<T1OOX(QVG6
MH\JZBN^D.3>YZIIJZHM];0,AI)S YTKW .(&<C#3NW]:BZVT)7Z1IJ:>NK*&
MH;4/+&BFD<X@@9WY 4YZ[UON=*W+S:[*DB^L:Y[VM8"YSC@ =95XUAR97G2U
MC;=*Z:DEAVVL>R%SBZ,N&[.0!C.[O(5FT1.I2*6M$S$>%&1$63$1;&R6.XWR
M2I9:J9U0ZGA,\N'!H:P<3DD=O#BMGHC3M%J*IK(J^]TMH;!#SC7U&,2'L&2/
MM\RQFT0RBLSX5M$/%%DQ$1$!$1 1$0%:-!:TN.C[FV>D>Z2C>X=(I7'Q9!^Q
MW8?V*KHI,1,:E:VFL[A[8L5UI+Y::6Y6^3G*:H9MM/6.T'S@Y!4Y<'_<VW]X
MJ;C89GDQN9TJ 'J((#P._+3Z"N\+S<E.2VGM8<G4I%A$18-HB(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B#\3S1T\$DT[VQ
MQ1M+WO<<!H R25Y=Y4^42JU7724E%(^&R1.Q'&-QFQ^&_P#8.KO74?W0M_?;
M=*P6RG>6RW*0M>1QYIF"X>DEH[LKS:NOA\<:YI>=QF:=].!$1=;@$1$!%T6P
M\DEYO5DH[I!76R*"J9ML;-(\.[CXN,[E6]8:/NVDJV&GN\3 )@3%+$[:8\#C
M@^;(W''%81>LSJ);)Q7B.:8[*\BN/*7HMNB[A14S:\UO2(>=VC%S>SOQC&3E
M4Y95F+1N&-JS6=2(B*L1$1 1$0$4FV4AK[C2TC98XG3RMB$DA(:TN.,G'4MI
MK/2]=I*\>#KDZ)\IC;*U\1):YISPR >((]"FXWI>6=;^FB17ZW\EUVJZ6RRN
MK;? ^[@NIHI7O#B POWX;Y(^D+14FDKC5:S=IEAB%>V9\)<2=CQ0279QG&!G
M@L>>L_;*<=H^E>16&^Z2N-FU6S3]08I*V1\;&.C)+';>,$$@'B<<.HK;/Y-K
MHW6;-,BLH'5[H.?+P]VPT8)P3LYS@=G6KSU]G3MXTI"+HU[Y)+O9[565]1<;
M4^.EC=(]D<KB\@#> "WBN<I6T6\):EJ=K0(KUI;DPO6H].F\44M*R$[?-QRN
M<'R;/9@$;R"./4J*00<'<0D6B>T$TM6(F8\B(MC:K)<;K35]1;Z9TT-#$9ZA
MX< (V;]^\[^!W#?N5F=)$3/AKD5DTEIVBOE'=IJV]TML?11<Y''/C,YP=PR1
MV#AD[QN5;2)WV)K,1$B(K-JC35):**S2T%ZIKI-7Q[;X8 -J%V!AIP3UG&_!
MW'<DS$=B*S,3,*RBGWVSU]BN+Z"[4YIZM@#G1ES78!&1O!(X* D=R8UVD1$5
M01$07#DYUW7Z.N32QSY[9([]_I2=Q'E-['?7UKU;:Z^FNEOIZZAE$M-.P21O
M'6"O$2[W^YMO[YJ.XV*=^1!BI@!ZFDX>.[.R?[Q7+Q&.)CFAW<'FF)Y)\.UH
MB+C>D(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB#\5$T=/!)/.]L<,;2][W' :T#))7EOE2Y0ZO5E?)2T<CX;)$[$<0W&7'X;^
MWS#J[UU']T/?WV[2]/:Z=Y;+<9"'D?\ 9,P2/22WT97F]=?#XXUS2\[C,T[Z
M<"(I]@M<U[O-';:5\;)ZJ01L=(2&@GMP"NKPX8C?:$!%U&HY$M1QL?S-7:YY
M6#/-,F<''UM ]:KN@]$RZFU3562LJ'VZ>FC>^0F+;(<UP:6D9';]"QZE9C>V
MR<-XF(F/*H(L]PI^B5]33;6WS,KH]K&,X)&<>A8%FU"(B B(@(B("+;Z2T_4
MZGOL%JH9(8ZB8.+72DAHV6EQS@$\ KE=^2"\VNVUE9/<K2YE+$^5[&2OVB&@
MD@ MX[EA-ZQ.IEG7':T;B.SFR(BS8"(MC8K)<;]524UIIG5$T<9F>T.#<,'$
MY) ZPIO2Q$SVAKD1%4$1$!%9K]HVOLVFK7?)9Z:>AN&.;,+G$L);G#L@8.X]
MO I8]&U]WTQ<[]'/304%!D/,SG!SR #AN =^\#?C>5CS1K;/DMO6E9166[Z.
MKK7I*VZAGFIG4=>X,C8QSML$AQW@C'X)ZU]U/HVOT[9K1<JR:FD@N48DB;$Y
MQ<T%H=XV0.IPX93FB2:6CZ5E%9=::.KM)&@%PFII>F1F1G,N<< 8XY [56E8
MF)C<,;5FLZD1=(L_(_?ZVWQ5=944%M$P!CCJI"'G/#( ..[CYE3M5Z?J],WJ
M:V7!\#ZB( DPOVFX(R.H=7:L8O69U$LK8[5C<PU"*99K=/=[K26^D -14RMB
M9G@"3C)\W6K'KS0%TT9%22W&6FGBJ7.:U\!<0TC&XY [?H*LVB)TD4M,3:([
M0J"(LE-!+55,5/3L,DTKPQC!Q<XG 'K63%C13;U:JRRW*:WW.'F*N'&W'M!V
M,@$;P2.!"V^L-.T5AAM;Z&]TMT-7"9)&P8_>3NW'!/')XX.X[E-PRY9[_HK:
M(K)IO3M%=K'>*^JO=+034,>W%32XVIS@G WCLQN!WE)G7E*UFTZA6T6QMEDN
M-SHJ^KH:9TM-01B2IDV@!&TYP=YW\#N'8M<FS4B(BJ++H76-RTA=&U%#(7TS
MR.?IG'Q)6_L/8?V;EZQT]>*2_6>FN5NDVZ:=NTW/%IZVGS@Y"\4KM/[FZ_OC
MN%?8IGDPRLZ3"#U/& X#O!!_NKFSXXF.:'9PF::VY)\2[ZB(N)Z@B(@(B("(
MB B(@(B("(B B(@(B("(HM=4.B#8X1M3R;FCL\Y0?NIJXJ? >27G@QN\E8.>
MKI=\<#(F]7..W^H++24C( 7..W,[W3SQ*DH(.S<?+IO44V+CY=-ZBIR((.Q<
M?+IO44V+CY=-ZBIR((.Q<?+IO44V+CY=-ZBIR((.Q<?+IO44V+CY=-ZBIR((
M.Q<?+IO44V+CY=-ZBIR((.Q<?+IO44V+CY=-ZBIR((.Q<?+IO44V+CY=-ZBI
MR((.Q<?+IO45P[]TB^K%588JIS"P,F<W8SC)+ ?J"[^N/_NDK4^IT];;G&W/
M0YG1OQU-D W^MH'I6W!.KPY^)C>*=//*(B]%XXB(@GZ>^'[9_:HO^L+T9K:P
M6Z3E#M>H;EJ2BMC*&.-QIY)&MDDV7N=UN&XYQP/6O-MKJ&TESI*F0$LAF9(X
M-XD!P.[U*U<JVJZ/6&HX;A;X:B&)E,V$MG #LASCG<3N\8+3>DVM&G1BR5I2
M=^X7>QWZDU'^Z#I:ZW>-2;$D4;R,;8; \;6._/HPOQ;:*[R<IFKJNU6.W7)C
M*A[#-< !% [:SM G?G&<@+GG)U?Z?3.KZ&[5L4LL$ D#F1 %QVHW-&,D#B5=
M[/REV4/U317B@KGVF\5+YVF#9$K0X %I\8#@!P*QM28GM'TV4R5M'\4ZG<S_
M (;_ )1K7#<.2V>[7*DLS+Q23- GM9!807AN">YW YWK<VFGAET9:YM 6W3]
MQ:R(=,@JF#G7NV1D%W4[.<[7FQN7.+SKNQ2: N&F++:JND@?(QU.][P\N >U
MSG2'.YQ(.X9'!3--:OT'8JNFNE%:+U3W2*/9='%*.9>XMP<Y?PZ\8]"QY+<K
M.,E.;>X\?]^DGD@HH;GRE:@BNUHIH,P2DT3H1LP'G&#9 QNP#C*LV@+C9-7S
M7VQ5&G+;!;*)N(.;C\<LR6Y+N.UN!R,'BJ'I#E&IK=R@7C4=UI)RROB<QL5/
MAQ9XS2,Y(SN;Q43DRUM0:5NUYJJZGJI65K-E@A#26^,3OR1VJVI:=S^S''DK
M74;[;G:]Z7N5KUWI#5%-/I^W445O@+J8P1@.8"UY:<^4"WB..54N22CO<=ON
M-;;+'9ZJ N %==,!D)'N@#Q.<C.-VY:SDWUE0Z7M.HJ6M@J97W*$11&$-(:0
MUX\;)'E#AE;'2&N;%#H2?2^J*&NEI3(7L?1EN3XP=@Y<,8/>K-9C<1'9*WK;
MEFT]]2L/++::630=HO<E);8;LZH$,TMNP8I 0_."..]HX\-X7,^3V]>Q_6-K
MN#G;,3)@R7\F[Q7?02?0K+K+75IO.AJ33]KMD]"VDJ0^)KG![>; <!DYSM':
MR=W;O7.5GCK/+,6:LMXYXM7]'HFBTG'1\MUQN\H:VWPTIN(<?<A[P6GZ1([U
M*N\DFI?#7*5J!E828;W'(0P_T3XK?0PN"B7'E8IZKD\=9V4M2V\RTC*.6I(;
ML.:-Q.<YWMSU<7%<[T?>3I_4]MNF'.;33![VLXN9P<!YR"5KK2TUGF_9MMEK
M6U>7QO<_U=LT4X<G^E[9%4X;/<[XZGD)W'8#C'GN\3/]Y?JDMHT9'REW@#8R
M_8ICPP7MVP!_>E8/0N=\K&O*;5U5;#:H*FEIZ,/?B4-!,CB"3XI/8/65M>4;
ME0I-3Z1CM=%25,%5))')5/D#0QVR-X&"2?&#>(X!3DM/>?ORSZM(W$3X\?V;
MCD;I::MY+M54U=5MHZ665S9*APR(VF-N7+G.M[!9;(VC-CU!%>#+M\X&,#>:
MQC'6>.3ZELM)ZRH;/H#4%BJ(*E]5<=KFWL#=AN6!OC9.>KJ"HBVUK,6F7/>]
M9I6OVNW(U8_#FO:!KV[5/2'I<N[=AGN?^8M7:S:;U?Y=<6V]43X+=7XZ!(][
M2W+6[(. 21DM8[UKCO)MK2WZ0L][S3U4EXK(^;@E8&[$>&G9R2<^Z.3@=06'
M1W*->;3J*DK+M=+G7T#"1-3OG<_::01N#CC(W'T+"]+6F9AMQ9*4K$3]^?\
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MGCV"ZF> Q_7C.VTXSOP1NR=ZT')YKF@TOJ:[U,UOE-IN&TWF8<%T3=HEH&2
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MZ%UE0Z?TGJ2UU<%3)/<XC'$Z(-+6DL<WQLD'BX<,I%;369GSV.?'%HB/'?\
MROG)5>(Z3DDO]3';*$OH=O:#F9%3ANU^^=O''<HVE*RBY1=-:HMTMIMM)=6Q
MB>E%- UN  , 'C[IHS_753Y--;6NPV:[V74-%45-MN&]QI\;0RW9(WD<1C>#
MNPMER<N#^5.DK=&6NNBLCCS,@FR<,V1MESLD<<.QGL2:ZYI*9-Q6-_I,,]TH
MZ/2_(E1">DIS=[S)MMD?&#(QAWY!(R/$#1WN7)%TCEXOC;GK(T%,X=$MD8IV
MAO#;XOQ]#?[JYNMN*)Y=S]M&:8YN6/$=A73D:DF9RCVCHQ:)'&1OC<,&-V<J
MEKJ'[GBU/K-;OKRT\U00.=M?TWC8 ]1=ZE<DZI*88WDKKV]$;%Q\NF]138N/
METWJ*G(O,>V@[%Q\NF]138N/ETWJ*G(@@[%Q\NF]138N/ETWJ*G(@@[%Q\NF
M]138N/ETWJ*G(@@[%Q\NF]138N/ETWJ*G(@@[%Q\NF]138N/ETWJ*G(@@9N+
M-Y;!(.QI(/TI'< '\W41NA?V.X'N*GK'/#'/&62M#FE!^F/#AD%?I:5SI+=.
M&/)="[W+OV+:T\S96 @H,J(B H% .?J:BI=O\;FV>8!3G'#2?,H=F'_DZ,]N
M3])0341$!$1 1$0$1$!$1 1$0$1$!$1 4&^6NFO5HJ[;7-VJ>IC,;L<1V$><
M'!'<IR)'8F-]I>,]8:;K=+7N>W7!ARPYCD \65G4X?\ [N.Y:5>RM7:6M>J[
M::.[0;6-\<K-TD1[6G]G K@FI^1C4%LE>^T<W=*7B-@AD@'G:3]1*[L>>+1J
MWEY6;A;4G=>\.8(MW/I+44#RV:PW1I'_ +(_'KPL7L9OOQ)<_P!$D^Q;^:/;
MFY;>FI1;;V,WWXDN?Z))]B>QF^_$ES_1)/L3<'+/IJ46V]C-]^)+G^B2?8GL
M9OOQ)<_T23[$W!RSZ:E%MO8S??B2Y_HDGV)[&;[\27/]$D^Q-P<L^FI1;;V,
MWWXDN?Z))]B>QF^_$ES_ $23[$W!RSZ:E%MO8S??B2Y_HDGV)[&;[\27/]$D
M^Q-P<L^FI1;;V,WWXDN?Z))]B>QF^_$ES_1)/L3<'+/IJ46V]C-]^)+G^B2?
M8GL9OOQ)<_T23[$W!RSZ:E%MO8S??B2Y_HDGV)[&;[\27/\ 1)/L3<'+/IJ4
M6V]C-]^)+G^B2?8GL9OOQ)<_T23[$W!RSZ:E%MO8S??B2Y_HDGV)[&;[\27/
M]$D^Q-P<L^FI1;;V,WWXDN?Z))]B>QF^_$ES_1)/L3<'+/IJ46V]C-]^)+G^
MB2?8GL9OOQ)<_P!$D^Q-P<L^DS3.M=0:9A?#9K@^&![MHQ.8U[<]H#@<'N7Y
MU+K*_:E8V.\W&2>%IVA$ UC,]NRT $]ZB^QF^_$ES_1)/L3V,WWXDN?Z))]B
MQU7>V6\FN7OIJ46V]C-]^)+G^B2?8GL9OOQ)<_T23[%EN&/+/IJ46V]C-]^)
M+G^B2?8GL9OOQ)<_T23[$W!RSZ:E%MO8S??B2Y_HDGV+],TO?WN#66.Z.<>H
M4DGV)S0<L^FG6>AI*BOK(:6CB?-43.#(XV#)<3U*[:?Y)M57:1O.T7@^ \9*
ML[)']WW7T+NO)_R=VK1T?.Q9J[DYN'U4C<$#K#!^"/I\ZU7S5K';O+?BX:]Y
M[]H2.3+2;-(:9BHW%KJV4\[4O' O/4/,!N]9ZU;$1<$S,SN7JUK%8Y8$1%&0
MB(@(B("(B B(@(B("(B B(@A7B 3T3SCQF>,/VK66*K+AL..]I(*WT@S&\'@
M00J5:Y2VYRL!W9_8%47<;PB_$)RP%?M14!XZ5<@P[XJ<!Q':X\%/4&U^,:MY
MXF8CU*<@(B("(B B(@(B("(B B(@(B("(B#5:ILE-J*PUEKK/>JAF X#>QPW
MM</.#@KR#J6QUNG;Q46VY1%D\1W'\%[>IS3U@KVFJ[K31]JU=0"GND1$K,\U
M41[I(SYCUCS'<MV'+R=I\.;B,'5C<>7CM%TK4O(YJ.URO=;F1W2E'!T)#7X\
M[">/<2J?-I34,+RV6Q71KAVTDGV+MB];>)>7;%>O:8:5%MO8S??B2Y_HDGV)
M[&;[\27/]$D^Q9;A.6?34HMM[&;[\27/]$D^Q/8S??B2Y_HDGV)N#EGTU*+;
M>QF^_$ES_1)/L3V,WWXDN?Z))]B;@Y9]-2BVWL9OOQ)<_P!$D^Q/8S??B2Y_
MHDGV)N#EGTU*+;>QF^_$ES_1)/L3V,WWXDN?Z))]B;@Y9]-2BVWL9OOQ)<_T
M23[$]C-]^)+G^B2?8FX.6?34HMM[&;[\27/]$D^Q/8S??B2Y_HDGV)N#EGTU
M*+;>QF^_$ES_ $23[$]C-]^)+G^B2?8FX.6?34HMM[&;[\27/]$D^Q/8S??B
M2Y_HDGV)N#EGTU*+;>QF^_$ES_1)/L3V,WWXDN?Z))]B;@Y9]-2BVWL9OOQ)
M<_T23[$]C-]^)+G^B2?8FX.6?34HMM[&;[\27/\ 1)/L3V,WWXDN?Z))]B;@
MY9]-2BVWL9OOQ)<_T23[$]C-]^)+G^B2?8FX.6?34HMM[&;[\27/]$D^Q/8S
M??B2Y_HDGV)N#EGTU326N!'$'(5CU+KC4.I*9E->+B^:G8<B)K&QM)[2&@9]
M*@^QF^_$ES_1)/L3V,WWXDN?Z))]BD\L]UCGB-0U*+;>QF^_$ES_ $23[$]C
M-]^)+G^B2?8KN$Y9]-2BW$>EM02.#8[%=7./4*23[%:M.\D6J+M(TU-*VVTY
MXR5+L.QYF#?GOPI-ZQYE:X[V[1"CVJW55VN,%#;X73U4[MAC&]9_8/.O76@-
M,0Z3TU36V,A\WOD\@_#D/$]VX >8!1-!:"M6CJ8]#:9ZZ08EJY!XSAV ?@CS
M>LE6U<6;+S]H\/3X;A^E_%;R(B+0ZA$1 1$0$1$!$1 1$0$1$!$1 42YTPJ:
M1XQX[?&;WJ6B#06:L)<8W'>#A;]IR,JEMDYB]R1MX9_:1^Q6^E=M1-/F52&5
M0)QTBY10G?'$.<<.T]2GJ#1[[C6D\1L#Z%%3D1$!$1 1$0$1$!$1 1$0$1$&
MIU58Z;4=@K+76;HZAF \#)8X;VN'<<%>0M1V2MT]=ZBVW.(QSQ'CU/;U.:>L
M%>TU7-:Z.M6KJ 07.(B9@/,U$>Z2,^8]8\QW+=AR\G:?#FXCA^K&X\O'B+I.
MI>1S4EKD>ZW1QW2F'!\)#7X\[#U]Q*J$VE-0PO+9;%=6N';22?8NV+UMXEY=
ML5Z]IAI46V]C-]^)+G^B2?8GL9OOQ)<_T23[%EN$Y9]-2BVWL9OOQ)<_T23[
M$]C-]^)+G^B2?8FX.6?34HMM[&;[\27/]$D^Q/8S??B2Y_HDGV)N#EGTU*+;
M>QF^_$ES_1)/L3V,WWXDN?Z))]B;@Y9]-2BVWL9OOQ)<_P!$D^Q/8S??B2Y_
MHDGV)N#EGTU*+;>QF^_$ES_1)/L3V,WWXDN?Z))]B;@Y9]-2BVWL9OOQ)<_T
M23[$]C-]^)+G^B2?8FX.6?34HMM[&;[\27/]$D^Q/8S??B2Y_HDGV)N#EGTU
M*+;>QF^_$ES_ $23[$]C-]^)+G^B2?8FX.6?34HMM[&;[\27/]$D^Q/8S??B
M2Y_HDGV)N#EGTU*+;>QF^_$ES_1)/L3V,WWXDN?Z))]B;@Y9]-2BVWL9OOQ)
M<_T23[$]C-]^)+G^B2?8FX.6?34HMM[&;[\27/\ 1)/L3V,WWXDN?Z))]B;@
MY9]-2BVWL9OOQ)<_T23[$]C-]^)+G^B2?8FX.6?34HMM[&;[\27/]$D^Q/8S
M??B2Y_HDGV)N#EGTU*+;>QF^_$ES_1)/L3V,WWXDN?Z))]B;@Y9]-2BVWL9O
MOQ)<_P!$D^Q/8S??B2Y_HDGV)N#EGTU*+;>QF^_$ES_1)/L3V,WWXDN?Z))]
MB;@Y9]-2K'8=;7^PVB:VVBO--2RO,C@V-I=M$ $AQ&1N X%0O8S??B2Y_HDG
MV)[&;[\27/\ 1)/L4GEGRL<]>\-4][GO<][BY[CDN)R2>U?%N&:7O[W!K+'=
M'$]0I)#^Q62P<E&JKM(WG*#H$!XRU9V,?W?=?0DWK'F2,=[3J(4BCIIZRJBI
MJ2)\T\K@QD;!DN)X +UER6Z1;I#33*:79=7SGG:IXW^-C<T'L W>L]:C\GW)
MS:M'LY]N:RYN&'54C<;/:&#\$?3YU=UQYLW/VCP]+AN'Z?\ %;R(B+G=8B(@
M(B("(B B(@(B("(B"+<H!44<C<>,!M-[PM-9*LA[HG'>W<K&J/32&.\RL!W;
ME81>&G(18Z<YB"**_4GO;NY1;-\'1>GZRI4GO;NY1;-\'1>GZR@F(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(/C_<.
M[E0K?\,3=_[ KZ_W#NY4*W_#$W?^P*PB]4_O063J6.G]Z"R'@HJ#:?<5/Y=W
M[%.4&T^XJ?R[OV*<A B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@HE6?_.)W?\ YG*YT'O#>Y4NL^Z)W?\ YG*YT'O#
M>Y64A)4&B_A]=WL^I3E!H?X?7=[/J45.1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%06_#LOH5^5!;\.R^A6$7BD]Y
M")2>\A%%9)/>W=RBV;X.B]/UE2I/>W=RBV;X.B]/UE!,1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0?'^X=W*A6_P"&
M)N_]@5]?[AW<J%;_ (8F[_V!6$7JG]Z"R'@L=/[T%D/!14&T^XJ?R[OV*<H-
MI]Q4_EW?L4Y"!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1!0ZS[HG=_^9RN=![PWN5,K/NB=W_YG*YT'O#>Y64A)4&A
M_A]=WL^I3E!H?X?7=[/J45.1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0%06_#LOH5^5!;\.R^A6$7BD]Y")2>\A%%9
M)/>W=RBV;X.B]/UE2I/>W=RBV;X.B]/UE!,1$0$1$!$1 1:34VH/ G1HX;5<
M[I55)<(X:&':X8R7/<0Q@WCB1GJRL.D]5TVHI*^F%)66^Y4#VLJJ*L8&R1[0
MRUVXD%I ."#U(+"BJNI=9QV6^P6B&S7:ZUTM,:O8H(V.V(P[9R=I[>M;JPW*
M2ZVYM5-;JVW/<XCH]8UK9!@\2&DC![T&P1$0$1$!$1 1<XY6-95FD[[HR.&J
MIJ6WW"X<S723AH:(@69.T?<[B=ZB5'*(*WE?TY8=/7:VU]FJZ69]2:61DV)&
MM>0-II./<C<@ZDBXK9>4F]'EPKM-W)\)L1J)*.G(C <R4,#VY=UYP1Z?,E'R
MDWJX<N\&GJ5T(TT:BHH_>P7/DA@+G^-YGD(.U(O+\'*[K!MAK;U[(=.R2TU:
M:9EFEB J9V[0 <UK3M$>-Q\Q7I:WU3Y[535=5"ZFDDA;+)$[C&2W):>[@@E(
MO/-/RH:P%GI=<5$E![%9[IT+P:(?WQD.2.<YSCM;CYL]2D7OE&UE.W5>I+'-
M;H]/:=KQ1FBEAVGU0#@USMOB.(.[J/FWC3OR*AZCGU?>Z2TUFC;C:K7:ZBD%
M5-4UD9DD;D!S0![G&#O/F/I^<BFK+CK'1?A"\QPBJBJ9*;GH6EK)PW'[XT>?
M..\'N07U%P^V:BY1M1:CUE'IVXVAL%CN$E/%2U5-OF:'.V6[0Z\-QE;^P\L5
MIGY/*34=YAE@JI:@T+J*F89))*@?@QCKR"#OX9QG/$.HHJ+9>5*P7*VWJJG;
M7VV:SQ\[6T==3F*>)N-QV,G.?VCM"SZ+Y0:/5<KA3VB]T$!I^E1U-?2\U#+'
MD#::_)!X@]R"YHN<6_EBT[6W"EB937:.WU=3T2FNLM*6TDTN<;+7YSO(ZPNC
MH"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B(/C_<.[E0K?\,3=_[ KZ_W#NY4*W_#$W?^P*PB]4_O060\%CI_
M>@LAX**@VGW%3^7=^Q3E!M/N*G\N[]BG(0(B("(B B(@(B("(B B(@(BKM%J
M^WU>M[AI6*.H%QHJ9M5(]S1S98[9Q@YSGQAU(+$BJ]GUO;+K7ZFI*:.J$NGW
M[%47L #CAQ\3?O\ <'CCJ6'D[Y0+-KRVUE;9ND11TLG-RLJ6ACAD9!W$C''U
M%!;D7-;5RS::NEBU!=Z2&XFDLHC-03$T%X>XM:6#:W[QUX6;37*]I^^7BAMC
MJ:[6VJKQFDZ?2&)L^[(V7 D'(X=2#HB+7Z@O%%8+-5W6ZS"&BI6&21^,[NP#
MK). !VE5'2G*M8-0SU4#H[A:YJ>E-=L7*#F><IP,F5N\Y;C>@OR+GNDN5K3^
MI;W36RF@N=))6->ZBFK*;FXJL-SGFW9.>![.';N6+4?+#8+%=JRBJ:*]314,
M@AJZR&B)@@<<;G.)':. W]64'1T6NK[S24>G:B][1FH(:5U9M1#)?&&;>6YX
MY'!4&T<MVEZZ2DZ5!=[73U;MF"KKJ38@D/#<\$CT\$'3T7XDFCB:'22,8T[@
M7. !7U[V,87O<UK!O+B< (/TB_+'LD8'QN:YAX.:<@KY%+'*TF*1CP#@EISO
M0?M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$04.L^Z)W?_ )G*YT'O#>Y4RL^Z)W?_ )G*YT'O#>Y6
M4A)4&A_A]=WL^I3E!H?X?7=[/J45.1$0$1$!$1 15_4D.IJFJ@AT]56NAI=@
MF:IJH7SR;6=S6Q@M&,=9=Z%!Y/K_ '&[.O=OOC:8W&SUG19)Z5I;%,"QKVN
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MRO,DDTCO=/>X[W./:@_=\K;C1QQ&UVHW%SB0]HJ&1; ZCXW%:GPWJ7^2+_\
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MT9!FZ2_S>I.DO\WJ6%$&;I+_ #>I.DO\WJ6%$&;I+_-ZDZ2_S>I8409NDO\
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MK$:RUQ4-PDHXJC+FRP-JV-A+@?=-#"",]C3U!!V 7>A-U\&BI9TSF14<WG\
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M@?XIVCM-(R-^_@5IG:DU'-I.LUE355&VW0&69EL=3Y+Z>-[FG,NUD/(:2,#
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MFQ&1Z5>56-9?"ND/SO\ _:U"#-0>RKID73_ ?1=K]\YCG=O'FSNRK"B("(B
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M89;<TMG#TFE1$1:F\1$0$1$'(]4_?\TC_8*OZBNE+FNJ?O\ FD?[!5_45TI
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M$6AU"(B B(@+E_[I7[TMR_+T_P"M:NH+E_[I7[TMR_+T_P"M:A"^C@%]7P<
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M87S,#<\<Y'4!O)7I>A,AHJ<S^^F-NW_6QO7/N3#1%/5VRVWRLD:^*IB94,A
MWG.\!Q[.&X>LC<NJ]'C[/I3+>+>&OX/@,O"UM;+VF==D)%-Z/'V?2G1X^SZ5
MJ>\A(IO1X^SZ4Z/'V?2@A(IO1X^SZ4Z/'V?2@A(IO1X^SZ4Z/'V?2@A*L:R^
M%=(?G?\ ^UJ%=.CQ]GTJK:T@8+MHW XWG''_ -DJ4&\13>CQ]GTIT>/L^E!"
M59N6ES'6RW+352+5<Y#M2@-VJ>J/_>Q[LG^FW#O.>"N?1X^SZ4Z/'V?2@IMK
MU0.FQVS4%,;5=GG$;'NVH:D]L,FX._JG#AV=:LJ_5TLUONM#)1W*DBJ::0>-
M'(,@^?S'S]2K)H+SI4[5")[]9!QII'YK*<?]V\G$K1Y+L.['.X(+(JO0??*O
M7YJH_P!;4K=4FH[#56>6Z15T8I(3LRE^6OB=Y#V'QFN_HD95$H]<6%FN;C<'
MFI;1U%%3TS'\WP=&^9SB1G.,2-QU\=RL5F?#GS<7AP3%<MXB9]NDHLMOFHKC
M21U5#*R>GD&6O8[(*D='C[/I4;XF+1N/"$BF]'C[/I3H\?9]**A(IO1X^SZ4
MZ/'V?2@A(IO1X^SZ4Z/'V?2@A(IO1X^SZ4Z/'V?2@A*L:&XZA_.]1_E6'6FO
M:#3]8ZAI:8UE8SWP;>RR/S$[\GS*L:&UY04E56PW6F="VNK'U//,=M-C+\;B
M..!CBLXQVF-Z>??Y7A*9.E:_?_OWX=413&0PO:',PYI&00<@A?>CQ]GTK!Z"
M$BF]'C[/I3H\?9]*"$BF]'C[/I3H\?9]*"$BF]'C[/I3H\?9]*"$BF]'C[/I
M3H\?9]*"$BF]'C[/I3H\?9]*"$BF]'C[/I3H\?9]*#\47!_H4A?F.-K,[(QE
M?I 1$0%06_#LOH5^5!;\.R^A6$7BD]Y")2>\A%%9)/>W=RBV;X.B]/UE2I/>
MW=RBV;X.B]/UE!,1$04346H+E!RI:<L5)4,AHJB!\TX<P'G/=8 )W@^)U=JN
M%XDDBM%=)!*(9F0/<R0@$,<&G!(.[<JQRB:(9JN.DJ*6L?;[M1$NIZEF=W7@
MXW\0""."IT^@^4*ZPFAO.K:?P<_Q9.:<YSG-["-AN>XE;8BMHCOISS:]9F-;
MWX7?DKOU7J/15%<;D6NJW.D8]S6AH=LO(!P.&["MBUFF;+2Z>L=):Z$.YBG;
ML@NXN).2X^<DDK9K"TQ,SINI$Q6(MY43E1M&IKY'0T-B90R6ASBZX0S53Z=]
M0T<(]IK7$,/X6,$C=GBL]#)K2*SUL#++IZAFAIMF@CBJY)(ML8 :YNPW9;CL
M\RNB+%DH=QLVI*#4<>H['!;:JLJZ&.DN5#-.Z%CGL)+9(W[+N!<X8(WC'6MI
MH#3]99:6Y5-XE@EN]UJW5M48,\VPD!K8V$[R&M:!D\=ZM"("(B#EVI_XP&B_
MS=5_45U%<NU/_& T7^;JOZBNHH"(B B(@(B("(B B(@(B(/S(';#N;+0_!V2
MX9&?.J/J:OUC8K%5W)U9I^84[0XQBAF;M9(''GO.KTJMRH_<#>/R;?\ K:@E
M4$.J6U<1KZZR24H/[XV&BE8\CS$RD ^@K?HB B(@(B("JNH_NXTA_7J_U*M2
MH^HKQ;3KG3 %?2_\.^I$W[ZW$9,6 ';]V3N36V-KUI_-.EX1&D. +2"#O!'6
MB,A$1 1$0%5M/?=UJWNH_P!6Y6E5;3WW=:M[J/\ 5N06E$1 1$0$1$!$1 6*
MJIX:NFFIZF-LL$S#'(QPR'-(P0?,05E1!S/7VA],T5@BEI+'0PRFX4,9<R/!
MV7U<37#N+20?,598= :4@F9+#8+>R1C@YKA$,@C>"OSRE_<U#^<[=_C85:4!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$'Q_N'=RH5O^&)N_]@5]?[AW<J%;_AB;
MO_8%81>J?WH+(>"QT_O060\%%0;3[BI_+N_8LEUKH;9;*NOJMKF*6)TTFR,G
M9:"3@=P6.T^XJ?R[OV*9+&R6-T<K&OC>"US7#((/40JGTYO[=.D_+KOT?_\
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MXK=%GHD!' D'?*X>4[=V-"T_(S%)';*\N&&.D81NZ\'/T;)]*Z(M-HU.GTO
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M B(@K7*']S/_ +[1?XJ)655KE#^YG_WVB_Q42LJ B(@(B("(B B(@(B("(B
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M>:>"WN:Z:!P;L.#MX#79W^EOK5NY1-*:EN>J[7>M+5='2ST=.Z(/G.\$EV<
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MWIQT^0X;)?I5O$RLZ(BQ=@B(@(B("(B B(@(B("(B B(@(B(/C_<.[E0K?\
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MUD=2L<MQIHS4Y94GF(FS.Q%G(=P [3YEEJ=,6*JI(J:LL]OJ88V!C6ST[),
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M76ZBKPP5]'3U(9G9YZ)K]G/'&1N5)M]BM!Y4;W";50&)MIHW-8:=FR"9:C)
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MOL=2XAK)I'[=)*?Z$^  3Y+PUWF*Y7W*UHC2' %I!!W@A$!$1 1$0$1$!$1
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MBMMLHZ&G&(::%D+!V-:T ?0$$E$1 1$0$1$!5WE'^]]J?\V5/ZIRL2KO*/\
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MJ6MM.CK3%<?!S"^LED!(&/= 8(X<.LDYP-RZ:3N-:^O;BO&IFT6^_7Z-MR%
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M4U5?V1R&YU$8A?(YY(#=VX#@/<A<VU3RHTWLCL(MTERAHX:B05T9IR.=;@8
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M101B-H)XG &%)0$1$!$1 1$0$1$%8Y1ON<A_.5O_ ,9"K.JQRC?<Y#^<K?\
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M_P#8%?7^X=W*A6_X8F[_ -@5A%ZI_>@LAX+'3^]!9#P45!M/N*G\N[]BG$@
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MIRL"K_*']P.I?S;4_JG+F=S<6_\ @%-^2;]2D*/;_P" 4WY)OU*0@(B("(B
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M7OB=LET-KJ)&'N<UA!'G!06%570__E"HO-_=O%PJ3%3G_P!GARQF/,7<X_\
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M%OLM)T:U4<-+#G:(C;@N/:X\7'SG)4RX^2=,L&;JUVT70=1WW?<ZH6*A=_\
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MW +IS6K-9AQ\-2\7B?K2Y(B+C>B(B(*'6?=$[O\ \SE<Z#WAO<J96?=$[O\
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MUS=);ZP.9!3U0,LE(6XSS<A.2S!QLNSC=@XW+JBYMRWVJ:KLU'7PM+Q1O<)
M.IK\;_06CUK.D1-HVX?D[Y,?"WMB\Z_]_P"')XK]=HKB*]EQJ^F8V>=,I+B,
MYP<\1GJX+NO)OJ=^I;*Y]4&BMIW".79& [/!V.K._P!(*\\-:Y[@U@+G$X
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MLI"2H-#_  ^N[V?4IR@T/\/KN]GU**G(BTVLK94WG2]RMU#*V*IJ(BR-[B0
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M'/<P.=@YW[W'/GRMMRE2.;H6\QQG#ZF#HC3YY2(Q]+U8XHVQ1,C8,,8 T#L
M052CUS35T!EI++?Y8@]\9<VA.-IKBUPX\001Z%YFO-%/;KI4TM5%+%*QY\25
MNR[!WC(ZMQ"]/\G'W.S?G&O_ ,7*J_<-.4'*'?ZNLJF%EJH0ZC@GAPU]3*'>
M.[:P<L81LCJ)V_,MV')%)[N;B<$Y8[>8>>:.G?53MB9U[W.QN:.LE>LM$44M
MNTG:Z6H:YDL< VF.XLSOV3W9QZ%4.3+1EHIHZNK=$^>>FN-3!&92" (IG-:X
M@  G#0<G.#PPNEJYLL7[0QX;AYQ;FWD1$6AUB(B B(@(B("(B B(@(B("(B
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M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$05E_WRXOS0_P#7-5F59?\
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M5?4%U+/+&VC@#LMCC;& 3YBYY=GS *N>V]H3^45/\W)_I3VWM"?RBI_FY/\
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M[5MV_G(U;^D!=11!R[VK;M_.1JW](">U;=OYR-6_I 7440<N]JV[?SD:M_2
MGM6W;^<C5OZ0%U%$'+O:MNW\Y&K?T@)[5MV_G(U;^D!=11!QB^Z#O%LJK+"W
ME"U9(+A6BD)-5C8'-2/VN&_WO&/.MM[5MV_G(U;^D!6?6_PGH_\ /(_PU0K4
M@Y=[5MV_G(U;^D!/:MNW\Y&K?T@+J*(.7>U;=OYR-6_I 3VK;M_.1JW]("ZB
MB#EWM6W;^<C5OZ0$]JV[?SD:M_2 NHH@Y=[5MV_G(U;^D!/:MNW\Y&K?T@+J
M*(.7>U;=OYR-6_I 3VK;M_.1JW]("ZBB#E=JT94T&KF4,VKM2U-4:!\PJWSQ
M%P9SC1S>'1NW9WYRNA6.URVN*5DUUN%R+W A]88R6>8;#&[N_*U;_OEQ?FA_
MZYJLR B(@(B(*'6?=$[O_P SE<Z#WAO<J96?=$[O_P SE<Z#WAO<K*0DJ#0_
MP^N[V?4IR@T/\/KN]GU**G(B("(B B(@T>O 7:'U$&@DFW5  '7^].6JM5]H
MM,<EUCN5W=+'2PT%(QY9&Y[@7,8T>*-_$A7%.*#F%-?*#0^N=5^R*9]'17:2
M&OHJET;G,EQ$&2,R ?&!8/%XD$+<<D5)4Q:>K[A64\M,^[W.IN3(96[+V1R/
M\0.'4=D X\ZNY /$(@CU-#253@ZJI8)G 8!DC#B!Z5A\#VWXNH_F&_8IR(*5
M2VBV^V7<AX/H\"T4QQS+>)FGR>'F'J"L_@>V_%U'\PW[%IJ7[YMR_,]+^NJ%
M9T$'P/;?BZC^8;]BK6L.3NS:B8Q[88J.K8-ELL43<$=CF]:N:*Q,QWAKRXJ9
MJS3)&XERBS\CM'3U(?<*J&:('W,4&RYWI)W>K/G71H;%:8(6116RB;&QH:UH
M@;N ]"V**S:;>6OA^$Q<-&L4:0? ]M^+J/YAOV)X'MOQ=1_,-^Q3D6+H0? ]
MM^+J/YAOV)X'MOQ=1_,-^Q3D00? ]M^+J/YAOV)X'MOQ=1_,-^Q3D04ODRMU
M%4\GVGIJBCII9I**)SWOB:YSCL\22-Y5F\#VWXNH_F&_8M)R5?>XTU_8(O\
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M3LN\H+:Z;J[Q64LK[_:H+9.U^&1PU?2 YN..=EN-^=R#;(B(/C_<.[E0K?\
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M&\K7:+U'<;C=[U9+_24L%UM9B<^2D>YT,T<H):YNUO!\4@@H+:B(@(B("(B
MB(@(L-;4LHZ.>IE;(Z.&-TCFQL+W$ 9W-&\G=P"J.@]7U^H[Y?Z*X6AUK;0-
MIY(8Y7YF<R4/(,@&YIPT'9ZLX.]!8S:V'43;MSKMMM*:7F\;L%X=G/H6Q7/*
M346LKU<KVW3]#8.@6^ODH0^LGF;(]S TDX:TC'C8]"Z!!SG,Q\^&"79&V&'+
M=KKQYD'[1$0$1$%#K/NB=W_YG*YT'O#>Y4RL^Z)W?_F<KG0>\-[E92$E0:'^
M'UW>SZE.4&A_A]=WL^I14Y$1 1$0$1$!$1 1$0$1$'X$48F=,(V"5S0POV1M
M%H)(&>S>?65^US^NJ[[J36UWL]FO+K+06:*'GIHJ=DLD\\K2\#QP0&M:!P&2
M3Q6VY.;Y6WFSUD5W,3KI;*V:W54D3=ELKXSN>!U;32TX\Y06I$1 1$0$1$!$
M1 1$0?B"&.GA9%!&R*)@V6L8T-:T=@ X+]J@ZMH]245'=KO)K6.VP4[7RT\#
M:&+F6M&2ULA?ESB<8)!'F"LVC;E57G2=GN5PI^C5=72QS2Q8(V7.:"< [P$&
MX1$0$1$!$1 1$0%^)(8Y71NEC8]T;MMA<T'9=@C([#@D9\Y7[6DUM?V:8TM<
M;N^(SNIHQS<0..<D<0UC<^=Q:/2@W:*DZ19=9KDR6ZZRIZ^LC:356JCC@$,1
M(]SN!D\4GB7;\*[("(B B(@(B("(B OQ'#%&^1\<;&/E=M/<UH!>< 9/:< #
MT!?M<ZCJ=1:LU'J*&U7XV2AM%0**)D5+',^:78:]SY-L'Q?&  &,]J#HJ*L\
MG5_J-1::94U[(F7"GGEHZH0^X,L3RQQ;YCC([U9D!$1 1$0$1$!$1 7X@AB@
MB;%!&R*-O!C&AH'H"Y]<+[JB'E+L%%4,IJ&PUD]3 R%N)):@1PN<)'._ &0,
M-&_CGL5AU#:=07*X-\&ZB\$6]L8\6"D9),^3)R2Y^0&XQN#<\=Z"QHJ?R8WN
MXWFT7)EXEBJ:JVW&>WFKB9L-J1&0!)LC<#OP0-V05<$!$1 1$0$1$!$4"_5%
MPIK5/+9J)E=7@ 10/E$;220,N<> &<GKP-V]!,EBCEV.=C8_8<'MVF@[+AP(
M["OVJ3R57:\76W7QNHJJ&IK:&[U%'MPQ"-@:P-W-''&2<$Y/:J[R=5FH-3VR
MV72?7C6R5!,SK:RCIB1&'G#<XVM[0-_'>@ZPB(@*@M^'9?0K\J"WX=E]"L(O
M%)[R$2D]Y"**R2>]N[E%LWP=%Z?K*E2>]N[E%LWP=%Z?K*"8B(@(B("(B B(
M@(B("HO+>QSN3:Y2-:7,@EIYY !G][9.QSO4 3Z%>E^)XHYX9(9XV212-+'L
M>,M<T[B".L(*#RIS1U;]$4]+(V2>HOU+/#L'),; Y[WCS!O7YPN@JM6#0VF]
M/W#IMHM<4%4&%C'E[WF-IXA@<2&#S-PK*@(B("(B B(@(B("C7&*2HHIJ>"K
M?23RL+8YV!I=&<>Z <""1QW@A25JM1Z=M6HZ6.GO5&VIBB?SD?C.8YCL$9:Y
MI!!P3P*"@6BCJM-\KE#37&Y.O]3=Z&8-JJAH;/1LC+7;.&X8(W$]30=H<2NJ
M+1:<TC8M.333V>WL@J)@&R3N>Z65S1U%[R78\V5O4!$1 1$0$1$!$1 7);/8
M7W?E-UY%67BY4.)J65D-#.:=\C#  UY>/&+00X  XSG.5UI:'4>C[#J.>*>\
M6]D]1$TL;,V1\3]D\6ES""6^8G"#4\D]SK;CI^NCN%6ZN-!<JFAAK'XVJB*-
M^&O)&XGJ)''"NBBVNW4=JM\%#;::*EHX&[,<43=EK1Y@I2 B(@(B("(B B(@
MT&N-.^R:Q=#CJC1U44T5535 9M\U-&X.:2WK&1O'G5!O4.H*WE%T30WJXVZ>
MIIZB2N=36Z%S&QQ,B<TRR%SB=[G-:!N&]W'JZG=;?376WS45<QTE-,-E[6O<
MPD9S[II!'#J*U^G-+673AG=9J!E/+/CG92YTDDF.&T]Q+B/,2@W2(B B(@(B
M("(B B(@H/(O/%3<E5NGJ)&10Q.JGOD>X-:UHJ)222> 6.VLGU[?Z"]S1O@T
MO;)3/;HWM+7UTV"T5!!]S&T$[ XG.UPP%:3IBS'3;[ :&/P.\.:ZFVG;)#G%
MYWYSO<2>*TE-R6Z-IIHI8+(QDD3@YA$\NX@Y'X2"Z(B("(B B(@(B("HO*M[
MK1G_ /D=)]4BO2AW*UT=SZ)TZ!LW19VU4.21L2MSLN&.S)0:;56DJ34=RMU9
M+<;E0U= R5L3Z&<1.V9-D.R<$_@#AA:;D^K;A3ZMU1IRJND]WHK8*>2"JJ-D
MRQF1KBZ)[@ '$;((.,X.]6'4FD;)J.:":\47/30-+8Y62OB>T'B-IC@<>92]
M/V&UZ>H>AV6BBI*<N+W-C&]SCQ<XG>X^<DE!LD1$'Q_N'=RH5O\ AB;O_8%?
M7^X=W*A6_P"&)N_]@5A%ZI_>@LAX+'3^]!9#P45!M/N*G\N[]BG*#:?<5/Y=
MW[%.0@1$0$1$!$1 1$0%0*V1EOY;J&>K>V.*X6-]+3O><!TL<X>Y@/;LNSCS
M*_K77VR6N_471+W04U=3;0<(YXPX!W41G@?.$%0T;*ROY4M;U](X24D4='1&
M1ARUTK&O<\ ]K=MH/>N@*':+506:ACHK31P4=(SW,4# QH[3@=:F("(B B(@
M(B("(B JUJNT4^HXW4S-17*UOI@YLO@VK;$X;0!\?<2,#>.'%655V\Z(TQ>Z
MYU;=K#;JNK=@.FD@!<[ P-H]>X=:#1<B53SFDZNCB%.^DMMPGHJ:I@8&,JHV
M.&)<#<223DCB02K^L-%24]#2Q4U%!%3TT0V611,#&M'8 -P69 1$0$1$!$1
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MH-0ZLM]AN]HMU:VH-1<Y.:@,; 6@[36^,21C>X=JU&I>4NQV&]FU3MK*JK8
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M!N'1Y/\ I*X=R4<H5CTIH>>EKY)GU_2'RLIXXG$O!:T#QO<C>#UKOK@'-+7
M$$8(/6HD-KM\,@DAH:6-XX.9"T$>G"UUM$1,3#?>EIM%JSIRKDNH;M8-$ZGU
M%/2.97UH?504[VD$AC7$$CC@EQW=@\ZH%\U#/?\ 0DLURU/5UETEDRZUQP!L
M4;6O]TXAN,8P<]I [5Z@4.*U6^'GN9H*2/GMTNS"T;?];=O]*RC+&YF8:[</
M/+%8GLX[K6EDM6F]!ZQHV$S6VGIHYP/PHRQI /F]T/[ZS\G=MHG<GNH]0:KV
MQ#>GO?4/:"7"(.(R,;_=%Q] 5AY0M/:IU+.;)0/M]'IE_-E\N_G<-P2W'8"
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M4_A/KZAQ^EY6[#DBD[EJRTF\:ACY&;3J"UZ2LHKKO25UNFIA4X?3R=(!E&V
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MDCU(*EX6NO8[Y2>%KKV.^4K;T"+R1ZDZ!%Y(]2"I>%KKV.^4GA:Z]COE*V]
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)$!$1 1$0?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g50309g89f08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g89f08.jpg
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ME<(D=(*S0U9DHM/P)41%8X2TP^$X=H.CU":%I/$8)T?_Q  ; 0$!  ,! 0$
M             0(#! 4'!O_$ #81 0 " 0$' 04&!P$! 0$    ! A$#!!(3
M%"$Q44$R4F%QD14B,Z&QP046-('1X?!3!D(C_]H # ,!  (1 Q$ /P#ZI1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1%AK:NGH:26JK)F04\32]\C
MS@-'64&98:JJIZ2/;JIXH&>5(\-'M*X#KSAGK:R66DTKFDI!WO*GMS+)Z6@^
M]'U]BY+75U57SNGKJF:IF=SOF>7N/SE=--FF>L]'%J;96LXK&7V,=4V $@WR
MU@C_ +7'^*_/=5I_Y=M?[7'^*^,D6?+1Y:N>MX?9ONJT_P#+MK_:X_Q3W5:?
M^7;7^UQ_BOC)$Y:/)SUO#[-]U6G_ )=M?[7'^*>ZK3_R[:_VN/\ %?&2)RT>
M3GK>'V;[JM/_ "[:_P!KC_%/=5I_Y=M?[7'^*^,D3EH\G/6\/LWW5:?^7;7^
MUQ_BGNJT_P#+MK_:X_Q7QDB<M'DYZWA]F^ZK3_R[:_VN/\4]U6G_ )=M?[7'
M^*^,D3EH\G/6\/LWW5:?^7;7^UQ_BGNJT_\ +MK_ &N/\5\9(G+1Y.>MX?9O
MNJT_\NVO]KC_ !3W5:?^7;7^UQ_BOC)$Y:/)SUO#[-]U6G_EVU_M<?XI[JM/
M_+MK_:X_Q7QDB<M'DYZWA]F^ZK3_ ,NVO]KC_%/=5I_Y=M?[7'^*^,D3EH\G
M/6\/LWW5:?\ EVU_M<?XI[JM/_+MK_:X_P 5\9(G+1Y.>MX?9ONJT_\ +MK_
M &N/\4]U6G_EVU_M<?XKXR1.6CR<];P^S?=5I_Y=M?[7'^*>ZK3_ ,NVO]KC
M_%?&2)RT>3GK>'V;[JM/_+MK_:X_Q3W5:?\ EVU_M<?XKXR1.6CR<];P^S?=
M5I_Y=M?[7'^*>ZK3_P NVO\ :X_Q7QDB<M'DYZWA]F^ZK3_R[:_VN/\ %/=5
MI_Y=M?[7'^*^,D3EH\G/6\/LWW5:?^7;7^UQ_BGNJT_\NVO]KC_%?&2)RT>3
MGK>'V;[JM/\ R[:_VN/\4]U6G_EVU_M<?XKXR1.6CR<];P^S?=5I_P"7;7^U
MQ_BGNJT_\NVO]KC_ !7QDB<M'DYZWA]M45TM]<<4-=2U)_\ <S-?]A6XOAIC
MW1O#F.+7#>"#@A7_ $=PK:@T_*R.JG=<Z ;C#4N)<!_=?SCY\CT+&VS3':6R
MFVQ/M1A]3(H32.I[;JJU-KK5-M-YI(G;GQ.ZG#_R"IM<TQ,=)=L3$QF!$111
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$18JNIAHZ:6HJI60P1-+WR/.&M YR2@RK%4U,%+'QE3-'#'Y4C@T>T
MK@NO>&BJJ)9:/28Y/3CO362-S(_TM:=S1Z3O[%R*XW"LN509[A5SU4QYWS2%
MY]I7139YGK/1QZFV5K.*QE]B.U18&G#KY:P>HU<?XK\]U6G_ )=M?[7'^*^,
MD6SEH\M//6\/LWW5:?\ EVU_M<?XI[JM/_+MK_:X_P 5\9(G+1Y.>MX?9ONJ
MT_\ +MK_ &N/\4]U6G_EVU_M<?XKXR1.6CR<];P^S?=5I_Y=M?[7'^*>ZK3_
M ,NVO]KC_%?&2)RT>3GK>'V;[JM/_+MK_:X_Q3W5:?\ EVU_M<?XKXR1.6CR
M<];P^S?=5I_Y=M?[7'^*>ZK3_P NVO\ :X_Q7QDB<M'DYZWA]F^ZK3_R[:_V
MN/\ %/=5I_Y=M?[7'^*^,D3EH\G/6\/LWW5:?^7;7^UQ_BGNJT_\NVO]KC_%
M?&2)RT>3GK>'V;[JM/\ R[:_VN/\4]U6G_EVU_M<?XKXR1.6CR<];P^S?=5I
M_P"7;7^UQ_BGNJT_\NVO]KC_ !7QDB<M'DYZWA]F^ZK3_P NVO\ :X_Q3W5:
M?^7;7^UQ_BOC)$Y:/)SUO#[-]U6G_EVU_M<?XI[JM/\ R[:_VN/\5\9(G+1Y
M.>MX?9ONJT_\NVO]KC_%/=5I_P"7;7^UQ_BOC)$Y:/)SUO#[-]U6G_EVU_M<
M?XI[JM/_ "[:_P!KC_%?&2)RT>3GK>'V;[JM/_+MK_:X_P 4]U6G_EVU_M<?
MXKXR1.6CR<];P^S?=5I_Y=M?[7'^*>ZK3_R[:_VN/\5\9(G+1Y.>MX?9ONJT
M_P#+MK_:X_Q3W5:?^7;7^UQ_BOC)$Y:/)SUO#[-]U6G_ )=M?[7'^*>ZK3_R
M[:_VN/\ %?&2)RT>3GK>'V;[JM/_ "[:_P!KC_%!JK3YYK[:_P!KC_%?&2)R
MT>3GK>'V[1W"CKFDT573U '3%(U_V%;*^'()I:>5LM/*^*1N\/8XM(["%TK1
M7#!>K++'#>7NNM!S'C#_ #S!UA_3V.]H6%MFF/9EMIMM9G%HP^F44;IZ^4&H
M;7%<+54-FIW[MVXM/2UPZ".I22YIC#LB8F,P(B(HB(@(B("(B B(@(B("(B
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MK[&X0+6Z\Z+O%!&-J66G<8V];V]\T>T!?'*[=FG[LP\S;8^_$_ 1$72XA$1
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M(B B(@(B("(B J3J[QHSUON"NRI.KO&C/6^X*PDI^Q> 9V*7418O ,[%+J+
MH^]_!F?I I!1][^#,_2!($@B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B"DZM\:M]
M8?NA6&R>";V*O:M\:M]8?NA6&R>";V*I"51$45J7;Q?-V?>LU)\%A]1OV+#=
MO%\W9]ZS4GP6'U&_8@RHB("(B B(@(B("(B B(@(B("(B B(@(B("(B#7FHJ
M::JAJ986.GASQ;R-[<\^%CBM=#$:HQTL3359X\@>$SG.?:?:MQ$&DZU4#J!M
M"ZDA=2-][$6Y:-^=WM*_+;:+?;-OD%)%"7[G%HWD=JWD01+=.6=IE+;=3#C1
MA_><^_/S?,MR6W4DTM-)+3QN?3>!<1O9S<WL"VD0:XH:85QK1 SE1;L&7'?;
M/4M'4MH[L4+(V2\340R-EAEQG9<%+(@C:VRT-R$;[G203SM:&E^/J!Y\9RLI
MM5 :#D/)(>2<_%!N&\^5NH@CJ*QVRAG$U'10PR@$;36X."OTV6W&AY&:.'DN
MUM\7L[MKK4@B#5=;Z1U13SNIXS-3C9B?C>P<V M%EG>_4K[K52M>&1<53Q@>
M\'22>LY/M4PB#6KJ"EKFQMK(&3"-VVT.&<'K6RB((NJT]::NI-146^!\Q.2X
MMYSZ>M9[A::"X1QQUM)%,R/W@</>]BW40:E);**DD<^EI8H7.8&.+&XRT<P7
MB.T4$= ^B920BD><NBV>])Z_J"WD08Z:"*E@9#3L#(F##6CF 6*6@I9:V*LD
M@8ZIB&RR0C>T;^;VE;*(-9U#2NKFUKH&&J:W8;+CO@.KZRL9M5"751-+%FJ&
M)SCPG:MU$&*FIXJ:G9!3QMCA8,-8!N 6C!8+5!5\JAM].R<'(<&<QZP.8*31
M!K.H:5U<RM= PU3&[#9<=\!OW?65^0VZDADJ7Q4\;'U.^8@>_P"?G]I6TB#0
M[CV_D+:/D</)6NVQ%L][GK2DLUNHZM]32T4,4[LY>UN#OY\=7S+?1!K4U!2T
MTU1+! R.2H.U*YHWO._G]I6.&U4,-#)1Q4L3:60DOB [TY__ ++=1!CIH(J:
M!D-.QL<3!LM:WF 4=/IRSSS/EFM].^1[BYSBW>2><J51!'U-EMU52Q4U11PR
M0Q#$;2WW@]!YPL]OM]);H##0P1P1D[1:P8R>LK91!J4EMHZ.>:>EIHXI9CF1
M[1@NWYWK7KK#:Z^?CJNA@EEZ7EN">W'.I-$&I/;**HA@AFI8G10$&)A;N9CF
MP%JSZ=M$]6ZIFM\#YG.VG.+><]9',5*H@    # '0H"#3D4=PN1EXN:W5I$K
MJ=[?>R \X]!4^B#5GMU)/R;CJ>-_)R##D>\(YL>P+\[FT?&53^3Q[=4W9F./
M"#&,%;:(-!UFMSJ%E&:.$TK';;8MG<#OW_65K7&SON%[H*N>5O):/+V0@;W2
M=9/4-RF$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$%(U7XV9ZQ^P*Q63P+>
MQ5W5?C9GK'[ K%9/ M[%4A*HB**CY_'--ZA^]2"CY_'--ZA^]2" B(@(B("(
MB B(@(B("(B#7J:*FJ9H):B%DDD#MJ)SAO8>L>P+S%;J.*IGJ(Z>-L\XQ(\#
M>\>E;2(-)EJH&T!HA20\D._BBW+?8O%MLMNMDCGT%'%"]PP7-&\CJRI!$$4-
M.V@2RR"W4^W*"''8Y\\_9\RVI+91R"E$E-&[DN#!D>#QC&/8%MH@UC0TIKA6
MF!G*@W8$N.^QU+3U):!>;=Q DXJ9CQ+%+C.P\<Q4JB",J[+17*.%UUI8*BH8
MP-+]G';CIQG.Y9NY5 +>:$4D(I#O,0;AIWY^T+=1!&T5BME%.)J2AABE (#F
MMP<%>NXMNY#R/D</)=K;XK9W;76I!$&JZWTCJBGG=3QF6G&S$[&]@YL!:,=G
M>[4K[K52M?L1<53Q@>\'22>L[_:IA$&M+04LM;%62P,=4Q##)"-[1OYO:4K:
M"EKN*Y7 R7BG;3-H>]/6%LH@CKA9+;<9A+6T4,TH&-MPWX[>E9*RU4-921TM
M32Q24\> QA;N;@8&.K<MU$&@+/;Q'2L%)%L4IVH1CP9SG(^=9*FW4=35PU-1
M31R5$/@Y'#);OSN^=;:(-"XV>WW)['UU)%.]FYKG#>!U=BS4E!2TCI74M/'$
M9<;>PW&UCF6RB"/H++;K?4/GHJ.*&5X(+F#&[J]"Q'3EG-5R@VZGXW.UG9W9
MZ\<RE40:5RM5#<@SE]+%/L>]+QO'SKW1V^DHI)7TE-%"Z7&WL-QG',MI$&M5
M4-+5RP2U,#))(';<3G#>P[MX]@6PYH<TM< 6D8(/2OU$$3'INS1ME:VVTP$G
MON]Y]^?F^9;L%!2P5<M3# QE1* 'R ;W8ZULH@C[C9K=<I625U'%-(P8#G#?
MCJ6=M!2MK>6-@8*G8V.,QOV>I;*((Q]AM3ZM]4^@IW3OSM.+>?/.<=?I66*T
MT$,M/+%21-DIV[$3@-[!OW#VGVK>1 6M3T-+3U,]1! QD\WA'@;W=JV40:L%
MOI*=]2Z&GC8ZI.9B![\[^?VE>8[70QT#J)E-&VD=G,0'>E;B(,<$$4%.R"&-
MK(6-V6L W =2T*:P6JFJ^4T]!3QS@Y#@WF/HZOF4FB#7Y#3<NY;Q#.5;.QQN
M.^V>I>(;;1PMJ6Q4T;14DF8 >$SG.?:5MH@C>X-J,<;#04Y9&US& LR&@DD@
M?.2L]MMM';8G1T%/' QQRX,'.?25MH@C:RPVNLJN455!!)-TN<WG[>OYU%:R
MM%3<>Y3:*!KXX*@/D;D !G8?L5G1!HVZT6^VOD?0TD4#W^^<QN\^CL]"\&QV
MPT;Z3D4/)WOXQT>SN+NOM4BB#0H[-;J.2)]+1PQ/B!#'-;@C//O6%FG;0RJY
M2VWT_';6UM;/3UXYE*H@CZNRVVKK&U531PR5#<8D(W[N;M6>&AI8:R:JB@8V
MHF&)) -[NU;*(-."V44%//!#31LAGR96 ;GY&#E9Z2FAHZ=D%+&V*%GO6-&X
M;\K*B B(@(B("(B B(@(B("(B J3J[QHSUON"NRI.KO&C/6^X*PDI^Q> 9V*
M7418O ,[%+J+ H^]_!F?I I!1][^#,_2!($@B(@(B("(B B(@(B("(B B(@(
MB("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(
MB("(B"DZM\:M]8?NA6&R>";V*O:M\:M]8?NA6&R>";V*I"51$45J7;Q?-V?>
MLU)\%A]1OV+#=O%\W9]ZS4GP6'U&_8@RHB("(B B(@(B("QU,\-+ ^:IECAA
M8,NDD<&M:/23S+(N-\(-UMUQX4Z:S7ZFJ[E;+;0MJH[530.G=5U+W$ NC&YS
M6,:3WVX$[^?>'5K5=[;=XY'VFX4=<R,[+W4TS9 T]1V2<+Q37VTU5P?04UTH
M)JYF=JGCJ&.D;CGRT'*YAJ?5]FIN#/6$FE:%UDNU)"R*>D?2"DGA,A#&/+0.
MIQ(()7KA T19M.<%,E79:&FI+K9(8ZNFKHHPV;C(R"7%^,NVM^<\^4'7D6M;
M*GEMNI*K&./B9+CJV@#]ZC[[JFQ6":**]7:BH996[3&SRAA<,XR,H)E% 6K6
M>FKM4BGME^MM3.2 (XZAI<2>8 9WJ?0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$04C5?C9GK'[ K%9/ M[%7=5^-F>L?L
M"L5D\"WL52$JB(HJ/G\<TWJ'[U(*/G\<TWJ'[U(("(B B(@(B((36.H8-,V.
M2NFC=/.YS8::F9[^HF<<,C;Z2?8,GH53'"+4G@@I]8MML3JR<L:RCXTAI<Z?
MB@-K&?3S*JLX0M,W'75;==2W"6FAM+I*2U4;J29^'<TE2[981M.]ZW?N:#TE
M8^"RGMFO.!JWZ9I;K-2U]O<R>=T<!)B<)W/9[X;+LXZ"?2BNCV*X:TGND,=[
ML-II* YXR:"X.E>W<<8:6#._ YU;ERV[3ZFT->M/35>HI+]:;I<8K;-3U=-'
M')$Z3.S(QS ,X(W@CF^KH-WO=NLYB[I5(@XW.QEKCG&,\P/6$1(HN/<+VH([
MK3Z:&G*^5SZ>\03U7$ET>( ';1.<9&\;M_8NHLG<]H<UY+2,@H)!%H<;)Y93
MC9/+*#?1:'&R>64XV3RR@WT6AQLGEE.-D\LH-]%H<;)Y93C9/+*#?1:'&R>6
M4XV3RR@WT6AQLGEE.-D\LH-]%H<;)Y93C9/+*#?1:'&R>64XV3RR@WT6AQLG
MEE.-D\LH-]%H<;)Y93C9/+*#?1:'&R>64XV3RR@WT6AQLGEE.-D\LH-]%H<;
M)Y93C9/+*#?1:'&R>64XV3RR@WT6AQLGEE.-D\LH-]%H<;)Y93C9/+*#?1:'
M&R>64XV3RR@WT6AQLGEE.-D\LH-]%H<;)Y93C9/+*#?1:'&R>64XV3RR@WT6
MAQLGEE.-D\LH-]%H<;)Y93C9/+*#?1:'&R>64XV3RR@WT6AQLGEE.-D\LH-]
M%H<;)Y93C9/+*#?1:'&R>64XV3RR@WT6AQLGEE.-D\LH-]%H<;)Y93C9/+*#
M?1:'&R>64XV3RR@WT6AQLGEE9*>1[I0"XD(-M$1 1$0$1$!4G5WC1GK?<%=E
M2=7>-&>M]P5A)3]B\ SL4NHBQ> 9V*746!1][^#,_2!2"C[W\&9^D"0)!$1
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M8_BVANTTA^0<<X]"Z8!@8&X+FW\HH[-#HMQYAJ*F/U/72D!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M8$1%%$1$!$1!6ZC^D:W_ .$U/_.@5D5;J/Z1K?\ X34_\Z!61 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M]P5V5)U=XT9ZWW!6$E/V+P#.Q2ZB+%X!G8I=18%'WOX,S](%(*/O?P9GZ0)
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M"(B OQ^UL.V,%V-V>;*_4057CM;_ !'3?[;/_P"$OQT^MFM)-!IO<,_#)_\
MPE:UYE\$_L*"CZ>O>LKY8Z"Z4UMT_'#60,G8V2LFV@'#(!Q%SJ0X[6_Q'3?[
M;/\ ^$O7!;_1QIG_  Z#]P*T(-:VFL=0Q&YLIV5F/YQM.\OC!ST$@$[L="V4
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1!2-5^-F>L?L"L5D\"WL5=U7XV9ZQ^P*Q63P+>Q5(2J(BBH^?QS3>H?O4@H^
M?QS3>H?O4@@(B("(B B(@(J!PC72KN51[DK#*Z.KJ(#/<:J,[Z2D&<X/0]^-
MEO4,GH5'H*^MEX&^#VS4E9/3RWZIBHIZB-Y$C8<O=)LNZ"0W&?2@[NBY+>;!
M0\'.I-*7#3 GI*.XW%EJKJ4SODCF$K7;$A#B>^:YO..M=:0<E_E);M,Z<S\O
M4OV/72%S;^4J =(V(](OE-]DBZ2@J^I/SPTA^GJ?_EWJT*KZD_/#2'Z>I_\
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M@U3<'_N(+0B(@(B("(B J3J[QHSUON"NRI.KO&C/6^X*PDI^Q> 9V*7418O
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MU:-3&].'3HYW(R(B+!M$1$')N&3\_."__%G?Z%UE<FX9/S\X+_\ %G?Z%UE
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M/T=W!OHQQS[F+4#_ ':=K?L7SSPOZ?BT[K:JIJ.F;34$K&2T[&##0TM ./\
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M8V#+Y7DX:QHZ7.. .U:;=W3I^S'[)9%RK27"!=8M#ZPO>KX(&U5EK9H>30#
M;LL86QYZ3M/V=I8[A>]=:9T_3:JO]7;*NWYCDK[7#2&-U-$\@$LDVB7.;M#(
M(P=ZQ9NLHOQCFO8U[""UPR".D+1N5ZM5KD9'<[G0T;WC::VHG9&7#K <1E!S
M7AD_/S@O_P 6=_H765Q?A3O5KN>ON#,6RY4588[J2\4\[9-D'8QG!.%V;C&>
M6WVH/2+SQC/+;[4XQGEM]J#THC5]U[AZ6NUSYW4M-)*P>4X-.R/G.!\ZE>,9
MY;?:J?PBO;6]P+(UP/=*YQ<:,_\ 0PYG?GT'BVM_XD$SHRU=P])VBV.WR4U-
M''(?*?COC\[LGYU,KSQC/+;[4XQGEM]J#TB\\8SRV^U.,9Y;?:@](O/&,\MO
MM3C&>6WVH/2+SQC/+;[4XQGEM]J#TB\\8SRV^U.,9Y;?:@](O/&,\MOM3C&>
M6WVH/2+SQC/+;[4XQGEM]J#TB\\8SRV^U.,9Y;?:@](O/&,\MOM3C&>6WVH/
M2+SQC/+;[4XQGEM]J#TB\\8SRV^U.,9Y;?:@](O/&,\MOM3C&>6WVH/2+SQC
M/+;[4XQGEM]J#FO#S;Z1NCZB[-@V+G#LP1U43BQXC>[#F.((VFD$C9.1O7S*
MOL[5=HIM1:=KK542-:RICV0_GV7 Y:[YB 5\C:DT_<=.7*2BNE.Z*1I.R\;V
M2#RFGI"[-FM&)CU>;MM9WHMZ(I?1G\F^NFGTG7TLKBZ.FJOYO/0'-!(]N3\Z
M^?;;;ZNYU;*6WTTM34/YF1MR5]'Z3X,:.TZ?I,UU30Z@ +Y*^AGV7 G?L$'+
M7L'4X$<YW966T6C=PQV*LS?>]'345)[M:CT[WM^HF7NWM_\ 7[6S$S1UR4Y.
M3VQD^J%8K%J"TWVDY3:*^"JB!P[8=WS#U.:=[3Z" 5PO42B+SQC/+;[4XQGE
MM]J#TB\\8SRV^U.,9Y;?:@](O/&,\MOM3C&>6WVH/2+SQC/+;[4XQGEM]J#T
MB\\8SRV^U.,9Y;?:@](O/&,\MOM3C&>6WVH/2+SQC/+;[4XQGEM]J#TB\\8S
MRV^U.,9Y;?:@](O/&,\MOM3C&>6WVH/2+SQC/+;[4XQGEM]J#TB\\8SRV^U.
M,9Y;?:@](O/&,\MOM3C&>6WVH/2+SQC/+;[4XQGEM]J#TB\\8SRV^U.,9Y;?
M:@](O/&,\MOM3C&>6WVH/2("",@Y"("(B B(@I&J_&S/6/V!6*R>!;V*NZK\
M;,]8_8%8K)X%O8JD)5$114?/XYIO4/WJ04?/XYIO4/WJ00%7N$*Z5%ET7=[A
M1.V:F& \6[&=EQ(:#\V<_,K"H"\7*Q7&IK-,W.JA;43PX?3R.V"]CP=[2><]
MF\+*O=C?MC+BVJ:KNW'I:V6NBM-3J:Z0,J:NL;2QY!<,@'<0,#)<<9W>E=(X
M';W<KA;+G;;V8WUMHJ32N?&T-! W ;@!N((YN;"SZ'X,K/I&YRW"DEJ:FJ<T
MLC=.6GBVGGQ@#>>;*]6.EL6@9*B"INW&U]VK \B4@RR/>0  UN_&2=_I6VUJ
MVC=AS:=+4MOVZ+NB(M#K$1$!$1!R7^4P2W0UL<!G9O%,?WUUI<F_E,?F%0?X
MM3?ZEUE!5=3_ )YZ-_3U/_R[U:E5=3_GGHW]/4__ "[U:D!0^J--6K4]!R2\
MTK9F-.6/!V7QGK:X;PMZZ5S;=0R54D-3.UF,QTT+I9#DXW-;O*@/=K3?(VI/
M\IG_ (58G'6$F(F,2YS:^"*Q2ZUNMNFJ:]])14U-4,;MM!<973 AQ#>8<4.;
M!WE<WX57446L*JWVJDAI:&W 4D3(VX)QO<7'G)VB[>5W"WZD$.M+U<9+'J(4
MM51TD,3NY4V2Z-TY=NV=WA&^U<,X48'-UG<:P4E;34U;(9XN5T[X'.S[[O7
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M #P@M2(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("K.N]&6W6-M;3W
M.CGBR8*B,=]&3S]H/2%9D5B9B<PEJQ:,2^9X.!VZU5_N=MI;C0EM 8]N63;:
M7![=H8: >CTKKO!QP;V_1VU4NE-;='MV34.;LA@Z0P=';S]BDM._GSJ[MI/^
M45:5LMK7M&)EIIL^G2<Q B(M3>(B("(B J3J[QHSUON"NRI.KO&C/6^X*PDI
M^Q> 9V*7418O ,[%+J+ H^]_!F?I I!1][^#,_2!($@B(@(B("(B B(@(B("
MK^N?$8_3Q?O*P*OZY\1C]/%^\D"GHB+)@(B("(B B(@(B("UJ7X36>N/W0ME
M:U+\)K/7'[H0;*(B B(@(B("(B B(@TKWXIJO47*%U>]^*:KU%RA;]'U?E/_
M *3OI_W_ &%)6*Z36FIFG@@AG#X70O9,TN:6NW'."%&K<M=RK+74&:WU#X)'
M-+'%O2WJ(.XC<%ME^<TK;EHMG"TTU';;Y9H*ZM@IK/L5K*=\\(<(Y&%I<>])
M/?#'..O>IEE+'74>H2R[VEM+R2.""..1Y;3QME:1M=Y[3OR2J!=+O7W4QFX5
M4DPC&&-.YK>P#<%KP5<]/#410RN9'.T,E:/ZX!! /S@+'=EW5VW3K.-W/3OV
MF>DQVCIZ_OW>.*DV"\,<8]K8VP#C/5E76SW&/55_Y'=K119J0X25$#7,DBPT
M]_G:(W8&XC"J+;C5LM_(6SO%)QO'\6.;C,8VNW"WZO5%ZJZ:2"HN,SHY!LO
MP"\=3B!D_.K,3+3L^M32GK,XZ9C$8GX=_P T[IJX4M8(X:F"42TE%+3RU37C
M8;39)<[9QG:PXM&_G<%MW$TEU8T24,+146N6M;,,[4)87AC&G. T-8UN,;\D
M\ZH<55-#3SP12.;%/@2-'];!R,_.MEEXKX[:ZWLJI!1NR#'Z"<D9Y\9WXYE)
MKX;:;;&YN7C/]H_[MZ]^K01$6;SG8N ?X#=_7C^QRZDN6\ _P&[^O']CEU)<
M=_:E]&_A?])I_(1$6#O$1$!$1!2=6^-6^L/W0K#9/!-[%7M6^-6^L/W0K#9/
M!-[%4A*HB**U+MXOF[/O6:D^"P^HW[%ANWB^;L^]9J3X+#ZC?L0941$!$1 1
M$0:-\M]%=;34T5T8'T4K<2@O+1L@YYQC',N)53N!ZGK'4_$SRAIP98GSN9[=
MK?\ ,NH<*S*F3@\OK:$.,W$;PWGV,C;_ .[M+FND+EP81:.I([K!1\N$(%2)
MJ=SI3)COL. /.>;!]BWZ4?=SU_LY=:8FV.G]W4M!VO3]NLO&:3##;ZIW&[39
M7/#G8Q_6)(YL85'U/=+C)PDB:Z:6U!7V:S .M[**F$D<U0X=].XEP]Z#LM&_
M&\[BL_\ )Y9(--W5\;9&6^2N<:42<^S@9^X=H*ZHM>I&+3#=HSFD3C#YDJ[M
M47;07"G1Q6.[PF>Z2U[I980&0ACH'.B>0XX?LM)QOW=*ZQPQ7&FEX&;Q4Q/;
M)%64;&T^R<\89"T,QUYR%;;5IZVVQMU;2P=Y<ZE]55-D<7B21X#7;CT$ ;N9
M5VW<%VF:"OI:B.&LDAI)..I:.>LDDIZ=_.',C)P".CJ6#8MMHA?36FB@E\)%
M QCNT- *5MLH*Y[7UU%2U+FC#3-$UY ]&0MM$'&>%ZVT-!KC@T-#14U,7W5P
M<88FLVO><^ NJ+FO#7^>_!E_BKO]"Z4@(B("J3?_ $CPGO/OHK/;0WT"6H?D
M_.&0CZ:MJJ/!W_MD-ZO)WFYW&9\;NN*/$,?S8CS_ ,2"W(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("UZZF@JJ9\=3#%-'@][(T.'L*V%XE\$_
ML*"L<%M/#%H#3\D4,;'RT,+GN:T O)8-Y/25:E6>#+^CS3?^'P_N!69 5?OF
MDK7=:H5NQ+171HPVOHG\3./07#WP]#@1Z%8$04[EFJ-/;KC3#4-O;_ZS1,$=
M4P?WH<[+^UA!_NJ<L.H;7?HGOM59',Z,XEB.6RQ'J>PX<T]H"E5!W[2UJO<K
M*BJ@=%7QC$5;3/,-1'V/;OQZ#D>A!.(J=MZJT]X5K=2VUO\ 6C#8:U@]+=T<
MOS;!]!4Q8-36J^F2.@J?]JB\-2S-,4\1_O1NPX=N,()E$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1!OP>!;V+VO$'@6]B]H"(B B(@I&J_&S/6/
MV!6*R>!;V*NZK\;,]8_8%8K)X%O8JD)5$114?/XYIO4/WJ04?/XYIO4/WJ00
M%6-8Z&LFK&M==*=S:E@V65,)V9&CJSS$>@@JSJHR:OD9PDQ:7Y(PQOIN4<HV
MSD'!.-G'HZUE7.<U87W<8MZJF.!VHB'%TFL+K#2^:P>;YG@?4I[27!=8=/UC
M*YXFN-P:=IL]40[9=UM:-V?2<E7Q%E.K:>F6,:&G6<Q B(M;:(B("(B#DO\
M*9(&@: DX NU-_J7467"B>R%S*NG<V9VS$1(")#U-W[SV+EW\IH!V@:$$9!N
MU,#_ -Y=+CL]OCCI8V4D364SB^$ >\<3G(05K5-QHFZOTG(ZLIQ'#55+)'&1
MN&.Y._<3G<5;75E*V26-U3")(F<9(TO&6-\HCH'I5,U59K>_5NEH7TD1BJ*N
MIDE;C<]W)WG)5ODME')//,^GC,L\?$R.(WO9Y)]"#VRNI'NA:RJ@<Z<$Q 2
MF0#G+>OYEY%QHC$V05E-Q;G\4'<:W!?Y.<\_H7B.U4,;Z5\=-&UU*TMA('@P
M><!>!9;<(&PBCBXILO'M;C<'^5VH,[J^D89]NJ@;Q&.-S(!Q>>;:W[OG4+JV
MQV+5E"VWW9\+W;''0O9(!*P>6T]7U%9K]9IJBFJ.X[;=%4U3F\I=60.E;(T
M[L->TYSC?GK4,+'JH3LF%7ID2LBXAKNYTV0SR?#<RL3CK"3$6C$N4V?@HMUS
MN]SACU+&RDI:P4L1XMKG3YACD[T[0&?YS&X'F].%>:W@LT8_3SJ..J$$U,_#
MZ_CVF0/.[#^CH][N]'2MJT:+U';:JKEAJ]-?SM6*N-IM\Q$3N*C9WO\ /#'@
MP>G?[!OR:=U+)%41/J=,.CJ).-E:;=-A[N?)_G^=9SK7GU:HV?3CT<YLW!!;
MVZIN-%=KP]]'0P15!<R,1<8UY?D$DG :&C)_O#F70>"-UKI+++10FB;7T]7-
M0ODCV ^I;$]QC<2-[OYM[3G?SE;UFIC-K._P7$13/[FT3)=AI:QQ=QP?@$D@
M'9&[)Y@M.PVJBM7"==Z9E-&QM11P5]+@>\< 8)0/F;%[5+7M?O+*FE33]F%S
M%RH3$)!64W%E_%!W&MP7^3G//Z%^NKZ-G'[=5 WB,<;F0#B\\VUU?.L LMN$
M#811Q<4V7CPW&X/\KM7J2TT$G*]NEC=RO''Y'A,<V5@V,XK:4RMB%3"9',XU
MK-L9+/* ZO2O++A1/;"YE73N;,=F(B0$2'J;OWGL7@6RB%0R<4T?&LBXAKL;
MPSR>Q>([/;XXZ5C*2)K*5Q?" />.)R2$&5UQHFQRR.K*8,B?Q<CC*W#'=1.=
MQ]"]NK:5DDL;JF%LD3.,D:7@%C?*(Z!Z5K/LMNDAJ(GT<1CGDXV5I&Y[^L^E
M99+91R33S/IXS+/'Q4KB-[V=1]"#VRNI'N@:RJ@<Z<%T0$@)D YRWK^9>1<J
M$Q-D%93&-S^*#N-;@O\ )!SS^A>8[50Q24KXZ:-KZ5I;"0/!@C! 6,66W"!D
M HXA$R7CVMQN#_*[4&=U?2,X_;JH&\1CC<R <7GFVM^[YUZ%;2F1L8J83(YG
M&ANV,EGE8ZO2L,EIH).5[=+&[E>./R/"8YLKT+91"=DPIHQ*R+B&NQO$?D]B
M#TRX4;VPN95T[FSDMB(D!$A'.&[]_P R_'7&B9'+(ZLIFLB=L2.,K0&.ZB<[
MCZ%BCL]OC92L921-;2N+X0!X,DY)"_)++;I(:B)]'$Z.HDXV5I&Y[NLH-EU;
M2LDEC=4PM?$SC)&EX!8WRB.@>E?C*ZD>^%K*J!SIAM1 2 F0=;>L=BQR6RBD
MFJ)7TT;I*B/BI7$;WLYL'T)':Z*.2EDCIHVOI6ED) ]X#T!!Z%QHC$V05E,8
MW/XH.XUN"_R<YY_0M&^:EM-DHZBHKZV," [+HHSMR%Q!(:&#>7'!W>A0VIJV
MT69M/:J*V-N-VGDY12VV'<XOYN->>9C!TO/S9.Y>+'H>%U5/=M4BGN5ZJ<EQ
M:S$-,#CO(@=_0 7'OCZ!N0:E)03:MK8:O5[X:>A:!44=AXUKLM&\2U&#WYZ0
MWWK?2=XNK+A1.9 Z.KIRR8[,1$C</(W8;OW_ #+R+91"H9.*:/C61<0UV-X9
MY/8O$=GM\<=*QE)$UE*XOA '@R3DD?.@RNN-$V.5[JRF#(G\7(XRMPQWDDYW
M'T+%<7T573U=%/6<5_-;4O%5)BDC9Y6TTAS>T$+\?9;<^&>)]'$8YY..E:1N
M>_RCZ5DDME%)-42OIHW23Q\5*XC>]G4?0@K+-)V)[X6LO-[<Z<;40&H*LF0=
M;?YW?\RP#1VF3*VN%VNIE=_LS:CN_59._/%AW&]>_95MCM=%')2OCIHVOI6E
MD) \&#N("QMLMN; R$4<0B9+Q[6XW!_E=J"NNTK86<?MWJ]MXC'&YU#5CB\\
MVU_.[OG4]9XK?:Z=E#35TDN6F<<JK'U$A:?ZVT]Q<6_/A9I+302<KVZ6-W*\
M<?D>$QS97H6RB$[9A31\:V'B&NQO$?D]B#VRX4;VPN95T[FSDMB(D!XPCG#=
M^_YE^.N-$V.61U93!D3^+D<96X8[J)SN/H6*.SV^-E*QE)$UM*XNA '@R3DD
M+\?9;<^&>)]'$8YY.-E:1N>_K/I0;+JVE;)+&ZIA#XF[<C2\98WK(Z!Z5^,K
MJ5[X6,J8'.F;M1 2 F0=;>L=BQR6RBDFJ)7TT9DJ(^*E<1O>WFP?0D=KHHI:
M62.FC:^F:60D#WC2,8"#T+E0F)L@K*8QN?Q37<:W!?Y(.>?T+]=7T;./VZNG
M;Q&.-S(!Q>>;:W[OG6 66W-@9 *.(1,EX]K<;@_RNU>I+102"KVZ6)W*\<?D
M>$QS909Q6TIE$0J8>,+.-#-L9+/*QU>E>67"C>V%S*NG<V<EL1$@(D(YPW?O
M^9>1;*(5#9Q31\:V+B [&\,\GL6..SV^-E*QE)$UM*XNA '@R3DD(,KKC1-C
MDD=64P9$_BWN,K<-=Y).=Q]"]NK:5DDL;JF%KX6[<C2\ L;UD= ]*UGV6W/A
MGA?1Q&.>3C9&D;G/ZSZ5DDME%)-43/IHW2U$?%2N(WO9C&#Z$&1E=2/?"QE5
M YTPVH@) 3(.MO6.Q>1<J$Q-D%93&-[^+:[C6X+_ "0<\_H7F.UT4<E+)'31
MM?3-+(2![P'H"QMLMN;!'"VCB$4<O'-;C<'^5VH,[Z^C9Q^W5P-XC'&YD XO
M/-M;]WSKURVEXP1\IAXPLXT-VQDL\K'5Z5@DM-!)RO;I8W<KQQ^1X3'-E>Q;
M*(3MF%-'QK8N(#L;Q'Y/8@],N%&]L#F5=.YLY(B(D!XPCG#=^_YE^.N-$V.6
M1U93!D3^+D<96X8[R2<[CZ%CCM%OC92L921-;2N+H !X,DY)"\OLMN?#/$^C
MB,<\G'2-(W/?Y1]*#9=6TK))6.J8&OB;MR-,@!8WK/4/2OQE;2O?"QE3 Y\S
M=J)HD!,@ZV]8[%CDME%)+42OIHW25$?%2N(WO;C&"D=KHHI:62.FC:^F860N
M ]XTC& @]"Y41B;(*RF,;G\6UW&MP7^2#GG]"_75]&P3E]73M$&!+F0#B\\V
MUOW?.L#;+;FP,A%'$(F2\<UN-P?Y7:O4EHH)!5A]+$X59!GR/"8YLH,XK:4R
MB,5,/&%G&ANV,['E8ZO2O++A1O; YE73N;.2V(B0'C".<-W[_F7D6RC$XG%/
M'QHBX@.QOXOR>Q>([/;XV4K&4D36TKBZ$ >#).20@]/NMNC#C)7TC0QQ8[:F
M:,.'.#OY_0OPW>VASFFX4@+1EPXYNX>G>M6HTU9:AY?/:Z220O<_;=&"X.=C
M:(/.,X&>O"PC1VFP&@6*VAK3EK13M 8>MHQAI](WH(?3MTM_NXU4>74N).2%
MAXUO?8B.<;]ZLXO%L(!%QHR"=D'CV[SU<ZT#H[3A#@ZQ6UP=O>#3M(>>MPQW
MQ])ROT:1T\U^V+-0<9S;?$MVB.HGG(]',@G$1$!$1 1$0%2=7>-&>M]P5V5)
MU=XT9ZWW!6$E/V+P#.Q2ZB+%X!G8I=18%'WOX,S](%(*/O?P9GZ0) D$1$!$
M1 1$0$1$!$1 5?USXC'Z>+]Y6!5_7/B,?IXOWD@4]$19,!$1 1$0$1$!$1 6
MM2_":SUQ^Z%LK6I?A-9ZX_="#91$0$1$!$1 1$0$1$&E>_%-5ZBY5L.\D^Q=
M9N>^AESU#[5[Y)3?%XOH!9TONO+_ (C_  R-NFLS;&,^F>[D>P[R3[$V'>2?
M8NN<DIOB\7T G)*;XO%] +/C?!YG\MU_]/R_VY'L.\D^Q-AWDGV+KG)*;XO%
M] )R2F^+Q?0"<;X'\MU_]/R_VY'L.\D^Q-AWDGV+KG)*;XO%] )R2F^+Q?0"
M<;X'\MU_]/R_VY'L.\D^Q-AWDGV+KG)*;XO%] )R2F^+Q?0"<;X'\MU_]/R_
MVY'L.\D^Q-AWDGV+KG)*;XO%] )R2F^+Q?0"<;X'\MU_]/R_VR<! (HKOD$=
M_']CEU)4W@_C9'5W1L;&L;LPG#1CRU<EIM.9R_1[+H\#1KI9SB!$18MXB(@(
MB(*3JWQJWUA^Z%8;)X)O8J]JWQJWUA^Z%8;)X)O8JD)5$116I=O%\W9]ZS4G
MP6'U&_8L-V\7S=GWK-2?!8?4;]B#*B(@(B("(B"'UC5W&@TS<*NRT\=37PQ[
M<<,C2X/P1M# ()[W.[*Y_HVP:(U79:6\5MLML=PDSRB&&5T3&2 G(V-K=U_.
MNCZCM3;W9*NVR3RT[*ANP98CAS=^=WL7,?R$67Y6N/L9^"VTFL5Q,XESZM;3
M;,1F'5K='1PTD<%N; RFB&PUD. UHZ@!S+958T#HZET9;JBCHJF>H9-+QQ=-
MC(. ,;AZ%9UKG&>C=7..L8$1%&0B(@Y'PU_GOP9?XJ[_ $+I2YKPU_GOP9?X
MJ[_0NE("(B"%UI='672=VN$>3-!3O,0'3(1A@^=Q 6;2]K;9-.6RV-P>24T<
M)/60T GYSDJ&UY_MM7IRS#>*VXLFE;UQ0 S'/HVFQC_B5M0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!>)?!/["O:\2^"?V%!7.#+^CS3?^'P
M_N!695G@R_H\TW_A\/[@5F0$1$!$1 4/?]-VJ_"-UQI0ZHB\#4QN,<T1ZV2-
MPYOS%3"(*=Q.JM/?!Y6ZEMS?^CG+8:U@]#]S)/\ B#3Z2I2PZKM5ZG=2P3/I
M[C&,R4-6PPU#.UCMY'I&1Z5.J+OU@M=^@;%=:..HV#F.0Y;)$>MCQAS3Z00@
ME$5.Y!J?3^^UU8O]O;_ZI7O#*EH_N3XP_L>,_P!Y2%DU=;+G5\AD,UONH&30
M5S.*F[6@[GCTM)""PHB("(B B(@(B("(B B(@(B("(B B(@(B("(B#?@\"WL
M7M>(/ M[%[0$1$!$1!2-5^-F>L?L"L5D\"WL5=U7XV9ZQ^P*Q63P+>Q5(2J(
MBBH^?QS3>H?O4@H^?QS3>H?O4@@+A/"!IYVJ.&B.V,K7T1?0M?QS&;1& XXQ
MD?:N[+CFJM4PZ<X:8IKI5S16QM"-IK07#:(=CO0MNCG,X\-&T1$UC>[9AB_(
M?-_ULJOV8_\ B*^<'>CWZ/H*NF?<Y+@9Y1)MOCV-G QCWQ43^6'1WQ^?]F?^
M"LVE-56K55-/4669\L4+PQY=&68.,]*MYU)C[W9-.NC%ON=_FG$1%I= B(@(
MB(.2?RG0[\GE*68VFW2G(SU]\KCM:W\WIO\ 63_PJH?RF?Z/*;_$Z?[7+K*"
MA7&UZTK;M::]WN=:^WOD>U@?-A^W&6'/>^G*D]K6_F]-_K)_X5:D01EC-Y,<
MO=UMO;)D<7R-SR,=.=H!2:(@(B("(B"D2&ZC7.H>X;:%U3R6@VN6%X9LYJ>;
M9!.<X^M0>JG:NH-2::N\\=A$G'OMN8WS;)$X&-O(YMN-F,=)"MEH_I#U)_N5
M#^]4*N\,VJ+-1Z<K+9)71]V1Q=130L!<YLL;VR,+L>]WM'/T%6(F>D):T5C,
MRWK3>-9W*KNT$=-IYCK=5"E>7238<[BHY,C=S8D ^8J1VM;^;TW^LG_A54X.
M>$#3]9>K^V2LY++<K@*BG94-V-IO$0QXVN8':8[=GJ754FLU[I6];1FLY8Z;
MCN31<JXL5&P.,XO.SM8WXSOQE9$11D(B("*NUVJXZ.LFIW6>^S&-VSQD- ][
M'>EKASA8/=I"!XBU'_EDB"THJ?0Z^HJZCAJZ.SZAFIIF"2.1EMD+7M(R"#U*
M5L^HH[I5\G9;+Q2G9+N,JZ-\3-W1M'I]"";1%YED9#$^25[61L!<Y[C@- YR
M3T!!Z50O.I*NON,UCT>R*HN,9V:NND&U3T'K8]_)U1C_ (L#GTWW&XZY>Z"P
M336[38.S+=6][-5CI;3Y]ZWKE^CUJW6:U4-EMT-!:Z:.FI(AAL;![23SDGG)
M.\H-'2^FZ2P13.C?+57"I(?5UU0=J:H=UN/0!T-& !S!3:(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B J3J[Q
MHSUON"NRI.KO&C/6^X*PDI^Q> 9V*7418O ,[%+J+ H^]_!F?I I!1][^#,_
M2!($@B(@(B(*+PR7*MM>EJ2>W54U-,ZYTD1?$XM)8Z4!S>PA4[6NI[O8N&2.
MI%?4#3M)%2,K:4O/%-9.Z2/C2/[KM@JS<._YG47^+47_ #@HZYV6#47"7K:T
M56.*K+!30YQ[TE\F'=H.#\R*L_"I>*JU:4?#:9"R\7.:.W4)!WB64XVAZK=I
MW_"N<45\OT? ';]1"Z5T]?;+@:BHE=(2^HA95.8YC^MNR>;^ZMO@QN-;K;4U
MH-VBD:[2-&ZGJ@\>_N#G.B)].(V$^@O4MP.VR.\\"'<R?'%5G+H'9Z Z:49^
MM!^\-U\NYM=FMNCZR2"YU_'5K)878)A@A=(1N\HE@^=9=>:LJ:_@NLU78*E]
M+<=12TE+2RQ.PZ-\I!=CL <%7> :6JU%>77"YL<':>M45B:'CGE#G&0]N&1@
M]JC]#4<\G"9;]'3,=R/25775S 1N,<FR:?YQQKB.Q!W^)G%QL9M.=L@#+CDG
MM*@=<^(Q^GB_>5@5?USXC'Z>+]Y(13T1%DP$1$!$1 1$0$1$!:U+\)K/7'[H
M6RM:E^$UGKC]T(-E$1 1$0$1$!$1 1$0:UR^ R]@^U;*UKE\!E[!]JV4!$1
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MB**CY_'--ZA^]2"CY_'--ZA^]2" N.Z\MUOI.%&GO.JV4GN??2<4./<UY>\
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MC:;+L@[^K"D8K?4T=-FGB+ZJ5N]X(Q&T] ]/I6E:X1%52S5#>]I07N:>EPW
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M7,7./B_]K9*V21I:PNPW<W&"=W2KO6P\(D=95-MU7I>>C?(XP2544[)8V$G
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M^K8Q!<>YM#\2IOU3?P6RQC8V-8QH:QHP !@ +TB B(@(B("(B B(@(B("(B
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M4SW6:JL6K(Z&ED#?]DJ+<RH:P@8):[::X9Y\'.]6J*-D,3(X6-CC8 UK6C
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MU0N??RG03P3UA'14P'_OKH%/O@C]4?8@R(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MB9&"SD^-[@3_ %L]',K-I^KTUIB[1WFCNM=<*B .,%+R/B<N+2!MOVR,;]^
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M?V9R?YG'^">['A&_LSD_S./\$'4$7+_=CPC?V9R?YG'^">['A&_LSD_S./\
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MYW#-\M:3_52?P**U35<+VG-/5]XK;MIB2FHXC+(V*%Y<0.K+0/K7;E2N&O\
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M$=6>@>@;E/HB B(@(B(*GK[PFG_\2B5L6M6T%-6F U4+9##()8\Y[UPYBME
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MJ)PTTEO?H^ETE::.G[KW&:.*VTT,8;Q&R\%THQ[QK6@Y/S+8M$#;CPX7F2M
MF?9K530TVV,[#I2YSW@=#C@#/4@O=BO-MOUO976:M@K:1Q($L+PX9'.#U'T%
M;ZYQIJ)EJX:M3V^C:V.DKK=3W%\3=S1*'NC+@.@D $]:Z.@(B("(B B(@(B(
M"(B B(@(B(-2[7.AM%#)676LIZ.DC]]+/(&-'SE0^G=<Z9U'5NI;'>Z*LJ6@
MN,3'X>0.<@'>1V*3OM+0U-O>^Y4#*^*F_P!H;"Z$2NVF@D%K3SNY\=JY/<;]
M2:OX2](T\-OJ['+;9WU/'W2 TLM0W8(XF%IWN!SOYMPZ4'1M1:WTUINLCI+Y
M>J.BJ9 '-BD?WV#S$@<P])4]2U$-7315%++'-!*T/CDC<'->T\Q!'.%SG@@I
MH+B=8W>LBCFJZZ]5-/(^1H<>)C(8R/U0!S>E9>!+_9K7J6T1YY):;[5TE,WG
M#(LM>&CLVR@Z*B(@(B("I.KO&C/6^X*[*DZN\:,];[@K"2G[%X!G8I=1%B\
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MM=@'&!T]/,J-P34K;APGUEYTW;ZF@TX(W MD&&G+0-D;R/?=]@$XPN]$ C!
M(]* 8&!S+9&I$5Q$-%M*;6BTSV< @OT.A.&+4=9?*6KXBK;((C"P$N#GM<TC
M)&1@$=JW.%.KEM?"%I?5LE)4/M8IXBXAN]I#G$M/0'8>-Q*[D6@D9 ..9?I
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M8%8K)X%O8J[JOQLSUC]@5BLG@6]BJ0E41%%1\_CFF]0_>I!1\_CFF]0_>I!
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M>'-.04'ZBQ2U,$4C62S1,>[WK7/ )[ LI( ))  WDE 18GU,#'1M?-&UTGO
M7 ;79UK*@(L3ZF".5L3YHVRN]ZPN )[ JUIVZ7&OIM2_SL3ZBDK9H*7C0&L:
M&@;(=CHST\Z"U(M6V/J3;:=]P,/*C&#*83WFUTXST+)!54]02()XI2.<,>'8
M]B#,BBJ*^TE5=;C0L>UKZ(L:]SG##BX$X'9C>I0O:'!I< XC(&=Z#]115YJJ
MI]LD?89J%]4U[6YG?E@W[P<=.%HZGN=70WG3T%-*&15=28YAL@[3=G.-_-\R
M"QHL453!+(YD4T;WM]\UK@2.T+(7M#PPN&V1D-SO0?J+\<]K2T.< 7' R><J
M-O%YI[7/00S[WUDXA8,@8W$EQ] Q]:"311ETGKBZA-J?1NC=.ULYF<=\?3L8
M_K*2>]K&ESW!K1O))P @_46.">*H9M02QRMYLL<'#ZEZ=(QNUM/:-D9=D\P]
M*#TBQP3Q5#-J"6.5O-EC@X?4LB B(@(B("(B"DZM\:M]8?NA6&R>";V*O:M\
M:M]8?NA6&R>";V*I"51$45J7;Q?-V?>LU)\%A]1OV+#=O%\W9]ZS4GP6'U&_
M8@RHB("(B B(@(B("H>JK=273A"L=+<(&ST[J68ECB<$CFYE?%0M6T N7"#8
MZ8U-53!U+*>,II.+>,=12!ANUJI=+:ET_)I_;IG5M2()Z5LA+)&'G=LD]"L=
MXU$^FN@MEJM\MRN(9QDD;'B-L3>@N<=PSU+U9M*6ZUUO+6FHJJW&R*BKE,KV
MCT9YE5J2DJY.$+45/'=Y;;/,(98PR-CN.8&XW;0/-S;ON5%KT_J 7.JJJ&KI
M):"Y4P#I*>1P=WIYG-<-Q"_+I=[K!724]ML$]:V, F9T[(6'(SAN>=:]GTX^
MBU$^Z5=WFKJQU,8-F1C&=YM \S<=(^M1UGJ[MJ>6XU$=V[F45-4OIV0PQ,<_
MO?ZSG.SCLPH-FJOD=\T/J"5L$E-/!3U$$\$GOHWB,Y'I7FW7R"RZ)L)>Q]15
MSTL,=/31^_E=L#</1UGH5>T\YK],Z^<RI=5-VJC$[L9D_FCWV[=O]"P:>;4:
M=DL5]O#V55OJZ2.F$NS\!! V,>@CG/7GYZ.IT[I'P1NGC$4I:"Y@=M;)ZL]*
MI^L])V0V:]7(V^/EO$2S<;M.SM[).<9QSJZ AP!!!!W@A0^LOS1O7^YS?N%0
M0>BM*61MFLMR%!&*[D\4W&[3L[>R#G&<<ZQ7%DNJ]75=HDGEBLUM8PU$<3BT
MSR.&0TD?U0/L]EAT9^:-E_W.']P*O4%3'8>$2[PU[Q##=F1S4\KSAKG-!!;G
MKWGZNL*B3ET'IM\08+7'&6\SXWN:X?."K,T!H &X#<%1^$BQ43[-<[QM3MK6
M1 M<V=P;D8 [T'',K58238[<222:>,DGU0H-'4.H8[3/34D%+-77&ISQ--#@
M$@<[B3N ]*]6B[5\PJ77FTNM<<#-OC'5#9&N&_.\<V %"SR,I>%>%]60UM3;
M>*IW.YBX/R6CTXS[5-:RBDJ=+7>GIM\[J5^&#G.X[L>GF0146KKA60.K;7IR
MKJK8,[,YF8QSP.<M8=Y"D9=3TATG+?J1KIZ=D>WQ>=EV0<%IZB"O6CJREETA
M;)X98Q!'2L:\Y #"UN' ]6""J/2 NX,-4U# 135-7--3[O\ HRYH&/G!5%PM
M&HZJ[UD)H;/.ZU/)!KI)&L&X'>UAWN&1C*Q7'5XIKW66BFMT]77Q",Q1QN X
MS:;DDD[F@;LD]84UI]K66*VM8 UHIHP .CO0JY96-/"=J-Y VA30 'T%HS]@
M4$C6ZC?;K12SW&WRQW&J>8HJ")XD>Y^3@!PW8Q@YZ,K%1ZFJ&72FH;Y:9;9)
M5Y%/)QS96/</ZI(YBHC7\<@U7IF8UKZ&',T0J0UKN+>YN[WV[?S+?JM*U-54
M4$ESU#4U+*:H941L?#&T%[3NW@ JC:NFIY(KM):[-;9KI70M#I@R1L;(@>8.
M<=V?0L_=>Y"P5-;+998JR(D"E,S#D >^VN;'U[E$:)>R#5&JZ2<AM8ZKXX-=
MSNC([TCK S]:M5R(?;:P-(<1$\8'7LG<H*KH"[W6X66B;<+;*^G?&XNKGU#7
M;>\_U??>A9M.W:AH] &Z6ZWFGHX62R"F$FT>]<X'OCUD++P;/:_0=LV7 XB<
M#CH.TY5ZQ_T)U'^[U'_,>@FAJZOJ*+E]MT[55-N#=LS&9K'$#G+6'>X?:I&I
MU700Z8AO;1+)!, (HVCOWO)QL8Z\@^PK9TXT-TI;&M  Y%%N_P" +GM/%"[@
M9I:B61\3Z24SPN:W:Q()G!N1U;\*BRW#5MVMKJ05VFW1BKE$,1%:PC;/,UQQ
M@%6^G?))3QOFCXJ5S071[6ULG&\9'/A4SD5TU'-;&WFKM,=+33,JC'1R%[Y7
MM&X;]P&\\V5=U!S^DU'?7ZON\,5FGG9#'$T4QJF-XKG.USXR[/1U!6?4%_BL
MT-,'P2U%;5.V(*6+!>]W3OY@!TE0]A(;PE:G:2 YT-.X#K ;SKSJ-S:7A"TY
M551#:9\4T#'N]ZV0C=\YSA4;<&J:F"OIJ6_V>6V"J=Q<$W'-EC<_H:2WF)5H
M5,X4WMDLM'11D&MJ:R(4[![[(.\CLZ_2KFH*=IO^D75_JTO_ "UL2ZIJJFKJ
MHK#9IKG%2O,<L_'-B9MCG:W/OB%KZ<_I$U?ZM+_RU!<'=MN$]GFIX=05%%44
MU1(R>F;#&XL=M<_?#.]46-NM:5]);JIM-*(:BKY%/MG9=2R]3@I;4]ZCL-HD
MK98G3$.:QD33@R.<< #[?F5?ET<SW.7VC;6OK*JM>9^,>UK2V8;QS<V2![5&
M6RXG6%UTU"_)CH8>6U@/GFG8:#Z=H$]A06R^:@%KY'3LI):JYU?@J2)PSN&7
M$N.X =:PVK4DLUW;:[Q;9+;72,,D(,K962@<^'#I'4H#4\$YX2;<1<7VYL]"
M8H9VL:[+P\DL[X8W@CZE+LTQ.;S;:ZXWVHJY:1[G0QOBC9G(P1WH!YOL4&K+
M41TG"97U,[MF&&R\8\]31)D_8L]-JB[U=-'64FF*F6@D <Q_*8Q(YIYCL?\
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M;6VGJJB&*"OJV4SMF>:FIR^.(CG!=Z/0I*IU#:Z:S1W62K9R&0#8D:"=LGF
M WY]"CN#6G9!HFV;(&96&5Y\HN<225I\'+&,I[Y0[(,%)=)FPM(W-;D$ =AR
M@W*36ENFK(*>II[A0F=VS"^KIS&R0] !_%694OA$<VY\@T_2?SE?4SLE./\
MH8VG)D/5U>G>KH@T)KI'%>J>VF"H=)/&Z42M9F-H'07=!6^JY6W*JCUY;;>R
M7%'+222/CV1O<#N.>=0W="OO&IKI;WWWN.:601P4S(V;<K<>_P NY\]007Q%
MIVBGJZ6A;%<*WEM0"<S<6(\C.[<-W,MQ 1$0$1$!$1 1$0$1$!4G5WC1GK?<
M%=E2=7>-&>M]P5A)3]B\ SL4NHBQ> 9V*746!1][^#,_2!2"C[W\&9^D"0)!
M$1 1$0$1$!$1 5.UC^=VC_\ >)OW0KBJ_J&T5-??]/UD'%\30RR/EVG8.'-
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MW1.:,9YCD?\ GM#]TY_2#JSU:7]PJ)T3I^@NK[Y472!M6&7*>**.7)9&,Y)
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MZ-V5-:ZM-3>].S45%Q?'/?&X;9P,!P)^Q:^L[%77BIL\ENGC@?13.FXQ^_!
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M<C>-_.%MH@Q5%/%44LM/,W:AE88WMSC+2,$>Q?E)204E'%24\893Q,$;&9R
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M<:Z:1@?(6LR X@#H',K0UP<T.:06G>".E!^HJYHVY5=QDOHK)>,%-<98(N]
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MM)<*)P;/3/<'$9&6X=S$''.HF"MNNH+_ '>DI+B+91V^00XCB:^60D'+B79
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KT08.3,Z@G)F=06=$&#DS.H)R9G4%G1!A;3L'0%D:P-Y@O2("(B B(@__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Submission<br></strong></div></th>
<th class="th"><div>Apr. 08, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissionLineItems', window );"><strong>Submission [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0002114044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">Hemab Therapeutics Holdings, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FormTp', window );">Form Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissnTp', window );">Submission Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeExhibitTp', window );">Fee Exhibit Type</a></td>
<td class="text">EX-FILING FEES<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeExhibitTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeExhibitTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:feeExhibitTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FormTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FormTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissnTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissnTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Offerings - Offering: 1<br></strong></div></th>
<th class="th">
<div>Apr. 08, 2026 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 100,000,000.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 13,810.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">Maximum Aggregate Offering Price estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended. Includes the aggregate offering price of additional shares that the underwriters have the option to purchase from the registrant, if any. Amount of Registration Fee is calculated pursuant to Rule 457(o) under the Securities Act of 1933, as amended, based on an estimate of the proposed Maximum Aggregate Offering Price.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of registration fee (amount due after offsets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxAggtOfferingPric">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate offering price for the offering that is being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxAggtOfferingPric</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative100TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTitl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The title of the class of securities being registered (for each class being registered).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTitl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Type of securities: "Asset-backed Securities", "ADRs/ADSs", "Debt", "Debt Convertible into Equity", "Equity", "Face Amount Certificates", "Limited Partnership Interests", "Mortgage Backed Securities", "Non-Convertible Debt", "Unallocated (Universal) Shelf", "Exchange Traded Vehicle Securities", "Other"</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_PrevslyPdFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_PrevslyPdFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_Rule457oFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 457<br> -Subsection o<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_Rule457oFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fees Summary<br></strong></div></th>
<th class="th">
<div>Apr. 08, 2026 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesSummaryLineItems', window );"><strong>Fees Summary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOfferingAmt', window );">Total Offering</a></td>
<td class="nump">$ 100,000,000.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlPrevslyPdAmt', window );">Previously Paid Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlFeeAmt', window );">Total Fee Amount</a></td>
<td class="nump">13,810.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOffsetAmt', window );">Total Offset Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_NetFeeAmt', window );">Net Fee</a></td>
<td class="nump">$ 13,810.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTableNa', window );">Offering Table N/A</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OffsetTableNa', window );">Offset Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CombinedProspectusTableNa', window );">Combined Prospectus Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_CombinedProspectusTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_CombinedProspectusTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesSummaryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesSummaryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_NetFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_NetFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOfferingAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOfferingAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOffsetAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOffsetAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlPrevslyPdAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlPrevslyPdAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>2</ContextCount>
  <ElementCount>21</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>1</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>2</UnitCount>
  <MyReports>
    <Report instance="d50309dexfilingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995210 - Document - Submission</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/submissionTable</Role>
      <ShortName>Submission</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d50309dexfilingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995211 - Document - Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesOfferingTable</Role>
      <ShortName>Offerings</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d50309dexfilingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995215 - Document - Fees Summary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesSummaryTable</Role>
      <ShortName>Fees Summary</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="EX-FILING FEES" original="d50309dexfilingfees.htm">d50309dexfilingfees.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="3">http://xbrl.sec.gov/dei/2026</BaseTaxonomy>
    <BaseTaxonomy items="20">http://xbrl.sec.gov/ffd/2026</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>45
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d50309dexfilingfees.htm": {
   "dts": {
    "inline": {
     "local": [
      "d50309dexfilingfees.htm"
     ]
    },
    "schema": {
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/deprecated-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2026/dei-2026.xsd",
      "https://xbrl.sec.gov/ffd/2026/ffd-2026.xsd"
     ]
    }
   },
   "keyStandard": 21,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 8,
    "http://xbrl.sec.gov/ffd/2026": 6,
    "http://xbrl.sec.gov/dei/2026": 2
   },
   "contextCount": 2,
   "entityCount": 1,
   "segmentCount": 1,
   "elementCount": 107,
   "unitCount": 2,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ffd/2026": 20,
    "http://xbrl.sec.gov/dei/2026": 3
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/ffd/role/document/submissionTable",
     "longName": "995210 - Document - Submission",
     "shortName": "Submission",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
     "longName": "995211 - Document - Offerings",
     "shortName": "Offerings",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "offrl_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d50309dexfilingfees.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "offrl_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d50309dexfilingfees.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable",
     "longName": "995215 - Document - Fees Summary",
     "shortName": "Fees Summary",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "3",
     "firstAnchor": {
      "contextRef": "rc",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d50309dexfilingfees.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "rc",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d50309dexfilingfees.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ffd_AggtRedRpPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "AggtRedRpPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtRedRpPricPrrFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "AggtRedRpPricPrrFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Prior Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, Prior FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtSalesPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "AggtSalesPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Sales Price, Fiscal Year",
        "terseLabel": "Aggregate Sales Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtRedCdts": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "AmtRedCdts",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Redemption Credits",
        "terseLabel": "Redemption Credits"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtSctiesRcvd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "AmtSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Received",
        "terseLabel": "Amount of Securities Received",
        "documentation": "Amount of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_AmtSctiesRegd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "AmtSctiesRegd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Registered",
        "terseLabel": "Amount Registered",
        "documentation": "The amount of securities being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CeasedOprsDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CeasedOprsDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ceased Operations Date",
        "terseLabel": "Ceased Operations Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CfwdFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CfwdFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Form Type",
        "terseLabel": "Carry Forward Form Type",
        "documentation": "The Form Type of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrevslyPdFee": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CfwdPrevslyPdFee",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Previously Paid Fee",
        "terseLabel": "Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward",
        "documentation": "The fee previously paid in connection with the securities being brought forward from the prior shelf registration statement on which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CfwdPrrFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Prior Effective Date",
        "terseLabel": "Carry Forward Initial Effective Date",
        "documentation": "The initial effective date of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CfwdPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward File Number",
        "terseLabel": "Carry Forward File Number",
        "documentation": "The EDGAR File Number of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). If the prior registration statement has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CmbndPrspctsItemAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CmbndPrspctsItemAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Item [Axis]",
        "terseLabel": "Combined Prospectus",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different references to earlier prospectuses on a single fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CmbndPrspctsLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Line Items]",
        "terseLabel": "Combined Prospectus:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CmbndPrspctsTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Table]",
        "terseLabel": "Combined Prospectus Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CombinedProspectusTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CombinedProspectusTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Table [N/A]",
        "terseLabel": "Combined Prospectus Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CshPdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CshPdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid by Registrant in Transaction",
        "terseLabel": "Cash Consideration Paid",
        "documentation": "Amount of cash consideration paid by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ffd_CshRcvdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CshRcvdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Received by Registrant in Transaction",
        "terseLabel": "Cash Consideration Received",
        "documentation": "Amount of cash consideration received by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "ffd_FeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Amount",
        "terseLabel": "Amount of Registration Fee",
        "documentation": "Total amount of registration fee (amount due after offsets)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeExhibitTp": {
     "xbrltype": "feeExhibitTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeeExhibitTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Exhibit Type",
        "terseLabel": "Fee Exhibit Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeeIntrstAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeeIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Interest Amount",
        "terseLabel": "Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeeNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note",
        "terseLabel": "Fee Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNoteMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeeNoteMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note Maximum Aggregate Offering Price",
        "terseLabel": "Fee Note MAOP"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeeRate",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Rate",
        "terseLabel": "Fee Rate",
        "documentation": "The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesOthrRuleFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeesOthrRuleFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees, Other Rule [Flag]",
        "terseLabel": "Other Rule",
        "documentation": "Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesSummaryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeesSummaryLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees Summary [Line Items]",
        "terseLabel": "Fees Summary:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FnlPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FnlPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final Prospectus [Flag]",
        "terseLabel": "Final Prospectus"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FormTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Form Type",
        "terseLabel": "Form Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_GnlInstrIIhiFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "GnlInstrIIhiFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Instruction II.H,I [Flag]",
        "terseLabel": "General Instruction II.H,I"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrCity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "IssrBizAdrCity",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, City",
        "terseLabel": "City"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStatOrCtryCd": {
     "xbrltype": "stateOrCountryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "IssrBizAdrStatOrCtryCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, State or Country Code",
        "terseLabel": "State or Country Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "IssrBizAdrStrt1",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 1",
        "terseLabel": "Street 1"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt2": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "IssrBizAdrStrt2",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 2",
        "terseLabel": "Street 2"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrZipCd": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "IssrBizAdrZipCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Zip Code",
        "terseLabel": "Zip Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrNm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "IssrNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Name",
        "terseLabel": "Issuer Name"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_MaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "MaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum Aggregate Offering Price",
        "documentation": "The maximum aggregate offering price for the offering that is being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_MaxOfferingPricPerScty": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "MaxOfferingPricPerScty",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Offering Price per Security",
        "terseLabel": "Proposed Maximum Offering Price per Unit",
        "documentation": "The maximum offering price per share/unit being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetFeeAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "NetFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Fee Amount",
        "terseLabel": "Net Fee"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetSalesAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "NetSalesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Sales Amount",
        "terseLabel": "Net Sales"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvDsclsr": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "NrrtvDsclsr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure",
        "terseLabel": "Narrative Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "NrrtvMaxAggtAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Amount",
        "terseLabel": "Narrative - Max Aggregate Offering Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "NrrtvMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Price",
        "terseLabel": "Narrative - Max Aggregate Offering Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Axis]",
        "terseLabel": "Offering",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different security offerings on a single fee bearing submission."
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Line Items]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Note",
        "terseLabel": "Offering Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Title",
        "terseLabel": "Security Class Title",
        "documentation": "The title of the class of securities being registered (for each class being registered)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Type",
        "terseLabel": "Security Type",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Table]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Table [N/A]",
        "terseLabel": "Offering Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset [Axis]",
        "terseLabel": "Offset",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different offsets as applied to a fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetClmInitlFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetClmInitlFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claim Initial Filing Date",
        "terseLabel": "Initial Filing Date",
        "documentation": "The initial filing date of the earlier registration statement with which the earlier (offsetting) fee was paid for a claimed offset. If the offset fee was paid with an amendment, do not provide the amendment date under this element; instead, provide the date of the initial filing (i.e. the \"parent\" filing) ."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Amount",
        "terseLabel": "Fee Offset Claimed",
        "documentation": "The amount of offsetting fees being claimed."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdInd": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetClmdInd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Indicator",
        "terseLabel": "Offset Claimed"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetExpltnForClmdAmt": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetExpltnForClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Explanation for Claimed Amount",
        "terseLabel": "Explanation for Claimed Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetLineItems",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset:",
        "label": "Offset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Note",
        "terseLabel": "Offset Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetPrrFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Fee Amount",
        "terseLabel": "Fee Paid with Fee Offset Source",
        "documentation": "The fee previously paid from which an offset is being derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior File Number",
        "terseLabel": "File Number",
        "documentation": "The EDGAR File Number of the earlier registration statement with which the earlier (offsetting) fee was paid. If the offset filing for the offset has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFilerNm": {
     "xbrltype": "filerNameItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrFilerNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Filer Name",
        "terseLabel": "Registrant or Filer Name",
        "documentation": "The name of the registrant that filed the earlier registration statement with which the earlier (offsetting) fee was paid."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Form Type",
        "terseLabel": "Form or Filing Type",
        "documentation": "The Form Type of the offset filing."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrNbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal8ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrNbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Number of Securities",
        "terseLabel": "Unsold Securities Associated with Fee Offset Claimed",
        "documentation": "The number of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Title",
        "terseLabel": "Security Title Associated with Fee Offset Claimed",
        "documentation": "The title of the class of securities from which offset fees were derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Type",
        "terseLabel": "Security Type Associated with Fee Offset Claimed",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrUnsoldOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrUnsoldOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Offering Amount",
        "terseLabel": "Unsold Aggregate Offering Amount Associated with Fee Offset Claimed",
        "documentation": "The aggregate offering amount of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetSrcFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetSrcFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Source Filing Date",
        "terseLabel": "Filing Date",
        "documentation": "The filing date of the earlier registration statement with which the earlier (offsetting) fee was paid in an offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset Payment:",
        "label": "Offset [Table]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Table [N/A]",
        "terseLabel": "Offset Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_PrevslyPdFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "PrevslyPdFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Previously Paid [Flag]",
        "terseLabel": "Fee Previously Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RegnFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "RegnFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration File Number",
        "terseLabel": "Registration File Number"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RptgFsclYrEndDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "RptgFsclYrEndDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Fiscal Year End Date",
        "terseLabel": "Reporting FY End Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule011Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 0-11 [Flag]",
        "terseLabel": "Rule 0-11"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011a2OffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule011a2OffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 0-11(a)(2) Offset",
        "label": "Rule 0-11(a)(2) Offset [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule415a6Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule415a6Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 415(a)(6) [Flag]",
        "terseLabel": "Rule 415(a)(6)",
        "documentation": "Checkbox indicating whether filer is claiming a 415(a)(6) carryforward."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_Rule429AggtOfferingAmt": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429AggtOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Aggregate Offering Amount",
        "terseLabel": "Maximum Aggregate Offering Price of Securities Previously Registered",
        "documentation": "The maximum aggregate offering amount of unsold securities registered on the prior registration statement that are carried forward under Rule 429. Only applicable if 457(o) was used in the fee calculation for the prior registration statement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429CmbndPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429CmbndPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Combined Prospectus [Flag]",
        "terseLabel": "Rule 429",
        "documentation": "Checkbox indicating whether filer is using a combined prospectus under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429EarlierFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier File Number",
        "terseLabel": "File Number",
        "documentation": "The Securities Act File Number of the earlier effective registration statement(s) from which securities may be offered and sold using the combined prospectus pursuant to Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429EarlierFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier Form Type",
        "terseLabel": "Form Type",
        "documentation": "The Form Type of the earlier registration statement from which unsold securities are carried forward under Rule 429. This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429InitlFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429InitlFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Initial Effective Date",
        "terseLabel": "Initial Effective Date",
        "documentation": "The filing date of the earlier registration statement from which unsold securities are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429NbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429NbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Number Of Unsold Securities",
        "terseLabel": "Amount of Securities Previously Registered",
        "documentation": "The number of securities registered on the prior registration statement that are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429PrspctsNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429PrspctsNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Prospectus Note",
        "terseLabel": "Combined Prospectus Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429SctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Title",
        "terseLabel": "Security Class Title"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429SctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Type",
        "terseLabel": "Security Type"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule457aFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457aFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(a) [Flag]",
        "terseLabel": "Rule 457(a)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ffd_Rule457bOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457bOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(b) Offset [Flag]",
        "terseLabel": "Rule 457(b) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(b) or 0-11(a)(2)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ffd_Rule457fFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457fFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(f) [Flag]",
        "terseLabel": "Rule 457(f)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_Rule457oFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457oFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(o) [Flag]",
        "terseLabel": "Rule 457(o)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ffd_Rule457pOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457pOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(p) Offset [Flag]",
        "terseLabel": "Rule 457(p) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(p)."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ffd_Rule457rFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457rFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(r) [Flag]",
        "terseLabel": "Rule 457(r)"
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ffd_Rule457sFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457sFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(s) Flag",
        "terseLabel": "Rule 457(s)"
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ffd_Rule457uFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457uFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(u) [Flag]",
        "terseLabel": "Rule 457(u)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(u) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ffd_Scties424iAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Scties424iAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Axis]",
        "terseLabel": "Securities, 424I"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Scties424iLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Line Items]",
        "terseLabel": "Securities, 424I:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Scties424iTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Table]",
        "terseLabel": "Securities, 424I Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Securities424iTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Securities424iNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities 424I [N/A]",
        "terseLabel": "Securities 424I N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "SubmissionLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission [Line Items]",
        "terseLabel": "Items"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissnTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "SubmissnTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission Type",
        "terseLabel": "Submission Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TermntnCmpltnWdrwl": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TermntnCmpltnWdrwl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination / Completion / Withdrawal Statement",
        "terseLabel": "Termination / Withdrawal Statement"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TtlFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee Amount",
        "terseLabel": "Total Fee Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlFeeAndIntrstAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TtlFeeAndIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee and Interest Amount",
        "terseLabel": "Total Fee and Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TtlOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offering Amount",
        "terseLabel": "Total Offering"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOffsetAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TtlOffsetAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offset Amount",
        "terseLabel": "Total Offset Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlPrevslyPdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TtlPrevslyPdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Previously Paid Amount",
        "terseLabel": "Previously Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlTxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TtlTxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Transaction Valuation",
        "terseLabel": "Total Transaction Valuation"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Valuation",
        "terseLabel": "Transaction Valuation"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_ValSctiesRcvd": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "ValSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received",
        "terseLabel": "Value of Securities Received",
        "documentation": "Value of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_ValSctiesRcvdPerShr": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "ValSctiesRcvdPerShr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received, Per Share",
        "terseLabel": "Value of Securities Received, Per Share",
        "documentation": "Value per share of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form). This is included in the explanation of 457(f) fee calculation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "415",
   "Subsection": "a"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "429"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "f"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "o"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "p"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "r"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "s"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "u"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Subsection": "f",
   "Section": "457"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>46
<FILENAME>0001193125-26-151378-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-26-151378-xbrl.zip
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M9_FK^3:[+]CV"'[;S\\X[M[E+<%>S^OW9:ZH)K[9:V_V:AC!*H"#MXC]/_"
MMXC]\]CK;4.UNJ'J&23^W2))?[CXO]](K?DQY:O=5.UE ]5_MV'GHP#V_7N$
M[M&SJ&1^CE#OQP\-B*5G2YE]0^;"<;L?"IPV86'CH>!NF#MNPMLV8^ZP:6]"
M8:O!]D8*KC?)7K\Z%\^X-TVW[*&&OI+9G8H*V597&8,V_G])AO\%4$L! A0#
M%     @ &H6*7"3QJ.VK"@  Z40  !<              ( !     &0U,#,P
H.61E>&9I;&EN9V9E97,N:'1M4$L%!@     !  $ 10   . *      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>d50309dexfilingfees_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2026"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2026/ffd-2026.xsd"
      xlink:type="simple"/>
    <context id="rc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002114044</identifier>
        </entity>
        <period>
            <startDate>2026-04-08</startDate>
            <endDate>2026-04-08</endDate>
        </period>
    </context>
    <context id="offrl_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002114044</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-08</startDate>
            <endDate>2026-04-08</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <ffd:FormTp contextRef="rc" id="ixv-330">S-1</ffd:FormTp>
    <ffd:SubmissnTp contextRef="rc" id="ixv-331">S-1</ffd:SubmissnTp>
    <ffd:FeeExhibitTp contextRef="rc" id="ixv-332">EX-FILING FEES</ffd:FeeExhibitTp>
    <dei:EntityCentralIndexKey contextRef="rc" id="ixv-333">0002114044</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-334">Hemab Therapeutics Holdings, Inc.</dei:EntityRegistrantName>
    <ffd:OfferingTableNa contextRef="rc" id="hiddenrcOfferingTableNa" xsi:nil="true"/>
    <ffd:OffsetTableNa contextRef="rc" id="hiddenrcOffsetTableNa">N/A</ffd:OffsetTableNa>
    <ffd:CombinedProspectusTableNa contextRef="rc" id="hiddenrcCombinedProspectusTableNa">N/A</ffd:CombinedProspectusTableNa>
    <ffd:FormTp contextRef="rc" id="ixv-362">S-1</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-363">Hemab Therapeutics Holdings, Inc.</dei:EntityRegistrantName>
    <ffd:PrevslyPdFlg contextRef="offrl_1" id="ixv-364">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="offrl_1" id="ixv-365">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_1" id="ixv-366">Common Stock, par value $0.0001 per share</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="offrl_1" id="ixv-367">true</ffd:Rule457oFlg>
    <ffd:MaxAggtOfferingPric
      contextRef="offrl_1"
      decimals="2"
      id="ixv-368"
      unitRef="USD">100000000.00</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="offrl_1"
      decimals="7"
      id="ixv-369"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="offrl_1"
      decimals="2"
      id="ixv-370"
      unitRef="USD">13810.00</ffd:FeeAmt>
    <ffd:TtlOfferingAmt contextRef="rc" decimals="2" id="ixv-371" unitRef="USD">100000000.00</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt contextRef="rc" decimals="2" id="ixv-372" unitRef="USD">13810.00</ffd:TtlFeeAmt>
    <ffd:TtlPrevslyPdAmt contextRef="rc" decimals="2" id="ixv-373" unitRef="USD">0.00</ffd:TtlPrevslyPdAmt>
    <ffd:TtlOffsetAmt contextRef="rc" decimals="2" id="ixv-374" unitRef="USD">0.00</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt contextRef="rc" decimals="2" id="ixv-375" unitRef="USD">13810.00</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="offrl_1" id="ixv-376">Maximum Aggregate Offering Price estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended. Includes the aggregate offering price of additional shares that the underwriters have the option to purchase from the registrant, if any. Amount of Registration Fee is calculated pursuant to Rule 457(o) under the Securities Act of 1933, as amended, based on an estimate of the proposed Maximum Aggregate Offering Price.</ffd:OfferingNote>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
